Evaluation	O
of	O
Outcome	O
Following	O
Coronectomy	O
for	O
the	O
Management	O
of	O
Mandibular	O
Third	O
Molars	O
in	O
Close	O
Proximity	O
to	O
Inferior	O
Alveolar	O
Nerve	O
.	O

Iatrogenic	O
damage	O
to	O
Inferior	O
Alveolar	O
Nerve	O
(	O
IAN	O
)	O
is	O
a	O
significant	O
risk	O
factor	O
following	O
prophylactic	O
or	O
therapeutic	O
removal	O
of	O
impacted	O
mandibular	O
third	O
molar	O
.	O

The	O
risk	O
to	O
IAN	O
injury	O
increases	O
many	O
fold	O
,	O
when	O
the	O
third	O
molar	O
root	O
overlaps	O
the	O
nerve	O
canal	O
as	O
identified	O
by	O
the	O
radiographic	B-P
imaging	I-P
.	O

Various	O
methods	O
like	O
orthodontic	O
assisted	O
extraction	O
,	O
staged	O
removal	O
of	O
tooth	O
or	O
coronectomy	O
have	O
been	O
advocated	O
to	O
reduce	O
the	O
incidence	O
of	O
IAN	O
injury	O
in	O
high	O
risk	O
cases	O
with	O
variable	O
outcome	O
.	O

The	O
aim	O
of	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
fate	O
of	O
the	O
root	O
(	O
resorbed	O
,	O
exfoliated	O
,	O
covered	O
by	O
bone	O
)	O
after	O
coronectomy	O
or	O
intentional	O
root	O
retention	O
of	O
impacted	O
mandibular	O
3	O
(	O
rd	O
)	O
molars	O
in	O
patients	O
with	O
high	O
risk	O
for	O
inferior	O
alveolar	O
nerve	O
damage	O
as	O
evaluated	O
by	O
the	O
intra	B-P
oral	I-P
periapical	I-P
radiograph	I-P
.	O

Twenty	O
impacted	O
mandibular	O
third	O
molar	O
teeth	O
,	O
in	O
18	O
patients	O
with	O
high	O
risk	O
of	O
injury	O
to	O
IAN	O
based	O
on	O
Rood	O
's	O
Criteria	O
in	O
an	O
intra	B-P
oral	I-P
periapical	I-P
radiographic	I-P
examination	I-P
,	O
between	O
the	O
age	O
group	O
of	O
18	O
to	O
40	O
years	O
,	O
were	O
included	O
in	O
the	O
study	O
.	O

Preoperatively	O
the	O
impacted	O
third	O
molars	O
were	O
evaluated	O
clinically	O
as	O
well	O
as	O
radiographically	O
.	O

Pederson	O
Difficulty	O
Index	O
and	O
Winter	O
's	O
Classification	O
of	O
impacted	O
tooth	O
was	O
recorded	O
.	O

Coronectomy	O
was	O
done	O
at	O
the	O
cemento	O
enamel	O
junction	O
leaving	O
the	O
roots	O
2-3mm	O
below	O
the	O
alveolar	O
crest	O
and	O
primary	O
closure	O
was	O
done	O
.	O

Patients	O
were	O
evaluated	O
periodically	O
for	O
two	O
years	O
at	O
six	O
months	O
interval	O
.	O

Post	O
operative	O
pain	O
,	O
swelling	O
,	O
IAN	O
injury	O
or	O
any	O
other	O
complications	O
were	O
observed	O
and	O
recorded	O
.	O

None	O
of	O
the	O
patients	O
had	O
IAN	O
injury	O
and	O
none	O
required	O
second	O
surgical	O
removal	O
.	O

There	O
was	O
no	O
incidence	O
of	O
post-operative	O
infection	O
and	O
none	O
required	O
second	O
surgical	O
intervention	O
.	O

However	O
,	O
two	O
of	O
our	O
patients	O
had	O
failed	O
coronectomy	O
(	O
10	O
%	O
)	O
due	O
to	O
mobilization	O
of	O
roots	O
intra	O
operatively	O
and	O
the	O
roots	O
were	O
removed	O
.	O

One	O
patient	O
developed	O
profuse	O
bleeding	O
intra-operatively	O
in	O
the	O
failed	O
coronectomy	O
case	O
.	O

One	O
patient	O
had	O
temporary	O
lingual	O
nerve	O
paresthesia	O
.	O

Coronectomy	O
procedure	O
is	O
effective	O
in	O
controlling	O
inferior	O
alveolar	O
nerve	O
injury	O
following	O
third	O
molar	O
surgery	O
,	O
in	O
radiographically	O
evaluated	O
high	O
risk	O
cases	O
and	O
it	O
has	O
very	O
low	O
incidence	O
of	O
complications	O
.	O

Extremely	O
Giant	O
Liver	O
Hemangioma	O
(	O
50	O
cm	O
)	O
with	O
Kasabach-Merritt	O
Syndrome	O
.	O

A	O
33-	O
year	O
-	O
old	O
male	O
has	O
been	O
found	O
with	O
a	O
giant	O
liver	O
hemangioma	O
of	O
initial	O
size	O
29	O
cm	O
for	O
5	O
years	O
.	O

He	O
received	O
arterial	O
embolization	O
twice	O
in	O
order	O
to	O
shrink	O
the	O
tumor	O
;	O
however	O
,	O
no	O
effect	O
was	O
obtained	O
.	O

The	O
tumor	O
had	O
rapidly	O
grown	O
to	O
50	O
cm	O
and	O
caused	O
abnormalities	O
in	O
the	O
hematological	O
and	O
coagulative	O
systems	O
.	O

Preoperative	O
computed	B-P
tomography	I-P
revealed	O
that	O
the	O
right	O
hepatic	O
vein	O
,	O
right	O
hepatic	O
artery	O
,	O
and	O
right	O
portal	O
vein	O
were	O
not	O
involved	O
by	O
the	O
hemangioma	O
.	O

Resection	O
of	O
the	O
giant	O
liver	O
hemangioma	O
was	O
successfully	O
performed	O
after	O
intraoperative	O
intentional	O
bloodletting	O
with	O
concurrent	O
blood	O
salvage	O
.	O

All	O
hematological	O
and	O
coagulative	O
abnormalities	O
had	O
returned	O
to	O
normal	O
after	O
the	O
procedure	O
.	O

Effects	O
of	O
morphology	O
and	O
surface	O
hydroxyl	O
on	O
the	O
toxicity	O
of	O
BiOCl	O
in	O
human	O
HaCaT	O
cells	O
.	O

Recently	O
,	O
bismuth	O
oxychloride	O
nanomaterials	O
(	O
BiOCls	O
)	O
are	O
showing	O
great	O
promise	O
in	O
pollutant	O
removal	O
.	O

Residues	O
from	O
these	O
environmental	O
remediations	O
are	O
potential	O
hazardous	O
materials	O
.	O

Unfortunately	O
,	O
human	O
health	O
risks	O
of	O
BiOCls	O
are	O
still	O
unexplored	O
widely	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
focused	O
on	O
the	O
influence	O
of	O
physicochemical	O
properties	O
on	O
the	O
cytotoxicity	O
of	O
BiOCls	O
toward	O
a	O
human	O
skin	O
derived	O
cell	O
line	O
(	O
HaCaT	O
)	O
.	O

Results	O
showed	O
that	O
morphology	O
and	O
surface	O
hydroxyl	O
both	O
had	O
a	O
profound	O
effect	O
on	O
the	O
toxicity	O
of	O
BiOCls	O
.	O

Microsphere-shaped	O
BiOCl	O
caused	O
less	O
toxicity	O
than	O
nanosheet-shaped	O
BiOCl	O
because	O
of	O
weaker	O
particle-membrane	O
interactions	O
,	O
while	O
the	O
presence	O
of	O
surface	O
hydroxyl	O
on	O
microsphere-shaped	O
BiOCl	O
significantly	O
raised	O
the	O
toxicity	O
owing	O
to	O
the	O
increased	O
interaction	O
with	O
cell	O
membrane	O
.	O

Both	O
microsphere-shaped	O
BiOCl	O
with	O
surface	O
hydroxyl	O
and	O
nanosheet-shaped	O
BiOCl	O
caused	O
significant	O
cell	O
membrane	O
damage	O
(	O
PI	B-P
uptake	I-P
and	O
LDH	B-P
release	I-P
)	O
,	O
however	O
,	O
based	O
on	O
the	O
different	O
mechanism	O
.	O

The	O
former	O
may	O
be	O
a	O
predominant	O
``	O
chemical	O
''	O
mechanism	O
involved	O
an	O
oxidative	O
stress	O
paradigm	O
,	O
as	O
manifested	O
by	O
elevated	O
ROS	O
and	O
depleted	O
GSH	O
,	O
while	O
the	O
latter	O
is	O
mainly	O
due	O
to	O
a	O
direct	O
``	O
physical	O
``	O
damage	O
to	O
cell	O
membrane	O
.	O

Both	O
``	O
physical	O
``	O
and	O
``	O
chemical	O
''	O
response	O
led	O
to	O
cell	O
death	O
.	O

Furthermore	O
,	O
a	O
set	O
of	O
experiments	O
including	O
MMP	O
collapse	O
,	O
cell	O
cycle	O
arrest	O
,	O
and	O
apoptosis	O
/	O
necrosis	O
were	O
conducted	O
to	O
propose	O
a	O
scenario	O
for	O
toxicological	O
aspects	O
of	O
BiOCls	O
.	O

Data	O
presented	O
here	O
would	O
help	O
to	O
enable	O
the	O
rational	O
design	O
of	O
BiOCls	O
for	O
either	O
reducing	O
their	O
unintended	O
consequences	O
or	O
increasing	O
their	O
application	O
potentials	O
.	O

Effect	O
of	O
Xenotransplantation	O
Site	O
on	O
MicroRNA	O
Expression	O
of	O
Human	O
Colon	O
Cancer	O
Stem	O
Cells	O
.	O

Cancer	O
stem	O
cells	O
(	O
CSCs	O
)	O
have	O
a	O
high	O
tumorigenic	O
ability	O
to	O
form	O
patient-derived	O
tumor	O
xenografts	O
(	O
PDXs	O
)	O
.	O

PDXs	O
are	O
an	O
attractive	O
pre-clinical	O
model	O
,	O
but	O
gene	O
expression	O
and	O
biological	O
behavior	O
of	O
cancer	O
cells	O
in	O
the	O
tumor	O
will	O
change	O
during	O
establishment	O
and	O
passage	O
of	O
PDXs	O
.	O

Human	O
colon	O
cancer	O
PDX	O
was	O
established	O
and	O
passaged	B-P
either	O
subcutaneously	O
or	O
orthotopically	O
into	O
the	O
murine	O
intestine	O
.	O

Histology	O
and	O
flow	B-P
cytometric	I-P
profile	B-P
of	O
the	O
surgical	O
specimen	O
and	O
the	O
PDX	O
were	O
analyzed	O
.	O

CSCs	O
were	O
then	O
isolated	O
from	O
the	O
tumors	O
and	O
their	O
microRNA	O
(	O
miRNA	O
)	O
expression	O
was	O
analyzed	O
by	O
semi-quantitative	B-P
polymerase	I-P
chain	I-P
reaction	I-P
.	O

The	O
surgical	O
specimens	O
and	O
PDXs	O
were	O
histologically	O
similar	O
.	O

The	O
size	O
of	O
CSC	O
population	O
increased	O
and	O
expression	O
of	O
miRNA	O
s	O
in	O
CSCs	O
changed	O
in	O
the	O
passaged	B-P
PDXs	O
.	O

Expression	O
of	O
oncogenic	O
miRNAs	O
was	O
highly	O
up-regulated	O
in	O
the	O
CSCs	O
of	O
the	O
orthotopically	O
passaged	B-P
PDXs	O
.	O

The	O
xenotransplantation	O
site	O
and	O
the	O
number	O
of	O
tumor	O
passages	B-P
affect	O
the	O
miRNA	O
expression	O
of	O
human	O
colon	O
CSCs	O
.	O

The	O
Effect	O
of	O
Sodium	O
Fluoride	O
on	O
Cell	O
Apoptosis	O
and	O
the	O
Mechanism	O
of	O
Human	O
Lung	O
BEAS-2B	O
Cells	O
In	O
Vitro	O
.	O

Sodium	O
fluoride	O
(	O
NaF	O
)	O
is	O
a	O
source	O
of	O
fluoride	O
ions	O
used	O
in	O
many	O
applications	O
.	O

Previous	O
studies	O
found	O
that	O
NaF	O
suppressed	O
the	O
proliferation	O
of	O
osteoblast	O
MC3T3	O
E1	O
cells	O
and	O
induced	O
the	O
apoptosis	O
of	O
chondrocytes	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
effects	O
of	O
NaF	O
on	O
human	O
lung	O
BEAS-2B	O
cells	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
mode	O
of	O
cell	O
death	O
induced	O
by	O
NaF	O
and	O
its	O
underlying	O
molecular	O
mechanisms	O
.	O

BEAS-2B	O
cells	O
were	O
treated	O
with	O
NaF	O
at	O
concentrations	O
of	O
0	O
,	O
0.25	O
,	O
0.5	O
,	O
1.0	O
,	O
2.0	O
,	O
and	O
4.0	O
mmol/L	O
.	O

Cell	O
viability	O
decreased	O
and	O
apoptotic	O
cells	O
significantly	O
increased	O
as	O
concentrations	O
of	O
NaF	O
increased	O
over	O
specific	O
periods	O
of	O
time	O
.	O

The	O
IC50	O
of	O
NaF	O
was	O
1.9	O
and	O
0.9	O
mM	O
after	O
24	O
and	O
48	O
h	O
,	O
respectively	O
.	O

The	O
rates	O
of	O
apoptosis	O
increased	O
from	O
4.8	O
to	O
37.7	O
%	O
after	O
NaF	O
exposure	O
.	O

HE	B-P
staining	I-P
,	O
electron	B-P
microscopy	I-P
,	O
and	O
single	O
cell	O
gel	O
electrophoresis	O
revealed	O
that	O
morphological	O
changes	O
of	O
apoptosis	O
increased	O
with	O
exposure	O
concentrations	O
.	O

RT-PCR	O
and	O
Western	O
blotting	O
were	O
used	O
to	O
detect	O
the	O
apoptotic	O
pathways	O
.	O

The	O
expressions	O
of	O
bax	O
,	O
caspase-3	O
,	O
caspase-9	O
,	O
p53	O
,	O
and	O
the	O
cytoplasmic	O
CytC	O
of	O
the	O
NaF	O
groups	O
increased	O
,	O
while	O
bcl-2	O
and	O
mitochondrial	O
CytC	O
decreased	O
compared	O
with	O
that	O
of	O
the	O
control	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Further	O
,	O
the	O
fluorescence	O
intensities	O
of	O
ROS	O
in	O
the	O
NaF	O
groups	O
were	O
higher	O
than	O
those	O
in	O
the	O
control	O
group	O
,	O
and	O
the	O
membrane	O
potential	O
of	O
mitochondria	O
in	O
the	O
NaF	O
group	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
the	O
control	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

These	O
findings	O
suggested	O
that	O
NaF	O
induced	O
apoptosis	O
in	O
the	O
BEAS-2B	O
cells	O
through	O
mitochondria	O
-mediated	O
signal	O
pathways	O
.	O

Our	O
study	O
provides	O
the	O
theoretical	O
foundation	O
and	O
experimental	O
basis	O
for	O
exploring	O
the	O
mechanisms	O
of	O
human	O
lung	O
epithelial	O
cell	O
damage	O
and	O
cytotoxicity	O
induced	O
by	O
fluorine	O
.	O

Accurate	O
Quantification	O
of	O
Laminarin	O
in	O
Marine	O
Organic	O
Matter	O
with	O
Enzymes	O
from	O
Marine	O
Microbes	O
.	O

Marine	O
algae	O
produce	O
a	O
variety	O
of	O
glycans	O
,	O
which	O
fulfill	O
diverse	O
biological	O
functions	O
and	O
fuel	O
the	O
carbon	O
and	O
energy	O
demands	O
of	O
heterotrophic	O
microbes	O
.	O

A	O
common	O
approach	O
to	O
analysis	O
of	O
marine	O
organic	O
matter	O
uses	O
acid	O
to	O
hydrolyze	O
the	O
glycans	O
into	O
measurable	O
monosaccharides	O
.	O

The	O
monosaccharides	O
may	O
be	O
derived	O
from	O
different	O
glycans	O
that	O
are	O
built	O
with	O
the	O
same	O
monosaccharides	O
,	O
however	O
,	O
and	O
this	O
approach	O
does	O
not	O
distinguish	O
between	O
glycans	O
in	O
natural	O
samples	O
.	O

Here	O
we	O
use	O
enzymes	O
to	O
digest	O
selectively	O
and	O
thereby	O
quantify	O
laminarin	O
in	O
particulate	O
organic	O
matter	O
.	O

Environmental	O
metaproteome	O
data	O
revealed	O
carbohydrate	O
-active	O
enzymes	O
from	O
marine	O
flavobacteria	O
as	O
tools	O
for	O
selective	O
hydrolysis	O
of	O
the	O
algal	O
β-glucan	O
laminarin	O
.	O

The	O
enzymes	O
digested	O
laminarin	O
into	O
glucose	O
and	O
oligosaccharides	O
,	O
which	O
we	O
measured	O
with	O
standard	O
methods	O
to	O
establish	O
the	O
amounts	O
of	O
laminarin	O
in	O
the	O
samples	O
.	O

We	O
cloned	O
,	O
expressed	O
,	O
purified	O
,	O
and	O
characterized	O
three	O
new	O
glycoside	O
hydrolases	O
(	O
GHs	O
)	O
of	O
Formosa	O
bacteria	O
:	O
two	O
are	O
endo-β-1,3-glucanases	O
,	O
of	O
the	O
GH16	O
and	O
GH17	O
families	O
,	O
and	O
the	O
other	O
is	O
a	O
GH30	O
exo-β-1,6-glucanase	O
.	O

Formosa	O
sp	O
.	O

nov	O
strain	O
Hel1_33_131	O
GH30	O
(	O
FbGH30	O
)	O
removed	O
the	O
β-1,6-glucose	O
side	O
chains	O
,	O
and	O
Formosa	O
agariphila	O
GH17A	O
(	O
FaGH17A	O
)	O
and	O
FaGH16A	O
hydrolyzed	O
the	O
β-1,3-glucose	O
backbone	O
of	O
laminarin	O
.	O

Specificity	O
profiling	O
with	O
a	O
library	O
of	O
glucan	O
oligosaccharides	O
and	O
polysaccharides	O
revealed	O
that	O
FaGH17A	O
and	O
FbGH30	O
were	O
highly	O
specific	O
enzymes	O
,	O
while	O
FaGH16A	O
also	O
hydrolyzed	O
mixed-linked	O
glucans	O
with	O
β-1,4-glucose	O
.	O

Therefore	O
,	O
we	O
chose	O
the	O
more	O
specific	O
FaGH17A	O
and	O
FbGH30	O
to	O
quantify	O
laminarin	O
in	O
two	O
cultured	O
diatoms	O
,	O
namely	O
,	O
Thalassiosira	O
weissflogii	O
and	O
Thalassiosira	O
pseudonana	O
,	O
and	O
in	O
seawater	O
samples	O
from	O
the	O
North	O
Sea	O
and	O
the	O
Arctic	O
Ocean	O
.	O

Combined	O
,	O
these	O
results	O
demonstrate	O
the	O
potential	O
of	O
enzymes	O
for	O
faster	O
,	O
stereospecific	O
,	O
and	O
sequence	O
-	O
specific	O
analysis	O
of	O
select	O
glycans	O
in	O
marine	O
organic	O
matter	O
.IMPORTANCE	O
Marine	O
algae	O
synthesize	O
substantial	O
amounts	O
of	O
the	O
glucose	O
polymer	O
laminarin	O
for	O
energy	O
and	O
carbon	O
storage	O
.	O

Its	O
concentrations	O
,	O
rates	O
of	O
production	O
by	O
autotrophic	O
organisms	O
,	O
and	O
rates	O
of	O
digestion	O
by	O
heterotrophic	O
organisms	O
remain	O
unknown	O
.	O

Here	O
we	O
present	O
a	O
method	O
based	O
on	O
enzymes	O
that	O
hydrolyze	O
laminarin	O
and	O
enable	O
its	O
quantification	O
even	O
in	O
crude	O
substrate	O
mixtures	O
,	O
without	O
purification	O
.	O

Compared	O
to	O
the	O
commonly	O
used	O
acid	O
hydrolysis	O
,	O
the	O
enzymatic	O
method	O
presented	O
here	O
is	O
faster	O
and	O
stereospecific	O
and	O
selectively	O
cleaves	O
laminarin	O
in	O
mixtures	O
of	O
glycans	O
,	O
releasing	O
only	O
glucose	O
and	O
oligosaccharides	O
,	O
which	O
can	O
be	O
easily	O
quantified	O
with	O
reducing	O
sugar	O
assays	B-P
.	O

Genital	O
and	O
Extragenital	O
Gonorrhea	O
and	O
Chlamydia	O
in	O
Children	O
and	O
Adolescents	O
Evaluated	O
for	O
Sexual	O
Abuse	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
use	O
of	O
a	O
nucleic	B-P
acid	I-P
amplification	I-P
test	I-P
in	O
detecting	O
genital	O
and	O
extragenital	O
Neisseria	O
gonorrhoeae	O
(	O
NG	O
)	O
and	O
Chlamydia	O
trachomatis	O
(	O
CT	O
)	O
in	O
children	O
and	O
adolescents	O
assessed	O
for	O
sexual	O
abuse	O
/	O
assault	O
.	O

The	O
charts	O
of	O
children	O
aged	O
0	O
to	O
17	O
years	O
,	O
consecutively	O
evaluated	O
for	O
sexual	O
victimization	O
,	O
in	O
emergency	O
department	O
and	O
outpatient	O
settings	O
were	O
reviewed	O
.	O

Data	O
extracted	O
included	O
age	O
,	O
sex	O
,	O
type	O
of	O
sexual	O
contact	O
,	O
anogenital	O
findings	O
,	O
previous	O
sexual	O
contact	O
,	O
toxicology	O
results	O
,	O
and	O
sites	O
tested	B-P
for	O
NG	O
and	O
CT.	O
Of	O
the	O
1319	O
patients	O
who	O
were	O
tested	B-P
,	O
579	O
were	O
tested	B-P
at	O
more	O
than	O
1	O
site	O
,	O
and	O
120	O
had	O
at	O
least	O
1	O
infected	O
site	O
.	O

Chlamydia	O
trachomatis	O
was	O
identified	O
in	O
104	O
patients	O
,	O
and	O
NG	O
was	O
found	O
in	O
33	O
.	O

In	O
bivariate	O
analysis	O
,	O
a	O
positive	O
test	O
was	O
associated	O
with	O
female	O
sex	O
,	O
age	O
older	O
than	O
11	O
years	O
,	O
previous	O
sexual	O
contact	O
,	O
acute	O
or	O
healed	O
genital	O
injury	O
,	O
drug/alcohol	O
intoxication	O
,	O
and	O
examination	O
within	O
72	O
hours	O
of	O
sexual	O
contact	O
.	O

Fifty-one	O
patients	O
had	O
positive	O
anal	O
tests	B-P
,	O
and	O
24	O
had	O
positive	O
oral	O
tests	B-P
.	O

More	O
than	O
75	O
%	O
of	O
patients	O
with	O
positive	O
extragenital	B-P
tests	I-P
had	O
additional	O
positive	O
tests	B-P
or	O
anogenital	O
injury	O
.	O

Most	O
with	O
a	O
positive	O
anal	O
(	O
59	O
%	O
)	O
or	O
oral	O
(	O
77	O
%	O
)	O
test	B-P
did	O
not	O
report	O
that	O
the	O
assailant	O
's	O
genitals	O
came	O
into	O
contact	O
with	O
that	O
site	O
.	O

Positive	O
tests	B-P
for	O
NG	O
and	O
CT	O
in	O
patients	O
evaluated	O
for	O
sexual	O
victimization	O
may	O
represent	O
infection	O
from	O
sexual	O
contact	O
,	O
contiguous	O
spread	O
of	O
infection	O
,	O
or	O
the	O
presence	O
of	O
infected	O
assailant	O
secretions	O
.	O

Relying	O
on	O
patient	O
reports	O
of	O
symptoms	O
,	O
or	O
types	O
of	O
sexual	O
contact	O
,	O
to	O
determine	O
need	O
for	O
testing	O
may	O
miss	O
NG	O
and	O
CT	O
infections	O
in	O
patients	O
evaluated	O
for	O
sexual	O
victimization	O
.	O

A	O
standardized	O
approach	O
for	O
the	O
assessment	O
and	O
treatment	O
of	O
internationally	O
adopted	O
children	O
with	O
a	O
previously	O
repaired	O
anorectal	O
malformation	O
(	O
ARM	O
)	O
.	O

A	O
significant	O
number	O
of	O
internationally	O
adopted	O
children	O
have	O
congenital	O
birth	O
defects	O
.	O

As	O
a	O
specialist	O
center	O
for	O
colorectal	O
diagnoses	B-P
,	O
we	O
evaluate	O
such	O
children	O
with	O
an	O
anorectal	O
malformation	O
(	O
ARM	O
)	O
and	O
have	O
found	O
that	O
a	O
significant	O
number	O
need	O
a	O
reoperation	O
.	O

Knowledge	O
of	O
the	O
common	O
complications	O
following	O
ARM	O
surgery	O
has	O
led	O
us	O
to	O
develop	O
treatment	O
algorithms	O
for	O
patients	O
with	O
unknown	O
past	O
medical	O
and	O
surgical	O
history	O
,	O
a	O
situation	O
typically	O
encountered	O
in	O
the	O
adopted	O
population	O
.	O

The	O
results	O
of	O
investigations	O
,	O
indications	O
,	O
and	O
rate	O
of	O
reoperation	O
were	O
assessed	O
for	O
adopted	O
children	O
with	O
an	O
ARM	O
evaluated	O
between	O
2014	O
and	O
2016	O
.	O

56	O
patients	O
(	O
28	O
males	O
)	O
were	O
identified	O
.	O

76.8	O
%	O
required	O
reoperative	O
surgery	O
.	O

Mislocation	O
of	O
the	O
anus	O
outside	O
the	O
sphincter	O
complex	O
was	O
seen	O
in	O
50	O
%	O
of	O
males	O
and	O
39.3	O
%	O
of	O
females	O
.	O

Anal	O
stricture	O
,	O
rectal	O
prolapse	O
,	O
retained	O
vaginal	O
septum	O
,	O
and	O
a	O
strictured	O
vaginal	O
introitus	O
were	O
also	O
common	O
.	O

The	O
reoperative	O
surgery	O
rate	O
in	O
the	O
internationally	O
adopted	O
child	O
with	O
an	O
ARM	O
is	O
high	O
.	O

Complete	O
,	O
systematic	O
evaluation	O
of	O
these	O
children	O
is	O
required	O
to	O
identify	O
complications	O
following	O
initial	O
repair	O
.	O

Development	O
of	O
mechanisms	O
to	O
improve	O
the	O
primary	O
surgical	O
care	O
these	O
children	O
receive	O
is	O
needed	O
.	O

Autonomic	O
,	O
functional	O
,	O
skeletal	O
muscle	O
,	O
and	O
cardiac	O
abnormalities	O
are	O
associated	O
with	O
increased	O
ergoreflex	O
sensitivity	O
in	O
mitochondrial	O
disease	O
.	O

Mitochondrial	O
disease	O
(	O
MD	O
)	O
is	O
a	O
genetic	O
disorder	O
affecting	O
skeletal	O
muscles	O
,	O
with	O
possible	O
myocardial	O
disease	O
.	O

The	O
ergoreflex	O
,	O
sensitive	O
to	O
skeletal	O
muscle	O
work	O
,	O
regulates	O
ventilatory	O
and	O
autonomic	O
responses	O
to	O
exercise	O
.	O

We	O
hypothesized	O
the	O
presence	O
of	O
an	O
increased	O
ergoreflex	O
sensitivity	O
in	O
MD	O
patients	O
,	O
its	O
association	O
with	O
abnormal	O
ventilatory	O
and	O
autonomic	O
responses	O
,	O
and	O
possibly	O
with	O
subclinical	O
cardiac	O
involvement	O
.	O

Twenty-five	O
MD	O
patients	O
(	O
aged	O
46	O
±	O
3	O
years	O
,	O
32	O
%	O
male	O
)	O
with	O
skeletal	O
myopathy	O
but	O
without	O
known	O
cardiac	O
disease	O
,	O
underwent	O
a	O
thorough	O
evaluation	O
including	O
BNPs	B-P
,	O
galectin-3	B-P
,	O
soluble	B-P
suppression	I-P
of	O
tumorigenesis	O
2	O
(	O
sST2	B-P
)	O
,	O
high	O
sensitivity	O
troponin	B-P
T/I	I-P
,	O
catecholamines	B-P
,	O
ECG	O
,	O
24-h	O
ECG	O
recording	O
,	O
cardiopulmonary	B-P
exercise	I-P
testing	I-P
,	O
echocardiography	B-P
,	O
cardiac/muscle	B-P
magnetic	I-P
resonance	I-P
(	O
C/MMR	B-P
)	O
,	O
and	O
ergoreflex	O
assessment	O
.	O

Thirteen	O
age-	O
and	O
sex-matched	O
healthy	O
controls	O
were	O
chosen	O
.	O

Among	O
these	O
myopathic	O
patients	O
,	O
subclinical	O
cardiac	O
damage	O
was	O
detected	O
in	O
up	O
to	O
80	O
%	O
,	O
with	O
44	O
%	O
showing	O
fibrosis	O
at	O
CMR	B-P
.	O

Ergoreflex	O
sensitivity	O
was	O
markedly	O
higher	O
in	O
patients	O
than	O
in	O
controls	O
(	O
64	O
%	O
vs.	O
37	O
%	O
,	O
P	O
<	O
0.001	O
)	O
,	O
and	O
correlated	O
with	O
muscle	O
fat	O
to	O
water	O
ratio	O
and	O
extracellular	O
volume	O
at	O
MMR	B-P
(	O
both	O
P	O
<	O
0.05	O
)	O
.	O

Among	O
patients	O
,	O
ergoreflex	O
sensitivity	O
was	O
higher	O
in	O
those	O
with	O
cardiac	O
involvement	O
(	O
P	O
=	O
0.034	O
)	O
.	O

Patients	O
showed	O
a	O
lower	O
peak	O
oxygen	O
consumption	O
(	O
VO2	O
/kg	O
)	O
than	O
controls	O
(	O
P	O
<	O
0.001	O
)	O
,	O
as	O
well	O
as	O
ventilatory	O
inefficiency	O
(	O
P	O
=	O
0.024	O
)	O
.	O

Ergoreflex	O
sensitivity	O
correlated	O
with	O
reduced	O
workload	O
and	O
peak	O
VO2	O
/kg	O
(	O
both	O
P	O
<	O
0.001	O
)	O
,	O
and	O
several	O
indicators	O
of	O
autonomic	O
imbalance	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Plasma	O
norepinephrine	O
was	O
the	O
unique	O
predictor	O
of	O
myocardial	O
fibrosis	O
at	O
univariate	O
analysis	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Skeletal	O
myopathy	O
in	O
MD	O
is	O
characterized	O
by	O
enhanced	O
ergoreflex	O
sensitivity	O
,	O
which	O
is	O
associated	O
with	O
a	O
higher	O
incidence	O
of	O
cardiac	O
involvement	O
,	O
exercise	O
intolerance	O
,	O
and	O
sympathetic	O
activation	O
.	O

Transcriptome	O
and	O
Metabolome	O
Analyses	O
of	O
Glucosinolates	O
in	O
Two	O
Broccoli	O
Cultivars	O
Following	O
Jasmonate	O
Treatment	O
for	O
the	O
Induction	O
of	O
Glucosinolate	O
Defense	O
to	O
Trichoplusia	O
ni	O
(	O
Hübner	O
)	O
.	O

Lepidopteran	O
larvae	O
growth	O
is	O
influenced	O
by	O
host	O
plant	O
glucosinolate	O
(	O
GS	O
)	O
concentrations	O
,	O
which	O
are	O
,	O
in	O
turn	O
,	O
influenced	O
by	O
the	O
phytohormone	O
jasmonate	O
(	O
JA	O
)	O
.	O

In	O
order	O
to	O
elucidate	O
insect	O
resistance	O
biomarkers	O
to	O
lepidopteran	O
pests	O
,	O
transcriptome	O
and	O
metabolome	O
analyses	O
following	O
JA	O
treatments	O
were	O
conducted	O
with	O
two	O
broccoli	O
cultivars	O
,	O
Green	O
Magic	O
and	O
VI-158	O
,	O
which	O
have	O
differentially	O
induced	O
indole	O
GSs	O
,	O
neoglucobrassicin	O
and	O
glucobrassicin	O
,	O
respectively	O
.	O

To	O
test	O
these	O
two	O
inducible	O
GSs	O
on	O
growth	O
of	O
cabbage	O
looper	O
(	O
Trichoplusia	O
ni	O
)	O
,	O
eight	O
neonate	O
cabbage	O
looper	O
larvae	O
were	O
placed	O
onto	O
each	O
of	O
three	O
plants	O
per	O
JA	O
treatments	O
(	O
0	O
,	O
100	O
,	O
200	O
,	O
400	O
µM	O
)	O
three	O
days	O
after	O
treatment	O
.	O

After	O
five	O
days	O
of	O
feeding	O
,	O
weight	O
of	O
larvae	O
and	O
their	O
survival	O
rate	O
was	O
found	O
to	O
decrease	O
with	O
increasing	O
JA	O
concentrations	O
in	O
both	O
broccoli	O
cultivars	O
.	O

JA	O
-	O
inducible	O
GSs	O
were	O
measured	O
by	O
high	B-P
performance	I-P
liquid	I-P
chromatography	I-P
.	O

Neoglucobrassicin	O
in	O
Green	O
Magic	O
and	O
glucobrassicin	O
in	O
VI-158	O
leaves	O
were	O
increased	O
in	O
a	O
dose-dependent	O
manner	O
.	O

One	O
or	O
both	O
of	O
these	O
glucosinolates	O
and/or	O
their	O
hydrolysis	O
products	O
showed	O
significant	O
inverse	O
correlations	O
with	O
larval	O
weight	O
and	O
survival	O
(	O
five	O
days	O
after	O
treatment	O
)	O
while	O
being	O
positively	O
correlated	O
with	O
the	O
number	O
of	O
days	O
to	O
pupation	O
.	O

This	O
implies	O
that	O
these	O
two	O
JA	O
-	O
inducible	O
glucosinolates	O
can	O
influence	O
the	O
growth	O
and	O
survival	O
of	O
cabbage	O
looper	O
larvae	O
.	O

Transcriptome	O
profiling	O
supported	O
the	O
observed	O
changes	O
in	O
glucosinolate	O
and	O
their	O
hydrolysis	O
product	O
concentrations	O
following	O
JA	O
treatments	O
.	O

Several	O
genes	O
related	O
to	O
GS	O
metabolism	O
differentiate	O
the	O
two	O
broccoli	O
cultivars	O
in	O
their	O
pattern	O
of	O
transcriptional	O
response	O
to	O
JA	O
treatments	O
.	O

Indicative	O
of	O
the	O
corresponding	O
change	O
in	O
indole	O
GS	O
concentrations	O
,	O
transcripts	O
of	O
the	O
transcription	O
factor	O
MYB122	O
,	O
core	O
structure	O
biosynthesis	O
genes	O
(	O
CYP79B2	O
,	O
UGT74B1	O
,	O
SUR1	O
,	O
SOT16	O
,	O
SOT17	O
,	O
and	O
SOT18	O
)	O
,	O
an	O
indole	O
glucosinolate	O
side	O
chain	O
modification	O
gene	O
(	O
IGMT1	O
)	O
,	O
and	O
several	O
glucosinolate	O
hydrolysis	O
genes	O
(	O
TGG1	O
,	O
TGG2	O
,	O
and	O
ESM1	O
)	O
were	O
significantly	O
increased	O
in	O
Green	O
Magic	O
(	O
statistically	O
significant	O
in	O
most	O
cases	O
at	O
400	O
µM	O
)	O
while	O
UGT74B1	O
and	O
MYB122	O
were	O
significantly	O
increased	O
in	O
VI-158	O
.	O

Therefore	O
,	O
these	O
metabolite	O
and	O
transcript	O
biomarker	O
results	O
indicate	O
that	O
transcriptome	O
profiling	O
can	O
identify	O
genes	O
associated	O
with	O
the	O
formation	O
of	O
two	O
different	O
indole	O
GS	O
and	O
their	O
hydrolysis	O
products	O
.	O

Therefore	O
,	O
these	O
metabolite	O
and	O
transcript	O
biomarkers	O
could	O
be	O
useful	O
in	O
an	O
effective	O
marker	O
-	O
assisted	O
breeding	O
strategy	O
for	O
resistance	O
to	O
generalist	O
lepidopteran	O
pests	O
in	O
broccoli	O
and	O
potentially	O
other	O
Brassica	O
vegetables	O
.	O

A	O
novel	O
quantitative	O
PCR	O
detects	O
Babesia	O
infection	O
in	O
patients	O
not	O
identified	O
by	O
currently	O
available	O
non-nucleic	B-P
acid	I-P
amplification	I-P
tests	I-P
.	O

Ticks	O
transmit	O
Babesia	O
microti	O
,	O
the	O
causative	O
agents	O
of	O
babesiosis	O
in	O
North	O
America	O
and	O
Europe	O
.	O

Babesiosis	O
is	O
now	O
endemic	O
in	O
Northeastern	O
USA	O
and	O
affects	O
people	O
of	O
all	O
ages	O
.	O

Babesia	O
species	O
infect	O
erythrocytes	O
and	O
can	O
be	O
transmitted	O
through	O
blood	O
transfusion	O
.	O

Whole	O
blood	O
and	O
blood	O
products	O
,	O
which	O
are	O
not	O
tested	O
for	O
Babesia	O
,	O
can	O
cause	O
transfusion	O
-	O
transmitted	O
babesiosis	O
(	O
TTB	O
)	O
resulting	O
in	O
severe	O
consequences	O
in	O
the	O
immuno-compromised	O
patients	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
epidemiological	O
evaluation	O
of	O
babesiosis	O
in	O
a	O
tick-infested	O
state	O
.	O

We	O
examined	O
blood	O
samples	O
from	O
192	O
patients	O
who	O
visited	O
clinics	O
during	O
the	O
active	O
tick-borne	O
diseases	O
season	O
,	O
using	O
a	O
newly	O
developed	O
qPCR	O
assay	O
that	O
uses	O
the	O
specific	O
molecular	O
beacon	O
probe	O
.	O

Due	O
to	O
the	O
absence	O
of	O
clear	O
symptomology	O
,	O
clinical	O
laboratories	O
did	O
not	O
test	O
131	O
samples	O
by	O
IFA	B-P
,	O
FISH	O
or	O
microscopic	B-P
examination	I-P
of	O
Giemsa-stained	O
blood	B-P
smears	I-P
.	O

Babesia	O
infection	O
was	O
detected	O
in	O
all	O
age	O
groups	O
by	O
FISH	O
and	O
microscopy	B-P
;	O
notably	O
patients	O
>	O
40	O
years	O
of	O
age	O
represented	O
64	O
%	O
of	O
tested	O
samples	O
and	O
13	O
%	O
were	O
younger	O
patients	O
.	O

We	O
tested	O
all	O
samples	O
using	O
qPCR	O
and	O
found	O
that	O
38	O
%	O
were	O
positive	O
for	O
Babesia	O
.	O

Of	O
28	O
samples	O
that	O
were	O
positive	O
by	O
FISH	O
,	O
27	O
(	O
96	O
%	O
)	O
were	O
also	O
positive	O
by	O
qPCR	O
indicating	O
high	O
congruency	O
between	O
nucleic	B-P
acid	I-P
based	I-P
tests	I-P
.	O

Interestingly	O
,	O
of	O
78	O
asymptomatic	O
samples	O
not	O
tested	O
by	O
FISH	O
,	O
22	O
were	O
positive	O
by	O
our	O
qPCR	O
.	O

Direct	O
detection	O
of	O
Babesia	O
relies	O
upon	O
microscopic	B-P
examination	I-P
of	O
patient	O
blood	B-P
smears	I-P
,	O
which	O
is	O
labor	O
intensive	O
,	O
difficult	O
to	O
scale	O
up	O
,	O
requires	O
specific	O
expertise	O
and	O
is	O
hence	O
,	O
often	O
not	O
performed	O
.	O

In	O
fact	O
,	O
a	O
clinical	O
laboratory	O
examined	O
only	O
23	O
of	O
86	O
blood	O
samples	O
obtained	O
from	O
two	O
different	O
counties	O
by	O
microscopy	B-P
.	O

By	O
considering	O
individuals	O
positive	O
for	O
Babesia	O
infection	O
when	O
results	O
from	O
currently	O
available	O
microscopy	B-P
,	O
FISH	O
or	O
serological	B-P
tests	I-P
were	O
positive	O
,	O
we	O
found	O
that	O
our	O
qPCR	O
is	O
highly	O
sensitive	O
(	O
96.2	O
%	O
)	O
and	O
showed	O
a	O
specificity	O
of	O
70.5	O
%	O
for	O
Babesia	O
.	O

Robust	O
qPCR	O
using	O
specific	O
probes	O
can	O
be	O
highly	O
useful	O
for	O
efficient	O
and	O
appropriate	O
diagnosis	O
of	O
babesiosis	O
in	O
patients	O
in	O
conjunction	O
with	O
conventional	O
diagnostics	O
,	O
or	O
as	O
a	O
stand-alone	O
test	O
,	O
especially	O
for	O
donated	O
blood	B-P
screening	I-P
.	O

The	O
use	O
of	O
a	O
nucleic	B-P
acid	I-P
amplification	I-P
test	I-P
based	O
screening	B-P
of	I-P
blood	I-P
and	O
blood	O
products	O
could	O
prevent	O
TTB	O
.	O

A	O
miniature	O
bird	O
-borne	O
passive	O
air	O
sampler	O
for	O
monitoring	O
halogenated	O
flame	O
retardants	O
.	O

Birds	O
have	O
been	O
used	O
intensively	O
as	O
biomonitors	O
of	O
halogenated	O
flame	O
retardants	O
(	O
HFRs	O
)	O
,	O
and	O
several	O
studies	O
have	O
reported	O
elevated	O
tissue	O
concentrations	O
and	O
inter-	O
individual	O
variability	O
for	O
these	O
contaminants	O
.	O

While	O
diet	O
is	O
known	O
to	O
be	O
an	O
important	O
exposure	O
pathway	O
for	O
HFRs	O
in	O
birds	O
,	O
it	O
has	O
been	O
suggested	O
that	O
exposure	O
through	O
air	O
may	O
represent	O
an	O
underestimated	O
source	O
of	O
HFRs	O
for	O
certain	O
species	O
.	O

However	O
,	O
a	O
method	O
was	O
not	O
available	O
for	O
measuring	O
the	O
atmospheric	O
exposure	O
of	O
individual	O
birds	O
to	O
HFRs	O
or	O
other	O
semi-volatile	O
contaminants	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
develop	O
a	O
bird	O
-borne	O
passive	O
air	O
sampler	O
(	O
PAS	O
)	O
enabling	O
the	O
determination	B-P
of	O
individual	O
atmospheric	O
exposure	O
to	O
gas	O
-	O
and	O
particle-phase	O
HFRs	O
using	O
the	O
ring-billed	O
gull	O
(	O
Larus	O
delawarensis	O
)	O
nesting	O
in	O
the	O
Montreal	O
area	O
(	O
QC	O
,	O
Canada	O
)	O
.	O

The	O
new	O
miniaturized	O
elliptical-shaped	O
PAS	O
(	O
mean	O
weight	O
:	O
2.72g	O
)	O
was	O
tested	O
using	O
two	B-P
sorbent	I-P
types	I-P
during	O
three	O
exposure	O
periods	O
(	O
one	O
,	O
two	O
and	O
three	O
weeks	O
)	O
.	O

Results	O
showed	O
that	O
PAS	O
using	O
polyurethane	O
foam	O
(	O
PUF	O
)	O
combined	O
with	O
a	O
glass	O
fiber	O
filter	O
collected	O
all	O
major	O
polybrominated	O
diphenyl	O
ethers	O
(	O
PBDEs	O
)	O
and	O
exhibited	O
better	O
performance	O
for	O
collecting	O
highly	O
hydrophobic	O
DecaBDE	O
mixture	O
congeners	O
compared	O
to	O
the	O
PAS	O
using	O
polydimethylsiloxane	O
(	O
PDMS	O
)	O
.	O

Emerging	O
HFRs	O
including	O
hexabromobenzene	O
,	O
Dechlorane	O
604	O
Component	O
B	O
,	O
and	O
Dechlorane	O
plus	O
(	O
DP	O
)	O
isomers	O
also	O
were	O
sampled	B-P
by	O
the	O
PUF	O
-based	O
PAS	O
.	O

Sampling	B-P
rates	O
for	O
most	O
HFRs	O
were	O
comparable	O
between	O
the	O
three	O
exposure	O
periods	O
.	O

This	O
novel	O
bird	O
-borne	O
PAS	O
provides	O
valuable	O
information	O
on	O
the	O
non-dietary	O
exposure	O
of	O
free-ranging	O
birds	O
to	O
HFRs	O
.	O

Evaluation	O
of	O
analytical	O
methods	O
for	O
the	O
determination	B-P
of	O
the	O
physicochemical	O
properties	O
of	O
fermented	O
,	O
granulated	O
,	O
and	O
roasted	O
cassava	O
pulp	O
-	O
gari	O
.	O

Simple	O
but	O
reliable	O
methods	O
for	O
the	O
determination	B-P
of	O
the	O
physicochemical	O
properties	O
of	O
gari	O
were	O
evaluated	O
for	O
the	O
parameters	O
,	O
such	O
as	O
grain	O
size	O
,	O
bulk	O
density	O
,	O
swelling	O
index	O
,	O
moisture	O
content	O
,	O
gross	O
calorific	O
value	O
,	O
cyanide	O
content	O
,	O
and	O
acidity	O
content	O
.	O

The	O
grain	O
sizes	O
were	O
between	O
525	O
and	O
928	O
μm	O
(	O
weighted	O
means	O
)	O
,	O
the	O
bulk	O
densities	O
between	O
0.541	O
and	O
0.699	O
g/cm³	O
,	O
and	O
the	O
swelling	O
indices	O
between	O
3.21	O
and	O
4.33	O
.	O

The	O
moisture	O
contents	O
ranged	O
from	O
4.30	O
to	O
9.19	O
%	O
.	O

The	O
gross	O
calorific	O
values	O
were	O
found	O
between	O
15.45	O
and	O
15.82	O
kJ/g	O
.	O

The	O
cyanide	O
contents	O
were	O
between	O
0	O
and	O
4.8	O
ppm	O
.	O

The	O
acidity	O
contents	O
varied	O
among	O
0.55	O
and	O
1.62	O
%	O
.	O

Correlation	O
tests	O
verified	O
the	O
influences	O
of	O
the	O
grain	O
size	O
and	O
the	O
moisture	O
content	O
on	O
the	O
acidity	O
content	O
with	O
a	O
probability	O
of	O
99.9	O
%	O
.	O

The	O
methods	O
were	O
regarded	O
as	O
suitable	O
and	O
adaptable	O
for	O
the	O
application	O
in	O
small	O
and	O
medium	O
cassava	O
-	O
processing	O
industries	O
with	O
special	O
regard	O
to	O
the	O
respect	O
of	O
the	O
consumer	O
`	O
s	O
health	O
safety	O
.	O

Sensitivity	O
and	O
Specificity	O
of	O
Plasma	O
ALT	O
,	O
ALP	O
,	O
and	O
Bile	O
Acids	O
for	O
Hepatitis	O
in	O
Labrador	O
Retrievers	O
.	O

Biochemical	O
indicators	O
for	O
diagnosing	O
liver	O
disease	O
are	O
plasma	O
alanine	O
aminotransferase	O
activity	O
(	O
ALT	O
)	O
,	O
alkaline	O
phosphatase	O
activity	O
(	O
ALP	O
)	O
,	O
and	O
bile	B-P
acid	I-P
concentration	I-P
(	O
BA	O
)	O
.	O

To	O
determine	O
the	O
sensitivity	O
and	O
specificity	O
of	O
ALT	O
,	O
ALP	O
,	O
and	O
BA	O
for	O
detecting	O
primary	O
hepatitis	O
(	O
PH	O
)	O
in	O
clinically	O
healthy	O
Labrador	O
retrievers	O
and	O
investigate	O
whether	O
ALT	O
and	O
ALP	O
can	O
discriminate	O
between	O
dogs	O
with	O
PH	O
and	O
nonspecific	O
reactive	O
hepatitis	O
(	O
RH	O
)	O
.	O

191	O
clinically	O
healthy	O
and	O
51	O
clinically	O
ill	O
Labrador	O
retrievers	O
with	O
hepatic	O
histopathology	O
.	O

Retrospective	O
study	O
.	O

Medical	O
records	O
were	O
reviewed	O
for	O
ALT	O
,	O
ALP	O
,	O
preprandial	O
BA	O
,	O
liver	O
histopathology	O
,	O
and	O
hepatic	O
copper	O
concentrations	O
.	O

In	O
64	O
%	O
(	O
122/191	O
)	O
of	O
the	O
clinically	O
healthy	O
Labrador	O
retrievers	O
,	O
hepatic	O
histology	O
revealed	O
inflammatory	O
infiltrates	O
.	O

This	O
frequency	O
might	O
be	O
biased	O
because	O
part	O
of	O
them	O
was	O
included	O
as	O
first-line	O
relatives	O
of	O
dogs	O
with	O
copper-associated	O
hepatitis	O
.	O

Sensitivity	O
of	O
ALT	O
,	O
ALP	O
,	O
and	O
BA	O
in	O
this	O
population	O
for	O
detecting	O
acute	O
hepatitis	O
was	O
45	O
,	O
15	O
,	O
and	O
15	O
%	O
,	O
respectively	O
.	O

For	O
chronic	O
hepatitis	O
,	O
sensitivity	O
was	O
71	O
,	O
35	O
,	O
and	O
13	O
%	O
,	O
respectively	O
.	O

Specificity	O
of	O
ALT	O
,	O
ALP	O
,	O
and	O
BA	O
was	O
>	O
90	O
%	O
for	O
AH	O
,	O
CH	O
,	O
and	O
RH	O
.	O

When	O
increased	O
liver	O
enzymes	O
were	O
present	O
,	O
median	O
ALT	O
was	O
significantly	O
higher	O
in	O
PH	O
cases	O
(	O
312	O
U/L	O
,	O
range	O
38-1,369	O
)	O
compared	O
to	O
RH	O
cases	O
(	O
91	O
U/L	O
,	O
range	O
39-139	O
)	O
(	O
P	O
<	O
.001	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
ALP	O
between	O
dogs	O
with	O
a	O
PH	O
and	O
a	O
RH	O
(	O
P	O
=	O
.361	O
)	O
.	O

Histopathologic	O
abnormalities	O
in	O
the	O
liver	O
were	O
present	O
in	O
the	O
majority	O
of	O
apparent	O
clinically	O
healthy	O
Labrador	O
retrievers	O
.	O

The	O
sensitivity	O
of	O
ALT	O
,	O
ALP	O
,	O
and	O
BA	O
for	O
detecting	O
acute	O
and	O
chronic	O
hepatitis	O
in	O
this	O
population	O
was	O
low	O
.	O

More	O
sensitive	O
biomarkers	O
are	O
needed	O
for	O
early	B-P
detection	I-P
of	O
liver	O
disease	O
in	O
apparent	O
clinically	O
healthy	O
dogs	O
.	O

Subcellular	O
reprogramming	O
of	O
metabolism	O
during	O
cold	O
acclimation	O
in	O
Arabidopsis	O
thaliana	O
.	O

Metabolite	O
changes	O
in	O
plant	O
leaves	O
during	O
exposure	O
to	O
low	O
temperatures	O
involve	O
re-allocation	O
of	O
a	O
large	O
number	O
of	O
metabolites	O
between	O
sub-cellular	O
compartments	O
.	O

Therefore	O
,	O
metabolite	O
determination	B-P
at	O
the	O
whole	O
cell	O
level	O
may	O
be	O
insufficient	O
for	O
interpretation	O
of	O
the	O
functional	O
significance	O
of	O
cellular	O
compounds	O
.	O

To	O
investigate	O
the	O
cold	O
-	O
induced	O
metabolite	O
dynamics	O
at	O
the	O
level	O
of	O
individual	O
sub-cellular	O
compartments	O
,	O
an	O
integrative	O
platform	O
was	O
developed	O
that	O
combines	O
quantitative	O
metabolite	O
profiling	O
by	O
gas	B-P
chromatography	I-P
coupled	I-P
to	I-P
mass	I-P
spectrometry	I-P
(	O
GC-MS	B-P
)	O
with	O
the	O
non-aqueous	B-P
fractionation	I-P
technique	I-P
allowing	O
separation	O
of	O
cytosol	O
,	O
vacuole	O
and	O
the	O
plastidial	O
compartment	O
.	O

Two	O
mutants	O
of	O
Arabidopsis	O
thaliana	O
representing	O
antipodes	O
in	O
the	O
diversion	O
of	O
carbohydrate	O
metabolism	O
between	O
sucrose	O
and	O
starch	O
were	O
compared	O
to	O
Col-0	O
wildtype	O
before	O
and	O
after	O
cold	O
acclimation	O
to	O
investigate	O
interactions	O
of	O
cold	O
acclimation	O
with	O
subcellular	O
re-programming	O
of	O
metabolism	O
.	O

A	O
multivariate	O
analysis	O
of	O
the	O
data	O
set	O
revealed	O
dominant	O
effects	O
of	O
compartmentation	O
on	O
metabolite	O
concentrations	O
that	O
were	O
modulated	O
by	O
environmental	O
condition	O
and	O
genetic	O
determinants	O
.	O

While	O
for	O
both	O
,	O
the	O
starchless	O
mutant	O
of	O
plastidial	O
phospho-gluco	O
mutase	O
(	O
pgm	O
)	O
and	O
a	O
mutant	O
defective	O
in	O
sucrose-phosphate	O
synthase	O
A1	O
,	O
metabolic	O
constraints	O
,	O
especially	O
at	O
low	O
temperature	O
,	O
could	O
be	O
uncovered	O
based	O
on	O
subcellularly	O
resolved	O
metabolite	O
profiles	O
,	O
only	O
pgm	O
had	O
lowered	O
freezing	O
tolerance	O
.	O

Metabolic	O
profiles	O
of	O
pgm	O
point	O
to	O
redox	O
imbalance	O
as	O
a	O
possible	O
reason	O
for	O
reduced	O
cold	O
acclimation	O
capacity	O
.	O

Solifenacin	O
in	O
the	O
Elderly	O
:	O
Results	O
of	O
an	O
Observational	O
Study	O
Measuring	O
Efficacy	O
,	O
Tolerability	O
and	O
Cognitive	O
Effects	O
.	O

The	O
study	O
aimed	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
solifenacin	O
in	O
older	O
patients	O
with	O
overactive	O
bladder	O
(	O
OAB	O
)	O
.	O

Observational	O
data	O
on	O
patients	O
aged	O
≥70	O
years	O
and	O
the	O
prescribed	O
flexible	O
dose	O
of	O
solifenacin	O
for	O
OAB	O
were	O
collected	O
at	O
294	O
offices	O
of	O
German	O
general	O
practitioners	O
.	O

Baseline	O
and	O
week	O
12	O
data	O
included	O
type	O
and	O
severity	O
of	O
OAB	O
symptoms	O
,	O
adverse	O
events	O
,	O
quality	O
of	O
life	O
,	O
and	O
change	O
in	O
cognitive	O
function	O
per	O
Mini	B-P
Mental	I-P
State	I-P
Examination	I-P
(	O
MMSE	B-P
)	O
.	O

Mean	O
age	O
of	O
774	O
patients	O
was	O
78	O
±	O
6	O
years	O
.	O

A	O
decrease	O
was	O
observed	O
in	O
all	O
OAB	O
symptoms	O
including	O
a	O
reduction	O
of	O
urinary	O
urgency	O
and	O
micturition	O
,	O
each	O
by	O
4	O
episodes	O
per	O
24	O
h.	O
No	O
change	O
in	O
mean	O
MMSE	O
score	O
s	O
was	O
apparent	O
at	O
week	O
12	O
.	O

Adverse	O
events	O
and	O
treatment	O
discontinuations	O
were	O
low	O
at	O
5.8	O
and	O
0.5	O
%	O
,	O
respectively	O
.	O

Solifenacin	O
was	O
well-tolerated	O
while	O
OAB	O
symptoms	O
declined	O
at	O
week	O
12	O
.	O

No	O
relevant	O
effect	O
of	O
solifenacin	O
on	O
cognitive	O
function	O
was	O
observed	O
in	O
this	O
elderly	O
population	O
.	O

Mercury	O
Mining	O
in	O
Mexico	O
:	O
I	O
.	O

Community	O
Engagement	O
to	O
Improve	O
Health	O
Outcomes	O
from	O
Artisanal	O
Mining	O
.	O

Mercury	O
is	O
an	O
element	O
that	O
can	O
not	O
be	O
destroyed	O
and	O
is	O
a	O
global	O
threat	O
to	O
human	O
and	O
environmental	O
health	O
.	O

In	O
Latin	O
America	O
and	O
the	O
Caribbean	O
,	O
artisanal	O
and	O
small-scale	O
gold	O
mining	O
represents	O
the	O
main	O
source	O
of	O
mercury	O
emissions	O
,	O
releases	O
,	O
and	O
consumption	O
.	O

However	O
,	O
another	O
source	O
of	O
concern	O
is	O
the	O
primary	O
production	O
of	O
mercury	O
.	O

In	O
the	O
case	O
of	O
Mexico	O
,	O
in	O
the	O
past	O
2	O
years	O
the	O
informal	O
production	O
of	O
mercury	O
mining	O
has	O
increased	O
10-fold	O
.	O

Considering	O
this	O
scenario	O
,	O
an	O
intervention	O
program	O
was	O
initiated	O
to	O
reduce	O
health	O
risks	O
in	O
the	O
mining	O
communities	O
.	O

The	O
program	O
's	O
final	O
goal	O
is	O
to	O
introduce	O
different	O
alternatives	O
in	O
line	O
to	O
stop	O
the	O
mining	O
of	O
mercury	O
,	O
but	O
introducing	O
at	O
the	O
same	O
time	O
,	O
a	O
community	O
-based	O
development	O
program	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
present	O
results	O
from	O
a	O
preliminary	O
study	O
in	O
the	O
community	O
of	O
Plazuela	O
,	O
located	O
in	O
the	O
municipality	O
of	O
Peñamiller	O
in	O
the	O
State	O
of	O
Queretaro	O
,	O
Mexico	O
.	O

Total	O
mercury	O
was	O
measured	O
in	O
urine	O
and	O
environmental	O
samples	O
using	O
atomic	B-P
absorption	I-P
spectrometry	I-P
by	I-P
cold	I-P
vapor	I-P
technique	I-P
.	O

Urine	O
samples	O
were	O
collected	O
from	O
children	O
aged	O
6-14	O
years	O
and	O
who	O
had	O
lived	O
in	O
the	O
selected	O
area	O
from	O
birth	O
.	O

Urine	O
samples	O
were	O
also	O
collected	O
from	O
miners	O
who	O
were	O
currently	O
working	O
in	O
the	O
mine	O
.	O

To	O
confirm	O
the	O
presence	O
of	O
mercury	O
in	O
the	O
community	O
,	O
mining	O
waste	O
,	O
water	O
,	O
soil	O
,	O
and	O
sediment	O
samples	O
were	O
collected	O
from	O
those	O
high-risk	O
areas	O
identified	O
by	O
members	O
of	O
the	O
community	O
.	O

Children	O
,	O
women	O
,	O
and	O
miners	O
were	O
heavily	O
exposed	O
to	O
mercury	O
(	O
urine	O
samples	O
)	O
;	O
and	O
in	O
agreement	O
,	O
we	O
registered	O
high	O
concentrations	O
of	O
mercury	O
in	O
soils	O
and	O
sediments	O
.	O

Considering	O
these	O
results	O
and	O
taking	O
into	O
account	O
that	O
the	O
risk	O
perception	O
toward	O
mercury	O
toxicity	O
is	O
very	O
low	O
in	O
the	O
community	O
(	O
mining	O
is	O
the	O
only	O
economic	O
activity	O
)	O
,	O
an	O
integral	O
intervention	O
program	O
has	O
started	O
.	O

Chondrocyte	O
proliferation	O
,	O
viability	O
and	O
differentiation	O
is	O
declined	O
following	O
administration	O
of	O
methylphenidate	O
utilized	O
for	O
the	O
treatment	O
of	O
attention-deficit/hyperactivity	O
disorder	O
.	O

Methylphenidate	O
(	O
MPH	O
)	O
derivative	O
drugs	O
are	O
used	O
because	O
of	O
psychostimulants	O
effects	O
on	O
attention-deficit	O
hyperactivity	O
disorder	O
in	O
children	O
and	O
adults	O
.	O

As	O
far	O
as	O
we	O
know	O
,	O
toxic	O
or	O
anti-proliferative	O
effects	O
of	O
MPH	O
against	O
cartilage	O
tissue	O
were	O
not	O
studied	O
in	O
the	O
literature	O
.	O

The	O
present	O
study	O
was	O
carried	O
out	O
to	O
investigate	O
the	O
possible	O
effects	O
of	O
MPH	O
on	O
the	O
proliferation	O
,	O
viability	O
and	O
differentiation	O
of	O
primary	O
human	O
chondrocytes	O
,	O
in	O
vitro	O
.	O

Monolayer	O
primary	O
chondrocyte	O
cultures	B-P
were	O
prepared	O
using	O
osteochondral	O
tissue	O
obtained	O
from	O
patients	O
who	O
underwent	O
a	O
total	O
knee	O
prosthesis	O
operation	O
.	O

Stock	O
solution	O
of	O
MPH	O
was	O
prepared	O
and	O
aliquots	O
having	O
1-1000	O
µM	O
concentrations	O
of	O
the	O
drug	O
was	O
composed	O
.	O

These	O
solutions	O
were	O
applied	O
to	O
the	O
wells	O
containing	O
cultured	O
chondrocyte	O
samples	O
within	O
the	O
well	O
plates	O
.	O

Control	O
groups	O
were	O
composed	O
of	O
pure	O
chondrocyte	O
culture	B-P
and	O
no	O
solution	O
was	O
added	O
into	O
them	O
.	O

All	O
groups	O
were	O
evaluated	O
at	O
24	O
,	O
48	O
and	O
72	O
h	O
in	O
order	O
to	O
determine	O
the	O
possible	O
negative	O
effects	O
of	O
the	O
drug	O
on	O
the	O
chondrocytes	O
.	O

The	O
data	O
were	O
evaluated	O
by	O
Tukey	O
's	O
honestly	O
significantly	O
different	O
test	O
following	O
analysis	O
of	O
variance	O
.	O

In	O
the	O
group	O
where	O
MPH	O
was	O
applied	O
,	O
it	O
was	O
found	O
that	O
viability	O
,	O
proliferation	O
and	O
stage-specific	O
embryonic	O
antigen-1	O
protein	O
expression	O
were	O
decreased	O
in	O
comparison	O
to	O
the	O
control	O
group	O
.	O

It	O
was	O
emphasized	O
that	O
clinicians	O
should	O
not	O
disregard	O
the	O
fact	O
that	O
this	O
drug	O
might	O
suppress	O
chondrocyte	O
cell	O
proliferation	O
and	O
chondrogenic	O
differentiation	O
.	O

Beneficial	O
effect	O
of	O
Cu	O
on	O
Ti-Nb-Ta-Zr	O
sputtered	O
uniform/adhesive	O
gum	O
films	O
accelerating	O
bacterial	O
inactivation	O
under	O
indoor	O
visible	O
light	O
.	O

This	O
article	O
presents	O
the	O
evidence	O
for	O
the	O
significant	O
effect	O
of	O
copper	O
accelerating	O
the	O
bacterial	O
inactivation	O
on	O
Ti-Nb-Ta-Zr	O
(	O
TNTZ	O
)	O
sputtered	O
films	O
on	O
glass	O
up	O
to	O
a	O
Cu	O
content	O
of	O
8.3	O
at.	O
%	O
.	O

These	O
films	O
were	O
deposited	O
by	O
dc	B-P
magnetron	I-P
co-sputtering	I-P
of	O
an	O
alloy	O
target	O
Ti-23Nb-0.7Ta-2Zr	O
(	O
at.	O
%	O
)	O
and	O
a	O
Cu	O
target	O
.	O

The	O
fastest	O
bacterial	O
inactivation	O
of	O
E.	O
coli	O
on	O
this	O
later	O
TNTZ	O
-	O
Cu	O
surface	O
proceeded	O
within	O
∼75	O
min	O
.	O

The	O
films	O
deposited	O
by	O
magnetron	B-P
sputtering	I-P
are	O
chemically	O
homogenous	O
.	O

The	O
film	O
roughness	O
evaluated	O
by	O
atomic	B-P
force	I-P
spectroscopy	I-P
(	O
AFM	B-P
)	O
on	O
the	O
TNTZ	O
-	O
Cu	O
8.3	O
at.	O
%	O
Cu	O
sample	O
presented	O
an	O
RMS	O
-	O
value	O
of	O
20.1nm	O
being	O
the	O
highest	O
RMS	O
of	O
any	O
Cu	O
-sputtered	O
TNTZ	O
sample	O
.	O

The	O
implication	O
of	O
the	O
RMS	O
value	O
found	O
for	O
this	O
sample	O
leading	O
to	O
the	O
fastest	O
interfacial	O
bacterial	O
inactivation	O
kinetics	O
is	O
also	O
discussed	O
.	O

Values	O
for	O
the	O
Young	O
's	O
modulus	O
and	O
hardness	O
are	O
reported	O
for	O
the	O
TNTZ	O
films	O
in	O
the	O
presence	O
of	O
various	O
Cu	O
-	O
contents	O
.	O

Evaluation	O
of	O
the	O
bacterial	O
inactivation	O
kinetics	O
of	O
E.	O
coli	O
under	O
low	O
intensity	O
actinic	O
hospital	O
light	O
and	O
in	O
the	O
dark	O
was	O
carried	O
out	O
.	O

The	O
stable	O
repetitive	O
bacterial	O
inactivation	O
was	O
consistent	O
with	O
the	O
extremely	O
low	O
Cu-ion	O
release	O
from	O
the	O
samples	O
of	O
0.4	O
ppb	O
.	O

Evidence	O
is	O
presented	O
by	O
the	O
bacterial	O
inactivation	O
dependence	O
on	O
the	O
applied	O
light	O
intensity	O
for	O
the	O
intervention	O
of	O
Cu	O
as	O
semiconductor	O
CuO	O
during	O
the	O
bacterial	O
inactivation	O
at	O
the	O
TNTZ	O
-	O
Cu	O
interface	O
.	O

The	O
mechanism	O
of	O
CuO	O
-	O
intervention	O
under	O
light	O
is	O
suggested	O
based	O
on	O
the	O
pH	O
/and	O
potential	O
changes	O
registered	O
during	O
bacterial	O
disinfection	O
.	O

Reduction	O
in	O
Hospital-Wide	O
Clinical	B-P
Laboratory	I-P
Specimen	I-P
Identification	I-P
Errors	O
following	O
Process	O
Interventions	O
:	O
A	O
10-	O
Year	O
Retrospective	O
Observational	O
Study	O
.	O

Accurate	O
patient	O
identification	O
and	O
specimen	O
labeling	O
at	O
the	O
time	O
of	O
collection	O
are	O
crucial	O
steps	O
in	O
the	O
prevention	O
of	O
medical	O
errors	O
,	O
thereby	O
improving	O
patient	O
safety	O
.	O

All	O
patient	O
specimen	O
identification	O
errors	O
that	O
occurred	O
in	O
the	O
outpatient	O
department	O
(	O
OPD	O
)	O
,	O
emergency	O
department	O
(	O
ED	O
)	O
,	O
and	O
inpatient	O
department	O
(	O
IPD	O
)	O
of	O
a	O
3,800-	O
bed	O
academic	O
medical	O
center	O
in	O
Taiwan	O
were	O
documented	O
and	O
analyzed	O
retrospectively	O
from	O
2005	O
to	O
2014	O
.	O

To	O
reduce	O
such	O
errors	O
,	O
the	O
following	O
series	O
of	O
strategies	O
were	O
implemented	O
:	O
a	O
restrictive	O
specimen	O
acceptance	O
policy	O
for	O
the	O
ED	O
and	O
IPD	O
in	O
2006	O
;	O
a	O
computer-assisted	B-P
barcode	O
positive	O
patient	O
identification	O
system	O
for	O
the	O
ED	O
and	O
IPD	O
in	O
2007	O
and	O
2010	O
,	O
and	O
automated	O
sample	O
labeling	O
combined	O
with	O
electronic	O
identification	O
systems	O
introduced	O
to	O
the	O
OPD	O
in	O
2009	O
.	O

Of	O
the	O
2000345	O
specimens	O
collected	O
in	O
2005	O
,	O
1023	O
(	O
0.0511	O
%	O
)	O
were	O
identified	O
as	O
having	O
patient	O
identification	O
errors	O
,	O
compared	O
with	O
58	O
errors	O
(	O
0.0015	O
%	O
)	O
among	O
3761238	O
specimens	O
collected	O
in	O
2014	O
,	O
after	O
serial	O
interventions	O
;	O
this	O
represents	O
a	O
97	O
%	O
relative	O
reduction	O
.	O

The	O
total	O
number	O
(	O
rate	O
)	O
of	O
institutional	O
identification	O
errors	O
contributed	O
from	O
the	O
ED	O
,	O
IPD	O
,	O
and	O
OPD	O
over	O
a	O
10-	O
year	O
period	O
were	O
423	O
(	O
0.1058	O
%	O
)	O
,	O
556	O
(	O
0.0587	O
%	O
)	O
,	O
and	O
44	O
(	O
0.0067	O
%	O
)	O
errors	O
before	O
the	O
interventions	O
,	O
and	O
3	O
(	O
0.0007	O
%	O
)	O
,	O
52	O
(	O
0.0045	O
%	O
)	O
and	O
3	O
(	O
0.0001	O
%	O
)	O
after	O
interventions	O
,	O
representing	O
relative	O
99	O
%	O
,	O
92	O
%	O
and	O
98	O
%	O
reductions	O
,	O
respectively	O
.	O

Accurate	O
patient	O
identification	O
is	O
a	O
challenge	O
of	O
patient	O
safety	O
in	O
different	O
health	O
settings	O
.	O

The	O
data	O
collected	O
in	O
our	O
study	O
indicate	O
that	O
a	O
restrictive	O
specimen	O
acceptance	O
policy	O
,	O
computer-generated	B-P
positive	O
identification	O
systems	O
,	O
and	O
interdisciplinary	O
cooperation	O
can	O
significantly	O
reduce	O
patient	O
identification	O
errors	O
.	O

γ-Butenolide	O
and	O
furanone	O
derivatives	O
from	O
the	O
soil	O
-derived	O
fungus	O
Aspergillus	O
sclerotiorum	O
PSU-RSPG178	O
.	O

Chromatographic	B-P
separation	I-P
of	O
the	O
broth	O
extract	O
of	O
the	O
soil	O
-derived	O
fungus	O
Aspergillus	O
sclerotiorum	O
PSU-RSPG178	O
resulted	O
in	O
isolation	O
of	O
four	O
γ-butenolide-furanone	O
dimers	O
,	O
aspersclerotiorones	O
A-D	O
,	O
a	O
furanone	O
derivative	O
,	O
aspersclerotiorone	O
E	O
,	O
and	O
two	O
γ-butenolide	O
derivatives	O
,	O
aspersclerotiorones	O
F	O
and	O
G	O
,	O
together	O
with	O
six	O
known	O
compounds	O
,	O
penicillic	O
acid	O
,	O
dihydropenicillic	O
acid	O
,	O
5,6-dihydro-6-hydroxypenicillic	O
acid	O
,	O
6-methoxy-5,6-dihydropenicillic	O
acid	O
,	O
coculnol	O
and	O
(	O
4R,5R	O
)	O
-4,5-dihydroxy-3-methoxy-5-methylcyclohex-2-en-1-one	O
.	O

Their	O
structures	O
were	O
determined	O
by	O
spectroscopic	B-P
evidence	I-P
.	O

For	O
aspersclerotiorones	O
A	O
and	O
B	O
,	O
the	O
structures	O
were	O
confirmed	O
by	O
single-crystal	B-P
X-ray	I-P
diffraction	I-P
crystallography	I-P
.	O

Penicillic	O
acid	O
displayed	O
weak	O
antibacterial	O
activity	O
against	O
Staphylococcus	O
aureus	O
and	O
Escherichia	O
coli	O
with	O
equal	O
MIC	O
values	O
of	O
128	O
μg/mL	O
,	O
and	O
it	O
was	O
noncytotoxic	O
towards	O
African	O
green	O
monkey	O
kidney	O
fibroblast	O
cells	O
.	O

MicroRNA-26a	O
protects	O
against	O
cardiac	O
hypertrophy	O
via	O
inhibiting	O
GATA4	O
in	O
rat	O
model	O
and	O
cultured	O
cardiomyocytes..	O
Pathological	O
cardiac	O
hypertrophy	O
is	O
characterized	O
by	O
deleterious	O
changes	O
developed	O
in	O
cardiovascular	O
diseases	O
,	O
whereas	O
microRNAs	O
(	O
miRNAs	O
)	O
are	O
involved	O
in	O
the	O
mediation	O
of	O
cardiac	O
hypertrophy	O
.	O

To	O
investigate	O
the	O
role	O
of	O
microRNA-26a	O
(	O
miR-26a	O
)	O
in	O
regulating	O
cardiac	O
hypertrophy	O
and	O
its	O
functioning	O
mechanisms	O
,	O
overexpression	O
and	O
suppression	O
of	O
miR-26a	O
via	O
its	O
mimic	O
and	O
inhibitor	O
in	O
a	O
transverse	O
abdominal	O
aortic	O
constriction	O
(	O
TAAC	O
)	O
-	O
induced	O
rat	O
model	O
and	O
in	O
angiotensin	O
II	O
(	O
Ang	O
II	O
)	O
-	O
induced	O
cardiomyocytes	O
(	O
CMs	O
)	O
was	O
performed	O
.	O

In	O
the	O
rat	O
model	O
,	O
the	O
heart	O
weight	O
(	O
HW	O
)	O
compared	O
with	O
the	O
body	O
weight	O
(	O
BW	O
)	O
,	O
the	O
CM	O
area	O
,	O
and	O
expression	O
of	O
the	O
hypertrophy	O
-	O
associated	O
factors	O
,	O
atrial	O
natriuretic	O
factor	O
(	O
ANF	O
)	O
and	O
ß-myosin	O
heavy	O
chain	O
(	O
ß-MHC	O
)	O
,	O
were	O
assessed	O
.	O

In	O
CMs	O
,	O
the	O
protein	O
synthesis	O
rate	O
was	O
determined	O
using	O
a	O
leucine	B-P
incorporation	I-P
assay	I-P
.	O

Mutation	O
of	O
the	O
GATA-binding	O
protein	O
4	O
(	O
GATA4	O
)	O
3'-untranslated	O
region	O
(	O
UTR	O
)	O
and	O
overexpression	O
of	O
GATA4	O
were	O
performed	O
to	O
confirm	O
whether	O
GATA4	O
is	O
the	O
target	O
of	O
miR-26a	O
.	O

The	O
results	O
indicated	O
that	O
miR-26a	O
was	O
significantly	O
downregulated	O
in	O
the	O
heart	O
tissue	O
of	O
the	O
rat	O
model	O
,	O
as	O
well	O
as	O
in	O
Ang	O
II	O
-	O
induced	O
CMs	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
TAAC	O
-	O
induced	O
rat	O
model	O
exhibited	O
a	O
higher	O
HW	O
/	O
BW	O
ratio	O
,	O
a	O
larger	O
CM	O
area	O
,	O
and	O
higher	O
expression	O
levels	O
of	O
ANF	O
and	O
ß-MHC	O
.	O

CMs	O
,	O
upon	O
Ang	O
II	O
treatment	O
,	O
also	O
demonstrated	O
a	O
larger	O
CM	O
area	O
,	O
higher	O
levels	O
of	O
ANF	O
and	O
ß-MHC	O
,	O
as	O
well	O
as	O
accelerated	O
protein	O
synthesis	O
.	O

miR-26a	O
was	O
not	O
able	O
to	O
regulate	O
GATA4	O
with	O
mutations	O
in	O
the	O
3'-UTR	O
,	O
indicating	O
that	O
GATA4	O
was	O
the	O
direct	O
target	O
of	O
miR-26a	O
.	O

Overexpression	O
of	O
GATA4	O
abrogated	O
the	O
inhibitory	O
functions	O
of	O
miR-26a	O
in	O
cardiac	O
hypertrophy	O
.	O

Taken	O
together	O
,	O
the	O
present	O
study	O
suggested	O
an	O
anti-hypertrophic	O
role	O
of	O
miR-26a	O
in	O
cardiac	O
hypertrophy	O
,	O
possibly	O
via	O
inhibition	O
of	O
GATA4	O
.	O

These	O
findings	O
may	O
be	O
useful	O
in	O
terms	O
of	O
facilitating	O
cardiac	O
treatment	O
,	O
with	O
potential	O
therapeutic	O
targets	O
and	O
strategies	O
.	O

Three-Dimensional	O
HyCoSy	B-P
With	O
Perfluoropropane-Albumin	O
Microspheres	O
as	O
Contrast	O
Agents	O
and	O
Normal	O
Saline	O
Injections	O
Into	O
the	O
Pelvic	O
Cavity	O
for	O
Morphological	O
Assessment	O
of	O
the	O
Fallopian	O
Tube	O
in	O
Infertile	O
Women	O
.	O

To	O
apply	O
the	O
three-dimensional	O
(	O
3D	O
)	O
hysterosalpingo-contrast	B-P
sonography	I-P
(	O
HyCoSy	B-P
)	O
with	O
perfluoropropane-albumin	O
microspheres	O
as	O
contrast	O
agents	O
and	O
normal	O
saline	O
injections	O
into	O
the	O
pelvic	O
cavity	O
for	O
assessment	B-P
of	I-P
the	I-P
tubal	I-P
patency	I-P
and	O
adhesions	O
of	O
fimbrial	O
parts	O
.	O

Fifty-five	O
infertile	O
female	O
patients	O
were	O
recruited	O
to	O
undergo	O
3D	O
HyCoSy	B-P
with	O
normal	O
saline	O
injected	O
into	O
the	O
pelvic	O
cavity	O
,	O
in	O
which	O
the	O
tubal	O
patency	O
was	O
observed	O
by	O
visualizing	O
the	O
spillage	O
of	O
contrast	O
agents	O
from	O
the	O
fimbriae	O
,	O
and	O
the	O
fimbrial	O
adhesion	O
was	O
confirmed	O
by	O
the	O
finger-like	O
projections	O
of	O
the	O
fimbriae	O
and	O
their	O
floating	O
and	O
moving	O
status	O
.	O

Of	O
the	O
55	O
patients	O
,	O
bilateral	O
tubal	O
patency	O
was	O
observed	O
in	O
44	O
(	O
80.0	O
%	O
)	O
,	O
unilateral	O
tubal	O
patency	O
and	O
the	O
other	O
partial	O
occlusion	O
in	O
7	O
(	O
12.7	O
%	O
)	O
,	O
unilateral	O
partial	O
occlusion	O
and	O
the	O
other	O
complete	O
occlusion	O
in	O
3	O
(	O
5.4	O
%	O
)	O
,	O
and	O
bilateral	O
complete	O
occlusion	O
in	O
1	O
(	O
1.8	O
%	O
)	O
.	O

The	O
fimbrial	O
parts	O
were	O
observed	O
in	O
105	O
fallopian	O
tubes	O
,	O
among	O
which	O
101	O
were	O
seen	O
with	O
the	O
finger-like	O
fimbriae	O
floated	O
and	O
moved	O
in	O
the	O
pelvic	O
cavity	O
,	O
whereas	O
4	O
tubes	O
were	O
not	O
because	O
of	O
adhesion	O
to	O
the	O
pelvic	O
cavity	O
(	O
n	O
=	O
3	O
)	O
or	O
the	O
ovary	O
and	O
intestine	O
(	O
n	O
=	O
1	O
)	O
.	O

More	O
than	O
three	O
visible	O
,	O
quite	O
long	O
,	O
and	O
distributed	O
evenly	O
finger-like	O
projection	O
s	O
were	O
present	O
for	O
the	O
patent	O
fimbrial	O
parts	O
;	O
however	O
,	O
fewer	O
,	O
flat	O
,	O
and	O
not	O
evenly	O
distributed	O
finger-like	O
projection	O
s	O
were	O
present	O
for	O
the	O
adhesive	O
tubes	O
.	O

No	O
serious	O
complications	O
occurred	O
during	O
or	O
after	O
this	O
procedure	B-P
.	O

Combination	O
of	O
3D	O
HyCoSy	B-P
with	O
normal	O
saline	O
injected	O
into	O
the	O
pelvic	O
cavity	O
may	O
be	O
a	O
feasible	O
and	O
safe	O
procedure	B-P
to	O
assess	O
tubal	O
patency	O
and	O
adhesions	O
of	O
the	O
fimbrial	O
parts	O
.	O

Usefulness	O
of	O
Embolization	O
for	O
Iatrogenic	O
Dural	O
Arteriovenous	O
Fistula	O
Associated	O
with	O
Recurrent	O
Chronic	O
Subdural	O
Hematoma	O
:	O
A	O
Case	O
Report	O
and	O
Literature	O
Review	O
.	O

Refractory	O
chronic	O
subdural	O
hematomas	O
due	O
to	O
iatrogenic	O
dural	O
arteriovenous	O
fistulas	O
(	O
dAVFs	O
)	O
are	O
difficult	O
to	O
treat	O
.	O

We	O
report	O
our	O
experience	O
and	O
propose	O
a	O
guideline	O
on	O
basis	O
of	O
a	O
literature	O
review	O
for	O
the	O
usefulness	O
of	O
embolization	O
of	O
middle	O
meningeal	O
artery	O
(	O
MMA	O
)	O
for	O
the	O
treatment	O
of	O
the	O
same	O
.	O

We	O
report	O
a	O
case	O
with	O
right	O
hemiparesis	O
and	O
aphasia	O
1	O
month	O
after	O
a	O
fall	O
from	O
a	O
bicycle	O
.	O

Computed	B-P
tomography	I-P
scan	I-P
of	O
the	O
head	O
showed	O
left	O
chronic	O
subdural	O
hematoma	O
,	O
which	O
was	O
evacuated	O
by	O
burr-hole	O
drainage	O
.	O

The	O
postoperative	O
course	O
was	O
complicated	O
by	O
reaccumulation	O
within	O
short	O
period	O
of	O
time	O
.	O

On	O
superselective	B-P
digital	I-P
subtraction	I-P
angiography	I-P
of	O
MMA	O
,	O
iatrogenic	O
dAVF	O
was	O
found	O
on	O
left	O
side	O
.	O

We	O
embolized	O
successfully	O
it	O
using	O
n-butyl	O
cyanoacrylate	O
after	O
a	O
third	O
irrigation	O
.	O

No	O
reaccumulation	O
found	O
in	O
the	O
postoperative	O
period	O
or	O
at	O
last	O
follow-up	O
.	O

We	O
propose	O
treatment	O
protocol	O
based	O
on	O
our	O
experience	O
and	O
literature	O
review	O
.	O

Refractory	O
chronic	O
subdural	O
hematoma	O
with	O
reaccumulation	O
within	O
a	O
short	O
interval	O
should	O
be	O
subjected	O
to	O
digital	B-P
subtraction	I-P
angiography	I-P
of	O
the	O
MMA	O
.	O

Embolization	O
of	O
ipsilateral	O
MMA	O
is	O
safe	O
,	O
effective	O
,	O
and	O
a	O
useful	O
option	O
for	O
the	O
treatment	O
of	O
iatrogenic	O
dAVF	O
and	O
resolution	O
of	O
hematoma	O
.	O

Identification	O
of	O
novel	O
macrolides	O
with	O
antibacterial	O
,	O
anti-inflammatory	O
and	O
type	O
I	O
and	O
III	O
IFN	O
-	O
augmenting	O
activity	O
in	O
airway	O
epithelium	O
.	O

Exacerbations	O
of	O
asthma	O
and	O
COPD	O
are	O
triggered	O
by	O
rhinoviruses	O
.	O

Uncontrolled	O
inflammatory	O
pathways	O
,	O
pathogenic	O
bacterial	O
burden	O
and	O
impaired	O
antiviral	O
immunity	O
are	O
thought	O
to	O
be	O
important	O
factors	O
in	O
disease	O
severity	O
and	O
duration	O
.	O

Macrolides	O
including	O
azithromycin	O
are	O
often	O
used	O
to	O
treat	O
the	O
above	O
diseases	O
,	O
but	O
exhibit	O
variable	O
levels	O
of	O
efficacy	O
.	O

Inhaled	O
corticosteroids	O
are	O
also	O
readily	O
used	O
in	O
treatment	O
,	O
but	O
may	O
lack	O
specificity	O
.	O

Ideally	O
,	O
new	O
treatment	O
alternatives	O
should	O
suppress	O
unwanted	O
inflammation	O
,	O
but	O
spare	O
beneficial	O
antiviral	O
immunity	O
.	O

In	O
the	O
present	O
study	B-P
,	O
we	O
screened	O
225	O
novel	O
macrolides	O
and	O
tested	O
them	O
for	O
enhanced	O
antiviral	O
activity	O
against	O
rhinovirus	O
,	O
as	O
well	O
as	O
anti-inflammatory	O
activity	O
and	O
activity	O
against	O
Gram-positive	O
and	O
Gram-negative	O
bacteria	O
.	O

Primary	O
bronchial	O
epithelial	O
cells	O
were	O
grown	O
from	O
10	O
asthmatic	O
individuals	O
and	O
the	O
effects	O
of	O
macrolides	O
on	O
rhinovirus	O
replication	O
were	O
also	O
examined	O
.	O

Another	O
30	O
structurally	O
similar	O
macrolides	O
were	O
also	O
examined	O
.	O

The	O
oleandomycin	O
derivative	O
Mac5	O
,	O
compared	O
with	O
azithromycin	O
,	O
showed	O
superior	O
induction	O
(	O
up	O
to	O
5-fold	O
,	O
EC	O
50	O
=	O
5-11	O
μM	O
)	O
of	O
rhinovirus	O
-	O
induced	O
type	O
I	O
IFNβ	O
,	O
type	O
III	O
IFNλ1	O
and	O
type	O
III	O
IFNλ2/3	O
mRNA	O
and	O
the	O
IFN	O
-	O
stimulated	O
genes	O
viperin	O
and	O
MxA	O
,	O
yet	O
had	O
no	O
effect	O
on	O
IL-6	O
and	O
IL-8	O
mRNA	O
.	O

Mac5	O
also	O
suppressed	O
rhinovirus	O
replication	O
at	O
48	O
h	O
,	O
proving	O
antiviral	O
activity	O
.	O

Mac5	O
showed	O
antibacterial	O
activity	O
against	O
Gram-positive	O
Streptococcus	O
pneumoniae	O
;	O
however	O
,	O
it	O
did	O
not	O
have	O
any	O
antibacterial	O
properties	O
compared	O
with	O
azithromycin	O
when	O
used	O
against	O
Gram-negative	O
Escherichia	O
coli	O
(	O
as	O
a	O
model	O
organism	O
)	O
and	O
also	O
the	O
respiratory	O
pathogens	O
Pseudomonas	O
aeruginosa	O
and	O
non-typeable	O
Haemophilus	O
influenzae	O
.	O

Further	O
non-toxic	O
Mac5	O
derivatives	O
were	O
identified	O
with	O
various	O
anti-inflammatory	O
,	O
antiviral	O
and	O
antibacterial	O
activities	O
.	O

The	O
data	O
support	O
the	O
idea	O
that	O
macrolides	O
have	O
antiviral	O
properties	O
through	O
a	O
mechanism	O
that	O
is	O
yet	O
to	O
be	O
ascertained	O
.	O

We	O
also	O
provide	O
evidence	O
that	O
macrolides	O
can	O
be	O
developed	O
with	O
anti-inflammatory	O
,	O
antibacterial	O
and	O
antiviral	O
activity	O
and	O
show	O
surprising	O
versatility	O
depending	O
on	O
the	O
clinical	O
need	O
.	O

A	O
Novel	O
Multiplex	O
PCR	O
Assay	B-P
for	O
the	O
Detection	O
of	O
Chlorhexidine	O
/	O
Quaternary	O
Ammonium	O
,	O
Mupirocin	O
and	O
Methicillin	O
Resistance	O
Genes	O
with	O
Simultaneous	O
Discrimination	O
of	O
Staphylococcus	O
aureus	O
from	O
Coagulase-Negative	O
Staphylococci	O
.	O

Methicillin-resistant	O
Staphylococcus	O
aureus	O
(	O
MRSA	O
)	O
is	O
a	O
clinically	O
significant	O
pathogen	O
resistant	O
to	O
a	O
wide	O
variety	O
of	O
antibiotics	O
and	O
responsible	O
for	O
a	O
large	O
number	O
of	O
nosocomial	O
infections	O
worldwide	O
.	O

The	O
Agency	O
for	O
Healthcare	O
Research	O
and	O
Quality	O
and	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
recently	O
recommended	O
to	O
adopt	O
universal	O
mupirocin	O
/	O
chlorhexidine	O
decolonization	O
of	O
all	O
admitted	O
intensive	O
care	O
unit	O
patients	O
,	O
rather	O
than	O
MRSA	O
screening	O
with	O
targeted	O
treatments	O
,	O
which	O
raises	O
the	O
serious	O
concern	O
about	O
the	O
selection	O
of	O
resistance	O
to	O
mupirocin	O
and	O
chlorhexidine	O
in	O
strains	O
of	O
staphylococci	O
.	O

Thus	O
,	O
a	O
simple	O
,	O
rapid	O
,	O
and	O
reliable	O
approach	O
will	O
be	O
paramount	O
in	O
monitoring	O
the	O
resistance	O
prevalence	O
to	O
these	O
agents	O
.	O

We	O
developed	O
a	O
simple	O
multiplex	O
PCR	O
assay	B-P
capable	O
of	O
screening	O
Staphylococcus	O
isolates	O
for	O
the	O
presence	O
of	O
antiseptic	O
resistance	O
genes	O
for	O
chlorhexidine	O
and	O
quaternary	O
ammonium	O
compounds	O
,	O
as	O
well	O
as	O
mupirocin	O
-	O
and	O
methicillin-resistance	O
genes	O
,	O
while	O
simultaneously	O
discriminating	O
S.	O
aureus	O
from	O
coagulase-negative	O
staphylococci	O
(	O
CoNS	O
)	O
.	O

The	O
assay	B-P
incorporates	O
7	O
PCR	O
targets	O
,	O
including	O
staph	O
16S-rRNA	O
(	O
specifically	O
detecting	O
Staphylococcus	O
sp	O
.	O

)	O
,	O
nuc	O
(	O
distinguishing	O
S.	O
aureus	O
from	O
CoNS	O
)	O
,	O
mecA	O
(	O
distinguishing	O
MRSA	O
from	O
methicillin-susceptible	O
S.	O
aureus	O
)	O
,	O
mupA	O
and	O
mupB	O
(	O
identifying	O
high-level	O
mupirocin	O
resistance	O
)	O
,	O
qac	O
and	O
smr	O
(	O
identifying	O
chlorhexidine	O
and	O
quaternary	O
ammonium	O
resistance	O
)	O
.	O

Our	O
assay	O
demonstrated	O
100	O
%	O
sensitivity	O
,	O
specificity	O
and	O
accuracy	O
in	O
a	O
total	O
of	O
23	O
variant	O
antiseptic	O
/	O
antibiotic-resistant	O
control	O
strains	O
.	O

Further	O
validation	O
of	O
our	O
assay	O
using	O
378	O
randomly	O
selected	O
and	O
previously	O
well-characterized	O
local	O
clinical	O
isolates	O
confirmed	O
its	O
feasibility	O
and	O
practicality	O
.	O

This	O
may	O
prove	O
to	O
be	O
a	O
useful	O
tool	O
for	O
multidrug-resistant	O
staphylococci	O
monitoring	O
in	O
clinical	O
laboratories	O
,	O
particularly	O
in	O
the	O
wake	O
of	O
increased	O
chlorhexidine	O
and	O
mupirocin	O
treatments	O
.	O

Mono-sulfonated	O
tetrazolium	O
salt	O
based	O
NAD	O
(	O
P	O
)	O
H	O
detection	O
reagents	O
suitable	O
for	O
dehydrogenase	O
and	O
real-time	O
cell	B-P
viability	I-P
assays	I-P
.	O

Glutamate	O
dehydrogenase	O
(	O
GDH	O
)	O
catalyzes	O
the	O
oxidative	O
deamination	O
of	O
L-glutamate	O
and	O
is	O
important	O
for	O
several	O
biological	O
processes	O
.	O

For	O
GDH	O
inhibitor	O
screening	B-P
,	O
we	O
developed	O
a	O
novel	O
mono-sulfonated	O
tetrazolium	O
salt	O
(	O
EZMTT	O
)	O
,	O
which	O
can	O
be	O
synthesized	O
using	O
H2O2	O
oxidation	O
and	O
purified	O
easily	O
on	O
silica	O
gel	O
in	O
large	O
quantities	O
.	O

The	O
EZMTT	O
detection	O
method	O
showed	O
linear	O
dose	O
responses	O
to	O
NAD	O
(	O
P	O
)	O
H	O
,	O
dehydrogenase	O
concentration	O
and	O
cell	B-P
numbers	I-P
.	O

In	O
E.	O
coli	O
GDH	B-P
assay	I-P
,	O
the	O
EZMTT	O
method	O
showed	O
excellent	O
assay	O
reproducibility	O
with	O
a	O
Z	O
factor	O
of	O
0.9	O
and	O
caused	O
no	O
false	O
positives	O
in	O
the	O
presence	O
of	O
antioxidants	O
(	O
such	O
as	O
BME	O
)	O
.	O

Using	O
the	O
EZMTT	O
-	O
formazan	O
-	O
NAD	O
(	O
P	O
)	O
H	O
system	O
,	O
we	O
showed	O
that	O
EGCG	O
is	O
a	O
potent	O
E.	O
coli	O
GDH	O
inhibitor	O
(	O
IC50	O
45	O
nM	O
)	O
and	O
identified	O
that	O
Ebselen	O
,	O
a	O
multifunctional	O
thioredoxin	O
reductase	O
inhibitor	O
,	O
inactivated	O
E.	O
coli	O
GDH	O
(	O
IC50	O
213	O
nM	O
)	O
.	O

In	O
cell-based	O
assays	O
at	O
0.5	O
mM	O
tetrazolium	O
concentration	O
,	O
EZMTT	O
showed	O
essentially	O
no	O
toxicity	O
after	O
a	O
3-day	O
incubation	O
,	O
whereas	O
40	O
%	O
of	O
inhibition	O
was	O
observed	O
for	O
WST-8	O
.	O

In	O
conclusion	O
,	O
EZMTT	O
is	O
a	O
novel	O
tetrazolium	O
salt	O
which	O
provides	O
improved	O
features	O
that	O
are	O
suitable	O
for	O
dehydrogenases	O
and	O
real-time	O
cell-based	O
high-throughput	B-P
screening	I-P
(	O
HTS	O
)	O
.	O

MiR-424-5p	O
participates	O
in	O
esophageal	O
squamous	O
cell	O
carcinoma	O
invasion	O
and	O
metastasis	O
via	O
SMAD7	O
pathway	O
mediated	O
EMT	O
.	O

ESCC	O
is	O
a	O
life-threatening	O
disease	O
due	O
to	O
invasion	O
and	O
metastasis	O
in	O
the	O
early	O
stage	O
.	O

Great	O
efforts	O
had	O
been	O
made	O
to	O
detect	O
the	O
molecular	O
mechanisms	O
which	O
led	O
to	O
the	O
invasion	O
and	O
metastasis	O
in	O
ESCC	O
.	O

Recent	O
evidence	O
had	O
suggested	O
that	O
deregulation	O
of	O
miR-424-5p	O
took	O
an	O
important	O
role	O
in	O
cancers	O
.	O

However	O
,	O
its	O
role	O
and	O
functional	O
mechanism	O
in	O
ESCC	O
had	O
seldom	O
been	O
elucidated	O
.	O

The	O
expression	O
levels	O
of	O
miR-424-5p	O
were	O
detected	O
in	O
ESCC	O
tissues	O
and	O
cell	O
lines	O
by	O
real-time	O
PCR	O
methods	O
.	O

Then	O
,	O
the	O
invasion	O
,	O
metastasis	O
and	O
proliferation	O
ability	O
of	O
ESCC	O
cell	O
lines	O
transfected	O
with	O
miR-424-5p	O
mimics	O
were	O
analyzed	O
separately	O
by	O
transwell	B-P
invasion	I-P
assay	I-P
,	O
wound	B-P
healing	I-P
assay	I-P
and	O
cell	O
proliferation	O
assay	O
.	O

Finally	O
,	O
the	O
target	O
gene	O
of	O
miR-424-5p	O
was	O
studied	O
and	O
verified	O
by	O
luciferase	B-P
activity	I-P
assay	I-P
.	O

And	O
the	O
role	O
of	O
miR-424-5p	O
in	O
EMT	O
was	O
also	O
investigated	O
by	O
real-time	O
PCR	O
and	O
western	B-P
blot	I-P
assay	I-P
.	O

We	O
showed	O
that	O
the	O
expression	O
levels	O
of	O
miR-424-5p	O
were	O
decreased	O
both	O
in	O
ESCC	O
tissues	O
and	O
cell	O
lines	O
.	O

Furthermore	O
,	O
the	O
expression	O
levels	O
of	O
miR-424-5p	O
were	O
negatively	O
linked	O
to	O
lymph	O
node	O
metastasis	O
in	O
ESCC	O
tissues	O
.	O

Restoration	O
of	O
miR-424-5p	O
in	O
EC-1	O
cells	O
by	O
using	O
miR-424-5p	O
mimics	O
could	O
decrease	O
the	O
invasion	O
,	O
metastasis	O
and	O
proliferation	O
of	O
EC-1	O
cells	O
,	O
indicating	O
its	O
role	O
in	O
inhibition	O
on	O
the	O
invasion	O
and	O
metastasis	O
ability	O
of	O
ESCC	O
cells	O
and	O
tissues	O
.	O

In	O
addition	O
,	O
we	O
demonstrated	O
that	O
SMAD7	O
was	O
a	O
specific	O
target	O
gene	O
for	O
miR-424-5p	O
by	O
luciferase	B-P
activity	I-P
assay	I-P
and	O
miR-424-5p	O
could	O
not	O
only	O
negatively	O
regulate	O
SMAD7	O
expression	O
but	O
also	O
participate	O
in	O
EMT	O
via	O
SMAD7	O
,	O
because	O
overexpression	O
of	O
SMAD7	O
could	O
partly	O
enhance	O
the	O
miR-424-5p	O
anti-EMT	O
function	O
.	O

Our	O
results	O
described	O
that	O
miR-424-5p	O
-	O
SMAD7	O
pathway	O
contributed	O
to	O
ESCC	O
invasion	O
and	O
metastasis	O
and	O
up-regulation	O
of	O
miR-424-5p	O
perhaps	O
provided	O
a	O
strategy	O
for	O
preventing	O
tumor	O
invasion	O
,	O
metastasis	O
.	O

A	O
novel	O
method	O
for	O
interactive	O
multi-objective	O
dose-guided	O
patient	O
positioning	O
.	O

In	O
intensity-modulated	O
radiation	O
therapy	O
(	O
IMRT	O
)	O
,	O
3D	O
in-room	O
imaging	B-P
data	O
is	O
typically	O
utilized	O
for	O
accurate	O
patient	O
alignment	O
on	O
the	O
basis	O
of	O
anatomical	O
landmarks	O
.	O

In	O
the	O
presence	O
of	O
non-rigid	O
anatomical	O
changes	O
,	O
it	O
is	O
often	O
not	O
obvious	O
which	O
patient	O
position	O
is	O
most	O
suitable	O
.	O

Thus	O
,	O
dose	O
-guided	O
patient	O
alignment	O
is	O
an	O
interesting	O
approach	O
to	O
use	O
available	O
in-room	O
imaging	B-P
data	O
for	O
up-to-date	O
dose	O
calculation	O
,	O
aimed	O
at	O
finding	O
the	O
position	O
that	O
yields	O
the	O
optimal	O
dose	O
distribution	O
.	O

This	O
contribution	O
presents	O
the	O
first	O
implementation	O
of	O
dose	O
-guided	O
patient	O
alignment	O
as	O
multi-criteria	O
optimization	O
problem	O
.	O

User-defined	O
clinical	O
objectives	O
are	O
employed	O
for	O
setting	O
up	O
a	O
multi-objective	O
problem	O
.	O

Using	O
pre-calculated	O
dose	O
distributions	O
at	O
a	O
limited	O
number	O
of	O
patient	O
shifts	O
and	O
dose	O
interpolation	O
,	O
a	O
continuous	O
space	O
of	O
Pareto-efficient	O
patient	O
shifts	O
becomes	O
accessible	O
.	O

Pareto	O
sliders	O
facilitate	O
interactive	O
browsing	O
of	O
the	O
possible	O
shifts	O
with	O
real-time	O
dose	O
display	O
to	O
the	O
user	O
.	O

Dose	O
interpolation	O
accuracy	O
is	O
validated	O
and	O
the	O
potential	O
of	O
multi-objective	O
dose-guided	O
positioning	O
demonstrated	O
for	O
three	O
head	O
and	O
neck	O
(	O
H	O
&	O
N	O
)	O
and	O
three	O
prostate	O
cancer	O
patients	O
.	O

Dose-guided	O
positioning	O
is	O
compared	O
to	O
replanning	O
for	O
all	O
cases	O
.	O

A	O
delineated	O
replanning	O
CT	B-P
served	O
as	O
surrogate	O
for	O
in-room	O
imaging	B-P
data	O
.	O

Dose	O
interpolation	O
accuracy	O
was	O
high	O
.	O

Using	O
a	O
[	O
Formula	O
:	O
see	O
text	O
]	O
dose	O
difference	O
criterion	O
,	O
a	O
median	O
pass-rate	O
of	O
95.7	O
%	O
for	O
H	O
&	O
N	O
and	O
99.6	O
%	O
for	O
prostate	O
cases	O
was	O
determined	O
in	O
a	O
comparison	O
to	O
exact	O
dose	O
calculations	O
.	O

For	O
all	O
patients	O
,	O
dose-guided	O
positioning	O
allowed	O
to	O
find	O
a	O
clinically	O
preferable	O
dose	O
distribution	O
compared	O
to	O
bony	O
anatomy	O
based	O
alignment	O
.	O

For	O
all	O
H	O
&	O
N	O
cases	O
,	O
mean	O
dose	O
to	O
the	O
spared	O
parotid	O
glands	O
was	O
below	O
[	O
Formula	O
:	O
see	O
text	O
]	O
(	O
up	O
to	O
[	O
Formula	O
:	O
see	O
text	O
]	O
with	O
bony	O
alignment	O
)	O
and	O
clinical	O
target	O
volume	O
(	O
CTV	O
)	O
[	O
Formula	O
:	O
see	O
text	O
]	O
above	O
99.1	O
%	O
(	O
compared	O
to	O
95.1	O
%	O
)	O
.	O

For	O
all	O
prostate	O
patients	O
,	O
CTV	O
[	O
Formula	O
:	O
see	O
text	O
]	O
was	O
above	O
98.9	O
%	O
(	O
compared	O
to	O
88.5	O
%	O
)	O
and	O
[	O
Formula	O
:	O
see	O
text	O
]	O
to	O
the	O
rectum	O
below	O
[	O
Formula	O
:	O
see	O
text	O
]	O
(	O
compared	O
to	O
56.1	O
%	O
)	O
.	O

Replanning	O
yielded	O
improved	O
results	O
for	O
the	O
H	O
&	O
N	O
cases	O
.	O

For	O
the	O
prostate	O
cases	O
,	O
differences	O
to	O
dose-guided	O
positioning	O
were	O
minor	O
.	O

Frequency	O
distribution	O
of	O
interleukin-10	O
haplotypes	O
(	O
-1082	O
A	O
>	O
G	O
,	O
-819	O
C	O
>	O
T	O
,	O
and	O
-592	O
C	O
>	O
A	O
)	O
in	O
a	O
Mexican	O
population	O
.	O

Interleukin	O
10	O
(	O
IL-10	O
)	O
is	O
an	O
immunoregulatory	O
cytokine	O
with	O
multiple	O
roles	O
in	O
the	O
immune	O
system	O
.	O

Three	O
single	O
nucleotide	O
polymorphisms	O
at	O
positions	O
-1082	O
(	O
A	O
>	O
G	O
)	O
,	O
-819	O
(	O
C	O
>	O
T	O
)	O
,	O
and	O
-592	O
(	O
C	O
>	O
A	O
)	O
in	O
the	O
promoter	O
region	O
of	O
the	O
IL10	O
gene	O
are	O
believed	O
to	O
be	O
associated	O
with	O
different	O
inflammatory	O
,	O
infectious	O
,	O
and	O
autoimmune	O
diseases	O
.	O

These	O
polymorphisms	O
exhibit	O
a	O
strong	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
and	O
form	O
three	O
principal	O
haplotypes	O
(	O
GCC	O
,	O
ACC	O
,	O
and	O
ATA	O
)	O
.	O

The	O
GCC	O
and	O
ATA	O
haplotypes	O
have	O
been	O
associated	O
with	O
high	O
and	O
low	O
levels	O
of	O
IL-10	O
production	O
,	O
respectively	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
establish	O
the	O
allele	O
and	O
haplotype	O
frequencies	O
of	O
the	O
IL10	O
polymorphisms	O
in	O
Mestizos	O
from	O
western	O
Mexico	O
.	O

SNPs	O
were	O
analyzed	O
in	O
340	O
healthy	O
unrelated	O
Mestizos	O
from	O
western	O
Mexico	O
by	O
polymerase	O
chain	O
reaction	O
-	O
restriction	B-P
fragment	I-P
length	I-P
polymorphism	I-P
.	O

The	O
studied	O
population	O
presented	O
significant	O
differences	O
,	O
in	O
the	O
distribution	O
of	O
IL10	O
polymorphisms	O
,	O
from	O
the	O
Asian	O
,	O
African	O
,	O
and	O
European	O
populations	O
.	O

We	O
also	O
observed	O
a	O
strong	O
LD	O
within	O
-1082	O
A	O
>	O
G	O
,	O
-819	O
C	O
>	O
T	O
,	O
and	O
-592	O
C	O
>	O
A	O
(	O
100	O
%	O
pc	O
=	O
7.735	O
x	O
10	O
(	O
-18	O
)	O
)	O
.	O

The	O
haplotypes	O
ACC	O
(	O
45.4	O
%	O
)	O
,	O
ATA	O
(	O
22.0	O
%	O
)	O
,	O
GTA	O
(	O
14.9	O
%	O
)	O
,	O
and	O
GCC	O
(	O
13.9	O
%	O
)	O
were	O
most	O
frequently	O
observed	O
in	O
this	O
population	O
.	O

The	O
haplotype	O
frequencies	O
,	O
however	O
,	O
differed	O
from	O
those	O
reported	O
previously	O
in	O
Mestizos	O
from	O
central	O
Mexico	O
,	O
Asians	O
,	O
Africans	O
,	O
and	O
European	O
Caucasians	O
,	O
suggesting	O
a	O
differential	O
gene	O
flow	O
in	O
the	O
Mexican	O
Mestizo	O
population	O
.	O

This	O
could	O
account	O
for	O
the	O
genetic	O
variability	O
between	O
Mexicans	O
and	O
populations	O
of	O
other	O
ethnicities	O
.	O

The	O
study	O
of	O
these	O
polymorphisms	O
and	O
their	O
haplotypes	O
could	O
help	O
in	O
expanding	O
our	O
knowledge	O
to	O
design	O
future	O
disease	O
-	O
risk	O
studies	O
on	O
the	O
western	O
Mexican	O
population	O
.	O

Effects	O
of	O
Static	B-P
Cold	I-P
Storage	I-P
and	O
Hypothermic	O
Machine	O
Perfusion	O
on	O
Oxidative	B-P
Stress	I-P
Factors	I-P
,	O
Adhesion	O
Molecules	O
,	O
and	O
Zinc	O
Finger	O
Transcription	O
Factor	O
Proteins	O
Before	O
and	O
After	O
Liver	O
Transplantation	O
.	O

BACKGROUND	O
This	O
study	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
static	B-P
cold	I-P
storage	I-P
(	O
SCS	B-P
)	O
and	O
hypothermic	O
machine	O
perfusion	O
(	O
HMP	O
)	O
on	O
the	O
oxidative	B-P
stress	I-P
factors	I-P
(	O
OSF	B-P
)	O
,	O
adhesion	O
molecules	O
(	O
AM	O
)	O
,	O
and	O
zinc	O
finger	O
transcription	O
factor	O
(	O
Snail	O
)	O
before	O
and	O
after	O
liver	O
transplantation	O
.	O

MATERIAL	O
AND	O
METHODS	O
Experimental	O
dogs	O
were	O
randomly	O
divided	O
into	O
donor	O
(	O
group	O
A	O
)	O
,	O
SCS	B-P
(	O
group	O
B	O
)	O
,	O
and	O
HMP	O
(	O
group	O
C	O
)	O
(	O
n=30	O
)	O
groups	O
.	O

Livers	O
retrieved	O
from	O
group	O
A	O
were	O
transplanted	O
into	O
group	O
B	O
after	O
SCS	B-P
,	O
and	O
the	O
livers	O
sampled	O
from	O
group	O
B	O
were	O
transplanted	O
into	O
group	O
C	O
after	O
HMP	O
.	O

The	O
dogs	O
in	O
group	O
A	O
were	O
euthanized	O
and	O
discarded	O
,	O
and	O
the	O
livers	O
sampled	O
from	O
group	O
C	O
were	O
used	O
for	O
other	O
experiments	O
.	O

Twenty	O
dogs	O
with	O
successful	O
liver	O
transplants	O
were	O
randomly	O
selected	O
from	O
groups	O
B	O
and	O
C	O
for	O
analysis	O
.	O

RESULTS	O
During	O
the	O
liver	O
sampling	O
process	O
,	O
the	O
levels	O
of	O
OSF	B-P
,	O
AM	O
,	O
and	O
Snail	O
between	O
the	O
2	O
groups	O
showed	O
no	O
significant	O
differences	O
(	O
P	O
>	O
0.05	O
)	O
;	O
before	O
the	O
transplantation	O
,	O
the	O
levels	O
of	O
chemokine	O
CXCL14	O
and	O
Snail	O
between	O
the	O
2	O
groups	O
showed	O
no	O
significant	O
differences	O
(	O
P	O
>	O
0.05	O
)	O
,	O
and	O
compared	O
with	O
group	O
B	O
,	O
HIF-1α	O
and	O
P-selectin	O
in	O
group	O
C	O
were	O
lower	O
(	O
P	O
<	O
0.01	O
)	O
;	O
60	O
min	O
after	O
the	O
transplantation	O
,	O
HIF-1α	O
,	O
chemokine	O
CXCL14	O
,	O
P-selectin	O
,	O
and	O
Snail	O
in	O
group	O
C	O
were	O
lower	O
than	O
that	O
in	O
group	O
B	O
(	O
P	O
<	O
0.01	O
)	O
.	O

CONCLUSIONS	O
HMP	O
can	O
significantly	O
reduce	O
the	O
levels	O
of	O
OSF	B-P
and	O
inflammatory	O
factors	O
,	O
which	O
is	O
conducive	O
for	O
liver	O
transplantation	O
.	O

Relationship	O
between	O
genetic	O
polymorphisms	O
of	O
methylenetetrahydrofolate	O
reductase	O
and	O
breast	O
cancer	O
chemotherapy	O
response	O
.	O

Activity	O
of	O
methylenetetrahydrofolate	O
reductase	O
(	O
MTHFR	O
)	O
,	O
an	O
enzyme	O
involved	O
in	O
folate	O
metabolism	O
,	O
is	O
influenced	O
by	O
mutations	O
in	O
the	O
corresponding	O
gene	O
,	O
contributing	O
to	O
a	O
decrease	O
in	O
5,10-MTHF	O
.	O

Due	O
to	O
such	O
polymorphisms	O
,	O
individuals	O
differ	O
in	O
MTHFR	O
enzyme	O
activity	O
and	O
plasma	B-P
folate	I-P
levels	I-P
.	O

We	O
investigated	O
the	O
relationship	O
between	O
two	O
common	O
MTHFR	O
polymorphisms	O
(	O
C677T	O
and	O
A1298C	O
)	O
and	O
breast	O
cancer	O
(	O
BC	O
)	O
chemotherapy	O
response	O
.	O

From	O
February	O
2013	O
to	O
January	O
2016	O
,	O
148	O
advanced	O
BC	O
patients	O
at	O
the	O
Center	O
Hospital	O
of	O
Cangzhou	O
were	O
enrolled	O
and	O
treated	O
with	O
six	O
different	O
chemotherapy	O
regimens	O
.	O

Subjects	O
were	O
genotyped	O
using	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
.	O

Forty-one	O
(	O
27.7	O
%	O
)	O
,	O
70	O
(	O
47.3	O
%	O
)	O
,	O
and	O
37	O
(	O
25.0	O
%	O
)	O
patients	O
carried	O
the	O
C/C	O
,	O
C/T	O
,	O
and	O
T/T	O
C677T	O
genotypes	O
,	O
respectively	O
;	O
101	O
(	O
68.2	O
%	O
)	O
,	O
42	O
(	O
28.4	O
%	O
)	O
,	O
and	O
5	O
(	O
3.4	O
%	O
)	O
had	O
the	O
A/A	O
,	O
A/C	O
,	O
and	O
C/C	O
genotypes	O
of	O
A1298C	O
,	O
respectively	O
.	O

Total	O
chemotherapy	O
efficacy	O
was	O
66.9	O
%	O
(	O
99/148	O
)	O
,	O
with	O
7	O
(	O
4.7	O
%	O
)	O
,	O
92	O
(	O
62.2	O
%	O
)	O
,	O
36	O
(	O
24.3	O
%	O
)	O
,	O
and	O
13	O
(	O
8.8	O
%	O
)	O
cases	O
showing	O
complete	O
response	O
,	O
partial	O
response	O
,	O
no	O
change	O
,	O
and	O
progressive	O
disease	O
,	O
respectively	O
.	O

Chemotherapy	O
regimens	O
did	O
not	O
differ	O
in	O
effectiveness	O
(	O
P	O
>	O
0.05	O
)	O
.	O

Efficacy	O
rates	O
associated	O
with	O
C677T	O
C/C	O
,	O
C/T	O
,	O
and	O
T/T	O
genotypes	O
were	O
58.5	O
,	O
58.6	O
,	O
and	O
91.9	O
%	O
,	O
respectively	O
,	O
with	O
T/T	O
carriers	O
exhibiting	O
significantly	O
better	O
responses	O
than	O
the	O
C/C	O
(	O
P	O
<	O
0.05	O
)	O
and	O
C/T	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Effectiveness	O
among	O
A1298C	O
A/A	O
,	O
A/C	O
,	O
and	O
C/C	O
carriers	O
was	O
70.6	O
,	O
64.3	O
,	O
and	O
0.0	O
%	O
,	O
respectively	O
,	O
but	O
no	O
difference	O
was	O
established	O
between	O
these	O
genotypes	O
in	O
this	O
regard	O
(	O
P	O
>	O
0.05	O
)	O
.	O

The	O
MTHFR	O
C677T	O
genotype	O
may	O
be	O
associated	O
with	O
BC	O
chemotherapy	O
response	O
,	O
and	O
could	O
be	O
of	O
great	O
value	O
in	O
guiding	O
individualized	O
treatment	O
for	O
this	O
disease	O
.	O

Clinical	O
significance	O
of	O
human	O
intestinal	O
spirochetosis	O
:	O
a	O
retrospective	O
study	O
.	O

The	O
clinical	O
and	O
pathological	O
features	O
of	O
human	O
intestinal	O
spirochetosis	O
(	O
HIS	O
)	O
are	O
not	O
well	O
known	O
.	O

Here	O
we	O
report	O
55	O
patients	O
with	O
HIS	O
who	O
were	O
diagnosed	O
at	O
our	O
institution	O
during	O
the	O
past	O
5	O
years	O
.	O

Seven	O
patients	O
presented	O
with	O
symptoms	O
such	O
as	O
abdominal	O
pain	O
or	O
diarrhea	O
,	O
while	O
the	O
others	O
were	O
incidentally	O
diagnosed	O
during	O
screening	B-P
colonoscopy	I-P
.	O

Most	O
patients	O
had	O
non-specific	O
endoscopic	B-P
findings	O
,	O
including	O
intestinal	O
edema	O
or	O
erosion	O
.	O

The	O
diagnosis	O
of	O
HIS	O
was	O
histologically	O
confirmed	O
via	O
hematoxylin	B-P
and	I-P
eosin	I-P
staining	I-P
,	O
periodic	B-P
acid-Schiff	I-P
staining	I-P
,	O
and/or	O
immunohistochemistry	B-P
using	O
anti-Treponema	O
pallidum	O
antibody	O
.	O

Among	O
the	O
55	O
patients	O
,	O
five	O
were	O
diagnosed	O
with	O
diseases	O
other	O
than	O
HIS	O
(	O
amoebic	O
colitis	O
,	O
three	O
;	O
ulcerative	O
colitis	O
,	O
one	O
)	O
.	O

Sixteen	O
patients	O
were	O
treated	O
with	O
either	O
amoxicillin	O
or	O
metronidazole	O
;	O
only	O
metronidazole	O
proved	O
to	O
be	O
effective	O
.	O

The	O
clinical	O
significance	O
of	O
asymptomatic	O
HIS	O
remains	O
unknown	O
.	O

Some	O
case	O
reports	O
suggest	O
a	O
risk	O
for	O
increased	O
severity	O
in	O
patients	O
with	O
immunodeficiency	O
and/or	O
sexually	O
transmitted	O
diseases	O
.	O

Therefore	O
,	O
aggressive	O
treatment	O
for	O
HIS	O
should	O
be	O
considered	O
,	O
particularly	O
in	O
high-risk	O
patients	O
.	O

Molecular	O
serum	O
signature	O
of	O
treatment	O
resistant	O
depression	O
.	O

A	O
substantial	O
number	O
of	O
patients	O
suffering	O
from	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
do	O
not	O
respond	O
to	O
multiple	O
trials	O
of	O
anti-depressants	O
,	O
develop	O
a	O
chronic	O
course	O
of	O
disease	O
and	O
become	O
treatment	O
resistant	O
.	O

Most	O
of	O
the	O
studies	O
investigating	O
molecular	O
changes	O
in	O
treatment-resistant	O
depression	O
(	O
TRD	O
)	O
have	O
only	O
examined	O
a	O
limited	O
number	O
of	O
molecules	O
and	O
genes	O
.	O

Consequently	O
,	O
biomarkers	O
associated	O
with	O
TRD	O
are	O
still	O
lacking	O
.	O

This	O
study	O
aimed	O
to	O
use	O
recently	O
advanced	O
high-throughput	O
proteomic	O
platforms	O
to	O
identify	O
peripheral	O
biomarkers	O
of	O
TRD	O
defined	O
by	O
two	O
staging	O
models	O
,	O
the	O
Thase	O
and	O
Rush	O
staging	O
model	O
(	O
TRM	O
)	O
and	O
the	O
Maudsley	O
Staging	O
Model	O
(	O
MSM	O
)	O
.	O

Serum	O
collected	O
from	O
an	O
inpatient	O
cohort	O
of	O
65	O
individuals	O
suffering	O
from	O
MDD	O
was	O
analysed	O
using	O
two	O
different	O
mass	B-P
spectrometric-based	I-P
platforms	I-P
,	O
label-free	B-P
liquid	I-P
chromatography	I-P
mass	I-P
spectrometry	I-P
(	O
LC-MS	B-P
(	I-P
E	I-P
)	I-P
)	O
and	O
selective	O
reaction	O
monitoring	O
(	O
SRM	O
)	O
,	O
as	O
well	O
as	O
a	O
multiplex	B-P
bead	I-P
based	I-P
assay	I-P
.	O

In	O
the	O
LC-MS	B-P
(	I-P
E	I-P
)	I-P
analysis	I-P
,	O
proteins	O
involved	O
in	O
the	O
acute	O
phase	O
response	O
and	O
complement	O
activation	O
and	O
coagulation	O
were	O
significantly	O
different	O
between	O
the	O
staging	O
groups	O
in	O
both	O
models	O
.	O

In	O
the	O
multiplex	B-P
bead-based	I-P
assay	I-P
analysis	O
TNF-α	B-P
levels	I-P
(	O
log	O
(	O
odds	O
)	O
=	O
-4.95	O
,	O
p	O
=	O
0.045	O
)	O
were	O
significantly	O
different	O
in	O
the	O
TRM	O
comparison	O
.	O

Using	O
SRM	O
,	O
significant	O
changes	O
of	O
three	O
apolipoproteins	O
A-I	O
(	O
β	O
=	O
0.029	O
,	O
p	O
=	O
0.035	O
)	O
,	O
M	O
(	O
β	O
=	O
-0.017	O
,	O
p	O
=	O
0.009	O
)	O
and	O
F	O
(	O
β	O
=	O
-0.031	O
,	O
p	O
=	O
0.024	O
)	O
were	O
associated	O
with	O
the	O
TRM	O
but	O
not	O
the	O
MSM	O
.	O

Overall	O
,	O
our	O
findings	O
suggest	O
that	O
proteins	O
,	O
which	O
are	O
involved	O
in	O
immune	O
and	O
complement	O
activation	O
,	O
may	O
represent	O
potential	O
biomarkers	O
that	O
could	O
be	O
used	O
by	O
clinicians	O
to	O
identify	O
high-risk	O
patients	O
.	O

Nevertheless	O
,	O
given	O
that	O
the	O
molecular	O
changes	O
between	O
the	O
staging	O
groups	O
were	O
subtle	O
,	O
the	O
results	O
need	O
to	O
be	O
interpreted	O
cautiously	O
.	O

Pesticide	O
residues	O
in	O
orange	O
fruit	O
from	O
citrus	O
orchards	O
in	O
Nuevo	O
Leon	O
State	O
,	O
Mexico	O
.	O

Some	O
international	O
organisations	O
established	O
maximum	O
residue	O
limits	O
(	O
MRLs	O
)	O
in	O
food	O
to	O
protect	O
human	O
health	O
.	O

Mexico	O
lacks	O
regulations	O
in	O
this	O
matter	O
,	O
affecting	O
national	O
and	O
international	O
trade	O
from	O
agroindustry	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
diagnose	O
pesticide	O
residues	O
in	O
oranges	O
from	O
Nuevo	O
Leon	O
,	O
México	O
,	O
in	O
citrus	O
orchards	O
.	O

In	O
May	O
2014	O
,	O
100	O
orange	O
fruit	O
samples	O
were	O
taken	O
randomly	O
from	O
orchards	O
and	O
subjected	O
to	O
analysis	B-P
for	O
93	O
pesticides	O
at	O
residual	O
level	O
by	O
GC	B-P
/	O
QQQ-MS	B-P
and	O
LCQ-TOF-MS	B-P
.	O

Results	O
showed	O
the	O
presence	O
of	O
15	O
pesticide	O
residues	O
in	O
the	O
samples	O
.	O

The	O
comparison	O
of	O
the	O
residual	O
levels	O
of	O
pesticides	O
found	O
in	O
orange	O
samples	O
among	O
the	O
MRLs	O
allowed	O
by	O
USA	O
,	O
EU	O
and	O
Japanese	O
regulations	O
demonstrated	O
that	O
all	O
samples	O
were	O
below	O
MRLs	O
issued	O
by	O
USA	O
and	O
Japan	O
.	O

Some	O
orange	O
samples	O
were	O
above	O
MRLs	O
issued	O
by	O
the	O
EU	O
.	O

This	O
provides	O
a	O
basis	O
to	O
establish	O
strategies	O
in	O
order	O
to	O
satisfy	O
International	O
Standards	O
to	O
protect	O
human	O
health	O
and	O
encourage	O
Food	O
Safety	O
in	O
Mexico	O
.	O

Effects	O
of	O
Covering	O
Surgical	O
Wounds	O
with	O
Polyglycolic	O
Acid	O
Sheets	O
for	O
Posttonsillectomy	O
Pain	O
.	O

Postoperative	O
pain	O
is	O
a	O
remaining	O
issue	O
in	O
tonsillectomy	O
.	O

Polyglycolic	O
acid	O
(	O
PGA	O
)	O
is	O
a	O
biocompatible	O
material	O
used	O
for	O
absorbent	O
suture	O
reinforcement	O
,	O
and	O
its	O
sheet	O
has	O
been	O
applied	O
for	O
covering	O
defects	O
after	O
resection	O
of	O
oral	O
carcinoma	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
examine	O
whether	O
the	O
attachment	O
of	O
a	O
PGA	O
sheet	O
to	O
surgical	O
wounds	O
would	O
reduce	O
posttonsillectomy	O
pain	O
.	O

In	O
this	O
prospective	O
single-blind	O
study	O
,	O
17	O
consecutive	O
adult	O
patients	O
were	O
recruited	O
who	O
needed	O
to	O
undergo	O
tonsillectomy	O
,	O
mainly	O
due	O
to	O
habitual	O
tonsillitis	O
.	O

Following	O
bilateral	O
tonsillectomies	O
,	O
a	O
PGA	O
sheet	O
was	O
attached	O
with	O
fibrin	O
glue	O
to	O
only	O
1	O
side	O
,	O
without	O
notification	O
to	O
patients	O
of	O
which	O
side	O
.	O

Postoperative	O
pain	O
of	O
each	O
side	O
was	O
separately	O
evaluated	O
with	O
a	O
visual	B-P
analog	I-P
scale	I-P
at	O
4	O
time	O
points	O
:	O
before	O
each	O
meal	O
and	O
before	O
sleep	O
.	O

Postoperative	O
pain	O
of	O
both	O
the	O
PGA	O
sheet	O
-attached	O
and	O
nonattached	O
sides	O
was	O
most	O
severe	O
before	O
breakfast	O
among	O
4	O
time	O
points	O
.	O

Postoperative	O
pain	O
measured	O
before	O
breakfast	O
was	O
significantly	O
more	O
severe	O
in	O
the	O
PGA	O
sheet	O
-attached	O
side	O
than	O
the	O
nonattached	O
side	O
.	O

As	O
such	O
,	O
this	O
study	O
provided	O
solid	O
data	O
on	O
the	O
negative	O
effects	O
of	O
PGA	O
sheeting	O
on	O
posttonsillectomy	O
pain	O
.	O

Slower	O
but	O
not	O
faster	O
unilateral	O
fatiguing	O
knee	O
extensions	O
alter	O
contralateral	O
limb	O
performance	O
without	O
impairment	O
of	O
maximal	O
torque	O
output	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
effects	O
of	O
unilateral	O
fatigue	O
of	O
the	O
knee	O
extensors	O
at	O
different	O
movement	O
velocities	O
on	O
neuromuscular	O
performance	O
in	O
the	O
fatigued	O
and	O
non-fatigued	O
leg	O
.	O

Unilateral	O
fatigue	O
of	O
the	O
knee	O
extensors	O
was	O
induced	O
in	O
11	O
healthy	O
young	O
men	O
(	O
23.7	O
±	O
3.8	O
years	O
)	O
at	O
slower	O
(	O
60°/s	O
;	O
FAT60	O
)	O
and	O
faster	O
movement	O
velocities	B-P
(	O
240°/s	O
;	O
FAT240	O
)	O
using	O
an	O
isokinetic	O
dynamometer	O
.	O

A	O
resting	O
control	O
(	O
CON	O
)	O
condition	O
was	O
included	O
.	O

The	O
fatigue	O
protocols	O
consisted	O
of	O
five	O
sets	O
of	O
15	O
maximal	O
concentric	O
knee	O
extensions	O
using	O
the	O
dominant	O
leg	O
.	O

Before	O
and	O
after	O
fatigue	O
,	O
peak	O
isokinetic	O
torque	O
(	O
PIT	O
)	O
and	O
time	O
to	O
PIT	O
(	O
TTP	O
)	O
of	O
the	O
knee	O
extensors	O
as	O
well	O
as	O
electromyographic	O
(	O
EMG	O
)	O
activity	O
of	O
vastus	O
medialis	O
,	O
vastus	O
lateralis	O
,	O
and	O
biceps	O
femoris	O
muscles	O
were	O
assessed	O
at	O
60	O
and	O
240°/s	O
movement	O
velocities	B-P
in	O
the	O
fatigued	O
and	O
non-fatigued	O
leg	O
.	O

In	O
the	O
fatigue	O
d	O
leg	O
,	O
significantly	O
greater	O
PIT	O
decrements	O
were	O
observed	O
following	O
FAT60	O
and	O
FAT240	O
(	O
11-19	O
%	O
)	O
compared	O
to	O
CON	O
(	O
3-4	O
%	O
,	O
p	O
=	O
.002	O
,	O
d	O
=	O
2.3	O
)	O
.	O

Further	O
,	O
EMG	O
activity	O
increased	O
in	O
vastus	O
lateralis	O
and	O
biceps	O
femoris	O
muscle	O
following	O
FAT240	O
only	O
(	O
8-28	O
%	O
,	O
0.018	O
≤	O
p	O
≤	O
.024	O
,	O
d	O
=	O
1.8	O
)	O
.	O

In	O
the	O
non-fatigued	O
leg	O
,	O
shorter	O
TTP	O
values	O
were	O
found	O
after	O
the	O
FAT60	O
protocol	O
(	O
11-15	O
%	O
,	O
p	O
=	O
.023	O
,	O
d	O
=	O
2.4	O
)	O
.	O

No	O
significant	O
changes	O
were	O
found	O
for	O
EMG	O
data	O
in	O
the	O
non-fatigued	O
leg	O
.	O

The	O
present	O
study	O
revealed	O
that	O
both	O
slower	O
and	O
faster	O
velocity	B-P
fatiguing	O
contractions	O
failed	O
to	O
show	O
any	O
evidence	O
of	O
cross-over	O
fatigue	O
on	O
PIT	O
.	O

However	O
,	O
unilateral	O
knee	O
extensor	O
fatigue	O
protocols	O
conducted	O
at	O
slower	O
movement	O
velocities	B-P
(	O
i.e.	O
,	O
60°/s	O
)	O
appear	O
to	O
modulate	O
torque	O
production	O
on	O
the	O
non-fatigued	O
side	O
(	O
evident	O
in	O
shorter	O
TTP	O
values	O
)	O
.	O

Cardiovascular	B-P
magnetic	I-P
resonance	I-P
features	O
of	O
mechanical	O
dyssynchrony	O
in	O
patients	O
with	O
left	O
bundle	O
branch	O
block	O
.	O

Patients	O
with	O
left	O
bundle	O
branch	O
block	O
(	O
LBBB	O
)	O
can	O
exhibit	O
mechanical	O
dyssynchrony	O
which	O
may	O
contribute	O
to	O
heart	O
failure	O
;	O
such	O
patients	O
may	O
benefit	O
from	O
cardiac	O
resynchronization	O
treatment	O
(	O
CRT	O
)	O
.	O

While	O
cardiac	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	O
CMR	B-P
)	O
has	O
become	O
a	O
common	O
part	O
of	O
heart	O
failure	O
work-up	B-P
,	O
CMR	B-P
features	O
of	O
mechanical	O
dyssynchrony	O
in	O
patients	O
with	O
LBBB	O
have	O
not	O
been	O
well	O
characterized	O
.	O

This	O
study	O
aims	O
to	O
investigate	O
the	O
potential	O
of	O
CMR	B-P
to	O
characterize	O
mechanical	O
features	O
of	O
LBBB	O
.	O

CMR	B-P
examinations	O
from	O
43	O
patients	O
with	O
LBBB	O
on	O
their	O
electrocardiogram	O
,	O
but	O
without	O
significant	O
focal	O
structural	O
abnormalities	O
,	O
and	O
from	O
43	O
age-	O
and	O
gender	O
-matched	O
normal	O
controls	O
were	O
retrospectively	O
reviewed	O
.	O

The	O
following	O
mechanical	O
features	O
of	O
LBBB	O
were	O
evaluated	O
:	O
septal	O
flash	O
(	O
SF	O
)	O
,	O
apical	O
rocking	O
(	O
AR	O
)	O
,	O
delayed	O
aortic	O
valve	O
opening	O
measured	O
relative	O
to	O
both	O
end-diastole	O
(	O
AVOED	O
)	O
and	O
pulmonic	O
valve	O
opening	O
(	O
AVOPVO	O
)	O
,	O
delayed	O
left-ventricular	O
(	O
LV	O
)	O
free-wall	O
contraction	O
,	O
and	O
curvatures	O
of	O
the	O
septum	O
and	O
LV	O
free-wall	O
.	O

Septal	O
displacement	O
curves	O
were	O
also	O
generated	O
,	O
using	O
feature	O
-tracking	O
techniques	O
.	O

The	O
echocardiographic	B-P
findings	O
of	O
LBBB	O
were	O
also	O
reviewed	O
in	O
those	O
subjects	O
for	O
whom	O
they	O
were	O
available	O
.	O

LBBB	O
was	O
significantly	O
associated	O
with	O
the	O
presence	O
of	O
SF	O
and	O
AR	O
;	O
within	O
the	O
LBBB	O
group	O
,	O
79	O
%	O
had	O
SF	O
and	O
65	O
%	O
had	O
AR	O
.	O

Delayed	O
AVOED	O
,	O
AVOPVO	O
,	O
and	O
delayed	O
LV	O
free-wall	O
contraction	O
were	O
significantly	O
associated	O
with	O
LBBB	O
.	O

AVOED	O
and	O
AVOPVO	O
positively	O
correlated	O
with	O
QRS	O
duration	O
and	O
negatively	O
correlated	O
with	O
ejection	B-P
fraction	I-P
.	O

Hearts	O
with	O
electrocardiographic	B-P
evidence	O
of	O
LBBB	O
showed	O
lower	O
septal-to-LV	O
free-wall	O
curvature	O
ratios	O
at	O
end-diastole	O
compared	O
to	O
normal	O
controls	O
.	O

CMR	B-P
can	O
be	O
used	O
to	O
identify	O
and	O
evaluate	O
mechanical	O
dyssynchrony	O
in	O
patients	O
with	O
LBBB	O
.	O

None	O
of	O
the	O
normal	O
controls	O
showed	O
the	O
mechanical	O
features	O
associated	O
with	O
LBBB	O
.	O

Moreover	O
,	O
not	O
all	O
patients	O
with	O
LBBB	O
showed	O
the	O
same	O
degree	O
of	O
mechanical	O
dyssynchrony	O
,	O
which	O
could	O
have	O
implications	O
for	O
CRT	O
.	O

Sella	O
turcica	O
bridging	O
and	O
dental	O
anomalies	O
:	O
is	O
there	O
an	O
association	O
?	O
.	O

Sella	O
turcica	O
bridging	O
(	O
STB	O
)	O
,	O
or	O
calcification	O
of	O
the	O
interclinoid	O
ligament	O
of	O
sella	O
turcica	O
,	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
some	O
dental	O
anomalies	O
(	O
palatal	O
canine	O
impaction	O
and	O
transposition	O
)	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
find	O
any	O
association	O
between	O
canine	O
impaction	O
,	O
hyperdontia	O
or	O
hypodontia	O
and	O
sellar	O
dimensions	O
or	O
bridging	O
.	O

Lateral	O
cephalometric	B-P
radiographs	B-P
from	O
78	O
patients	O
with	O
impacted	O
canines	O
,	O
68	O
with	O
dental	O
agenesis	O
and	O
17	O
with	O
hyperdontia	O
were	O
collected	O
.	O

Linear	O
dimensions	O
of	O
sella	O
turcica	O
were	O
calculated	O
and	O
compared	O
to	O
those	O
of	O
a	O
control	O
group	O
(	O
47	O
individuals	O
)	O
.	O

A	O
standardize	O
scoring	O
scale	O
was	O
used	O
to	O
quantify	O
the	O
extent	O
of	O
STB	O
from	O
each	O
radiographs	B-P
.	O

The	O
frequency	O
of	O
partial	O
and	O
complete	O
calcifications	O
of	O
sella	O
in	O
patients	O
with	O
dental	O
anomalies	O
is	O
increased	O
when	O
compared	O
to	O
controls	O
.	O

STB	O
can	O
influence	O
the	O
interclinoid	O
distance	O
but	O
does	O
not	O
affect	O
other	O
linear	O
dimensions	O
of	O
sella	O
.	O

No	O
statistically	O
significant	O
difference	O
has	O
been	O
found	O
in	O
sellar	O
dimensions	O
and	O
STB	O
expression	O
when	O
evaluating	O
radiographs	B-P
at	O
different	O
ages	O
.	O

STB	O
is	O
frequently	O
found	O
in	O
patients	O
with	O
dental	O
abnormalities	O
.	O

Development	O
of	O
molecularly	O
imprinted	O
polymers	O
specific	O
for	O
blood	O
antigens	O
for	O
application	O
in	O
antibody-free	B-P
blood	I-P
typing	I-P
.	O

A	O
novel	O
approach	O
in	O
antibody-free	B-P
blood	I-P
typing	I-P
based	O
on	O
molecularly	O
imprinted	O
polymeric	O
nanoparticles	O
is	O
described	O
.	O

Fatigue	O
in	O
multiple	O
sclerosis	O
:	O
Associations	O
with	O
clinical	O
,	O
MRI	B-P
and	O
CSF	O
parameters	O
.	O

Damage	O
of	O
different	O
brain	O
structures	O
has	O
been	O
related	O
to	O
fatigue	O
.	O

Alternatively	O
,	O
functional	O
alterations	O
of	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
cells	O
by	O
the	O
inflammatory	O
milieu	O
within	O
the	O
CNS	O
may	O
be	O
responsible	O
for	O
the	O
development	O
of	O
fatigue	O
.	O

To	O
investigate	O
the	O
effect	O
of	O
structural	O
brain	O
damage	O
and	O
inflammatory	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
changes	O
on	O
fatigue	O
in	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
.	O

We	O
determined	O
the	O
association	O
of	O
different	O
clinical	O
,	O
CSF	O
and	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
parameters	O
with	O
prevalence	O
and	O
severity	O
of	O
fatigue	O
,	O
as	O
measured	O
by	O
the	O
Fatigue	O
Scale	O
for	O
Motor	O
and	O
Cognitive	O
Functions	O
in	O
68	O
early	O
MS	O
patients	O
(	O
discovery	O
cohort	O
)	O
.	O

We	O
validated	O
our	O
findings	O
in	O
two	O
MS	O
cohorts	O
:	O
the	O
MRI	B-P
validation	O
cohort	O
(	O
N	O
=	O
233	O
)	O
for	O
the	O
clinical	O
and	O
MRI	B-P
parameters	O
,	O
and	O
the	O
CSF	O
validation	O
cohort	O
(	O
N	O
=	O
81	O
)	O
for	O
the	O
clinical	O
and	O
CSF	O
parameters	O
.	O

Fatigue	O
was	O
associated	O
with	O
clinical	O
disability	O
.	O

Fatigue	O
did	O
not	O
correlate	O
with	O
any	O
CSF	O
parameter	O
but	O
correlated	O
negatively	O
with	O
total	O
and	O
cortical	O
grey	O
matter	O
volume	O
.	O

However	O
,	O
when	O
controlling	O
for	O
Expanded	O
Disability	O
Status	O
Scale	O
(	O
EDSS	O
)	O
in	O
a	O
multivariate	O
model	O
,	O
these	O
associations	O
lost	O
significance	O
.	O

Disability	O
and	O
disease	O
duration	O
best	O
explain	O
fatigue	O
severity	O
but	O
none	O
of	O
the	O
tested	O
MRI	B-P
or	O
CSF	O
parameter	O
was	O
reliably	O
associated	O
with	O
fatigue	O
.	O

7-Hydroxytropolone	O
produced	O
and	O
utilized	O
as	O
an	O
iron	O
-	O
scavenger	O
by	O
Pseudomonas	O
donghuensis	O
.	O

Pseudomonas	O
donghuensis	O
can	O
excrete	O
large	O
quantities	O
of	O
iron	O
chelating	O
substances	O
in	O
iron-restricted	O
environments	O
.	O

At	O
least	O
two	O
kinds	O
of	O
iron	O
-	O
chelator	O
can	O
be	O
found	O
in	O
the	O
culture	O
supernatant	O
:	O
fluorescent	O
siderophores	O
pyoverdins	O
,	O
and	O
an	O
ethyl	O
acetate	O
-extractable	O
non-fluorescent	O
substance	O
.	O

The	O
non-fluorescent	O
substance	O
was	O
the	O
dominant	O
contributor	O
to	O
the	O
iron	O
chelating	O
activity	O
of	O
the	O
culture	O
supernatant	O
of	O
P.	O
donghuensis	O
.	O

Electron	O
ionization	O
mass	O
spectrometry	O
,	O
NMR	B-P
spectroscopy	I-P
,	O
and	O
IR	B-P
spectroscopy	I-P
identified	O
the	O
non-fluorescent	O
iron	O
-	O
chelator	O
as	O
7-hydroxytropolone	O
.	O

The	O
stoichiometry	O
of	O
7-hydroxytropolone	O
ferric	O
complex	O
was	O
determined	O
to	O
be	O
2:1	O
by	O
the	O
continuous	O
variation	O
method	O
.	O

The	O
production	O
of	O
7-hydroxytropolone	O
was	O
repressible	O
by	O
iron	O
in	O
the	O
medium	O
.	O

Moreover	O
,	O
the	O
inhibited	O
growth	O
of	O
doubly	O
siderophore-deficient	O
strain	O
of	O
P.	O
donghuensis	O
under	O
iron-limiting	O
conditions	O
could	O
be	O
partly	O
restored	O
by	O
7-hydroxytropolone	O
.	O

Thus	O
,	O
7-hydroxytropolone	O
was	O
considered	O
to	O
play	O
a	O
previously	O
undiscovered	O
role	O
as	O
an	O
iron	O
-	O
scavenger	O
for	O
P.	O
donghuensis	O
.	O

Zinc	O
transporter	O
ZIP10	O
forms	O
a	O
heteromer	O
with	O
ZIP6	O
which	O
regulates	O
embryonic	O
development	O
and	O
cell	O
migration	O
.	O

There	O
is	O
growing	O
evidence	O
that	O
zinc	O
and	O
its	O
transporters	O
are	O
involved	O
in	O
cell	O
migration	O
during	O
development	O
and	O
in	O
cancer	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
show	O
that	O
zinc	O
transporter	O
ZIP10	O
(	O
SLC39A10	O
)	O
stimulates	O
cell	O
motility	O
and	O
proliferation	O
,	O
both	O
in	O
mammalian	O
cells	O
and	O
in	O
the	O
zebrafish	O
embryo	O
.	O

This	O
is	O
associated	O
with	O
inactivation	O
of	O
GSK-3α	O
and	O
-3ß	O
and	O
downregulation	O
of	O
E-cadherin	O
(	O
CDH1	O
)	O
.	O

Morpholino	O
-mediated	O
knock-down	O
of	O
zip10	O
causes	O
delayed	O
epiboly	O
and	O
deformities	O
of	O
the	O
head	O
,	O
eye	O
,	O
heart	O
and	O
tail	O
.	O

Furthermore	O
,	O
zip10	O
deficiency	O
results	O
in	O
overexpression	O
of	O
cdh1	O
,	O
zip6	O
and	O
stat3	O
,	O
the	O
latter	O
gene	O
product	O
driving	O
transcription	O
of	O
both	O
zip6	O
and	O
zip10	O
The	O
non-reduntant	O
requirement	O
of	O
Zip6	O
and	O
Zip10	O
for	O
epithelial	O
to	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
is	O
consistent	O
with	O
our	O
finding	O
that	O
they	O
exist	O
as	O
a	O
heteromer	O
.	O

We	O
postulate	O
that	O
a	O
subset	O
of	O
ZIPs	O
carrying	O
PrP-like	O
ectodomains	O
,	O
including	O
ZIP6	O
and	O
ZIP10	O
,	O
are	O
integral	O
to	O
cellular	B-P
pathways	O
and	O
plasticity	O
programs	O
,	O
such	O
as	O
EMT	O
.	O

Association	O
between	O
ventricular	O
filling	O
patterns	O
and	O
the	O
extent	O
of	O
late	B-P
enhancement	I-P
on	O
magnetic	B-P
resonance	I-P
imaging	I-P
in	O
patients	O
with	O
hypertrophic	O
cardiomyopathy	O
.	O

To	O
explore	O
the	O
relationship	O
between	O
ventricular	O
filling	O
curves	O
and	O
the	O
extent	O
of	O
late	B-P
enhancement	I-P
on	O
cardiac	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
in	O
patients	O
with	O
hypertrophic	O
cardiomyopathy	O
.	O

We	O
retrospectively	O
included	O
consecutive	O
patients	O
with	O
suspected	O
and/or	O
confirmed	O
hypertrophic	O
cardiomyopathy	O
and	O
a	O
control	O
group	O
of	O
patients	O
matched	O
for	O
age	O
and	O
sex	O
who	O
underwent	O
cardiac	O
MRI	B-P
with	O
evaluation	O
of	O
late	B-P
enhancement	I-P
.	O

Among	O
other	O
determinations	O
,	O
we	O
evaluated	O
the	O
following	O
parameters	O
on	O
cine	O
sequences	O
:	O
peak	O
filling	O
rate	O
,	O
time	O
to	O
the	O
first	O
peak	O
filling	O
rate	O
,	O
and	O
filling	O
rate	O
normalized	O
to	O
the	O
filling	O
volume	O
.	O

Late	B-P
enhancement	I-P
was	O
observed	O
in	O
29	O
(	O
73	O
%	O
)	O
of	O
the	O
40	O
patients	O
with	O
hypertrophic	O
cardiomyopathy	O
.	O

The	O
normalized	O
peak	O
filling	O
rate	O
was	O
significantly	O
lower	O
in	O
patients	O
with	O
late	B-P
enhancement	I-P
(	O
4.9	O
±	O
1.6	O
in	O
those	O
with	O
hypertrophic	O
cardiomyopathy	O
positive	O
for	O
late	B-P
enhancement	I-P
vs.	O
5.8	O
±	O
2.2	O
in	O
those	O
with	O
hypertrophic	O
cardiomyopathy	O
negative	O
for	O
late	B-P
enhancement	I-P
vs.	O
6.3	O
±	O
1.5	O
in	O
controls	O
,	O
p	O
=	O
0.008	O
)	O
and	O
the	O
time	O
to	O
peak	O
filling	O
was	O
longer	O
in	O
patients	O
with	O
late	B-P
enhancement	I-P
(	O
540.6	O
±	O
89.7	O
ms	O
vs.	O
505.5	O
±	O
99.3	O
ms	O
in	O
those	O
with	O
hypertrophic	O
cardiomyopathy	O
negative	O
for	O
late	B-P
enhancement	I-P
vs.	O
486.9	O
±	O
86.3	O
ms	O
in	O
controls	O
,	O
p	O
=	O
0.02	O
)	O
.	O

When	O
the	O
population	O
was	O
stratified	O
into	O
three	O
groups	O
in	O
function	O
of	O
the	O
normalized	O
peak	O
filling	O
rate	O
,	O
significant	O
differences	O
were	O
observed	O
among	O
groups	O
for	O
age	O
(	O
p	O
=	O
0.002	O
)	O
,	O
mean	O
wall	O
thickness	O
(	O
p	O
=	O
0.036	O
)	O
,	O
and	O
myocardial	O
mass	O
(	O
p	O
=	O
0.046	O
)	O
and	O
atrial	O
dimensions	O
,	O
whereas	O
no	O
significant	O
differences	O
with	O
respect	O
to	O
late	B-P
enhancement	I-P
were	O
seen	O
.	O

In	O
patients	O
with	O
hypertrophic	O
cardiomyopathy	O
,	O
we	O
found	O
a	O
significant	O
association	O
between	O
ventricular	O
filling	O
patterns	O
and	O
age	O
,	O
wall	O
thicknesses	O
,	O
and	O
atrial	O
dimensions	O
,	O
but	O
not	O
with	O
the	O
extent	O
of	O
late	B-P
enhancement	I-P
.	O

Moberg	B-P
Picking-Up	I-P
Test	I-P
in	O
patients	O
with	O
hand	O
osteoarthritis	O
.	O

Clinical	O
measurement	O
.	O

The	O
Moberg	B-P
Pick-up	I-P
Test	I-P
(	O
MPUT	B-P
)	O
was	O
previously	O
used	O
to	O
evaluate	O
functional	O
performance	O
in	O
patients	O
with	O
hand	O
inflammatory	O
disease	O
.	O

This	O
is	O
the	O
first	O
study	O
using	O
the	O
MPUT	B-P
in	O
hand	O
osteoarthritis	O
(	O
OA	O
)	O
.	O

Compare	O
the	O
functional	O
performance	O
(	O
MPUT	B-P
)	O
in	O
hand	O
OA	O
patients	O
and	O
healthy	O
controls	O
.	O

Fifty	O
hand	O
OA	O
patients	O
and	O
50	O
controls	O
were	O
assessed	O
using	O
the	O
MPUT	B-P
,	O
AUSCAN	O
and	O
Cochin	O
questionnaires	O
,	O
grip	O
and	O
pinch	B-P
strength	I-P
,	O
pain	O
using	O
a	O
visual	B-P
analog	I-P
scale	I-P
and	O
a	O
Likert	O
scale	O
regarding	O
difficulty	O
to	O
perform	O
MPUT	B-P
.	O

In	O
the	O
MPUT	B-P
evaluation	O
,	O
the	O
OA	O
group	O
presented	O
a	O
statistically	O
significant	O
difference	O
from	O
the	O
control	O
group	O
.	O

The	O
OA	O
group	O
spent	O
more	O
time	O
executing	O
test	O
.	O

The	O
grip	O
and	O
pinch	B-P
strength	I-P
measurements	I-P
showed	O
higher	O
values	O
for	O
the	O
control	O
group	O
.	O

The	O
OA	O
group	O
reported	O
a	O
greater	O
difficulty	O
than	O
the	O
control	O
group	O
in	O
performing	O
the	O
test	O
.	O

The	O
MPUT	B-P
is	O
a	O
short	O
and	O
easy	O
to	O
apply	O
test	O
,	O
which	O
can	O
be	O
safely	O
used	O
to	O
assess	O
the	O
functional	O
performance	O
of	O
the	O
hand	O
OA	O
.	O

II	O
.	O

CD177	O
(	O
+	O
)	O
neutrophils	O
as	O
functionally	O
activated	O
neutrophils	O
negatively	O
regulate	O
IBD	O
.	O

Neutrophils	O
are	O
accumulated	O
in	O
inflamed	O
mucosa	O
of	O
IBD	O
and	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
.	O

CD177	O
is	O
expressed	O
in	O
neutrophils	O
specifically	O
and	O
upregulated	O
during	O
inflammation	O
.	O

However	O
,	O
the	O
role	O
of	O
CD177	O
(	O
+	O
)	O
neutrophils	O
in	O
pathogenesis	O
of	O
IBD	O
remains	O
elusive	O
.	O

Expression	O
of	O
CD177	O
was	O
analysed	O
in	O
peripheral	O
blood	O
and	O
intestinal	O
mucosa	O
from	O
patients	O
with	O
IBD	O
using	O
quantitative	O
RT-PCR	O
,	O
flow	B-P
cytometry	I-P
and	O
immunohistochemistry	B-P
.	O

CD177	O
(	O
+	O
)	O
and	O
CD177	O
(	O
-	O
)	O
neutrophils	O
were	O
isolated	O
to	O
determine	O
gene	O
differences	O
by	O
RNA	O
sequencing	O
.	O

Colitis	O
was	O
established	O
in	O
CD177	O
(	O
-/-	O
)	O
and	O
wild-type	O
mice	O
in	O
response	O
to	O
dextran	O
sulfate	O
sodium	O
(	O
DSS	O
)	O
insults	O
to	O
determine	O
the	O
role	O
of	O
CD177	O
(	O
+	O
)	O
neutrophils	O
in	O
IBD	O
.	O

CD177	O
(	O
+	O
)	O
neutrophils	O
were	O
markedly	O
increased	O
in	O
peripheral	O
blood	O
and	O
inflamed	O
mucosa	O
from	O
patients	O
with	O
active	O
IBD	O
compared	O
with	O
healthy	O
controls	O
.	O

RNA	O
sequencing	O
revealed	O
that	O
differential	O
gene	O
expression	O
between	O
CD177	O
(	O
+	O
)	O
and	O
CD177	O
(	O
-	O
)	O
neutrophils	O
from	O
patients	O
with	O
IBD	O
was	O
associated	O
with	O
response	O
to	O
bacterial	O
defence	O
,	O
hydrogen	O
peroxide	O
and	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
.	O

CD177	O
(	O
+	O
)	O
neutrophils	O
produced	O
lower	O
levels	O
of	O
proinflammatory	O
cytokines	O
(	O
ie	O
,	O
interferon-γ	O
,	O
interleukin	O
(	O
IL	O
)	O
-6	O
,	O
IL-17A	O
)	O
,	O
but	O
higher	O
levels	O
of	O
IL-22	O
and	O
transforming	O
growth	O
factor-β	O
,	O
and	O
exhibited	O
increased	O
bactericidal	O
activities	O
(	O
ie	O
,	O
ROS	O
,	O
antimicrobial	O
peptides	O
,	O
neutrophil	O
extracellular	O
trap	O
)	O
compared	O
with	O
CD177	O
(	O
-	O
)	O
subset	O
.	O

CD177	O
(	O
-/-	O
)	O
mice	O
developed	O
more	O
severe	O
colitis	O
on	O
DSS	O
insults	O
compared	O
with	O
wild-type	O
mice	O
.	O

Moreover	O
,	O
CD177	O
deficiency	O
led	O
to	O
compromised	O
intestinal	O
barrier	O
and	O
impaired	O
antibacterial	O
immunity	O
through	O
decreased	O
production	O
of	O
IL-22	O
by	O
CD177	O
(	O
-	O
)	O
neutrophils	O
.	O

CD177	O
(	O
+	O
)	O
neutrophils	O
represent	O
functionally	O
activated	O
population	O
and	O
play	O
a	O
protective	O
role	O
in	O
IBD	O
through	O
increased	O
bactericidal	O
activity	O
and	O
IL-22	O
production	O
.	O

Targeting	O
CD177	O
(	O
+	O
)	O
neutrophils	O
may	O
be	O
beneficial	O
for	O
treatment	O
of	O
IBD	O
.	O

12-Lead	B-P
electrocardiogram	I-P
as	O
a	O
predictor	O
of	O
sudden	O
cardiac	O
death	O
:	O
from	O
epidemiology	O
to	O
clinical	O
practice	O
.	O

Sudden	O
cardiac	O
death	O
(	O
SCD	O
)	O
causes	O
a	O
high	O
burden	O
of	O
premature	O
deaths	O
in	O
the	O
population	O
affecting	O
subjects	O
of	O
all	O
ages	O
.	O

The	O
identification	O
of	O
subjects	O
at	O
high	O
risk	O
for	O
SCD	O
is	O
of	O
great	O
importance	O
as	O
the	O
prevention	O
of	O
many	O
of	O
these	O
events	O
would	O
be	O
possible	O
with	O
the	O
treatment	O
of	O
underlying	O
cardiac	O
diseases	O
and	O
the	O
use	O
of	O
implantable	O
cardioverter-defibrillators	O
(	O
ICD	O
)	O
.	O

However	O
,	O
the	O
current	O
selection	O
of	O
patients	O
for	O
ICD	O
therapy	O
is	O
based	O
solely	O
on	O
left	O
ventricular	O
ejection	O
fraction	O
,	O
and	O
thus	O
a	O
substantial	O
portion	O
of	O
patients	O
at	O
high	O
risk	O
does	O
not	O
qualify	O
for	O
the	O
therapy	O
.	O

Role	O
of	O
the	O
standard	B-P
electrocardiogram	I-P
(	O
ECG	B-P
)	O
in	O
SCD	O
risk	O
stratification	O
has	O
been	O
under	O
active	O
research	O
during	O
the	O
last	O
decade	O
and	O
multiple	O
abnormalities	O
of	O
depolarization	O
and	O
repolarization	O
on	O
the	O
ECG	B-P
associated	O
with	O
an	O
increased	O
risk	O
of	O
SCD	O
have	O
been	O
identified	O
.	O

In	O
this	O
review	O
,	O
we	O
describe	O
the	O
basic	O
pathophysiological	O
principles	O
behind	O
these	O
changes	O
.	O

We	O
also	O
review	O
the	O
current	O
knowledge	O
of	O
the	O
prognostic	O
significance	O
of	O
ECG	B-P
predictors	O
of	O
SCD	O
in	O
the	O
general	O
population	O
,	O
and	O
in	O
patients	O
with	O
coronary	O
heart	O
disease	O
(	O
CHD	O
)	O
,	O
heart	O
failure	O
,	O
cardiomyopathies	O
,	O
and	O
in	O
inheritable	O
arrhythmia	O
syndromes	O
.	O

Also	O
,	O
insights	O
into	O
the	O
novel	O
digital	O
ECG	B-P
signal	O
processing	O
techniques	O
are	O
provided	O
.	O

Heterotopic	O
ossification	O
after	O
the	O
use	O
of	O
recombinant	O
human	O
bone	O
morphogenetic	O
protein-7	O
.	O

To	O
present	O
the	O
incidence	O
of	O
heterotopic	O
ossification	O
after	O
the	O
use	O
of	O
recombinant	O
human	O
bone	O
morphogenetic	O
protein-7	O
(	O
rhBMP-7	O
)	O
for	O
the	O
treatment	O
of	O
nonunions	O
.	O

Bone	O
morphogenetic	O
proteins	O
(	O
BMPs	O
)	O
promote	O
bone	O
formation	O
by	O
auto-induction	O
.	O

Recombinant	O
human	O
BMP-7	O
in	O
combination	O
with	O
bone	O
grafts	O
was	O
used	O
in	O
84	O
patients	O
for	O
the	O
treatment	O
of	O
long	O
bone	O
nonunions	O
.	O

All	O
patients	O
were	O
evaluated	O
radiographicaly	B-P
for	O
the	O
development	O
of	O
heterotopic	O
ossification	O
during	O
the	O
standard	O
assessment	O
for	O
the	O
nonunion	O
healing	O
.	O

In	O
all	O
patients	O
(	O
80.9	O
%	O
)	O
with	O
radiographic	O
signs	O
of	O
heterotopic	O
ossification	O
,	O
a	O
CT	B-P
scan	I-P
was	O
performed	O
.	O

Nonunion	O
site	O
palpation	B-P
and	O
ROM	B-P
evaluation	I-P
of	O
the	O
adjacent	O
joints	O
were	O
also	O
carried	O
out	O
.	O

Factors	O
related	O
to	O
the	O
patient	O
(	O
age	O
,	O
gender	O
)	O
,	O
the	O
nonunion	O
(	O
location	O
,	O
size	O
,	O
chronicity	O
,	O
number	O
of	O
previous	O
procedures	O
,	O
infection	O
,	O
surrounding	O
tissues	O
condition	O
)	O
and	O
the	O
surgical	O
procedure	O
(	O
graft	O
and	O
fixation	O
type	O
,	O
amount	O
of	O
rhBMP-7	O
)	O
were	O
correlated	O
with	O
the	O
development	O
of	O
heterotopic	O
ossification	O
and	O
statistical	O
analysis	O
with	O
Pearsons	O
χ	O
(	O
2	O
)	O
test	O
was	O
performed	O
.	O

Eighty	O
point	O
nine	O
percent	O
of	O
the	O
nonunions	O
treated	O
with	O
rhBMP-7	O
,	O
healed	O
with	O
no	O
need	O
for	O
further	O
procedures	O
.	O

Heterotopic	O
bone	O
formation	O
occurred	O
in	O
15	O
of	O
84	O
patients	O
(	O
17.8	O
%	O
)	O
and	O
it	O
was	O
apparent	O
in	O
the	O
routine	O
radiological	O
evaluation	O
of	O
the	O
nonunion	O
site	O
,	O
in	O
a	O
mean	O
time	O
of	O
5.5	O
mo	O
after	O
the	O
rhBMP-7	O
application	O
(	O
range	O
3-12	O
)	O
.	O

The	O
heterotopic	O
ossification	O
was	O
located	O
at	O
the	O
femur	O
in	O
8	O
cases	O
,	O
at	O
the	O
tibia	O
in	O
6	O
,	O
and	O
at	O
the	O
humerus	O
in	O
οne	O
patient	O
.	O

In	O
4	O
patients	O
a	O
palpable	O
mass	O
was	O
present	O
and	O
only	O
in	O
one	O
patient	O
,	O
with	O
a	O
para-articular	O
knee	O
nonunion	O
treated	O
with	O
rhBMP-7	O
,	O
the	O
size	O
of	O
heterotopic	O
ossification	O
affected	O
the	O
knee	O
range	O
of	O
motion	O
.	O

All	O
the	O
patients	O
with	O
heterotopic	O
ossification	O
were	O
male	O
.	O

Statistical	O
analysis	O
proved	O
that	O
patient	O
's	O
gender	O
was	O
the	O
only	O
important	O
factor	O
for	O
the	O
development	O
of	O
heterotopic	O
ossification	O
(	O
P	O
=	O
0.007	O
)	O
.	O

Heterotopic	O
ossification	O
after	O
the	O
use	O
of	O
rhBMP-7	O
in	O
nonunions	O
was	O
common	O
but	O
it	O
did	O
not	O
compromise	O
the	O
final	O
clinical	O
outcome	O
in	O
most	O
cases	O
,	O
and	O
affected	O
only	O
male	O
patients	O
.	O

Ultra-low	O
activities	O
of	O
a	O
common	O
radioisotope	O
for	O
permission	O
-free	O
tracking	O
of	O
a	O
drosophilid	O
fly	O
in	O
its	O
natural	O
habitat	O
.	O

Knowledge	O
of	O
a	O
species	O
'	O
ecology	O
,	O
including	O
its	O
movement	O
in	O
time	O
and	O
space	O
,	O
is	O
key	O
for	O
many	O
questions	O
in	O
biology	O
and	O
conservation	O
.	O

While	O
numerous	O
tools	O
for	O
tracking	O
larger	O
animals	O
are	O
available	O
,	O
millimetre-sized	O
insects	O
are	O
averse	O
to	O
standard	O
tracking	O
and	O
labelling	O
procedures	O
.	O

Here	O
,	O
we	O
evaluated	O
the	O
applicability	O
of	O
ultra-low	O
,	O
permission	O
-	O
exempt	O
activities	O
of	O
the	O
metastable	O
isomer	O
of	O
the	O
radionuclide	O
Technetium-99	O
for	O
labelling	O
and	O
field	O
detection	O
of	O
the	O
mountain	O
fly	O
Drosophila	O
nigrosparsa	O
.	O

We	O
demonstrate	O
that	O
an	O
activity	O
of	O
less	O
than	O
10	O
MBq	O
is	O
sufficient	O
to	O
label	O
dozens	O
of	O
flies	O
and	O
detect	O
single	O
individuals	O
using	O
standard	O
radiation	O
protection	O
monitors	B-P
.	O

The	O
methodology	O
presented	O
here	O
is	O
applicable	O
to	O
many	O
small-sized	O
,	O
low-mobility	O
animals	O
as	O
well	O
as	O
independent	O
from	O
light	O
and	O
weather	O
conditions	O
and	O
visual	O
contact	O
with	O
the	O
target	O
organism	O
.	O

Functional	O
states	O
of	O
rat	O
cortical	O
circuits	O
during	O
the	O
unpredictable	O
availability	O
of	O
a	O
reward	O
-	O
related	O
cue	O
.	O

Proper	O
performance	O
of	O
acquired	O
abilities	O
can	O
be	O
disturbed	O
by	O
the	O
unexpected	O
occurrence	O
of	O
external	O
changes	O
.	O

Rats	O
trained	O
with	O
an	O
operant	O
conditioning	O
task	O
(	O
to	O
press	O
a	O
lever	O
in	O
order	O
to	O
obtain	O
a	O
food	O
pellet	O
)	O
using	O
a	O
fixed-ratio	O
schedule	O
(	O
1:1	O
)	O
were	O
subsequently	O
placed	O
in	O
a	O
Skinner	O
box	O
in	O
which	O
the	O
lever	O
could	O
be	O
removed	O
randomly	O
.	O

Field	O
postsynaptic	O
potentials	O
(	O
fPSPs	O
)	O
were	O
chronically	O
evoked	O
in	O
perforant	O
pathway	O
-	O
hippocampal	O
CA1	O
(	O
PP-CA1	O
)	O
,	O
CA1	O
-	O
subiculum	O
(	O
CA1	O
-	O
SUB	O
)	O
,	O
CA1	O
-	O
medial	O
prefrontal	O
cortex	O
(	O
CA1	O
-	O
mPFC	O
)	O
,	O
mPFC	O
-	O
nucleus	O
accumbens	O
(	O
mPFC	O
-	O
NAc	O
)	O
,	O
and	O
mPFC	O
-	O
basolateral	O
amygdala	O
(	O
mPFC	O
-	O
BLA	O
)	O
synapses	O
during	O
lever	O
IN	O
and	O
lever	O
OUT	O
situations	O
.	O

While	O
lever	O
presses	O
were	O
accompanied	O
by	O
a	O
significant	O
increase	O
in	O
fPSP	O
slopes	O
at	O
the	O
five	O
synapses	O
,	O
the	O
unpredictable	O
absence	O
of	O
the	O
lever	O
were	O
accompanied	O
by	O
decreased	O
fPSP	O
slopes	O
in	O
all	O
,	O
except	O
PP-CA1	O
synapses	O
.	O

Spectral	B-P
analysis	I-P
of	O
local	O
field	O
potentials	O
(	O
LFPs	O
)	O
recorded	O
when	O
the	O
animal	O
approached	O
the	O
corresponding	O
area	O
in	O
the	O
lever	O
OUT	O
situation	O
presented	O
lower	O
spectral	O
powers	O
than	O
during	O
lever	O
IN	O
occasions	O
for	O
all	O
recording	O
sites	O
,	O
apart	O
from	O
CA1	O
.	O

Thus	O
,	O
the	O
unpredictable	O
availability	O
of	O
a	O
reward	O
-	O
related	O
cue	O
modified	O
the	O
activity	O
of	O
cortical	O
and	O
subcortical	O
areas	O
related	O
with	O
the	O
acquisition	O
of	O
operant	O
learning	O
tasks	O
,	O
suggesting	O
an	O
immediate	O
functional	O
reorganization	O
of	O
these	O
neural	O
circuits	O
to	O
address	O
the	O
changed	O
situation	O
and	O
to	O
modify	O
ongoing	O
behaviors	O
accordingly	O
.	O

Evaluation	O
of	O
Soft	O
Tissue	O
Sarcoma	O
Response	O
to	O
Preoperative	O
Chemoradiotherapy	O
Using	O
Dynamic	B-P
Contrast-Enhanced	I-P
Magnetic	I-P
Resonance	I-P
Imaging	I-P
.	O

This	O
study	O
aims	O
to	O
assess	O
the	O
utility	O
of	O
quantitative	B-P
dynamic	I-P
contrast-enhanced	I-P
(	I-P
DCE	I-P
)	I-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	I-P
MRI	I-P
)	I-P
parameters	O
in	O
comparison	O
with	O
imaging	B-P
tumor	O
size	O
for	O
early	O
prediction	O
and	O
evaluation	O
of	O
soft	O
tissue	O
sarcoma	O
response	O
to	O
preoperative	O
chemoradiotherapy	O
.	O

In	O
total	O
,	O
20	O
patients	O
with	O
intermediate-	O
to	O
high-grade	O
soft	O
tissue	O
sarcomas	O
received	O
either	O
a	O
phase	O
I	O
trial	O
regimen	O
of	O
sorafenib	O
+	O
chemoradiotherapy	O
(	O
n	O
=	O
8	O
)	O
or	O
chemoradiotherapy	O
only	O
(	O
n	O
=	O
12	O
)	O
,	O
and	O
underwent	O
DCE-MRI	B-P
at	O
baseline	O
,	O
after	O
2	O
weeks	O
of	O
treatment	O
with	O
sorafenib	O
or	O
after	O
the	O
first	O
chemotherapy	O
cycle	O
,	O
and	O
after	O
therapy	O
completion	O
.	O

MRI	B-P
tumor	O
size	O
in	O
the	O
longest	O
diameter	O
(	O
LD	O
)	O
was	O
measured	O
according	O
to	O
the	O
RECIST	O
(	O
Response	O
Evaluation	O
Criteria	O
In	O
Solid	O
Tumors	O
)	O
guidelines	O
.	O

Pharmacokinetic	O
analyses	O
of	O
DCE-MRI	B-P
data	O
were	O
performed	O
using	O
the	O
Shutter-Speed	O
model	O
.	O

After	O
only	O
2	O
weeks	O
of	O
treatment	O
with	O
sorafenib	O
or	O
after	O
1	O
chemotherapy	O
cycle	O
,	O
K	O
(	O
trans	O
)	O
(	O
rate	O
constant	O
for	O
plasma	O
/	O
interstitium	O
contrast	O
agent	O
transfer	O
)	O
and	O
its	O
percent	O
change	O
were	O
good	O
early	O
predictors	O
of	O
optimal	O
versus	O
suboptimal	O
pathological	O
response	O
with	O
univariate	O
logistic	O
regression	O
C	O
statistics	O
values	O
of	O
0.90	O
and	O
0.80	O
,	O
respectively	O
,	O
whereas	O
RECIST	O
LD	O
percent	O
change	O
was	O
only	O
a	O
fair	O
predictor	O
(	O
C	O
=	O
0.72	O
)	O
.	O

Post-therapy	O
K	O
(	O
trans	O
)	O
,	O
ve	O
(	O
extravascular	O
and	O
extracellular	O
volume	O
fraction	O
)	O
,	O
and	O
kep	O
(	O
intravasation	O
rate	O
constant	O
)	O
,	O
not	O
RECIST	O
LD	O
,	O
were	O
excellent	O
(	O
C	O
>	O
0.90	O
)	O
markers	O
of	O
therapy	O
response	O
.	O

Several	O
DCE-MRI	B-P
parameters	O
before	O
,	O
during	O
,	O
and	O
after	O
therapy	O
showed	O
significant	O
(	O
P	O
<	O
.05	O
)	O
correlations	O
with	O
percent	O
necrosis	O
of	O
resected	O
tumor	O
specimens	O
.	O

In	O
conclusion	O
,	O
absolute	O
values	O
and	O
percent	O
changes	O
of	O
quantitative	O
DCE-MRI	B-P
parameters	O
provide	O
better	O
early	O
prediction	O
and	O
evaluation	O
of	O
the	O
pathological	O
response	O
of	O
soft	O
tissue	O
sarcoma	O
to	O
preoperative	O
chemoradiotherapy	O
than	O
the	O
conventional	O
measurement	O
of	O
imaging	B-P
tumor	O
size	O
change	O
.	O

Performance	O
of	O
ANTI-HCV	B-P
testing	I-P
in	O
dried	O
blood	O
spots	O
and	O
saliva	O
according	O
to	O
HIV	O
status	O
.	O

The	O
use	O
of	O
saliva	O
and	O
dried	O
blood	O
spots	O
(	O
DBS	O
)	O
could	O
increase	O
access	O
to	O
HCV	O
diagnosis	O
for	O
high-risk	O
populations	O
,	O
such	O
as	O
HIV-infected	O
individuals	O
,	O
but	O
the	O
performance	O
of	O
these	O
assays	B-P
has	O
not	O
been	O
well	O
established	O
in	O
this	O
group	O
.	O

This	O
study	O
aims	O
to	O
evaluate	O
HIV	O
status	O
,	O
particularly	O
TCD4	O
(	O
+	O
)	O
cell	O
count	B-P
and	O
viral	B-P
load	I-P
,	O
in	O
the	O
performance	O
of	O
anti-HCV	B-P
testing	I-P
using	O
DBS	O
and	O
saliva	O
.	O

A	O
total	O
of	O
961	O
individuals	O
classified	O
as	O
HCV+	O
,	O
HIV+	O
,	O
or	O
HIV	O
/	O
HCV+	O
,	O
as	O
well	O
as	O
negative	O
controls	O
,	O
donated	O
serum	O
,	O
DBS	O
,	O
and	O
saliva	O
samples	O
for	O
anti-HCV	B-P
testing	I-P
using	O
a	O
commercial	O
enzyme	B-P
immunoassay	I-P
.	O

Sample	O
volume	O
was	O
modified	O
for	O
DBS	O
and	O
saliva	O
,	O
and	O
an	O
ROC	O
curve	O
was	O
used	O
for	O
cut-off	O
determination	B-P
in	O
saliva	O
.	O

Anti-HCV	O
sensitivities	O
were	O
greater	O
than	O
93	O
%	O
using	O
DBS	O
and	O
saliva	O
in	O
the	O
HCV+	O
group	O
,	O
while	O
they	O
were	O
83.3	O
%	O
and	O
95.6	O
%	O
for	O
HCV	O
/	O
HIV+	O
individuals	O
for	O
DBS	O
and	O
saliva	O
assays	B-P
,	O
respectively	O
.	O

Specificity	O
varied	O
from	O
91.7	O
%	O
to	O
100	O
%	O
using	O
saliva	O
and	O
DBS	O
in	O
HIV	O
monoinfected	O
and	O
control	O
subjects	O
.	O

When	O
only	O
anti-HCV	O
/	O
HCV	O
RNA+	O
serum	O
samples	O
,	O
that	O
is	O
,	O
true	O
positives	O
,	O
were	O
considered	O
,	O
the	O
sensitivities	O
were	O
98.3	O
%	O
and	O
100	O
%	O
for	O
DBS	O
and	O
saliva	O
,	O
respectively	O
,	O
in	O
the	O
HCV+	O
group	O
and	O
91.6	O
%	O
and	O
94.8	O
%	O
for	O
DBS	O
and	O
saliva	O
,	O
respectively	O
,	O
in	O
the	O
HIV	O
/	O
HCV+	O
group	O
.	O

High	O
absorbance	O
values	O
were	O
observed	O
among	O
those	O
presenting	O
with	O
HCV	B-P
RNA	I-P
in	O
serum	O
and	O
low	O
HIV	B-P
viral	I-P
load	I-P
(	O
less	O
than	O
50	O
copies/mL	O
)	O
.	O

In	O
conclusion	O
,	O
DBS	O
and	O
saliva	O
samples	O
could	O
be	O
used	O
for	O
anti-HCV	O
detection	O
,	O
particularly	O
to	O
identify	O
active	O
HCV	O
cases	O
,	O
but	O
low	O
sensitivity	O
was	O
observed	O
for	O
anti-HCV	B-P
testing	I-P
using	O
DBS	O
in	O
the	O
HIV	O
/	O
HCV+	O
group	O
.	O

An	O
ultrasensitive	O
electrochemiluminescence	B-P
sensor	O
based	O
on	O
reduced	O
graphene	O
oxide	O
-	O
copper	O
sulfide	O
composite	O
coupled	O
with	O
capillary	B-P
electrophoresis	I-P
for	O
determination	B-P
of	O
amlodipine	O
besylate	O
in	O
mice	O
plasma	O
.	O

A	O
new	O
electrochemiluminescence	B-P
(	O
ECL	B-P
)	O
sensor	O
based	O
on	O
reduced	O
graphene	O
oxide	O
-	O
copper	O
sulfide	O
(	O
rGO	O
-	O
CuS	O
)	O
composite	O
coupled	O
with	O
capillary	B-P
electrophoresis	I-P
(	O
CE	B-P
)	O
was	O
constructed	O
for	O
the	O
ultrasensitive	O
detection	O
of	O
amlodipine	O
besylate	O
(	O
AML	O
)	O
for	O
the	O
first	O
time	O
.	O

In	O
this	O
work	O
,	O
rGO	O
-	O
CuS	O
composite	O
was	O
synthesized	O
by	O
one-pot	O
hydrothermal	O
method	O
and	O
used	O
for	O
electrode	O
modification	O
.	O

The	O
electrochemical	B-P
and	O
ECL	B-P
behaviors	O
of	O
the	O
sensor	O
were	O
investigated	O
.	O

More	O
than	O
5-fold	O
enhance	O
in	O
ECL	B-P
intensity	O
was	O
observed	O
after	O
modified	O
with	O
rGO	O
-	O
CuS	O
composite	O
.	O

The	O
results	O
can	O
be	O
ascribed	O
to	O
the	O
presence	O
of	O
rGO	O
-	O
CuS	O
composite	O
on	O
the	O
electrode	O
surface	O
that	O
facilitates	O
the	O
electron	O
transfer	O
rate	O
between	O
the	O
electroactive	O
center	O
of	O
Ru	O
(	O
bpy	O
)	O
3	O
(	O
2+	O
)	O
and	O
the	O
electrode	O
.	O

The	O
ECL	B-P
sensor	O
was	O
coupled	O
with	O
CE	B-P
to	O
improve	O
the	O
selectivity	O
and	O
the	O
CE	B-P
-	O
ECL	B-P
parameters	O
that	O
affect	O
separation	O
and	O
detection	O
were	O
optimized	O
.	O

Under	O
the	O
optimum	O
conditions	O
,	O
the	O
linear	O
ranges	O
for	O
AML	O
was	O
0.008-5.0μg/mL	O
with	O
a	O
detection	O
limit	O
of	O
2.8ng/mL	O
(	O
S/N=3	O
)	O
.	O

The	O
method	B-P
displayed	O
the	O
advantages	O
of	O
high	O
sensitivity	O
,	O
good	O
selectivity	O
,	O
wide	O
linear	O
range	O
,	O
low	O
detection	O
limit	O
and	O
fine	O
reproducibility	O
,	O
and	O
was	O
used	O
to	O
analyze	O
AML	O
in	O
mice	O
plasma	O
with	O
a	O
satisfactory	O
result	O
,	O
which	O
holds	O
a	O
great	O
potential	O
in	O
the	O
field	O
of	O
pharmaceutical	O
analysis	O
.	O

Discordance	O
in	O
pathology	O
report	O
after	O
central	B-P
pathology	I-P
review	I-P
:	O
Implications	O
for	O
breast	O
cancer	O
adjuvant	O
treatment	O
.	O

Pathological	O
predictive	O
factors	O
are	O
the	O
most	O
important	O
markers	O
when	O
selecting	O
early	O
breast	O
cancer	O
adjuvant	O
therapy	O
.	O

In	O
randomized	O
clinical	O
trials	O
the	O
variability	O
in	O
pathology	O
report	O
after	O
central	B-P
pathology	I-P
review	I-P
is	O
noteworthy	O
.	O

We	O
evaluated	O
the	O
discordance	O
rate	O
(	O
DR	O
)	O
and	O
inter-rater	O
agreement	O
between	O
local	O
and	O
central	O
histopathological	O
report	O
and	O
the	O
clinical	O
implication	O
on	O
treatment	O
decision	O
.	O

A	O
retrospective	O
analysis	O
was	O
conducted	O
in	O
a	O
series	O
of	O
consecutive	O
early	O
breast	O
cancer	O
tumors	O
diagnosed	O
by	O
local	O
pathologists	O
and	O
subsequently	O
reviewed	O
at	O
the	O
Pathology	O
Division	O
of	O
European	O
Institute	O
of	O
Oncology	O
.	O

The	O
inter-rater	O
agreement	O
(	O
k	O
)	O
between	O
local	O
and	O
central	O
pathology	O
was	O
calculated	O
for	O
Ki-67	O
,	O
grading	O
,	O
hormone	O
receptors	O
(	O
ER	O
/	O
PgR	O
)	O
and	O
HER2/neu	O
.	O

The	O
Bland-Altman	O
plots	O
were	O
derived	O
to	O
determine	O
discrepancies	O
in	O
Ki-67	O
,	O
ER	O
and	O
PgR	O
.	O

DR	O
was	O
calculated	O
for	O
ER	O
/	O
PgR	O
and	O
HER2	O
.	O

From	O
2007	O
to	O
2013	O
,	O
187	O
pathology	O
specimens	O
from	O
10	O
Cancer	O
Centers	O
were	O
reviewed	O
.	O

Substantial	O
agreement	O
was	O
observed	O
for	O
ER	O
(	O
k0.612	O
;	O
95	O
%	O
CI	O
,	O
0538-0.686	O
)	O
,	O
PgR	O
(	O
k0.659	O
;	O
95	O
%	O
CI	O
,	O
0580-0.737	O
)	O
,	O
Ki-67	O
(	O
k0.609	O
;	O
95	O
%	O
CI	O
,	O
0.534-0.684	O
)	O
and	O
grading	O
(	O
k0.669	O
;	O
95	O
%	O
CI	O
,	O
0.569-0.769	O
)	O
.	O

Moderate	O
agreement	O
was	O
found	O
for	O
HER2	O
(	O
k0.546	O
;	O
95	O
%	O
CI	O
,	O
0444-0.649	O
)	O
.	O

DR	O
was	O
9.5	O
%	O
(	O
negativity	O
to	O
positivity	O
)	O
and	O
31.7	O
%	O
(	O
positivity	O
to	O
negativity	O
)	O
for	O
HER2	O
and	O
26.2	O
%	O
(	O
negativity	O
to	O
positivity	O
)	O
and	O
12.5	O
%	O
(	O
positivity	O
to	O
negativity	O
)	O
for	O
ER	O
/	O
PgR	O
.	O

According	O
to	O
changes	O
in	O
Her2	O
and	O
ER	O
/	O
PgR	O
status	O
,	O
23	O
(	O
12.2	O
%	O
)	O
and	O
33	O
(	O
17.6	O
%	O
)	O
systemic	O
prescription	O
were	O
respectively	O
modified	O
.	O

In	O
our	O
retrospective	O
analysis	O
,	O
central	B-P
pathological	I-P
review	I-P
has	O
a	O
significant	O
impact	O
in	O
the	O
decision-making	O
process	O
in	O
early	O
breast	O
cancer	O
,	O
as	O
shown	O
in	O
clinical	O
trials	O
.	O

Further	O
studies	O
are	O
warranted	O
to	O
confirm	O
these	O
provocative	O
results	O
.	O

Comparison	O
of	O
left	O
ventricular	O
ejection	O
fraction	O
values	O
obtained	O
using	O
invasive	O
contrast	B-P
left	I-P
ventriculography	I-P
,	O
two-dimensional	B-P
echocardiography	I-P
,	O
and	O
gated	B-P
single-photon	B-P
emission	I-P
computed	I-P
tomography	I-P
.	O

Left	O
ventricular	O
ejection	O
fraction	O
can	O
be	O
measured	O
by	O
a	O
variety	O
of	O
invasive	O
and	O
non-invasive	O
cardiac	B-P
techniques	I-P
.	O

This	O
study	O
assesses	O
the	O
relation	O
of	O
three	O
diagnostic	O
modalities	O
to	O
each	O
other	O
in	O
the	O
measurement	O
of	O
left	O
ventricular	O
ejection	O
fraction	O
:	O
invasive	O
contrast	B-P
left	I-P
ventriculography	I-P
,	O
two-dimensional	B-P
echocardiography	I-P
,	O
and	O
quantitative	O
gated	B-P
single-photon	B-P
emission	I-P
computed	I-P
tomography	I-P
.	O

Retrospective	O
chart	O
review	O
was	O
conducted	O
on	O
58	O
patients	O
hospitalized	O
with	O
chest	O
pain	O
,	O
who	O
underwent	O
left	O
ventricular	O
ejection	O
fraction	O
evaluation	O
using	O
each	O
of	O
the	O
aforementioned	O
modalities	O
within	O
a	O
3-month	O
period	O
not	O
interrupted	O
by	O
myocardial	O
infarction	O
or	O
revascularization	O
.	O

The	O
mean	O
left	O
ventricular	O
ejection	O
fraction	O
values	O
were	O
as	O
follows	O
:	O
invasive	O
contrast	B-P
left	I-P
ventriculography	I-P
(	O
0.44±0.15	O
)	O
,	O
two-dimensional	B-P
echocardiography	I-P
(	O
0.46±0.13	O
)	O
,	O
and	O
gated	B-P
single-photon	B-P
emission	I-P
computed	I-P
tomography	I-P
(	O
0.37±0.10	O
)	O
.	O

Correlations	O
coefficients	O
and	O
associated	O
p	O
values	O
were	O
as	O
follows	O
:	O
invasive	O
contrast	B-P
left	I-P
ventriculography	I-P
versus	O
two-dimensional	B-P
echocardiography	I-P
(	O
r=0.69	O
,	O
p	O
<	O
0.001	O
)	O
,	O
invasive	O
contrast	B-P
left	I-P
ventriculography	I-P
versus	O
gated	B-P
single-photon	B-P
emission	I-P
computed	I-P
tomography	I-P
(	O
r=0.80	O
,	O
p	O
<	O
0.0001	O
)	O
,	O
and	O
gated	B-P
single-photon	B-P
emission	I-P
computed	I-P
tomography	I-P
versus	O
two-dimensional	B-P
echocardiography	I-P
(	O
r=0.69	O
,	O
p	O
<	O
0.001	O
)	O
.	O

Our	O
results	O
indicate	O
that	O
strong	O
positive	O
correlations	O
exist	O
among	O
the	O
three	O
techniques	B-P
studied	O
.	O

Technical	O
note	O
:	O
A	O
preliminary	O
comparative	O
study	O
between	O
classical	O
and	O
interventional	O
radiological	O
approaches	O
for	O
multi-phase	O
post-mortem	B-P
CT	I-P
angiography	B-P
.	O

Multi-phase	O
post-mortem	B-P
computed	I-P
tomography	I-P
angiography	I-P
(	O
MPMCTA	B-P
)	O
is	O
a	O
new	O
diagnostic	B-P
tool	I-P
,	O
used	O
in	O
forensic	O
pathology	O
.	O

On	O
the	O
one	O
hand	O
,	O
this	O
technique	O
allows	O
a	O
better	O
and	O
direct	O
visualization	O
of	O
vascular	O
and	O
solid	O
organ	O
lesions	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
invasiveness	O
of	O
the	O
procedure	O
-which	O
requires	O
surgical	O
denudation	O
(	O
inguinal	O
and/or	O
cervical	O
)	O
and	O
the	O
insertion	O
of	O
surgical	O
cannulas	O
-leads	O
to	O
many	O
relatives	O
refusing	O
scientific	B-P
autopsies	I-P
.	O

Our	O
hypothesis	O
states	O
that	O
a	O
minimally-invasive	O
procedure	O
combining	O
interventional	O
radiological	O
techniques	O
with	O
MPMCTA	B-P
(	O
replacement	O
of	O
surgical	O
cannulas	O
by	O
radiological	O
catheters	O
)	O
will	O
improve	O
the	O
approval	O
rate	O
of	O
scientific	B-P
autopsies	I-P
by	O
families	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
feasibility	O
of	O
the	O
minimally-invasive	O
MPMCTA	B-P
approach	O
and	O
to	O
compare	O
its	O
performance	O
to	O
the	O
current	O
reference-standard	O
(	O
the	O
conventional	O
approach	O
)	O
.	O

We	O
included	O
consecutively	O
16	O
corpses	O
divided	O
in	O
two	O
groups	O
according	O
to	O
the	O
contrast	O
enhancement	O
approach	O
:	O
radiological	O
catheters	O
(	O
n=8	O
)	O
,	O
and	O
surgical	O
cannulas	O
(	O
n=8	O
)	O
.	O

Corpses	O
were	O
chosen	O
and	O
assigned	O
randomly	O
from	O
our	O
local	O
data	O
.	O

The	O
quality	O
of	O
the	O
imaging	B-P
procedure	I-P
was	O
compared	O
according	O
to	O
four	O
items	O
:	O
global	O
vascular	O
opacification	O
,	O
cerebral	O
venous	O
opacification	O
,	O
and	O
lower	O
limbs	O
opacification	O
(	O
arterial	O
and	O
venous	O
)	O
.	O

A	O
minimally-invasive	O
approach	O
for	O
scientific	B-P
autopsies	I-P
is	O
feasible	O
through	O
a	O
radiological	O
catheter	O
.	O

Vascular	O
opacification	O
was	O
optimal	O
in	O
8	O
out	O
of	O
8	O
cases	O
and	O
was	O
no	O
less	O
effective	O
than	O
the	O
control	O
reference	O
group	O
using	O
surgical	O
cannula	O
incision	O
associated	O
with	O
their	O
non-occlusive	O
aspects	O
.	O

Effect	O
of	O
magnesium	O
supplementation	O
on	O
depression	O
status	O
in	O
depressed	O
patients	O
with	O
magnesium	O
deficiency	O
:	O
A	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
magnesium	O
supplementation	O
on	O
the	O
depression	O
status	O
of	O
depressed	O
patients	O
suffering	O
from	O
magnesium	O
deficiency	O
.	O

Sixty	O
depressed	O
people	O
suffering	O
from	O
hypomagnesemia	O
participated	O
in	O
this	O
trial	O
.	O

The	O
individuals	O
were	O
randomly	O
categorized	O
into	O
two	O
groups	O
of	O
30	O
members	O
;	O
one	O
receiving	O
two	O
250-mg	O
tablets	O
of	O
magnesium	O
oxide	O
(	O
MG	O
)	O
daily	O
and	O
the	O
other	O
receiving	O
placebo	O
(	O
PG	O
)	O
for	O
8	O
wk	O
.	O

The	O
Beck	B-P
Depression	I-P
Inventory-II	I-P
was	O
conducted	O
and	O
the	O
concentration	O
of	O
serum	B-P
magnesium	I-P
was	I-P
measured	I-P
.	O

At	O
the	O
end	O
of	O
intervention	O
,	O
88.5	O
%	O
of	O
the	O
MG	O
and	O
48.1	O
%	O
of	O
the	O
PG	O
(	O
P	O
=	O
0.002	O
)	O
had	O
a	O
normal	O
level	O
of	O
magnesium	O
.	O

The	O
mean	O
changes	O
of	O
serum	O
magnesium	O
were	O
significantly	O
different	O
across	O
the	O
two	O
groups	O
.	O

After	O
the	O
intervention	O
,	O
the	O
mean	O
Beck	O
score	O
significantly	O
declined	O
.	O

However	O
,	O
in	O
the	O
MG	O
,	O
this	O
reduction	O
was	O
more	O
significant	O
than	O
in	O
the	O
PG	O
(	O
P	O
=	O
0.02	O
)	O
,	O
so	O
that	O
the	O
mean	O
changes	O
in	O
this	O
group	O
experienced	O
15.65	O
±	O
8.9	O
reduction	O
,	O
but	O
in	O
the	O
PG	O
,	O
it	O
declined	O
by	O
10.40	O
±	O
7.9	O
.	O

Daily	O
consumption	O
of	O
500	O
mg	O
magnesium	O
oxide	O
tablets	O
for	O
≥8	O
wk	O
by	O
depressed	O
patients	O
suffering	O
from	O
magnesium	O
deficiency	O
leads	O
to	O
improvements	O
in	O
depression	O
status	O
and	O
magnesium	O
levels	O
.	O

Therefore	O
,	O
assessment	B-P
of	I-P
the	I-P
magnesium	I-P
serum	I-P
and	O
resolving	O
this	O
deficiency	O
positively	O
influence	O
the	O
treatment	O
of	O
depressed	O
patients	O
.	O

Multivariate	O
Imaging	B-P
Genetics	O
Study	O
of	O
MRI	B-P
Gray	O
Matter	O
Volume	O
and	O
SNPs	O
Reveals	O
Biological	O
Pathways	O
Correlated	O
with	O
Brain	O
Structural	O
Differences	O
in	O
Attention	O
Deficit	O
Hyperactivity	O
Disorder	O
.	O

Attention	O
deficit	O
hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
is	O
a	O
prevalent	O
neurodevelopmental	O
disorder	O
affecting	O
children	O
,	O
adolescents	O
,	O
and	O
adults	O
.	O

Its	O
etiology	O
is	O
not	O
well	O
understood	O
,	O
but	O
it	O
is	O
increasingly	O
believed	O
to	O
result	O
from	O
diverse	O
pathophysiologies	O
that	O
affect	O
the	O
structure	O
and	O
function	O
of	O
specific	O
brain	O
circuits	O
.	O

Although	O
one	O
of	O
the	O
best-studied	O
neurobiological	O
abnormalities	O
in	O
ADHD	O
is	O
reduced	O
fronto-striatal-cerebellar	O
gray	O
matter	O
(	O
GM	O
)	O
volume	O
,	O
its	O
specific	O
genetic	O
correlates	O
are	O
largely	O
unknown	O
.	O

In	O
this	O
study	O
,	O
T1-weighted	B-P
MR	I-P
images	I-P
of	I-P
brain	I-P
structure	I-P
were	O
collected	O
from	O
198	O
adolescents	O
(	O
63	O
ADHD	O
-	O
diagnosed	O
)	O
.	O

A	O
multivariate	O
parallel	O
independent	O
component	O
analysis	O
(	O
Para-ICA	O
)	O
technique	O
-identified	O
imaging	B-P
genetic	O
relationships	O
between	O
regional	O
GM	O
volume	O
and	O
single	O
nucleotide	O
polymorphism	O
data	O
.	O

Para-ICA	O
analyses	O
extracted	O
14	O
components	O
from	O
genetic	O
data	O
and	O
9	O
from	O
MR	B-P
data	O
.	O

An	O
iterative	O
cross-validation	O
using	O
randomly	O
chosen	O
subsamples	O
indicated	O
acceptable	O
stability	O
of	O
these	O
ICA	O
solutions	O
.	O

A	O
series	O
of	O
partial	O
correlation	O
analyses	O
controlling	O
for	O
age	O
,	O
sex	O
,	O
and	O
ethnicity	O
revealed	O
two	O
genotype-phenotype	O
component	O
pairs	O
significantly	O
differed	O
between	O
ADHD	O
and	O
non-ADHD	O
groups	O
,	O
after	O
a	O
Bonferroni	O
correction	O
for	O
multiple	O
comparisons	O
.	O

The	O
brain	O
phenotype	O
component	O
not	O
only	O
included	O
structures	O
frequently	O
found	O
to	O
have	O
abnormally	O
low	O
volume	O
in	O
previous	O
ADHD	O
studies	O
but	O
was	O
also	O
significantly	O
associated	O
with	O
ADHD	O
differences	O
in	O
symptom	O
severity	O
and	O
performance	O
on	O
cognitive	O
tests	O
frequently	O
found	O
to	O
be	O
impaired	O
in	O
patients	O
diagnosed	O
with	O
the	O
disorder	O
.	O

Pathway	O
analysis	O
of	O
the	O
genotype	O
component	O
identified	O
several	O
different	O
biological	O
pathways	O
linked	O
to	O
these	O
structural	O
abnormalities	O
in	O
ADHD	O
.	O

Some	O
of	O
these	O
pathways	O
implicate	O
well-known	O
dopaminergic	O
neurotransmission	O
and	O
neurodevelopment	O
hypothesized	O
to	O
be	O
abnormal	O
in	O
ADHD	O
.	O

Other	O
more	O
recently	O
implicated	O
pathways	O
included	O
glutamatergic	O
and	O
GABA-eric	O
physiological	O
systems	O
;	O
others	O
might	O
reflect	O
sources	O
of	O
shared	O
liability	O
to	O
disturbances	O
commonly	O
found	O
in	O
ADHD	O
,	O
such	O
as	O
sleep	O
abnormalities	O
.	O

C-5a-substituted	O
validamine	O
type	O
glycosidase	O
inhibitors	O
.	O

A	O
series	O
of	O
N-alkyl	O
derivatives	O
of	O
the	O
D-galactosidase	O
inhibitor	O
1,4-di-epi-validamine	O
featuring	O
lipophilic	O
substituents	O
at	O
position	O
C-5a	O
was	O
prepared	O
and	O
screened	B-P
for	O
their	O
glycosidase	O
inhibitory	O
properties	O
.	O

Products	O
turned	O
out	O
selective	O
for	O
β-galactosidases	O
as	O
well	O
as	O
β-glucosidases	O
.	O

Estrogen	O
deficiency	O
accelerates	O
lumbar	O
facet	O
joints	O
arthritis	O
.	O

Dramatic	O
increase	O
in	O
the	O
prevalence	O
of	O
lumbar	O
facet	O
joint	O
(	O
LFJ	O
)	O
arthritis	O
in	O
women	O
around	O
the	O
age	O
of	O
menopause	O
indicates	O
a	O
protective	O
role	O
for	O
estrogen	O
in	O
LFJ	O
arthritis	O
.	O

To	O
date	O
,	O
there	O
is	O
no	O
evidence	O
for	O
this	O
indication	O
and	O
the	O
mechanism	O
of	O
such	O
an	O
effect	O
remains	O
poorly	O
understood	O
.	O

In	O
this	O
study	O
,	O
ovariectomized	O
(	O
OVX	O
)	O
mice	O
were	O
used	O
to	O
mimic	O
the	O
estrogen	O
-	O
deficient	O
status	O
of	O
post-menopausal	O
women	O
.	O

Micro-CT	B-P
and	O
immunohistochemistry	B-P
was	O
employed	O
to	O
assess	O
the	O
morphological	O
and	O
molecular	O
changes	O
in	O
ovariectomy	O
-	O
induced	O
LFJ	O
arthritis	O
.	O

The	O
results	O
show	O
that	O
the	O
LFJ	O
subchondral	O
bone	O
mass	O
was	O
significantly	O
decreased	O
in	O
OVX	O
mice	O
,	O
with	O
increased	O
cavities	O
on	O
the	O
interface	O
of	O
the	O
subchondral	O
bone	O
.	O

Severe	O
cartilage	O
degradation	O
was	O
observed	O
in	O
ovariectomy	O
-	O
induced	O
LFJ	O
arthritis	O
.	O

Increased	O
blood	O
vessels	O
and	O
innervations	O
were	O
also	O
found	O
in	O
degenerated	O
LFJ	O
,	O
particularly	O
in	O
the	O
subchondral	O
bone	O
area	O
.	O

17β-Estradiol	O
treatment	O
efficiently	O
suppressed	O
LFJ	O
subchondral	O
bone	O
turnover	O
,	O
markedly	O
inhibited	O
cartilage	O
degradation	O
,	O
and	O
increased	O
blood	O
vessel	O
and	O
nerve	O
ending	O
growth	O
in	O
degenerated	O
LFJ	O
in	O
OVX	O
mice	O
.	O

Our	O
study	O
reveals	O
that	O
estrogen	O
is	O
a	O
key	O
factor	O
in	O
regulating	O
LFJ	O
metabolism	O
.	O

Severe	O
LFJ	O
degeneration	O
occurs	O
when	O
estrogen	O
is	O
absent	O
in	O
vivo	O
.	O

Collapsed	O
subchondral	O
bone	O
may	O
be	O
the	O
initiation	O
of	O
this	O
process	O
,	O
and	O
estrogen	O
replacement	O
therapy	O
can	O
effectively	O
prevent	O
degeneration	O
of	O
LFJ	O
under	O
estrogen	O
-	O
deficient	O
conditions	O
.	O

Cross	O
reactivity	O
of	O
immune	O
responses	O
to	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
infection	O
.	O

Because	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
)	O
exhibits	O
extensive	O
genetic	O
variation	O
among	O
field	O
isolates	O
,	O
characterizing	O
the	O
extent	O
of	O
cross	O
reactivity	O
of	O
immune	O
responses	O
,	O
and	O
most	O
importantly	O
cell-mediated	O
immunity	O
(	O
CMI	O
)	O
,	O
could	O
help	O
in	O
the	O
development	O
of	O
broadly	O
cross-protective	O
vaccines	O
.	O

We	O
infected	O
12	O
PRRSV	O
-naïve	O
pigs	O
with	O
PRRSV	O
strain	O
FL12	O
and	O
determined	O
the	O
number	O
of	O
interferon	O
(	O
IFN	O
)	O
-γ	O
secreting	O
cells	O
(	O
SC	O
)	O
by	O
ELISpot	B-P
assay	I-P
using	O
ten	O
type	O
2	O
and	O
one	O
type	O
1	O
PRRSV	O
isolates	O
as	O
recall	O
antigens	O
.	O

The	O
number	O
of	O
IFN-γ	O
SC	O
was	O
extremely	O
variable	O
among	O
animals	O
,	O
and	O
with	O
exceptions	O
,	O
late	O
to	O
appear	O
.	O

Cross	O
reactivity	O
of	O
IFN-γ	O
SC	O
among	O
type	O
2	O
isolates	O
was	O
broad	O
,	O
and	O
we	O
found	O
no	O
evidence	O
of	O
an	O
association	O
between	O
increased	O
genetic	O
distance	O
among	O
isolates	O
and	O
the	O
intensity	O
of	O
the	O
CMI	O
response	O
.	O

Comparable	O
to	O
IFN-γ	O
SC	O
,	O
total	O
antibodies	O
evaluated	O
by	O
indirect	B-P
immunofluorescence	I-P
assay	I-P
(	O
IFA	B-P
)	O
were	O
cross	O
reactive	O
,	O
however	O
,	O
neutralizing	O
antibody	O
titers	O
could	O
only	O
be	O
detected	O
against	O
the	O
strain	O
used	O
for	O
infection	O
.	O

Finally	O
,	O
we	O
observed	O
a	O
moderate	O
association	O
between	O
homologous	O
IFN-γ	O
SC	O
and	O
neutralizing	O
antibodies	O
.	O

Predictive	O
biomarkers	O
and	O
effectiveness	O
of	O
MUC1	O
-targeted	O
dendritic-cell	O
-based	O
vaccine	O
in	O
patients	O
with	O
refractory	O
non-small	O
cell	O
lung	O
cancer	O
.	O

The	O
dendritic	O
cell	O
(	O
DC	O
)	O
-based	O
vaccine	O
targeting	O
the	O
highly	O
immunogenic	O
tumor	O
antigen	O
,	O
MUC1	O
,	O
has	O
been	O
promising	O
for	O
a	O
cancer	O
immunotherapy	O
;	O
however	O
,	O
predictive	O
biomarkers	O
for	O
beneficial	O
clinical	O
responses	O
of	O
the	O
vaccine	O
remain	O
to	O
be	O
determined	O
.	O

DCs	O
loaded	O
with	O
MUC1-derived	O
peptide	O
were	O
subcutaneously	O
administered	O
to	O
patients	O
with	O
MUC1-positive	O
non-small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
that	O
was	O
refractory	O
to	O
standard	O
anticancer	O
therapies	O
,	O
every	O
2	O
weeks	O
.	O

The	O
effectiveness	O
and	O
tolerability	O
of	O
the	O
vaccine	O
were	O
evaluated	O
,	O
and	O
predictive	O
biomarkers	O
of	O
clinical	O
responses	O
were	O
explored	O
.	O

Between	O
August	O
2005	O
and	O
May	O
2015	O
,	O
40	O
patients	O
received	O
the	O
vaccines	O
.	O

The	O
median	O
survival	O
time	O
(	O
MST	O
)	O
after	O
the	O
initial	O
vaccination	O
was	O
7.4	O
months	O
,	O
and	O
the	O
1-year	O
survival	O
rate	O
was	O
25.0	O
%	O
.	O

The	O
MST	O
for	O
patients	O
who	O
received	O
more	O
than	O
six	O
vaccinations	O
was	O
9.5	O
months	O
,	O
and	O
the	O
1-year	O
survival	O
rate	O
was	O
39.3	O
%	O
.	O

In	O
this	O
cohort	O
,	O
patients	O
who	O
experienced	O
immune-related	O
adverse	O
events	O
,	O
including	O
skin	O
reactions	O
at	O
the	O
vaccination	O
site	O
and	O
fever	O
,	O
had	O
significantly	O
longer	O
survival	O
times	O
compared	O
with	O
patients	O
without	O
those	O
immune-related	O
adverse	O
events	O
(	O
12.6	O
versus	O
6.7	O
months	O
,	O
p	O
=	O
0.042	O
)	O
.	O

Longer	O
survival	O
times	O
were	O
also	O
observed	O
in	O
patients	O
whose	O
peripheral	B-P
white	I-P
blood	I-P
cells	I-P
contained	O
>	O
20.0	O
%	O
lymphocytes	B-P
(	O
12.6	O
versus	O
4.5	O
months	O
;	O
p	O
=	O
0.014	O
)	O
.	O

MUC1	O
-specific	O
cytotoxic	O
immune	O
responses	O
were	O
achieved	O
in	O
all	O
of	O
seven	O
patients	O
analyzed	O
who	O
received	O
six	O
vaccinations	O
.	O

The	O
MUC1	O
-targeted	O
DC	O
-based	O
vaccine	O
induced	O
an	O
antitumor	O
immune	O
response	O
that	O
promoted	O
prolonged	O
survival	O
of	O
patients	O
with	O
refractory	O
NSCLC	O
.	O

The	O
occurrence	O
of	O
immune-related	O
adverse	O
events	O
and	O
having	O
a	O
higher	O
percentage	O
of	O
peripheral	B-P
lymphocytes	I-P
were	O
predictive	O
biomarkers	O
of	O
a	O
beneficial	O
clinical	O
response	O
during	O
cancer	O
immunotherapy	O
for	O
NSCLC	O
.	O

Neural	O
Correlates	O
of	O
Belief	O
and	O
Emotion	O
Attribution	O
in	O
Schizophrenia	O
.	O

Impaired	O
mental	O
state	O
attribution	O
is	O
a	O
core	O
social	O
cognitive	O
deficit	O
in	O
schizophrenia	O
.	O

With	O
functional	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	O
fMRI	B-P
)	O
,	O
this	O
study	O
examined	O
the	O
extent	O
to	O
which	O
the	O
core	O
neural	O
system	O
of	O
mental	O
state	O
attribution	O
is	O
involved	O
in	O
mental	O
state	O
attribution	O
,	O
focusing	O
on	O
belief	O
attribution	O
and	O
emotion	O
attribution	O
.	O

Fifteen	O
schizophrenia	O
outpatients	O
and	O
14	O
healthy	O
controls	O
performed	O
two	O
mental	O
state	O
attribution	O
tasks	O
in	O
the	O
scanner	O
.	O

In	O
a	O
Belief	O
Attribution	O
Task	O
,	O
after	O
reading	O
a	O
short	O
vignette	O
,	O
participants	O
were	O
asked	O
infer	O
either	O
the	O
belief	O
of	O
a	O
character	O
(	O
a	O
false	O
belief	O
condition	O
)	O
or	O
a	O
physical	O
state	O
of	O
an	O
affair	O
(	O
a	O
false	O
photograph	O
condition	O
)	O
.	O

In	O
an	O
Emotion	O
Attribution	O
Task	O
,	O
participants	O
were	O
asked	O
either	O
to	O
judge	O
whether	O
character	O
(	O
s	O
)	O
in	O
pictures	O
felt	O
unpleasant	O
,	O
pleasant	O
,	O
or	O
neutral	O
emotion	O
(	O
other	O
condition	O
)	O
or	O
to	O
look	O
at	O
pictures	O
that	O
did	O
not	O
have	O
any	O
human	O
characters	O
(	O
view	O
condition	O
)	O
.	O

fMRI	B-P
data	O
were	O
analyzing	O
focusing	O
on	O
a	O
priori	O
regions	O
of	O
interest	O
(	O
ROIs	O
)	O
of	O
the	O
core	O
neural	O
systems	O
of	O
mental	O
state	O
attribution	O
:	O
the	O
medial	O
prefrontal	O
cortex	O
(	O
mPFC	O
)	O
,	O
temporoparietal	O
junction	O
(	O
TPJ	O
)	O
and	O
precuneus	O
.	O

An	O
exploratory	O
whole	O
brain	O
analysis	O
was	O
also	O
performed	O
.	O

Both	O
patients	O
and	O
controls	O
showed	O
greater	O
activation	O
in	O
all	O
four	O
ROIs	O
during	O
the	O
Belief	O
Attribution	O
Task	O
than	O
the	O
Emotion	O
Attribution	O
Task	O
.	O

Patients	O
also	O
showed	O
less	O
activation	O
in	O
the	O
precuneus	O
and	O
left	O
TPJ	O
compared	O
to	O
controls	O
during	O
the	O
Belief	O
Attribution	O
Task	O
.	O

No	O
significant	O
group	O
difference	O
was	O
found	O
during	O
the	O
Emotion	O
Attribution	O
Task	O
in	O
any	O
of	O
ROIs	O
.	O

An	O
exploratory	O
whole	O
brain	O
analysis	O
showed	O
a	O
similar	O
pattern	O
of	O
neural	O
activation	O
s.	O
These	O
findings	O
suggest	O
that	O
while	O
schizophrenia	O
patients	O
rely	O
on	O
the	O
same	O
neural	O
network	O
as	O
controls	O
do	O
when	O
attributing	O
beliefs	O
of	O
others	O
,	O
patients	O
did	O
not	O
show	O
reduced	O
activation	O
in	O
the	O
key	O
regions	O
such	O
as	O
the	O
TPJ	O
.	O

Further	O
,	O
this	O
study	O
did	O
not	O
find	O
evidence	O
for	O
aberrant	O
neural	O
activation	O
during	O
emotion	O
attribution	O
or	O
recruitment	O
of	O
compensatory	O
brain	O
regions	O
in	O
schizophrenia	O
.	O

Fully	O
automated	O
disc	B-P
diffusion	I-P
for	O
rapid	O
antibiotic	B-P
susceptibility	I-P
test	I-P
results	O
:	O
a	O
proof-of-principle	O
study	O
.	O

Antibiotic	O
resistance	O
poses	O
a	O
significant	O
threat	O
to	O
patients	O
suffering	O
from	O
infectious	O
diseases	O
.	O

Early	O
readings	O
of	O
antibiotic	B-P
susceptibility	I-P
test	I-P
(	O
AST	B-P
)	O
results	O
could	O
be	O
of	O
critical	O
importance	O
to	O
ensure	O
adequate	O
treatment	O
.	O

Disc	B-P
diffusion	I-P
is	O
a	O
well-standardized	O
,	O
established	O
and	O
cost	O
-	O
efficient	O
AST	B-P
procedure	I-P
;	O
however	O
,	O
its	O
use	O
in	O
the	O
clinical	O
laboratory	O
is	O
hampered	O
by	O
the	O
many	O
manual	O
steps	O
involved	O
,	O
and	O
an	O
incubation	O
time	O
of	O
16-18	O
h	O
,	O
which	O
is	O
required	O
to	O
achieve	O
reliable	O
test	O
results	O
.	O

We	O
have	O
evaluated	O
a	O
fully	O
automated	O
system	O
for	O
its	O
potential	O
for	O
early	O
reading	O
of	O
disc	B-P
diffusion	I-P
diameters	O
after	O
6-12	O
h	O
of	O
incubation	B-P
.	O

We	O
assessed	O
availability	O
of	O
results	O
,	O
methodological	O
precision	O
,	O
categorical	O
agreement	O
and	O
interpretation	O
errors	O
as	O
compared	O
with	O
an	O
18	O
h	O
standard	O
.	O

In	O
total	O
,	O
1028	O
clinical	O
strains	O
(	O
291	O
Escherichia	O
coli	O
,	O
272	O
Klebsiella	O
pneumoniae	O
,	O
176	O
Staphylococcus	O
aureus	O
and	O
289	O
Staphylococcus	O
epidermidis	O
)	O
were	O
included	O
in	O
this	O
study	O
.	O

Disc	B-P
diffusion	I-P
plates	O
were	O
streaked	O
,	O
incubated	B-P
and	O
imaged	O
using	O
the	O
WASPLab	O
TM	O
automation	O
system	O
.	O

Our	O
results	O
demonstrate	O
that	O
:	O
(	O
i	O
)	O
early	O
AST	B-P
reading	O
is	O
possible	O
for	O
important	O
pathogens	O
;	O
(	O
ii	O
)	O
methodological	O
precision	O
is	O
not	O
hampered	O
at	O
early	O
timepoints	O
;	O
and	O
(	O
iii	O
)	O
species	O
-	O
specific	O
reading	O
times	O
must	O
be	O
selected	O
.	O

As	O
inhibition	O
zone	O
diameters	O
change	O
over	O
time	O
and	O
are	O
phenotype	O
/	O
drug	O
combination	O
dependent	O
,	O
specific	O
cut-offs	O
and	O
expert	O
rules	O
will	O
be	O
essential	O
to	O
ensure	O
reliable	O
interpretation	O
and	O
reporting	O
of	O
early	O
susceptibility	O
testing	O
results	O
.	O

Effect	O
of	O
type	O
2	O
diabetes	O
mellitus	O
on	O
the	O
pharmacokinetics	O
and	O
transplacental	O
transfer	O
of	O
nifedipine	O
in	O
hypertensive	O
pregnant	O
women	O
.	O

Diabetes	O
mellitus	O
can	O
inhibit	O
cytochrome	O
P450	O
3A4	O
,	O
an	O
enzyme	O
responsible	O
for	O
the	O
metabolism	O
of	O
nifedipine	O
,	O
used	O
for	O
the	O
treatment	O
of	O
hypertension	O
in	O
pregnant	O
women	O
.	O

We	O
aimed	O
to	O
assess	O
the	O
effect	O
of	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
on	O
the	O
pharmacokinetics	O
,	O
placental	O
transfer	O
and	O
distribution	O
of	O
nifedipine	O
in	O
amniotic	O
fluid	O
in	O
hypertensive	O
pregnant	O
women	O
.	O

The	O
study	O
was	O
conducted	O
in	O
12	O
hypertensive	O
pregnant	O
women	O
[	O
control	O
group	O
(	O
CG	O
)	O
]	O
and	O
10	O
hypertensive	O
pregnant	O
women	O
with	O
T2DM	O
taking	O
slow-release	O
nifedipine	O
(	O
20	O
mg	O
,	O
12/12	O
h	O
)	O
.	O

On	O
the	O
34th	O
week	O
of	O
gestation	O
,	O
serial	O
blood	O
samples	O
were	O
collected	O
(	O
0-12	O
h	O
)	O
after	O
administration	O
of	O
the	O
medication	O
.	O

At	O
delivery	O
,	O
samples	O
of	O
maternal	O
and	O
fetal	O
blood	O
and	O
amniotic	O
fluid	O
were	O
collected	O
for	O
determination	B-P
of	O
nifedipine	O
distribution	O
in	O
these	O
compartments	O
.	O

The	O
median	O
pharmacokinetic	O
parameters	O
of	O
CG	O
were	O
:	O
peak	O
plasma	O
concentration	O
(	O
Cmax	O
)	O
26.41	O
ng	O
ml	O
(	O
-1	O
)	O
,	O
time	O
to	O
reach	O
Cmax	O
(	O
tmax	O
)	O
1.79	O
h	O
,	O
area	O
under	O
the	O
plasma	O
concentration	O
vs.	O
time	O
curve	O
from	O
0-12	O
h	O
(	O
AUC	O
0-12	O
)	O
235.99	O
ng.h	O
ml	O
(	O
-1	O
)	O
,	O
half-life	O
(	O
t½	O
)	O
4.34	O
h	O
,	O
volume	O
of	O
distribution	O
divided	O
by	O
bioavailability	O
(	O
Vd	O
/	O
F	O
)	O
560.96	O
l	O
,	O
and	O
ClT	O
/	O
F	O
84.77	O
l	O
h	O
(	O
-1	O
)	O
.	O

The	O
parameters	O
for	O
T2DM	O
group	O
were	O
:	O
Cmax	O
23.52	O
ng	O
ml	O
(	O
-1	O
)	O
,	O
tmax	O
1.48	O
h	O
,	O
AUC	O
0-12	O
202.23	O
ng.h	O
ml	O
(	O
-1	O
)	O
,	O
t½	O
5.00	O
h	O
,	O
Vd	O
/	O
F	O
609.40	O
l	O
,	O
and	O
apparent	O
total	O
clearance	O
(	O
ClT	O
/	O
F	O
)	O
98.94	O
l	O
h	O
(	O
-1	O
)	O
.	O

The	O
ratios	O
of	O
plasma	O
concentrations	O
of	O
nifedipine	O
in	O
the	O
umbilical	O
vein	O
,	O
intervillous	O
space	O
and	O
amniotic	O
fluid	O
to	O
those	O
in	O
the	O
maternal	O
vein	O
for	O
CG	O
and	O
T2DM	O
were	O
0.53	O
and	O
0.44	O
,	O
0.78	O
and	O
0.87	O
,	O
respectively	O
,	O
with	O
an	O
amniotic	O
fluid	O
/	O
maternal	O
plasma	O
ratio	O
of	O
0.05	O
for	O
both	O
groups	O
.	O

The	O
ratios	O
of	O
plasma	O
concentrations	O
in	O
the	O
umbilical	O
artery	O
to	O
those	O
in	O
the	O
umbilical	O
vein	O
were	O
0.82	O
for	O
CG	O
and	O
0.88	O
for	O
T2DM	O
.	O

There	O
was	O
no	O
influence	O
of	O
T2DM	O
on	O
the	O
pharmacokinetics	O
or	O
placental	O
transfer	O
of	O
nifedipine	O
in	O
hypertensive	O
women	O
with	O
controlled	O
diabetes	O
.	O

Identification	B-P
of	O
yeasts	O
isolated	O
from	O
raffia	O
wine	O
(	O
Raphia	O
hookeri	O
)	O
produced	O
in	O
Côte	O
d'Ivoire	O
and	O
genotyping	B-P
of	O
Saccharomyces	O
cerevisiae	O
strains	O
by	O
PCR	O
inter-delta	O
.	O

Raffia	O
wine	O
is	O
a	O
traditional	O
alcoholic	O
beverage	O
produced	O
in	O
several	O
African	O
countries	O
where	O
it	O
plays	O
a	O
significant	O
role	O
in	O
traditional	O
customs	O
and	O
population	O
diet	O
.	O

Alcoholic	O
fermentation	O
of	O
this	O
beverage	O
is	O
ensured	O
by	O
a	O
complex	O
natural	O
yeast	O
flora	O
which	O
plays	O
a	O
decisive	O
role	O
in	O
the	O
quality	O
of	O
the	O
final	O
product	O
.	O

This	O
present	O
study	O
aims	O
to	O
evaluate	O
the	O
distribution	O
and	O
the	O
diversity	O
of	O
the	O
yeast	O
strains	O
isolated	O
in	O
raffia	O
wine	O
from	O
four	O
sampling	O
areas	O
(	O
Abengourou	O
,	O
Alépé	O
,	O
Grand-Lahou	O
and	O
Adzopé	O
)	O
in	O
Côte	O
d'Ivoire	O
.	O

Based	O
on	O
the	O
D1/D2	O
domain	O
of	O
the	O
LSU	O
rDNA	O
sequence	O
analysis	O
,	O
nine	O
species	O
belonging	O
to	O
six	O
genera	O
were	O
distinguished	O
.	O

With	O
a	O
percentage	O
of	O
69.5	O
%	O
out	O
of	O
171	O
yeast	O
isolates	O
,	O
Saccharomyces	O
cerevisiae	O
was	O
the	O
predominant	O
species	O
in	O
the	O
raffia	O
wine	O
,	O
followed	O
by	O
Kodamaea	O
ohmeri	O
(	O
20.4	O
%	O
)	O
.	O

The	O
other	O
species	O
isolated	O
were	O
Candida	O
haemulonii	O
(	O
4.1	O
%	O
)	O
,	O
Candida	O
phangngensis	O
(	O
1.8	O
%	O
)	O
,	O
Pichia	O
kudriavzevii	O
(	O
1.2	O
%	O
)	O
,	O
Hanseniaspora	O
jakobsenii	O
(	O
1.2	O
%	O
)	O
,	O
Candida	O
silvae	O
(	O
0.6	O
%	O
)	O
,	O
Hanseniaspora	O
guilliermondii	O
(	O
0.6	O
%	O
)	O
and	O
Meyerozyma	O
caribbica	O
(	O
0.6	O
%	O
)	O
.	O

The	O
molecular	O
characterization	O
of	O
S.	O
cerevisiae	O
isolates	O
at	O
the	O
strain	O
level	O
using	O
the	O
PCR-interdelta	O
method	O
revealed	O
the	O
presence	O
of	O
21	O
profiles	B-P
(	O
named	O
I	O
to	O
XXI	O
)	O
within	O
115	O
isolates	O
.	O

Only	O
four	O
profiles	B-P
(	O
I	O
,	O
III	O
,	O
V	O
and	O
XI	O
)	O
were	O
shared	O
by	O
the	O
four	O
areas	O
under	O
study	O
.	O

Phenotypic	O
characterization	O
of	O
K.	O
ohmeri	O
strains	O
showed	O
two	O
subgroups	O
for	O
sugar	O
fermentation	O
and	O
no	O
diversity	O
for	O
the	O
nitrogen	O
compound	O
assimilations	O
and	O
the	O
growth	O
at	O
different	O
temperatures	O
.	O

Caryocar	O
brasiliense	O
oil	O
improves	O
cardiac	O
function	O
by	O
increasing	O
Serca2a	O
/	O
PLB	O
ratio	O
despite	O
no	O
significant	O
changes	O
in	O
cardiovascular	O
risk	O
factors	O
in	O
rats	O
.	O

Caryocar	O
brasiliense	O
(	O
pequi	O
)	O
oil	O
is	O
high	O
in	O
monounsaturated	O
fat	O
acids	O
(	O
MUFA	O
)	O
,	O
especially	O
oleic	O
,	O
and	O
in	O
carotenoids	O
,	O
which	O
have	O
been	O
associated	O
with	O
protection	O
against	O
cardiovascular	O
disease	O
.	O

However	O
,	O
this	O
food	O
is	O
poorly	O
studied	O
in	O
this	O
context	O
,	O
especially	O
in	O
the	O
cardiac	O
function	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
a	O
long-term	O
intake	O
of	O
pequi	O
oil	O
in	O
systemic	O
cardiovascular	O
risk	O
factors	O
and	O
in	O
the	O
ex	O
vivo	O
cardiac	O
function	O
of	O
rats	O
.	O

Previously	O
,	O
we	O
determined	O
fatty	O
acids	O
and	O
carotenoids	O
in	O
pequi	O
oil	O
.	O

Next	O
,	O
male	O
rats	O
were	O
divided	O
in	O
C	O
-	O
control	O
group	O
feed	O
a	O
standard	O
diet	O
,	O
and	O
PO	O
-	O
pequi	O
oil	O
group	O
fed	O
the	O
same	O
diet	O
added	O
pequi	O
oil	O
(	O
+2.25	O
g.100	O
g	O
(	O
-1	O
)	O
)	O
.	O

After	O
15	O
weeks	O
,	O
plasma	O
lipids	O
,	O
glucose	O
,	O
insulin	O
,	O
blood	O
pressure	O
,	O
heart	O
rate	O
,	O
hepatic	O
lipids	O
were	O
accessed	O
and	O
visceral	O
fat	O
pads	O
were	O
harvested	O
.	O

Hearts	O
were	O
used	O
for	O
the	O
ex	O
vivo	O
cardiac	O
function	O
,	O
histologic	B-P
assays	I-P
,	O
SERCA2a	O
and	O
phospholanban	O
(	O
PLB	O
)	O
determinations	O
.	O

In	O
agreement	O
with	O
scientific	O
data	O
,	O
pequi	O
oil	O
had	O
expressive	O
amounts	O
MUFA	O
,	O
especially	O
oleic	O
acid	O
,	O
and	O
carotenoids	O
.	O

Hepatic	O
triglycerides	O
(	O
TG	O
)	O
were	O
reduced	O
by	O
pequi	O
oil	O
intake	O
(	O
p	O
<	O
0.05	O
)	O
.	O

All	O
others	O
cardiovascular	O
risk	O
factors	O
were	O
not	O
changed	O
.	O

The	O
intrinsic	O
heart	O
rate	O
was	O
lower	O
in	O
PO	O
group	O
(	O
p	O
<	O
0.05	O
)	O
.	O

SERCA2a	O
content	O
was	O
higher	O
in	O
this	O
group	O
(	O
p	O
<	O
0.05	O
)	O
,	O
without	O
affecting	O
PLB	O
.	O

Also	O
,	O
SERCA2a	O
/	O
PLB	O
ratio	O
increased	O
in	O
PO	O
group	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Pequi	O
oil	O
intake	O
improved	O
cardiac	O
function	O
ex	O
vivo	O
,	O
despite	O
no	O
significant	O
changes	O
in	O
systemic	O
cardiovascular	O
risk	O
factors	O
.	O

The	O
higher	O
lipid	O
offer	O
in	O
pequi	O
oil	O
diet	O
,	O
its	O
composition	O
in	O
oleic	O
acid	O
and	O
carotenoids	O
could	O
be	O
related	O
to	O
those	O
effects	O
.	O

Theranostic	O
Upconversion	O
Nanobeacons	O
for	O
Tumor	O
mRNA	O
Ratiometric	B-P
Fluorescence	I-P
Detection	I-P
and	O
Imaging	B-P
-	O
Monitored	O
Drug	O
Delivery	O
.	O

Remote	O
optical	O
detection	O
and	O
imaging	B-P
of	O
specific	O
tumor	O
-related	O
biomarkers	O
and	O
simultaneous	O
activation	O
of	O
therapy	O
according	O
to	O
the	O
expression	O
level	O
of	O
the	O
biomarkers	O
in	O
tumor	O
site	O
with	O
theranostic	O
probes	O
should	O
be	O
an	O
effective	O
modality	O
for	O
treatment	O
of	O
cancers	O
.	O

Herein	O
,	O
an	O
upconversion	O
nanobeacon	O
(	O
UCNPs	O
-	O
MB	O
/	O
Dox	O
)	O
is	O
proposed	O
as	O
a	O
new	O
theranostic	O
nanoprobe	O
to	O
ratiometrically	O
detect	O
and	O
visualize	O
the	O
thymidine	O
kinase	O
1	O
(	O
TK1	O
)	O
mRNA	O
that	O
can	O
simultaneously	O
trigger	O
the	O
Dox	O
release	O
to	O
activate	O
the	O
chemotherapy	O
accordingly	O
.	O

UCNPs	O
-	O
MB	O
/	O
Dox	O
is	O
constructed	O
with	O
the	O
conjugation	O
of	O
a	O
TK1	O
mRNA	O
-specific	O
molecular	O
beacon	O
(	O
MB	O
)	O
bearing	O
a	O
quencher	O
(	O
BHQ-1	O
)	O
and	O
an	O
alkene	O
handle	O
modified	O
upconversion	O
nanoparticle	O
(	O
UCNP	O
)	O
through	O
click	O
reaction	O
and	O
subsequently	O
loading	O
with	O
a	O
chemotherapy	O
drug	O
(	O
Dox	O
)	O
.	O

With	O
this	O
nanobeacon	O
,	O
quantitative	O
ratiometric	O
upconversion	O
detection	O
of	O
the	O
target	O
with	O
high	O
sensitivity	O
and	O
selectivity	O
as	O
well	O
as	O
the	O
target	O
triggered	O
Dox	O
release	O
in	O
vitro	O
is	O
demonstrated	B-P
.	O

The	O
sensitive	O
and	O
selective	O
ratiometric	O
detection	O
and	O
imaging	B-P
of	O
TK1	O
mRNA	O
under	O
the	O
irradiation	O
of	O
near	O
infrared	O
light	O
(	O
980	O
nm	O
)	O
and	O
the	O
mRNA	O
-dependent	O
release	O
of	O
Dox	O
for	O
chemotherapy	O
in	O
the	O
tumor	O
MCF-7	O
cells	O
and	O
A549	O
cells	O
are	O
also	O
shown	O
.	O

This	O
work	O
provides	O
a	O
smart	O
and	O
robust	O
platform	O
for	O
gene	O
-related	O
tumor	O
theranostics	O
.	O

Generalized	O
Weakness	O
in	O
a	O
Transplant	O
Patient	O
:	O
A	O
Case	O
Presentation	O
.	O

Generalized	O
weakness	O
in	O
transplant	O
patients	O
is	O
a	O
major	O
complaint	O
in	O
tertiary	O
rehabilitation	O
hospitals	O
.	O

The	O
diagnosis	O
and	O
management	O
of	O
generalized	O
weakness	O
in	O
this	O
population	O
pose	O
challenges	O
for	O
physicians	O
.	O

We	O
present	O
the	O
case	O
of	O
a	O
transplant	O
patient	O
with	O
generalized	O
weakness	O
who	O
was	O
eventually	O
diagnosed	O
with	O
calciphylaxis	O
using	O
a	O
multidisciplinary	B-P
diagnostic	I-P
approach	I-P
of	O
electrodiagnostics	B-P
,	O
vascular	O
study	B-P
,	O
and	O
skin	B-P
biopsy	I-P
.	O

Calciphylaxis	O
is	O
a	O
rare	O
cutaneous	O
disorder	O
that	O
mimics	O
other	O
collagen	O
vascular	O
diseases	O
in	O
its	O
presentation	O
and	O
fulminant	O
course	O
.	O

Physiatrists	O
should	O
be	O
cognizant	O
of	O
calciphylaxis	O
,	O
as	O
it	O
signals	O
a	O
poor	O
prognosis	O
if	O
not	O
correctly	O
diagnosed	O
and	O
treated	O
in	O
a	O
timely	O
manner	O
,	O
with	O
high	O
incidence	O
of	O
sepsis	O
,	O
wound	O
pain	O
,	O
and	O
disability	O
.	O

V	O
.	O

Pathways	O
to	O
Suicide	O
in	O
Australian	O
Farmers	O
:	O
A	O
Life	O
Chart	O
Analysis	O
.	O

Farmers	O
have	O
been	O
found	O
to	O
be	O
at	O
increased	O
risk	O
of	O
suicide	O
in	O
Australia	O
.	O

The	O
Interpersonal-Psychological	O
Theory	O
of	O
Suicidal	O
Behaviour	O
suggests	O
that	O
the	O
proximal	O
factors	O
leading	O
to	O
the	O
suicidal	O
desire	O
or	O
ideation	O
include	O
an	O
individual	O
's	O
experiences	O
of	O
both	O
perceived	O
burdensomeness	O
and	O
thwarted	O
belongingness	O
.	O

Suicidal	O
desire	O
with	O
acquired	O
capability	O
to	O
engage	O
in	O
lethal	O
self-injury	O
is	O
predictive	O
of	O
suicidal	O
behaviour	O
.	O

This	O
study	O
investigates	O
the	O
pathways	O
to	O
suicide	O
of	O
18	O
Australian	O
male	O
farmers	O
in	O
order	O
to	O
understand	O
the	O
suicidal	O
process	O
and	O
antecedents	O
to	O
suicide	O
in	O
Australian	O
male	O
farmers	O
.	O

The	O
psychological	B-P
autopsy	I-P
(	O
PA	B-P
)	O
method	O
was	O
used	O
to	O
generate	O
life	O
charts	O
.	O

Two	O
pathways	O
with	O
distinct	O
suicidal	O
processes	O
were	O
identified	O
:	O
acute	O
situational	O
(	O
romantic	O
relationship	O
problems	O
and	O
financial	O
concerns	O
/	O
pending	O
retirement	O
)	O
and	O
protracted	O
(	O
long-term	O
psychiatric	O
disorder	O
)	O
.	O

Long	O
working	O
hours	O
,	O
interpersonal	O
conflicts	O
,	O
physical	O
illnesses	O
and	O
pain	O
,	O
alcohol	O
abuse	O
,	O
access	O
to	O
firearms	O
,	O
and	O
exposure	O
to	O
drought	O
were	O
additional	O
common	O
factors	O
identified	O
.	O

An	O
understanding	O
of	O
the	O
interrelatedness	O
of	O
diverse	O
distal	O
and	O
proximal	O
risk	O
factors	O
on	O
suicidal	O
pathways	O
in	O
the	O
wider	O
environmental	O
context	O
for	O
male	O
farmers	O
is	O
required	O
when	O
developing	O
and	O
implementing	O
rural	O
suicide	O
prevention	O
activities	O
.	O

Anti-helminthic	O
activity	O
of	O
Momordica	O
charantia	O
L.	O
against	O
Fasciola	O
hepatica	O
eggs	O
after	O
twelve	O
days	O
of	O
incubation	B-P
in	O
vitro	O
.	O

Fasciolosis	O
,	O
a	O
parasitic	O
disease	O
caused	O
by	O
the	O
trematode	O
Fasciola	O
hepatica	O
underreported	O
is	O
expanding	O
both	O
in	O
human	O
and	O
animal	O
population	O
,	O
throughout	O
the	O
world	O
.	O

The	O
constant	O
use	O
of	O
synthetic	O
drugs	O
to	O
treat	O
this	O
condition	O
has	O
led	O
to	O
the	O
natural	O
selection	O
of	O
resistant	O
strains	O
of	O
the	O
parasite	O
.	O

Hence	O
,	O
there	O
is	O
a	O
growing	O
focus	O
on	O
the	O
potential	O
anti-helminthic	O
properties	O
of	O
medicinal	O
plants	O
and	O
phytopharmaceuticals	O
.	O

The	O
current	O
study	O
assessed	O
the	O
potential	O
anti-fasciolicide	O
action	O
of	O
Momordica	O
charantia	O
leaf	O
extracts	O
and	O
fractions	O
on	O
the	O
eggs	O
of	O
F.	O
hepatica	O
parasites	O
.	O

The	O
lyophilized	O
crude	O
extract	O
(	O
CE	O
)	O
of	O
M.	O
charantia	O
leaves	O
and	O
its	O
sub-fractions	O
,	O
obtained	O
from	O
liquid-liquid	B-P
partitioning	I-P
with	O
organic	O
solvents	O
,	O
were	O
analysed	O
by	O
High	B-P
Performance	I-P
Liquid	I-P
Chromatography	I-P
(	O
HPLC	B-P
)	O
,	O
suspended	O
in	O
1	O
%	O
DMSO	O
and	O
used	O
in	O
in	O
vitro	O
tests	B-P
.	O

Quadruplicates	O
of	O
50	O
F.	O
hepatica	O
eggs	O
were	O
incubated	B-P
at	O
23°C	O
with	O
M.	O
charantia	O
leaf	O
CE	O
in	O
different	O
concentrations	O
.	O

After	O
12	O
days	O
no	O
larvae	O
were	O
formed	O
in	O
eggs	O
incubated	B-P
with	O
CE	O
concentrations	O
above	O
12.5mg/mL	O
.	O

Eggs	O
incubated	B-P
with	O
CE	O
sub-fractions	O
at	O
concentrations	O
of	O
1000	O
,	O
100	O
,	O
10	O
,	O
1	O
,	O
0.1	O
,	O
0.01μg/mL	O
affected	O
embryonic	O
development	O
,	O
with	O
n-butanol	O
presenting	O
the	O
strongest	O
inhibition	O
of	O
miracidia	O
formation	O
.	O

In	O
contrast	O
,	O
on	O
the	O
12th	O
day	O
,	O
90	O
%	O
of	O
the	O
miracidia	O
hatched	O
in	O
the	O
control	O
experiments	O
using	O
0.03	O
%	O
DMSO	O
whereas	O
embryogenesis	O
was	O
completely	O
abolished	O
with	O
any	O
concentration	O
of	O
albendazole	O
sulphoxide	O
ABZ	O
(	O
SO	O
)	O
.	O

Chemical	B-P
analysis	I-P
of	O
the	O
CE	O
and	O
sub-fractions	O
revealed	O
a	O
prominent	O
presence	O
of	O
flavonoids	O
.	O

HPLC-MS	B-P
confirmed	O
Quercetin	O
to	O
be	O
one	O
of	O
the	O
main	O
flavonoids	O
present	O
in	O
the	O
CE	O
and	O
the	O
n-butanol	O
subfraction	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
analyse	O
the	O
potential	O
anti-fasciolicide	O
action	O
of	O
M.	O
charantia	O
leaf	O
CE	O
and	O
subfractions	O
.	O

NADPH	O
oxidase-produced	O
superoxide	O
mediated	O
a	O
50-Hz	O
magnetic	O
field	O
-induced	O
epidermal	O
growth	O
factor	O
receptor	O
clustering	O
.	O

A	O
50-Hz	O
magnetic	O
field	O
(	O
MF	O
)	O
was	O
found	O
to	O
induce	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
clustering	O
in	O
our	O
previous	O
study	O
.	O

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
that	O
mediated	O
MF	O
-induced	O
EGFR	O
clustering	O
.	O

Human	O
amniotic	O
epithelial	O
(	O
FL	O
)	O
cells	O
were	O
exposed	O
to	O
a	O
50-Hz	O
MF	O
.	O

Total	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
,	O
cytoplasmic	O
and	O
mitochondrial	O
superoxide	O
production	O
were	O
detected	O
by	O
DCFH-DA	O
,	O
DHE	O
and	O
MitoSOX	O
,	O
respectively	O
.	O

EGFR	O
clustering	O
was	O
analyzed	O
using	O
confocal	B-P
microscopy	I-P
after	O
indirect	B-P
immunofluorescence	I-P
staining	B-P
.	O

Results	O
showed	O
that	O
exposing	O
FL	O
cells	O
to	O
MF	O
at	O
intensity	O
higher	O
than	O
0.2	O
mT	O
for	O
15	O
min	O
enhanced	O
total	O
ROS	O
production	O
.	O

Additionally	O
,	O
enhanced	O
total	O
ROS	O
and	O
cytoplasmic	O
superoxide	O
production	O
were	O
observed	O
after	O
exposing	O
cells	O
to	O
MF	O
at	O
0.4	O
mT	O
for	O
5	O
,	O
15	O
,	O
or	O
30	O
min	O
,	O
while	O
mitochondrial	O
superoxide	O
production	O
for	O
15	O
or	O
30	O
min	O
.	O

Pretreatment	O
with	O
Nox	O
inhibitor	O
,	O
DPI	O
,	O
effectively	O
inhibited	O
MF	O
-induced	O
cytoplasmic	O
superoxide	O
production	O
and	O
subsequent	O
EGFR	O
clustering	O
while	O
mitochondrial	O
superoxide	O
production	O
was	O
not	O
affected	O
.	O

Nox-produced	O
superoxide	O
mediated	O
a	O
50-	O
Hz	O
magnetic	O
field	O
-induced	O
EGFR	O
clustering	O
.	O

Development	O
of	O
a	O
novel	O
near-infrared	O
fluorescent	O
theranostic	O
combretastain	O
A-4	O
analogue	O
,	O
YK-5-252	O
,	O
to	O
target	O
triple	O
negative	O
breast	O
cancer	O
.	O

The	O
treatment	O
of	O
triple	O
negative	O
breast	O
cancer	O
(	O
TNBC	O
)	O
is	O
a	O
significant	O
challenge	O
to	O
cancer	O
research	O
.	O

The	O
lack	O
of	O
hormone	O
receptors	O
limits	O
the	O
treatment	O
options	O
available	O
to	O
patients	O
with	O
this	O
diagnosis	O
,	O
forcing	O
them	O
to	O
endure	O
prolonged	O
radiation	O
and	O
chemotherapy	O
.	O

Anti-angiogenesis	O
is	O
a	O
chemotherapeutic	O
strategy	O
that	O
targets	O
the	O
vasculature	O
of	O
tumors	O
.	O

Combretastatin	O
A-4	O
(	O
CA-4	O
)	O
is	O
a	O
well-known	O
vasculature	O
-	O
disrupting	O
agent	O
,	O
which	O
has	O
been	O
shown	O
to	O
effectively	O
kill	O
a	O
variety	O
of	O
cancers	O
through	O
inhibition	O
of	O
tubulin	O
polymerization	O
.	O

Due	O
to	O
its	O
toxicity	O
,	O
small	O
molecule	O
analogues	O
of	O
CA-4	O
have	O
been	O
sought	O
out	O
.	O

We	O
have	O
designed	O
a	O
novel	O
dual	O
action	O
CA-4	O
prodrug	O
,	O
YK-5-252	O
,	O
which	O
releases	O
the	O
drug	O
through	O
a	O
disulfide	O
bond	O
cleavage	O
mechanism	O
and	O
contains	O
a	O
near-infrared	O
(	O
NIR	O
)	O
fluorophore	O
,	O
which	O
allows	O
fluorescence	O
monitoring	O
of	O
cleavage	O
.	O

This	O
disulfide	O
linkage	O
causes	O
CA-4	O
to	O
become	O
effective	O
only	O
when	O
released	O
by	O
glutathione	O
(	O
GSH	O
)	O
reducing	O
the	O
toxicity	O
of	O
the	O
drug	O
while	O
simultaneously	O
releasing	O
the	O
NIR	O
fluorophore	O
.	O

Therefore	O
the	O
prodrug	O
,	O
YK-5-252	O
,	O
represents	O
a	O
novel	O
CA-4	O
analogue	O
which	O
has	O
reduced	O
toxicity	O
and	O
can	O
be	O
used	O
for	O
theranostics	O
imaging	B-P
.	O

Whole-body	O
strength	O
training	O
with	O
Huber	O
Motion	O
Lab	O
and	O
traditional	O
strength	O
training	O
in	O
cardiac	O
rehabilitation	O
:	O
A	O
randomized	O
controlled	O
study	O
.	O

Isometric	O
strengthening	O
has	O
been	O
rarely	O
studied	O
in	O
patients	O
with	O
coronary	O
heart	O
disease	O
(	O
CHD	O
)	O
,	O
mainly	O
because	O
of	O
possible	O
potential	O
side	O
effects	O
and	O
lack	O
of	O
appropriate	O
and	O
reliable	O
devices	O
.	O

We	O
aimed	O
to	O
compare	O
2	O
different	O
modes	O
of	O
resistance	O
training	O
,	O
an	O
isometric	O
mode	O
with	O
the	O
Huber	O
Motion	O
Lab	O
(	O
HML	O
)	O
and	O
traditional	O
strength	O
training	O
(	O
TST	O
)	O
,	O
in	O
CHD	O
patients	O
undergoing	O
a	O
cardiac	O
rehabilitation	O
program	O
.	O

We	O
randomly	O
assigned	O
50	O
patients	O
to	O
HML	O
or	O
TST	O
.	O

Patients	O
underwent	O
complete	O
blinded	O
evaluation	O
before	O
and	O
after	O
the	O
rehabilitation	O
program	O
,	O
including	O
testing	B-P
for	I-P
cardiopulmonary	I-P
exercise	I-P
,	O
maximal	B-P
isometric	I-P
voluntary	I-P
contraction	I-P
,	O
endothelial	O
function	O
and	O
body	O
composition	O
.	O

After	O
4	O
weeks	O
of	O
training	O
(	O
16	O
sessions	O
)	O
,	O
the	O
groups	O
did	O
not	O
differ	O
in	O
body	O
composition	O
,	O
anthropometric	O
characteristics	O
,	O
or	O
endothelial	O
function	O
.	O

With	O
HML	O
,	O
peak	O
power	O
output	O
(	O
P=0.035	O
)	O
,	O
maximal	O
heart	O
rate	O
(	O
P	O
<	O
0.01	O
)	O
and	O
gain	O
of	O
force	O
measured	O
in	O
the	O
chest	O
press	O
position	O
(	O
P	O
<	O
0.02	O
)	O
were	O
greater	O
after	O
versus	O
before	O
training	O
.	O

Both	O
protocols	O
appeared	O
to	O
be	O
well	O
tolerated	O
,	O
safe	O
and	O
feasible	O
for	O
these	O
CHD	O
patients	O
.	O

A	O
training	O
protocol	O
involving	O
6s	O
phases	O
of	O
isometric	O
contractions	O
with	O
10s	O
of	O
passive	O
recovery	O
on	O
an	O
HML	O
device	O
could	O
be	O
safely	O
implemented	O
in	O
rehabilitation	O
programs	O
for	O
patients	O
with	O
CHD	O
and	O
improve	O
functional	O
outcomes	O
.	O

Do	O
post-trauma	O
symptoms	O
mediate	O
the	O
relation	O
between	O
neurobiological	O
stress	O
parameters	O
and	O
conduct	O
problems	O
in	O
girls	O
?	O
.	O

Attenuated	O
activity	O
of	O
stress-regulating	O
systems	O
has	O
consistently	O
been	O
reported	O
in	O
boys	O
with	O
conduct	O
problems	O
.	O

Results	O
in	O
studies	O
of	O
girls	O
are	O
inconsistent	O
,	O
which	O
may	O
result	O
from	O
the	O
high	O
prevalence	O
of	O
comorbid	O
post-trauma	O
symptoms	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
investigate	O
post-trauma	O
symptoms	O
as	O
a	O
potential	O
mediator	O
in	O
the	O
relation	O
between	O
stress-regulation	O
systems	O
functioning	O
and	O
conduct	O
problems	O
in	O
female	O
adolescents	O
.	O

The	O
sample	O
consisted	O
of	O
78	O
female	O
adolescents	O
(	O
mean	O
age	O
15.4	O
;	O
SD	O
1.1	O
)	O
admitted	O
to	O
a	O
closed	O
treatment	O
institution	O
.	O

The	O
diagnosis	B-P
of	O
disruptive	O
behaviour	O
disorder	O
(	O
DBD	O
)	O
was	O
assessed	O
by	O
a	O
structured	O
interview-	O
the	O
diagnostic	O
interview	O
schedule	O
for	O
children	O
version	O
IV	O
(	O
DISC-IV	O
)	O
.	O

To	O
assess	O
post-trauma	O
symptoms	O
and	O
externalizing	O
behaviour	O
problems	O
,	O
self-report	O
questionnaires	O
,	O
youth	O
self	O
report	O
(	O
YSR	O
)	O
and	O
the	O
trauma	O
symptom	O
checklist	O
for	O
Children	O
(	O
TSCC	O
)	O
were	O
used	O
.	O

The	O
cortisol	O
awakenings	O
response	O
(	O
CAR	O
)	O
measured	O
hypothalamic-pituitary-adrenal	O
(	O
HPA	O
)	O
axis	O
activity	O
,	O
whereas	O
autonomous	O
nervous	O
system	O
(	O
ANS	O
)	O
activity	O
was	O
assessed	O
by	O
heart	O
rate	O
(	O
HR	O
)	O
,	O
pre-ejection	O
period	O
(	O
PEP	O
)	O
and	O
respiratory	O
sinus	O
arrhythmia	O
(	O
RSA	O
)	O
.	O

Independent	O
t-tests	O
were	O
used	O
to	O
compare	O
girls	O
with	O
and	O
without	O
DBD	O
,	O
while	O
path	O
analyses	O
tested	O
for	O
the	O
mediating	O
role	O
of	O
post-	O
trauma	O
symptoms	O
in	O
the	O
relation	O
between	O
stress	O
regulating	O
systems	O
and	O
externalizing	O
behaviour	O
.	O

Females	O
with	O
DBD	O
(	O
n	O
=	O
37	O
)	O
reported	O
significantly	O
higher	O
rates	O
of	O
post-trauma	O
symptoms	O
and	O
externalizing	O
behaviour	O
problems	O
than	O
girls	O
without	O
DBD	O
(	O
n	O
=	O
39	O
)	O
.	O

Path	O
analysis	O
found	O
no	O
relation	O
between	O
CAR	O
and	O
externalizing	O
behaviour	O
problems	O
.	O

With	O
regard	O
to	O
ANS	O
activity	O
,	O
positive	O
direct	O
effects	O
on	O
externalizing	O
behaviour	O
problems	O
were	O
present	O
for	O
HR	O
(	O
standardized	O
β	O
=	O
0.306	O
,	O
p	O
=	O
0.020	O
)	O
and	O
PEP	O
(	O
standardized	O
β	O
=	O
-0.323	O
,	O
p	O
=	O
0.031	O
)	O
,	O
though	O
not	O
for	O
RSA	O
.	O

Furthermore	O
,	O
no	O
relation-whether	O
direct	O
or	O
indirect-could	O
be	O
determined	O
from	O
post-trauma	O
symptoms	O
.	O

Present	O
findings	O
demonstrate	O
that	O
the	O
neurobiological	O
characteristics	O
of	O
female	O
externalizing	O
behaviour	O
differ	O
from	O
males	O
,	O
since	O
girls	O
showed	O
heightened	O
instead	O
of	O
attenuated	O
ANS	O
activity	O
.	O

While	O
the	O
prevalence	O
of	O
post-trauma	O
symptoms	O
was	O
high	O
in	O
girls	O
with	O
DBD	O
,	O
it	O
did	O
not	O
mediate	O
the	O
relation	O
between	O
stress	O
parameters	O
and	O
externalizing	O
behaviour	O
.	O

Clinical	O
implications	O
and	O
future	O
directions	O
are	O
discussed	O
.	O

Retrospective	O
study	O
of	O
24	O
cases	O
of	O
acute	O
appendiceal	O
diverticulitis	O
:	O
CT	B-P
findings	O
and	O
pathological	O
correlations	O
.	O

Appendiceal	O
diverticulitis	O
is	O
relatively	O
rare	O
and	O
is	O
difficult	O
to	O
distinguish	O
clinically	O
and	O
radiologically	O
from	O
acute	O
appendicitis	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
computed	B-P
tomography	I-P
(	B-P
CT	I-P
)	O
findings	O
of	O
acute	O
appendiceal	O
diverticulitis	O
.	O

Among	O
the	O
1329	O
patients	O
who	O
underwent	O
appendectomy	O
at	O
our	O
institution	O
between	O
January	O
2010	O
and	O
July	O
2015	O
,	O
28	O
were	O
diagnosed	O
pathologically	O
with	O
appendiceal	O
diverticulitis	O
,	O
including	O
24	O
patients	O
who	O
were	O
evaluated	O
by	O
preoperative	O
CT	B-P
.	O

The	O
control	O
group	O
consisted	O
of	O
38	O
patients	O
without	O
diverticulitis	O
.	O

Average	O
age	O
of	O
patients	O
,	O
ratio	O
of	O
males	O
to	O
females	O
,	O
appendiceal	O
diameter	O
,	O
presence	O
of	O
a	O
diverticulum	O
,	O
diverticular	O
enhancement	O
,	O
peri-appendiceal	O
fat	O
stranding	O
,	O
peri-appendiceal	O
loculated	O
fluid	O
and	O
perforation	O
,	O
and	O
the	O
presence	O
of	O
appendicolith	O
were	O
evaluated	O
retrospectively	O
.	O

Peri-appendiceal	O
fat	O
stranding	O
(	O
p	O
<	O
0.005	O
)	O
,	O
appendiceal	O
diameter	O
(	O
p	O
<	O
0.005	O
)	O
,	O
and	O
peri-appendiceal	O
loculated	O
fluid	O
differed	O
significantly	O
between	O
the	O
diverticulitis	O
and	O
non	O
-	O
diverticulitis	O
groups	O
(	O
p	O
<	O
0.005	O
)	O
.	O

Although	O
relatively	O
uncommon	O
,	O
appendiceal	O
diverticulitis	O
should	O
be	O
included	O
in	O
the	O
differential	B-P
diagnosis	I-P
of	O
acute	O
appendicitis	O
.	O

It	O
differs	O
from	O
typical	O
acute	O
appendicitis	O
by	O
the	O
presence	O
of	O
an	O
inflamed	O
diverticulum	O
,	O
seen	O
on	O
CT	B-P
.	O

These	O
patients	O
are	O
also	O
more	O
likely	O
to	O
have	O
peri-appendiceal	O
extra-luminal	O
loculated	O
fluid	O
,	O
peri-appendiceal	O
fat	O
stranding	O
,	O
and	O
a	O
larger	O
diameter	O
of	O
the	O
appendix	O
.	O

The	O
latter	O
finding	O
is	O
likely	O
due	O
to	O
the	O
increased	O
intraluminal	O
pressure	O
.	O

The	O
Association	O
between	O
Sexually	O
Transmitted	O
Infections	O
,	O
Length	O
of	O
Service	O
and	O
Other	O
Demographic	O
Factors	O
in	O
the	O
U.S.	O
Military	O
.	O

Numerous	O
studies	O
have	O
found	O
higher	O
rates	O
of	O
sexually	O
transmitted	O
infections	O
(	O
STIs	O
)	O
among	O
military	O
personnel	O
than	O
the	O
general	O
population	O
,	O
but	O
the	O
cumulative	O
risk	O
of	O
acquiring	O
STIs	O
throughout	O
an	O
individual	O
's	O
military	O
career	O
has	O
not	O
been	O
described	O
.	O

Using	O
ICD-9	O
diagnosis	O
codes	O
,	O
we	O
analyzed	O
the	O
medical	O
records	O
of	O
100,005	O
individuals	O
from	O
all	O
service	O
branches	O
,	O
divided	O
in	O
equal	O
cohorts	O
(	O
n	O
=	O
6,667	O
)	O
between	O
1997	O
and	O
2011	O
.	O

As	O
women	O
receive	O
frequent	O
STI	O
screening	B-P
compared	O
to	O
men	O
,	O
these	O
groups	O
were	O
analyzed	O
separately	O
.	O

Incidence	O
rates	O
were	O
calculated	O
for	O
pathogen	O
-specific	O
STIs	O
along	O
with	O
syndromic	O
diagnoses	O
.	O

Descriptive	O
statistics	O
were	O
used	O
to	O
characterize	O
the	O
individuals	O
within	O
each	O
accession	O
year	O
cohort	O
;	O
repeat	O
infections	O
were	O
censored	O
.	O

The	O
total	O
sample	O
included	O
29,010	O
females	O
and	O
70,995	O
males	O
.	O

The	O
STI	O
incidence	O
rates	O
(	O
per	O
100	O
person-years	O
)	O
for	O
women	O
and	O
men	O
,	O
respectively	O
,	O
were	O
as	O
follows	O
:	O
chlamydia	O
(	O
3.5	O
and	O
0.7	O
)	O
,	O
gonorrhea	O
(	O
1.1	O
and	O
0.4	O
)	O
,	O
HIV	O
(	O
0.04	O
and	O
0.07	O
)	O
and	O
syphilis	O
(	O
0.14	O
and	O
0.15	O
)	O
.	O

During	O
the	O
study	O
period	O
,	O
22	O
%	O
of	O
women	O
and	O
3.3	O
%	O
of	O
men	O
received	O
a	O
pathogen-specific	O
STI	O
diagnosis	O
;	O
inclusion	O
of	O
syndromic	O
diagnoses	O
increased	O
STI	O
prevalence	O
to	O
41	O
%	O
and	O
5.5	O
%	O
,	O
respectively	O
.	O

In	O
multivariate	O
analyses	O
,	O
factors	O
associated	O
with	O
etiologic	O
and	O
syndromic	O
STIs	O
among	O
women	O
included	O
African	O
American	O
race	O
,	O
younger	O
age	O
and	O
fewer	O
years	O
of	O
education	O
.	O

In	O
the	O
overall	O
sample	O
,	O
increasing	O
number	O
of	O
years	O
of	O
service	O
was	O
associated	O
with	O
an	O
increased	O
likelihood	O
of	O
an	O
STI	O
diagnosis	O
(	O
p	O
<	O
0.001	O
for	O
trend	O
)	O
.	O

In	O
this	O
survey	O
of	O
military	O
personnel	O
,	O
we	O
found	O
very	O
high	O
rates	O
of	O
STI	O
acquisition	O
throughout	O
military	O
service	O
,	O
especially	O
among	O
women	O
,	O
demonstrating	O
that	O
STI-related	O
risk	O
is	O
significant	O
and	O
ongoing	O
throughout	O
military	O
service	O
.	O

Lower	O
STI	O
incidence	O
rates	O
among	O
men	O
may	O
represent	O
under-	O
diagnosis	O
and	O
demonstrate	O
a	O
need	O
for	O
enhancing	O
Male-Direct	O
sreening	O
and	O
diagnostic	B-P
interventions	I-P
.	I-P

Detection	O
of	O
AMA-M2	O
in	O
human	O
saliva	O
:	O
Potentials	O
in	O
diagnosis	O
and	O
monitoring	O
of	O
primary	O
biliary	O
cholangitis	O
.	O

Serum	O
anti-mitochondrial	O
antibody	O
type	O
2	O
(	O
AMA-M2	O
)	O
is	O
considered	O
as	O
a	O
pivotal	O
biomarker	O
for	O
the	O
diagnosis	O
of	O
primary	O
biliary	O
cholangitis	O
(	O
PBC	O
)	O
.	O

However	O
,	O
serological	B-P
tests	I-P
have	O
many	O
limitations	O
,	O
including	O
inconvenience	O
,	O
invasiveness	O
,	O
and	O
infection	O
risks	O
.	O

Thus	O
,	O
a	O
less	O
invasive	O
approach	O
to	O
detect	O
AMA-M2	B-P
titer	I-P
is	O
desirable	O
.	O

We	O
examined	O
salivary	O
AMA-M2	O
of	O
potential	O
PBC	O
patients	O
and	O
found	O
that	O
AMA-M2	O
could	O
be	O
detected	O
only	O
in	O
saliva	O
of	O
serum	O
AMA-M2-positive	O
PBC	O
patients	O
,	O
but	O
not	O
in	O
saliva	O
of	O
serum	O
AMA-M2-negative	O
PBC	O
patients	O
,	O
oral	O
lichen	O
planus	O
patients	O
(	O
OLP	O
)	O
patients	O
,	O
or	O
healthy	O
controls	O
.	O

Furthermore	O
,	O
the	O
concentration	O
of	O
salivary	O
AMA-M2	O
was	O
positively	O
correlated	O
with	O
the	O
amount	O
of	O
serum	O
AMA-M2	O
in	O
patients	O
.	O

The	O
salivary	O
inflammatory	O
cytokines	O
were	O
increased	O
in	O
the	O
PBC	O
,	O
consistent	O
with	O
the	O
results	O
of	O
serum	O
test	B-P
.	O

These	O
findings	O
indicated	O
that	O
saliva	O
might	O
be	O
a	O
less	O
invasive	O
and	O
cost-effective	O
medium	O
to	O
accurately	O
test	O
for	O
AMA-M2	B-P
levels	I-P
and	O
this	O
is	O
a	O
promising	O
development	O
for	O
the	O
diagnosis	O
and	O
monitoring	O
of	O
PBC	O
.	O

Prevalence	O
and	O
correlates	O
of	O
binge	O
eating	O
disorder	O
related	O
features	O
in	O
the	O
community	O
.	O

Binge	O
eating	O
disorder	O
(	O
BED	O
)	O
is	O
associated	O
with	O
high	O
levels	O
of	O
obesity	O
and	O
psychological	O
suffering	O
,	O
but	O
little	O
is	O
known	O
about	O
1	O
)	O
the	O
distribution	O
of	O
features	O
of	O
BED	O
in	O
the	O
general	O
population	O
and	O
2	O
)	O
their	O
consequences	O
for	O
weight	O
development	O
and	O
psychological	O
distress	O
in	O
young	O
adulthood	O
.	O

We	O
investigated	O
the	O
prevalence	O
of	O
features	O
of	O
BED	O
and	O
their	O
association	O
with	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
and	O
psychological	O
distress	O
among	O
men	O
(	O
n	O
=	O
2423	O
)	O
and	O
women	O
(	O
n	O
=	O
2825	O
)	O
from	O
the	O
longitudinal	O
community-based	O
FinnTwin16	O
cohort	O
(	O
born	O
1975-1979	O
)	O
.	O

Seven	O
eating	O
-related	O
cognitions	O
and	O
behaviors	O
similar	O
to	O
the	O
defining	O
features	O
of	O
BED	O
were	O
extracted	O
from	O
the	O
Eating	O
Disorder	O
Inventory-2	O
and	O
were	O
assessed	O
at	O
a	O
mean	O
age	O
of	O
24	O
.	O

BMI	O
and	O
psychological	O
distress	O
,	O
measured	O
with	O
the	O
General	B-P
Health	I-P
Questionnaire	I-P
,	O
were	O
assessed	O
at	O
ages	O
24	O
and	O
34	O
.	O

We	O
assessed	O
prevalence	O
of	O
the	O
features	O
and	O
their	O
association	O
with	O
BMI	O
and	O
psychological	O
distress	O
cross-sectionally	O
and	O
prospectively	O
.	O

More	O
than	O
half	O
of	O
our	O
participants	O
reported	O
at	O
least	O
one	O
feature	O
of	O
BED	O
;	O
clustering	O
of	O
several	O
features	O
in	O
one	O
individual	O
was	O
less	O
common	O
,	O
particularly	O
among	O
men	O
.	O

The	O
most	O
frequently	O
reported	O
feature	O
was	O
'	O
stuffing	O
oneself	O
with	O
food	O
'	O
,	O
whereas	O
the	O
least	O
common	O
was	O
'	O
eating	O
or	O
drinking	O
in	O
secrecy	O
'	O
.	O

All	O
individual	O
features	O
of	O
BED	O
and	O
their	O
clustering	O
particularly	O
were	O
associated	O
with	O
higher	O
BMI	O
and	O
more	O
psychological	O
distress	O
cross-sectionally	O
.	O

Prospectively	O
,	O
the	O
clustering	O
of	O
features	O
of	O
BED	O
predicted	O
increase	O
in	O
psychological	O
distress	O
but	O
not	O
additional	O
weight	O
gain	O
when	O
baseline	O
BMI	O
was	O
accounted	O
for	O
.	O

In	O
summary	O
,	O
although	O
some	O
features	O
of	O
BED	O
were	O
common	O
,	O
the	O
clustering	O
of	O
several	O
features	O
in	O
one	O
individual	O
was	O
not	O
.	O

The	O
features	O
were	O
cumulatively	O
associated	O
with	O
BMI	O
and	O
psychological	O
distress	O
and	O
predicted	O
further	O
increase	O
in	O
psychological	O
distress	O
over	O
ten	O
years	O
of	O
follow-up	O
.	O

In	O
Vivo	O
Three-Dimensional	O
Patellar	O
Mechanics	O
:	O
Normal	O
Knees	O
Compared	O
with	O
Domed	O
and	O
Anatomic	O
Patellar	O
Components	O
.	O

Patellofemoral	O
complications	O
are	O
a	O
major	O
cause	O
of	O
revision	O
surgery	O
following	O
total	O
knee	O
arthroplasty	O
(	O
TKA	O
)	O
.	O

High	O
forces	O
occurring	O
at	O
the	O
patellofemoral	O
articulation	O
coupled	O
with	O
a	O
small	O
patellofemoral	O
contact	O
area	O
pose	O
substantial	O
design	O
challenges	O
.	O

In	O
this	O
study	O
,	O
the	O
three-dimensional	O
(	O
3D	O
)	O
in	O
vivo	O
mechanics	O
of	O
domed	O
and	O
anatomically	O
shaped	O
patellar	O
components	O
were	O
compared	O
with	O
those	O
of	O
native	O
patellae	O
.	O

Ten	O
normal	O
knees	O
,	O
10	O
treated	O
with	O
an	O
LCS-PS	O
(	O
low	O
contact	O
stress-posterior	O
stabilized	O
)	O
TKA	O
(	O
anatomically	O
shaped	O
patellar	O
component	O
)	O
,	O
and	O
10	O
treated	O
with	O
a	O
PFC	O
Sigma	O
RP-PS	O
(	O
press-fit	O
condylar	O
Sigma	O
rotating	O
platform-posterior	O
stabilized	O
)	O
TKA	O
(	O
domed	O
patellar	O
component	O
)	O
were	O
analyzed	O
under	O
fluoroscopic	B-P
surveillance	O
while	O
the	O
patient	O
performed	O
a	O
weight-bearing	O
deep	O
knee	O
bend	O
from	O
full	O
knee	O
extension	O
to	O
maximum	O
knee	O
flexion	O
.	O

Relevant	O
bone	O
geometries	O
were	O
segmented	O
out	O
from	O
computed	B-P
tomography	I-P
(	O
CT	B-P
)	O
scans	B-P
,	O
and	O
computer-assisted-design	O
(	O
CAD	O
)	O
models	O
of	O
the	O
implanted	O
components	O
were	O
obtained	O
from	O
the	O
manufacturer	O
.	O

Three-dimensional	O
patellofemoral	O
kinematics	O
were	O
obtained	O
using	O
a	O
3D	O
-to-	O
2D	O
registration	O
process	O
.	O

Contact	O
mechanics	O
were	O
calculated	O
using	O
a	O
distance	O
map	O
between	O
the	O
articulating	O
patellar	O
and	O
femoral	O
surfaces	O
.	O

Both	O
patellar	O
component	O
designs	O
exhibited	O
good	O
rotational	O
kinematics	O
and	O
tracked	O
well	O
within	O
the	O
femoral	O
trochlea	O
when	O
compared	O
with	O
the	O
normal	O
patella	O
.	O

The	O
contact	O
areas	O
in	O
the	O
TKA	O
groups	O
peaked	O
at	O
60°	O
of	O
knee	O
flexion	O
(	O
mean	O
and	O
standard	O
deviation	O
,	O
201	O
±	O
63.4	O
mm	O
for	O
the	O
LCS-PS	O
group	O
and	O
218	O
±	O
95.4	O
mm	O
for	O
the	O
Sigma	O
RP-PS	O
group	O
)	O
,	O
and	O
the	O
areas	O
were	O
substantially	O
smaller	O
than	O
those	O
previously	O
reported	O
for	O
the	O
normal	O
patella	O
.	O

Contact	O
points	O
in	O
the	O
TKA	O
groups	O
stayed	O
close	O
to	O
the	O
center	O
of	O
the	O
patellar	O
components	O
.	O

Both	O
designs	O
performed	O
satisfactorily	O
,	O
although	O
patellofemoral	O
contact	O
areas	O
were	O
reduced	O
in	O
comparison	O
with	O
those	O
in	O
the	O
native	O
patella	O
.	O

Therapeutic	O
Level	O
III	O
.	O

See	O
Instructions	O
for	O
Authors	O
for	O
a	O
complete	O
description	O
of	O
levels	O
of	O
evidence	O
.	O

Entrapment	O
of	O
the	O
posterior	O
femoral	O
cutaneous	O
nerve	O
and	O
its	O
inferior	O
cluneal	O
branches	O
:	O
anatomical	O
basis	O
of	O
surgery	O
for	O
inferior	O
cluneal	O
neuralgia	O
.	O

The	O
apparent	O
failure	O
of	O
pudendal	O
nerve	O
surgery	O
in	O
some	O
patients	O
has	O
led	O
us	O
to	O
suggest	O
the	O
possibility	O
of	O
entrapment	O
of	O
other	O
adjacent	O
nerve	O
structures	O
,	O
leading	O
to	O
the	O
concept	O
of	O
inferior	O
cluneal	O
neuralgia	O
.	O

Via	O
its	O
numerous	O
collateral	O
branches	O
,	O
the	O
posterior	O
femoral	O
cutaneous	O
nerve	O
innervates	O
a	O
very	O
extensive	O
territory	O
including	O
the	O
posterior	O
surface	O
of	O
the	O
thigh	O
,	O
the	O
infragluteal	O
fold	O
,	O
the	O
skin	O
over	O
the	O
ischial	O
tuberosity	O
,	O
but	O
also	O
the	O
lateral	O
anal	O
region	O
,	O
scrotum	O
or	O
labium	O
majus	O
via	O
its	O
perineal	O
branch	O
.	O

We	O
described	O
the	O
pathophysiological	O
features	O
of	O
cluneal	O
neuralgia	O
,	O
the	O
surgical	B-P
technique	I-P
and	O
our	O
preliminary	O
results	O
.	O

We	O
performed	O
a	O
transmuscular	O
approach	O
leading	O
to	O
the	O
fat	O
of	O
the	O
deep	O
gluteal	O
region	O
.	O

Exploration	O
was	O
continued	O
cranially	O
underneath	O
the	O
piriformis	O
,	O
looking	O
for	O
potential	O
entrapments	O
affecting	O
the	O
posterior	O
femoral	O
cutaneous	O
nerve	O
and	O
the	O
sciatic	O
nerve	O
.	O

Nerve	O
decompression	O
on	O
the	O
lateral	O
surface	O
of	O
the	O
ischial	O
tuberosity	O
was	O
then	O
performed	O
.	O

A	O
constant	O
anatomical	O
finding	O
must	O
be	O
highlighted	O
:	O
the	O
presence	O
of	O
a	O
lateral	O
fibrous	O
expansion	O
from	O
the	O
ischium	O
passing	O
behind	O
the	O
nerves	O
and	O
vessels	O
,	O
especially	O
the	O
posterior	O
femoral	O
cutaneous	O
nerve	O
and	O
its	O
perineal	O
branches	O
.	O

In	O
our	O
patients	O
,	O
release	O
of	O
this	O
expansion	O
allowed	O
decompression	O
of	O
the	O
nerve	O
trapped	O
by	O
this	O
expansion	O
.	O

Cluneal	O
neuralgia	O
constitutes	O
a	O
distinct	O
entity	O
of	O
perineal	O
pain	O
,	O
which	O
must	O
be	O
identified	O
and	O
distinguished	O
from	O
pudendal	O
neuralgia	O
.	O

Surgery	O
should	O
be	O
performed	O
via	O
a	O
transgluteal	O
approach	O
.	O

A	O
lateral	O
ischial	O
obstacle	O
must	O
be	O
investigated	O
,	O
in	O
the	O
form	O
of	O
a	O
constant	O
fibrous	O
expansion	O
,	O
which	O
,	O
like	O
a	O
retinaculum	O
,	O
can	O
cause	O
nerve	O
entrapment	O
.	O

Human	O
cathelicidin	O
LL-37	O
enhance	O
the	O
antibiofilm	O
effect	O
of	O
EGCG	O
on	O
Streptococcus	O
mutans	O
.	O

Streptococcus	O
mutans	O
forms	O
biofilms	O
as	O
a	O
resistance	O
mechanism	O
against	O
antimicrobial	O
agents	O
in	O
the	O
human	O
oral	O
cavity	O
.	O

We	O
recently	O
showed	O
that	O
human	O
cathelicidin	O
LL-37	O
exhibits	O
inhibitory	O
effects	O
on	O
biofilm	O
formation	O
of	O
S.	O
mutans	O
through	O
interaction	O
with	O
lipoteichoic	O
acid	O
(	O
LTA	O
)	O
,	O
but	O
without	O
antibacterial	O
or	O
biofilm	O
dispersal	O
abilities	O
.	O

(	O
-	O
)	O
-Epigallocatechin	O
gallate	O
(	O
EGCG	O
)	O
is	O
the	O
most	O
abundant	O
constituent	O
of	O
tea	O
catechins	O
that	O
has	O
the	O
greatest	O
anti-infective	O
potential	O
to	O
inhibit	O
the	O
growth	O
of	O
various	O
microorganisms	O
and	O
biofilm	O
formation	O
.	O

Therefore	O
,	O
in	O
this	O
study	O
,	O
we	O
evaluated	O
whether	O
LL-37	O
interacts	O
with	O
EGCG	O
to	O
enhance	O
the	O
antibiofilm	O
effect	O
of	O
EGCG	O
on	O
S.	O
mutans	O
biofilm	O
formation	O
.	O

Clinical	O
S.	O
mutans	O
strains	O
(	O
n	O
=	O
10	O
)	O
isolated	O
from	O
children	O
's	O
saliva	O
were	O
tested	O
in	O
a	O
biofilm	O
formation	O
assay	B-P
.	O

The	O
antibiofilm	O
effect	O
of	O
EGCG	O
with	O
and	O
without	O
LL-37	O
was	O
analyzed	O
by	O
the	O
minimum	O
biofilm	O
eradication	O
concentration	O
assay	B-P
and	O
confirmed	O
using	O
field	O
emission-scanning	B-P
electron	I-P
microscopy	I-P
.	O

In	O
addition	O
,	O
the	O
interaction	O
among	O
EGCG	O
,	O
LL-37	O
,	O
and	O
LTA	O
of	O
S.	O
mutans	O
was	O
determined	O
using	O
quartz	O
crystal	O
microbalance	O
analysis	O
.	O

EGCG	O
killed	O
100	O
%	O
of	O
planktonic	O
S.	O
mutans	O
within	O
5	O
h	O
,	O
inhibited	O
biofilm	O
formation	O
within	O
24	O
h	O
,	O
and	O
reduced	O
bacteria	O
cells	O
in	O
preformed	O
biofilms	O
within	O
3	O
h	O
at	O
a	O
concentration	O
of	O
0.2	O
mg/mL	O
.	O

However	O
,	O
EGCG	O
did	O
not	O
appear	O
to	O
interact	O
with	O
LTA	O
.	O

LL-37	O
effectively	O
enhanced	O
the	O
bactericidal	O
activity	O
of	O
EGCG	O
against	O
biofilm	O
formation	O
and	O
preformed	O
biofilms	O
as	O
determined	O
by	O
quantitative	O
crystal	O
violet	O
staining	B-P
and	O
field	O
emission-scanning	B-P
electron	I-P
microscopy	I-P
.	O

In	O
addition	O
,	O
quartz	O
crystal	O
microbalance	O
analysis	O
revealed	O
that	O
LL-37	O
interacted	O
with	O
EGCG	O
and	O
promoted	O
binding	O
between	O
EGCG	O
and	O
LTA	O
of	O
S.	O
mutans	O
.	O

We	O
show	O
that	O
LL-37	O
enhances	O
the	O
antibiofilm	O
effect	O
of	O
EGCG	O
on	O
S.	O
mutans	O
.	O

This	O
finding	O
provides	O
new	O
knowledge	O
for	O
dental	O
treatment	O
by	O
using	O
LL-37	O
as	O
a	O
potential	O
antibiofilm	O
compound	O
.	O

Synaptic	O
NMDA	O
Receptor	O
Activation	O
Induces	O
Ubiquitination	O
and	O
Degradation	O
of	O
STEP61	O
.	O

NMDA	O
receptor	O
signaling	O
is	O
critical	O
for	O
the	O
development	O
of	O
synaptic	O
plasticity	O
,	O
learning	O
,	O
and	O
memory	O
,	O
and	O
dysregulation	O
of	O
NMDAR	O
signaling	O
is	O
implicated	O
in	O
a	O
number	O
of	O
neurological	O
disorders	O
including	O
schizophrenia	O
(	O
SZ	O
)	O
.	O

Previous	O
work	O
has	O
demonstrated	O
that	O
the	O
STriatal-Enriched	O
protein	O
tyrosine	O
Phosphatase	O
61	O
kDa	O
(	O
STEP61	O
)	O
is	O
elevated	O
in	O
human	O
SZ	O
postmortem	B-P
cortical	O
samples	O
and	O
after	O
administration	O
of	O
psychotomimetics	O
to	O
cultures	B-P
or	O
mice	O
.	O

Here	O
,	O
we	O
report	O
that	O
activation	O
of	O
synaptic	O
NMDAR	O
by	O
bicuculline	O
or	O
D-serine	O
results	O
in	O
the	O
ubiquitination	O
and	O
proteasomal	O
degradation	O
of	O
STEP61	O
,	O
and	O
increased	O
surface	O
localization	O
of	O
GluN1	O
/	O
GluN2B	O
receptors	O
.	O

Moreover	O
,	O
bicuculline	O
or	O
D-serine	O
treatments	O
rescue	O
the	O
motor	O
and	O
cognitive	O
deficits	O
in	O
MK-801	O
-treated	O
mice	O
and	O
reduce	O
STEP61	O
in	O
mouse	O
frontal	O
cortex	O
.	O

These	O
results	O
suggest	O
that	O
STEP61	O
may	O
contribute	O
to	O
the	O
therapeutic	O
effects	O
of	O
D-serine	O
.	O

Activity	O
patterns	O
of	O
serotonin	O
neurons	O
underlying	O
cognitive	O
flexibility	O
.	O

Serotonin	O
is	O
implicated	O
in	O
mood	O
and	O
affective	O
disorders	O
.	O

However	O
,	O
growing	O
evidence	O
suggests	O
that	O
a	O
core	O
endogenous	O
role	O
is	O
to	O
promote	O
flexible	O
adaptation	O
to	O
changes	O
in	O
the	O
causal	O
structure	O
of	O
the	O
environment	O
,	O
through	O
behavioral	O
inhibition	O
and	O
enhanced	O
plasticity	O
.	O

We	O
used	O
long-term	O
photometric	B-P
recordings	I-P
in	O
mice	O
to	O
study	O
a	O
population	O
of	O
dorsal	O
raphe	O
serotonin	O
neurons	O
,	O
whose	O
activity	O
we	O
could	O
link	O
to	O
normal	O
reversal	O
learning	O
using	O
pharmacogenetics	O
.	O

We	O
found	O
that	O
these	O
neurons	O
are	O
activated	O
by	O
both	O
positive	O
and	O
negative	O
prediction	O
errors	O
,	O
and	O
thus	O
report	O
signals	O
similar	O
to	O
those	O
proposed	O
to	O
promote	O
learning	O
in	O
conditions	O
of	O
uncertainty	O
.	O

Furthermore	O
,	O
by	O
comparing	O
the	O
cue	O
responses	O
of	O
serotonin	O
and	O
dopamine	O
neurons	O
,	O
we	O
found	O
differences	O
in	O
learning	O
rates	O
that	O
could	O
explain	O
the	O
importance	O
of	O
serotonin	O
in	O
inhibiting	O
perseverative	O
responding	O
.	O

Our	O
findings	O
show	O
how	O
the	O
activity	O
patterns	O
of	O
serotonin	O
neurons	O
support	O
a	O
role	O
in	O
cognitive	O
flexibility	O
,	O
and	O
suggest	O
a	O
revised	O
model	O
of	O
dopamine	O
-	O
serotonin	O
opponency	O
with	O
potential	O
clinical	O
implications	O
.	O

Bioactive	O
Constituents	O
from	O
an	O
Endophytic	O
Fungus	O
,	O
Penicillium	O
polonicum	O
NFW9	O
,	O
associated	O
with	O
Taxus	O
fauna	O
.	O

Endophytic	O
fungi	O
are	O
being	O
recognized	O
as	O
vital	O
and	O
untapped	O
sources	O
of	O
a	O
variety	O
of	O
structurally	O
novel	O
and	O
unique	O
bioactive	O
secondary	O
metabolites	O
in	O
the	O
field	O
of	O
natural	O
products	O
drug	O
discovery	O
.	O

Herein	O
,	O
this	O
study	O
reports	O
the	O
isolation	O
and	O
characterization	O
of	O
secondary	O
metabolites	O
from	O
an	O
endophytic	O
fungus	O
Penicillium	O
polonicum	O
(	O
NFW9	O
)	O
associated	O
with	O
Taxus	O
fuana	O
.	O

Extracts	O
of	O
the	O
endophytic	O
fungus	O
cultured	O
on	O
potato	O
dextrose	O
agar	O
were	O
purified	O
using	O
several	O
chromatographic	B-P
techniques	I-P
.	O

Biological	O
evaluation	O
was	O
performed	O
based	O
on	O
their	O
abilities	O
to	O
inhibit	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-α	O
)	O
-	O
induced	O
nuclear	O
factor-kappa	O
B	O
(	O
NF-κB	O
)	O
and	O
cytotoxicity	B-P
assays	I-P
.	O

Bioactivity	O
-	O
directed	O
fractionation	O
of	O
the	O
ethyl	O
acetate	O
extract	O
of	O
a	O
fermentation	O
culture	B-P
of	O
an	O
endophytic	O
fungus	O
,	O
Penicillium	O
polonicum	O
led	O
to	O
the	O
isolation	O
of	O
a	O
dimeric	O
anthraquinone	O
,	O
(	O
R	O
)	O
-1,1',3,3',5,5'-hexahydroxy-7,7'-dimethyl	O
[	O
2,2'-bianthracene	O
]	O
-9,9',10,10'-tetraone	O
(	O
1	O
)	O
,	O
a	O
steroidal	O
furanoid	O
(	O
-	O
)	O
-wortmannolone	O
(	O
2	O
)	O
,	O
along	O
with	O
three	O
other	O
compounds	O
(	O
3	O
	O
4	O
)	O
.	O

Moreover	O
,	O
this	O
is	O
the	O
first	O
report	O
on	O
the	O
isolation	O
of	O
compound	O
1	O
from	O
an	O
endophytic	O
fungus	O
.	O

All	O
purified	O
metabolites	O
were	O
characterized	O
by	O
NMR	B-P
and	O
MS	B-P
data	O
analyses	O
.	O

The	O
stereo	O
structure	O
of	O
compound	O
1	O
was	O
determined	O
by	O
the	O
measurement	O
of	O
specific	O
optical	O
rotation	O
and	O
CD	O
spectrum	O
.	O

The	O
relative	O
stereochemistry	O
of	O
2	O
was	O
confirmed	O
by	O
single-crystal	B-P
X-ray	I-P
diffraction	I-P
.	O

Compounds	O
2	O
	O
3	O
showed	O
inhibitory	O
activities	O
in	O
TNF-α	O
-	O
induced	O
NF-κB	O
assay	B-P
with	O
IC50	O
values	O
in	O
the	O
range	O
of	O
0.472.11	O
µM	O
.	O

Compounds	O
1	O
,	O
4	O
and	O
5	O
showed	O
moderate	O
inhibition	O
against	O
NF-κB	O
and	O
cancer	O
cell	O
lines	O
.	O

The	O
endophytic	O
fungus	O
Penicillium	O
polonicum	O
of	O
Taxus	O
fuana	O
is	O
capable	O
of	O
producing	O
biologically	O
active	O
natural	O
compounds	O
.	O

Our	O
results	O
provide	O
a	O
scientific	O
rationale	O
for	O
further	O
chemical	O
investigations	O
into	O
endophyte	O
-producing	O
natural	O
products	O
,	O
drug	O
discovery	O
and	O
development	O
.	O

Signs	O
of	O
dysarthria	O
in	O
adults	O
with	O
22q11.2	O
deletion	O
syndrome	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
how	O
adults	O
with	O
22q11.2	O
deletion	O
syndrome	O
(	O
22q11DS	O
)	O
performed	O
on	O
dysarthria	O
and	O
intelligibility	O
tests	B-P
compared	O
with	O
a	O
control	O
group	O
.	O

Ten	O
participants	O
with	O
confirmed	O
22q11.2	O
deletion	O
,	O
five	O
males	O
and	O
five	O
females	O
with	O
a	O
mean	O
age	O
of	O
31	O
years	O
(	O
range	O
:	O
19-49	O
)	O
,	O
were	O
compared	O
with	O
a	O
control	O
group	O
matched	O
for	O
gender	O
and	O
age	O
(	O
five	O
males	O
and	O
five	O
females	O
,	O
mean	O
age	O
:	O
32	O
years	O
,	O
range	O
:	O
19-49	O
)	O
.	O

Assessment	O
of	O
non-verbal	B-P
and	I-P
verbal	I-P
tasks	I-P
reflecting	O
respiration	O
,	O
phonation	O
,	O
oral	O
motor	O
function	O
,	O
velopharyngeal	B-P
function	I-P
,	O
articulation	O
,	O
and	O
prosody	O
was	O
performed	O
as	O
well	O
as	O
the	O
Swedish	O
Test	O
of	O
Intelligibility	O
(	O
STI	O
)	O
.	O

All	O
assessments	O
were	O
made	O
by	O
two	O
raters	O
;	O
inter-rater	O
and	O
intra-rater	O
reliability	O
was	O
acceptable	O
.	O

The	O
participants	O
with	O
22q11DS	O
had	O
significantly	O
more	O
problems	O
than	O
the	O
control	O
group	O
on	O
all	O
investigated	O
dimensions	O
except	O
the	O
STI	O
.	O

Overall	O
,	O
the	O
severity	O
of	O
their	O
speech	O
deviation	O
was	O
rated	O
as	O
mild	O
to	O
moderate	O
.	O

The	O
largest	O
difficulties	O
were	O
found	O
regarding	O
speech	O
respiration	O
,	O
phonation	O
,	O
oral	O
motor	O
function	O
,	O
and	O
velopharyngeal	B-P
function	I-P
.	O

The	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
a	O
neurological	O
etiology	O
could	O
be	O
added	O
to	O
the	O
previously	O
described	O
structural	O
etiology	O
explaining	O
the	O
speech	O
difficulties	O
found	O
in	O
22q11DS	O
.	O

Signs	O
of	O
difficulties	O
in	O
both	O
speech	O
motor	O
planning	O
and	O
speech	O
motor	O
programming	O
were	O
found	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
confirm	O
the	O
results	O
,	O
as	O
are	O
studies	O
of	O
the	O
association	O
between	O
structural	O
brain	O
abnormalities	O
and	O
neurological	O
speech	O
symptoms	O
.	O

For	O
clinical	O
purposes	O
,	O
it	O
is	O
important	O
that	O
clinicians	O
have	O
knowledge	O
about	O
the	O
variable	O
speech	O
symptoms	O
that	O
may	O
occur	O
in	O
individuals	O
with	O
22q11DS	O
and	O
that	O
they	O
be	O
aware	O
of	O
the	O
complexity	O
of	O
the	O
etiology	O
of	O
such	O
speech	O
symptoms	O
.	O

©	O
2017	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

The	O
A312	O
Allele	O
(	O
c.280A	O
>	O
T	O
)	O
Is	O
Responsible	O
for	O
the	O
Weak	O
A	O
Phenotype	O
.	O

The	O
ABO*A312	O
allele	O
was	O
found	O
in	O
a	O
71-	O
year-old	O
Korean	O
male	O
with	O
ABO	O
discrepancy	O
and	O
in	O
his	O
two	O
sons	O
.	O

Although	O
the	O
ABO*A312	O
allele	O
(	O
c.280A	O
>	O
T	O
,	O
I94F	O
)	O
in	O
an	O
AwB	O
case	O
was	O
registered	O
in	O
GenBank	O
,	O
the	O
impact	O
of	O
the	O
I94F	O
mutation	O
of	O
the	O
ABO	O
gene	O
on	O
the	O
activity	O
of	O
A	O
transferase	O
has	O
not	O
been	O
studied	O
.	O

Transient	B-P
transfection	I-P
experiments	I-P
were	O
performed	O
in	O
HeLa	O
cells	O
using	O
A101	O
,	O
A102	O
,	O
and	O
A312	O
alleles	O
synthesized	O
by	O
site-directed	O
mutagenesis	O
,	O
and	O
the	O
functional	O
expression	O
level	O
of	O
A	O
antigen	O
was	O
assessed	O
by	O
flow	B-P
cytometry	I-P
.	O

The	O
results	O
showed	O
that	O
the	O
A102	O
and	O
A312	O
alleles	O
expressed	O
A	O
antigen	O
levels	O
that	O
were	O
80.28	O
%	O
and	O
19.32	O
%	O
,	O
respectively	O
,	O
of	O
that	O
of	O
the	O
A101	O
allele	O
.	O

Our	O
study	O
results	O
demonstrate	O
that	O
the	O
c.280A	O
>	O
T	O
variant	O
is	O
responsible	O
for	O
the	O
weakened	O
expression	O
of	O
A	O
antigen	O
.	O

Improved	O
individualized	O
prediction	O
of	O
schizophrenia	O
in	O
subjects	O
at	O
familial	O
high	O
risk	O
,	O
based	O
on	O
neuroanatomical	O
data	O
,	O
schizotypal	O
and	O
neurocognitive	O
features	O
.	O

To	O
date	O
,	O
there	O
are	O
no	O
reliable	O
markers	O
for	O
predicting	O
onset	O
of	O
schizophrenia	O
in	O
individuals	O
at	O
high	O
risk	O
(	O
HR	O
)	O
.	O

Substantial	O
promise	O
is	O
,	O
however	O
,	O
shown	O
by	O
a	O
variety	O
of	O
pattern	O
classification	O
approaches	O
to	O
neuroimaging	B-P
data	I-P
.	O

Here	O
,	O
we	O
examined	O
the	O
predictive	O
accuracy	O
of	O
support	O
vector	O
machine	O
(	O
SVM	O
)	O
in	O
later	O
diagnosing	O
schizophrenia	O
,	O
at	O
a	O
single-subject	O
level	O
,	O
using	O
a	O
cohort	O
of	O
HR	O
individuals	O
drawn	O
from	O
multiply	O
affected	O
families	O
and	O
a	O
combination	O
of	O
neuroanatomical	O
,	O
schizotypal	O
and	O
neurocognitive	O
variables	O
.	O

Baseline	O
structural	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
,	O
schizotypal	O
and	O
neurocognitive	O
data	O
from	O
17	O
HR	O
subjects	O
,	O
who	O
subsequently	O
developed	O
schizophrenia	O
and	O
a	O
matched	O
group	O
of	O
17	O
HR	O
subjects	O
who	O
did	O
not	O
make	O
the	O
transition	O
,	O
yet	O
had	O
psychotic	O
symptoms	O
,	O
were	O
included	O
in	O
the	O
analysis	O
.	O

We	O
employed	O
recursive	O
feature	O
elimination	O
(	O
RFE	O
)	O
,	O
in	O
a	O
nested	O
cross-validation	O
scheme	O
to	O
identify	O
the	O
most	O
significant	O
predictors	O
of	O
disease	O
transition	O
and	O
enhance	O
diagnostic	O
performance	O
.	O

Classification	O
accuracy	O
was	O
94	O
%	O
when	O
a	O
self-completed	O
measure	O
of	O
schizotypy	O
,	O
a	O
declarative	O
memory	O
test	O
and	O
structural	O
MRI	B-P
data	O
were	O
combined	O
into	O
a	O
single	O
learning	O
algorithm	O
;	O
higher	O
than	O
when	O
either	O
quantitative	O
measure	O
was	O
used	O
alone	O
.	O

The	O
discriminative	O
neuroanatomical	O
pattern	O
involved	O
gray	O
matter	O
volume	O
differences	O
in	O
frontal	O
,	O
orbito-frontal	O
and	O
occipital	O
lobe	O
regions	O
bilaterally	O
as	O
well	O
as	O
parts	O
of	O
the	O
superior	O
,	O
medial	O
temporal	O
lobe	O
and	O
cerebellar	O
regions	O
.	O

Our	O
findings	O
suggest	O
that	O
an	O
early	O
SVM	O
-based	O
prediction	O
of	O
schizophrenia	O
is	O
possible	O
and	O
can	O
be	O
improved	O
by	O
combining	O
schizotypal	O
and	O
neurocognitive	O
features	O
with	O
neuroanatomical	O
variables	O
.	O

However	O
,	O
our	O
predictive	O
model	O
needs	O
to	O
be	O
tested	O
by	O
classifying	O
a	O
new	O
,	O
independent	O
HR	O
cohort	O
in	O
order	O
to	O
estimate	O
its	O
validity	O
.	O

The	O
knee	O
joint	O
loose	O
body	O
as	O
a	O
source	O
of	O
viable	O
autologous	O
human	O
chondrocytes	O
.	O

Loose	O
bodies	O
are	O
fragments	O
of	O
cartilage	O
or	O
bone	O
present	O
in	O
the	O
synovial	O
fluid	O
.	O

In	O
the	O
present	O
study	O
we	O
assessed	O
if	O
loose	O
bodies	O
could	O
be	O
used	O
as	O
a	O
source	O
of	O
autologous	O
human	O
chondrocytes	O
for	O
experimental	O
purposes	O
.	O

Histochemical	B-P
examination	I-P
of	O
loose	O
bodies	O
and	O
differential	O
enzymatic	B-P
digestions	I-P
were	O
undertaken	O
,	O
the	O
isolated	O
cells	O
were	O
cultured	O
in	O
alginate	O
bead	O
microspheres	O
and	O
immunolocalisations	B-P
were	O
undertaken	O
for	O
chondrogenic	O
markers	O
such	O
as	O
aggrecan	O
,	O
and	O
type	O
II	O
collagen	O
.	O

Isolated	O
loose	O
body	O
cells	O
had	O
high	O
viability	O
(	O
≥90	O
%	O
viable	O
)	O
,	O
expressed	O
chondrogenic	O
markers	O
(	O
aggrecan	O
,	O
type	O
II	O
collagen	O
)	O
but	O
no	O
type	O
I	O
collagen	O
.	O

Loose	O
bodies	O
may	O
be	O
a	O
useful	O
source	O
of	O
autologous	O
chondrocytes	O
of	O
high	O
viability	O
.	O

Magnetic	B-P
resonance	I-P
spectroscopy	I-P
of	O
current	O
hand	O
amputees	O
reveals	O
evidence	O
for	O
neuronal	O
-level	O
changes	O
in	O
former	O
sensorimotor	O
cortex	O
.	O

Deafferentation	O
is	O
accompanied	O
by	O
large-scale	O
functional	O
reorganization	O
of	O
maps	O
in	O
the	O
primary	O
sensory	O
and	O
motor	O
areas	O
of	O
the	O
hemisphere	O
contralateral	O
to	O
injury	O
.	O

Animal	O
models	O
of	O
deafferentation	O
suggest	O
a	O
variety	O
of	O
cellular	O
-level	O
changes	O
including	O
depression	O
of	O
neuronal	O
metabolism	O
and	O
even	O
neuronal	O
death	O
.	O

Whether	O
similar	O
neuronal	O
changes	O
contribute	O
to	O
patterns	O
of	O
reorganization	O
within	O
the	O
contralateral	O
sensorimotor	O
cortex	O
of	O
chronic	O
human	O
amputees	O
is	O
uncertain	O
.	O

We	O
used	O
functional	O
MRI-guided	B-P
proton	I-P
magnetic	I-P
resonance	I-P
spectroscopy	I-P
to	O
test	O
the	O
hypothesis	O
that	O
unilateral	O
deafferentation	O
is	O
associated	O
with	O
lower	O
levels	O
of	O
N-acetylaspartate	O
(	O
NAA	O
,	O
a	O
putative	O
marker	O
of	O
neuronal	O
integrity	O
)	O
in	O
the	O
sensorimotor	O
hand	O
territory	O
located	O
contralateral	O
to	O
the	O
missing	O
hand	O
in	O
chronic	O
amputees	O
(	O
n	O
=	O
19	O
)	O
compared	O
with	O
the	O
analogous	O
hand	O
territory	O
of	O
age-	O
and	O
sex-matched	O
healthy	O
controls	O
(	O
n	O
=	O
28	O
)	O
.	O

We	O
also	O
tested	O
whether	O
former	O
amputees	O
[	O
i.e.	O
,	O
recipients	O
of	O
replanted	O
(	O
n	O
=	O
3	O
)	O
or	O
transplanted	O
(	O
n	O
=	O
2	O
)	O
hands	O
]	O
exhibit	O
NAA	O
levels	O
that	O
are	O
indistinguishable	O
from	O
controls	O
,	O
possible	O
evidence	O
for	O
reversal	O
of	O
the	O
effects	O
of	O
deafferentation	O
.	O

As	O
predicted	O
,	O
relative	O
to	O
controls	O
,	O
current	O
amputees	O
exhibited	O
lower	O
levels	O
of	O
NAA	O
that	O
were	O
negatively	O
and	O
significantly	O
correlated	O
with	O
the	O
time	O
after	O
amputation	O
.	O

Contrary	O
to	O
our	O
prediction	O
,	O
NAA	O
levels	O
in	O
both	O
replanted	O
and	O
transplanted	O
patients	O
fell	O
within	O
the	O
range	O
of	O
the	O
current	O
amputees	O
.	O

We	O
suggest	O
that	O
lower	O
levels	O
of	O
NAA	O
in	O
current	O
amputees	O
reflects	O
altered	O
neuronal	O
integrity	O
consequent	O
to	O
chronic	O
deafferentation	O
.	O

Thus	O
local	O
changes	O
in	O
NAA	O
levels	O
may	O
provide	O
a	O
means	O
of	O
assessing	O
neuroplastic	O
changes	O
in	O
deafferented	O
cortex	O
.	O

Results	O
from	O
former	O
amputees	O
suggest	O
that	O
these	O
changes	O
may	O
not	O
be	O
readily	O
reversible	O
through	O
reafferentation	O
.NEW	O
&	O
NOTEWORTHY	O
This	O
study	O
is	O
the	O
first	O
to	O
use	O
functional	O
magnetic	B-P
resonance-guided	I-P
magnetic	I-P
resonance	I-P
spectroscopy	I-P
to	O
examine	O
neurochemical	O
mechanisms	O
underlying	O
functional	O
reorganization	O
in	O
the	O
primary	O
somatosensory	O
and	O
motor	O
cortices	O
consequent	O
to	O
upper	O
extremity	O
amputation	O
and	O
its	O
potential	O
reversal	O
through	O
hand	O
replantation	O
or	O
transplantation	O
.	O

We	O
provide	O
evidence	O
for	O
selective	O
alteration	O
of	O
cortical	O
neuronal	O
integrity	O
associated	O
with	O
amputation	O
-	O
related	O
deafferentation	O
that	O
may	O
not	O
be	O
reversible	O
.	O

Tzumin	O
A	O
and	O
B	O
,	O
two	O
new	O
lignan	O
derivatives	O
from	O
the	O
barks	O
of	O
Sassafras	O
tzumu	O
.	O

Two	O
new	O
lignan	O
compounds	O
,	O
5'-allyl-2,2'-dihydroxy-	O
[	O
1,1'-biphenyl	O
]	O
-5-carboxylic	O
acid	O
(	O
1	O
)	O
and	O
4,4'-diallyl-	O
[	O
1,1'-biphenyl	O
]	O
-2,2'-diol	O
(	O
2	O
)	O
,	O
together	O
with	O
four	O
known	O
compounds	O
(	O
3-6	O
)	O
,	O
were	O
isolated	O
from	O
the	O
barks	O
of	O
Sassafras	O
tzumu	O
.	O

The	O
new	O
compounds	O
were	O
determined	O
by	O
NMR	B-P
(	I-P
(	I-P
1	I-P
)	I-P
H	I-P
and	O
(	B-P
13	I-P
)	I-P
C	I-P
NMR	I-P
,	O
HSQC	B-P
,	O
HMBC	B-P
,	O
(	B-P
1	I-P
)	I-P
H-	I-P
(	I-P
1	I-P
)	I-P
H	I-P
COSY	I-P
,	O
NOESY	B-P
/	O
ROESY	B-P
)	O
,	O
and	O
MS	B-P
analysis	O
.	O

Compounds	O
1-3	O
showed	O
potent	O
AChE	O
inhibitory	O
activities	O
,	O
with	O
IC50	O
values	O
of	O
2.00	O
,	O
1.81	O
and	O
1.91	O
μM	O
,	O
respectively	O
.	O

A	O
randomized	O
trial	O
of	O
Plasma-Lyte	O
A	O
and	O
0.9	O
%	O
sodium	O
chloride	O
in	O
acute	O
pediatric	O
gastroenteritis	O
.	O

Compare	O
the	O
efficacy	O
and	O
safety	O
of	O
Plasma-Lyte	O
A	O
(	O
PLA	O
)	O
versus	O
0.9	O
%	O
sodium	O
chloride	O
(	O
NaCl	O
)	O
intravenous	O
(	O
IV	O
)	O
fluid	O
replacement	O
in	O
children	O
with	O
moderate	O
to	O
severe	O
dehydration	O
secondary	O
to	O
acute	O
gastroenteritis	O
(	O
AGE	O
)	O
.	O

Prospective	O
,	O
randomized	O
,	O
double-blind	O
study	O
conducted	O
at	O
eight	O
pediatric	O
emergency	O
departments	O
(	O
EDs	O
)	O
in	O
the	O
US	O
and	O
Canada	O
(	O
NCT	O
#	O
01234883	O
)	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
serum	O
bicarbonate	O
level	O
at	O
4	O
h.	O
Secondary	O
outcomes	O
included	O
safety	O
and	O
tolerability	O
.	O

The	O
hypothesis	O
was	O
that	O
PLA	O
would	O
be	O
superior	O
to	O
0.9	O
%	O
NaCl	O
in	O
improvement	B-P
of	I-P
4-h	I-P
bicarbonate	I-P
.	O

Patients	O
(	O
n	O
=	O
100	O
)	O
aged	O
≥6	O
months	O
to	O
<	O
11	O
years	O
with	O
AGE	O
-induced	O
moderate-to-	O
severe	O
dehydration	O
were	O
enrolled	O
.	O

Patients	O
with	O
a	O
baseline	O
bicarbonate	O
level	O
≤22	O
mEq/L	O
formed	O
the	O
modified	O
intent	O
to	O
treat	O
(	O
mITT	O
)	O
group	O
.	O

At	O
baseline	O
,	O
the	O
treatment	O
groups	O
were	O
comparable	O
except	O
that	O
the	O
PLA	O
group	O
was	O
older	O
.	O

At	O
hour	O
4	O
,	O
the	O
PLA	O
group	O
had	O
greater	O
increases	O
in	O
serum	O
bicarbonate	O
from	O
baseline	O
than	O
did	O
the	O
0.9	O
%	O
NaCl	O
group	O
(	O
mean	O
±	O
SD	O
at	O
4	O
h	O
:	O
18	O
±	O
3.74	O
vs	O
18.0	O
±	O
3.67	O
;	O
change	O
from	O
baseline	O
of	O
1.6	O
and	O
0.0	O
,	O
respectively	O
;	O
P	O
=	O
.004	O
)	O
.	O

Both	O
treatment	O
groups	O
received	O
similar	O
fluid	O
volumes	O
.	O

The	O
PLA	O
group	O
had	O
less	O
abdominal	O
pain	O
and	O
better	O
dehydration	O
scores	O
at	O
hour	O
2	O
(	O
both	O
P	O
=	O
.03	O
)	O
but	O
not	O
at	O
hour	O
4	O
(	O
P	O
=	O
0.15	O
and	O
0.08	O
,	O
respectively	O
)	O
.	O

No	O
patient	O
experienced	O
clinically	O
relevant	O
worsening	O
of	O
laboratory	O
findings	O
or	O
physical	O
examination	O
,	O
and	O
hospital	O
admission	O
rates	O
were	O
similar	O
.	O

One	O
patient	O
in	O
each	O
treatment	O
group	O
developed	O
hyponatremia	O
.	O

Four	O
patients	O
developed	O
hyperkalemia	O
(	O
PLA	O
:1	O
,	O
0.9	O
%	O
NaCl	O
:3	O
)	O
.	O

In	O
comparison	O
with	O
0.9	O
%	O
NaCl	O
,	O
PLA	O
for	O
rehydration	O
in	O
children	O
with	O
AGE	O
was	O
well	O
tolerated	O
and	O
led	O
to	O
more	O
rapid	O
improvement	B-P
in	I-P
serum	I-P
bicarbonate	I-P
and	O
dehydration	O
score	O
.	O

NCT	O
#	O
01234883	O
(	O
Registration	O
Date	O
:	O
November	O
3	O
,	O
2010	O
)	O
.	O

The	O
use	O
of	O
informativity	O
in	O
the	O
development	O
of	O
robust	O
viromics	O
-based	O
examinations	O
.	O

Metagenomics	O
-based	O
studies	O
have	O
provided	O
insight	O
into	O
many	O
of	O
the	O
complex	O
microbial	O
communities	O
responsible	O
for	O
maintaining	O
life	O
on	O
this	O
planet	O
.	O

Sequencing	O
efforts	O
often	O
uncover	O
novel	O
genetic	O
content	O
;	O
this	O
is	O
most	O
evident	O
for	O
phage	O
communities	O
,	O
in	O
which	O
upwards	O
of	O
90	O
%	O
of	O
all	O
sequences	O
exhibit	O
no	O
similarity	O
to	O
any	O
sequence	O
in	O
current	O
data	O
repositories	O
.	O

For	O
the	O
small	O
fraction	O
that	O
can	O
be	O
identified	O
,	O
the	O
top	O
BLAST	O
hit	O
is	O
generally	O
posited	O
as	O
being	O
representative	O
of	O
a	O
viral	O
taxon	O
present	O
in	O
the	O
sample	O
of	O
origin	O
.	O

Homology	O
-based	O
classification	O
,	O
however	O
,	O
can	O
be	O
misleading	O
as	O
sequence	O
repositories	O
capture	O
but	O
a	O
small	O
fraction	O
of	O
phage	O
diversity	O
.	O

Furthermore	O
,	O
lateral	O
gene	O
transfer	O
is	O
pervasive	O
within	O
phage	O
communities	O
.	O

As	O
such	O
,	O
the	O
presence	O
of	O
a	O
particular	O
gene	O
may	O
not	O
be	O
indicative	O
of	O
the	O
presence	O
of	O
a	O
particular	O
viral	O
species	O
.	O

Rather	O
,	O
it	O
is	O
just	O
that	O
:	O
an	O
indication	O
of	O
the	O
presence	O
of	O
a	O
specific	O
gene	O
.	O

To	O
circumvent	O
this	O
limitation	O
,	O
we	O
have	O
developed	O
a	O
new	O
method	O
for	O
the	O
analysis	B-P
of	I-P
viral	I-P
metagenomic	I-P
datasets	I-P
.	O

BLAST	O
hits	O
are	O
weighted	O
,	O
integrating	O
the	O
sequence	O
identity	O
and	O
length	O
of	O
alignments	O
as	O
well	O
as	O
a	O
taxonomic	O
signal	O
,	O
such	O
that	O
each	O
gene	O
is	O
evaluated	O
with	O
respect	O
to	O
its	O
information	O
content	O
.	O

Through	O
this	O
quantifiable	O
metric	O
,	O
predictions	O
of	O
viral	O
community	O
structure	O
can	O
be	O
made	O
with	O
confidence	O
.	O

As	O
a	O
proof-of-concept	O
,	O
the	O
approach	O
presented	O
here	O
was	O
implemented	O
and	O
applied	O
to	O
seven	O
freshwater	O
viral	O
metagenomes	O
.	O

While	O
providing	O
a	O
robust	O
method	O
for	O
evaluating	O
viral	O
metagenomic	O
data	O
,	O
the	O
tool	O
is	O
versatile	O
and	O
can	O
easily	O
be	O
customized	O
to	O
investigations	O
of	O
any	O
environment	O
or	O
biome	O
.	O

Platelet	O
proteome	O
reveals	O
novel	O
pathways	O
of	O
platelet	O
activation	O
and	O
platelet	O
-	O
mediated	O
immunoregulation	O
in	O
dengue	O
.	O

Dengue	O
is	O
the	O
most	O
prevalent	O
human	O
arbovirus	O
disease	O
worldwide	O
.	O

Dengue	O
virus	O
(	O
DENV	O
)	O
infection	O
causes	O
syndromes	O
varying	O
from	O
self-limiting	O
febrile	O
illness	O
to	O
severe	O
dengue	O
.	O

Although	O
dengue	O
pathophysiology	O
is	O
not	O
completely	O
understood	O
,	O
it	O
is	O
widely	O
accepted	O
that	O
increased	O
inflammation	O
plays	O
important	O
roles	O
in	O
dengue	O
pathogenesis	O
.	O

Platelets	O
are	O
blood	O
cells	O
classically	O
known	O
as	O
effectors	O
of	O
hemostasis	O
which	O
have	O
been	O
increasingly	O
recognized	O
to	O
have	O
major	O
immune	O
and	O
inflammatory	O
activities	O
.	O

Nevertheless	O
,	O
the	O
phenotype	O
and	O
effector	O
functions	O
of	O
platelets	O
in	O
dengue	O
pathogenesis	O
are	O
not	O
completely	O
understood	O
.	O

Here	O
we	O
used	O
quantitative	O
proteomics	B-P
to	O
investigate	O
the	O
protein	B-P
content	I-P
of	O
platelets	O
in	O
clinical	O
samples	O
from	O
patients	O
with	O
dengue	O
compared	O
to	O
platelets	O
from	O
healthy	O
donors	O
.	O

Our	O
assays	B-P
revealed	O
a	O
set	O
of	O
252	O
differentially	O
abundant	O
proteins	O
.	O

In	O
silico	O
analyses	O
associated	O
these	O
proteins	O
with	O
key	O
molecular	O
events	O
including	O
platelet	O
activation	O
and	O
inflammatory	O
responses	O
,	O
and	O
with	O
events	O
not	O
previously	O
attributed	O
to	O
platelets	O
during	O
dengue	O
infection	O
including	O
antigen	O
processing	O
and	O
presentation	O
,	O
proteasome	O
activity	O
,	O
and	O
expression	O
of	O
histones	O
.	O

From	O
these	O
results	O
,	O
we	O
conducted	O
functional	O
assays	B-P
using	O
samples	O
from	O
a	O
larger	O
cohort	O
of	O
patients	O
and	O
demonstrated	O
evidence	O
for	O
platelet	O
activation	O
indicated	O
by	O
P-selectin	O
(	O
CD62P	O
)	O
translocation	O
and	O
secretion	O
of	O
granule-stored	O
chemokines	O
by	O
platelets	O
.	O

In	O
addition	O
,	O
we	O
found	O
evidence	O
that	O
DENV	O
infection	O
triggers	O
HLA	O
class	O
I	O
synthesis	O
and	O
surface	O
expression	O
by	O
a	O
mechanism	O
depending	O
on	O
functional	O
proteasome	O
activity	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
cell-free	O
histone	O
H2A	O
released	O
during	O
dengue	O
infection	O
binds	O
to	O
platelets	O
,	O
increasing	O
platelet	O
activation	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
functional	O
importance	O
of	O
HLA	O
class	O
I	O
,	O
proteasome	O
subunits	O
,	O
and	O
histones	O
that	O
we	O
found	O
exclusively	O
in	O
proteome	O
analysis	O
of	O
platelets	O
in	O
samples	O
from	O
dengue	O
patients	O
.	O

Our	O
study	O
provides	O
the	O
first	O
in-depth	O
characterization	O
of	O
the	O
platelet	O
proteome	O
in	O
dengue	O
,	O
and	O
sheds	O
light	O
on	O
new	O
mechanisms	O
of	O
platelet	O
activation	O
and	O
platelet	O
-	O
mediated	O
immune	O
and	O
inflammatory	O
responses	O
.	O

Functional	O
Analysis	O
of	O
a	O
Bacterial	O
Antifreeze	O
Protein	O
Indicates	O
a	O
Cooperative	O
Effect	O
between	O
Its	O
Two	O
Ice-Binding	O
Domains	O
.	O

Antifreeze	O
proteins	O
make	O
up	O
a	O
class	O
of	O
ice-binding	O
proteins	O
(	O
IBPs	O
)	O
that	O
are	O
possessed	O
and	O
expressed	O
by	O
certain	O
cold	O
-	O
adapted	O
organisms	O
to	O
enhance	O
their	O
freezing	O
tolerance	O
.	O

Here	O
we	O
report	O
the	O
biophysical	O
and	O
functional	O
characterization	O
of	O
an	O
IBP	O
discovered	O
in	O
a	O
bacterium	O
recovered	O
from	O
a	O
deep	O
glacial	O
ice	O
core	O
drilled	O
at	O
Vostok	O
Station	O
,	O
Antarctica	O
(	O
IBPv	O
)	O
.	O

Our	O
study	O
showed	O
that	O
the	O
recombinant	O
protein	O
rIBPv	O
exhibited	O
a	O
thermal	O
hysteresis	O
of	O
2	O
°C	O
at	O
concentrations	O
of	O
>	O
50	O
μM	O
,	O
effectively	O
inhibited	O
ice	O
recrystallization	O
,	O
and	O
enhanced	O
bacterial	O
viability	O
during	O
freeze-thaw	O
cycling	O
.	O

Circular	B-P
dichroism	I-P
scans	I-P
indicated	O
that	O
rIBPv	O
mainly	O
consists	O
of	O
β	O
strands	O
,	O
and	O
its	O
denaturing	O
temperature	O
was	O
53.5	O
°C	O
.	O

Multiple-sequence	O
alignment	O
of	O
homologous	O
IBPs	O
predicted	O
that	O
IBPv	O
contains	O
two	O
ice-binding	O
domains	O
,	O
a	O
feature	O
unique	O
among	O
known	O
IBPs	O
.	O

To	O
examine	O
functional	O
differences	O
between	O
the	O
IBPv	O
domains	O
,	O
each	O
domain	O
was	O
cloned	O
,	O
expressed	O
,	O
and	O
purified	O
.	O

The	O
second	O
domain	O
(	O
domain	O
B	O
)	O
expressed	O
greater	O
ice	O
binding	O
activity	O
.	O

Data	O
from	O
thermal	O
hysteresis	O
and	O
gel	B-P
filtration	I-P
assays	I-P
supported	O
the	O
idea	O
that	O
the	O
two	O
domains	O
cooperate	O
to	O
achieve	O
a	O
higher	O
ice	O
binding	O
effect	O
by	O
forming	O
heterodimers	O
.	O

However	O
,	O
physical	O
linkage	O
of	O
the	O
domains	O
was	O
not	O
required	O
for	O
this	O
effect	O
.	O

Metabolic	O
signatures	O
of	O
birthweight	O
in	O
18	O
288	O
adolescents	O
and	O
adults	O
.	O

Lower	O
birthweight	O
is	O
associated	O
with	O
increased	O
susceptibility	O
to	O
cardiometabolic	O
diseases	O
in	O
adulthood	O
,	O
but	O
the	O
underlying	O
molecular	O
pathways	O
are	O
incompletely	O
understood	O
.	O

We	O
examined	O
associations	O
of	O
birthweight	O
with	O
a	O
comprehensive	O
metabolic	O
profile	O
measured	O
in	O
adolescents	O
and	O
adults	O
.	O

High-throughput	B-P
nuclear	O
magnetic	O
resonance	O
metabolomics	O
and	O
biochemical	B-P
assays	I-P
were	O
used	O
to	O
quantify	O
87	O
circulating	O
metabolic	O
measures	O
in	O
seven	O
cohorts	O
from	O
Finland	O
and	O
the	O
UK	O
,	O
comprising	O
altogether	O
18	O
288	O
individuals	O
(	O
mean	O
age	O
26	O
years	O
,	O
range	O
15-75	O
)	O
.	O

Metabolic	O
associations	O
with	O
birthweight	O
were	O
assessed	O
by	O
linear	O
regression	O
models	O
adjusted	O
for	O
sex	O
,	O
gestational	O
age	O
and	O
age	O
at	O
blood	B-P
sampling	I-P
.	O

The	O
metabolic	O
associations	O
with	O
birthweight	O
were	O
compared	O
with	O
the	O
corresponding	O
associations	O
with	O
adult	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
.	O

Lower	O
birthweight	O
adjusted	O
for	O
gestational	O
age	O
was	O
adversely	O
associated	O
with	O
cardiometabolic	O
biomarkers	O
,	O
including	O
lipoprotein	O
subclasses	O
,	O
fatty	O
acids	O
,	O
amino	O
acids	O
and	O
markers	O
of	O
inflammation	O
and	O
impaired	O
liver	O
function	O
(	O
P	O
<	O
0.0015	O
for	O
46	O
measures	O
)	O
.	O

Associations	O
were	O
consistent	O
across	O
cohorts	O
with	O
different	O
ages	O
at	O
metabolic	O
profiling	O
,	O
but	O
the	O
magnitudes	O
were	O
weak	O
.	O

The	O
pattern	O
of	O
metabolic	O
deviations	O
associated	O
with	O
lower	O
birthweight	O
resembled	O
the	O
metabolic	O
signature	O
of	O
higher	O
adult	O
BMI	O
(	O
R	O
(	O
2	O
)	O
=	O
0.77	O
)	O
assessed	O
at	O
the	O
same	O
time	O
as	O
the	O
metabolic	O
profiling	O
.	O

The	O
resemblance	O
indicated	O
that	O
1	O
kg	O
lower	O
birthweight	O
is	O
associated	O
with	O
similar	O
metabolic	O
aberrations	O
as	O
caused	O
by	O
0.92	O
units	O
higher	O
BMI	O
in	O
adulthood	O
.	O

Lower	O
birthweight	O
adjusted	O
for	O
gestational	O
age	O
is	O
associated	O
with	O
adverse	O
biomarker	O
aberrations	O
across	O
multiple	O
metabolic	O
pathways	O
.	O

Coherent	O
metabolic	O
signatures	O
between	O
lower	O
birthweight	O
and	O
higher	O
adult	O
adiposity	O
suggest	O
that	O
shared	O
molecular	O
pathways	O
may	O
potentially	O
underpin	O
the	O
metabolic	O
deviations	O
.	O

However	O
,	O
the	O
magnitudes	O
of	O
metabolic	O
associations	O
with	O
birthweight	O
are	O
modest	O
in	O
comparison	O
to	O
the	O
effects	O
of	O
adiposity	O
,	O
implying	O
that	O
birthweight	O
is	O
only	O
a	O
weak	O
indicator	O
of	O
the	O
metabolic	O
risk	O
profile	O
in	O
adulthood	O
.	O

Neo-yoke	O
repair	O
for	O
severe	O
hypospadias	O
:	O
A	O
simple	O
modification	O
for	O
better	O
outcome	O
.	O

Although	O
staged	O
repair	O
for	O
reconstructing	O
severe	O
hypospadias	O
is	O
more	O
popular	O
,	O
various	O
one-stage	O
repairs	O
have	O
been	O
attempted	O
.	O

Koyanagi	O
repair	O
(	O
parameatal-based	O
and	O
fully	O
extended	O
circumferential	O
foreskin	O
flap	O
urethroplasty	O
)	O
has	O
enabled	O
correction	O
of	O
severe	O
hypospadias	O
in	O
one	O
stage	O
.	O

However	O
,	O
its	O
un-acceptably	O
high	O
incidence	O
of	O
complications	O
has	O
initiated	O
a	O
series	O
of	O
technical	O
modifications	O
,	O
including	O
the	O
``	O
yoke	O
''	O
repair	O
.	O

To	O
retrospectively	O
analyze	O
the	O
outcome	O
of	O
a	O
proposed	O
modification	O
of	O
the	O
originally	O
described	O
yoke	O
repair	O
,	O
for	O
patients	O
with	O
severe	O
hypospadias	O
.	O

This	O
modification	O
was	O
developed	O
to	O
reduce	O
complications	O
.	O

Over	O
4	O
years	O
(	O
between	O
Jan	O
2011	O
and	O
Jan	O
2015	O
)	O
,	O
all	O
cases	O
of	O
severe	O
hypospadias	O
were	O
included	O
in	O
this	O
study	O
;	O
except	O
those	O
with	O
prior	O
attempts	O
at	O
repair	O
,	O
circumcised	O
cases	O
,	O
and	O
cases	O
with	O
severe	O
hypogonadism	O
-	O
because	O
of	O
partial	O
androgen	O
insensitivity	O
-	O
not	O
responding	O
to	O
hormonal	O
manipulations	O
.	O

The	O
make-up	O
of	O
the	O
neo-urethra	O
in	O
this	O
modification	O
is	O
the	O
urethral	O
plate	O
with	O
its	O
spongiosal	O
tissue	O
proximally	O
,	O
a	O
circum-coronal	O
preputial	O
pedicled	O
flap	O
in	O
the	O
middle	O
,	O
and	O
an	O
incorporated	O
part	O
of	O
the	O
augmented	O
preputial	O
flap	O
and	O
the	O
preserved	B-P
V-shaped	O
glanular	O
urethra	O
,	O
distally	O
.	O

Close	O
postoperative	O
follow-up	O
was	O
conducted	O
to	O
investigate	O
the	O
outcome	O
.	O

Thirty-one	O
children	O
with	O
a	O
median	O
age	O
of	O
32.48	O
months	O
had	O
repair	O
of	O
severe	O
hypospadias	O
using	O
the	O
neo-yoke	O
technique	O
.	O

After	O
a	O
median	O
follow-up	O
of	O
26.7	O
months	O
,	O
the	O
overall	O
complication	O
rate	O
was	O
16.1	O
%	O
.	O

Four	O
children	O
developed	O
urethrocutaneous	O
fistula	O
(	O
12.9	O
%	O
)	O
.	O

Meatal	O
drop-back	O
occurred	O
in	O
one	O
case	O
(	O
3.2	O
%	O
)	O
.	O

No	O
meatal	O
stenosis	O
or	O
urethral	O
sacculation	O
was	O
detected	O
during	O
follow-up	O
of	O
the	O
studied	O
group	O
.	O

Almost	O
all	O
cases	O
had	O
cosmetically	O
appealing	O
outlook	O
.	O

Single-staged	O
repair	O
of	O
severe	O
hypospadias	O
using	O
parameatal	O
foreskin	O
-	O
based	O
urethroplasty	O
has	O
passed	O
through	O
different	O
modifications	O
,	O
all	O
aimed	O
at	O
optimizing	O
the	O
outcome	O
(	O
Table	O
)	O
.	O

Neo-yoke	O
repair	O
for	O
severe	O
hypospadias	O
is	O
a	O
natural	O
development	O
of	O
established	O
one-stage	O
techniques	O
,	O
which	O
resulted	O
in	O
better	O
mid-term	O
outcomes	O
.	O

However	O
,	O
an	O
extended	O
study	O
is	O
needed	O
to	O
declare	O
the	O
long-term	O
results	O
.	O

De	O
novo	O
assembly	O
of	O
the	O
blunt	O
snout	O
bream	O
(	O
Megalobrama	O
amblycephala	O
)	O
gill	O
transcriptome	O
to	O
identify	O
ammonia	O
exposure	O
associated	O
microRNAs	O
and	O
their	O
targets	O
.	O

De	O
novo	O
transcriptome	O
sequencing	O
is	O
a	O
robust	O
method	O
for	O
microRNA	O
(	O
miRNA	O
)	O
target	O
gene	O
prediction	O
,	O
especially	O
for	O
organisms	O
without	O
reference	O
genomes	O
.	O

Following	O
exposure	O
of	O
Megalobrama	O
amblycephala	O
to	O
ammonia	O
(	O
0.1	O
or	O
20	O
mg	O
L	O
(	O
-1	O
)	O
)	O
,	O
two	O
cDNA	O
libraries	O
were	O
constructed	O
from	O
the	O
fish	O
gills	O
and	O
sequenced	O
using	O
Illumina	O
HiSeq	O
2000	O
.	O

Over	O
90	O
million	O
reads	O
were	O
generated	O
and	O
de	O
novo	O
assembled	O
into	O
46	O
,	O
615	O
unigenes	O
,	O
which	O
were	O
then	O
extensively	O
annotated	O
by	O
comparing	O
to	O
different	O
protein	O
databases	O
,	O
followed	O
by	O
biochemical	O
pathway	O
prediction	O
.	O

The	O
expression	O
of	O
2666	O
unigenes	O
significantly	O
differed	O
;	O
1961	O
were	O
up-regulated	O
,	O
while	O
975	O
were	O
down-regulated	O
.	O

Among	O
these	O
,	O
250	O
unigenes	O
were	O
identified	O
as	O
the	O
targets	O
for	O
10	O
conserved	O
and	O
4	O
putative	O
novel	O
miRNA	O
families	O
by	O
miRNA	O
target	O
computational	B-P
prediction	I-P
.	O

We	O
examined	O
expression	O
of	O
ssa-miRNA-21	O
and	O
its	O
target	O
genes	O
by	O
real-time	O
quantitative	O
PCR	O
and	O
found	O
agreement	O
with	O
the	O
sequencing	O
data	O
.	O

This	O
study	O
demonstrates	O
the	O
feasibility	O
of	O
identifying	O
miRNA	O
targets	O
by	O
transcriptome	O
analysis	O
.	O

The	O
transcriptome	O
assembly	O
data	O
represent	O
a	O
substantial	O
increase	O
in	O
the	O
genomic	O
resources	O
available	O
for	O
Megalobrama	O
amblycephala	O
and	O
will	O
be	O
useful	O
for	O
gene	O
expression	O
profile	O
analysis	O
and	O
miRNA	O
functional	O
annotation	O
.	O

Numerical	O
simulation	O
of	O
emitted	O
particle	O
characteristics	O
and	O
airway	O
deposition	O
distribution	O
of	O
Symbicort	O
(	O
®	O
)	O
Turbuhaler	O
(	O
®	O
)	O
dry	O
powder	O
fixed	O
combination	O
aerosol	O
drug	O
.	O

One	O
of	O
the	O
most	O
widespread	O
dry	O
powder	O
fixed	O
combinations	O
used	O
in	O
asthma	O
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
management	O
is	O
Symbicort	O
(	O
®	O
)	O
Turbuhaler	O
(	O
®	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
simulate	O
the	O
deposition	O
distribution	O
of	O
both	O
components	O
of	O
this	O
drug	O
within	O
the	O
airways	O
based	O
on	O
realistic	O
airflow	B-P
measurements	I-P
.	O

Breathing	O
parameters	O
of	O
25	O
healthy	O
adults	O
(	O
11	O
females	O
and	O
14	O
males	O
)	O
were	O
acquired	O
while	O
inhaling	O
through	O
Turbuhaler	O
(	O
®	O
)	O
.	O

Individual	O
specific	O
emitted	O
doses	O
and	O
particle	O
size	O
distributions	O
of	O
Symbicort	O
(	O
®	O
)	O
Turbuhaler	O
(	O
®	O
)	O
were	O
determined	O
.	O

A	O
self-developed	O
particle	O
deposition	O
model	O
was	O
adapted	O
and	O
validated	O
to	O
simulate	O
the	O
deposition	O
of	O
budesonide	O
(	O
inhaled	O
corticosteroid	O
;	O
ICS	O
)	O
and	O
formoterol	O
(	O
long	O
acting	O
β2	O
agonist	O
;	O
LABA	O
)	O
in	O
the	O
upper	O
airways	O
and	O
lungs	O
of	O
the	O
healthy	O
volunteers	O
.	O

Based	O
on	O
current	O
simulations	O
the	O
emitted	O
doses	O
varied	O
between	O
50.4	O
%	O
and	O
92.5	O
%	O
of	O
the	O
metered	O
dose	O
for	O
the	O
ICS	O
,	O
and	O
between	O
38	O
%	O
and	O
96.1	O
%	O
in	O
case	O
of	O
LABA	O
component	O
depending	O
on	O
the	O
individual	O
inhalation	O
flow	O
rate	O
.	O

This	O
variability	O
induced	O
a	O
notable	O
inter-	O
individual	O
spread	O
of	O
the	O
deposited	O
lung	O
doses	O
(	O
mean	O
:	O
33.6	O
%	O
,	O
range	O
:	O
20.4	O
%	O
-48.8	O
%	O
for	O
budesonide	O
and	O
mean	O
:	O
29.8	O
%	O
,	O
range	O
:	O
16.4	O
%	O
-42.9	O
%	O
for	O
formoterol	O
)	O
.	O

Significant	O
inter-gender	O
differences	O
were	O
also	O
observed	O
.	O

Average	O
lung	O
dose	O
of	O
budesonide	O
was	O
29.2	O
%	O
of	O
the	O
metered	O
dose	O
for	O
females	O
and	O
37	O
%	O
for	O
males	O
,	O
while	O
formoterol	O
deposited	O
with	O
26.4	O
%	O
efficiency	O
for	O
females	O
and	O
32.5	O
%	O
for	O
males	O
.	O

Present	O
results	O
also	O
highlighted	O
the	O
importance	O
of	O
breath-holding	O
after	O
inhalation	O
of	O
the	O
drug	O
.	O

About	O
a	O
half	O
of	O
the	O
total	O
lung	O
deposition	O
occurred	O
during	O
breath-hold	O
at	O
9.6s	O
average	O
breath-hold	O
time	O
.	O

Calculated	O
depositions	O
confirmed	O
appropriate	O
lung	O
deposition	O
of	O
Symbicort	O
(	O
®	O
)	O
Turbuhaler	O
(	O
®	O
)	O
for	O
both	O
genders	O
,	O
however	O
more	O
effort	O
for	O
optimal	O
inhalation	O
technique	O
is	O
advised	O
for	O
persons	O
with	O
low	O
vital	O
capacity	O
.	O

This	O
study	O
demonstrated	O
the	O
possibility	O
of	O
personalized	O
prediction	O
of	O
airway	O
deposition	O
of	O
aerosol	O
drugs	O
by	O
numerical	O
simulations	O
.	O

The	O
methodology	O
developed	O
in	O
this	O
study	O
will	O
be	O
applicable	O
also	O
to	O
other	O
marketed	O
drugs	O
in	O
the	O
future	O
.	O

Complete	O
Genome	B-P
Sequence	I-P
Analysis	I-P
of	O
a	O
Naturally	O
Reassorted	O
Infectious	O
Bursal	O
Disease	O
Virus	O
from	O
India	O
.	O

The	O
novel	O
infectious	O
bursal	O
disease	O
virus	O
(	O
IBDV	O
)	O
isolate	O
BGE14/ABT1/MVC/India	O
is	O
a	O
very	O
virulent	O
IBDV	O
that	O
was	O
isolated	O
from	O
broiler	O
flocks	O
in	O
southern	O
parts	O
of	O
India	O
during	O
2014	O
.	O

Here	O
,	O
we	O
report	O
,	O
for	O
the	O
first	O
time	O
in	O
India	O
,	O
the	O
complete	O
genome	O
sequence	O
of	O
BGE14/ABT1/MVC/India	O
,	O
a	O
reassortment	O
strain	O
with	O
segments	O
A	O
and	O
B	O
derived	O
from	O
a	O
very	O
virulent	O
IBDV	O
strain	O
and	O
an	O
attenuated	O
IBDV	O
,	O
respectively	O
.	O

The	O
findings	O
from	O
this	O
study	O
provide	O
additional	O
insight	O
into	O
the	O
genetic	O
exchange	O
between	O
attenuated	O
and	O
very	O
virulent	O
strains	O
of	O
IBDV	O
circulating	O
in	O
the	O
field	O
.	O

Assessment	O
of	O
Interleukin-17A	O
,	O
Interleukin-10	O
and	O
Transforming	O
Growth	O
Factor-Beta1	O
Serum	O
Titers	O
in	O
Relapsing	O
Remitting	O
Multiple	O
Sclerosis	O
Patients	O
Treated	O
with	O
Avonex	O
,	O
Possible	O
Biomarkers	O
for	O
Treatment	O
Response	O
.	O

Individual	O
response	O
to	O
interferon	O
beta	O
(	O
IFN-β	O
)	O
1a	O
treatment	O
is	O
heterogeneous	O
in	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
.	O

Our	O
objective	O
was	O
to	O
find	O
a	O
connection	O
between	O
serum	O
levels	O
of	O
interleukin	O
(	O
IL	O
)	O
-10	O
,	O
IL-17	O
and	O
transforming	O
growth	O
factor	O
beta	O
(	O
TGF-β	O
)	O
1	O
in	O
MS	O
patients	O
treated	O
with	O
IFN-β	O
in	O
order	O
to	O
identify	O
the	O
nonresponders	O
(	O
NR	O
)	O
.	O

We	O
included	O
in	O
the	O
study	O
32	O
healthy	O
subjects	O
and	O
32	O
MS	O
patients	O
:	O
10	O
naive	O
,	O
10	O
early	O
treated	O
and	O
12	O
late	O
treated	O
with	O
INF-β1a	O
.	O

Serum	O
determination	B-P
of	O
cytokines	O
and	O
brain	B-P
MRI	I-P
were	O
performed	O
at	O
the	O
beginning	O
of	O
the	O
study	O
,	O
after	O
6	O
and	O
12	O
months	O
.	O

Rio	O
score	O
was	O
calculated	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O

MS	O
patients	O
had	O
initially	O
a	O
significant	O
higher	O
level	O
of	O
IL-17	O
and	O
a	O
lower	O
level	O
of	O
TGF-β1	O
compared	O
to	O
healthy	O
subjects	O
.	O

IL-17	O
level	O
in	O
early	O
treated	O
patients	O
was	O
significantly	O
lower	O
compared	O
to	O
the	O
naive	O
and	O
late	O
treated	O
groups	O
.	O

INF-β1a	O
treatment	O
significantly	O
increased	O
IL-10	O
and	O
decreased	O
IL-17	O
levels	O
.	O

Initial	O
low	O
levels	O
of	O
IL-10	O
were	O
associated	O
with	O
an	O
increase	O
in	O
physical	O
disability	O
.	O

IL-17	O
levels	O
positively	O
correlated	O
with	O
the	O
number	O
of	O
relapses	O
and	O
MRI	B-P
activity	O
.	O

Nine	O
patients	O
were	O
NR	O
to	O
Avonex	O
.	O

Patients	O
with	O
a	O
Rio	O
score	O
of	O
3	O
had	O
higher	O
initial	O
levels	O
of	O
IL-17	O
and	O
those	O
with	O
a	O
Rio	O
score	O
of	O
0	O
had	O
higher	O
initial	O
levels	O
of	O
IL-10	O
and	O
TGF-β1	O
.	O

IFN-β1a	O
decreased	O
IL-17	O
and	O
increased	O
IL-10	O
seric	O
levels	O
;	O
IL-17	O
significantly	O
correlated	O
with	O
MS	O
activity	O
;	O
TGF-β1	O
activity	O
is	O
titer-dependent	O
,	O
increased	O
levels	O
were	O
associated	O
with	O
IL-17	O
inhibition	O
;	O
NR	O
patients	O
to	O
IFN-β1a	O
will	O
have	O
initial	O
high	O
IL-17	O
and	O
low	O
IL-10	O
and	O
TGF-β	O
seric	O
levels	O
.	O

High	O
Performance	O
Reduction	O
of	O
H2O2	O
with	O
an	O
Electron	O
Transport	O
Decaheme	O
Cytochrome	O
on	O
a	O
Porous	O
ITO	O
Electrode	O
.	O

The	O
decaheme	O
cytochrome	O
MtrC	O
from	O
Shewanella	O
oneidensis	O
MR-1	O
immobilized	O
on	O
an	O
ITO	O
electrode	O
displays	O
unprecedented	O
H2O2	O
reduction	O
activity	O
.	O

Although	O
MtrC	O
showed	O
lower	O
peroxidase	O
activity	O
in	O
solution	O
compared	O
to	O
horseradish	O
peroxidase	O
,	O
the	O
ten	O
heme	O
cofactors	O
enable	O
excellent	O
electronic	O
communication	O
and	O
a	O
superior	O
activity	O
on	O
the	O
electrode	O
surface	O
.	O

A	O
hierarchical	O
ITO	O
electrode	O
enabled	O
optimal	O
immobilization	O
of	O
MtrC	O
and	O
a	O
high	O
current	O
density	O
of	O
1	O
mA	O
cm	O
(	O
-2	O
)	O
at	O
0.4	O
V	O
vs	O
SHE	O
could	O
be	O
obtained	O
at	O
pH	O
6.5	O
(	O
Eonset	O
=	O
0.72	O
V	O
)	O
.	O

UV-visible	O
and	O
Resonance	B-P
Raman	I-P
spectroelectrochemical	I-P
studies	I-P
suggest	O
the	O
formation	O
of	O
a	O
high	O
valent	O
iron-oxo	O
species	O
as	O
the	O
catalytic	O
intermediate	O
.	O

Our	O
findings	O
demonstrate	O
the	O
potential	O
of	O
multiheme	O
cytochromes	O
to	O
catalyze	O
technologically	O
relevant	O
reactions	O
and	O
establish	O
MtrC	O
as	O
a	O
new	O
benchmark	O
in	O
biotechnological	O
H2O2	O
reduction	O
with	O
scope	O
for	O
applications	O
in	O
fuel	O
cells	O
and	O
biosensors	O
.	O

Intratympanic	O
steroid	O
delivery	O
by	O
an	O
indwelling	O
catheter	O
in	O
refractory	O
severe	O
sudden	O
sensorineural	O
hearing	O
loss	O
.	O

Many	O
studies	O
over	O
the	O
last	O
decade	O
showed	O
favorable	O
outcomes	O
with	O
intratympanic	O
(	O
IT	O
)	O
steroid	O
treatment	O
,	O
alone	O
as	O
salvage	O
treatment	O
or	O
in	O
combination	O
with	O
conventional	O
systemic	O
therapy	O
(	O
ST	O
)	O
.	O

However	O
,	O
in	O
severe	O
to	O
profound	O
sensorineural	O
hearing	O
loss	O
resistant	O
to	O
ST	O
,	O
the	O
optimal	O
infusion	O
mode	O
,	O
the	O
type	O
and	O
concentration	O
of	O
the	O
solution	O
,	O
the	O
preferable	O
drug	O
,	O
its	O
total	O
amount	O
,	O
and	O
the	O
duration	O
and	O
fractionation	O
of	O
the	O
treatment	O
are	O
still	O
debated	O
.	O

Aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
feasibility	O
and	O
the	O
outcomes	O
of	O
a	O
direct	O
and	O
constant	O
IT	O
delivery	O
of	O
dexamethasone	O
(	O
DEX	O
)	O
by	O
means	O
of	O
a	O
new	O
indwelling	O
catheter	O
.	O

A	O
prospective	O
case-control	O
study	O
in	O
a	O
tertiary	O
referral	O
university	O
hospital	O
.	O

Ninety-nine	O
subjects	O
treated	O
with	O
ST	O
only	O
and	O
28	O
with	O
additional	O
IT	O
DEX	O
have	O
been	O
included	O
in	O
the	O
study	O
.	O

A	O
4	O
Fr	O
catheter	O
inserted	O
in	O
a	O
sub-annular	O
fashion	O
with	O
a	O
minimal	O
postero-inferior	O
tympanotomy	O
through	O
and	O
endocanalar	O
approach	O
under	O
local	O
anesthesia	O
.	O

DEX	O
4mg/ml	O
delivered	O
daily	O
,	O
up	O
to	O
7	O
days	O
.	O

Daily	O
bone	B-P
and	I-P
air-conducted	I-P
pure	I-P
tone	I-P
and	O
speech	B-P
audiometry	I-P
were	O
performed	O
with	O
a	O
follow-up	O
at	O
1	O
,	O
3	O
,	O
6	O
months	O
after	O
treatment	O
.	O

Twenty-one	O
out	O
of	O
28	O
patients	O
(	O
75	O
%	O
)	O
refractory	O
to	O
ST	O
gained	O
on	O
average	O
24.0dB±20.5dB	O
HL	O
after	O
IT	O
-	O
DEX	O
,	O
compared	O
to	O
35.4	O
%	O
(	O
average	O
6.7dB±16.6dB	O
HL	O
)	O
of	O
those	O
receiving	O
only	O
medical	O
ST	O
(	O
p	O
<	O
0.001	O
)	O
.	O

No	O
significant	O
side	O
effects	O
were	O
noted	O
.	O

In	O
severe	O
to	O
profound	O
sudden	O
deafness	O
refractory	O
to	O
conventional	O
ST	O
,	O
the	O
daily	O
perfusion	O
of	O
4mg/ml	O
DEX	O
through	O
an	O
intratympanic	O
catheter	O
is	O
an	O
easy	O
,	O
well	O
accepted	O
procedure	O
that	O
enables	O
patients	O
to	O
receive	O
a	O
drug	O
in	O
the	O
middle	O
ear	O
in	O
a	O
repeatable	O
or	O
sustained	O
form	O
,	O
with	O
minimal	O
discomfort	O
and	O
a	O
partial	O
rescue	O
(	O
67.86	O
%	O
)	O
and	O
a	O
speech	O
recognition	O
gain	O
of	O
39	O
%	O
.	O

The	O
Abundance	O
of	O
Endofungal	O
Bacterium	O
Rhizobium	O
radiobacter	O
(	O
syn	O
.	O

Agrobacterium	O
tumefaciens	O
)	O
Increases	O
in	O
Its	O
Fungal	O
Host	O
Piriformospora	O
indica	O
during	O
the	O
Tripartite	O
Sebacinalean	O
Symbiosis	O
with	O
Higher	O
Plants	O
.	O

Rhizobium	O
radiobacter	O
(	O
syn	O
.	O

Agrobacterium	O
tumefaciens	O
,	O
syn.	O
``	O

Agrobacterium	O
fabrum	O
``	O
)	O
is	O
an	O
endofungal	O
bacterium	O
of	O
the	O
fungal	O
mutualist	O
Piriformospora	O
(	O
syn	O
.	O

Serendipita	O
)	O
indica	O
(	O
Basidiomycota	O
)	O
,	O
which	O
together	O
form	O
a	O
tripartite	O
Sebacinalean	O
symbiosis	O
with	O
a	O
broad	O
range	O
of	O
plants	O
.	O

R.	O
radiobacter	O
strain	O
F4	O
(	O
RrF4	O
)	O
,	O
isolated	O
from	O
P.	O
indica	O
DSM	O
11827	O
,	O
induces	O
growth	O
promotion	O
and	O
systemic	O
resistance	O
in	O
cereal	O
crops	O
,	O
including	O
barley	O
and	O
wheat	O
,	O
suggesting	O
that	O
R.	O
radiobacter	O
contributes	O
to	O
a	O
successful	O
symbiosis	O
.	O

Here	O
,	O
we	O
studied	O
the	O
impact	O
of	O
endobacteria	O
on	O
the	O
morphology	O
and	O
the	O
beneficial	O
activity	O
of	O
P.	O
indica	O
during	O
interactions	O
with	O
plants	O
.	O

Low	O
numbers	O
of	O
endobacteria	O
were	O
detected	O
in	O
the	O
axenically	B-P
grown	I-P
P.	O
indica	O
(	O
long	O
term	O
lab-cultured	B-P
,	O
lcPiri	O
)	O
whereas	O
mycelia	O
colonizing	O
the	O
plant	O
root	O
contained	O
increased	O
numbers	O
of	O
bacteria	O
.	O

Higher	O
numbers	O
of	O
endobacteria	O
were	O
also	O
found	O
in	O
axenic	B-P
cultures	I-P
of	O
P.	O
indica	O
that	O
was	O
freshly	O
re-isolated	O
(	O
riPiri	O
)	O
from	O
plant	O
roots	O
,	O
though	O
numbers	O
dropped	O
during	O
repeated	O
axenic	B-P
re-cultivation	I-P
.	O

Prolonged	O
treatments	O
of	O
P.	O
indica	O
cultures	B-P
with	O
various	O
antibiotics	O
could	O
not	O
completely	O
eliminate	O
the	O
bacterium	O
,	O
though	O
the	O
number	O
of	O
detectable	O
endobacteria	O
decreased	O
significantly	O
,	O
resulting	O
in	O
partial-cured	O
P.	O
indica	O
(	O
pcPiri	O
)	O
.	O

pcPiri	O
showed	O
reduced	O
growth	O
in	O
axenic	B-P
cultures	I-P
and	O
poor	O
sporulation	O
.	O

Consistent	O
with	O
this	O
,	O
pcPiri	O
also	O
showed	O
reduced	O
plant	O
growth	O
promotion	O
and	O
reduced	O
systemic	O
resistanc	O
e	O
against	O
powdery	O
mildew	O
infection	O
as	O
compared	O
with	O
riPiri	O
and	O
lcPiri	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
assumption	O
that	O
the	O
endobacterium	O
R.	O
radiobacter	O
improves	O
P.	O
indica	O
's	O
fitness	O
and	O
thus	O
contributes	O
to	O
the	O
success	O
of	O
the	O
tripartite	O
Sebacinalean	O
symbiosis	O
.	O

Serum	B-P
C-Reactive	I-P
Protein	I-P
in	O
Children	O
with	O
Liver	O
Disease	O
and	O
Ascites	O
.	O

The	O
diagnosis	O
of	O
peritonitis	O
as	O
a	O
complication	O
of	O
cirrhosis	O
is	O
an	O
important	O
clinical	O
problem	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
serum	B-P
C-reactive	I-P
protein	I-P
levels	I-P
as	O
a	O
diagnostic	O
factor	O
for	O
spontaneous	O
bacterial	O
peritonitis	O
(	O
SBP	O
)	O
in	O
child	O
patients	O
with	O
liver	O
disease	O
.	O

In	O
this	O
study	O
,	O
150	O
children	O
diagnosed	O
with	O
liver	O
disease	O
and	O
ascites	O
upon	O
admission	O
to	O
Nemazee	O
Teaching	O
Hospital	O
(	O
Shiraz	O
,	O
Iran	O
)	O
were	O
examined	O
.	O

Patients	O
were	O
divided	O
into	O
spontaneous	O
bacterial	O
peritonitis	O
and	O
sterile	O
ascetic	O
fluid	O
groups	O
according	O
to	O
the	O
PMN	B-P
count	I-P
≥	O
250/mm	O
(	O
3	O
)	O
in	O
the	O
ascetic	O
fluids	O
.	O

Routine	B-P
laboratory	I-P
tests	I-P
were	O
conducted	O
and	O
quantitative	O
C-reactive	B-P
protein	I-P
(	I-P
CRP	I-P
)	I-P
levels	I-P
were	O
measured	O
for	O
all	O
of	O
the	O
patients	O
.	O

Accuracy	O
,	O
sensitivity	O
,	O
and	O
specificity	O
of	O
CRP	B-P
was	O
evaluated	O
for	O
diagnosis	O
of	O
SBP	O
.	O

Of	O
150	O
cirrhotic	O
patients	O
,	O
109	O
patients	O
presented	O
without	O
SBP	O
(	O
52.29	O
%	O
male	O
,	O
mean	O
age	O
:	O
5.02	O
±	O
4.49	O
years	O
)	O
and	O
41	O
patients	O
presented	O
with	O
SBP	O
(	O
51.21	O
%	O
male	O
,	O
mean	O
age	O
:	O
4.71	O
years	O
)	O
.	O

Cell	B-P
counts	I-P
,	O
protein	O
levels	O
,	O
albumin	O
levels	O
,	O
and	O
lactate	B-P
dehydrogenize	I-P
(	I-P
LDH	I-P
)	I-P
levels	I-P
of	O
the	O
ascetic	O
fluid	O
and	O
serum	O
samples	O
in	O
the	O
SBP	O
group	O
were	O
higher	O
than	O
the	O
rates	O
for	O
those	O
without	O
SBP	O
(	O
P	O
<	O
0.05	O
(	O
.	O

The	O
mean	O
±	O
SD	O
of	O
CRP	B-P
in	O
the	O
SBP	O
group	O
(	O
36.89	O
±	O
23.43	O
)	O
increased	O
significantly	O
compared	O
to	O
the	O
rate	O
among	O
those	O
without	O
SBP	O
(	O
21.59	O
±	O
15.43	O
,	O
P	O
=	O
0.001	O
)	O
.	O

The	O
percentages	O
for	O
sensitivity	O
and	O
specificity	O
of	O
CRP	B-P
,	O
the	O
diagnosis	O
of	O
SBP	O
based	O
on	O
the	O
PMN	B-P
count	I-P
≥	O
250/mm	O
(	O
3	O
)	O
,	O
and	O
cultured	O
ascites	O
were	O
69.23	O
%	O
,	O
90.25	O
%	O
,	O
88.43	O
%	O
,	O
and	O
84.32	O
%	O
,	O
respectively	O
.	O

The	O
areas	O
under	O
the	O
curve	O
of	O
CRP	B-P
for	O
SBP	O
based	O
on	O
the	O
PMN	B-P
count	I-P
≥	O
250/mm	O
(	O
3	O
)	O
and	O
cultured	O
ascites	O
was	O
0.94	O
(	O
CI	O
95	O
%	O
:	O
0.90	O
to	O
0.96	O
)	O
and	O
0.85	O
(	O
CI	O
95	O
%	O
:	O
0.84	O
to	O
0.92	O
)	O
,	O
respectively	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Our	O
study	O
showed	O
that	O
CRP	B-P
is	O
a	O
marker	O
with	O
high	O
sensitivity	O
and	O
specificity	O
for	O
the	O
diagnosis	O
of	O
SBP	O
in	O
cirrhotic	O
children	O
.	O

Adenosine	O
and	O
the	O
adenosine	O
A2A	O
receptor	O
agonist	O
,	O
CGS21680	O
,	O
upregulate	O
CD39	O
and	O
CD73	O
expression	O
through	O
E2F-1	O
and	O
CREB	O
in	O
regulatory	O
T	O
cells	O
isolated	O
from	O
septic	O
mice	O
.	O

The	O
number	O
of	O
regulatory	O
T	O
cells	O
(	O
Treg	O
cells	O
)	O
and	O
the	O
expression	O
of	O
ectonucleoside	O
triphosphate	O
diphosphohydrolase	O
1	O
(	O
ENTPD1	O
;	O
also	O
known	O
as	O
CD39	O
)	O
and	O
5'-ectonucleotidase	O
(	O
NT5E	O
;	O
also	O
known	O
as	O
CD73	O
)	O
on	O
the	O
Treg	O
cell	O
surface	O
are	O
increased	O
during	O
sepsis	O
.	O

In	O
this	O
study	O
,	O
to	O
determine	O
the	O
factors	O
leading	O
to	O
the	O
high	O
expression	O
of	O
CD39	O
and	O
CD73	O
,	O
and	O
the	O
regulation	O
of	O
the	O
CD39	O
/	O
CD73	O
/	O
adenosine	O
pathway	O
in	O
Treg	O
cells	O
under	O
septic	O
conditions	O
,	O
we	O
constructed	O
a	O
mouse	O
model	O
of	O
sepsis	O
and	O
separated	O
the	O
Treg	O
cells	O
using	O
a	O
flow	O
cytometer	O
.	O

The	O
Treg	O
cells	O
isolated	O
from	O
the	O
peritoneal	O
lavage	O
and	O
splenocytes	O
of	O
the	O
mice	O
were	O
treated	O
with	O
adenosine	O
or	O
the	O
specific	O
adenosine	O
A2A	O
receptor	O
agonist	O
,	O
CGS21680	O
,	O
and	O
were	O
transfected	O
with	O
specific	O
siRNA	O
targeting	O
E2F	O
transcription	O
factor	O
1	O
(	O
E2F-1	O
)	O
or	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
response	O
element-binding	O
protein	O
(	O
CREB	O
)	O
,	O
which	O
are	O
predicted	O
transcription	O
regulatory	O
factors	O
of	O
CD39	O
or	O
CD73	O
.	O

The	O
regulatory	O
relationships	O
among	O
these	O
factors	O
were	O
then	O
determined	O
by	O
western	B-P
blot	I-P
analysis	I-P
and	O
dual-luciferase	B-P
reporter	I-P
assay	I-P
.	O

In	O
addition	O
,	O
changes	O
in	O
adenosine	O
metabolism	O
were	O
measured	O
in	O
the	O
treated	O
cells	O
.	O

The	O
results	O
revealed	O
that	O
adenosine	O
and	O
CGS21680	O
significantly	O
upregulated	O
CD39	O
and	O
CD73	O
expression	O
(	O
P	O
<	O
0.01	O
)	O
.	O

E2F-1	O
and	O
CREB	O
induced	O
CD39	O
and	O
CD73	O
expression	O
,	O
and	O
were	O
upregulated	O
by	O
adenosine	O
and	O
CGS21680	O
.	O

Adenosine	O
triphosphate	O
(	O
ATP	O
)	O
hydrolysis	O
and	O
adenosine	O
generation	O
were	O
inhibited	O
by	O
the	O
knockdown	O
of	O
E2F-1	O
or	O
CREB	O
,	O
and	O
were	O
accelerated	O
in	O
the	O
presence	O
of	O
CGS21680	O
.	O

Based	O
on	O
these	O
results	O
,	O
it	O
can	O
be	O
inferred	O
that	O
adenosine	O
,	O
the	O
adenosine	O
A2A	O
receptor	O
agonist	O
,	O
E2F-1	O
and	O
CREB	O
are	O
the	O
possible	O
factors	O
contributing	O
to	O
the	O
high	O
expression	O
of	O
CD39	O
and	O
CD73	O
on	O
the	O
Treg	O
cell	O
surface	O
during	O
sepsis	O
.	O

Adenosine	O
and	O
its	O
A2A	O
receptor	O
agonist	O
served	O
as	O
the	O
signal	O
transducer	O
factors	O
of	O
the	O
CD39	O
/	O
CD73	O
/	O
adenosine	O
pathway	O
,	O
accelerating	O
adenosine	O
generation	O
.	O

Our	O
study	O
may	O
benefit	O
further	O
research	O
on	O
adenosine	O
metabolism	O
for	O
the	O
treatment	O
of	O
sepsis	O
.	O

Audiovisual	O
integration	O
supports	O
face	O
-	O
name	O
associative	O
memory	O
formation	O
.	O

Prior	O
multisensory	O
experience	O
influences	O
how	O
we	O
perceive	O
our	O
environment	O
,	O
and	O
hence	O
how	O
memories	O
are	O
encoded	O
for	O
subsequent	O
retrieval	O
.	O

This	O
study	O
investigated	O
if	O
audiovisual	O
(	O
AV	O
)	O
integration	O
and	O
associative	O
memory	O
formation	O
rely	O
on	O
overlapping	O
or	O
distinct	O
processes	O
.	O

Our	O
functional	O
magnetic	B-P
resonance	I-P
imaging	I-P
results	O
demonstrate	O
that	O
the	O
neural	O
mechanisms	O
underlying	O
AV	O
integration	O
and	O
associative	O
memory	O
overlap	O
substantially	O
.	O

In	O
particular	O
,	O
activity	O
in	O
anterior	O
superior	O
temporal	O
sulcus	O
(	O
STS	O
)	O
is	O
increased	O
during	O
AV	O
integration	O
and	O
also	O
determines	O
the	O
success	O
of	O
novel	O
AV	O
face	O
-	O
name	O
association	O
formation	O
.	O

Dynamic	O
causal	O
modeling	O
results	O
further	O
demonstrate	O
how	O
the	O
anterior	O
STS	O
interacts	O
with	O
the	O
associative	O
memory	O
system	O
to	O
facilitate	O
successful	O
memory	O
formation	O
for	O
AV	O
face	O
-	O
name	O
associations	O
.	O

Specifically	O
,	O
the	O
connection	O
of	O
fusiform	O
gyrus	O
to	O
anterior	O
STS	O
is	O
enhanced	O
while	O
the	O
reverse	O
connection	O
is	O
reduced	O
when	O
participants	O
subsequently	O
remembered	O
both	O
face	O
and	O
name	O
.	O

Collectively	O
,	O
our	O
results	O
demonstrate	O
how	O
multisensory	O
associative	O
memories	O
can	O
be	O
formed	O
for	O
subsequent	O
retrieval	O
.	O

Coffee	O
-	O
Antihypertensive	O
Drug	O
Interaction	O
:	O
A	O
Hemodynamic	O
and	O
Pharmacokinetic	O
Study	O
With	O
Felodipine	O
.	O

A	O
period	O
of	O
abstinence	O
from	O
coffee	O
to	O
permit	O
caffeine	O
elimination	O
appears	O
to	O
enable	O
increased	O
blood	O
pressure	O
on	O
subsequent	O
exposure	O
.	O

We	O
hypothesized	O
that	O
this	O
would	O
offset	O
the	O
antihypertensive	O
effect	O
of	O
the	O
dihydropyridine	O
calcium	O
channel	O
blocker	O
felodipine	O
.	O

A	O
randomized	O
,	O
single-dose	O
,	O
crossover	O
study	O
assessed	O
hemodynamic	O
and	O
pharmacokinetic	O
effects	O
following	O
2	O
days	O
without	O
coffee	O
and	O
caffeine	O
-	O
containing	O
foods	O
.	O

Consistently	O
brewed	O
black	O
coffee	O
(	O
2×300ml	O
)	O
,	O
felodipine	O
maximum	O
recommended	O
dose	O
(	O
10mg	O
)	O
,	O
and	O
coffee	O
plus	O
felodipine	O
were	O
tested	O
in	O
middle-aged	O
normotensive	O
subjects	O
.	O

Pretreatment	O
plasma	O
caffeine	B-P
concentrations	I-P
were	O
unquantifiable	O
.	O

After	O
coffee	O
,	O
blood	O
pressure	O
changes	O
(	O
mm	O
Hg	O
)	O
averaged	O
over	O
study	O
hours	O
1-4	O
were	O
increased	O
for	O
brachial	O
systolic	O
(	O
7.6	O
,	O
P	O
<	O
0.001	O
)	O
and	O
diastolic	O
(	O
4.9	O
,	O
P	O
<	O
0.001	O
)	O
and	O
aortic	O
systolic	O
(	O
7.4	O
,	O
P	O
<	O
0.001	O
)	O
,	O
pulse	O
(	O
3.0	O
,	O
P	O
<	O
0.05	O
)	O
and	O
augmentation	O
(	O
1.4	O
,	O
P	O
<	O
0.05	O
)	O
relative	O
to	O
baseline	O
.	O

After	O
coffee	O
plus	O
felodipine	O
,	O
they	O
were	O
higher	O
for	O
brachial	O
systolic	O
(	O
4.0	O
,	O
P	O
<	O
0.05	O
)	O
and	O
diastolic	O
(	O
3.9	O
,	O
P	O
<	O
0.001	O
)	O
and	O
aortic	O
systolic	O
(	O
4.6	O
,	O
P	O
<	O
0.05	O
)	O
compared	O
to	O
felodipine	O
alone	O
.	O

The	O
pressor	O
effects	O
of	O
coffee	O
and	O
its	O
modulation	O
by	O
felodipine	O
were	O
variable	O
among	O
individuals	O
.	O

Coffee	O
containing	O
caffeine	O
(	O
127mg	O
)	O
caused	O
maximum	O
pressor	O
effect	O
.	O

Caffeine	O
and	O
felodipine	O
pharmacokinetics	O
were	O
similar	O
for	O
coffee	O
and	O
felodipine	O
given	O
alone	O
or	O
in	O
combination	O
indicating	O
an	O
interaction	O
having	O
a	O
pharmacodynamic	O
basis	O
.	O

Plasma	O
felodipine	O
concentration	O
-	O
diastolic	O
blood	O
pressure	O
reduction	O
relationship	O
shifted	O
with	O
coffee	O
such	O
that	O
doubling	O
the	O
felodipine	O
concentration	O
would	O
eliminate	O
the	O
pressor	O
effect	O
.	O

However	O
,	O
this	O
may	O
increase	O
the	O
risk	O
of	O
adverse	O
drug	O
events	O
particularly	O
during	O
the	O
timeframe	O
without	O
coffee	O
.	O

Intermittent	O
coffee	O
ingestion	O
might	O
complicate	O
hypertension	O
diagnosis	O
and	O
management	O
for	O
many	O
individuals	O
.	O

The	O
impact	O
of	O
noninvasive	O
follicular	O
thyroid	O
neoplasm	O
with	O
papillary-like	O
nuclear	O
features	O
on	O
the	O
performance	O
of	O
the	O
Afirma	O
gene	O
expression	O
classifier	O
.	O

A	O
recent	O
revision	O
in	O
thyroid	O
tumor	O
nomenclature	O
has	O
resulted	O
in	O
a	O
change	O
from	O
a	O
malignant	O
diagnosis	O
(	O
noninvasive	O
follicular	O
variant	O
of	O
papillary	O
thyroid	O
carcinoma	O
)	O
to	O
one	O
that	O
is	O
nonmalignant	O
(	O
noninvasive	O
follicular	O
thyroid	O
neoplasm	O
with	O
papillary-like	O
nuclear	O
features	O
[	O
NIFTP	O
]	O
)	O
.	O

The	O
objective	O
of	O
the	O
current	O
study	O
was	O
to	O
evaluate	O
the	O
impact	O
of	O
this	O
change	O
on	O
the	O
performance	O
of	O
the	O
Afirma	O
gene	O
expression	O
classifier	O
(	O
GEC	O
)	O
.	O

The	O
authors	O
retrospectively	O
analyzed	O
consecutive	O
thyroid	B-P
fine-needle	I-P
aspiration	I-P
specimens	O
with	O
indeterminate	O
diagnoses	B-P
on	O
which	O
GEC	O
was	O
performed	O
.	O

Surgical	O
pathology	O
material	O
was	O
reviewed	O
with	O
the	O
reclassification	O
of	O
nodules	O
into	O
NIFTP	O
.	O

GEC	O
testing	O
was	O
performed	O
on	O
384	O
fine-needle	B-P
aspiration	I-P
specimens	O
diagnosed	O
as	O
atypia	O
of	O
undetermined	O
significance	O
(	O
AUS	O
)	O
(	O
304	O
cases	O
)	O
and	O
suspicious	O
for	O
a	O
follicular	O
neoplasm	O
(	O
SFN	O
)	O
(	O
80	O
cases	O
)	O
and	O
yielded	O
a	O
suspicious	O
result	O
in	O
152	O
of	O
the	O
AUS	O
cases	O
(	O
50	O
%	O
)	O
and	O
50	O
of	O
the	O
SFN	O
cases	O
(	O
63	O
%	O
)	O
.	O

Thyroidectomy	O
was	O
performed	O
on	O
177	O
patients	O
.	O

After	O
reclassifying	O
NIFTP	O
,	O
the	O
positive	O
predictive	O
value	O
of	O
GEC	O
decreased	O
from	O
42	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
95	O
%	O
CI	O
]	O
,	O
39	O
%	O
-45	O
%	O
)	O
to	O
24	O
%	O
(	O
95	O
%	O
CI	O
,	O
22	O
%	O
-26	O
%	O
)	O
in	O
the	O
AUS	O
group	O
and	O
from	O
23	O
%	O
(	O
95	O
%	O
CI	O
,	O
19	O
%	O
-27	O
%	O
)	O
to	O
13	O
%	O
(	O
95	O
%	O
CI	O
,	O
9	O
%	O
-18	O
%	O
)	O
in	O
the	O
SFN	O
group	O
.	O

Total	O
thyroidectomy	O
was	O
performed	O
more	O
frequently	O
than	O
a	O
partial	O
thyroidectomy	O
in	O
patients	O
with	O
AUS	O
with	O
a	O
suspicious	O
GEC	O
result	O
compared	O
with	O
pre-GEC	O
controls	O
(	O
68	O
%	O
vs	O
49	O
%	O
;	O
P	O
=	O
.037	O
)	O
.	O

Reclassification	O
of	O
NIFTP	O
significantly	O
decreases	O
the	O
positive	O
predictive	O
value	O
of	O
GEC	O
in	O
indeterminate	O
thyroid	O
nodules	O
.	O

Nevertheless	O
,	O
the	O
majority	O
of	O
patients	O
with	O
indeterminate	O
thyroid	O
nodules	O
with	O
a	O
suspicious	O
GEC	O
result	O
in	O
the	O
study	O
institution	O
have	O
undergone	O
total	O
thyroidectomy	O
.	O

This	O
finding	O
raises	O
concerns	O
over	O
reliance	O
on	O
a	O
suspicious	O
GEC	O
result	O
by	O
clinicians	O
to	O
justify	O
total	O
thyroidectomy	O
.	O

Cancer	O
Cytopathol	O
2017	O
.	O

©	O
2017	O
American	O
Cancer	O
Society	O
.	O

A	O
simple	O
and	O
biosafe	O
method	O
for	O
isolation	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
.	O

Human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECS	O
)	O
are	O
used	O
as	O
an	O
irreplaceable	O
tool	O
for	O
the	O
study	O
of	O
vascular	O
diseases	O
.	O

However	O
,	O
the	O
technicians	O
who	O
isolate	B-P
HUVECs	O
are	O
largely	O
exposed	O
to	O
potential	O
infectious	O
threats	O
.	O

Here	O
we	O
report	O
the	O
development	O
of	O
a	O
specialized	O
instrument	O
to	O
protect	O
researchers	O
from	O
known	O
or	O
unknown	O
infectious	O
agents	O
when	O
they	O
operate	O
on	O
human	O
umbilical	O
cords	O
.	O

This	O
instrument	O
can	O
be	O
assembled	O
by	O
common	O
laboratory	O
supplies	O
and	O
adapted	O
to	O
accommodate	O
umbilical	O
cords	O
of	O
different	O
lengths	O
.	O

When	O
the	O
cord	O
is	O
enclosed	O
within	O
the	O
instrument	O
,	O
the	O
risk	O
of	O
sample	O
contamination	O
and	O
operator	O
infection	O
is	O
greatly	O
reduced	O
.	O

Using	O
our	O
instrument	O
,	O
endothelial	O
cells	O
were	O
successfully	O
isolated	O
from	O
human	O
umbilical	O
veins	O
without	O
contamination	O
.	O

The	O
cells	O
were	O
verified	O
by	O
their	O
cobblestone-like	O
morphology	O
and	O
by	O
immunofluorescence	B-P
staining	I-P
(	O
Factor	B-P
VIII	I-P
and	O
CD31	O
positivity	O
and	O
α-SMA	O
negativity	O
)	O
.	O

Our	O
instrument	O
simplifies	O
and	O
optimizes	O
the	O
cell	O
extraction	O
process	O
,	O
and	O
most	O
importantly	O
elevates	O
the	O
biosafety	O
to	O
a	O
higher	O
level	O
during	O
the	O
isolation	B-P
of	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
.	O

Critical	O
role	O
for	O
GLP-1	O
in	O
symptomatic	O
post-bariatric	O
hypoglycaemia	O
.	O

Post-bariatric	O
hypoglycaemia	O
(	O
PBH	O
)	O
is	O
a	O
rare	O
,	O
but	O
severe	O
,	O
metabolic	O
disorder	O
arising	O
months	O
to	O
years	O
after	O
bariatric	O
surgery	O
.	O

It	O
is	O
characterised	O
by	O
symptomatic	O
postprandial	O
hypoglycaemia	O
,	O
with	O
inappropriately	O
elevated	O
insulin	O
concentrations	O
.	O

The	O
relative	O
contribution	O
of	O
exaggerated	O
incretin	O
hormone	O
signalling	O
to	O
dysregulated	O
insulin	O
secretion	O
and	O
symptomatic	O
hypoglycaemia	O
is	O
a	O
subject	O
of	O
ongoing	O
inquiry	O
.	O

This	O
study	O
was	O
designed	O
to	O
test	O
the	O
hypothesis	O
that	O
PBH	O
and	O
associated	O
symptoms	O
are	O
primarily	O
mediated	O
by	O
glucagon-like	O
peptide-1	O
(	O
GLP-1	O
)	O
.	O

We	O
conducted	O
a	O
double-blinded	O
crossover	O
study	O
wherein	O
eight	O
participants	O
with	O
confirmed	O
PBH	O
were	O
assigned	O
in	O
random	O
order	O
to	O
intravenous	O
infusion	O
of	O
the	O
GLP-1	O
receptor	O
(	O
GLP-1r	O
)	O
antagonist	O
.	O

Exendin	O
(	O
9-39	O
)	O
(	O
Ex-9	O
)	O
,	O
or	O
placebo	O
during	O
an	O
OGTT	B-P
on	O
two	O
separate	O
days	O
at	O
the	O
Stanford	O
University	O
Clinical	O
and	O
Translational	O
Research	O
Unit	O
.	O

Metabolic	O
,	O
symptomatic	O
and	O
pharmacokinetic	O
variables	O
were	O
evaluated	O
.	O

Results	O
were	O
compared	O
with	O
a	O
cohort	O
of	O
BMI	O
-	O
and	O
glucose	O
-matched	O
non-surgical	O
controls	O
(	O
NSCs	O
)	O
.	O

Infusion	O
of	O
Ex-9	O
decreased	O
the	O
time	O
to	O
peak	O
glucose	O
and	O
rate	O
of	O
glucose	O
decline	O
during	O
OGTT	B-P
,	O
and	O
raised	O
the	O
postprandial	O
nadir	O
by	O
over	O
70	O
%	O
,	O
normalising	O
it	O
relative	O
to	O
NSCs	O
and	O
preventing	O
hypoglycaemia	O
in	O
all	O
PBH	O
participants	O
.	O

Insulin	O
AUC	O
and	O
secretion	O
rate	O
decreased	O
by	O
57	O
%	O
and	O
71	O
%	O
respectively	O
,	O
and	O
peak	O
postprandial	O
insulin	O
was	O
normalised	O
relative	O
to	O
NSCs	O
.	O

Autonomic	O
and	O
neuroglycopenic	O
symptoms	O
were	O
significantly	O
reduced	O
during	O
Ex-9	O
infusion	O
.	O

GLP-1r	O
blockade	O
prevented	O
hypoglycaemia	O
in	O
100	O
%	O
of	O
individuals	O
,	O
normalised	O
beta	O
cell	O
function	O
and	O
reversed	O
neuroglycopenic	O
symptoms	O
,	O
supporting	O
the	O
conclusion	O
that	O
GLP-1	O
plays	O
a	O
primary	O
role	O
in	O
mediating	O
hyperinsulinaemic	O
hypoglycaemia	O
in	O
PBH	O
.	O

Competitive	O
antagonism	O
at	O
the	O
GLP-1r	O
merits	O
consideration	O
as	O
a	O
therapeutic	O
strategy	O
.	O

ClinicalTrials.gov	O
NCT02550145	O
.	O

Comparison	O
of	O
the	O
analgesic	O
efficacy	O
of	O
oral	O
ketorolac	O
versus	O
intramuscular	O
tramadol	O
after	O
third	O
molar	O
surgery	O
:	O
A	O
parallel	O
,	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	O
clinical	O
trial	O
.	O

Preemptive	O
analgesia	O
is	O
considered	O
an	O
alternative	O
for	O
treating	O
the	O
postsurgical	O
pain	O
of	O
third	O
molar	O
removal	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
preemptive	O
analgesic	O
efficacy	O
of	O
oral	O
ketorolac	O
versus	O
intramuscular	O
tramadol	O
after	O
a	O
mandibular	O
third	O
molar	O
surgery	O
.	O

A	O
parallel	O
,	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	O
clinical	O
trial	O
was	O
carried	O
out	O
.	O

Thirty	O
patients	O
were	O
randomized	O
into	O
two	O
treatment	O
groups	O
using	O
a	O
series	O
of	O
random	O
numbers	O
:	O
Group	O
A	O
,	O
oral	O
ketorolac	O
10	O
mg	O
plus	O
intramuscular	O
placebo	O
(	O
1	O
mL	O
saline	O
solution	O
)	O
;	O
or	O
Group	O
B	O
,	O
oral	O
placebo	O
(	O
similar	O
tablet	O
to	O
oral	O
ketorolac	O
)	O
plus	O
intramuscular	O
tramadol	O
50	O
mg	O
diluted	O
in	O
1	O
mL	O
saline	O
solution	O
.	O

These	O
treatments	O
were	O
given	O
30	O
min	O
before	O
the	O
surgery	O
.	O

We	O
evaluated	O
the	O
time	O
of	O
first	O
analgesic	O
rescue	O
medication	O
,	O
pain	O
intensity	O
,	O
total	O
analgesic	O
consumption	O
and	O
adverse	O
effects	O
.	O

Patients	O
taking	O
oral	O
ketorolac	O
had	O
longer	O
time	O
of	O
analgesic	O
covering	O
and	O
less	O
postoperative	O
pain	O
when	O
compared	O
with	O
patients	O
receiving	O
intramuscular	O
tramadol	O
.	O

According	O
to	O
the	O
VAS	B-P
and	O
UAC	O
results	O
,	O
this	O
study	O
suggests	O
that	O
10	O
mg	O
of	O
oral	O
ketorolac	O
had	O
superior	O
analgesic	O
effect	O
than	O
50	O
mg	O
of	O
tramadol	O
when	O
administered	O
before	O
a	O
mandibular	O
third	O
molar	O
surgery	O
.	O

Simultaneous	O
thrombosis	O
of	O
multiple	O
coronary	O
arteries	O
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
.	O

We	O
present	O
a	O
case	O
of	O
simultaneous	O
coronary	O
thrombosis	O
of	O
the	O
left	O
main	O
,	O
the	O
left	O
anterior	O
descending	O
artery	O
and	O
the	O
right	O
coronary	O
artery	O
in	O
a	O
patient	O
,	O
recently	O
diagnosed	B-P
with	O
rheumatoid	O
arthritis	O
.	O

Stem	O
cell	O
registry	O
programme	O
for	O
patients	O
with	O
ischemic	O
cardiomyopathy	O
undergoing	O
coronary	O
artery	O
bypass	O
grafting	O
:	O
what	O
benefits	O
does	O
it	O
derive	O
?	O
.	O

Standardization	O
of	O
stem	O
cell	O
therapy	O
requires	O
application	O
of	O
appropriate	O
methods	O
to	O
evaluate	O
safety	O
and	O
efficac	O
y	O
,	O
including	O
long-term	O
pharmacovigilance	O
.	O

To	O
accomplish	O
this	O
objective	O
,	O
a	O
long-term	O
registry	O
programme	O
was	O
installed	O
.	O

We	O
analysed	O
150	O
patients	O
with	O
ischemic	O
cardiomyopathy	O
,	O
who	O
received	O
intramyocardial	O
CD133+	O
bone	O
marrow	O
mononuclear	O
stem	O
cell	O
treatment	O
combined	O
with	O
coronary	O
artery	O
bypass	O
grafting	O
(	O
CABG	O
)	O
or	O
CABG	O
alone	O
.	O

The	O
mortality	O
rate	O
,	O
major	O
adverse	O
cerebral	O
and	O
cardiac	O
events	O
,	O
and	O
functional	O
outcome	O
parameters	O
were	O
evaluated	O
for	O
the	O
time	O
period	O
up	O
to	O
14	O
years	O
follow-up	O
.	O

As	O
a	O
result	O
,	O
we	O
have	O
stratified	O
the	O
patient	O
population	O
(	O
96	O
patients	O
)	O
into	O
responders	O
and	O
non-responders	O
.	O

Furthermore	O
,	O
the	O
analysis	O
of	O
relevant	O
predictors	O
of	O
good	O
response	O
to	O
CD133+	O
bone	O
marrow	O
mononuclear	O
stem	O
cell	O
treatment	O
was	O
performed	O
.	O

Several	O
positive	O
tendencies	O
related	O
to	O
stem	O
cells	O
transplantation	O
were	O
demonstrated	O
.	O

First	O
,	O
no	O
significant	O
difference	O
in	O
major	O
adverse	O
cardiovascular	O
and	O
cerebral	O
events	O
was	O
observed	O
between	O
stem	O
cell	O
and	O
control	O
group	O
up	O
to	O
14	O
years	O
follow-up	O
.	O

Second	O
,	O
an	O
improvement	O
of	O
left	O
ventricle	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
in	O
stem	O
cell	O
group	O
retained	O
for	O
5	O
years	O
in	O
contrast	O
with	O
CABG	O
-	O
only	O
group	O
,	O
where	O
no	O
significant	O
changes	O
in	O
LVEF	O
after	O
2	O
years	O
were	O
observed	O
.	O

In	O
addition	O
,	O
LVEF	O
under	O
30	O
%	O
and	O
left	B-P
ventricle	I-P
end	I-P
diastolic	I-P
diameter	I-P
above	O
60	O
mm	O
were	O
independent	O
predictors	O
of	O
functional	O
response	O
to	O
CD133+	O
cell	O
therapy	O
.	O

Participants	O
with	O
overt	O
heart	O
failure	O
benefit	O
most	O
from	O
CABG	O
combined	O
with	O
intramyocardial	O
injection	O
of	O
CD133+	O
bone	O
marrow	O
mononuclear	O
cell	O
within	O
the	O
group	O
.	O

An	O
improvement	O
LVEF	O
in	O
stem	O
cell	O
group	O
remained	O
for	O
5	O
years	O
in	O
contrast	O
with	O
the	O
CABG	O
-	O
only	O
group	O
.	O

The	O
patients	O
,	O
in	O
whom	O
the	O
improvement	O
of	O
both	O
LVEF	O
and	O
LVED	B-P
was	O
observed	O
,	O
have	O
benefited	O
by	O
increased	O
life	O
expectancy	O
.	O

Evaluation	O
of	O
in	O
vitro	O
and	O
in	O
vivo	O
anti-urolithiatic	O
activity	O
of	O
silver	O
nanoparticles	O
containing	O
aqueous	O
leaf	O
extract	O
of	O
Tragia	O
involucrata	O
.	O

The	O
present	O
investigation	O
is	O
focused	O
on	O
exploring	O
the	O
anti-urolithiatic	O
potential	O
of	O
aqueous	O
leaf	O
extract	O
of	O
Tragia	O
involucrata	O
(	O
TIA	O
)	O
and	O
its	O
silver	O
nanoparticles	O
(	O
AgNPs	O
)	O
and	O
to	O
quantify	O
the	O
total	O
phenol	O
,	O
flavonoid	O
,	O
terpenoid	O
and	O
sterol	O
contents	O
present	O
in	O
TIA	O
.	O

Quantification	O
results	O
suggested	O
TIA	O
to	O
be	O
a	O
rich	O
source	O
of	O
phenol	O
,	O
flavonoid	O
and	O
terpenoid	O
and	O
less	O
of	O
sterol	O
content	O
.	O

The	O
AgNPs	O
were	O
synthesized	O
by	O
a	O
simple	O
green	O
method	O
using	O
aqueous	O
extract	O
of	O
T.	O
involucrata	O
.	O

The	O
formation	O
of	O
AgNPs	O
was	O
confirmed	O
through	O
UV	B-P
spectroscopy	I-P
,	O
particle	O
size	O
analysis	O
,	O
zeta	O
potential	O
,	O
X-ray	B-P
diffraction	I-P
and	O
transmission	B-P
electron	I-P
microscopy	I-P
.	O

The	O
in	O
vitro	O
struvite	O
growth	O
inhibitory	O
activity	O
of	O
the	O
extract	O
was	O
performed	O
using	O
a	O
single	O
gel	O
diffusion	O
method	O
.	O

Samples	O
incorporated	O
with	O
higher	O
concentration	O
of	O
2	O
%	O
TIA	O
and	O
AgNPs	O
(	O
200	O
μg	O
mL	O
(	O
-1	O
)	O
)	O
exhibited	O
potent	O
crystal	O
growth	O
inhibitory	O
activity	O
which	O
was	O
further	O
supported	O
by	O
the	O
dissolution	O
of	O
crystals	O
in	O
gel	O
medium	O
.	O

Calcium	O
oxalate	O
stone	O
formation	O
was	O
induced	O
in	O
rats	O
by	O
the	O
oral	O
administration	O
of	O
ethylene	O
glycol	O
in	O
water	O
.	O

Stone	O
formation	O
was	O
assessed	O
by	O
increase	O
in	O
the	O
levels	O
of	O
calcium	O
and	O
phosphorous	O
in	O
the	O
urine	O
and	O
accumulation	O
of	O
nitrogenous	O
substances	O
like	O
urea	O
,	O
creatinine	O
in	O
renal	O
tissues	O
and	O
blood	O
.	O

Prophylactic	O
treatment	O
with	O
TIA	O
and	O
AgNPs	O
showed	O
significant	O
anti-urolithiatic	O
activity	O
with	O
normalization	O
of	O
the	O
mineral	O
contents	O
of	O
the	O
urine	O
and	O
serum	O
samples	O
.	O

Histopathological	O
analysis	O
of	O
the	O
kidney	O
of	O
TIA	O
-	O
and	O
AgNP	O
-	O
treated	O
animals	O
showed	O
no	O
CaOx	O
deposits	O
and	O
a	O
normal	O
architecture	O
of	O
the	O
kidney	O
cells	O
.	O

We	O
conclude	O
that	O
aqueous	O
extract	O
of	O
T.	O
involucrata	O
and	O
its	O
AgNPs	O
has	O
potential	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
recurrent	O
stones	O
.	O

Antiproliferative	O
and	O
apoptotic	O
effects	O
of	O
a	O
specific	O
anti-insulin-like	O
growth	O
factor	O
I	O
receptor	O
single	O
chain	O
antibody	O
on	O
breast	O
cancer	O
cells	O
.	O

Insulin-like	O
growth	O
factor	O
I	O
receptor	O
(	O
IGF-IR	O
)	O
is	O
expressed	O
on	O
breast	O
cancer	O
cells	O
and	O
involves	O
in	O
metastasis	O
,	O
survival	O
,	O
and	O
proliferation	O
.	O

Currently	O
,	O
application	O
of	O
IGF-IR	O
-targeting	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
,	O
alone	O
or	O
in	O
combination	O
with	O
other	O
drugs	O
,	O
is	O
a	O
promising	O
strategy	O
for	O
breast	O
cancer	O
therapy	O
.	O

Single-chain	O
fragment	O
variable	O
(	O
scFv	O
)	O
antibodies	O
have	O
been	O
introduced	O
as	O
appropriate	O
tools	O
for	O
tumor-targeting	O
purposes	O
because	O
of	O
their	O
advantages	O
over	O
whole	O
antibodies	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
employed	O
a	O
naïve	O
phage	O
library	O
and	O
isolated	O
scFvs	O
against	O
a	O
specific	O
epitope	O
from	O
extracellular	O
domain	O
of	O
IGF-IR	O
by	O
panning	O
process	O
.	O

The	O
selected	O
scFvs	O
were	O
further	O
characterized	O
using	O
polyclonal	B-P
and	O
monoclonal	B-P
phage	I-P
ELISA	I-P
,	O
soluble	O
monoclonal	B-P
ELISA	I-P
,	O
and	O
colony	O
PCR	O
and	O
sequencing	O
.	O

Antiproliferative	O
and	O
apoptotic	O
effects	O
of	O
selected	O
scFv	O
antibodies	O
on	O
breast	O
cancer	O
cell	O
lines	O
were	O
also	O
evaluated	O
by	O
MTT	O
and	O
Annexin	B-P
V/PI	I-P
assays	I-P
.	O

The	O
results	O
of	O
ELISA	B-P
indicated	O
specific	O
reactions	O
of	O
the	O
isolated	O
scFvs	O
against	O
the	O
IGF-IR	O
peptide	O
,	O
and	O
analyses	B-P
of	I-P
PCR	I-P
product	I-P
and	O
sequencing	O
confirmed	O
the	O
presence	O
of	O
full	O
length	O
VH	O
and	O
Vκ	O
inserts	O
.	O

Treatment	O
of	O
MCF7	O
and	O
SKBR3	O
cells	O
with	O
anti-IGF-IR	O
scFv	O
led	O
to	O
a	O
significant	O
growth	O
inhibition	O
.	O

The	O
results	O
also	O
showed	O
that	O
scFv	O
treatment	O
significantly	O
augmented	O
trastuzumab	O
growth	O
inhibitory	O
effects	O
on	O
SKBR3	O
cells	O
.	O

The	O
percentage	O
of	O
the	O
apoptotic	O
MCF7	O
and	O
SKBR3	O
cells	O
after	O
24-h	O
treatment	O
with	O
scFv	O
was	O
39	O
and	O
30.70	O
%	O
,	O
respectively	O
.	O

Twenty-four-hour	O
treatment	O
with	O
scFv	O
in	O
combination	O
with	O
trastuzumab	O
resulted	O
in	O
44.75	O
%	O
apoptosis	O
of	O
SKBR3	O
cells	O
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrate	O
that	O
the	O
targeting	O
of	O
IGF-IR	O
by	O
scFv	O
can	O
be	O
an	O
effective	O
strategy	O
in	O
the	O
treatment	O
of	O
breast	O
cancer	O
and	O
provide	O
further	O
evidence	O
for	O
effectiveness	O
of	O
dual	O
targeting	O
of	O
HER2	O
and	O
IGF-IR	O
in	O
breast	O
cancer	O
therapy	O
.	O

Evaluation	O
of	O
MIF	O
-173	O
G/C	O
Polymorphism	O
in	O
Turkish	O
Patients	O
with	O
Ankylosing	O
Spondylitis	O
.	O

Ankylosing	O
spondylitis	O
(	O
AS	O
)	O
is	O
a	O
chronic	O
inflammatory	O
disease	O
mainly	O
affecting	O
the	O
spine	O
and	O
sacroiliac	O
joints	O
.	O

Macrophage	O
migration	O
inhibitory	O
(	O
MIF	O
)	O
factor	O
is	O
a	O
regulatory	O
cytokine	O
that	O
inhibits	O
random	O
immune	O
cell	O
migration	O
.	O

MIF	O
gene	O
promoter	O
polymorphisms	O
play	O
a	O
role	O
in	O
the	O
progression	O
of	O
several	O
inflammatory	O
disorders	O
.	O

To	O
investigate	O
the	O
relationship	O
between	O
the	O
MIF	O
gene	O
-173	O
G/C	O
single-nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
and	O
AS	O
.	O

Cross-sectional	O
study	O
.	O

In	O
this	O
study	O
,	O
a	O
total	O
of	O
161	O
AS	O
and	O
194	O
normal	O
controls	O
were	O
recruited	O
.	O

The	O
MIF	O
gene	O
-173	O
G/C	O
SNP	O
was	O
analyzed	O
by	O
polymerase	O
chain	O
reaction	O
using	O
the	O
restriction	B-P
fragment	I-P
length	I-P
polymorphism	I-P
method	I-P
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
groups	O
in	O
terms	O
of	O
genotype	O
distribution	O
(	O
p	O
>	O
0.05	O
)	O
.	O

When	O
wild-type	O
G/G	O
and	O
G/C+C/C	O
genotypes	O
are	O
compared	O
in	O
terms	O
of	O
clinical	O
characteristics	O
,	O
there	O
is	O
a	O
significant	O
difference	O
between	O
the	O
average	O
age	O
and	O
the	O
duration	O
of	O
disease	O
in	O
AS	O
patients	O
(	O
p	O
<	O
0.05	O
)	O
.	O

No	O
significant	O
relationship	O
between	O
AS	O
disease	O
and	O
MIF	O
-173	O
G/C	O
polymorphism	O
was	O
found	O
.	O

MIF	O
-173	O
G/C	O
polymorphism	O
(	O
C	O
allele	O
)	O
may	O
affect	O
the	O
time	O
of	O
onset	O
and	O
the	O
duration	O
of	O
disease	O
in	O
AS	O
patients	O
.	O

Prognostic	O
implications	O
of	O
the	O
intrinsic	O
molecular	O
subtypes	O
in	O
male	O
breast	O
cancer	O
.	O

Intrinsic	B-P
molecular	I-P
subtyping	I-P
has	O
been	O
widely	O
used	O
in	O
female	O
breast	O
cancer	O
,	O
and	O
it	O
has	O
proven	O
its	O
significance	O
.	O

In	O
this	O
article	O
,	O
we	O
aimed	O
to	O
study	O
the	O
intrinsic	O
subtypes	O
of	O
male	O
breast	O
cancer	O
(	O
MBC	O
)	O
in	O
correlation	O
with	O
clinicopathological	O
features	O
.	O

We	O
retrospectively	O
identified	O
130	O
MBC	O
cases	O
from	O
2004	O
to	O
2013	O
.	O

Intrinsic	O
molecular	O
subtypes	O
were	O
determined	O
by	O
immunohistochemistry	B-P
(	O
IHC	B-P
)	O
.	O

From	O
a	O
total	O
of	O
130	O
MBC	O
cases	O
,	O
45.4	O
%	O
of	O
tumors	O
were	O
luminal	O
A	O
subtype	O
,	O
44.6	O
%	O
were	O
luminal	O
B	O
,	O
5	O
%	O
were	O
HER2	O
positive	O
and	O
5	O
%	O
were	O
triple	O
negative	O
tumors	O
.	O

There	O
were	O
statistically	O
significant	O
differences	O
between	O
different	O
IHC	B-P
intrinsic	O
subtypes	O
regarding	O
tumor	O
size	O
(	O
p=0.001	O
)	O
,	O
estrogen	O
receptor	O
(	O
ER	O
)	O
status	O
(	O
p=0.001	O
)	O
,	O
progesterone	O
receptor	O
(	O
PR	O
)	O
status	O
(	O
p=0.001	O
)	O
,	O
HER2	O
status	O
(	O
p=0.001	O
)	O
and	O
Ki67	O
proliferation	O
index	O
(	O
p=0.001	O
)	O
.	O

The	O
distribution	O
of	O
breast	O
cancer	O
intrinsic	O
subtypes	O
in	O
males	O
is	O
different	O
compared	O
to	O
its	O
female	O
counterpart	O
;	O
however	O
,	O
they	O
do	O
n't	O
seem	O
to	O
give	O
the	O
same	O
prognostic	O
value	O
.	O

Airway	O
inflammation	O
phenotype	O
prediction	O
in	O
asthma	O
patients	O
using	O
lung	O
sound	B-P
analysis	I-P
with	O
fractional	O
exhaled	O
nitric	O
oxide	O
.	O

We	O
previously	O
reported	O
the	O
results	O
of	O
lung	O
sound	B-P
analysis	I-P
in	O
patients	O
with	O
bronchial	O
asthma	O
and	O
demonstrated	O
that	O
the	O
exhalation	O
-to-	O
inhalation	O
sound	O
pressure	O
ratio	O
in	O
the	O
low	O
frequency	O
range	O
between	O
100	O
and	O
200	O
Hz	O
(	O
E/I	O
LF	O
)	O
was	O
correlated	O
with	O
the	O
presence	O
of	O
airway	O
inflammation	O
and	O
airway	O
obstruction	O
.	O

We	O
classified	O
asthma	O
patients	O
by	O
airway	O
inflammation	O
phenotype	O
using	O
the	O
induced	O
sputum	O
eosinophil	O
and	O
neutrophil	O
ratio	O
and	O
determined	O
whether	O
this	O
phenotype	O
could	O
be	O
predicted	O
using	O
E/I	O
LF	O
and	O
fractional	O
exhaled	O
nitric	O
oxide	O
values	O
.	O

Steroid-naive	O
bronchial	O
asthma	O
patients	O
were	O
classified	O
into	O
four	O
phenotypes	O
,	O
including	O
``	O
Low	O
inflammation	O
``	O
(	O
35	O
patients	O
)	O
,	O
``	O
Eosinophilic	O
type	O
``	O
(	O
58	O
patients	O
)	O
,	O
``	O
Neutrophilic	O
type	O
``	O
(	O
15	O
patients	O
)	O
,	O
and	O
``	O
Mixed	O
type	O
``	O
(	O
15	O
patients	O
)	O
based	O
on	O
the	O
results	O
of	O
induced	O
sputum	O
examinations	O
.	O

The	O
E/I	O
LF	O
data	O
and	O
FeNO	O
levels	O
were	O
then	O
evaluated	O
for	O
the	O
four	O
phenotype	O
groups	O
;	O
the	O
prediction	O
powers	O
of	O
these	O
two	O
indices	O
were	O
then	O
analyzed	O
for	O
each	O
phenotype	O
.	O

The	O
median	O
E/I	O
LF	O
value	O
was	O
highest	O
in	O
the	O
``	O
Mixed	O
type	O
``	O
and	O
lowest	O
in	O
the	O
``	O
Low	O
inflammation	O
``	O
group	O
.	O

FeNO	O
differentiated	O
between	O
the	O
``	O
Low	O
inflammation	O
``	O
and	O
``	O
Eosinophilic	O
type	O
``	O
groups	O
,	O
``	O
Low	O
inflammation	O
``	O
and	O
``	O
Neutrophilic	O
type	O
``	O
groups	O
,	O
and	O
``	O
Neutrophilic	O
type	O
``	O
and	O
``	O
Mixed	O
type	O
``	O
(	O
p	O
<	O
0.0001	O
,	O
p	O
=	O
0.007	O
,	O
and	O
p	O
=	O
0.04	O
,	O
respectively	O
)	O
.	O

E/I	O
LF	O
differentiated	O
between	O
the	O
``	O
Low	O
inflammation	O
``	O
and	O
``	O
Eosinophilic	O
type	O
``	O
groups	O
(	O
p	O
=	O
0.006	O
)	O
.	O

E/I	O
LF	O
could	O
distinguish	O
the	O
``	O
Mixed	O
type	O
``	O
group	O
from	O
the	O
``	O
Low	O
inflammation	O
``	O
and	O
``	O
Eosinophilic	O
type	O
``	O
groups	O
(	O
p	O
=	O
0.002	O
)	O
.	O

A	O
combination	O
of	O
the	O
E/I	O
LF	O
value	O
and	O
FeNO	O
may	O
be	O
useful	O
for	O
the	O
classification	O
of	O
the	O
airway	O
inflammation	O
phenotype	O
in	O
patients	O
with	O
bronchial	O
asthma	O
.	O

Use	O
of	O
Platelet	B-P
Function	I-P
Testing	I-P
Before	O
Pipeline	O
Embolization	O
Device	O
Placement	O
:	O
A	O
Multicenter	O
Cohort	O
Study	O
.	O

Thromboembolic	O
complications	O
constitute	O
a	O
significant	O
source	O
of	O
morbidity	O
after	O
neurointerventional	O
procedures	O
.	O

Flow	O
diversion	O
using	O
the	O
pipeline	O
embolization	O
device	O
for	O
the	O
treatment	O
of	O
intracranial	O
aneurysms	O
necessitates	O
the	O
use	O
of	O
dual	O
antiplatelet	O
therapy	O
to	O
reduce	O
this	O
risk	O
.	O

The	O
use	O
of	O
platelet	B-P
function	I-P
testing	I-P
before	O
pipeline	O
embolization	O
device	O
placement	O
remains	O
controversial	O
.	O

A	O
retrospective	O
review	O
of	O
prospectively	O
maintained	O
databases	O
at	O
3	O
academic	O
institutions	O
was	O
performed	O
from	O
the	O
years	O
2009	O
to	O
2016	O
to	O
identify	O
patients	O
with	O
intracranial	O
aneurysms	O
treated	O
with	O
pipeline	O
embolization	O
device	O
placement	O
.	O

Clinical	O
and	O
radiographic	O
data	O
were	O
analyzed	O
with	O
emphasis	O
on	O
thromboembolic	O
complications	O
and	O
clopidogrel	O
responsiveness	O
.	O

A	O
total	O
of	O
402	O
patients	O
underwent	O
414	O
pipeline	O
embolization	O
device	O
procedures	O
for	O
the	O
treatment	O
of	O
465	O
intracranial	O
aneurysms	O
.	O

Thromboembolic	O
complications	O
were	O
encountered	O
in	O
9.2	O
%	O
of	O
procedures	O
and	O
were	O
symptomatic	O
in	O
5.6	O
%	O
.	O

Clopidogrel	O
nonresponders	O
experienced	O
a	O
significantly	O
higher	O
rate	O
of	O
thromboembolic	O
complications	O
compared	O
with	O
clopidogrel	O
responders	O
(	O
17.4	O
%	O
versus	O
5.6	O
%	O
)	O
.	O

This	O
risk	O
was	O
significantly	O
lower	O
in	O
nonresponders	O
who	O
were	O
switched	O
to	O
ticagrelor	O
when	O
compared	O
with	O
patients	O
who	O
remained	O
on	O
clopidogrel	O
(	O
2.7	O
%	O
versus	O
24.4	O
%	O
)	O
.	O

In	O
patients	O
who	O
remained	O
on	O
clopidogrel	O
,	O
the	O
rate	O
of	O
thromboembolic	O
complications	O
was	O
significantly	O
lower	O
in	O
those	O
who	O
received	O
a	O
clopidogrel	O
boost	O
within	O
24	O
hours	O
pre-procedure	O
when	O
compared	O
with	O
those	O
who	O
did	O
not	O
(	O
9.8	O
%	O
versus	O
51.9	O
%	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
rate	O
of	O
hemorrhagic	O
complications	O
between	O
groups	O
.	O

Clopidogrel	O
nonresponders	O
experienced	O
a	O
significantly	O
higher	O
rate	O
of	O
thromboembolic	O
complications	O
when	O
compared	O
with	O
clopidogrel	O
responders	O
.	O

However	O
,	O
this	O
risk	O
seems	O
to	O
be	O
mitigated	O
in	O
nonresponders	O
who	O
were	O
switched	O
to	O
ticagrelor	O
or	O
received	O
a	O
clopidogrel	O
boost	O
within	O
24	O
hours	O
pre-procedure	O
.	O

The	O
Psychometric	B-P
Costs	I-P
of	O
Applicants	O
'	O
Faking	O
:	O
Examining	O
Measurement	O
Invariance	O
and	O
Retest	O
Correlations	O
Across	O
Response	O
Conditions	O
.	O

This	O
study	O
examines	O
the	O
stability	O
of	O
the	O
response	O
process	O
and	O
the	O
rank-order	O
of	O
respondents	O
responding	O
to	O
3	O
personality	O
scales	O
in	O
4	O
different	O
response	O
conditions	O
.	O

Applicants	O
to	O
the	O
University	O
College	O
of	O
Teacher	O
Education	O
Styria	O
(	O
N	O
=	O
243	O
)	O
completed	O
personality	O
scales	O
as	O
part	O
of	O
their	O
college	O
admission	O
process	O
.	O

Half	O
a	O
year	O
later	O
,	O
they	O
retook	O
the	O
same	O
personality	O
scales	O
in	O
1	O
of	O
3	O
randomly	O
assigned	O
experimental	O
response	O
conditions	O
:	O
honest	O
,	O
faking-good	O
,	O
or	O
reproduce	O
.	O

Longitudinal	O
means	O
and	O
covariance	O
structure	O
analyses	O
showed	O
that	O
applicants	O
'	O
response	O
processes	O
could	O
be	O
partially	O
reproduced	O
after	O
half	O
a	O
year	O
,	O
and	O
respondents	O
seemed	O
to	O
rely	O
on	O
an	O
honest	O
response	O
behavior	O
as	O
a	O
frame	O
of	O
reference	O
.	O

Additionally	O
,	O
applicants	O
'	O
faking	O
behavior	O
and	O
instructed	O
faking	O
(	O
faking-good	O
)	O
caused	O
differences	O
in	O
the	O
latent	O
retest	O
correlations	O
and	O
consistently	O
affected	O
measurement	O
properties	O
.	O

The	O
varying	O
latent	O
retest	O
correlations	O
indicated	O
that	O
faking	O
can	O
distort	O
respondents	O
'	O
rank-order	O
and	O
thus	O
the	O
fairness	O
of	O
subsequent	O
selection	O
decisions	O
,	O
depending	O
on	O
the	O
kind	O
of	O
faking	O
behavior	O
.	O

Instructed	O
faking	O
(	O
faking-good	O
)	O
even	O
affected	O
weak	O
measurement	O
invariance	O
,	O
whereas	O
applicants	O
'	O
faking	O
behavior	O
did	O
not	O
.	O

Consequently	O
,	O
correlations	O
with	O
personality	O
scales	O
-which	O
can	O
be	O
utilized	O
for	O
predictive	O
validity	O
-may	O
be	O
readily	O
interpreted	O
for	O
applicants	O
.	O

Faking	O
behavior	O
also	O
introduced	O
a	O
uniform	O
bias	O
,	O
implying	O
that	O
the	O
classically	O
observed	O
mean	O
raw	O
score	O
differences	O
may	O
not	O
be	O
readily	O
interpreted	O
.	O

Enhanced	O
gastric	O
stability	O
of	O
esomeprazole	O
by	O
molecular	O
interaction	O
and	O
modulation	O
of	O
microenvironmental	O
pH	O
with	O
alkalizers	O
in	O
solid	O
dispersion	O
.	O

Due	O
to	O
the	O
instability	O
of	O
esomeprazole	O
magnesium	O
dihydrate	O
(	O
EPM	O
)	O
,	O
a	O
proton	O
pump	O
inhibitor	O
,	O
in	O
gastric	O
fluid	O
,	O
enteric-coated	O
dosage	O
form	O
is	O
commonly	O
used	O
for	O
therapeutic	O
application	O
.	O

In	O
this	O
study	O
,	O
we	O
prepared	O
new	O
gastric	O
fluid	O
resistant	O
solid	O
dispersions	O
(	O
SDs	O
)	O
containing	O
alkalizers	O
.	O

Then	O
,	O
new	O
mechanistic	O
evidence	O
regarding	O
the	O
effects	O
of	O
pharmaceutical	O
alkalizers	O
on	O
the	O
aqueous	O
stability	O
of	O
EPM	O
in	O
simulated	O
gastric	O
fluid	O
was	O
investigated	O
.	O

The	O
alkalizer	O
-loaded	O
SD	O
were	O
prepared	O
by	O
dissolving	O
or	O
dispersing	O
EPM	O
,	O
hydroxypropyl	O
methylcellulose	O
(	O
HPMC	O
)	O
6	O
cps	O
,	O
and	O
an	O
alkalizer	O
,	O
in	O
ethanol	O
50	O
%	O
(	O
v/v	O
)	O
followed	O
by	O
spray	B-P
drying	I-P
.	O

Nine	O
different	O
alkalizer	O
s	O
were	O
assessed	O
for	O
in	O
vitro	O
stability	O
in	O
two	O
media	O
,	O
simulated	O
gastric	O
fluid	O
(	O
pH	O
1.2	O
buffer	O
)	O
and	O
simulated	O
intestinal	O
fluid	O
(	O
pH	O
6.8	O
buffer	O
)	O
.	O

The	O
microenvironmental	O
pH	O
(	O
pHM	O
)	O
was	O
measured	O
to	O
evaluate	O
the	O
effect	O
of	O
the	O
alkalizer	O
on	O
the	O
pHM	O
of	O
SDs	O
.	O

Drug	O
crystallinity	O
and	O
morphology	O
of	O
the	O
SDs	O
were	O
also	O
examined	O
by	O
differential	B-P
scanning	I-P
calorimetry	I-P
(	O
DSC	B-P
)	O
,	O
powder	B-P
X-ray	I-P
diffraction	I-P
(	O
PXRD	B-P
)	O
,	O
and	O
scanning	B-P
electron	I-P
microscopy	I-P
(	O
SEM	B-P
)	O
.	O

The	O
interactions	O
among	O
EPM	O
,	O
the	O
polymer	O
,	O
and	O
the	O
alkalizer	O
were	O
elucidated	O
by	O
Fourier	O
transform	O
infrared	O
(	O
FTIR	O
)	O
spectroscopy	O
.	O

The	O
in	O
vivo	O
absorption	O
studies	O
of	O
the	O
optimized	O
alkalizer	O
-containing	O
SD	O
and	O
the	O
enteric-coated	O
reference	O
tablet	O
Nexium	O
(	O
®	O
)	O
were	O
then	O
conducted	O
in	O
beagle	O
dogs	O
.	O

Among	O
alkalizer	O
s	O
,	O
MgO	O
loaded	O
in	O
SDs	O
proved	O
to	O
be	O
the	O
best	O
alkalizer	O
to	O
stabilize	O
EPM	O
in	O
simulated	O
gastric	O
fluid	O
.	O

pHM	O
values	O
of	O
the	O
alkalizer	O
-containing	O
SDs	O
were	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
SD	O
without	O
alkalizer	O
.	O

The	O
pHM	O
values	O
decreased	O
in	O
the	O
following	O
order	O
:	O
MgO	O
,	O
Na2CO3	O
,	O
Ca	O
(	O
OH	O
)	O
2	O
,	O
and	O
no	O
alkalizer	O
.	O

DSC	B-P
and	O
PXRD	B-P
data	O
exhibited	O
a	O
change	O
in	O
the	O
drug	O
crystallinity	O
of	O
the	O
SDs	O
from	O
crystalline	O
to	O
amorphous	O
form	O
.	O

SEM	B-P
data	O
showed	O
a	O
relatively	O
spherical	O
shape	O
of	O
the	O
MgO	O
-loaded	O
SD	O
compared	O
to	O
the	O
less-defined	O
shape	O
of	O
pure	O
drug	O
.	O

FTIR	O
indicated	O
a	O
strong	O
molecular	O
interaction	O
among	O
EPM	O
,	O
alkalizer	O
and	O
polymer	O
;	O
in	O
particular	O
,	O
MgO	O
showed	O
the	O
strongest	O
interaction	O
with	O
EPM	O
.	O

It	O
was	O
evident	O
that	O
alkalizer	O
interacts	O
with	O
benzimidazole	O
ring	O
and/or	O
sulfonyl	O
group	O
of	O
EPM	O
for	O
enhancing	O
EPM	O
stability	O
in	O
gastric	O
fluid	O
.	O

Regarding	O
the	O
in	O
vivo	O
absorption	O
studies	O
in	O
beagle	O
dogs	O
,	O
the	O
optimized	O
SD	O
(	O
C16	O
)	O
was	O
bioequivalent	O
to	O
the	O
reference	O
Nexium	O
(	O
®	O
)	O
and	O
had	O
a	O
considerable	O
greater	O
absorption	O
at	O
the	O
early	O
stages	O
.	O

The	O
current	O
alkalizer	O
-containing	O
SD	O
could	O
provide	O
a	O
promising	O
approach	O
for	O
aqueous	O
stabilization	O
of	O
acid	O
-	O
labile	O
drugs	O
without	O
using	O
enteric	O
coating	O
method	O
.	O

Prediction	O
of	O
extravasation	O
in	O
pelvic	O
fracture	O
using	O
coagulation	O
biomarkers	O
.	O

To	O
evaluate	O
the	O
usefulness	O
of	O
coagulation	O
biomarkers	O
,	O
which	O
are	O
easy	O
and	O
quick	O
to	O
analyze	O
in	O
emergency	O
settings	O
,	O
for	O
prediction	O
of	O
arterial	O
extravasation	O
due	O
to	O
pelvic	O
fracture	O
.	O

The	O
medical	O
records	O
of	O
pelvic	O
fracture	O
patients	O
transferred	O
to	O
the	O
emergency	O
department	O
of	O
Gunma	O
University	O
Hospital	O
between	O
December	O
2009	O
and	O
May	O
2015	O
were	O
reviewed	O
.	O

Patients	O
were	O
divided	O
into	O
two	O
groups	O
,	O
those	O
with	O
(	O
Extra	O
(	O
+	O
)	O
)	O
and	O
without	O
(	O
Extra	O
(	O
-	O
)	O
)	O
arterial	O
extravasation	O
on	O
enhanced	O
CT	B-P
or	O
angiography	B-P
.	O

Levels	O
of	O
fibrin	B-P
degradation	I-P
products	I-P
(	O
FDP	B-P
)	O
,	O
D-dimer	B-P
,	O
fibrinogen	B-P
,	O
the	O
ratio	B-P
of	I-P
FDP	I-P
to	I-P
fibrinogen	I-P
,	O
the	O
ratio	B-P
of	I-P
D-dimer	I-P
to	I-P
fibrinogen	I-P
,	O
systolic	O
blood	O
pressure	O
,	O
heart	O
rate	O
,	O
the	O
Glasgow	O
Coma	O
Scale	O
,	O
pH	O
,	O
base	B-P
excess	I-P
,	O
hemoglobin	B-P
and	O
lactate	B-P
levels	O
,	O
the	O
pattern	O
of	O
pelvic	O
injury	O
,	O
and	O
injury	O
severity	O
score	O
were	O
measured	O
at	O
hospital	O
admission	O
,	O
and	O
compared	O
between	O
the	O
two	O
groups	O
.	O

Parameters	O
with	O
a	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
were	O
used	O
to	O
construct	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curves	O
.	O

The	O
study	O
included	O
29	O
patients	O
with	O
pelvic	O
fracture	O
.	O

FDP	O
,	O
D-dimer	O
,	O
the	O
ratio	O
of	O
FDP	O
to	O
fibrinogen	O
and	O
the	O
ratio	O
of	O
D-dimer	O
to	O
fibrinogen	O
were	O
the	O
most	O
useful	O
parameters	O
for	O
predicting	O
arterial	O
extravasation	O
due	O
to	O
pelvic	O
fracture	O
.	O

FDP	O
,	O
D-dimer	O
,	O
the	O
ratio	O
of	O
FDP	O
to	O
fibrinogen	O
,	O
the	O
ratio	O
of	O
D-dimer	O
to	O
fibrinogen	O
,	O
and	O
hemoglobin	O
and	O
lactate	O
levels	O
were	O
significantly	O
higher	O
in	O
the	O
Extra	O
(	O
+	O
)	O
group	O
than	O
in	O
the	O
Extra	O
(	O
-	O
)	O
group	O
(	O
FDP	O
,	O
354.8μg/mL	O
[	O
median	O
]	O
versus	O
96.6μg/mL	O
;	O
D-dimer	O
,	O
122.3μg/mL	O
versus	O
42.1μg/mL	O
;	O
the	O
ratio	O
of	O
FDP	O
to	O
fibrinogen	O
,	O
3.39	O
versus	O
0.42	O
;	O
the	O
ratio	O
of	O
D-dimer	O
to	O
fibrinogen	O
,	O
1.14	O
versus	O
0.18	O
;	O
hemoglobin	O
,	O
10.5g/dL	O
versus	O
13.5g/dL	O
;	O
lactate	O
,	O
3.5mmol/L	O
versus	O
1.7mmol/L	O
)	O
.	O

The	O
area	O
under	O
the	O
ROC	O
curves	O
for	O
FDP	O
,	O
D-dimer	O
,	O
the	O
ratio	O
of	O
FDP	O
to	O
fibrinogen	O
,	O
the	O
ratio	O
of	O
D-dimer	O
to	O
fibrinogen	O
,	O
hemoglobin	O
and	O
lactate	O
levels	O
were	O
0.900	O
,	O
0.882	O
,	O
0.918	O
,	O
0.900	O
,	O
0.815	O
and	O
0.765	O
,	O
respectively	O
.	O

Coagulation	O
biomarkers	O
,	O
and	O
hemoglobin	O
and	O
lactate	O
levels	O
could	O
be	O
useful	O
to	O
predict	O
the	O
existence	O
of	O
arterial	O
extravasation	O
due	O
to	O
pelvic	O
fracture	O
.	O

The	O
ratio	O
of	O
FDP	O
to	O
fibrinogen	O
and	O
the	O
ratio	O
of	O
D-dimer	O
to	O
fibrinogen	O
were	O
the	O
most	O
accurate	O
markers	O
.	O

Coagulation	O
biomarkers	O
may	O
enable	O
more	O
rapid	O
and	O
specific	O
treatment	O
for	O
pelvic	O
fracture	O
.	O

Antenatal	O
consultation	O
following	O
limb	O
malformation	O
discovery	O
using	O
ultrasound	B-P
scan	I-P
.	O

Our	O
unit	O
has	O
been	O
providing	O
antenatal	O
consultations	O
for	O
30	O
years	O
following	O
the	O
discovery	O
of	O
limb	O
malformation	O
with	O
the	O
fetus	O
.	O

Each	O
of	O
these	O
consultations	O
is	O
specific	O
and	O
carried	O
out	O
by	O
a	O
multi-professional	O
team	O
.	O

It	O
requires	O
a	O
physical	O
and	O
rehabilitation	O
doctor	O
,	O
an	O
orthopedic	O
surgeon	O
,	O
an	O
occupational	O
therapist	O
for	O
upper	O
limb	O
malformation	O
,	O
a	O
physiotherapist	O
for	O
lower	O
malformation	O
and	O
a	O
psychologist	O
.	O

This	O
multidisciplinary	O
consultation	O
is	O
unique	O
because	O
of	O
each	O
pregnancy	O
story	O
,	O
because	O
of	O
each	O
patient	O
life	O
story	O
but	O
also	O
because	O
of	O
the	O
words	O
used	O
by	O
the	O
sonologist	O
when	O
announcing	O
the	O
diagnosis	O
.	O

We	O
deal	O
with	O
couples	O
shocked	O
by	O
the	O
prenatal	B-P
diagnosis	I-P
.	O

We	O
help	O
them	O
get	O
acceptance	O
of	O
the	O
child	O
to	O
be	O
born	O
and	O
to	O
forget	O
about	O
their	O
imaginary	O
child	O
.	O

Medical	O
information	O
is	O
often	O
perceived	O
as	O
being	O
``	O
a	O
surfeit	O
of	O
information	O
``	O
difficult	O
to	O
handle	O
by	O
the	O
couple	O
stunned	O
by	O
the	O
overwhelming	O
diagnosis	O
.	O

We	O
must	O
stress	O
that	O
it	O
is	O
critical	O
to	O
not	O
only	O
have	O
a	O
good	O
medical	O
description	O
of	O
the	O
malformations	O
and	O
potential	O
treatments	O
but	O
also	O
a	O
good	O
psychological	O
support	O
(	O
parents	O
personal	O
life	O
story	O
,	O
self-defense	O
mechanism	O
,	O
guilt	O
feeling	O
)	O
.	O

The	O
ethical	O
aspect	O
of	O
this	O
consultation	O
is	O
also	O
important	O
.	O

Team	O
members	O
must	O
be	O
as	O
neutral	O
as	O
possible	O
in	O
their	O
assessments	O
in	O
order	O
to	O
let	O
the	O
couple	O
take	O
the	O
final	O
decision	O
:	O
the	O
continuation	O
of	O
the	O
pregnancy	O
or	O
a	O
request	O
of	O
voluntary	O
termination	O
of	O
pregnancy	O
.	O

These	O
prenatal	O
consultations	O
highlight	O
the	O
importance	O
of	O
the	O
multidisciplinary	O
global	O
care	O
.	O

Effect	O
of	O
alpha	O
lipoic	O
acid	O
on	O
in	O
vitro	O
development	O
of	O
bovine	O
secondary	O
preantral	O
follicles	O
.	O

The	O
present	O
study	O
aimed	O
to	O
evaluate	O
the	O
in	O
vitro	O
effect	O
of	O
alpha	O
lipoic	O
acid	O
(	O
ALA	O
)	O
addition	O
to	O
the	O
culture	O
medium	O
on	O
the	O
development	O
of	O
the	O
bovine	O
secondary	O
preantral	O
follicles	O
.	O

Bovine	O
secondary	O
preantral	O
follicles	O
were	O
collected	O
and	O
divided	O
into	O
two	O
groups	O
depending	O
on	O
their	O
size	O
(	O
80-100	O
μm	O
and	O
100-110	O
μm	O
)	O
.	O

They	O
were	O
cultured	O
in	O
vitro	O
for	O
15	O
days	O
(	O
D	O
)	O
using	O
different	O
media	O
including	O
at	O
three	O
different	O
doses	O
of	O
ALA	O
.	O

The	O
genes	O
expression	O
levels	O
of	O
follicle-stimulating	O
hormone	O
beta-subunit	O
(	O
FSHR	O
)	O
,	O
insulin-like	O
growth	O
factor	O
(	O
IGF-1	O
)	O
,	O
Activin	O
,	O
luteinizing	O
hormone/choriogonadotropin	O
receptor	O
,	O
bone	O
morphogenetic	O
protein	O
receptor	O
type	O
IA	O
,	O
transforming	O
growth	O
factor	O
beta	O
receptor	O
1	O
,	O
growth	O
differentiation	O
factor	O
9	O
,	O
BCL2-associated	O
X	O
protein	O
(	O
BAX	O
)	O
,	O
and	O
C-Myc	O
were	O
studied	O
using	O
real-time	O
polymerase	O
chain	O
reaction	O
.	O

The	O
protein	O
expression	O
levels	O
of	O
FSHR	O
,	O
IGF-1	O
,	O
and	O
BAX	O
were	O
measured	O
using	O
Western	B-P
blot	I-P
analysis	I-P
.	O

The	O
results	O
of	O
the	O
present	O
work	O
revealed	O
that	O
in	O
vitro	O
addition	O
of	O
ALA	O
-	O
induced	O
significant	O
increase	O
in	O
the	O
growth	O
and	O
development	O
of	O
secondary	O
preantral	O
follicles	O
throughout	O
the	O
culture	B-P
period	O
as	O
compared	O
to	O
control	O
.	O

The	O
FSHR	O
,	O
IGF-1	O
,	O
luteinizing	O
hormone/choriogonadotropin	O
receptor	O
,	O
bone	O
morphogenetic	O
protein	O
receptor	O
type	O
IA	O
,	O
transforming	O
growth	O
factor	O
beta	O
receptor	O
1	O
,	O
growth	O
differentiation	O
factor	O
9	O
,	O
and	O
Activin	O
A	O
genes	O
were	O
upregulated	O
in	O
ALA	O
-	O
treated	O
follicles	O
as	O
compared	O
to	O
the	O
control	O
.	O

On	O
contrary	O
,	O
preapoptotic	O
genes	O
BAX	O
and	O
C-Myc	O
were	O
downregulated	O
in	O
treated	O
follicles	O
compared	O
to	O
control	O
ones	O
.	O

The	O
protein	O
levels	O
of	O
FSHR	O
and	O
IGF-1	O
were	O
highly	O
expressed	O
in	O
treated	O
follicles	O
compared	O
to	O
control	O
;	O
however	O
,	O
BAX	O
protein	O
was	O
downregulated	O
in	O
the	O
treated	O
follicles	O
groups	O
.	O

The	O
addition	O
of	O
ALA	O
to	O
the	O
culture	O
medium	O
enhances	O
secondary	O
preantral	O
follicles	O
development	O
and	O
growth	O
.	O

Conventional	O
and	O
Iontophoresis	O
Corneal	O
Cross-Linking	O
for	O
Keratoconus	O
:	O
Efficacy	O
and	O
Assessment	O
by	O
Optical	B-P
Coherence	I-P
Tomography	I-P
and	O
Confocal	B-P
Microscopy	I-P
.	O

To	O
compare	O
the	O
efficacy	O
,	O
safety	O
,	O
and	O
microstructural	O
corneal	O
changes	O
during	O
2	O
years	O
after	O
conventional	O
corneal	O
collagen	O
cross-linking	O
(	O
C	O
-	O
CXL	O
)	O
and	O
transepithelial	O
corneal	O
CXL	O
by	O
iontophoresis	O
(	O
I	O
-	O
CXL	O
)	O
for	O
keratoconus	O
.	O

Eighty	O
eyes	O
of	O
80	O
patients	O
with	O
progressive	O
keratoconus	O
were	O
treated	O
by	O
C	O
-	O
CXL	O
(	O
n	O
=	O
40	O
)	O
or	O
I	O
-	O
CXL	O
(	O
n	O
=	O
40	O
)	O
.	O

Patients	O
were	O
investigated	O
before	O
surgery	O
and	O
1	O
,	O
3	O
,	O
6	O
,	O
12	O
,	O
and	O
24	O
months	O
after	O
treatment	O
.	O

We	O
measured	O
central	O
corneal	O
thickness	O
and	O
maximal	O
simulated	O
keratometry	O
values	O
(	O
Kmax	O
)	O
and	O
performed	O
specular	B-P
microscopy	I-P
and	O
in	O
vivo	O
confocal	B-P
microscopy	I-P
at	O
each	O
time	O
point	O
.	O

The	O
demarcation	O
line	O
was	O
assessed	O
1	O
month	O
after	O
treatment	O
.	O

Kmax	O
remained	O
stable	O
after	O
I	O
-	O
CXL	O
during	O
the	O
entire	O
study	O
period	O
(	O
P	O
=	O
0.56	O
)	O
,	O
whereas	O
the	O
average	O
keratometry	O
increased	O
by	O
0.2	O
diopter	O
(	O
50.9	O
±	O
5.6-51.1	O
±	O
5.2	O
)	O
.	O

Kmax	O
significantly	O
decreased	O
1	O
(	O
P	O
=	O
0.02	O
)	O
to	O
2	O
years	O
(	O
P	O
<	O
0.01	O
)	O
after	O
C	O
-	O
CXL	O
,	O
with	O
an	O
average	O
decrease	O
of	O
1.1	O
diopters	O
(	O
49.9	O
±	O
4.5-48.8	O
±	O
4.2	O
)	O
.	O

The	O
failure	O
rate	O
of	O
I	O
-	O
CXL	O
was	O
20	O
%	O
and	O
that	O
of	O
C	O
-	O
CXL	O
7.5	O
%	O
.	O

The	O
demarcation	O
line	O
was	O
superficially	O
visible	O
in	O
35	O
%	O
of	O
cases	O
after	O
I	O
-	O
CXL	O
compared	O
with	O
95	O
%	O
of	O
cases	O
after	O
C	O
-	O
CXL	O
.	O

Endothelial	O
cell	O
density	O
and	O
central	O
corneal	O
thickness	O
remained	O
stable	O
during	O
the	O
entire	O
study	O
period	O
.	O

The	O
change	O
in	O
Kmax	O
2	O
years	O
after	O
C	O
-	O
CXL	O
and	O
I	O
-	O
CXL	O
and	O
the	O
preoperative	O
Kmax	O
were	O
negatively	O
correlated	O
(	O
r	O
=	O
0.14	O
,	O
P	O
=	O
0.013	O
,	O
and	O
r	O
=	O
0.17	O
,	O
P	O
=	O
0.007	O
,	O
respectively	O
)	O
.	O

I	O
-	O
CXL	O
halted	O
progression	O
of	O
keratoconus	O
less	O
efficiently	O
than	O
did	O
C	O
-	O
CXL	O
after	O
2	O
years	O
of	O
follow-up	O
.	O

Longer	O
prospective	O
studies	O
are	O
still	O
needed	O
to	O
ensure	O
I	O
-	O
CXL	O
efficacy	O
.	O

Amphetamine	O
Withdrawal	O
Differentially	O
Increases	O
the	O
Expression	O
of	O
Organic	O
Cation	O
Transporter	O
3	O
and	O
Serotonin	O
Transporter	O
in	O
Limbic	O
Brain	O
Regions	O
.	O

Amphetamine	O
withdrawal	O
increases	O
anxiety	O
and	O
stress	O
sensitivity	O
related	O
to	O
blunted	O
ventral	O
hippocampus	O
(	O
vHipp	O
)	O
and	O
enhances	O
the	O
central	O
nucleus	O
of	O
the	O
amygdala	O
(	O
CeA	O
)	O
serotonin	O
responses	O
.	O

Extracellular	O
serotonin	O
levels	O
are	O
regulated	O
by	O
the	O
serotonin	O
transporter	O
(	O
SERT	O
)	O
and	O
organic	O
cation	O
transporter	O
3	O
(	O
OCT3	O
)	O
,	O
and	O
vHipp	O
OCT3	O
expression	O
is	O
enhanced	O
during	O
24	O
hours	O
of	O
amphetamine	O
withdrawal	O
,	O
while	O
SERT	O
expression	O
is	O
unaltered	O
.	O

Here	O
,	O
we	O
tested	O
whether	O
OCT3	O
and	O
SERT	O
expression	O
in	O
the	O
CeA	O
is	O
also	O
affected	O
during	O
acute	O
withdrawal	O
to	O
explain	O
opposing	O
regional	O
alterations	O
in	O
limbic	O
serotonergic	O
neurotransmission	O
and	O
if	O
respective	O
changes	O
continued	O
with	O
two	O
weeks	O
of	O
withdrawal	O
.	O

We	O
also	O
determined	O
whether	O
changes	O
in	O
transporter	O
expression	O
were	O
confined	O
to	O
these	O
regions	O
.	O

Male	O
rats	O
received	O
amphetamine	O
or	O
saline	O
for	O
two	O
weeks	O
followed	O
by	O
24	O
hours	O
or	O
two	O
weeks	O
of	O
withdrawal	O
,	O
with	O
transporter	O
expression	O
measured	O
using	O
Western	B-P
immunoblot	I-P
.	O

OCT3	O
and	O
SERT	O
expression	O
increased	O
in	O
the	O
CeA	O
at	O
both	O
withdrawal	O
timepoints	O
.	O

In	O
the	O
vHipp	O
,	O
OCT3	O
expression	O
increased	O
only	O
at	O
24	O
hours	O
of	O
withdrawal	O
,	O
with	O
an	O
equivalent	O
pattern	O
seen	O
in	O
the	O
dorsomedial	O
hypothalamus	O
.	O

No	O
changes	O
were	O
evident	O
in	O
any	O
other	O
regions	O
sampled	O
.	O

These	O
regionally	O
specific	O
changes	O
in	O
limbic	O
OCT3	O
and	O
SERT	O
expression	O
may	O
partially	O
contribute	O
to	O
the	O
serotonergic	O
imbalance	O
and	O
negative	O
affect	O
during	O
amphetamine	O
withdrawal	O
.	O

Identifying	O
the	O
presence	O
of	O
Parkinson	O
's	O
disease	O
using	O
low-frequency	O
fluctuations	O
in	O
BOLD	B-P
signals	I-P
.	O

Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
is	O
a	O
chronic	O
,	O
progressive	O
,	O
and	O
degenerative	O
neurological	O
disorder	O
that	O
is	O
characterized	O
by	O
the	O
degeneration	O
of	O
dopamine	O
neurons	O
in	O
the	O
substantia	O
nigra	O
and	O
the	O
formation	O
of	O
intracellular	O
Lewy	O
inclusion	O
bodies	O
.	O

Resting-state	B-P
functional	I-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	O
RS-fMRI	B-P
)	O
has	O
demonstrated	O
evidence	O
of	O
changes	O
in	O
metabolic	O
patterns	O
in	O
individuals	O
with	O
PD	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
presence	O
of	O
PD	O
could	O
be	O
``	O
predicted	O
``	O
based	O
on	O
resting	O
fluctuations	O
in	O
the	O
blood	O
oxygenation	O
level	O
dependent	O
signal	O
.	O

We	O
utilized	O
RS-fMRI	B-P
to	O
measure	O
the	O
amplitude	O
of	O
low-frequency	O
fluctuation	O
(	O
ALFF	O
)	O
and	O
the	O
fractional	O
ALFF	O
(	O
fALFF	O
)	O
in	O
51	O
patients	O
with	O
PD	O
and	O
50	O
age	O
-	O
and	O
sex	O
-matched	O
healthy	O
controls	O
.	O

Compared	O
with	O
the	O
healthy	O
controls	O
,	O
the	O
individuals	O
with	O
PD	O
exhibited	O
altered	O
ALFFs	O
in	O
the	O
bilateral	O
lingual	O
gyrus	O
and	O
left	O
putamen	O
and	O
an	O
altered	O
fALFF	O
in	O
the	O
right	O
cerebellum	O
posterior	O
lobe	O
.	O

Support	O
vector	O
machines	O
(	O
SVMs	O
)	O
,	O
which	O
comprise	O
a	O
supervised	O
pattern	O
recognition	O
method	O
that	O
enables	O
predictions	O
at	O
the	O
individual	O
level	O
,	O
were	O
trained	O
to	O
separate	O
individuals	O
with	O
PD	O
from	O
healthy	O
controls	O
based	O
on	O
the	O
ALFF	O
and	O
fALFF	O
.	O

Using	O
the	O
leave-one-out	O
cross-validation	O
method	O
to	O
analyze	O
our	O
sample	O
,	O
we	O
reliably	O
distinguished	O
the	O
participants	O
with	O
PD	O
from	O
the	O
controls	O
with	O
92	O
%	O
sensitivity	O
and	O
87	O
%	O
specificity	O
.	O

Overall	O
,	O
these	O
findings	O
suggest	O
that	O
the	O
SVM	O
-	O
neuroimaging	B-P
approach	O
may	O
be	O
of	O
particular	O
clinical	O
value	O
because	O
it	O
enables	O
the	O
accurate	O
identification	O
of	O
PD	O
at	O
the	O
individual	O
level	O
.	O

RS-fMRI	B-P
should	O
be	O
considered	O
for	O
development	O
as	O
a	O
biomarker	O
and	O
an	O
analytical	O
tool	O
for	O
the	O
evaluation	O
of	O
PD	O
.	O

Interobserver	O
and	O
Intraobserver	O
Reliability	O
of	O
Clinical	O
Assessments	O
in	O
Knee	O
Osteoarthritis	O
.	O

Clinical	O
examination	O
of	O
the	O
knee	O
is	O
subject	O
to	O
measurement	O
error	O
.	O

The	O
aim	O
of	O
this	O
analysis	O
was	O
to	O
determine	O
interobserver	O
and	O
intraobserver	O
reliability	O
of	O
commonly	O
used	O
clinical	O
tests	O
in	O
patients	O
with	O
knee	O
osteoarthritis	O
(	O
OA	O
)	O
.	O

We	O
studied	O
subjects	O
with	O
symptomatic	O
knee	O
OA	O
who	O
were	O
participants	O
in	O
an	O
open-label	O
clinical	O
trial	O
of	O
intraarticular	O
steroid	O
therapy	O
.	O

Following	O
standardization	O
of	O
the	O
clinical	B-P
test	I-P
procedures	I-P
,	O
2	O
clinicians	O
assessed	O
25	O
subjects	O
independently	O
at	O
the	O
same	O
visit	O
,	O
and	O
the	O
same	O
clinician	O
assessed	O
88	O
subjects	O
over	O
an	O
interval	O
period	O
of	O
2-10	O
weeks	O
;	O
in	O
both	O
cases	O
prior	O
to	O
the	O
steroid	O
intervention	O
.	O

Clinical	O
examination	O
included	O
assessment	O
of	O
bony	O
enlargement	O
,	O
crepitus	O
,	O
quadriceps	O
wasting	O
,	O
knee	O
effusion	O
,	O
joint-line	O
and	O
anserine	O
tenderness	O
,	O
and	O
knee	O
range	O
of	O
movement	O
(	O
ROM	O
)	O
.	O

Intraclass	O
correlation	O
coefficients	O
(	O
ICC	O
)	O
,	O
estimated	O
kappa	O
(	O
κ	O
)	O
,	O
weighted	O
kappa	O
(	O
κω	O
)	O
,	O
and	O
Bland-Altman	O
plots	O
were	O
used	O
to	O
determine	O
interobserver	O
and	O
intraobserver	O
levels	O
of	O
agreement	O
.	O

Using	O
Landis	O
and	O
Koch	O
criteria	O
,	O
interobserver	O
κ	O
scores	O
were	O
moderate	O
for	O
patellofemoral	O
joint	O
(	O
κ	O
=	O
0.53	O
)	O
and	O
anserine	O
tenderness	O
(	O
κ	O
=	O
0.48	O
)	O
;	O
good	O
for	O
bony	O
enlargement	O
(	O
κ	O
=	O
0.66	O
)	O
,	O
quadriceps	O
wasting	O
(	O
κ	O
=	O
0.78	O
)	O
,	O
crepitus	O
(	O
κ	O
=	O
0.78	O
)	O
,	O
medial	O
tibiofemoral	O
joint	O
tenderness	O
(	O
κ	O
=	O
0.76	O
)	O
,	O
and	O
effusion	O
assessed	O
by	O
ballottement	O
(	O
κ	O
=	O
0.73	O
)	O
and	O
bulge	B-P
sign	I-P
(	O
κω	O
=	O
0.78	O
)	O
;	O
and	O
excellent	O
for	O
lateral	O
tibiofemoral	O
joint	O
tenderness	O
(	O
κ	O
=	O
1.00	O
)	O
,	O
flexion	O
(	O
ICC	O
=	O
0.97	O
)	O
,	O
and	O
extension	O
(	O
ICC	O
=	O
0.87	O
)	O
ROM	O
.	O

Intraobserver	O
κ	O
scores	O
were	O
moderate	O
for	O
lateral	O
tibiofemoral	O
joint	O
tenderness	O
(	O
κ	O
=	O
0.60	O
)	O
;	O
good	O
for	O
crepitus	O
(	O
κ	O
=	O
0.78	O
)	O
,	O
effusion	O
assessed	O
by	O
ballottement	O
test	O
(	O
κ	O
=	O
0.77	O
)	O
,	O
patellofemoral	O
joint	O
(	O
κ	O
=	O
0.66	O
)	O
,	O
medial	O
tibiofemoral	O
joint	O
(	O
κ	O
=	O
0.64	O
)	O
,	O
and	O
anserine	O
tenderness	O
(	O
κ	O
=	O
0.73	O
)	O
;	O
and	O
excellent	O
for	O
effusion	O
assessed	O
by	O
bulge	B-P
sign	I-P
(	O
κω	O
=	O
0.83	O
)	O
,	O
bony	O
enlargement	O
(	O
κ	O
=	O
0.98	O
)	O
,	O
quadriceps	O
wasting	O
(	O
κ	O
=	O
0.83	O
)	O
,	O
flexion	O
(	O
ICC	O
=	O
0.99	O
)	O
,	O
and	O
extension	O
(	O
ICC	O
=	O
0.96	O
)	O
ROM	O
.	O

Among	O
individuals	O
with	O
symptomatic	O
knee	O
OA	O
,	O
the	O
reliability	O
of	O
clinical	O
examination	O
of	O
the	O
knee	O
was	O
at	O
least	O
good	O
for	O
the	O
majority	O
of	O
clinical	O
signs	O
of	O
knee	O
OA	O
.	O

Intrinsic	O
inter-network	O
brain	O
dysfunction	O
correlates	O
with	O
symptom	O
dimensions	O
in	O
late-life	O
depression	O
.	O

Prior	O
studies	O
have	O
demonstrated	O
dysfunctions	O
within	O
the	O
core	O
neurocognitive	O
networks	O
(	O
the	O
executive	O
control	O
[	O
ECN	O
]	O
,	O
default	O
mode	O
[	O
DMN	O
]	O
and	O
salience	O
[	O
SN	O
]	O
networks	O
)	O
in	O
late-life	O
depression	O
(	O
LLD	O
)	O
.	O

Whether	O
inter-network	O
dysfunctional	O
connectivity	O
is	O
present	O
in	O
LLD	O
,	O
and	O
if	O
such	O
disruptions	O
are	O
associated	O
with	O
core	O
symptom	O
dimensions	O
is	O
unknown	O
.	O

A	O
cross-sectional	B-P
resting-state	I-P
functional	I-P
connectivity	I-P
magnetic	I-P
resonance	I-P
imaging	I-P
investigation	O
was	O
conducted	O
of	O
LLD	O
(	O
n	O
=	O
39	O
)	O
and	O
age	O
-	O
and	O
gender	O
-equated	O
healthy	O
comparison	O
(	O
HC	O
)	O
(	O
n	O
=	O
29	O
)	O
participants	O
.	O

Dual	O
regression	O
independent	O
component	O
analysis	O
approach	O
was	O
used	O
to	O
identify	O
components	O
that	O
represented	O
the	O
ECN	O
,	O
DMN	O
and	O
SN	O
.	O

The	O
intrinsic	O
inter-network	O
connectivity	O
was	O
compared	O
between	O
LLD	O
and	O
HC	O
participants	O
and	O
the	O
relationship	O
of	O
inter-network	O
connectivity	O
abnormalities	O
with	O
dimensional	O
measures	O
was	O
examined	O
.	O

Relative	O
to	O
HC	O
participants	O
,	O
LLD	O
subjects	O
showed	O
decreased	O
inter-network	O
connectivity	O
between	O
the	O
bilateral	O
ECN	O
and	O
default	O
mode	O
subcortical	O
(	O
thalamus	O
,	O
basal	O
ganglia	O
and	O
ventral	O
striatum	O
)	O
networks	O
,	O
and	O
the	O
left	O
ECN	O
and	O
SN	O
insula	O
component	O
;	O
and	O
increased	O
inter-network	O
connections	O
between	O
the	O
left	O
ECN	O
and	O
posterior	O
DMN	O
and	O
salience	O
(	O
dorsal	O
anterior	O
cingulate	O
)	O
network	O
components	O
.	O

Distinct	O
inter-network	O
connectivity	O
abnormalities	O
correlated	O
with	O
depression	O
and	O
anxiety	O
severity	O
,	O
and	O
executive	O
dysfunction	O
in	O
LLD	O
participants	O
.	O

LLD	O
subjects	O
also	O
showed	O
pronounced	O
intra-network	O
connectivity	O
differences	O
within	O
the	O
ECN	O
,	O
whereas	O
fewer	O
but	O
significant	O
DMN	O
and	O
SN	O
disruptions	O
were	O
also	O
detected	O
.	O

Investigating	O
the	O
intrinsic	O
inter-network	O
functional	O
connectivity	O
could	O
provide	O
a	O
mechanistic	O
framework	O
to	O
better	O
understand	O
the	O
neural	O
basis	O
that	O
underlies	O
core	O
symptom	O
dimensions	O
in	O
LLD	O
.	O

Inter-network	O
connectivity	O
measures	O
have	O
the	O
potential	O
to	O
be	O
neuroimaging	O
biomarkers	O
of	O
symptom	O
dimensions	O
comprising	O
LLD	O
,	O
and	O
may	O
assist	O
in	O
developing	O
symptom	O
-specific	O
treatment	O
algorithms	O
.	O

miR‑221	O
targets	O
HMGA2	O
to	O
inhibit	O
bleomycin	O
‑induced	O
pulmonary	O
fibrosis	O
by	O
regulating	O
TGF‑β1	O
/	O
Smad3	O
-induced	O
EMT	O
.	O

MicroRNA	O
(	O
miR	O
)	O
-221	O
plays	O
an	O
essential	O
role	O
in	O
the	O
epithelial-mesenchymal	O
transition	O
(	O
EMT	O
)	O
.	O

High	O
mobility	O
group	O
AT-hook	O
2	O
(	O
HMGA2	O
)	O
,	O
is	O
a	O
key	O
regulator	O
of	O
EMT	O
.	O

However	O
,	O
the	O
role	O
of	O
miR‑221	O
in	O
pulmonary	O
fibrosis	O
,	O
and	O
the	O
association	O
between	O
miR‑221	O
and	O
HMGA2	O
remain	O
largely	O
unknown	O
.	O

For	O
this	O
purpose	O
,	O
we	O
examined	O
the	O
expression	O
of	O
miR‑221	O
and	O
HMGA2	O
in	O
human	O
idiopathic	O
pulmonary	O
fibrosis	O
(	O
IPF	O
)	O
tissues	O
and	O
pulmonary	O
cells	O
,	O
namely	O
the	O
adenocarcinoma	O
A549	O
and	O
human	O
bronchial	O
epithelium	O
(	O
HBE	O
)	O
cell	O
lines	O
,	O
and	O
found	O
that	O
the	O
expression	O
of	O
miR‑221	O
was	O
inhibited	O
in	O
both	O
tissues	O
and	O
cells	O
whereas	O
high	O
mRNA	O
and	O
protein	O
expression	O
of	O
HMGA2	O
was	O
observed	O
.	O

Additionally	O
,	O
transforming	O
growth	O
factor‑β1	O
(	O
TGF‑β1	O
)	O
induced	O
the	O
EMT	O
,	O
characterized	O
by	O
the	O
upregulated	O
expression	B-P
of	O
the	O
mesenchymal	O
markers	O
,	O
namely	O
N‑cadherin	O
,	O
vimentin	O
,	O
α‑smooth	O
muscle	O
actin	O
,	O
collagen	O
I	O
and	O
collagen	O
III	O
,	O
and	O
the	O
downregulated	O
expression	B-P
of	O
the	O
epithelial	O
marker	O
E-cadherin	O
in	O
A549	O
and	O
HBE	O
cells	O
.	O

We	O
then	O
performed	O
transfection	O
with	O
miR‑221	O
mimics	O
,	O
and	O
found	O
that	O
the	O
expression	O
of	O
phosphorylated	O
-	O
Smad3	O
in	O
miR‑221	O
‑	O
overexpressing	O
cells	O
was	O
significantly	O
downregulated	O
,	O
compared	O
with	O
that	O
in	O
the	O
TGF‑β1	O
-treated	O
cells	O
without	O
transfection	O
.	O

Furthermore	O
,	O
the	O
overexpression	O
of	O
miR‑221	O
decreased	O
the	O
expression	O
of	O
HMGA2	O
,	O
suppressed	O
the	O
EMT	O
,	O
and	O
inhibited	O
the	O
proliferation	O
of	O
A549	O
and	O
HBE	O
cells	O
.	O

HMGA2	O
was	O
directly	O
targeted	O
by	O
miR‑221	O
which	O
was	O
confirmed	O
by	O
the	O
dual-luciferase	O
reporter	O
gene	B-P
assay	I-P
.	O

Finally	O
,	O
a	O
mouse	O
model	O
of	O
bleomycin	O
(	O
BLM	O
)	O
‑induced	O
pulmonary	O
fibrosis	O
was	O
used	O
to	O
confirm	O
the	O
effect	O
of	O
miR‑221	O
on	O
EMT	O
.	O

Hematoxylin	B-P
and	I-P
eosin	I-P
staining	I-P
showed	O
that	O
BLM	O
induced	O
thicker	O
alveolar	O
walls	O
and	O
more	O
collagen	O
deposition	O
,	O
whereas	O
miR‑221	O
treatment	O
reduced	O
lung	O
fibrosis	O
and	O
the	O
tissues	O
exhibited	O
thinner	O
alveolar	O
walls	O
and	O
normal	O
lung	O
alveoli	O
.	O

Furthermore	O
,	O
the	O
EMT	O
process	O
was	O
suppressed	O
following	O
miR‑221	O
injection	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
sugest	O
that	O
miR‑221	O
targets	O
HMGA2	O
to	O
inhibit	O
BLM	O
‑induced	O
pulmonary	O
fibrosis	O
through	O
the	O
TGF‑β1	O
/	O
Smad3	O
signaling	O
pathway	O
.	O

Associations	O
of	O
gender	O
and	O
a	O
proxy	O
of	O
female	O
menopausal	O
status	O
with	O
histological	O
features	O
of	O
drug-induced	O
liver	O
injury	O
.	O

Gender	O
and	O
menopause	O
may	O
contribute	O
to	O
type	O
and	O
severity	O
of	O
drug-induced	O
liver	O
injury	O
(	O
DILI	O
)	O
by	O
influencing	O
host	O
responses	O
to	O
injury	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
associations	O
of	O
gender	O
and	O
female	O
age	O
50	O
[	O
a	O
proxy	O
of	O
menopause	O
]	O
with	O
histological	O
features	O
of	O
liver	O
injury	O
in	O
212	O
adults	O
enrolled	O
in	O
the	O
Drug-Induced	O
Liver	O
Injury	O
Network	O
(	O
DILIN	O
)	O
registry	O
.	O

All	O
participants	O
had	O
a	O
causality	O
score	O
of	O
at	O
least	O
'	O
probable	O
'	O
,	O
a	O
liver	B-P
biopsy	I-P
within	O
30	O
days	O
of	O
DILI	O
onset	O
,	O
and	O
no	O
prior	O
chronic	O
liver	O
disease	O
.	O

Biochemical	O
and	O
histological	O
injury	O
types	O
were	O
classified	O
as	O
hepatocellular	O
or	O
cholestatic/mixed	O
injury	O
.	O

The	O
cohort	O
was	O
divided	O
into	O
three	O
gender	O
/	O
age	O
categories	O
:	O
men	O
(	O
41.0	O
%	O
)	O
,	O
women	O
<	O
50	O
years	O
(	O
27.4	O
%	O
)	O
and	O
women	O
≥50	O
years	O
of	O
age	O
(	O
31.6	O
%	O
)	O
.	O

Interaction	O
of	O
gender	O
and	O
age	O
category	O
(	O
≥50	O
or	O
not	O
)	O
was	O
assessed	O
.	O

Hepatocellular	O
injury	O
was	O
more	O
prevalent	O
in	O
women	O
<	O
50	O
years	O
vs.	O
others	O
(	O
P=.002	O
)	O
.	O

After	O
adjusting	O
for	O
biochemical	O
injury	O
types	O
,	O
black	O
race	O
and	O
possible	O
ageing	O
effects	O
,	O
more	O
severe	O
interface	O
hepatitis	O
was	O
noted	O
in	O
biopsies	B-P
of	O
women	O
<	O
50	O
years	O
compared	O
to	O
those	O
of	O
men	O
and	O
women	O
≥50	O
years	O
(	O
P=.009	O
and	O
P=.055	O
respectively	O
)	O
.	O

Compared	O
to	O
those	O
of	O
men	O
,	O
biopsies	B-P
of	O
women	O
showed	O
greater	O
plasma	O
cell	O
infiltration	O
,	O
hepatocyte	O
apoptosis	O
,	O
hepatocyte	O
rosettes	O
and	O
lobular	O
disarray	O
but	O
less	O
iron	O
-	O
positive	O
hepatocytes	O
and	O
histological	O
cholestasis	O
(	O
P	O
<	O
.05	O
)	O
.	O

These	O
associations	O
persisted	O
after	O
excluding	O
cases	O
of	O
amoxicillin/clavulanic	O
acid	O
,	O
anabolic	O
steroids	O
or	O
nitrofurantoin	O
DILI	O
which	O
showed	O
gender	O
-specific	O
distributions	O
.	O

Gender	O
and	O
a	O
proxy	O
of	O
menopause	O
were	O
associated	O
with	O
various	O
features	O
of	O
inflammation	O
and	O
injury	O
in	O
DILI	O
.	O

On	O
the	O
development	O
of	O
conjunctival	O
hyperemia	O
computer-assisted	B-P
diagnosis	I-P
tools	I-P
:	O
Influence	O
of	O
feature	O
selection	O
and	O
class	O
imbalance	O
in	O
automatic	O
gradings	O
.	O

The	O
sudden	O
increase	O
of	O
blood	O
flow	O
in	O
the	O
bulbar	O
conjunctiva	O
,	O
known	O
as	O
hyperemia	O
,	O
is	O
associated	O
to	O
a	O
red	O
hue	O
of	O
variable	O
intensity	O
.	O

Experts	O
measure	O
hyperemia	O
using	O
levels	O
in	O
a	O
grading	O
scale	O
,	O
a	O
procedure	O
that	O
is	O
subjective	O
,	O
non-repeatable	O
and	O
time	O
consuming	O
,	O
thus	O
creating	O
a	O
need	O
for	O
its	O
automatisation	O
.	O

However	O
,	O
the	O
task	O
is	O
far	O
from	O
straightforward	O
due	O
to	O
data	O
issues	O
such	O
as	O
class	O
imbalance	O
or	O
correlated	O
features	O
.	O

In	O
this	O
paper	O
,	O
we	O
study	O
the	O
specific	O
features	O
of	O
hyperemia	O
and	O
propose	O
various	O
approaches	O
to	O
address	O
these	O
problems	O
in	O
the	O
context	O
of	O
an	O
automatic	O
framework	O
for	O
hyperemia	O
grading	O
.	O

Oversampling	O
,	O
undersampling	O
and	O
SMOTE	O
approaches	O
were	O
applied	O
in	O
order	O
to	O
tackle	O
the	O
problem	O
of	O
class	O
imbalance	O
.	O

25	O
features	O
were	O
computed	O
for	O
each	O
image	O
and	O
regression	O
methods	O
were	O
then	O
used	O
to	O
transform	O
them	O
into	O
a	O
value	O
on	O
the	O
grading	O
scale	O
.	O

The	O
values	O
and	O
relationships	O
among	O
features	O
and	O
experts	O
'	O
values	O
were	O
analysed	O
,	O
and	O
five	O
feature	O
selection	O
techniques	O
were	O
subsequently	O
studied	O
.	O

The	O
lowest	O
mean	O
square	O
error	O
(	O
MSE	O
)	O
for	O
the	O
regression	O
systems	O
trained	O
with	O
individual	O
features	O
is	O
below	O
0.1	O
for	O
both	O
scales	O
.	O

Multi-layer	O
perceptron	O
(	O
MLP	O
)	O
obtains	O
the	O
best	O
values	O
,	O
but	O
is	O
less	O
consistent	O
than	O
the	O
random	O
forest	O
(	O
RF	O
)	O
method	O
.	O

When	O
all	O
features	O
are	O
combined	O
,	O
the	O
best	O
results	O
for	O
both	O
scales	O
are	O
achieved	O
with	O
MLP	O
.	O

Correlation	O
based	O
feature	O
selection	O
(	O
CFS	O
)	O
and	O
M5	O
provide	O
the	O
best	O
results	O
,	O
MSE	O
=0.108	O
and	O
MSE	O
=0.061	O
respectively	O
.	O

Finally	O
,	O
the	O
class	O
imbalance	O
problem	O
is	O
minimised	O
with	O
the	O
SMOTE	O
approach	O
for	O
both	O
scales	O
(	O
MSE	O
<	O
0.006	O
)	O
.	O

Machine	O
learning	O
methods	O
are	O
able	O
to	O
perform	O
an	O
objective	O
assessment	O
of	O
hyperemia	O
grading	O
,	O
removing	O
both	O
intra-	O
and	O
inter-expert	O
subjectivity	O
while	O
providing	O
a	O
gain	O
in	O
computation	O
time	O
.	O

SMOTE	O
and	O
oversampling	O
approaches	O
minimise	O
the	O
class	O
imbalance	O
problem	O
,	O
while	O
feature	O
selection	O
reduces	O
the	O
number	O
of	O
features	O
from	O
25	O
to	O
3-5	O
without	O
worsening	O
the	O
MSE	O
.	O

As	O
the	O
differences	O
between	O
the	O
system	O
and	O
a	O
human	O
expert	O
are	O
similar	O
to	O
the	O
differences	O
between	O
experts	O
,	O
we	O
can	O
therefore	O
conclude	O
that	O
the	O
system	O
behaves	O
like	O
an	O
expert	O
.	O

Anatomical	O
subgroup	O
analysis	O
of	O
the	O
MERIDIAN	O
cohort	O
:	O
Posterior	O
fossa	O
abnormalities	O
.	O

To	O
assess	O
the	O
diagnostic	O
and	O
clinical	O
contribution	O
of	O
in	B-P
utero	I-P
magnetic	I-P
resonance	I-P
(	I-P
iuMR	I-P
)	I-P
imaging	I-P
in	O
fetuses	O
diagnosed	O
with	O
abnormalities	O
of	O
the	O
posterior	O
fossa	O
as	O
the	O
only	O
intracranial	O
abnormality	O
recognised	O
on	O
antenatal	B-P
ultrasonography	I-P
(	O
USS	B-P
)	O
.	O

We	O
report	O
a	O
sub-group	O
analysis	O
of	O
fetuses	O
with	O
abnormalities	O
of	O
the	O
posterior	O
fossa	O
diagnosed	O
on	O
antenatal	B-P
USS	I-P
(	O
with	O
or	O
without	O
ventriculomegaly	O
)	O
from	O
the	O
MERIDIAN	O
cohort	O
who	O
had	O
iuMR	B-P
imaging	I-P
within	O
2	O
weeks	O
of	O
USS	B-P
and	O
outcome	O
reference	O
data	O
were	O
available	O
.	O

The	O
diagnostic	O
accuracy	O
of	O
USS	B-P
and	O
iuMR	B-P
are	O
reported	O
as	O
well	O
as	O
indicators	O
of	O
diagnostic	O
confidence	O
and	O
effects	O
on	O
prognosis	O
and	O
clinical	O
management	O
.	O

Abnormalities	O
confined	O
to	O
the	O
posterior	O
fossa	O
according	O
to	O
USS	B-P
were	O
found	O
in	O
81	O
fetuses	O
(	O
67	O
with	O
parenchymal	O
and	O
14	O
with	O
CSF	O
-containing	O
lesions	O
)	O
.	O

The	O
overall	O
diagnostic	O
accuracy	O
for	O
detecting	O
an	O
isolated	O
posterior	O
fossa	O
abnormality	O
was	O
65	O
%	O
for	O
USS	B-P
and	O
88	O
%	O
for	O
iuMR	B-P
(	O
difference	O
=	O
22	O
%	O
,	O
95	O
%	O
CI	O
:	O
14.0	O
to	O
30.5	O
%	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

There	O
was	O
an	O
improvement	O
in	O
'	O
appropriate	O
'	O
diagnostic	O
confidence	O
as	O
assessed	O
by	O
a	O
score	O
-	O
based	O
weighted	O
average	O
'	O
method	O
(	O
p	O
<	O
0.0001	O
)	O
and	O
a	O
three-fold	O
reduction	O
in	O
'high	O
confidence	O
but	O
incorrect	O
diagnoses	O
'	O
was	O
achieved	O
by	O
using	O
iuMR	B-P
imaging	I-P
.	O

The	O
prognostic	O
information	O
given	O
to	O
the	O
women	O
after	O
iuMR	B-P
imaging	I-P
changed	O
in	O
44	O
%	O
of	O
cases	O
and	O
the	O
overall	O
effect	O
of	O
iuMR	B-P
on	O
clinical	O
management	O
was	O
considered	O
to	O
be	O
'	O
significant	O
'	O
,	O
'	O
major	O
'	O
or	O
'	O
decisive	O
'	O
in	O
35	O
%	O
of	O
cases	O
.	O

Our	O
data	O
suggests	O
that	O
any	O
woman	O
whose	O
fetus	O
has	O
a	O
posterior	O
fossa	O
abnormality	O
as	O
the	O
only	O
intracranial	O
finding	O
on	O
USS	B-P
should	O
have	O
iuMR	B-P
imaging	I-P
for	O
further	O
evaluation	O
.	O

This	O
is	O
on	O
the	O
basis	O
of	O
improved	O
diagnostic	O
accuracy	O
and	O
confidence	O
which	O
has	O
substantial	O
effects	O
on	O
the	O
prognostic	O
information	O
given	O
to	O
women	O
and	O
changes	O
in	O
clinical	O
management	O
.	O

Differences	O
in	O
depression	O
,	O
treatment	O
satisfaction	O
and	O
injection	O
behavior	O
in	O
adults	O
with	O
type	O
1	O
diabetes	O
and	O
different	O
degrees	O
of	O
lipohypertrophy	O
.	O

To	O
assess	O
the	O
prevalence	O
of	O
lipohypertrophy	O
,	O
and	O
to	O
compare	O
differences	O
in	O
external	O
,	O
personal	O
,	O
and	O
regimen	O
factors	O
in	O
adults	O
with	O
type	O
1	O
diabetes	O
and	O
different	O
degrees	O
of	O
lipohypertrophy	O
.	O

Suboptimal	O
insulin	O
injection	O
behavior	O
is	O
associated	O
with	O
lipohypertrophy	O
,	O
which	O
may	O
affect	O
insulin	O
absorption	O
and	O
lead	O
to	O
blood	O
glucose	O
fluctuations	O
.	O

Few	O
,	O
if	O
any	O
studies	O
have	O
investigated	O
how	O
external	O
,	O
personal	O
,	O
and	O
regimen	O
factors	O
differ	O
in	O
people	O
with	O
type	O
1	O
diabetes	O
and	O
different	O
degrees	O
of	O
lipohypertrophy	O
.	O

A	O
cross-sectional	O
study	O
including	O
adults	O
with	O
type	O
1	O
diabetes	O
at	O
a	O
diabetes	O
outpatient	O
clinic	O
in	O
a	O
Norwegian	O
university	O
hospital	O
.	O

Participants	O
(	O
n=215	O
)	O
were	O
included	O
consecutively	O
at	O
scheduled	O
appointments	O
.	O

Sociodemographic	O
-	O
,	O
diabetes	O
-	O
and	O
insulin	O
treatment	O
data	O
,	O
and	O
self-report	O
questionnaires	O
concerning	O
patient	O
activation	O
(	O
PAM	O
)	O
,	O
depression	O
(	O
PHQ-2	O
)	O
,	O
diabetes	O
distress	O
(	O
DDS	O
)	O
,	O
type	O
D	O
personality	O
(	O
DS14	O
)	O
,	O
treatment	O
satisfaction	O
(	O
ITSQ	O
)	O
,	O
and	O
motivation	O
(	O
TSRQ	O
)	O
,	O
were	O
collected	O
.	O

Lipohypertrophic	O
injection	O
sites	O
were	O
identified	O
by	O
palpation	B-P
by	O
diabetes	O
specialist	O
nurses	O
.	O

Lipohypertrophy	O
was	O
present	O
in	O
53	O
%	O
and	O
was	O
more	O
frequent	O
in	O
insulin	O
pen	O
users	O
(	O
63	O
%	O
)	O
compared	O
to	O
insulin	O
pump	O
users	O
(	O
34	O
%	O
)	O
.	O

Participants	O
with	O
two	O
or	O
more	O
lipohypertrophic	O
areas	O
had	O
higher	O
depression	O
scores	O
,	O
lower	O
treatment	O
satisfaction	O
with	O
glycemic	O
control	O
,	O
higher	O
bolus	O
doses	O
,	O
and	O
reported	O
suboptimal	O
injection	O
behavior	O
compared	O
to	O
those	O
with	O
no	O
lipohypertrophic	O
areas	O
.	O

There	O
were	O
no	O
differences	O
in	O
patient	O
activation	O
,	O
diabetes	O
distress	O
,	O
type	O
D	O
personality	O
,	O
or	O
motivation	O
between	O
the	O
groups	O
.	O

Compared	O
to	O
pump	O
treatment	O
,	O
pen	O
treatment	O
requires	O
greater	O
awareness	O
of	O
injection	O
technique	O
.	O

Depressive	O
symptoms	O
and	O
lower	O
treatment	O
satisfaction	O
might	O
affect	O
diabetes	O
self-management	O
and	O
glycemic	O
control	O
,	O
but	O
the	O
association	O
with	O
lipohypertrophy	O
needs	O
further	O
exploration	O
.	O

Lipohypertrophy	O
is	O
more	O
frequent	O
in	O
insulin	O
pen	O
users	O
compared	O
to	O
pump	O
users	O
.	O

Nurses	O
should	O
focus	O
on	O
injection	O
technique	O
education	O
,	O
and	O
should	O
also	O
screen	O
for	O
depressive	O
symptoms	O
and	O
treatment	O
satisfaction	O
as	O
those	O
factors	O
could	O
be	O
associated	O
with	O
development	O
of	O
lipohypertrophy	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Physical	O
Activity	O
and	O
Abnormal	O
Blood	O
Glucose	O
Among	O
Healthy	O
Weight	O
Adults	O
.	O

Physical	O
activity	O
has	O
been	O
linked	O
to	O
prevention	O
and	O
treatment	O
of	O
prediabetes	O
and	O
diabetes	O
in	O
overweight	O
and	O
obese	O
adults	O
.	O

This	O
study	O
examines	O
the	O
relationship	O
between	O
low	O
physical	O
activity	O
levels	O
and	O
risk	O
of	O
abnormal	O
blood	O
glucose	O
(	O
prediabetes	O
or	O
undiagnosed	O
diabetes	O
)	O
in	O
healthy	O
weight	O
adults	O
.	O

Data	O
from	O
the	O
2014	O
Health	O
Survey	O
for	O
England	O
were	O
analyzed	O
in	O
July	O
2016	O
,	O
focusing	O
on	O
adults	O
with	O
a	O
BMI	O
≥18.5	O
and	O
<	O
25	O
who	O
had	O
never	O
been	O
diagnosed	O
with	O
diabetes	O
(	O
N=1,153	O
)	O
.	O

Abnormal	O
blood	O
glucose	O
was	O
defined	O
as	O
hemoglobin	B-P
A1c	I-P
≥5.7	O
.	O

Physical	O
activity	O
was	O
measured	O
through	O
the	O
International	O
Physical	O
Activity	O
Questionnaire	O
.	O

Bivariate	O
analyses	O
and	O
Poisson	O
models	O
were	O
conducted	O
on	O
the	O
effect	O
of	O
physical	O
activity	O
on	O
abnormal	O
blood	O
glucose	O
,	O
controlling	O
for	O
age	O
,	O
sex	O
,	O
waist	O
to	O
hip	O
ratio	O
,	O
sitting	O
time	O
,	O
age	O
X	O
physical	O
activity	O
interaction	O
,	O
sex	O
X	O
physical	O
activity	O
,	O
and	O
race	O
.	O

Abnormal	O
blood	O
glucose	O
was	O
detected	O
in	O
23.7	O
%	O
of	O
individuals	O
with	O
low	O
activity	O
levels	O
,	O
14.8	O
%	O
of	O
those	O
with	O
medium	O
activity	O
levels	O
,	O
and	O
12.2	O
%	O
of	O
those	O
with	O
high	O
activity	O
levels	O
(	O
p	O
<	O
0.003	O
)	O
.	O

Similarly	O
,	O
25.4	O
%	O
of	O
inactive	O
individuals	O
(	O
physically	O
active	O
for	O
<	O
30	O
minutes	O
per	O
week	O
)	O
were	O
more	O
likely	O
to	O
have	O
abnormal	O
blood	O
glucose	O
levels	O
than	O
active	O
individuals	O
(	O
13.4	O
%	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

Higher	O
physical	O
activity	O
was	O
associated	O
with	O
a	O
lower	O
likelihood	O
of	O
abnormal	O
blood	O
glucose	O
in	O
an	O
adjusted	O
Poisson	O
regression	O
.	O

Among	O
healthy	O
weight	O
adults	O
,	O
low	O
physical	O
activity	O
levels	O
are	O
significantly	O
associated	O
with	O
abnormal	O
blood	O
glucose	O
(	O
prediabetes	O
and	O
undiagnosed	O
diabetes	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
healthy	O
weight	O
individuals	O
may	O
benefit	O
from	O
physical	O
exercise	O
.	O

Fenretinide	O
targets	O
the	O
side	O
population	O
in	O
myeloma	O
cell	O
line	O
NCI-H929	O
and	O
potentiates	O
the	O
efficacy	O
of	O
antimyeloma	O
with	O
bortezomib	O
and	O
dexamethasone	O
regimen	O
.	O

Side	O
population	O
(	O
SP	O
)	O
cells	O
,	O
a	O
subset	O
of	O
enriched	O
tumor	O
initiating	O
cells	O
,	O
have	O
been	O
demonstrated	O
to	O
have	O
stem	O
cell	O
-like	O
properties	O
in	O
multiple	O
myeloma	O
(	O
MM	O
)	O
by	O
us	O
as	O
well	O
as	O
other	O
previous	O
studies	O
.	O

A	O
lack	O
of	O
agents	O
targeting	O
tumor	O
initiating	O
cells	O
,	O
however	O
,	O
represents	O
a	O
challenge	O
in	O
the	O
treatment	O
of	O
MM	O
.	O

Previously	O
,	O
fenretinide	O
,	O
a	O
well-tolerated	O
vitamin	O
A	O
derivative	O
,	O
has	O
been	O
shown	O
to	O
exert	O
effect	O
on	O
leukemic	O
stem	O
cells	O
,	O
but	O
its	O
actions	O
against	O
myeloma	O
stem-like	O
cells	O
are	O
still	O
unknown	O
.	O

In	O
this	O
study	O
,	O
the	O
effects	O
of	O
fenretinide	O
on	O
myeloma	O
stem-like	O
cells	O
characteristic	O
was	O
comprehensively	O
examined	O
in	O
SP	O
and	O
non-SP	O
(	O
MP	O
)	O
cells	O
of	O
NCI-H929	O
cell	O
sorted	O
by	O
flow	B-P
cytometry	I-P
-based	O
on	O
Hoechst	O
33342	O
stain	O
.	O

We	O
find	O
that	O
fenretinide	O
is	O
capable	O
of	O
eradicating	O
MM	O
SP	O
and	O
MP	O
cells	O
,	O
but	O
not	O
normal	O
bone	O
marrow	O
mononuclear	O
cells	O
(	O
BMMCs	O
)	O
at	O
physiologically	O
achievable	O
concentrations	O
.	O

Fenretinide	O
alone	O
exerted	O
a	O
selective	O
cytotoxic	O
effect	O
on	O
MM	O
SP	O
cells	O
,	O
as	O
well	O
as	O
in	O
combination	O
with	O
bortezomib	O
and	O
dexamethasone	O
.	O

In	O
particular	O
,	O
SP	O
cells	O
were	O
highly	O
sensitive	O
to	O
fenretinide	O
,	O
and	O
in	O
combination	O
with	O
bortezomib	O
and	O
dexamethasone	O
in	O
colony	O
formation	O
and	O
apoptosis	O
assays	B-P
.	O

Accordingly	O
,	O
the	O
apparent	O
fenretinide	O
-induced-	O
apoptosis	O
was	O
linked	O
to	O
the	O
rapid	O
generation	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
.	O

Therefore	O
,	O
we	O
propose	O
that	O
fenretinide	O
is	O
a	O
potent	O
agent	O
that	O
targets	O
tumor	O
initiating	O
cells	O
and	O
may	O
be	O
a	O
promising	O
therapeutic	O
agent	O
in	O
MM	O
treatment	O
.	O

Parallel	O
artificial	O
liquid	O
membrane	O
extraction	B-P
of	O
new	O
psychoactive	O
substances	O
in	O
plasma	O
and	O
whole	O
blood	O
.	O

Parallel	O
artificial	O
liquid	O
membrane	O
extraction	B-P
(	O
PALME	B-P
)	O
was	O
combined	O
with	O
ultra-high	B-P
performance	I-P
liquid	I-P
chromatography-mass	I-P
spectrometry	I-P
(	O
UHPLC-MS	B-P
)	O
and	O
the	O
potential	O
for	O
screening	O
of	O
new	O
psychoactive	O
substances	O
(	O
NPS	O
)	O
was	O
investigated	O
for	O
the	O
first	O
time	O
.	O

PALME	B-P
was	O
performed	O
in	O
96-	O
well	O
format	O
comprising	O
a	O
donor	O
plate	O
,	O
a	O
supported	O
liquid	O
membrane	O
(	O
SLM	O
)	O
,	O
and	O
an	O
acceptor	O
plate	O
.	O

Uncharged	O
NPS	O
were	O
extracted	B-P
from	O
plasma	O
or	O
whole	O
blood	O
,	O
across	O
an	O
organic	O
SLM	O
,	O
and	O
into	O
an	O
aqueous	O
acceptor	O
solution	O
,	O
facilitated	O
by	O
a	O
pH	O
gradient	O
.	O

MDAI	O
(	O
5,6-methylenedioxy-2-aminoindane	O
)	O
,	O
methylone	O
,	O
PFA	O
(	O
para-fluoroamphetamine	O
)	O
,	O
mCPP	O
(	O
meta-chlorophenylpiperazine	O
)	O
,	O
pentedrone	O
,	O
methoxetamine	O
,	O
MDPV	O
(	O
methylenedioxypyrovalerone	O
)	O
,	O
ethylphenidate	O
,	O
2C-E	O
(	O
2,5-dimethoxy-4-ethylphenethylamine	O
)	O
,	O
bromo-dragonfly	O
,	O
and	O
AH-7921	O
(	O
3,4-dichloro-N-	O
{	O
[	O
1-	O
(	O
dimethylamino	O
)	O
cyclohexyl	O
]	O
methyl	O
}	O
benzamide	O
)	O
were	O
selected	O
as	O
representative	O
NPS	O
.	O

Optimization	O
of	O
operational	O
parameters	O
was	O
necessary	O
as	O
the	O
NPS	O
were	O
novel	O
to	O
PALME	B-P
,	O
and	O
because	O
PALME	B-P
was	O
performed	O
from	O
whole	O
blood	O
for	O
the	O
very	O
first	O
time	O
.	O

In	O
the	O
PALME	B-P
method	O
developed	O
for	O
plasma	O
,	O
NPS	O
were	O
extracted	B-P
from	O
a	O
250μL	O
alkalized	B-P
donor	O
solution	O
consisting	O
of	O
125μL	O
plasma	O
sample	O
,	O
115μL	O
40mM	O
NaOH	O
,	O
and	O
10μL	O
internal	O
standard	O
.	O

In	O
the	O
PALME	B-P
method	O
from	O
whole	O
blood	O
,	O
the	O
250μL	O
alkalized	B-P
donor	O
solution	O
consisted	O
of	O
100μL	O
whole	O
blood	O
,	O
50μL	O
deionized	O
water	O
,	O
75μL	O
80mM	O
NaOH	O
,	O
and	O
25μL	O
internal	O
standard	O
.	O

In	O
both	O
method	O
s	O
,	O
extraction	B-P
was	O
accomplished	O
across	O
an	O
SLM	O
of	O
5μL	O
dodecyl	O
acetate	O
with	O
1	O
%	O
trioctylamine	O
(	O
w/w	O
)	O
,	O
and	O
further	O
into	O
an	O
acidic	O
acceptor	O
solution	O
of	O
50μL	O
20mM	O
formic	O
acid	O
.	O

The	O
extraction	B-P
was	O
promoted	O
by	O
agitation	O
at	O
900	O
rpm	O
and	O
was	O
carried	O
out	O
for	O
120min	O
.	O

Method	O
validation	O
was	O
performed	O
and	O
the	O
following	O
parameters	O
were	O
considered	O
:	O
linearity	O
,	O
limits	O
of	O
quantification	O
(	O
LOQ	O
)	O
,	O
intra	O
-	O
and	O
inter	O
-	O
day	O
precision	O
,	O
accuracy	O
,	O
extraction	B-P
recoveries	O
,	O
carry	O
-	O
over	O
,	O
and	O
matrix	O
effects	O
.	O

The	O
validation	O
results	O
were	O
in	O
accordance	O
with	O
FDA	O
guidelines	O
.	O

The	O
Bindex	O
(	O
®	O
)	O
ultrasound	O
device	O
:	O
reliability	O
of	O
cortical	O
bone	O
thickness	O
measures	O
and	O
their	O
relationship	O
to	O
regional	O
bone	O
mineral	O
density	O
.	O

The	O
Bindex	O
(	O
®	O
)	O
quantitative	O
ultrasound	O
(	O
QUS	O
)	O
device	O
is	O
currently	O
available	O
and	O
this	O
study	O
analyzed	O
(	O
I	O
)	O
its	O
relative	O
and	O
absolute	O
intra-	O
and	O
inter-session	O
reliability	O
and	O
(	O
II	O
)	O
the	O
relationship	O
between	O
the	O
data	O
provided	O
by	O
Bindex	O
(	O
®	O
)	O
-QUS	O
and	O
the	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
measured	O
by	O
dual-energy	B-P
x-ray	I-P
absorptiometry	I-P
at	O
corresponding	O
skeletal	O
sites	O
in	O
young	O
and	O
healthy	O
subjects	O
(	O
age	O
:	O
25.0	O
±	O
3.6	O
years	O
)	O
.	O

Bindex	O
(	O
®	O
)	O
-QUS	O
calculates	O
a	O
density	O
index	O
on	O
the	O
basis	O
of	O
the	O
thickness	O
of	O
cortical	O
bone	O
measured	O
at	O
the	O
distal	O
radius	O
and	O
the	O
distal	O
plus	O
proximal	O
tibia	O
.	O

The	O
data	O
show	O
a	O
very	O
good	O
relative	O
and	O
absolute	O
intra-	O
(	O
ICC	O
=	O
0.977	O
,	O
CV	O
=	O
1.5	O
%	O
)	O
and	O
inter-session	O
reliability	O
(	O
ICC	O
=	O
0.978	O
,	O
CV	O
=	O
1.4	O
%	O
)	O
for	O
the	O
density	O
index	O
.	O

The	O
highest	O
positive	O
correlations	O
were	O
found	O
between	O
cortical	O
thickness	O
and	O
BMD	O
for	O
the	O
distal	O
radius	O
and	O
distal	O
tibia	O
(	O
r	O
⩾	O
0.71	O
,	O
p	O
<	O
0.001	O
)	O
.	O

The	O
data	O
indicate	O
that	O
the	O
Bindex	O
(	O
®	O
)	O
-QUS	O
parameters	O
are	O
repeatable	O
within	O
and	O
between	O
measurement	O
sessions	O
.	O

Furthermore	O
,	O
the	O
measurements	O
reflect	O
the	O
BMD	O
at	O
specific	O
skeletal	O
sites	O
.	O

Bindex	O
(	O
®	O
)	O
-QUS	O
might	O
be	O
a	O
useful	O
tool	O
for	O
the	O
measurement	O
of	O
skeletal	O
adaptations	O
.	O

ANTI	O
ANGIOGENIC	O
EFFECT	O
OF	O
CHEBULAGIC	O
ACID	O
INVOLVES	O
INHIBITION	O
OF	O
VEGFR2	O
AND	O
GSK3β	O
DEPENDENT	O
SIGNALING	O
PATHWAYS	O
.	O

Inhibition	O
of	O
angiogenesis	O
is	O
a	O
useful	O
strategy	O
to	O
prevent	O
cancer	O
growth	O
,	O
which	O
targets	O
new	O
vessels	O
that	O
grow	O
to	O
nourish	O
actively	O
proliferating	O
tumor	O
cells	O
.	O

Endothelial	O
cells	O
can	O
use	O
a	O
number	O
of	O
different	O
pathways	O
to	O
cause	O
angiogenesis	O
and	O
each	O
step	O
in	O
these	O
pathways	O
can	O
be	O
targeted	O
.	O

The	O
use	O
of	O
multi	O
targeted	O
drugs	O
is	O
gaining	O
much	O
importance	O
in	O
this	O
scenario	O
.	O

Our	O
previous	O
results	O
have	O
shown	O
the	O
anti	O
angiogenic	O
effect	O
of	O
Chebulagic	O
acid	O
-	O
a	O
benzopyran	O
tannin	O
present	O
in	O
the	O
fruits	O
of	O
Terminalia	O
chebula	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
examine	O
the	O
molecular	O
mechanism	O
of	O
the	O
anti	O
angiogenic	O
effect	O
of	O
chebulagic	O
acid	O
.	O

Results	O
of	O
our	O
investigations	O
using	O
molecular	O
docking	O
studies	O
and	O
HUVECs	O
in	O
culture	B-P
suggested	O
that	O
Chebulagic	O
acid	O
inhibited	O
GSK-3β	O
dependent	O
β-catenin	O
phosphorylation	O
,	O
an	O
important	O
mediator	O
of	O
VE-cadherin	O
/	O
β-catenin	O
signaling	O
and	O
VEGFR2	O
phosphorylation	O
which	O
is	O
an	O
important	O
step	O
involved	O
in	O
VEGF	O
signaling	O
.	O

Chebulagic	O
acid	O
inhibits	O
angiogenesis	O
by	O
blocking	O
both	O
VEGF	O
/	O
VEGFR2	O
and	O
cell-cell	O
contact	O
dependent	O
downstream	O
signaling	O
pathway	O
.	O

Systemic	O
matrix	O
metalloproteinase-8	O
response	O
in	O
chronic	O
tonsillitis	O
.	O

The	O
development	O
of	O
several	O
life-long	O
diseases	O
,	O
such	O
as	O
coronary	O
heart	O
disease	O
,	O
is	O
affected	O
by	O
low-grade	O
systemic	O
inflammation	O
.	O

Data	O
on	O
the	O
potential	O
long-term	O
health	O
effects	O
of	O
chronic	O
tonsillitis	O
are	O
limited	O
.	O

Many	O
inflammatory	O
conditions	O
present	O
with	O
enhanced	O
systemic	O
matrix	O
metalloproteinase	O
(	O
MMP	O
)	O
-8	O
response	O
.	O

In	O
head	O
and	O
neck	O
cancer	O
,	O
high	O
plasma	O
level	O
of	O
tissue	O
inhibitor	O
of	O
metalloproteinase	O
(	O
TIMP	O
)	O
-1	O
predicts	O
poor	O
prognosis	O
.	O

We	O
analyzed	O
S-MMP-8	O
with	O
immunofluorometric	B-P
assay	I-P
and	O
S-TIMP-1	O
with	O
an	O
immunosorbent	B-P
assay	I-P
in	O
175	O
consecutive	O
patients	O
undergoing	O
tonsillectomy	O
for	O
benign	O
tonsillar	O
disease	O
,	O
and	O
in	O
33	O
control	O
patients	O
with	O
tonsillar	O
squamous	O
cell	O
carcinoma	O
.	O

Tonsillar	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
status	O
was	O
determined	O
by	O
PCR	O
.	O

In	O
patients	O
with	O
benign	O
tonsillar	O
disease	O
,	O
chronic	O
tonsillitis	O
without	O
hypertrophy	O
was	O
associated	O
with	O
enhanced	O
systemic	O
MMP-8	O
response	O
.	O

Compared	O
to	O
patients	O
with	O
benign	O
tonsillar	O
disease	O
,	O
patients	O
with	O
tonsillar	O
squamous	O
cell	O
carcinoma	O
had	O
significantly	O
higher	O
concentrations	O
of	O
S-MMP-8	O
and	O
S-TIMP-1	O
.	O

Neither	O
S-MMP-8	O
nor	O
S-TIMP-1	O
correlated	O
with	O
tonsillar	O
HPV	O
positivity	O
.	O

Myometrial	O
relaxation	O
of	O
mice	O
via	O
expression	O
of	O
two	O
pore	O
domain	O
acid	O
sensitive	O
K	O
(	O
+	O
)	O
(	O
TASK-2	O
)	O
channels	O
.	O

Myometrial	O
relaxation	O
of	O
mouse	O
via	O
expression	O
of	O
two-pore	O
domain	O
acid	O
sensitive	O
(	O
TASK	O
)	O
channels	O
was	O
studied	O
.	O

In	O
our	O
previous	O
report	O
,	O
we	O
suggested	O
that	O
two-pore	O
domain	O
acid-sensing	O
K	O
(	O
+	O
)	O
channels	O
(	O
TASK-2	O
)	O
might	O
be	O
one	O
of	O
the	O
candidates	O
for	O
the	O
regulation	O
of	O
uterine	O
circular	O
smooth	O
muscles	O
in	O
mice	O
.	O

In	O
this	O
study	O
,	O
we	O
tried	O
to	O
show	O
the	O
mechanisms	O
of	O
relaxation	O
via	O
TASK-2	O
channels	O
in	O
marine	O
myometrium	O
.	O

Isometric	O
contraction	O
measurements	O
and	O
patch	O
clamp	O
technique	O
were	O
used	O
to	O
verify	O
TASK	O
conductance	O
in	O
murine	O
myometrium	O
.	O

Western	B-P
blot	I-P
and	O
immunehistochemical	B-P
study	I-P
under	O
confocal	B-P
microscopy	I-P
were	O
used	O
to	O
investigate	O
molecular	O
identity	O
of	O
TASK	O
channel	O
.	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
TEA	O
and	O
4-AP	O
insensitive	O
non-inactivating	O
outward	O
K	O
(	O
+	O
)	O
current	O
(	O
NIOK	O
)	O
may	O
be	O
responsible	O
for	O
the	O
quiescence	O
of	O
murine	O
pregnant	O
longitudinal	O
myometrium	O
.	O

The	O
characteristics	O
of	O
NIOK	O
coincided	O
with	O
two-pore	O
domain	O
acid-sensing	O
K	O
(	O
+	O
)	O
channels	O
(	O
TASK-2	O
)	O
.	O

NIOK	O
in	O
the	O
presence	O
of	O
K	O
(	O
+	O
)	O
channel	O
blockers	O
was	O
inhibited	O
further	O
by	O
TASK	O
inhibitors	O
such	O
as	O
quinidine	O
,	O
bupivacaine	O
,	O
lidocaine	O
,	O
and	O
extracellular	O
acidosis	O
.	O

Furthermore	O
,	O
oxytocin	O
and	O
estrogen	O
inhibited	O
NIOK	O
in	O
pregnant	O
myometrium	O
.	O

When	O
compared	O
to	O
non-pregnant	O
myometrium	O
,	O
pregnant	O
myometrium	O
showed	O
stronger	O
inhibition	O
of	O
NIOK	O
by	O
quinidine	O
and	O
increased	O
immunohistochemical	B-P
expression	I-P
of	O
TASK-2	O
.	O

Finally	O
,	O
TASK-2	O
inhibitors	O
induced	O
strong	O
myometrial	O
contraction	O
even	O
in	O
the	O
presence	O
of	O
L-methionine	O
,	O
a	O
known	O
inhibitor	O
of	O
stretch-activated	O
channels	O
in	O
the	O
longitudinal	O
myometrium	O
of	O
mouse	O
.	O

Activation	O
of	O
TASK-2	O
channels	O
seems	O
to	O
play	O
an	O
essential	O
role	O
for	O
relaxing	O
uterus	O
during	O
pregnancy	O
and	O
it	O
might	O
be	O
one	O
of	O
the	O
alternatives	O
for	O
preventing	O
preterm	O
delivery	O
.	O

Multidetector	B-P
CT	I-P
of	O
expected	O
findings	O
and	O
complications	O
after	O
contemporary	O
inguinal	O
hernia	O
repair	O
surgery	O
.	O

Inguinal	O
hernia	O
repair	O
(	O
IHR	O
)	O
with	O
prosthetic	O
mesh	O
implantation	O
is	O
the	O
most	O
common	O
procedure	O
in	O
general	O
surgery	O
,	O
and	O
may	O
be	O
performed	O
using	O
either	O
an	O
open	O
or	O
laparoscopic	O
approach	O
.	O

This	O
paper	O
provides	O
an	O
overview	O
of	O
contemporary	O
tension-free	O
IHR	O
techniques	O
and	O
materials	O
,	O
and	O
illustrates	O
the	O
expected	O
postoperative	O
imaging	O
findings	O
and	O
iatrogenic	O
injuries	O
.	O

Emphasis	O
is	O
placed	O
on	O
multidetector	B-P
CT	I-P
,	O
which	O
represents	O
the	O
ideal	O
modality	O
to	O
comprehensively	O
visualize	O
the	O
operated	O
groin	O
region	O
and	O
deeper	O
intra-abdominal	O
structures	O
.	O

CT	B-P
consistently	O
depicts	O
seroma	O
,	O
mesh	O
infections	O
,	O
hemorrhages	O
,	O
bowel	O
complications	O
and	O
urinary	O
bladder	O
injuries	O
,	O
and	O
thus	O
generally	O
provides	O
a	O
consistent	O
basis	O
for	O
therapeutic	O
choice	O
.	O

Since	O
radiologists	O
are	O
increasingly	O
requested	O
to	O
investigate	O
suspected	O
iatrogenic	O
complications	O
,	O
this	O
paper	O
aims	O
to	O
provide	O
an	O
increased	O
familiarity	O
with	O
early	O
CT	B-P
studies	B-P
after	O
IHR	O
,	O
including	O
complications	O
and	O
normal	O
postoperative	O
appearances	O
such	O
as	O
focal	O
pseudolesions	O
,	O
in	O
order	O
to	O
avoid	O
misinterpretation	O
and	O
inappropriate	O
management	O
.	O

An	O
amperometric	O
H2O2	O
biosensor	O
based	O
on	O
hemoglobin	O
nanoparticles	O
immobilized	O
onto	O
a	O
gold	O
electrode	O
.	O

The	O
nanoparticles	O
(	O
NPs	O
)	O
of	O
hemoglobin	O
(	O
Hb	O
)	O
were	O
prepared	O
by	O
desolvation	O
method	O
and	O
characterized	O
by	O
transmission	B-P
electron	I-P
microscopy	I-P
(	O
TEM	B-P
)	O
,	O
ultraviolet	B-P
(	I-P
UV	I-P
)	I-P
spectroscopy	I-P
and	O
Fourier-transform	O
infrared	O
spectroscopy	O
(	O
FTIR	O
)	O
.	O

An	O
amperometric	O
H2O2	O
biosensor	O
was	O
constructed	O
by	O
immobilizing	O
Hb	O
NPs	O
covalently	O
onto	O
a	O
polycrystalline	O
Au	O
electrode	O
(	O
Au	O
E	O
)	O
.	O

Hb	O
NPs	O
/	O
Au	O
E	O
was	O
characterized	O
by	O
scanning	B-P
electron	I-P
microscopy	I-P
(	O
SEM	B-P
)	O
,	O
cyclic	O
voltammetry	O
(	O
CV	O
)	O
and	O
electrochemical	B-P
impedance	I-P
spectra	I-P
(	O
EIS	B-P
)	O
before	O
and	O
after	O
immobilization	O
of	O
Hb	O
NPs	O
.	O

The	O
Hb	O
NPs	O
/	O
Au	O
electrode	O
showed	O
optimum	O
response	O
within	O
2.5s	O
at	O
pH	O
6.5	O
in	O
0.1M	O
sodium	O
phosphate	O
buffer	O
containing	O
100μM	O
H2O2	O
and	O
30⁰C	O
,	O
when	O
operated	O
at	O
-0.2V	O
against	O
Ag/AgCl	O
.	O

The	O
H	O
bN	O
Ps/	O
A	O
uE	O
exhibited	O
Vmax	O
of	O
5.161±0.1	O
μA	O
cm	O
(	O
-2	O
)	O
with	O
Michaelis-Menten	O
constant	O
(	O
Km	O
)	O
of	O
0.1±0.01mM	O
.	O

The	O
biosensor	O
showed	O
lower	O
detection	O
limit	O
(	O
1.0μM	O
)	O
,	O
high	B-P
sensitivity	I-P
(	O
129±0.25μA	O
cm	O
(	O
-2	O
)	O
mM	O
(	O
-1	O
)	O
)	O
and	O
wider	O
linear	O
range	O
(	O
1.0-1200μM	O
)	O
for	O
H2O2	O
as	O
compared	O
to	O
earlier	O
biosensors	O
.	O

The	O
analytical	O
recoveries	O
of	O
added	O
H2O2	O
in	O
serum	O
(	O
0.5μM	O
and1.0μM	O
)	O
were	O
97.77	O
%	O
and	O
98.01	O
%	O
respectively	O
and	O
within	O
and	O
between	O
batch	O
coefficients	O
of	O
variation	O
(	O
CV	O
)	O
were	O
3.16	O
%	O
and	O
3.36	O
%	O
respectively	O
.	O

There	O
was	O
a	O
good	O
correlation	O
between	O
sera	O
H2O2	O
values	O
obtained	O
by	O
standard	O
enzymic	O
colourimetric	B-P
method	I-P
and	O
the	O
present	O
biosensor	O
(	O
R	O
(	O
2	O
)	O
=0.99	O
)	O
.	O

The	O
biosensor	O
measured	O
H2O2	O
level	O
in	O
sera	O
of	O
apparently	O
healthy	O
subjects	O
and	O
persons	O
suffering	O
from	O
diabetes	O
type	O
II	O
.	O

The	O
Hb	O
NPs	O
/	O
Au	O
electrode	O
lost	O
10	O
%	O
of	O
its	O
initial	O
activity	O
after	O
90	O
days	O
of	O
its	O
regular	O
uses	O
,	O
when	O
stored	O
dry	O
at	O
4	O
(	O
o	O
)	O
C	O
.	O

PROTECTIVE	O
EFFECTS	O
OF	O
DIPEPTIDYL	O
PEPTIDASE-4	O
INHIBITORS	O
ON	O
PROGRESSION	O
OF	O
DIABETIC	O
RETINOPATHY	O
IN	O
PATIENTS	O
WITH	O
TYPE	O
2	O
DIABETES	O
.	O

To	O
investigate	O
the	O
effects	O
of	O
dipeptidyl	O
peptidase-4	O
inhibitors	O
(	O
DPP4	O
)	O
on	O
the	O
progression	O
of	O
diabetic	O
retinopathy	O
(	O
DR	O
)	O
in	O
patients	O
with	O
Type	O
2	O
diabetes	O
based	O
on	O
the	O
DR	O
severity	O
scale	O
.	O

The	O
medical	O
records	O
of	O
82	O
patients	O
with	O
Type	O
2	O
diabetes	O
enrolled	O
from	O
2005	O
to	O
2015	O
were	O
retrospectively	O
reviewed	O
.	O

Fundus	B-P
photographs	I-P
were	O
graded	O
using	O
Early	O
Treatment	O
Diabetic	O
Retinopathy	O
Study	O
methods	O
.	O

The	O
associations	O
between	O
baseline	O
risk	O
factors	O
and	O
progression	O
of	O
DR	O
were	O
investigated	O
.	O

Seven	O
of	O
28	O
patients	O
treated	O
with	O
DPP4	O
inhibitors	O
and	O
26	O
of	O
54	O
treated	O
with	O
other	O
hypoglycemic	O
agents	O
showed	O
progression	O
of	O
retinopathy	O
,	O
defined	O
as	O
one	O
or	O
more	O
steps	O
on	O
the	O
Early	O
Treatment	O
Diabetic	O
Retinopathy	O
Study	O
scale	O
(	O
P	O
=	O
0.043	O
)	O
.	O

Only	O
treatment	O
with	O
DPP4	O
inhibitors	O
significantly	O
reduced	O
the	O
progression	O
of	O
DR	O
in	O
patients	O
after	O
propensity	O
score	O
matching	O
(	O
P	O
=	O
0.009	O
)	O
.	O

Treatment	O
with	O
DPP4	O
inhibitors	O
was	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
DR	O
progression	O
(	O
P	O
=	O
0.011	O
)	O
.	O

Treatment	O
with	O
DPP4	O
inhibitors	O
was	O
the	O
independent	O
protective	O
factor	O
against	O
the	O
progression	O
of	O
DR	O
,	O
aside	O
from	O
improving	O
glycemic	O
control	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
show	O
the	O
benefits	O
of	O
DPP4	O
inhibitors	O
in	O
reducing	O
DR	O
progression	O
,	O
and	O
provides	O
encouraging	O
preliminary	O
data	O
for	O
further	O
evaluation	O
of	O
DPP4	O
inhibitors	O
in	O
the	O
progression	O
of	O
DR	O
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
.	O

Renal	O
Function	O
and	O
the	O
Risk	O
of	O
Stroke	O
and	O
Bleeding	O
in	O
Patients	O
With	O
Atrial	O
Fibrillation	O
:	O
An	O
Observational	O
Cohort	O
Study	O
.	O

We	O
sought	O
to	O
determine	O
the	O
risk	O
of	O
stroke	O
/	O
thromboembolism	O
and	O
bleeding	O
associated	O
with	O
reduced	O
renal	O
function	O
in	O
patients	O
with	O
atrial	O
fibrillation	O
and	O
the	O
risk	O
of	O
stroke	O
and	O
bleeding	O
associated	O
with	O
warfarin	O
treatment	O
in	O
specific	O
estimated	B-P
glomerular	I-P
filtration	I-P
rate	I-P
(	O
eGFR	B-P
)	O
groups	O
.	O

We	O
conducted	O
a	O
register-based	O
cohort	O
study	O
and	O
included	O
patients	O
discharged	O
with	O
nonvalvular	O
atrial	O
fibrillation	O
from	O
1997	O
to	O
2011	O
with	O
available	O
eGFR	B-P
.	O

A	O
total	O
of	O
17	O
349	O
patients	O
were	O
identified	O
with	O
eGFR	B-P
available	O
at	O
baseline	O
.	O

All	O
levels	O
of	O
lower	O
eGFR	B-P
were	O
associated	O
with	O
higher	O
risk	O
of	O
stroke	O
/	O
thromboembolism	O
and	O
bleeding	O
.	O

Use	O
of	O
warfarin	O
was	O
associated	O
with	O
higher	O
bleeding	O
risk	O
in	O
all	O
eGFR	B-P
groups	O
;	O
hazard	O
ratios	O
1.23	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.97-1.56	O
)	O
,	O
1.26	O
(	O
95	O
%	O
CI	O
,	O
1.14-1.40	O
)	O
,	O
1.18	O
(	O
95	O
%	O
CI	O
,	O
1.07-1.31	O
)	O
,	O
1.11	O
(	O
95	O
%	O
CI	O
,	O
0.87-1.42	O
)	O
,	O
2.01	O
(	O
95	O
%	O
CI	O
,	O
1.14-3.54	O
)	O
in	O
patients	O
with	O
eGFR	B-P
≥90	O
,	O
60	O
to	O
89	O
,	O
30	O
to	O
59	O
,	O
15	O
to	O
29	O
,	O
and	O
<	O
15	O
mL/min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
,	O
respectively	O
.	O

Use	O
of	O
warfarin	O
was	O
associated	O
with	O
lower	O
risk	O
of	O
stroke	O
/	O
thromboembolism	O
in	O
patients	O
with	O
eGFR	B-P
≥15	O
mL/min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
;	O
hazard	O
ratios	O
0.57	O
(	O
95	O
%	O
CI	O
,	O
0.43-0.76	O
)	O
,	O
0.57	O
(	O
95	O
%	O
CI	O
,	O
0.51-0.64	O
)	O
,	O
0.48	O
(	O
95	O
%	O
CI	O
,	O
0.44-0.54	O
)	O
,	O
0.60	O
(	O
95	O
%	O
CI	O
,	O
0.45-0.80	O
)	O
in	O
patients	O
with	O
eGFR	B-P
≥90	O
,	O
60	O
to	O
89	O
,	O
30	O
to	O
59	O
,	O
and	O
15	O
to	O
29	O
mL/min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
,	O
respectively	O
.	O

Use	O
of	O
warfarin	O
was	O
not	O
associated	O
with	O
lower	O
risk	O
of	O
stroke	O
/	O
thromboembolism	O
in	O
patients	O
with	O
eGFR	B-P
<	O
15	O
mL/min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
;	O
hazard	O
ratio	O
1.18	O
(	O
95	O
%	O
CI	O
,	O
0.58-2.40	O
)	O
.	O

In	O
patients	O
with	O
atrial	O
fibrillation	O
,	O
the	O
risk	O
of	O
stroke	O
and	O
bleeding	O
was	O
associated	O
with	O
levels	O
of	O
renal	O
function	O
.	O

Warfarin	O
treatment	O
was	O
associated	O
with	O
higher	O
risk	O
of	O
bleeding	O
in	O
all	O
eGFR	B-P
groups	O
and	O
lower	O
risk	O
of	O
stroke	O
in	O
patients	O
with	O
eGFR	B-P
≥15	O
mL/min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
.	O

Site	O
-	O
,	O
Technique	O
-	O
,	O
and	O
Time	O
-	O
Related	O
Aspects	O
of	O
the	O
Postmortem	B-P
Redistribution	O
of	O
Diazepam	O
,	O
Methadone	O
,	O
Morphine	O
,	O
and	O
their	O
Metabolites	O
:	O
Interest	O
of	O
Popliteal	O
Vein	O
Blood	B-P
Sampling	I-P
.	O

Sampling	O
site	O
,	O
technique	O
,	O
and	O
time	O
influence	O
postmortem	B-P
drug	O
concentrations	O
.	O

In	O
57	O
cases	O
,	O
we	O
studied	O
drug	O
concentration	O
differences	O
as	O
follows	O
:	O
subclavian	O
vein	O
-	O
dissection	O
/	O
clamping	O
versus	O
blind	O
stick	O
,	O
femoral	O
vein	O
-	O
dissection	O
/	O
clamping	O
versus	O
blind	O
stick	O
,	O
right	O
cardiac	O
chamber	O
,	O
and	O
popliteal	O
vein	O
-	O
dissection	O
and	O
clamping	O
only	O
.	O

Cases	O
were	O
distributed	O
in	O
group	O
#	O
1	O
(	O
all	O
cases	O
with	O
both	O
techniques	O
)	O
,	O
group	O
#	O
2	O
(	O
dissection	O
/	O
clamping	O
)	O
,	O
and	O
group	O
#	O
3	O
(	O
blind	O
stick	O
)	O
.	O

Sampled	O
drugs	O
were	O
diazepam	O
,	O
methadone	O
,	O
morphine	O
,	O
and	O
their	O
metabolites	O
.	O

To	O
assess	O
PMR	O
,	O
mean	O
concentrations	O
and	O
ratios	O
were	O
calculated	O
for	O
each	O
group	O
.	O

Time-dependent	O
variations	O
of	O
blood	O
concentrations	O
and	O
ratios	O
were	O
also	O
assessed	O
.	O

Results	O
indicate	O
that	O
site	O
,	O
method	O
,	O
and	O
time	O
may	O
influence	O
postmortem	B-P
distribution	O
interpretation	O
in	O
different	O
ways	O
.	O

Popliteal	O
blood	O
seems	O
less	O
subject	O
to	O
PMR	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
is	O
the	O
first	O
to	O
evaluate	O
concurrently	O
three	O
main	O
aspects	O
of	O
PMR	O
and	O
confirms	O
that	O
the	O
popliteal	O
vein	O
may	O
represent	O
a	O
site	O
that	O
is	O
more	O
resistant	O
to	O
the	O
changes	O
seen	O
as	O
a	O
result	O
of	O
PMR	O
.	O

An	O
Accessible	O
and	O
Pragmatic	O
Experimental	O
Model	O
of	O
Nonalcoholic	O
Fatty	O
Liver	O
Disease	O
.	O

BACKGROUND	O
There	O
is	O
no	O
convenient	O
cheap	O
pragmatic	O
experimental	O
model	O
for	O
Nonalcoholic	O
Fatty	O
Liver	O
Disease	O
(	O
NAFLD	O
)	O
/	O
Nonalcoholic	O
Steatohepatitis	O
(	O
NASH	O
)	O
.	O

Our	O
objective	O
was	O
to	O
create	O
a	O
pragmatic	O
model	O
of	O
NAFLD	O
/	O
NASH	O
.	O

METHODS	O
Sprague-Dawley	O
rats	O
were	O
fed	O
a	O
high-fat	O
,	O
high	O
sugar	O
homemade	O
diet	O
ad	O
libitum	O
for	O
seven	O
weeks	O
.	O

The	O
high-fat	O
,	O
high	O
sugar	O
diet	O
included	O
59	O
%	O
of	O
energy	O
derived	O
from	O
fat	O
,	O
30	O
%	O
from	O
carbohydrates	O
,	O
and	O
11	O
%	O
from	O
protein	O
.	O

Serum	B-P
levels	I-P
of	I-P
fasting	I-P
glucose	I-P
,	O
triglyceride	B-P
,	O
cholesterol	B-P
,	O
liver	B-P
enzymes	I-P
,	O
insulin	B-P
,	O
and	O
hepatic	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-α	O
)	O
gene	O
expression	O
were	O
determined	O
.	O

Hepatic	O
histology	B-P
was	O
examined	O
by	O
H	B-P
&	I-P
E	I-P
stain	I-P
.	O

RESULTS	O
Rats	O
fed	O
the	O
high-fat	O
,	O
high	O
sugar	O
diet	O
developed	O
hepatic	O
steatosis	O
,	O
and	O
a	O
moderate	O
inflammation	O
,	O
which	O
was	O
associated	O
with	O
increased	O
serum	O
levels	O
of	O
liver	O
enzymes	O
,	O
glucose	O
,	O
insulin	O
,	O
triglyceride	O
,	O
cholesterol	O
,	O
and	O
hepatic	O
TNF-α	O
gene	O
expression	O
.	O

CONCLUSION	O
This	O
rat	O
model	O
resembles	O
the	O
key	O
features	O
of	O
human	O
NAFLD	O
/	O
NASH	O
and	O
provides	O
a	O
simple	O
pragmatic	O
experimental	O
model	O
for	O
elucidating	O
the	O
disease	O
prevention	O
and	O
treatment	O
.	O

When	O
and	O
how	O
should	O
we	O
manage	O
thoracic	O
aortic	O
injuries	O
in	O
the	O
modern	O
era	O
?	O
.	O

A	O
best	O
evidence	O
topic	O
in	O
cardiovascular	O
surgery	O
was	O
written	O
according	O
to	O
a	O
structured	O
protocol	O
.	O

The	O
question	O
addressed	O
was	O
what	O
are	O
the	O
optimum	O
treatment	O
modality	O
and	O
timing	O
of	O
intervention	O
for	O
blunt	O
thoracic	O
aortic	O
injury	O
(	O
BTAI	O
)	O
in	O
the	O
modern	O
era	O
?	O

Of	O
the	O
697	O
papers	O
found	O
using	O
the	O
reported	O
search	O
,	O
14	O
(	O
5	O
meta-analyses	O
,	O
2	O
prospective	O
and	O
7	O
retrospective	O
studies	O
)	O
represented	O
the	O
best	O
evidence	O
to	O
answer	O
the	O
clinical	O
question	O
.	O

The	O
author	O
,	O
journal	O
,	O
country	O
,	O
date	O
of	O
publication	O
,	O
patient	O
group	O
studied	O
,	O
study	O
type	O
,	O
relevant	O
outcomes	O
,	O
results	O
and	O
weakness	O
of	O
these	O
papers	O
are	O
tabulated	O
.	O

All	O
five	O
meta-analyses	O
reported	O
a	O
reduction	O
in	O
mortality	O
with	O
thoracic	O
endovascular	O
aortic	O
repair	O
(	O
TEVAR	O
)	O
compared	O
with	O
open	O
repair	O
(	O
OR	O
)	O
,	O
but	O
only	O
four	O
found	O
the	O
same	O
benefit	O
on	O
paraplegia	O
rate	O
.	O

Similarly	O
,	O
the	O
two	O
prospective	O
and	O
four	O
retrospective	O
studies	O
showed	O
significantly	O
lower	O
mortality	O
with	O
TEVAR	O
than	O
with	O
OR	O
.	O

Only	O
one	O
study	O
(	O
a	O
meta-analysis	O
)	O
reported	O
a	O
significantly	O
lower	O
stroke	O
rate	O
with	O
TEVAR	O
than	O
with	O
OR	O
,	O
whereas	O
the	O
13	O
others	O
reported	O
a	O
similar	O
or	O
even	O
higher	O
stroke	O
rate	O
.	O

Other	O
complication	O
rates	O
were	O
identical	O
.	O

Four	O
studies	O
demonstrated	O
that	O
non-operative	O
management	O
(	O
NOM	O
)	O
as	O
a	O
treatment	O
option	O
for	O
BTAI	O
was	O
associated	O
with	O
increased	O
mortality	O
,	O
even	O
if	O
it	O
has	O
declined	O
in	O
recent	O
years	O
.	O

One	O
study	O
emphasized	O
that	O
some	O
cases	O
with	O
minimal	O
aortic	O
injuries	O
(	O
Grade	O
I	O
and	O
II	O
on	O
CT	B-P
scan	I-P
)	O
could	O
benefit	O
from	O
NOM	O
.	O

Regarding	O
the	O
timing	O
of	O
repair	O
,	O
only	O
three	O
studies	O
analysed	O
outcomes	O
of	O
delayed	O
repair	O
and	O
reported	O
significantly	O
lower	O
mortality	O
than	O
for	O
early	O
repair	O
.	O

We	O
conclude	O
that	O
with	O
lower	O
mortality	O
and	O
similar	O
overall	O
complications	O
including	O
paraplegia	O
but	O
higher	O
stroke	O
rate	O
,	O
TEVAR	O
is	O
the	O
most	O
suitable	O
treatment	O
for	O
BTAI	O
in	O
the	O
modern	O
era	O
,	O
where	O
expertise	O
exists	O
,	O
especially	O
for	O
cases	O
of	O
multiple	O
associated	O
injuries	O
and	O
in	O
the	O
older	O
age	O
group	O
.	O

Delayed	O
aortic	O
repair	O
can	O
be	O
proposed	O
based	O
on	O
CT	B-P
scan	I-P
analysis	I-P
,	O
but	O
emergent	O
repair	O
should	O
still	O
be	O
advocated	O
for	O
imminent	O
free	O
aortic	O
rupture	O
.	O

NOM	O
remains	O
a	O
therapeutic	O
option	O
but	O
only	O
with	O
selected	O
patients	O
.	O

Individual	O
differences	O
in	O
behavioral	O
activation	O
and	O
cardiac	O
vagal	O
control	O
influence	O
affective	O
startle	O
modification	O
.	O

The	O
startle	O
response	O
(	O
SR	O
)	O
has	O
a	O
close	O
relationship	O
with	O
stress	O
responses	O
.	O

Startle	O
modification	O
(	O
SRM	O
)	O
has	O
been	O
widely	O
used	O
to	O
study	O
stress	O
disorders	O
(	O
e.g.	O
,	O
posttraumatic	O
stress	O
disorder	O
)	O
.	O

The	O
framework	O
of	O
the	O
behavioral	O
inhibition	O
and	O
activation	O
systems	O
(	O
BIS	O
/	O
BAS	O
)	O
has	O
been	O
thought	O
to	O
correspond	O
with	O
withdrawal	O
and	O
approach	O
motivational	O
processes	O
underlying	O
affective	O
SRM	O
and	O
can	O
influence	O
stress	O
reactivity	O
.	O

Vagally-mediated	O
cardiac	O
activity	O
as	O
indexed	O
by	O
heart	O
rate	O
variability	O
(	O
HRV	O
)	O
has	O
been	O
associated	O
with	O
SRM	O
and	O
regulatory	O
processes	O
during	O
stress	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
influence	O
of	O
individual	O
differences	O
in	O
the	O
BIS	O
/	O
BAS	O
and	O
resting	O
HRV	O
on	O
affective	O
SRM	O
were	O
examined	O
.	O

Eighty-six	O
subjects	O
viewed	O
affective	O
pictures	O
while	O
acoustic	O
SR	O
stimuli	O
were	O
delivered	O
.	O

Individual	O
differences	O
in	O
motivation	O
were	O
measured	O
by	O
the	O
BIS/BAS	O
scales	O
.	O

The	O
magnitude	O
of	O
SR	O
was	O
assessed	O
as	O
electromyographic	B-P
activity	O
of	O
the	O
SR	O
eyeblink	O
during	O
pictures	O
of	O
different	O
valences	O
.	O

Resting	O
HRV	O
was	O
derived	O
from	O
electrocardiography	B-P
.	O

In	O
contrast	O
to	O
previous	O
studies	O
,	O
the	O
present	O
results	O
showed	O
that	O
startle	O
inhibition	O
and	O
potentiation	O
were	O
related	O
to	O
BAS	O
and	O
HRV	O
,	O
but	O
not	O
to	O
BIS	O
.	O

There	O
was	O
also	O
an	O
interaction	O
of	O
BAS	O
and	O
HRV	O
,	O
indicating	O
that	O
the	O
relationship	O
between	O
HRV	O
and	O
SRM	O
strengthened	O
as	O
BAS	O
scores	O
decreased	O
.	O

The	O
present	O
findings	O
suggest	O
that	O
BAS	O
may	O
relate	O
to	O
both	O
withdrawal	O
and	O
approach	O
,	O
and	O
trait	O
stress	O
reactivity	O
is	O
influence	O
d	O
by	O
BAS	O
and	O
cardiac	O
vagal	O
activity	O
.	O

In	O
addition	O
,	O
BAS	O
moderates	O
the	O
relationship	O
between	O
cardiac	O
vagal	O
activity	O
and	O
SRM	O
.	O

These	O
findings	O
have	O
both	O
theoretical	O
and	O
practical	O
implications	O
for	O
the	O
study	O
of	O
SRM	O
,	O
stress	O
disorders	O
,	O
and	O
health	O
.	O

A	O
parametric	O
ribcage	O
geometry	O
model	O
accounting	O
for	O
variations	O
among	O
the	O
adult	O
population	O
.	O

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
develop	O
a	O
parametric	O
ribcage	O
model	O
that	O
can	O
account	O
for	O
morphological	O
variations	O
among	O
the	O
adult	O
population	O
.	O

Ribcage	O
geometries	O
,	O
including	O
12	O
pair	O
of	O
ribs	O
,	O
sternum	O
,	O
and	O
thoracic	O
spine	O
,	O
were	O
collected	O
from	O
CT	B-P
scans	I-P
of	O
101	O
adult	O
subjects	O
through	O
image	O
segmentation	O
,	O
landmark	O
identification	O
(	O
1016	O
for	O
each	O
subject	O
)	O
,	O
symmetry	O
adjustment	O
,	O
and	O
template	O
mesh	O
mapping	O
(	O
26,180	O
elements	O
for	O
each	O
subject	O
)	O
.	O

Generalized	O
procrustes	O
analysis	O
(	O
GPA	O
)	O
,	O
principal	O
component	O
analysis	O
(	O
PCA	O
)	O
,	O
and	O
regression	O
analysis	O
were	O
used	O
to	O
develop	O
a	O
parametric	O
ribcage	O
model	O
,	O
which	O
can	O
predict	O
nodal	O
locations	O
of	O
the	O
template	O
mesh	O
according	O
to	O
age	O
,	O
sex	O
,	O
height	O
,	O
and	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
.	O

Two	O
regression	O
models	O
,	O
a	O
quadratic	O
model	O
for	O
estimating	O
the	O
ribcage	O
size	O
and	O
a	O
linear	O
model	O
for	O
estimating	O
the	O
ribcage	O
shape	O
,	O
were	O
developed	O
.	O

The	O
results	O
showed	O
that	O
the	O
ribcage	O
size	O
was	O
dominated	O
by	O
the	O
height	O
(	O
p=0.000	O
)	O
and	O
age	O
-	O
sex	O
-	O
interaction	O
(	O
p=0.007	O
)	O
and	O
the	O
ribcage	O
shape	O
was	O
significantly	O
affected	O
by	O
the	O
age	O
(	O
p=0.0005	O
)	O
,	O
sex	O
(	O
p=0.0002	O
)	O
,	O
height	O
(	O
p=0.0064	O
)	O
and	O
BMI	O
(	O
p=0.0000	O
)	O
.	O

Along	O
with	O
proper	O
assignment	O
of	O
cortical	O
bone	O
thickness	O
,	O
material	O
properties	O
and	O
failure	O
properties	O
,	O
this	O
parametric	O
ribcage	O
model	O
can	O
directly	O
serve	O
as	O
the	O
mesh	O
of	O
finite	O
element	O
ribcage	O
models	O
for	O
quantifying	O
effects	O
of	O
human	O
characteristics	O
on	O
thoracic	O
injury	O
risks	O
.	O

Doxorubicin	O
Has	O
Dose-Dependent	O
Toxicity	O
on	O
Mouse	O
Ovarian	O
Follicle	O
Development	O
,	O
Hormone	O
Secretion	O
,	O
and	O
Oocyte	O
Maturation	O
.	O

Doxorubicin	O
(	O
DOX	O
)	O
,	O
one	O
of	O
the	O
most	O
commonly	O
used	O
anticancer	O
medications	O
,	O
has	O
been	O
reported	O
to	O
affect	O
fertility	O
by	O
damaging	O
ovarian	O
follicles	O
;	O
however	O
,	O
the	O
dose-dependent	O
toxicity	O
of	O
DOX	O
on	O
the	O
dynamic	O
follicle	O
development	O
and	O
oocyte	O
maturation	O
has	O
not	O
been	O
well-defined	O
.	O

Our	O
objective	O
is	O
to	O
determine	O
the	O
effects	O
of	O
human	O
-	O
relevant	O
exposure	O
levels	O
of	O
DOX	O
on	O
follicular	O
functions	O
across	O
developmental	O
time	O
.	O

In	O
vitro	O
cultured	B-P
multilayered	O
secondary	O
mouse	O
follicles	O
were	O
treated	O
with	O
DOX	O
at	O
0	O
,	O
2	O
,	O
20	O
,	O
100	O
,	O
and	O
200	O
nM	O
for	O
24	O
h	O
,	O
and	O
follicle	O
development	O
,	O
hormone	O
secretion	O
,	O
and	O
oocyte	O
maturation	O
were	O
analyzed	O
.	O

DOX	O
caused	O
dose-dependent	O
toxicity	O
on	O
follicle	O
growth	O
,	O
survival	O
,	O
and	O
secretion	O
of	O
17β-estradiol	O
(	O
E2	O
)	O
.	O

At	O
200	O
nM	O
,	O
DOX	O
induced	O
DNA	O
damage	O
and	O
apoptosis	O
in	O
follicle	O
somatic	O
cells	O
first	O
and	O
then	O
in	O
oocytes	O
,	O
which	O
was	O
correlated	O
with	O
the	O
uptake	O
of	O
DOX	O
first	O
to	O
the	O
somatic	O
cells	O
followed	O
by	O
germ	O
cells	O
.	O

Follicles	O
treated	O
with	O
DOX	O
at	O
0	O
,	O
2	O
,	O
and	O
20	O
nM	O
showed	O
similar	O
oocyte	O
metaphase	O
II	O
(	O
MII	O
)	O
percentages	O
after	O
in	O
vitro	O
oocyte	O
maturation	O
;	O
however	O
,	O
20	O
nM	O
DOX	O
significantly	O
increased	O
the	O
number	O
of	O
MII	O
oocytes	O
with	O
abnormal	O
spindle	O
morphology	O
and	O
chromosome	O
misalignment	O
.	O

In	O
an	O
effort	O
to	O
harmonize	O
the	O
in	O
vitro	O
study	O
to	O
in	O
vivo	O
treatment	O
,	O
dose-dependent	O
toxicity	O
on	O
oocyte	O
meiotic	O
maturation	O
was	O
found	O
in	O
16-day-old	O
CD-1	O
mice	O
treated	O
with	O
DOX	O
at	O
0	O
,	O
0.4	O
,	O
2	O
,	O
and	O
10	O
mg/kg	O
,	O
consistent	O
with	O
the	O
in	O
vitro	O
oocyte	O
maturation	O
outcomes	O
.	O

Our	O
study	O
demonstrates	O
that	O
DOX	O
has	O
dose-dependent	O
toxicity	O
on	O
ovarian	O
follicle	O
development	O
,	O
hormone	O
secretion	O
,	O
and	O
oocyte	O
maturation	O
,	O
which	O
are	O
three	O
key	O
factors	O
to	O
support	O
the	O
female	O
reproductive	O
and	O
endocrine	O
functions	O
.	O

Hepatitis	O
C	O
virus	O
impairs	O
natural	O
killer	O
cell	O
activity	O
via	O
viral	O
serine	O
protease	O
NS3	O
.	O

Hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
infection	O
is	O
characterized	O
by	O
a	O
high	O
frequency	O
of	O
chronic	O
cases	O
owing	O
to	O
the	O
impairment	O
of	O
innate	O
and	O
adaptive	O
immune	O
responses	O
.	O

The	O
modulation	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
functions	O
by	O
HCV	O
leads	O
to	O
an	O
impaired	O
innate	O
immune	O
response	O
.	O

However	O
,	O
the	O
underling	O
mechanisms	O
and	O
roles	O
of	O
HCV	O
proteins	O
in	O
this	O
immune	O
evasion	O
are	O
controversial	O
,	O
especially	O
in	O
the	O
early	O
phase	O
of	O
HCV	O
infection	O
.	O

To	O
investigate	O
the	O
role	O
of	O
HCV	O
nonstructural	O
proteins	O
especially	O
NS3	O
in	O
the	O
impairment	O
of	O
NK	O
functions	O
,	O
NK	O
cells	O
were	O
isolated	O
from	O
the	O
PBMCs	O
by	O
negative	B-P
selection	I-P
.	O

To	O
assess	O
the	O
direct	O
cytotoxicity	O
and	O
IFN-γ	O
production	O
capability	O
of	O
NK	O
cells	O
,	O
co-cultured	B-P
with	O
uninfected	O
,	O
HCV-infected	O
,	O
HCV-NS3	O
DNA	O
-	O
transfected	O
Huh-7.5	O
,	O
or	O
HCV-NS	O
replicon	O
cells	O
.	O

To	O
determine	O
the	O
effect	O
of	O
an	O
NS3	O
serine	O
protease	O
inhibitor	O
,	O
HCV	O
-infected	O
Huh-7.5	O
cells	O
were	O
treated	O
with	O
BILN-2061	O
.	O

Then	O
,	O
NK	O
cells	O
were	O
harvested	B-P
and	O
further	O
co-cultured	B-P
with	O
K-562	O
target	O
cells	O
.	O

NK	O
cell	O
functions	O
were	O
analyzed	O
by	O
flow	B-P
cytometry	I-P
and	O
enzyme-linked	B-P
immunosorbent	I-P
assay	I-P
.	O

When	O
co-cultured	B-P
with	O
HCV-infected	O
Huh-7.5	O
cells	O
,	O
the	O
natural	O
cytotoxicity	O
and	O
IFN-γ	O
production	O
capability	O
of	O
NK	O
cells	O
were	O
significantly	O
reduced	O
.	O

NK	O
cell	O
functions	O
were	O
inhibited	O
to	O
similar	O
levels	O
upon	O
co-culture	B-P
with	O
HCV-NS	O
replicon	O
cells	O
,	O
NS3	O
-	O
transfected	O
cells	O
,	O
and	O
HCV-infected	O
Huh-7.5	O
cells	O
.	O

These	O
reductions	O
were	O
restored	O
by	O
BILN-2061	O
-	O
treatment	O
.	O

Furthermore	O
,	O
BILN-2061	O
-	O
treatment	O
significantly	O
increased	O
degranulation	O
against	O
K-562	O
target	O
cells	O
and	O
IFN-γ	O
productivity	O
in	O
NK	O
cells	O
.	O

Consistent	O
with	O
these	O
findings	O
,	O
the	O
expression	O
levels	O
of	O
activating	O
NK	O
cell	O
receptors	O
,	O
such	O
as	O
NKp46	O
and	O
NKp30	O
,	O
were	O
also	O
increased	O
.	O

In	O
HCV-infected	O
cells	O
,	O
the	O
serine	O
protease	O
NS3	O
may	O
play	O
a	O
role	O
in	O
the	O
abrogation	O
of	O
NK	O
cell	O
functions	O
in	O
the	O
early	O
phase	O
of	O
infection	O
through	O
downregulation	O
of	O
NKp46	O
and	O
NKp30	O
receptors	O
on	O
NK	O
cells	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
NS3	O
represents	O
a	O
novel	O
drug	O
target	O
for	O
the	O
treatment	O
of	O
HCV	O
infections	O
.	O

Extending	O
'	O
Contact	O
Tracing	O
'	O
into	O
the	O
Community	O
within	O
a	O
50-Metre	O
Radius	O
of	O
an	O
Index	O
Tuberculosis	O
Patient	O
Using	O
Xpert	B-P
MTB/RIF	I-P
in	O
Urban	O
,	O
Pakistan	O
:	O
Did	O
It	O
Increase	O
Case	O
Detection	O
?	O
.	O

Currently	O
,	O
only	O
62	O
%	O
of	O
incident	O
tuberculosis	O
(	O
TB	O
)	O
cases	O
are	O
reported	O
to	O
the	O
national	O
programme	O
in	O
Pakistan	O
.	O

Several	O
innovative	O
interventions	O
are	O
being	O
recommended	O
to	O
detect	O
the	O
remaining	O
'missed	O
'	O
TB	O
cases	O
.	O

One	O
such	O
intervention	O
involved	O
expanding	O
contact	O
investigation	O
to	O
the	O
community	O
using	O
the	O
Xpert	B-P
MTB/RIF	I-P
test	I-P
.	O

This	O
was	O
a	O
before	O
and	O
after	O
intervention	O
study	O
involving	O
retrospective	O
record	O
review	O
.	O

Passive	O
case	O
finding	O
and	O
household	O
contact	O
investigation	O
was	O
routinely	O
done	O
in	O
the	O
pre-	O
intervention	O
period	O
July	O
2011-June	O
2013	O
.	O

Four	O
districts	O
with	O
a	O
high	O
concentration	O
of	O
slums	O
were	O
selected	O
as	O
intervention	O
areas	O
;	O
Lahore	O
,	O
Rawalpindi	O
,	O
Faisalabad	O
and	O
Islamabad	O
.	O

Here	O
,	O
in	O
the	O
intervention	O
period	O
,	O
July	O
2013-June	O
2015	O
,	O
contact	O
investigation	O
beyond	O
household	O
was	O
conducted	O
:	O
all	O
people	O
staying	O
within	O
a	O
radius	O
of	O
50	O
metres	O
(	O
using	O
Geographical	O
Information	O
System	O
)	O
from	O
the	O
household	O
of	O
smear	O
positive	O
TB	O
patients	O
were	O
screened	O
for	O
tuberculosis	O
.	O

Those	O
with	O
presumptive	O
TB	O
were	O
investigated	O
using	O
smear	B-P
microscopy	I-P
and	O
the	O
Xpert	B-P
MTB/RIF	I-P
test	I-P
was	O
performed	O
on	O
smear	O
negative	O
patients	O
.	O

All	O
the	O
diagnosed	O
TB	O
patients	O
were	O
linked	O
to	O
TB	O
treatment	O
and	O
care	O
.	O

A	O
total	O
of	O
783043	O
contacts	O
were	O
screened	O
for	O
tuberculosis	O
:	O
23741	O
(	O
3.0	O
%	O
)	O
presumptive	O
TB	O
patients	O
were	O
identified	O
of	O
whom	O
,	O
4710	O
(	O
19.8	O
%	O
)	O
all	O
forms	O
and	O
4084	O
(	O
17.2	O
%	O
)	O
bacteriologically	O
confirmed	O
TB	O
patients	O
were	O
detected	O
.	O

The	O
contribution	O
of	O
Xpert	B-P
MTB/RIF	I-P
to	O
bacteriologically	O
confirmed	O
TB	O
patients	O
was	O
7.6	O
%	O
.	O

The	O
yield	O
among	O
investigated	O
presumptive	O
child	O
TB	O
patients	O
was	O
5.1	O
%	O
.	O

The	O
overall	O
yield	O
of	O
all	O
forms	O
TB	O
patients	O
among	O
investigated	O
was	O
22.3	O
%	O
among	O
household	O
and	O
19.1	O
%	O
in	O
close	O
community	O
.	O

The	O
intervention	O
contributed	O
an	O
increase	O
of	O
case	O
detection	O
of	O
bacteriologically	O
confirmed	O
tuberculosis	O
by	O
6.8	O
%	O
and	O
all	O
forms	O
TB	O
patients	O
by	O
7.9	O
%	O
.	O

Community	O
contact	O
investigation	O
beyond	O
household	O
not	O
only	O
detected	O
additional	O
TB	O
patients	O
but	O
also	O
increased	O
TB	O
case	O
detection	O
.	O

However	O
,	O
further	O
long	O
term	O
assessments	O
and	O
cost-effectiveness	O
studies	O
are	O
required	O
before	O
national	O
scale-up	O
.	O

Ammonia	O
as	O
an	O
In	O
Situ	O
Sanitizer	O
:	O
Influence	O
of	O
Virus	O
Genome	O
Type	O
on	O
Inactivation	O
.	O

Treatment	O
of	O
human	O
excreta	O
and	O
animal	O
manure	O
(	O
HEAM	O
)	O
is	O
key	O
in	O
controlling	O
the	O
spread	O
of	O
persistent	O
enteric	O
pathogens	O
,	O
such	O
as	O
viruses	O
.	O

The	O
extent	O
of	O
virus	B-P
inactivation	I-P
during	O
HEAM	O
storage	O
and	O
treatment	O
appears	O
to	O
vary	O
with	O
virus	O
genome	O
type	O
,	O
although	O
the	O
reasons	O
for	O
this	O
variability	O
are	O
not	O
clear	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
inactivation	O
of	O
viruses	O
of	O
different	O
genome	O
types	O
under	O
conditions	O
representative	O
of	O
HEAM	O
storage	O
or	O
mesophilic	O
digestion	O
.	O

The	O
goals	O
were	O
to	O
characterize	O
the	O
influence	O
of	O
HEAM	O
solution	O
conditions	O
on	O
inactivation	O
and	O
to	O
determine	O
the	O
potential	O
mechanisms	O
involved	O
.	O

Specifically	O
,	O
eight	O
viruses	O
representing	O
the	O
four	O
viral	O
genome	O
types	O
(	O
single-stranded	O
RNA	O
[	O
ssRNA	O
]	O
,	O
double-stranded	O
RNA	O
[	O
dsRNA	O
]	O
,	O
single-stranded	O
DNA	O
[	O
ssDNA	O
]	O
,	O
and	O
double-stranded	O
DNA	O
[	O
dsDNA	O
]	O
)	O
were	O
exposed	O
to	O
synthetic	O
solutions	O
with	O
well-controlled	O
temperature	O
(	O
20	O
to	O
35°C	O
)	O
,	O
pH	O
(	O
8	O
to	O
9	O
)	O
,	O
and	O
ammonia	O
(	O
NH3	O
)	O
concentrations	O
(	O
0	O
to	O
40	O
mmol	O
liter	O
(	O
-1	O
)	O
)	O
.	O

DNA	O
and	O
dsRNA	O
viruses	O
were	O
considerably	O
more	O
resistant	O
than	O
ssRNA	O
viruses	O
,	O
resulting	O
in	O
up	O
to	O
1,000-fold-longer	O
treatment	O
times	O
to	O
reach	O
a	O
4-log	O
inactivation	O
.	O

The	O
apparently	O
slower	O
inactivation	O
of	O
DNA	O
viruses	O
was	O
rationalized	O
by	O
the	O
higher	O
stability	B-P
of	O
DNA	O
than	O
that	O
of	O
ssRNA	O
in	O
HEAM	O
.	O

Pushing	O
the	O
system	O
toward	O
harsher	O
pH	O
(	O
>	O
9	O
)	O
and	O
temperature	O
(	O
>	O
35°C	O
)	O
conditions	O
,	O
such	O
as	O
those	O
encountered	O
in	O
thermophilic	O
digestion	O
and	O
alkaline	O
treatments	O
,	O
led	O
to	O
more	O
consistent	O
inactivation	O
kinetics	O
among	O
ssRNA	O
and	O
other	O
viruses	O
.	O

This	O
suggests	O
that	O
the	O
dependence	O
of	O
inactivation	O
on	O
genome	O
type	O
disappeared	O
in	O
favor	O
of	O
protein	O
-mediated	O
inactivation	O
mechanisms	O
common	O
to	O
all	O
viruses	O
.	O

Finally	O
,	O
we	O
recommend	O
the	O
use	O
of	O
MS2	O
as	O
a	O
conservative	O
indicator	O
to	O
assess	O
the	O
inactivation	O
of	O
ssRNA	O
viruses	O
and	O
the	O
stable	O
ΦX174	O
or	O
dsDNA	O
phages	O
as	O
indicators	O
for	O
persistent	O
viruses	O
.	O

Viruses	O
are	O
among	O
the	O
most	O
environmentally	O
persistent	O
pathogens	O
.	O

They	O
can	O
be	O
present	O
in	O
high	O
concentrations	O
in	O
human	O
excreta	O
and	O
animal	O
manure	O
(	O
HEAM	O
)	O
.	O

Therefore	O
,	O
appropriate	O
treatment	O
of	O
HEAM	O
is	O
important	O
prior	O
to	O
its	O
reuse	O
or	O
discharge	O
into	O
the	O
environment	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
factors	O
that	O
determine	O
the	O
persistence	O
of	O
viruses	O
in	O
HEAM	O
,	O
and	O
we	O
determined	O
the	O
main	O
mechanisms	O
that	O
lead	O
to	O
their	O
inactivation	O
.	O

Unlike	O
other	O
organisms	O
,	O
viruses	O
can	O
have	O
four	O
different	O
genome	O
types	O
(	O
double-	O
or	O
single-stranded	O
RNA	O
or	O
DNA	O
)	O
,	O
and	O
the	O
viruses	O
studied	O
herein	O
represent	O
all	O
four	O
types	O
.	O

Genome	O
type	O
appeared	O
to	O
be	O
the	O
major	O
determinant	O
for	O
persistence	O
.	O

Single-stranded	O
RNA	O
viruses	O
are	O
the	O
most	O
labile	O
,	O
because	O
this	O
genome	O
type	O
is	O
susceptible	O
to	O
degradation	O
in	O
HEAM	O
.	O

In	O
contrast	O
,	O
the	O
other	O
genome	O
types	O
are	O
more	O
stable	O
;	O
therefore	O
,	O
inactivation	O
is	O
slower	O
and	O
mainly	O
driven	O
by	O
the	O
degradation	O
of	O
viral	O
proteins	O
.	O

Overall	O
,	O
this	O
study	O
allows	O
us	O
to	O
better	O
understand	O
the	O
behavior	O
of	O
viruses	O
in	O
HEAM	O
.	O

MRI	B-P
findings	O
of	O
isolated	O
tubal	O
torsions	O
:	O
case	O
series	O
of	O
12	O
patients	O
:	O
MRI	B-P
findings	O
suggesting	O
isolated	O
tubal	O
torsions	O
,	O
correlating	O
with	O
surgical	O
findings	O
.	O

To	O
investigate	O
specific	O
MRI	B-P
findings	O
for	O
the	O
prompt	O
diagnosis	O
of	O
tubal	O
torsion	O
by	O
reviewing	O
12	O
cases	O
.	O

The	O
MRI	B-P
findings	O
presenting	O
surgically	O
and	O
pathologically	O
proven	O
isolated	O
tubal	O
torsion	O
were	O
evaluated	O
.	O

Key	O
specific	O
findings	O
,	O
including	O
whirlpool	O
sign	O
and	O
plicae	O
tubaliae	O
,	O
were	O
frequently	O
associated	O
with	O
the	O
diseases	O
and	O
were	O
grouped	O
for	O
three	O
types	O
.	O

Knowledge	O
of	O
specific	O
MRI	B-P
findings	O
and	O
the	O
types	O
of	O
tubal	O
torsion	O
may	O
lead	O
to	O
a	O
correct	O
and	O
prompt	O
diagnosis	O
,	O
resulting	O
in	O
preservation	O
of	O
fertility	O
.	O

Unusual	O
asymptomatic	O
presentation	O
of	O
bladder	O
cancer	O
metastatic	O
to	O
the	O
penis	O
.	O

Penile	O
metastasis	O
is	O
an	O
extremely	O
rare	O
event	O
and	O
mainly	O
originate	O
from	O
primary	O
pelvic	O
tumor	O
sites	O
such	O
us	O
urinary	O
bladder	O
,	O
gastro-intestinal	O
tract	O
and	O
prostate	O
and	O
more	O
rarely	O
from	O
respiratory	O
system	O
,	O
bone	O
tumors	O
and	O
melanoma	O
.	O

Here	O
we	O
describe	O
the	O
unusual	O
presentation	O
of	O
two	O
bladder	O
urothelial	O
cancer	O
metastatic	O
to	O
the	O
penis	O
with	O
no	O
relevant	O
clinical	O
symptoms	O
.	O

Namely	O
,	O
a	O
69	O
years-old	O
man	O
with	O
a	O
warthy	O
lesions	O
of	O
the	O
foreskin	O
and	O
the	O
glans	O
misunderstood	O
for	O
a	O
condylomata	O
that	O
at	O
histological	B-P
and	O
immunohistochemical	B-P
analysis	I-P
showed	O
a	O
bladder	O
urothelial	O
carcinoma	O
;	O
and	O
a	O
71	O
years-old	O
man	O
with	O
reddish	O
skin	O
lesion	O
of	O
the	O
glans	O
,	O
a	O
previous	O
history	O
of	O
bladder	O
and	O
urethral	O
carcinoma	O
and	O
histological	O
pagetoid	O
spread	O
of	O
urothelial	O
cancer	O
to	O
the	O
glans	O
.	O

Recurrent	O
bladder	O
urothelial	O
carcinoma	O
is	O
usually	O
a	O
visceral	O
disease	O
that	O
rarely	O
presents	O
as	O
a	O
superficial	O
asymptomatic	O
skin	O
lesion	O
.	O

The	O
two	O
reported	O
cases	O
were	O
asymptomatic	O
superficial	O
penis	O
metastases	O
with	O
a	O
relatively	O
slow	O
growth	O
and	O
a	O
fairy	O
good	O
prognosis	O
after	O
conservative	O
surgical	O
approach	O
.	O

Accurate	O
clinical	O
examination	O
of	O
the	O
penis	O
is	O
mandatory	O
for	O
males	O
with	O
history	O
of	O
bladder	O
cancer	O
.	O

Spontaneous	O
activity	O
is	O
correlated	O
with	O
coding	O
density	O
in	O
primary	O
auditory	O
cortex	O
.	O

Sensory	O
neurons	O
across	O
sensory	O
modalities	O
and	O
specific	O
processing	O
areas	O
have	O
diverse	O
levels	O
of	O
spontaneous	O
firing	O
rates	O
(	O
SFRs	O
)	O
in	O
the	O
absence	O
of	O
sensory	O
stimuli	O
.	O

However	O
,	O
the	O
functional	O
significance	O
of	O
this	O
spontaneous	O
activity	O
is	O
not	O
well-understood	O
.	O

Previous	O
studies	O
in	O
the	O
auditory	O
system	O
have	O
demonstrated	O
that	O
different	O
levels	O
of	O
spontaneous	O
activity	O
are	O
correlated	O
with	O
a	O
variety	O
of	O
physiological	O
and	O
anatomic	O
properties	O
,	O
suggesting	O
that	O
neurons	O
with	O
differing	O
SFRs	O
make	O
unique	O
contributions	O
to	O
the	O
encoding	O
of	O
auditory	O
stimuli	O
.	O

Additionally	O
,	O
altered	O
SFRs	O
are	O
a	O
correlate	O
of	O
tinnitus	O
,	O
arising	O
in	O
several	O
auditory	O
areas	O
after	O
exposure	O
to	O
ototoxic	O
substances	O
and	O
noise	O
trauma	O
.	O

In	O
this	O
study	O
,	O
we	O
recorded	B-P
single-unit	I-P
activity	I-P
from	O
primary	O
auditory	O
cortex	O
of	O
awake	O
marmoset	O
monkeys	O
while	O
delivering	O
wide-band	O
random-spectrum	O
stimuli	O
and	O
white	O
Gaussian	O
noise	O
(	O
WGN	O
)	O
to	O
examine	O
any	O
divergences	O
in	O
stimulus	O
encoding	O
properties	O
across	O
SFR	O
classes	O
.	O

We	O
found	O
that	O
higher	O
levels	O
of	O
spontaneous	O
activity	O
were	O
associated	O
with	O
both	O
higher	O
levels	O
of	O
activation	O
relative	O
to	O
suppression	O
across	O
a	O
variety	O
of	O
wide-band	O
stimuli	O
and	O
higher	O
driven	O
rates	O
in	O
response	O
to	O
WGN	O
.	O

Moreover	O
,	O
response	O
latencies	O
to	O
WGN	O
were	O
negatively	O
correlated	O
with	O
the	O
level	O
of	O
activation	O
in	O
response	O
to	O
both	O
stimulus	O
types	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
a	O
novel	O
view	O
of	O
the	O
role	O
spontaneous	O
spiking	O
may	O
play	O
during	O
normal	O
stimulus	O
processing	O
in	O
primary	O
auditory	O
cortex	O
and	O
how	O
it	O
may	O
malfunction	O
in	O
cases	O
of	O
tinnitus	O
.	O

Genome-Wide	O
SNP	O
Linkage	O
Mapping	O
and	O
QTL	O
Analysis	B-P
for	O
Fiber	O
Quality	O
and	O
Yield	O
Traits	O
in	O
the	O
Upland	O
Cotton	O
Recombinant	O
Inbred	O
Lines	O
Population	O
.	O

It	O
is	O
of	O
significance	O
to	O
discover	O
genes	O
related	O
to	O
fiber	O
quality	O
and	O
yield	O
traits	O
and	O
tightly	O
linked	O
markers	O
for	O
marker-assisted	O
selection	O
(	O
MAS	O
)	O
in	O
cotton	O
breeding	O
.	O

In	O
this	O
study	O
,	O
188	O
F8	O
recombinant	O
inbred	O
lines	O
(	O
RILs	O
)	O
,	O
derived	O
from	O
a	O
intraspecific	O
cross	O
between	O
HS46	O
and	O
MARCABUCAG8US-1-88	O
were	O
genotyped	O
by	O
the	O
cotton	O
63K	O
single	B-P
nucleotide	I-P
polymorphism	I-P
(	I-P
SNP	I-P
)	I-P
assay	I-P
.	O

Field	O
trials	O
were	O
conducted	O
in	O
Sanya	O
,	O
Hainan	O
Province	O
,	O
during	O
the	O
2014-2015	O
cropping	O
seasons	O
under	O
standard	O
conditions	O
.	O

Results	O
revealed	O
significant	O
differences	O
(	O
P	O
<	O
0.05	O
)	O
among	O
RILs	O
,	O
environments	O
and	O
replications	O
for	O
fiber	O
quality	O
and	O
yield	O
traits	O
.	O

Broad-sense	O
heritabilities	O
of	O
all	O
traits	O
including	O
fiber	O
length	O
,	O
fiber	O
uniformity	O
,	O
micronaire	O
,	O
fiber	O
elongation	O
,	O
fiber	O
strength	O
,	O
boll	O
weight	O
,	O
and	O
lint	O
percentage	O
ranged	O
from	O
0.26	O
to	O
0.66	O
.	O

A	O
1784.28	O
cM	O
(	O
centimorgans	O
)	O
linkage	O
map	O
,	O
harboring	O
2618	O
polymorphic	O
SNP	O
markers	O
,	O
was	O
constructed	O
,	O
which	O
had	O
0.68	O
cM	O
per	O
marker	O
density	O
.	O

Seventy-one	O
quantitative	O
trait	O
locus	O
(	O
QTLs	O
)	O
for	O
fiber	O
quality	O
and	O
yield	O
traits	O
were	O
detected	O
on	O
21	O
chromosomes	O
,	O
explaining	O
4.70~32.28	O
%	O
phenotypic	O
variance	O
,	O
in	O
which	O
16	O
were	O
identified	O
as	O
stable	O
QTLs	O
across	O
two	O
environments	O
.	O

Meanwhile	O
,	O
12	O
certain	O
regions	O
were	O
investigated	O
to	O
be	O
involved	O
in	O
the	O
control	O
of	O
one	O
(	O
hotspot	O
)	O
or	O
more	O
(	O
cluster	O
)	O
traits	O
,	O
mainly	O
focused	O
on	O
Chr05	O
,	O
Chr09	O
,	O
Chr10	O
,	O
Chr14	O
,	O
Chr19	O
,	O
and	O
Chr20	O
.	O

Nineteen	O
pairs	O
of	O
epistatic	O
QTLs	O
(	O
e-QTLs	O
)	O
were	O
identified	O
,	O
of	O
which	O
two	O
pairs	O
involved	O
in	O
two	O
additive	O
QTLs	O
.	O

These	O
additive	O
QTLs	O
,	O
e-QTLs	O
,	O
and	O
QTL	O
clusters	O
were	O
tightly	O
linked	O
to	O
SNP	O
markers	O
,	O
which	O
may	O
serve	O
as	O
target	O
regions	O
for	O
map-based	O
cloning	O
,	O
gene	O
discovery	O
,	O
and	O
MAS	O
in	O
cotton	O
breeding	O
.	O

Rotation-Driven	O
Microfluidic	O
Disc	O
for	O
White	B-P
Blood	I-P
Cell	I-P
Enumeration	I-P
Using	O
Magnetic	O
Bead	O
Aggregation	O
.	O

We	O
recently	O
defined	O
a	O
magnetic	B-P
bead-based	I-P
assay	I-P
that	O
exploited	O
an	O
agglutination	O
-like	O
response	O
for	O
DNA	O
and	O
applied	O
it	O
to	O
DNA	O
-	O
containing	O
cell	O
enumeration	O
using	O
inexpensive	O
benchtop	O
hardware	O
[	O
J	O
.	O

Am	O
.	O

Chem	O
.	O

Soc	O
.	O

2012	O
,	O
134	O
(	O
12	O
)	O
,	O
5689	O
-	O
96	O
]	O
.	O

Although	O
cost	O
-	O
efficient	O
,	O
the	O
open-well	B-P
format	I-P
assay	I-P
required	O
numerous	O
manual	O
steps	O
,	O
and	O
the	O
magnetic	O
field	O
actuation	O
scheme	O
was	O
not	O
readily	O
adaptable	O
for	O
integration	O
.	O

Here	O
,	O
we	O
demonstrate	O
a	O
low	O
-	O
cost	O
(	O
<	O
$	O
2	O
in-lab	O
)	O
,	O
higher-throughput	B-P
``	I-P
pinwheel	I-P
assay	I-P
''	I-P
platform	O
that	O
relies	O
on	O
a	O
combination	O
of	O
a	O
disposable	O
rotation-driven	O
microdisc	O
(	O
RDM	O
)	O
,	O
and	O
a	O
simple	O
bidirectional	O
rotating	O
magnetic	O
field	O
(	O
bi-RMF	O
)	O
.	O

The	O
assay	B-P
was	O
transformed	O
into	O
an	O
integrated	B-P
microfluidic	I-P
system	I-P
using	O
a	O
multilayered	O
polyester	O
microfluidic	O
disc	O
created	O
through	O
laser	O
print	O
,	O
cut	O
and	O
laminate	O
fabrication	O
,	O
with	O
fluid	O
flow	O
controlled	O
by	O
rotation	O
speed	O
without	O
any	O
mechanical	O
valves	O
.	O

The	O
RDM	O
accepts	O
four	O
samples	O
that	O
undergo	O
on-chip	O
dilution	O
to	O
five	O
different	O
concentrations	O
that	O
cover	O
the	O
effective	O
concentration	O
range	O
needed	O
for	O
downstream	O
cell	B-P
counting	I-P
by	O
pinwheel	B-P
assay	I-P
.	O

We	O
show	O
that	O
a	O
bi-RMF	O
is	O
effective	O
for	O
the	O
simultaneous	O
actuation	O
of	O
pinwheel	B-P
assays	I-P
in	O
20	O
detection	O
chambers	O
.	O

The	O
optimization	O
of	O
the	O
bi-RMF	O
frequencies	O
allows	O
the	O
RDM	O
-based	O
pinwheel	B-P
assay	I-P
detect	O
human	O
genomic	O
DNA	O
down	O
to	O
a	O
mass	O
of	O
human	O
genomic	O
DNA	O
(	O
5.5	O
picograms	O
)	O
that	O
is	O
roughly	O
equal	O
to	O
the	O
mass	O
in	O
a	O
single	O
cell	O
.	O

For	O
proof	O
of	O
principle	O
,	O
enumeration	O
of	O
the	O
white	O
blood	O
cells	O
in	O
human	O
blood	O
samples	O
on	O
the	O
RDM	O
provided	O
data	O
correlating	O
well	O
(	O
C.V.	O
of	O
10	O
%	O
)	O
with	O
those	O
obtained	O
in	O
a	O
clinical	O
lab	O
.	O

Fusing	O
the	O
cost	O
-	O
effective	O
RDM	O
with	O
a	O
simple	O
bi-RMF	O
provides	O
a	O
promising	O
strategy	O
for	O
automation	O
and	O
multiplexing	O
of	O
magnetic	O
particle	O
-based	O
agglutination	B-P
assays	I-P
.	O

Dobutamine	B-P
Stress	I-P
Echocardiography	I-P
:	O
Impact	O
of	O
Abnormal	O
Blood	O
Potassium	O
Levels	O
on	O
Cardiac	O
Arrhythmias	O
.	O

Guidelines	O
suggest	O
that	O
an	O
abnormal	O
blood	O
potassium	O
level	O
is	O
a	O
relative	O
contraindication	O
to	O
performing	O
dobutamine	B-P
stress	I-P
echocardiography	I-P
(	O
DSE	B-P
)	O
.	O

However	O
,	O
this	O
has	O
not	O
been	O
previously	O
studied	O
.	O

We	O
reviewed	O
a	O
consecutive	O
series	O
of	O
patients	O
who	O
had	O
potassium	O
testing	O
within	O
48	O
hours	O
of	O
undergoing	O
DSE	B-P
for	O
the	O
evaluation	O
of	O
myocardial	O
ischemia	O
over	O
a	O
10-	O
year	O
period	O
(	O
N	O
=	O
13,198	O
)	O
.	O

Normal	O
potassium	O
range	O
in	O
our	O
laboratory	O
is	O
3.6-5.2	O
mmol/L	O
.	O

Hemolyzed	O
samples	O
were	O
not	O
included	O
.	O

The	O
association	O
of	O
potassium	O
levels	O
with	O
the	O
development	O
of	O
supraventricular	O
and	O
ventricular	O
arrhythmias	O
was	O
assessed	O
.	O

The	O
incidence	O
of	O
clinically	O
significant	O
arrhythmias	O
was	O
very	O
low	O
(	O
supraventricular	O
tachycardia	O
/	O
atrial	O
fibrillation	O
,	O
4.9	O
%	O
;	O
nonsustained	O
ventricular	O
tachycardia	O
,	O
2.9	O
%	O
;	O
sustained	O
ventricular	O
tachycardia	O
or	O
ventricular	O
fibrillation	O
,	O
0.1	O
%	O
)	O
,	O
confirming	O
the	O
overall	O
safety	O
of	O
DSE	B-P
.	O

Most	O
arrhythmias	O
(	O
88	O
%	O
)	O
occurred	O
in	O
patients	O
with	O
normal	O
potassium	O
levels	O
,	O
and	O
arrhythmia	O
rates	O
remained	O
low	O
in	O
patients	O
with	O
potassium	O
abnormalities	O
.	O

Patients	O
with	O
hyperkalemia	O
had	O
a	O
lower	O
risk	O
of	O
developing	O
mild	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
0.39	O
;	O
95	O
%	O
CI	O
,	O
0.22-0.71	O
)	O
and	O
severe	O
(	O
OR	O
,	O
0.13	O
;	O
95	O
%	O
CI	O
,	O
0.01-0.68	O
)	O
supraventricular	O
arrhythmias	O
as	O
well	O
as	O
mild	O
ventricular	O
arrhythmias	O
(	O
OR	O
,	O
0.58	O
;	O
95	O
%	O
CI	O
,	O
0.40-0.83	O
)	O
.	O

Even	O
though	O
events	O
were	O
rare	O
,	O
patients	O
with	O
severe	O
hypokalemia	O
(	O
potassium	O
levels	O
≤	O
3.1	O
mmol/L	O
)	O
had	O
an	O
increased	O
risk	O
of	O
supraventricular	O
arrhythmia	O
and	O
ventricular	O
ectopy	O
.	O

DSE	B-P
is	O
safe	O
even	O
in	O
the	O
setting	O
of	O
abnormalities	O
in	O
blood	O
potassium	O
concentrations	O
,	O
and	O
hence	O
cancellation	O
of	O
DSE	B-P
in	O
patients	O
with	O
potassium	O
abnormalities	O
does	O
not	O
appear	O
warranted	O
.	O

Elevated	O
potassium	O
levels	O
are	O
associated	O
with	O
lower	O
rates	O
of	O
clinically	O
significant	O
supraventricular	O
and	O
ventricular	O
arrhythmias	O
.	O

While	O
remaining	O
at	O
relatively	O
low	O
risk	O
,	O
patients	O
with	O
very	O
low	O
potassium	O
levels	O
(	O
≤3.1	O
mmol/L	O
)	O
at	O
the	O
time	O
of	O
DSE	B-P
have	O
a	O
modestly	O
increased	O
risk	O
of	O
arrhythmia	O
.	O

Consideration	O
could	O
be	O
given	O
to	O
correcting	O
severe	O
hypokalemia	O
prior	O
to	O
DSE	B-P
.	O

Discovery	O
and	O
Optimization	O
of	O
a	O
Novel	O
Triazole	O
Series	O
of	O
GPR142	O
Agonists	O
for	O
the	O
Treatment	O
of	O
Type	O
2	O
Diabetes	O
.	O

GPR142	O
has	O
been	O
identified	O
as	O
a	O
potential	O
glucose-stimulated	O
insulin	O
secretion	O
(	O
GSIS	O
)	O
target	O
for	O
the	O
treatment	O
of	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
.	O

A	O
class	O
of	O
triazole	O
GPR142	O
agonists	O
was	O
discovered	O
through	O
a	O
high	B-P
throughput	I-P
screen	I-P
.	O

The	O
lead	O
compound	O
4	O
suffered	O
from	O
poor	O
metabolic	O
stability	O
and	O
poor	O
solubility	O
.	O

Lead	O
optimization	O
strategies	O
to	O
improve	O
potency	O
,	O
efficacy	O
,	O
metabolic	O
stability	O
,	O
and	O
solubility	O
are	O
described	O
.	O

This	O
optimization	O
led	O
to	O
compound	O
20e	O
,	O
which	O
showed	O
significant	O
reduction	O
of	O
glucose	O
excursion	O
in	O
wild-type	O
but	O
not	O
in	O
GPR142	O
deficient	O
mice	O
in	O
an	O
oral	B-P
glucose	I-P
tolerance	I-P
test	I-P
(	O
oGTT	B-P
)	O
study	O
.	O

These	O
studies	O
provide	O
strong	O
evidence	O
that	O
reduction	O
of	O
glucose	O
excursion	O
through	O
treatment	O
with	O
20e	O
is	O
GPR142	O
-mediated	O
,	O
and	O
GPR142	O
agonists	O
could	O
be	O
used	O
as	O
a	O
potential	O
treatment	O
for	O
type	O
2	O
diabetes	O
.	O

Trisaccharide	O
containing	O
α2,3-linked	O
sialic	O
acid	O
is	O
a	O
receptor	O
for	O
mumps	O
virus	O
.	O

Mumps	O
virus	O
(	O
MuV	O
)	O
remains	O
an	O
important	O
pathogen	O
worldwide	O
,	O
causing	O
epidemic	O
parotitis	O
,	O
orchitis	O
,	O
meningitis	O
,	O
and	O
encephalitis	O
.	O

Here	O
we	O
show	O
that	O
MuV	O
preferentially	O
uses	O
a	O
trisaccharide	O
containing	O
α2,3-linked	O
sialic	O
acid	O
in	O
unbranched	O
sugar	O
chains	O
as	O
a	O
receptor	O
.	O

Crystal	O
structures	O
of	O
the	O
MuV	O
attachment	O
protein	O
hemagglutinin-neuraminidase	O
(	O
MuV	O
-	O
HN	O
)	O
alone	O
and	O
in	O
complex	O
with	O
the	O
α2,3-sialylated	O
trisaccharide	O
revealed	O
that	O
in	O
addition	O
to	O
the	O
interaction	O
between	O
the	O
MuV	O
-	O
HN	O
active	O
site	O
residues	O
and	O
sialic	O
acid	O
,	O
other	O
residues	O
,	O
including	O
an	O
aromatic	O
residue	O
,	O
stabilize	O
the	O
third	O
sugar	O
of	O
the	O
trisaccharide	O
.	O

The	O
importance	O
of	O
the	O
aromatic	O
residue	O
and	O
the	O
third	O
sugar	O
in	O
the	O
MuV	O
-	O
HN	O
-	O
receptor	O
interaction	O
was	O
confirmed	O
by	O
computational	O
energy	O
calculations	O
,	O
isothermal	O
titration	O
calorimetry	O
studies	O
,	O
and	O
glycan-binding	B-P
assays	I-P
.	O

Furthermore	O
,	O
MuV	O
-	O
HN	O
was	O
found	O
to	O
bind	O
more	O
efficiently	O
to	O
unbranched	O
α2,3-sialylated	O
sugar	O
chains	O
compared	O
with	O
branched	O
ones	O
.	O

Important	O
ly	O
,	O
the	O
strategically	O
located	O
aromatic	O
residue	O
is	O
conserved	O
among	O
the	O
HN	O
protein	O
s	O
of	O
sialic	O
acid	O
-using	O
paramyxoviruses	O
,	O
and	O
alanine	O
substitution	O
compromised	O
their	O
ability	O
to	O
support	O
cell-cell	O
fusion	O
.	O

These	O
results	O
suggest	O
that	O
not	O
only	O
the	O
terminal	O
sialic	O
acid	O
but	O
also	O
the	O
adjacent	O
sugar	O
moiety	O
contribute	O
to	O
receptor	O
function	O
for	O
mumps	O
and	O
these	O
paramyxoviruses	O
.	O

The	O
distribution	O
of	O
structurally	O
different	O
sialylated	O
glycans	O
in	O
tissues	O
and	O
organs	O
may	O
explain	O
in	O
part	O
MuV	O
's	O
distinct	O
tropism	O
to	O
glandular	O
tissues	O
and	O
the	O
central	O
nervous	O
system	O
.	O

In	O
the	O
crystal	O
structure	O
,	O
the	O
epitopes	O
for	O
neutralizing	O
antibodies	O
are	O
located	O
around	O
the	O
α-helices	O
of	O
MuV	O
-	O
HN	O
that	O
are	O
not	O
well	O
conserved	O
in	O
amino	O
acid	O
sequences	O
among	O
different	O
genotypes	O
of	O
MuV	O
.	O

This	O
may	O
explain	O
the	O
fact	O
that	O
MuV	O
reinfection	O
sometimes	O
occurs	O
.	O

A	O
nano-delivery	O
system	O
for	O
bioactive	O
ingredients	O
using	O
supercritical	O
carbon	O
dioxide	O
and	O
its	O
release	O
behaviors	O
.	O

For	O
the	O
purpose	O
of	O
ensuring	O
the	O
bioavailability	O
of	O
bioactive	O
ingredients	O
,	O
a	O
nano-delivery	O
system	O
with	O
low	O
toxicity	O
was	O
developed	O
using	O
supercritical	O
carbon	O
dioxide	O
(	O
SC	O
-	O
CO2	O
)	O
.	O

Compared	O
to	O
thin-film	B-P
hydration	I-P
(	O
TFH	B-P
)	O
,	O
obtaining	O
nano-scale	O
liposomes	O
is	O
easier	O
using	O
SC	O
-	O
CO2	O
.	O

The	O
characteristic	O
of	O
these	O
liposomes	O
was	O
also	O
demonstrated	O
by	O
the	O
analysis	O
of	O
particle	O
size	O
and	O
morphology	O
.	O

An	O
in	O
vitro	O
release	O
study	O
showed	O
that	O
liposomes	O
produced	O
using	O
SC	O
-	O
CO2	O
were	O
resistant	O
to	O
low	O
pH	O
in	O
simulated	O
gastric	O
conditions	O
.	O

In	O
a	O
simulated	O
intestinal	O
environment	O
,	O
enteric	O
solubility	O
of	O
these	O
liposomes	O
was	O
enhanced	O
,	O
which	O
are	O
important	O
properties	O
for	O
controlled	O
releasing	O
bioactive	O
ingredient	O
.	O

Furthermore	O
,	O
SC	O
-	O
CO2	O
-produced	O
liposomes	O
had	O
a	O
higher	O
storage	O
stability	O
than	O
those	O
produced	O
using	O
TFH	B-P
.	O

Analysis	O
of	O
the	O
organic	O
solvent	O
residue	O
in	O
the	O
liposomes	O
by	O
gas	B-P
chromatography-mass	I-P
spectrometry	I-P
(	O
GC-MS	B-P
)	O
indicated	O
that	O
SC	O
-	O
CO2	O
-produced	O
liposomes	O
had	O
lower	O
toxicity	O
than	O
those	O
produced	O
by	O
TFH	B-P
.	O

A	O
chemical	O
free	O
nano-delivery	O
system	O
using	O
SC	O
-	O
CO2	O
has	O
been	O
revealed	O
for	O
storage	O
and	O
controlled	O
release	O
of	O
bioactive	O
ingredients	O
.	O

PI3Kδ	O
and	O
PI3Kγ	O
isoforms	O
have	O
distinct	O
functions	O
in	O
regulating	O
pro-tumoural	O
signalling	O
in	O
the	O
multiple	O
myeloma	O
microenvironment	O
.	O

Phosphoinositide-3-kinase	O
and	O
protein	O
kinase	O
B	O
(	O
PI3K	O
-	O
AKT	O
)	O
is	O
upregulated	O
in	O
multiple	O
myeloma	O
(	O
MM	O
)	O
.	O

Using	O
a	O
combination	O
of	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
lentivirus	O
-mediated	O
knockdown	O
and	O
pharmacologic	O
isoform-	O
specific	O
inhibition	O
we	O
investigated	O
the	O
role	O
of	O
the	O
PI3K	O
p110γ	O
(	O
PI3Kγ	O
)	O
subunit	O
in	O
regulating	O
MM	O
proliferation	O
and	O
bone	O
marrow	O
microenvironment	O
-	O
induced	O
MM	O
interactions	O
.	O

We	O
compared	O
this	O
with	O
inhibition	O
of	O
the	O
PI3K	O
p110δ	O
(	O
PI3kδ	O
)	O
subunit	O
and	O
with	O
combined	O
PI3kδ	O
/	O
γ	O
dual	O
inhibition	O
.	O

We	O
found	O
that	O
MM	O
cell	O
adhesion	O
and	O
migration	O
were	O
PI3Kγ	O
-	O
specific	O
functions	O
,	O
with	O
PI3kδ	O
inhibition	O
having	O
no	O
effect	O
in	O
MM	O
adhesion	O
or	O
migration	O
assays	B-P
.	O

At	O
concentration	O
of	O
the	O
dual	O
PI3Kδ	O
/	O
γ	O
inhibitor	O
duvelisib	O
,	O
which	O
can	O
be	O
achieved	O
in	O
vivo	O
we	O
saw	O
a	O
decrease	O
in	O
AKT	O
phosphorylation	O
at	O
s473	O
after	O
tumour	O
activation	O
by	O
bone	O
marrow	O
stromal	O
cells	O
(	O
BMSC	O
)	O
and	O
interleukin-6	O
.	O

Moreover	O
,	O
after	O
drug	O
treatment	O
of	O
BMSC	O
/	O
tumour	O
co-culture	B-P
activation	O
assays	B-P
only	O
dual	O
PI3kδ	O
/	O
γ	O
inhibition	O
was	O
able	O
to	O
induce	O
MM	O
apoptosis	O
.	O

shRNA	O
lentiviral	O
-mediated	O
targeting	O
of	O
either	O
PI3Kδ	O
or	O
PI3Kγ	O
alone	O
,	O
or	O
both	O
in	O
combination	O
,	O
increased	O
survival	O
of	O
NSG	O
mice	O
xeno-transplanted	O
with	O
MM	O
cells	O
.	O

Moreover	O
,	O
treatment	O
with	O
duvelisib	O
reduced	O
MM	O
tumour	O
burden	O
in	O
vivo	O
.	O

We	O
report	O
that	O
PI3Kδ	O
and	O
PI3Kγ	O
isoforms	O
have	O
distinct	O
functions	O
in	O
MM	O
and	O
that	O
combined	O
PI3kδ	O
/	O
γ	O
isoform	O
inhibition	O
has	O
anti	O
-	O
MM	O
activity	O
.	O

Here	O
we	O
provide	O
a	O
scientific	O
rationale	O
for	O
trials	O
of	O
dual	O
PI3kδ	O
/	O
γ	O
inhibition	O
in	O
patients	O
with	O
MM	O
.	O

Rotary	O
and	O
High	O
-	O
Pressure	O
Nozzle	O
Spray	O
Plume	O
Droplet	O
Analysis	O
For	O
Aerially	O
Applied	O
Mosquito	O
Adulticides	O
:	O
Laser	B-P
Diffraction	I-P
Characterization	I-P
.	O

The	O
droplet	O
spectrum	O
of	O
a	O
mosquito	O
adulticide	O
spray	O
plume	O
determines	O
its	O
ability	O
to	O
drift	O
through	O
the	O
target	O
area	O
,	O
impinge	O
on	O
the	O
mosquito	O
,	O
deliver	O
a	O
toxic	O
dose	O
,	O
and	O
the	O
risk	O
of	O
environmental	O
contamination	O
.	O

This	O
paper	O
provides	O
data	O
on	O
droplet	O
spectra	O
produced	O
from	O
6	O
nozzles	O
in	O
a	O
high	O
-	O
pressure	O
nozzle	O
spray	O
system	O
and	O
5	O
rotary	O
nozzle	O
systems	O
for	O
common	O
mosquito	O
adulticides	O
.	O

Spray	O
plume	O
spectra	O
were	O
measured	O
by	O
laser	B-P
diffraction	I-P
.	O

High	O
-	O
pressure	O
nozzles	O
were	O
evaluated	O
at	O
pressure	O
s	O
ranging	O
from	O
500	O
psi	O
to	O
6,000	O
psi	O
.	O

Rotary	O
nozzles	O
were	O
evaluated	O
at	O
rotational	O
speeds	O
ranging	O
from	O
500	O
rpm	O
to	O
24,000	O
rpm	O
.	O

Measurements	O
were	O
made	O
at	O
wind	O
speeds	O
of	O
129	O
km/h	O
(	O
80	O
mph	O
)	O
to	O
225	O
km/h	O
(	O
140	O
mph	O
)	O
.	O

Adulticides	O
included	O
were	O
Fyfanon	O
(	O
®	O
)	O
,	O
Aqua-Reslin	O
(	O
®	O
)	O
,	O
Dibrom	O
(	O
®	O
)	O
,	O
Duet	O
(	O
®	O
)	O
,	O
Permanone	O
(	O
®	O
)	O
,	O
and	O
the	O
inert	O
mineral	O
oil	O
,	O
Orchex	O
(	O
®	O
)	O
796	O
.	O

High-	O
pressure	O
nozzles	O
produced	O
spray	O
plumes	O
within	O
the	O
US	O
Environmental	O
Protection	O
Agency	O
(	O
EPA	O
)	O
label	O
requirements	O
for	O
all	O
configurations	O
tested	O
except	O
for	O
one	O
at	O
a	O
wind	O
speed	O
of	O
225	O
km/h	O
,	O
BETE	O
(	O
®	O
)	O
MW125	O
.	O

Air	O
speed	O
had	O
no	O
significant	O
effect	O
on	O
the	O
spray	O
plume	O
volume	O
median	O
diameter	O
(	O
Dv	O
(	O
0.5	O
)	O
)	O
at	O
the	O
speeds	O
tested	O
with	O
Fyfanon	O
(	O
®	O
)	O
.	O

The	O
spray	O
plume	O
90	O
%	O
drop	O
volume	O
diameter	O
(	O
Dv	O
(	O
0.9	O
)	O
)	O
significantly	O
decreased	O
,	O
13	O
%	O
at	O
the	O
higher	O
wind	O
speed	O
of	O
225	O
km/h	O
.	O

Drop	O
size	O
was	O
inversely	O
related	O
to	O
pressure	O
.	O

Dilution	O
of	O
the	O
product	O
formulations	O
increased	O
the	O
Dv	O
(	O
0.5	O
)	O
of	O
the	O
spray	O
plume	O
but	O
it	O
did	O
not	O
exceed	O
the	O
label	O
requirements	O
.	O

For	O
the	O
PJ15	O
nozzle	O
,	O
orientation	O
of	O
the	O
nozzle	O
into	O
the	O
wind	O
of	O
up	O
to	O
135°	O
showed	O
a	O
significant	O
increase	O
in	O
Dv	O
(	O
0.5	O
)	O
at	O
500	O
psi	O
,	O
750	O
psi	O
,	O
and	O
1,500	O
psi	O
.	O

The	O
Dv	O
(	O
0.5	O
)	O
varied	O
<	O
5	O
μm	O
over	O
the	O
3	O
angles	O
examined	O
for	O
any	O
specific	O
pressure	O
.	O

Rotary	O
nozzles	O
produced	O
spray	O
plumes	O
within	O
the	O
EPA	O
label	O
requirements	O
for	O
all	O
test	O
configurations	O
examined	O
.	O

Air	O
speed	O
had	O
no	O
significant	O
effect	O
on	O
Dv	O
(	O
0.5	O
)	O
or	O
Dv	O
(	O
0.9	O
)	O
of	O
the	O
plume	O
at	O
speeds	O
tested	O
with	O
Fyfanon	O
for	O
the	O
ASC	O
A20	O
nozzle	O
.	O

The	O
rotary	O
AU5000	O
nozzle	O
using	O
Orchex	O
796	O
produced	O
plumes	O
of	O
larger	O
drops	O
in	O
all	O
configurations	O
than	O
any	O
of	O
the	O
rotary	O
nozzles	O
of	O
similar	O
configurations	O
using	O
active	O
ingredient	O
formulations	O
and	O
within	O
EPA	O
label	O
requirements	O
.	O

Clinical	O
Features	O
of	O
Smokers	O
With	O
Radiological	B-P
Emphysema	O
But	O
Without	O
Airway	O
Limitation	O
.	O

The	O
clinical	O
characteristics	O
of	O
patients	O
with	O
emphysema	O
but	O
without	O
airway	O
limitations	O
remain	O
unknown	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
clinical	O
features	O
of	O
current	O
and	O
former	O
smokers	O
without	O
airflow	O
limitation	O
who	O
have	O
radiologic	B-P
emphysema	O
on	O
chest	B-P
CT	I-P
scans	I-P
vs	O
a	O
control	O
group	O
of	O
current	O
and	O
ex-smokers	O
without	O
emphysema	O
.	O

Subjects	O
enrolled	O
had	O
anthropometric	B-P
characteristics	I-P
recorded	O
,	O
provided	O
a	O
medical	O
history	O
,	O
and	O
underwent	O
low-dose	O
chest	B-P
CT	I-P
scanning	I-P
.	O

The	O
following	O
parameters	O
were	O
also	O
evaluated	O
:	O
pulmonary	B-P
function	I-P
tests	I-P
including	O
diffusion	B-P
capacity	I-P
for	I-P
carbon	I-P
monoxide	I-P
(	O
Dlco	B-P
)	O
,	O
the	O
modified	O
Medical	O
Research	O
Council	O
dyspnea	O
score	O
,	O
COPD	O
assessment	O
test	O
(	O
CAT	O
)	O
,	O
and	O
6-min	B-P
walk	I-P
test	I-P
(	O
6MWT	B-P
)	O
.	O

A	O
comparison	O
was	O
conducted	O
between	O
those	O
with	O
and	O
without	O
CT	B-P
-	O
confirmed	O
emphysema	O
.	O

Of	O
the	O
203	O
subjects	O
,	O
154	O
had	O
emphysema	O
,	O
and	O
49	O
did	O
not	O
.	O

Adjusted	O
group	O
comparisons	O
revealed	O
that	O
a	O
higher	O
proportion	O
of	O
patients	O
with	O
emphysema	O
according	O
to	O
low-dose	O
chest	B-P
CT	I-P
scanning	I-P
had	O
an	O
abnormal	O
Dlco	O
value	O
(	O
<	O
80	O
%	O
)	O
(	O
46	O
%	O
vs	O
19	O
%	O
;	O
P	O
=	O
.02	O
)	O
,	O
a	O
decrease	O
in	O
percentage	O
of	O
oxygen	O
saturation	O
>	O
4	O
%	O
during	O
the	O
6MWT	B-P
(	O
8.5	O
%	O
vs	O
0	O
;	O
P	O
=	O
.04	O
)	O
,	O
and	O
an	O
altered	O
quality	O
of	O
life	O
(	O
CAT	O
score	O
≥	O
10	O
)	O
(	O
32	O
%	O
vs	O
14	O
%	O
;	O
P	O
=	O
.01	O
)	O
.	O

A	O
detailed	O
analysis	O
of	O
the	O
CAT	O
questionnaire	O
items	O
revealed	O
that	O
more	O
patients	O
with	O
emphysema	O
had	O
a	O
score	O
≥	O
1	O
in	O
the	O
``	O
chest	O
tightness	O
``	O
(	O
P	O
=	O
.05	O
)	O
and	O
``	O
limitation	O
when	O
doing	O
activities	O
at	O
home	O
``	O
(	O
P	O
<	O
.01	O
)	O
items	O
compared	O
with	O
those	O
with	O
no	O
emphysema	O
.	O

They	O
also	O
experienced	O
significantly	O
more	O
exacerbations	O
in	O
the	O
previous	O
year	O
(	O
0.19	O
vs	O
0.04	O
;	O
P	O
=	O
.02	O
)	O
.	O

A	O
significant	O
proportion	O
of	O
smokers	O
with	O
emphysema	O
according	O
to	O
low-dose	O
chest	B-P
CT	I-P
scanning	I-P
but	O
without	O
airway	O
limitation	O
had	O
alterations	O
in	O
their	O
quality	O
of	O
life	O
,	O
number	O
of	O
exacerbations	O
,	O
Dlco	B-P
values	O
,	O
and	O
oxygen	O
saturation	O
during	O
the	O
6MWT	B-P
test	I-P
.	O

Visualization	B-P
for	O
Understanding	O
Uncertainty	O
in	O
Activation	O
Volumes	O
for	O
Deep	O
Brain	O
Stimulation	O
.	O

We	O
have	O
created	O
the	O
Neurostimulation	O
Uncertainty	O
Viewer	O
(	O
nuView	O
or	O
νView	O
)	O
tool	O
for	O
exploring	O
data	O
arising	O
from	O
deep	O
brain	O
stimulation	O
(	O
DBS	O
)	O
.	O

Simulated	O
volume	O
of	O
tissue	O
activated	O
(	O
VTA	O
)	O
,	O
using	O
clinical	B-P
electrode	I-P
placements	I-P
,	O
are	O
recorded	O
along	O
with	O
patient	O
outcomes	O
in	O
the	O
Unified	O
Parkinson	O
's	O
disease	O
rating	O
scale	O
(	O
UPDRS	O
)	O
.	O

The	O
data	O
is	O
volumetric	O
and	O
sparse	O
,	O
with	O
multi-value	O
patient	O
results	O
for	O
each	O
activated	O
voxel	O
in	O
the	O
simulation	O
.	O

νView	O
provides	O
a	O
collection	O
of	O
visual	O
methods	O
to	O
explore	O
the	O
activated	O
tissue	O
to	O
enhance	O
understanding	O
of	O
electrode	O
usage	O
for	O
improved	O
therapy	O
with	O
DBS	O
.	O

Involvement	O
of	O
apoptotic	O
pathways	O
in	O
docosahexaenoic	O
acid	O
-induced	O
benefit	O
in	O
prostate	O
cancer	O
:	O
Pathway-focused	O
gene	O
expression	O
analysis	O
using	O
RT	O
(	O
2	O
)	O
Profile	O
PCR	O
Array	O
System	O
.	O

Present	O
study	O
aimed	O
to	O
better	O
understand	O
the	O
potential	O
apoptotic	O
pathways	O
that	O
involved	O
in	O
docosahexaenoic	O
acid	O
(	O
DHA	O
)	O
-induced	O
apoptosis	O
of	O
prostate	O
cancer	O
cells	O
.	O

Human	O
prostate	O
cancer	O
DU145	O
cells	O
were	O
treated	O
with	O
different	O
concentrations	O
of	O
fish	O
oil	O
,	O
omega-3	O
PUFA	O
(	O
DHA	O
,	O
and	O
Eicosapentaenoic	O
acid	O
,	O
EPA	O
)	O
,	O
or	O
omega-6	O
PUFA	O
(	O
Arachidonic	O
acid	O
,	O
AA	O
)	O
.	O

Cell	O
viability	O
and	O
apoptosis	O
were	O
evaluated	O
by	O
MTT	O
assay	O
and	O
Hoechst	B-P
staining	I-P
.	O

Pathway-focused	O
gene	O
expression	O
profiling	O
of	O
DU145	O
cells	O
was	O
analyzed	O
with	O
the	O
RT	O
(	O
2	O
)	O
Profile	O
PCR	O
Array	O
System	O
.	O

The	O
results	O
were	O
verified	O
by	O
real	O
time	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
RT-qPCR	O
)	O
.	O

AA	O
exposure	O
showed	O
no	O
obvious	O
effect	O
on	O
viability	O
of	O
DU145	O
cells	O
.	O

However	O
,	O
exposure	O
with	O
fish	O
oil	O
,	O
EPA	O
,	O
or	O
DHA	O
for	O
24	O
h	O
significantly	O
affected	O
cell	O
viability	O
.	O

The	O
growth	O
inhibition	O
of	O
DHA	O
was	O
more	O
pronounced	O
than	O
that	O
of	O
EPA	O
and	O
showed	O
a	O
time-dependent	O
increase	O
.	O

DHA	O
exposure	O
caused	O
typical	O
apoptotic	O
characteristics	O
.	O

Ten	O
genes	O
were	O
more	O
expressed	O
,	O
while	O
5	O
genes	O
were	O
less	O
expressed	O
following	O
DHA	O
exposure	O
.	O

RT-qPCR	O
confirmed	O
the	O
time	O
dependent	O
effect	O
of	O
DHA	O
on	O
the	O
expression	O
of	O
these	O
differentially	O
expressed	O
genes	O
.	O

KEGG	O
pathway	O
analysis	O
showed	O
that	O
DHA	O
may	O
induce	O
the	O
apoptosis	O
of	O
cancer	O
cells	O
preferentially	O
through	O
mediating	O
P53	O
,	O
MAPK	O
,	O
TNF	O
,	O
PI3K/AKT	O
,	O
and	O
NF-κB	O
signaling	O
pathways	O
.	O

Our	O
study	O
demonstrated	O
the	O
beneficial	O
action	O
of	O
DHA	O
on	O
human	O
prostate	O
carcinoma	O
cell	O
line	O
DU145	O
.	O

The	O
pro-apoptotic	O
effect	O
of	O
DHA	O
on	O
DU145	O
cells	O
may	O
involve	O
mediation	O
various	O
pathways	O
,	O
especially	O
P53	O
,	O
MAPK	O
,	O
TNF	O
,	O
PI3K/AKT	O
,	O
and	O
NF-κB	O
signaling	O
pathways	O
.	O

Molecular	O
mechanisms	O
of	O
DHA	O
on	O
apoptosis	O
of	O
cancer	O
cells	O
still	O
need	O
to	O
be	O
further	O
clarified	O
.	O

Knee	O
joint	O
kinematics	O
with	O
dynamic	O
augmentation	O
of	O
primary	O
anterior	O
cruciate	O
ligament	O
repair	O
-	O
a	O
biomechanical	O
study	O
.	O

Dynamic	O
augmentation	O
of	O
anterior	O
cruciate	O
ligament	O
tears	O
seems	O
to	O
reduce	O
anteroposterior	O
knee	O
translation	O
close	O
to	O
the	O
pre	O
-	O
injury	O
level	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
biomechanically	O
investigate	O
the	O
course	O
of	O
translation	O
during	O
a	O
simulated	O
early	O
post-operative	O
phase	O
.	O

It	O
is	O
hypothesized	O
that	O
anteroposterior	O
translation	O
is	O
maintained	O
at	O
the	O
immediate	O
post-operative	O
level	O
over	O
a	O
simulated	O
rehabilitation	O
period	O
of	O
50'000	O
gait	O
cycles	O
.	O

Eight	O
fresh	O
-	O
frozen	O
human	O
cadaveric	O
knee	O
joints	O
from	O
donors	O
with	O
a	O
mean	O
age	O
of	O
35.5	O
(	O
range	O
25-40	O
)	O
years	O
were	O
subjected	O
to	O
50'000	O
cycles	O
of	O
0°-70°-0°	O
flexion-extension	O
movements	O
in	O
a	O
custom-made	O
test	B-P
setup	I-P
.	O

Anteroposterior	O
translation	O
was	O
assessed	O
with	O
simulated	O
Lachman/KT-1000	B-P
testing	I-P
in	O
0°	O
,	O
15°	O
,	O
30°	O
,	O
60°	O
and	O
90°	O
of	O
flexion	O
in	O
knee	O
joints	O
treated	O
with	O
the	O
novel	O
technique	O
initially	O
and	O
after	O
50'000	O
cycles	O
testing	O
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
the	O
Wilcoxon	O
Signed-Rank	O
Test	O
.	O

The	O
level	O
of	O
significance	O
was	O
set	O
at	O
p	O
=	O
0.05	O
.	O

Anteroposterior	O
translation	O
changed	O
non	O
-	O
significantly	O
for	O
all	O
flexion	O
angles	O
between	O
cycle	O
0	O
and	O
50'000	O
(	O
p	O
=	O
0.39	O
to	O
p	O
=	O
0.89	O
)	O
,	O
except	O
for	O
30°	O
flexion	O
,	O
where	O
a	O
significant	O
increase	O
by	O
1.4	O
mm	O
was	O
found	O
(	O
p	O
=	O
0.03	O
)	O
.	O

Increase	O
in	O
anteroposterior	O
translation	O
of	O
knees	O
treated	O
with	O
this	O
dynamic	O
augmentation	O
procedure	O
is	O
low	O
.	O

The	O
procedure	O
maintains	O
translation	O
close	O
to	O
the	O
immediate	O
post-operative	O
level	O
over	O
a	O
simulated	O
rehabilitation	O
period	O
of	O
50'000	O
gait	O
cycles	O
and	O
therefore	O
supports	O
anterior	O
cruciate	O
ligament	O
repair	O
during	O
biological	O
healing	O
.	O

Ecology	O
and	O
Feeding	O
Habits	O
Drive	O
Infection	O
of	O
Water	O
Bugs	O
with	O
Mycobacterium	O
ulcerans	O
.	O

Mycobacterium	O
ulcerans	O
(	O
MU	O
)	O
,	O
the	O
causative	O
agent	O
of	O
Buruli	O
ulcer	O
,	O
is	O
present	O
in	O
a	O
wide	O
spectrum	O
of	O
environments	O
,	O
including	O
terrestrial	O
and	O
aquatic	O
ecosystems	O
in	O
tropical	O
regions	O
.	O

The	O
most	O
promising	O
studies	B-P
on	O
the	O
epidemiological	O
risk	O
of	O
this	O
disease	O
suggest	O
that	O
some	O
ecological	O
settings	O
may	O
favor	O
infection	O
of	O
animals	O
with	O
MU	O
including	O
human	O
.	O

A	O
species	O
'	O
needs	O
and	O
impacts	O
on	O
resources	O
and	O
the	O
environment	O
,	O
i.e.	O
,	O
its	O
ecological	O
niche	O
,	O
may	O
influence	O
its	O
susceptibility	O
to	O
be	O
infected	O
by	O
this	O
microbial	O
form	O
.	O

For	O
example	O
,	O
some	O
Naucoridae	O
may	O
dive	O
in	O
fresh	O
waters	O
to	O
prey	O
upon	O
infected	O
animals	O
and	O
thus	O
may	O
get	O
infected	O
with	O
MU	O
.	O

However	O
,	O
these	O
studies	B-P
have	O
rarely	O
considered	O
that	O
inference	O
on	O
the	O
ecological	O
settings	O
favoring	O
infection	O
and	O
transmission	O
may	O
be	O
confounded	O
because	O
host	O
carrier	O
sister	O
species	O
have	O
similar	O
ecological	O
niches	O
,	O
and	O
potentially	O
the	O
same	O
host	O
-	O
microbe	O
interactions	O
.	O

Hence	O
,	O
a	O
relationship	O
between	O
the	O
ecological	O
niche	O
of	O
Naucoridae	O
and	O
its	O
infection	O
with	O
MU	O
may	O
be	O
due	O
to	O
a	O
symbiotic	O
relationship	O
between	O
the	O
host	O
and	O
the	O
pathogen	O
,	O
rather	O
than	O
its	O
ecological	O
niche	O
.	O

To	O
account	O
for	O
this	O
confounding	O
effect	O
,	O
we	O
investigated	O
the	O
relationships	O
between	O
surrogates	O
of	O
the	O
ecological	O
niche	O
of	O
water	O
bug	O
species	O
and	O
their	O
susceptibility	O
to	O
MU	O
,	O
by	O
performing	O
phylogenetic	O
comparative	O
analyses	O
on	O
a	O
large	O
dataset	O
of	O
11	O
families	O
of	O
water	O
bugs	O
collected	O
in	O
10	O
different	O
sites	O
across	O
Cameroon	O
,	O
central	O
Africa	O
.	O

Our	O
results	O
indicate	O
that	O
MU	O
circulates	O
and	O
infects	O
a	O
couple	O
of	O
host	O
taxa	O
,	O
i.e.	O
,	O
Belostomatidae	O
,	O
Naucoridae	O
,	O
living	O
both	O
in	O
the	O
aquatic	O
vegetation	O
and	O
as	O
predators	O
inside	O
the	O
trophic	O
network	O
and	O
sister	O
species	O
of	O
water	O
bugs	O
have	O
indeed	O
similar	O
host	O
-	O
microbe	O
interactions	O
with	O
MU	O
.	O

Contrasting	O
effects	O
of	O
intra	O
-	O
and	O
interspecific	O
identity	O
and	O
richness	O
of	O
ectomycorrhizal	O
fungi	O
on	O
host	O
plants	O
,	O
nutrient	O
retention	O
and	O
multifunctionality	O
.	O

A	O
major	O
gap	O
in	O
our	O
understanding	O
of	O
biodiversity	O
-	O
ecosystem	O
function	O
relationships	O
concerns	O
the	O
role	O
of	O
intra	O
-	O
and	O
interspecific	O
diversity	O
of	O
mycorrhizal	O
fungi	O
,	O
which	O
are	O
critical	O
for	O
plant	O
fitness	O
,	O
biogeochemical	O
cycling	O
and	O
other	O
processes	O
.	O

Here	O
,	O
we	O
test	O
the	O
hypothesis	O
that	O
the	O
identity	O
and	O
richness	O
of	O
ectomycorrhizal	O
(	O
ECM	O
)	O
fungi	O
at	O
the	O
intra-	O
and	O
interspecific	O
levels	O
affect	O
ecosystem	O
multifunctionality	O
by	O
regulating	O
plant	O
and	O
fungal	O
productivity	O
,	O
soil	O
CO2	O
efflux	O
and	O
nutrient	O
retention	O
.	O

Microcosms	O
containing	O
Scots	O
pine	O
(	O
Pinus	O
sylvestris	O
)	O
seedlings	O
colonized	O
by	O
different	O
ECM	O
fungal	O
isolates	O
,	O
in	O
monocultures	B-P
and	O
mixtures	B-P
,	O
enabled	O
us	O
to	O
test	O
for	O
both	O
intra-	O
and	O
interspecific	O
identity	O
and	O
richness	O
effects	O
,	O
and	O
transgressive	O
overyielding	O
.	O

Intra-	O
and	O
interspecific	O
identity	O
had	O
modest	O
but	O
significant	O
effects	O
on	O
plant	O
and	O
fungal	O
productivity	O
and	O
nutrient	O
retention	O
,	O
but	O
no	O
effect	O
on	O
CO2	O
efflux	O
.	O

Intraspecific	O
richness	O
increased	O
plant	O
root	O
productivity	O
and	O
ECM	O
root	O
tips	O
but	O
decreased	O
hyphal	O
length	O
,	O
whereas	O
interspecific	O
richness	O
had	O
no	O
effects	O
.	O

Interspecific	O
mixtures	O
outperformed	O
the	O
most	O
productive	O
monocultures	B-P
in	O
only	O
10	O
%	O
of	O
the	O
cases	O
,	O
compared	O
with	O
42	O
%	O
for	O
the	O
intraspecific	O
mixtures	O
.	O

Both	O
intra	O
-	O
and	O
interspecific	O
identity	O
and	O
richness	O
of	O
ECM	O
fungi	O
regulate	O
ecosystem	O
multifunctionality	O
,	O
but	O
their	O
effects	O
on	O
the	O
direction	O
and	O
magnitude	O
of	O
individual	O
variables	O
differ	O
.	O

Transgressive	O
overyielding	O
suggests	O
that	O
positive	O
niche	O
complementarity	O
effects	O
are	O
driving	O
some	O
of	O
the	O
responses	O
to	O
intraspecific	O
richness	O
.	O

Country	O
-	O
specific	O
chemical	O
signatures	O
of	O
persistent	O
organic	O
pollutants	O
(	O
POPs	O
)	O
in	O
breast	O
milk	O
of	O
French	O
,	O
Danish	O
and	O
Finnish	O
women	O
.	O

The	O
present	O
study	O
compares	O
concentrations	O
and	O
chemical	B-P
profiles	I-P
of	O
an	O
extended	O
range	O
of	O
persistent	O
organic	O
pollutants	O
(	O
dioxins	O
,	O
polychlorobiphenyls	O
,	O
brominated	O
flame	O
retardants	O
and	O
organochlorine	O
pesticides	O
)	O
in	O
breast	O
milk	O
samples	O
from	O
French	O
(	O
n	O
=	O
96	O
)	O
,	O
Danish	O
(	O
n	O
=	O
438	O
)	O
and	O
Finnish	O
(	O
n	O
=	O
22	O
)	O
women	O
.	O

Median	O
exposure	O
levels	O
observed	O
in	O
French	O
women	O
(	O
WHO	O
-	O
TEQ	O
2005	O
PCDD/F	O
=	O
6.1	O
pg/g	O
l.w.	O
,	O
WHO	O
-	O
TEQ	O
2005	O
dl-PCB	O
=	O
4.3	O
pg/g	O
l.w.	O
,	O
sum	O
of	O
6	O
ndl-PCB	O
=	O
85.2	O
ng/g	O
l.w.	O
,	O
sum	O
of	O
7	O
i-PBDE	O
=	O
1.5	O
ng/g	O
l.w	O
.	O
)	O

appeared	O
overall	O
lower	O
than	O
in	O
Danish	O
and	O
Finnish	O
women	O
for	O
all	O
examined	O
POPs	O
,	O
except	O
for	O
α-HBCD	O
(	O
2-fold	O
higher	O
level	O
at	O
0.6	O
ng/g	O
l.w.	O
)	O
.	O

Furthermore	O
,	O
the	O
observed	O
exposure	O
levels	O
of	O
dioxins	O
and	O
PCBs	O
were	O
higher	O
in	O
Danish	O
women	O
(	O
WHO	O
-	O
TEQ	O
2005	O
PCDD/F	O
=	O
13.2	O
pg/g	O
l.w.	O
,	O
WHO	O
-	O
TEQ	O
2005	O
dl-PCB	O
=	O
6.6	O
pg/g	O
l.w.	O
,	O
sum	O
of	O
6	O
ndl-PCB	O
=	O
162.8	O
ng/g	O
l.w	O
.	O
)	O

compared	O
to	O
Finnish	O
women	O
(	O
WHO	O
-	O
TEQ	O
2005	O
PCDD/F	O
=	O
9.0	O
pg/g	O
l.w.	O
,	O
WHO	O
-	O
TEQ	O
2005	O
dl-PCB	O
=	O
4.6	O
pg/g	O
l.w.	O
,	O
sum	O
of	O
6	O
ndl-PCB	O
=	O
104.0	O
ng/g	O
l.w	O
.	O

)	O
,	O
whereas	O
the	O
concentrations	O
of	O
PBDEs	O
were	O
similar	O
for	O
Danish	O
and	O
Finnish	O
women	O
(	O
sum	O
of	O
7	O
i-PBDE	O
=	O
4.9	O
and	O
5.2	O
ng/g	O
l.w	O
.	O

respectively	O
)	O
.	O

The	O
organochlorine	O
(	O
OC	O
)	O
pesticide	O
contamination	O
profile	O
,	O
determined	O
in	O
a	O
subset	O
of	O
French	O
samples	O
,	O
was	O
dominated	O
by	O
p	O
,	O
p'-DDE	O
(	O
56.6	O
%	O
)	O
,	O
followed	O
by	O
β-HCH	O
(	O
14.2	O
%	O
)	O
,	O
HCB	O
(	O
9.7	O
%	O
)	O
and	O
dieldrin	O
(	O
5.2	O
%	O
)	O
,	O
while	O
other	O
compounds	O
were	O
only	O
minor	O
contributors	O
(	O
<	O
5	O
%	O
)	O
.	O

The	O
three	O
countries	O
appeared	O
to	O
be	O
discriminated	O
by	O
the	O
observed	O
contamination	O
patterns	O
of	O
the	O
PCDD/F	O
versus	O
PCB	O
,	O
and	O
the	O
1,2,3,6,7,8-HxCDD	O
versus	O
1,2,3,4,7,8-HxCDD	O
ratios	O
,	O
in	O
addition	O
to	O
the	O
relative	O
contributions	O
of	O
specific	O
congeners	O
to	O
the	O
contamination	O
profile	O
(	O
PCBs	O
#	O
118	O
and	O
#	O
156	O
,	O
PBDEs	O
#	O
28	O
,	O
#	O
47	O
,	O
#	O
99	O
and	O
#	O
153	O
)	O
.	O

In	O
conclusion	O
,	O
unique	O
chemical	O
signatures	O
were	O
observed	O
for	O
each	O
country	O
on	O
the	O
basis	O
of	O
some	O
POP	O
congeners	O
.	O

Future	O
biomonitoring	O
studies	O
will	O
need	O
to	O
consider	O
the	O
high	O
variability	O
of	O
individual	O
exposure	O
profiles	O
in	O
relation	O
to	O
multiple	O
exposure	O
sources	O
but	O
also	O
physiological	O
and	O
metabolic	O
differences	O
.	O

CS	O
-	O
PEG	O
decorated	O
PLGA	O
nano-prototype	O
for	O
delivery	O
of	O
bioactive	O
compounds	O
:	O
A	O
novel	O
approach	O
for	O
induction	O
of	O
apoptosis	O
in	O
HepG2	O
cell	O
line	O
.	O

Polymer	O
-	O
based	O
nanoparticles	O
are	O
used	O
as	O
vectors	O
for	O
cancer	O
drug	O
delivery	O
.	O

The	O
bioactive	O
compounds	O
(	O
quercetin	O
,	O
ellagic	O
acid	O
and	O
gallic	O
acid	O
)	O
are	O
well	O
known	O
to	O
be	O
not	O
only	O
antioxidants	O
but	O
also	O
chemopreventive	O
candidates	O
against	O
various	O
types	O
of	O
cancers	O
.	O

To	O
circumvent	O
the	O
low	O
bioavailability	O
and	O
the	O
short	O
half-life	O
time	O
obstacles	O
,	O
we	O
hypothesized	O
a	O
novel	O
PLGA	O
nano-platform	O
functionalized	O
with	O
CS	O
and	O
PEG	O
to	O
encapsulate	O
these	O
phytochemicals	O
.	O

This	O
encapsulation	O
will	O
protect	O
the	O
compounds	O
from	O
the	O
phagocytic	O
uptake	O
and	O
deliver	O
PLGA-CS-PEG	O
nano-prototype	O
with	O
high	O
biodegradability	O
and	O
biosafety	O
.	O

Three	O
consequent	O
types	O
of	O
PLGA-based	O
nanocomposites	O
were	O
prepared	O
and	O
characterized	O
.	O

Furthermore	O
,	O
we	O
investigated	O
the	O
newly	O
synthesized	O
nano-formulations	O
against	O
human	O
hepatocellular	O
carcinoma	O
(	O
HepG2	O
)	O
and	O
colorectal	O
cancer	O
(	O
HCT	O
116	O
)	O
cell	O
lines	O
using	O
cell	O
growth	O
inhibition	O
assays	B-P
,	O
followed	O
by	O
apoptosis	O
and	O
necrosis	O
assays	B-P
using	O
flow	B-P
cytometry	I-P
to	O
detect	B-P
the	O
underlying	O
mechanism	O
of	O
HepG2	O
cell	O
death	O
.	O

Through	O
Malvern	O
Zeta	O
Sizer	O
,	O
we	O
recorded	O
that	O
the	O
average	O
diameters	O
of	O
the	O
nano-prototypes	O
ranged	O
from	O
150	O
to	O
300nm	O
.	O

The	O
cytotoxic	B-P
activity	I-P
of	O
quercetin	O
,	O
ellagic	O
acid	O
,	O
and	O
gallic	O
acid	O
-	O
encapsulated	O
PLGA	O
,	O
PLGA-CS	O
,	O
and	O
PLGA-CS-PEG	O
nano-prototypes	O
it	O
has	O
been	O
found	O
that	O
they	O
reduce	O
the	O
IC50s	O
of	O
the	O
HepG2	O
cells	O
values	O
by	O
2.2	O
,	O
2.9	O
,	O
2.8-	O
folds	O
,	O
1	O
,	O
1.5	O
,	O
2.7-	O
folds	O
,	O
and	O
0.9	O
,	O
0.7	O
,	O
1.5-	O
folds	O
,	O
respectively	O
.	O

Mechanistically	O
,	O
the	O
nano-platforms	O
of	O
quercetin	O
seem	O
to	O
be	O
dependent	O
on	O
both	O
apoptosis	O
and	O
necrosis	O
,	O
while	O
those	O
of	O
ellagic	O
acid	O
and	O
gallic	O
acid	O
are	O
mainly	O
dependent	O
on	O
apoptosis	O
.	O

CS	O
-	O
PEG	O
-blended	O
PLGA	O
nano-delivery	O
system	O
of	O
quercetin	O
,	O
ellagic	O
acid	O
and	O
gallic	O
acid	O
can	O
potentiate	O
apoptosis-mediated	O
cell	O
death	O
in	O
HepG2	O
cell	O
line	O
.	O

Establishment	O
and	O
application	O
of	O
a	O
flow	B-P
cytometry	I-P
-based	O
method	O
for	O
detecting	O
histone	O
acetylation	O
levels	O
.	O

Histone	O
deacetylase	O
inhibitors	O
,	O
which	O
have	O
also	O
received	O
attention	O
in	O
AIDS	O
and	O
other	O
diseases	O
,	O
are	O
a	O
new	O
class	O
of	O
anticancer	O
drugs	O
developed	O
in	O
recent	O
years	O
.	O

However	O
,	O
there	O
is	O
still	O
a	O
lack	O
of	O
a	O
unified	O
and	O
reliable	O
method	O
for	O
detecting	O
histone	O
acetylation	O
levels	O
in	O
basic	O
and	O
clinical	O
research	O
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
flow	B-P
cytometry	I-P
-based	O
method	O
to	O
detect	O
histone	O
acetylation	O
levels	O
by	O
comparing	O
different	O
sample	O
processing	O
temperature	O
(	O
on	O
ice	O
vs.	O
room	O
temperature	O
)	O
,	O
permeabilization	O
method	O
(	O
intracellular	O
vs.	O
nuclear	O
)	O
,	O
antibody	O
dose	O
(	O
antibody	B-P
titration	I-P
)	O
and	O
antibody	O
incubation	O
time	O
(	O
time	O
gradient	O
)	O
using	O
whole	O
blood	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

In	O
addition	O
,	O
we	O
applied	O
this	O
optimized	O
method	O
in	O
in	O
vitro	O
experiment	O
and	O
clinical	O
trial	O
of	O
Chidamide	O
(	O
the	O
only	O
China	O
FDA	O
approved	O
HDACi	O
)	O
,	O
the	O
result	O
of	O
which	O
confirmed	O
that	O
the	O
flow	B-P
cytometry	I-P
-based	O
method	O
for	O
detecting	O
histone	O
acetylation	O
levels	O
is	O
a	O
reliable	O
,	O
fast	O
and	O
convenient	O
method	O
which	O
can	O
be	O
used	O
in	O
basic	O
and	O
clinical	O
research	O
.	O

Mechanics	O
,	O
thermodynamics	O
,	O
and	O
kinetics	O
of	O
ligand	O
binding	O
to	O
biopolymers	O
.	O

Ligands	O
binding	O
to	O
polymers	O
regulate	O
polymer	O
functions	O
by	O
changing	O
their	O
physical	O
and	O
chemical	O
properties	O
.	O

This	O
ligand	O
regulation	O
plays	O
a	O
key	O
role	O
in	O
many	O
biological	O
processes	O
.	O

We	O
propose	O
here	O
a	O
model	O
to	O
explain	O
the	O
mechanical	O
,	O
thermodynamic	O
,	O
and	O
kinetic	O
properties	O
of	O
the	O
process	O
of	O
binding	O
of	O
small	O
ligands	O
to	O
long	O
biopolymers	O
.	O

These	O
properties	O
can	O
now	O
be	O
measured	O
at	O
the	O
single	O
molecule	O
level	O
using	O
force	B-P
spectroscopy	I-P
techniques	I-P
.	O

Our	O
model	O
performs	O
an	O
effective	O
decomposition	O
of	O
the	O
ligand-polymer	O
system	O
on	O
its	O
covered	O
and	O
uncovered	O
regions	O
,	O
showing	O
that	O
the	O
elastic	O
properties	O
of	O
the	O
ligand	O
-	O
polymer	O
depend	O
explicitly	O
on	O
the	O
ligand	O
coverage	O
of	O
the	O
polymer	O
(	O
i.e.	O
,	O
the	O
fraction	O
of	O
the	O
polymer	O
covered	O
by	O
the	O
ligand	O
)	O
.	O

The	O
equilibrium	O
coverage	O
that	O
minimizes	O
the	O
free	O
energy	O
of	O
the	O
ligand-polymer	O
system	O
is	O
computed	O
as	O
a	O
function	O
of	O
the	O
applied	O
force	O
.	O

We	O
show	O
how	O
ligands	O
tune	O
the	O
mechanical	O
properties	O
of	O
a	O
polymer	O
,	O
in	O
particular	O
its	O
length	O
and	O
stiffness	O
,	O
in	O
a	O
force	O
dependent	O
manner	O
.	O

In	O
addition	O
,	O
it	O
is	O
shown	O
how	O
ligand	O
binding	O
can	O
be	O
regulated	O
applying	O
mechanical	O
tension	O
on	O
the	O
polymer	O
.	O

Moreover	O
,	O
the	O
binding	O
kinetics	O
study	O
shows	O
that	O
,	O
in	O
the	O
case	O
where	O
the	O
ligand	O
binds	O
and	O
organizes	O
the	O
polymer	O
in	O
different	O
modes	O
,	O
the	O
binding	O
process	O
can	O
present	O
transient	O
shortening	O
or	O
lengthening	O
of	O
the	O
polymer	O
,	O
caused	O
by	O
changes	O
in	O
the	O
relative	O
coverage	O
by	O
the	O
different	O
ligand	O
modes	O
.	O

Our	O
model	O
will	O
be	O
useful	O
to	O
understand	O
ligand-binding	O
regulation	O
of	O
biological	O
processes	O
,	O
such	O
as	O
the	O
metabolism	O
of	O
nucleic	O
acid	O
.	O

In	O
particular	O
,	O
this	O
model	O
allows	O
estimating	O
the	O
coverage	O
fraction	O
and	O
the	O
ligand	O
mode	O
characteristics	O
from	O
the	O
force	O
extension	O
curves	O
of	O
a	O
ligand-polymer	O
system	O
.	O

Salivary	O
Colony	O
Stimulating	O
Factor-1	O
,	O
Interleukin-34	O
,	O
and	O
Matrix	O
Metalloproteinase-8	O
as	O
Markers	O
of	O
Periodontal	O
Disease	O
.	O

Colony-stimulating	O
factor	O
(	O
CSF	O
)	O
-1	O
and	O
interleukin	O
(	O
IL	O
)	O
-34	O
are	O
macrophage	O
growth	O
factors	O
and	O
regulators	O
of	O
osteoclastogenesis	O
.	O

The	O
potential	O
involvement	O
of	O
CSF-1	O
and	O
IL-34	O
in	O
periodontal	O
disease	O
is	O
yet	O
unknown	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
presence	O
of	O
CSF-1	O
and	O
IL-34	O
in	O
whole	O
saliva	O
in	O
relation	O
to	O
periodontal	O
disease	O
.	O

Protocol	O
validation	O
was	O
assessed	O
in	O
saliva	O
of	O
healthy	O
donors	O
(	O
n=21	O
)	O
by	O
ELISA	B-P
.	O

Salivary	O
CSF-1	O
,	O
IL-34	O
,	O
and	O
matrix	O
metalloproteinase	O
(	O
MMP	O
)	O
-8	O
,	O
a	O
biomarker	O
candidate	O
of	O
periodontitis	O
,	O
were	O
determined	O
in	O
48	O
patients	O
(	O
29	O
periodontitis	O
,	O
12	O
gingivitis	O
,	O
7	O
healthy	O
)	O
and	O
related	O
to	O
the	O
clinical	O
periodontal	O
parameters	O
bleeding	O
on	O
probing	O
(	O
BOP	O
)	O
,	O
probing	O
depth	O
(	O
PD	O
)	O
,	O
clinical	O
attachment	O
loss	O
(	O
AL	O
)	O
,	O
and	O
plaque	O
index	O
(	O
PI	O
)	O
.	O

An	O
additional	O
separate	O
group	O
of	O
gingivitis	O
(	O
n=21	O
)	O
and	O
part	O
of	O
periodontitis	O
patients	O
(	O
n=11	O
)	O
were	O
subjected	O
to	O
non-surgical	O
periodontal	O
treatment	O
whereupon	O
changes	O
in	O
salivary	O
CSF-1	O
,	O
IL-34	O
,	O
and	O
MMP-8	O
levels	O
were	O
determined	O
and	O
related	O
to	O
periodontal	O
outcome	O
.	O

Periodontitis	O
patients	O
displayed	O
higher	O
CSF-1	O
and	O
MMP-8	O
levels	O
in	O
saliva	O
compared	O
to	O
healthy	O
,	O
while	O
IL-34	O
levels	O
were	O
lower	O
.	O

Higher	O
CSF-1	O
/	O
IL-34	O
ratio	O
was	O
observed	O
in	O
periodontitis	O
patients	O
compared	O
to	O
healthy	O
.	O

There	O
was	O
a	O
positive	O
correlation	O
between	O
CSF-1	O
and	O
MMP-8	O
which	O
both	O
correlated	O
negatively	O
to	O
IL-34	O
,	O
in	O
gingivitis	O
and	O
periodontitis	O
.	O

Clinical	O
periodontal	O
parameters	O
correlated	O
positively	O
to	O
CSF-1	O
,	O
MMP-8	O
,	O
and	O
to	O
the	O
CSF-1	O
/	O
IL-34	O
ratio	O
and	O
negatively	O
to	O
IL-34	O
in	O
periodontitis	O
patients	O
.	O

Following	O
treatment	O
CSF-1	O
and	O
MMP-8	O
levels	O
decreased	O
along	O
with	O
clinical	O
improvement	O
in	O
gingivitis	O
patients	O
.	O

CSF-1	O
and	O
IL-34	O
are	O
present	O
in	O
saliva	O
and	O
seem	O
to	O
have	O
complementary	O
roles	O
in	O
periodontal	O
disease	O
,	O
IL-34	O
in	O
steady-state	O
and	O
CSF-1	O
in	O
inflammation	O
.	O

Risk	O
Factors	O
Associated	O
With	O
Repeated	O
HIV	B-P
Testing	I-P
Among	O
Internet	O
-Using	O
Men	O
Who	O
Have	O
Sex	O
With	O
Men	O
.	O

Men	O
who	O
have	O
sex	O
with	O
men	O
(	O
MSM	O
)	O
represent	O
a	O
disproportionately	O
impacted	O
risk	O
group	O
for	O
HIV	O
incidence	O
among	O
at-risk	O
U.S.	O
Few	O
studies	O
have	O
identified	O
risk	O
factors	O
associated	O
with	O
HIV	B-P
testing	I-P
frequency	O
both	O
within	O
and	O
outside	O
of	O
traditional	O
health	O
care	O
settings	O
.	O

MSM	O
enrolled	O
in	O
a	O
prospective	O
cohort	O
were	O
mailed	O
at-home	O
specimen	O
collection	O
kits	O
and	O
followed	O
for	O
a	O
year	O
.	O

Incidence	O
density	O
rate	O
ratios	O
(	O
IDRR	O
)	O
of	O
testing	O
were	O
calculated	O
,	O
and	O
generalized	O
estimating	O
equations	O
were	O
used	O
to	O
analyze	O
the	O
association	O
between	O
HIV	B-P
testing	I-P
and	O
behavioral	O
factors	O
.	O

The	O
incidence	O
rate	O
of	O
testing	O
was	O
higher	O
among	O
Black	O
MSM	O
than	O
White	O
MSM	O
(	O
IDRR	O
:	O
1.3	O
,	O
95	O
%	O
confidence	O
interval	O
CI	O
[	O
1.1	O
,	O
1.5	O
]	O
)	O
and	O
higher	O
among	O
MSM	O
who	O
reported	O
3+	O
condomless	O
anal	O
intercourse	O
partners	O
(	O
CAI	O
)	O
than	O
MSM	O
who	O
reported	O
no	O
CAI	O
(	O
IDRR	O
:	O
1.6	O
,	O
95	O
%	O
CI	O
[	O
1.3	O
,	O
2.0	O
]	O
)	O
.	O

Increasing	O
availability	O
of	O
HIV	B-P
testing	I-P
outside	O
traditional	O
health	O
care	O
settings	O
,	O
including	O
at-home	O
testing	O
kits	O
,	O
in	O
conjunction	O
with	O
targeted	O
behavioral	O
interventions	O
and	O
biomedical	O
treatment	O
preventions	O
is	O
needed	O
.	O

Beneficial	O
effects	O
of	O
natural	O
eggshell	O
membrane	O
(	O
NEM	O
)	O
on	O
multiple	O
indices	O
of	O
arthritis	O
in	O
collagen-induced	O
arthritic	O
rats	O
.	O

This	O
study	O
was	O
performed	O
to	O
evaluate	O
the	O
potential	O
efficacy	O
of	O
natural	O
eggshell	O
membrane	O
(	O
NEM	O
)	O
in	O
collagen-induced	O
arthritic	O
rats	O
,	O
a	O
well-established	O
rodent	O
model	O
of	O
inflammation	O
and	O
rheumatoid	O
arthritis	O
.	O

Rats	O
with	O
developing	O
type	O
II	O
collagen-induced	O
arthritis	O
(	O
CIA	O
)	O
were	O
treated	O
once	O
daily	O
by	O
oral	O
gavage	O
on	O
study	O
days	O
-14	O
to	O
17	O
with	O
vehicle	O
or	O
NEM	O
(	O
52	O
mg/kg	O
body	O
weight	O
)	O
.	O

Rats	O
were	O
euthanized	O
on	O
study	O
day	O
17	O
.	O

Efficacy	O
was	O
assessed	O
by	O
daily	O
ankle	O
caliper	O
measurements	O
,	O
ankle	O
diameter	O
expressed	O
as	O
area	O
under	O
the	O
curve	O
(	O
AUCd0-17	O
)	O
,	O
and	O
histopathologic	O
evaluation	O
of	O
ankles	O
and	O
knees	O
.	O

Serum	O
biomarkers	O
of	O
cartilage	O
function	O
and	O
inflammation	O
[	O
collagen	B-P
type	I-P
II	I-P
C-telopeptide	I-P
(	O
CTXII	B-P
)	O
,	O
cartilage	B-P
oligomeric	I-P
matrix	I-P
protein	I-P
(	O
COMP	B-P
)	O
,	O
and	O
alpha-2-macroglobulin	B-P
(	O
A2M	B-P
)	O
]	O
were	O
measured	O
by	O
ELISA	B-P
.	O

Treatment	O
with	O
NEM	O
resulted	O
in	O
significant	O
beneficial	O
effects	O
on	O
the	O
daily	O
ankle	O
diameter	O
measurements	O
and	O
ankle	O
diameter	O
AUC	O
.	O

Ankle	O
and	O
knee	O
histopathology	O
scores	O
were	O
significantly	O
reduced	O
(	O
36	O
%	O
and	O
43	O
%	O
reduction	O
of	O
summed	O
individual	O
histopathology	O
scores	O
for	O
ankle	O
and	O
knee	O
,	O
respectively	O
;	O
p	O
<	O
0.05	O
)	O
toward	O
normal	O
for	O
rats	O
given	O
NEM	O
compared	O
to	O
vehicle	O
controls	O
.	O

The	O
percent	O
reduction	O
of	O
serum	O
CTXII	B-P
,	O
COMP	B-P
,	O
and	O
A2M	B-P
in	O
NEM	O
-	O
treated	O
rats	O
ranged	O
from	O
30	O
%	O
to	O
72	O
%	O
(	O
p	O
<	O
0.05	O
)	O
.	O

NEM	O
significantly	O
improved	O
multiple	O
aspects	O
of	O
inflammatory	O
arthritis	O
including	O
inflammation	O
,	O
pannus	O
,	O
cartilage	O
damage	O
,	O
bone	O
resorption	O
,	O
and	O
periosteal	O
bone	O
formation	O
.	O

This	O
study	O
provides	O
further	O
support	O
for	O
the	O
use	O
of	O
CTXII	O
,	O
COMP	O
,	O
and	O
A2M	O
as	O
relevant	O
biomarkers	O
that	O
were	O
responsive	O
to	O
NEM	O
.	O

Clinical	O
heterogeneity	O
of	O
LRRK2	O
p.I2012T	O
mutation	O
.	O

Leucine-rich	O
repeat	O
kinase	O
2	O
(	O
LRRK2	O
)	O
mutations	O
are	O
the	O
most	O
common	O
genetic	O
cause	O
of	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
.	O

However	O
,	O
only	O
few	O
cases	O
carrying	O
LRRK2	O
mutations	O
have	O
been	O
reported	O
in	O
Taiwanese	O
PD	O
patients	O
.	O

We	O
used	O
targeted	O
next	O
generation	O
sequencing	O
(	O
NGS	O
)	O
,	O
covering	O
24	O
candidate	O
genes	O
involved	O
in	O
neurodegenerative	O
disorders	O
,	O
to	O
analyze	O
40	O
probands	O
with	O
familial	O
PD	O
,	O
and	O
10	O
patients	O
with	O
mixed	O
neurodegenerative	O
disorders	O
.	O

Sanger	O
sequencing	O
of	O
the	O
identified	O
mutation	O
in	O
the	O
first	O
set	O
of	O
the	O
study	O
was	O
performed	O
in	O
additional	O
270	O
PD	O
patients	O
,	O
including	O
139	O
familial	O
PD	O
and	O
131	O
early-onset	O
PD	O
(	O
onset	O
age	O
less	O
than	O
50	O
years	O
old	O
)	O
,	O
and	O
300	O
age/gender	O
matched	O
control	O
subjects	O
.	O

We	O
found	O
a	O
missense	O
variant	O
,	O
p.I2012T	O
,	O
in	O
the	O
LRRK2	O
gene	O
in	O
one	O
sporadic	O
patient	O
having	O
early-onset	O
frontotemporal	O
dementia	O
with	O
parkinsonism	O
and	O
dystonia	O
.	O

Sanger	O
sequencing	O
this	O
substitution	O
in	O
additional	O
270	O
PD	O
patients	O
in	O
the	O
second	O
set	O
of	O
the	O
study	O
revealed	O
two	O
additional	O
variant	O
carriers	O
:	O
one	O
having	O
autosomal-dominant	O
familial	O
PD	O
,	O
and	O
one	O
with	O
sporadic	O
PD	O
.	O

The	O
p.I2012T	O
substitution	O
was	O
absent	O
in	O
300	O
normal	O
control	O
subjects	O
.	O

Analyzing	O
family	O
members	O
of	O
the	O
proband	O
with	O
p.I2012T	O
revealed	O
co-segregation	O
of	O
the	O
variant	O
and	O
parkinsonism	O
.	O

Clinical	O
presentations	O
,	O
levodopa	O
responses	O
,	O
and	O
(	O
Tc99m	O
)	O
TRODAT	O
-	O
SPECT	O
imaging	O
findings	O
of	O
this	O
index	O
family	O
were	O
similar	O
to	O
idiopathic	O
PD	O
.	O

Our	O
results	O
revealed	O
clinical	O
heterogeneity	O
of	O
the	O
LRRK2	O
p.I2012T	O
substitution	O
,	O
and	O
demonstrated	O
the	O
use	O
of	O
targeted	O
NGS	O
for	O
genetic	B-P
diagnosis	I-P
in	O
multiplex	O
families	O
with	O
PD	O
or	O
mixed	O
neurodegenerative	O
disorders	O
.	O

Serum	B-P
mass	I-P
profile	I-P
signature	O
as	O
a	O
biomarker	O
of	O
early	O
lung	O
cancer	O
.	O

Circulating	O
molecular	O
biomarkers	O
of	O
lung	O
cancer	O
may	O
allow	O
the	O
pre-selection	O
of	O
candidates	O
for	O
computed	B-P
tomography	I-P
screening	O
or	O
increase	O
its	O
efficacy	O
.	O

We	O
aimed	O
to	O
identify	O
features	O
of	O
serum	B-P
mass	I-P
profile	I-P
distinguishing	O
individuals	O
with	O
early	O
lung	O
cancer	O
from	O
healthy	O
participants	O
of	O
the	O
lung	O
cancer	O
screening	O
program	O
.	O

Blood	O
samples	O
were	O
collected	O
during	O
a	O
low-dose	O
computed	B-P
tomography	I-P
(	O
LD-CT	B-P
)	O
screening	O
program	O
performed	O
by	O
one	O
institution	O
(	O
Medical	O
University	O
of	O
Gdansk	O
,	O
Poland	O
)	O
.	O

MALDI-ToF	O
mass	O
spectrometry	O
was	O
used	O
to	O
characterize	O
the	O
low-	O
molecular-weight	O
(	O
1000-14,000Da	O
)	O
serum	O
fraction	O
.	O

The	O
analysis	O
comprised	O
95	O
patients	O
with	O
early	O
stage	O
lung	O
cancer	O
(	O
including	O
30	O
screen-detected	O
cases	O
)	O
and	O
a	O
matched	O
group	O
of	O
285	O
healthy	O
controls	O
.	O

The	O
cases	O
were	O
split	O
into	O
two	O
independent	O
cohorts	O
(	O
discovery	O
and	O
validation	O
)	O
,	O
analyzed	O
separately	O
6	O
months	O
apart	O
.	O

Several	O
molecular	O
components	O
of	O
serum	O
(	O
putatively	O
components	O
of	O
endogenous	O
peptidome	O
)	O
discriminating	O
patients	O
with	O
early	O
lung	O
cancer	O
from	O
controls	O
were	O
identified	O
in	O
a	O
discovery	O
cohort	O
.	O

This	O
allowed	O
building	O
an	O
effective	O
cancer	O
classifier	O
as	O
a	O
model	O
tuned	O
to	O
maximize	O
negative	O
predictive	O
value	O
,	O
with	O
an	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
of	O
0.88	O
,	O
a	O
negative	O
predictive	O
value	O
of	O
100	O
%	O
,	O
and	O
a	O
positive	O
predictive	O
value	O
of	O
48	O
%	O
.	O

However	O
,	O
the	O
classifier	O
performed	O
worse	O
in	O
a	O
validation	O
cohort	O
including	O
independent	O
sample	O
sets	O
(	O
AUC	O
0.73	O
,	O
NPV	O
88	O
%	O
and	O
PPV	O
30	O
%	O
)	O
.	O

We	O
developed	O
a	O
serum	B-P
mass	I-P
profile	I-P
-based	O
signature	O
identifying	O
patients	O
with	O
early	O
lung	O
cancer	O
.	O

Although	O
this	O
marker	O
has	O
insufficient	O
value	O
as	O
a	O
stand-alone	O
preselecting	O
tool	O
for	O
LD-CT	B-P
screening	O
,	O
its	O
potential	O
clinical	O
usefulness	O
in	O
evaluation	O
of	O
indeterminate	O
pulmonary	O
nodules	O
deserves	O
further	O
investigation	O
.	O

The	O
Prevalence	O
of	O
Sleep	O
Apnea	O
in	O
Type	O
B	O
Aortic	O
Dissection	O
:	O
Implications	O
for	O
False	O
Lumen	O
Thrombosis	O
.	O

Obstructive	O
sleep	O
apnea	O
(	O
OSA	O
)	O
has	O
been	O
implicated	O
in	O
aortic	O
dissection	O
.	O

Thrombosis	O
of	O
the	O
false	O
lumen	O
is	O
associated	O
with	O
a	O
prognosis	O
of	O
type	O
B	O
aortic	O
dissection	O
(	O
AoD	O
)	O
,	O
and	O
partial	O
thrombosis	O
has	O
been	O
reported	O
to	O
be	O
an	O
independent	O
predictor	O
of	O
mortality	O
.	O

This	O
study	O
sought	O
to	O
explore	O
whether	O
the	O
severity	O
of	O
OSA	O
is	O
associated	O
with	O
false	O
lumen	O
thrombosis	O
.	O

In	O
this	O
observational	O
study	O
,	O
151	O
type	O
B	O
AoD	O
patients	O
were	O
recruited	O
consecutively	O
from	O
2013	O
to	O
2015	O
.	O

The	O
status	O
of	O
the	O
false	O
lumen	O
was	O
classified	O
as	O
patent	O
,	O
partially	O
thrombosed	O
,	O
or	O
completely	O
thrombosed	O
based	O
on	O
a	O
computer	B-P
tomography	I-P
angiography	I-P
image	O
.	O

Patients	O
were	O
divided	O
into	O
non-OSA	O
group	O
(	O
apnea-hypopnea	O
index	O
[	O
AHI	O
]	O
<	O
5	O
)	O
,	O
and	O
mild	O
(	O
5	O
≤	O
AHI	O
≤	O
15	O
)	O
,	O
moderate	O
(	O
15	O
<	O
AHI	O
≤	O
30	O
)	O
,	O
and	O
severe	O
OSA	O
groups	O
(	O
AHI	O
>	O
30	O
)	O
using	O
the	O
AHI	O
.	O

The	O
prevalence	O
of	O
OSA	O
in	O
type	O
B	O
dissection	O
was	O
66.2	O
%	O
.	O

Among	O
151	O
cases	O
,	O
51	O
patients	O
(	O
33.8	O
%	O
)	O
were	O
in	O
the	O
non-OSA	O
group	O
,	O
56	O
(	O
37.1	O
%	O
)	O
were	O
in	O
the	O
mild	O
group	O
,	O
21	O
(	O
13.9	O
%	O
)	O
were	O
in	O
the	O
moderate	O
group	O
,	O
and	O
23	O
(	O
15.2	O
%	O
)	O
were	O
in	O
the	O
severe	O
group	O
.	O

Additionally	O
,	O
a	O
partially	O
thrombosed	O
false	O
lumen	O
was	O
observed	O
in	O
88	O
patients	O
(	O
58.3	O
%	O
)	O
.	O

Multivariable	O
analysis	O
revealed	O
that	O
OSA	O
severity	O
was	O
positively	O
associated	O
with	O
partial	O
thrombosis	O
(	O
odds	O
ratio	O
,	O
1.784	O
,	O
95	O
%	O
confidence	O
interval	O
:	O
1.182-2.691	O
,	O
P	O
=	O
.006	O
)	O
after	O
adjusting	O
for	O
other	O
confounding	O
factors	O
.	O

OSA	O
was	O
present	O
in	O
two-thirds	O
of	O
patients	O
with	O
type	O
B	O
AoD	O
.	O

The	O
severity	O
of	O
OSA	O
was	O
significantly	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
partial	O
false	O
lumen	O
thrombosis	O
.	O

OSA	O
may	O
therefore	O
be	O
implicated	O
in	O
both	O
the	O
etiology	O
and	O
prognosis	O
of	O
AoD	O
.	O

Body	O
mass	O
index	O
and	O
suicide	O
methods	O
.	O

Overweight	O
and	O
obesity	O
is	O
associated	O
with	O
lower	O
rates	O
of	O
suicide	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
association	O
with	O
different	O
suicide	O
methods	O
.	O

We	O
studied	O
the	O
association	O
between	O
groups	O
of	O
body	O
mass	O
index	O
and	O
suicide	O
methods	O
.	O

We	O
identified	O
all	O
medicolegal	O
autopsy	B-P
cases	O
with	O
a	O
cause	O
of	O
death	O
due	O
to	O
external	O
causes	O
in	O
Sweden	O
during	O
1999-2013	O
(	O
N	O
=	O
39,368	O
)	O
and	O
included	O
11,715	O
suicides	O
and	O
13,316	O
accidents	O
or	O
homicides	O
as	O
controls	O
.	O

We	O
applied	O
multinomial	O
regression	O
models	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
year	O
and	O
season	O
of	O
death	O
.	O

Obesity	O
was	O
associated	O
with	O
suicidal	O
intoxication	O
,	O
OR	O
1.15	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1.02	O
,	O
1.30	O
]	O
and	O
negatively	O
associated	O
with	O
all	O
other	O
suicide	O
methods	O
studied	O
.	O

Underweight	O
showed	O
a	O
negative	O
association	O
with	O
suicidal	O
drowning	O
and	O
there	O
was	O
an	O
indication	O
towards	O
a	O
negative	O
association	O
with	O
hanging	O
in	O
men	O
OR	O
0.81	O
(	O
95	O
%	O
CI	O
0.65	O
,	O
1.01	O
)	O
.	O

We	O
conclude	O
that	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
is	O
associated	O
with	O
the	O
choice	O
of	O
suicide	O
method	O
.	O

This	O
may	O
be	O
of	O
importance	O
in	O
a	O
public	O
health	O
perspective	O
,	O
e.g	O
.	O

potential	O
for	O
prevention	O
of	O
intoxications	O
.	O

In	O
the	O
practice	O
of	O
forensic	O
medicine	O
,	O
the	O
physician	O
's	O
level	O
of	O
suspicion	O
may	O
rise	O
if	O
the	O
apparent	O
suicidal	O
method	O
is	O
less	O
common	O
for	O
the	O
individual	O
characteristics	O
of	O
the	O
deceased	O
,	O
such	O
as	O
BMI	O
.	O

An	O
Analysis	O
of	O
Systematic	O
Elemental	O
Changes	O
in	O
Decomposing	O
Bone	O
.	O

The	O
aim	O
of	O
this	O
pilot	O
study	O
was	O
to	O
investigate	O
compositional	O
changes	O
in	O
bone	O
during	O
decomposition	O
.	O

Elemental	O
concentrations	O
of	O
barium	O
,	O
calcium	O
,	O
iron	O
,	O
potassium	O
,	O
magnesium	O
,	O
zinc	O
and	O
phosphorus	O
in	O
porcine	O
bone	O
(	O
as	O
an	O
experimental	O
analog	O
for	O
human	O
bone	O
)	O
were	O
analyzed	O
by	O
inductively	B-P
coupled	I-P
plasma	I-P
optical	I-P
emission	I-P
spectroscopy	I-P
(	O
ICP-OES	B-P
)	O
.	O

The	O
samples	O
were	O
taken	O
from	O
porcine	O
bone	O
subjected	O
to	O
shallow	O
burial	O
and	O
surface	O
depositions	O
at	O
28-	O
day	O
intervals	O
for	O
a	O
period	O
of	O
140	O
days	O
.	O

Results	O
indicated	O
that	O
ICP-OES	B-P
elemental	O
profiling	O
has	O
potential	O
to	O
be	O
developed	O
as	O
a	O
forensic	B-P
test	I-P
for	O
determining	O
whether	O
a	O
bone	O
sample	O
originates	O
from	O
the	O
early	O
stages	O
of	O
soft	O
tissue	O
putrefaction	O
.	O

Significant	O
changes	O
in	O
iron	O
,	O
sodium	O
and	O
potassium	O
concentrations	O
were	O
found	O
over	O
140	O
days	O
.	O

These	O
elements	O
are	O
known	O
to	O
be	O
primarily	O
associated	O
with	O
proteins	O
and/or	O
tissue	O
fluids	O
within	O
the	O
bone	O
.	O

Changes	O
in	O
their	O
respective	O
concentrations	O
may	O
therefore	O
be	O
linked	O
to	O
dehydration	O
over	O
time	O
and	O
in	O
turn	O
may	O
be	O
indicative	O
of	O
time	O
since	O
deposition	O
.	O

Urticarial	O
exanthema	O
due	O
to	O
hepatitis	O
B	O
in	O
a	O
pregnant	O
woman	O
,	O
mimicking	O
a	O
polymorphic	O
eruption	O
of	O
pregnancy	O
.	O

Hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
infection	O
in	O
pregnant	O
women	O
is	O
very	O
rare	O
in	O
western	O
countries	O
,	O
thus	O
,	O
cutaneous	O
manifestation	O
of	O
HBV	O
infection	O
may	O
be	O
confused	O
with	O
a	O
dermatosis	O
specific	O
of	O
pregnancy	O
.	O

We	O
report	O
a	O
39-year-old	O
woman	O
who	O
presented	O
in	O
her	O
20th	O
week	O
of	O
pregnancy	O
with	O
a	O
pruritic	O
rash	O
,	O
which	O
consisted	O
of	O
generalized	O
erythematous	O
plaques	O
,	O
some	O
of	O
them	O
with	O
a	O
purple	O
centre	O
.	O

Serology	B-P
testing	I-P
showed	O
acute	O
HBV	O
infection	O
,	O
and	O
a	O
biopsy	B-P
revealed	O
a	O
superficial	O
and	O
interstitial	O
perivascular	O
inflammatory	O
infiltrate	O
of	O
lymphocytes	O
and	O
eosinophils	O
.	O

A	O
diagnosis	O
of	O
exanthema	O
due	O
to	O
acute	O
hepatitis	O
B	O
infection	O
was	O
established	O
.	O

The	O
patient	O
delivered	O
a	O
clinically	O
healthy	O
boy	O
,	O
who	O
was	O
given	O
the	O
first	O
dose	O
of	O
the	O
HBV	O
vaccine	O
and	O
intravenous	O
specific	O
immunoglobulin	O
,	O
followed	O
by	O
the	O
second	O
dose	O
2	O
months	O
later	O
,	O
and	O
did	O
not	O
get	O
infected	O
with	O
HBV	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
describing	O
HBV	O
exanthema	O
in	O
a	O
pregnant	O
woman	O
,	O
which	O
led	O
to	O
early	O
action	O
for	O
the	O
newborn	O
,	O
avoiding	O
vertical	O
transmission	O
and	O
its	O
high	O
prevalence	O
of	O
cirrhosis	O
and	O
hepatocellular	O
carcinoma	O
.	O

Women	O
's	O
perspectives	O
on	O
human	O
papillomavirus	O
self-sampling	B-P
in	O
the	O
context	O
of	O
the	O
UK	O
cervical	O
screening	O
programme	O
.	O

Testing	O
for	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
is	O
being	O
incorporated	O
into	O
the	O
cervical	O
screening	O
programme	O
,	O
with	O
the	O
probable	O
future	O
introduction	O
of	O
HPV	O
as	O
a	O
primary	O
test	O
and	O
a	O
possibility	O
of	O
HPV	O
self-sampling	B-P
.	O

In	O
anticipation	O
of	O
this	O
development	O
,	O
we	O
sought	O
to	O
inform	O
future	O
policy	O
and	O
practice	O
by	O
identifying	O
potential	O
barriers	O
to	O
HPV	O
self-sampling	B-P
.	O

A	O
cross-sectional	O
survey	O
of	O
194	O
women	O
aged	O
20-64	O
years	O
was	O
conducted	O
.	O

Logistic	O
regression	O
analysis	O
was	O
used	O
to	O
identify	O
determinants	O
of	O
self-sampling	B-P
intentions	O
.	O

A	O
purposive	O
subsample	O
of	O
19	O
women	O
who	O
reported	O
low	O
self-sampling	B-P
intentions	O
were	O
interviewed	O
.	O

Interviews	O
were	O
framework-analysed	O
.	O

Most	O
survey	O
participants	O
(	O
N=133	O
,	O
69.3	O
%	O
)	O
intended	O
to	O
HPV	O
self-sample	O
.	O

Lower	O
intention	O
was	O
associated	O
with	O
lower	O
self-efficacy	O
(	O
OR=24.96	O
,	O
P≤.001	O
)	O
,	O
lower	O
education	O
(	O
OR=6.06	O
,	O
P≤.05	O
)	O
and	O
lower	O
perceived	O
importance	O
of	O
HPV	O
as	O
a	O
cause	O
of	O
cervical	O
cancer	O
(	O
OR=2.33	O
,	O
P≤.05	O
)	O
.	O

Interviews	O
revealed	O
personal	O
and	O
system-related	O
barriers	O
.	O

Personal	O
barriers	O
included	O
a	O
lack	O
of	O
knowledge	O
about	O
HPV	O
self-sampling	B-P
,	O
women	O
's	O
low	O
confidence	O
in	O
their	O
ability	O
to	O
self-sample	O
correctly	O
and	O
low	O
confidence	O
in	O
the	O
subsequent	O
results	O
.	O

System-related	O
factors	O
included	O
a	O
lack	O
of	O
confidence	O
in	O
the	O
rationale	O
for	O
modifying	O
the	O
current	O
cervical	O
screening	O
programme	O
,	O
and	O
concerns	O
about	O
sample	O
contamination	O
and	O
identity	O
theft	O
.	O

Insights	O
gained	O
from	O
this	O
research	O
can	O
be	O
used	O
to	O
guide	O
further	O
enquiry	O
into	O
the	O
possibility	O
of	O
HPV	O
self-sampling	B-P
and	O
to	O
help	O
inform	O
future	O
policy	O
and	O
practice	O
.	O

Personal	O
and	O
system-related	O
barriers	O
including	O
low	O
confidence	O
in	O
the	O
reasons	O
for	O
changing	O
current	O
cervical	O
screening	O
provision	O
need	O
to	O
be	O
addressed	O
,	O
should	O
HPV	O
self-sampling	B-P
be	O
incorporated	O
into	O
the	O
cervical	O
screening	O
programme	O
.	O

Executive	O
function	O
fails	O
to	O
predict	O
smoking	O
outcomes	O
in	O
a	O
clinical	O
trial	O
to	O
motivate	O
smokers	O
to	O
quit	O
.	O

Executive	O
function	O
(	O
EF	O
)	O
is	O
considered	O
an	O
important	O
mediator	O
of	O
health	O
outcomes	O
.	O

It	O
is	O
hypothesized	O
that	O
those	O
with	O
better	O
EF	O
are	O
more	O
likely	O
to	O
succeed	O
in	O
turning	O
their	O
intentions	O
into	O
actual	O
health	O
behaviors	O
.	O

Prior	O
studies	O
indicate	O
EF	O
is	O
associated	O
with	O
smoking	O
cessation	O
.	O

Experimental	O
and	O
longitudinal	O
studies	O
,	O
however	O
,	O
have	O
yielded	O
mixed	O
results	O
.	O

Few	O
studies	O
have	O
examined	O
whether	O
EF	O
predicts	O
post-treatment	O
smoking	O
behavior	O
.	O

Fewer	O
still	O
have	O
done	O
so	O
prospectively	O
in	O
a	O
large	O
trial	O
.	O

We	O
sought	O
to	O
determine	O
if	O
EF	O
predicts	O
quit	O
attempts	O
and	O
cessation	O
among	O
community	O
smokers	O
in	O
a	O
large	O
randomized	O
trial	O
evaluating	O
the	O
efficacy	O
of	O
motivational	O
interventions	O
for	O
encouraging	O
cessation	O
.	O

Participants	O
(	O
N=255	O
)	O
completed	O
a	O
baseline	O
assessment	O
that	O
included	O
a	O
cognitive	B-P
battery	I-P
to	I-P
assess	I-P
EF	O
(	O
Oral	O
Trail	O
Making	O
Test	O
B	O
,	O
Stroop	B-P
,	O
Controlled	O
Oral	O
Word	O
Association	O
Test	O
)	O
.	O

Participants	O
were	O
then	O
randomized	O
to	O
4	O
sessions	O
of	O
Motivational	O
Interviewing	O
or	O
Health	O
Education	O
or	O
one	O
session	O
of	O
Brief	O
Advice	O
to	O
quit	O
.	O

Quit	O
attempts	O
and	O
cessation	O
were	O
assessed	O
at	O
weeks	O
12	O
and	O
26	O
.	O

In	O
regression	O
analyses	O
,	O
none	O
of	O
the	O
EF	O
measures	O
were	O
statistically	O
significant	O
predictors	O
of	O
quit	O
attempts	O
or	O
cessation	O
(	O
all	O
ps	O
>	O
0.20	O
)	O
.	O

Our	O
data	O
did	O
not	O
support	O
models	O
of	O
health	O
behavior	O
that	O
emphasize	O
EF	O
as	O
a	O
mediator	O
of	O
health	O
outcomes	O
.	O

Methodological	O
shortcomings	O
weaken	O
the	O
existing	O
support	O
for	O
an	O
association	O
between	O
EF	O
and	O
smoking	O
behavior	O
.	O

We	O
suggest	O
methodological	O
improvements	O
that	O
could	O
help	O
move	O
this	O
potentially	O
important	O
area	O
of	O
research	O
forward	O
.	O

Breaking	O
sitting	O
with	O
light	O
activities	O
vs	O
structured	O
exercise	O
:	O
a	O
randomised	O
crossover	O
study	O
demonstrating	O
benefits	O
for	O
glycaemic	O
control	O
and	O
insulin	O
sensitivity	O
in	O
type	O
2	O
diabetes	O
.	O

We	O
aimed	O
to	O
examine	O
the	O
effects	O
of	O
breaking	O
sitting	O
with	O
standing	O
and	O
light-intensity	O
walking	O
vs	O
an	O
energy	O
-matched	O
bout	O
of	O
structured	O
exercise	O
on	O
24	O
h	O
glucose	O
levels	O
and	O
insulin	O
resistance	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
.	O

In	O
a	O
randomised	O
crossover	O
study	O
,	O
19	O
patients	O
with	O
type	O
2	O
diabetes	O
(	O
13	O
men	O
/6	O
women	O
,	O
63	O
±	O
9	O
years	O
old	O
)	O
who	O
were	O
not	O
using	O
insulin	O
each	O
followed	O
three	O
regimens	O
under	O
free-living	O
condition	O
s	O
,	O
each	O
lasting	O
4	O
days	O
:	O
(	O
1	O
)	O
Sitting	O
:	O
4415	O
steps	O
/	O
day	O
with	O
14	O
h	O
sitting	O
/	O
day	O
;	O
(	O
2	O
)	O
Exercise	O
:	O
4823	O
steps	O
/	O
day	O
with	O
1.1	O
h/	O
day	O
of	O
sitting	O
replaced	O
by	O
moderate	O
-	O
to	O
vigorous-intensity	O
cycling	O
(	O
at	O
an	O
intensity	O
of	O
5.9	O
metabolic	O
equivalents	O
[	O
METs	O
]	O
)	O
;	O
and	O
(	O
3	O
)	O
Sit	O
Less	O
:	O
17,502	O
steps	O
/	O
day	O
with	O
4.7	O
h/	O
day	O
of	O
sitting	O
replaced	O
by	O
standing	O
and	O
light-intensity	O
walking	O
(	O
an	O
additional	O
2.5	O
h	O
and	O
2.2	O
h	O
,	O
respectively	O
,	O
compared	O
with	O
the	O
hours	O
spent	O
doing	O
these	O
activities	O
in	O
the	O
Sitting	O
regimen	O
)	O
.	O

Blocked	O
randomisation	O
was	O
performed	O
using	O
a	O
block	O
size	O
of	O
six	O
regimen	O
orders	O
using	O
sealed	O
,	O
non-translucent	O
envelopes	O
.	O

Individuals	O
who	O
assessed	O
the	O
outcomes	O
were	O
blinded	O
to	O
group	O
assignment	O
.	O

Meals	O
were	O
standardised	O
during	O
each	O
intervention	O
.	O

Physical	O
activity	O
and	O
glucose	O
levels	O
were	O
assessed	O
for	O
24	O
h/	O
day	O
by	O
accelerometry	B-P
(	O
activPAL	B-P
)	O
and	O
a	O
glucose	O
monitor	O
(	O
iPro2	O
)	O
,	O
respectively	O
.	O

The	O
incremental	O
AUC	O
(	O
iAUC	O
)	O
for	O
24	O
h	O
glucose	O
(	O
primary	O
outcome	O
)	O
and	O
insulin	O
resistance	O
(	O
HOMA2-IR	O
)	O
were	O
assessed	O
on	O
days	O
4	O
and	O
5	O
,	O
respectively	O
.	O

The	O
iAUC	O
for	O
24	O
h	O
glucose	O
(	O
mean	O
±	O
SEM	O
)	O
was	O
significantly	O
lower	O
during	O
the	O
Sit	O
Less	O
intervention	O
than	O
in	O
Sitting	O
(	O
1263	O
±	O
189	O
min	O
×	O
mmol/l	O
vs	O
1974	O
±	O
324	O
min	O
×	O
mmol/l	O
;	O
p	O
=	O
0.002	O
)	O
,	O
and	O
was	O
similar	O
between	O
Sit	O
Less	O
and	O
Exercise	O
(	O
Exercise	O
:	O
1383	O
±	O
194	O
min	O
×	O
mmol/l	O
;	O
p	O
=	O
0.499	O
)	O
.	O

Exercise	O
failed	O
to	O
improve	O
HOMA2-IR	O
compared	O
with	O
Sitting	O
(	O
2.06	O
±	O
0.28	O
vs	O
2.16	O
±	O
0.26	O
;	O
p	O
=	O
0.177	O
)	O
.	O

In	O
contrast	O
,	O
Sit	O
Less	O
(	O
1.89	O
±	O
0.26	O
)	O
significantly	O
reduced	O
HOMA2-IR	O
compared	O
with	O
Exercise	O
(	O
p	O
=	O
0.015	O
)	O
as	O
well	O
as	O
Sitting	O
(	O
p	O
=	O
0.001	O
)	O
.	O

Breaking	O
sitting	O
with	O
standing	O
and	O
light-intensity	O
walking	O
effectively	O
improved	O
24	O
h	O
glucose	O
levels	O
and	O
improved	O
insulin	O
sensitivity	O
in	O
individuals	O
with	O
type	O
2	O
diabetes	O
to	O
a	O
greater	O
extent	O
than	O
structured	O
exercise	O
.	O

Thus	O
,	O
our	O
results	O
suggest	O
that	O
breaking	O
sitting	O
with	O
standing	O
and	O
light-intensity	O
walking	O
may	O
be	O
an	O
alternative	O
to	O
structured	O
exercise	O
to	O
promote	O
glycaemic	O
control	O
in	O
patients	O
type	O
2	O
diabetes	O
.	O

Clinicaltrials.gov	O
NCT02371239	O
FUNDING	O
:	O
:	O
The	O
study	O
was	O
supported	O
by	O
a	O
Kootstra	O
grant	O
from	O
Maastricht	O
University	O
Medical	O
Centre	O
(	O
+	O
)	O
,	O
and	O
the	O
Dutch	O
Heart	O
Foundation	O
.	O

Financial	O
support	O
was	O
also	O
provided	O
by	O
Novo	O
Nordisk	O
BV	O
,	O
and	O
Medtronic	O
and	O
Roche	O
made	O
the	O
equipment	O
available	O
for	O
continuous	O
glucose	O
monitoring	O
.	O

Can	O
diaphragmatic	B-P
ultrasonography	I-P
performed	O
during	O
the	O
T-tube	O
trial	O
predict	O
weaning	O
failure	O
?	O

The	O
role	O
of	O
diaphragmatic	O
rapid	O
shallow	O
breathing	O
index	O
.	O

The	O
rapid	O
shallow	O
breathing	O
index	O
(	O
RSBI	O
)	O
,	O
which	O
is	O
the	O
ratio	O
between	O
respiratory	O
rate	O
(	O
RR	O
)	O
and	O
tidal	O
volume	O
(	O
VT	O
)	O
,	O
is	O
one	O
of	O
the	O
most	O
widely	O
used	O
indices	O
to	O
predict	O
weaning	O
outcome	O
.	O

Whereas	O
the	O
diaphragm	O
plays	O
a	O
fundamental	O
role	O
in	O
generating	O
VT	O
,	O
in	O
the	O
case	O
of	O
diaphragmatic	O
dysfunction	O
the	O
inspiratory	O
accessory	O
muscles	O
may	O
contribute	O
.	O

If	O
this	O
occurs	O
during	O
a	O
weaning	O
trial	O
,	O
delayed	O
weaning	O
failure	O
is	O
likely	O
since	O
the	O
accessory	O
muscles	O
are	O
more	O
fatigable	O
than	O
the	O
diaphragm	O
.	O

Hence	O
,	O
we	O
hypothesised	O
that	O
the	O
traditional	O
RSBI	O
could	O
be	O
implemented	O
by	O
substituting	O
VT	O
with	O
the	O
ultrasonographic	B-P
evaluation	I-P
of	O
diaphragmatic	O
displacement	O
(	O
DD	O
)	O
.	O

We	O
named	O
the	O
new	O
index	O
the	O
diaphragmatic	O
-	O
RSBI	O
(	O
D	O
-	O
RSBI	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
ability	O
of	O
the	O
traditional	O
RSBI	O
and	O
D	O
-	O
RSBI	O
to	O
predict	O
weaning	O
failure	O
in	O
ready-to-wean	O
patients	O
.	O

We	O
performed	O
a	O
prospective	O
observational	O
study	O
.	O

During	O
a	O
T-tube	O
spontaneous	O
breathing	O
trial	O
(	O
SBT	O
)	O
we	O
simultaneously	O
evaluated	O
right	O
hemidiaphragm	O
displacement	O
(	O
i.e.	O
,	O
DD	O
)	O
by	O
using	O
M-mode	B-P
ultrasonography	I-P
as	O
well	O
as	O
the	O
RSBI	O
.	O

Outcome	O
of	O
the	O
weaning	O
attempt	O
,	O
length	O
of	O
mechanical	O
ventilation	O
,	O
length	O
of	O
intensive	O
care	O
unit	O
and	O
hospital	O
stay	O
,	O
and	O
hospital	O
mortality	O
were	O
recorded	O
.	O

Receiver	O
operator	O
characteristic	O
(	O
ROC	O
)	O
curves	O
were	O
used	O
to	O
evaluate	O
the	O
diagnostic	O
accuracy	O
of	O
D	O
-	O
RSBI	O
and	O
RSBI	O
.	O

We	O
enrolled	O
51	O
patients	O
requiring	O
mechanical	O
ventilation	O
for	O
more	O
than	O
48	O
h	O
who	O
were	O
ready	O
to	O
perform	O
a	O
SBT	O
.	O

Most	O
of	O
the	O
patients	O
,	O
34	O
(	O
66	O
%	O
)	O
,	O
were	O
successfully	O
weaned	O
from	O
mechanical	O
ventilation	O
.	O

When	O
considering	O
the	O
17	O
patients	O
that	O
failed	O
the	O
weaning	O
attempt	O
,	O
11	O
(	O
64	O
%	O
)	O
had	O
to	O
be	O
reconnected	O
to	O
the	O
ventilator	O
during	O
the	O
SBT	O
,	O
three	O
(	O
18	O
%	O
)	O
had	O
to	O
be	O
re-intubated	O
within	O
48	O
h	O
of	O
extubation	O
,	O
and	O
three	O
(	O
18	O
%	O
)	O
required	O
non-invasive	O
ventilation	O
support	O
within	O
48	O
h	O
of	O
extubation	O
.	O

The	O
areas	O
under	O
the	O
ROC	O
curves	O
for	O
D	O
-	O
RSBI	O
and	O
RSBI	O
were	O
0.89	O
and	O
0.72	O
,	O
respectively	O
(	O
P	O
=	O
0.006	O
)	O
.	O

D	O
-	O
RSBI	O
(	O
RR	O
/	O
DD	O
)	O
was	O
more	O
accurate	O
than	O
traditional	O
RSBI	O
(	O
RR	O
/	O
VT	O
)	O
in	O
predicting	O
the	O
weaning	O
outcome	O
.	O

Our	O
clinical	O
trial	O
was	O
retrospectively	O
registered	O
with	O
ClinicalTrials.gov	O
(	O
identifier	O
:	O
NCT02696018	O
)	O
.	O

ClinicalTrials.gov	O
processed	O
our	O
record	O
on	O
25	O
February	O
2016	O
.	O

Utility	O
of	O
Ward-Based	O
Retinal	B-P
Photography	I-P
in	O
Stroke	O
Patients	O
.	O

Improvements	O
in	O
acute	O
care	O
of	O
stroke	O
patients	O
have	O
decreased	O
mortality	O
,	O
but	O
survivors	O
are	O
still	O
at	O
increased	O
risk	O
of	O
future	O
vascular	O
events	O
and	O
mitigation	O
of	O
this	O
risk	O
requires	O
thorough	O
assessment	O
of	O
the	O
underlying	O
factors	O
leading	O
to	O
the	O
stroke	O
.	O

The	O
brain	O
and	O
eye	O
share	O
a	O
common	O
embryological	O
origin	O
and	O
numerous	O
similarities	O
exist	O
between	O
the	O
small	O
vessels	O
of	O
the	O
retina	O
and	O
brain	O
.	O

Recent	O
population-based	O
studies	O
have	O
demonstrated	O
a	O
close	O
link	O
between	O
retina	O
l	O
vascular	O
changes	O
and	O
stroke	O
,	O
suggesting	O
that	O
retinal	B-P
photography	I-P
could	O
have	O
utility	O
in	O
assessing	O
underlying	O
stroke	O
risk	O
factors	O
and	O
prognosis	O
after	O
stroke	O
.	O

Modern	O
imaging	O
equipment	O
can	O
facilitate	O
precise	O
measurement	O
and	O
monitoring	O
of	O
vascular	O
features	O
.	O

However	O
,	O
use	O
of	O
this	O
equipment	O
is	O
a	O
challenge	O
in	O
the	O
stroke	O
ward	O
setting	O
as	O
patients	O
are	O
frequently	O
unable	O
to	O
maintain	O
the	O
required	O
seated	O
position	O
,	O
and	O
pupil	B-P
dilatation	I-P
is	O
often	O
not	O
feasible	O
as	O
it	O
could	O
potentially	O
obscure	O
important	O
neurological	O
signs	O
of	O
stroke	O
progression	O
.	O

This	O
small	O
study	O
investigated	O
the	O
utility	O
of	O
a	O
novel	O
handheld	O
,	O
nonmydriatic	O
retinal	O
camera	O
in	O
the	O
stroke	O
ward	O
and	O
explored	O
associations	O
between	O
retinal	O
vascular	O
features	O
and	O
stroke	O
risk	O
factors	O
.	O

This	O
camera	O
circumvented	O
the	O
practical	O
limitations	O
of	O
conducting	O
retinal	B-P
photography	I-P
in	O
the	O
stroke	O
ward	O
setting	O
.	O

A	O
positive	O
correlation	O
was	O
found	O
between	O
carotid	O
disease	O
and	O
both	O
mean	O
width	O
of	O
arterioles	O
(	O
r	O
=	O
.40	O
,	O
P	O
=	O
.00571	O
)	O
and	O
venules	O
(	O
r	O
=	O
.30	O
,	O
P	O
=	O
.0381	O
)	O
.	O

The	O
results	O
provide	O
further	O
evidence	O
that	O
retinal	O
vascular	O
features	O
are	O
clinically	O
informative	O
about	O
underlying	O
stroke	O
risk	O
factors	O
and	O
demonstrate	O
the	O
utility	O
of	O
handheld	O
retinal	B-P
photography	I-P
in	O
the	O
stroke	O
ward	O
.	O

Inflammatory	O
pain	O
-related	O
traits	O
of	O
sensory	O
DRG	O
neurons	O
innervating	O
the	O
hip	O
joints	O
.	O

Hip	O
pain	O
is	O
transmitted	O
to	O
the	O
dorsal	O
horn	O
of	O
the	O
spinal	O
cord	O
via	O
the	O
dorsal	O
root	O
ganglion	O
(	O
DRG	O
)	O
,	O
which	O
contains	O
two	O
types	O
of	O
neurons	O
with	O
differential	O
sensitivity	O
to	O
neurotrophic	O
factors	O
.	O

If	O
either	O
type	O
predominantly	O
innervates	O
the	O
hip	O
joint	O
,	O
it	O
may	O
represent	O
a	O
good	O
target	O
for	O
hip	O
joint	O
pain	O
treatment	O
.	O

Inflammation	O
was	O
induced	O
in	O
the	O
left	O
hip	O
joint	O
of	O
rats	O
(	O
n	O
=	O
10	O
)	O
by	O
using	O
complete	O
Freund	O
's	O
adjuvant	O
.	O

Fluoro-Gold	O
(	O
FG	O
)	O
was	O
applied	O
to	O
the	O
hip	O
joint	O
after	O
7	O
days	O
,	O
and	O
T12	O
-	O
L6	O
DRGs	O
were	O
double-stained	B-P
for	O
calcitonin	O
gene-related	O
peptide	O
(	O
CGRP	O
)	O
and	O
isolection-IB4	O
1	O
week	O
later	O
.	O

FG	O
-labeled	O
neurons	O
in	O
the	O
control	O
group	O
were	O
distributed	O
throughout	O
the	O
left	O
DRG	O
from	O
T13	O
to	O
L5	O
,	O
primarily	O
in	O
L2	O
to	O
L4	O
,	O
and	O
CGRP	O
-positive	O
neurons	O
were	O
significantly	O
more	O
frequent	O
than	O
IB4	O
-	O
binding	O
neurons	O
.	O

In	O
the	O
inflammatory	O
group	O
,	O
FG	O
-labeled	O
neurons	O
were	O
similarly	O
distributed	O
,	O
primarily	O
at	O
L3	O
and	O
L4	O
,	O
and	O
CGRP	O
-positive	O
neurons	O
were	O
significantly	O
more	O
frequent	O
than	O
IB4	O
-	O
binding	O
neurons	O
.	O

The	O
percentage	O
of	O
CGRP	O
-positive	O
neurons	O
was	O
significantly	O
greater	O
in	O
the	O
inflammatory	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Most	O
small	O
neurons	O
innervating	O
the	O
hip	O
joint	O
express	O
CGRP	O
.	O

Furthermore	O
,	O
hip	O
joint	O
inflammation	O
caused	O
an	O
increase	O
in	O
CGRP	O
-positive	O
neurons	O
,	O
but	O
not	O
in	O
IB4	O
-	O
binding	O
neurons	O
.	O

Our	O
results	O
suggest	O
that	O
CGRP	O
-	O
expressing	O
nerve	O
growth	O
factor	O
-dependent	O
neurons	O
are	O
primarily	O
responsible	O
for	O
hip	O
joint	O
pain	O
and	O
may	O
represent	O
therapeutic	O
targets	O
.	O

Investigation	O
on	O
evaluation	O
criteria	O
of	O
backwashing	O
effects	O
for	O
a	O
pilot-scale	O
BAF	O
treating	O
petrochemical	O
wastewater	O
.	O

Parameters	O
for	O
evaluation	O
criteria	O
of	O
air	O
-	O
water	O
backwashing	O
effect	O
s	O
of	O
a	O
pilot-scale	O
biological	O
aerated	O
filter	O
(	O
BAF	O
)	O
treating	O
petrochemical	O
wastewater	O
were	O
investigated	O
.	O

The	O
parameters	O
included	O
the	O
suspended	O
solids	O
(	O
SS	O
)	O
and	O
specific	O
oxygen	O
uptake	O
rate	O
(	O
SOUR	O
)	O
of	O
the	O
backwashing	O
effluent	O
,	O
recovery	O
of	O
the	O
BAF	O
after	O
backwashing	O
,	O
and	O
the	O
removal	O
of	O
the	O
biomass	O
/	O
bioactivity	O
attached	O
on	O
the	O
filter	O
media	O
after	O
backwashing	O
.	O

Results	O
showed	O
that	O
the	O
weight	O
of	O
the	O
total	O
sludge	O
produced	O
in	O
the	O
backwashing	O
effluent	O
increased	O
with	O
the	O
increase	O
in	O
water	O
-	O
backwashing	O
intensity	O
,	O
while	O
the	O
total	O
SOUR	O
of	O
backwashing	O
effluent	O
rose	O
notably	O
with	O
the	O
increase	O
of	O
air	O
-	O
backwashing	O
intensity	O
.	O

The	O
optimal	O
backwashing	O
intensity	O
of	O
14	O
L/	O
(	O
m	O
(	O
2	O
)	O
·s	O
)	O
for	O
air	O
and	O
4	O
L/	O
(	O
m	O
(	O
2	O
)	O
·s	O
)	O
for	O
water	O
were	O
obtained	O
.	O

When	O
the	O
BAF	O
was	O
backwashed	O
on	O
this	O
condition	O
,	O
the	O
BAF	O
recovered	O
with	O
high	O
average	O
removal	O
of	O
chemical	O
oxygen	O
demand	O
(	O
COD	O
)	O
and	O
ammonia	O
nitrogen	O
[	O
Formula	O
:	O
see	O
text	O
]	O
of	O
14.3	O
%	O
and	O
50.3	O
%	O
,	O
respectively	O
.	O

High	O
amount	O
of	O
biomass	O
removal	O
at	O
15.8	O
%	O
and	O
low	O
level	O
of	O
bioactivity	O
removal	O
at	O
8.8	O
%	O
attached	O
on	O
the	O
filter	O
media	O
were	O
also	O
found	O
.	O

Concentrations	O
of	O
the	O
benzene	O
,	O
toluene	O
,	O
ethylbenzene	O
and	O
(	O
o-	O
,	O
m-	O
,	O
p-	O
)	O
xylenes	O
(	O
BTEX	O
)	O
and	O
phenol	O
in	O
the	O
backwashed	O
sludge	O
were	O
analyzed	O
,	O
showing	O
that	O
the	O
backwashing	O
was	O
essential	O
to	O
remove	O
some	O
aromatic	O
compounds	O
adsorbed	B-P
in	O
the	O
microorganisms	O
.	O

Comparative	O
life	O
cycle	O
assessment	O
study	O
on	O
environmental	O
impact	O
of	O
oil	O
production	O
from	O
micro-algae	O
and	O
terrestrial	O
oilseed	O
crops	O
.	O

In	O
this	O
study	O
the	O
LCA	B-P
methodology	I-P
is	O
applied	O
in	O
order	O
to	O
satisfy	O
two	O
goals	O
:	O
i	O
)	O
to	O
evaluate	O
the	O
hot	O
spots	O
in	O
site-specific	O
production	O
chain	O
of	O
biodiesel	O
from	O
terrestrial	O
and	O
micro-algae	O
feedstock	O
;	O
ii	O
)	O
to	O
compare	O
quantitatively	O
,	O
utilizing	O
primary	O
data	O
,	O
the	O
impacts	O
of	O
the	O
first	O
generation	O
in	O
respect	O
to	O
the	O
third	O
generation	O
bio-fuels	O
.	O

Results	O
show	O
that	O
micro-algae	O
are	O
neither	O
competitive	O
yet	O
with	O
traditional	O
oil	O
crops	O
nor	O
with	O
fossil	O
fuel	O
.	O

The	O
use	O
of	O
renewable	O
technologies	O
as	O
photovoltaics	O
and	O
biogas	O
self	O
production	O
might	O
increase	O
the	O
competitiveness	O
of	O
micro-algae	O
oil	O
.	O

Further	O
investigations	O
are	O
however	O
necessary	O
to	O
optimize	O
their	O
production	O
chain	O
and	O
to	O
increase	O
the	O
added	O
value	O
of	O
co-products	O
.	O

Emergency	O
general	O
surgery	O
specific	O
frailty	O
index	O
:	O
A	O
validation	O
study	O
.	O

Assessment	O
of	O
operative	O
risk	O
in	O
geriatric	O
patients	O
undergoing	O
emergency	O
general	O
surgery	O
(	O
EGS	O
)	O
is	O
challenging	O
.	O

Frailty	O
is	O
an	O
established	O
measure	O
for	O
risk	O
assessment	O
in	O
surgical	O
cases	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
validate	O
a	O
modified	O
15	O
variable	O
emergency	O
general	O
surgery	O
specific	O
frailty	O
index	O
(	O
EGSFI	O
)	O
.	O

We	O
prospectively	O
collected	O
geriatric	O
(	O
age	O
>	O
65	O
)	O
emergency	O
general	O
surgery	O
patients	O
for	O
1-	O
year	O
.	O

Post-operative	O
complications	O
were	O
collected	O
.	O

Frailty	O
Index	O
was	O
calculated	B-P
for	O
200	O
patients	O
based	O
on	O
their	O
pre-admission	O
condition	O
using	O
50-	O
variable	O
modified	O
Rockwood	O
Frailty	O
Index	O
(	O
FI	O
)	O
.	O

EGSFI	O
was	O
developed	O
based	O
on	O
the	O
regression	O
model	O
for	O
complications	O
and	O
the	O
most	O
significant	O
factors	O
in	O
the	O
FI	O
.	O

ROC	O
curve	O
analysis	O
was	O
performed	O
to	O
determine	O
cutoff	O
for	O
frail	O
status	O
.	O

We	O
validated	O
our	O
results	O
using	O
60	O
patients	O
for	O
predicting	O
complications	O
.	O

A	O
total	O
of	O
260	O
patients	O
(	O
200	O
developing	O
,	O
60	O
Validation	O
)	O
were	O
enrolled	O
in	O
this	O
study	O
.	O

Mean	O
age	O
was	O
71	O
±	O
11	O
years	O
,	O
and	O
33	O
%	O
developed	O
complications	O
.	O

Most	O
common	O
complications	O
were	O
pneumonia	O
(	O
12	O
%	O
)	O
,	O
UTI	O
(	O
9	O
%	O
)	O
,	O
and	O
wound	O
infection	O
(	O
7	O
%	O
)	O
.	O

Univariate	O
analysis	O
identified	O
15	O
variables	O
significantly	O
associated	O
with	O
complications	O
that	O
were	O
used	O
to	O
develop	O
the	O
EGSFI	O
.	O

A	O
cutoff	O
frailty	O
score	O
of	O
0.325	O
was	O
identified	O
using	O
ROC	O
curve	O
analysis	O
for	O
frail	O
status	O
.Sixty-	O
patients	O
(	O
frail	O
:	O
18	O
,	O
non-frail	O
:	O
42	O
)	O
were	O
enrolled	O
in	O
the	O
validation	O
cohort	O
.	O

Frail	O
patients	O
were	O
more	O
likely	O
to	O
have	O
post-operative	O
complications	O
(	O
47	O
%	O
vs.	O
20	O
%	O
,	O
p	O
<	O
0.001	O
)	O
compared	O
to	O
nonfrail	O
patients	O
.	O

Frail	O
status	O
based	O
on	O
EGSFI	O
was	O
a	O
significant	O
predictor	O
of	O
post-operative	O
complications	O
(	O
OR	O
=7.3	O
,	O
95	O
%	O
CI	O
=	O
1.7	O
-	O
19.8	O
;	O
p=0.006	O
)	O
.	O

Age	O
was	O
not	O
associated	O
with	O
postoperative	O
complications	O
(	O
OR	O
=0.99	O
,	O
95	O
%	O
CI	O
=	O
0.92	O
-1.06	O
;	O
p=0.86	O
)	O
.	O

The	O
15-	O
variable	O
validated	O
EGSFI	O
is	O
a	O
simple	O
and	O
reliable	O
bedside	O
tool	O
to	O
determine	O
the	O
frailty	O
status	O
of	O
patients	O
undergoing	O
emergency	O
general	O
surgery	O
.	O

Frail	O
status	O
as	O
determined	O
by	O
Abstract	O
the	O
EGSFI	O
is	O
an	O
independent	O
predictor	O
of	O
post-operative	O
complications	O
and	O
mortality	O
in	O
geriatric	O
emergency	O
general	O
surgery	O
patients	O
.	O

Level	O
II	O
,	O
Prognostic	O
Studies	O
-	O
Investigating	O
the	O
Effect	O
of	O
a	O
Patient	O
Characteristic	O
on	O
the	O
Outcome	O
of	O
Disease	O
.	O

Hepatic	O
and	O
renal	O
toxicological	O
evaluations	O
of	O
an	O
industrial	O
ovotoxic	O
chemical	O
,	O
4-vinylcyclohexene	O
diepoxide	O
,	O
in	O
both	O
sexes	O
of	O
Wistar	O
rats	O
.	O

4-Vinylcyclohexene	O
diepoxide	O
(	O
VCD	O
)	O
is	O
an	O
industrial	O
occupational	O
health	O
hazard	O
chemical	O
because	O
it	O
induces	O
ovotoxicity	O
in	O
rodents	O
.	O

The	O
current	O
study	O
investigated	O
the	O
impacts	O
of	O
VCD	O
on	O
selected	O
hepatic	O
and	O
renal	O
markers	O
of	O
oxidative	O
stress	O
and	O
inflammation	O
in	O
both	O
sexes	O
of	O
Wistar	O
rats	O
.	O

Thus	O
,	O
male	O
and	O
female	O
rats	O
were	O
randomly	O
distributed	O
into	O
four	O
groups	O
of	O
ten	O
rats	O
per	O
group	O
,	O
and	O
dosed	O
orally	O
with	O
VCD	O
for	O
28	O
days	O
.	O

The	O
control	O
male	O
and	O
female	O
groups	O
of	O
rats	O
received	O
corn	O
oil	O
only	O
,	O
while	O
each	O
of	O
the	O
three	O
remaining	O
groups	O
of	O
both	O
sexes	O
of	O
rats	O
received	O
VCD	O
(	O
100	O
,	O
250	O
and	O
500	O
mg/kg	O
BW	O
)	O
respectively	O
.	O

Thereafter	O
,	O
biomarkers	O
of	O
hepatic	O
and	O
renal	O
oxidative	O
damage	O
,	O
inflammation	O
and	O
immunohistochemical	B-P
expressions	I-P
of	O
iNOS	O
,	O
COX-2	O
,	O
caspase-9	O
and	O
caspase-3	O
were	O
evaluated	O
.	O

The	O
results	O
revealed	O
that	O
VCD	O
increased	O
markers	O
of	O
liver	O
and	O
kidney	O
functions	O
,	O
oxidative	O
damage	O
and	O
inflammation	O
,	O
and	O
disrupted	O
the	O
antioxidant	O
homeostasis	O
of	O
the	O
rats	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Lastly	O
,	O
VCD	O
enhanced	O
the	O
immunohistochemical	B-P
expressions	I-P
of	O
iNOS	O
,	O
COX-2	O
,	O
caspase-9	O
and	O
caspase-3	O
in	O
the	O
liver	O
of	O
the	O
rats	O
.	O

Thus	O
,	O
our	O
data	O
imply	O
that	O
VCD	O
induced	O
toxicity	O
in	O
the	O
liver	O
and	O
kidney	O
of	O
rats	O
via	O
the	O
combined	O
impacts	O
of	O
oxidative	O
damage	O
and	O
inflammation	O
.	O

Mass-spectrometry	B-P
analysis	O
of	O
histone	O
post-translational	O
modifications	O
in	O
pathology	O
tissue	O
using	O
the	O
PAT-H-MS	B-P
approach	O
.	O

Aberrant	O
histone	O
post-translational	O
modifications	O
(	O
hPTMs	O
)	O
have	O
been	O
implicated	O
with	O
various	O
pathologies	O
,	O
including	O
cancer	O
,	O
and	O
may	O
represent	O
useful	O
epigenetic	O
biomarkers	O
.	O

The	O
data	O
described	O
here	O
provide	O
a	O
mass	B-P
spectrometry	I-P
-based	O
quantitative	O
analysis	O
of	O
hPTMs	O
from	O
formalin-fixed	O
paraffin-embedded	O
(	O
FFPE	O
)	O
tissues	O
,	O
from	O
which	O
histones	O
were	O
extracted	O
through	O
the	O
recently	O
developed	O
PAT-H-MS	B-P
method	I-P
.	O

First	O
,	O
we	O
analyzed	O
FFPE	O
samples	O
from	O
mouse	O
spleen	O
and	O
liver	O
or	O
human	O
breast	O
cancer	O
up	O
to	O
six	O
years	O
old	O
,	O
together	O
with	O
their	O
corresponding	O
fresh	O
frozen	O
tissue	O
.	O

We	O
then	O
combined	O
the	O
PAT-H-MS	B-P
approach	O
with	O
a	O
histone	O
-focused	O
version	O
of	O
the	O
super-SILAC	O
strategy	O
-using	O
a	O
mix	O
of	O
histones	O
from	O
four	O
breast	O
cancer	O
cell	O
lines	O
as	O
a	O
spike-in	O
standard	O
-	O
to	O
accurately	O
quantify	O
hPTMs	O
from	O
breast	O
cancer	O
specimens	O
belonging	O
to	O
different	O
subtypes	O
.	O

The	O
data	O
,	O
which	O
are	O
associated	O
with	O
a	O
recent	O
publication	O
(	O
Pathology	O
tissue	O
-	O
quantitative	B-P
mass	I-P
spectrometry	I-P
analysis	O
to	O
profile	B-P
histone	O
post-translational	O
modification	O
patterns	O
in	O
patient	O
samples	O
(	O
Noberini	O
,	O
2015	O
)	O
[	O
1	O
]	O
)	O
,	O
are	O
deposited	O
at	O
the	O
ProteomeXchange	O
Consortium	O
via	O
the	O
PRIDE	O
partner	O
repository	O
with	O
the	O
dataset	O
identifier	O
PXD002669	O
.	O

F901318	O
represents	O
a	O
novel	O
class	O
of	O
antifungal	O
drug	O
that	O
inhibits	O
dihydroorotate	O
dehydrogenase	O
.	O

There	O
is	O
an	O
important	O
medical	O
need	O
for	O
new	O
antifungal	O
agents	O
with	O
novel	O
mechanisms	O
of	O
action	O
to	O
treat	O
the	O
increasing	O
number	O
of	O
patients	O
with	O
life-threatening	O
systemic	O
fungal	O
disease	O
and	O
to	O
overcome	O
the	O
growing	O
problem	O
of	O
resistance	O
to	O
current	O
therapies	O
.	O

F901318	O
,	O
the	O
leading	O
representative	O
of	O
a	O
novel	O
class	O
of	O
drug	O
,	O
the	O
orotomides	O
,	O
is	O
an	O
antifungal	O
drug	O
in	O
clinical	O
development	O
that	O
demonstrates	O
excellent	O
potency	O
against	O
a	O
broad	O
range	O
of	O
dimorphic	O
and	O
filamentous	O
fungi	O
.	O

In	O
vitro	O
susceptibility	B-P
testing	I-P
of	O
F901318	O
against	O
more	O
than	O
100	O
strains	O
from	O
the	O
four	O
main	O
pathogenic	O
Aspergillus	O
spp	O
.	O

revealed	O
minimal	O
inhibitory	O
concentrations	O
of	O
≤0.06	O
µg/mL-	O
greater	O
potency	O
than	O
the	O
leading	O
antifungal	O
classes	O
.	O

An	O
investigation	O
into	O
the	O
mechanism	O
of	O
action	O
of	O
F901318	O
found	O
that	O
it	O
acts	O
via	O
inhibition	O
of	O
the	O
pyrimidine	O
biosynthesis	O
enzyme	O
dihydroorotate	O
dehydrogenase	O
(	O
DHODH	O
)	O
in	O
a	O
fungal	O
-	O
specific	O
manner	O
.	O

Homology	O
modeling	O
of	O
Aspergillus	O
fumigatus	O
DHODH	O
has	O
identified	O
a	O
predicted	O
binding	O
mode	O
of	O
the	O
inhibitor	O
and	O
important	O
interacting	O
amino	O
acid	O
residues	O
.	O

In	O
a	O
murine	O
pulmonary	O
model	O
of	O
aspergillosis	O
,	O
F901318	O
displays	O
in	O
vivo	O
efficacy	O
against	O
a	O
strain	O
of	O
A.	O
fumigatus	O
sensitive	O
to	O
the	O
azole	O
class	O
of	O
antifungals	O
and	O
a	O
strain	O
displaying	O
an	O
azole	O
-	O
resistant	O
phenotype	O
.	O

F901318	O
is	O
currently	O
in	O
late	O
Phase	O
1	O
clinical	O
trials	O
,	O
offering	O
hope	O
that	O
the	O
antifungal	O
armamentarium	O
can	O
be	O
expanded	O
to	O
include	O
a	O
class	O
of	O
agent	O
with	O
a	O
mechanism	O
of	O
action	O
distinct	O
from	O
currently	O
marketed	O
antifungals	O
.	O

Lubiprostone	O
Accelerates	O
Intestinal	O
Transit	O
and	O
Alleviates	O
Small	O
Intestinal	O
Bacterial	O
Overgrowth	O
in	O
Patients	O
With	O
Chronic	O
Constipation	O
.	O

Lubiprostone	O
is	O
an	O
effective	O
treatment	O
for	O
chronic	O
constipation	O
(	O
CC	O
)	O
.	O

The	O
mechanism	O
of	O
action	O
of	O
lubiprostone	O
is	O
through	O
increasing	O
fluid	O
secretion	O
and	O
lubrication	O
of	O
the	O
intestinal	O
lumen	O
.	O

The	O
effects	O
of	O
lubiprostone	O
on	O
gastrointestinal	O
transit	O
and	O
small	O
intestinal	O
bacterial	O
overgrowth	O
(	O
SIBO	O
)	O
have	O
not	O
been	O
adequately	O
explored	O
.	O

The	O
current	O
study	O
was	O
designed	O
to	O
investigate	O
whether	O
lubiprostone	O
(	O
1	O
)	O
alters	O
gastrointestinal	O
transit	O
and	O
(	O
2	O
)	O
affects	O
SIBO	O
in	O
patients	O
with	O
constipation	O
.	O

A	O
total	O
of	O
29	O
female	O
patients	O
(	O
mean	O
age	O
=	O
39	O
years	O
;	O
range	O
:	O
19-64	O
)	O
with	O
CC	O
received	O
2	O
weeks	O
of	O
lubiprostone	O
(	O
24mcg	O
b.i.d.	O
,	O
P.O.	O
)	O
.	O

Stool	O
consistency	O
based	O
on	O
Bristol	O
stool	O
scale	O
and	O
the	O
frequency	O
of	O
bowel	O
movements	O
(	O
BMs	O
)	O
were	O
recorded	O
.	O

Gastric	O
emptying	O
time	O
,	O
small	O
bowel	O
transit	O
time	O
,	O
colon	O
transit	O
time	O
(	O
CTT	O
)	O
,	O
combined	O
small	O
and	O
large	O
bowel	O
transit	O
time	O
(	O
SLBTT	O
)	O
and	O
whole	O
gut	O
transit	O
time	O
were	O
measured	O
using	O
wireless	B-P
motility	I-P
capsule	I-P
.	O

The	O
SIBO	O
status	O
was	O
assessed	O
by	O
the	O
lactulose	B-P
breath	I-P
test	I-P
.	O

Data	O
were	O
analyzed	O
using	O
Wilcoxon	O
rank	O
,	O
Mann-Whitney	O
U	O
,	O
Spearman׳s	O
rank	O
correlation	O
and	O
Chi-square	O
tests	O
.	O

Lubiprostone	O
significantly	O
softened	O
the	O
stool	O
and	O
increased	O
the	O
frequency	O
of	O
BM	O
from	O
median	O
of	O
2	O
to	O
4	O
times	O
per	O
week	O
.	O

The	O
CTT	O
and	O
SLBTT	O
were	O
significantly	O
shorter	O
in	O
responders	O
to	O
lubiprostone	O
(	O
i.e.	O
,	O
those	O
with	O
≥	O
2	O
times	O
increase	O
in	O
the	O
number	O
of	O
their	O
weekly	O
BM	O
)	O
compared	O
with	O
nonresponders	O
.	O

The	O
higher	O
frequency	O
of	O
BM	O
after	O
treatment	O
was	O
significantly	O
correlated	O
with	O
the	O
acceleration	O
of	O
CTT	O
,	O
SLBTT	O
and	O
whole	O
gut	O
transit	O
time	O
.	O

In	O
all	O
,	O
17	O
out	O
of	O
25	O
(	O
68	O
%	O
)	O
patients	O
,	O
who	O
were	O
tested	O
for	O
SIBO	O
at	O
baseline	O
,	O
were	O
positive	O
.	O

In	O
addition	O
,	O
7	O
out	O
of	O
17	O
(	O
41	O
%	O
)	O
SIBO	O
-	O
positive	O
patients	O
became	O
SIBO	O
-	O
negative	O
after	O
lubiprostone	O
treatment	O
(	O
P	O
<	O
0.05	O
)	O
.	O

In	O
CC	O
,	O
lubiprostone	O
improves	O
the	O
frequency	O
of	O
BMs	O
,	O
softens	O
the	O
stool	O
,	O
accelerates	O
intestinal	O
transit	O
and	O
decreases	O
accompanying	O
SIBO	O
.	O

The	O
improvement	O
of	O
SIBO	O
could	O
be	O
explained	O
by	O
the	O
cleansing	O
effect	O
of	O
increased	O
intestinal	O
fluid	O
and	O
mucus	O
combined	O
with	O
enhanced	O
intestinal	O
motility	O
with	O
lubiprostone	O
.	O

Coxiella	O
burnetii	O
isolates	O
originating	O
from	O
infected	O
cattle	O
induce	O
a	O
more	O
pronounced	O
proinflammatory	O
cytokine	O
response	O
compared	O
to	O
isolates	O
from	O
infected	O
goats	O
and	O
sheep	O
.	O

Coxiella	O
burnetii	O
is	O
the	O
causative	O
agent	O
of	O
Q	O
fever	O
.	O

Although	O
the	O
prevalence	O
of	O
C.	O
burnetii	O
in	O
cattle	O
is	O
much	O
higher	O
than	O
in	O
goats	O
and	O
sheep	O
,	O
infected	O
cattle	O
are	O
rarely	O
associated	O
with	O
human	O
outbreaks	O
.	O

We	O
investigated	O
whether	O
the	O
immune	O
response	O
of	O
humans	O
differs	O
after	O
contact	O
with	O
C.	O
burnetii	O
isolates	O
from	O
different	O
host	O
origins	O
or	O
with	O
different	O
multilocus	B-P
variable	I-P
number	I-P
of	I-P
tandem	I-P
repeat	I-P
analysis	I-P
(	O
MLVA	B-P
)	O
genotypes	O
.	O

Cytokine	O
responses	O
were	O
measured	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
stimulated	O
with	O
16	O
C.	O
burnetii	O
isolates	O
with	O
known	O
MLVA	B-P
genotype	O
from	O
goats	O
,	O
sheep	O
,	O
cattle	O
,	O
acute	O
and	O
chronic	O
Q	O
fever	O
patients	O
.	O

Coxiella	O
burnetii	O
isolates	O
originating	O
from	O
cattle	O
induce	O
significantly	O
more	O
IL-1β	O
,	O
TNF-α	O
and	O
IL-22	O
than	O
the	O
isolates	O
from	O
goats	O
,	O
sheep	O
or	O
chronic	O
Q	O
fever	O
patients	O
.	O

Comparing	O
the	O
cytokine	O
induction	O
of	O
the	O
isolates	O
based	O
on	O
their	O
MVLA	B-P
genotype	O
did	O
not	O
reveal	O
differences	O
in	O
response	O
between	O
the	O
MLVA	B-P
genotypes	O
.	O

The	O
proinflammatory	O
cytokine	O
response	O
induced	O
in	O
human	O
PBMCs	O
by	O
C.	O
burnetii	O
isolates	O
from	O
cattle	O
may	O
explain	O
the	O
low	O
incidence	O
of	O
human	O
Q	O
fever	O
outbreaks	O
caused	O
by	O
cattle	O
.	O

The	O
cytokine	O
profile	O
of	O
PBMCs	O
stimulated	O
with	O
C.	O
burnetii	O
isolates	O
from	O
chronic	O
Q	O
fever	O
patients	O
resembles	O
isolates	O
from	O
goats	O
.	O

Furthermore	O
,	O
cytokine	O
responses	O
seem	O
to	O
be	O
depending	O
on	O
host	O
origin	O
than	O
on	O
MLVA	B-P
genotype	O
.	O

Incidence	O
of	O
Diabetes	O
Mellitus	O
and	O
Obesity	O
and	O
the	O
Overlap	O
of	O
Comorbidities	O
in	O
HIV+	O
Hispanics	O
Initiating	O
Antiretroviral	O
Therapy	O
.	O

Cardiovascular	O
disease	O
(	O
CVD	O
)	O
is	O
a	O
leading	O
health	O
threat	O
for	O
HIV+	O
patients	O
on	O
antiretroviral	O
therapy	O
(	O
ART	O
)	O
;	O
cardiometabolic	O
comorbidities	O
are	O
key	O
predictors	O
of	O
risk	O
.	O

Data	O
are	O
limited	O
on	O
incidence	O
of	O
metabolic	O
comorbidities	O
in	O
HIV+	O
individuals	O
initiating	O
ART	O
in	O
low	O
and	O
middle	O
income	O
countries	O
(	O
LMICs	O
)	O
,	O
particularly	O
for	O
Hispanics	O
.	O

We	O
examined	O
incidence	O
of	O
diabetes	O
and	O
obesity	O
in	O
a	O
prospective	O
cohort	O
of	O
those	O
initiating	O
ART	O
in	O
the	O
Dominican	O
Republic	O
.	O

Participants	O
≥18	O
years	O
,	O
initiating	O
ART	O
<	O
90	O
days	O
prior	O
to	O
study	O
enrollment	O
,	O
were	O
examined	O
for	O
incidence	O
of	O
impaired	O
fasting	O
glucose	O
(	O
IFG	O
)	O
,	O
diabetes	O
mellitus	O
(	O
DM	O
)	O
,	O
overweight	O
,	O
and	O
obesity	O
.	O

Fasting	B-P
plasma	I-P
glucose	I-P
(	O
FPG	B-P
)	O
100-125mg/dl	O
defined	O
IFG	O
;	O
FPG	B-P
≥126	O
mg/dl	O
,	O
diagnosis	O
per	O
medical	O
record	O
,	O
or	O
use	O
of	O
hypoglycemic	O
medication	O
defined	O
DM	O
.	O

Overweight	O
and	O
obesity	O
were	O
BMI	O
25-30	O
and	O
≥30kg/m2	O
,	O
respectively	O
.	O

Dyslipidemia	O
was	O
total	O
cholesterol	O
≥240mg/dl	O
or	O
use	O
of	O
lipid-lowering	O
medication	O
.	O

Framingham	O
risk	O
equation	O
was	O
used	O
to	O
determine	O
ten-year	O
CVD	O
risk	O
at	O
the	O
end	O
of	O
observation	O
.	O

Of	O
153	O
initiating	O
ART	O
,	O
8	O
(	O
6	O
%	O
)	O
had	O
DM	O
and	O
23	O
(	O
16	O
%	O
)	O
had	O
IFG	O
at	O
baseline	O
,	O
6	O
developed	O
DM	O
(	O
28/1000	O
person	O
-	O
years	O
follow	O
up	O
[	O
PYFU	O
]	O
)	O
and	O
46	O
developed	O
IFG	O
(	O
329/1000	O
PYFU	O
)	O
.	O

At	O
baseline	O
,	O
24	O
(	O
18	O
%	O
)	O
were	O
obese	O
and	O
36	O
(	O
27	O
%	O
)	O
were	O
overweight	O
,	O
15	O
became	O
obese	O
(	O
69/1000	O
PYFU	O
)	O
and	O
22	O
became	O
overweight	O
(	O
163/1000	O
PYFU	O
)	O
.	O

Median	O
observation	O
periods	O
for	O
the	O
diabetes	O
and	O
obesity	O
analyses	O
were	O
23.5	O
months	O
and	O
24.3	O
months	O
,	O
respectively	O
.	O

Increased	O
CVD	O
risk	O
(	O
≥10	O
%	O
10-year	O
Framingham	O
risk	O
score	O
)	O
was	O
present	O
for	O
13	O
%	O
of	O
the	O
cohort	O
;	O
79	O
%	O
of	O
the	O
cohort	O
had	O
≥1	O
cardiometabolic	O
comorbidity	O
,	O
48	O
%	O
had	O
≥2	O
,	O
and	O
13	O
%	O
had	O
all	O
three	O
.	O

In	O
this	O
Hispanic	O
cohort	O
in	O
an	O
LMIC	O
,	O
incidences	O
of	O
IFG	O
/	O
DM	O
and	O
overweight	O
/	O
obesity	O
were	O
similar	O
to	O
or	O
higher	O
than	O
that	O
found	O
in	O
high	O
income	O
countries	O
,	O
and	O
cardiometabolic	O
disorders	O
affected	O
three-quarters	O
of	O
those	O
initiating	O
ART	O
.	O

Care	O
models	O
incorporating	O
cardiovascular	O
risk	O
reduction	O
into	O
HIV	O
treatment	O
programs	O
are	O
needed	O
to	O
prevent	O
CVD	O
-	O
associated	O
mortality	O
in	O
this	O
vulnerable	O
population	O
.	O

Abstract	O
and	O
Effector-Selective	O
Decision	O
Signals	O
Exhibit	O
Qualitatively	O
Distinct	O
Dynamics	O
before	O
Delayed	O
Perceptual	O
Reports	O
.	O

Electrophysiological	B-P
research	I-P
has	O
isolated	O
neural	O
signatures	O
of	O
decision	O
formation	O
in	O
a	O
variety	O
of	O
brain	O
regions	O
.	O

Studies	B-P
in	O
rodents	O
and	O
monkeys	O
have	O
focused	O
primarily	O
on	O
effector-selective	O
signals	O
that	O
translate	O
the	O
emerging	O
decision	O
into	O
a	O
specific	O
motor	O
plan	O
,	O
but	O
,	O
more	O
recently	O
,	O
research	O
on	O
the	O
human	O
brain	O
has	O
identified	O
an	O
abstract	O
signature	O
of	O
evidence	O
accumulation	O
that	O
does	O
not	O
appear	O
to	O
play	O
any	O
direct	O
role	O
in	O
action	O
preparation	O
.	O

The	O
functional	O
dissociations	O
between	O
these	O
distinct	O
signal	O
types	O
have	O
only	O
begun	O
to	O
be	O
characterized	O
,	O
and	O
their	O
dynamics	O
during	O
decisions	O
with	O
deferred	O
actions	O
with	O
or	O
without	O
foreknowledge	O
of	O
stimulus-effector	O
mapping	O
,	O
a	O
commonly	O
studied	O
task	O
scenario	O
in	O
single-unit	B-P
and	O
functional	B-P
imaging	I-P
investigations	O
,	O
have	O
not	O
been	O
established	O
.	O

Here	O
we	O
traced	O
the	O
dynamics	O
of	O
distinct	O
abstract	O
and	O
effector-selective	O
decision	O
signals	O
in	O
the	O
form	O
of	O
the	O
broad-band	O
centro-parietal	O
positivity	O
(	O
CPP	O
)	O
and	O
limb-selective	O
β-band	O
(	O
8-16	O
and	O
18-30	O
Hz	O
)	O
EEG	B-P
activity	O
,	O
respectively	O
,	O
during	O
delayed	O
-	O
reported	O
motion	O
direction	O
decisions	O
with	O
and	O
without	O
foreknowledge	O
of	O
direction	O
-	O
response	O
mapping	O
.	O

With	O
foreknowledge	O
,	O
the	O
CPP	O
and	O
β-band	O
signals	O
exhibited	O
a	O
similar	O
gradual	O
build-up	O
following	O
evidence	O
onset	O
,	O
but	O
whereas	O
choice	O
-	O
predictive	O
β-band	O
activity	O
persisted	O
up	O
until	O
the	O
delayed	O
response	O
,	O
the	O
CPP	O
dropped	O
toward	O
baseline	O
after	O
peaking	O
.	O

Without	O
foreknowledge	O
,	O
the	O
CPP	O
exhibited	O
identical	O
dynamics	O
,	O
whereas	O
choice	O
-	O
selective	O
β-band	O
activity	O
was	O
eliminated	O
.	O

These	O
findings	O
highlight	O
qualitative	O
functional	O
distinctions	O
between	O
effector-selective	O
and	O
abstract	O
decision	O
signals	O
and	O
are	O
of	O
relevance	O
to	O
the	O
assumptions	O
founding	O
functional	O
neuroimaging	O
investigations	O
of	O
decision-making	O
.	O

Neural	O
signatures	O
of	O
evidence	O
accumulation	O
have	O
been	O
isolated	O
in	O
numerous	O
brain	O
regions	O
.	O

Although	O
animal	O
neurophysiology	O
has	O
largely	O
concentrated	O
on	O
effector-selective	O
decision	O
signals	O
that	O
translate	O
the	O
emerging	O
decision	O
into	O
a	O
specific	O
motor	O
plan	O
,	O
recent	O
research	O
on	O
the	O
human	O
brain	O
has	O
isolated	O
abstract	O
neural	O
signatures	O
of	O
decision	O
formation	O
that	O
are	O
independent	O
of	O
specific	O
sensory	O
and	O
motor	O
requirements	O
.	O

Here	O
,	O
we	O
examine	O
the	O
functional	O
distinctions	O
between	O
the	O
two	O
distinct	O
classes	O
of	O
decision	O
variable	O
signal	O
during	O
decisions	O
with	O
deferred	O
actions	O
with	O
and	O
without	O
foreknowledge	O
of	O
stimulus-effector	O
mapping	O
.	O

We	O
find	O
salient	O
distinctions	O
in	O
the	O
dynamics	O
of	O
abstract	O
versus	O
effector-selective	O
decision	O
signals	O
in	O
the	O
human	O
brain	O
,	O
in	O
terms	O
of	O
sustainment	O
through	O
response	O
delays	O
and	O
contingency	O
on	O
foreknowledge	O
of	O
stimulus-response	O
mapping	O
.	O

IN	O
VITRO	O
ANTIMICROBIAL	O
SCREENING	O
OF	O
AQUILARIA	O
AGALLOCHA	O
ROOTS	O
.	O

It	O
was	O
previously	O
shown	O
that	O
some	O
parts	O
of	O
Aquilaria	O
agallocha	O
,	O
which	O
is	O
commonly	O
known	O
as	O
oud	O
or	O
oodh	O
,	O
such	O
as	O
roots	O
have	O
been	O
used	O
as	O
a	O
traditional	O
medical	O
herbal	O
in	O
different	O
countries	O
.	O

In	O
Turkey	O
A.	O
agallocha	O
is	O
one	O
of	O
the	O
ingredients	O
while	O
preparing	O
famous	O
Mesir	O
paste	O
,	O
which	O
was	O
invented	O
as	O
a	O
medicinal	O
paste	O
and	O
used	O
from	O
the	O
Ottoman	O
period	O
to	O
now	O
at	O
least	O
for	O
500	O
years	O
.	O

The	O
identification	O
the	O
in	O
vitro	O
antimicrobial	O
activity	O
of	O
ethanol	O
extract	O
of	O
A.	O
agallocha	O
roots	O
is	O
main	O
purpose	O
of	O
this	O
analysis	O
.	O

By	O
using	O
17	O
bacteria	O
and	O
1	O
fungi	O
,	O
which	O
include	O
Bacillus	O
,	O
Candida	O
,	O
Enterobacter	O
,	O
Enterococcus	O
,	O
Escherichia	O
,	O
Klebsiella	O
,	O
Listeria	O
,	O
Pseudomonas	O
,	O
Salmonella	O
and	O
Staphylococcus	O
genera	O
,	O
the	O
activity	O
of	O
A.	O
agallocha	O
root	O
extracts	O
were	O
analysed	O
by	O
the	O
help	O
of	O
the	O
disk	B-P
diffusion	I-P
method	I-P
,	O
that	O
is	O
one	O
of	O
the	O
methods	B-P
commonly	O
used	O
to	O
determine	O
antimicrobial	O
activities	O
.	O

As	O
a	O
result	O
of	O
the	O
study	O
it	O
was	O
observed	O
that	O
ethanol	O
extracts	O
of	O
A.	O
agallocha	O
roots	O
have	O
a	O
clear	O
antimicrobial	O
activity	O
against	O
nearly	O
all	O
microorganism	O
used	O
in	O
the	O
study	O
,	O
but	O
only	O
two	O
bacteria	O
namely	O
E.	O
coli	O
ATCC	O
25922	O
and	O
S.	O
typhimurium	O
SL	O
1344	O
.	O

According	O
to	O
the	O
disk	B-P
diffusion	I-P
test	I-P
results	O
it	O
may	O
be	O
possible	O
to	O
propose	O
that	O
A.	O
agallocha	O
roots	O
should	O
have	O
a	O
medicinal	O
uses	O
especially	O
against	O
E.	O
faecium	O
,	O
L.	O
monocytogenes	O
ATCC	O
7644	O
,	O
B.	O
subtilis	O
DSMZ	O
1971	O
,	O
C.	O
albicans	O
DSMZ	O
1386	O
,	O
S.	O
epidermidis	O
DSMZ	O
20044	O
and	O
S.	O
aureus	O
ATCC	O
25923	O
.	O

Quantification	O
of	O
urinary	O
mono-hydroxylated	O
metabolites	O
of	O
polycyclic	O
aromatic	O
hydrocarbons	O
by	O
on-line	B-P
solid	I-P
phase	I-P
extraction	I-P
-	O
high	B-P
performance	I-P
liquid	I-P
chromatography-tandem	I-P
mass	I-P
spectrometry	I-P
.	O

Human	O
exposure	O
to	O
polycyclic	O
aromatic	O
hydrocarbons	O
(	O
PAHs	O
)	O
can	O
be	O
assessed	O
through	O
monitoring	O
of	O
urinary	O
mono-hydroxylated	O
PAHs	O
(	O
OH-PAHs	O
)	O
.	O

Gas	B-P
chromatography	I-P
(	O
GC	B-P
)	O
has	O
been	O
widely	O
used	O
to	O
separate	O
OH-PAHs	O
before	O
quantification	O
by	O
mass	B-P
spectrometry	I-P
in	O
biomonitoring	O
studies	O
.	O

However	O
,	O
because	O
GC	B-P
requires	O
derivatization	O
,	O
it	O
can	O
be	O
time	O
consuming	O
.	O

We	O
developed	O
an	O
on-line	B-P
solid	I-P
phase	I-P
extraction	I-P
coupled	O
to	O
isotope	O
dilution	O
-	O
high	B-P
performance	I-P
liquid	I-P
chromatography-tandem	I-P
mass	I-P
spectrometry	I-P
(	O
on-line-SPE	B-P
-	O
HPLC-MS	B-P
/	O
MS	B-P
)	O
method	O
for	O
the	O
quantification	O
in	O
urine	O
of	O
1-OH-naphthalene	O
,	O
2-OH-naphthalene	O
,	O
2-OH-fluorene	O
,	O
3-OH-fluorene	O
,	O
1-OH-phenanthrene	O
,	O
the	O
sum	O
of	O
2-OH	O
and	O
3-OH-phenanthrene	O
,	O
4-OH-phenanthrene	O
,	O
and	O
1-OH-pyrene	O
.	O

The	O
method	O
,	O
which	O
employed	O
a	O
96-	O
well	O
plate	O
platform	O
and	O
on-line	B-P
SPE	I-P
,	O
showed	O
good	O
sensitivity	O
(	O
i.e.	O
,	O
limits	O
of	O
detection	O
ranged	O
from	O
0.007	O
to	O
0.09	O
ng/mL	O
)	O
and	O
used	O
only	O
100	O
μL	O
of	O
urine	O
.	O

Accuracy	O
,	O
calculated	B-P
from	O
the	O
recovery	O
percentage	O
at	O
three	O
spiking	O
levels	O
,	O
varied	O
from	O
94	O
to	O
113	O
%	O
,	O
depending	O
on	O
the	O
analyte	O
.	O

The	O
inter	O
-	O
and	O
intra	O
-	O
day	O
precision	O
,	O
calculated	B-P
from	O
20	O
repeated	O
measurements	O
of	O
two	O
quality	O
control	O
materials	O
,	O
varied	O
from	O
5.2	O
to	O
16.7	O
%	O
.	O

Adequate	O
method	O
performance	O
was	O
also	O
confirmed	O
by	O
acceptable	O
recovery	O
(	O
83-102	O
%	O
)	O
of	O
two	O
NIST	O
standard	O
reference	O
materials	O
(	O
3672	O
and	O
3673	O
)	O
.	O

This	O
high-throughput	O
on-line-SPE	B-P
-	O
HPLC-MS	B-P
/	O
MS	B-P
method	O
can	O
be	O
applied	O
in	O
large	O
-	O
scale	O
epidemiological	O
studies	O
.	O

Graphical	O
abstract	O
Example	O
LC-MS	O
chromatogram	O
of	O
urinary	O
mono-hydroxylated	O
PAH	O
metabolites	O
.	O

Differential	O
miRNA	O
expression	O
analysis	O
during	O
late	O
stage	O
terminal	O
hindgut	O
development	O
in	O
fetal	O
rats	O
.	O

Terminal	O
hindgut	O
deformity	O
is	O
the	O
leading	O
digestive	O
tract	O
malformation	O
,	O
however	O
,	O
the	O
etiology	O
and	O
pathogenesis	O
remained	O
unknown	O
.	O

To	O
date	O
,	O
gene	O
expression	O
abnormalities	O
were	O
considered	O
the	O
primary	O
cause	O
of	O
these	O
diseases	O
.	O

miRNAs	O
have	O
been	O
found	O
to	O
play	O
an	O
important	O
role	O
in	O
regulating	O
the	O
expression	O
of	O
genes	O
.	O

A	O
total	O
of	O
24	O
pregnant	O
rats	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
.	O

The	O
experimental	O
group	O
(	O
n=12	O
)	O
received	O
1	O
%	O
ethylenethiourea	O
(	O
125mg/kg	O
)	O
by	O
gavage	O
on	O
gestational	O
day	O
11	O
,	O
while	O
the	O
control	O
group	O
(	O
n=12	O
)	O
received	O
the	O
same	O
volume	O
of	O
distilled	O
water	O
.	O

From	O
each	O
group	O
,	O
fetal	O
rats	O
were	O
obtained	O
by	O
cesarean	O
section	O
on	O
gestational	O
day	O
16	O
.	O

For	O
the	O
extraction	O
of	O
total	O
RNA	O
,	O
1	O
cm	O
rectum	O
samples	O
were	O
obtained	O
from	O
four	O
fetal	O
rats	O
that	O
had	O
similar	O
weights	O
.	O

Chip	O
hybridization	O
was	O
conducted	O
after	O
poly	O
(	O
A	O
)	O
and	O
biotin	O
were	O
added	O
to	O
the	O
RNA	O
samples	O
,	O
and	O
this	O
was	O
followed	O
by	O
washing	O
,	O
dyeing	O
,	O
and	O
scanning	B-P
of	O
the	O
chip	O
.	O

Differences	O
identified	O
in	O
the	O
miRNA	O
expression	O
profiles	O
and	O
the	O
target	O
gene	O
analysis	O
results	O
were	O
further	O
analyzed	O
to	O
identify	O
potential	O
regulators	O
of	O
terminal	O
hindgut	O
development	O
.	O

Compared	O
with	O
the	O
control	O
group	O
,	O
111	O
miRNAs	O
expressed	O
in	O
the	O
terminal	O
hindgut	O
of	O
the	O
experimental	O
group	O
were	O
up-regulated	O
on	O
gestational	O
day	O
16	O
,	O
while	O
117	O
miRNAs	O
were	O
down-regulated	O
.	O

The	O
ten	O
miRNAs	O
with	O
the	O
greatest	O
differential	O
expression	O
profiles	O
between	O
the	O
experimental	O
and	O
control	O
samples	O
were	O
selected	O
for	O
target	O
gene	O
prediction	O
,	O
pathway	O
analysis	O
,	O
and	O
gene	O
ontology	O
analysis	O
.	O

A	O
subset	O
of	O
these	O
miRNAs	O
was	O
found	O
to	O
be	O
closely	O
related	O
to	O
rat	O
fetus	O
terminal	O
hindgut	O
growth	O
and	O
development	O
.	O

In	O
addition	O
,	O
target	O
gene	O
analysis	O
showed	O
that	O
miR-193	O
may	O
have	O
an	O
important	O
role	O
in	O
regulating	O
a	O
key	O
gene	O
in	O
anorectal	O
development	O
,	O
Hoxd13	O
.	O

This	O
role	O
was	O
confirmed	O
in	O
a	O
dual	B-P
luciferase	I-P
reporter	I-P
assay	I-P
when	O
miR-193	O
was	O
able	O
to	O
inhibit	O
expression	O
of	O
a	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
the	O
Hoxd13	O
gene	O
in	O
the	O
human	O
embryonic	O
kidney	O
cell	O
line	O
,	O
293T	O
.	O

Real-time	O
PCR	O
and	O
Western	O
blotting	O
experiments	O
further	O
showed	O
that	O
the	O
expression	O
of	O
Hoxd13	O
was	O
significantly	O
lower	O
when	O
miR-193	O
was	O
highly	O
expressed	O
in	O
rat	O
intestinal	O
epithelial	O
cells	O
.	O

The	O
differences	O
in	O
both	O
sets	O
of	O
experiments	O
were	O
statistically	O
significant	O
compared	O
with	O
the	O
negative	O
control	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

These	O
data	O
support	O
an	O
important	O
regulatory	O
role	O
for	O
miRNAs	O
in	O
the	O
expression	O
of	O
target	O
genes	O
during	O
terminal	O
hindgut	O
development	O
in	O
fetal	O
rats	O
.	O

In	O
particular	O
,	O
miR-193	O
-mediated	O
inhibition	O
of	O
Hoxd13	O
was	O
found	O
to	O
be	O
significant	O
in	O
rat	O
intestinal	O
epithelial	O
cells	O
.	O

Improving	O
protein	O
complex	O
prediction	O
by	O
reconstructing	O
a	O
high-confidence	O
protein-protein	O
interaction	O
network	O
of	O
Escherichia	O
coli	O
from	O
different	O
physical	O
interaction	O
data	O
sources	O
.	O

Although	O
different	O
protein-protein	O
physical	O
interaction	O
(	O
PPI	O
)	O
datasets	O
exist	O
for	O
Escherichia	O
coli	O
,	O
no	O
common	O
methodology	O
exists	O
to	O
integrate	O
these	O
datasets	O
and	O
extract	O
reliable	O
modules	O
reflecting	O
the	O
existing	O
biological	O
process	O
and	O
protein	O
complexes	O
.	O

Naïve	O
Bayesian	O
formula	O
is	O
the	O
highly	O
accepted	O
method	O
to	O
integrate	O
different	O
PPI	O
datasets	O
into	O
a	O
single	O
weighted	O
PPI	O
network	O
,	O
but	O
detecting	O
proper	O
weights	O
in	O
such	O
network	O
is	O
still	O
a	O
major	O
problem	O
.	O

In	O
this	O
paper	O
,	O
we	O
proposed	O
a	O
new	O
methodology	O
to	O
integrate	O
various	O
physical	O
PPI	O
datasets	O
into	O
a	O
single	O
weighted	O
PPI	O
network	O
in	O
a	O
way	O
that	O
the	O
detected	O
modules	O
in	O
PPI	O
network	O
exhibit	O
the	O
highest	O
similarity	O
to	O
available	O
functional	O
modules	O
.	O

We	O
used	O
the	O
co-expression	O
modules	O
as	O
functional	O
modules	O
,	O
and	O
we	O
shown	O
that	O
direct	O
functional	O
modules	O
detected	O
from	O
Gene	O
Ontology	O
terms	O
could	O
be	O
used	O
as	O
an	O
alternative	O
dataset	O
.	O

After	O
running	O
this	O
integrating	O
methodology	O
over	O
six	O
different	O
physical	O
PPI	O
datasets	O
,	O
orthologous	O
high-confidence	O
interactions	O
from	O
a	O
related	O
organism	O
and	O
two	O
AP-MS	B-P
PPI	O
datasets	O
gained	O
high	O
weights	O
in	O
the	O
integrated	O
networks	O
,	O
while	O
the	O
weights	O
for	O
one	O
AP-MS	B-P
PPI	O
dataset	O
and	O
two	O
other	O
datasets	O
derived	O
from	O
public	O
databases	O
have	O
converged	O
to	O
zero	O
.	O

The	O
majority	O
of	O
detected	O
modules	O
shaped	O
around	O
one	O
or	O
few	O
hub	O
protein	O
(	O
s	O
)	O
.	O

Still	O
,	O
a	O
large	O
number	O
of	O
highly	O
interacting	O
protein	O
modules	O
were	O
detected	O
which	O
are	O
functionally	O
relevant	O
and	O
are	O
likely	O
to	O
construct	O
protein	O
complexes	O
.	O

We	O
provided	O
a	O
new	O
high	O
confidence	O
protein	O
complex	O
prediction	O
method	O
supported	O
by	O
functional	O
studies	O
and	O
literature	O
mining	O
.	O

Biochemical	O
evidence	O
for	O
a	O
mitochondrial	O
genetic	O
modifier	O
in	O
the	O
phenotypic	O
manifestation	O
of	O
Leber	O
's	O
hereditary	O
optic	O
neuropathy	O
-associated	O
mitochondrial	O
DNA	O
mutation	O
.	O

Leber	O
's	O
hereditary	O
optic	O
neuropathy	O
(	O
LHON	O
)	O
is	O
the	O
most	O
common	O
mitochondrial	O
disease	O
.	O

Mitochondrial	O
modifiers	O
are	O
proposed	O
to	O
modify	O
the	O
phenotypic	O
expression	O
of	O
primary	O
LHON	O
-associated	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
mutations	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
the	O
LHON	O
susceptibility	O
allele	O
(	O
m.14502T	O
>	O
C	O
,	O
p.	O
58I	O
>	O
V	O
)	O
in	O
the	O
ND6	O
gene	O
modulated	O
the	O
phenotypic	O
expression	O
of	O
primary	O
LHON	O
-associated	O
m.11778G	O
>	O
A	O
mutation	O
.	O

Twenty-two	O
Han	O
Chinese	O
pedigrees	O
carrying	O
m.14502T	O
>	O
C	O
and	O
m.11778G	O
>	O
A	O
mutations	O
exhibited	O
significantly	O
higher	O
penetrance	O
of	O
optic	O
neuropathy	O
than	O
those	O
carrying	O
only	O
m.11778G	O
>	O
A	O
mutation	O
.	O

We	O
performed	O
functional	O
assays	B-P
using	O
the	O
cybrid	O
cell	O
models	O
,	O
generated	O
by	O
fusing	O
mtDNA-less	O
ρ	O
(	O
o	O
)	O
cells	O
with	O
enucleated	O
cells	O
from	O
LHON	O
patients	O
carrying	O
both	O
m.11778G	O
>	O
A	O
and	O
m.14502T	O
>	O
C	O
mutations	O
,	O
only	O
m.14502T	O
>	O
C	O
or	O
m.11778G	O
>	O
A	O
mutation	O
and	O
a	O
control	O
belonging	O
to	O
the	O
same	O
mtDNA	O
haplogroup	O
.	O

These	O
cybrids	O
cell	O
lines	O
bearing	O
m.14502T	O
>	O
C	O
mutation	O
exhibited	O
mild	O
effects	O
on	O
mitochondrial	O
functions	O
compared	O
with	O
those	O
carrying	O
only	O
m.11778G	O
>	O
A	O
mutation	O
.	O

However	O
,	O
more	O
severe	O
mitochondrial	O
dysfunctions	O
were	O
observed	O
in	O
cell	O
lines	O
bearing	O
both	O
m.14502T	O
>	O
C	O
and	O
m.11778G	O
>	O
A	O
mutations	O
than	O
those	O
carrying	O
only	O
m.11778G	O
>	O
A	O
or	O
m.14502T	O
>	O
C	O
mutation	O
.	O

In	O
particular	O
,	O
the	O
m.14502T	O
>	O
C	O
mutation	O
altered	O
assemble	O
of	O
complex	O
I	O
,	O
thereby	O
aggravating	O
the	O
respiratory	O
phenotypes	O
associated	O
with	O
m.11778G	O
>	O
A	O
mutation	O
,	O
resulted	O
in	O
a	O
more	O
defective	O
complex	O
I	O
.	O

Furthermore	O
,	O
more	O
reductions	O
in	O
the	O
levels	O
of	O
mitochondrial	O
ATP	O
and	O
increasing	O
production	O
of	O
reactive	O
oxygen	O
species	O
were	O
also	O
observed	O
in	O
mutant	O
cells	O
bearing	O
both	O
m.14502T	O
>	O
C	O
and	O
m.11778G	O
>	O
A	O
mutation	O
than	O
those	O
carrying	O
only	O
11778G	O
>	O
A	O
mutation	O
.	O

Our	O
findings	O
provided	O
new	O
insights	O
into	O
the	O
pathophysiology	O
of	O
LHON	O
that	O
were	O
manifested	O
by	O
interaction	O
between	O
primary	O
and	O
secondary	O
mtDNA	O
mutations	O
.	O

Derivation	O
of	O
a	O
Predictive	O
Score	O
for	O
Hemorrhagic	O
Progression	O
of	O
Cerebral	O
Contusions	O
in	O
Moderate	O
and	O
Severe	O
Traumatic	O
Brain	O
Injury	O
.	O

After	O
traumatic	O
brain	O
injury	O
(	O
TBI	O
)	O
,	O
hemorrhagic	O
progression	O
of	O
contusions	O
(	O
HPCs	O
)	O
occurs	O
frequently	O
.	O

However	O
,	O
there	O
is	O
no	O
established	O
predictive	O
score	O
to	O
identify	O
high-risk	O
patients	O
for	O
HPC	O
.	O

Consecutive	O
patients	O
who	O
were	O
hospitalized	O
(	O
2008-2013	O
)	O
with	O
non-penetrating	O
moderate	O
or	O
severe	O
TBI	O
were	O
studied	O
.	O

The	O
primary	O
outcome	O
was	O
HPC	O
,	O
defined	O
by	O
both	O
a	O
relative	O
increase	O
in	O
contusion	O
volume	O
by	O
≥30	O
%	O
and	O
an	O
absolute	O
increase	O
by	O
≥10	O
mL	O
on	O
serial	O
imaging	O
.	O

Logistic	O
regression	O
models	O
were	O
created	O
to	O
identify	O
independent	O
risk	O
factors	O
for	O
HPC	O
.	O

The	O
HPC	O
Score	O
was	O
then	O
derived	O
based	O
on	O
the	O
final	O
model	O
.	O

Among	O
a	O
total	O
of	O
286	O
eligible	O
patients	O
,	O
61	O
(	O
21	O
%	O
)	O
patients	O
developed	O
HPC	O
.	O

On	O
univariate	O
analyses	O
,	O
HPC	O
was	O
associated	O
with	O
older	O
age	O
,	O
higher	O
initial	O
blood	O
pressure	O
,	O
antiplatelet	O
medications	O
,	O
anticoagulants	O
,	O
subarachnoid	O
hemorrhage	O
(	O
SAH	O
)	O
subdural	O
hematoma	O
(	O
SDH	O
)	O
,	O
skull	O
fracture	O
,	O
frontal	O
contusion	O
,	O
larger	O
contusion	O
volume	O
,	O
and	O
shorter	O
interval	O
from	O
injury	O
to	O
initial	B-P
CT	I-P
.	O

In	O
the	O
final	O
model	O
,	O
SAH	O
(	O
OR	O
6.33	O
,	O
95	O
%	O
CI	O
,	O
1.80-22.23	O
)	O
,	O
SDH	O
(	O
OR	O
3.46	O
,	O
95	O
%	O
CI	O
,	O
1.39-8.63	O
)	O
,	O
and	O
skull	O
fracture	O
(	O
OR	O
2.67	O
,	O
95	O
%	O
CI	O
,	O
1.28-5.58	O
)	O
were	O
associated	O
with	O
HPC	O
.	O

Based	O
on	O
these	O
factors	O
,	O
the	O
HPC	O
Score	O
was	O
derived	O
(	O
SAH	O
=	O
2	O
points	O
,	O
SDH	O
=	O
1	O
point	O
,	O
and	O
skull	O
fracture	O
=	O
1	O
point	O
)	O
.	O

This	O
score	O
had	O
an	O
area	O
under	O
the	O
receiver	O
operating	O
curve	O
of	O
0.77	O
.	O

Patients	O
with	O
a	O
score	O
of	O
0-2	O
had	O
a	O
4.0	O
%	O
incidence	O
of	O
HPC	O
,	O
while	O
patients	O
with	O
a	O
score	O
of	O
3-4	O
had	O
a	O
34.6	O
%	O
incidence	O
of	O
HPC	O
.	O

A	O
simple	O
HPC	O
Score	O
was	O
developed	O
for	O
early	O
risk	O
stratification	O
of	O
HPC	O
in	O
patients	O
with	O
moderate	O
or	O
severe	O
TBI	O
.	O

Influence	O
of	O
increased	O
epicardial	O
adipose	O
tissue	O
volume	O
on	O
1-year	O
in-stent	O
restenosis	O
in	O
patients	O
who	O
received	O
coronary	O
stent	O
implantation	O
.	O

Epicardial	O
adipose	O
tissue	O
(	O
EAT	O
)	O
is	O
significantly	O
associated	O
with	O
the	O
formation	O
and	O
composition	O
of	O
coronary	O
atherosclerotic	O
plaque	O
,	O
cardiac	O
events	O
and	O
the	O
clinical	O
prognosis	O
of	O
coronary	O
heart	O
disease	O
.	O

But	O
,	O
whether	O
increased	O
EAT	O
deposition	O
may	O
affect	O
the	O
incidence	O
of	O
in-stent	O
restenosis	O
(	O
ISR	O
)	O
is	O
currently	O
unclear	O
.	O

This	O
study	O
used	O
coronary	B-P
computed	I-P
tomography	I-P
angiography	I-P
(	O
CCTA	B-P
)	O
as	O
a	O
mean	O
to	O
investigate	O
whether	O
increased	O
EAT	O
volume	O
was	O
associated	O
with	O
ISR	O
.	O

A	O
total	O
of	O
364	O
patients	O
who	O
underwent	O
64-slice	B-P
CCTA	I-P
examination	O
for	O
the	O
evaluation	O
of	O
suspected	O
coronary	O
artery	O
disease	O
,	O
and	O
subsequently	O
underwent	O
percutaneous	O
coronary	O
intervention	O
(	O
PCI	O
)	O
for	O
the	O
first	O
time	O
,	O
and	O
then	O
accepted	O
coronary	B-P
angiography	I-P
(	O
CA	B-P
)	O
follow-up	O
for	O
ISR	O
examination	O
in	O
one	O
year	O
,	O
were	O
retrospectively	O
included	O
in	O
this	O
study	O
.	O

EAT	O
volume	O
was	O
measured	O
by	O
CCTA	B-P
examination	O
.	O

CA	B-P
follow-up	O
was	O
obtained	O
between	O
9	O
and	O
15	O
months	O
.	O

ISR	O
was	O
deﬁned	O
as	O
≥	O
50	O
%	O
luminal	O
diameter	O
narrowing	O
of	O
the	O
stent	O
segment	O
or	O
peri-stent	O
segment	O
.	O

EAT	O
volume	O
was	O
compared	O
between	O
patients	O
with	O
and	O
without	O
ISR	O
and	O
additional	O
well-known	O
predictors	O
of	O
ISR	O
were	O
compared	O
.	O

EAT	O
volume	O
was	O
signiﬁcantly	O
increased	O
in	O
patients	O
with	O
ISR	O
compared	O
with	O
those	O
without	O
ISR	O
(	O
154.5	O
±	O
74.6	O
mL	O
vs.	O
131.0	O
±	O
52.2	O
mL	O
,	O
P	O
<	O
0.001	O
)	O
.	O

The	O
relation	O
between	O
ISR	O
and	O
EAT	O
volume	O
remained	O
signiﬁcant	O
after	O
adjustment	O
for	O
conventional	O
cardiovascular	O
risk	O
factors	O
and	O
angiographic	O
parameters	O
.	O

EAT	O
volume	O
was	O
related	O
with	O
ISR	O
and	O
may	O
provide	O
additional	O
information	O
for	O
future	O
ISR	O
.	O

Extrapulmonary	O
Small	O
Cell	O
Carcinoma	O
of	O
the	O
Seminal	O
Vesicles	O
and	O
Prostate	O
Demonstrated	O
on	O
18F-FDG	B-P
Positron	I-P
Emission	I-P
Tomography/Computed	I-P
Tomography	I-P
.	O

Extrapulmonary	O
primary	O
small	O
cell	O
carcinomas	O
arising	O
from	O
the	O
urogenital	O
tract	O
is	O
infrequent	O
.	O

It	O
can	O
rarely	O
arise	O
from	O
the	O
prostate	O
and	O
even	O
more	O
rarely	O
from	O
the	O
seminal	O
vesicles	O
.	O

We	O
present	O
a	O
79-	O
year	O
-old	O
male	O
who	O
was	O
admitted	O
due	O
to	O
acute	O
renal	O
failure	O
with	O
a	O
history	O
of	O
radical	O
radiotherapy	O
for	O
prostate	O
adenocarcinoma	O
13	O
years	O
ago	O
.	O

The	O
prostate	O
specific	O
antigen	O
level	O
was	O
not	O
elevated	O
.	O

An	O
abdominopelvic	B-P
computed	I-P
tomography	I-P
(	I-P
CT	I-P
)	I-P
scan	I-P
showed	O
markedly	O
enlarged	O
seminal	O
vesicles	O
causing	O
bilateral	O
ureteral	O
obstruction	O
and	O
a	O
mildly	O
enlarged	O
prostate	O
.	O

Further	O
evaluation	O
with	O
fluorine-18-fluorodeoxyglucose	B-P
(	I-P
18F-FDG	I-P
)	I-P
positron	I-P
emission	I-P
tomography/CT	I-P
demonstrated	O
extensive	O
18F-FDG	O
uptake	O
in	O
the	O
pelvis	O
with	O
diffuse	O
involvement	O
of	O
both	O
seminal	O
vesicles	O
and	O
the	O
prostate	O
without	O
pathologic	O
uptake	O
in	O
the	O
lungs	O
or	O
elsewhere	O
in	O
the	O
body	O
.	O

Core	B-P
biopsies	I-P
of	O
the	O
prostate	O
and	O
both	O
seminal	O
vesicles	O
revealed	O
diffuse	O
involvement	O
by	O
small	O
cell	O
carcinoma	O
.	O

Therapy	O
could	O
not	O
be	O
instituted	O
due	O
to	O
a	O
rapid	O
deterioration	O
in	O
the	O
patient	O
's	O
clinical	O
condition	O
.	O

Botulinum	O
Toxin	O
Use	O
in	O
Refractory	O
Pain	O
and	O
Other	O
Symptoms	O
in	O
Parkinsonism	O
.	O

Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
and	O
other	O
parkinsonian	O
syndromes	O
are	O
chronic	O
,	O
progressive	O
neurodegenerative	O
diseases	O
.	O

With	O
advancing	O
disease	O
,	O
both	O
motor	O
and	O
non-motor	O
symptoms	O
represent	O
a	O
considerable	O
burden	O
and	O
symptom	O
relief	O
and	O
quality	O
of	O
life	O
improvement	O
become	O
the	O
main	O
goal	O
of	O
treatment	O
.	O

Botulinum	O
toxins	O
(	O
BTX	O
)	O
are	O
an	O
effective	O
treatment	O
modality	O
for	O
many	O
neurological	O
conditions	O
.	O

To	O
understand	O
the	O
potential	O
usefulness	O
of	O
BTX	O
in	O
this	O
population	O
,	O
we	O
performed	O
a	O
retrospective	O
chart	O
review	O
of	O
all	O
patients	O
with	O
a	O
clinical	B-P
diagnosis	I-P
of	O
idiopathic	O
PD	O
and	O
atypical	O
parkinsonism	O
who	O
received	O
treatment	O
with	O
BTX	O
injections	O
in	O
our	O
center	O
from	O
1995	O
to	O
2014	O
for	O
a	O
variety	O
of	O
symptoms	O
.	O

Response	O
to	O
BTX	O
was	O
assessed	O
using	O
a	O
subjective	O
Clinical	O
Global	O
Impression	O
.	O

Records	O
of	O
160	O
patients	O
were	O
reviewed	O
.	O

Probable	O
idiopathic	O
PD	O
was	O
the	O
diagnosis	O
in	O
117	O
patients	O
(	O
73.1	O
%	O
)	O
.	O

The	O
main	O
indication	O
for	O
BTX	O
treatment	O
was	O
pain	O
(	O
50.6	O
%	O
of	O
cases	O
)	O
.	O

Other	O
indications	O
were	O
the	O
treatment	O
of	O
functional	O
impairment	O
resulting	O
from	O
dystonia	O
(	O
26.25	O
%	O
)	O
,	O
sialorrhea	O
(	O
18.75	O
%	O
)	O
,	O
freezing	O
of	O
gait	O
,	O
and	O
camptocormia	O
.	O

Considering	O
pain	O
as	O
indication	O
,	O
81	O
%	O
of	O
all	O
patients	O
with	O
PD	O
reported	O
benefits	O
after	O
the	O
first	O
BTX	O
injections	O
.	O

This	O
benefit	O
was	O
maintained	O
after	O
the	O
last	O
recorded	O
visit	O
without	O
significant	O
difference	O
in	O
outcome	O
compared	O
with	O
the	O
first	O
injection	O
(	O
p=0.067	O
)	O
.	O

Similar	O
results	O
were	O
observed	O
in	O
patients	O
with	O
atypical	O
parkinsonism	O
.	O

Our	O
results	O
confirm	O
the	O
safety	O
and	O
efficacy	O
of	O
different	O
uses	O
of	O
BTX	O
in	O
the	O
symptomatic	O
treatment	O
of	O
patients	O
with	O
parkinsonism	O
even	O
in	O
advanced	O
stages	O
of	O
the	O
disease	O
,	O
and	O
suggest	O
BTX	O
treatment	O
could	O
have	O
a	O
safe	O
and	O
useful	O
role	O
in	O
the	O
treatment	O
of	O
pain	O
in	O
this	O
population	O
.	O

Gender	O
and	O
Direction	O
of	O
Effect	O
of	O
Alcohol	O
Problems	O
and	O
Internalizing	O
Symptoms	O
in	O
a	O
Longitudinal	O
Sample	O
of	O
College	O
Students	O
.	O

Alcohol	O
problems	O
and	O
internalizing	O
symptoms	O
are	O
consistently	O
found	O
to	O
be	O
associated	O
but	O
how	O
they	O
relate	O
to	O
each	O
other	O
is	O
unclear	O
.	O

The	O
present	O
study	O
aimed	O
to	O
address	O
limitations	O
in	O
the	O
literature	O
of	O
comorbidity	O
of	O
alcohol	O
problems	O
and	O
internalizing	O
symptoms	O
by	O
investigating	O
the	O
direction	O
of	O
effect	O
between	O
the	O
phenotypes	O
and	O
possible	O
gender	O
differences	O
in	O
college	O
students	O
.	O

We	O
utilized	O
data	O
from	O
a	O
large	O
longitudinal	O
study	O
of	O
college	O
students	O
from	O
the	O
United	O
States	O
(	O
N	O
=	O
2607	O
)	O
.	O

Three	O
waves	O
of	O
questionnaire-based	O
data	O
were	O
collected	O
over	O
the	O
first	O
two	O
years	O
of	O
college	O
(	O
in	O
2011-2013	O
)	O
.	O

Cross-lagged	O
models	O
were	O
applied	O
to	O
examine	O
the	O
possible	O
direction	O
of	O
effect	O
of	O
internalizing	O
symptoms	O
and	O
alcohol	O
problems	O
.	O

Possible	O
effects	O
of	O
gender	O
were	O
investigated	O
using	O
multigroup	O
modeling	O
.	O

There	O
were	O
significant	O
correlations	O
between	O
alcohol	O
problems	O
and	O
internalizing	O
symptoms	O
.	O

A	O
direction	O
of	O
effect	O
was	O
found	O
between	O
alcohol	O
problems	O
and	O
internalizing	O
symptoms	O
but	O
differed	O
between	O
genders	O
.	O

A	O
unidirectional	O
relationship	O
varying	O
with	O
age	O
was	O
identified	O
for	O
males	O
where	O
alcohol	O
problems	O
initially	O
predicted	O
internalizing	O
symptoms	O
followed	O
by	O
internalizing	O
symptoms	O
predicting	O
alcohol	O
problems	O
.	O

For	O
females	O
,	O
a	O
unidirectional	O
relationship	O
existed	O
wherein	O
alcohol	O
problems	O
predicted	O
internalizing	O
symptoms	O
.	O

Conclusions/Importance	O
:	O
We	O
conclude	O
that	O
the	O
relationship	O
between	O
alcohol	O
problems	O
and	O
internalizing	O
symptoms	O
is	O
complex	O
and	O
differ	O
between	O
genders	O
.	O

In	O
males	O
,	O
both	O
phenotypes	O
are	O
predictive	O
of	O
each	O
other	O
,	O
while	O
in	O
females	O
the	O
relationship	O
is	O
driven	O
by	O
alcohol	O
problems	O
.	O

Importantly	O
,	O
our	O
study	O
examines	O
a	O
population-based	O
sample	O
,	O
revealing	O
that	O
the	O
observed	O
relationships	O
between	O
alcohol	O
problems	O
and	O
internalizing	O
symptoms	O
are	O
not	O
limited	O
to	O
individuals	O
with	O
clinically	B-P
diagnosed	I-P
mental	O
health	O
or	O
substance	O
use	O
problems	O
.	O

Systematic	O
Quantification	O
of	O
GPCR	O
/	O
cAMP	O
-	O
Controlled	O
Protein	O
Kinase	O
A	O
Interactions	O
.	O

The	O
diffusible	O
second	O
messenger	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
originates	O
from	O
multiple	O
G	O
protein-coupled	O
receptor	O
(	O
GPCR	O
)	O
cascades	O
activating	O
the	O
intracellular	O
key	O
effector	O
protein	O
kinase	O
A	O
(	O
PKA	O
)	O
.	O

Spatially	O
and	O
temporally	O
restricted	O
cAMP	O
-	O
fluxes	O
are	O
directly	O
sensed	O
by	O
macromolecular	O
PKA	O
complexes	O
.	O

The	O
consequences	O
are	O
alterations	O
of	O
molecular	O
interactions	O
,	O
which	O
lead	O
to	O
activation	O
of	O
compartmentalized	O
PKA	O
phosphotransferase	O
activities	O
,	O
regulating	O
a	O
vast	O
array	O
of	O
cellular	O
functions	O
.	O

To	O
decode	O
cell-type	O
and	O
cell-compartment	O
specific	O
PKA	O
functions	O
,	O
the	O
spatio-temporal	O
dynamics	O
of	O
small	O
molecule	O
:	O
protein	O
interactions	O
,	O
protein	O
:	O
protein	O
interactions	O
(	O
PPIs	O
)	O
,	O
cAMP	O
-	O
mobilization	O
,	O
and	O
phosphotransferase	O
activities	O
need	O
to	O
be	O
determined	O
directly	O
in	O
the	O
appropriate	O
cellular	O
context	O
.	O

A	O
collection	O
of	O
cell-based	O
reporters	O
has	O
been	O
developed	O
to	O
either	O
visualize	O
or	O
quantitatively	O
measure	O
kinase	O
activities	O
or	O
PKA	O
complex	O
formation	O
/	O
dissociation	O
.	O

In	O
this	O
review	O
,	O
we	O
list	O
a	O
collection	O
of	O
unimolecular	O
and	O
bimolecular	O
PKA	O
biosensors	O
,	O
followed	O
by	O
the	O
specification	O
of	O
the	O
modular	O
design	O
of	O
a	O
Renilla	O
luciferase	O
based	O
protein-fragment	B-P
complementation	I-P
assay	I-P
(	O
PCA	B-P
)	O
platform	O
for	O
measuring	O
PKA	O
network	O
interactions	O
.	O

We	O
discuss	O
the	O
application	O
spectrum	B-P
of	O
the	O
PCA	B-P
reporter	O
to	O
identify	O
,	O
quantify	O
,	O
and	O
dissect	O
dynamic	O
and	O
transient	O
PKA	O
complexes	O
downstream	O
of	O
specific	O
GPCR	O
activities	O
.	O

We	O
specify	O
the	O
implementation	O
of	O
a	O
PCA	B-P
PKA	O
platform	O
to	O
systematically	O
quantify	O
the	O
concurrent	O
involvement	O
of	O
receptor	O
-	O
cAMP	O
signaling	O
,	O
post-translational	O
modifications	O
,	O
and	O
kinase	O
subunit	O
mutations	O
/	O
perturbations	O
in	O
PKA	O
activation	O
.	O

The	O
systematic	O
quantification	O
of	O
transient	O
PKA	O
network	O
interactions	O
will	O
contribute	O
to	O
a	O
better	O
understanding	O
how	O
GPCR	O
-recognized	O
input	O
signals	O
are	O
streamlined	O
through	O
the	O
compartmentalized	O
and	O
cAMP	O
-	O
interacting	O
PKA	O
signalosome	O
.	O

Heightened	O
HIV	O
antibody	O
responses	O
in	O
postpartum	O
women	O
as	O
exemplified	O
by	O
recent	O
infection	B-P
assays	I-P
:	O
implications	O
for	O
incidence	O
estimates	O
.	O

Laboratory	B-P
assays	I-P
that	O
identify	O
recent	O
HIV	O
infections	O
are	O
important	O
for	O
assessing	O
impacts	O
of	O
interventions	O
aimed	O
at	O
reducing	O
HIV	O
incidence	O
.	O

Kinetics	O
of	O
HIV	O
humoral	O
responses	O
can	O
vary	O
with	O
inherent	O
assay	O
properties	O
,	O
and	O
between	O
HIV	O
subtypes	O
,	O
populations	O
and	O
physiological	O
states	O
.	O

They	O
are	O
important	O
in	O
determining	O
mean	O
duration	O
of	O
recent	O
infection	O
(	O
MDRI	O
)	O
for	O
antibody-based	B-P
assays	I-P
for	O
detecting	O
recent	O
HIV	O
infections	O
.	O

We	O
determined	O
MDRIs	O
for	O
BED-CEIA	B-P
,	O
LAg	B-P
and	O
BRAI	B-P
assays	I-P
for	O
101	O
seroconverting	O
postpartum	O
women	O
,	O
recruited	O
in	O
Harare	O
in	O
1997-	O
2000	O
during	O
the	O
Zimbabwe	O
Vitamin	O
A	O
for	O
Mothers	O
and	O
Babies	O
(	O
ZVITAMBO	O
)	O
Trial	O
,	O
comparing	O
them	O
against	O
published	O
MDRIs	O
estimated	O
from	O
seroconverting	O
cases	O
in	O
the	O
general	O
population	O
.	O

We	O
also	O
compared	O
MDRIs	O
for	O
women	O
who	O
seroconverted	O
either	O
during	O
the	O
first	O
nine	O
months	O
,	O
or	O
at	O
later	O
stages	O
,	O
postpartum	O
.	O

At	O
cut-offs	O
(	O
C	O
)	O
of	O
0.8	O
for	O
BED	B-P
,	O
1.5	O
for	O
LAg	B-P
and	O
40	O
%	O
for	O
BRAI	B-P
,	O
estimated	O
MDRIs	O
for	O
postpartum	O
mothers	O
,	O
were	O
192	O
,	O
104	O
and	O
144	O
days	O
,	O
33	O
%	O
,	O
32-41	O
%	O
and	O
52	O
%	O
lower	O
than	O
published	O
estimates	O
of	O
287	O
,	O
152-177	O
and	O
298	O
days	O
,	O
respectively	O
,	O
for	O
clade	O
C	O
samples	O
from	O
general	O
populations	O
.	O

Point	O
estimates	O
of	O
MDRI	O
values	O
were	O
7	O
-	O
19	O
%	O
shorter	O
for	O
women	O
who	O
seroconverted	O
in	O
the	O
first	O
9-	O
months	O
postpartum	O
,	O
compared	O
with	O
those	O
seroconverting	O
later	O
.	O

MDRI	O
values	O
for	O
three	O
HIV	O
incidence	O
biomarkers	O
are	O
longer	O
in	O
the	O
general	O
population	O
than	O
among	O
postpartum	O
women	O
,	O
particularly	O
those	O
who	O
recently	O
gave	O
birth	O
,	O
consistent	O
with	O
heightened	O
immunologic	O
activation	O
soon	O
after	O
birth	O
.	O

Our	O
results	O
provide	O
a	O
caution	O
that	O
MDRI	O
may	O
vary	O
significantly	O
between	O
subjects	O
in	O
different	O
physiological	O
states	O
.	O

Dynamic	B-P
Contrast-enhanced	I-P
MR	I-P
Imaging	I-P
in	O
Renal	O
Cell	O
Carcinoma	O
:	O
Reproducibility	O
of	O
Histogram	O
Analysis	O
on	O
Pharmacokinetic	O
Parameters	O
.	O

Pharmacokinetic	O
parameters	O
derived	O
from	O
dynamic	B-P
contrast-enhanced	I-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	O
DCE-MRI	B-P
)	O
have	O
been	O
increasingly	O
used	O
to	O
evaluate	O
the	O
permeability	O
of	O
tumor	O
vessel	O
.	O

Histogram	O
metrics	O
are	O
a	O
recognized	O
promising	O
method	O
of	O
quantitative	O
MR	B-P
imaging	I-P
that	O
has	O
been	O
recently	O
introduced	O
in	O
analysis	O
of	O
DCE-MRI	B-P
pharmacokinetic	O
parameters	O
in	O
oncology	O
due	O
to	O
tumor	O
heterogeneity	O
.	O

In	O
this	O
study	O
,	O
21	O
patients	O
with	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
underwent	O
paired	O
DCE-MRI	B-P
studies	O
on	O
a	O
3.0	O
T	O
MR	O
system	O
.	O

Extended	O
Tofts	O
model	O
and	O
population-based	O
arterial	O
input	O
function	O
were	O
used	O
to	O
calculate	O
kinetic	O
parameters	O
of	O
RCC	O
tumors	O
.	O

Mean	O
value	O
and	O
histogram	O
metrics	O
(	O
Mode	O
,	O
Skewness	O
and	O
Kurtosis	O
)	O
of	O
each	O
pharmacokinetic	O
parameter	O
were	O
generated	O
automatically	O
using	O
ImageJ	O
software	O
.	O

Intra-	O
and	O
inter-observer	O
reproducibility	O
and	O
scan-rescan	O
reproducibility	O
were	O
evaluated	O
using	O
intra-class	O
correlation	O
coefficients	O
(	O
ICCs	O
)	O
and	O
coefficient	O
of	O
variation	O
(	O
CoV	O
)	O
.	O

Our	O
results	O
demonstrated	O
that	O
the	O
histogram	O
method	O
(	O
Mode	O
,	O
Skewness	O
and	O
Kurtosis	O
)	O
was	O
not	O
superior	O
to	O
the	O
conventional	O
Mean	O
value	O
method	O
in	O
reproducibility	O
evaluation	O
on	O
DCE-MRI	B-P
pharmacokinetic	O
parameters	O
(	O
K	O
(	O
trans	O
)	O
&	O
Ve	O
)	O
in	O
renal	O
cell	O
carcinoma	O
,	O
especially	O
for	O
Skewness	O
and	O
Kurtosis	O
which	O
showed	O
lower	O
intra-	O
,	O
inter-observer	O
and	O
scan-rescan	O
reproducibility	O
than	O
Mean	O
value	O
.	O

Our	O
findings	O
suggest	O
that	O
additional	O
studies	O
are	O
necessary	O
before	O
wide	O
incorporation	O
of	O
histogram	O
metrics	O
in	O
quantitative	O
analysis	O
of	O
DCE-MRI	B-P
pharmacokinetic	O
parameters	O
.	O

Cultivation	B-P
of	O
four	O
microalgae	O
species	O
in	O
the	O
effluent	O
of	O
anaerobic	O
digester	O
for	O
biodiesel	O
production	O
.	O

This	O
study	O
investigated	O
if	O
an	O
effluent	O
from	O
anaerobic	O
digestion	O
(	O
AD	O
)	O
system	O
can	O
be	O
used	O
as	O
a	O
nutrients	O
source	O
for	O
the	O
microalgae	O
cultivation	B-P
,	O
and	O
in	O
so	O
doing	O
,	O
if	O
the	O
effluent	O
can	O
be	O
properly	O
treated	O
.	O

Nitrogen	O
and	O
phosphorus	O
in	O
the	O
AD	O
effluent	O
well	O
supported	O
microalgal	O
growth	O
,	O
and	O
their	O
removal	O
efficiency	O
reached	O
>	O
97.9	O
%	O
and	O
99.2	O
%	O
,	O
respectively	O
.	O

Among	O
four	O
different	O
algal	O
species	O
tested	O
,	O
Micractinium	O
inermum	O
particularly	O
stood	O
out	O
,	O
showing	O
the	O
highest	O
biomass	O
and	O
FAME	O
productivity	O
:	O
0.16gL	O
(	O
-1	O
)	O
d	O
(	O
-1	O
)	O
with	O
3.23gL	O
(	O
-1	O
)	O
of	O
dry	O
cell	O
weight	O
,	O
and	O
0.04gL	O
(	O
-1	O
)	O
d	O
(	O
-1	O
)	O
with	O
27.54	O
%	O
(	O
w/w	O
)	O
of	O
FAME	O
contents	O
,	O
respectively	O
.	O

As	O
the	O
concentrations	O
of	O
the	O
nutrients	O
decreased	O
over	O
time	O
,	O
the	O
FAME	O
contents	O
were	O
increased	O
and	O
its	O
quality	O
as	O
well	O
,	O
satisfying	O
several	O
biodiesel	O
quality	O
standards	O
.	O

This	O
study	O
supports	O
that	O
the	O
AD	O
effluent	O
can	O
indeed	O
serve	O
as	O
a	O
cheap	O
and	O
nutrient	O
-	O
rich	O
medium	O
for	O
microalgae	O
cultivation	B-P
,	O
and	O
equally	O
importantly	O
,	O
microalgae	O
can	O
be	O
a	O
workable	O
treatment	O
option	O
for	O
it	O
.	O

Transcatheter	O
tricuspid	O
valve-in-valve	O
replacement	O
:	O
one-year	O
results	O
:	O
Alternative	O
to	O
surgery	O
in	O
high-risk	O
patients	O
.	O

Although	O
rheumatic	O
heart	O
disease	O
is	O
becoming	O
uncommon	O
in	O
industrialized	O
countries	O
,	O
its	O
global	O
burden	O
is	O
still	O
significant	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
70-year-old	O
male	O
with	O
rheumatic	O
heart	O
disease	O
,	O
who	O
underwent	O
4	O
previous	O
heart	O
valve	O
replacement	O
surgeries	O
,	O
and	O
presented	O
to	O
our	O
hospital	O
with	O
refractory	O
heart	O
failure	O
(	O
NYHA	O
functional	O
class	O
IV	O
)	O
due	O
to	O
severe	O
stenosis	O
of	O
a	O
previously	O
implanted	O
tricuspid	O
bioprosthesis	O
.	O

The	O
Heart	O
Team	O
deemed	O
the	O
patient	O
as	O
inoperable	O
/	O
high-risk	O
for	O
surgery	O
.	O

As	O
an	O
alternative	O
,	O
a	O
transcatheter	O
tricuspid	O
valve-in-valve	O
replacement	O
was	O
decided	O
upon	O
and	O
later	O
executed	O
through	O
the	O
right	O
femoral	O
vein	O
,	O
with	O
the	O
insertion	O
of	O
an	O
Edwards	O
SAPIEN	O
XT	O
29	O
no	O
.	O

(	O
Edwards	O
Lifesciences	O
,	O
Irvine	O
,	O
CA	O
,	O
USA	O
)	O
through	O
the	O
inferior	O
vena	O
cava	O
,	O
towards	O
the	O
RV	O
,	O
followed	O
by	O
direct	O
implantation	O
in	O
the	O
tricuspid	O
bioprosthesis	O
(	O
valve-in-valve	O
)	O
,	O
under	O
rapid	O
pacing	O
,	O
without	O
complications	O
.	O

A	O
substantial	O
clinical	O
and	O
echocardiographic	B-P
improvement	O
was	O
noted	O
after	O
the	O
procedure	O
and	O
the	O
patient	O
was	O
subsequently	O
discharged	O
in	O
NYHA	O
functional	O
class	O
II	O
.	O

These	O
favourable	O
outcomes	O
persisted	O
through	O
the	O
1-year	O
follow-up	O
period	O
.	O

This	O
case	O
report	O
adds	O
to	O
the	O
current	O
body	O
of	O
evidence	O
that	O
tricuspid	O
valve	O
implantation	O
stands	O
as	O
a	O
viable	O
and	O
reliable	O
alternative	O
in	O
the	O
treatment	O
of	O
degenerated	O
bioprosthesis	O
in	O
high-surgical-risk	O
patients	O
.	O

Association	O
of	O
Autoimmune	O
Encephalitis	O
With	O
Combined	O
Immune	O
Checkpoint	O
Inhibitor	O
Treatment	O
for	O
Metastatic	O
Cancer	O
.	O

Paraneoplastic	O
encephalitides	O
usually	O
precede	O
a	O
diagnosis	B-P
of	I-P
cancer	I-P
and	O
are	O
often	O
refractory	O
to	O
immunosuppressive	O
therapy	O
.	O

Conversely	O
,	O
autoimmune	O
encephalitides	O
are	O
reversible	O
conditions	O
that	O
can	O
occur	O
in	O
the	O
presence	O
or	O
absence	O
of	O
cancer	O
.	O

To	O
report	O
the	O
induction	O
of	O
autoimmune	O
encephalitis	O
in	O
2	O
patients	O
after	O
treatment	O
of	O
metastatic	O
cancer	O
with	O
a	O
combination	O
of	O
the	O
immune	O
checkpoint	O
inhibitors	O
nivolumab	O
and	O
ipilimumab	O
.	O

A	O
retrospective	O
case	O
study	O
was	O
conducted	O
of	O
the	O
clinical	O
and	O
management	O
course	O
of	O
2	O
patients	O
with	O
progressive	O
,	O
treatment	O
-	O
refractory	O
metastatic	O
cancer	O
who	O
were	O
treated	O
with	O
a	O
single	O
dose	O
each	O
(	O
concomitantly	O
)	O
of	O
the	O
immune	O
checkpoint	O
inhibitors	O
nivolumab	O
,	O
1	O
mg/kg	O
,	O
and	O
ipilimumab	O
,	O
3	O
mg/kg	O
.	O

Nivolumab	O
and	O
ipilimumab	O
.	O

The	O
clinical	O
response	O
to	O
immunosuppressive	O
therapy	O
in	O
suspected	O
autoimmune	O
encephalitis	O
in	O
the	O
setting	O
of	O
immune	O
checkpoint	O
inhibitor	O
use	O
.	O

Autoantibody	B-P
testing	I-P
confirmed	O
identification	O
of	O
anti-N-methyl-D-aspartate	O
receptor	O
antibodies	O
in	O
the	O
cerebrospinal	O
fluid	O
of	O
1	O
patient	O
.	O

Withdrawal	O
of	O
immune	O
checkpoint	O
inhibitors	O
and	O
initiation	O
of	O
immunosuppressive	O
therapy	O
,	O
consisting	O
of	O
intravenous	O
methylprednisolone	O
sodium	O
succinate	O
equivalent	O
to	O
1000	O
mg	O
of	O
methylprednisolone	O
for	O
5	O
days	O
,	O
0.4	O
mg/kg/d	O
of	O
intravenous	O
immunoglobulin	O
for	O
5	O
days	O
,	O
and	O
2	O
doses	O
of	O
rituximab	O
,	O
1000	O
mg	O
,	O
in	O
1	O
patient	O
and	O
oral	O
prednisone	O
,	O
60	O
mg/d	O
,	O
in	O
the	O
other	O
patient	O
,	O
resulted	O
in	O
improved	O
neurologic	O
symptoms	O
.	O

Immune	O
checkpoint	O
inhibition	O
may	O
favor	O
the	O
development	O
of	O
immune	O
responses	O
against	O
neuronal	O
antigens	O
,	O
leading	O
to	O
autoimmune	O
encephalitis	O
.	O

Early	O
recognition	O
and	O
treatment	O
of	O
autoimmune	O
encephalitis	O
in	O
patients	O
receiving	O
immune	O
checkpoint	O
blockade	O
therapy	O
will	O
likely	O
be	O
essential	O
for	O
maximizing	O
clinical	O
recovery	O
and	O
minimizing	O
the	O
effect	O
of	O
drug-related	O
toxic	O
effects	O
.	O

The	O
mechanisms	O
by	O
which	O
immune	O
checkpoint	O
inhibition	O
may	O
contribute	O
to	O
autoimmune	O
encephalitis	O
require	O
further	O
study	O
.	O

Fluorescence	B-P
hyperspectral	I-P
imaging	I-P
(	O
fHSI	B-P
)	O
using	O
a	O
spectrally	O
resolved	O
detector	O
array	O
.	O

The	O
ability	O
to	O
resolve	O
multiple	O
fluorescent	O
emissions	O
from	O
different	O
biological	O
targets	O
in	O
video	O
rate	O
applications	O
,	O
such	O
as	O
endoscopy	B-P
and	O
intraoperative	B-P
imaging	I-P
,	O
has	O
traditionally	O
been	O
limited	O
by	O
the	O
use	O
of	O
filter-based	O
imaging	O
systems	O
.	O

Hyperspectral	B-P
imaging	I-P
(	O
HSI	B-P
)	O
facilitates	O
the	O
detection	O
of	O
both	O
spatial	O
and	O
spectral	O
information	O
in	O
a	O
single	O
data	O
acquisition	O
,	O
however	O
,	O
instrumentation	O
for	O
HSI	B-P
is	O
typically	O
complex	O
,	O
bulky	O
and	O
expensive	O
.	O

We	O
sought	O
to	O
overcome	O
these	O
limitations	O
using	O
a	O
novel	O
robust	O
and	O
low	O
cost	O
HSI	B-P
camera	O
based	O
on	O
a	O
spectrally	O
resolved	O
detector	O
array	O
(	O
SRDA	O
)	O
.	O

We	O
integrated	O
this	O
HSI	B-P
camera	O
into	O
a	O
wide-field	O
reflectance-based	B-P
imaging	O
system	O
operating	O
in	O
the	O
near-infrared	O
range	O
to	O
assess	O
the	O
suitability	O
for	O
in	B-P
vivo	I-P
imaging	I-P
of	O
exogenous	O
fluorescent	O
contrast	O
agents	O
.	O

Using	O
this	O
fluorescence	B-P
HSI	I-P
(	O
fHSI	B-P
)	O
system	O
,	O
we	O
were	O
able	O
to	O
accurately	O
resolve	O
the	O
presence	O
and	O
concentration	O
of	O
at	O
least	O
7	O
fluorescent	O
dyes	O
in	O
solution	O
.	O

We	O
also	O
demonstrate	O
high	O
spectral	O
unmixing	O
precision	O
,	O
signal	O
linearity	O
with	O
dye	O
concentration	O
and	O
at	O
depth	O
in	O
tissue	O
mimicking	O
phantoms	O
,	O
and	O
delineate	O
4	O
fluorescent	O
dyes	O
in	O
vivo	O
.	O

Our	O
approach	O
,	O
including	O
statistical	O
background	O
removal	O
,	O
could	O
be	O
directly	O
generalised	O
to	O
broader	O
spectral	O
ranges	O
,	O
for	O
example	O
,	O
to	O
resolve	O
tissue	O
reflectance	B-P
or	O
autofluorescence	B-P
and	O
in	O
future	O
be	O
tailored	O
to	O
video	O
rate	O
applications	O
requiring	O
snapshot	O
HSI	B-P
data	O
acquisition	O
.	O

Automated	O
characterization	O
and	O
counting	O
of	O
Ki-67	O
protein	O
for	O
breast	O
cancer	O
prognosis	O
:	O
A	O
quantitative	O
immunohistochemistry	B-P
approach	O
.	O

Ki-67	O
protein	O
expression	O
plays	O
an	O
important	O
role	O
in	O
predicting	O
the	O
proliferative	O
status	O
of	O
tumour	O
cell	O
s	O
and	O
deciding	O
the	O
future	O
course	O
of	O
therapy	O
in	O
breast	O
cancer	O
.	O

Immunohistochemical	B-P
(	I-P
IHC	I-P
)	I-P
determination	I-P
of	O
Ki-67	B-P
score	I-P
or	O
labelling	B-P
index	I-P
,	O
by	O
estimating	O
the	O
fraction	O
of	O
Ki67	O
positively	O
stained	O
tumour	O
cells	O
,	O
is	O
the	O
most	O
widely	O
practiced	O
method	B-P
to	O
assess	O
tumour	O
proliferation	O
(	O
Dowsett	O
et	O
al	O
.	O

2011	O
)	O
.	O

Accurate	O
manual	B-P
counting	I-P
of	O
these	O
cells	O
(	O
specifically	O
nuclei	O
)	O
due	O
to	O
complex	O
and	O
dense	O
distribution	O
of	O
cells	O
,	O
therefore	O
,	O
becomes	O
critical	O
and	O
presents	O
a	O
major	O
challenge	O
to	O
pathologists	O
.	O

In	O
this	O
paper	O
,	O
we	O
suggest	O
a	O
hybrid	O
clustering	O
algorithm	O
to	O
quantify	O
the	O
proliferative	O
index	O
of	O
breast	O
cancer	O
cells	O
based	O
on	O
automated	B-P
counting	I-P
of	O
Ki-67	O
nuclei	O
.	O

The	O
proposed	O
methodology	B-P
initially	O
pre-processes	O
the	O
IHC	B-P
images	O
of	O
Ki-67	O
stained	O
slides	O
of	O
breast	O
cancer	O
.	O

The	O
RGB	O
images	O
are	O
converted	O
to	O
grey	O
,	O
L*a*b*	O
,	O
HSI	O
,	O
YCbCr	O
,	O
YIQ	O
and	O
XYZ	O
colour	O
space	O
.	O

All	O
the	O
stained	O
cells	O
are	O
then	O
characterized	O
by	O
two	B-P
stage	I-P
segmentation	I-P
process	I-P
.	O

Fuzzy	O
C-means	O
quantifies	O
all	O
the	O
stained	O
cells	O
as	O
one	O
cluster	O
.	O

The	O
blue	O
channel	O
of	O
the	O
first	O
stage	O
output	O
is	O
given	O
as	O
input	O
to	O
k-means	O
algorithm	O
,	O
which	O
provides	O
separate	O
cluster	O
for	O
Ki-67	O
positive	O
and	O
negative	O
cells	O
.	O

The	O
count	O
of	O
positive	O
and	O
negative	O
nuclei	O
is	O
used	O
to	O
calculate	B-P
the	O
F-measure	O
for	O
each	O
colour	O
space	O
.	O

A	O
comparative	O
study	O
of	O
our	O
work	O
with	O
the	O
expert	O
opinion	O
is	O
studied	O
to	O
evaluate	O
the	O
error	O
rate	O
.	O

The	O
positive	O
and	O
negative	O
nuclei	O
detection	O
results	O
for	O
all	O
colour	O
space	O
s	O
are	O
compared	O
with	O
the	O
ground	O
truth	O
for	O
validation	O
and	O
F-measure	O
is	O
calculated	B-P
.	O

The	O
F-measure	O
for	O
L*a*b*	O
colour	O
space	O
(	O
0.8847	O
)	O
provides	O
the	O
best	O
statistical	O
result	O
as	O
compared	O
to	O
grey	O
,	O
HSI	O
,	O
YCbCr	O
,	O
YIQ	O
and	O
XYZ	O
colour	O
space	O
.	O

Further	O
,	O
a	O
study	O
is	O
carried	O
out	O
to	O
count	O
nuclei	O
manually	B-P
and	O
automatically	B-P
from	O
the	O
proposed	O
algorithm	O
with	O
an	O
average	O
error	O
rate	O
of	O
6.84	O
%	O
which	O
is	O
significant	O
.	O

The	O
study	O
provides	O
an	O
automated	O
count	O
of	O
positive	O
and	O
negative	O
nuclei	O
using	O
L*a*b*	O
colour	O
space	O
and	O
hybrid	O
segmentation	O
technique	O
.	O

Computerized	B-P
evaluation	I-P
of	O
proliferation	O
index	O
can	O
aid	O
pathologist	O
in	O
assessing	O
breast	O
cancer	O
severity	O
.	O

The	O
proposed	O
methodology	B-P
,	O
further	O
,	O
has	O
the	O
potential	O
advantage	O
of	O
saving	O
time	O
and	O
assisting	O
in	O
decision	O
making	O
over	O
the	O
present	O
manual	B-P
procedure	I-P
and	O
could	O
evolve	O
as	O
an	O
assistive	O
pathological	O
decision	O
support	O
system	O
.	O

Simvastatin	O
enhances	O
the	O
hippocampal	O
klotho	O
in	O
a	O
rat	O
model	O
of	O
streptozotocin	O
-	O
induced	O
cognitive	O
decline	O
.	O

Brain	O
oxidative	O
status	O
is	O
a	O
crucial	O
factor	O
in	O
the	O
development	O
of	O
sporadic	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

Klotho	O
,	O
an	O
anti-aging	O
protein	O
,	O
diminishes	O
oxidative	O
stress	O
by	O
the	O
induction	O
of	O
manganese	O
superoxide	O
dismutase	O
(	O
MnSOD	O
)	O
.	O

Thus	O
,	O
the	O
substances	O
that	O
increase	O
klotho	O
expression	O
could	O
be	O
considered	O
as	O
a	O
potential	O
treatment	O
for	O
Alzheimer	O
's	O
disease	O
when	O
the	O
oxidative	O
imbalance	O
is	O
present	O
.	O

Statins	O
are	O
suggested	O
to	O
up-regulate	O
klotho	O
expression	O
.	O

We	O
examined	O
the	O
effect	O
of	O
simvastatin	O
(	O
5mg/kg	O
,	O
daily	O
for	O
3	O
weeks	O
)	O
on	O
hippocampal	O
klotho	O
and	O
MnSOD	O
expression	O
in	O
the	O
cognitive	O
declined	O
animal	O
model	O
induced	O
by	O
intracerebroventricular	O
(	O
ICV	O
)	O
-	O
streptozotocin	O
(	O
STZ	O
)	O
administration	O
.	O

Cognitive	B-P
assessment	I-P
was	O
performed	O
by	O
the	O
Morris	O
Water	O
Maze	O
(	O
MWM	O
)	O
test	O
.	O

The	O
results	O
indicated	O
that	O
mean	O
escape	O
latency	O
and	O
distance	O
were	O
prolonged	O
in	O
the	O
ICV	O
-	O
STZ	O
group	O
compared	O
with	O
the	O
control	O
group	O
.	O

The	O
expression	O
of	O
klotho	O
and	O
MnSOD	O
were	O
also	O
down	O
regulated	O
in	O
the	O
hippocampus	O
.	O

Furthermore	O
,	O
improved	O
spatial	O
performance	O
was	O
observed	O
in	O
simvastatin	O
-	O
treated	O
animals	O
.	O

This	O
effect	O
could	O
be	O
related	O
to	O
increase	O
in	O
oxidative	O
stress	O
tolerance	O
as	O
evidenced	O
by	O
klotho	O
and	O
MnSOD	O
up-regulation	O
.	O

Our	O
current	O
study	O
indicates	O
that	O
klotho	O
upregulation	O
may	O
be	O
a	O
neuroprotective	O
mechanism	O
of	O
simvastatin	O
against	O
cognitive	O
decline	O
in	O
AD	O
.	O

Radiation	O
-	O
induced	O
Parotid	O
Gland	O
Atrophy	O
in	O
Patients	O
with	O
Head	O
and	O
Neck	O
Cancer	O
After	O
Carbon-ion	O
Radiotherapy	O
.	O

This	O
study	O
aimed	O
to	O
clarify	O
the	O
relationship	O
between	O
dosimetric	B-P
factors	O
and	O
parotid	O
gland	O
(	O
PG	O
)	O
atrophy	O
after	O
carbon	O
ion	O
radiotherapy	O
(	O
C-ion	O
RT	O
)	O
.	O

Fifty-four	O
patients	O
with	O
head	O
and	O
neck	O
tumours	O
were	O
enrolled	O
and	O
93	O
irradiated	O
PGs	O
were	O
analyzed	O
.	O

Thirty	O
and	O
24	O
patients	O
were	O
treated	O
with	O
total	O
doses	O
[	O
relative	O
biological	O
effectiveness	O
(	O
RBE	O
)	O
]	O
of	O
57.6	O
Gy	O
and	O
64.0	O
Gy	O
,	O
respectively	O
,	O
in	O
16	O
fractions	O
.	O

PG	O
volumes	O
were	O
measured	B-P
using	O
computed	O
tomographic	O
images	O
obtained	O
before	O
C-ion	O
RT	O
and	O
every	O
3-6	O
months	O
thereafter	O
.	O

The	O
median	O
follow-up	O
period	O
was	O
46.4	O
months	O
(	O
range	O
=24.0-123.0	O
months	O
)	O
.	O

Univariate	O
analysis	O
showed	O
that	O
PG	O
volumes	O
receiving	O
more	O
than	O
5	O
,	O
10	O
,	O
15	O
,	O
and	O
20	O
Gy	O
RBE	O
(	O
V5	O
,	O
V10	O
,	O
V15	O
and	O
V20	O
,	O
respectively	O
)	O
,	O
mean	O
dose	O
,	O
and	O
maximum	O
dose	O
were	O
significantly	O
associated	O
with	O
PG	O
atrophy	O
.	O

Multivariate	O
analysis	O
indicated	O
that	O
only	O
V5	O
was	O
significantly	O
associated	O
with	O
atrophy	O
.	O

Increasing	O
V5	O
was	O
a	O
significant	O
risk	O
factor	O
for	O
PG	O
atrophy	O
after	O
C-ion	O
RT	O
.	O

Safety	O
of	O
Large	O
-	O
Volume	O
,	O
Same	O
-	O
Day	O
Oral	O
Bowel	O
Preparations	O
During	O
Deep	O
Sedation	O
:	O
A	O
Prospective	O
Observational	O
Study	O
.	O

Colonoscopy	B-P
quality	O
is	O
directly	O
related	O
to	O
the	O
bowel	O
preparation	O
.	O

It	O
is	O
well	O
established	O
that	O
bowel	O
preparations	O
are	O
improved	O
when	O
at	O
least	O
part	O
of	O
the	O
laxative	O
is	O
ingested	O
on	O
the	O
day	O
of	O
the	O
procedure	O
.	O

However	O
,	O
there	O
is	O
concern	O
that	O
this	O
can	O
result	O
in	O
higher	O
gastric	O
residual	O
volumes	O
(	O
GRV	O
)	O
and	O
increase	O
the	O
risk	O
of	O
pulmonary	O
aspiration	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
evaluate	O
GRV	O
and	O
gastric	O
pH	O
in	O
patients	O
who	O
received	O
day	O
-	O
before	O
bowel	O
preparation	O
versus	O
those	O
ingesting	O
their	O
laxative	O
on	O
the	O
day	O
of	O
colonoscopy	B-P
under	O
anesthesiologist	O
-	O
directed	O
propofol	O
deep	O
sedation	O
.	O

This	O
is	O
a	O
prospective	O
observational	O
study	O
for	O
patients	O
undergoing	O
same	O
-	O
day	O
upper	O
endoscopy	B-P
and	O
colonoscopy	B-P
.	O

All	O
included	O
patients	O
had	O
large	O
-	O
volume	O
polyethylene	O
glycol	O
lavage	O
preparation	O
and	O
received	O
propofol	O
sedation	O
.	O

Gastric	O
fluid	O
was	O
collected	O
during	O
the	O
upper	O
endoscopy	B-P
for	O
volume	O
and	O
pH	O
measurement	O
.	O

The	O
study	O
included	O
428	O
patients	O
with	O
56	O
%	O
receiving	O
same	O
-	O
day	O
laxative	O
preparation	O
and	O
the	O
remainder	O
evening	O
-	O
before	O
preparation	O
.	O

Mean	O
±	O
SD	O
GRV	O
was	O
18.1	O
±	O
10.2	O
mL	O
,	O
16.3	O
±	O
16.5	O
mL	O
in	O
each	O
of	O
these	O
preparation	O
groups	O
,	O
respectively	O
(	O
P	O
=	O
.69	O
)	O
.	O

GRV	O
≥	O
25	O
mL	O
or	O
higher	O
than	O
expected	O
GRV	O
adjusted	O
by	O
weight	O
(	O
0.4	O
mL/kg	O
)	O
were	O
also	O
not	O
different	O
among	O
the	O
study	O
groups	O
(	O
P	O
=	O
.90	O
and	O
P	O
=	O
.87	O
,	O
respectively	O
)	O
.	O

Evaluating	O
GRV	O
based	O
on	O
time	O
since	O
last	O
ingestion	O
of	O
preparation	O
(	O
3-5	O
,	O
5-7	O
,	O
>	O
7	O
hours	O
)	O
did	O
not	O
result	O
in	O
any	O
differences	O
(	O
P	O
=	O
.56	O
)	O
.	O

Gastric	O
pH	O
was	O
also	O
similar	O
between	O
the	O
bowel	O
preparation	O
groups	O
(	O
P	O
=	O
.23	O
)	O
,	O
with	O
mean	O
±	O
SD	O
of	O
2.5	O
±	O
1.4	O
for	O
evening	O
-	O
before	O
and	O
2.5	O
±	O
1.3	O
for	O
the	O
same	O
-	O
day	O
preparation	O
.	O

There	O
were	O
more	O
inadequate	O
bowel	O
preparations	O
in	O
day	O
before	O
bowel	O
preparations	O
(	O
P	O
=	O
.001	O
)	O
.	O

A	O
large	O
-	O
volume	O
bowel	O
preparation	O
regimen	O
finished	O
on	O
the	O
day	O
of	O
colonoscopy	B-P
as	O
close	O
as	O
3	O
hours	O
before	O
the	O
procedure	O
result	O
s	O
in	O
no	O
increase	O
in	O
GRV	O
or	O
decrease	O
in	O
gastric	O
pH	O
.	O

The	O
cancer	O
Warburg	O
effect	O
may	O
be	O
a	O
testable	O
example	O
of	O
the	O
minimum	O
entropy	O
production	O
rate	O
principle	O
.	O

Cancer	O
cells	O
consume	O
more	O
glucose	O
by	O
glycolytic	O
fermentation	O
to	O
lactate	O
than	O
by	O
respiration	O
,	O
a	O
characteristic	O
known	O
as	O
the	O
Warburg	O
effect	O
.	O

In	O
contrast	O
with	O
the	O
34	O
moles	O
of	O
ATP	O
produced	O
by	O
respiration	O
,	O
fermentation	O
produces	O
two	O
moles	O
of	O
ATP	O
per	O
mole	O
of	O
glucose	O
consumed	O
,	O
which	O
poses	O
a	O
puzzle	O
on	O
the	O
function	O
of	O
the	O
Warburg	O
effect	O
.	O

Productions	O
of	O
free	O
energy	O
(	O
ΔG	O
)	O
,	O
enthalpy	O
(	O
ΔH	O
)	O
and	O
entropy	O
(	O
ΔS	O
)	O
per	O
mole	O
linearly	O
vary	O
with	O
the	O
fraction	O
(	O
x	O
)	O
of	O
glucose	O
consumed	O
by	O
fermentation	O
that	O
is	O
frequently	O
estimated	O
around	O
0.9	O
.	O

Hence	O
,	O
calculation	O
shows	O
that	O
,	O
in	O
respect	O
to	O
pure	O
respiration	O
,	O
the	O
predominant	O
fermentative	O
metabolism	O
decreases	O
around	O
10	O
%	O
the	O
production	O
of	O
entropy	O
per	O
mole	O
of	O
glucose	O
consumed	O
in	O
cancer	O
cells	O
.	O

We	O
hypothesize	O
that	O
increased	O
fermentation	O
could	O
allow	O
cancer	O
cells	O
to	O
accomplish	O
the	O
Prigogine	O
theorem	O
of	O
the	O
trend	O
to	O
minimize	O
the	O
rate	O
of	O
production	O
of	O
entropy	O
.	O

According	O
the	O
theorem	O
,	O
open	O
cellular	O
systems	O
near	O
the	O
steady	O
state	O
could	O
evolve	O
to	O
minimize	O
the	O
rates	O
of	O
entropy	O
production	O
that	O
may	O
be	O
reached	O
by	O
modified	O
replicating	O
cells	O
producing	O
entropy	O
at	O
low	O
rate	O
.	O

Remarkably	O
,	O
at	O
CO2	O
concentrations	O
above	O
930	O
ppm	O
,	O
glucose	O
respiration	O
produces	O
less	O
entropy	O
than	O
fermentation	O
,	O
which	O
suggests	O
experimental	O
tests	B-P
to	O
validate	O
the	O
hypothesis	O
of	O
minimization	O
of	O
the	O
rate	O
of	O
entropy	O
production	O
through	O
the	O
Warburg	O
effect	O
.	O

New	O
Diterpenoids	O
from	O
Clerodendranthus	O
spicatus	O
.	O

Two	O
new	O
diterpenoids	O
,	O
neoorthosiphonones	O
B	O
and	O
C	O
(	O
1	O
and	O
2	O
)	O
,	O
and	O
one	O
known	O
diterpenoid	O
,	O
were	O
isolated	O
from	O
the	O
aerial	O
parts	O
of	O
Clerodendranthus	O
spicatus	O
.	O

Their	O
structures	O
including	O
absolute	O
configurations	O
were	O
determined	O
by	O
comprehensive	O
spectroscopic	B-P
analyses	I-P
and	O
X-ray	B-P
crystallographic	I-P
methods	I-P
.	O

No	O
compound	O
was	O
found	O
to	O
inhibit	O
fibronectin	O
production	O
at	O
the	O
concentration	O
of	O
20	O
μM	O
.	O

Mucosa	O
-	O
associated	O
biohydrogenating	O
microbes	O
protect	O
the	O
simulated	O
colon	O
microbiome	O
from	O
stress	O
associated	O
with	O
high	O
concentrations	O
of	O
poly-unsaturated	O
fat	O
.	O

Polyunsaturated	O
fatty	O
acids	O
(	O
PUFAs	O
)	O
may	O
affect	O
colon	O
microbiome	O
homeostasis	O
by	O
exerting	O
(	O
specific	O
)	O
antimicrobial	O
effects	O
and/or	O
interfering	O
with	O
mucosal	O
biofilm	O
formation	O
at	O
the	O
gut	O
mucosal	O
interface	O
.	O

We	O
used	O
standardized	B-P
batch	I-P
incubations	I-P
and	O
the	O
Mucosal-Simulator	O
of	O
the	O
Human	O
Microbial	O
Intestinal	O
Ecosystem	O
(	O
M-SHIME	O
)	O
to	O
show	O
the	O
in	O
vitro	O
luminal	O
and	O
mucosal	O
effects	O
of	O
the	O
main	O
PUFA	O
in	O
the	O
Western	O
diet	O
,	O
linoleic	O
acid	O
(	O
LA	O
)	O
.	O

High	O
concentrations	O
of	O
LA	O
were	O
found	O
to	O
decrease	O
butyrate	O
production	O
and	O
Faecalibacterium	O
prausnitzii	O
numbers	O
dependent	O
on	O
LA	O
biohydrogenation	O
to	O
vaccenic	O
acid	O
(	O
VA	O
)	O
and	O
stearic	O
acid	O
(	O
SA	O
)	O
.	O

In	O
faecal	O
batch	B-P
incubations	I-P
,	O
LA	O
biohydrogenation	O
and	O
butyrate	O
production	O
were	O
positively	O
correlated	O
and	O
SA	O
did	O
not	O
inhibit	O
butyrate	O
production	O
.	O

In	O
the	O
M-SHIME	O
,	O
addition	O
of	O
a	O
mucosal	O
environment	O
stimulated	O
biohydrogenation	O
to	O
SA	O
and	O
protected	O
F.	O
prausnitzii	O
from	O
inhibition	O
by	O
LA	O
.	O

This	O
was	O
probably	O
due	O
to	O
the	O
preference	O
of	O
two	O
biohydrogenating	O
genera	O
Roseburia	O
and	O
Pseudobutyrivibrio	O
for	O
the	O
mucosal	O
niche	O
.	O

Co-culture	B-P
batch	B-P
incubations	I-P
using	O
Roseburia	O
hominis	O
and	O
F.	O
prausnitzii	O
validated	O
these	O
observations	O
.	O

Correlations	O
networks	O
further	O
uncovered	O
the	O
central	O
role	O
of	O
Roseburia	O
and	O
Pseudobutyrivibrio	O
in	O
protecting	O
luminal	O
and	O
mucosal	B-P
SHIME	I-P
microbiota	I-P
from	O
LA	O
-	O
induced	O
stress	O
.	O

Our	O
results	O
confirm	O
how	O
cross-shielding	O
interactions	O
provide	O
resilience	O
to	O
the	O
microbiome	O
and	O
demonstrate	O
the	O
importance	O
of	O
biohydrogenating	O
,	O
mucosal	O
bacteria	O
for	O
recovery	O
from	O
LA	O
stress	O
.	O

Iterative	O
Development	O
and	O
Evaluation	O
of	O
a	O
Pharmacogenomic	O
-Guided	O
Clinical	O
Decision	O
Support	O
System	O
for	O
Warfarin	O
Dosing	O
.	O

Pharmacogenomic	O
-guided	O
dosing	O
has	O
the	O
potential	O
to	O
improve	O
patient	O
outcomes	O
but	O
its	O
implementation	O
has	O
been	O
met	O
with	O
clinical	O
challenges	O
.	O

Our	O
objective	O
was	O
to	O
develop	O
and	O
evaluate	O
a	O
clinical	O
decision	O
support	O
system	O
(	O
CDSS	O
)	O
for	O
pharmacogenomic	O
-guided	O
warfarin	O
dosing	O
designed	O
for	O
physicians	O
and	O
pharmacists	O
.	O

Twelve	O
physicians	O
and	O
pharmacists	O
completed	O
6	O
prescribing	O
tasks	O
using	O
simulated	O
patient	O
scenarios	O
in	O
two	O
iterations	O
(	O
development	O
and	O
validation	O
phases	O
)	O
of	O
a	O
newly	O
developed	O
pharmacogenomic	O
-driven	O
CDSS	O
prototype	O
.	O

For	O
each	O
scenario	O
,	O
usability	O
was	O
measured	O
via	O
efficiency	O
,	O
recorded	O
as	O
time	O
to	O
task	O
completion	O
,	O
and	O
participants	O
'	O
perceived	O
satisfaction	O
which	O
were	O
compared	O
using	O
Kruskal-Wallis	O
and	O
Mann	O
Whitney	O
U	O
tests	O
,	O
respectively	O
.	O

Debrief	O
interviews	O
were	O
conducted	O
and	O
qualitatively	B-P
analyzed	I-P
.	O

Usability	O
findings	O
from	O
the	O
first	O
(	O
i.e	O
.	O

development	O
)	O
iteration	O
were	O
incorporated	O
into	O
the	O
CDSS	O
design	O
for	O
the	O
second	O
(	O
i.e	O
.	O

validation	O
)	O
iteration	O
.	O

During	O
the	O
CDSS	O
validation	O
iteration	O
,	O
participants	O
took	O
more	O
time	O
to	O
complete	O
tasks	O
with	O
a	O
median	O
(	O
IQR	O
)	O
of	O
183	O
(	O
124-247	O
)	O
seconds	O
versus	O
101	O
(	O
73.5-197	O
)	O
seconds	O
in	O
the	O
development	O
iteration	O
(	O
p=0.01	O
)	O
.	O

This	O
increase	O
in	O
time	O
on	O
task	O
was	O
due	O
to	O
the	O
increase	O
in	O
time	O
spent	O
in	O
the	O
CDSS	O
corresponding	O
to	O
several	O
design	O
changes	O
.	O

Efficiency	O
differences	O
that	O
were	O
observed	O
between	O
pharmacists	O
and	O
physicians	O
in	O
the	O
development	O
iteration	O
were	O
eliminated	O
in	O
the	O
validation	O
iteration	O
.	O

The	O
increased	O
use	O
of	O
the	O
CDSS	O
corresponded	O
to	O
a	O
greater	O
acceptance	O
of	O
CDSS	O
recommended	O
doses	O
in	O
the	O
validation	O
iteration	O
(	O
4	O
%	O
in	O
the	O
first	O
iteration	O
vs.	O
37.5	O
%	O
in	O
the	O
second	O
iteration	O
,	O
p	O
<	O
0.001	O
)	O
.	O

Overall	O
satisfaction	O
did	O
not	O
change	O
statistically	O
between	O
the	O
iterations	O
but	O
the	O
qualitative	B-P
analysis	I-P
revealed	O
greater	O
trust	O
in	O
the	O
second	O
prototype	O
.	O

A	O
pharmacogenomic	O
-guided	O
CDSS	O
has	O
been	O
developed	O
using	O
warfarin	O
as	O
the	O
test	O
drug	O
.	O

The	O
final	O
CDSS	O
prototype	O
was	O
trusted	O
by	O
prescribers	O
and	O
significantly	O
increased	O
the	O
time	O
using	O
the	O
tool	O
and	O
acceptance	O
of	O
the	O
recommended	O
doses	O
.	O

This	O
study	O
is	O
an	O
important	O
step	O
toward	O
incorporating	O
pharmacogenomics	O
into	O
CDSS	O
design	O
for	O
clinical	O
testing	O
.	O

Preliminary	O
investigation	O
of	O
energy	O
comparation	O
between	O
gyroscope	O
,	O
electromyography	B-P
and	O
VO2	O
wearable	O
sensors	O
.	O

Building	O
on	O
previous	O
experiments	O
in	O
the	O
domain	O
of	O
energy	O
expenditure	O
estimation	O
using	O
wearable	O
sensors	O
,	O
the	O
measurements	O
of	O
energy	O
ratios	O
of	O
a	O
runner	O
on	O
a	O
treadmill	O
were	O
analyzed	O
to	O
observe	O
any	O
commonalities	O
between	O
an	O
inertia	O
measurement	O
unit	O
and	O
an	O
electromyograph	B-P
sensor	O
.	O

The	O
subjects	O
were	O
equipped	O
with	O
a	O
VO2	O
gas	O
measurement	O
device	O
,	O
an	O
Inertial	O
Measurement	O
Unit	O
(	O
IMU	O
)	O
measuring	O
gyroscopic	B-P
activity	I-P
and	O
an	O
electromyography	B-P
(	O
EMG	B-P
)	O
sensor	O
network	O
whilst	O
running	O
at	O
5	O
different	O
speeds	O
on	O
a	O
calibrated	O
treadmill	O
.	O

The	O
observed	O
results	O
established	O
a	O
co-linear	O
relationship	O
with	O
the	O
gyroscope	O
based	O
measurements	O
,	O
EMG	B-P
based	O
measurements	O
with	O
the	O
VO2	B-P
measurements	I-P
.	O

The	O
effect	O
of	O
Nigella	O
sativa	O
on	O
inflammation	O
-	O
induced	O
myocardial	O
fibrosis	O
in	O
male	O
rats	O
.	O

Nigella	O
sativa	O
(	O
NS	O
)	O
(	O
Ranunculaceae	O
)	O
used	O
as	O
a	O
protective	O
and	O
therapeutic	O
traditional	O
medicine	O
.	O

This	O
study	O
evaluates	O
the	O
effect	O
of	O
NS	O
on	O
inflammation	O
-	O
induced	O
myocardial	O
fibrosis	O
,	O
serum	O
and	O
tissue	O
inflammatory	O
markers	O
,	O
and	O
oxidative	O
stress	O
status	O
in	O
male	O
rats	O
.	O

Fifty	O
male	O
Wistar	O
rats	O
were	O
divided	O
into	O
five	O
groups	O
:	O
(	O
1	O
)	O
control	O
;	O
(	O
2	O
)	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
1	O
mg/kg/day	O
;	O
(	O
3	O
)	O
LPS	O
+	O
NS	O
(	O
hydroalcoholic	O
extract	O
)	O
,	O
100	O
mg/kg/day	O
;	O
(	O
4	O
)	O
LPS	O
+	O
NS	O
,	O
200	O
mg/kg/day	O
;	O
(	O
5	O
)	O
LPS	O
+	O
NS	O
,	O
400	O
mg/kg/day	O
(	O
n	O
=	O
10	O
in	O
each	O
group	O
)	O
.	O

The	O
duration	O
of	O
LPS	O
administration	O
was	O
two	O
weeks	O
.	O

At	O
the	O
end	O
of	O
the	O
experiment	O
,	O
blood	O
samples	O
were	O
taken	O
and	O
ventricles	O
were	O
homogenized	B-P
and	O
stained	B-P
for	O
histological	B-P
evaluation	O
.	O

Serum	O
nitrite	B-P
levels	I-P
were	O
lower	O
in	O
LPS	O
group	O
than	O
the	O
control	O
group	O
(	O
22.98	O
±	O
1.03	O
vs	O
28.5	O
±	O
0.93	O
μmol/L	O
)	O
,	O
in	O
which	O
they	O
were	O
significantly	O
increased	O
by	O
NS	O
treatment	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Higher	O
levels	B-P
of	I-P
heart	I-P
interlukine-6	I-P
(	O
IL-6	B-P
)	O
and	O
tumor	B-P
necrosis	I-P
factor-α	I-P
(	O
TNF-α	B-P
)	O
were	O
observed	O
in	O
LPS	O
group	O
compared	O
to	O
the	O
controls	O
(	O
IL-6	B-P
:	O
6805	O
±	O
656	O
vs	O
4733	O
±	O
691	O
pg/mL	O
;	O
TNF-α	B-P
:	O
6504	O
±	O
501	O
vs	O
5309	O
±	O
452	O
pg/mL	O
)	O
,	O
in	O
which	O
they	O
were	O
reduced	O
by	O
NS	O
400	O
mg/kg	O
compared	O
to	O
LPS	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O

A	O
significant	O
increment	O
of	O
malondialdehyde	O
and	O
reduction	O
in	O
heart	O
total	O
thiol	O
,	O
superoxide	O
dismutase	O
and	O
catalase	O
concentrations	O
were	O
observed	O
in	O
LPS	O
group	O
(	O
p	O
<	O
0.05	O
)	O
which	O
significantly	O
restored	O
with	O
treatment	O
by	O
three	O
doses	O
of	O
NS	O
.	O

Histopathological	O
studies	O
showed	O
higher	O
inflammatory	O
cell	O
infiltrates	O
,	O
cardiac	O
fibrosis	O
,	O
and	O
collagen	O
deposition	O
in	O
LPS	O
group	O
,	O
which	O
were	O
reduced	O
by	O
the	O
administration	O
of	O
NS	O
.	O

Treatment	O
by	O
NS	O
reduced	O
myocardial	O
fibrosis	O
in	O
inflammation	O
-	O
induced	O
fibrosis	O
,	O
possibly	O
through	O
improving	O
oxidative	O
/	O
anti-oxidative	O
balance	O
.	O

BREEDING	O
AND	O
GENETICS	O
SYMPOSIUM	O
:	O
Breeding	O
for	O
resilience	O
to	O
heat	O
stress	O
effects	O
in	O
dairy	O
ruminants	O
.	O

A	O
comprehensive	O
review	O
.	O

Selection	O
for	O
heat	O
tolerant	O
(	O
HT	O
)	O
animals	O
in	O
dairy	O
production	O
has	O
been	O
so	O
far	O
linked	O
to	O
estimation	O
of	O
declines	O
in	O
production	O
using	O
milk	O
recording	O
and	O
meteorological	O
information	O
on	O
the	O
day	O
of	O
control	O
using	O
reaction	O
norms	O
.	O

Results	O
from	O
these	O
models	O
show	O
that	O
there	O
is	O
a	O
reasonable	O
amount	O
of	O
genetic	O
variability	O
in	O
the	O
individual	O
response	O
to	O
high	O
heat	O
loads	O
,	O
which	O
makes	O
feasible	O
selection	O
of	O
HT	O
animals	O
at	O
low	O
costs	O
.	O

However	O
,	O
the	O
antagonistic	O
relationship	O
between	O
level	O
of	O
production	O
and	O
response	O
to	O
heat	O
stress	O
(	O
HS	O
)	O
implies	O
that	O
selection	O
for	O
HT	O
animals	O
under	O
this	O
approach	O
must	O
be	O
done	O
with	O
caution	O
so	O
that	O
productivity	O
is	O
not	O
damaged	O
.	O

Decomposition	O
of	O
the	O
genetic	O
variability	O
in	O
principal	O
components	O
(	O
PC	O
)	O
can	O
provide	O
selection	O
criteria	O
independent	O
of	O
milk	O
production	O
level	O
although	O
biological	O
interpretation	O
of	O
PC	O
is	O
difficult	O
.	O

Moreover	O
,	O
given	O
that	O
response	O
to	O
heat	O
stress	O
for	O
each	O
animal	O
is	O
estimated	O
with	O
very	O
sparse	O
information	O
collected	O
under	O
different	O
physiological	O
and	O
management	O
circumstances	O
,	O
biased	O
(	O
normally	O
underestimation	O
)	O
and	O
lack	O
of	O
accuracy	O
may	O
be	O
expected	O
.	O

Alternative	O
phenotypic	O
characterization	O
of	O
HT	O
can	O
come	O
from	O
the	O
use	O
of	O
physiological	O
traits	O
,	O
which	O
have	O
also	O
shown	O
moderate	O
heritability	O
.	O

However	O
,	O
costs	O
of	O
a	O
large	O
scale	O
implementation	O
based	O
on	O
physiological	O
characteristics	O
has	O
precluded	O
its	O
use	O
.	O

Another	O
alternative	O
is	O
the	O
use	O
of	O
biomarkers	O
that	O
define	O
heat	O
tolerance	O
.	O

A	O
review	O
of	O
biomarkers	O
of	O
HS	O
from	O
more	O
recent	O
studies	O
is	O
provided	O
.	O

Of	O
particular	O
interest	O
are	O
milk	O
biomarkers	O
,	O
which	O
together	O
with	O
infrared	B-P
spectra	I-P
prediction	O
equations	O
can	O
provide	O
useful	O
tools	O
for	O
genetic	O
selection	O
.	O

In	O
the	O
'omics	O
'	O
era	O
,	O
genomics	O
,	O
transcriptomics	O
,	O
proteomics	O
and	O
metabolomics	O
have	O
been	O
already	O
used	O
to	O
detect	O
genes	O
affecting	O
HT	O
.	O

A	O
review	O
of	O
findings	O
in	O
these	O
areas	O
is	O
also	O
provided	O
.	O

Except	O
for	O
the	O
slick	O
hair	O
gene	O
,	O
there	O
are	O
no	O
other	O
genes	O
for	O
which	O
variants	O
have	O
been	O
clearly	O
associated	O
with	O
HT	O
.	O

However	O
,	O
integration	O
of	O
omics	O
information	O
could	O
help	O
in	O
pointing	O
at	O
knots	O
of	O
the	O
HS	O
control	O
network	O
and	O
,	O
in	O
the	O
end	O
,	O
to	O
a	O
panel	O
of	O
markers	O
to	O
be	O
used	O
in	O
the	O
selection	O
of	O
HT	O
animals	O
.	O

Overall	O
,	O
HT	O
is	O
a	O
complex	O
phenomenon	O
that	O
requires	O
integration	O
of	O
fine	O
phenotypes	O
and	O
omics	O
information	O
to	O
provide	O
accurate	O
tools	O
for	O
selection	O
without	O
damaging	O
productivity	O
.	O

Technological	O
developments	O
to	O
make	O
on-farm	O
implementation	O
feasible	O
and	O
with	O
greater	O
insight	O
into	O
the	O
key	O
biomarkers	O
and	O
genes	O
involved	O
in	O
HT	O
are	O
needed	O
.	O

White	O
matter	O
deficits	O
in	O
schizophrenia	O
are	O
global	O
and	O
do	O
n't	O
progress	O
with	O
age	O
.	O

Diffusion	B-P
tensor	I-P
imaging	I-P
has	O
revealed	O
differences	O
in	O
all	O
examined	O
white	O
matter	O
tracts	O
in	O
schizophrenia	O
,	O
with	O
a	O
range	O
of	O
explanations	O
for	O
why	O
this	O
may	O
be	O
.	O

The	O
distribution	O
and	O
timing	O
of	O
differences	O
may	O
help	O
explain	O
their	O
origin	O
;	O
however	O
,	O
results	O
are	O
usually	O
dependent	O
on	O
the	O
analytical	O
method	O
.	O

We	O
therefore	O
sought	O
to	O
examine	O
the	O
extent	O
of	O
differences	O
and	O
their	O
relationship	O
with	O
age	O
using	O
two	O
different	O
methods	O
.	O

A	O
combined	O
voxel	O
-based	O
whole-brain	O
study	O
and	O
a	O
tract	O
-based	O
spatial-statistics	O
study	O
of	O
104	O
patients	O
with	O
schizophrenia	O
and	O
200	O
matched	O
healthy	O
controls	O
,	O
aged	O
between	O
17	O
and	O
63	O
years	O
.	O

Fractional	O
anisotropy	O
was	O
reduced	O
throughout	O
the	O
brain	O
in	O
both	O
analyses	O
.	O

The	O
relationship	O
of	O
fractional	O
anisotropy	O
with	O
age	O
differed	O
between	O
patients	O
and	O
controls	O
,	O
with	O
controls	O
showing	O
the	O
gentle	O
fractional	O
anisotropy	O
decline	O
widely	O
noted	O
but	O
patients	O
showing	O
an	O
essentially	O
flat	O
relationship	O
:	O
younger	O
patients	O
had	O
lower	O
fractional	O
anisotropy	O
than	O
controls	O
,	O
but	O
the	O
difference	O
disappeared	O
with	O
age	O
.	O

Mean	O
diffusivity	O
was	O
widely	O
increased	O
in	O
patients	O
.	O

Reduction	O
in	O
fractional	O
anisotropy	O
and	O
increase	O
in	O
mean	O
diffusivity	O
would	O
be	O
consistent	O
with	O
global	O
disruption	O
in	O
myelination	O
;	O
the	O
relationship	O
with	O
age	O
would	O
suggest	O
this	O
is	O
present	O
already	O
at	O
the	O
onset	O
of	O
their	O
illness	O
,	O
but	O
does	O
not	O
progress	O
.	O

The	O
short-term	O
effects	O
of	O
farmed	O
fish	O
food	O
consumed	O
by	O
wild	O
fish	O
congregating	O
outside	O
the	O
farms	O
.	O

We	O
simulated	O
in	O
the	O
laboratory	O
the	O
possible	O
effects	O
on	O
fatty	O
acids	O
and	O
immune	O
status	O
of	O
wild	O
fish	O
arriving	O
for	O
the	O
first	O
time	O
in	O
the	O
vicinity	O
of	O
a	O
sea-cage	O
fish	O
farm	O
,	O
shifting	O
their	O
natural	O
diet	O
to	O
commercial	O
feed	O
consumption	O
,	O
rich	O
in	O
fatty	O
acids	O
of	O
vegetable	O
origin	O
.	O

The	O
flesh	O
fatty	O
acid	O
profile	O
of	O
golden	O
mullet	O
specimens	O
was	O
altered	O
after	O
2weeks	O
of	O
commercial	O
feed	O
consumption	O
,	O
showing	O
an	O
increase	O
in	O
fatty	O
acids	O
of	O
vegetable	O
origin	O
.	O

The	O
serum	B-P
peroxidase	I-P
and	O
bactericidal	O
activities	O
,	O
and	O
head-kidney	O
leucocyte	O
phagocytic	O
capacity	O
,	O
increased	O
after	O
eight	O
weeks	O
of	O
the	O
new	O
diet	O
,	O
while	O
the	O
respiratory	O
burst	O
activity	O
decreased	O
.	O

The	O
extent	O
of	O
these	O
changes	O
can	O
not	O
be	O
considered	O
large	O
enough	O
to	O
regard	O
them	O
as	O
compromising	O
the	O
health	O
status	O
of	O
fish	O
.	O

More	O
research	O
is	O
needed	O
in	O
order	O
to	O
elucidate	O
whether	O
the	O
rapid	O
assimilation	O
of	O
the	O
dietary	O
fatty	O
acids	O
could	O
harm	O
the	O
immune	O
status	O
of	O
fish	O
when	O
feeding	O
for	O
longer	O
periods	O
than	O
two	O
months	O
.	O

A	O
Variant	O
in	O
the	O
BACH2	O
Gene	O
Is	O
Associated	O
With	O
Susceptibility	O
to	O
Autoimmune	O
Addison	O
's	O
Disease	O
in	O
Humans	O
.	O

Autoimmune	O
Addison	O
's	O
disease	O
(	O
AAD	O
)	O
is	O
a	O
rare	O
but	O
highly	O
heritable	O
condition	O
.	O

The	O
BACH2	O
protein	O
plays	O
a	O
crucial	O
role	O
in	O
T	O
lymphocyte	O
maturation	O
,	O
and	O
allelic	O
variation	O
in	O
its	O
gene	O
has	O
been	O
associated	O
with	O
a	O
number	O
of	O
autoimmune	O
conditions	O
.	O

We	O
aimed	O
to	O
determine	O
whether	O
alleles	O
of	O
the	O
rs3757247	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
in	O
the	O
BACH2	O
gene	O
are	O
associated	O
with	O
AAD	O
.	O

This	O
case-control	O
association	O
study	O
was	O
performed	O
in	O
two	O
phases	O
using	O
Taqman	B-P
chemistry	I-P
.	O

In	O
the	O
first	O
phase	O
,	O
the	O
rs3757247	O
SNP	O
was	O
genotyped	O
in	O
358	O
UK	O
AAD	O
subjects	O
and	O
166	O
local	O
control	O
subjects	O
.	O

Genotype	O
data	O
were	O
also	O
available	O
from	O
5154	O
healthy	O
UK	O
controls	O
from	O
the	O
Wellcome	O
Trust	O
(	O
WTCCC2	O
)	O
for	O
comparison	O
.	O

In	O
the	O
second	O
phase	O
,	O
the	O
SNP	O
was	O
genotyped	O
in	O
a	O
validation	O
cohort	O
comprising	O
317	O
Norwegian	O
AAD	O
subjects	O
and	O
365	O
controls	O
.	O

The	O
frequency	O
of	O
the	O
minor	O
T	O
allele	O
was	O
significantly	O
higher	O
in	O
subjects	O
with	O
AAD	O
from	O
the	O
United	O
Kingdom	O
compared	O
to	O
both	O
the	O
local	O
and	O
WTCCC2	O
control	O
cohorts	O
(	O
58	O
%	O
vs	O
45	O
and	O
48	O
%	O
,	O
respectively	O
)	O
(	O
local	O
controls	O
,	O
P	O
=	O
1.1	O
×	O
10	O
(	O
-4	O
)	O
;	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
1.68	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.29-2.18	O
;	O
WTCCC2	O
controls	O
,	O
P	O
=	O
1.4	O
×	O
10	O
(	O
-6	O
)	O
;	O
OR	O
,	O
1.44	O
;	O
95	O
%	O
CI	O
,	O
1.23-1.69	O
)	O
.	O

This	O
finding	O
was	O
replicated	O
in	O
the	O
Norwegian	O
validation	O
cohort	O
(	O
P	O
=	O
.0015	O
;	O
OR	O
,	O
1.41	O
;	O
95	O
%	O
CI	O
,	O
1.14-1.75	O
)	O
.	O

Subgroup	O
analysis	O
showed	O
that	O
this	O
association	O
is	O
present	O
in	O
subjects	O
with	O
both	O
isolated	O
AAD	O
(	O
OR	O
,	O
1.53	O
;	O
95	O
%	O
CI	O
,	O
1.22-1.92	O
)	O
and	O
autoimmune	O
polyglandular	O
syndrome	O
type	O
2	O
(	O
OR	O
,	O
1.37	O
;	O
95	O
%	O
CI	O
,	O
1.12-1.69	O
)	O
in	O
the	O
UK	O
cohort	O
,	O
and	O
with	O
autoimmune	O
polyglandular	O
syndrome	O
type	O
2	O
in	O
the	O
Norwegian	O
cohort	O
(	O
OR	O
,	O
1.58	O
;	O
95	O
%	O
CI	O
,	O
1.22-2.06	O
)	O
.	O

We	O
have	O
demonstrated	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
allelic	O
variability	O
at	O
the	O
BACH2	O
locus	O
is	O
associated	O
with	O
susceptibility	O
to	O
AAD	O
.	O

Given	O
its	O
association	O
with	O
multiple	O
autoimmune	O
conditions	O
,	O
BACH2	O
can	O
be	O
considered	O
a	O
``	O
universal	O
''	O
autoimmune	O
susceptibility	O
locus	O
.	O

The	O
clinico-	O
radiological	O
paradox	O
of	O
cognitive	O
function	O
and	O
MRI	B-P
burden	O
of	O
white	O
matter	O
lesions	O
in	O
people	O
with	O
multiple	O
sclerosis	O
:	O
A	O
systematic	O
review	O
and	O
meta-analysis	O
.	O

Moderate	O
correlation	O
exists	O
between	O
the	O
imaging	O
quantification	O
of	O
brain	O
white	O
matter	O
lesions	O
and	O
cognitive	O
performance	O
in	O
people	O
with	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
.	O

This	O
may	O
reflect	O
the	O
greater	O
importance	O
of	O
other	O
features	O
,	O
including	O
subvisible	O
pathology	O
,	O
or	O
methodological	O
limitations	O
of	O
the	O
primary	O
literature	O
.	O

To	O
summarise	O
the	O
cognitive	O
clinico-	O
radiological	O
paradox	O
and	O
explore	O
the	O
potential	O
methodological	O
factors	O
that	O
could	O
influence	O
the	O
assessment	O
of	O
this	O
relationship	O
.	O

Systematic	O
review	O
and	O
meta-analysis	O
of	O
primary	O
research	O
relating	O
cognitive	O
function	O
to	O
white	O
matter	O
lesion	O
burden	O
.	O

Fifty	O
papers	O
met	O
eligibility	O
criteria	O
for	O
review	O
,	O
and	O
meta-analysis	O
of	O
overall	O
results	O
was	O
possible	O
in	O
thirty-two	O
(	O
2050	O
participants	O
)	O
.	O

Aggregate	O
correlation	O
between	O
cognition	O
and	O
T2	O
lesion	O
burden	O
was	O
r	O
=	O
-0.30	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
-0.34	O
,	O
-0.26	O
)	O
.	O

Wide	O
methodological	O
variability	O
was	O
seen	O
,	O
particularly	O
related	O
to	O
key	O
factors	O
in	O
the	O
cognitive	O
data	O
capture	O
and	O
image	B-P
analysis	I-P
techniques	I-P
.	O

Resolving	O
the	O
persistent	O
clinico-	O
radiological	O
paradox	O
will	O
likely	O
require	O
simultaneous	O
evaluation	O
of	O
multiple	O
components	O
of	O
the	O
complex	O
pathology	O
using	O
optimum	O
measurement	O
techniques	O
for	O
both	O
cognitive	O
and	O
MRI	B-P
feature	O
quantification	O
.	O

We	O
recommend	O
a	O
consensus	O
initiative	O
to	O
support	O
common	O
standards	O
for	O
image	B-P
analysis	I-P
in	O
MS	O
,	O
enabling	O
benchmarking	O
while	O
also	O
supporting	O
ongoing	O
innovation	O
.	O

Craving	O
behavioral	O
intervention	O
for	O
internet	O
gaming	O
disorder	O
:	O
remediation	O
of	O
functional	O
connectivity	O
of	O
the	O
ventral	O
striatum	O
.	O

Psychobehavioral	O
intervention	O
is	O
an	O
effective	O
treatment	O
of	O
Internet	O
addiction	O
,	O
including	O
Internet	O
gaming	O
disorder	O
(	O
IGD	O
)	O
.	O

However	O
,	O
the	O
neural	O
mechanisms	O
underlying	O
its	O
efficacy	O
remain	O
unclear	O
.	O

Cortical	O
-	O
ventral	O
striatum	O
(	O
VS	O
)	O
circuitry	O
is	O
a	O
common	O
target	O
of	O
psychobehavioral	O
interventions	O
in	O
drug	O
addiction	O
,	O
and	O
cortical	O
-	O
VS	O
dysfunction	O
has	O
been	O
reported	O
in	O
IGD	O
;	O
hence	O
,	O
the	O
primary	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
how	O
the	O
VS	O
circuitry	O
responds	O
to	O
psychobehavioral	O
interventions	O
in	O
IGD	O
.	O

In	O
a	O
cross-sectional	O
study	O
,	O
we	O
examined	O
resting-state	O
functional	O
connectivity	O
of	O
the	O
VS	O
in	O
74	O
IGD	O
subjects	O
(	O
IGDs	O
)	O
and	O
41	O
healthy	O
controls	O
(	O
HCs	O
)	O
.	O

In	O
a	O
follow-up	O
craving	O
behavioral	O
intervention	O
(	O
CBI	O
)	O
study	O
,	O
of	O
the	O
74	O
IGD	O
subjects	O
,	O
20	O
IGD	O
subjects	O
received	O
CBI	O
(	O
CBI+	O
)	O
and	O
16	O
IGD	O
subjects	O
did	O
not	O
(	O
CBI-	O
)	O
.	O

All	O
participants	O
were	O
scanned	B-P
twice	O
with	O
similar	O
time	O
interval	O
to	O
assess	O
the	O
effects	O
of	O
CBI	O
.	O

IGD	O
subjects	O
showed	O
greater	O
resting-state	O
functional	O
connectivity	O
of	O
the	O
VS	O
to	O
left	O
inferior	O
parietal	O
lobule	O
(	O
lIPL	O
)	O
,	O
right	O
inferior	O
frontal	O
gyrus	O
and	O
left	O
middle	O
frontal	O
gyrus	O
,	O
in	O
positive	O
association	O
with	O
the	O
severity	O
of	O
IGD	O
.	O

Moreover	O
,	O
compared	O
with	O
CBI-	O
,	O
CBI+	O
showed	O
significantly	O
greater	O
decrease	O
in	O
VS	O
-	O
lIPL	O
connectivity	O
,	O
along	O
with	O
amelioration	O
in	O
addiction	O
severity	O
following	O
the	O
intervention	O
.	O

These	O
findings	O
demonstrated	O
that	O
functional	O
connectivity	O
between	O
VS	O
and	O
lIPL	O
,	O
each	O
presumably	O
mediating	O
gaming	O
craving	O
and	O
attentional	O
bias	O
,	O
may	O
be	O
a	O
potential	O
biomarker	O
of	O
the	O
efficacy	O
of	O
psychobehavioral	O
intervention	O
.	O

These	O
results	O
also	O
suggested	O
that	O
non-invasive	O
techniques	O
such	O
as	O
transcranial	O
magnetic	O
or	O
direct	O
current	O
stimulation	O
targeting	O
the	O
VS	O
-	O
lIPL	O
circuitry	O
may	O
be	O
used	O
in	O
the	O
treatment	O
of	O
Internet	O
gaming	O
disorders	O
.	O

Ultrasound	B-P
assessment	O
of	O
lung	O
consolidation	O
and	O
reaeration	O
after	O
pleural	O
effusion	O
drainage	O
in	O
patients	O
with	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
:	O
a	O
pilot	O
study	O
.	O

The	O
aim	O
of	O
the	O
pilot	O
study	O
was	O
to	O
assess	O
by	O
ultrasound	B-P
changes	O
in	O
dimensions	O
of	O
lung	O
consolidation	O
and	O
reaeration	O
after	O
drainage	O
of	O
large	O
pleural	O
effusion	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
.	O

Lung	B-P
ultrasound	I-P
and	O
blood	B-P
gas	I-P
were	O
performed	O
before	O
,	O
2	O
hours	O
(	O
H2	O
)	O
and	O
24	O
hours	O
(	O
H24	O
)	O
after	O
drainage	O
of	O
pleural	O
effusion	O
.	O

Lung	O
ultrasound	O
aeration	O
score	O
was	O
calculated	O
.	O

Cephalocaudal	O
dimension	O
and	O
diaphragmatic	O
transversal	O
area	O
of	O
lung	O
consolidation	O
were	O
measured	O
.	O

Ten	O
patients	O
were	O
studied	O
.	O

Median	O
volume	O
of	O
drained	O
effusion	O
was	O
675	O
ml	O
at	O
H2	O
and	O
895	O
at	O
H24	O
.	O

Two	O
hours	O
after	O
drainage	O
,	O
dimension	O
of	O
cephalocaudal	O
consolidation	O
and	O
diaphragmatic	O
transversal	O
area	O
decreased	O
significantly	O
.	O

Lung	O
reaeration	O
after	O
drainage	O
occurred	O
mainly	O
in	O
latero-inferior	O
and	O
postero-superior	O
regions	O
.	O

PaO2/FiO2	B-P
increased	O
significantly	O
at	O
H24	O
.	O

Ultrasound	B-P
is	O
a	O
useful	O
method	O
to	O
assess	O
lung	O
consolidation	O
after	O
pleural	O
effusion	O
drainage	O
.	O

Drainage	O
of	O
pleural	O
effusion	O
may	O
lead	O
to	O
a	O
decrease	O
of	O
lung	O
consolidation	O
and	O
improvement	O
of	O
lung	O
reaeration	O
.	O

Ultrasonic	B-P
computed	I-P
tomography	I-P
imaging	I-P
of	O
iron	O
oxide	O
nanoparticles	O
.	O

Iron	O
oxide	O
nanoparticles	O
(	O
IONPs	O
)	O
are	O
becoming	O
increasingly	O
used	O
and	O
intensively	O
investigated	O
in	O
the	O
field	O
of	O
medical	B-P
imaging	I-P
.	O

They	O
are	O
currently	O
FDA	O
approved	O
for	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
,	O
and	O
it	O
would	O
be	O
highly	O
desirable	O
to	O
visualize	O
them	O
by	O
ultrasound	O
as	O
well	O
.	O

Previous	O
reports	O
using	O
the	O
conventional	O
ultrasound	B-P
B-scan	I-P
(	I-P
pulse-echo	I-P
)	I-P
imaging	I-P
technique	I-P
have	O
shown	O
very	O
limited	O
detectability	O
of	O
these	O
particles	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
explore	O
the	O
feasibility	O
of	O
imaging	B-P
IONPs	O
using	O
the	O
through-transmission	O
ultrasound	O
methodology	O
and	O
demonstrate	O
their	O
detectability	O
using	O
ultrasonic	B-P
computed	I-P
tomography	I-P
(	O
UCT	B-P
)	O
.	O

Commercially	O
available	O
IONPs	O
were	O
acoustically	O
analysed	O
to	O
quantify	O
their	O
effect	O
on	O
the	O
speed	O
of	O
sound	O
(	O
SOS	O
)	O
and	O
acoustic	O
attenuation	O
as	O
a	O
function	O
of	O
concentration	O
.	O

Next	O
,	O
through-transmission	B-P
projection	I-P
and	O
UCT	B-P
imaging	I-P
were	O
performed	O
on	O
a	O
breast	O
mimicking	O
phantom	O
and	O
on	O
an	O
ex	O
vivo	O
tissue	O
model	O
,	O
to	O
which	O
IONPs	O
were	O
injected	O
.	O

Finally	O
,	O
an	O
MRI	B-P
scan	I-P
was	O
performed	O
to	O
verify	O
that	O
the	O
same	O
particles	O
examined	O
in	O
the	O
ultrasound	O
experiment	O
can	O
be	O
imaged	O
by	O
magnetic	O
resonance	O
,	O
using	O
the	O
same	O
clinically	O
relevant	O
concentrations	O
.	O

The	O
results	O
have	O
shown	O
a	O
consistent	O
concentration	O
dependent	O
speed	O
of	O
sound	O
increase	O
(	O
1.86	O
[	O
Formula	O
:	O
see	O
text	O
]	O
rise	O
per	O
100	O
µg	O
·	O
ml	O
(	O
-1	O
)	O
IONPs	O
)	O
.	O

Imaging	B-P
based	O
on	O
this	O
property	O
has	O
shown	O
a	O
substantial	O
contrast-to-noise	O
ratio	O
improvement	O
(	O
up	O
to	O
5	O
fold	O
,	O
p	O
<	O
0.01	O
)	O
.	O

The	O
SOS	O
-related	O
effect	O
generated	O
a	O
well	O
discernible	O
image	O
contrast	O
and	O
allowed	O
the	O
detection	O
of	O
the	O
particles	O
existence	O
and	O
location	O
,	O
in	O
both	O
raster-scan	B-P
projection	I-P
and	O
UCT	B-P
imaging	I-P
.	O

Conversely	O
,	O
no	O
significant	O
change	O
in	O
the	O
acoustic	O
attenuation	O
coefficient	O
was	O
noted	O
.	O

Based	O
on	O
these	O
findings	O
,	O
it	O
is	O
concluded	O
that	O
IONPs	O
can	O
be	O
used	O
as	O
an	O
effective	O
SOS	O
-	O
based	O
contrast	O
agent	O
,	O
potentially	O
useful	O
for	O
ultrasonic	O
breast	O
imaging	B-P
.	O

Furthermore	O
,	O
the	O
particle	O
offers	O
the	O
capacity	O
of	O
significantly	O
enhancing	O
diagnosis	O
accuracy	O
using	O
multimodal	B-P
MRI	B-P
-	O
ultrasound	B-P
imaging	I-P
capabilities	O
.	O

Folate	O
and	O
vitamin	O
B12	O
concentrations	O
are	O
associated	O
with	O
plasma	O
DHA	O
and	O
EPA	O
fatty	O
acids	O
in	O
European	O
adolescents	O
:	O
the	O
Healthy	O
Lifestyle	O
in	O
Europe	O
by	O
Nutrition	O
in	O
Adolescence	O
(	O
HELENA	O
)	O
study	O
.	O

This	O
study	O
aimed	O
to	O
examine	O
the	O
association	O
between	O
vitamin	O
B6	O
,	O
folate	O
and	O
vitamin	O
B12	O
biomarkers	O
and	O
plasma	O
fatty	O
acids	O
in	O
European	O
adolescents	O
.	O

A	O
subsample	O
from	O
the	O
Healthy	O
Lifestyle	O
in	O
Europe	O
by	O
Nutrition	O
in	O
Adolescence	O
study	O
with	O
valid	O
data	O
on	O
B-vitamins	O
and	O
fatty	O
acid	O
blood	O
parameters	O
,	O
and	O
all	O
the	O
other	O
covariates	O
used	O
in	O
the	O
analyses	O
such	O
as	O
BMI	O
,	O
Diet	O
Quality	O
Index	O
,	O
education	O
of	O
the	O
mother	O
and	O
physical	O
activity	O
assessed	O
by	O
a	O
questionnaire	O
,	O
was	O
selected	O
resulting	O
in	O
674	O
cases	O
(	O
43	O
%	O
males	O
)	O
.	O

B-vitamin	O
biomarkers	O
were	O
measured	O
by	O
chromatography	B-P
and	O
immunoassay	B-P
and	O
fatty	O
acids	O
by	O
enzymatic	B-P
analyses	O
.	O

Linear	O
mixed	O
models	O
elucidated	O
the	O
association	O
between	O
B-vitamins	O
and	O
fatty	O
acid	O
blood	O
parameters	O
(	O
changes	O
in	O
fatty	O
acid	O
profiles	B-P
according	O
to	O
change	O
in	O
10	O
units	O
of	O
vitamin	O
B	O
biomarkers	O
)	O
.	O

DHA	O
,	O
EPA	O
)	O
and	O
n-3	O
fatty	O
acids	O
showed	O
positive	O
associations	O
with	O
B-vitamin	O
biomarkers	O
,	O
mainly	O
with	O
those	O
corresponding	O
to	O
folate	O
and	O
vitamin	O
B12	O
.	O

Contrarily	O
,	O
negative	O
associations	O
were	O
found	O
with	O
n-6	O
:	O
n-3	O
ratio	O
,	O
trans-fatty	O
acids	O
and	O
oleic	O
:	O
stearic	O
ratio	O
.	O

With	O
total	O
homocysteine	O
(	O
tHcy	O
)	O
,	O
all	O
the	O
associations	O
found	O
with	O
these	O
parameters	O
were	O
opposite	O
(	O
for	O
instance	O
,	O
an	O
increase	O
of	O
10	O
nmol/l	O
in	O
red	O
blood	O
cell	O
folate	O
or	O
holotranscobalamin	O
in	O
females	O
produces	O
an	O
increase	O
of	O
15·85	O
µmol/l	O
of	O
EPA	O
(	O
P	O
value	O
<	O
0·01	O
)	O
,	O
whereas	O
an	O
increase	O
of	O
10	O
nmol/l	O
of	O
tHcy	O
in	O
males	O
produces	O
a	O
decrease	O
of	O
2·06	O
µmol/l	O
of	O
DHA	O
(	O
P	O
value	O
<	O
0·05	O
)	O
.	O

Positive	O
associations	O
between	O
B-vitamins	O
and	O
specific	O
fatty	O
acids	O
might	O
suggest	O
underlying	O
mechanisms	O
between	O
B-vitamins	O
and	O
CVD	O
and	O
it	O
is	O
worth	O
the	O
attention	O
of	O
public	O
health	O
policies	O
.	O

Phenol	O
red	O
-	O
silk	O
tyrosine	O
cross-linked	O
hydrogels	O
.	O

Phenol	O
red	O
is	O
a	O
cytocompatible	O
pH	O
sensing	O
dye	O
that	O
is	O
commonly	O
added	O
to	O
cell	O
culture	O
media	O
,	O
but	O
removed	O
from	O
some	O
media	O
formulations	O
due	O
to	O
its	O
structural	O
mimicry	O
of	O
estrogen	O
.	O

Phenol	O
red	O
free	O
media	O
is	O
also	O
used	O
during	O
live	B-P
cell	I-P
imaging	I-P
,	O
to	O
avoid	O
absorbance	O
and	O
fluorescence	O
quenching	O
of	O
fluorophores	O
.	O

To	O
overcome	O
these	O
complications	O
,	O
we	O
developed	O
cytocompatible	O
and	O
degradable	O
phenol	O
red	O
-	O
silk	O
tyrosine	O
cross-linked	O
hydrogels	O
using	O
horseradish	O
peroxidase	O
(	O
HRP	O
)	O
enzyme	O
and	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
.	O

Phenol	O
red	O
added	O
to	O
silk	O
during	O
tyrosine	O
crosslinking	O
accelerated	O
di-tyrosine	O
formation	O
in	O
a	O
concentration	O
-	O
dependent	O
reaction	O
.	O

Phenol	O
red	O
diffusion	O
studies	O
and	O
UV-Vis	B-P
spectra	I-P
of	O
phenol	O
red	O
-	O
silk	O
tyrosine	O
hydrogels	O
at	O
different	O
pHs	O
showed	O
altered	O
absorption	O
bands	O
,	O
confirming	O
entrapment	O
of	O
dye	O
within	O
the	O
hydrogel	O
network	O
.	O

LC-MS	B-P
of	O
HRP	O
-reacted	O
phenol	O
red	O
and	O
N-acetyl-l-tyrosine	O
reaction	O
products	O
confirmed	O
covalent	O
bonds	O
between	O
the	O
phenolic	O
hydroxyl	O
group	O
of	O
phenol	O
red	O
and	O
tyrosine	O
on	O
the	O
silk	O
.	O

At	O
lower	O
phenol	O
red	O
concentrations	O
,	O
leak-proof	O
hydrogels	O
which	O
did	O
not	O
release	O
phenol	O
red	O
were	O
fabricated	O
and	O
found	O
to	O
be	O
cytocompatible	O
based	O
on	O
live-dead	B-P
staining	I-P
and	O
alamar	O
blue	O
assessments	O
of	O
encapsulated	O
fibroblasts	O
.	O

Due	O
to	O
the	O
spectral	O
overlap	O
between	O
phenol	O
red	O
absorbance	O
at	O
415	O
nm	O
and	O
di-tyrosine	O
fluorescence	O
at	O
417	O
nm	O
,	O
phenol	O
red	O
-	O
silk	O
hydrogels	O
provide	O
both	O
absorbance	O
and	O
fluorescence	O
-based	O
pH	O
sensing	O
.	O

With	O
an	O
average	O
pKa	O
of	O
6.8	O
and	O
good	O
cytocompatibiltiy	O
,	O
phenol	O
red	O
-	O
silk	O
hydrogels	O
are	O
useful	O
for	O
pH	O
sensing	O
in	O
phenol	O
red	O
free	O
systems	O
,	O
cellular	O
microenvironments	O
and	O
bioreactors	O
.	O

Phenol	O
red	O
entrapped	O
within	O
hydrogels	O
facilitates	O
pH	O
sensing	O
in	O
phenol	O
red	O
free	O
environments	O
.	O

Leak-proof	O
phenol	O
red	O
based	O
pH	O
sensors	O
require	O
covalent	O
binding	O
techniques	O
,	O
but	O
are	O
complicated	O
due	O
to	O
the	O
lack	O
of	O
amino	O
or	O
carboxyl	O
groups	O
on	O
phenol	O
red	O
.	O

Currently	O
,	O
there	O
is	O
no	O
simple	O
,	O
reliable	O
technique	O
to	O
covalently	O
link	O
phenol	O
red	O
to	O
hydrogel	O
matrices	O
,	O
for	O
real-time	O
pH	O
sensing	O
in	O
cell	B-P
culture	I-P
environments	O
.	O

Herein	O
,	O
we	O
take	O
advantage	O
of	O
phenolic	O
groups	O
for	O
covalent	O
linkage	O
of	O
phenol	O
red	O
to	O
silk	O
tyrosine	O
in	O
the	O
presence	O
of	O
HRP	O
and	O
H2O2	O
.	O

The	O
novelty	O
of	O
the	O
current	O
system	O
stems	O
from	O
its	O
simplicity	O
and	O
the	O
use	O
of	O
silk	O
protein	O
to	O
create	O
a	O
cytocompatible	O
,	O
degradable	O
sensor	O
capable	O
of	O
real-time	O
pH	O
sensing	O
in	O
cell	O
culture	O
microenvironments	O
.	O

Physical	O
and	O
virtual	O
modelling	O
of	O
the	O
head	O
and	O
neck	O
for	O
surgical	O
simulation	O
and	O
training	O
.	O

Investigation	O
and	O
surgical	O
manipulation	O
of	O
the	O
larynx	O
,	O
pharynx	O
,	O
and	O
oesophagus	O
suffer	O
from	O
inherent	O
challenges	O
with	O
access	O
to	O
the	O
sites	O
of	O
interest	O
.	O

To	O
reduce	O
trauma	O
and	O
external	O
scarring	O
,	O
visualization	O
and	O
minimally	O
invasive	O
interventions	O
by	O
the	O
transnasal	O
or	O
transoral	O
routes	O
have	O
become	O
more	O
prevalent	O
.	O

This	O
article	O
discusses	O
engineering	O
methods	O
used	O
to	O
understand	O
and	O
overcome	O
the	O
mechanical	O
constraints	O
inside	O
the	O
airway	O
and	O
upper	O
gastrointestinal	O
tract	O
,	O
and	O
examines	O
the	O
role	O
that	O
robotics	O
and	O
engineering	O
are	O
beginning	O
to	O
play	O
in	O
modelling	O
of	O
surgical	O
interventions	O
in	O
this	O
region	O
.	O

Although	O
robotic	O
solutions	O
to	O
minimally	O
invasive	O
surgery	O
of	O
the	O
airway	O
and	O
upper	O
gastrointestinal	O
tract	O
already	O
exist	O
,	O
there	O
is	O
still	O
scope	O
for	O
increasing	O
the	O
breadth	O
of	O
their	O
use	O
.	O

Physical	O
and	O
virtual	O
models	O
of	O
these	O
organs	O
are	O
used	O
to	O
investigate	O
the	O
capability	O
and	O
limitations	O
of	O
manual	O
and	O
robotic	O
surgical	O
interventions	O
in	O
this	O
region	O
.	O

Understanding	O
the	O
tissue	O
mechanics	O
and	O
tool	O
capabilities	O
is	O
central	O
to	O
improving	O
outcomes	O
in	O
the	O
clinical	O
setting	O
.	O

Both	O
physical	O
and	O
virtual	O
modelling	O
modalities	O
are	O
used	O
in	O
training	O
surgeons	O
for	O
both	O
manual	O
-	O
assisted	O
and	O
robot-assisted	O
surgeries	O
.	O

Minimally	O
invasive	O
surgical	O
interventions	O
via	O
the	O
transnasal	O
and	O
the	O
transoral	O
route	O
are	O
strong	O
candidates	O
for	O
overcoming	O
access	O
issues	O
to	O
the	O
airway	O
.	O

They	O
are	O
likely	O
to	O
become	O
more	O
robotically	O
driven	O
as	O
the	O
demand	O
for	O
higher	O
dexterity	O
and	O
accuracy	O
increases	O
for	O
fine	O
manipulation	O
.	O

Physical	O
and	O
virtual	B-P
organ	O
models	O
are	O
required	O
to	O
enable	O
surgical	O
training	O
for	O
these	O
procedures	O
.	O

MinorityReport	O
,	O
software	O
for	O
generalized	O
analysis	O
of	O
causal	O
genetic	B-P
variants	I-P
.	O

The	O
widespread	O
availability	O
of	O
next	O
generation	O
genome	O
sequencing	O
technologies	O
has	O
enabled	O
a	O
wide	O
range	O
of	O
variant	B-P
detection	I-P
applications	O
,	O
especially	O
in	B-P
cancer	I-P
and	O
inborn	O
genetic	O
disorders	O
.	O

For	O
model	O
systems	O
and	O
microorganisms	O
,	O
the	O
same	O
technology	O
may	O
be	O
used	O
to	O
discover	O
the	O
causative	O
mutations	O
for	O
any	O
phenotype	B-P
,	O
including	O
those	O
generated	O
in	O
response	O
to	O
chemical	O
perturbation	O
.	O

In	O
the	O
case	O
of	O
pathogenic	O
organisms	O
,	O
these	O
approaches	O
have	O
allowed	O
the	O
determination	B-P
of	I-P
drug	O
targets	O
by	O
means	O
of	O
resistance	O
selection	O
followed	O
by	O
genome	O
sequencing	O
.	O

MinorityReport	O
is	O
open	O
source	O
software	O
written	O
in	O
python	O
that	O
facilitates	O
the	O
comparison	O
of	O
any	O
two	O
sets	O
of	O
genome	O
alignments	O
for	O
the	O
purpose	O
of	O
rapidly	O
identifying	O
the	O
spectrum	O
of	O
nonsynonymous	O
changes	O
,	O
insertions	O
or	O
deletions	O
,	O
and	O
copy	O
number	O
variations	O
in	O
a	O
presumed	O
mutant	O
relative	O
to	O
its	O
parent	O
.	O

Specifically	O
,	O
MinorityReport	O
relates	O
mapped	O
sequence	O
reads	O
in	O
SAM	O
format	O
output	O
from	O
any	O
alignment	O
tool	O
for	O
both	O
the	O
mutant	O
and	O
parent	O
genome	O
,	O
relative	O
to	O
a	O
reference	O
genome	O
,	O
and	O
produces	O
the	O
set	O
of	O
variants	O
that	O
distinguishes	O
the	O
mutant	O
from	O
the	O
parent	O
,	O
all	O
presented	O
in	O
an	O
intuitive	O
,	O
straightforward	O
report	O
format	O
.	O

MinorityReport	O
features	O
tunable	O
parameters	O
for	O
evaluating	O
evidence	O
and	O
a	O
scoring	O
system	O
that	O
prioritizes	O
reported	O
variants	O
based	O
on	O
relative	O
proportions	O
of	O
read	O
counts	O
supporting	O
the	O
variant	O
in	O
the	O
mutant	O
versus	O
parent	O
data	O
sets	O
.	O

The	O
utility	O
of	O
MinorityReport	O
is	O
demonstrated	O
using	O
previously	O
published	O
publicly	O
available	O
data	O
sets	O
to	O
find	O
the	O
determinants	B-P
of	I-P
resistance	I-P
for	O
novel	O
anti-malarial	O
drugs	O
.	O

MinorityReport	O
is	O
readily	O
available	O
(	O
github	O
:	O
JeremyHorst/	O
MinorityReport	O
)	O
to	O
identify	O
the	O
genetic	O
mechanisms	O
of	O
drug	O
resistance	O
in	O
Plasmodium	O
,	O
genotype-phenotype	O
relationships	O
in	O
human	O
diads	O
,	O
or	O
genomic	O
variations	O
between	O
any	O
two	O
related	O
organisms	O
.	O

A	O
pilot	O
study	O
on	O
transient	O
ischemic	O
stroke	O
induced	O
with	O
endothelin-1	O
in	O
the	O
rhesus	O
monkeys	O
.	O

Endothelin-1	O
(	O
ET-1	O
)	O
,	O
a	O
vasoconstrictor	O
,	O
has	O
recently	O
been	O
used	O
to	O
induce	O
focal	O
ischemia	O
in	O
rodents	O
and	O
marmoset	O
monkeys	O
.	O

The	O
rhesus	O
monkey	O
,	O
however	O
,	O
has	O
numerous	O
advantages	O
to	O
the	O
rodent	O
and	O
marmoset	O
that	O
make	O
it	O
a	O
superior	O
and	O
irreplaceable	O
animal	O
model	O
for	O
studying	O
stroke	O
in	O
the	O
brain	O
.	O

In	O
the	O
present	O
study	O
,	O
after	O
mapping	O
the	O
preferred	O
hand	O
representation	O
in	O
two	O
healthy	O
male	O
monkeys	O
with	O
intracortical	O
micro-stimulation	O
,	O
ET-1	O
was	O
microinjected	O
into	O
the	O
contralateral	O
motor	O
cortex	O
(	O
M1	O
)	O
to	O
its	O
preferred	O
hand	O
.	O

The	O
monkeys	O
had	O
been	O
trained	O
in	O
three	O
manual	O
dexterity	O
tasks	O
before	O
the	O
microinjection	O
and	O
were	O
tested	O
for	O
these	O
tasks	O
following	O
the	O
ET-1	O
injection	O
.	O

Brain	B-P
Magnetic	I-P
Resonance	I-P
Imaging	I-P
scans	I-P
were	O
performed	O
1	O
,	O
7	O
,	O
14	O
and	O
28	O
days	O
post	O
ischemia	O
.	O

It	O
was	O
found	O
that	O
ET-1	O
impaired	O
the	O
manual	O
dexterity	O
of	O
the	O
monkeys	O
in	O
the	O
vertical	O
slot	O
and	O
rotating	O
Brinkman	O
board	O
tasks	O
3-8	O
days	O
after	O
the	O
injection	O
.	O

Brain	B-P
imaging	I-P
found	O
that	O
severe	O
edema	O
was	O
present	O
7	O
days	O
after	O
the	O
focal	O
ischemia	O
.	O

This	O
data	O
suggest	O
that	O
ET-1	O
can	O
induce	O
transient	O
ischemic	O
stroke	O
in	O
rhesus	O
monkey	O
and	O
that	O
ET-1	O
induced	O
focal	O
ischemia	O
in	O
non-human	O
primates	O
is	O
a	O
potential	O
model	O
to	O
study	O
the	O
mechanism	O
of	O
stroke	O
and	O
brain	O
repair	O
after	O
stroke	O
.	O

Molecular	O
diversity	O
of	O
α-gliadin	O
expressed	O
genes	O
in	O
genetically	O
contrasted	O
spelt	O
(	O
Triticum	O
aestivum	O
ssp	O
.	O

spelta	O
)	O
accessions	O
and	O
comparison	O
with	O
bread	O
wheat	O
(	O
T.	O
aestivum	O
ssp	O
.	O

aestivum	O
)	O
and	O
related	O
diploid	O
Triticum	O
and	O
Aegilops	O
species	O
.	O

The	O
gluten	O
proteins	O
of	O
cereals	O
such	O
as	O
bread	O
wheat	O
(	O
Triticum	O
aestivum	O
ssp	O
.	O

aestivum	O
)	O
and	O
spelt	O
(	O
T.	O
aestivum	O
ssp	O
.	O

spelta	O
)	O
are	O
responsible	O
for	O
celiac	O
disease	O
(	O
CD	O
)	O
.	O

The	O
α-gliadins	O
constitute	O
the	O
most	O
immunogenic	O
class	O
of	O
gluten	O
proteins	O
as	O
they	O
include	O
four	O
main	O
T-cell	O
stimulatory	O
epitopes	O
that	O
affect	O
CD	O
patients	O
.	O

Spelt	O
has	O
been	O
less	O
studied	O
than	O
bread	O
wheat	O
and	O
could	O
constitute	O
a	O
source	O
of	O
valuable	O
diversity	O
.	O

The	O
objective	O
of	O
this	O
work	O
was	O
to	O
study	O
the	O
genetic	O
diversity	O
of	O
spelt	O
α-gliadin	O
transcripts	O
and	O
to	O
compare	O
it	O
with	O
those	O
of	O
bread	O
wheat	O
.	O

Genotyping	B-P
data	O
from	O
85	O
spelt	O
accessions	O
obtained	O
with	O
19	O
simple	O
sequence	O
repeat	O
(	O
SSR	O
)	O
markers	O
were	O
used	O
to	O
select	O
11	O
contrasted	O
accessions	O
,	O
from	O
which	O
446	O
full	O
open	O
reading	O
frame	O
α-gliadin	O
genes	O
were	O
cloned	O
and	O
sequenced	B-P
,	O
which	O
revealed	O
a	O
high	O
allelic	O
diversity	O
.	O

High	O
variations	O
among	O
the	O
accessions	O
were	O
highlighted	O
,	O
in	O
terms	O
of	O
the	O
proportion	O
of	O
α-gliadin	O
sequences	O
from	O
each	O
of	O
the	O
three	O
genomes	O
(	O
A	O
,	O
B	O
and	O
D	O
)	O
,	O
and	O
their	O
composition	O
in	O
the	O
four	O
T-cell	O
stimulatory	O
epitopes	O
.	O

An	O
accession	O
from	O
Tajikistan	O
stood	O
out	O
,	O
having	O
a	O
particularly	O
high	O
proportion	O
of	O
α-gliadins	O
from	O
the	O
B	O
genome	O
and	O
a	O
low	O
immunogenic	O
content	O
.	O

Even	O
if	O
no	O
clear	O
separation	O
between	O
spelt	O
and	O
bread	O
wheat	O
sequences	O
was	O
shown	O
,	O
spelt	O
α-gliadins	O
displayed	O
specific	O
features	O
concerning	O
e.g	O
.	O

the	O
frequencies	O
of	O
some	O
amino	O
acid	O
substitutions	O
.	O

Given	O
this	O
observation	O
and	O
the	O
variations	O
in	O
toxicity	O
revealed	O
in	O
the	O
spelt	O
accessions	O
in	O
this	O
study	O
,	O
the	O
high	O
genetic	O
diversity	O
held	O
in	O
spelt	O
germplasm	O
collections	O
could	O
be	O
a	O
valuable	O
resource	O
in	O
the	O
development	O
of	O
safer	O
varieties	O
for	O
CD	O
patients	O
.	O

Effect	O
of	O
organic	O
and	O
inorganic	O
selenium	O
supplementation	O
on	O
semen	B-P
quality	I-P
and	O
blood	O
enzymes	O
in	O
buffalo	O
bulls	O
.	O

The	O
present	O
study	O
aimed	O
to	O
evaluate	O
the	O
effect	O
of	O
organic	O
and	O
inorganic	O
selenium	O
(	O
Se	O
)	O
supplementation	O
on	O
semen	B-P
quality	I-P
and	O
blood	O
serum	O
profiles	B-P
of	O
buffalo	O
bulls	O
.	O

Nine	O
mature	O
buffalo	O
bulls	O
were	O
divided	O
into	O
three	O
groups	O
:	O
control	O
(	O
non-supplemented	O
)	O
;	O
organic	O
Se	O
(	O
10	O
mg	O
Sel-Plex	O
®/head	O
twice	O
weekly	O
)	O
and	O
inorganic	O
Se	O
(	O
10	O
mg	O
sodium	O
selenite	O
/head	O
twice	O
weekly	O
)	O
.	O

Semen	O
was	O
collected	O
twice	O
a	O
week	O
for	O
3	O
months	O
during	O
Se	O
supplementation	O
.	O

Semen	O
properties	O
were	O
evaluated	O
from	O
fresh	O
ejaculate	O
.	O

Moreover	O
,	O
fructose	O
concentration	O
,	O
aspartate	O
and	O
alanine	O
transaminase	O
(	O
AST	O
and	O
ALT	O
)	O
activities	O
,	O
total	B-P
protein	I-P
and	O
total	B-P
cholesterol	I-P
were	O
assayed	B-P
in	O
seminal	O
plasma	O
.	O

Additionally	O
AST	O
,	O
ALT	O
,	O
testosterone	O
and	O
Se	O
levels	O
were	O
determined	O
in	O
the	O
blood	O
serum	O
.	O

Results	O
showed	O
that	O
Se	O
supplementation	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
influences	O
the	O
semen	O
parameters	O
during	O
3	O
months	O
of	O
treatment	O
.	O

Organic	O
Se	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
increased	O
the	O
percentage	O
of	O
viable	O
sperms	O
compared	O
to	O
inorganic	O
Se	O
and	O
the	O
control	O
group	O
.	O

Fructose	O
concentration	O
was	O
significantly	O
higher	O
(	O
P	O
<	O
0.05	O
)	O
in	O
the	O
seminal	O
plasma	O
of	O
organic	O
Se	O
-	O
treated	O
bulls	O
.	O

Serum	O
testosterone	O
and	O
Se	O
concentrations	O
were	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
increased	O
in	O
the	O
Se	O
supplemented	O
groups	O
than	O
the	O
control	O
group	O
.	O

In	O
conclusion	O
,	O
Se	O
supplementation	O
improved	O
the	O
parameters	O
of	O
buffalo	O
bull	O
semen	O
and	O
more	O
precisely	O
,	O
organic	O
Se	O
was	O
more	O
effective	O
for	O
the	O
improvement	O
of	O
semen	B-P
quality	I-P
and	O
some	O
blood	O
components	O
than	O
inorganic	O
Se	O
.	O

The	O
Role	O
of	O
the	O
Iron	B-P
Stain	I-P
in	O
Assessing	O
Intracranial	O
Hemorrhage	O
.	O

The	O
timing	O
of	O
the	O
breakdown	O
of	O
red	O
blood	O
cells	O
and	O
organization	O
of	O
hemorrhage	O
has	O
significance	O
in	O
the	O
catabolism	O
of	O
heme	O
and	O
the	O
processing	O
of	O
iron	O
,	O
but	O
also	O
has	O
a	O
practical	O
application	O
in	O
terms	O
of	O
assigning	O
,	O
or	O
attempting	O
to	O
assign	O
,	O
a	O
time	O
course	O
with	O
respect	O
to	O
traumatic	O
events	O
(	O
e.g	O
.	O

contusions	O
and	O
hemorrhages	O
)	O
.	O

Attempts	O
to	O
date	O
contusions	O
,	O
however	O
,	O
have	O
generally	O
been	O
unsuccessful	O
by	O
macroscopic	B-P
observation	I-P
,	O
whereas	O
the	O
microscopic	B-P
observations	I-P
provide	O
broad	O
data	O
but	O
are	O
also	O
anatomically	O
imprecise	O
as	O
a	O
function	O
of	O
time	O
.	O

Intracranial	O
lesions	O
are	O
of	O
particular	O
significance	O
with	O
respect	O
to	O
the	O
timing	O
of	O
organizing	O
hemorrhage	O
given	O
the	O
acute	O
,	O
and	O
often	O
life-threatening	O
nature	O
of	O
the	O
hemorrhages	O
,	O
and	O
the	O
medicolegal	B-P
investigation	I-P
into	O
potential	O
crimes	O
.	O

Of	O
concern	O
is	O
that	O
the	O
Prussian	B-P
Blue	I-P
reaction	I-P
for	O
iron	O
,	O
a	O
relatively	O
straightforward	O
histochemical	B-P
reaction	O
that	O
has	O
been	O
in	O
use	O
for	O
over	O
150	O
years	O
,	O
is	O
sometimes	O
suggested	O
as	O
a	O
diagnostic	B-P
test	I-P
for	O
chronicity	O
.	O

Therefore	O
,	O
this	O
study	O
examined	O
the	O
utility	O
of	O
the	O
Prussian	O
Blue	O
iron	O
stain	O
in	O
living	O
patients	O
with	O
intracranial	O
hemorrhages	O
and	O
well-defined	O
symptom	O
onset	O
,	O
to	O
test	O
whether	O
the	O
presence	O
of	O
Prussian	O
Blue	O
reactivity	O
could	O
be	O
correlated	O
with	O
chronicity	O
.	O

It	O
was	O
found	O
that	O
out	O
of	O
12	O
cases	O
with	O
intracranial	O
hemorrhage	O
,	O
eight	O
cases	O
showed	O
at	O
least	O
focal	O
iron	O
reactivity	O
.	O

The	O
duration	O
from	O
symptom	O
onset	O
to	O
surgery	O
in	O
those	O
eight	O
cases	O
ranged	O
from	O
<	O
24	O
hours	O
to	O
more	O
than	O
3	O
days	O
.	O

Of	O
those	O
cases	O
with	O
no	O
iron	O
reactivity	O
,	O
the	O
duration	O
from	O
symptom	O
onset	O
to	O
surgery	O
ranged	O
from	O
<	O
24	O
hours	O
to	O
six	O
days	O
.	O

In	O
conclusion	O
,	O
the	O
Prussian	B-P
Blue	I-P
reaction	I-P
was	O
unreliable	O
as	O
an	O
indicator	O
of	O
timing	O
in	O
intracranial	O
hemorrhage	O
.	O

The	O
use	O
of	O
the	O
Prussian	B-P
blue	I-P
reaction	I-P
as	O
an	O
independent	O
indicator	O
of	O
chronicity	O
is	O
therefore	O
not	O
valid	O
and	O
can	O
be	O
misleading	O
.	O

Caution	O
is	O
indicated	O
when	O
employing	O
iron	B-P
staining	I-P
for	O
timing	O
purposes	O
,	O
as	O
its	O
only	O
use	O
is	O
to	O
highlight	O
,	O
as	O
opposed	O
to	O
identify	O
,	O
pre-existing	O
lesions	O
.	O

With	O
respect	O
to	O
brain	O
lesions	O
,	O
the	O
Prussian	B-P
blue	I-P
reaction	I-P
should	O
not	O
be	O
used	O
in	O
place	O
of	O
the	O
clinical	O
timing	O
of	O
the	O
neurologic	O
decline	O
,	O
or	O
clinical	O
data	O
that	O
is	O
otherwise	O
more	O
accurate	O
and	O
less	O
susceptible	O
to	O
false	O
positive	O
results	O
.	O

Sudden	O
sensorineural	O
hearing	O
loss	O
:	O
is	O
there	O
a	O
relationship	O
between	O
routine	O
haematological	O
parameters	O
and	O
audiogram	B-P
shapes	O
?	O
.	O

To	O
investigate	O
the	O
relationship	O
between	O
haematological	O
routine	O
parameters	O
and	O
audiogram	B-P
shapes	O
in	O
patients	O
affected	O
by	O
sudden	O
sensorineural	O
hearing	O
loss	O
(	O
SSNHL	O
)	O
.	O

A	O
retrospective	O
study	O
.	O

All	O
patients	O
were	O
divided	O
into	O
four	O
groups	O
according	O
to	O
the	O
audiometric	B-P
curve	O
and	O
mean	O
values	O
of	O
haematological	O
parameters	O
(	O
haemoglobin	B-P
,	O
white	O
blood	O
cell	O
,	O
neutrophils	B-P
and	O
lymphocytes	B-P
relative	I-P
count	I-P
,	O
platelet	O
count	O
,	O
haematocrit	B-P
,	O
prothrombin	B-P
time	I-P
,	O
activated	B-P
partial	I-P
thromboplastin	I-P
time	I-P
,	O
fibrinogen	O
and	O
neutrophil-to-lymphocite	B-P
ratio	I-P
)	O
of	O
each	O
group	O
were	O
statistically	O
compared	O
.	O

The	O
prognostic	O
role	O
of	O
blood	B-P
profile	I-P
and	O
coagulation	B-P
test	I-P
was	O
also	O
examined	O
.	O

A	O
cohort	O
of	O
183	O
SSNHL	O
patients	O
without	O
comorbidities	O
.	O

With	O
a	O
48.78	O
%	O
of	O
complete	O
hearing	O
recovery	O
,	O
individuals	O
affected	O
by	O
upsloping	O
hearing	O
loss	O
presented	O
a	O
better	O
prognosis	O
instead	O
of	O
flat	O
(	O
18.36	O
%	O
)	O
,	O
downsloping	O
(	O
19.23	O
%	O
)	O
and	O
anacusis	O
(	O
2.45	O
%	O
)	O
groups	O
(	O
p	O
=	O
0.0001	O
)	O
.	O

The	O
multivariate	O
analysis	O
of	O
complete	B-P
blood	I-P
count	I-P
values	I-P
revealed	O
lower	O
mean	O
percentage	O
of	O
lymphocytes	O
(	O
p	O
=	O
0.041	O
)	O
and	O
higher	O
platelet	O
levels	O
(	O
p	O
=	O
0.015	O
)	O
in	O
case	O
of	O
downsloping	O
hearing	O
loss	O
;	O
with	O
the	O
exception	O
of	O
fibrinogen	O
(	O
p	O
=	O
0.041	O
)	O
,	O
none	O
of	O
the	O
main	O
haematological	O
parameters	O
studied	O
resulted	O
associated	O
with	O
poorer	O
prognosis	O
.	O

Our	O
work	O
suggested	O
a	O
lack	O
of	O
association	O
between	O
haematological	O
parameters	O
and	O
a	O
defined	O
audiometric	B-P
picture	O
in	O
SSNHL	O
patients	O
;	O
furthermore	O
,	O
only	O
fibrinogen	O
seems	O
to	O
influence	O
the	O
prognosis	O
of	O
this	O
disease	O
.	O

CXCL14	O
-	O
CXCR4	O
and	O
CXCL12	O
-	O
CXCR4	O
Axes	O
May	O
Play	O
Important	O
Roles	O
in	O
the	O
Unique	O
Invasion	O
Process	O
of	O
Endometrioid	O
Carcinoma	O
With	O
MELF-Pattern	O
Myoinvasion	O
.	O

The	O
term	O
``	O
MELF-pattern	O
myometrial	O
invasion	O
``	O
(	O
MELF	O
pattern	O
)	O
denotes	O
an	O
unusual	O
morphology	O
of	O
myometrial	O
invasion	O
in	O
endometrioid	O
carcinomas	O
,	O
and	O
is	O
associated	O
with	O
frequent	O
lymphovascular	O
invasion	O
and	O
lymph	O
node	O
metastasis	O
.	O

In	O
this	O
study	O
,	O
tumor	O
cells	O
were	O
directly	O
collected	O
from	O
a	O
MELF	O
pattern	O
site	O
,	O
using	O
laser	B-P
microdissection	I-P
.	O

Comprehensive	O
microarray	B-P
analysis	I-P
of	O
the	O
genes	O
was	O
conducted	O
,	O
and	O
based	O
on	O
the	O
results	O
,	O
expression	O
of	O
a	O
metastasis	O
progression	O
gene	O
,	O
CXCR4	O
,	O
and	O
its	O
ligands	O
CXCL14	O
and	O
CXCL12	O
,	O
was	O
further	O
investigated	O
.	O

In	O
vitro	O
studies	O
of	O
endometrioid	O
carcinoma	O
cell	O
lines	O
revealed	O
elevated	O
invasion	O
activity	O
in	O
a	O
manner	O
dependent	O
on	O
the	O
CXCL14	O
-	O
CXCR4	O
or	O
CXCL12	O
-	O
CXCR4	O
axis	O
.	O

Immunohistochemical	B-P
analysis	I-P
of	O
93	O
(	O
MELF	O
group	O
,	O
46	O
;	O
non-MELF	O
group	O
,	O
47	O
)	O
cases	O
illustrated	O
CXCR4	O
was	O
expressed	O
in	O
all	O
endometrioid	O
carcinomas	O
,	O
while	O
based	O
on	O
CXCL14	O
and	O
CXCL12	O
expression	O
score	O
,	O
high	O
proportions	O
of	O
cells	O
were	O
positive	O
at	O
the	O
sites	O
of	O
the	O
MELF	O
pattern	O
(	O
P	O
<	O
0.01	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
progression-free	O
survival	O
or	O
overall	O
survival	O
between	O
MELF	O
group	O
and	O
non-MELF	O
group	O
by	O
Kaplan-Meier	O
analysis	O
.	O

These	O
findings	O
suggest	O
a	O
possibility	O
that	O
cells	O
at	O
the	O
sites	O
of	O
MELF	O
pattern	O
had	O
acquired	O
increased	O
invasiveness	O
through	O
the	O
function	O
of	O
the	O
CXCL14	O
-	O
CXCR4	O
and	O
CXCL12	O
-	O
CXCR4	O
axes	O
.	O

Developmental	O
Profile	B-P
and	O
Diagnoses	O
in	O
Children	O
Presenting	O
with	O
Motor	O
Stereotypies	O
.	O

Motor	O
stereotypies	O
represent	O
a	O
typical	O
example	O
of	O
the	O
difficulty	O
in	O
distinguishing	O
non-clinical	O
behaviors	O
(	O
physiological	O
and	O
transient	O
)	O
from	O
symptoms	O
or	O
among	O
different	O
disorders	O
[	O
``	O
primary	O
stereotypies	O
,	O
''	O
associated	O
with	O
autistic	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
,	O
intellectual	O
disabilities	O
,	O
genetic	O
syndromes	O
,	O
and	O
sensory	O
impairment	O
]	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
obtain	O
an	O
accurate	O
assessment	O
on	O
the	O
relationship	O
between	O
stereotypies	O
and	O
neurodevelopmental	O
disorders	O
.	O

We	O
studied	O
23	O
children	O
(	O
3	O
girls	O
)	O
,	O
aged	O
36-95	O
months	O
,	O
who	O
requested	O
a	O
consultation	O
due	O
to	O
the	O
persistence	O
or	O
increased	O
severity	O
of	O
motor	O
stereotypies	O
.	O

None	O
of	O
the	O
patients	O
had	O
a	O
previous	O
diagnosis	O
of	O
ASD	O
.	O

The	O
assessment	O
included	O
the	O
Motor	O
Severity	O
Stereotypy	O
Scale	O
(	O
MSSS	O
)	O
,	O
the	O
Repetitive	O
Behavior	O
Scale-Revised	O
(	O
RBS-R	O
)	O
,	O
the	O
Raven	O
's	O
Colored	O
Progressive	O
Matrices	O
,	O
the	O
Child	O
Behavior	O
CheckList	O
for	O
ages	O
1½-5	O
or	O
4-18	O
(	O
CBCL	O
)	O
,	O
the	O
Social	O
Responsiveness	O
Scale	O
(	O
SRS	O
)	O
,	O
and	O
the	O
Autism	O
Diagnostic	O
Observation	O
Schedule-second	O
edition	O
(	O
ADOS	O
2	O
)	O
.	O

All	O
patients	O
were	O
showing	O
motor	O
stereotypies	O
for	O
periods	O
of	O
time	O
varying	O
from	O
6	O
to	O
77	O
months	O
.	O

The	O
MSSS	O
showed	O
that	O
each	O
child	O
had	O
a	O
limited	O
number	O
of	O
stereotypies	O
;	O
their	O
frequency	O
and	O
intensity	O
were	O
mild	O
.	O

The	O
interference	O
of	O
stereotypies	O
was	O
variable	O
;	O
the	O
impairment	O
in	O
daily	O
life	O
was	O
mild	O
.	O

The	O
RBS-R	O
scores	O
were	O
positive	O
for	O
the	O
subscale	O
of	O
``	O
stereotypic	O
behaviors	O
``	O
in	O
all	O
children	O
.	O

Moreover	O
,	O
several	O
children	O
presented	O
other	O
repetitive	O
behaviors	O
,	O
mainly	O
``	O
ritualistic	O
behavior	O
``	O
and	O
``	O
sameness	O
behavior	O
.	O
''	O

All	O
patients	O
showed	O
a	O
normal	O
cognitive	O
level	O
.	O

The	O
CBCL	O
evidenced	O
behavioral	O
problems	O
in	O
22	O
%	O
of	O
the	O
children	O
:	O
internalizing	O
problems	O
,	O
attention	O
,	O
and	O
withdrawn	O
were	O
the	O
main	O
complaints	O
.	O

On	O
the	O
SRS	O
,	O
all	O
but	O
one	O
of	O
the	O
tested	O
patients	O
obtained	O
clinical	O
scores	O
in	O
the	O
clinical	O
range	O
for	O
at	O
least	O
one	O
area	O
.	O

On	O
the	O
ADOS	O
2	O
,	O
4	O
patients	O
obtained	O
scores	O
indicating	O
a	O
moderate	O
level	O
of	O
ASD	O
symptoms	O
,	O
4	O
had	O
a	O
mild	O
level	O
,	O
and	O
15	O
showed	O
no	O
or	O
minimal	O
signs	O
of	O
ASD	O
.	O

Motor	O
stereotypies	O
in	O
children	O
with	O
normal	O
cognitive	O
level	O
represent	O
a	O
challenging	O
diagnostic	O
issue	O
for	O
which	O
a	O
finely	O
tailored	O
assessment	O
is	O
mandatory	O
in	O
order	O
to	O
define	O
a	O
precise	O
developmental	O
profile	O
.	O

Thus	O
,	O
careful	O
and	O
cautious	O
use	O
of	O
standardized	O
tests	O
is	O
warranted	O
to	O
avoid	O
misdiagnosis	O
.	O

Furthermore	O
,	O
it	O
is	O
hard	O
to	O
consider	O
motor	O
stereotypies	O
,	O
even	O
the	O
primary	O
ones	O
,	O
exclusively	O
as	O
a	O
movement	O
disorder	O
.	O

Clinical	O
and	O
radiographic	O
outcomes	O
of	O
bilateral	O
decompression	O
via	O
a	O
unilateral	O
approach	O
with	O
transforaminal	O
lumbar	O
interbody	O
fusion	O
for	O
degenerative	O
lumbar	O
spondylolisthesis	O
with	O
stenosis	O
.	O

Laminectomy	O
with	O
posterior	O
lumbar	O
interbody	O
fusion	O
(	O
PLIF	O
)	O
has	O
been	O
shown	O
to	O
achieve	O
satisfactory	O
clinical	O
outcomes	O
,	O
but	O
it	O
leads	O
to	O
potential	O
adverse	O
consequences	O
associated	O
with	O
extensive	O
disruption	O
of	O
posterior	O
bony	O
and	O
soft	O
tissue	O
structures	O
.	O

This	O
study	O
aimed	O
to	O
compare	O
the	O
clinical	O
and	O
radiographic	O
outcomes	O
of	O
bilateral	O
decompression	O
via	O
a	O
unilateral	O
approach	O
(	O
BDUA	O
)	O
with	O
transforaminal	O
lumbar	O
interbody	O
fusion	O
(	O
TLIF	O
)	O
and	O
laminectomy	O
with	O
PLIF	O
in	O
the	O
treatment	O
of	O
degenerative	O
lumbar	O
spondylolisthesis	O
(	O
DLS	O
)	O
with	O
stenosis	O
.	O

This	O
is	O
a	O
prospective	O
cohort	O
study	O
.	O

This	O
study	O
compared	O
43	O
patients	O
undergoing	O
BDUA	O
+	O
TLIF	O
and	O
40	O
patients	O
undergoing	O
laminectomy	O
+	O
PLIF	O
.	O

Visual	B-P
analog	I-P
scale	I-P
(	O
VAS	B-P
)	O
for	O
low	O
back	O
pain	O
and	O
leg	O
pain	O
,	O
Oswestry	O
Disability	O
Index	O
(	O
ODI	O
)	O
,	O
and	O
Zurich	O
Claudication	O
Questionnaire	O
(	O
ZCQ	O
)	O
score	O
.	O

The	O
clinical	O
outcomes	O
were	O
assessed	O
,	O
and	O
intraoperative	O
data	O
and	O
complications	O
were	O
collected	O
.	O

Radiographic	O
outcomes	O
included	O
slippage	O
of	O
the	O
vertebra	O
,	O
disc	O
space	O
height	O
,	O
segmental	O
lordosis	O
,	O
and	O
final	O
fusion	O
rate	O
.	O

This	O
study	O
was	O
supported	O
by	O
a	O
grant	O
from	O
The	O
National	O
Natural	O
Science	O
Foundation	O
of	O
China	O
(	O
81572168	O
)	O
.	O

There	O
were	O
significant	O
improvements	O
in	O
clinical	O
and	O
radiographic	O
outcomes	O
from	O
before	O
surgery	O
to	O
3	O
months	O
and	O
2	O
years	O
after	O
surgery	O
within	O
each	O
group	O
.	O

Analysis	O
of	O
leg	O
pain	O
VAS	O
and	O
ZCQ	O
scores	O
showed	O
no	O
significant	O
differences	O
in	O
improvement	O
between	O
groups	O
at	O
either	O
follow-up	O
.	O

The	O
mean	O
improvements	O
in	O
low	O
back	O
pain	O
VAS	B-P
and	O
ODI	O
scores	O
were	O
significantly	O
greater	O
in	O
the	O
BDUA	O
+	O
TLIF	O
group	O
than	O
in	O
the	O
laminectomy	O
+	O
PLIF	O
group	O
.	O

No	O
significant	O
difference	O
was	O
found	O
in	O
the	O
final	O
fusion	O
rate	O
at	O
2-year	O
follow-up	O
.	O

The	O
BDUA	O
+	O
TLIF	O
group	O
had	O
significantly	O
less	O
blood	O
loss	O
,	O
shorter	O
length	O
of	O
postoperative	O
hospital	O
stay	O
,	O
and	O
lower	O
complication	O
rate	O
compared	O
with	O
the	O
laminectomy	O
+	O
PLIF	O
group	O
.	O

When	O
compared	O
with	O
the	O
conventional	O
laminectomy	O
+	O
PLIF	O
procedure	O
,	O
the	O
BDUA	O
+	O
TLIF	O
procedure	O
achieves	O
similar	O
and	O
satisfactory	O
effects	O
of	O
decompression	O
and	O
fusion	O
for	O
DLS	O
with	O
stenosis	O
.	O

The	O
BDUA	O
+	O
TLIF	O
procedure	O
appears	O
to	O
be	O
associated	O
with	O
less	O
postoperative	O
low	O
back	O
discomfort	O
and	O
quicker	O
recovery	O
.	O

Prediction	O
of	O
Estrogenic	O
Bioactivity	O
of	O
Environmental	O
Chemical	O
Metabolites	O
.	O

The	O
US	O
Environmental	O
Protection	O
Agency	O
's	O
(	O
EPA	O
)	O
Endocrine	O
Disruptor	O
Screening	O
Program	O
(	O
EDSP	O
)	O
is	O
using	O
in	O
vitro	O
data	O
generated	O
from	O
ToxCast	O
/	O
Tox21	O
high-throughput	B-P
screening	I-P
assays	I-P
to	O
assess	O
the	O
endocrine	O
activity	O
of	O
environmental	O
chemicals	O
.	O

Considering	O
that	O
in	O
vitro	O
assays	O
may	O
have	O
limited	O
metabolic	O
capacity	O
,	O
inactive	O
chemicals	O
that	O
are	O
biotransformed	O
into	O
metabolites	O
with	O
endocrine	O
bioactivity	O
may	O
be	O
missed	O
for	O
further	O
screening	O
and	O
testing	O
.	O

Therefore	O
,	O
there	O
is	O
a	O
value	O
in	O
developing	O
novel	O
approaches	O
to	O
account	O
for	O
metabolism	O
and	O
endocrine	O
activity	O
of	O
both	O
parent	O
chemicals	O
and	O
their	O
associated	O
metabolites	O
.	O

We	O
used	O
commercially	O
available	O
software	O
to	O
predict	O
metabolites	O
of	O
50	O
parent	O
compounds	O
,	O
out	O
of	O
which	O
38	O
chemicals	O
are	O
known	O
to	O
have	O
estrogenic	O
metabolites	O
,	O
and	O
12	O
compounds	O
and	O
their	O
metabolites	O
are	O
negative	O
for	O
estrogenic	O
activity	O
.	O

Three	O
ER	O
QSAR	O
models	O
were	O
used	O
to	O
determine	O
potential	O
estrogen	O
bioactivity	O
of	O
the	O
parent	O
compounds	O
and	O
predicted	O
metabolites	O
,	O
the	O
outputs	O
of	O
the	O
models	O
were	O
averaged	O
,	O
and	O
the	O
chemicals	O
were	O
then	O
ranked	O
based	O
on	O
the	O
total	O
estrogenicity	O
of	O
the	O
parent	O
chemical	O
and	O
metabolites	O
.	O

The	O
metabolite	O
prediction	O
software	O
correctly	O
identified	O
known	O
estrogenic	O
metabolites	O
for	O
26	O
out	O
of	O
27	O
parent	O
chemicals	O
with	O
associated	O
metabolite	O
data	O
,	O
and	O
39	O
out	O
of	O
46	O
estrogenic	O
metabolites	O
were	O
predicted	O
as	O
potential	O
biotransformation	O
products	O
derived	O
from	O
the	O
parent	O
chemical	O
.	O

The	O
QSAR	O
models	O
estimated	O
stronger	O
estrogenic	O
activity	O
for	O
the	O
majority	O
of	O
the	O
known	O
estrogenic	O
metabolites	O
compared	O
to	O
their	O
parent	O
chemicals	O
.	O

Finally	O
,	O
the	O
three	O
models	O
identified	O
a	O
similar	O
set	O
of	O
parent	O
compounds	O
as	O
top	O
ranked	O
chemicals	O
based	O
on	O
the	O
estrogenicity	O
of	O
putative	O
metabolites	O
.	O

This	O
proposed	O
in	O
silico	O
approach	O
is	O
an	O
inexpensive	O
and	O
rapid	O
strategy	O
for	O
the	O
detection	O
of	O
chemicals	O
with	O
estrogenic	O
metabolites	O
and	O
may	O
reduce	O
potential	O
false	O
negative	O
results	O
from	O
in	O
vitro	O
assays	O
.	O

Social	O
cognition	O
in	O
schizophrenia	O
:	O
Factor	O
structure	O
of	O
emotion	O
processing	O
and	O
theory	O
of	O
mind	O
.	O

Factor	O
analytic	O
studies	O
examining	O
social	O
cognition	O
in	O
schizophrenia	O
have	O
yielded	O
inconsistent	O
results	O
most	O
likely	O
due	O
to	O
the	O
varying	O
number	O
and	O
quality	O
of	O
measures	O
.	O

With	O
the	O
recent	O
conclusion	O
of	O
Phase	O
3	O
of	O
the	O
Social	O
Cognition	O
Psychometric	B-P
Evaluation	I-P
(	I-P
SCOPE	I-P
)	I-P
Study	I-P
,	O
the	O
most	O
psychometrically	B-P
sound	B-P
measures	I-P
of	O
social	O
cognition	O
have	O
been	O
identified	O
.	O

Therefore	O
,	O
the	O
aims	O
of	O
the	O
present	O
study	O
were	O
to	O
:	O
1	O
)	O
examine	O
the	O
factor	O
structure	O
of	O
social	O
cognition	O
in	O
schizophrenia	O
through	O
the	O
utilization	O
of	O
psychometrically	B-P
sound	B-P
measures	I-P
,	O
2	O
)	O
examine	O
the	O
stability	O
of	O
the	O
factor	O
structure	O
across	O
two	O
study	O
visits	O
,	O
3	O
)	O
compare	O
the	O
factor	O
structure	O
of	O
social	O
cognition	O
in	O
schizophrenia	O
to	O
that	O
in	O
healthy	O
controls	O
,	O
and	O
4	O
)	O
examine	O
the	O
relationship	O
between	O
the	O
factors	O
and	O
relevant	O
outcome	O
measures	O
including	O
social	O
functioning	O
and	O
symptoms	O
.	O

Results	O
supported	O
a	O
one-factor	O
model	O
for	O
the	O
patient	O
and	O
healthy	O
control	O
samples	O
at	O
both	O
visits	O
.	O

This	O
single	O
factor	O
was	O
significantly	O
associated	O
with	O
negative	O
symptoms	O
in	O
the	O
schizophrenia	O
sample	O
and	O
with	O
social	O
functioning	O
in	O
both	O
groups	O
at	O
both	O
study	O
visits	O
.	O

Regeneration	O
of	O
mandibular	O
ameloblastoma	O
defect	O
with	O
the	O
help	O
of	O
autologous	O
dental	O
pulp	O
stem	O
cells	O
and	O
buccal	O
pad	O
of	O
fat	O
stromal	O
vascular	O
fraction	O
.	O

Ameloblastoma	O
is	O
benign	O
odontogenic	O
tumor	O
,	O
which	O
is	O
locally	O
aggressive	O
in	O
behavior	O
.	O

Till	O
date	O
,	O
the	O
treatment	O
of	O
choice	O
is	O
resection	O
and	O
reconstruction	O
using	O
a	O
variety	O
of	O
modalities	O
.	O

Inadequate	O
resection	O
may	O
lead	O
to	O
many	O
complications	O
such	O
as	O
bone	O
deformity	O
and	O
dysfunction	O
.	O

This	O
report	O
is	O
about	O
a	O
14-	O
year-old	O
male	O
with	O
ameloblastoma	O
treated	O
with	O
autologous	O
dental	O
pulp	O
stem	O
cells	O
(	O
DPSCs	O
)	O
and	O
stromal	O
vascular	O
fraction	O
(	O
SVF	O
)	O
and	O
evidence	O
of	O
bone	O
regeneration	O
.	O

Marsupialization	O
was	O
performed	O
;	O
tooth	O
was	O
extracted	O
and	O
sent	O
for	O
DPSC	O
cultivation	O
.	O

On	O
the	O
day	O
of	O
surgery	O
,	O
SVF	O
was	O
processed	O
from	O
buccal	O
pad	O
of	O
fat	O
,	O
and	O
platelet-rich	O
fibrin	O
(	O
PRF	O
)	O
was	O
prepared	O
from	O
patient	O
's	O
peripheral	O
blood	O
.	O

During	O
the	O
procedure	O
,	O
labial	O
plate	O
resection	O
and	O
curating	O
of	O
tumor	O
lining	O
were	O
done	O
.	O

After	O
which	O
,	O
a	O
mesh	O
packed	O
with	O
SyboGraft	O
T-plug	O
,	O
prepared	O
SVF	O
,	O
DPSCs	O
,	O
and	O
PRF	O
were	O
placed	O
over	O
lingual	O
cortex	O
and	O
pressure	O
dressing	O
was	O
done	O
.	O

After	O
the	O
1	O
(	O
st	O
)	O
month	O
of	O
surgery	O
the	O
postoperative	O
course	O
was	O
uneventful	O
,	O
the	O
wound	O
shrinkage	O
led	O
to	O
exposure	O
of	O
mesh	O
in	O
the	O
intraoral	O
region	O
.	O

Removal	O
of	O
exposed	O
mesh	O
was	O
done	O
.	O

The	O
correction	O
surgery	O
with	O
removal	O
of	O
part	O
of	O
mesh	O
and	O
primary	O
closure	O
was	O
achieved	O
with	O
SyboGraft	O
plug	O
,	O
SVF	O
and	O
PRF	O
.	O

Enhanced	O
bone	O
formation	O
was	O
seen	O
in	O
post-operative	O
OPG	B-P
and	O
CT	B-P
Scan	I-P
after	O
10	O
(	O
th	O
)	O
month	O
.	O

In	O
this	O
article	O
,	O
we	O
propose	O
an	O
innovative	O
approach	O
to	O
manage	O
these	O
cases	O
by	O
using	O
a	O
combination	O
of	O
autologous	O
DPSC	O
and	O
buccal	O
pad	O
of	O
fat	O
SVF	O
to	O
regenerate	O
a	O
mandibular	O
defect	O
left	O
by	O
the	O
resection	O
of	O
an	O
ameloblastoma	O
with	O
1.5	O
year	O
follow-up	O
.	O

We	O
were	O
able	O
to	O
demonstrate	O
bone	O
regeneration	O
using	O
this	O
technique	O
with	O
no	O
recurrence	O
of	O
tumor	O
.	O

Validity	O
and	O
reliability	O
of	O
fluoroscopy	B-P
for	O
digital	B-P
radiography	I-P
:	O
a	O
new	O
way	O
to	O
evaluate	O
diaphragmatic	O
mobility	O
.	O

Fluoroscopy	B-P
is	O
considered	O
the	O
most	O
accurate	O
method	O
to	O
evaluate	O
the	O
diaphragm	O
,	O
yet	O
most	O
existing	O
methods	O
for	O
measuring	O
diaphragmatic	O
mobility	O
using	O
fluoroscopy	B-P
are	O
complex	O
.	O

To	O
assess	O
the	O
validity	O
and	O
reliability	O
of	O
a	O
new	O
evaluation	O
method	O
of	O
diaphragmatic	O
motion	O
using	O
fluoroscopy	B-P
by	O
digital	B-P
radiography	I-P
of	O
healthy	O
adults	O
.	O

Twenty-six	O
adults	O
were	O
evaluated	O
,	O
according	O
to	O
the	O
parameters	O
:	O
anthropometry	O
and	O
pulmonary	B-P
function	I-P
test	I-P
.	O

The	O
evaluation	O
of	O
diaphragm	O
mobility	O
by	O
means	O
of	O
fluoroscopy	B-P
by	O
digital	B-P
radiography	I-P
method	O
was	O
randomly	O
conducted	O
by	O
two	O
raters	O
(	O
A	O
and	O
B	O
)	O
.	O

The	O
Pearson	O
correlation	O
coefficient	O
and	O
the	O
intraclass	O
correlation	O
coefficient	O
(	O
ICC	O
)	O
were	O
used	O
to	O
assess	O
the	O
concurrent	O
validity	O
.	O

The	O
inter-rater	O
and	O
intra-rater	O
reliability	O
of	O
the	O
measurement	O
of	O
diaphragmatic	O
motion	O
was	O
determined	O
using	O
ICC	O
and	O
a	O
confidence	O
interval	O
of	O
95	O
%	O
.	O

There	O
was	O
a	O
relationship	O
in	O
the	O
assessment	O
of	O
the	O
concurrent	O
validity	O
.	O

There	O
was	O
good	O
inter-rater	O
reliability	O
for	O
right	O
hemidiaphragm	O
mobility	O
and	O
moderate	O
reliability	O
for	O
left	O
hemidiaphragm	O
in	O
the	O
first	O
assessment	O
.	O

In	O
the	O
second	O
assessment	O
,	O
there	O
was	O
good	O
reliability	O
for	O
the	O
mobility	O
of	O
both	O
hemidiaphragms	O
.	O

There	O
was	O
good	O
intra-rater	O
reliability	O
in	O
the	O
mobility	O
of	O
both	O
hemidiaphragms	O
for	O
raters	O
A	O
and	O
B	O
.	O

The	O
evaluation	O
of	O
diaphragmatic	O
motion	O
using	O
fluoroscopy	B-P
by	O
digital	B-P
radiography	I-P
proved	O
to	O
be	O
a	O
valid	O
and	O
reliable	O
method	O
of	O
healthy	O
adults	O
.	O

Interleukin-15	O
as	O
a	O
potential	O
new	O
target	O
in	O
Sjögren	O
's	O
syndrome	O
-	O
associated	O
inflammation	O
.	O

IL-15	O
is	O
a	O
key	O
regulatory	O
cytokine	O
that	O
shares	O
many	O
biological	O
properties	O
with	O
IL-2	O
.	O

Recently	O
,	O
it	O
has	O
been	O
shown	O
that	O
IL-15	O
could	O
be	O
up-regulated	O
in	O
T	O
cell	O
-mediated	O
inflammatory	O
disorders	O
,	O
such	O
as	O
rheumatoid	O
arthritis	O
and	O
inflammatory	O
bowel	O
diseases	O
.	O

However	O
,	O
the	O
role	O
and	O
expression	O
of	O
IL-15	O
in	O
the	O
inflammatory	O
autoimmune	O
disease	O
Sjögren	O
's	O
syndrome	O
(	O
SS	O
)	O
has	O
not	O
been	O
investigated	O
.	O

In	O
the	O
present	O
study	O
we	O
evaluated	O
the	O
expression	O
of	O
IL-15	O
mRNA	O
and	O
protein	O
in	O
minor	O
salivary	O
gland	O
(	O
MSG	O
)	O
biopsy	O
specimens	O
and	O
in	O
human	O
salivary	O
gland	O
epithelial	O
cell	O
(	O
SGEC	O
)	O
cultures	B-P
obtained	O
from	O
patients	O
with	O
primary	O
SS	O
(	O
pSS	O
)	O
and	O
compared	O
their	O
expression	O
with	O
that	O
seen	O
in	O
normal	O
healthy	O
control	O
subjects	O
.	O

IL-15	O
gene	O
and	O
protein	O
analysis	O
revealed	O
that	O
SGEC	O
are	O
able	O
to	O
produce	O
IL-15	O
.	O

Results	O
obtained	O
demonstrated	O
that	O
the	O
number	O
of	O
IL-15	O
(	O
+	O
)	O
cultured	O
SGEC	O
was	O
significantly	O
higher	O
in	O
cells	O
derived	O
from	O
patients	O
with	O
pSS	O
in	O
comparison	O
with	O
SGEC	O
from	O
healthy	O
subjects	O
;	O
similar	O
results	O
were	O
obtained	O
for	O
IL-15	O
immunoreactivity	O
by	O
using	O
immunohistochemistry	B-P
that	O
revealed	O
a	O
strong	O
expression	O
both	O
in	O
acinar	O
and	O
in	O
ductal	O
cells	O
from	O
pSS	O
MSG	O
.	O

These	O
studies	O
could	O
provide	O
a	O
rational	O
basis	O
to	O
determine	O
whether	O
IL-15	O
could	O
be	O
a	O
good	O
candidate	O
for	O
anti-cytokine	O
therapy	O
in	O
chronic	O
inflammatory	O
pSS	O
diseases	O
.	O

The	O
value	O
of	O
transesophageal	B-P
echocardiography	I-P
for	O
embolic	O
strokes	O
of	O
undetermined	O
source	O
.	O

Our	O
aim	O
was	O
to	O
evaluate	O
the	O
diagnostic	B-P
yield	I-P
of	O
transesophageal	B-P
echocardiography	I-P
(	O
TEE	B-P
)	O
in	O
consecutive	O
patients	O
with	O
ischemic	O
stroke	O
(	O
IS	O
)	O
fulfilling	O
the	O
diagnostic	O
criteria	O
of	O
embolic	O
strokes	O
of	O
undetermined	O
source	O
(	O
ESUS	O
)	O
.	O

We	O
prospectively	O
evaluated	O
consecutive	O
patients	O
with	O
acute	O
IS	O
satisfying	O
ESUS	O
criteria	O
who	O
underwent	O
in-	O
hospital	O
TEE	B-P
examination	I-P
in	O
3	O
tertiary	O
care	O
stroke	O
centers	O
during	O
a	O
12-month	O
period	O
.	O

We	O
also	O
performed	O
a	O
systematic	O
review	O
and	O
meta-analysis	O
estimating	O
the	O
cumulative	O
effect	O
of	O
TEE	B-P
findings	O
on	O
therapeutic	O
management	O
for	O
secondary	O
stroke	O
prevention	O
among	O
different	O
IS	O
subgroups	O
.	O

We	O
identified	O
61	O
patients	O
with	O
ESUS	O
who	O
underwent	O
investigation	O
with	O
TEE	B-P
(	O
mean	O
age	O
44	O
±	O
12	O
years	O
,	O
49	O
%	O
men	O
,	O
median	O
NIH	O
Stroke	O
Scale	O
score	O
=	O
5	O
points	O
[	O
interquartile	O
range	O
:	O
3-8	O
]	O
)	O
.	O

TEE	B-P
revealed	O
additional	O
findings	O
in	O
52	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
40	O
%	O
-65	O
%	O
)	O
of	O
the	O
study	O
population	O
.	O

TEE	B-P
findings	O
changed	O
management	O
(	O
initiation	O
of	O
anticoagulation	O
therapy	O
,	O
administration	O
of	O
IV	O
antibiotic	O
therapy	O
,	O
and	O
patent	O
foramen	O
ovale	O
closure	O
)	O
in	O
10	O
(	O
16	O
%	O
[	O
95	O
%	O
CI	O
:	O
9	O
%	O
-28	O
%	O
]	O
)	O
patients	O
.	O

The	O
pooled	O
rate	O
of	O
reported	O
anticoagulation	O
therapy	O
attributed	O
to	O
abnormal	O
TEE	B-P
findings	O
among	O
3,562	O
acute	O
IS	O
patients	O
included	O
in	O
the	O
meta-analysis	O
(	O
12	O
studies	O
)	O
was	O
8.7	O
%	O
(	O
95	O
%	O
CI	O
:	O
7.3	O
%	O
-10.4	O
%	O
)	O
.	O

In	O
subgroup	O
analysis	O
,	O
the	O
rates	O
of	O
initiation	O
of	O
anticoagulation	O
therapy	O
on	O
the	O
basis	O
of	O
TEE	B-P
investigation	O
did	O
not	O
differ	O
(	O
p	O
=	O
0.315	O
)	O
among	O
patients	O
with	O
cryptogenic	O
stroke	O
(	O
6.9	O
%	O
[	O
95	O
%	O
CI	O
:	O
4.9	O
%	O
-9.6	O
%	O
]	O
)	O
,	O
ESUS	O
(	O
8.1	O
%	O
[	O
95	O
%	O
CI	O
:	O
3.4	O
%	O
-18.1	O
%	O
]	O
)	O
,	O
and	O
IS	O
(	O
9.4	O
%	O
[	O
95	O
%	O
CI	O
:	O
7.5	O
%	O
-11.8	O
%	O
]	O
)	O
.	O

Abnormal	O
TEE	B-P
findings	O
may	O
decisively	O
affect	O
the	O
selection	O
of	O
appropriate	O
therapeutic	O
strategy	O
in	O
approximately	O
1	O
of	O
7	O
patients	O
with	O
ESUS	O
.	O

Differences	O
in	O
pain	O
experience	O
and	O
cooperation	O
between	O
consecutive	O
surgeries	O
in	O
patients	O
undergoing	O
phacoemulsification	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
compare	O
pain	O
experience	O
and	O
cooperation	O
between	O
consecutive	O
surgeries	O
in	O
patients	O
undergoing	O
phacoemulsification	O
in	O
both	O
eyes	O
,	O
using	O
sub-Tenon	O
's	O
local	O
anesthesia	O
without	O
sedation	O
.	O

In	O
this	O
study	O
,	O
268	O
patients	O
with	O
bilateral	O
senile	O
cataracts	O
were	O
recruited	O
.	O

All	O
operations	O
were	O
performed	O
without	O
sedation	O
,	O
using	O
a	O
clear	O
corneal	O
phacoemulsification	O
technique	O
and	O
sub-Tenon	O
's	O
local	O
anesthesia	O
,	O
by	O
one	O
of	O
four	O
surgeons	O
.	O

The	O
first	O
surgery	O
was	O
performed	O
on	O
the	O
eye	O
with	O
the	O
higher	O
grade	O
cataract	O
.	O

The	O
other	O
eye	O
was	O
operated	O
on	O
within	O
3	O
months	O
by	O
the	O
same	O
surgeon	O
(	O
mean	O
interval	O
1.9	O
±	O
1.1	O
months	O
)	O
.	O

All	O
patients	O
were	O
asked	O
to	O
grade	O
their	O
pain	O
experience	O
during	O
induction	O
and	O
maintenance	O
of	O
anesthesia	O
and	O
also	O
during	O
the	O
phacoemulsification	O
surgery	O
,	O
using	O
a	O
visual	B-P
analogue	I-P
scale	I-P
(	O
VAS	B-P
)	O
from	O
0	O
(	O
no	O
pain	O
)	O
to	O
10	O
(	O
unbearable	O
pain	O
)	O
administered	O
after	O
the	O
surgery	O
.	O

The	O
cooperation	O
of	O
the	O
patient	O
was	O
graded	O
from	O
0	O
(	O
no	O
event	O
)	O
to	O
3	O
(	O
markedeye	O
and	O
head	O
movement	O
and	O
lid	O
squeezing	O
)	O
by	O
the	O
attending	O
surgeon	O
.	O

The	O
VAS	O
scores	O
and	O
cooperation	O
scores	O
of	O
the	O
patients	O
were	O
the	O
outcome	O
measurements	O
.	O

The	O
mean	O
pain	O
score	O
was	O
2.11	O
±	O
0.79	O
in	O
the	O
first	O
eye	O
and	O
3.33	O
±	O
0.80	O
in	O
the	O
second	O
eye	O
during	O
the	O
administration	O
of	O
sub-Tenon	O
's	O
anesthesia	O
,	O
and	O
1.50	O
±	O
0.60	O
in	O
the	O
first	O
eye	O
and	O
2.10	O
±	O
0.57	O
in	O
the	O
second	O
eye	O
during	O
the	O
phacoemulsification	O
surgery	O
.	O

The	O
patient	O
cooperation	O
score	O
was	O
1.60	O
±	O
0.75	O
in	O
the	O
first	O
surgery	O
and	O
2.08	O
±	O
0.72	O
in	O
the	O
second	O
surgery	O
.	O

The	O
differences	O
between	O
the	O
first	O
and	O
second	O
surgeries	O
were	O
statistically	O
significant	O
for	O
all	O
outcome	O
measures	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Patients	O
who	O
previously	O
underwent	O
phaco	O
surgery	O
in	O
one	O
eye	O
experienced	O
more	O
pain	O
and	O
showed	O
worse	O
cooperation	O
during	O
the	O
phaco	O
surgery	O
in	O
the	O
second	O
eye	O
,	O
especially	O
if	O
there	O
was	O
a	O
short	O
time	O
between	O
the	O
surgeries	O
,	O
viz.	O
,	O
less	O
than	O
3	O
months	O
.	O

Therefore	O
,	O
if	O
the	O
surgeon	O
has	O
difficulty	O
in	O
the	O
first	O
operation	O
gaining	O
the	O
patient	O
's	O
cooperation	O
,	O
the	O
surgeon	O
must	O
be	O
careful	O
:	O
if	O
contralateral	O
eye	O
surgery	O
is	O
required	O
,	O
the	O
addition	O
of	O
sedation	O
/	O
analgesia	O
should	O
be	O
considered	O
or	O
the	O
surgery	O
postponed	O
for	O
a	O
while	O
to	O
abolish	O
the	O
influence	O
of	O
recent	O
memory	O
on	O
the	O
patient	O
's	O
subsequent	O
pain	O
experience	O
.	O

Sleep	O
architecture	O
in	O
Pierre-Robin	O
sequence	O
:	O
The	O
effect	O
of	O
mandibular	O
distraction	O
osteogenesis	O
.	O

Pierre-Robin	O
Sequence	O
(	O
PRS	O
)	O
,	O
a	O
triad	O
of	O
micro	O
/	O
retrognathia	O
,	O
glossoptosis	O
,	O
and	O
upper	O
airway	O
obstruction	O
,	O
usually	O
in	O
conjunction	O
with	O
a	O
cleft	O
palate	O
is	O
frequently	O
associated	O
with	O
significant	O
morbidity	O
.	O

Mandibular	O
distraction	O
osteogenesis	O
(	O
MDO	O
)	O
is	O
an	O
effective	O
treatment	O
modality	O
to	O
address	O
retroglossal	O
upper	O
airway	O
obstruction	O
by	O
increasing	O
the	O
anterior-posterior	O
diameter	O
of	O
the	O
infant	O
airway	O
.	O

Although	O
MDO	O
has	O
been	O
shown	O
to	O
improve	O
the	O
apnea-hypopnea	O
index	O
(	O
AHI	O
)	O
in	O
children	O
with	O
PRS	O
,	O
the	O
consequences	O
of	O
MDO	O
on	O
other	O
aspects	O
of	O
infant	O
sleep	O
,	O
including	O
hypercapnea	O
,	O
hypoxia	O
,	O
the	O
REM	O
to	O
Non-REM	O
ratio	O
,	O
as	O
well	O
as	O
its	O
effect	O
on	O
central	O
and	O
mixed	O
apneas	O
has	O
not	O
been	O
investigated	O
with	O
an	O
adequate	O
sample	O
size	O
.	O

To	O
characterize	O
the	O
effect	O
of	O
MDO	O
on	O
key	O
components	O
of	O
sleep	O
architecture	O
in	O
infants	O
with	O
PRS	O
.	O

Charts	O
from	O
32	O
infants	O
with	O
PRS	O
that	O
were	O
addressed	O
with	O
MDO	O
at	O
our	O
tertiary-care	O
children	O
's	O
hospital	O
were	O
retrospectively	O
reviewed	O
.	O

Of	O
these	O
,	O
26	O
infants	O
(	O
57.7	O
%	O
male	O
;	O
mean	O
age	O
=	O
4.1	O
weeks	O
,	O
SD	O
=	O
5.0	O
)	O
had	O
pre-	O
and	O
post-operative	O
polysomnograms	B-P
(	O
PSG	B-P
)	O
.	O

Paired	O
samples	O
t-tests	O
were	O
used	O
to	O
compare	O
pre-	O
and	O
post	O
-	O
MDO	O
sleep	O
architecture	O
mean	O
score	O
differences	O
.	O

Among	O
the	O
26	O
infants	O
,	O
73.1	O
%	O
demonstrated	O
severe	O
pre	O
-	O
MDO	O
sleep	O
apnea	O
(	O
AHI	O
>	O
10	O
)	O
.	O

Several	O
aspects	O
of	O
sleep	O
architecture	O
were	O
found	O
to	O
improve	O
post-operatively	O
.	O

Significant	O
improvements	O
were	O
found	O
in	O
AHI	O
(	O
30.3	O
vs.	O
8.7	O
;	O
t	O
=	O
4.1	O
,	O
p	O
<	O
0.001	O
)	O
,	O
obstructive	O
apneas	O
(	O
79.3	O
vs.	O
5.8	O
;	O
t	O
=	O
4.0	O
,	O
p	O
<	O
0.001	O
)	O
,	O
hypopneas	O
(	O
48.1	O
vs.	O
22.1	O
;	O
t	O
=	O
2.2	O
,	O
p	O
=	O
0.040	O
)	O
,	O
time	O
spent	O
below	O
90	O
%	O
SpO2	B-P
(	O
3.9	O
%	O
vs.	O
0.7	O
%	O
;	O
t	O
=	O
3.3	O
,	O
p	O
=	O
0.003	O
)	O
,	O
and	O
lowest	O
SpO2	B-P
nadir	O
(	O
75.4	O
%	O
vs.	O
82.9	O
%	O
;	O
3.4	O
,	O
p	O
=	O
0.002	O
)	O
.	O

In	O
addition	O
,	O
a	O
marginally	O
significant	O
improvement	O
was	O
found	O
for	O
mixed	O
apnea	O
(	O
6.3	O
vs.	O
1.6	O
;	O
t	O
=	O
1.99	O
,	O
p	O
=	O
0.058	O
)	O
.	O

MDO	O
improve	O
s	O
several	O
sleep	O
architecture	O
parameters	O
in	O
this	O
sample	O
of	O
infants	O
with	O
PRS	O
.	O

Statistically	O
significant	O
improvement	O
was	O
seen	O
in	O
obstructive	O
apneas	O
,	O
hypopneas	O
,	O
AHI	O
,	O
obstructive	O
AHI	O
,	O
and	O
several	O
indicators	O
of	O
hypoxia	O
during	O
sleep	O
.	O

Spectral	B-P
fingerprints	I-P
of	O
large-scale	O
cortical	O
dynamics	O
during	O
ambiguous	O
motion	O
perception	O
.	O

Ambiguous	O
stimuli	O
have	O
been	O
widely	O
used	O
to	O
study	O
the	O
neuronal	O
correlates	O
of	O
consciousness	O
.	O

Recently	O
,	O
it	O
has	O
been	O
suggested	O
that	O
conscious	O
perception	O
might	O
arise	O
from	O
the	O
dynamic	O
interplay	O
of	O
functionally	O
specialized	O
but	O
widely	O
distributed	O
cortical	O
areas	O
.	O

While	O
previous	O
research	O
mainly	O
focused	O
on	O
phase	O
coupling	O
as	O
a	O
correlate	O
of	O
cortical	O
communication	O
,	O
more	O
recent	O
findings	O
indicated	O
that	O
additional	O
coupling	O
modes	O
might	O
coexist	O
and	O
possibly	O
subserve	O
distinct	O
cortical	O
functions	O
.	O

Here	O
,	O
we	O
studied	O
two	O
coupling	O
modes	O
,	O
namely	O
phase	O
and	O
envelope	O
coupling	O
,	O
which	O
might	O
differ	O
in	O
their	O
origins	O
,	O
putative	O
functions	O
and	O
dynamics	O
.	O

Therefore	O
,	O
we	O
recorded	O
128-channel	O
EEG	B-P
while	O
participants	O
performed	O
a	O
bistable	B-P
motion	I-P
task	I-P
and	O
utilized	O
state-of-the-art	O
source-space	O
connectivity	O
analysis	O
techniques	O
to	O
study	O
the	O
functional	O
relevance	O
of	O
different	O
coupling	O
modes	O
for	O
cortical	O
communication	O
.	O

Our	O
results	O
indicate	O
that	O
gamma-band	O
phase	O
coupling	O
in	O
extrastriate	O
visual	O
cortex	O
might	O
mediate	O
the	O
integration	O
of	O
visual	B-P
tokens	I-P
into	O
a	O
moving	O
stimulus	O
during	O
ambiguous	O
visual	B-P
stimulation	I-P
.	O

Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
long-range	O
fronto-occipital	O
gamma-band	O
envelope	O
coupling	O
sustains	O
the	O
horizontal	O
percept	O
during	O
ambiguous	O
motion	O
perception	O
.	O

Additionally	O
,	O
our	O
results	O
support	O
the	O
idea	O
that	O
local	O
parieto-occipital	O
alpha-band	O
phase	O
coupling	O
controls	O
the	O
inter-	O
hemispheric	O
information	O
transfer	O
.	O

These	O
findings	O
provide	O
correlative	O
evidence	O
for	O
the	O
notion	O
that	O
synchronized	O
oscillatory	O
brain	O
activity	O
reflects	O
the	O
processing	O
of	O
sensory	O
input	O
as	O
well	O
as	O
the	O
information	O
integration	O
across	O
several	O
spatiotemporal	O
scales	O
.	O

The	O
results	O
indicate	O
that	O
distinct	O
coupling	O
modes	O
are	O
involved	O
in	O
different	O
cortical	O
computations	O
and	O
that	O
the	O
rich	O
spatiotemporal	O
correlation	O
structure	O
of	O
the	O
brain	O
might	O
constitute	O
the	O
functional	O
architecture	O
for	O
cortical	O
processing	O
and	O
specific	O
multi-site	O
communication	O
.	O

Hum	O
Brain	O
Mapp	O
37:4099-4111	O
,	O
2016	O
.	O

©	O
2016	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

Mucosal	O
and	O
cutaneous	O
human	O
papillomaviruses	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
papillomas	O
.	O

Conflicting	O
data	O
exist	O
regarding	O
the	O
contribution	O
of	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
to	O
the	O
development	O
of	O
head	O
and	O
neck	O
squamous	O
cell	O
papillomas	O
.	O

Formalin-fixed	O
paraffin-embedded	O
papillomas	O
were	O
tested	O
for	O
28	O
mucosal	O
and	O
79	O
cutaneous	O
HPVs	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-based	O
methods	O
.	O

Eighty-three	O
papillomas	O
(	O
43	O
oropharyngeal	O
,	O
31	O
oral	O
,	O
6	O
laryngeal	O
,	O
and	O
3	O
nasopharyngeal	O
)	O
were	O
analyzed	O
.	O

Twenty-four	O
samples	O
(	O
28.9	O
%	O
)	O
harbored	O
mucosal	O
HPVs	O
:	O
3	O
oropharyngeal	O
(	O
6.9	O
%	O
)	O
,	O
15	O
oral	O
(	O
48.3	O
%	O
)	O
,	O
4	O
laryngeal	O
(	O
66.7	O
%	O
)	O
,	O
and	O
2	O
nasopharyngeal	O
papillomas	O
(	O
66.7	O
%	O
)	O
.	O

Eighty-one	O
cases	O
were	O
also	O
tested	O
for	O
cutaneous	O
HPVs	O
,	O
detected	O
in	O
16	O
lesions	O
(	O
19.7	O
%	O
)	O
:	O
11	O
(	O
13.5	O
%	O
)	O
harbored	O
only	O
cutaneous	O
types	O
,	O
and	O
5	O
(	O
6.2	O
%	O
)	O
were	O
positive	O
for	O
both	O
cutaneous	O
and	O
mucosal	O
HPVs	O
.	O

Among	O
these	O
81	O
cases	O
,	O
prevalence	O
of	O
mucosal	O
and/or	O
cutaneous	O
HPV	O
infection	O
was	O
43.2	O
%	O
.	O

HPV	B-P
DNA	I-P
detection	I-P
in	O
a	O
fraction	O
of	O
head	O
and	O
neck	O
papillomas	O
supports	O
the	O
role	O
of	O
HPV	O
in	O
their	O
development	O
.	O

However	O
,	O
other	O
markers	O
need	O
to	O
be	O
considered	O
to	O
confirm	O
the	O
association	O
of	O
HPV	O
infection	O
with	O
these	O
lesions	O
.	O

©	O
2016	O
Wiley	O
Periodicals	O
,	O
Inc.	O
Head	O
Neck	O
39	O
:	O
254-259	O
,	O
2017	O
.	O

Genome-Wide	O
Detection	O
of	O
Selective	O
Signatures	O
in	O
Chicken	O
through	O
High	O
Density	O
SNPs	O
.	O

Chicken	O
is	O
recognized	O
as	O
an	O
excellent	O
model	O
for	O
studies	O
of	O
genetic	O
mechanism	O
of	O
phenotypic	O
and	O
genomic	O
evolution	O
,	O
with	O
large	O
effective	O
population	O
size	O
and	O
strong	O
human	O
-driven	O
selection	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
performed	O
Extended	O
Haplotype	O
Homozygosity	O
(	O
EHH	O
)	O
tests	O
to	O
identify	O
significant	O
core	O
regions	O
employing	O
600K	O
SNP	O
Chicken	O
chip	O
in	O
an	O
F2	O
population	O
of	O
1,534	O
hens	O
,	O
which	O
was	O
derived	O
from	O
reciprocal	O
crosses	O
between	O
White	O
Leghorn	O
and	O
Dongxiang	O
chicken	O
.	O

Results	O
indicated	O
that	O
a	O
total	O
of	O
49,151	O
core	O
regions	O
with	O
an	O
average	O
length	O
of	O
9.79	O
Kb	O
were	O
identified	O
,	O
which	O
occupied	O
approximately	O
52.15	O
%	O
of	O
genome	O
across	O
all	O
autosomes	O
,	O
and	O
806	O
significant	O
core	O
regions	O
attracted	O
us	O
mostly	O
.	O

Genes	O
in	O
candidate	O
regions	O
may	O
experience	O
positive	B-P
selection	I-P
and	O
were	O
considered	O
to	O
have	O
possible	O
influence	O
on	O
beneficial	O
economic	O
traits	O
.	O

A	O
panel	O
of	O
genes	O
including	O
AASDHPPT	O
,	O
GDPD5	O
,	O
PAR3	O
,	O
SOX6	O
,	O
GPC1	O
and	O
a	O
signal	O
pathway	O
of	O
AKT1	O
were	O
detected	O
with	O
the	O
most	O
extreme	O
P-values	O
.	O

Further	O
enrichment	O
analyses	O
indicated	O
that	O
these	O
genes	O
were	O
associated	O
with	O
immune	O
function	O
,	O
sensory	O
organ	O
development	O
and	O
neurogenesis	O
,	O
and	O
may	O
have	O
experienced	O
positive	B-P
selection	I-P
in	O
chicken	O
.	O

Moreover	O
,	O
some	O
of	O
core	O
regions	O
exactly	O
overlapped	O
with	O
genes	O
excavated	O
in	O
our	O
previous	O
GWAS	O
,	O
suggesting	O
that	O
these	O
genes	O
have	O
undergone	O
positive	B-P
selection	I-P
may	O
affect	O
egg	O
production	O
.	O

Findings	O
in	O
our	O
study	O
could	O
draw	O
a	O
comparatively	O
integrate	O
genome-wide	O
map	O
of	O
selection	O
signature	O
in	O
the	O
chicken	O
genome	O
,	O
and	O
would	O
be	O
worthy	O
for	O
explicating	O
the	O
genetic	O
mechanisms	O
of	O
phenotypic	O
diversity	O
in	O
poultry	O
breeding	O
.	O

Outcome	O
of	O
obese	O
and	O
diabetic	O
patients	O
underwent	O
laparoscopic	O
gastric	O
bypass	O
:	O
when	O
the	O
surgery	O
fails	O
.	O

The	O
beneficial	O
effects	O
of	O
bariatric	O
surgery	O
on	O
diabetes	O
and	O
obesity	O
have	O
been	O
widely	O
demonstrated	O
in	O
literature	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
the	O
rate	O
of	O
failure	O
of	O
laparoscopic	O
gastric	O
bypass	O
both	O
in	O
terms	O
of	O
weight	O
loss	O
and	O
metabolic	O
remission	O
after	O
one	O
follow-up	O
year	O
.	O

A	O
longitudinal	O
,	O
multicentric	O
prospective	O
study	O
was	O
carried	O
out	O
on	O
771	O
patients	O
affected	O
by	O
pathological	O
obesity	O
.	O

The	O
following	O
parameters	O
were	O
recorded	O
for	O
each	O
patient	O
before	B-P
surgery	I-P
:	O
anthropometric	O
,	O
metabolic	O
,	O
social	O
,	O
smoking	O
habits	O
and	O
previous	O
failure	O
of	O
other	O
bariatric	O
procedures	O
.	O

After	O
1	O
follow-up	O
year	O
,	O
final	O
weight	O
,	O
final	O
BMI	O
,	O
final	O
percentage	O
of	O
lost	O
excess	O
body	O
weight	O
and	O
percentage	O
of	O
lost	O
BMI	O
were	O
evaluated	O
.	O

Statistical	O
analysis	O
showed	O
a	O
correlation	O
between	O
BMI	O
>	O
50	O
Kg/m2	O
,	O
presence	O
of	O
metabolic	O
syndrome	O
,	O
presence	O
of	O
diabetes	O
,	O
gastric	O
pouch	O
volume	O
greater	O
than	O
60	O
ml	O
and	O
failure	O
of	O
weight	O
loss	O
outcome	O
.	O

Statistical	O
analysis	O
of	O
metabolic	O
failure	O
has	O
recognized	O
a	O
high	O
preoperative	O
HbA1c	O
%	O
value	O
as	O
a	O
statistically	O
significant	O
negative	O
predictive	O
factor	O
.	O

Bariatric	O
Surgery	O
is	O
the	O
most	O
effective	O
treatment	O
for	O
weight	O
loss	O
and	O
metabolic	O
improvement	O
.	O

However	O
,	O
in	O
our	O
study	O
,	O
surgery	O
did	O
not	O
achieve	O
the	O
expected	O
outcome	O
in	O
patients	O
with	O
specific	O
metabolic	O
,	O
anthropometric	O
and	O
surgical	O
characteristics	O
(	O
BMI	O
>	O
50	O
Kg/m2	O
,	O
presence	O
of	O
metabolic	O
syndrome	O
,	O
presence	O
of	O
T2DM	O
with	O
high	O
preoperative	O
HbA1c	O
%	O
level	O
and	O
gastric	O
pouch	O
volume	O
greater	O
than	O
60	O
ml	O
)	O
.	O

Characterization	O
of	O
electrocorticogram	B-P
high	O
-	O
gamma	O
signal	O
in	O
response	O
to	O
varying	O
upper	O
extremity	O
movement	O
velocity	O
.	O

The	O
mechanism	O
by	O
which	O
the	O
human	O
primary	O
motor	O
cortex	O
(	O
M1	O
)	O
encodes	O
upper	O
extremity	O
movement	O
kinematics	O
is	O
not	O
fully	O
understood	O
.	O

For	O
example	O
,	O
human	O
electrocorticogram	B-P
(	O
ECoG	B-P
)	O
signals	O
have	O
been	O
shown	O
to	O
modulate	O
with	O
upper	O
extremity	O
movement	O
s	O
;	O
however	O
,	O
this	O
relationship	O
has	O
not	O
been	O
explicitly	O
characterized	O
.	O

To	O
address	O
this	O
issue	O
,	O
we	O
recorded	O
high	O
-	O
density	O
ECoG	B-P
signals	O
from	O
patients	O
undergoing	O
epilepsy	O
surgery	O
evaluation	O
as	O
they	O
performed	O
elementary	O
upper	O
extremity	O
movements	O
while	O
systematically	O
varying	O
movement	O
speed	O
and	O
duration	O
.	O

Specifically	O
,	O
subjects	O
performed	O
intermittent	O
pincer	O
grasp	O
/	O
release	O
,	O
elbow	O
flexion	O
/	O
extension	O
,	O
and	O
shoulder	O
flexion	O
/	O
extension	O
at	O
slow	O
,	O
moderate	O
,	O
and	O
fast	O
speeds	O
.	O

In	O
all	O
movements	O
,	O
bursts	O
of	O
power	O
in	O
the	O
high	O
-	O
[	O
Formula	O
:	O
see	O
text	O
]	O
band	O
(	O
80-160	O
Hz	O
)	O
were	O
observed	O
in	O
M1	O
.	O

In	O
addition	O
,	O
the	O
amplitude	O
of	O
these	O
power	O
bursts	O
and	O
the	O
area	O
of	O
M1	O
with	O
elevated	O
high	O
-	O
[	O
Formula	O
:	O
see	O
text	O
]	O
activity	O
were	O
directly	O
proportional	O
to	O
the	O
movement	O
speed	O
.	O

Likewise	O
,	O
the	O
duration	O
of	O
elevated	O
high	O
-	O
[	O
Formula	O
:	O
see	O
text	O
]	O
activity	O
increased	O
with	O
movement	O
duration	O
.	O

Based	O
on	O
linear	O
regression	O
,	O
M1	O
high	O
-	O
[	O
Formula	O
:	O
see	O
text	O
]	O
power	O
amplitude	O
and	O
duration	O
covaried	O
with	O
movement	O
speed	O
and	O
duration	O
,	O
respectively	O
,	O
with	O
an	O
average	O
[	O
Formula	O
:	O
see	O
text	O
]	O
of	O
[	O
Formula	O
:	O
see	O
text	O
]	O
and	O
[	O
Formula	O
:	O
see	O
text	O
]	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
encoding	O
of	O
upper	O
extremity	O
movement	O
speed	O
by	O
M1	O
high	O
-	O
[	O
Formula	O
:	O
see	O
text	O
]	O
activity	O
is	O
primarily	O
linear	O
.	O

Also	O
,	O
the	O
fact	O
that	O
this	O
activity	O
remained	O
elevated	O
throughout	O
a	O
movement	O
suggests	O
that	O
M1	O
does	O
not	O
merely	O
generate	O
transient	O
instructions	O
for	O
a	O
specific	O
movement	O
duration	O
,	O
but	O
instead	O
is	O
responsible	O
for	O
the	O
entirety	O
of	O
the	O
movement	O
.	O

Finally	O
,	O
the	O
spatial	O
distribution	O
of	O
high	O
-	O
[	O
Formula	O
:	O
see	O
text	O
]	O
activity	O
suggests	O
the	O
presence	O
of	O
a	O
recruitment	O
phenomenon	O
in	O
which	O
higher	O
speeds	O
or	O
increased	O
muscle	O
activity	O
involve	O
activation	O
of	O
larger	O
M1	O
area	O
s	O
.	O

A	O
Concurrent	O
Case	O
of	O
Ménétrier	O
's	O
Disease	O
and	O
Signet	O
Ring	O
Carcinoma	O
.	O

Ménétrier	O
's	O
disease	O
,	O
also	O
known	O
as	O
hyperplastic	O
protein-losing	O
gastropathy	O
,	O
is	O
a	O
rare	O
,	O
idiopathic	O
,	O
acquired	O
,	O
premalignant	O
condition	O
associated	O
with	O
gastric	O
carcinoma	O
.	O

Its	O
association	O
with	O
signet	O
ring	O
cell	O
cancer	O
of	O
the	O
stomach	O
has	O
been	O
previously	O
reported	O
only	O
twice	O
.	O

We	O
present	O
the	O
third	O
case	O
of	O
histologically	O
confirmed	O
concurrent	O
Ménétrier	O
's	O
disease	O
with	O
signet	O
ring	O
carcinoma	O
of	O
the	O
stomach	O
,	O
interrogated	O
by	O
esophagogastroduodenoscopy	B-P
and	O
endoscopic	B-P
ultrasound	I-P
.	O

Analyzing	O
Endosomal	O
Docking	O
,	O
Fusion	O
,	O
Sorting	O
,	O
and	O
Budding	O
Mechanisms	O
in	O
Isolated	O
Organelles	O
.	O

Due	O
to	O
their	O
central	O
role	O
in	O
the	O
reception	O
and	O
sorting	O
of	O
newly	O
internalized	O
material	O
,	O
early	O
endosomes	O
undergo	O
extensive	O
membrane	O
remodeling	O
.	O

They	O
dock	O
and	O
fuse	O
with	O
endocytic	O
carrier	O
vesicles	O
originating	O
from	O
the	O
plasma	O
membrane	O
,	O
sort	O
the	O
internalized	O
material	O
in	O
internal	O
microdomains	O
,	O
and	O
allow	O
the	O
budding	O
of	O
new	O
carrier	O
vesicles	O
from	O
their	O
membrane	O
,	O
destined	O
to	O
fuse	O
with	O
the	O
plasma	O
membrane	O
(	O
recycling	O
)	O
or	O
other	O
organelles	O
.	O

Early	O
endosomal	O
compartments	O
might	O
also	O
be	O
involved	O
in	O
the	O
recycling	O
of	O
synaptic	O
vesicles	O
in	O
nerve	O
terminals	O
.	O

The	O
present	O
protocol	O
describes	O
a	O
technique	O
allowing	O
to	O
assess	O
the	O
mechanistic	O
and	O
molecular	O
aspects	O
of	O
the	O
membrane	O
remodeling	O
processes	O
of	O
docking	O
,	O
fusion	O
,	O
sorting	O
,	O
and	O
budding	O
in	O
early	O
endosomes	O
of	O
neuron	O
-like	O
(	O
and	O
other	O
)	O
cells	O
.	O

It	O
involves	O
the	O
fluorescent	B-P
labeling	I-P
and	O
isolation	O
of	O
endosomal	O
organelles	O
,	O
the	O
setup	O
of	O
assays	B-P
allowing	O
for	O
docking	O
/	O
fusion	O
or	O
sorting	O
/	O
budding	O
in	O
vitro	O
,	O
and	O
finally	O
the	O
assessment	O
and	O
quantification	O
of	O
the	O
membrane	O
remodeling	O
events	O
by	O
fluorescent	B-P
microscopy	I-P
.	O

The	O
technique	O
can	O
be	O
easily	O
manipulated	O
by	O
the	O
addition	O
of	O
inhibitors	O
or	O
activators	O
,	O
and	O
can	O
be	O
combined	O
with	O
other	O
techniques	O
,	O
such	O
as	O
immunostaining	B-P
and	O
high-resolution	B-P
microscopy	I-P
,	O
expanding	O
the	O
experimental	O
possibilities	O
in	O
the	O
investigation	O
of	O
early	O
endosomal	O
characteristics	O
.	O

Function	O
of	O
terahertz	B-P
spectra	I-P
in	O
monitoring	O
the	O
decomposing	O
process	O
of	O
biological	O
macromolecules	O
and	O
in	O
investigating	O
the	O
causes	O
of	O
photoinhibition	O
.	O

Chlorophyll	O
a	O
and	O
β-carotene	O
play	O
an	O
important	O
role	O
in	O
harvesting	O
light	O
energy	O
,	O
which	O
is	O
used	O
to	O
drive	O
photosynthesis	O
in	O
plants	O
.	O

In	O
this	O
study	O
,	O
terahertz	B-P
(	O
THz	B-P
)	O
and	O
visible	B-P
range	I-P
spectra	I-P
of	O
chlorophyll	O
a	O
and	O
β-carotene	O
and	O
their	O
changes	O
under	O
light	O
treatment	O
were	O
investigated	O
.	O

The	O
results	O
show	O
that	O
the	O
all	O
THz	B-P
transmission	I-P
and	O
absorption	B-P
spectra	I-P
of	O
chlorophyll	O
a	O
and	O
β-carotene	O
changed	O
upon	O
light	O
treatment	O
,	O
with	O
the	O
maximum	O
changes	O
at	O
15	O
min	O
of	O
illumination	B-P
indicating	O
the	O
greatest	O
changes	O
of	O
the	O
collective	O
vibrational	O
mode	O
of	O
chlorophyll	O
a	O
and	O
β-carotene	O
.	O

The	O
absorption	B-P
spectra	I-P
of	O
chlorophyll	O
a	O
in	O
the	O
visible	O
light	O
region	O
decreased	O
upon	O
light	O
treatment	O
,	O
signifying	O
the	O
degradation	O
of	O
chlorophyll	O
a	O
molecules	O
.	O

It	O
can	O
be	O
inferred	O
from	O
these	O
results	O
that	O
the	O
THz	B-P
spectra	I-P
are	O
very	O
sensitive	O
in	O
monitoring	O
the	O
changes	O
of	O
the	O
collective	O
vibrational	O
mode	O
,	O
despite	O
the	O
absence	O
of	O
changes	O
in	O
molecular	O
configuration	O
.	O

The	O
THz	B-P
spectra	I-P
can	O
therefore	O
be	O
used	O
to	O
monitor	O
the	O
decomposing	O
process	O
of	O
biological	O
macromolecules	O
;	O
however	O
,	O
visible	B-P
absorption	I-P
spectra	I-P
can	O
only	O
be	O
used	O
to	O
monitor	O
the	O
breakdown	O
extent	O
of	O
biological	O
macromolecules	O
.	O

Influence	O
of	O
Surface	O
Properties	O
on	O
Adhesion	O
Forces	O
and	O
Attachment	O
of	O
Streptococcus	O
mutans	O
to	O
Zirconia	O
In	O
Vitro	O
.	O

Zirconia	O
is	O
becoming	O
a	O
prevalent	O
material	O
in	O
dentistry	O
.	O

However	O
,	O
any	O
foreign	O
bodies	O
inserted	O
may	O
provide	O
new	O
niches	O
for	O
the	O
bacteria	O
in	O
oral	O
cavity	O
.	O

The	O
object	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
effect	O
of	O
surface	O
properties	O
including	O
surface	O
roughness	O
and	O
hydrophobicity	O
on	O
the	O
adhesion	O
and	O
biofilm	O
formation	O
of	O
Streptococcus	O
mutans	O
(	O
S.	O
mutans	O
)	O
to	O
zirconia	O
.	O

Atomic	B-P
force	I-P
microscopy	I-P
was	O
employed	O
to	O
determine	O
the	O
zirconia	O
surface	O
morphology	O
and	O
the	O
adhesion	O
forces	O
between	O
the	O
S.	O
mutans	O
and	O
zirconia	O
.	O

The	O
results	O
showed	O
that	O
the	O
surface	O
roughness	O
was	O
nanoscale	O
and	O
significantly	O
different	O
among	O
tested	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
:	O
Coarse	O
(	O
23.94	O
±	O
2.52	O
nm	O
)	O
>	O
Medium	O
(	O
17.00	O
±	O
3.81	O
nm	O
)	O
>	O
Fine	O
(	O
11.89	O
±	O
1.68	O
nm	O
)	O
.	O

The	O
contact	O
angles	O
of	O
the	O
Coarse	O
group	O
were	O
the	O
highest	O
,	O
followed	O
by	O
the	O
Medium	O
and	O
the	O
Fine	O
groups	O
.	O

Increasing	O
the	O
surface	O
roughness	O
and	O
hydrophobicity	O
resulted	O
in	O
an	O
increase	O
of	O
adhesion	O
forces	O
and	O
early	O
attachment	O
(	O
2	O
h	O
and	O
4	O
h	O
)	O
of	O
S.	O
mutans	O
on	O
the	O
zirconia	O
but	O
no	O
influence	O
on	O
the	O
further	O
development	O
of	O
biofilm	O
(	O
6	O
h~24	O
h	O
)	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
surface	O
roughness	O
in	O
nanoscale	O
and	O
hydrophobicity	O
of	O
zirconia	O
had	O
influence	O
on	O
the	O
S.	O
mutans	O
initial	O
adhesion	O
force	O
and	O
early	O
attachment	O
instead	O
of	O
whole	O
stages	O
of	O
biofilm	O
formation	O
.	O

Photocatalytic	O
and	O
antibacterial	O
response	O
of	O
biosynthesized	O
gold	O
nanoparticles	O
.	O

Increase	O
in	O
the	O
bacterial	O
resistance	O
to	O
available	O
antibiotics	O
and	O
water	O
contamination	O
by	O
different	O
toxic	O
organic	O
dyes	O
are	O
both	O
severe	O
problems	O
throughout	O
the	O
world	O
.	O

To	O
overcome	O
these	O
concerns	O
,	O
new	O
methodologies	O
including	O
synthesis	O
of	O
nontoxic	O
,	O
human	O
friendly	O
and	O
efficient	O
nanoparticles	O
is	O
required	O
.	O

These	O
nanoparticles	O
not	O
even	O
inhibit	O
the	O
growth	O
of	O
microorganisms	O
but	O
are	O
also	O
effective	O
in	O
the	O
degradation	O
of	O
toxic	O
organics	O
in	O
waste	O
water	O
thus	O
providing	O
a	O
clean	O
and	O
human	O
friendly	O
environment	O
.	O

The	O
use	O
of	O
plants	O
extracts	O
to	O
synthesize	O
and	O
stabilize	O
noble	O
metal	O
nanoparticles	O
have	O
been	O
considered	O
as	O
safe	O
,	O
cost-effective	O
,	O
eco-benign	O
and	O
green	O
approach	O
nowadays	O
.	O

In	O
the	O
present	O
study	O
,	O
Longan	O
fruit	O
juice	O
proficiently	O
reduced	O
ionic	O
gold	O
(	O
Au	O
(	O
+3	O
)	O
)	O
to	O
gold	O
nanoparticles	O
(	O
AuNPs	O
)	O
as	O
well	O
as	O
mediated	O
the	O
stabilization	O
of	O
AuNPs	O
.	O

The	O
antibacterial	O
activity	O
of	O
AuNPs	O
was	O
carried	O
out	O
against	O
both	O
gram	O
positive	O
and	O
gram	O
negative	O
bacteria	O
using	O
agar	B-P
well	I-P
diffusion	I-P
method	I-P
,	O
followed	O
by	O
the	O
determination	O
of	O
Minimum	B-P
inhibitory	I-P
concentration	I-P
(	O
MIC	B-P
)	O
values	O
.	O

AuNPs	O
were	O
found	O
to	O
have	O
significant	O
antibacterial	O
activity	O
against	O
Escherichia	O
coli	O
with	O
MIC	B-P
values	O
of	O
75μg/ml	O
while	O
outstanding	O
MIC	B-P
values	O
of	O
50μg/ml	O
against	O
Staphylococcus	O
areous	O
and	O
Basilus	O
subtilus	O
.	O

AuNPs	O
revealed	O
significant	O
photocatalytic	O
degradation	O
(	O
76	O
%	O
)	O
of	O
methylene	O
blue	O
in	O
time	O
period	O
of	O
55	O
min	O
,	O
indicating	O
the	O
effective	O
photocatalytic	O
property	O
of	O
biosynthesized	O
AuNPs	O
(	O
K=0.29/min	O
,	O
r	O
(	O
2	O
)	O
=0.95	O
)	O
.	O

The	O
considerable	O
antibacterial	O
and	O
photocatalytic	O
activities	O
of	O
the	O
photosynthesized	O
AuNPs	O
can	O
be	O
attributed	O
towards	O
their	O
small	O
size	O
,	O
spherical	O
morphology	O
and	O
uniform	O
dispersion	O
.	O

Our	O
finding	O
suggests	O
the	O
possible	O
therapeutic	O
potential	O
of	O
biogenic	O
AuNPs	O
in	O
the	O
development	O
of	O
new	O
antibacterial	O
agents	O
as	O
well	O
as	O
in	O
the	O
development	O
of	O
effective	O
photocatalysts	O
.	O

Towards	O
next-generation	O
sequencing	O
analytics	O
for	O
foodborne	O
RNA	O
viruses	O
:	O
Examining	O
the	O
effect	O
of	O
RNA	O
input	O
quantity	O
and	O
viral	O
RNA	O
purity	O
.	O

Detection	B-P
and	O
identification	B-P
of	O
viruses	O
in	O
food	O
samples	O
are	O
technically	O
challenging	O
due	O
largely	O
to	O
the	O
low	O
viral	O
copy	O
number	O
in	O
contaminated	O
food	O
items	O
,	O
and	O
the	O
lack	O
of	O
effective	O
culture	B-P
enrichment	I-P
methods	I-P
that	O
are	O
amenable	O
to	O
regulatory	O
applications	O
for	O
many	O
of	O
the	O
common	O
foodborne	O
viruses	O
.	O

Using	O
an	O
Illumina	O
MiSeq	O
platform	O
and	O
two	O
hepatitis	O
A	O
virus	O
(	O
HAV	O
)	O
cell-culture	B-P
adapted	O
strains	O
as	O
a	O
representative	O
enteric	O
virus	O
species	O
,	O
this	O
study	O
examined	O
the	O
limits	O
of	O
single-stranded	O
RNA	O
(	O
ssRNA	O
)	O
viral	B-P
detection	I-P
following	O
next-generation	O
sequencing	O
without	O
pre-amplification	O
of	O
the	O
viral	O
genome	O
.	O

Complete	O
viral	O
genome	O
sequences	O
were	O
obtained	O
from	O
HAV	O
samples	O
of	O
varying	O
purities	O
and	O
with	O
an	O
input	O
as	O
low	O
as	O
2ng	O
total	O
RNA	O
containing	O
1.4×10	O
(	O
5	O
)	O
copies	O
of	O
viral	O
RNA	O
.	O

In	O
addition	O
,	O
single	O
nucleotide	O
variations	O
were	O
reproducibly	O
detected	O
over	O
the	O
range	O
of	O
concentrations	O
examined	O
,	O
and	O
their	O
identity	O
confirmed	O
by	O
alternate	O
sequencing	O
technology	O
.	O

In	O
summary	O
,	O
next-generation	O
sequencing	O
technology	O
has	O
the	O
potential	O
for	O
sensitive	O
detection	B-P
/	O
identification	B-P
of	O
a	O
viral	O
genome	O
at	O
a	O
low	O
copy	O
number	O
.	O

This	O
study	O
provides	O
a	O
benchmark	O
for	O
metagenomic	O
sequencing	O
application	O
as	O
is	O
required	O
for	O
virus	B-P
detection	I-P
in	O
complex	O
food	O
matrices	O
using	O
a	O
culture	B-P
-independent	O
diagnostic	B-P
approach	I-P
.	O

An	O
easy	O
to	O
produce	O
and	O
economical	O
three-dimensional	O
brain	O
phantom	O
for	O
stereotactic	B-P
computed	I-P
tomographic-guided	I-P
brain	I-P
biopsy	I-P
training	O
in	O
the	O
dog	O
.	O

To	O
develop	O
and	O
validate	O
a	O
three-dimensional	O
(	O
3D	O
)	O
brain	O
phantom	O
that	O
can	O
be	O
incorporated	O
into	O
existing	O
stereotactic	O
headframes	O
to	O
simulate	O
stereotactic	B-P
brain	I-P
biopsy	I-P
(	O
SBB	B-P
)	O
and	O
train	O
veterinary	O
surgeons	O
.	O

Experimental	O
study	O
.	O

Canine	O
brain	O
phantoms	O
were	O
fabricated	O
from	O
osteological	O
skull	O
specimens	O
,	O
agarose	O
brain	O
parenchyma	O
,	O
and	O
cheddar	O
and	O
mozzarella	O
cheese	O
molds	O
(	O
simulating	O
meningiomas	O
and	O
gliomas	O
)	O
.	O

The	O
neuroradiologic	O
and	O
viscoelastic	O
properties	O
of	O
phantoms	O
were	O
quantified	O
with	O
computed	B-P
tomography	I-P
(	O
CT	B-P
)	O
and	O
oscillatory	O
compression	O
tests	O
,	O
respectively	O
.	O

Phantoms	O
were	O
validated	O
by	O
experienced	O
and	O
novice	O
operators	O
performing	O
SBB	B-P
on	O
phantoms	O
containing	O
randomly	O
placed	O
,	O
focal	O
targets	O
.	O

Target	O
yield	O
and	O
needle	O
placement	O
error	O
(	O
NPE	O
)	O
were	O
compared	O
between	O
operators	O
.	O

Phantoms	O
were	O
produced	O
in	O
<	O
4	O
hours	O
,	O
at	O
an	O
average	O
cost	O
of	O
$	O
92	O
.	O

The	O
CT	B-P
appearances	O
of	O
the	O
phantom	O
skull	O
,	O
agarose	O
,	O
and	O
cheese	O
components	O
approximated	O
the	O
in	O
vivo	O
features	O
of	O
skull	O
,	O
brain	O
parenchyma	O
,	O
and	O
contrast-enhancing	B-P
tumors	O
of	O
meningeal	O
and	O
glial	O
origin	O
,	O
respectively	O
.	O

The	O
complex	O
moduli	O
of	O
the	O
agarose	O
and	O
cheeses	O
were	O
comparable	O
to	O
the	O
viscoelastic	O
properties	O
of	O
in	O
vivo	O
brain	O
tissues	O
and	O
brain	O
tumors	O
.	O

The	O
overall	O
diagnostic	O
yield	O
of	O
SBB	B-P
was	O
88	O
%	O
.	O

Although	O
NPE	O
did	O
not	O
differ	O
between	O
novice	O
(	O
median	O
3.68	O
mm	O
;	O
range	O
,	O
1.46-14.54	O
mm	O
)	O
and	O
experienced	O
surgeons	O
(	O
median	O
1.17	O
mm	O
,	O
range	O
,	O
0.78-1.58	O
mm	O
)	O
,	O
our	O
results	O
support	O
the	O
relevance	O
of	O
the	O
learning	O
curve	O
associated	O
with	O
the	O
SBB	B-P
procedure	I-P
.	O

This	O
3D	O
phantom	O
replicates	O
anatomical	O
,	O
CT	B-P
,	O
and	O
tactile	O
features	O
of	O
brain	O
tissues	O
and	O
tumors	O
and	O
can	O
be	O
used	O
to	O
develop	O
the	O
technical	O
skills	O
required	O
to	O
perform	O
SBB	B-P
.	O

Differential	B-P
proteomics	I-P
profiling	I-P
identifies	O
LDPs	O
and	O
biological	O
functions	O
in	O
high-fat	O
diet	O
-	O
induced	O
fatty	O
livers	O
.	O

Eukaryotic	O
cells	O
store	O
neutral	O
lipids	O
in	O
cytoplasmic	O
lipid	O
droplets	O
(	O
LDs	O
)	O
enclosed	O
in	O
a	O
monolayer	O
of	O
phospholipids	O
and	O
associated	O
proteins	O
[	O
LD	O
proteins	O
(	O
LDPs	O
)	O
]	O
.	O

Growing	O
evidence	O
has	O
demonstrated	O
that	O
LDPs	O
play	O
important	O
roles	O
in	O
the	O
pathogenesis	O
of	O
liver	O
diseases	O
.	O

However	O
,	O
the	O
composition	O
of	O
liver	O
LDPs	O
and	O
the	O
role	O
of	O
their	O
alterations	O
in	O
hepatosteatosis	O
are	O
not	O
well-understood	O
.	O

In	O
this	O
study	O
,	O
we	O
performed	O
liver	O
proteome	O
and	O
LD	O
sub-proteome	B-P
profiling	I-P
to	O
identify	O
enriched	O
proteins	O
in	O
LDs	O
as	O
LDPs	O
,	O
and	O
quantified	O
their	O
changes	O
in	O
a	O
high-fat	O
diet	O
(	O
HFD	O
)	O
-	O
induced	O
fatty	O
liver	O
model	O
.	O

Among	O
5,000	O
quantified	O
liver	O
proteins	O
,	O
101	O
were	O
enriched	O
by	O
greater	O
than	O
10-fold	O
in	O
the	O
LD	O
sub-proteome	O
and	O
were	O
classified	O
as	O
LDPs	O
.	O

Differential	B-P
profiling	I-P
of	O
LDPs	O
in	O
HFD	O
-	O
induced	O
fatty	O
liver	O
provided	O
a	O
list	O
of	O
candidate	O
LDPs	O
for	O
functional	O
investigation	O
.	O

We	O
tested	O
the	O
function	O
of	O
an	O
upregulated	O
LDP	O
,	O
S100a10	O
,	O
in	O
vivo	O
with	O
adenovirus	O
-mediated	O
gene	O
silencing	O
and	O
found	O
,	O
unexpectedly	O
,	O
that	O
knockdown	O
of	O
S100a10	O
accelerated	O
progression	O
of	O
HFD	O
-	O
induced	O
liver	O
steatosis	O
.	O

The	O
S100A10	O
interactome	O
revealed	O
a	O
connection	O
between	O
S100A10	O
and	O
lipid	O
transporting	O
proteins	O
,	O
suggesting	O
that	O
S100A10	O
regulates	O
the	O
development	O
and	O
formation	O
of	O
LDs	O
by	O
transporting	O
and	O
trafficking	O
.	O

This	O
study	O
identified	O
LD	O
-enriched	O
sub-proteome	O
in	O
homeostatic	O
as	O
well	O
as	O
HFD	O
-	O
induced	O
fatty	O
livers	O
,	O
providing	O
a	O
rich	O
resource	O
for	O
the	O
LDP	O
research	O
field	O
.	O

The	O
metastasis	O
suppressor	O
CD82/KAI1	O
inhibits	O
fibronectin	O
adhesion	O
-	O
induced	O
epithelial-to-mesenchymal	O
transition	O
in	O
prostate	O
cancer	O
cells	O
by	O
repressing	O
the	O
associated	O
integrin	O
signaling	O
.	O

The	O
transmembrane	O
protein	O
CD82/KAI1	O
suppresses	O
the	O
metastatic	O
potential	O
of	O
various	O
cancer	O
cell	O
types	O
.	O

Moreover	O
,	O
decrease	O
or	O
loss	O
of	O
CD82	O
expression	O
is	O
closely	O
associated	O
with	O
malignancy	O
and	O
poor	O
prognosis	O
in	O
many	O
human	O
cancers	O
including	O
prostate	O
cancer	O
.	O

Despite	O
intense	O
scrutiny	O
,	O
the	O
mechanisms	O
underlying	O
the	O
metastasis	O
-	O
suppressing	O
role	O
of	O
CD82	O
are	O
still	O
not	O
fully	O
understood	O
.	O

Here	O
,	O
we	O
found	O
that	O
a	O
fibronectin	O
matrix	O
induced	O
mesenchymal	O
phenotypes	O
in	O
human	O
prostate	O
cancer	O
cells	O
with	O
no	O
or	O
low	O
CD82	O
expression	O
levels	O
.	O

However	O
,	O
high	O
CD82	O
expression	O
rendered	O
prostate	O
cancer	O
cells	O
to	O
have	O
intensified	O
epithelial	O
characteristics	O
upon	O
fibronectin	O
engagement	O
,	O
along	O
with	O
decreased	O
cell	O
motility	O
and	O
invasiveness	O
.	O

The	O
CD82	O
function	O
of	O
inhibiting	O
fibronectin	O
-	O
induced	O
epithelial-to-mesenchymal	O
transition	O
(	O
EMT	O
)	O
was	O
dependent	O
not	O
only	O
on	O
CD82	O
interactions	O
with	O
fibronectin	O
-	O
binding	O
α3β1	O
/	O
α5β1	O
integrins	O
but	O
also	O
on	O
the	O
integrin-mediated	O
intracellular	O
signaling	O
events	O
.	O

Notably	O
,	O
CD82	O
attenuated	O
the	O
FAK-Src	O
and	O
ILK	O
pathways	O
downstream	O
of	O
the	O
fibronectin	O
-	O
receptor	O
integrins	O
.	O

Immunofluorescence	B-P
staining	B-P
of	O
human	O
prostate	O
cancer	O
tissue	O
specimens	O
illustrated	O
a	O
negative	O
association	O
of	O
CD82	O
with	O
EMT	O
-related	O
gene	O
expression	O
as	O
well	O
as	O
prostate	O
malignancy	O
.	O

Altogether	O
,	O
these	O
results	O
suggest	O
that	O
CD82	O
suppresses	O
EMT	O
in	O
prostate	O
cancer	O
cells	O
adhered	O
to	O
the	O
fibronectin	O
matrix	O
by	O
repressing	O
adhesion	O
signaling	O
through	O
lateral	O
interactions	O
with	O
the	O
associated	O
α3β1	O
and	O
α5β1	O
integrins	O
,	O
leading	O
to	O
reduced	O
cell	O
migration	O
and	O
invasive	O
capacities	O
.	O

Cloning	O
and	O
sequence	O
analysis	O
of	O
Wild	O
Argali	O
short	O
palate	O
,	O
lung	O
and	O
nasal	O
epithelium	O
clone	O
1	O
cDNA	O
.	O

Experiments	O
were	O
conducted	O
to	O
clone	O
the	O
sequence	O
of	O
Wild	O
Argali	O
short	O
palate	O
,	O
lung	O
and	O
nasal	O
epithelium	O
clone	O
1	O
(	O
SPLUNC1	O
)	O
cDNA	O
,	O
and	O
to	O
lay	O
the	O
foundation	O
for	O
further	O
study	O
the	O
biological	O
function	O
of	O
Wild	O
Argali	O
SPLUNC1	O
.	O

The	O
complete	O
sequence	O
of	O
Wild	O
Argali	O
SPLUNC1	O
cDNA	O
was	O
generated	O
by	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
.	O

The	O
entire	O
coding	O
sequence	O
was	O
inserted	O
into	O
the	O
pPIC9K	O
vector	O
and	O
expressed	O
in	O
Pichia	O
pastoris	O
(	O
P.	O
pastoris	O
)	O
GS115	O
.	O

The	O
recombinant	O
SPLUNC1	O
protein	O
was	O
detected	O
by	O
Western	B-P
blot	I-P
and	O
purified	O
by	O
Ni	B-P
(	I-P
2+	I-P
)	I-P
chelate	I-P
affinity	I-P
chromatography	I-P
.	O

The	O
test	O
of	O
effect	O
of	O
the	O
protein	O
on	O
Mycoplasma	O
ovipneumoniae	O
(	O
MO	O
)	O
was	O
performed	O
with	O
real-time	O
polymerase	O
chain	O
reaction	O
.	O

The	O
Wild	O
Argali	O
SPLUNC1	O
cDNA	O
was	O
1,076	O
bp	O
with	O
an	O
open	O
reading	O
frame	O
of	O
768	O
bp	O
,	O
which	O
encoded	O
a	O
26.49	O
kDa	O
protein	O
composed	O
of	O
255	O
amino	O
acids	O
.	O

Its	O
amino	O
acid	O
sequence	O
shared	O
98.4	O
%	O
,	O
96.9	O
%	O
,	O
94.5	O
%	O
,	O
90.2	O
%	O
,	O
80.8	O
%	O
,	O
78.4	O
%	O
,	O
78.3	O
%	O
,	O
72.5	O
%	O
,	O
72.3	O
%	O
,	O
68.8	O
%	O
identity	O
with	O
those	O
of	O
SPLUNC1	O
cDNA	O
from	O
Ovis	O
aries	O
(	O
accession	O
no	O
.	O

NP_001288334.1	O
)	O
,	O
Capra	O
hircus	O
(	O
accession	O
no	O
.	O

XP_005688516.1	O
)	O
,	O
Pantholops	O
hodgsonii	O
(	O
accession	O
no	O
.	O

XP_005979709.1	O
)	O
,	O
Bos	O
taurus	O
(	O
accession	O
no	O
.	O

NP_776851.1	O
)	O
,	O
Felis	O
catus	O
(	O
accession	O
no	O
.	O

XP_006929910.1	O
)	O
,	O
Homo	O
sapiens	O
(	O
accession	O
no	O
.	O

NP_001230122.1	O
)	O
,	O
Sus	O
scrofa	O
(	O
accession	O
no	O
.	O

NP_001005727.1	O
)	O
,	O
Chinchilla	O
lanigera	O
(	O
accession	O
no	O
.	O

NP_001269294.1	O
)	O
,	O
Mus	O
musculus	O
(	O
accession	O
no	O
.	O

NP_035256.2	O
)	O
,	O
and	O
Rattus	O
norvegicus	O
(	O
accession	O
no	O
.	O

NP_742028.1	O
)	O
,	O
respectively	O
.	O

The	O
recombinant	O
protein	O
corresponded	O
to	O
the	O
expected	O
molecular	O
mass	O
of	O
25.47	O
kDa	O
as	O
judged	O
by	O
sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gel	O
electrophoresis	O
,	O
and	O
it	O
was	O
detected	O
in	O
the	O
supernatant	O
of	O
P.	O
pastoris	O
,	O
and	O
it	O
could	O
be	O
purified	O
.	O

The	O
results	O
from	O
the	O
test	O
of	O
inhibition	O
effect	O
of	O
argali	O
recombinant	O
SPLUNC1	O
protein	O
on	O
MO	O
showed	O
that	O
the	O
product	O
could	O
inhibit	O
MO	O
very	O
well	O
(	O
p	O
<	O
0.01	O
)	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
Wild	O
Argali	O
SPLUNC1	O
was	O
different	O
from	O
other	O
organisms	O
.	O

The	O
recombinant	O
SPLUNC1	O
protein	O
has	O
good	O
biological	O
activity	O
.	O

CXCR4	O
(	O
CD184	O
)	O
expression	O
on	O
stem	O
cell	O
harvest	O
and	O
CD34	O
(	O
+	O
)	O
cells	O
post-transplant	O
.	O

CXCR4	O
is	O
a	O
receptor	O
for	O
stromal-derived	O
factor-1	O
(	O
SDF-1	O
)	O
,	O
a	O
molecule	O
that	O
has	O
a	O
chemotactic	O
activity	O
for	O
lymphocytes	O
and	O
is	O
important	O
in	O
homing	O
of	O
hematopoietic	O
stem	O
cells	O
to	O
their	O
adult	O
marrow	O
.	O

We	O
evaluated	O
the	O
CXCR4	O
(	O
CD184	O
)	O
expression	O
in	O
the	O
harvest	O
cells	O
and	O
in	O
the	O
post-transplant	O
bone	O
marrow	O
(	O
BM	O
)	O
and	O
its	O
relation	O
to	O
engraftment	O
,	O
as	O
determined	O
by	O
the	O
consensus	O
criteria	O
and	O
chimerism	O
.	O

This	O
is	O
a	O
prospective	O
study	O
which	O
included	O
30	O
patients	O
undergoing	O
hematopoietic	O
stem	O
cell	O
transplantation	O
;	O
15	O
patients	O
received	O
autograft	O
and	O
15	O
patients	O
received	O
allograft	O
on	O
dates	O
between	O
January	O
2012	O
and	O
May	O
2014	O
.	O

We	O
assessed	O
CD184	O
(	O
CXCR4	O
)	O
using	O
flow	B-P
cytometry	I-P
in	O
the	O
harvest	O
cells	O
together	O
with	O
post-transplant	O
BM	O
assessment	O
on	O
Day	O
28	O
and	O
Day	O
90	O
for	O
complete	O
morphologic	O
,	O
molecular	B-P
studies	I-P
,	O
and	O
detection	O
of	O
CD184	O
expression	O
on	O
CD34	O
(	O
+	O
)	O
cells	O
with	O
chimerism	O
studies	O
on	O
total	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

Diagnoses	O
of	O
the	O
enrolled	O
patients	O
were	O
as	O
follows	O
:	O
seven	O
(	O
24.1	O
%	O
)	O
with	O
acute	O
myeloid	O
leukemia	O
,	O
eight	O
(	O
27.6	O
%	O
)	O
with	O
multiple	O
myeloma	O
,	O
four	O
(	O
13.8	O
%	O
)	O
with	O
acute	O
lymphoblastic	O
leukemia	O
,	O
three	O
(	O
10.3	O
%	O
)	O
with	O
non-Hodgkin	O
lymphoma	O
,	O
two	O
(	O
6.9	O
%	O
)	O
with	O
myelodysplastic	O
syndromes	O
,	O
two	O
(	O
6.9	O
%	O
)	O
with	O
aplastic	O
anemia	O
,	O
two	O
(	O
6.9	O
%	O
)	O
with	O
chronic	O
myeloid	O
leukemia	O
,	O
one	O
(	O
3.4	O
%	O
)	O
with	O
Hodgkin	O
lymphoma	O
,	O
and	O
one	O
(	O
3.4	O
%	O
)	O
with	O
plasmacytomas	O
.	O

One	O
patient	O
died	O
and	O
was	O
excluded	O
from	O
the	O
study	O
because	O
there	O
were	O
not	O
enough	O
data	O
about	O
engraftment	O
.	O

There	O
was	O
no	O
statistical	O
significance	O
between	O
the	O
level	O
of	O
CD184	O
in	O
stem	O
cell	O
harvest	O
and	O
the	O
prediction	O
of	O
successful	O
engraftment	O
(	O
p	O
>	O
0.05	O
)	O
as	O
well	O
as	O
in	O
Day	O
28	O
BM	O
sample	O
(	O
p	O
>	O
0.05	O
)	O
,	O
whereas	O
there	O
was	O
a	O
statistical	O
significance	O
between	O
the	O
level	O
of	O
CD184	O
in	O
Day	O
90	O
BM	O
sample	O
and	O
the	O
occurrence	O
of	O
successful	O
engraftment	O
(	O
p=0.002	O
)	O
.	O

SDF-1	O
/	O
CXCR4	O
axis	O
plays	O
a	O
crucial	O
role	O
in	O
engraftment	O
;	O
however	O
,	O
more	O
studies	O
are	O
warranted	O
to	O
assess	O
their	O
expression	O
post-transplant	O
.	O

Evaluating	O
the	O
ligand	O
(	O
chemokine	O
,	O
SDF-1	O
)	O
or	O
its	O
receptor	O
(	O
CXCR4	O
)	O
may	O
serve	O
as	O
potential	O
surrogate	O
markers	O
for	O
assessment	O
of	O
engraftment	O
.	O

Diffuse	O
traumatic	O
brain	O
injury	O
affects	O
chronic	O
corticosterone	O
function	O
in	O
the	O
rat	O
.	O

As	O
many	O
as	O
20-55	O
%	O
of	O
patients	O
with	O
a	O
history	O
of	O
traumatic	O
brain	O
injury	O
(	O
TBI	O
)	O
experience	O
chronic	O
endocrine	O
dysfunction	O
,	O
leading	O
to	O
impaired	O
quality	O
of	O
life	O
,	O
impaired	O
rehabilitation	O
efforts	O
and	O
lowered	O
life	O
expectancy	O
.	O

Endocrine	O
dysfunction	O
after	O
TBI	O
is	O
thought	O
to	O
result	O
from	O
acceleration	O
-	O
deceleration	O
forces	O
to	O
the	O
brain	O
within	O
the	O
skull	O
,	O
creating	O
enduring	O
hypothalamic	O
and	O
pituitary	O
neuropathology	O
,	O
and	O
subsequent	O
hypothalamic	O
-pituitary	O
endocrine	O
(	O
HPE	O
)	O
dysfunction	O
.	O

These	O
experiments	O
were	O
designed	O
to	O
test	O
the	O
hypothesis	O
that	O
a	O
single	O
diffuse	O
TBI	O
results	O
in	O
chronic	O
dysfunction	O
of	O
corticosterone	O
(	O
CORT	O
)	O
,	O
a	O
glucocorticoid	O
released	O
in	O
response	O
to	O
stress	O
and	O
testosterone	O
.	O

We	O
used	O
a	O
rodent	O
model	O
of	O
diffuse	O
TBI	O
induced	O
by	O
midline	O
fluid	O
percussion	O
injury	O
(	O
mFPI	O
)	O
.	O

At	O
2	O
months	O
postinjury	O
compared	O
with	O
uninjured	O
control	O
animals	O
,	O
circulating	O
levels	O
of	O
CORT	O
were	O
evaluated	O
at	O
rest	O
,	O
under	O
restraint	O
stress	O
and	O
in	O
response	O
to	O
dexamethasone	O
,	O
a	O
synthetic	O
glucocorticoid	O
commonly	O
used	O
to	O
test	O
HPE	O
axis	O
regulation	O
.	O

Testosterone	O
was	O
evaluated	O
at	O
rest	O
.	O

Further	O
,	O
we	O
assessed	O
changes	O
in	O
injury	O
-	O
induced	O
neuron	O
morphology	O
(	O
Golgi	B-P
stain	I-P
)	O
,	O
neuropathology	O
(	O
silver	B-P
stain	I-P
)	O
and	O
activated	O
astrocytes	O
(	O
GFAP	B-P
)	O
in	O
the	O
paraventricular	O
nucleus	O
(	O
PVN	O
)	O
of	O
the	O
hypothalamus	O
.	O

Resting	O
plasma	O
CORT	O
levels	O
were	O
decreased	O
at	O
2	O
months	O
postinjury	O
and	O
there	O
was	O
a	O
blunted	O
CORT	O
increase	O
in	O
response	O
to	O
restraint	O
induced	O
stress	O
.	O

No	O
changes	O
in	O
testosterone	O
were	O
measured	O
.	O

These	O
changes	O
in	O
CORT	O
were	O
observed	O
concomitantly	O
with	O
altered	O
complexity	O
of	O
neuron	O
processes	O
in	O
the	O
PVN	O
over	O
time	O
,	O
devoid	O
of	O
neuropathology	O
or	O
astrocytosis	O
.	O

Results	O
provide	O
evidence	O
that	O
a	O
single	O
moderate	O
diffuse	O
TBI	O
leads	O
to	O
changes	O
in	O
CORT	O
function	O
,	O
which	O
can	O
contribute	O
to	O
the	O
persistence	O
of	O
symptoms	O
related	O
to	O
endocrine	O
dysfunction	O
.	O

Future	O
experiments	O
aim	O
to	O
evaluate	O
additional	O
HP-related	O
hormones	O
and	O
endocrine	O
circuit	O
pathology	O
following	O
diffuse	O
TBI	O
.	O

E-WIN	O
Project	O
2016	O
:	O
Evaluating	O
the	O
current	O
gender	O
situation	O
in	O
neurosurgery	O
across	O
Europe	O
.	O

An	O
interactive	O
,	O
multiple-level	O
Survey	O
.	O

The	O
proportion	O
of	O
females	O
among	O
neurosurgeons	O
appears	O
to	O
be	O
growing	O
worldwide	O
with	O
time	O
.	O

Official	O
data	O
concerning	O
the	O
current	O
situation	O
across	O
Europe	O
have	O
not	O
yet	O
been	O
published	O
.	O

Thus	O
,	O
there	O
are	O
still	O
concerns	O
about	O
gender	O
inequality	O
.	O

The	O
E-WIN	O
Project	O
2016	O
was	O
designed	O
to	O
recognize	O
the	O
current	O
situation	O
across	O
Europe	O
.	O

The	O
office	O
holders	O
of	O
the	O
national	O
neurosurgical	O
societies	O
of	O
39	O
countries	O
forming	O
the	O
EANS	O
were	O
contacted	O
to	O
provide	O
data	O
stating	O
the	O
proportion	O
of	O
females	O
in	O
neurosurgery	O
.	O

Obtained	O
data	O
were	O
supplied	O
with	O
the	O
results	O
of	O
an	O
online	O
survey	O
.	O

The	O
response	O
rate	O
of	O
national	O
office	O
holders	O
was	O
90	O
%	O
.	O

Total	O
number	O
of	O
reported	O
neurosurgeons	O
was	O
n=12985	O
,	O
overall	O
proportion	O
of	O
females	O
represented	O
12	O
%	O
.	O

A	O
total	O
of	O
n=237	O
responses	O
to	O
online	O
questionnaire	O
were	O
taken	O
into	O
account	O
.	O

The	O
overall	O
proportion	O
of	O
female	O
responders	O
was	O
30	O
%	O
.	O

There	O
was	O
no	O
inter-	O
gender	O
variability	O
in	O
responses	O
regarding	O
amount	O
of	O
working	O
time	O
per	O
week	O
,	O
exposure	O
to	O
surgeries	O
or	O
administrative	O
work	O
.	O

Male	O
responders	O
reported	O
dedicating	O
significantly	O
more	O
time	O
to	O
scientific	B-P
work	I-P
and	O
feeling	O
more	O
confident	O
dictating	O
own	O
career	O
direction	O
.	O

Female	O
responders	O
reported	O
being	O
less	O
often	O
married	O
,	O
having	O
a	O
smaller	O
number	O
of	O
children	O
,	O
a	O
stronger	O
perception	O
of	O
gender	O
significance	O
level	O
and	O
a	O
higher	O
appreciation	O
of	O
personal	O
qualities	O
.	O

Neurosurgery	O
is	O
challenging	O
field	O
of	O
medicine	O
.	O

The	O
results	O
of	O
our	O
survey	O
did	O
not	O
imply	O
an	O
overall	O
feeling	O
of	O
gender	O
inequality	O
among	O
European	O
responders	O
,	O
although	O
women	O
feel	O
the	O
gender	O
issue	O
to	O
be	O
more	O
important	O
than	O
men	O
,	O
and	O
have	O
to	O
sacrifice	O
more	O
of	O
their	O
personal	O
life	O
.	O

CyberKnife	O
stereotactic	O
radiosurgery	O
for	O
the	O
treatment	O
of	O
symptomatic	O
vertebral	O
hemangiomas	O
:	O
a	O
single-institution	O
experience	O
.	O

OBJECTIVE	O
Symptomatic	O
vertebral	O
hemangiomas	O
(	O
SVHs	O
)	O
are	O
a	O
very	O
rare	O
pathology	O
that	O
can	O
present	O
with	O
persistent	O
pain	O
or	O
neurological	O
deficits	O
that	O
warrant	O
surgical	O
intervention	O
.	O

Given	O
the	O
relative	O
rarity	O
and	O
difficulty	O
in	O
assessment	O
,	O
the	O
authors	O
sought	O
to	O
present	O
a	O
dedicated	O
series	O
of	O
SVHs	O
treated	O
using	O
stereotactic	O
radiosurgery	O
(	O
SRS	O
)	O
to	O
provide	O
insight	O
into	O
clinical	B-P
decision	I-P
making	I-P
.	O

METHODS	O
A	O
retrospective	O
review	O
of	O
a	O
single	O
institution	O
's	O
experience	O
with	O
hypofractionated	O
radiosurgery	O
for	O
SVH	O
from	O
2004	O
to	O
2011	O
was	O
conducted	O
to	O
determine	O
the	O
clinical	O
and	O
radiographic	O
outcomes	O
following	O
SRS	O
treatment	O
.	O

The	O
authors	O
report	O
and	O
analyze	O
the	O
treatment	O
course	O
of	O
5	O
patients	O
with	O
7	O
lesions	O
,	O
2	O
of	O
which	O
were	O
treated	O
primarily	O
by	O
SRS	O
.	O

RESULTS	O
Of	O
the	O
5	O
patients	O
studied	O
,	O
4	O
presented	O
with	O
a	O
chief	O
complaint	O
of	O
pain	O
refractory	O
to	O
conservative	O
measures	O
.	O

Three	O
patients	O
reported	O
dysesthesias	O
,	O
and	O
2	O
reported	O
upper-extremity	O
weakness	O
.	O

Following	O
radiosurgery	O
,	O
4	O
of	O
5	O
patients	O
exhibited	O
improvement	O
in	O
their	O
primary	O
symptoms	O
(	O
3	O
for	O
pain	O
and	O
1	O
for	O
weakness	O
)	O
,	O
achieving	O
a	O
clinical	O
response	O
after	O
a	O
mean	O
period	O
of	O
1	O
year	O
.	O

In	O
2	O
cases	O
there	O
was	O
20	O
%	O
-40	O
%	O
reduction	O
in	O
lesion	O
size	O
in	O
the	O
most	O
responsive	O
dimension	O
as	O
noted	O
on	O
images	O
.	O

All	O
treatments	O
were	O
well	O
tolerated	O
.	O

CONCLUSIONS	O
SRS	O
for	O
SVH	O
is	O
a	O
safe	O
and	O
feasible	O
treatment	O
strategy	O
,	O
comparable	O
to	O
prior	O
radiotherapy	O
studies	O
,	O
and	O
in	O
select	O
cases	O
may	O
successfully	O
confer	O
delayed	O
decompressive	O
effects	O
.	O

Additional	O
investigation	O
will	O
determine	O
future	O
patient	O
selection	O
and	O
how	O
conformal	O
SRS	O
treatment	O
can	O
best	O
be	O
administered	O
.	O

Large-scale	O
synthesis	O
and	O
structural	O
analysis	O
of	O
a	O
synthetic	O
glycopeptide	O
dendrimer	O
as	O
an	O
anti-cancer	O
vaccine	O
candidate	O
.	O

Herein	O
,	O
we	O
report	O
a	O
new	O
process	O
that	O
enables	O
the	O
gram-scale	O
production	O
of	O
a	O
fully	O
synthetic	O
anti-cancer	O
vaccine	O
for	O
human	O
use	O
.	O

This	O
therapeutic	O
vaccine	O
candidate	O
,	O
named	O
MAG-Tn3	O
,	O
is	O
a	O
high-molecular-weight	O
tetrameric	O
glycopeptide	O
encompassing	O
carbohydrate	O
tumor-associated	O
Tn	O
antigen	O
clusters	O
and	O
peptidic	O
CD4	O
(	O
+	O
)	O
T-cell	O
epitopes	O
.	O

The	O
synthetic	O
process	O
involves	O
(	O
i	O
)	O
the	O
stepwise	O
solid-phase	O
assembly	O
of	O
protected	O
amino	O
acids	O
,	O
including	O
the	O
high	O
value-added	O
Tn	O
building	O
blocks	O
with	O
only	O
1.5	O
equivalents	O
,	O
(	O
ii	O
)	O
a	O
single	O
isolated	O
intermediate	O
,	O
and	O
(	O
iii	O
)	O
the	O
simultaneous	O
deprotection	O
of	O
36	O
hindered	O
protective	O
groups	O
.	O

The	O
resulting	O
MAG-Tn3	O
was	O
unambiguously	O
characterized	O
using	O
a	O
combination	O
of	O
techniques	O
,	O
including	O
a	O
structural	O
analysis	O
by	O
nuclear	B-P
magnetic	I-P
resonance	I-P
spectroscopy	I-P
.	O

The	O
four	O
peptidic	O
chains	O
are	O
flexible	O
in	O
solution	O
,	O
with	O
a	O
more	O
constrained	O
but	O
extended	O
conformation	O
at	O
the	O
Tn3	O
antigen	O
motif	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
,	O
when	O
injected	O
into	O
HLA-DR1	O
-	O
expressing	O
transgenic	O
mice	O
,	O
this	O
vaccine	O
induces	O
Tn-specific	O
antibodies	O
that	O
mediate	O
the	O
killing	O
of	O
human	O
Tn-positive	O
tumor	O
cells	O
.	O

These	O
studies	O
led	O
to	O
a	O
clinical	O
batch	O
of	O
the	O
MAG-Tn3	O
,	O
currently	O
investigated	O
in	O
breast	O
cancer	O
patients	O
(	O
phase	O
I	O
clinical	O
trial	O
)	O
.	O

The	O
current	O
study	O
demonstrates	O
the	O
feasibility	O
of	O
the	O
multigram-scale	O
synthesis	O
of	O
a	O
highly	O
pure	O
complex	O
glycopeptide	O
,	O
and	O
it	O
opens	O
new	O
avenues	O
for	O
the	O
use	O
of	O
synthetic	O
glycopeptides	O
as	O
drugs	O
in	O
humans	O
.	O

Double-Network	O
Hydrogel	O
with	O
Tunable	O
Mechanical	O
Performance	O
and	O
Biocompatibility	O
for	O
the	O
Fabrication	O
of	O
Stem	O
Cells	O
-	O
Encapsulated	O
Fibers	O
and	O
3D	O
Assemble	O
.	O

Fabrication	O
of	O
cell	O
-	O
encapsulated	O
fibers	O
could	O
greatly	O
contribute	O
to	O
tissue	O
engineering	O
and	O
regenerative	O
medicine	O
.	O

However	O
,	O
existing	O
methods	O
suffered	O
from	O
not	O
only	O
unavoidability	O
of	O
cell	O
damaging	O
conditions	O
and/or	O
sophisticated	O
equipment	O
,	O
but	O
also	O
unavailability	O
of	O
proper	O
materials	O
to	O
satisfy	O
both	O
mechanical	O
and	O
biological	O
expectations	O
.	O

In	O
this	O
work	O
,	O
a	O
simple	O
method	O
is	O
proposed	O
to	O
prepare	O
cell	O
-	O
encapsulated	O
fibers	O
with	O
tunable	O
mechanical	O
strength	O
and	O
stretching	O
behavior	O
as	O
well	O
as	O
diameter	O
and	O
microstructure	O
.	O

The	O
hydrogel	O
fibers	O
are	O
made	O
from	O
optimal	O
combination	O
of	O
alginate	O
and	O
poly	O
(	O
N-iso-propylacrylamide	O
)	O
-poly	O
(	O
ethylene	O
glycol	O
)	O
,	O
characteristics	O
of	O
double-network	O
hydrogel	O
,	O
with	O
enough	O
stiffness	O
and	O
flexibility	O
to	O
create	O
a	O
variety	O
of	O
three	O
dimensional	O
structures	O
like	O
parallel	O
helical	O
and	O
different	O
knots	O
without	O
crack	O
.	O

Furthermore	O
,	O
such	O
hydrogel	O
fibers	O
exhibit	O
better	O
compatibility	O
as	O
indicated	O
by	O
the	O
viability	O
,	O
proliferation	O
and	O
expression	O
of	O
pluripotency	O
markers	O
of	O
embryonic	O
stem	O
cells	O
encapsulated	O
after	O
4-day	O
culture	B-P
.	O

The	O
double-network	O
hydrogel	O
possesses	O
specific	O
quick	O
responses	O
to	O
either	O
of	O
alginate	O
lyase	O
,	O
EDTA	O
or	O
lower	O
environmental	O
temperature	O
which	O
facilitate	O
the	O
optional	O
degradation	O
of	O
fibers	O
or	O
fibrous	O
assemblies	O
to	O
release	O
the	O
cells	O
encapsulated	O
for	O
subsequent	O
assay	B-P
or	O
treatment	O
.	O

Improved	O
protocol	O
for	O
the	O
isolation	B-P
of	O
naïve	O
follicular	O
dendritic	O
cells	O
.	O

Follicular	O
dendritic	O
cells	O
(	O
FDCs	O
)	O
in	O
lymphoid	O
organs	O
play	O
an	O
important	O
role	O
in	O
the	O
humoral	O
immune	O
response	O
.	O

However	O
,	O
because	O
the	O
isolation	O
of	O
FDCs	O
is	O
difficult	O
due	O
to	O
their	O
very	O
small	O
population	O
size	O
and	O
fragility	O
under	O
mechanical	O
and	O
chemical	O
stresses	O
,	O
the	O
genetic	O
and	O
biochemical	O
characteristics	O
of	O
FDCs	O
remain	O
unclear	O
.	O

Previously	O
,	O
we	O
identified	O
FDCs	O
as	O
ICAM-1	O
(	O
+	O
)	O
cells	O
in	O
the	O
CD45	O
(	O
-	O
)	O
non-hematopoietic	O
cell	O
fraction	O
from	O
naïve	O
mouse	O
spleen	O
after	O
cell	B-P
separation	I-P
by	O
means	O
of	O
digestion	O
with	O
a	O
combination	O
of	O
enzymes	O
.	O

In	O
the	O
present	O
study	O
,	O
using	O
a	O
new	O
combination	O
of	O
enzymes	O
,	O
we	O
found	O
that	O
FDCs	O
are	O
highly	O
enriched	O
in	O
the	O
CD45	O
(	O
-	O
)	O
ICAM-1	O
(	O
+	O
)	O
CD21	O
/	O
35	O
(	O
+	O
)	O
cell	O
fraction	O
.	O

CD45	O
(	O
-	O
)	O
ICAM-1	O
(	O
+	O
)	O
CD21	O
/	O
35	O
(	O
+	O
)	O
cells	O
in	O
the	O
mouse	O
spleen	O
retained	O
an	O
antigen	O
administered	O
in	O
vivo	O
for	O
more	O
than	O
7	O
days	O
.	O

Moreover	O
,	O
CD45	O
(	O
-	O
)	O
ICAM-1	O
(	O
+	O
)	O
CD21	O
/	O
35	O
(	O
+	O
)	O
cells	O
isolated	O
from	O
the	O
spleen	O
of	O
mice	O
administered	O
with	O
a	O
cognate	O
antigen	O
enhanced	O
the	O
survival	O
and	O
proliferation	O
of	O
antigen-specific	O
B	O
cells	O
in	O
vitro	O
.	O

Our	O
improved	O
protocol	O
for	O
the	O
isolation	B-P
of	O
naïve	O
FDCs	O
will	O
be	O
useful	O
for	O
the	O
analysis	O
of	O
FDCs	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Impact	O
of	O
Revised	O
Broad-Spectrum	O
Cephalosporin	O
Clinical	O
and	O
Laboratory	O
Standards	O
Institute	O
Breakpoints	B-P
on	O
Susceptibility	O
in	O
Enterobacteriaceae	O
Producing	O
AmpC	O
β-Lactamase	O
.	O

We	O
evaluated	O
the	O
impact	O
of	O
revised	O
Clinical	O
and	O
Laboratory	O
Standards	O
Institute	O
(	O
CLSI	O
)	O
breakpoints	B-P
for	O
broad-spectrum	O
cephalosporins	O
(	O
BSCs	O
)	O
on	O
the	O
susceptibilities	O
of	O
1,742	O
isolates	O
of	O
Enterobacter	O
species	O
,	O
Serratia	O
marcescens	O
,	O
Citrobacter	O
freundii	O
,	O
and	O
Morganella	O
morganii	O
.	O

The	O
2011	O
CLSI	O
criteria	O
for	O
cefotaxime	O
and	O
ceftazidime	O
reduced	O
the	O
rates	O
of	O
susceptibility	O
by	O
2.9	O
%	O
and	O
5.9	O
%	O
,	O
respectively	O
.	O

The	O
2014	O
CLSI	O
criteria	O
for	O
cefepime	O
reduced	O
the	O
rate	O
of	O
susceptibility	O
by	O
13.9	O
%	O
,	O
and	O
categorized	O
11.8	O
%	O
isolates	O
as	O
susceptible-dose	O
dependent	O
(	O
SDD	O
)	O
for	O
cefepime	O
.	O

Among	O
183	O
isolates	O
with	O
extended-spectrum	O
β-lactamase	O
(	O
ESBL	O
)	O
phenotype	O
,	O
implementation	O
of	O
the	O
new	O
criteria	O
reduced	O
the	O
rates	O
of	O
susceptibility	O
to	O
cefotaxime	O
,	O
ceftazidime	O
,	O
and	O
cefepime	O
by	O
2.8	O
%	O
,	O
14.8	O
%	O
,	O
and	O
53.6	O
%	O
,	O
respectively	O
.	O

The	O
proportion	O
of	O
ESBL	O
phenotype	O
among	O
BSC	O
-	O
susceptible	O
isolates	O
was	O
low	O
(	O
0.9	O
%	O
for	O
cefotaxime	O
,	O
3.0	O
%	O
for	O
ceftazidime	O
,	O
and	O
3.3	O
%	O
for	O
cefepime	O
)	O
.	O

In	O
summary	O
,	O
implementation	O
of	O
new	O
CLSI	O
criteria	O
led	O
to	O
little	O
change	O
in	O
susceptibility	O
to	O
cefotaxime	O
and	O
ceftazidime	O
but	O
a	O
substantial	O
change	O
in	O
susceptibility	O
to	O
cefepime	O
.	O

The	O
recognition	O
of	O
revised	O
CLSI	O
criteria	O
for	O
BSC	O
and	O
SDD	O
will	O
help	O
clinicians	O
to	O
select	O
the	O
optimal	O
antibiotic	O
and	O
dosing	O
regimen	O
.	O

Variability	O
in	O
conditioned	O
pain	O
modulation	O
predicts	O
response	O
to	O
NSAID	O
treatment	O
in	O
patients	O
with	O
knee	O
osteoarthritis	O
.	O

Patients	O
with	O
painful	O
knee	O
osteoarthritis	O
(	O
OA	O
)	O
demonstrate	O
hyperalgesia	O
and	O
altered	O
pain-modulatory	O
responses	O
.	O

While	O
some	O
prior	O
work	O
has	O
demonstrated	O
cross-sectional	O
associations	O
between	O
laboratory	O
and	O
clinical	O
pain	O
measures	O
,	O
it	O
is	O
unknown	O
whether	O
individual	O
variability	O
in	O
quantitative	B-P
sensory	I-P
testing	I-P
(	O
QST	B-P
)	O
responses	O
at	O
baseline	O
can	O
prospectively	O
predict	O
analgesic	O
treatment	O
responses	O
.	O

Patients	O
with	O
knee	O
OA	O
(	O
n	O
=	O
35	O
)	O
were	O
compared	O
on	O
QST	B-P
responses	O
to	O
a	O
demographically	O
-matched	O
pain-free	O
control	O
group	O
(	O
n	O
=	O
39	O
)	O
,	O
after	O
which	O
patients	O
completed	O
a	O
month-long	O
treatment	O
study	O
of	O
diclofenac	O
sodium	O
topical	O
gel	O
(	O
1	O
%	O
)	O
,	O
applied	O
up	O
to	O
4	O
times	O
daily	O
.	O

OA	O
patients	O
demonstrated	O
reduced	O
pain	O
thresholds	O
at	O
multiple	O
anatomic	O
sites	O
,	O
as	O
well	O
as	O
reduced	O
conditioned	O
pain	O
modulation	O
(	O
CPM	O
)	O
and	O
enhanced	O
temporal	O
summation	O
of	O
pain	O
.	O

The	O
most	O
pain-sensitive	O
patients	O
tended	O
to	O
report	O
the	O
most	O
intense	O
and	O
neuropathic	O
OA	O
pain	O
.	O

Following	O
diclofenac	O
treatment	O
,	O
the	O
knee	O
OA	O
cohort	O
showed	O
a	O
roughly	O
30	O
%	O
improvement	O
in	O
pain	O
,	O
regardless	O
of	O
the	O
presence	O
or	O
absence	O
of	O
neuropathic	O
symptoms	O
.	O

Baseline	O
CPM	O
scores	O
,	O
an	O
index	O
of	O
endogenous	O
pain-inhibitory	O
capacity	O
,	O
were	O
prospectively	O
associated	O
with	O
treatment	O
-related	O
changes	O
in	O
clinical	O
pain	O
.	O

Specifically	O
,	O
participants	O
with	O
higher	O
CPM	O
at	O
baseline	O
(	O
i.e.	O
,	O
better	O
functioning	O
endogenous	O
pain	O
-	O
inhibitory	O
systems	O
)	O
showed	O
more	O
reduction	O
in	O
pain	O
at	O
the	O
end	O
of	O
treatment	O
(	O
p	O
<	O
.05	O
)	O
.	O

These	O
results	O
support	O
prior	O
findings	O
of	O
amplified	O
pain	O
sensitivity	O
and	O
reduced	O
pain-inhibition	O
in	O
OA	O
patients	O
.	O

Moreover	O
,	O
the	O
moderate	O
to	O
strong	O
associations	O
between	O
laboratory-based	O
measures	O
of	O
pain	O
sensitivity	O
and	O
indices	O
of	O
clinical	O
pain	O
highlight	O
the	O
clinical	O
relevance	O
of	O
QST	B-P
in	O
this	O
sample	O
.	O

Finally	O
,	O
the	O
prospective	O
association	O
between	O
CPM	O
and	O
diclofenac	O
response	O
suggests	O
that	O
QST-based	B-P
phenotyping	O
may	O
have	O
utility	O
in	O
explaining	O
inter-patient	O
variability	O
in	O
long-term	O
analgesic	O
treatment	O
outcomes	O
.	O

ClinicalTrials	O
.Gov	O
Identifier	O
:	O
NCT01383954	O
.	O

Registered	O
June	O
22	O
,	O
2011	O
.	O

The	O
Relationship	O
Between	O
Thyroid	O
Function	O
and	O
the	O
Prevalence	O
of	O
Type	O
2	O
Diabetes	O
Mellitus	O
in	O
Euthyroid	O
Subjects	O
.	O

Thyroid	O
hormones	O
(	O
THs	O
)	O
are	O
primarily	O
responsible	O
for	O
the	O
regulation	O
of	O
energy	O
balance	O
and	O
metabolism	O
,	O
suggesting	O
that	O
TH	B-P
levels	I-P
may	O
contribute	O
to	O
the	O
development	O
of	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
.	O

However	O
,	O
few	O
studies	O
have	O
investigated	O
the	O
relationship	O
between	O
TH	O
and	O
T2DM	O
in	O
a	O
general	O
population	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
whether	O
serum	O
TH	B-P
levels	I-P
within	O
the	O
reference	O
range	O
are	O
related	O
to	O
T2DM	O
.	O

A	O
cross-sectional	O
study	O
(	O
n	O
=	O
15,296	O
)	O
was	O
performed	O
in	O
Tianjin	O
,	O
China	O
.	O

Serum	O
free	O
triiodothyronine	O
(	O
FT3	O
)	O
,	O
free	O
thyroxine	O
(	O
FT4	O
)	O
,	O
and	O
thyroid-stimulating	O
hormone	O
(	O
TSH	O
)	O
levels	O
were	O
measured	O
by	O
chemiluminescence	B-P
immunoassay	I-P
,	O
and	O
T2DM	O
was	O
defined	O
according	O
to	O
the	O
American	O
Diabetes	O
Association	O
criteria	O
.	O

Multiple	O
logistic	O
regression	O
models	O
were	O
used	O
to	O
assess	O
the	O
sex	O
-	O
specific	O
relationships	O
between	O
FT3	O
,	O
FT4	O
,	O
FT3	O
/	O
FT4	O
ratios	O
,	O
and	O
TSH	O
quintiles	O
and	O
T2DM	O
.	O

The	O
prevalence	O
of	O
T2DM	O
was	O
16.2	O
%	O
in	O
males	O
and	O
7.7	O
%	O
in	O
females	O
.	O

In	O
males	O
,	O
the	O
multivariable-adjusted	O
odds	O
ratios	O
(	O
95	O
%	O
confidence	O
interval	O
)	O
of	O
T2DM	O
for	O
increasing	O
quintiles	O
of	O
FT3	O
,	O
FT4	O
,	O
and	O
FT3	O
/	O
FT4	O
ratios	O
were	O
1.00	O
,	O
0.75	O
(	O
0.63	O
to	O
0.89	O
)	O
,	O
0.70	O
(	O
0.58	O
to	O
0.84	O
)	O
,	O
0.63	O
(	O
0.52	O
to	O
0.76	O
)	O
,	O
0.56	O
(	O
0.46	O
to	O
0.68	O
;	O
P	O
for	O
trend	O
<	O
0.0001	O
)	O
;	O
1.00	O
,	O
1.05	O
(	O
0.87	O
to	O
1.27	O
)	O
,	O
1.16	O
(	O
0.96	O
to	O
1.40	O
)	O
,	O
1.09	O
(	O
0.90	O
to	O
1.31	O
)	O
,	O
1.29	O
(	O
1.07	O
to	O
1.56	O
;	O
P	O
for	O
trend	O
=	O
0.01	O
)	O
;	O
and	O
1.00	O
,	O
0.69	O
(	O
0.58	O
to	O
0.83	O
)	O
,	O
0.72	O
(	O
0.60	O
to	O
0.86	O
)	O
,	O
0.59	O
(	O
0.48	O
to	O
0.71	O
)	O
,	O
and	O
0.55	O
(	O
0.46	O
to	O
0.66	O
;	O
P	O
for	O
trend	O
<	O
0.0001	O
)	O
,	O
respectively	O
.	O

Similar	O
results	O
also	O
were	O
observed	O
in	O
females	O
.	O

In	O
contrast	O
,	O
a	O
strong	O
negative	O
correlation	O
between	O
TSH	O
and	O
T2DM	O
was	O
observed	O
in	O
males	O
,	O
but	O
not	O
in	O
females	O
.	O

This	O
study	O
demonstrated	O
that	O
decreased	O
FT3	O
,	O
FT3	O
/	O
FT4	O
ratios	O
,	O
and	O
increased	O
FT4	O
levels	O
are	O
independently	O
related	O
to	O
a	O
higher	O
prevalence	O
of	O
T2DM	O
in	O
both	O
males	O
and	O
females	O
,	O
and	O
TSH	O
is	O
inversely	O
related	O
to	O
T2DM	O
in	O
males	O
only	O
.	O

Effect	O
of	O
single-dose	O
carbapenem	O
exposure	O
on	O
transcriptional	O
expression	O
of	O
blaNDM-1	O
and	O
mexA	O
in	O
Pseudomonas	O
aeruginosa	O
.	O

The	O
therapeutic	O
option	O
of	O
a	O
carbapenem	O
antibiotic	O
is	O
compromised	O
in	O
Pseudomonas	O
aeruginosa	O
owing	O
both	O
to	O
acquired	O
and	O
intrinsic	O
resistance	O
mechanisms	O
.	O

In	O
recent	O
years	O
,	O
New	O
Delhi	O
metallo-β-lactamase	O
has	O
been	O
the	O
focus	O
as	O
a	O
predominant	O
carbapenem	O
resistance	O
determinant	O
.	O

However	O
,	O
it	O
is	O
unclear	O
which	O
of	O
the	O
mechanisms	O
might	O
be	O
adopted	O
by	O
a	O
P.	O
aeruginosa	O
strain	O
possessing	O
both	O
blaNDM-1	O
and	O
an	O
overexpressed	O
MexAB-OprM	O
system	O
during	O
carbapenem	O
therapy	O
.	O

This	O
study	O
investigated	O
the	O
interplay	O
of	O
both	O
mechanisms	O
in	O
clinical	O
isolates	O
of	O
P.	O
aeruginosa	O
when	O
exposed	O
to	O
meropenem	O
.	O

Five	O
strains	O
were	O
used	O
:	O
(	O
i	O
)	O
strain	O
overexpressing	O
MexAB-OprM	O
but	O
with	O
no	O
blaNDM-1	O
;	O
(	O
ii	O
)	O
strain	O
harbouring	O
blaNDM-1	O
but	O
expressing	O
MexAB-OprM	O
at	O
basal	O
level	O
;	O
(	O
iii	O
)	O
strain	O
possessing	O
blaNDM-1	O
and	O
overexpressing	O
MexAB-OprM	O
;	O
(	O
iv	O
)	O
P.	O
aeruginosa	O
PAO1	O
;	O
and	O
(	O
v	O
)	O
P.	O
aeruginosa	O
K2733-PAO1	O
(	O
ΔMexAB-OprM	O
ΔMexCD-OprJ	O
ΔMexEF-OprN	O
ΔMexXY-OprM	O
)	O
into	O
which	O
blaNDM-1	O
was	O
cloned	O
.	O

Strains	O
were	O
incubated	O
in	O
Luria-Bertani	O
broth	O
with	O
and	O
without	O
1μg/mL	O
meropenem	O
.	O

Total	B-P
RNA	I-P
was	O
isolated	O
at	O
45-min	O
intervals	O
and	O
was	O
immediately	O
reverse	O
transcribed	O
to	O
cDNA	O
.	O

This	O
was	O
repeated	O
for	O
6h	O
.	O

Quantitative	O
real-time	O
PCR	O
was	O
performed	O
for	O
both	O
resistance	O
mechanisms	O
.	O

Meropenem	O
exposure	O
did	O
not	O
significantly	O
elevate	O
transcription	O
of	O
either	O
the	O
blaNDM-1	O
or	O
mexA	O
gene	O
.	O

However	O
,	O
an	O
interesting	O
finding	O
was	O
that	O
upon	O
single-dose	O
exposure	O
to	O
carbapenem	O
,	O
the	O
efflux	O
pump	O
system	O
played	O
a	O
major	O
role	O
in	O
bacterial	O
survival	O
compared	O
with	O
NDM-1	O
.	O

This	O
study	O
gives	O
an	O
insight	O
into	O
the	O
bacterial	O
response	O
to	O
carbapenem	O
antibiotic	O
when	O
two	O
different	O
resistance	O
mechanisms	O
coexist	O
.	O

This	O
type	O
of	O
study	O
would	O
be	O
helpful	O
in	O
designing	O
future	O
antimicrobials	O
.	O

Neonatal	O
diffusion	B-P
tensor	I-P
brain	I-P
imaging	I-P
predicts	O
later	O
motor	O
outcome	O
in	O
preterm	O
neonates	O
with	O
white	O
matter	O
abnormalities	O
.	O

White	O
matter	O
(	O
WM	O
)	O
abnormalities	O
associated	O
with	O
prematurity	O
are	O
one	O
of	O
the	O
most	O
important	O
causes	O
of	O
neurological	O
disability	O
that	O
involves	O
spastic	O
motor	O
deficits	O
in	O
preterm	O
newborns	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
regional	O
microstructural	O
changes	O
in	O
diffusion	B-P
tensor	I-P
imaging	I-P
(	O
DTI	B-P
)	O
associated	O
with	O
WM	O
abnormalities	O
.	O

We	O
prospectively	O
studied	O
extremely	O
low	O
birth	O
weight	O
(	O
ELBW	O
;	O
<	O
1000	O
g	O
)	O
preterm	O
infants	O
who	O
were	O
admitted	O
to	O
the	O
Neonatal	O
Intensive	O
Care	O
Unit	O
of	O
Hanyang	O
University	O
Hospital	O
between	O
February	O
2011	O
and	O
February	O
2014	O
.	O

WM	O
abnormalities	O
were	O
assessed	O
with	O
conventional	O
magnetic	B-P
resonance	I-P
(	I-P
MR	I-P
)	I-P
imaging	I-P
and	O
DTI	B-P
near	O
term-equivalent	O
age	O
before	O
discharge	O
.	O

Region-of-interests	O
(	O
ROIs	O
)	O
measurements	O
were	O
performed	O
to	O
examine	O
the	O
regional	O
distribution	O
of	O
fractional	O
anisotropy	O
(	O
FA	O
)	O
values	O
.	O

Thirty-two	O
out	O
of	O
72	O
ELBW	O
infants	O
underwent	O
conventional	O
MR	B-P
imaging	I-P
and	O
DTI	B-P
at	O
term-equivalent	O
age	O
.	O

Ten	O
of	O
these	O
infants	O
developed	O
WM	O
abnormalities	O
associated	O
with	O
prematurity	O
.	O

Five	O
of	O
ten	O
of	O
those	O
with	O
WM	O
abnormalities	O
developed	O
cerebral	O
palsy	O
(	O
CP	O
)	O
.	O

DTI	B-P
in	O
the	O
WM	O
abnormalities	O
with	O
CP	O
showed	O
a	O
significant	O
reduction	O
of	O
mean	O
FA	O
in	O
the	O
genu	O
of	O
the	O
corpus	O
callosum	O
(	O
p	O
=	O
0.022	O
)	O
,	O
the	O
ipsilateral	O
posterior	O
limb	O
of	O
the	O
internal	O
capsule	O
(	O
p	O
=	O
0.019	O
)	O
,	O
and	O
the	O
ipsilateral	O
centrum	O
semiovale	O
(	O
p	O
=	O
0.012	O
)	O
compared	O
to	O
normal	O
WM	O
and	O
WM	O
abnormalities	O
without	O
CP	O
.	O

In	O
infants	O
having	O
WM	O
abnormalities	O
with	O
CP	O
,	O
early	O
FA	O
values	O
in	O
neonatal	O
DTI	B-P
revealed	O
abnormalities	O
of	O
the	O
WM	O
regions	O
prior	O
to	O
the	O
manifestation	O
of	O
hemiparesis	O
.	O

DTI	B-P
performed	O
at	O
term	O
equivalent	O
age	O
shows	O
different	O
FA	O
values	O
in	O
WM	O
regions	O
among	O
infants	O
with	O
or	O
without	O
WM	O
abnormalities	O
associated	O
with	O
prematurity	O
and/or	O
CP	O
.	O

Low	O
FA	O
values	O
of	O
ROIs	O
in	O
DTI	B-P
are	O
related	O
with	O
later	O
development	O
of	O
spastic	O
CP	O
in	O
preterm	O
infants	O
with	O
WM	O
abnormalities	O
.	O

mRNA	O
N6-methyladenosine	O
methylation	O
of	O
postnatal	O
liver	O
development	O
in	O
pig	O
.	O

N6-methyladenosine	O
(	O
m6A	O
)	O
is	O
a	O
ubiquitous	O
reversible	O
epigenetic	O
RNA	O
modification	O
that	O
plays	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
post-transcriptional	O
protein	O
coding	O
gene	O
expression	O
.	O

Liver	O
is	O
a	O
vital	O
organ	O
and	O
plays	O
a	O
major	O
role	O
in	O
metabolism	O
with	O
numerous	O
functions	O
.	O

Information	O
concerning	O
the	O
dynamic	O
patterns	O
of	O
mRNA	O
m6A	O
methylation	O
during	O
postnatal	O
development	O
of	O
liver	O
has	O
been	O
long	O
overdue	O
and	O
elucidation	O
of	O
this	O
information	O
will	O
benefit	O
for	O
further	O
deciphering	O
a	O
multitude	O
of	O
functional	O
outcomes	O
of	O
mRNA	O
m6A	O
methylation	O
.	O

Here	O
,	O
we	O
profile	B-P
transcriptome	O
-wide	O
m6A	O
in	O
porcine	O
liver	O
at	O
three	O
developmental	O
stages	O
:	O
newborn	O
(	O
0	O
day	O
)	O
,	O
suckling	O
(	O
21	O
days	O
)	O
and	O
adult	O
(	O
2	O
years	O
)	O
.	O

About	O
33	O
%	O
of	O
transcribed	O
genes	O
were	O
modified	O
by	O
m6A	O
,	O
with	O
1.33	O
to	O
1.42	O
m6A	O
peaks	O
per	O
modified	O
gene	O
.	O

m6A	O
was	O
distributed	O
predominantly	O
around	O
stop	O
codons	O
.	O

The	O
consensus	O
motif	O
sequence	O
RRm6ACH	O
was	O
observed	O
in	O
78.90	O
%	O
of	O
m6A	O
peaks	O
.	O

A	O
negative	O
correlation	O
(	O
average	O
Pearson	O
's	O
r	O
=	O
-0.45	O
,	O
P	O
<	O
10-16	O
)	O
was	O
found	O
between	O
levels	O
of	O
m6A	O
methylation	O
and	O
gene	O
expression	O
.	O

Functional	O
enrichment	O
analysis	O
of	O
genes	O
consistently	O
modified	O
by	O
m6A	O
methylation	O
at	O
all	O
three	O
stages	O
showed	O
genes	O
relevant	O
to	O
important	O
functions	O
,	O
including	O
regulation	O
of	O
growth	O
and	O
development	O
,	O
regulation	O
of	O
metabolic	O
processes	O
and	O
protein	O
catabolic	O
processes	O
.	O

Genes	O
with	O
higher	O
m6A	O
methylation	O
and	O
lower	O
expression	O
levels	O
at	O
any	O
particular	O
stage	O
were	O
associated	O
with	O
the	O
biological	O
processes	O
required	O
for	O
or	O
unique	O
to	O
that	O
stage	O
.	O

We	O
suggest	O
that	O
differential	O
m6A	O
methylation	O
may	O
be	O
important	O
for	O
the	O
regulation	O
of	O
nutrient	O
metabolism	O
in	O
porcine	O
liver	O
.	O

The	O
efficacy	O
of	O
human	O
placenta	O
-derived	O
mesenchymal	O
stem	O
cells	O
on	O
radiation	O
enteropathy	O
along	O
with	O
proteomic	O
biomarkers	O
predicting	O
a	O
favorable	O
response	O
.	O

Radiation	O
enteropathy	O
is	O
a	O
common	O
complication	O
in	O
patients	O
with	O
abdominopelvic	O
cancer	O
,	O
but	O
no	O
treatment	O
has	O
yet	O
been	O
established	O
.	O

Stem	O
cell	O
therapy	O
may	O
be	O
a	O
viable	O
therapeutic	O
option	O
because	O
intestinal	O
stem	O
cells	O
are	O
highly	O
vulnerable	O
to	O
ionizing	O
radiation	O
(	O
IR	O
)	O
and	O
stem	O
cell	O
loss	O
explains	O
its	O
intractability	O
to	O
general	O
treatment	O
.	O

Here	O
,	O
we	O
investigated	O
either	O
prophylactic	O
or	O
therapeutic	O
efficacy	O
of	O
human	O
placenta	O
-derived	O
mesenchymal	O
stem	O
cells	O
(	O
hPDSCs	O
)	O
against	O
radiation	O
enteropathy	O
and	O
could	O
identify	O
biomarkers	O
predicting	O
a	O
favorable	O
response	O
to	O
stem	O
cell	O
therapy	O
.	O

We	O
challenged	O
a	O
radiation-induced	O
enteropathy	O
model	O
with	O
hPDSCs	O
.	O

After	O
sacrifice	O
,	O
we	O
checked	O
the	O
gross	O
anatomy	O
of	O
small	O
intestine	O
,	O
histology	O
gross	O
,	O
and	O
analyzed	O
that	O
,	O
accompanied	O
with	O
molecular	O
changes	O
implicated	O
in	O
this	O
model	O
.	O

hPDSCs	O
significantly	O
improved	O
the	O
outcome	O
of	O
mice	O
induced	O
with	O
either	O
radiation	O
enteropathy	O
or	O
lethal	O
radiation	O
syndrome	O
(	O
P	O
<	O
0.01	O
)	O
.	O

hPDSCs	O
exerted	O
inhibitory	O
actions	O
on	O
inflammatory	O
cytokines	O
,	O
the	O
re-establishment	O
of	O
epithelium	O
homeostasis	O
was	O
completed	O
with	O
increasing	O
endogenous	O
restorative	O
processes	O
as	O
assessed	O
with	O
increased	O
levels	O
of	O
proliferative	O
markers	O
in	O
the	O
hPDSCs	O
group	O
,	O
and	O
a	O
significant	O
inhibition	O
of	O
IR	O
-	O
induced	O
apoptosis	O
.	O

The	O
preservation	B-P
of	O
cells	O
expressing	O
lysozyme	O
,	O
and	O
Musashi-1	O
were	O
significantly	O
increased	O
in	O
the	O
hPDSC	O
treatment	O
group	O
.	O

Both	O
preventive	O
and	O
therapeutic	O
efficacies	O
of	O
hPDSCs	O
were	O
noted	O
against	O
IR-induced	O
enteropathy	O
.	O

Label-free	O
quantification	O
was	O
used	O
to	O
identify	O
biomarkers	O
which	O
predict	O
favorable	O
responses	O
after	O
hPDSC	O
treatment	O
,	O
and	O
finally	O
glutathione	O
S-transferase-mu	O
type	O
,	O
interleukin-10	O
,	O
and	O
peroxiredoxin-2	O
were	O
validated	O
as	O
proteomic	O
biomarkers	O
predicting	O
a	O
favorable	O
response	O
to	O
hPDSCs	O
in	O
radiation	O
enteropathy	O
.	O

hPDSCs	O
may	O
be	O
a	O
useful	O
prophylactic	O
and	O
therapeutic	O
cell	O
therapy	O
for	O
radiation	O
enteropathy	O
.	O

Staphylococcus	O
pseudintermedius	O
Human	O
Infection	O
Cases	O
in	O
Spain	O
:	O
Dog	O
-to-	O
Human	O
Transmission	O
.	O

Staphylococcus	O
pseudintermedius	O
is	O
an	O
opportunistic	O
pathogen	O
that	O
has	O
been	O
identified	O
as	O
infectious	O
agent	O
or	O
colonizer	O
mainly	O
in	O
dogs	O
.	O

S.	O
pseudintermedius	O
has	O
been	O
also	O
detected	O
in	O
humans	O
and	O
more	O
specifically	O
in	O
people	O
in	O
contact	O
with	O
dogs	O
.	O

In	O
this	O
study	O
,	O
the	O
possible	O
S.	O
pseudintermedius	O
pet	O
-to-	O
human	O
transmission	O
was	O
analyzed	O
in	O
four	O
clinical	O
human	O
cases	O
.	O

Two	O
patients	O
were	O
dog	O
owners	O
and	O
S.	O
pseudintermedius	O
was	O
also	O
detected	O
as	O
colonizer	O
in	O
these	O
healthy	O
animals	O
.	O

S.	O
pseudintermedius	O
isolates	O
from	O
patients	O
and	O
dogs	O
of	O
the	O
same	O
household	O
showed	O
identical	O
pulsed-field	B-P
gel	I-P
electrophoresis	I-P
patterns	O
,	O
sequence	O
types	O
(	O
STs	O
)	O
,	O
and	O
antimicrobial	O
resistance	O
phenotypes	O
and	O
genotypes	O
,	O
and	O
were	O
methicillin	O
susceptible	O
.	O

Resistance	O
to	O
erythromycin	O
,	O
clindamycin	O
,	O
tetracycline	O
,	O
trimetoprim-sulfamethoxazole	O
,	O
and/or	O
ciprofloxacin	O
was	O
identified	O
among	O
S.	O
pseudintermedius	O
strains	O
.	O

The	O
lineages	O
ST241	O
and	O
the	O
new	O
ST521	O
were	O
detected	O
in	O
the	O
strains	O
of	O
the	O
two	O
dog	O
-	O
owner	O
patients	O
,	O
respectively	O
.	O

The	O
strains	O
from	O
the	O
other	O
two	O
patients	O
presented	O
two	O
new	O
STs	O
,	O
ST719	O
and	O
ST720	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
description	O
of	O
human	O
infections	O
caused	O
by	O
S.	O
pseudintermedius	O
in	O
Spain	O
.	O

Meningitis	O
due	O
to	O
Moraxella	O
nonliquefaciens	O
in	O
a	O
paediatric	O
patient	O
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

Introduction	O
.	O

Moraxella	O
nonliquefaciens	O
is	O
an	O
unusual	O
organism	O
to	O
be	O
isolated	O
from	O
cerebral	O
spinal	O
fluid	O
(	O
CSF	O
)	O
and	O
there	O
exists	O
only	O
one	O
case	O
report	O
of	O
M.	O
nonliquefaciens	O
meningitis	O
from	O
a	O
neonate	O
.	O

Moraxella	O
species	O
normally	O
exist	O
as	O
part	O
of	O
the	O
human	O
upper	O
respiratory	O
tract	O
flora	O
and	O
rarely	O
cause	O
invasive	O
human	O
disease	O
.	O

There	O
are	O
only	O
a	O
handful	O
of	O
case	O
reports	O
implicating	O
the	O
organism	O
as	O
a	O
cause	O
of	O
endocarditis	O
,	O
bacteraemia	O
,	O
septic	O
arthritis	O
and	O
endophthalmitis	O
.	O

Identification	O
to	O
the	O
species	O
level	O
based	O
on	O
routine	O
laboratory	O
techniques	O
has	O
been	O
challenging	O
,	O
with	O
final	O
identification	O
often	O
made	O
through	O
16S	B-P
rRNA	I-P
sequencing	I-P
.	O

With	O
the	O
use	O
of	O
a	O
newer	O
diagnostic	O
tool	O
,	O
matrix-assisted	O
laser	O
desorption	O
ionization-time	O
of	O
flight	O
(	O
MALDI-TOF	O
)	O
MS	O
,	O
we	O
were	O
able	O
to	O
rapidly	O
identify	O
the	O
organism	O
and	O
initiate	O
appropriate	O
treatment	O
.	O

Case	O
presentation	O
.	O

We	O
present	O
a	O
rare	O
care	O
of	O
M.	O
nonliquefaciens	O
meningitis	O
in	O
a	O
paediatric	O
patient	O
with	O
an	O
underlying	O
cranial	O
anatomical	O
defect	O
due	O
to	O
Crouzon	O
syndrome	O
.	O

She	O
had	O
been	O
admitted	O
to	O
hospital	O
3	O
months	O
previously	O
with	O
Streptococcus	O
pneumoniae	O
meningitis	O
and	O
mastoiditis	O
,	O
and	O
returned	O
to	O
the	O
emergency	O
department	O
with	O
meningismus	O
.	O

CSF	B-P
culture	I-P
grew	O
M.	O
nonliquefaciens	O
.	O

She	O
was	O
treated	O
with	O
ceftriaxone	O
with	O
rapid	O
improvement	O
and	O
eventually	O
was	O
taken	O
for	O
endoscopic	B-P
surgical	I-P
repair	O
of	O
a	O
right	O
encephalocele	O
defect	O
.	O

Conclusion	O
.	O

The	O
use	O
of	O
MALDI-TOF	O
MS	O
allowed	O
for	O
the	O
rapid	O
identification	O
of	O
the	O
organism	O
.	O

The	O
patient	O
recovered	O
with	O
appropriate	O
antimicrobial	O
therapy	O
and	O
eventual	O
surgical	O
correction	O
.	O

An	O
underlying	O
anatomical	O
defect	O
should	O
be	O
considered	O
in	O
all	O
patients	O
who	O
present	O
with	O
meningitis	O
due	O
to	O
this	O
unusual	O
organism	O
.	O

A	O
novel	O
combination	O
treatment	O
to	O
stimulate	O
bone	O
healing	O
and	O
regeneration	O
under	O
hypoxic	O
conditions	O
:	O
photobiomodulation	O
and	O
melatonin	O
.	O

Melatonin	O
has	O
anabolic	O
effects	O
on	O
the	O
bone	O
,	O
even	O
under	O
hypoxia	O
,	O
and	O
laser	O
irradiation	O
has	O
been	O
shown	O
to	O
improve	O
osteoblastic	O
differentiation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
laser	O
irradiation	O
and	O
melatonin	O
would	O
have	O
synergistic	O
effects	O
on	O
osteoblastic	O
differentiation	O
and	O
mineralization	O
under	O
hypoxic	O
conditions	O
.	O

MC3T3-E1	O
cells	O
were	O
exposed	O
to	O
1	O
%	O
oxygen	O
tension	O
for	O
the	O
hypoxia	O
condition	O
.	O

The	O
cells	O
were	O
divided	O
into	O
four	O
groups	O
:	O
G1	O
-	O
osteoblast	O
differentiation	O
medium	O
only	O
(	O
as	O
the	O
hypoxic	O
condition	O
)	O
,	O
G2	O
-	O
treatment	O
with	O
50	O
μM	O
melatonin	O
only	O
,	O
G3	O
-	O
laser	O
irradiation	O
(	O
808	O
nm	O
,	O
80	O
mW	O
,	O
GaAlAs	O
diode	O
)	O
only	O
,	O
and	O
G4	O
-	O
treatment	O
with	O
50	O
μM	O
melatonin	O
and	O
laser	O
irradiation	O
(	O
808	O
nm	O
,	O
80	O
mW	O
,	O
GaAlAs	O
diode	O
)	O
.	O

Immunoblotting	B-P
showed	O
that	O
osterix	O
expression	O
was	O
markedly	O
increased	O
in	O
the	O
melatonin	O
-	O
treated	O
and	O
laser-irradiated	O
cells	O
at	O
48	O
and	O
72	O
h.	O
In	O
addition	O
,	O
alkaline	O
phosphatase	O
activity	O
significantly	O
increased	O
and	O
continued	O
to	O
rise	O
throughout	O
the	O
experiment	O
.	O

Alizarin	B-P
Red	I-P
staining	I-P
showed	O
markedly	O
increased	O
mineralized	O
nodules	O
as	O
compared	O
with	O
only	O
melatonin	O
-	O
treated	O
or	O
laser-irradiated	O
cells	O
at	O
day	O
7	O
,	O
which	O
significantly	O
increased	O
by	O
day	O
14	O
.	O

Moreover	O
,	O
when	O
melatonin	O
-	O
treated	O
cells	O
were	O
laser-irradiated	O
,	O
the	O
differentiation	O
and	O
mineralization	O
of	O
cells	O
were	O
found	O
to	O
involve	O
p38	O
MAPK	O
and	O
PRKD1	O
signaling	O
mechanisms	O
.	O

However	O
,	O
the	O
enhanced	O
effects	O
of	O
laser	O
irradiation	O
with	O
melatonin	O
were	O
markedly	O
inhibited	O
when	O
the	O
cells	O
were	O
treated	O
with	O
luzindole	O
,	O
a	O
selective	O
melatonin	O
receptor	O
antagonist	O
.	O

Therefore	O
,	O
we	O
concluded	O
that	O
laser	O
irradiation	O
could	O
promote	O
the	O
effect	O
of	O
melatonin	O
on	O
the	O
differentiation	O
and	O
mineralization	O
of	O
MC3T3-E1	O
cells	O
under	O
hypoxic	O
conditions	O
,	O
and	O
that	O
this	O
process	O
is	O
mediated	O
through	O
melatonin	O
1/2	O
receptors	O
and	O
PKRD	O
/	O
p38	O
signaling	O
pathways	O
.	O

Endpoints	O
for	O
screening	B-P
thyroid	O
cancer	O
in	O
the	O
Republic	O
of	O
Korea	O
:	O
thyroid	O
specialists	O
'	O
perspectives	O
.	O

Cancer	B-P
screening	I-P
is	O
aimed	O
primarily	O
at	O
reducing	O
deaths	O
from	O
the	O
specific	O
cancer	O
.	O

Thyroid-specific	O
cancer	O
mortality	O
may	O
be	O
the	O
most	O
ambitious	O
endpoint	O
for	O
obtaining	O
estimates	O
of	O
screening	O
effect	O
.	O

Numerous	O
observations	B-P
have	O
accumulated	O
over	O
the	O
years	O
,	O
indicating	O
that	O
thyroid	O
cancer	O
mortality	O
endpoint	O
has	O
been	O
difficult	O
to	O
study	O
and	O
is	O
confounded	O
by	O
population	O
heterogeneity	O
,	O
provision	O
of	O
randomization	O
,	O
and	O
requirement	O
of	O
large	O
cohorts	O
with	O
sufficiently	O
long	O
follow-up	O
due	O
to	O
the	O
excellent	O
prognosis	O
of	O
the	O
cancer	O
.	O

Accordingly	O
,	O
it	O
may	O
be	O
important	O
to	O
reconsider	O
how	O
to	O
best	O
measure	O
thyroid	O
cancer	O
screening	B-P
efficacy	O
.	O

Recommendations	O
against	O
thyroid	O
cancer	O
screening	B-P
should	O
be	O
based	O
upon	O
trials	O
designed	O
to	O
evaluate	O
its	O
effectiveness	O
not	O
only	O
in	O
significant	O
reduction	O
in	O
cancer	O
mortality	O
,	O
but	O
also	O
of	O
other	O
distinct	O
endpoint	O
s.	O
It	O
is	O
desirable	O
to	O
evaluate	O
derivative	O
endpoints	O
that	O
can	O
reliably	O
predict	O
reductions	O
in	O
mortality	O
.	O

The	O
term	O
``	O
derivative	O
''	O
means	O
a	O
variable	O
that	O
is	O
related	O
to	O
the	O
true	O
endpoint	O
and	O
is	O
likely	O
to	O
be	O
observable	O
before	O
the	O
primary	O
endpoint	O
.	O

Derivative	O
endpoints	O
may	O
include	O
thyroid	O
cancer	O
incidence	O
,	O
the	O
proportion	O
of	O
early-stage	O
tumors	O
detected	O
,	O
more	O
treatable	O
stage	O
,	O
the	O
identification	O
of	O
small	O
tumors	O
(	O
to	O
maintain	O
in	O
observation	O
)	O
,	O
decrease	O
in	O
the	O
number	O
of	O
people	O
who	O
develop	O
metastatic	O
disease	O
,	O
the	O
increased	O
chance	O
of	O
lesser	O
extent	O
surgery	O
,	O
and	O
the	O
application	O
of	O
minimally	O
invasive	O
approaches	O
,	O
as	O
well	O
as	O
no	O
need	O
for	O
lifelong	O
thyroid	O
replacement	O
therapy	O
,	O
a	O
consistent	O
follow-up	O
,	O
low-dose	O
or	O
no	O
RAI	B-P
administration	I-P
and	O
risk	O
factor	O
assessments	O
where	O
case	O
findings	O
should	O
be	O
continuous	O
.	O

The	O
Korean	O
guidelines	O
for	O
thyroid	O
cancer	O
national-level	O
screening	O
were	O
published	O
by	O
a	O
relevant	O
group	O
of	O
multidisciplinary	B-P
thyroid	I-P
experts	I-P
.	O

It	O
was	O
concluded	O
that	O
the	O
evidence	O
is	O
insufficient	O
to	O
balance	O
the	O
benefits	O
and	O
harms	O
of	O
thyroid	O
cancer	O
screening	B-P
.	O

However	O
,	O
the	O
paper	O
seems	O
to	O
raise	O
the	O
necessary	O
investments	O
in	O
future	O
research	O
and	O
demand	O
a	O
complete	O
analysis	O
for	O
derivative	O
endpoints	O
,	O
and	O
offer	O
screening	O
participants	O
with	O
complete	O
information	O
necessary	O
to	O
make	O
decisions	O
that	O
will	O
provide	O
them	O
with	O
the	O
most	O
value	O
when	O
a	O
small	O
thyroid	O
cancer	O
is	O
screen-	O
identified	O
.	O

The	O
effects	O
of	O
captopril	O
on	O
lipopolysaccharide	O
induced	O
learning	O
and	O
memory	O
impairments	O
and	O
the	O
brain	O
cytokine	O
levels	O
and	O
oxidative	O
damage	O
in	O
rats	O
.	O

Renin-angiotensin	O
system	O
has	O
a	O
role	O
in	O
inflammation	O
and	O
also	O
involves	O
in	O
learning	O
and	O
memory	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effects	O
of	O
captopril	O
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induced	O
learning	O
and	O
memory	O
impairments	O
,	O
hippocampal	O
cytokine	O
levels	O
and	O
brain	O
tissues	O
oxidative	O
damage	O
was	O
investigated	O
.	O

The	O
rats	O
were	O
divided	O
and	O
treated	O
:	O
[	O
1	O
]	O
saline	O
(	O
Control	O
)	O
,	O
[	O
2	O
]	O
LPS	O
(	O
1mg/kg	O
)	O
,	O
[	O
3-5	O
]	O
10	O
,	O
50	O
or	O
100mg/kg	O
captopril	O
30min	O
before	O
LPS	O
.	O

The	O
treatment	O
was	O
started	O
since	O
six	O
days	O
before	O
the	O
behavioral	B-P
experiments	I-P
and	O
continued	O
during	O
the	O
behavioral	B-P
tests	I-P
(	O
LPS	O
injection	O
two	O
h	O
before	O
each	O
behavioral	B-P
experiment	I-P
)	O
.	O

Administration	O
of	O
LPS	O
prolonged	O
the	O
escape	O
latency	O
and	O
traveled	O
path	O
to	O
find	O
the	O
platform	O
in	O
Morris	B-P
water	I-P
maze	I-P
(	I-P
MWM	I-P
)	I-P
test	I-P
(	O
P	O
<	O
0.01-P	O
<	O
0.001	O
)	O
while	O
,	O
shortened	O
the	O
latency	O
to	O
enter	O
the	O
dark	O
compartment	O
in	O
passive	O
avoidance	O
(	O
PA	O
)	O
test	B-P
(	O
P	O
<	O
0.001	O
)	O
.	O

Pretreatment	O
by	O
all	O
doses	O
of	O
captopril	O
improved	O
performances	O
of	O
the	O
rats	O
in	O
MWM	B-P
(	O
P	O
<	O
0.05-P	O
<	O
0.001	O
)	O
and	O
also	O
prolonged	O
the	O
latency	O
to	O
enter	O
the	O
dark	O
in	O
PA	O
test	B-P
(	O
P	O
<	O
0.001	O
)	O
.	O

LPS	O
also	O
increased	O
IL-6	O
,	O
TNF-α	O
,	O
malondialdehyde	O
(	O
MDA	O
)	O
and	O
nitric	O
oxide	O
(	O
NO	O
)	O
metabolites	O
in	O
the	O
hippocampal	O
tissues	O
(	O
P	O
<	O
0.05-P	O
<	O
0.001	O
)	O
which	O
were	O
prevented	O
by	O
captopril	O
(	O
P	O
<	O
0.05-P	O
<	O
0.001	O
)	O
.	O

The	O
thiol	O
,	O
superoxide	O
dismutase	O
(	O
SOD	O
)	O
and	O
catalase	O
(	O
CAT	O
)	O
in	O
the	O
hippocampus	O
of	O
LPS	O
group	O
were	O
lower	O
than	O
the	O
control	O
(	O
P	O
<	O
0.001	O
)	O
while	O
,	O
they	O
were	O
enhanced	O
when	O
the	O
aniamls	O
were	O
pretreated	O
by	O
captopril	O
(	O
P	O
<	O
0.01-P	O
<	O
0.001	O
)	O
.	O

The	O
results	O
of	O
present	O
study	O
showed	O
that	O
captopril	O
improved	O
the	O
LPS	O
-	O
induced	O
learning	O
and	O
memory	O
impairments	O
in	O
rats	O
which	O
were	O
accompanied	O
with	O
attenuating	O
hippocampal	O
cytokine	O
levels	O
and	O
improving	O
the	O
brain	O
tissues	O
oxidative	O
damage	O
criteria	O
.	O

Ultrasonography	B-P
for	O
acute	O
appendicitis	O
-	O
the	O
way	O
it	O
looks	O
today	O
.	O

Despite	O
sophisticated	O
physical	O
examination	O
and	O
laboratory	B-P
support	I-P
,	O
diagnosis	O
of	O
acute	O
appendicitis	O
remained	O
challenging	O
in	O
clinical	O
practice	O
with	O
a	O
negative	O
appendectomy	O
rate	O
of	O
15	O
-	O
30	O
%	O
.	O

As	O
a	O
remarkable	O
clue	O
and	O
as	O
early	O
as	O
1986	O
,	O
ultrasonography	B-P
(	O
US	B-P
)	O
has	O
been	O
proven	O
a	O
reliable	O
diagnostic	B-P
method	I-P
that	O
is	O
also	O
explicitly	O
helpful	O
in	O
difficult	O
cases	O
with	O
atypical	O
presentation	O
and	O
enables	O
to	O
rule	O
out	O
many	O
differential	B-P
diagnoses	I-P
.Recent	O
publications	O
emphasized	O
the	O
role	O
of	O
multidetector	B-P
computed	I-P
tomography	I-P
(	O
CT	B-P
)	O
resulting	O
in	O
a	O
significant	O
reduction	O
of	O
false	O
negative	O
findings	O
at	O
operation	O
.	O

Extensive	O
as	O
well	O
as	O
uncritical	O
application	O
of	O
this	O
method	O
even	O
in	O
children	O
inevitably	O
causes	O
substantial	O
radiation	O
exposure	O
,	O
a	O
sequel	O
to	O
either	O
pure	O
ignorance	O
or	O
unqualified/	O
inadequate	O
performance	O
of	O
US	B-P
in	O
this	O
particular	O
situation	O
,	O
which	O
in	O
turn	O
can	O
be	O
considered	O
sequel	O
to	O
either	O
egocentric	O
or	O
economic	O
preponderance	O
.Recent	O
data	O
shed	O
new	O
light	O
on	O
the	O
role	O
of	O
US	B-P
(	O
and	O
CT	B-P
)	O
in	O
acute	O
appendicitis	O
.	O

Therefore	O
,	O
1	O
generation	O
after	O
US	B-P
with	I-P
graded	I-P
compression	I-P
was	O
etched	O
in	O
stone	O
as	O
the	O
method	O
of	O
choice	O
for	O
diagnosing	O
acute	O
appendicitis	O
(	O
Puylaert	O
)	O
,	O
a	O
visual	O
arousal	O
fostering	O
its	O
role	O
and	O
performance	O
in	O
clinical	O
medicine	O
appears	O
justified	O
.	O

Generation	O
and	O
analyses	O
of	O
human	O
synthetic	O
antibody	O
libraries	O
and	O
their	O
application	O
for	O
protein	O
microarrays	O
.	O

Antibody	O
-based	O
proteomics	O
offers	O
distinct	O
advantages	O
in	O
the	O
analysis	O
of	O
complex	O
samples	O
for	O
discovery	O
and	O
validation	O
of	O
biomarkers	O
associated	O
with	O
disease	O
.	O

However	O
,	O
its	O
large-scale	O
implementation	O
requires	O
tools	O
and	O
technologies	O
that	O
allow	O
development	O
of	O
suitable	O
antibody	O
or	O
antibody	O
fragments	O
in	O
a	O
high-throughput	O
manner	O
.	O

To	O
address	O
this	O
we	O
designed	O
and	O
constructed	O
two	O
human	O
synthetic	O
antibody	O
fragment	O
(	O
scFv	O
)	O
libraries	O
denoted	O
HelL-11	O
and	O
HelL-13	O
.	O

By	O
the	O
use	O
of	O
phage	O
display	O
technology	O
,	O
in	O
total	O
466	O
unique	O
scFv	O
antibodies	O
specific	O
for	O
114	O
different	O
antigens	O
were	O
generated	O
.	O

The	O
specificities	O
of	O
these	O
antibodies	O
were	O
analyzed	O
in	O
a	O
variety	O
of	O
immunochemical	B-P
assays	I-P
and	O
a	O
subset	O
was	O
further	O
evaluated	O
for	O
functionality	O
in	O
protein	O
microarray	O
applications	O
.	O

This	O
high-throughput	O
approach	O
demonstrates	O
the	O
ability	O
to	O
rapidly	O
generate	O
a	O
wealth	O
of	O
reagents	O
not	O
only	O
for	O
proteome	O
research	O
,	O
but	O
potentially	O
also	O
for	O
diagnostics	O
and	O
therapeutics	O
.	O

In	O
addition	O
,	O
this	O
work	O
provides	O
a	O
great	O
example	O
on	O
how	O
a	O
synthetic	O
approach	O
can	O
be	O
used	O
to	O
optimize	O
library	O
designs	O
.	O

By	O
having	O
precise	O
control	O
of	O
the	O
diversity	O
introduced	O
into	O
the	O
antigen	O
-	O
binding	O
sites	O
,	O
synthetic	O
libraries	O
offer	O
increased	O
understanding	O
of	O
how	O
different	O
diversity	O
contributes	O
to	O
antibody	O
binding	O
reactivity	O
and	O
stability	O
,	O
thereby	O
providing	O
the	O
key	O
to	O
future	O
library	O
optimization	O
.	O

Evaluation	O
of	O
a	O
New	O
Brain	O
Tissue	O
Probe	O
for	O
Cerebral	O
Blood	O
Flow	O
Monitoring	O
in	O
an	O
Experimental	O
Pig	O
Model	O
.	O

Bedside	O
monitoring	O
of	O
cerebral	O
blood	O
flow	O
(	O
CBF	O
)	O
may	O
provide	O
new	O
insights	O
into	O
the	O
pathophysiology	O
of	O
brain	O
injury	O
,	O
allow	O
early	O
detection	O
of	O
secondary	O
ischemia	O
,	O
and	O
help	O
guide	O
therapy	O
.	O

To	O
evaluate	O
a	O
new	O
brain	O
tissue	O
probe	O
for	O
serial	O
CBF	O
monitoring	O
using	O
near-infrared	B-P
spectroscopy	I-P
and	O
indocyanine	O
green	O
dye	B-P
dilution	I-P
(	O
NeMo	O
Probe	O
)	O
compared	O
with	O
the	O
existing	O
thermal	O
diffusion	O
probe	O
(	O
QFlow	O
500	O
Probe	O
)	O
.	O

In	O
7	O
pigs	O
,	O
the	O
NeMo	O
Probe	O
and	O
QFlow	O
500	O
Probe	O
were	O
inserted	O
into	O
the	O
subcortical	O
white	O
matter	O
.	O

Parallel	O
measurements	O
were	O
recorded	O
during	O
(	O
1	O
)	O
baseline	O
,	O
(	O
2	O
)	O
hypotension	O
,	O
(	O
3	O
)	O
hypertension	O
,	O
and	O
(	O
4	O
)	O
hyperventilation	O
.	O

Thereafter	O
,	O
protocol	O
points	O
1	O
through	O
4	O
were	O
repeated	O
once	O
.	O

The	O
Spearman	O
correlation	O
(	O
rs	O
)	O
,	O
Bland-Altman	O
plot	O
,	O
concordance	O
rate	O
,	O
and	O
coefficient	O
of	O
variation	O
were	O
used	O
for	O
statistical	O
analysis	O
.	O

There	O
was	O
poor	O
agreement	O
between	O
56	O
pairs	O
of	O
absolute	O
CBF	O
values	O
(	O
rs	O
=	O
0.52	O
,	O
P	O
<	O
.001	O
)	O
.	O

The	O
mean	O
bias	O
was	O
10.7	O
mL·100	O
g·min	O
with	O
limits	O
of	O
agreement	O
of	O
-33.0	O
to	O
54.3	O
mL·100	O
g·min	O
.	O

The	O
analysis	O
of	O
49	O
pairs	O
of	O
changes	O
in	O
CBF	O
showed	O
a	O
good	O
correlation	O
(	O
rs	O
=	O
0.83	O
,	O
P	O
<	O
.001	O
)	O
,	O
and	O
the	O
concordance	O
rate	O
was	O
93.3	O
%	O
.	O

The	O
coefficient	O
of	O
variation	O
from	O
repeated	O
measurements	O
under	O
comparable	O
physiological	O
conditions	O
was	O
51.6	O
%	O
for	O
the	O
QFlow	O
500	O
Probe	O
and	O
12.9	O
%	O
for	O
the	O
NeMo	O
Probe	O
.	O

Absolute	O
CBF	O
values	O
obtained	O
with	O
the	O
NeMo	O
Probe	O
and	O
QFlow	O
500	O
Probe	O
can	O
not	O
be	O
interpreted	O
as	O
equivalent	O
.	O

However	O
,	O
the	O
NeMo	O
Probe	O
provides	O
acceptable	O
trending	O
ability	O
and	O
reproducibility	O
from	O
repeated	O
measurements	O
,	O
whereas	O
the	O
reproducibility	O
of	O
the	O
QFlow	O
500	O
Probe	O
was	O
poor	O
.	O

Future	O
clinical	O
studies	O
are	O
warranted	O
to	O
evaluate	O
the	O
NeMo	O
Probe	O
in	O
the	O
setting	O
of	O
acute	O
brain	O
injury	O
.	O

CBF	O
,	O
cerebral	O
blood	O
flow	O
CBV	O
,	O
cerebral	O
blood	O
volume	O
ICG	O
,	O
indocyanine	O
green	O
ICP	O
,	O
intracranial	O
pressure	O
MAP	O
,	O
mean	O
arterial	O
pressure	O
mttICG	O
,	O
mean	O
transit	O
time	O
of	O
indocyanine	O
green	O
NIRS	B-P
,	O
near-infrared	B-P
spectroscopy	I-P
.	O

Is	O
Localized	O
Scleroderma	O
Caused	O
by	O
Borrelia	O
burgdorferi	O
?	O
.	O

Despite	O
considerable	O
achievements	O
in	O
the	O
study	O
of	O
localized	O
scleroderma	O
,	O
the	O
etiology	O
of	O
the	O
disease	O
has	O
not	O
been	O
investigated	O
completely	O
.	O

Borrelia	O
burgdorferi	O
-the	O
agent	O
of	O
Lyme	O
disease	O
-is	O
suggested	O
to	O
be	O
one	O
of	O
the	O
possible	O
etiological	O
factors	O
of	O
localized	O
scleroderma	O
.	O

However	O
,	O
among	O
scientists	O
,	O
this	O
hypothesis	O
is	O
quite	O
controversial	O
.	O

We	O
have	O
conducted	O
investigations	O
of	O
the	O
level	O
of	O
IgM	O
and	O
IgG	O
class	O
antibodies	O
to	O
B.	O
burgdorferi	O
in	O
the	O
serum	O
of	O
patients	O
with	O
localized	O
scleroderma	O
.	O

To	O
rationally	O
substantiate	O
the	O
role	O
of	O
B.	O
burgdorferi	O
in	O
the	O
occurrence	O
of	O
localized	O
scleroderma	O
,	O
thirty-two	O
patients	O
with	O
localized	O
scleroderma	O
treated	O
at	O
an	O
in-patient	O
department	O
were	O
examined	O
.	O

The	O
level	O
of	O
anti-Borrelia	O
antibodies	O
was	O
determined	O
in	O
ELISA	B-P
.	O

Diagnostic	O
levels	O
of	O
IgM	O
and/or	O
IgG	O
were	O
detected	O
in	O
18.8	O
%	O
of	O
patients	O
with	O
localized	O
scleroderma	O
,	O
which	O
is	O
more	O
than	O
in	O
the	O
population	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Positive	O
levels	O
of	O
anti-Borrelia	O
antibodies	O
in	O
patients	O
with	O
localized	O
scleroderma	O
confirm	O
the	O
borreliosis	O
nature	O
of	O
the	O
disease	O
,	O
requiring	O
conduction	O
of	O
complex	O
antimicrobial	O
treatment	O
.	O

Artificial	O
spatiotemporal	O
touch	O
inputs	O
reveal	O
complementary	O
decoding	O
in	O
neocortical	O
neurons	O
.	O

Investigations	O
of	O
the	O
mechanisms	O
of	O
touch	O
perception	O
and	O
decoding	O
has	O
been	O
hampered	O
by	O
difficulties	O
in	O
achieving	O
invariant	O
patterns	O
of	O
skin	O
sensor	O
activation	O
.	O

To	O
obtain	O
reproducible	O
spatiotemporal	O
patterns	O
of	O
activation	O
of	O
sensory	O
afferents	O
,	O
we	O
used	O
an	O
artificial	O
fingertip	O
equipped	O
with	O
an	O
array	O
of	O
neuromorphic	O
sensors	O
.	O

The	O
artificial	O
fingertip	O
was	O
used	O
to	O
transduce	O
real-world	O
haptic	O
stimuli	O
into	O
spatiotemporal	O
patterns	O
of	O
spikes	O
.	O

These	O
spike	O
patterns	O
were	O
delivered	O
to	O
the	O
skin	O
afferents	O
of	O
the	O
second	O
digit	O
of	O
rats	O
via	O
an	O
array	O
of	O
stimulation	O
electrodes	O
.	O

Combined	O
with	O
low	O
-	O
noise	O
intra	O
-	O
and	O
extracellular	O
recordings	O
from	O
neocortical	O
neurons	O
in	O
vivo	O
,	O
this	O
approach	O
provided	O
a	O
previously	O
inaccessible	O
high	B-P
resolution	I-P
analysis	O
of	O
the	O
representation	O
of	O
tactile	O
information	O
in	O
the	O
neocortical	O
neuronal	O
circuitry	O
.	O

The	O
results	O
indicate	O
high	O
information	O
content	O
in	O
individual	O
neurons	O
and	O
reveal	O
multiple	O
novel	O
neuronal	O
tactile	O
coding	O
features	O
such	O
as	O
heterogeneous	O
and	O
complementary	O
spatiotemporal	O
input	O
selectivity	O
also	O
between	O
neighboring	O
neurons	O
.	O

Such	O
neuronal	O
heterogeneity	O
and	O
complementariness	O
can	O
potentially	O
support	O
a	O
very	O
high	O
decoding	O
capacity	O
in	O
a	O
limited	O
population	O
of	O
neurons	O
.	O

Our	O
results	O
also	O
indicate	O
a	O
potential	O
neuroprosthetic	O
approach	O
to	O
communicate	O
with	O
the	O
brain	O
at	O
a	O
very	O
high	B-P
resolution	I-P
and	O
provide	O
a	O
potential	O
novel	O
solution	O
for	O
evaluating	O
the	O
degree	O
or	O
state	O
of	O
neurological	O
disease	O
in	O
animal	O
models	O
.	O

Knee	O
Loading	O
Deficits	O
During	O
Dynamic	O
Tasks	O
in	O
Individuals	O
Following	O
ACL	O
Reconstruction	O
.	O

Study	O
Design	O
Controlled	B-P
laboratory	I-P
study	I-P
,	O
cross-sectional	O
.	O

Background	O
Well	O
documented	O
deficits	O
in	O
sagittal	O
plane	O
knee	O
loading	O
,	O
during	O
dynamic	O
tasks	O
indicate	O
individuals	O
limit	O
the	O
magnitude	O
of	O
knee	O
loading	O
following	O
anterior	O
cruciate	O
ligament	O
reconstruction	O
(	O
ACLR	O
)	O
.	O

It	O
is	O
unknown	O
how	O
these	O
individuals	O
modulate	O
the	O
speed	O
of	O
knee	O
flexion	O
during	O
loading	O
,	O
which	O
is	O
particularly	O
important	O
as	O
they	O
progress	O
to	O
running	O
during	O
rehabilitation	O
.	O

Objective	O
To	O
investigate	O
how	O
individuals	O
following	O
anterior	O
cruciate	O
ligament	O
reconstruction	O
perform	O
dynamic	O
knee	O
loading	O
tasks	O
compared	O
to	O
healthy	O
controls	O
.	O

Methods	O
Two	O
groups	O
of	O
recreationally	O
active	O
individuals	O
participated	O
;	O
15	O
healthy	O
controls	O
(	O
CTRL	O
)	O
and	O
15	O
post-ACLR	O
(	O
ACLR	O
)	O
.	O

Participants	O
performed	O
3	O
trials	O
of	O
over-ground	O
running	O
(	O
RUN	O
)	O
and	O
a	O
single	O
limb	O
loading	O
(	O
SLL	O
)	O
task	O
.	O

Sagittal	O
plane	O
range	O
of	O
motion	O
,	O
peak	O
knee	O
extensor	O
moment	O
,	O
peak	O
knee	O
flexion	O
angular	O
velocity	O
,	O
peak	O
knee	O
power	O
absorption	O
,	O
and	O
rate	O
of	O
knee	O
extensor	O
moment	O
were	O
calculated	O
during	O
deceleration	O
.	O

Mixed-factor	O
multivariate	O
analysis	O
of	O
variance	O
was	O
performed	O
to	O
compare	O
differences	O
in	O
variables	O
between	O
groups	O
(	O
ACLR	O
and	O
CTRL	O
)	O
,	O
limbs	O
(	O
within	O
ACLR	O
)	O
and	O
tasks	O
(	O
within	O
CTRL	O
)	O
.	O

Results	O
Knee	O
power	O
absorption	O
,	O
knee	O
flexion	O
angular	O
velocity	O
and	O
rate	O
of	O
knee	O
extensor	O
moment	O
were	O
decreased	O
in	O
reconstructed	O
limbs	O
(	O
SLL	O
:5.6W/kg	O
;	O
325.8deg/s	O
;	O
10.5Nm/kg/s	O
,	O
RUN	O
:11.8W/kg	O
;	O
421.4deg/s	O
;	O
38.2Nm/kg/s	O
,	O
respectively	O
)	O
compared	O
to	O
non-surgical	O
limbs	O
(	O
SLL	O
:9.7W/kg	O
;	O
432.0deg/s	O
;	O
19.1Nm/kg/s	O
,	O
RUN	O
:18.8W/kg	O
;	O
494.1deg/s	O
;	O
72.8Nm/kg/s	O
,	O
respectively	O
)	O
during	O
both	O
tasks	O
(	O
p	O
<	O
0.001	O
)	O
.	O

The	O
magnitude	O
of	O
between	O
limb	O
differences	O
in	O
knee	O
flexion	O
angular	O
velocity	O
were	O
similar	O
in	O
both	O
tasks	O
.	O

Conclusion	O
Despite	O
lower	O
loading	O
demands	O
during	O
SLL	O
,	O
individuals	O
post-ACLR	O
exhibit	O
deficits	O
in	O
knee	O
dynamics	O
during	O
SLL	O
and	O
RUN	O
suggesting	O
an	O
inability	O
or	O
reluctance	O
to	O
dynamically	O
accommodate	O
forces	O
at	O
the	O
knee	O
when	O
progressing	O
to	O
running	O
in	O
rehabilitation	O
.	O

J	O
Orthop	O
Sports	O
Phys	O
Ther	O
,	O
Epub	O
12	O
May	O
2017.	O
doi:10.2519/jospt.2017.6912	O
.	O

The	O
``	O
tight	O
orbit	O
''	O
:	O
Incidence	O
and	O
management	O
of	O
the	O
orbital	O
compartment	O
syndrome	O
.	O

The	O
orbital	O
compartment	O
syndrome	O
(	O
OCS	O
)	O
constitutes	O
a	O
severe	O
emergency	O
,	O
requiring	O
immediate	O
clinical	B-P
diagnosis	I-P
and	O
surgical	O
decompression	O
.	O

The	O
key	O
symptom	O
is	O
progressive	O
visual	O
impairment	O
caused	O
by	O
an	O
increase	O
in	O
intraorbital	O
pressure	O
,	O
impairing	O
the	O
perfusion	O
of	O
relevant	O
neurovascular	O
and	O
neurosensory	O
structures	O
.	O

Intraorbital	O
bleeding	O
due	O
to	O
trauma	O
and	O
surgical	O
intervention	O
is	O
known	O
to	O
be	O
the	O
main	O
etiological	O
factor	O
.	O

A	O
retrospective	O
analysis	O
of	O
all	O
patients	O
affected	O
by	O
an	O
OCS	O
between	O
January	O
1	O
,	O
2012	O
,	O
and	O
May	O
31	O
,	O
2015	O
,	O
was	O
performed	O
.	O

Patients	O
'	O
records	O
were	O
reviewed	O
with	O
regard	O
to	O
etiology	O
,	O
initial	O
ophthalmologic	O
status	O
,	O
fracture	O
pattern	O
,	O
concomitant	O
medication	O
,	O
surgical	O
management	O
,	O
and	O
postoperative	O
outcome	O
.	O

The	O
incidence	O
of	O
OCS	O
was	O
calculated	O
based	O
on	O
the	O
total	O
number	O
of	O
craniomaxillofacial	O
(	O
CMF	O
)	O
emergencies	O
.	O

Within	O
3.5	O
years	O
,	O
a	O
total	O
of	O
18,093	O
CMF	O
emergencies	O
were	O
registered	O
.	O

In	O
16	O
patients	O
,	O
an	O
OCS	O
was	O
documented	O
,	O
corresponding	O
to	O
an	O
incidence	O
of	O
0.088	O
%	O
.	O

The	O
mean	O
patient	O
age	O
was	O
67.31	O
±	O
23.86	O
years	O
,	O
ranging	O
from	O
22	O
to	O
102	O
years	O
.	O

The	O
etiology	O
varied	O
,	O
but	O
trauma	O
with	O
subsequent	O
intraorbital	O
bleeding	O
was	O
the	O
main	O
cause	O
.	O

The	O
use	O
of	O
anticoagulative	O
medication	O
was	O
documented	O
in	O
50	O
%	O
of	O
the	O
cases	O
.	O

In	O
14	O
patients	O
,	O
immediate	O
surgical	O
orbital	O
decompression	O
was	O
performed	O
:	O
in	O
10	O
patients	O
,	O
vision	O
could	O
be	O
preserved	B-P
;	O
in	O
three	O
patients	O
,	O
blindness	O
resulted	O
;	O
and	O
one	O
patient	O
was	O
lost	O
to	O
follow-up	O
.	O

Two	O
patients	O
were	O
managed	O
without	O
surgery	O
.	O

With	O
regard	O
to	O
the	O
total	O
number	O
of	O
CMF	O
emergencies	O
,	O
OCS	O
is	O
a	O
rare	O
condition	O
.	O

Early	O
clinical	B-P
diagnosis	I-P
and	O
surgical	O
decompression	O
are	O
required	O
to	O
prevent	O
permanent	O
vision	O
impairment	O
.	O

Anticoagulative	O
medication	O
must	O
be	O
considered	O
as	O
a	O
predisposing	O
factor	O
for	O
an	O
orbital	O
compartment	O
syndrome	O
in	O
patients	O
affected	O
by	O
periorbital	O
trauma	O
.	O

Improvement	O
in	O
advanced	O
pancreatic	O
cancer	O
survival	O
with	O
novel	O
chemotherapeutic	O
strategies	O
-	O
experience	O
of	O
a	O
community	O
based	O
hospital	O
.	O

Background	O
:	O
New	O
chemotherapeutic	O
strategies	O
for	O
locally	O
advanced	O
or	O
metastatic	O
pancreatic	O
ductal	O
adenocarcinoma	O
(	O
PDAC	O
)	O
have	O
been	O
shown	O
to	O
improve	O
survival	O
in	O
randomized	O
clinical	O
trials	O
.	O

Little	O
is	O
known	O
about	O
the	O
use	O
of	O
such	O
chemotherapies	O
and	O
their	O
benefit	O
in	O
community-based	O
hospitals	O
.	O

This	O
retrospective	O
study	O
analyzes	O
the	O
overall	O
survival	O
of	O
these	O
patients	O
under	O
``	O
real	O
life	O
conditions	O
``	O
before	O
and	O
after	O
the	O
introduction	O
of	O
FOLFIRINOX	O
in	O
2011	O
.	O

Methods	O
:	O
We	O
retrospectively	O
identified	O
consecutive	O
patients	O
with	O
PDAC	O
who	O
were	O
treated	O
at	O
our	O
hospital	O
from	O
2011	O
to	O
June	O
2014	O
(	O
2011+	O
cohort	O
)	O
and	O
2004	O
to	O
2010	O
(	O
historical	O
cohort	O
)	O
.	O

Patients	O
were	O
included	O
if	O
PDAC	O
was	O
diagnosed	B-P
in	O
a	O
locally	O
advanced	O
or	O
metastatic	O
state	O
and	O
at	O
least	O
1	O
cycle	O
of	O
chemotherapy	O
was	O
given	O
.	O

Survival	O
was	O
assessed	O
until	O
April	O
2016	O
.	O

Patients	O
with	O
FOLFIRINOX	O
were	O
further	O
analyzed	O
regarding	O
drug	O
administration	O
and	O
side	O
effects	O
.	O

Results	O
:	O
128	O
patients	O
met	O
the	O
inclusion	O
criteria	O
.	O

Of	O
the	O
74	O
patients	O
in	O
the	O
historical	O
cohort	O
,	O
62	O
patients	O
received	O
Gemcitabine	O
.	O

Of	O
the	O
54	O
patients	O
diagnosed	B-P
between	O
2011	O
and	O
June	O
2014	O
,	O
28	O
patients	O
received	O
FOLFIRINOX	O
and	O
22	O
Gemcitabine	O
as	O
the	O
first-line	O
chemotherapy	O
.	O

Only	O
34	O
%	O
of	O
the	O
patients	O
in	O
the	O
historical	O
cohort	O
received	O
a	O
second-line	O
chemotherapy	O
in	O
comparison	O
to	O
69	O
%	O
in	O
the	O
2011+	O
cohort	O
.	O

Median	O
overall	O
survival	O
(	O
OS	O
)	O
showed	O
a	O
survival	O
of	O
13.1	O
months	O
(	O
95	O
%	O
CI	O
;	O
11.6	O
-	O
14.5	O
)	O
for	O
the	O
2011+	O
cohort	O
compared	O
to	O
9.6	O
months	O
(	O
95	O
%	O
CI	O
;	O
6.1	O
-	O
13.1	O
)	O
in	O
the	O
historical	O
group	O
.	O

Conclusion	O
:	O
This	O
study	O
shows	O
a	O
marked	O
improvement	O
in	O
survival	O
of	O
patients	O
diagnosed	B-P
with	O
locally	O
advanced	O
or	O
metastatic	O
PDAC	O
in	O
a	O
community-based	O
hospital	O
during	O
the	O
past	O
4	O
years	O
.	O

The	O
most	O
likely	O
reasons	O
are	O
the	O
use	O
of	O
new	O
polychemotherapies	O
like	O
FOLFIRINOX	O
and	O
the	O
use	O
of	O
second-line	O
chemotherapy	O
.	O

Grade	O
Group	O
Underestimation	O
in	O
Prostate	B-P
Biopsy	I-P
:	O
Predictive	O
Factors	O
and	O
Outcomes	O
in	O
Candidates	O
for	O
Active	O
Surveillance	O
.	O

We	O
intended	O
to	O
analyze	O
the	O
outcomes	O
and	O
predictive	O
factors	O
for	O
underestimating	O
the	O
prostate	O
cancer	O
(	O
PCa	O
)	O
grade	O
group	O
(	O
GG	O
)	O
from	O
prostate	B-P
biopsies	I-P
in	O
a	O
large	O
monocentric	O
cohort	O
of	O
patients	O
treated	O
by	O
minimally	O
invasive	O
radical	O
prostatectomy	O
(	O
RP	O
)	O
.	O

Using	O
a	O
monocentric	O
prospectively	O
maintained	O
database	O
,	O
we	O
included	O
3062	O
patients	O
who	O
underwent	O
minimally	O
invasive	O
RP	O
between	O
2006	O
and	O
2013	O
.	O

We	O
explored	O
clinicopathologic	O
features	O
and	O
outcomes	O
associated	O
with	O
a	O
GG	O
upgrade	O
from	O
biopsy	B-P
to	O
RP	O
.	O

Multivariate	O
logistic	O
regression	O
was	O
used	O
to	O
develop	O
and	O
validate	O
a	O
nomogram	O
to	O
predict	O
upgrading	O
for	O
GG1	O
.	O

Biopsy	B-P
GG	O
was	O
upgraded	O
after	O
RP	O
in	O
51.5	O
%	O
of	O
cases	O
.	O

Patients	O
upgraded	O
from	O
GG1	O
to	O
GG2	O
or	O
GG3	O
after	O
RP	O
had	O
a	O
longer	O
time	O
to	O
biochemical	O
recurrence	O
than	O
those	O
with	O
GG2	O
or	O
GG3	O
respectively	O
,	O
on	O
both	O
biopsy	B-P
and	O
RP	O
,	O
but	O
a	O
shorter	O
time	O
to	O
biochemical	O
recurrence	O
than	O
those	O
who	O
remained	O
GG1	O
after	O
RP	O
(	O
P	O
<	O
.0001	O
)	O
.	O

In	O
multivariate	O
analyses	O
,	O
variables	O
predicting	O
upgrading	O
for	O
GG1	O
PCa	O
were	O
age	O
(	O
P	O
=	O
.0014	O
)	O
,	O
abnormal	B-P
digital	I-P
rectal	I-P
examination	I-P
(	O
P	O
<	O
.0001	O
)	O
,	O
prostate	O
-specific	O
antigen	O
density	O
(	O
P	O
<	O
.0001	O
)	O
,	O
percentage	O
of	O
positive	O
cores	O
(	O
P	O
<	O
.0001	O
)	O
,	O
and	O
body	O
mass	O
index	O
(	O
P	O
=	O
.037	O
)	O
.	O

A	O
nomogram	O
was	O
generated	O
and	O
validated	O
internally	O
.	O

Biopsy	B-P
grading	O
system	O
is	O
misleading	O
in	O
approximately	O
50	O
%	O
of	O
cases	O
.	O

Upgrading	O
GG	O
from	O
biopsy	B-P
to	O
RP	O
may	O
have	O
consequences	O
on	O
clinical	O
outcomes	O
.	O

A	O
nomogram	O
using	O
clinicopathologic	O
features	O
could	O
aid	O
the	O
probability	O
of	O
needing	O
to	O
upgrade	O
GG1	O
patients	O
at	O
their	O
initial	O
evaluation	O
.	O

Risk	O
factors	O
for	O
hepatitis	O
C	O
virus	O
infection	O
in	O
the	O
Colombian	O
Caribbean	O
coast	O
:	O
A	O
case-control	O
study	O
.	O

An	O
estimated	O
6.8-8.9	O
million	O
people	O
are	O
infected	O
with	O
hepatitis	O
C	O
virus	O
in	O
Latin	O
America	O
,	O
of	O
which	O
less	O
than	O
1	O
%	O
receives	O
antiviral	O
treatment	O
.	O

Studies	O
so	O
far	O
in	O
Colombia	O
have	O
attempted	O
to	O
determine	O
the	O
prevalence	O
of	O
the	O
disease	O
in	O
some	O
risk	O
groups	O
,	O
thus	O
preventing	O
the	O
identification	O
of	O
other	O
factors	O
potentially	O
involved	O
in	O
the	O
spread	O
of	O
the	O
infection	O
.	O

To	O
identify	O
traditional	O
and	O
non-traditional	O
risk	O
factors	O
for	O
chronic	O
hepatitis	O
C	O
in	O
the	O
Colombian	O
Caribbean	O
coast	O
.	O

This	O
was	O
a	O
case-control	O
study	O
(	O
1:3	O
)	O
matched	O
by	O
health	O
care	O
provider	O
and	O
age	O
(	O
±	O
10	O
years	O
)	O
conducted	O
at	O
the	O
primary	O
care	O
level	O
of	O
gastroenterology	O
and	O
hepatology	O
outpatient	O
services	O
.	O

All	O
patients	O
with	O
a	O
positive	O
ELISA	B-P
underwent	O
a	O
confirmatory	O
viral	B-P
load	I-P
test	I-P
.	O

A	O
multivariate	O
logistic	O
regression	O
analysis	O
identified	O
the	O
independent	O
predictors	O
of	O
infection	O
.	O

Blood	O
transfusion	O
(	O
OR	O
=159.2	O
;	O
95	O
%	O
CI	O
:	O
35.4-715	O
;	O
p	O
<	O
0.001	O
)	O
and	O
history	O
of	O
hospitalization	O
before	O
1994	O
(	O
OR	O
=4.7	O
;	O
95	O
%	O
CI	O
:	O
1.3-17.1	O
;	O
p=0.018	O
)	O
were	O
identified	O
as	O
the	O
only	O
two	O
independent	O
predictors	O
of	O
infection	O
.	O

It	O
is	O
necessary	O
to	O
check	O
the	O
reproducibility	O
of	O
these	O
results	O
and	O
to	O
conduct	O
cost-effectiveness	O
studies	O
before	O
recommending	O
their	O
use	O
in	O
the	O
design	O
of	O
new	O
screening	O
strategies	O
.	O

Cluster	O
-	O
dependent	O
colistin	O
hetero-resistance	O
in	O
Enterobacter	O
cloacae	O
complex	O
.	O

Aims	O
of	O
this	O
study	O
were	O
to	O
:	O
(	O
i	O
)	O
evaluate	O
whether	O
the	O
cluster	O
membership	O
could	O
have	O
an	O
impact	O
on	O
hetero-resistance	O
phenotype	O
to	O
colistin	O
in	O
the	O
Enterobacter	O
cloacae	O
complex	O
(	O
ECC	O
)	O
;	O
and	O
(	O
ii	O
)	O
determine	O
the	O
genetic	O
mechanism	O
of	O
colistin	O
hetero-resistance	O
in	O
ECC	O
.	O

A	O
collection	O
of	O
124	O
clinical	O
isolates	O
belonging	O
to	O
13	O
clusters	O
were	O
used	O
to	O
analyse	O
the	O
hetero-resistance	O
phenotype	O
(	O
MICs	B-P
were	O
determined	O
using	O
the	O
broth	B-P
microdilution	I-P
method	I-P
,	O
Etest	B-P
and	O
population	B-P
analysis	I-P
profiling	I-P
)	O
.	O

Different	O
mutants	O
(	O
ΔphoP	O
,	O
ΔphoQ	O
,	O
ΔphoPQ	O
,	O
ΔpmrA	O
,	O
ΔpmrB	O
,	O
ΔpmrAB	O
,	O
ΔarnE	O
,	O
ΔarnF	O
and	O
ΔarnBCADTEF	O
)	O
were	O
constructed	O
and	O
tested	O
for	O
their	O
colistin	O
hetero-resistance	O
phenotype	O
.	O

Based	O
on	O
broth	B-P
microdilution	I-P
and	O
Etest	B-P
results	O
,	O
it	O
was	O
shown	O
that	O
the	O
hetero-resistance	O
to	O
colistin	O
depended	O
on	O
the	O
cluster	O
:	O
strains	O
from	O
clusters	O
I	O
,	O
II	O
,	O
IV	O
,	O
VII	O
,	O
IX	O
,	O
X	O
,	O
XI	O
and	O
XII	O
were	O
usually	O
hetero-resistant	O
,	O
whereas	O
those	O
from	O
clusters	O
III	O
,	O
V	O
,	O
VI	O
,	O
VIII	O
and	O
XIII	O
were	O
categorized	O
as	O
susceptible	O
.	O

However	O
,	O
for	O
some	O
cluster	O
V	O
and	O
VIII	O
strains	O
,	O
a	O
small	O
proportion	O
(	O
<	O
10	O
(	O
-7	O
)	O
)	O
of	O
cells	O
appeared	O
resistant	O
when	O
tested	O
by	O
population	O
analysis	O
profiling	O
.	O

From	O
a	O
mechanistic	O
point	O
of	O
view	O
,	O
analysis	O
of	O
mutants	O
revealed	O
that	O
the	O
mechanism	O
of	O
hetero-resistance	O
was	O
mainly	O
due	O
to	O
the	O
expression	O
of	O
the	O
arn	O
operon	O
and	O
the	O
phoP	O
/	O
phoQ	O
two-component	O
regulatory	O
system	O
.	O

Because	O
the	O
colistin	O
hetero-resistance	O
appeared	O
cluster	O
-	O
dependent	O
in	O
the	O
ECC	O
,	O
it	O
should	O
be	O
advocated	O
to	O
determine	O
the	O
cluster	O
of	O
the	O
strain	O
associated	O
with	O
the	O
infection	O
in	O
parallel	O
with	O
the	O
MIC	B-P
of	O
colistin	O
.	O

The	O
resistance	O
mechanism	O
may	O
not	O
be	O
similar	O
to	O
other	O
Enterobacteriaceae	O
since	O
only	O
the	O
two-component	O
regulatory	O
system	O
PhoP	O
/	O
PhoQ	O
(	O
and	O
not	O
PmrA	O
/	O
PmrB	O
)	O
seemed	O
to	O
play	O
a	O
role	O
in	O
resistance	O
regulation	O
.	O

Association	O
of	O
CKIP-1	O
P21A	O
polymorphism	O
with	O
risk	O
of	O
chronic	O
heart	O
failure	O
in	O
a	O
Chinese	O
population	O
.	O

Pathological	O
cardiac	O
hypertrophy	O
is	O
an	O
independent	O
risk	O
factor	O
for	O
chronic	O
heart	O
failure	O
.	O

Casein	O
kinase-2	O
interacting	O
protein-1	O
(	O
CKIP-1	O
)	O
can	O
inhibit	O
pathological	O
cardiac	O
hypertrophy	O
.	O

Therefore	O
,	O
we	O
investigated	O
whether	O
CKIP-1	O
nonsynonymous	O
polymorphism	O
rs2306235	O
(	O
Pro21Ala	O
)	O
contributes	O
to	O
risk	O
and	O
prognosis	O
of	O
chronic	O
heart	O
failure	O
in	O
a	O
Chinese	O
population	O
.	O

A	O
total	O
of	O
923	O
adult	O
patients	O
with	O
chronic	O
heart	O
failure	O
and	O
1020	O
age	O
-	O
and	O
gender	O
-matched	O
healthy	O
controls	O
were	O
recruited	O
.	O

CKIP-1	O
rs2306235	O
polymorphism	O
was	O
genotyped	B-P
using	O
PCR	O
-	O
restriction	B-P
fragment	I-P
length	I-P
polymorphism	I-P
.	O

Additional	O
follow-up	O
data	O
for	O
140	O
chronic	O
heart	O
failure	O
patients	O
was	O
evaluated	O
.	O

The	O
rs2306235	O
G	O
allele	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
chronic	O
heart	O
failure	O
(	O
OR	O
=	O
1.38	O
,	O
95	O
%	O
CI	O
=	O
1.09-1.75	O
,	O
p	O
=	O
0.007	O
)	O
,	O
especially	O
in	O
patients	O
with	O
hypertension	O
(	O
OR	O
=	O
1.45	O
,	O
95	O
%	O
CI	O
=	O
1.09-1.75	O
,	O
p	O
=	O
0.006	O
)	O
and	O
coronary	O
heart	O
disease	O
(	O
OR	O
=	O
1.41	O
,	O
95	O
%	O
CI	O
=	O
1.09-1.83	O
,	O
p	O
=	O
0.010	O
)	O
after	O
adjustment	O
for	O
multiple	O
cardiovascular	O
risk	O
factors	O
.	O

However	O
,	O
rs2306235	O
polymorphism	O
was	O
not	O
associated	O
with	O
cardiovascular	O
mortality	O
in	O
chronic	O
heart	O
failure	O
(	O
p	O
=	O
0.875	O
)	O
.	O

CKIP-1	O
rs2306235	O
polymorphism	O
may	O
be	O
a	O
risk	O
factor	O
for	O
chronic	O
heart	O
failure	O
in	O
a	O
Chinese	O
Han	O
population	O
.	O

Colorectal	O
Choriocarcinoma	O
in	O
a	O
Patient	O
with	O
Probable	O
Lynch	O
Syndrome	O
.	O

Personalized	O
therapy	O
of	O
colorectal	O
cancer	O
is	O
influenced	O
by	O
morphological	O
,	O
molecular	O
,	O
and	O
host-related	O
factors	O
.	O

Here	O
,	O
we	O
report	O
the	O
comprehensive	O
clinicopathological	O
and	O
molecular	O
analysis	O
of	O
an	O
extra-gestational	O
colorectal	O
choriocarcinoma	O
in	O
a	O
patient	O
with	O
probable	O
Lynch	O
syndrome	O
.	O

A	O
61-year-old	O
female	O
with	O
history	O
of	O
gastric	O
cancer	O
at	O
age	O
36	O
presented	O
with	O
a	O
transmurally	O
invasive	O
tumor	O
of	O
the	O
right	O
hemicolon	O
and	O
liver	O
metastasis	O
.	O

A	O
right	O
hemicolectomy	O
was	O
performed	O
.	O

Histopathological	O
analysis	O
showed	O
a	O
mixed	O
trophoblastic	O
and	O
syncytiotrophoblastic	O
differentiation	O
,	O
consistent	O
with	O
choriocarcinoma	O
.	O

Disease	O
progression	O
was	O
rapid	O
under	O
oxaliplatin	O
,	O
capecitabine	O
,	O
irinotecan	O
,	O
and	O
bevacizumab	O
.	O

Molecular	B-P
phenotyping	I-P
identified	O
loss	O
of	O
mismatch-repair	O
protein	O
immunostaining	B-P
for	O
PMS2	O
,	O
microsatellite	O
instability	O
,	O
a	O
lack	B-P
of	I-P
MLH1	I-P
promoter	I-P
methylation	I-P
,	O
and	O
lack	O
of	O
BRAF	O
mutation	O
suggestive	O
of	O
Lynch	O
syndrome	O
.	O

Targeted	O
next-generation	O
sequencing	O
revealed	O
an	O
ataxia	O
telangiectasia	O
mutated	O
(	O
p.P604S	O
)	O
missense	O
mutation	O
.	O

A	O
bleomycin	O
,	O
etoposide	O
,	O
and	O
cisplatin	O
treatment	O
protocol	O
targeting	O
germ	O
cell	O
neoplasia	O
lead	O
to	O
disease	O
remission	O
and	O
prolonged	O
survival	O
of	O
34	O
months	O
.	O

Comprehensive	O
immunohistochemical	B-P
and	O
genetic	B-P
testing	I-P
is	O
essential	O
to	O
identify	O
uncommon	O
cancers	O
possibly	O
related	O
to	O
Lynch	O
syndrome	O
.	O

For	O
rare	O
tumors	O
,	O
personalized	O
therapeutic	O
approaches	O
should	O
take	O
both	O
molecular	O
and	O
morphological	O
information	O
into	O
account	O
.	O

Influence	O
of	O
Plasma	O
Cell	O
Niche	O
Factors	O
on	O
the	O
Recruitment	O
and	O
Maintenance	O
of	O
IRF4hi	O
Plasma	O
Cells	O
and	O
Plasmablasts	O
in	O
Vaccinated	O
,	O
Simian	O
Immunodeficiency	O
Virus	O
-	O
Infected	O
Rhesus	O
Macaques	O
with	O
Low	O
and	O
High	O
Viremia	O
.	O

In	O
a	O
recent	O
study	O
,	O
we	O
found	O
that	O
protection	O
following	O
simian	O
immunodeficiency	O
virus	O
(	O
SIV	O
)	O
exposure	O
correlated	O
with	O
rectal	O
plasma	O
cell	O
frequency	O
in	O
vaccinated	O
female	O
rhesus	O
macaques	O
.	O

We	O
sought	O
to	O
determine	O
if	O
the	O
same	O
macaques	O
maintained	O
high	O
mucosal	O
plasma	O
cell	O
frequencies	O
postinfection	O
and	O
if	O
this	O
translated	O
to	O
reduced	O
viremia	O
.	O

Although	O
delayed	O
SIV	O
acquisition	O
did	O
not	O
predict	O
subsequent	O
viral	O
control	O
,	O
alterations	O
existed	O
in	O
the	O
distribution	O
of	O
plasma	O
cells	O
and	O
plasmablasts	O
between	O
macaques	O
that	O
exhibited	O
high	O
or	O
low	O
viremia	O
.	O

Flow	B-P
cytometric	I-P
analysis	I-P
of	O
cells	O
from	O
rectal	O
biopsy	O
specimens	O
,	O
bone	O
marrow	O
,	O
and	O
mesenteric	O
lymph	O
nodes	O
of	O
vaccinated	O
infected	O
,	O
unvaccinated	O
infected	O
,	O
and	O
uninfected	O
macaques	O
identified	O
two	O
main	O
IRF4	O
(	O
hi	O
)	O
subsets	O
of	O
interest	O
:	O
CD138	O
(	O
+	O
)	O
plasma	O
cells	O
,	O
and	O
CD138	O
(	O
-	O
)	O
plasmablasts	O
.	O

In	O
rectal	O
tissue	O
,	O
plasma	O
cell	O
frequency	O
positively	O
correlated	O
with	O
plasma	O
viremia	O
and	O
unvaccinated	O
macaques	O
had	O
increased	O
plasma	O
cells	O
and	O
plasmablasts	O
compared	O
to	O
vaccinated	O
animals	O
.	O

Likewise	O
,	O
plasmablast	O
frequency	O
in	O
the	O
mesenteric	O
lymph	O
node	O
correlated	O
with	O
viremia	O
.	O

However	O
,	O
in	O
bone	O
marrow	O
,	O
plasmablast	O
frequency	O
negatively	O
correlated	O
with	O
viremia	O
.	O

Accordingly	O
,	O
low-viremic	O
macaques	O
had	O
a	O
higher	O
frequency	O
of	O
both	O
bone	O
marrow	O
IRF4	O
(	O
hi	O
)	O
subsets	O
than	O
did	O
animals	O
with	O
high	O
viremia	O
.	O

Significant	O
reciprocal	O
relationships	O
between	O
rectal	O
and	O
bone	O
marrow	O
plasmablasts	O
suggested	O
that	O
efficient	O
trafficking	O
to	O
the	O
bone	O
marrow	O
as	O
opposed	O
to	O
the	O
rectal	O
mucosa	O
was	O
linked	O
to	O
viral	O
control	O
.	O

mRNA	O
expression	O
analysis	O
of	O
proteins	O
involved	O
in	O
establishment	O
of	O
plasma	O
cell	O
niches	O
in	O
sorted	O
bone	O
marrow	O
and	O
rectal	O
cell	O
populations	O
further	O
supported	O
this	O
model	O
and	O
revealed	O
differential	O
mRNA	O
expression	O
patterns	O
in	O
these	O
tissues	O
.	O

As	O
key	O
antibody	O
producers	O
,	O
plasma	O
cells	O
and	O
plasmablasts	O
are	O
critical	O
components	O
of	O
vaccine	O
-induced	O
immunity	O
to	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
in	O
humans	O
and	O
SIV	O
in	O
the	O
macaque	O
model	O
;	O
however	O
,	O
few	O
have	O
attempted	O
to	O
examine	O
the	O
role	O
of	O
these	O
cells	O
in	O
viral	O
suppression	O
postinfection	O
.	O

Our	O
results	O
suggest	O
that	O
plasmablast	O
trafficking	O
to	O
and	O
retention	O
in	O
the	O
bone	O
marrow	O
play	O
a	O
previously	O
unappreciated	O
role	O
in	O
viral	O
control	O
and	O
contrast	O
the	O
potential	O
contribution	O
of	O
mucosal	O
plasma	O
cells	O
to	O
mediate	O
protection	O
at	O
sites	O
of	O
infection	O
with	O
that	O
of	O
bone	O
marrow	O
plasmablasts	O
and	O
plasma	O
cells	O
to	O
control	O
viremia	O
during	O
chronic	O
infection	O
.	O

Manipulation	O
of	O
niche	O
factors	O
influencing	O
the	O
distribution	O
and	O
maintenance	O
of	O
these	O
critical	O
antibody-secreting	O
cells	O
may	O
serve	O
as	O
potential	O
therapeutic	O
targets	O
to	O
enhance	O
antiviral	O
responses	O
postvaccination	O
and	O
postinfection	O
.	O

LDLR	O
,	O
ApoB	O
and	O
ApoE	O
genes	O
polymorphisms	O
and	O
classical	O
risk	O
factors	O
in	O
premature	O
coronary	O
artery	O
disease	O
.	O

Lipoproteins	O
play	O
a	O
central	O
role	O
in	O
the	O
development	O
of	O
atherosclerotic	O
disease	O
.	O

So	O
,	O
with	O
their	O
ability	O
to	O
affect	O
lipid	O
levels	O
,	O
the	O
LDLR	O
,	O
ApoB	O
and	O
ApoE	O
polymorphisms	O
could	O
be	O
one	O
of	O
the	O
factors	O
influencing	O
development	O
of	O
atherosclerosis	O
.	O

This	O
hypothesis	O
has	O
been	O
tested	O
in	O
different	O
populations	O
with	O
conflicting	O
results	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
association	O
between	O
the	O
LDLR	O
,	O
ApoB	O
and	O
ApoE	O
genes	O
polymorphisms	O
with	O
premature	O
CAD	O
(	O
PCAD	O
)	O
in	O
Egyptians	O
.	O

One	O
hundred	O
thirty-five	O
patients	O
of	O
PCAD	O
and	O
one	O
hundred	O
thirty-two	O
ages	O
and	O
sex	O
matched	O
control	O
subjects	O
were	O
included	O
in	O
the	O
study	O
.	O

LDLR	O
and	O
ApoB	O
genes	O
polymorphisms	O
were	O
analyzed	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O

The	O
ApoE	O
genotypes	O
were	O
identified	O
by	O
multiplex	B-P
amplification	I-P
refractory	I-P
mutation	I-P
system	I-P
(	O
multi-AMRS	B-P
)	O
.	O

We	O
found	O
that	O
LDLR	O
A	O
(	O
+	O
)	O
A	O
(	O
+	O
)	O
genotype	O
,	O
ApoB	O
X	O
(	O
+	O
)	O
allele	O
and	O
ApoE	O
E4	O
allele	O
increased	O
the	O
risk	O
of	O
PCAD	O
by	O
1.8	O
,	O
2.1	O
and	O
12.1	O
respectively	O
.	O

The	O
present	O
study	O
proved	O
that	O
smoking	O
,	O
metabolic	O
syndrome	O
,	O
ApoB	O
X	O
(	O
+	O
)	O
X	O
(	O
+	O
)	O
genotype	O
and	O
ApoE	O
E4	O
allele	O
were	O
independent	O
risk	O
factors	O
for	O
the	O
development	O
of	O
PCAD	O
.	O

This	O
is	O
the	O
first	O
study	O
investigate	O
the	O
association	O
between	O
low	O
density	O
lipoprotein	O
receptor	O
,	O
apolipoprotein	O
B	O
and	O
apolipoprotein	O
E	O
genes	O
polymorphisms	O
with	O
PCAD	O
and	O
lipid	O
levels	O
in	O
Egyptians	O
and	O
we	O
concluded	O
that	O
the	O
LDLR	O
A	O
(	O
+	O
)	O
A	O
(	O
+	O
)	O
genotype	O
,	O
ApoB	O
X	O
(	O
+	O
)	O
allele	O
and	O
ApoE	O
E4	O
allele	O
may	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
development	O
of	O
PCAD	O
by	O
elevated	O
levels	B-P
of	I-P
total	I-P
cholesterol	I-P
(	I-P
TC	I-P
)	I-P
and	O
low	B-P
density	I-P
lipoprotein	I-P
(	O
LDLc	B-P
)	O
.	O

The	O
coexistence	O
of	O
CAD	O
risk	O
factors	O
with	O
LDLR	O
A	O
(	O
+	O
)	O
A	O
(	O
+	O
)	O
genotype	O
,	O
ApoB	O
X	O
(	O
+	O
)	O
allele	O
and	O
ApoE	O
E4	O
allele	O
may	O
increase	O
the	O
risk	O
of	O
the	O
development	O
of	O
PCAD	O
in	O
Egyptian	O
patients	O
.	O

Assessment	O
of	O
the	O
Extravascular	O
Implantable	O
Defibrillator	O
:	O
Feasibility	O
of	O
Substernal	O
Ventricular	O
Pacing	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
feasibility	O
of	O
ventricular	O
pacing	O
and	O
thresholds	O
from	O
within	O
the	O
substernal	O
space	O
to	O
examine	O
a	O
new	O
extravascular	O
ICD	O
configuration	O
with	O
pacing	O
capabilities	O
.	O

In	O
patients	O
undergoing	O
midline	O
sternotomy	O
,	O
a	O
duodecapolar	O
diagnostic	O
pacing	O
catheter	O
was	O
positioned	O
in	O
the	O
substernal	O
space	O
anterior	O
to	O
the	O
pericardium	O
,	O
and	O
a	O
cutaneous	O
patch	O
in	O
left	O
lateral	O
position	O
.	O

Different	O
unipolar	O
and	O
bipolar	O
pacing	O
configurations	O
were	O
assessed	O
.	O

Strength-duration	B-P
curves	I-P
were	O
performed	O
to	O
identify	O
the	O
optimal	O
output	B-P
,	O
starting	O
at	O
25	O
mA	O
with	O
a	O
pulse	O
width	O
of	O
10	O
milliseconds	O
.	O

Eight	O
patients	O
with	O
mean	O
age	O
69	O
±	O
9	O
years	O
were	O
included	O
.	O

In	O
5	O
,	O
ventricular	O
capture	O
was	O
achieved	O
in	O
≥1	O
configuration	O
.	O

The	O
mean	O
bipolar	O
pacing	O
thresholds	O
at	O
PW	O
10	O
,	O
5	O
,	O
3	O
,	O
1	O
milliseconds	O
were	O
12.4	O
±	O
3.7	O
mA	O
(	O
5	O
patients	O
)	O
,	O
13.3	O
±	O
5.8	O
mA	O
(	O
3	O
patients	O
)	O
,	O
18.3	O
±	O
5.7	O
mA	O
(	O
3	O
patients	O
)	O
,	O
and	O
25	O
±	O
0	O
mA	O
(	O
2	O
patients	O
)	O
,	O
respectively	O
.	O

The	O
60-mm	O
electrode	O
spacing	O
was	O
the	O
most	O
successful	O
bipolar	O
configuration	O
.	O

Unipolar	O
pacing	O
was	O
successful	O
in	O
3	O
out	O
of	O
4	O
patients	O
with	O
mean	O
thresholds	O
of	O
10	O
±	O
0	O
mA	O
at	O
10	O
milliseconds	O
(	O
3	O
patients	O
)	O
,	O
15	O
±	O
0	O
mA	O
at	O
5	O
milliseconds	O
(	O
3	O
patients	O
)	O
,	O
16.7	O
±	O
2.9	O
mA	O
at	O
3	O
milliseconds	O
(	O
3	O
patients	O
)	O
,	O
and	O
20	O
±	O
7.1	O
mA	O
at	O
1	O
milliseconds	O
(	O
2	O
patients	O
)	O
.	O

Ventricular	O
pacing	O
from	O
the	O
substernal	O
space	O
in	O
patients	O
with	O
midline	O
sternotomy	O
is	O
feasible	O
.	O

Closed	O
sternum	O
studies	O
are	O
needed	O
to	O
determine	O
pacing	O
thresholds	O
more	O
accurately	O
.	O

Limits	O
of	O
the	O
possible	O
:	O
diagnostic	O
image	O
quality	O
in	O
coronary	B-P
angiography	I-P
with	O
third-generation	B-P
dual-source	I-P
CT	I-P
.	O

The	O
usage	O
of	O
coronary	B-P
CT	I-P
angiography	I-P
(	O
CTA	B-P
)	O
is	O
appropriate	O
in	O
patients	O
with	O
acute	O
or	O
chronic	O
chest	O
pain	O
;	O
however	O
the	O
diagnostic	O
accuracy	O
may	O
be	O
challenged	O
with	O
increased	O
Agatston	O
score	O
(	O
AS	O
)	O
,	O
increased	O
heart	O
rate	O
,	O
arrhythmia	O
and	O
severe	O
obesity	O
.	O

Thus	O
,	O
we	O
aim	O
to	O
determine	O
the	O
potential	O
of	O
the	O
recently	O
introduced	O
third-generation	B-P
dual-source	I-P
CT	I-P
(	O
DSCT	B-P
)	O
for	O
CTA	B-P
in	O
a	O
'real-life	O
'	O
clinical	O
setting	O
.	O

Two	O
hundred	O
and	O
sixty-eight	O
consecutive	O
patients	O
(	O
age	O
:	O
67	O
±	O
10	O
years	O
;	O
BMI	O
:	O
27	O
±	O
5	O
kg/m²	O
;	O
61	O
%	O
male	O
)	O
undergoing	O
clinically	O
indicated	O
CTA	B-P
with	O
DSCT	B-P
were	O
included	O
in	O
the	O
retrospective	O
single-center	O
analysis	O
.	O

A	O
contrast-enhanced	O
volume	O
dataset	O
was	O
acquired	O
in	O
sequential	B-P
(	O
SSM	B-P
)	O
(	O
n	O
=	O
151	O
)	O
or	O
helical	B-P
scan	I-P
mode	I-P
(	O
HSM	B-P
)	O
(	O
n	O
=	O
117	O
)	O
.	O

Coronary	O
segments	O
were	O
classified	O
in	O
diagnostic	O
or	O
non-diagnostic	O
image	O
quality	O
.	O

A	O
subset	O
underwent	O
invasive	B-P
angiography	I-P
to	O
determine	O
the	O
diagnostic	O
accuracy	O
of	O
CTA	B-P
.	O

SSM	B-P
(	O
96.8	O
±	O
6	O
%	O
)	O
and	O
HSM	B-P
(	O
97.5	O
±	O
8	O
%	O
)	O
provided	O
no	O
significant	O
differences	O
in	O
the	O
overall	O
diagnostic	O
image	O
quality	O
.	O

However	O
,	O
AS	O
had	O
significant	O
influence	O
on	O
diagnostic	O
image	O
quality	O
exclusively	O
in	O
SSM	B-P
(	O
B	O
=	O
0.003	O
;	O
p	O
=	O
0.0001	O
)	O
,	O
but	O
not	O
in	O
HSM	B-P
.	O

Diagnostic	O
image	O
quality	O
significantly	O
decreased	O
in	O
SSM	B-P
in	O
patients	O
with	O
AS	O
≥2,000	O
(	O
p	O
=	O
0.03	O
)	O
.	O

SSM	B-P
(	O
sensitivity	O
:	O
93.9	O
%	O
;	O
specificity	O
:	O
96.7	O
%	O
;	O
PPV	O
:	O
88.6	O
%	O
;	O
NPV	O
:	O
98.3	O
%	O
)	O
and	O
HSM	B-P
(	O
sensitivity	O
:	O
97.4	O
%	O
;	O
specificity	O
:	O
94.3	O
%	O
;	O
PPV	O
:	O
86.0	O
%	O
;	O
NPV	O
:	O
99.0	O
%	O
)	O
provided	O
comparable	O
diagnostic	O
accuracy	O
(	O
p	O
=	O
n.s.	O
)	O
.	O

SSM	B-P
yielded	O
significantly	O
lower	O
radiation	O
doses	O
as	O
compared	O
to	O
HSM	B-P
(	O
2.1	O
±	O
2.0	O
vs.	O
5.1	O
±	O
3.3	O
mSv	O
;	O
p	O
=	O
0.0001	O
)	O
in	O
age	O
and	O
BMI	O
-matched	O
cohorts	O
.	O

SSM	B-P
in	O
third-generation	B-P
DSCT	I-P
enables	O
significant	O
dose	O
savings	O
and	O
provides	O
robust	O
diagnostic	O
image	O
quality	O
in	O
patients	O
with	O
AS	O
≤2000	O
independent	O
of	O
heart	O
rate	O
,	O
heart	O
rhythm	O
or	O
obesity	O
.	O

Different	O
Susceptibilities	O
between	O
Apoe	O
-	O
and	O
Ldlr	O
-	O
Deficient	O
Mice	O
to	O
Inflammation	O
-	O
Associated	O
Colorectal	O
Carcinogenesis	O
.	O

Hypercholesterolemia	O
resulting	O
in	O
atherosclerosis	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
ischemic	O
heart	O
disease	O
and	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
.	O

However	O
,	O
the	O
roles	O
of	O
apoliprotein	O
(	O
Apo	O
)	O
E	O
(	O
Apoe	O
)	O
and	O
low-density	O
lipoprotein	O
(	O
Ldl	O
)	O
receptor	O
(	O
Ldlr	O
)	O
in	O
colorectal	O
carcinogenesis	O
have	O
not	O
yet	O
been	O
investigated	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
susceptibility	O
of	O
Apoe	O
-	O
deficient	O
and	O
Ldlr	O
-	O
deficient	O
mice	O
,	O
which	O
are	O
genetic	O
animal	O
models	O
of	O
atherosclerosis	O
to	O
azoxymethane	O
(	O
AOM	O
)	O
/	O
dextran	O
sodium	O
sulfate	O
(	O
DSS	O
)	O
-	O
induced	O
colorectal	O
carcinogenesis	O
.	O

In	O
Experiment	O
1	O
,	O
male	O
Apoe	O
-	O
deficient	O
(	O
n	O
=	O
20	O
)	O
and	O
wild	O
type	O
(	O
WT	O
)	O
mice	O
(	O
C57BL/6J	O
,	O
n	O
=	O
21	O
)	O
were	O
treated	O
with	O
a	O
single	O
intraperitoneal	O
(	O
i.p	O
.	O
)	O

injection	O
of	O
AOM	O
(	O
10	O
mg/kg	O
body	O
weight	O
)	O
and	O
then	O
given	O
1.5	O
%	O
DSS	O
in	O
drinking	O
water	O
for	O
seven	O
days	O
.	O

They	O
were	O
maintained	O
up	O
to	O
week	O
20	O
and	O
sacrificed	O
for	O
the	O
histopathological	O
examination	O
of	O
colorectal	O
tumors	O
.	O

The	O
mRNA	O
expression	O
of	O
cyclooxygenase	O
(	O
Cox	O
)	O
-2	O
,	O
inducible	O
nitric	O
oxide	O
synthase	O
(	O
Nos2	O
)	O
,	O
tumor	O
necrosis	O
factor	O
(	O
Tnf	O
)	O
-α	O
interleukin	O
(	O
Il	O
)	O
-1β	O
,	O
and	O
Il-6	O
was	O
assayed	O
in	O
the	O
colorectal	O
mucosa	O
.	O

In	O
Experiment	O
2	O
,	O
male	O
Ldlr	O
-	O
deficient	O
(	O
n	O
=	O
14	O
)	O
and	O
WT	O
mice	O
(	O
C57BL/6J	O
,	O
n	O
=	O
10	O
)	O
were	O
given	O
a	O
single	O
i.p	O
.	O

injection	O
of	O
AOM	O
(	O
10	O
mg/kg	O
body	O
weight	O
)	O
and	O
then	O
given	O
2	O
%	O
DSS	O
in	O
drinking	O
water	O
for	O
seven	O
days	O
.	O

They	O
were	O
sacrificed	O
at	O
week	O
20	O
to	O
evaluate	O
their	O
colorectum	O
histopathologically	O
.	O

In	O
Experiment	O
1	O
,	O
the	O
multiplicity	O
of	O
CRCs	O
was	O
significantly	O
higher	O
in	O
the	O
Apoe	O
-	O
deficient	O
mice	O
(	O
2.75	O
±	O
1.48	O
)	O
than	O
in	O
the	O
WT	O
mice	O
(	O
0.62	O
±	O
0.67	O
)	O
.	O

The	O
serum	B-P
lipoprotein	I-P
levels	I-P
in	O
the	O
Apoe	O
-	O
deficient	O
mice	O
were	O
also	O
significantly	O
higher	O
than	O
in	O
the	O
WT	O
mice	O
.	O

In	O
Experiment	O
2	O
,	O
the	O
incidence	O
(	O
29	O
%	O
)	O
and	O
multiplicity	O
(	O
0.50	O
±	O
0.94	O
)	O
of	O
CRCs	O
in	O
the	O
Ldlr	O
mice	O
were	O
significantly	O
lower	O
than	O
in	O
the	O
WT	O
mice	O
(	O
80	O
%	O
incidence	O
and	O
3.10	O
±	O
2.38	O
multiplicity	O
)	O
.	O

The	O
mRNA	O
expression	O
of	O
two	O
inducible	O
enzymes	O
and	O
certain	O
pro-inflammatory	O
cytokines	O
in	O
the	O
colorectum	O
of	O
each	O
genotype	O
was	O
greater	O
than	O
in	O
the	O
respective	O
WT	O
mice	O
.	O

The	O
values	O
in	O
the	O
Apoe	O
-	O
deficient	O
mice	O
were	O
much	O
greater	O
than	O
in	O
the	O
Ldlr	O
mice	O
.	O

These	O
findings	O
suggest	O
that	O
Apoe	O
-	O
deficient	O
mice	O
showed	O
increased	O
susceptibility	O
to	O
inflammation	O
-	O
associated	O
colorectal	O
carcinogenesis	O
due	O
to	O
their	O
high	O
reactivity	O
to	O
inflammatory	O
stimuli	O
.	O

Readily	O
Accessible	O
and	O
Predictable	O
Naphthalene	O
-Based	O
Two-Photon	O
Fluorophore	O
with	O
Full	O
Visible	O
-	O
Color	O
Coverage	O
.	O

Herein	O
we	O
report	O
22	O
acedan	O
-derived	O
,	O
two-photon	O
fluorophores	O
with	O
synthetic	O
feasibility	O
and	O
full	O
coverage	O
of	O
visible	O
wavelength	O
emission	O
.	O

The	O
emission	O
wavelengths	O
were	O
predicted	O
by	O
computational	B-P
analysis	I-P
,	O
which	O
enabled	O
us	O
to	O
visualize	O
multicolor	O
images	O
by	O
two-photon	O
excitation	O
with	O
single	O
wavelength	O
,	O
and	O
to	O
design	O
a	O
turn-on	O
,	O
two-photon	O
fluorescence	O
sensor	O
for	O
endogenous	O
H2	O
O2	O
in	O
Raw	O
264.7	O
macrophage	O
and	O
rat	O
brain	O
hippocampus	O
ex	O
vivo	O
.	O

Ultrasonography	B-P
and	O
magnetic	B-P
resonance	I-P
imaging	I-P
evaluation	O
of	O
pediatric	O
spinal	O
anomalies	O
.	O

Spinal	O
dysraphisms	O
are	O
congenital	O
abnormalities	O
of	O
the	O
spine	O
due	O
to	O
imperfect	O
fusion	O
of	O
midline	O
mesenchymal	O
,	O
bony	O
and	O
neural	O
structures	O
.	O

Imaging	B-P
plays	O
a	O
vital	O
role	O
in	O
their	O
evaluation	O
as	O
significant	O
portion	O
of	O
patients	O
may	O
present	O
with	O
concurrent	O
anomalies	O
that	O
need	O
to	O
be	O
corrected	O
simultaneously	O
to	O
avoid	O
repeat	O
surgeries	O
.	O

The	O
aims	O
of	O
the	O
study	O
were	O
to	O
evaluate	O
Spinal	O
dysraphisms	O
using	O
USG	B-P
and	O
MRI	B-P
and	O
to	O
correlate	O
imaging	B-P
findings	O
with	O
operative	O
findings	O
in	O
patients	O
undergoing	O
surgery	O
.	O

Hospital	O
based	O
observational	O
study	O
conducted	O
over	O
a	O
period	O
of	O
year	O
.	O

38	O
cases	O
of	O
both	O
sexes	O
and	O
below	O
12	O
years	O
of	O
age	O
with	O
spinal	O
dysraphism	O
were	O
studied	O
.	O

USG	B-P
was	O
performed	O
in	O
29	O
cases	O
where	O
acoustic	O
window	O
was	O
available	O
for	O
proper	O
evaluation	O
.	O

MRI	B-P
was	O
performed	O
in	O
all	O
cases	O
.	O

USG	B-P
findings	O
were	O
compared	O
with	O
MRI	B-P
findings	O
and	O
operative	O
follow	O
up	O
was	O
taken	O
in	O
23	O
cases	O
who	O
underwent	O
operative	O
management	O
.	O

Results	O
were	O
analysed	O
using	O
percentage	O
and	O
arithmetic	O
mean	O
.	O

39.47	O
%	O
cases	O
were	O
male	O
and	O
60.53	O
%	O
cases	O
were	O
female	O
.	O

Neonatal	O
period	O
was	O
the	O
most	O
common	O
presenting	O
age	O
group	O
.	O

Closed	O
spinal	O
dysraphism	O
(	O
63.16	O
%	O
)	O
was	O
more	O
common	O
than	O
open	O
(	O
36.84	O
%	O
)	O
.	O

79.31	O
%	O
cases	O
showed	O
full	O
agreement	O
between	O
spinal	O
USG	B-P
and	O
MRI	B-P
examinations	O
and	O
6	O
out	O
of	O
20.69	O
%	O
showed	O
partial	O
agreement	O
.	O

On	O
operative	O
correlation	O
,	O
USG	B-P
findings	O
were	O
confirmatory	O
in	O
91.30	O
%	O
cases	O
and	O
MRI	B-P
findings	O
were	O
confirmatory	O
in	O
100	O
%	O
cases	O
.	O

USG	B-P
can	O
be	O
used	O
as	O
the	O
initial	O
modality	O
for	O
evaluation	O
of	O
spinal	O
dysraphism	O
as	O
well	O
as	O
for	O
screening	O
of	O
suspected	O
cases	O
.	O

MRI	B-P
is	O
indicated	O
to	O
confirm	O
abnormal	O
USG	B-P
findings	O
,	O
which	O
shows	O
all	O
concurrent	O
abnormalities	O
and	O
also	O
provides	O
additional	O
anatomical	O
details	O
relevant	O
to	O
surgical	O
planning	O
.	O

Association	O
of	O
kidney	O
disease	O
with	O
obstructive	O
sleep	O
apnea	O
in	O
a	O
population	O
study	O
of	O
men	O
.	O

To	O
determine	B-P
the	O
relationship	O
between	O
obstructive	O
sleep	O
apnea	O
(	O
OSA	O
)	O
and	O
chronic	O
kidney	O
disease	O
(	O
CKD	O
)	O
.	O

Previous	O
population	O
studies	O
of	O
the	O
association	O
are	O
sparse	O
,	O
conflicting	O
and	O
confined	O
largely	O
to	O
studies	O
of	O
administrative	O
data	O
.	O

Cross-sectional	O
analysis	O
in	O
unselected	O
participants	O
of	O
the	O
Men	O
Androgens	O
Inflammation	O
Lifestyle	O
Environment	O
and	O
Stress	O
(	O
MAILES	O
)	O
study	O
,	O
aged	O
>	O
40	O
y.	O
Renal	O
data	O
were	O
available	O
on	O
812	O
men	O
without	O
a	O
prior	O
OSA	O
diagnosis	O
who	O
underwent	O
full	O
in-home	O
polysomnography	B-P
(	O
Embletta	O
X100	O
)	O
in	O
2010-2011	O
.	O

CKD	O
was	O
defined	O
as	O
an	O
estimated	B-P
glomerular	I-P
filtration	I-P
rate	I-P
(	O
eGFR	B-P
)	O
<	O
60	O
mL/min/1.73m2	O
or	O
eGFR	B-P
≥60	O
and	O
albuminuria	O
(	O
albumin	B-P
creatinine	I-P
ratio	I-P
≥3.0	O
mg/mmol	O
)	O
.	O

CKD	O
[	O
10.5	O
%	O
,	O
n=85	O
(	O
Stage	O
1-3	O
,	O
9.7	O
%	O
;	O
Stage	O
4-5	O
,	O
0.7	O
%	O
)	O
]	O
of	O
predominantly	O
mild	O
severity	O
showed	O
significant	O
association	O
s	O
with	O
OSA	O
(	O
AHI≥10	O
)	O
:	O
odds	O
ratio	O
(	O
OR	O
)	O
=1.9	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:1.02-3.5	O
,	O
severe	O
OSA	O
(	O
AHI	O
≥30/h	O
)	O
:	O
OR	O
=2.6	O
,	O
95	O
%	O
CI:1.1-6.2	O
,	O
and	O
respiratory	O
related	O
arousal	O
index	O
:	O
≥7.6/h	O
OR	O
=2.3	O
,	O
95	O
%	O
CI	O
:	O
1.1-4.7	O
,	O
but	O
not	O
measures	O
of	O
hypoxemia	O
after	O
adjustment	O
for	O
age	O
,	O
hypertension	O
,	O
diabetes	O
,	O
smoking	O
,	O
obesity	O
,	O
and	O
NSAID	O
use	O
.	O

There	O
was	O
no	O
association	O
of	O
CKD	O
with	O
daytime	O
sleepiness	O
.	O

In	O
men	O
with	O
CKD	O
,	O
those	O
with	O
OSA	O
were	O
not	O
significantly	O
more	O
likely	O
to	O
report	O
symptoms	O
(	O
sleepiness	O
,	O
snoring	O
,	O
apneas	O
)	O
or	O
be	O
identified	O
with	O
the	O
STOP	O
OSA	O
screening	O
questionnaire	O
,	O
compared	O
to	O
men	O
without	O
OSA	O
.	O

Predominantly	O
mild	O
CKD	O
is	O
associated	O
with	O
severe	O
OSA	O
and	O
arousals	O
.	O

Further	O
population	O
studies	O
examining	O
the	O
longitudinal	O
relationship	O
between	O
CKD	O
and	O
OSA	O
are	O
warranted	O
.	O

Better	O
methods	O
are	O
needed	O
to	O
identify	O
OSA	O
in	O
CKD	O
which	O
may	O
have	O
few	O
symptoms	O
.	O

Systematic	O
mapping	O
of	O
functional	O
enhancer	O
-	O
promoter	O
connections	O
with	O
CRISPR	B-P
interference	I-P
.	O

Gene	O
expression	O
in	O
mammals	O
is	O
regulated	O
by	O
noncoding	O
elements	O
that	O
can	O
affect	O
physiology	O
and	O
disease	O
,	O
yet	O
the	O
functions	O
and	O
target	O
genes	O
of	O
most	O
noncoding	O
elements	O
remain	O
unknown	O
.	O

We	O
present	O
a	O
high-throughput	O
approach	O
that	O
uses	O
clustered	B-P
regularly	I-P
interspaced	I-P
short	I-P
palindromic	I-P
repeats	I-P
(	I-P
CRISPR	I-P
)	I-P
interference	I-P
(	O
CRISPRi	B-P
)	O
to	O
discover	O
regulatory	O
elements	O
and	O
identify	O
their	O
target	O
genes	O
.	O

We	O
assess	O
>	O
1	O
megabase	O
of	O
sequence	O
in	O
the	O
vicinity	O
of	O
two	O
essential	O
transcription	O
factors	O
,	O
MYC	O
and	O
GATA1	O
,	O
and	O
identify	O
nine	O
distal	O
enhancers	O
that	O
control	O
gene	O
expression	O
and	O
cellular	O
proliferation	O
.	O

Quantitative	O
features	O
of	O
chromatin	O
state	O
and	O
chromosome	O
conformation	O
distinguish	O
the	O
seven	O
enhancers	O
that	O
regulate	O
MYC	O
from	O
other	O
elements	O
that	O
do	O
not	O
,	O
suggesting	O
a	O
strategy	O
for	O
predicting	O
enhancer	O
-	O
promoter	O
connectivity	O
.	O

This	O
CRISPRi	B-P
-based	O
approach	O
can	O
be	O
applied	O
to	O
dissect	O
transcriptional	O
networks	O
and	O
interpret	O
the	O
contributions	O
of	O
noncoding	O
genetic	O
variation	O
to	O
human	O
disease	O
.	O

Argininosuccinic	O
Acid	O
Lyase	O
Deficiency	O
Missed	O
by	O
Newborn	B-P
Screen	I-P
.	O

Argininosuccinic	O
acid	O
lyase	O
(	O
ASL	O
)	O
deficiency	O
,	O
caused	O
by	O
mutations	O
in	O
the	O
ASL	O
gene	O
(	O
OMIM	O
:	O
608310	O
)	O
is	O
a	O
urea	O
cycle	O
disorder	O
that	O
has	O
pleiotropic	O
presentations	O
.	O

On	O
the	O
mild	O
end	O
,	O
ASL	O
deficiency	O
can	O
manifest	O
as	O
nonspecific	O
neurocognitive	O
abnormalities	O
without	O
readily	O
identifiable	O
signs	O
to	O
differentiate	O
it	O
from	O
other	O
causes	O
of	O
intellectual	O
disability	O
or	O
learning	O
disabilities	O
.	O

Dietary	O
management	O
and	O
arginine	O
supplementation	O
,	O
if	O
initiated	O
early	O
,	O
may	O
ameliorate	O
symptoms	O
.Because	O
of	O
the	O
nonspecific	O
nature	O
of	O
the	O
symptoms	O
and	O
the	O
possibility	O
for	O
therapeutic	O
management	O
,	O
ASL	O
deficiency	O
is	O
part	O
of	O
the	O
recommended	O
uniform	B-P
screening	I-P
panel	I-P
for	O
newborn	B-P
screening	I-P
in	O
the	O
USA	O
.	O

We	O
report	O
here	O
a	O
case	O
of	O
ASL	O
deficiency	O
that	O
was	O
missed	O
on	O
newborn	B-P
screening	I-P
in	O
the	O
USA	O
.The	O
case	O
reported	O
here	O
has	O
two	O
known	O
pathogenic	O
mutations	O
-	O
one	O
with	O
no	O
residual	O
activity	O
and	O
one	O
with	O
reported	O
10	O
%	O
residual	O
activity	O
.	O

Review	O
of	O
this	O
newborn	B-P
screening	I-P
results	O
showed	O
subtle	O
elevation	O
of	O
citrulline	O
,	O
overlapping	O
the	O
normal	O
range	O
.	O

These	O
findings	O
suggest	O
that	O
newborn	B-P
screening	I-P
may	O
be	O
missing	O
other	O
patients	O
with	O
ASL	O
deficiency	O
with	O
at	O
least	O
one	O
hypomorphic	O
allele	O
.	O

This	O
case	O
was	O
diagnosed	O
incidentally	O
,	O
but	O
in	O
retrospect	O
had	O
symptoms	O
best	O
attributed	O
in	O
full	O
or	O
in	O
part	O
to	O
his	O
ASA	O
deficiency	O
,	O
including	O
protein	O
aversion	O
,	O
developmental	O
delay	O
,	O
and	O
seizures	O
.	O

This	O
case	O
highlights	O
the	O
importance	O
of	O
considering	O
ASL	O
deficiency	O
in	O
patients	O
with	O
nonspecific	O
abnormal	O
neurocognitive	O
signs	O
,	O
such	O
as	O
epilepsy	O
and	O
developmental	O
delay	O
,	O
even	O
when	O
newborn	B-P
screening	I-P
was	O
normal	O
.	O

A	O
pilot	O
study	O
of	O
intraocular	O
lens	O
explantation	O
in	O
69	O
eyes	O
in	O
Chinese	O
patients	O
.	O

To	O
study	O
the	O
effects	O
of	O
intraocular	O
lens	O
(	O
IOL	O
)	O
explantation	O
and	O
demographic	O
characteristics	O
.	O

Retrospective	O
non-comparative	O
case	O
series	O
.	O

Clinical	O
data	O
recorded	O
from	O
patient	O
charts	O
included	O
the	O
following	O
:	O
demographic	O
,	O
preoperative	O
and	O
postoperative	O
characteristics	O
;	O
complications	O
;	O
surgical	O
methods	O
,	O
and	O
changes	O
in	O
visual	B-P
acuity	I-P
.	O

A	O
total	O
of	O
69	O
eyes	O
in	O
67	O
Chinese	O
patients	O
who	O
received	O
IOL	O
explants	O
were	O
studied	O
.	O

The	O
patients	O
'	O
mean	O
age	O
at	O
the	O
time	O
of	O
explantation	O
was	O
46.1	O
years	O
old	O
[	O
SD	O
22.5	O
(	O
6-85	O
)	O
]	O
,	O
and	O
37	O
patients	O
were	O
female	O
(	O
55.2	O
%	O
)	O
.	O

Regarding	O
employment	O
,	O
47.8	O
%	O
were	O
farmers	O
,	O
23.9	O
%	O
were	O
retired	O
,	O
16.4	O
%	O
were	O
students	O
,	O
4.5	O
%	O
were	O
unemployed	O
,	O
3	O
%	O
were	O
workers	O
,	O
and	O
4.5	O
%	O
were	O
other	O
(	O
including	O
staff	O
members	O
,	O
teachers	O
and	O
officers	O
)	O
.	O

The	O
main	O
reasons	O
for	O
explantation	O
were	O
dislocation	O
/	O
decentration	O
in	O
41	O
cases	O
(	O
59.4	O
%	O
)	O
and	O
retinal	O
detachment	O
in	O
10	O
cases	O
(	O
14.5	O
%	O
)	O
.	O

The	O
third	O
most	O
prevalent	O
cause	O
was	O
incorrect	O
lens	O
power	O
in	O
7	O
eyes	O
(	O
10.1	O
%	O
)	O
.	O

The	O
remaining	O
reasons	O
were	O
endophthalmitis	O
in	O
6	O
cases	O
(	O
8.7	O
%	O
)	O
,	O
posterior	O
capsular	O
opacity	O
in	O
3	O
eyes	O
(	O
4.3	O
%	O
)	O
,	O
and	O
impacting	O
retinal	O
surgery	O
operation	O
in	O
2	O
cases	O
(	O
2.9	O
%	O
)	O
.	O

The	O
main	O
comorbidities	O
were	O
high	O
myopia	O
in	O
18	O
eyes	O
(	O
26.1	O
%	O
)	O
,	O
trauma	O
in	O
8	O
eyes	O
(	O
11.6	O
%	O
)	O
,	O
retinal	O
detachment	O
in	O
6	O
eyes	O
(	O
8.7	O
%	O
)	O
,	O
congenital	O
cataracts	O
in	O
8	O
eyes	O
(	O
11.6	O
%	O
)	O
,	O
and	O
Marfan	O
's	O
syndrome	O
in	O
2	O
eyes	O
(	O
2.9	O
%	O
)	O
.	O

The	O
mean	O
time	O
from	O
implantation	O
to	O
explantation	O
was	O
4.0y	O
[	O
SD	O
4.2	O
(	O
0.005-15	O
)	O
]	O
.	O

Treatment	O
after	O
explantation	O
included	O
posterior	O
chamber	O
IOL	O
implantation	O
in	O
44	O
eyes	O
(	O
63.8	O
%	O
)	O
and	O
aphakia	O
in	O
25	O
eyes	O
(	O
36.2	O
%	O
)	O
.	O

After	O
surgery	O
,	O
the	O
best	O
corrected	O
visual	O
ability	O
(	O
BCVA	O
)	O
was	O
improved	O
in	O
50	O
cases	O
(	O
72.5	O
%	O
)	O
,	O
including	O
28	O
patients	O
(	O
40.6	O
%	O
)	O
in	O
whom	O
visual	O
ability	O
was	O
improved	O
by	O
more	O
than	O
two	O
lines	O
.	O

Dislocation	O
/	O
decentration	O
is	O
the	O
main	O
cause	O
for	O
explantation	O
,	O
and	O
high	O
myopia	O
is	O
a	O
main	O
risk	O
factor	O
.	O

Posterior	O
chamber	O
IOL	O
implantation	O
remains	O
the	O
most	O
elected	O
treatment	O
after	O
explantation	O
.	O

Sevoflurane	O
postconditioning	O
improves	O
myocardial	O
mitochondrial	O
respiratory	O
function	O
and	O
reduces	O
myocardial	O
ischemia	O
-	O
reperfusion	O
injury	O
by	O
up-regulating	O
HIF-1	O
.	O

Sevoflurane	O
postconditioning	O
(	O
SPostC	O
)	O
can	O
exert	O
myocardial	O
protective	O
effects	O
similar	O
to	O
ischemic	O
preconditioning	O
.	O

However	O
,	O
the	O
exact	O
myocardial	O
protection	O
mechanism	O
by	O
SPostC	O
is	O
unclear	O
.	O

Studies	O
indicate	O
that	O
hypoxia-inducible	O
factor-1	O
(	O
HIF-1	O
)	O
maintains	O
cellular	O
respiration	O
homeostasis	O
by	O
regulating	O
mitochondrial	O
respiratory	O
chain	O
enzyme	O
activity	O
under	O
hypoxic	O
conditions	O
.	O

This	O
study	O
investigated	O
whether	O
SPostC	O
could	O
regulate	O
the	O
expression	O
of	O
myocardial	O
HIF-1α	O
and	O
to	O
improve	O
mitochondrial	O
respiratory	O
function	O
,	O
thereby	O
relieving	O
myocardial	O
ischemia	O
-	O
reperfusion	O
injury	O
in	O
rats	O
.	O

The	O
myocardial	O
ischemia	O
-	O
reperfusion	O
rat	O
model	O
was	O
established	O
using	O
the	O
Langendorff	B-P
isolated	I-P
heart	I-P
perfusion	I-P
apparatus	I-P
.	O

Additionally	O
,	O
postconditioning	O
was	O
performed	O
using	O
sevoflurane	O
alone	O
or	O
in	O
combination	O
with	O
the	O
HIF-1α	O
inhibitor	O
2-methoxyestradiol	O
(	O
2ME2	O
)	O
.	O

The	O
changes	O
in	O
hemodynamic	O
parameters	O
,	O
HIF-1α	O
protein	O
expression	O
levels	O
,	O
mitochondrial	O
respiratory	O
function	O
and	O
enzyme	O
activity	O
,	O
mitochondrial	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
production	O
rates	O
,	O
and	O
mitochondrial	O
ultrastructure	O
were	O
measured	O
or	O
observed	O
.	O

Compared	O
to	O
the	O
ischemia	O
-	O
reperfusion	O
(	O
I	O
/	O
R	O
)	O
group	O
,	O
HIF-1α	O
expression	O
in	O
the	O
SPostC	O
group	O
was	O
significantly	O
up-regulated	O
.	O

Additionally	O
,	O
cardiac	O
function	O
indicators	O
,	O
mitochondrial	O
state	O
3	O
respiratory	O
rate	O
,	O
respiratory	O
control	O
ratio	O
(	O
RCR	O
)	O
,	O
cytochrome	O
C	O
oxidase	O
(	O
CcO	O
)	O
,	O
NADH	O
oxidase	O
(	O
NADHO	O
)	O
,	O
and	O
succinate	O
oxidase	O
(	O
SUCO	O
)	O
activities	O
,	O
mitochondrial	O
ROS	O
production	O
rate	O
,	O
and	O
mitochondrial	O
ultrastructure	O
were	O
significantly	O
better	O
than	O
those	O
in	O
the	O
I	O
/	O
R	O
group	O
.	O

However	O
,	O
these	O
advantages	O
were	O
completely	O
reversed	O
by	O
the	O
HIF-1α	O
specific	O
inhibitor	O
2ME2	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
myocardial	O
protective	O
function	O
of	O
SPostC	O
might	O
be	O
associated	O
with	O
the	O
improvement	O
of	O
mitochondrial	O
respiratory	O
function	O
after	O
up-regulation	O
of	O
HIF-1α	O
expression	O
.	O

Increased	O
RhoA	O
Activity	O
Predicts	O
Worse	O
Overall	O
Survival	O
in	O
Patients	O
Undergoing	O
Surgical	O
Resection	O
for	O
Lauren	O
Diffuse-Type	O
Gastric	O
Adenocarcinoma	O
.	O

Several	O
studies	O
have	O
reported	O
a	O
high	O
rate	O
of	O
RHOA	O
mutations	O
in	O
the	O
Lauren	O
diffuse-type	O
gastric	O
adenocarcinoma	O
(	O
GA	O
)	O
but	O
not	O
in	O
intestinal-type	O
GA	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
RhoA	O
activity	O
is	O
prognostic	O
for	O
overall	O
survival	O
(	O
OS	O
)	O
in	O
patients	O
with	O
resectable	O
GA.	O
Retrospective	O
review	O
was	O
performed	O
on	O
a	O
prospective	O
database	O
of	O
GA	O
patients	O
who	O
underwent	O
potentially	O
curative	O
resection	O
between	O
2003	O
and	O
2012	O
at	O
a	O
single	O
institution	O
.	O

Tissue	O
microarrays	O
were	O
constructed	O
from	O
surgical	B-P
specimens	I-P
and	O
analyzed	O
for	O
phosphorylated	O
RhoA	O
,	O
a	O
marker	O
of	O
inactive	O
RhoA	O
signaling	O
.	O

OS	O
was	O
estimated	O
by	O
the	O
Kaplan-Meier	O
method	O
,	O
and	O
multivariate	O
analysis	O
was	O
performed	O
by	O
Cox	O
proportional	O
hazards	O
regression	O
modeling	O
.	O

One	O
hundred	O
thirty-six	O
patients	O
with	O
diffuse-type	O
GA	O
and	O
129	O
patients	O
with	O
intestinal-type	O
GA	O
were	O
examined	O
.	O

Compared	O
to	O
intestinal-type	O
GA	O
,	O
diffuse-type	O
GA	O
tumors	O
were	O
significantly	O
associated	O
with	O
increased	O
tumor	O
size	O
and	O
advanced	O
tumor	O
,	O
node	O
,	O
metastasis	O
(	O
TNM	O
)	O
classification	O
system	O
stage	O
.	O

In	O
patients	O
with	O
diffuse-type	O
GA	O
,	O
high	O
RhoA	O
activity	O
was	O
associated	O
with	O
significantly	O
worse	O
OS	O
when	O
compared	O
to	O
low	O
RhoA	O
activity	O
(	O
5-year	O
OS	O
52.5	O
vs.	O
81.0	O
%	O
,	O
p	O
=	O
0.017	O
)	O
.	O

This	O
difference	O
in	O
OS	O
was	O
not	O
observed	O
in	O
patients	O
with	O
intestinal-type	O
GA	O
(	O
5-year	O
OS	O
83.9	O
vs.	O
81.6	O
%	O
,	O
p	O
=	O
0.766	O
)	O
.	O

On	O
multivariate	O
analysis	O
of	O
diffuse-type	O
GA	O
patients	O
,	O
high	O
RhoA	O
activity	O
was	O
an	O
independent	O
negative	O
prognostic	O
factor	O
for	O
OS	O
(	O
hazard	O
ratio	O
2.38	O
,	O
95	O
%	O
confidence	O
interval	O
1.07-5.28	O
)	O
.	O

Increased	O
RhoA	O
activity	O
is	O
predictive	O
of	O
worse	O
OS	O
in	O
patients	O
with	O
diffuse-type	O
GA	O
who	O
undergo	O
potentially	O
curative	O
surgical	O
resection	O
.	O

Along	O
with	O
findings	O
from	O
genomic	O
studies	O
,	O
these	O
results	O
suggest	O
RhoA	O
may	O
be	O
a	O
novel	O
therapeutic	O
target	O
in	O
diffuse-type	O
GA	O
.	O

Identification	O
of	O
Chlamydia	O
trachomatis	O
Antigens	O
Recognized	O
by	O
T	O
Cells	O
From	O
Highly	O
Exposed	O
Women	O
Who	O
Limit	O
or	O
Resist	O
Genital	O
Tract	O
Infection	O
.	O

Natural	O
infection	O
induces	O
partial	O
immunity	O
to	O
Chlamydia	O
trachomatis	O
Identification	O
of	O
chlamydial	O
antigens	O
that	O
induce	O
interferon	O
γ	O
(	O
IFN-	O
)	O
secretion	O
by	O
T	O
cells	O
from	O
immune	O
women	O
could	O
advance	O
vaccine	O
development	O
.	O

IFN-γ	O
production	O
by	O
CD4	O
(	O
+	O
)	O
and	O
CD8	O
(	O
+	O
)	O
peripheral	O
blood	O
T	O
cells	O
from	O
58	O
high-risk	O
women	O
was	O
measured	O
after	O
coculture	B-P
with	O
antigen-presenting	O
cells	O
preincubated	O
with	O
recombinant	O
Escherichia	O
coli	O
expressing	O
a	O
panel	O
of	O
275	O
chlamydial	O
antigens	O
.	O

Quantile	O
median	O
regression	O
analysis	O
was	O
used	O
to	O
compare	O
frequencies	O
of	O
IFN-γ	O
responses	O
in	O
women	O
with	O
only	O
cervical	O
infection	O
to	O
those	O
in	O
women	O
with	O
endometrial	O
infection	O
and	O
frequencies	O
in	O
women	O
who	O
remained	O
uninfected	O
for	O
over	O
1	O
year	O
to	O
those	O
in	O
women	O
who	O
developed	O
incident	O
infection	O
.	O

Statistical	O
methods	O
were	O
then	O
used	O
to	O
identify	O
proteins	O
associated	O
with	O
protection	O
.	O

A	O
higher	O
median	O
frequency	O
of	O
CD8	O
(	O
+	O
)	O
T-cell	O
responses	O
was	O
detected	O
in	O
women	O
with	O
lower	O
genital	O
tract	O
chlamydial	O
infection	O
,	O
compared	O
with	O
those	O
with	O
upper	O
genital	O
tract	O
chlamydial	O
infection	O
(	O
13.8	O
%	O
vs	O
9.5	O
%	O
;	O
P	O
=04	O
)	O
,	O
but	O
the	O
CD4	O
(	O
+	O
)	O
T-cell	O
response	O
frequencies	O
were	O
not	O
different	O
.	O

Women	O
who	O
remained	O
uninfected	O
displayed	O
a	O
greater	O
frequency	O
of	O
positive	O
CD4	O
(	O
+	O
)	O
T-cell	O
responses	O
(	O
29	O
%	O
vs	O
18	O
%	O
;	O
P	O
<	O
.0001	O
)	O
,	O
compared	O
with	O
women	O
who	O
had	O
incident	O
infection	O
,	O
while	O
the	O
frequencies	O
of	O
CD8	O
(	O
+	O
)	O
T-cell	O
responses	O
did	O
not	O
differ	O
.	O

A	O
subset	O
of	O
proteins	O
involved	O
in	O
central	O
metabolism	O
,	O
type	O
III	O
secretion	O
,	O
and	O
protein	O
synthesis	O
were	O
associated	O
with	O
protection	O
.	O

Investigations	O
in	O
naturally	O
exposed	O
women	O
reveal	O
protective	O
responses	O
and	O
identify	O
chlamydial	O
vaccine	O
candidate	O
antigens	O
.	O

A	O
Comparative	O
Study	O
of	O
Enamel	O
Surface	O
Roughness	O
After	O
Bleaching	O
With	O
Diode	O
Laser	O
and	O
Nd	O
:	O
YAG	O
Laser	O
.	O

Introduction	O
:	O
Bleaching	O
process	O
can	O
affect	O
surface	O
roughness	O
of	O
enamel	O
,	O
which	O
is	O
a	O
vital	O
factor	O
in	O
esthetic	O
and	O
resistance	O
of	O
tooth	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
surface	O
roughness	O
of	O
enamel	O
in	O
teeth	O
bleached	O
using	O
Diode	O
and	O
Neodymium-Doped	O
Yttrium	O
Aluminium	O
Garnet	O
(	O
Nd	O
:	O
YAG	O
)	O
lasers	O
with	O
those	O
bleached	O
using	O
conventional	O
method	O
.	O

Methods	O
:	O
In	O
this	O
study	O
,	O
75	O
anterior	O
human	O
teeth	O
from	O
upper	O
and	O
lower	O
jaws	O
(	O
These	O
teeth	O
extracted	O
because	O
of	O
periodontal	O
disease	O
)	O
were	O
randomly	O
divided	O
into	O
5	O
groups	O
.	O

Group	O
1	O
:	O
Laser	O
white	O
gel	O
(	O
Biolase	O
,	O
USA	O
)	O
with	O
45	O
%	O
hydrogen	O
peroxide	O
concentration	O
and	O
GaAlAs	O
Diode	O
laser	O
(	O
CHEESE	O
(	O
TM	O
)	O
,	O
GIGAA	O
,	O
China	O
)	O
,	O
group	O
2	O
:	O
Heydent	O
gel	O
(	O
JW	O
,	O
Germany	O
)	O
with	O
30	O
%	O
Hydrogen	O
peroxide	O
concentration	O
and	O
Diode	O
laser	O
,	O
group	O
3	O
:	O
Laser	O
white	O
gel	O
and	O
Nd	O
:	O
YAG	O
laser	O
(	O
FIDELIS	O
(	O
TM	O
)	O
,	O
Fotona	O
,	O
Slovenia	O
)	O
,	O
group	O
4	O
:	O
Heydent	O
gel	O
and	O
Nd	O
:	O
YAG	O
laser	O
and	O
group	O
5	O
:	O
The	O
Iranian	O
gel	O
Kimia	O
(	O
Iran	O
)	O
with	O
35	O
%	O
hydrogen	O
peroxide	O
concentration	O
were	O
used	O
.	O

Surface	O
roughness	O
of	O
the	O
samples	O
was	O
measured	O
using	O
the	O
Surface	O
Roughness	O
Tester	O
system	O
(	O
TR	O
200	O
Time	O
Group	O
,	O
Germany	O
)	O
before	O
and	O
after	O
bleaching	O
.	O

In	O
each	O
group	O
,	O
one	O
sample	O
was	O
randomly	O
selected	O
for	O
SEM	B-P
analysis	I-P
.	O

Results	O
:	O
The	O
results	O
showed	O
that	O
the	O
mean	O
surface	O
roughness	O
of	O
the	O
teeth	O
before	O
and	O
after	O
bleaching	O
had	O
a	O
significant	O
difference	O
in	O
all	O
the	O
study	O
groups	O
.	O

It	O
was	O
indicated	O
that	O
after	O
bleaching	O
,	O
the	O
mean	O
surface	O
roughness	O
had	O
increased	O
in	O
all	O
the	O
study	O
groups	O
.	O

The	O
highest	O
surface	O
roughness	O
was	O
seen	O
in	O
the	O
conventional	O
bleaching	O
group	O
and	O
the	O
lowest	O
surface	O
roughness	O
was	O
reported	O
in	O
group	O
3	O
(	O
laser	O
white	O
gel	O
+	O
diode	O
laser	O
)	O
,	O
in	O
which	O
the	O
average	O
surface	O
roughness	O
increased	O
by	O
only	O
0.1	O
μm	O
.	O

Conclusion	O
:	O
It	O
was	O
concluded	O
that	O
using	O
the	O
Laser	O
white	O
gel	O
and	O
the	O
diode	O
laser	O
for	O
bleaching	O
resulted	O
in	O
the	O
least	O
surface	O
roughness	O
compared	O
to	O
conventional	O
method	O
.	O

Macular	O
Ganglion	O
Cell	O
-	O
Inner	O
Plexiform	O
Layer	O
Thickness	O
Is	O
Associated	O
with	O
Clinical	O
Progression	O
in	O
Mild	O
Cognitive	O
Impairment	O
and	O
Alzheimers	O
Disease	O
.	O

We	O
investigated	O
the	O
association	O
of	O
the	O
macular	O
ganglion	O
cell	O
-	O
inner	O
plexiform	O
layer	O
(	O
GCIPL	O
)	O
and	O
peripapillary	O
retinal	O
nerve	O
fiber	O
layer	O
(	O
RNFL	O
)	O
thicknesses	O
with	O
disease	O
progression	O
in	O
mild	O
cognitive	O
impairment	O
(	O
MCI	O
)	O
and	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

We	O
recruited	O
42	O
patients	O
with	O
AD	O
,	O
26	O
with	O
MCI	O
,	O
and	O
66	O
normal	O
elderly	O
controls	O
.	O

The	O
thicknesses	O
of	O
the	O
RNFL	O
and	O
GCIPL	O
were	O
measured	O
via	O
spectral-domain	O
optic	O
coherent	O
tomography	O
in	O
all	O
participants	O
at	O
baseline	O
.	O

The	O
patients	O
with	O
MCI	O
or	O
AD	O
underwent	O
clinical	O
and	O
neuropsychological	B-P
tests	I-P
at	O
baseline	O
and	O
once	O
every	O
year	O
thereafter	O
for	O
2	O
years	O
.	O

The	O
Clinical	O
Dementia	O
Rating	O
scale-Sum	O
of	O
Boxes	O
(	O
CDR-SB	O
)	O
score	O
exhibited	O
significant	O
negative	O
relationships	O
with	O
the	O
average	O
GCIPL	O
thickness	O
(	O
β	O
=	O
-0.15	O
,	O
p	O
<	O
0.05	O
)	O
and	O
the	O
GCIPL	O
thickness	O
in	O
the	O
superotemporal	O
,	O
superonasal	O
,	O
and	O
inferonasal	O
sectors	O
.	O

The	O
composite	O
memory	O
score	O
exhibited	O
significant	O
positive	O
associations	O
with	O
the	O
average	O
GCIPL	O
thickness	O
and	O
the	O
GCIPL	O
thickness	O
in	O
the	O
superotemporal	O
,	O
inferonasal	O
,	O
and	O
inferotemporal	O
sectors	O
.	O

The	O
temporal	O
RNFL	O
thickness	O
,	O
the	O
average	O
and	O
minimum	O
GCIPL	O
thicknesses	O
,	O
and	O
the	O
GCIPL	O
thickness	O
in	O
the	O
inferonasal	O
,	O
inferior	O
,	O
and	O
inferotemporal	O
sectors	O
at	O
baseline	O
were	O
significantly	O
reduced	O
in	O
MCI	O
patients	O
who	O
were	O
converted	O
to	O
AD	O
compared	O
to	O
stable	O
MCI	O
patients	O
.	O

The	O
change	O
of	O
CDR-SB	O
from	O
baseline	O
to	O
2	O
years	O
exhibited	O
significant	O
negative	O
associations	O
with	O
the	O
average	O
(	O
β	O
=	O
-0.150	O
,	O
p	O
=	O
0.006	O
)	O
and	O
minimum	O
GCIPL	O
thicknesses	O
as	O
well	O
as	O
GCIPL	O
thickness	O
in	O
the	O
superotemporal	O
,	O
superior	O
,	O
superonasal	O
,	O
and	O
inferonasal	O
sectors	O
at	O
baseline	O
.	O

Our	O
data	O
suggest	O
that	O
macular	O
GCIPL	O
thickness	O
represents	O
a	O
promising	O
biomarker	O
for	O
monitoring	O
the	O
progression	O
of	O
MCI	O
and	O
AD	O
.	O

Influence	O
of	O
ozone	O
and	O
paracetic	O
acid	O
disinfection	O
on	O
adhesion	O
of	O
resilient	O
liners	O
to	O
acrylic	O
resin	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
paracetic	O
acid	O
(	O
PAA	O
)	O
and	O
ozone	O
disinfection	O
on	O
the	O
tensile	O
bond	O
strength	O
(	O
TBS	O
)	O
of	O
silicone-based	O
resilient	O
liners	O
to	O
acrylic	O
resins	O
.	O

One	O
hundred	O
and	O
twenty	O
dumbbell	O
shaped	O
heat-polymerized	O
acrylic	O
resins	O
were	O
prepared	O
.	O

From	O
the	O
mid	O
segment	O
of	O
the	O
specimens	O
,	O
3	O
mm	O
of	O
acrylic	O
were	O
grinded	O
off	O
and	O
separated	O
parts	O
were	O
reattached	O
by	O
resilient	O
liners	O
.	O

The	O
specimens	O
were	O
divided	O
into	O
2	O
control	O
(	O
control1	O
,	O
control7	O
)	O
and	O
4	O
test	O
groups	O
of	O
PAA	O
and	O
ozone	O
disinfection	O
(	O
PAA1	O
,	O
PAA7	O
,	O
ozone1	O
and	O
ozone7	O
;	O
n=10	O
)	O
.	O

While	O
control	O
groups	O
were	O
immersed	O
in	O
distilled	O
water	O
for	O
10	O
min	O
(	O
control1	O
)	O
and	O
7	O
days	O
(	O
control7	O
)	O
,	O
test	O
groups	O
were	O
subjected	O
to	O
PAA	O
(	O
16	O
g/L	O
)	O
or	O
ozone	O
rich	O
water	O
(	O
4	O
mg/L	O
)	O
for	O
1	O
cycle	O
(	O
10	O
min	O
for	O
PAA	O
and	O
60	O
min	O
for	O
ozone	O
)	O
per	O
day	O
for	O
7	O
days	O
prior	O
to	O
tensile	O
tests	B-P
.	O

Measurements	O
of	O
the	O
TBS	O
were	O
analyzed	O
using	O
3-way	O
ANOVA	O
and	O
Tukey	B-P
's	I-P
HSD	I-P
test	I-P
.	O

Adhesive	O
strength	O
of	O
Mollosil	O
decreased	O
significantly	O
by	O
application	O
of	O
ozone	O
disinfection	O
.	O

PAA	O
disinfection	O
had	O
no	O
negative	O
effect	O
on	O
the	O
TBS	O
values	O
of	O
Mollosil	O
and	O
Molloplast	O
B	O
to	O
acrylic	O
resin	O
.	O

Single	O
application	O
of	O
ozone	O
disinfection	O
did	O
not	O
have	O
any	O
negative	O
effect	O
on	O
TBS	O
values	O
of	O
Molloplast	O
B	O
,	O
but	O
prolonged	O
exposure	O
to	O
ozone	O
decreased	O
its	O
adhesive	O
strength	O
.	O

The	O
adhesion	O
of	O
resilient	O
liners	O
to	O
acrylic	O
was	O
not	O
adversely	O
affected	O
by	O
PAA	O
disinfection	O
.	O

Immersion	O
in	O
ozonated	O
water	O
significantly	O
decreased	O
TBS	O
of	O
Mollosil	O
.	O

Prolonged	O
exposure	O
to	O
ozone	O
negatively	O
affects	O
adhesion	O
of	O
Molloplast	O
B	O
to	O
denture	O
base	O
materials	O
.	O

Supramolecular	O
Recognition	O
of	O
Amino	O
Acids	O
by	O
Twisted	O
Cucurbit	O
[	O
14	O
]	O
uril	O
.	O

Binding	O
interactions	O
between	O
twisted	O
cucurbit	O
[	O
14	O
]	O
uril	O
(	O
tQ	O
[	O
14	O
]	O
)	O
and	O
twenty	O
standard	O
amino	O
acids	O
(	O
AAs	O
)	O
have	O
been	O
investigated	O
by	O
NMR	B-P
spectroscopy	I-P
and	O
isothermal	B-P
titration	I-P
calorimetry	I-P
(	B-P
ITC	I-P
)	I-P
in	O
aqueous	O
HCl	O
solutions	O
and	O
in	O
DMSO	O
.	O

The	O
results	O
showed	O
that	O
tQ	O
[	O
14	O
]	O
displays	O
clear	O
binding	O
affinity	O
for	O
AAs	O
with	O
a	O
positively	O
charged	O
side	O
chain	O
or	O
containing	O
an	O
aromatic	O
ring	O
,	O
but	O
weaker	O
binding	O
affinity	O
for	O
AAs	O
with	O
hydrophobic	O
or	O
polar	O
side	O
chains	O
,	O
with	O
the	O
binding	O
mode	O
depending	O
on	O
the	O
type	O
of	O
side	O
chain	O
present	O
in	O
the	O
AAs	O
.	O

Does	O
the	O
Use	O
of	O
Ibuprofen	O
in	O
Children	O
with	O
Extremity	O
Fractures	O
Increase	O
their	O
Risk	O
for	O
Bone	O
Healing	O
Complications	O
?	O
.	O

Despite	O
being	O
an	O
effective	O
analgesic	O
for	O
children	O
with	O
fractures	O
,	O
some	O
clinicians	O
may	O
avoid	O
prescribing	O
ibuprofen	O
due	O
to	O
its	O
potentially	O
harmful	O
effect	O
on	O
bone	O
healing	O
.	O

To	O
determine	O
if	O
exposure	O
to	O
ibuprofen	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
bone	O
healing	O
complications	O
in	O
children	O
with	O
fractures	O
.	O

We	O
performed	O
a	O
retrospective	O
study	O
of	O
children	O
aged	O
6	O
months	O
to	O
17	O
years	O
who	O
presented	O
to	O
the	O
pediatric	O
emergency	O
department	O
(	O
PED	O
)	O
with	O
a	O
fracture	O
of	O
the	O
tibia	O
,	O
femur	O
,	O
humerus	O
,	O
scaphoid	O
,	O
or	O
fifth	O
metatarsus	O
and	O
who	O
followed	O
up	O
with	O
the	O
orthopedic	O
service	O
.	O

We	O
chose	O
these	O
fractures	O
due	O
to	O
their	O
higher	O
risk	O
for	O
complications	O
.	O

We	O
classified	O
patients	O
as	O
exposed	O
if	O
they	O
received	O
ibuprofen	O
in	O
the	O
PED	O
or	O
during	O
hospitalization	O
or	O
were	O
prescribed	O
ibuprofen	O
at	O
discharge	O
.	O

The	O
main	O
outcome	O
was	O
a	O
bone	O
healing	O
complication	O
as	O
evidenced	O
by	O
nonunion	O
,	O
delayed	O
union	O
,	O
or	O
re-displacement	O
on	O
follow-up	O
radiographs	B-P
.	O

Of	O
the	O
808	O
patients	O
included	O
in	O
the	O
final	O
analysis	O
,	O
338	O
(	O
42	O
%	O
)	O
were	O
exposed	O
to	O
ibuprofen	O
.	O

Overall	O
,	O
27	O
(	O
3	O
%	O
)	O
patients	O
had	O
a	O
bone	O
healing	O
complication	O
;	O
8	O
(	O
1	O
%	O
)	O
developed	O
nonunion	O
,	O
3	O
(	O
0.4	O
%	O
)	O
developed	O
delayed	O
union	O
,	O
and	O
16	O
(	O
2	O
%	O
)	O
developed	O
re-displacement	O
.	O

Ten	O
(	O
3	O
%	O
)	O
patients	O
who	O
were	O
exposed	O
to	O
ibuprofen	O
,	O
and	O
17	O
(	O
4	O
%	O
)	O
who	O
were	O
not	O
,	O
developed	O
a	O
bone	O
healing	O
complication	O
(	O
odds	O
ratio	O
0.8	O
,	O
95	O
%	O
confidence	O
interval	O
0.4-1.8	O
;	O
p	O
=	O
0.61	O
)	O
.	O

There	O
was	O
no	O
significant	O
association	O
between	O
ibuprofen	O
exposure	O
and	O
the	O
development	O
of	O
a	O
bone	O
healing	O
complication	O
despite	O
adjustment	O
for	O
potential	O
confounders	O
.	O

Children	O
with	O
extremity	O
fractures	O
who	O
are	O
exposed	O
to	O
ibuprofen	O
do	O
not	O
seem	O
to	O
be	O
at	O
increased	O
risk	O
for	O
clinically	O
important	O
bone	O
healing	O
complications	O
.	O

Chaetomium	O
thermophilum	O
formate	O
dehydrogenase	O
has	O
high	O
activity	O
in	O
the	O
reduction	O
of	O
hydrogen	O
carbonate	O
(	O
HCO3	O
-	O
)	O
to	O
formate	O
.	O

While	O
formate	O
dehydrogenases	O
(	O
FDHs	O
)	O
have	O
been	O
used	O
for	O
cofactor	O
recycling	O
in	O
chemoenzymatic	O
synthesis	O
,	O
the	O
ability	O
of	O
FDH	O
to	O
reduce	O
CO2	O
could	O
also	O
be	O
utilized	O
in	O
the	O
conversion	O
of	O
CO2	O
to	O
useful	O
products	O
via	O
formate	O
(	O
HCOO	O
(	O
-	O
)	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
reduction	O
of	O
CO2	O
in	O
the	O
form	O
of	O
hydrogen	O
carbonate	O
(	O
HCO3	O
(	O
-	O
)	O
)	O
to	O
formate	O
by	O
FDHs	O
from	O
Candida	O
methylica	O
(	O
CmFDH	O
)	O
and	O
Chaetomium	O
thermophilum	O
(	O
CtFDH	O
)	O
in	O
a	O
NADH	O
-dependent	O
reaction	O
.	O

The	O
catalytic	O
performance	O
with	O
HCO3	O
(	O
-	O
)	O
as	O
a	O
substrate	O
was	O
evaluated	O
by	O
measuring	O
the	O
kinetic	O
rates	O
and	O
conducting	O
productivity	B-P
assays	I-P
.	O

CtFDH	O
showed	O
a	O
higher	O
efficiency	O
in	O
converting	O
HCO3	O
(	O
-	O
)	O
to	O
formate	O
than	O
CmFDH	O
,	O
whereas	O
CmFDH	O
was	O
better	O
in	O
the	O
oxidation	O
of	O
formate	O
.	O

The	O
pH	O
optimum	O
of	O
the	O
reduction	O
was	O
at	O
pH	O
7-8	O
.	O

However	O
,	O
the	O
high	O
concentrations	O
of	O
HCO3	O
(	O
-	O
)	O
reduced	O
the	O
reaction	O
rate	O
.	O

CtFDH	O
was	O
modeled	O
in	O
the	O
presence	O
of	O
HCO3	O
(	O
-	O
)	O
showing	O
that	O
it	O
fits	O
to	O
the	O
active	O
site	O
.	O

The	O
active	O
site	O
setting	O
for	O
hydride	O
transfer	O
in	O
CO2	O
reduction	O
was	O
modeled	O
.	O

The	O
hydride	O
donated	O
by	O
NADH	O
would	O
form	O
a	O
favorable	O
contact	O
to	O
the	O
carbon	O
atom	O
of	O
HCO3	O
(	O
-	O
)	O
,	O
resulting	O
in	O
a	O
surplus	O
of	O
electrons	O
within	O
the	O
molecule	O
.	O

This	O
would	O
cause	O
the	O
complex	O
formed	O
by	O
hydrogen	O
carbonate	O
and	O
the	O
hydride	O
to	O
break	O
into	O
formate	O
and	O
hydroxide	O
ions	O
.	O

Osthole	O
attenuates	O
lipid	O
accumulation	O
,	O
regulates	O
the	O
expression	O
of	O
inflammatory	O
mediators	O
,	O
and	O
increases	O
antioxidants	O
in	O
FL83B	O
cells	O
.	O

Osthole	O
is	O
found	O
in	O
Cnidium	O
monnieri	O
(	O
L.	O
)	O
and	O
has	O
anti-inflammatory	O
and	O
anti-oxidative	O
properties	O
.	O

It	O
also	O
inhibits	O
the	O
proliferation	O
of	O
hepatocellular	O
carcinoma	O
cells	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
osthole	O
suppressive	O
nonalcoholic	O
fatty	O
liver	O
disease	O
effects	O
in	O
oleic	O
acid	O
(	O
OA	O
)	O
-	O
induced	O
hepatic	O
steatosis	O
and	O
if	O
it	O
can	O
modulate	O
inflammatory	O
responses	O
and	O
oxidative	O
stress	O
.	O

FL83B	O
cell	O
s	O
were	O
pretreated	O
with	O
OA	O
(	O
250μΜ	O
)	O
for	O
24h	O
,	O
and	O
then	O
added	O
different	O
concentrations	O
of	O
osthole	O
(	O
3-100μM	O
)	O
for	O
24h	O
.	O

Subsequently	O
,	O
lipolysis	O
and	O
transcription	O
factors	O
of	O
adipogenesis	O
and	O
phosphorylation	O
of	O
AMP-activated	O
protein	O
kinase	O
proteins	O
were	O
measured	O
.	O

In	O
addition	O
,	O
cells	O
with	O
OA	O
-	O
induced	O
steatosis	O
were	O
H2O2	O
-	O
stimulated	O
,	O
and	O
then	O
incubated	B-P
with	O
osthole	O
to	O
evaluated	O
if	O
it	O
could	O
suppress	O
its	O
progression	O
to	O
steatohepatitis	O
.	O

Osthole	O
significantly	O
enhanced	O
glycerol	O
release	O
and	O
lipolysis	O
protein	O
expression	O
.	O

Osthole	O
also	O
promoted	O
phosphorylation	O
of	O
AMP-activated	O
protein	O
kinases	O
and	O
increased	O
the	O
activity	O
of	O
triglyceride	O
lipase	O
and	O
hormone-	O
sensitive	O
lipase	O
.	O

Osthole	O
suppressed	O
the	O
nuclear	O
transcription	O
factor	O
kappa-B	O
and	O
the	O
p38	O
mitogen-activated	O
protein	O
kinase	O
pathway	O
,	O
and	O
decreased	O
the	O
malondialdehyde	O
concentration	O
in	O
FL83B	O
cells	O
with	O
OA	O
-	O
induced	O
steatosis	O
that	O
were	O
treated	O
with	O
H2O2	O
.	O

These	O
results	O
suggest	O
that	O
osthole	O
might	O
suppress	O
nonalcoholic	O
fatty	O
liver	O
disease	O
by	O
decreasing	O
lipid	O
accumulation	O
,	O
and	O
through	O
its	O
anti-oxidative	O
and	O
anti-inflammatory	O
effects	O
via	O
blocked	O
NF-κB	O
and	O
MAPK	O
signaling	O
pathways	O
.	O

Antinociceptive	O
effect	O
of	O
tebanicline	O
for	O
various	O
noxious	O
stimuli	O
-induced	O
behaviours	O
in	O
mice	O
.	O

Tebanicline	O
(	O
ABT-594	O
)	O
,	O
an	O
analogue	O
of	O
epibatidine	O
,	O
exhibits	O
potent	O
antinociceptive	O
effects	O
and	O
high	O
affinity	O
for	O
the	O
nicotinic	O
acetylcholine	O
receptor	O
in	O
the	O
central	O
nervous	O
system	O
.	O

We	O
assessed	O
whether	O
tebanicline	O
exerts	O
an	O
effect	O
on	O
various	O
noxious	O
stimuli	O
and	O
mediates	O
the	O
nicotine	O
receptor	O
or	O
opioid	O
receptor	O
through	O
stimulation	O
.	O

The	O
antinociceptive	O
effects	O
of	O
tebanicline	O
were	O
determined	O
by	O
noxious	O
chemical	O
,	O
thermal	O
and	O
mechanical	O
stimuli	O
-induced	O
behaviours	O
in	O
mice	O
.	O

Tebanicline	O
had	O
dose-dependent	O
analgesic	O
effects	O
in	O
formalin	O
,	O
hot-plate	B-P
and	I-P
tail-pressure	I-P
tests	I-P
.	O

By	O
contrast	O
,	O
the	O
antinociceptive	O
effect	O
of	O
tebanicline	O
was	O
not	O
demonstrated	O
in	O
the	O
tail-flick	B-P
assay	I-P
.	O

Pre-treatment	O
with	O
mecamylamine	O
,	O
a	O
nicotinic	O
acetylcholine	O
receptor	O
antagonist	O
,	O
blocked	O
the	O
effects	O
of	O
tebanicline	O
in	O
formalin	O
,	O
tail-pressure	B-P
and	I-P
hot-plate	I-P
tests	I-P
.	O

Moreover	O
,	O
pre-treatment	O
with	O
naloxone	O
,	O
an	O
opioid	O
receptor	O
antagonist	O
,	O
only	O
partially	O
inhibited	O
the	O
effects	O
of	O
tebanicline	O
in	O
formalin	O
and	O
tail-pressure	B-P
tests	I-P
.	O

Tebanicline	O
produced	O
antinociception	O
in	O
persistent	O
chemical	O
(	O
formalin	O
)	O
,	O
acute	O
thermal	O
(	O
hot-plate	B-P
,	O
but	O
not	O
tail-flick	O
)	O
and	O
mechanical	O
(	O
tail-pressure	B-P
)	O
pain	O
states	O
.	O

Moreover	O
,	O
tebanicline	O
stimulated	O
the	O
nicotinic	O
acetylcholine	O
receptor	O
and	O
opioid	O
receptor	O
.	O

Is	O
the	O
inactivation	O
of	O
dentin	O
proteases	O
by	O
crosslinkers	O
reversible	O
?	O
.	O

Inactivation	O
of	O
dentin	O
proteases	O
by	O
crosslinkers	O
has	O
been	O
suggested	O
as	O
a	O
way	O
to	O
prevent	O
the	O
degradation	O
of	O
dentin	O
collagen	O
in	O
the	O
hybrid	O
layer	O
.	O

However	O
,	O
it	O
is	O
not	O
known	O
if	O
the	O
inhibition	O
is	O
reversible	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
inactivation	O
effect	O
of	O
various	O
crosslinkers	O
on	O
dentin	O
protease	O
activity	O
over	O
a	O
period	O
of	O
6	O
months	O
.	O

Demineralized	O
dentin	O
beams	O
(	O
1×2×6mm	O
,	O
n=10/group	O
)	O
were	O
treated	O
with	O
(	O
1	O
)	O
1	O
%	O
glutaraldehyde	O
(	O
GA1	O
)	O
,	O
(	O
2	O
)	O
5	O
%	O
glutaraldehyde	O
(	O
GA5	O
)	O
,	O
(	O
3	O
)	O
1	O
%	O
grape	O
seed	O
extract	O
(	O
GS1	O
)	O
,	O
(	O
4	O
)	O
5	O
%	O
grape	O
seed	O
extract	O
(	O
GS5	O
)	O
,	O
(	O
5	O
)	O
10	O
%	O
sumac	O
berry	O
extract	O
(	O
S	O
)	O
,	O
(	O
6	O
)	O
20μM	O
curcumin	O
(	O
CR20	O
)	O
,	O
and	O
(	O
7	O
)	O
200μM	O
curcumin	O
(	O
CR200	O
)	O
for	O
5min	O
.	O

Untreated	O
beams	O
served	O
as	O
control	O
.	O

The	O
beams	O
were	O
incubated	B-P
up	O
to	O
6	O
months	O
and	O
incubation	O
media	O
were	O
used	O
to	O
analyze	O
solubilized	O
telopeptide	O
(	O
ICTP	O
and	O
CTX	O
)	O
fragments	O
as	O
indicators	O
of	O
MMP	O
-	O
and	O
cathepsin	O
K	O
-mediated	O
degradation	O
after	O
1	O
,	O
3	O
and	O
6	O
months	O
of	O
incubation	B-P
.	O

The	O
relative	O
MMP	O
activity	O
of	O
dentin	O
beams	O
was	O
tested	O
using	O
a	O
generic	O
MMP	O
assay	B-P
.	O

Data	O
were	O
analyzed	O
using	O
repeated-measures	O
ANOVA	O
,	O
α=0.05	O
.	O

All	O
treated	O
groups	O
showed	O
significant	O
decrease	O
in	O
CTX	O
release	O
(	O
32.2-469.5pg/mg	O
dentin	O
)	O
and	O
ICTP	O
(	O
1.8-47.6ng/mg	O
dentin	O
)	O
fragments	O
during	O
the	O
first	O
month	O
of	O
incubation	B-P
compared	O
to	O
control	O
(	O
1159pg/mg	O
and	O
72.9ng/mg	O
dentin	O
,	O
respectively	O
)	O
.	O

GA5	O
,	O
GS5	O
and	O
CR200	O
maintained	O
their	O
inhibitory	O
effect	O
during	O
6-month	O
incubation	B-P
.	O

The	O
results	O
were	O
confirmed	O
by	O
dry	O
mass	O
loss	O
and	O
relative	O
MMP	O
activity	O
following	O
6	O
months	O
.	O

The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
the	O
long-term	O
effect	O
is	O
both	O
crosslinker	O
and	O
dose	O
dependent	O
.	O

Passive	O
case	O
detection	O
of	O
malaria	O
in	O
Ratanakiri	O
Province	O
(	O
Cambodia	O
)	O
to	O
detect	O
villages	O
at	O
higher	O
risk	O
for	O
malaria	O
.	O

Cambodia	O
reduced	O
malaria	O
incidence	O
by	O
more	O
than	O
75	O
%	O
between	O
2000	O
and	O
2015	O
,	O
a	O
target	O
of	O
the	O
Millennium	O
Development	O
Goal	O
6	O
.	O

The	O
Cambodian	O
Government	O
aims	O
to	O
eliminate	O
all	O
forms	O
of	O
malaria	O
by	O
2025	O
.	O

The	O
country	O
's	O
malaria	O
incidence	O
is	O
highly	O
variable	O
at	O
provincial	O
level	O
,	O
but	O
less	O
is	O
known	O
at	O
village	O
level	O
.	O

This	O
study	O
used	O
passive	O
case	O
detection	O
(	O
PCD	O
)	O
data	O
at	O
village	O
level	O
in	O
Ratanakiri	O
Province	O
from	O
2010	O
to	O
2014	O
to	O
describe	O
incidence	O
trends	O
and	O
identify	O
high-risk	O
areas	O
of	O
malaria	O
to	O
be	O
primarily	O
targeted	O
towards	O
malaria	O
elimination	O
.	O

In	O
2010	O
,	O
the	O
Cambodian	O
malaria	O
programme	O
created	O
a	O
Malaria	O
Information	O
System	O
(	O
MIS	O
)	O
to	O
capture	O
malaria	O
information	O
at	O
village	O
level	O
through	O
PCD	O
by	O
village	O
malaria	O
workers	O
and	O
health	O
facilities	O
.	O

The	O
MIS	O
data	O
of	O
Ratanakiri	O
Province	O
2010-2014	O
were	O
used	O
to	O
calculate	O
annual	O
incidence	O
rates	O
by	O
Plasmodium	O
species	O
at	O
province	O
and	O
commune	O
levels	O
.	O

For	O
estimating	O
the	O
trend	O
at	O
provincial	O
level	O
only	O
villages	O
reporting	O
each	O
year	O
were	O
selected	O
.	O

The	O
communal	O
incidences	O
and	O
the	O
number	O
of	O
cases	O
per	O
village	O
were	O
visualized	O
on	O
a	O
map	O
per	O
Plasmodium	O
species	O
and	O
per	O
year	O
.	O

Analysis	O
of	O
spatial	O
clustering	O
of	O
village	O
malaria	O
cases	O
by	O
Plasmodium	O
species	O
was	O
performed	O
by	O
year	O
.	O

Overall	O
,	O
malaria	O
annual	O
incidence	O
rates	O
per	O
1000	O
inhabitants	O
decreased	O
from	O
86	O
(	O
2010	O
)	O
to	O
30	O
(	O
2014	O
)	O
.	O

Falciparum	O
incidence	O
decreased	O
(	O
by	O
79	O
%	O
in	O
2014	O
compared	O
to	O
2010	O
;	O
CI	O
95	O
%	O
76-82	O
%	O
)	O
more	O
rapidly	O
than	O
vivax	O
incidence	O
(	O
by	O
19	O
%	O
in	O
2014	O
compared	O
to	O
2010	O
;	O
CI	O
95	O
%	O
5-32	O
%	O
)	O
.	O

There	O
were	O
ten	O
to	O
16	O
significant	O
spatial	O
clusters	O
each	O
year	O
.	O

Big	O
clusters	O
tended	O
to	O
extend	O
along	O
the	O
Cambodian-Vietnamese	O
border	O
and	O
along	O
the	O
Sesan	O
River	O
.	O

Three	O
clusters	O
appeared	O
throughout	O
all	O
years	O
(	O
2010-2014	O
)	O
:	O
one	O
with	O
21	O
villages	O
appeared	O
each	O
year	O
,	O
the	O
second	O
shrunk	O
progressively	O
from	O
2012	O
to	O
2014	O
and	O
the	O
third	O
was	O
split	O
into	O
two	O
smaller	O
clusters	O
in	O
2013	O
and	O
2014	O
.	O

The	O
decline	O
of	O
malaria	O
burden	O
can	O
be	O
attributed	O
to	O
intensive	O
malaria	O
control	O
activities	O
implemented	O
in	O
the	O
areas	O
:	O
distribution	O
of	O
a	O
long-lasting	O
insecticidal	O
net	O
per	O
person	O
and	O
early	B-P
diagnosis	I-P
and	O
prompt	O
treatment	O
.	O

Dihydro-artemisinin	O
piperaquine	O
was	O
the	O
only	O
first-line	O
treatment	O
for	O
all	O
malaria	O
cases	O
.	O

No	O
radical	O
treatment	O
with	O
primaquine	O
was	O
provided	O
for	O
Plasmodium	O
vivax	O
cases	O
,	O
which	O
could	O
explain	O
the	O
slow	O
decrease	O
of	O
P.	O
vivax	O
due	O
to	O
relapses	O
.	O

To	O
achieve	O
malaria	O
elimination	O
by	O
2025	O
,	O
priority	O
should	O
be	O
given	O
to	O
the	O
control	O
of	O
stable	O
malaria	O
clusters	O
appearing	O
over	O
time	O
.	O

Cartilage	O
inflammation	O
and	O
degeneration	O
is	O
enhanced	O
by	O
pro-inflammatory	O
(	O
M1	O
)	O
macrophages	O
in	O
vitro	O
,	O
but	O
not	O
inhibited	O
directly	O
by	O
anti-inflammatory	O
(	O
M2	O
)	O
macrophages	O
.	O

Macrophages	O
play	O
a	O
crucial	O
role	O
in	O
the	O
progression	O
of	O
osteoarthritis	O
(	O
OA	O
)	O
.	O

Their	O
phenotype	O
may	O
range	O
from	O
pro-inflammatory	O
to	O
anti-inflammatory	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
direct	O
effects	O
of	O
macrophage	O
subtypes	O
on	O
cartilage	O
by	O
culturing	B-P
macrophage	O
conditioned	O
medium	O
(	O
MCM	O
)	O
on	O
human	O
articular	O
cartilage	O
.	O

Human	O
OA	O
cartilage	O
explants	O
were	O
cultured	B-P
with	O
MCM	O
of	O
pro-inflammatory	O
M	O
(	O
IFNγ	O
+	O
TNFα	O
)	O
,	O
or	O
anti-inflammatory	O
M	O
(	O
IL-4	O
)	O
or	O
M	O
(	O
IL-10	O
)	O
human	O
monocyte-derived	O
macrophages	O
.	O

To	O
assess	O
effects	O
of	O
anti-inflammatory	O
macrophages	O
,	O
the	O
cartilage	O
was	O
cultured	B-P
with	O
a	O
combination	O
of	O
MCM	O
phenotypes	O
as	O
well	O
as	O
pre-stimulated	O
with	O
IFNγ	O
+	O
TNFα	O
cartilage	O
before	O
culture	B-P
with	O
MCM	O
.	O

The	O
reactions	O
of	O
the	O
explants	O
were	O
assessed	O
by	O
gene	O
expression	O
,	O
nitric	O
oxide	O
(	O
NO	O
)	O
production	O
and	O
release	O
of	O
glycosaminoglycans	O
(	O
GAGs	O
)	O
.	O

M	O
(	O
IFNγ	O
+	O
TNFα	O
)	O
MCM	O
affected	O
OA	O
cartilage	O
by	O
upregulation	O
of	O
IL1B	O
(	O
Interleukin	O
1β	O
)	O
,	O
IL6	O
,	O
MMP13	O
(	O
Matrix	O
Metalloproteinase-13	O
)	O
and	O
ADAMTS5	O
(	O
A	O
Disintegrin	O
And	O
Metalloproteinase	O
with	O
Thrombospondin	O
Motifs-5	O
)	O
,	O
while	O
inhibiting	O
ACAN	O
(	O
aggrecan	O
)	O
and	O
COL2A1	O
(	O
collagen	O
type	O
II	O
)	O
.	O

M	O
(	O
IL-10	O
)	O
upregulated	O
IL1B	O
and	O
Suppressor	O
of	O
cytokine	O
signaling	O
1	O
(	O
SOCS1	O
)	O
.	O

NO	O
production	O
and	O
GAG	O
release	O
by	O
the	O
cartilage	O
was	O
increased	O
when	O
cultured	B-P
with	O
M	O
(	O
IFNγ	O
+	O
TNFα	O
)	O
MCM	O
.	O

M	O
(	O
IL-4	O
)	O
and	O
M	O
(	O
IL-10	O
)	O
did	O
not	O
inhibit	O
the	O
effects	O
of	O
M	O
(	O
IFNγ	O
+	O
TNFα	O
)	O
MCM	O
of	O
neither	O
phenotype	O
affected	O
IFNγ	O
+	O
TNFα	O
pre-stimulated	O
cartilage	O
,	O
in	O
which	O
an	O
inflammatory	O
gene	O
response	O
was	O
deliberately	O
induced	O
.	O

M	O
(	O
IFNγ	O
+	O
TNFα	O
)	O
macrophages	O
have	O
a	O
prominent	O
direct	O
effect	O
on	O
OA	O
cartilage	O
,	O
while	O
M	O
(	O
IL-4	O
)	O
and	O
M	O
(	O
IL-10	O
)	O
do	O
not	O
inhibit	O
the	O
effects	O
of	O
M	O
(	O
IFNγ	O
+	O
TNFα	O
)	O
,	O
or	O
IFN	O
γ+	O
TNFα	O
induced	O
inflammation	O
of	O
the	O
cartilage	O
.	O

Therapies	O
aiming	O
at	O
inhibiting	O
cartilage	O
degeneration	O
may	O
take	O
this	O
into	O
account	O
by	O
directing	O
suppression	O
of	O
pro-inflammatory	O
macrophages	O
or	O
stimulation	O
of	O
anti-inflammatory	O
macrophages	O
.	O

Personalizing	O
lung	O
cancer	O
risk	O
prediction	O
and	O
imaging	B-P
follow-up	O
recommendations	O
using	O
the	O
National	O
Lung	O
Screening	O
Trial	O
dataset	O
.	O

To	O
demonstrate	O
a	O
data-driven	O
method	O
for	O
personalizing	O
lung	O
cancer	O
risk	O
prediction	O
using	O
a	O
large	O
clinical	O
dataset	O
.	O

An	O
algorithm	O
was	O
used	O
to	O
categorize	O
nodules	O
found	O
in	O
the	O
first	O
screening	B-P
year	O
of	O
the	O
National	O
Lung	O
Screening	O
Trial	O
as	O
malignant	O
or	O
nonmalignant	O
.	O

Risk	O
of	O
malignancy	O
for	O
nodules	O
was	O
calculated	O
based	O
on	O
size	O
criteria	O
according	O
to	O
the	O
Fleischner	O
Society	O
recommendations	O
from	O
2005	O
,	O
along	O
with	O
the	O
additional	O
discriminators	O
of	O
pack-years	O
smoking	O
history	O
,	O
sex	O
,	O
and	O
nodule	O
location	O
.	O

Imaging	B-P
follow-up	O
recommendations	O
were	O
assigned	O
according	O
to	O
Fleischner	O
size	O
category	O
malignancy	O
risk	O
.	O

Nodule	O
size	O
correlated	O
with	O
malignancy	O
risk	O
as	O
predicted	O
by	O
the	O
Fleischner	O
Society	O
recommendations	O
.	O

With	O
the	O
additional	O
discriminators	O
of	O
smoking	O
history	O
,	O
sex	O
,	O
and	O
nodule	O
location	O
,	O
significant	O
risk	O
stratification	O
was	O
observed	O
.	O

For	O
example	O
,	O
men	O
with	O
≥60	O
pack-years	O
smoking	O
history	O
and	O
upper	O
lobe	O
nodules	O
measuring	O
>	O
4	O
and	O
≤6	O
mm	O
demonstrated	O
significantly	O
increased	O
risk	O
of	O
malignancy	O
at	O
12.4	O
%	O
compared	O
to	O
the	O
mean	O
of	O
3.81	O
%	O
for	O
similarly	O
sized	O
nodules	O
(	O
P	O
<	O
.0001	O
)	O
.	O

Based	O
on	O
personalized	O
malignancy	O
risk	O
,	O
54	O
%	O
of	O
nodules	O
>	O
4	O
and	O
≤6	O
mm	O
were	O
reclassified	O
to	O
longer-term	O
follow-up	O
than	O
recommended	O
by	O
Fleischner	O
.	O

Twenty-seven	O
percent	O
of	O
nodules	O
≤4	O
mm	O
were	O
reclassified	O
to	O
shorter-term	O
follow-up	O
.	O

Using	O
available	O
clinical	O
datasets	O
such	O
as	O
the	O
National	O
Lung	O
Screening	O
Trial	O
in	O
conjunction	O
with	O
locally	O
collected	O
datasets	O
can	O
help	O
clinicians	O
provide	O
more	O
personalized	O
malignancy	O
risk	O
prediction	O
s	O
and	O
follow-up	O
recommendations	O
.	O

By	O
incorporating	O
3	O
demographic	O
data	O
points	O
,	O
the	O
risk	O
of	O
lung	O
nodule	O
malignancy	O
within	O
the	O
Fleischner	O
categories	O
can	O
be	O
considerably	O
stratified	O
and	O
more	O
personalized	O
follow-up	O
recommendations	O
can	O
be	O
made	O
.	O

Classification	O
of	O
Edible	O
Oils	O
Based	O
on	O
ATR-FTIR	O
Spectral	O
Information	O
During	O
a	O
Long	O
Heating	O
Treatment	O
.	O

Identification	O
of	O
oil	O
type	O
and	O
its	O
QC	O
are	O
important	O
concerns	O
in	O
food	O
control	O
laboratories	O
.	O

Classifying	O
edible	O
oils	O
that	O
have	O
not	O
been	O
used	O
(	O
i.e.	O
,	O
unheated	O
)	O
with	O
the	O
aid	O
of	O
vibrational	B-P
spectroscopy	I-P
has	O
previously	O
been	O
reported	O
.	O

However	O
,	O
the	O
classification	O
of	O
used	O
(	O
i.e.	O
,	O
heat-treated	O
)	O
oils	O
needs	O
special	O
attention	O
.	O

The	O
effect	O
of	O
long	O
heating	O
times	O
on	O
the	O
classification	O
of	O
four	O
kinds	O
of	O
edible	O
oils	O
(	O
canola	O
,	O
corn	O
,	O
frying	O
,	O
and	O
sunflower	O
)	O
based	O
on	O
attenuated	O
total	O
reflectance	O
(	O
ATR	O
)	O
-FTIR	O
spectra	O
was	O
surveyed	O
.	O

The	O
sampling	O
was	O
done	O
on	O
the	O
oils	O
during	O
a	O
36	O
h	O
heating	O
process	O
(	O
at	O
170°C	O
)	O
.	O

The	O
ATR-FTIR	O
spectra	O
of	O
the	O
samples	O
were	O
collected	O
in	O
the	O
range	O
of	O
4000-550	O
cm-1	O
.	O

Interval	O
extended	O
canonical	O
variates	O
analysis	O
(	O
ECVA	O
)	O
,	O
as	O
a	O
variable	O
selection	O
and	O
classification	O
tool	O
,	O
was	O
used	O
to	O
determine	O
the	O
best	O
intervals	O
during	O
the	O
heating	O
procedure	O
for	O
classification	O
.	O

Principal	O
component	O
analysis	O
discriminate	O
analysis	O
,	O
partial	O
least-squares	O
discriminate	O
analysis	O
,	O
and	O
ECVA	O
were	O
performed	O
on	O
the	O
selected	O
intervals	O
and	O
on	O
the	O
total	O
heating	O
time	O
.	O

The	O
effect	O
of	O
autoscaling	O
and	O
mean-centering	O
,	O
as	O
data	O
preprocessing	O
methods	O
,	O
was	O
also	O
investigated	O
.	O

The	O
ECVA	O
method	O
resulted	O
in	O
the	O
best	O
performances	O
for	O
classification	O
,	O
with	O
a	O
94	O
%	O
cross-validated	O
nonerror	O
rate	O
(	O
one	O
misclassification	O
)	O
for	O
the	O
heating	O
process	O
times	O
of	O
24-27	O
and	O
33-36	O
h	O
.	O

A	O
protocol	O
for	O
pressurized	B-P
liquid	I-P
extraction	I-P
and	O
processing	O
methods	O
to	O
isolate	O
modern	O
and	O
ancient	O
bone	O
cholesterol	O
for	O
compound-specific	O
stable	O
isotope	O
analysis	B-P
.	O

Bone	O
lipid	O
compound-specific	B-P
isotope	I-P
analysis	I-P
(	O
CSIA	B-P
)	O
and	O
bone	O
collagen	O
and	O
apatite	O
stable	O
isotope	O
ratio	O
analysis	B-P
are	O
important	O
sources	O
of	O
ecological	O
and	O
paleodietary	O
information	O
.	O

Pressurized	B-P
liquid	I-P
extraction	I-P
(	O
PLE	B-P
)	O
is	O
quicker	O
and	O
utilizes	O
less	O
solvent	O
than	O
traditional	O
methods	O
of	O
lipid	O
extraction	O
such	O
as	O
soxhlet	B-P
and	O
ultrasonication	O
.	O

This	O
study	O
facilitates	O
dietary	O
analysis	B-P
by	O
optimizing	O
and	O
testing	O
a	O
standardized	O
methodology	O
for	O
PLE	B-P
of	O
bone	O
cholesterol	O
.	O

Modern	O
and	O
archaeological	O
bones	O
were	O
extracted	O
by	O
PLE	B-P
using	O
varied	O
temperatures	O
,	O
solvent	O
solutions	O
,	O
and	O
sample	O
weights	O
.	O

The	O
efficiency	O
of	O
PLE	B-P
was	O
assessed	O
via	O
quantification	O
of	O
cholesterol	O
yields	O
.	O

Stable	O
isotopic	O
ratio	O
integrity	O
was	O
evaluated	O
by	O
comparing	O
isotopic	O
signatures	O
(	O
δ	O
(	O
13	O
)	O
C	O
and	O
δ	O
(	O
18	O
)	O
O	O
values	O
)	O
of	O
cholesterol	O
derived	O
from	O
whole	O
bone	O
,	O
bone	O
collagen	O
and	O
bone	O
apatite	O
.	O

Gas	B-P
chromatography/mass	I-P
spectrometry	I-P
(	O
GC/MS	B-P
)	O
and	O
gas	B-P
chromatography	I-P
isotope	I-P
ratio	I-P
mass	I-P
spectrometry	I-P
(	O
GC/IRMS	B-P
)	O
were	O
conducted	O
on	O
purified	O
collagen	O
and	O
lipid	O
extracts	O
to	O
assess	O
isotopic	O
responses	O
to	O
PLE	B-P
.	O

Lipid	O
yield	O
was	O
optimized	O
at	O
two	O
PLE	B-P
extraction	I-P
cycles	O
of	O
75	O
°C	O
using	O
dichloromethane	O
/	O
methanol	O
(	O
2:1	O
v/v	O
)	O
as	O
a	O
solvent	O
with	O
0.25-0.75	O
g	O
bone	O
sample	O
.	O

Following	O
lipid	O
extraction	B-P
,	O
saponification	O
combined	O
with	O
the	O
derivatization	O
of	O
the	O
neutral	O
fraction	O
using	O
trimethylsilylation	O
yielded	O
nearly	O
twice	O
the	O
cholesterol	O
of	O
non-saponified	O
or	O
non-derivatized	O
samples	O
.	O

It	O
was	O
also	O
found	O
that	O
lipids	O
extracted	O
from	O
purified	O
bone	O
collagen	O
and	O
apatite	O
could	O
be	O
used	O
for	O
cholesterol	O
CSIA	B-P
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
bulk	O
δ	O
(	O
13	O
)	O
C	O
values	O
of	O
collagen	O
extracted	O
from	O
bone	O
with	O
or	O
without	O
lipid	O
.	O

However	O
,	O
there	O
was	O
a	O
significant	O
depletion	O
in	O
(	O
18	O
)	O
O	O
of	O
bone	O
apatite	O
due	O
to	O
lipid	O
presence	O
or	O
processing	O
.	O

These	O
results	O
should	O
assist	O
sample	O
selection	O
and	O
provide	O
an	O
effective	O
,	O
alternative	O
extraction	B-P
method	I-P
for	O
bone	O
cholesterol	O
that	O
may	O
be	O
used	O
for	O
isotopic	O
and	O
paleodietary	O
analysis	B-P
.	O

Copyright	O
©	O
2016	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

Protocol	O
for	O
intraoperative	O
assessment	O
of	O
the	O
human	O
cerebrovascular	O
glycocalyx	O
.	O

Adequate	O
functioning	O
of	O
the	O
blood-brain	O
barrier	O
(	O
BBB	O
)	O
is	O
important	O
for	O
brain	O
homoeostasis	O
and	O
normal	O
neuronal	O
function	O
.	O

Disruption	O
of	O
the	O
BBB	O
has	O
been	O
described	O
in	O
several	O
neurological	O
diseases	O
.	O

Recent	O
reports	O
suggest	O
that	O
an	O
increased	O
permeability	O
of	O
the	O
BBB	O
also	O
contributes	O
to	O
increased	O
seizure	O
susceptibility	O
in	O
patients	O
with	O
epilepsy	O
.	O

The	O
endothelial	O
glycocalyx	O
is	O
coating	O
the	O
luminal	O
side	O
of	O
the	O
endothelium	O
and	O
can	O
be	O
considered	O
as	O
the	O
first	O
barrier	O
of	O
the	O
BBB	O
.	O

We	O
hypothesise	O
that	O
an	O
altered	O
glycocalyx	O
thickness	O
plays	O
a	O
role	O
in	O
the	O
aetiology	O
of	O
temporal	O
lobe	O
epilepsy	O
(	O
TLE	O
)	O
,	O
the	O
most	O
common	O
type	O
of	O
epilepsy	O
.	O

Here	O
,	O
we	O
propose	O
a	O
protocol	O
that	O
allows	O
intraoperative	O
assessment	O
of	O
the	O
cerebrovascular	O
glycocalyx	O
thickness	O
in	O
patients	O
with	O
TLE	O
and	O
assess	O
whether	O
its	O
thickness	O
is	O
decreased	O
in	O
patients	O
with	O
TLE	O
when	O
compared	O
with	O
controls	O
.	O

This	O
protocol	O
is	O
designed	O
as	O
a	O
prospective	O
observational	O
case-control	O
study	O
in	O
patients	O
who	O
undergo	O
resective	O
brain	O
surgery	O
as	O
treatment	O
for	O
TLE	O
.	O

Control	O
subjects	O
are	O
patients	O
without	O
a	O
history	O
of	O
epileptic	O
seizures	O
,	O
who	O
undergo	O
a	O
craniotomy	O
or	O
burr	O
hole	O
surgery	O
for	O
other	O
indications	O
.	O

Intraoperative	O
glycocalyx	O
thickness	O
measurements	O
of	O
sublingual	O
,	O
cortical	O
and	O
hippocampal	O
microcirculation	O
are	O
performed	O
by	O
video	B-P
microscopy	I-P
using	O
sidestream	B-P
dark-field	I-P
imaging	I-P
.	O

Demographic	O
details	O
,	O
seizure	O
characteristics	O
,	O
epilepsy	O
risk	O
factors	O
,	O
intraoperative	O
haemodynamic	O
parameters	O
and	O
histopathological	O
evaluation	O
are	O
additionally	O
recorded	O
.	O

This	O
protocol	O
has	O
been	O
ethically	O
approved	O
by	O
the	O
local	O
medical	O
ethical	O
committee	O
(	O
ID	O
:	O
NL51594.068.14	O
)	O
and	O
complies	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
principles	O
of	O
Good	O
Clinical	O
Practice	O
.	O

Informed	O
consent	O
is	O
obtained	O
before	O
study	O
enrolment	O
and	O
only	O
coded	O
data	O
will	O
be	O
stored	O
in	O
a	O
secured	O
database	O
,	O
enabling	O
an	O
audit	O
trail	O
.	O

Results	O
will	O
be	O
submitted	O
to	O
international	O
peer-reviewed	O
journals	O
and	O
presented	O
at	O
international	O
conferences	O
.	O

NTR5568	O
.	O

Historical	O
relationships	O
of	O
three	O
enigmatic	O
phasianid	O
genera	O
(	O
Aves	O
:	O
Galliformes	O
)	O
inferred	O
using	O
phylogenomic	O
and	O
mitogenomic	O
data	O
.	O

The	O
phylogeny	O
of	O
the	O
Phasianidae	O
(	O
pheasants	O
,	O
partridges	O
,	O
and	O
allies	O
)	O
has	O
been	O
studied	O
extensively	O
.	O

However	O
,	O
these	O
studies	O
have	O
largely	O
ignored	O
three	O
enigmatic	O
genera	O
because	O
of	O
scarce	O
DNA	O
source	O
material	O
and	O
limited	O
overlapping	O
phylogenetic	O
data	O
:	O
blood	O
pheasants	O
(	O
Ithaginis	O
)	O
,	O
snow	O
partridges	O
(	O
Lerwa	O
)	O
,	O
and	O
long-billed	O
partridges	O
(	O
Rhizothera	O
)	O
.	O

Thus	O
,	O
phylogenetic	O
positions	O
of	O
these	O
three	O
genera	O
remain	O
uncertain	O
in	O
what	O
is	O
otherwise	O
a	O
well-resolved	O
phylogeny	O
.	O

Previous	O
studies	O
using	O
different	O
data	O
types	O
place	O
Lerwa	O
and	O
Ithaginis	O
in	O
similar	O
positions	O
,	O
but	O
the	O
absence	O
of	O
overlapping	O
data	O
means	O
the	O
relationship	O
between	O
them	O
could	O
not	O
be	O
inferred	O
.	O

Rhizothera	O
was	O
originally	O
described	O
in	O
the	O
genus	O
Perdix	O
(	O
true	O
partridges	O
)	O
,	O
although	O
a	O
partial	O
cytochrome	O
b	O
(	O
CYB	O
)	O
sequence	O
suggests	O
it	O
is	O
sister	O
to	O
Pucrasia	O
(	O
koklass	O
pheasant	O
)	O
.	O

To	O
identify	O
robust	O
relationships	O
among	O
Ithaginis	O
,	O
Lerwa	O
,	O
Rhizothera	O
,	O
and	O
their	O
phasianid	O
relatives	O
,	O
we	O
used	O
3692	O
ultra-conserved	O
element	O
(	O
UCE	O
)	O
loci	O
and	O
complete	O
mitogenomes	O
from	O
19	O
species	O
including	O
previously	O
hypothesized	O
relatives	O
of	O
the	O
three	O
focal	O
genera	O
and	O
representatives	O
from	O
all	O
major	O
phasianid	O
clades	O
.	O

We	O
used	O
DNA	O
extracted	O
from	O
historical	O
specimen	O
toepads	O
for	O
species	O
that	O
lacked	O
fresh	O
tissue	O
in	O
museum	B-P
collections	I-P
.	O

Maximum	O
likelihood	O
and	O
multispecies	O
coalescent	O
UCE	O
analyses	O
strongly	O
supported	O
Lerwa	O
sister	O
to	O
a	O
large	O
clade	O
which	O
included	O
Ithaginis	O
at	O
its	O
base	O
,	O
and	O
also	O
including	O
turkey	O
,	O
grouse	O
,	O
typical	O
pheasants	O
,	O
tragopans	O
,	O
Pucrasia	O
,	O
and	O
Perdix	O
.	O

Rhizothera	O
was	O
also	O
in	O
this	O
clade	O
,	O
sister	O
to	O
a	O
diverse	O
group	O
comprising	O
Perdix	O
,	O
typical	O
pheasants	O
,	O
Pucrasia	O
,	O
turkey	O
and	O
grouse	O
.	O

Mitogenomic	O
genealogies	O
differed	O
from	O
UCEs	O
topologies	O
,	O
supporting	O
a	O
sister	O
relationship	O
between	O
Ithaginis	O
and	O
Lerwa	O
rather	O
than	O
a	O
grade	O
.	O

The	O
position	O
of	O
Rhizothera	O
using	O
mitogenomes	O
depended	O
on	O
analytical	O
choices	O
.	O

Unpartitioned	O
and	O
codon-based	O
analyses	O
placed	O
Rhizothera	O
sister	O
to	O
a	O
tragopan	O
clade	O
,	O
whereas	O
a	O
partitioned	O
DNA	O
model	O
of	O
the	O
mitogenome	O
was	O
congruent	O
with	O
UCE	O
results	O
.	O

In	O
all	O
mitogenome	B-P
analyses	I-P
,	O
Pucrasia	O
was	O
sister	O
to	O
a	O
clade	O
including	O
Perdix	O
and	O
the	O
typical	O
pheasants	O
with	O
high	O
support	O
,	O
in	O
contrast	O
to	O
UCEs	O
and	O
published	O
nuclear	O
intron	O
data	O
.	O

Due	O
to	O
the	O
strong	O
support	O
and	O
consistent	O
topology	O
provided	O
by	O
all	O
UCE	O
analyses	O
,	O
we	O
have	O
identified	O
phylogenetic	O
relationships	O
of	O
these	O
three	O
enigmatic	O
,	O
poorly-studied	O
,	O
phasianid	O
taxa	O
.	O

Characterization	O
and	O
antimicrobial	B-P
evaluation	I-P
of	O
SpPR-AMP1	O
,	O
a	O
proline-rich	O
antimicrobial	O
peptide	O
from	O
the	O
mud	O
crab	O
Scylla	O
paramamosain	O
.	O

Antimicrobial	O
peptide	O
(	O
AMP	O
)	O
is	O
an	O
important	O
molecule	O
in	O
the	O
innate	O
immune	O
system	O
.	O

Here	O
,	O
we	O
report	O
the	O
cloning	O
and	O
functional	O
studies	O
of	O
proline-rich	O
AMPs	O
(	O
PR-AMPs	O
)	O
from	O
the	O
three	O
species	O
of	O
mud	O
crab	O
:	O
Scylla	O
paramamosain	O
,	O
S.	O
serrata	O
,	O
and	O
the	O
swimming	O
crab	O
Portunus	O
pelagicus	O
.	O

The	O
deduced	O
peptides	O
revealed	O
that	O
they	O
contain	O
the	O
putative	O
signal	O
peptides	O
and	O
encode	O
for	O
mature	O
peptides	O
,	O
which	O
contain	O
sequence	O
architecture	O
similar	O
to	O
a	O
6.5-kDa	O
proline-rich	O
AMP	O
of	O
the	O
shore	O
crab	O
,	O
Carcinus	O
maenas	O
which	O
showed	O
similarity	O
with	O
the	O
bactenecin7	O
.	O

Tissue	O
distribuction	O
analysis	O
indicated	O
that	O
the	O
SpPR-AMP1	O
was	O
expressed	O
in	O
a	O
wide	O
range	O
of	O
adult	O
tissues	O
,	O
with	O
the	O
highest	O
expression	O
levels	O
in	O
the	O
crab	O
hemocyte	O
.	O

Challenge	O
experiments	O
showed	O
that	O
the	O
levels	O
of	O
SpPR-AMP1	O
mRNA	O
expression	O
were	O
up-regulated	O
in	O
the	O
hemocyte	O
after	O
peptidoglycan	O
stimulation	O
.	O

To	O
evaluate	O
the	O
biological	O
properties	O
of	O
mature	O
SpPR-AMP1	O
,	O
peptides	O
were	O
chemically	O
synthesized	O
and	O
recombinantly	O
expressed	O
.	O

SpPR-AMP1	O
showed	O
strong	O
antibacterial	O
activity	O
against	O
both	O
Gram-positive	O
bacteria	O
Micrococcus	O
luteus	O
and	O
Gram-negative	O
bacteria	O
Vibrio	O
harveyi	O
.	O

The	O
results	O
indicate	O
that	O
the	O
SpPR-AMP1	O
plays	O
a	O
role	O
in	O
crab	O
immunity	O
.	O

Development	O
and	O
Validation	O
of	O
a	O
New	O
Reliable	O
Method	B-P
for	O
the	O
Diagnosis	O
of	O
Avian	O
Botulism	O
.	O

Liver	O
is	O
a	O
reliable	O
matrix	O
for	O
laboratory	B-P
confirmation	O
of	O
avian	O
botulism	O
using	O
real-time	O
PCR	O
.	O

Here	O
,	O
we	O
developed	O
,	O
optimized	O
,	O
and	O
validated	O
the	O
analytical	O
steps	O
preceding	O
PCR	O
to	O
maximize	O
the	O
detection	O
of	O
Clostridium	O
botulinum	O
group	O
III	O
in	O
avian	O
liver	O
.	O

These	O
pre	O
-	O
PCR	O
steps	O
included	O
enrichment	O
incubation	B-P
of	O
the	O
whole	O
liver	O
(	O
maximum	O
25	O
g	O
)	O
at	O
37°C	B-P
for	O
at	O
least	O
24	O
h	O
in	O
an	O
anaerobic	O
chamber	O
and	O
DNA	O
extraction	O
using	O
an	O
enzymatic	B-P
digestion	I-P
step	O
followed	O
by	O
a	O
DNA	B-P
purification	I-P
step	O
.	O

Conditions	O
of	O
sample	O
storage	O
before	O
analysis	O
appear	O
to	O
have	O
a	O
strong	O
effect	O
on	O
the	O
detection	O
of	O
group	O
III	O
C.	O
botulinum	O
strains	O
and	O
our	O
results	O
recommend	O
storage	O
at	O
temperatures	O
below	O
-18°C	O
.	O

Short-term	O
storage	O
at	O
5°C	O
is	O
possible	O
for	O
up	O
to	O
24	O
h	O
,	O
but	O
a	O
decrease	O
in	O
sensitivity	O
was	O
observed	O
at	O
48	O
h	O
of	O
storage	O
at	O
this	O
temperature	O
.	O

Analysis	O
of	O
whole	O
livers	O
(	O
maximum	O
25	O
g	O
)	O
is	O
required	O
and	O
pooling	O
samples	O
before	O
enrichment	B-P
culturing	I-P
must	O
be	O
avoided	O
.	O

Pooling	O
is	O
however	O
possible	O
before	O
or	O
after	O
DNA	O
extraction	O
under	O
certain	O
conditions	O
.	O

Whole	O
livers	O
should	O
be	O
10-fold	O
diluted	O
in	O
enrichment	O
medium	O
and	O
homogenized	O
using	O
a	O
Pulsifier®	O
blender	O
(	O
Microgen	O
,	O
Surrey	O
,	O
UK	O
)	O
instead	O
of	O
a	O
conventional	O
paddle	O
blender	O
.	O

Spiked	O
liver	O
samples	O
showed	O
a	O
limit	O
of	O
detection	O
of	O
5	O
spores	O
/g	O
liver	O
for	O
types	O
C	O
and	O
D	O
and	O
250	O
spores	O
/g	O
for	O
type	O
E.	O
Using	O
the	O
method	B-P
developed	O
here	O
,	O
the	O
analysis	O
of	O
268	O
samples	O
from	O
73	O
suspected	O
outbreaks	O
showed	O
100	O
%	O
specificity	O
and	O
95.35	O
%	O
sensitivity	O
compared	O
with	O
other	O
PCR	O
-based	O
methods	B-P
considered	O
as	O
reference	O
.	O

The	O
mosaic	O
type	O
C	O
/	O
D	O
was	O
the	O
most	O
common	O
neurotoxin	O
type	O
found	O
in	O
examined	O
samples	O
,	O
which	O
included	O
both	O
wild	O
and	O
domestic	O
birds	O
.	O

Parametric	B-P
Surface	I-P
Diffeomorphometry	I-P
for	O
Low	B-P
Dimensional	I-P
Embeddings	I-P
of	O
Dense	O
Segmentations	O
and	O
Imagery	O
.	O

In	O
the	O
field	O
of	O
Computational	B-P
Anatomy	I-P
,	O
biological	O
form	O
(	O
including	O
our	O
focus	O
,	O
neuroanatomy	O
)	O
is	O
studied	O
quantitatively	O
through	O
the	O
action	O
of	O
the	O
diffeomorphism	O
group	O
on	O
example	O
anatomies	O
-	O
a	O
technique	O
called	O
diffeomorphometry	B-P
.	O

Here	O
we	O
design	O
an	O
algorithm	O
within	O
this	O
framework	O
to	O
pass	O
from	O
dense	O
objects	O
common	O
in	O
neuromaging	B-P
studies	O
(	O
binary	O
segmentations	O
,	O
structural	O
images	O
)	O
to	O
a	O
sparse	O
representation	O
defined	O
on	O
the	O
surface	O
boundaries	O
of	O
anatomical	O
structures	O
,	O
and	O
embedded	B-P
into	O
the	O
low	O
dimensional	O
coordinates	O
of	O
a	O
parametric	O
model	O
.	O

Our	O
main	O
new	O
contribution	O
is	O
to	O
introduce	O
an	O
expanded	O
group	O
action	O
to	O
simultaneously	O
deform	O
surfaces	O
through	O
direct	O
mapping	O
of	O
points	O
,	O
as	O
well	O
as	O
images	O
through	O
functional	O
composition	O
with	O
the	O
inverse	O
.	O

This	O
allows	O
us	O
to	O
index	O
the	O
diffeomorphisms	O
with	O
respect	O
to	O
two-dimensional	O
surface	O
geometries	O
like	O
subcortical	O
gray	O
matter	O
structures	O
,	O
but	O
explicitly	O
map	O
onto	O
cost	O
functions	O
determined	O
by	O
noisy	O
3-dimensional	O
measurements	O
.	O

We	O
consider	O
models	O
generated	O
from	O
empirical	O
covariance	O
of	O
training	O
data	O
,	O
as	O
well	O
as	O
bandlimited	O
(	O
Laplace-Beltrami	O
eigenfunction	O
)	O
models	O
when	O
no	O
such	O
data	O
is	O
available	O
.	O

We	O
show	O
applications	O
to	O
noisy	O
or	O
anomalous	O
segmentations	O
,	O
and	O
other	O
typical	O
problems	O
in	O
neuroimaging	B-P
studies	O
.	O

We	O
reproduce	O
statistical	O
results	O
detecting	O
changes	O
in	O
Alzheimer	O
's	O
disease	O
,	O
despite	O
dimensionality	O
reduction	O
.	O

Lastly	O
we	O
apply	O
our	O
algorithm	O
to	O
the	O
common	O
problem	O
of	O
segmenting	O
subcortical	O
structures	O
from	O
T1	B-P
MR	I-P
images	I-P
.	O

Propranolol	O
Effects	O
on	O
Decompression	O
Sickness	O
in	O
a	O
Simulated	O
DISSUB	O
Rescue	O
in	O
Swine	O
.	O

Disabled	O
submarine	O
(	O
DISSUB	O
)	O
survivors	O
may	O
face	O
elevated	O
CO2	O
levels	O
and	O
inert	O
gas	O
saturation	O
,	O
putting	O
them	O
at	O
risk	O
for	O
CO2	O
toxicity	O
and	O
decompression	O
sickness	O
(	O
DCS	O
)	O
.	O

Propranolol	O
was	O
shown	O
to	O
reduce	B-P
CO2	I-P
production	I-P
in	O
an	O
experimental	O
DISSUB	O
model	O
in	O
humans	O
but	O
its	O
effects	O
on	O
DCS	O
in	O
a	O
DISSUB	O
rescue	O
scenario	O
are	O
unknown	O
.	O

A	O
100	O
%	O
oxygen	O
prebreathe	O
(	O
OPB	O
)	O
reduces	O
DCS	O
incidence	O
and	O
severity	O
and	O
is	O
incorporated	O
into	O
some	O
DISSUB	O
rescue	O
protocols	O
.	O

We	O
used	O
a	O
swine	O
model	O
of	O
DISSUB	O
rescue	O
to	O
study	O
the	O
effect	O
of	O
propranolol	O
on	O
DCS	O
incidence	O
and	O
mortality	O
with	O
and	O
without	O
an	O
OPB	O
.	O

In	O
Experiment	O
1	O
,	O
male	O
Yorkshire	O
Swine	O
(	O
70	O
kg	O
)	O
were	O
pressurized	O
to	O
2.8	O
ATA	O
for	O
22	O
h.	O
Propranolol	O
1.0	O
mg	O
·	O
kg-1	O
(	O
IV	O
)	O
was	O
administered	O
at	O
21.25	O
h.	O
At	O
22	O
h	O
,	O
the	O
animal	O
was	O
rapidly	O
decompressed	O
and	O
observed	O
for	O
DCS	O
type	O
,	O
onset	O
time	O
,	O
and	O
mortality	O
.	O

Experimental	O
animals	O
(	O
N	O
=	O
21	O
;	O
69	O
±	O
4.1	O
kg	O
)	O
,	O
PROP1.0	O
,	O
were	O
compared	O
to	O
PROP1.0	O
-	O
OPB45	O
(	O
N	O
=	O
8	O
;	O
69	O
±	O
2.8	O
kg	O
)	O
with	O
the	O
same	O
dive	O
profile	O
,	O
except	O
for	O
a	O
45	O
min	O
OPB	O
prior	O
to	O
decompression	O
.	O

In	O
Experiment	O
2	O
,	O
the	O
same	O
methodology	O
was	O
used	O
with	O
the	O
following	O
changes	O
:	O
swine	O
pressurized	O
to	O
2.8	O
ATA	O
for	O
28	O
h	O
;	O
experimental	O
group	O
(	O
N	O
=	O
25	O
;	O
67	O
±	O
3.3	O
kg	O
)	O
,	O
PROP0.5	O
bis	O
,	O
propranolol	O
0.5	O
mg	O
·	O
kg-1	O
bis	O
(	O
twice	O
)	O
(	O
IV	O
)	O
was	O
administered	O
at	O
22	O
h	O
and	O
26	O
h.	O
Control	O
animals	O
(	O
N	O
=	O
25	O
;	O
67	O
±	O
3.9	O
kg	O
)	O
received	O
normal	O
saline	O
.	O

OPB	O
reduced	O
mortality	O
in	O
PROP1.0	O
-	O
OBP45	O
compared	O
to	O
PROP1.0	O
(	O
0	O
%	O
vs.	O
71	O
%	O
)	O
.	O

PROP0.5	O
bis	O
had	O
increased	O
mortality	O
compared	O
to	O
CONTROL	O
(	O
60-	O
%	O
vs.	O
4	O
%	O
)	O
.	O

Administration	O
of	O
beta	O
blockers	O
prior	O
to	O
saturation	O
decompression	O
appears	O
to	O
increase	O
DCS	O
and	O
worsen	O
mortality	O
in	O
a	O
swine	O
model	O
;	O
however	O
,	O
their	O
effects	O
in	O
bounce	O
diving	O
remain	O
unknown.Forbes	O
AS	O
,	O
Regis	O
DP	O
,	O
HallAA	O
,	O
Mahon	O
RT	O
,	O
Cronin	O
WA	O
.	O

Propranolol	O
effects	O
on	O
decompression	O
sickness	O
in	O
a	O
simulated	O
DISSUB	O
rescue	O
in	O
swine	O
.	O

Aerosp	O
Med	O
Hum	O
Perform	O
.	O

2017	O
;	O
88	O
(	O
4	O
)	O
:385-391	O
.	O

Analgesic	O
and	O
anti-inflammatory	O
actions	O
on	O
bradykinin	O
route	O
of	O
a	O
polysulfated	O
fraction	O
from	O
alga	O
Ulva	O
lactuca	O
.	O

We	O
investigated	O
structural	O
features	O
of	O
polysaccharides	O
from	O
Ulva	O
lactuca	O
and	O
their	O
effects	O
on	O
the	O
classical	O
models	O
of	O
nociception	O
and	O
inflammation	O
.	O

Crude	O
extract	O
was	O
obtained	O
by	O
enzymatic	B-P
digestion	I-P
and	O
isolated	O
by	O
ion	B-P
exchange	I-P
chromatography	I-P
on	O
DEAE-cellulose	O
.	O

The	O
fraction	O
with	O
higher	O
yield	O
was	O
used	O
in	O
the	O
tests	B-P
(	O
SP-Ul	O
)	O
.	O

Swiss	O
mice	O
received	O
SP-Ul	O
(	O
1	O
,	O
3	O
or	O
9mg/kg	O
;	O
i.v	O
.	O

)	O
,	O
30min	O
prior	O
to	O
injection	O
of	O
0.8	O
%	O
-	O
acetic	O
acid	O
or	O
1	O
%	O
-	O
formalin	O
or	O
prior	O
to	O
a	O
thermal	O
stimulus	O
.	O

At	O
same	O
doses	O
,	O
SP-Ul	O
was	O
tested	O
on	O
Wistar	O
rats	O
on	O
paw	O
edema	O
elicited	O
by	O
different	O
irritants	O
(	O
carrageenan	O
,	O
dextran	O
,	O
bradykinin	O
,	O
histamine	O
or	O
serotonin	O
)	O
.	O

The	O
results	O
of	O
infrared	O
characterization	O
indicated	O
the	O
presence	O
of	O
hydroxyl	O
groups	O
,	O
sulfate	O
,	O
uronic	O
acid	O
and	O
glycosidic	O
linkages	O
in	O
all	O
SP	O
fractions	O
spectrums	O
.	O

SP-Ul	O
decreased	O
significantly	O
the	O
antinociception	O
in	O
response	O
to	O
acetic	O
acid	O
or	O
formalin	O
(	O
second	O
phase	O
)	O
,	O
but	O
not	O
in	O
the	O
hot-plate	O
test	O
,	O
suggesting	O
that	O
its	O
analgesia	O
occurs	O
through	O
a	O
peripheral	O
mechanism	O
.	O

SP-Ul	O
did	O
not	O
reduce	O
carrageenan	O
-	O
induced	O
paw	O
edema	O
as	O
supported	O
by	O
both	O
histological	O
and	O
myeloperoxidase	O
activity	O
assessments	O
.	O

However	O
,	O
SP-Ul	O
(	O
1mg/kg	O
;	O
s.c.	O
)	O
reduced	O
dextran	O
-elicited	O
edema	O
,	O
showing	O
vascular	O
anti-inflammatory	O
effect	O
,	O
with	O
bradykinin	O
as	O
major	O
target	O
because	O
it	O
did	O
not	O
reduce	O
histamine	O
-	O
and	O
serotonin	O
-	O
induced	O
paw	O
edemas	O
.	O

Therefore	O
,	O
SP-Ul	O
acts	O
on	O
bradykinin	O
pathway	O
in	O
its	O
antinociceptive	O
and	O
anti-inflammatory	O
responses	O
.	O

Nucleic	B-P
acid	I-P
detection	I-P
with	O
CRISPR	O
-	O
Cas13a	O
/	O
C2c2	O
.	O

Rapid	O
,	O
inexpensive	O
,	O
and	O
sensitive	O
nucleic	B-P
acid	I-P
detection	I-P
may	O
aid	O
point-of-care	O
pathogen	O
detection	O
,	O
genotyping	B-P
,	O
and	O
disease	O
monitoring	O
.	O

The	O
RNA	O
-guided	O
,	O
RNA	O
-	O
targeting	O
clustered	O
regularly	O
interspaced	O
short	O
palindromic	O
repeats	O
(	O
CRISPR	O
)	O
effector	O
Cas13a	O
(	O
previously	O
known	O
as	O
C2c2	O
)	O
exhibits	O
a	O
``	O
collateral	O
effect	O
``	O
of	O
promiscuous	O
ribonuclease	O
activity	O
upon	O
target	O
recognition	O
.	O

We	O
combine	O
the	O
collateral	O
effect	O
of	O
Cas13a	O
with	O
isothermal	B-P
amplification	I-P
to	O
establish	O
a	O
CRISPR	O
-based	O
diagnostic	O
(	O
CRISPR	O
-	O
Dx	O
)	O
,	O
providing	O
rapid	O
DNA	O
or	O
RNA	O
detection	O
with	O
attomolar	O
sensitivity	O
and	O
single-base	O
mismatch	O
specificity	O
.	O

We	O
use	O
this	O
Cas13a	O
-based	O
molecular	O
detection	O
platform	O
,	O
termed	O
Specific	O
High-Sensitivity	O
Enzymatic	O
Reporter	O
UnLOCKing	O
(	O
SHERLOCK	O
)	O
,	O
to	O
detect	O
specific	O
strains	O
of	O
Zika	O
and	O
Dengue	O
virus	O
,	O
distinguish	O
pathogenic	O
bacteria	O
,	O
genotype	O
human	O
DNA	O
,	O
and	O
identify	O
mutations	O
in	O
cell-free	O
tumor	O
DNA	O
.	O

Furthermore	O
,	O
SHERLOCK	O
reaction	O
reagents	O
can	O
be	O
lyophilized	B-P
for	O
cold-chain	O
independence	O
and	O
long-term	O
storage	O
and	O
be	O
readily	O
reconstituted	O
on	O
paper	O
for	O
field	O
applications	O
.	O

Expression	O
of	O
caspase	O
3	O
in	O
ovarian	O
follicle	O
cells	O
of	O
the	O
lizard	O
Podarcis	O
sicula	O
.	O

In	O
this	O
study	O
,	O
our	O
aim	O
was	O
to	O
determine	O
whether	O
caspase	O
3	O
plays	O
a	O
role	O
,	O
during	O
previtellogenesis	O
,	O
in	O
the	O
ovarian	O
follicular	O
epithelium	O
of	O
the	O
lizard	O
Podarcis	O
sicula	O
.	O

We	O
investigated	O
the	O
presence	O
and	O
localization	O
of	O
proform	O
and	O
active	O
caspase	O
3	O
by	O
enzyme	B-P
assay	I-P
,	O
Western	O
blotting	O
and	O
immunocytochemistry	B-P
.	O

In	O
parallel	O
,	O
a	O
fragment	O
of	O
caspase	O
3	O
was	O
cloned	O
for	O
the	O
first	O
time	O
in	O
this	O
species	O
,	O
sequenced	O
and	O
used	O
for	O
in	O
situ	O
hybridization	O
to	O
localize	O
messengers	O
and	O
analysed	O
by	O
a	O
phylogenetic	O
survey	O
to	O
shed	O
light	O
on	O
its	O
homology	O
with	O
reptilian	O
caspases	O
.	O

Results	O
demonstrated	O
that	O
:	O
(	O
1	O
)	O
the	O
follicle	O
cells	O
expressed	O
a	O
caspase	O
of	O
the	O
3/7	O
group	O
and	O
the	O
mRNA	O
for	O
caspase	O
3	O
was	O
transcribed	O
in	O
the	O
stem	O
phase	O
and	O
was	O
completely	O
translated	O
during	O
cell	O
differentiation	O
;	O
(	O
2	O
)	O
the	O
proform	O
protein	O
was	O
stored	O
during	O
the	O
differentiated	O
(	O
nurse	O
)	O
stage	O
and	O
activated	O
at	O
the	O
end	O
of	O
previtellogenesis	O
provoking	O
the	O
degeneration	O
of	O
cells	O
;	O
(	O
3	O
)	O
the	O
predicted	O
protein	O
sequence	O
,	O
although	O
partial	O
,	O
had	O
a	O
strong	O
similarity	O
with	O
the	O
known	O
reptilian	O
caspases	O
3	O
.	O

The	O
epithelial	O
cells	O
of	O
the	O
ovarian	O
follicle	O
,	O
therefore	O
,	O
do	O
not	O
employ	O
caspase	O
3	O
during	O
the	O
nurse	O
stage	O
but	O
,	O
instead	O
,	O
prepare	O
for	O
apoptosis	O
long	O
before	O
the	O
process	O
actually	O
begins	O
.	O

The	O
relevance	O
of	O
this	O
strategy	O
is	O
discussed	O
.	O

Immature	O
stages	O
and	O
larval	O
chaetotaxy	O
of	O
Notofairchildia	O
stenygros	O
(	O
Quate	O
&	O
Alexander	O
)	O
(	O
Diptera	O
:	O
Psychodidae	O
:	O
Bruchomyiinae	O
)	O
.	O

Some	O
authors	O
have	O
hypothesized	O
that	O
Bruchomyiinae	O
is	O
``	O
the	O
most	O
plesiomorphic	O
subfamily	O
of	O
Psychodidae	O
``	O
and	O
its	O
members	O
``	O
are	O
among	O
the	O
most	O
primitive	O
living	O
Diptera	O
``	O
.	O

Although	O
Bruchomyiinae	O
is	O
of	O
no	O
medical	O
importance	O
,	O
it	O
is	O
of	O
great	O
evolutionary	O
significance	O
,	O
having	O
long	O
been	O
placed	O
as	O
the	O
sister	O
group	O
of	O
Phlebotominae	O
.	O

In	O
general	O
,	O
species	O
of	O
this	O
subfamily	O
are	O
rarely	O
collected	O
in	O
their	O
natural	O
environment	O
;	O
therefore	O
,	O
adults	O
and	O
,	O
even	O
more	O
so	O
,	O
the	O
immature	O
stages	O
of	O
these	O
flies	O
are	O
poorly	O
known	O
.	O

We	O
describe	O
the	O
egg	O
,	O
larvae	O
and	O
pupae	O
of	O
Notofairchildia	O
stenygros	O
and	O
provide	O
nomenclatural	O
notes	O
on	O
larval	O
chaetotaxy	O
based	O
on	O
analyses	O
using	O
scanning	B-P
electron	I-P
microscopy	I-P
(	O
SEM	B-P
)	O
and	O
optic	B-P
microscopy	I-P
.	O

The	O
morphology	O
of	O
immature	O
Nt	O
.	O

stenygros	O
is	O
compared	O
with	O
other	O
Bruchomyiinae	O
and	O
Psychodidae	O
species	O
,	O
especially	O
with	O
species	O
of	O
Phlebotominae	O
that	O
are	O
superficially	O
similar	O
to	O
Bruchomyiinae	O
.	O

Results	O
of	O
this	O
study	O
revealed	O
striking	O
morphological	O
differences	O
between	O
the	O
immature	O
stages	O
of	O
Bruchomyiinae	O
and	O
Phlebotominae	O
;	O
the	O
former	O
are	O
lacking	O
abdominal	O
pseudopods	O
and	O
microtrichia	O
on	O
the	O
cephalic	O
integument	O
,	O
both	O
of	O
which	O
are	O
present	O
in	O
the	O
larvae	O
of	O
Phlebotominae	O
.	O

These	O
morphological	O
differences	O
observed	O
in	O
the	O
immature	O
stages	O
between	O
members	O
of	O
the	O
two	O
subfamilies	O
support	O
the	O
findings	O
of	O
recent	O
molecular	B-P
studies	I-P
indicating	O
that	O
Bruchomyiinae	O
and	O
Phlebtominae	O
are	O
evolutionarily	O
not	O
closely	O
related	O
.	O

Notofairchildia	O
stenygros	O
is	O
now	O
the	O
fourth	O
species	O
of	O
Bruchomyiinae	O
for	O
which	O
the	O
immature	O
stages	O
are	O
described	O
.	O

CHOROIDAL	O
VASCULARITY	O
INDEX	O
:	O
A	O
Novel	O
Optical	B-P
Coherence	I-P
Tomography	I-P
Based	O
Parameter	O
in	O
Patients	O
With	O
Exudative	O
Age-Related	O
Macular	O
Degeneration	O
.	O

To	O
evaluate	O
choroidal	O
structural	O
changes	O
in	O
exudative	O
age-related	O
macular	O
degeneration	O
(	O
AMD	O
)	O
using	O
choroidal	O
vascularity	O
index	O
computed	O
from	O
image	O
binarization	O
on	O
spectral	B-P
domain	I-P
optical	I-P
coherence	I-P
tomography	I-P
with	O
enhanced	O
depth	B-P
imaging	I-P
.	O

This	O
prospective	O
case	O
series	O
included	O
42	O
consecutive	O
patients	O
with	O
unilateral	O
exudative	O
AMD	O
.	O

Choroidal	O
images	B-P
were	O
segmented	O
into	O
luminal	O
area	O
and	O
stromal	O
area	O
.	O

Choroidal	O
vascularity	O
index	O
was	O
defined	O
as	O
the	O
ratio	O
of	O
luminal	O
area	O
to	O
total	O
choroid	O
area	O
.	O

Mean	O
choroidal	O
vascularity	O
index	O
and	O
mean	O
choroidal	O
thickness	O
between	O
study	O
and	O
fellow	O
eyes	O
of	O
the	O
same	O
patient	O
with	O
dry	O
AMD	O
were	O
compared	O
using	O
Student	O
's	O
t-test	O
.	O

There	O
was	O
a	O
significantly	O
lower	O
choroidal	O
vascularity	O
index	O
in	O
eyes	O
with	O
exudative	O
AMD	O
(	O
60.14	O
±	O
4.55	O
vs.	O
62.75	O
±	O
4.82	O
,	O
P	O
<	O
0.01	O
)	O
.	O

Luminal	O
area	O
(	O
P	O
<	O
0.01	O
)	O
was	O
decreased	O
in	O
eyes	O
with	O
exudative	O
AMD	O
but	O
there	O
was	O
no	O
significant	O
difference	O
in	O
total	O
choroid	O
area	O
(	O
P	O
=	O
0.05	O
)	O
and	O
choroidal	O
thickness	O
(	O
P	O
=	O
0.93	O
)	O
between	O
study	O
and	O
fellow	O
eyes	O
.	O

Eyes	O
with	O
exudative	O
AMD	O
demonstrated	O
reduced	O
choroidal	O
vascularity	O
index	O
but	O
insignificant	O
differences	O
in	O
choroidal	O
thickness	O
compared	O
with	O
their	O
fellow	O
eyes	O
.	O

Choroidal	O
vascularity	O
index	O
may	O
be	O
a	O
potential	O
noninvasive	O
tool	O
for	O
studying	O
structural	O
changes	O
in	O
choroid	O
and	O
monitoring	O
choroidal	O
disease	O
in	O
exudative	O
AMD	O
.	O

Did	O
FIDELIS	O
projects	O
contribute	O
to	O
the	O
detection	O
of	O
new	O
smear	B-P
-	O
positive	O
pulmonary	O
tuberculosis	O
cases	O
in	O
China	O
?	O
.	O

Setting	O
:	O
The	O
first	O
phase	O
of	O
the	O
Fund	O
for	O
Innovative	O
DOTS	O
Expansion	O
through	O
Local	O
Initiatives	O
to	O
Stop	O
TB	O
(	O
FIDELIS	O
)	O
projects	O
in	O
China	O
started	O
in	O
2003	O
.	O

Objective	O
:	O
To	O
determine	O
whether	O
the	O
FIDELIS	O
projects	O
contribute	O
d	O
to	O
the	O
increased	O
case	O
detection	O
rate	O
for	O
new	O
smear	B-P
-	O
positive	O
pulmonary	O
tuberculosis	O
(	O
PTB	O
)	O
in	O
China	O
.	O

Methods	O
:	O
We	O
compared	O
the	O
case	O
notification	O
rates	O
(	O
CNRs	O
)	O
in	O
the	O
intervention	O
year	O
with	O
those	O
of	O
the	O
previous	O
year	O
in	O
the	O
FIDELIS	O
areas	O
,	O
then	O
compared	O
the	O
difference	O
between	O
the	O
CNRs	O
of	O
the	O
intervention	O
year	O
and	O
the	O
previous	O
year	O
in	O
the	O
FIDELIS	O
areas	O
with	O
those	O
in	O
the	O
non-FI-DELIS	O
areas	O
within	O
the	O
province	O
.	O

Results	O
:	O
There	O
was	O
an	O
increase	O
in	O
the	O
CNR	O
in	O
the	O
intervention	O
year	O
compared	O
with	O
the	O
previous	O
year	O
for	O
all	O
the	O
project	O
sites	O
.	O

The	O
differences	O
between	O
the	O
CNR	O
in	O
the	O
intervention	O
year	O
and	O
the	O
previous	O
year	O
ranged	O
from	O
6.4	O
to	O
31.1	O
per	O
100	O
000	O
population	O
in	O
the	O
FIDELIS	O
areas	O
and	O
from	O
2.9	O
to	O
20.4/100	O
000	O
in	O
the	O
non-FIDELIS	O
areas	O
.	O

Differences	O
-in-	O
differences	O
analysis	O
shows	O
that	O
the	O
differences	O
in	O
the	O
CNRs	O
in	O
the	O
FIDELIS	O
areas	O
were	O
not	O
statistically	O
significantly	O
different	O
from	O
those	O
in	O
the	O
non-	O
FIDELIS	O
areas	O
(	O
P	O
=	O
0.393	O
)	O
.	O

Conclusion	O
:	O
The	O
FIDELIS	O
projects	O
may	O
have	O
contributed	O
to	O
the	O
increase	O
in	O
case	O
detection	O
of	O
new	O
smear	B-P
-	O
positive	O
PTB	O
in	O
China	O
,	O
but	O
the	O
level	O
of	O
evidence	O
is	O
low	O
.	O

Physical	O
Exercise	O
for	O
Late-Life	O
Depression	O
:	O
Effects	O
on	O
Heart	O
Rate	O
Variability	O
.	O

Late-life	O
major	O
depression	O
is	O
associated	O
with	O
increased	O
cardiovascular	O
risk	O
and	O
impaired	O
autonomic	O
control	O
of	O
the	O
heart	O
,	O
as	O
evident	O
from	O
reduced	O
heart	O
rate	O
variability	O
(	O
HRV	O
)	O
.	O

Moreover	O
,	O
antidepressant	O
drug	O
therapy	O
also	O
might	O
be	O
associated	O
with	O
further	O
reductions	O
of	O
HRV	O
.	O

In	O
the	O
SEEDS	O
study	O
,	O
we	O
investigated	O
whether	O
sertraline	O
associated	O
with	O
physical	O
exercise	O
protocols	O
led	O
to	O
improvements	O
of	O
HRV	O
,	O
compared	O
with	O
antidepressant	O
drug	O
therapy	O
alone	O
.	O

Single-blind	O
randomized	O
controlled	O
trial	O
.	O

Psychiatric	O
consultation	O
-liaison	O
program	O
for	O
primary	O
care	O
.	O

Patients	O
aged	O
65-85	O
years	O
with	O
major	O
depression	O
,	O
recruited	O
from	O
primary	O
care	O
.	O

Sertraline	O
plus	O
structured	O
,	O
tailored	O
group	O
physical	O
exercise	O
(	O
S	O
+	O
EX	O
)	O
versus	O
sertraline	O
alone	O
(	O
S	O
)	O
for	O
24	O
weeks	O
.	O

HRV	O
indices	O
(	O
RR	O
,	O
percentage	O
of	O
NN	O
intervals	O
greater	O
than	O
50	O
msec	O
[	O
pNN50	O
]	O
,	O
square	O
root	O
of	O
the	O
mean	O
squared	O
differences	O
of	O
successive	O
NN	O
intervals	O
[	O
RMSSD	O
]	O
,	O
standard	O
deviation	O
of	O
heart	O
rate	O
[	O
SDHR	O
]	O
,	O
standard	O
deviation	O
of	O
the	O
NN	O
interval	O
[	O
SDNN	O
]	O
,	O
high-frequency	O
band	O
[	O
HF	O
]	O
,	O
low-frequency	O
band	O
[	O
LF	O
]	O
,	O
and	O
their	O
ratio	O
[	O
LF/HF	O
]	O
)	O
were	O
measured	O
at	O
baseline	O
,	O
week	O
12	O
,	O
and	O
week	O
24	O
.	O

Psychiatric	B-P
and	O
medical	O
assessments	O
.	O

Participants	O
displayed	O
significant	O
improvements	O
of	O
most	O
HRV	O
indices	O
over	O
time	O
,	O
irrespective	O
of	O
the	O
group	O
assignment	O
(	O
pNN50	O
,	O
RMSSD	O
,	O
SDHR	O
,	O
SDNN	O
,	O
HF	O
,	O
LF	O
,	O
and	O
LF/HF	O
)	O
.	O

Moreover	O
,	O
patients	O
in	O
the	O
S	O
+	O
EX	O
group	O
displayed	O
greater	O
increases	O
of	O
different	O
HRV	O
indices	O
(	O
RR	O
,	O
pNN50	O
,	O
RMSSD	O
,	O
SDHR	O
,	O
SDNN	O
,	O
HF	O
,	O
and	O
LF	O
)	O
compared	O
with	O
those	O
in	O
the	O
S	O
group	O
.	O

The	O
combination	O
of	O
structured	O
physical	O
exercise	O
and	O
sertraline	O
might	O
exert	O
positive	O
effects	O
on	O
the	O
autonomic	O
control	O
of	O
the	O
heart	O
among	O
older	O
patients	O
with	O
major	O
depression	O
.	O

Epigenotype	O
,	O
genotype	O
,	O
and	O
phenotype	O
analysis	O
of	O
patients	O
in	O
Taiwan	O
with	O
Beckwith-Wiedemann	O
syndrome	O
.	O

Beckwith-Wiedemann	O
syndrome	O
(	O
BWS	O
)	O
is	O
a	O
congenital	O
overgrowth	O
disorder	O
predisposing	O
to	O
tumorigenesis	O
that	O
results	O
from	O
abnormal	O
expression	O
or	O
function	O
of	O
imprinted	O
genes	O
of	O
chromosome	O
11p15.5	O
.	O

Forty-seven	O
patients	O
in	O
Taiwan	O
with	O
clinical	O
suspicion	O
of	O
BWS	O
were	O
referred	O
for	O
diagnostic	O
testing	O
based	O
on	O
methylation	B-P
profiling	I-P
of	O
H19	O
-associated	O
imprinting	O
center	O
(	O
IC	O
)	O
1	O
and	O
KCNQ1OT1	O
-associated	O
IC2	O
using	O
high-resolution	B-P
melting	I-P
analysis	I-P
,	O
multiplex	O
ligation-dependent	O
probe	O
amplification	O
,	O
or	O
high-resolution	B-P
quantitative	I-P
methylation	I-P
profiling	I-P
.	O

Twenty-eight	O
patients	O
received	O
a	O
clinical	B-P
diagnosis	I-P
of	O
BWS	O
(	O
the	O
presence	O
of	O
3	O
major	O
features	O
or	O
2	O
major	O
features	O
and	O
at	O
least	O
1	O
minor	O
feature	O
)	O
,	O
18	O
had	O
suspected	O
BWS	O
(	O
the	O
presence	O
of	O
at	O
least	O
1	O
major	O
feature	O
)	O
,	O
and	O
1	O
had	O
isolated	O
Wilms	O
'	O
tumor	O
.	O

Nineteen	O
patients	O
were	O
identified	O
with	O
IC2	O
hypomethylation	O
(	O
including	O
1	O
with	O
isolated	O
Wilms	O
'	O
tumor	O
)	O
,	O
1	O
with	O
IC1	O
hypermethylation	O
,	O
2	O
with	O
paternal	O
uniparental	O
disomy	O
,	O
and	O
1	O
with	O
CDKN1C	O
mutation	O
.	O

Several	O
clinical	O
features	O
were	O
found	O
to	O
be	O
statistically	O
different	O
(	O
P	O
<	O
0.05	O
)	O
between	O
the	O
2	O
groups-	O
clinical	B-P
diagnosis	I-P
of	O
BWS	O
(	O
n=28	O
)	O
or	O
suspected	O
BWS	O
(	O
n=18	O
)	O
-including	O
macroglossia	O
,	O
pre-	O
or	O
postnatal	O
gigantism	O
,	O
abdominal	O
wall	O
defect	O
,	O
ear	O
creases	O
,	O
facial	O
nevus	O
flammeus	O
,	O
BWS	O
score	O
,	O
and	O
the	O
molecular	B-P
diagnosis	I-P
rate	O
.	O

Molecular	O
lesion	O
was	O
detected	O
in	O
81	O
%	O
of	O
patients	O
with	O
the	O
presence	O
of	O
three	O
major	O
features	O
,	O
compared	O
with	O
33	O
%	O
and	O
28	O
%	O
of	O
those	O
with	O
two	O
or	O
one	O
major	O
feature	O
,	O
respectively	O
.	O

The	O
mean	O
BWS	O
score	O
was	O
5.6	O
for	O
19	O
subjects	O
with	O
``	O
IC2	O
hypomethylation	O
``	O
,	O
compared	O
with	O
3.8	O
for	O
2	O
subjects	O
with	O
pUPD	O
.	O

The	O
BWS	O
score	O
of	O
one	O
subject	O
with	O
CDKN1C	O
mutation	O
and	O
one	O
with	O
IC1	O
hypermethylation	O
was	O
6	O
and	O
7	O
,	O
respectively	O
.	O

The	O
BWS	O
score	O
was	O
positively	O
correlated	O
with	O
the	O
molecular	B-P
diagnosis	I-P
rate	O
(	O
P	O
<	O
0.01	O
)	O
.	O

The	O
BWS	O
database	O
of	O
epigenotype	O
,	O
genotype	O
,	O
and	O
phenotype	O
is	O
expected	O
to	O
promote	O
better	O
genetic	O
counseling	O
and	O
medical	O
care	O
of	O
these	O
patients	O
.	O

Lowering	O
the	O
overall	O
charge	O
on	O
TMPyP4	O
improves	O
its	O
selectivity	O
for	O
G-quadruplex	O
DNA	O
.	O

Ligands	O
that	O
stabilize	O
non-canonical	O
DNA	O
structures	O
called	O
G-quadruplexes	O
(	O
GQs	O
)	O
might	O
have	O
applications	O
in	O
medicine	O
as	O
anti-cancer	O
agents	O
,	O
due	O
to	O
the	O
involvement	O
of	O
GQ	O
DNA	O
in	O
a	O
variety	O
of	O
cancer-related	O
biological	O
processes	O
.	O

Five	O
derivatives	O
of	O
5,10,15,20-tetrakis	O
(	O
N-methyl-4-pyridyl	O
)	O
porphyrin	O
(	O
TMPyP4	O
)	O
,	O
where	O
a	O
N-methylpyridyl	O
group	O
was	O
replaced	O
with	O
phenyl	O
(	O
4P3	O
)	O
,	O
4-aminopheny	O
l	O
(	O
PN3M	O
)	O
,	O
4-phenylamidoproline	O
(	O
PL3M	O
)	O
,	O
or	O
4-carboxyphenyl	O
(	O
PC3M	O
and	O
P2C2M	O
)	O
were	O
investigated	O
for	O
their	O
interactions	O
with	O
human	O
telomeric	O
DNA	O
(	O
Tel22	O
)	O
using	O
fluorescence	B-P
resonance	I-P
energy	I-P
transfer	I-P
(	O
FRET	B-P
)	O
assay	O
,	O
and	O
UV-visible	O
and	O
circular	O
dichroism	O
spectroscopies	O
in	O
K	O
(	O
+	O
)	O
buffer	O
.	O

The	O
molecules	O
are	O
cationic	O
or	O
zwitterionic	O
with	O
an	O
overall	O
charge	O
of	O
3+	O
(	O
4P3	O
,	O
PN3M	O
,	O
and	O
PL3M	O
)	O
,	O
2+	O
(	O
PC3M	O
)	O
or	O
neutral	O
(	O
P2C2M	O
)	O
.	O

All	O
porphyrins	O
except	O
P2C2M	O
stabilize	O
human	O
telomeric	O
DNA	O
in	O
FRET	B-P
assays	I-P
by	O
∼20	O
°C	O
at	O
5	O
eq	O
CD	B-P
melting	I-P
experiments	I-P
suggest	O
that	O
4P3	O
is	O
the	O
most	O
stabilizing	O
ligand	O
with	O
a	O
stabilization	O
temperature	O
of	O
16.8	O
°C	O
at	O
4	O
eq	O
.	O

Importantly	O
,	O
4P3	O
,	O
PC3M	O
and	O
PL3M	O
demonstrate	O
excellent	O
selectivity	O
for	O
quadruplexes	O
,	O
far	O
superior	O
to	O
that	O
of	O
TMPyP4	O
.	O

Binding	O
constants	O
,	O
determined	O
using	O
UV-vis	B-P
titrations	I-P
,	O
correlate	O
with	O
charge	O
:	O
triply	O
cationic	O
4P3	O
,	O
PN3M	O
and	O
PL3M	O
display	O
Ka	O
of	O
5-9	O
μM	O
(	O
-1	O
)	O
,	O
doubly	O
cationic	O
PC3M	O
displays	O
Ka	O
of	O
1	O
μM	O
(	O
-1	O
)	O
,	O
and	O
neutral	O
P2C2M	O
displays	O
weak-to-no	O
binding	O
.	O

UV-vis	O
data	O
suggest	O
that	O
binding	O
interactions	O
are	O
driven	O
by	O
electrostatic	O
attractions	O
and	O
that	O
the	O
binding	O
mode	O
may	O
be	O
base-stacking	O
(	O
or	O
end-stacking	O
)	O
judging	O
by	O
the	O
high	O
values	O
of	O
red	O
shift	O
(	O
15-20	O
nm	O
)	O
and	O
hypochromicity	O
(	O
40-50	O
%	O
)	O
.	O

We	O
conclude	O
that	O
lowering	O
the	O
charge	O
on	O
TMPyP4	O
to	O
3+	O
can	O
achieve	O
the	O
desired	O
balance	O
between	O
stabilizing	O
ability	O
,	O
affinity	O
,	O
and	O
high	O
selectivity	O
required	O
for	O
an	O
excellent	O
quadruplex	O
ligand	O
.	O

Maternal	O
vascular	O
responses	O
to	O
hypoxia	O
in	O
a	O
rat	O
model	O
of	O
intrauterine	O
growth	O
restriction	O
.	O

Intrauterine	O
growth	O
restriction	O
(	O
IUGR	O
)	O
is	O
a	O
common	O
pregnancy	O
complication	O
and	O
is	O
a	O
leading	O
cause	O
of	O
fetal	O
morbidity	O
and	O
mortality	O
.	O

Placental	O
hypoxia	O
contributes	O
to	O
adverse	O
fetal	O
consequences	O
,	O
such	O
as	O
IUGR	O
.	O

Exposing	O
pregnant	O
rats	O
to	O
hypoxia	O
can	O
lead	O
to	O
IUGR	O
;	O
however	O
,	O
assessment	O
of	O
maternal	O
vascular	O
function	O
in	O
a	O
rat	O
model	O
of	O
hypoxia	O
,	O
and	O
the	O
mechanisms	O
that	O
may	O
contribute	O
to	O
adverse	O
pregnancy	O
outcomes	O
,	O
has	O
not	O
been	O
extensively	O
studied	O
.	O

We	O
hypothesized	O
that	O
exposing	O
pregnant	O
rats	O
to	O
hypoxia	O
will	O
affect	O
maternal	O
systemic	O
vascular	O
function	O
and	O
increase	O
the	O
uterine	O
artery	O
resistance	O
index	O
(	O
RI	O
)	O
,	O
which	O
will	O
be	O
associated	O
with	O
IUGR	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
pregnant	O
rats	O
were	O
kept	O
in	O
normoxia	O
(	O
21	O
%	O
O2	O
)	O
or	O
hypoxia	O
(	O
11	O
%	O
O2	O
)	O
from	O
gestational	O
day	O
(	O
GD	O
)	O
6	O
to	O
20	O
Maternal	O
blood	O
pressure	O
,	O
uteroplacental	O
resistance	O
index	O
(	O
RI	O
)	O
(	O
ultrasound	B-P
biomicroscopy	I-P
)	O
,	O
and	O
vascular	O
function	O
(	O
wire	B-P
myography	I-P
)	O
were	O
assessed	O
in	O
uterine	O
and	O
mesenteric	O
arteries	O
.	O

Fetal	O
weight	O
was	O
significantly	O
reduced	O
(	O
P	O
<	O
0.001	O
)	O
,	O
while	O
maternal	O
blood	O
pressure	O
was	O
increased	O
(	O
P	O
<	O
0.05	O
)	O
in	O
rats	O
exposed	O
to	O
hypoxia	O
.	O

Maternal	O
vascular	O
function	O
was	O
also	O
affected	O
after	O
exposure	O
to	O
hypoxia	O
,	O
including	O
impaired	O
endothelium	O
-dependent	O
vasodilation	O
responses	O
to	O
methacholine	O
in	O
isolated	O
uterine	O
arteries	O
(	O
pEC50	O
normoxia	O
:	O
6.55	O
±	O
0.23	O
vs.	O
hypoxia	O
:	O
5.02	O
±	O
0.35	O
,	O
P	O
<	O
0.01	O
)	O
and	O
a	O
reduced	O
uterine	O
artery	O
RI	O
in	O
vivo	O
(	O
normoxia	O
:	O
0.63	O
±	O
0.04	O
vs.	O
hypoxia	O
:	O
0.53	O
±	O
0.01	O
,	O
P	O
<	O
0.05	O
)	O
;	O
associated	O
with	O
an	O
increase	O
in	O
umbilical	O
vein	O
RI	O
(	O
normoxia	O
:	O
0.35	O
±	O
0.02	O
vs.	O
hypoxia	O
:	O
0.45	O
±	O
0.04	O
,	O
P	O
<	O
0.05	O
)	O
.	O

These	O
data	O
demonstrate	O
maternal	O
and	O
fetal	O
alterations	O
in	O
vascular	O
function	O
due	O
to	O
prenatal	O
exposure	O
to	O
hypoxia	O
.	O

Further	O
,	O
although	O
there	O
was	O
a	O
compensatory	O
reduction	O
in	O
uterine	O
artery	O
RI	O
in	O
the	O
hypoxia	O
groups	O
,	O
this	O
was	O
not	O
sufficient	O
to	O
prevent	O
IUGR	O
.	O

Clinical	O
manifestations	O
,	O
course	O
,	O
and	O
outcome	O
of	O
patients	O
with	O
neutralizing	O
anti-interferon-γ	O
autoantibodies	O
and	O
disseminated	O
nontuberculous	O
mycobacterial	O
infections	O
.	O

Neutralizing	O
anti-interferon-γ	O
autoantibody	O
(	O
nAIGA	O
)	O
-associated	O
immunodeficiency	O
is	O
an	O
emerging	O
medical	O
issue	O
worldwide	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
describe	O
and	O
discuss	O
the	O
clinical	O
features	O
and	O
outcomes	O
of	O
patients	O
with	O
nAIGAs	O
and	O
disseminated	O
infections	O
by	O
nontuberculous	O
mycobacteria	O
(	O
dNTM	O
)	O
.We	O
thoroughly	O
reviewed	O
the	O
medical	O
records	O
of	O
all	O
patients	O
.	O

Microorganisms	O
and	O
nAIGAs	O
were	O
identified	O
using	O
previously	O
described	O
methods	O
with	O
modifications	O
.	O

All	O
data	O
were	O
calculated	O
and	O
analyzed	O
using	O
SPSS	O
software	O
.Among	O
46	O
adult	O
patients	O
with	O
dNTM	O
infections	O
,	O
we	O
identified	O
45	O
cases	O
(	O
97.8	O
%	O
)	O
with	O
nAIGAs	O
.	O

The	O
average	O
patient	O
age	O
was	O
58.6	O
years	O
,	O
and	O
there	O
was	O
no	O
sex	O
predominance	O
.	O

Cervical	O
lymphadenitis	O
(	O
81.8	O
%	O
)	O
was	O
the	O
most	O
common	O
clinical	O
manifestation	O
.	O

Endocrine	O
disorder	O
was	O
the	O
leading	O
comorbidity	O
(	O
7	O
cases	O
)	O
.	O

Malignancies	O
were	O
found	O
in	O
4	O
patients	O
,	O
and	O
all	O
of	O
the	O
malignancies	O
originated	O
from	O
the	O
T-cell	O
/	O
macrophage	O
lineage	O
.	O

More	O
than	O
half	O
of	O
the	O
identifiable	O
isolates	O
were	O
slow-growing	O
NTMs	O
.	O

Twenty-eight	O
(	O
62.2	O
%	O
)	O
and	O
18	O
(	O
40.0	O
%	O
)	O
patients	O
had	O
a	O
history	O
of	O
zoster	O
and	O
salmonellosis	O
,	O
respectively	O
.	O

A	O
high	O
proportion	O
of	O
patients	O
with	O
recurrent	O
episodes	O
of	O
NTM	O
infection	O
or	O
a	O
history	O
of	O
zoster	O
and	O
dNTM	O
infection	O
had	O
initial	O
nAIGA	B-P
titers	I-P
≥10	O
dilution	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Twenty-seven	O
patients	O
(	O
60.0	O
%	O
)	O
required	O
long-term	O
antimycobacterial	O
therapy	O
and	O
had	O
at	O
least	O
1	O
episode	O
of	O
recurrent	O
NTM	O
disease	O
.	O

No	O
mortality	O
was	O
related	O
to	O
dNTM	O
infection	O
.In	O
Taiwan	O
,	O
nAIGAs	O
are	O
a	O
recently	O
recognized	O
mechanism	O
of	O
dNTM	O
infection	O
.	O

Long	O
term	O
of	O
antibiotic	O
treatment	O
and	O
adherence	O
to	O
medical	O
advice	O
are	O
necessary	O
to	O
improve	O
the	O
clinical	O
outcome	O
of	O
patients	O
with	O
nAIGAs	O
.	O

Tailor-made	O
drug	O
carrier	O
:	O
Comparison	O
of	O
formation-dependent	O
physicochemical	O
properties	O
within	O
self-assembled	O
aggregates	O
for	O
an	O
optimal	O
drug	O
carrier	O
.	O

Self-assembled	O
surfactant	O
aggregates	O
,	O
such	O
as	O
micelles	O
and	O
vesicles	O
,	O
have	O
been	O
investigated	O
for	O
their	O
application	O
as	O
drug	O
carriers	O
in	O
the	O
treatment	O
of	O
various	O
diseases	O
.	O

However	O
,	O
the	O
characteristics	O
that	O
decide	O
which	O
aggregate	O
is	O
the	O
best	O
drug	O
carrier	O
for	O
each	O
disease	O
have	O
not	O
yet	O
been	O
clarified	O
.	O

In	O
order	O
to	O
design	O
an	O
optimal	O
drug	O
carrier	O
for	O
each	O
disease	O
,	O
various	O
kinds	O
of	O
self-assembled	O
aggregates	O
,	O
such	O
as	O
spherical	O
micelles	O
,	O
lens-like	O
vesicles	O
,	O
and	O
tube-like	O
vesicles	O
,	O
were	O
evaluated	O
by	O
``	O
multiple	O
techniques	O
``	O
including	O
dynamic	B-P
light	I-P
scattering	I-P
,	O
differential	B-P
scanning	I-P
calorimetry	I-P
,	O
nuclear	B-P
magnetic	I-P
resonance	I-P
spectroscopy	I-P
,	O
and	O
fluorescence	B-P
measurement	I-P
using	O
the	O
Laurdan	O
probe	O
.	O

These	O
studies	O
led	O
to	O
the	O
compilation	O
of	O
a	O
database	O
on	O
the	O
formation-dependent	O
properties	O
of	O
self-assembled	O
aggregates	O
.	O

As	O
the	O
relationship	O
between	O
physicochemical	O
properties	O
of	O
self-assembled	O
aggregates	O
and	O
their	O
functions	O
as	O
drug	O
carriers	O
have	O
been	O
extensively	O
reported	O
,	O
this	O
database	O
can	O
be	O
utilized	O
for	O
designing	O
an	O
optimal	O
drug	O
carrier	O
,	O
i.e.	O
,	O
a	O
tailor-made	O
drug	O
carrier	O
.	O

Structural	O
Remodeling	O
of	O
Sympathetic	O
Innervation	O
in	O
Atherosclerotic	O
Blood	O
Vessels	O
:	O
Role	O
of	O
Atherosclerotic	O
Disease	O
Progression	O
and	O
Chronic	O
Social	O
Stress	O
.	O

The	O
sympathetic	O
nervous	O
system	O
(	O
SNS	O
)	O
can	O
undergo	O
dramatic	O
structural	O
plasticity	O
in	O
response	O
to	O
behavioral	O
factors	O
and/or	O
the	O
presence	O
of	O
disease	O
,	O
leading	O
to	O
SNS	O
hyperinnervation	O
of	O
peripheral	O
tissues	O
.	O

The	O
SNS	O
has	O
been	O
proposed	O
as	O
an	O
important	O
mediator	O
between	O
stressful	O
behavior	O
and	O
the	O
progression	O
of	O
atherosclerosis	O
in	O
the	O
vasculature	O
.	O

The	O
present	O
study	O
examined	O
whether	O
structural	O
remodeling	O
of	O
the	O
SNS	O
occurs	O
in	O
the	O
vasculature	O
in	O
a	O
genetically	O
hyperlipidemic	O
animal	O
model	O
of	O
atherosclerosis	O
,	O
the	O
Watanabe	O
heritable	O
hyperlipidemic	O
rabbit	O
(	O
WHHL	O
;	O
relative	O
to	O
normolipidemic	O
New	O
Zealand	O
white	O
rabbits	O
[	O
NZW	O
]	O
)	O
,	O
and	O
whether	O
SNS	O
plasticity	O
is	O
driven	O
by	O
the	O
progression	O
of	O
disease	O
and/or	O
by	O
stressful	O
social	O
behavior	O
.	O

WHHL	O
and	O
NZW	O
rabbits	O
were	O
assigned	O
to	O
an	O
unstable	O
or	O
stable	O
social	O
environment	O
for	O
4	O
months	O
.	O

Aortic	O
atherosclerosis	O
was	O
assessed	O
and	O
SNS	O
aortic	O
innervation	O
quantified	O
using	O
immunofluorescent	B-P
microscopy	I-P
.	O

Numerous	O
SNS	O
varicosities	O
were	O
observed	O
throughout	O
the	O
aorta	O
in	O
WHHLs	O
and	O
NZWs	O
,	O
extending	O
into	O
the	O
vascular	O
media	O
and	O
intima	O
,	O
an	O
innervation	O
pattern	O
not	O
previously	O
reported	O
.	O

WHHLs	O
exhibited	O
significantly	O
greater	O
innervation	O
than	O
NZWs	O
(	O
F	O
(	O
1,41	O
)	O
=	O
55.3	O
,	O
p	O
<	O
.001	O
)	O
,	O
with	O
extensive	O
innervation	O
of	O
the	O
atherosclerotic	O
neointima	O
.	O

The	O
innervation	O
density	O
was	O
highly	O
correlated	O
with	O
the	O
extent	O
of	O
disease	O
in	O
the	O
WHHLs	O
(	O
r	O
(	O
21	O
)	O
=	O
0.855	O
,	O
p	O
<	O
.001	O
)	O
.	O

Social	O
environment	O
did	O
not	O
influence	O
innervation	O
in	O
NZWs	O
(	O
aortic	O
arch	O
:	O
p	O
=	O
.078	O
,	O
thoracic	O
aorta	O
:	O
p	O
=	O
.34	O
)	O
or	O
WHHLs	O
(	O
arch	O
:	O
p	O
=	O
.97	O
,	O
thoracic	O
:	O
p	O
=	O
.61	O
)	O
.	O

The	O
findings	O
suggest	O
that	O
hyperinnervation	O
is	O
driven	O
largely	O
by	O
the	O
progression	O
of	O
disease	O
rather	O
than	O
social	O
environment	O
.	O

SNS	O
innervation	O
patterns	O
observed	O
in	O
atherosclerotic	O
human	O
and	O
mouse	O
aortas	O
were	O
consistent	O
with	O
the	O
rabbit	O
,	O
suggesting	O
that	O
SNS	O
hyperinnervation	O
of	O
the	O
diseased	O
vessel	O
wall	O
is	O
a	O
general	O
feature	O
across	O
mammalian	O
species	O
.	O

Effects	O
of	O
Inhalable	O
Microparticles	O
of	O
Seonpyejeongcheon-Tang	O
in	O
an	O
Asthma	O
Mouse	O
Model	O
:	O
-	O
Effects	O
of	O
Microparticles	O
of	O
SJT	O
.	O

Allergic	O
asthma	O
generally	O
presents	O
with	O
symptoms	O
of	O
wheezing	O
,	O
coughing	O
,	O
breathlessness	O
,	O
and	O
airway	O
inflammation	O
.	O

Seonpyejeongcheon-tang	O
(	O
SJT	O
)	O
consists	O
of	O
12	O
herbs	O
.	O

It	O
originated	O
from	O
Jeongcheon-tang	O
(	O
JT	O
)	O
,	O
also	O
known	O
as	O
Ding-chuan-tang	O
,	O
composed	O
of	O
7	O
herbs	O
,	O
in	O
She-sheng-zhong-miao-fang	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
effects	O
of	O
local	O
delivery	O
of	O
SJT	O
via	O
inhalable	O
microparticles	O
in	O
an	O
asthma	O
mouse	O
model	O
.	O

Microparticles	O
containing	O
SJT	O
were	O
produced	O
by	O
spray-drying	B-P
with	O
leucine	O
as	O
an	O
excipient	O
.	O

SJT	O
microparticles	O
were	O
evaluated	O
with	O
respect	O
to	O
their	O
aerodynamic	O
properties	O
,	O
in	O
vitro	O
cytotoxicity	B-P
,	O
in	O
vivo	O
toxicity	O
,	O
and	O
therapeutic	O
effects	O
on	O
ovalbumin	O
(	O
OVA	O
)	O
-	O
induced	O
asthma	O
in	O
comparison	O
with	O
orally-administered	O
SJT	O
.	O

SJT	O
microparticles	O
provided	O
desirable	O
aerodynamic	O
properties	O
(	O
fine	O
particle	O
fraction	O
of	O
48.9	O
%	O
±	O
6.4	O
%	O
and	O
mass	O
median	O
aerodynamic	O
diameter	O
of	O
3.7	O
±	O
0.3	O
μm	O
)	O
.	O

SJT	O
microparticles	O
did	O
not	O
show	O
any	O
cytotoxicity	B-P
against	O
RAW	O
264.7	O
macrophages	O
at	O
concentrations	O
of	O
0.01	O
-	O
3	O
mg/mL	O
.	O

Inhaled	O
SJT	O
microparticles	O
decreased	O
the	O
levels	O
of	O
IL-4	O
,	O
IL-5	O
,	O
IL-13	O
,	O
IL-17A	O
,	O
eotaxin	O
and	O
OVA-IgE	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
in	O
mice	O
with	O
OVA	O
-	O
induced	O
asthma	O
.	O

These	O
effects	O
were	O
verified	O
by	O
histological	O
evaluation	O
of	O
the	O
levels	O
of	O
infiltration	O
of	O
inflammatory	O
cells	O
and	O
collagen	O
,	O
destructions	O
of	O
alveoli	O
and	O
bronchioles	O
,	O
and	O
hyperplasia	O
of	O
goblet	O
cells	O
in	O
lung	O
tissues	O
.	O

The	O
effects	O
of	O
SJT	O
microparticles	O
in	O
the	O
asthma	O
model	O
were	O
equivalent	O
to	O
those	O
of	O
orally-administered	O
SJT	O
extract	O
.	O

This	O
study	O
suggests	O
that	O
SJT	O
is	O
a	O
promising	O
agent	O
for	O
inhalation	O
therapy	O
for	O
patients	O
with	O
asthma	O
.	O

Modeling	O
adsorption	B-P
of	O
brominated	O
,	O
chlorinated	O
and	O
mixed	O
bromo	O
/	O
chloro-dibenzo-p-dioxins	O
on	O
C60	O
fullerene	O
using	O
Nano-QSPR	O
.	O

Many	O
technological	O
implementations	O
in	O
the	O
field	O
of	O
nanotechnology	O
have	O
involved	O
carbon	O
nanomaterials	O
,	O
including	O
fullerenes	O
such	O
as	O
the	O
buckminsterfullerene	O
,	O
C60	O
.	O

The	O
unprecedented	O
properties	O
of	O
such	O
organic	O
nanomaterials	O
(	O
in	O
particular	O
their	O
large	O
surface	O
area	O
)	O
gained	O
extensive	O
attention	O
for	O
their	O
potential	O
use	O
as	O
organic	O
pollutant	O
sorbents	O
.	O

Sorption	O
interactions	O
can	O
be	O
very	O
hazardous	O
and	O
useful	O
at	O
the	O
same	O
time	O
.	O

This	O
work	O
investigates	O
the	O
influence	O
of	O
halogenation	O
by	O
bromine	O
and/or	O
chlorine	O
in	O
dibenzo-p-dioxins	O
on	O
their	O
sorption	O
ability	O
on	O
the	O
C60	O
fullerene	O
surface	O
.	O

Halogenated	O
dibenzo-p-dioxins	O
(	O
PXDDs	O
,	O
where	O
X	O
=	O
Br	O
or	O
Cl	O
)	O
are	O
ever-present	O
in	O
the	O
environment	O
and	O
accidently	O
produced	O
in	O
many	O
technological	O
processes	O
in	O
only	O
approximately	O
known	O
quantities	O
.	O

If	O
all	O
combinatorial	O
Br	O
and/or	O
Cl	O
dioxin	O
substitution	O
possibilities	O
are	O
present	O
in	O
the	O
environment	O
,	O
the	O
experimental	O
characterization	O
and	O
investigation	O
of	O
sorbent	O
effectiveness	O
is	O
more	O
than	O
difficult	O
.	O

In	O
this	O
work	O
,	O
we	O
have	O
developed	O
a	O
quantitative	O
structure-property	O
relationship	O
(	O
QSPR	O
)	O
model	O
(	O
R	O
(	O
2	O
)	O
=	O
0.998	O
)	O
,	O
predicting	O
the	O
adsorption	B-P
energy	O
[	O
kcal/mol	O
]	O
for	O
1,701	O
PXDDs	O
adsorbed	O
on	O
C60	O
(	O
PXDD	O
@	O
C60	O
)	O
.	O

Based	O
on	O
the	O
QSPR	O
model	O
reported	O
herein	O
,	O
we	O
concluded	O
that	O
the	O
lowest	O
energy	O
PXDD	O
@	O
C60	O
complexes	O
are	O
those	O
that	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
considers	O
to	O
be	O
less	O
dangerous	O
with	O
respect	O
to	O
the	O
aryl	O
hydrocarbon	O
receptor	O
(	O
AhR	O
)	O
toxicity	O
mechanism	O
.	O

Therefore	O
,	O
the	O
effectiveness	O
of	O
fullerenes	O
as	O
sorbent	O
agents	O
may	O
be	O
underestimated	O
as	O
sorption	O
could	O
be	O
less	O
effective	O
for	O
toxic	O
congeners	O
than	O
previously	O
believed	O
.	O

Development	O
of	O
a	O
Robotic	O
Colonoscopic	O
Manipulation	O
System	O
,	O
Using	O
Haptic	O
Feedback	O
Algorithm	O
.	O

Colonoscopy	B-P
is	O
one	O
of	O
the	O
most	O
effective	O
diagnostic	O
and	O
therapeutic	O
tools	O
for	O
colorectal	O
diseases	O
.	O

We	O
aim	O
to	O
propose	O
a	O
master-slave	O
robotic	O
colonoscopy	B-P
that	O
is	O
controllable	O
in	O
remote	O
site	O
using	O
conventional	O
colonoscopy	B-P
.	O

The	O
master	O
and	O
slave	O
robot	O
were	O
developed	O
to	O
use	O
conventional	O
flexible	O
colonoscopy	B-P
.	O

The	O
robotic	O
colonoscopic	O
procedure	O
was	O
performed	O
using	O
a	O
colonoscope	O
training	O
model	O
by	O
one	O
expert	O
endoscopist	O
and	O
two	O
unexperienced	O
engineers	O
.	O

To	O
provide	O
the	O
haptic	O
sensation	O
,	O
the	O
insertion	O
force	O
and	O
the	O
rotating	O
torque	O
were	O
measured	O
and	O
sent	O
to	O
the	O
master	O
robot	O
.	O

A	O
slave	O
robot	O
was	O
developed	O
to	O
hold	O
the	O
colonoscopy	B-P
and	O
its	O
knob	O
,	O
and	O
perform	O
insertion	O
,	O
rotation	O
,	O
and	O
two	O
tilting	O
motions	O
of	O
colonoscope	O
.	O

A	O
master	O
robot	O
was	O
designed	O
to	O
teach	O
motions	O
of	O
the	O
slave	O
robot	O
.	O

These	O
measured	O
force	O
and	O
torque	O
were	O
scaled	O
down	O
by	O
one	O
tenth	O
to	O
provide	O
the	O
operator	O
with	O
some	O
reflection	O
force	O
and	O
torque	O
at	O
the	O
haptic	O
device	O
.	O

The	O
haptic	O
sensation	O
and	O
feedback	O
system	O
was	O
successful	O
and	O
helpful	O
to	O
feel	O
the	O
constrained	O
force	O
or	O
torque	O
in	O
colon	O
.	O

The	O
insertion	O
time	O
using	O
robotic	O
system	O
decreased	O
with	O
repeated	O
procedures	O
.	O

This	O
work	O
proposed	O
a	O
robotic	O
approach	O
for	O
colonoscopy	B-P
using	O
haptic	O
feedback	O
algorithm	O
,	O
and	O
this	O
robotic	O
device	O
would	O
effectively	O
perform	O
colonoscopy	B-P
with	O
reduced	O
burden	O
and	O
comparable	O
safety	O
for	O
patients	O
in	O
remote	O
site	O
.	O

Asystole	O
From	O
Direct	B-P
Laryngoscopy	I-P
:	O
A	O
Case	O
Report	O
and	O
Literature	O
Review	O
.	O

The	O
rare	O
and	O
potentially	O
fatal	O
complication	O
of	O
asystole	O
during	O
direct	B-P
laryngoscopy	I-P
is	O
linked	O
to	O
direct	O
vagal	B-P
stimulation	I-P
.	O

This	O
case	O
describes	O
asystole	O
in	O
an	O
85-year-old	O
female	O
who	O
underwent	O
suspension	B-P
microlaryngoscopy	I-P
with	O
tracheal	O
dilation	O
for	O
subglottic	O
stenosis	O
.	O

Quick	O
recognition	O
of	O
this	O
rare	O
event	O
with	O
immediate	O
cessation	O
of	O
laryngoscopy	B-P
resulted	O
in	O
the	O
return	O
of	O
normal	O
sinus	O
rhythm	O
.	O

This	O
incident	O
emphasizes	O
the	O
implications	O
of	O
continued	O
vigilance	O
during	O
laryngoscopy	B-P
and	O
the	O
importance	O
of	O
communication	O
between	O
the	O
anesthesia	O
and	O
surgical	O
staff	O
to	O
identify	O
and	O
treat	O
this	O
rare	O
complication	O
.	O

The	O
case	O
was	O
successfully	O
concluded	O
by	O
premedication	O
with	O
an	O
anticholinergic	O
and	O
by	O
increasing	O
the	O
depth	O
of	O
anesthesia	O
.	O

Monitoring	O
proteolytic	O
processing	O
events	O
by	O
quantitative	B-P
mass	I-P
spectrometry	I-P
.	O

Protease	O
activity	O
plays	O
a	O
key	O
role	O
in	O
a	O
wide	O
variety	O
of	O
biological	O
processes	O
including	O
gene	O
expression	O
,	O
protein	O
turnover	O
and	O
development	O
.	O

misregulation	O
of	O
these	O
proteins	O
has	O
been	O
associated	O
with	O
many	O
cancer	O
types	O
such	O
as	O
prostate	O
,	O
breast	O
,	O
and	O
skin	O
cancer	O
.	O

thus	O
,	O
the	O
identification	O
of	O
protease	O
substrates	O
will	O
provide	O
key	O
information	O
to	O
understand	O
proteolysis	O
-related	O
pathologies	O
.	O

Areas	O
covered	O
:	O
Proteomics	O
-based	O
methods	O
to	O
investigate	O
proteolysis	O
activity	O
,	O
focusing	O
on	O
substrate	O
identification	O
,	O
protease	O
specificity	O
and	O
their	O
applications	O
in	O
systems	O
biology	O
are	O
reviewed	O
.	O

Their	O
quantification	O
strategies	O
,	O
challenges	O
and	O
pitfalls	O
are	O
underlined	O
and	O
the	O
biological	O
implications	O
of	O
protease	O
malfunction	O
are	O
highlighted	O
.	O

Expert	O
commentary	O
:	O
Dysregulated	O
protease	O
activity	O
is	O
a	O
hallmark	O
for	O
some	O
disease	O
pathologies	O
such	O
as	O
cancer	O
.	O

Current	O
biochemical	O
approaches	O
are	O
low	O
throughput	O
and	O
some	O
are	O
limited	O
by	O
the	O
amount	O
of	O
sample	O
required	O
to	O
obtain	O
reliable	O
results	O
.	O

Mass	B-P
spectrometry	I-P
based	O
proteomics	O
provides	O
a	O
suitable	O
platform	O
to	O
investigate	O
protease	O
activity	O
,	O
providing	O
information	O
about	O
substrate	O
specificity	O
and	O
mapping	B-P
cleavage	O
sites	O
.	O

Spine	O
fracture	O
prevalence	O
in	O
a	O
nationally	O
representative	O
sample	O
of	O
US	O
women	O
and	O
men	O
aged	O
≥40	O
years	O
:	O
results	O
from	O
the	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
(	O
NHANES	O
)	O
2013-2014	O
.	O

Spine	O
fracture	O
prevalence	O
is	O
similar	O
in	O
men	O
and	O
women	O
,	O
increasing	O
from	O
<	O
5	O
%	O
in	O
those	O
<	O
60	O
to	O
11	O
%	O
in	O
those	O
70-79	O
and	O
18	O
%	O
in	O
those	O
≥80	O
years	O
.	O

Prevalence	O
was	O
higher	O
with	O
age	O
,	O
lower	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
,	O
and	O
in	O
those	O
meeting	O
criteria	O
for	O
spine	B-P
imaging	I-P
.	O

Most	O
subjects	O
with	O
spine	O
fractures	O
were	O
unaware	O
of	O
them	O
.	O

Spine	O
fractures	O
have	O
substantial	O
medical	O
significance	O
but	O
are	O
seldom	O
recognized	O
.	O

This	O
study	O
collected	O
contemporary	O
nationally	O
representative	O
spine	O
fracture	O
prevalence	O
data	O
.	O

Cross-sectional	O
analysis	O
of	O
3330	O
US	O
adults	O
aged	O
≥40	O
years	O
participating	O
in	O
NHANES	O
2013-2014	O
with	O
evaluable	O
Vertebral	O
Fracture	O
Assessment	O
(	O
VFA	B-P
)	O
.	O

VFA	B-P
was	O
graded	O
by	O
semiquantitative	O
measurement	O
.	O

BMD	O
and	O
an	O
osteoporosis	O
questionnaire	O
were	O
collected	O
.	O

Overall	O
spine	O
fracture	O
prevalence	O
was	O
5.4	O
%	O
and	O
similar	O
in	O
men	O
and	O
women	O
.	O

Prevalence	O
increased	O
with	O
age	O
from	O
<	O
5	O
%	O
in	O
those	O
<	O
60	O
to	O
11	O
%	O
in	O
those	O
70-79	O
and	O
18	O
%	O
in	O
those	O
≥80	O
years	O
.	O

Fractures	O
were	O
more	O
common	O
in	O
non-Hispanic	O
whites	O
and	O
in	O
people	O
with	O
lower	O
body	O
mass	O
index	O
and	O
BMD	O
.	O

Among	O
subjects	O
with	O
spine	O
fracture	O
,	O
26	O
%	O
met	O
BMD	O
criteria	O
for	O
osteoporosis	O
.	O

Prevalence	O
was	O
higher	O
in	O
subjects	O
who	O
met	O
National	O
Osteoporosis	O
Foundation	O
(	O
NOF	O
)	O
criteria	O
for	O
spine	B-P
imaging	I-P
(	O
14	O
vs	O
4.7	O
%	O
,	O
P	O
<	O
0.001	O
)	O
.	O

Only	O
8	O
%	O
of	O
people	O
with	O
a	O
spine	O
fracture	O
diagnosed	O
by	O
VFA	B-P
had	O
a	O
self-reported	O
fracture	O
,	O
and	O
among	O
those	O
who	O
self-reported	O
a	O
spine	O
fracture	O
,	O
only	O
21	O
%	O
were	O
diagnosed	O
with	O
fracture	O
by	O
VFA	B-P
.	O

Spine	O
fracture	O
prevalence	O
is	O
similar	O
in	O
women	O
and	O
men	O
and	O
increases	O
with	O
age	O
and	O
lower	O
BMD	O
,	O
although	O
most	O
subjects	O
with	O
spine	O
fracture	O
do	O
not	O
meet	O
BMD	O
criteria	O
for	O
osteoporosis	O
.	O

Since	O
most	O
(	O
>	O
90	O
%	O
)	O
individuals	O
were	O
unaware	O
of	O
their	O
spine	O
fractures	O
,	O
lateral	O
spine	B-P
imaging	I-P
is	O
needed	O
to	O
identify	O
these	O
women	O
and	O
men	O
.	O

Spine	O
fracture	O
prevalence	O
was	O
threefold	O
higher	O
in	O
individuals	O
meeting	O
NOF	O
criteria	O
for	O
spine	B-P
imaging	I-P
(	O
∼1	O
in	O
7	O
undergoing	O
VFA	B-P
)	O
.	O

Identifying	O
spine	O
fractures	O
as	O
part	O
of	O
comprehensive	O
risk	O
assessment	O
may	O
improve	O
clinical	B-P
decision	I-P
making	I-P
.	O

Fluoranthene	O
degradation	O
and	O
binding	O
mechanism	O
study	O
based	O
on	O
the	O
active-site	O
structure	O
of	O
ring-hydroxylating	O
dioxygenase	O
in	O
Microbacterium	O
paraoxydans	O
JPM1	O
.	O

In	O
this	O
study	O
,	O
a	O
gram-positive	O
fluoranthene-degrading	O
bacterial	O
strain	O
was	O
isolated	O
from	O
crude	O
oil	O
in	O
Dagang	O
Oilfield	O
and	O
identified	O
as	O
Microbacterium	O
paraoxydans	O
JPM1	O
by	O
the	O
analysis	O
of	O
16S	O
rDNA	O
sequence	O
.	O

After	O
25	O
days	O
of	O
incubation	B-P
,	O
the	O
strain	O
JPM1	O
could	O
degrade	O
91.78	O
%	O
of	O
the	O
initial	O
amount	O
of	O
fluoranthene	O
.	O

Moreover	O
,	O
four	O
metabolites	O
9-fluorenone-1-carboxylic	O
acid	O
,	O
9-fluorenone	O
,	O
phthalic	O
acid	O
,	O
and	O
benzoic	O
acid	O
were	O
detected	O
in	O
the	O
culture	O
solution	O
.	O

The	O
gene	O
sequence	O
encoding	O
the	O
aromatic-ring-hydroxylating	O
dioxygenase	O
was	O
amplified	O
in	O
the	O
strain	O
JPM1	O
by	O
PCR	O
.	O

Based	O
on	O
the	O
translated	O
protein	O
sequence	O
,	O
a	O
homology	O
modeling	O
method	O
was	O
applied	O
to	O
build	O
the	O
crystal	O
structure	O
of	O
dioxygenase	O
.	O

Subsequently	O
,	O
the	O
interaction	O
mechanism	O
between	O
fluoranthene	O
and	O
the	O
active	O
site	O
of	O
dioxygenase	O
was	O
simulated	O
and	O
analyzed	O
by	O
molecular	O
docking	O
.	O

Consequently	O
,	O
a	O
feasible	O
degrading	O
pathway	O
of	O
fluoranthene	O
in	O
the	O
strain	O
JPM1	O
was	O
proposed	O
based	O
on	O
the	O
metabolites	O
and	O
the	O
interaction	O
analyses	O
.	O

Additionally	O
,	O
the	O
thermodynamic	O
analysis	O
showed	O
that	O
the	O
strain	O
JPM1	O
had	O
high	O
tolerance	O
for	O
fluoranthene	O
,	O
and	O
the	O
influence	O
of	O
fluoranthene	O
for	O
the	O
bacterial	O
growth	O
activity	O
was	O
negligible	O
under	O
100	O
to	O
400	O
mg	O
L	O
(	O
-1	O
)	O
concentrations	O
.	O

Taken	O
together	O
,	O
this	O
study	O
indicates	O
that	O
the	O
strain	O
JPM1	O
has	O
high	O
potential	O
for	O
further	O
study	O
in	O
bioremediation	O
of	O
polycyclic	O
aromatic	O
hydrocarbon	O
(	O
PAH	O
)	O
-	O
contaminated	O
sites	O
.	O

Insulin	O
-mediated	O
hypoglycaemia	O
secondary	O
to	O
recurrent	O
clear	O
cell	O
renal	O
carcinoma	O
.	O

Renal	O
cell	O
carcinoma	O
has	O
previously	O
been	O
associated	O
with	O
hypoglycaemia	O
in	O
the	O
setting	O
of	O
non-islet	O
cell	O
tumours	O
,	O
caused	O
by	O
a	O
paraneoplastic	O
phenomenon	O
relating	O
to	O
the	O
production	O
of	O
insulin-like	O
growth	O
factor	O
type	O
II	O
.	O

We	O
present	O
a	O
case	O
of	O
recurrent	O
clear	O
cell	O
renal	O
cell	O
carcinoma	O
,	O
leading	O
to	O
an	O
insulin	O
-mediated	O
paraneoplastic	O
phenomenon	O
causing	O
severe	O
recurrent	O
hypoglycaemia	O
.	O

Hypoglycaemina	O
was	O
managed	O
successfully	O
using	O
diazoxide	O
therapy	O
,	O
in	O
conjunction	O
with	O
pazopanib	O
and	O
radiotherapy	O
to	O
reduce	O
tumour	B-P
burden	I-P
.	O

An	O
electrochemical	B-P
genosensor	O
for	O
Leishmania	O
major	O
detection	O
based	O
on	O
dual	O
effect	O
of	O
immobilization	B-P
and	O
electrocatalysis	O
of	O
cobalt-zinc	O
ferrite	O
quantum	O
dots	O
.	O

Identification	O
of	O
Leishmania	O
parasites	O
is	O
important	O
in	O
diagnosis	O
and	O
clinical	O
studies	O
of	O
leishmaniasis	O
.	O

Although	O
epidemiological	O
and	O
clinical	O
methods	O
are	O
available	O
,	O
they	O
are	O
not	O
sufficient	O
for	O
identification	O
of	O
causative	O
agents	O
of	O
leishmaniasis	O
.	O

In	O
the	O
present	O
study	O
,	O
quantum	O
dots	O
of	O
magnetic	O
cobalt-zinc	O
ferrite	O
(	O
Co0.5Zn0.5Fe2O4	O
)	O
were	O
synthesized	O
and	O
characterized	O
by	O
physicochemical	O
methods	O
.	O

The	O
quantum	O
dots	O
were	O
then	O
employed	O
as	O
an	O
electrode	O
modifier	O
to	O
immobilize	O
a	O
24-mer	O
specific	O
single	O
stranded	O
DNA	O
probe	O
,	O
and	O
fabrication	O
of	O
a	O
label-free	O
,	O
PCR-free	O
and	O
signal-on	O
electrochemical	B-P
genosensor	O
for	O
the	O
detection	O
of	O
Leishmania	O
major	O
.	O

Hybridization	O
of	O
the	O
complementary	O
single	O
stranded	O
DNA	O
sequence	O
with	O
the	O
probe	O
under	O
the	O
selected	O
conditions	O
was	O
explored	O
using	O
methylene	O
blue	O
as	O
a	O
redox	O
marker	O
,	O
utilizing	O
the	O
electrocatalytic	O
effect	O
of	O
the	O
quantum	O
dots	O
on	O
the	O
methylene	O
blue	O
electroreduction	O
process	O
.	O

The	O
genosensor	O
could	O
detect	O
a	O
synthetic	O
single	O
stranded	O
DNA	O
target	O
in	O
a	O
range	O
of	O
1.0×10	O
(	O
-11	O
)	O
to	O
1.0×10	O
(	O
-18	O
)	O
molL	O
(	O
-1	O
)	O
with	O
a	O
limit	O
of	O
detection	O
of	O
2.0×10	O
(	O
-19	O
)	O
molL	O
(	O
-1	O
)	O
,	O
and	O
genomic	O
DNA	O
in	O
a	O
range	O
of	O
7.31×10	O
(	O
-14	O
)	O
to	O
7.31×10	O
(	O
-6	O
)	O
ngμL	O
(	O
-1	O
)	O
with	O
a	O
limit	O
of	O
detection	O
of	O
1.80×10	O
(	O
-14	O
)	O
ngμL	O
(	O
-1	O
)	O
with	O
a	O
high	O
selectivity	O
and	O
sensitivity	O
.	O

Subchondral	O
bone	O
microarchitecture	O
and	O
failure	O
mechanism	O
under	O
compression	O
:	O
A	O
finite	O
element	O
study	O
.	O

Subchondral	O
bone	O
(	O
SCB	O
)	O
microdamage	O
is	O
commonly	O
observed	O
in	O
traumatic	O
joint	O
injuries	O
and	O
has	O
been	O
strongly	O
associated	O
with	O
post-traumatic	O
osteoarthritis	O
(	O
PTOA	O
)	O
.	O

Knowledge	O
of	O
the	O
three-dimensional	O
stress	O
and	O
strain	O
distribution	O
within	O
the	O
SCB	O
tissue	O
helps	O
to	O
understand	O
the	O
mechanism	O
of	O
SCB	O
failure	O
,	O
and	O
may	O
lead	O
to	O
an	O
improved	O
understanding	O
of	O
mechanisms	O
of	O
PTOA	O
initiation	O
,	O
prevention	O
and	O
treatment	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
high-resolution	B-P
micro-computed	I-P
tomography	I-P
(	O
µCT	B-P
)	O
-based	O
finite	O
element	O
(	O
FE	O
)	O
modelling	O
of	O
cartilage-bone	O
to	O
evaluate	O
the	O
failure	O
mechanism	O
and	O
the	O
locations	O
of	O
SCB	O
tissue	O
at	O
high-risk	O
of	O
initial	O
failure	O
under	O
compression	O
.	O

The	O
µCT	O
images	O
of	O
five	O
cartilage-bone	O
specimens	O
with	O
an	O
average	O
SCB	O
thickness	O
of	O
1.23±0.20mm	O
were	O
used	O
to	O
develop	O
five	O
µCT-based	B-P
FE	O
models	O
.	O

The	O
FE	O
models	O
were	O
analysed	O
under	O
axial	O
compressions	O
of	O
approximately	O
30MPa	O
applied	O
to	O
the	O
cartilage	O
surface	O
while	O
the	O
bone	O
edges	O
were	O
constrained	O
.	O

Strain	O
and	O
stress-based	O
failure	O
criteria	O
were	O
then	O
applied	O
to	O
evaluate	O
the	O
failure	O
mechanism	O
of	O
the	O
SCB	O
tissue	O
under	O
excessive	O
compression	O
through	O
articular	O
cartilage	O
.	O

µCT-based	B-P
FE	O
models	O
predicted	O
two	O
locations	O
in	O
the	O
SCB	O
at	O
high-risk	O
of	O
initial	O
failure	O
:	O
(	O
1	O
)	O
the	O
interface	O
of	O
the	O
calcified	O
-	O
uncalcified	O
cartilage	O
due	O
to	O
excessive	O
tension	O
,	O
and	O
(	O
2	O
)	O
the	O
trabecular	O
bone	O
beneath	O
the	O
subchondral	O
plate	O
due	O
to	O
excessive	O
compression	O
.	O

µCT-based	B-P
FE	O
models	O
of	O
cartilage-bone	O
enabled	O
us	O
to	O
quantify	O
the	O
distribution	O
of	O
the	O
applied	O
compression	O
which	O
was	O
transferred	O
through	O
the	O
articular	O
cartilage	O
to	O
its	O
underlying	O
SCB	O
,	O
and	O
to	O
investigate	O
the	O
mechanism	O
and	O
the	O
mode	O
of	O
SCB	O
tissue	O
failure	O
.	O

Ultimately	O
,	O
the	O
results	O
will	O
help	O
to	O
understand	O
the	O
mechanism	O
of	O
injury	O
formation	O
in	O
relation	O
to	O
PTOA	O
.	O

Comparison	O
of	O
multiple	O
single-nucleotide	O
variant	O
association	B-P
tests	I-P
in	O
a	O
meta-analysis	O
of	O
Genetic	B-P
Analysis	I-P
Workshop	O
19	O
family	O
and	O
unrelated	O
data	O
.	O

Meta-analysis	O
has	O
been	O
widely	O
used	O
in	O
genetic	O
association	O
studies	O
to	O
increase	O
sample	O
size	O
and	O
to	O
improve	O
power	O
,	O
both	O
in	O
the	O
context	O
of	O
single-variant	B-P
analysis	I-P
,	O
as	O
well	O
as	O
for	O
gene	O
-based	O
tests	B-P
.	O

Meta-analysis	O
approaches	O
for	O
haplotype	O
analysis	O
have	O
not	O
been	O
extensively	O
developed	O
and	O
used	O
,	O
and	O
have	O
not	O
been	O
compared	O
with	O
other	O
ways	O
of	O
jointly	O
analysing	B-P
multiple	I-P
genetic	I-P
variants	I-P
.	O

We	O
propose	O
a	O
novel	O
meta-analysis	O
approach	O
for	O
a	O
gene	O
-based	O
haplotype	O
association	B-P
test	I-P
,	O
and	O
compare	O
it	O
with	O
an	O
existing	O
meta-analysis	O
approach	O
of	O
the	O
sequence	B-P
kernel	I-P
association	I-P
test	I-P
(	O
SKAT	B-P
)	O
,	O
using	O
the	O
unrelated	O
samples	O
and	O
family	O
samples	O
of	O
the	O
Genetic	B-P
Analysis	I-P
Workshop	O
19	O
data	O
sets	O
.	O

We	O
performed	O
association	B-P
tests	I-P
with	O
diastolic	O
blood	O
pressure	O
and	O
restricted	O
our	O
analyses	O
to	O
all	O
variants	O
in	O
exonic	O
regions	O
on	O
all	O
odd	O
chromosomes	O
.	O

Meta-analysis	O
of	O
haplotype	O
results	O
and	O
SKAT	B-P
identified	O
different	O
genes	O
.	O

The	O
most	O
significantly	O
associated	O
gene	O
identified	O
by	O
SKAT	B-P
was	O
the	O
ALCAM	O
gene	O
on	O
chromosome	O
3	O
with	O
a	O
p	O
value	O
of	O
7.0	O
×	O
10	O
(	O
-	O
5	O
)	O
.	O

Two	O
of	O
the	O
most	O
associated	O
genes	O
identified	O
by	O
the	O
haplotype	O
method	O
were	O
FPGT	O
(	O
p	O
=	O
6.7	O
×	O
10	O
(	O
-	O
8	O
)	O
)	O
on	O
chromosome	O
1	O
and	O
SPARC	O
(	O
p	O
=	O
3.3	O
×	O
10	O
(	O
-	O
7	O
)	O
)	O
on	O
chromosome	O
5	O
.	O

Both	O
genes	O
were	O
previously	O
implicated	O
in	O
blood	O
pressure	O
regulation	O
and	O
hypertension	O
.	O

We	O
compared	O
two	O
meta-analysis	O
approaches	O
to	O
jointly	O
analyze	O
multiple	O
variants	O
:	O
SKAT	B-P
and	O
haplotype	O
tests	B-P
.	O

The	O
difference	O
in	O
observed	O
results	O
may	O
be	O
because	O
the	O
haplotype	O
method	O
considered	O
all	O
observed	O
haplotypes	O
,	O
whereas	O
SKAT	B-P
weighted	O
variants	O
inversely	O
to	O
their	O
minor	O
allele	O
frequency	O
,	O
masking	O
the	O
effects	O
of	O
common	O
variants	O
.	O

The	O
two	O
approaches	O
identified	O
different	O
top	O
genes	O
,	O
and	O
appear	O
to	O
be	O
complementary	O
.	O

In	O
vivo	O
Distribution	O
and	O
Clearance	O
of	O
Purified	O
Capsular	O
Polysaccharide	O
from	O
Burkholderia	O
pseudomallei	O
in	O
a	O
Murine	O
Model	O
.	O

Burkholderia	O
pseudomallei	O
is	O
the	O
causative	O
agent	O
of	O
melioidosis	O
,	O
a	O
severe	O
infection	O
prominent	O
in	O
northern	O
Australia	O
and	O
Southeast	O
Asia	O
.	O

The	O
``	O
gold	O
standard	O
``	O
for	O
melioidosis	O
diagnosis	B-P
is	O
bacterial	B-P
isolation	I-P
,	O
which	O
takes	O
several	O
days	O
to	O
complete	O
.	O

The	O
resulting	O
delay	O
in	O
diagnosis	B-P
leads	O
to	O
delayed	O
treatments	O
,	O
which	O
could	O
result	O
in	O
death	O
.	O

In	O
an	O
attempt	O
to	O
develop	O
better	O
methods	B-P
for	O
early	B-P
diagnosis	I-P
of	O
melioidosis	O
,	O
B.	O
pseudomallei	O
capsular	O
polysaccharide	O
(	O
CPS	O
)	O
was	O
identified	O
as	O
an	O
important	O
diagnostic	O
biomarker	O
.	O

A	O
rapid	O
lateral	O
flow	O
immunoassay	B-P
utilizing	O
CPS	O
-	O
specific	O
monoclonal	O
antibody	O
was	O
developed	O
and	O
tested	O
in	O
endemic	O
regions	O
worldwide	O
.	O

However	O
,	O
the	O
in	O
vivo	O
fate	O
and	O
clearance	O
of	O
CPS	O
has	O
never	O
been	O
thoroughly	O
investigated	O
.	O

Here	O
,	O
we	O
injected	O
mice	O
with	O
purified	O
CPS	O
intravenously	O
and	O
determined	O
CPS	O
concentrations	O
in	O
serum	O
,	O
urine	O
,	O
and	O
major	O
organs	O
at	O
various	O
intervals	O
.	O

The	O
results	O
indicate	O
that	O
CPS	O
is	O
predominantly	O
eliminated	O
through	O
urine	O
and	O
no	O
CPS	O
accumulation	O
occurs	O
in	O
the	O
major	O
organs	O
.	O

Immunoblot	B-P
analysis	I-P
demonstrated	O
that	O
intact	O
CPS	O
was	O
excreted	O
through	O
urine	O
.	O

To	O
understand	O
how	O
a	O
large	O
molecule	O
like	O
CPS	O
was	O
eliminated	O
without	O
degradation	O
,	O
a	O
3-dimenational	O
structure	O
of	O
CPS	O
was	O
modeled	O
.	O

The	O
predicted	O
CPS	O
structure	O
has	O
a	O
rod-like	O
shape	O
with	O
a	O
small	O
diameter	O
that	O
could	O
allow	O
it	O
to	O
flow	O
through	O
the	O
glomerulus	O
of	O
the	O
kidney	O
.	O

CPS	O
clearance	O
was	O
determined	O
using	O
exponential	B-P
decay	I-P
models	I-P
and	O
the	O
corrected	O
Akaike	O
Information	O
Criterion	O
.	O

The	O
results	O
show	O
that	O
CPS	O
has	O
a	O
relatively	O
short	O
serum	O
half-life	O
of	O
2.9	O
to	O
4.4	O
hours	O
.	O

Therefore	O
,	O
the	O
presence	O
of	O
CPS	O
in	O
the	O
serum	O
and/or	O
urine	O
suggests	O
active	O
melioidosis	O
infection	O
and	O
provides	O
a	O
marker	O
to	O
monitor	O
treatment	O
of	O
melioidosis	O
.	O

C4b	O
binding	O
protein	O
negatively	O
regulates	O
TLR1	O
/	O
2	O
response	O
.	O

TLR2	O
associates	O
with	O
TLR1	O
and	O
recognizes	O
microbial	O
lipoproteins	O
.	O

Pam3CSK4	O
,	O
a	O
triacylated	O
lipoprotein	O
,	O
is	O
anchored	O
to	O
the	O
extracellular	O
domain	O
of	O
TLR1	O
and	O
TLR2	O
and	O
induces	O
pro-inflammatory	O
signals	O
.	O

Here	O
we	O
show	O
that	O
C4b	O
binding	O
protein	O
(	O
C4BP	O
)	O
,	O
which	O
is	O
a	O
complement	O
pathway	O
inhibitor	O
,	O
is	O
a	O
TLR2	O
-associated	O
molecule	O
.	O

Immunoprecipitation	B-P
assay	I-P
using	O
anti-TLR2	O
mAb	O
shows	O
that	O
C4BP	O
binds	O
to	O
TLR2	O
.	O

In	O
C4BP-deficient	O
mice	O
,	O
Pam3CSK4	O
-	O
induced	O
IL-6	O
levels	O
were	O
increased	O
compared	O
with	O
wild	O
type	O
mice	O
.	O

In	O
C4BP	O
-	O
expressing	O
cells	O
,	O
Pam3CSK4	O
-	O
induced	O
IL-8	O
production	O
was	O
reduced	O
depending	O
on	O
the	O
C4BP	O
expression	O
levels	O
.	O

These	O
results	O
reveal	O
the	O
important	O
role	O
of	O
C4BP	O
in	O
negative	O
regulation	O
of	O
TLR1	O
/	O
2	O
-	O
dependent	O
pro-inflammatory	O
cytokine	O
production	O
.	O

Furthermore	O
,	O
using	O
a	O
fluorescent	O
conjugated	O
Pam3CSK4	O
,	O
we	O
show	O
that	O
C4BP	O
blocks	O
the	O
binding	O
of	O
Pam3CSK4	O
to	O
TLR1	O
/	O
2	O
.	O

Finally	O
,	O
we	O
show	O
that	O
exogenous	O
C4BP	O
also	O
inhibits	O
Pam3CSK4	O
-	O
induced	O
signaling	O
leading	O
to	O
IL-8	O
production	O
.	O

Our	O
results	O
indicate	O
C4BP	O
binding	O
to	O
TLR2	O
and	O
consequent	O
neutralization	O
of	O
its	O
activity	O
otherwise	O
inducing	O
pro-inflammatory	O
cytokine	O
production	O
.	O

C4BP	O
is	O
a	O
negative	O
regulator	O
of	O
TLR1	O
/	O
2	O
activity	O
.	O

DNA	O
methylation	O
detection	O
at	O
single	O
base	O
resolution	O
using	O
targeted	O
next	O
generation	O
bisulfite	O
sequencing	O
and	O
cross	O
validation	O
using	O
capillary	O
sequencing	O
.	O

With	O
a	O
purpose	O
of	O
accurate	O
and	O
simultaneous	O
determination	B-P
of	O
DNA	O
methylation	O
from	O
multiple	O
loci	O
in	O
multiple	O
samples	O
,	O
here	O
,	O
we	O
are	O
demonstrating	O
a	O
method	O
to	O
aid	O
rapid	O
DNA	O
methylation	O
detection	O
of	O
genomic	O
sequences	O
.	O

Using	O
genomic	O
DNA	O
of	O
peripheral	O
blood	O
from	O
14	O
healthy	O
individuals	O
,	O
DNA	O
methylation	O
in	O
465	O
CpG	O
sites	O
from	O
12	O
loci	O
of	O
genes	O
(	O
ADAM22	O
,	O
ATF2	O
,	O
BCR	O
,	O
CD83	O
,	O
CREBBP	O
,	O
IL12B	O
,	O
IL17RA	O
,	O
MAP2K2	O
,	O
RBM38	O
,	O
TGFBR2	O
,	O
TGFBR3	O
,	O
and	O
WNT5A	O
)	O
was	O
analysed	O
by	O
targeted	O
next	O
generation	O
bisulfite	O
sequencing	O
.	O

Analysed	O
region	O
for	O
three	O
genes	O
,	O
BCR	O
,	O
IL17RA	O
and	O
RBM38	O
showed	O
an	O
absolute	O
mean	O
DNA	O
methylation	O
of	O
25.6	O
%	O
,	O
89.2	O
%	O
and	O
38.9	O
%	O
respectively	O
.	O

Other	O
nine	O
gene	O
loci	O
were	O
unmethylated	O
and	O
exhibited	O
<	O
10	O
%	O
absolute	O
mean	O
DNA	O
methylation	O
.	O

Two	O
genes	O
,	O
IL17RA	O
and	O
RBM38	O
were	O
technically	O
validated	O
using	O
direct	O
capillary	O
sequencing	O
and	O
results	O
were	O
comparable	O
with	O
positive	O
correlation	O
(	O
P=0.0088	O
&	O
P	O
<	O
0.0001	O
respectively	O
)	O
in	O
the	O
CpG	O
sites	O
for	O
DNA	O
methylation	O
.	O

All	O
CpG	O
sites	O
analysed	O
from	O
RBM38	O
genes	O
locus	O
displayed	O
95	O
%	O
limits	O
of	O
agreement	O
for	O
DNA	O
methylation	O
measurements	O
from	O
the	O
two	O
methods	O
.	O

The	O
present	O
approach	O
provides	O
a	O
fast	O
and	O
reliable	O
DNA	O
methylation	O
quantitative	O
data	O
at	O
single	O
base	O
resolution	O
with	O
good	O
coverage	O
of	O
the	O
CpG	O
sites	O
under	O
analysis	O
in	O
multiple	O
loci	O
and	O
samples	O
simultaneously	O
.	O

Use	O
of	O
targeted	O
next	O
generation	O
bisulfite	O
sequencing	O
may	O
provide	O
an	O
opportunity	O
to	O
explore	O
genes	O
in	O
the	O
discovery	O
panel	O
for	O
biomarker	O
identification	O
and	O
facilitate	O
functional	O
validation	O
.	O

Gastrocnemius	O
muscle-tendon	O
interaction	O
during	O
walking	O
in	O
typically-developing	O
adults	O
and	O
children	O
,	O
and	O
in	O
children	O
with	O
spastic	O
cerebral	O
palsy	O
.	O

Our	O
understanding	O
of	O
the	O
interaction	O
of	O
muscle	O
bellies	O
and	O
their	O
tendons	O
in	O
individuals	O
with	O
muscle	O
pathology	O
is	O
limited	O
.	O

Knowledge	O
of	O
these	O
interactions	O
may	O
inform	O
us	O
of	O
the	O
effects	O
of	O
musculoskeletal	O
pathologies	O
on	O
muscle-tendon	O
dynamics	O
and	O
the	O
subsequent	O
neurological	O
control	O
strategies	O
used	O
in	O
gait	O
.	O

Here	O
,	O
we	O
investigate	O
gastrocnemius	O
muscle-tendon	O
interaction	O
in	O
typically-developing	O
(	O
TD	O
)	O
adults	O
and	O
children	O
,	O
and	O
in	O
children	O
with	O
spastic	O
cerebral	O
palsy	O
(	O
SCP	O
)	O
.	O

We	O
recruited	O
six	O
TD	O
adults	O
(	O
4	O
female	O
;	O
mean	O
age	O
:	O
34	O
yrs	O
.	O

(	O
24-54	O
)	O
)	O
,	O
eight	O
TD	O
children	O
(	O
5	O
female	O
;	O
mean	O
age	O
:	O
10	O
yrs	O
.	O

(	O
6-12	O
)	O
)	O
and	O
eight	O
independently	O
ambulant	O
children	O
with	O
SCP	O
(	O
5	O
female	O
;	O
mean	O
age	O
9	O
yrs	O
.	O

(	O
6-12	O
)	O
;	O
3	O
unilaterally-affected	O
)	O
.	O

A	O
combination	O
of	O
3D	B-P
motion	I-P
capture	I-P
and	O
2D	B-P
real-time	I-P
ultrasound	I-P
imaging	I-P
were	O
used	O
to	O
compute	O
the	O
gastrocnemius	O
musculo-tendinous	O
unit	O
(	O
MTU	O
)	O
length	O
and	O
estimate	O
muscle	O
belly	O
and	O
tendon	O
length	O
s	O
during	O
walking	O
.	O

For	O
the	O
TD	O
subjects	O
,	O
the	O
measurements	O
were	O
made	O
for	O
heel-toe	O
walking	O
and	O
voluntary	O
toe-walking	O
.	O

The	O
gastrocnemius	O
muscle	O
bellies	O
of	O
children	O
with	O
SCP	O
lengthened	O
during	O
single	O
support	O
(	O
p	O
=	O
0.003	O
)	O
.	O

In	O
contrast	O
,	O
the	O
muscle	O
bellies	O
of	O
TD	O
subjects	O
did	O
not	O
demonstrate	O
an	O
increase	O
in	O
length	O
over	O
the	O
period	O
of	O
single	O
support	O
under	O
heel-toe	O
or	O
toe-walking	O
conditions	O
.	O

We	O
observed	O
lengthening	O
of	O
the	O
gastrocnemius	O
muscle	O
bellies	O
in	O
children	O
with	O
SCP	O
during	O
single	O
support	O
,	O
a	O
phase	O
of	O
the	O
gait	O
cycle	O
in	O
which	O
the	O
muscle	O
is	O
reported	O
consistently	O
to	O
be	O
active	O
.	O

Repeated	O
lengthening	O
of	O
muscle	O
bellies	O
while	O
they	O
are	O
active	O
may	O
lead	O
to	O
muscle	O
damage	O
and	O
have	O
implications	O
for	O
the	O
natural	O
history	O
of	O
gait	O
in	O
this	O
group	O
.	O

Predicting	O
Sources	O
of	O
Dissolved	O
Organic	O
Nitrogen	O
to	O
an	O
Estuary	O
from	O
an	O
Agro	O
-	O
Urban	O
Coastal	O
Watershed	O
.	O

Dissolved	O
organic	O
nitrogen	O
(	O
DON	O
)	O
is	O
the	O
nitrogen	O
(	O
N	O
)	O
-containing	O
component	O
of	O
dissolved	O
organic	O
matter	O
(	O
DOM	O
)	O
and	O
in	O
aquatic	O
ecosystems	O
is	O
part	O
of	O
the	O
biologically-reactive	O
nitrogen	O
pool	O
that	O
can	O
degrade	O
water	O
quality	O
in	O
N	O
-	O
sensitive	O
waters	O
.	O

Unlike	O
inorganic	O
N	O
(	O
nitrate	O
and	O
ammonium	O
)	O
DON	O
is	O
comprised	O
of	O
many	O
different	O
molecules	O
of	O
variable	O
reactivity	O
.	O

Few	O
methods	O
exist	O
to	O
track	O
the	O
sources	O
of	O
DON	O
in	O
watersheds	O
.	O

In	O
this	O
study	O
,	O
DOM	O
excitation-emission	B-P
matrix	I-P
(	I-P
EEM	I-P
)	I-P
fluorescence	I-P
of	O
eight	O
discrete	O
DON	O
sources	O
was	O
measured	O
and	O
modeled	O
with	O
parallel	O
factor	O
analysis	O
(	O
PARAFAC	O
)	O
and	O
the	O
resulting	O
model	O
(	O
``	O
FluorMod	O
``	O
)	O
was	O
fit	O
to	O
516	O
EEMs	B-P
measured	O
in	O
surface	O
waters	O
from	O
the	O
main	O
stem	O
of	O
the	O
Neuse	O
River	O
and	O
its	O
tributaries	O
,	O
located	O
in	O
eastern	O
North	O
Carolina	O
.	O

PARAFAC	O
components	O
were	O
positively	O
correlated	O
to	O
DON	O
concentration	O
and	O
principle	O
components	O
analysis	O
(	O
PCA	O
)	O
was	O
used	O
to	O
confirm	O
separation	O
of	O
the	O
eight	O
sources	O
.	O

Model	O
validation	O
was	O
achieved	O
by	O
measurement	O
of	O
source	O
samples	O
not	O
included	O
in	O
the	O
model	O
development	O
with	O
an	O
error	O
of	O
<	O
10	O
%	O
.	O

Application	O
of	O
FluorMod	O
to	O
surface	O
waters	O
of	O
streams	O
within	O
the	O
Neuse	O
River	O
Basin	O
showed	O
while	O
>	O
70	O
%	O
of	O
DON	O
was	O
attributed	O
to	O
natural	O
sources	O
,	O
non-point	O
sources	O
,	O
such	O
as	O
soil	O
and	O
poultry	O
litter	O
leachates	O
and	O
street	O
runoff	O
,	O
accounted	O
for	O
the	O
remaining	O
30	O
%	O
.	O

This	O
result	O
was	O
consistent	O
with	O
changes	O
in	O
land	O
use	O
from	O
urbanized	O
Raleigh	O
metropolitan	O
area	O
to	O
the	O
largely	O
agricultural	O
Southeastern	O
coastal	O
plain	O
.	O

Overall	O
,	O
the	O
predicted	O
fraction	O
of	O
non-point	O
DON	O
sources	O
was	O
consistent	O
with	O
previous	O
reports	O
of	O
increased	O
organic	O
N	O
inputs	O
in	O
this	O
river	O
basin	O
,	O
which	O
are	O
suspected	O
of	O
impacting	O
the	O
water	O
quality	O
of	O
its	O
estuary	O
.	O

Residual	O
contamination	O
and	O
bioburden	O
after	O
reprocessing	O
of	O
single-use	O
endoscopic	O
ultrasound	O
needles	O
:	O
An	O
ex	O
vivo	O
study	O
.	O

Endoscopic	O
ultrasound	O
(	O
EUS	O
)	O
aspiration	O
needles	O
are	O
single-use	O
devices	O
.	O

However	O
,	O
in	O
many	O
centers	O
,	O
because	O
of	O
cost	O
-	O
constraints	O
,	O
these	O
devices	O
are	O
reused	O
multiple	O
times	O
.	O

We	O
studied	O
microbiological	O
contamination	O
and	O
bioburden	O
on	O
reprocessed	O
needles	O
to	O
evaluate	O
whether	O
these	O
devices	O
can	O
be	O
successfully	O
sterilized	O
.	O

We	O
studied	O
10	O
EUS	O
needles	O
each	O
of	O
19	O
G	O
,	O
22	O
G	O
,	O
and	O
25	O
G	O
in	O
size	O
,	O
and	O
five	O
22-G	O
ProCore	O
needles	O
.	O

After	O
initial	O
use	O
,	O
each	O
needle	O
was	O
reprocessed	O
by	O
a	O
standardized	O
protocol	O
.	O

We	O
used	O
standard	O
microbiological	B-P
cultures	I-P
,	O
as	O
well	O
as	O
ATP	O
bioluminescence	B-P
technique	I-P
to	O
quantify	O
bioburden	O
as	O
relative	O
light	O
units	O
(	O
RLU	O
)	O
.	O

We	O
defined	O
significant	O
soil	O
contamination	O
by	O
RLU	O
values	O
>	O
200	O
.	O

We	O
also	O
used	O
extractant	O
fluid	O
to	O
disrupt	O
cell	O
membranes	O
in	O
an	O
attempt	O
to	O
enhance	O
ATP	O
detection	O
.	O

We	O
found	O
culture	O
positivity	O
in	O
3/34	O
(	O
8.8	O
%	O
)	O
,	O
and	O
detectable	O
bioburden	O
on	O
the	O
exposed	O
surface	O
of	O
33/35	O
(	O
94.3	O
%	O
)	O
,	O
and	O
inside	O
lumen	O
of	O
29	O
(	O
82.9	O
%	O
)	O
reprocessed	O
FNA	O
needles	O
.	O

Significant	O
bioburden	O
was	O
found	O
in	O
three	O
(	O
8.6	O
%	O
)	O
and	O
two	O
(	O
5.7	O
%	O
)	O
needles	O
on	O
the	O
surface	O
and	O
lumen	O
,	O
respectively	O
.	O

We	O
found	O
that	O
use	O
of	O
extractant	O
fluid	O
enhanced	O
detection	O
of	O
bioburden	O
.	O

Larger	O
(	O
19	O
G	O
)	O
needles	O
had	O
higher	O
surface	O
contamination	O
(	O
P	O
=	O
0.016	O
)	O
,	O
but	O
there	O
was	O
no	O
relation	O
of	O
luminal	O
contamination	O
with	O
needle	O
diameter	O
(	O
P	O
=	O
0.138	O
)	O
.	O

Sheath	O
design	O
and	O
presence	O
of	O
side	O
bevel	O
did	O
not	O
influence	O
extent	O
of	O
contamination	O
.	O

There	O
was	O
significant	O
correlation	O
between	O
the	O
surface	O
and	O
intraluminal	O
bioburden	O
(	O
P	O
<	O
0.001	O
)	O
.	O

There	O
is	O
significant	O
bioburden	O
in	O
reprocessed	O
EUS	O
needles	O
;	O
standard	O
microbiological	B-P
cultures	I-P
have	O
low	O
sensitivity	B-P
for	O
detection	O
of	O
needle	O
contamination	O
.	O

We	O
have	O
provided	O
objective	O
evidence	O
for	O
the	O
futility	O
of	O
reprocessing	O
attempts	O
,	O
and	O
practice	O
of	O
EUS	O
needle	O
reuse	O
should	O
be	O
discontinued	O
.	O

Genetically	O
encoded	O
calcium	O
indicators	O
for	O
studying	O
long-term	O
calcium	O
dynamics	O
during	O
apoptosis	O
.	O

Intracellular	O
calcium	O
release	O
is	O
essential	O
for	O
regulating	O
almost	O
all	O
cellular	O
functions	O
.	O

Specific	O
spatio-temporal	O
patterns	O
of	O
cytosolic	O
calcium	O
elevations	O
are	O
critical	O
determinants	O
of	O
cell	O
fate	O
in	O
response	O
to	O
pro-apoptotic	O
cellular	O
stressors	O
.	O

As	O
the	O
apoptotic	O
program	O
can	O
take	O
hours	O
or	O
days	O
,	O
measurement	O
of	O
long-term	O
calcium	O
dynamics	O
are	O
essential	O
for	O
understanding	O
the	O
mechanistic	O
role	O
of	O
calcium	O
in	O
apoptotic	O
cell	O
death	O
.	O

Due	O
to	O
the	O
technical	O
limitations	O
of	O
using	O
calcium	O
-	O
sensitive	O
dyes	O
to	O
measure	O
cytosolic	O
calcium	O
little	O
is	O
known	O
about	O
long-term	O
calcium	O
dynamics	O
in	O
living	O
cells	O
after	O
treatment	O
with	O
apoptosis	O
-	O
inducing	O
drugs	O
.	O

Genetically	O
encoded	O
calcium	O
indicators	O
could	O
potentially	O
overcome	O
some	O
of	O
the	O
limitations	O
of	O
calcium	O
-	O
sensitive	O
dyes	O
.	O

Here	O
,	O
we	O
compared	O
the	O
performance	O
of	O
the	O
genetically	O
encoded	O
calcium	O
indicators	O
GCaMP6s	O
and	O
GCaMP6f	O
with	O
the	O
ratiometric	O
dye	O
Fura-2	O
.	O

GCaMP6s	O
performed	O
as	O
well	O
or	O
better	O
than	O
Fura-2	O
in	O
detecting	O
agonist	O
-	O
induced	O
calcium	O
transients	O
.	O

We	O
then	O
examined	O
the	O
utility	O
of	O
GCaMP6s	O
for	O
continuously	O
measuring	O
apoptotic	O
calcium	B-P
release	I-P
over	O
the	O
course	O
of	O
ten	O
hours	O
after	O
treatment	O
with	O
staurosporine	O
.	O

We	O
found	O
that	O
GCaMP6s	O
was	O
suitable	O
for	O
measuring	O
apoptotic	O
calcium	B-P
release	I-P
over	O
long	O
time	O
courses	O
and	O
revealed	O
significant	O
heterogeneity	O
in	O
calcium	B-P
release	I-P
dynamics	O
in	O
individual	O
cells	O
challenged	O
with	O
staurosporine	O
.	O

Our	O
results	O
suggest	O
GCaMP6s	O
is	O
an	O
excellent	O
indicator	O
for	O
monitoring	O
long-term	O
changes	O
cytosolic	O
calcium	O
during	O
apoptosis	O
.	O

Evaluation	O
of	O
Three	O
Protein-Extraction	B-P
Methods	I-P
for	O
Proteome	O
Analysis	B-P
of	O
Maize	O
Leaf	O
Midrib	O
,	O
a	O
Compound	O
Tissue	O
Rich	O
in	O
Sclerenchyma	O
Cells	O
.	O

Leaf	O
morphology	O
is	O
closely	O
related	O
to	O
the	O
growth	O
and	O
development	O
of	O
maize	O
(	O
Zea	O
mays	O
L.	O
)	O
plants	O
and	O
final	O
kernel	O
production	O
.	O

As	O
an	O
important	O
part	O
of	O
the	O
maize	O
leaf	O
,	O
the	O
midrib	O
holds	O
leaf	O
blades	O
in	O
the	O
aerial	O
position	O
for	O
maximum	O
sunlight	O
capture	O
.	O

Leaf	O
midrib	O
s	O
of	O
adult	O
plants	O
contain	O
substantial	O
sclerenchyma	O
cells	O
with	O
heavily	O
thickened	O
and	O
lignified	O
secondary	O
walls	O
and	O
have	O
a	O
high	O
amount	O
of	O
phenolics	O
,	O
making	O
protein	B-P
extraction	I-P
and	O
proteome	O
analysis	B-P
difficult	O
in	O
leaf	O
midrib	O
tissue	O
.	O

In	O
the	O
present	O
study	O
,	O
three	O
protein-extraction	B-P
methods	I-P
that	O
are	O
commonly	O
used	O
in	O
plant	O
proteomics	O
,	O
i.e.	O
,	O
phenol	O
extraction	B-P
,	O
TCA	O
/	O
acetone	O
extraction	B-P
,	O
and	O
TCA	O
/	O
acetone	O
/	O
phenol	O
extraction	B-P
,	O
were	O
qualitatively	O
and	O
quantitatively	O
evaluated	O
based	O
on	O
2DE	O
maps	O
and	O
MS/MS	B-P
analysis	I-P
using	O
the	O
midribs	O
of	O
the	O
10th	O
newly	O
expanded	O
leaves	O
of	O
maize	O
plants	O
.	O

Microscopy	B-P
revealed	O
the	O
existence	O
of	O
substantial	O
amounts	O
of	O
sclerenchyma	O
underneath	O
maize	O
midrib	O
epidermises	O
(	O
particularly	O
abaxial	O
epidermises	O
)	O
.	O

The	O
spot-number	O
order	O
obtained	O
via	O
2DE	B-P
mapping	I-P
was	O
as	O
follows	O
:	O
phenol	O
extraction	B-P
(	O
655	O
)	O
>	O
TCA	O
/	O
acetone	O
extraction	B-P
(	O
589	O
)	O
>	O
TCA	O
/	O
acetone	O
/	O
phenol	O
extraction	B-P
(	O
545	O
)	O
.	O

MS/MS	B-P
analysis	I-P
identified	O
a	O
total	O
of	O
17	O
spots	O
that	O
exhibited	O
2-fold	O
changes	O
in	O
abundance	O
among	O
the	O
three	O
methods	O
(	O
using	O
phenol	O
extraction	B-P
as	O
a	O
control	O
)	O
.	O

Sixteen	O
of	O
the	O
proteins	O
identified	O
were	O
hydrophilic	O
,	O
with	O
GRAVY	O
values	O
ranging	O
from	O
-0.026	O
to	O
-0.487	O
.	O

For	O
all	O
three	O
methods	O
,	O
we	O
were	O
able	O
to	O
obtain	O
high-quality	O
protein	O
samples	O
and	O
good	O
2DE	B-P
maps	I-P
for	O
the	O
maize	O
leaf	O
midrib	O
.	O

However	O
,	O
phenol	O
extraction	B-P
produced	O
a	O
better	O
2DE	B-P
map	I-P
with	O
greater	O
resolution	O
between	O
spots	O
,	O
and	O
TCA	O
/	O
acetone	O
extraction	B-P
produced	O
higher	O
protein	O
yields	O
.	O

Thus	O
,	O
this	O
paper	O
includes	O
a	O
discussion	O
regarding	O
the	O
possible	O
reasons	O
for	O
differential	O
protein	B-P
extraction	I-P
among	O
the	O
three	O
methods	O
.	O

This	O
study	O
provides	O
useful	O
information	O
that	O
can	O
be	O
used	O
to	O
select	O
suitable	O
protein	B-P
extraction	I-P
methods	O
for	O
the	O
proteome	O
analysis	B-P
of	O
recalcitrant	O
plant	O
tissues	O
that	O
are	O
rich	O
in	O
sclerenchyma	O
cells	O
.	O

Mental	O
health	O
and	O
associated	O
factors	O
among	O
young	O
offenders	O
in	O
Chile	O
:	O
a	O
cross-sectional	O
study	O
.	O

Few	O
studies	O
in	O
Latin	O
America	O
have	O
explored	O
mental	O
disorder	O
among	O
young	O
offenders	O
,	O
or	O
variables	O
associated	O
with	O
it	O
.	O

Our	O
aim	O
was	O
to	O
test	O
for	O
associations	O
between	O
childhood	O
adversity	O
or	O
substance	O
misuse	O
and	O
psychiatric	O
disorders	O
among	O
young	O
offenders	O
.	O

Sentenced	O
adolescent	O
offenders	O
were	O
recruited	O
from	O
young	O
offenders	O
'	O
institutions	O
or	O
community	O
centres	O
provided	O
by	O
the	O
Chilean	O
National	O
Service	O
for	O
Minors	O
.	O

Psychiatric	O
disorders	O
were	O
assessed	O
using	O
the	O
Mini	B-P
International	I-P
Neuropsychiatric	I-P
Interview	I-P
,	O
conducted	O
by	O
trained	O
psychologists	O
.	O

A	O
trained	O
sociologist	O
used	O
an	O
ad	O
hoc	O
interview	O
to	O
collect	O
information	O
about	O
childhood	O
experiences	O
,	O
including	O
parenting	O
,	O
trauma	O
,	O
education	O
and	O
substance	O
misuse	O
.	O

Multivariable	O
logistic	O
regressions	O
were	O
used	O
to	O
analyse	O
data	O
.	O

The	O
most	O
prevalent	O
psychiatric	O
disorders	O
among	O
the	O
935	O
participants	O
were	O
marijuana	O
dependence	O
disorder	O
,	O
major	O
depressive	O
disorder	O
,	O
and	O
anxiety	O
disorders	O
.	O

Substance	O
use	O
disorders	O
were	O
less	O
frequent	O
among	O
young	O
offenders	O
who	O
were	O
serving	O
their	O
sentence	O
in	O
young	O
offenders	O
'	O
institutions	O
than	O
among	O
those	O
serving	O
in	O
community	O
centres	O
and	O
more	O
frequent	O
among	O
those	O
who	O
started	O
to	O
use	O
marijuana	O
at	O
an	O
earlier	O
age	O
.	O

Among	O
other	O
variables	O
,	O
childhood	O
maltreatment	O
was	O
related	O
to	O
major	O
depressive	O
disorder	O
,	O
and	O
maternal	O
death	O
to	O
anxiety	O
disorders	O
.	O

Higher	O
educational	O
status	O
was	O
related	O
to	O
a	O
lower	O
frequency	O
of	O
depressive	O
and	O
anxiety	O
disorders	O
.	O

Our	O
findings	O
suggest	O
that	O
greater	O
efforts	O
must	O
be	O
made	O
to	O
identify	O
vulnerable	O
young	O
people	O
much	O
earlier	O
.	O

Few	O
of	O
these	O
young	O
offenders	O
with	O
mental	O
health	O
problems	O
had	O
been	O
well	O
adjusted	O
in	O
health	O
,	O
education	O
or	O
socially	O
before	O
this	O
period	O
of	O
detention	O
.	O

©	O
2017	O
The	O
Authors	O
.	O

Criminal	O
Behaviour	O
and	O
Mental	O
Health	O
Published	O
by	O
John	O
Wiley	O
&	O
Sons	O
Ltd	O
.	O

Decomposition	O
of	O
xenobiotics	O
during	O
visible	O
light	O
irradiation	O
in	O
the	O
presence	O
of	O
immobilised	O
photosensitisers	O
:	O
kinetics	O
study	O
.	O

The	O
objective	O
of	O
this	O
work	O
was	O
to	O
study	O
the	O
photosensitised	O
oxidation	O
of	O
the	O
xenobiotics	O
benzylparaben	O
(	O
BeP	O
)	O
and	O
2,4dichlorophenol	O
(	O
2,4DCP	O
)	O
in	O
aqueous	O
solutions	O
using	O
photosensitisers	O
immobilised	O
into	O
chitosan	O
carrier	O
particles	O
and	O
visible	O
light	O
radiation	O
.	O

Zn	O
(	O
II	O
)	O
phthalocyanine	O
tetrasulfonate	O
tetrasodium	O
salt	O
and	O
Al	O
(	O
III	O
)	O
phthalocyanine	O
chloride	O
tetrasulfonic	O
acid	O
were	O
used	O
as	O
photosensitisers	O
.	O

The	O
major	O
role	O
of	O
the	O
singlet	O
oxygen	O
during	O
photodegradation	O
was	O
proven	O
by	O
using	O
scavengers	O
of	O
reactive	O
oxygen	O
species	O
.	O

The	O
influence	O
of	O
initial	O
xenobiotic	O
concentration	O
and	O
temperature	O
on	O
degradation	O
rate	O
was	O
examined	O
.	O

The	O
investigations	O
were	O
focused	O
on	O
kinetics	O
(	O
Langmuir-Hinshelwood	O
model	O
)	O
as	O
well	O
as	O
activation	O
energy	O
determination	B-P
.	O

Moreover	O
,	O
the	O
adsorption	O
isotherms	O
of	O
BeP	O
and	O
2,4DCP	O
into	O
chitosan	O
carrier	O
were	O
determined	O
using	O
the	O
Brunauer-Emmett-Teller	O
model	O
.	O

Considerations	O
on	O
the	O
Relevance	O
of	O
Cerebral	O
Fusiform	O
Aneurysms	O
Observed	O
During	O
HIV	O
Infection	O
.	O

Human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-associated	O
ectatic	O
cerebral	O
vasculitis	O
(	O
HIV	O
-	O
AECV	O
)	O
is	O
a	O
rare	O
form	O
of	O
vasculitis	O
with	O
diffuse	O
fusiform	O
aneurysms	O
.	O

Its	O
pathophysiology	O
remains	O
poorly	O
understood	O
.	O

Although	O
extensively	O
described	O
in	O
children	O
,	O
it	O
is	O
still	O
incompletely	O
studied	O
in	O
adults	O
.	O

Our	O
objective	O
was	O
to	O
present	O
five	O
adult	O
cases	O
with	O
emphasis	O
on	O
imaging	O
findings	O
and	O
long-term	O
evolution	O
.	O

From	O
2006	O
to	O
2014	O
,	O
we	O
included	O
5	O
HIV	O
-	O
infected	O
patients	O
presenting	O
with	O
fusiform	O
cerebral	O
aneurysms	O
.	O

Vessels	O
abnormalities	O
were	O
assessed	O
with	O
brain	O
computed	B-P
tomography	I-P
(	O
CT	B-P
)	O
angiography	B-P
,	O
magnetic	B-P
resonance	I-P
angiography	I-P
(	O
MRA	B-P
)	O
and/or	O
digital	B-P
subtraction	I-P
angiography	I-P
(	O
DSA	B-P
)	O
.	O

All	O
patients	O
had	O
MR	B-P
assessment	O
of	O
the	O
brain	O
.	O

Clinical	O
and	O
biological	O
data	O
were	O
analyzed	O
.	O

Fusiform	O
aneurysms	O
of	O
carotid	O
terminations	O
extending	O
to	O
middle	O
and	O
anterior	O
cerebral	O
arteries	O
were	O
bilateral	O
in	O
three	O
patients	O
and	O
unilateral	O
in	O
one	O
.	O

More	O
distal	O
fusiform	O
aneurysms	O
were	O
observed	O
in	O
four	O
patients	O
and	O
saccular	O
aneurysms	O
in	O
two	O
patients	O
,	O
two	O
patients	O
suffered	O
from	O
ischemic	O
lesions	O
while	O
none	O
experienced	O
hemorrhage	O
.	O

Unlike	O
recent	O
reviews	O
,	O
our	O
study	O
underlines	O
the	O
low	O
hemorrhagic	O
potential	O
of	O
HIV	O
-	O
AECV	O
and	O
long-term	O
follow-up	O
suggests	O
a	O
monophasic	O
evolution	O
under	O
antiretroviral	O
medication	O
.	O

Three-dimensional	O
constructive	O
interference	O
in	O
steady-state	O
(	O
3D-CISS	O
)	O
sequences	O
and	O
Phase-contrast	B-P
MRI	I-P
of	O
arrested	O
hydrocephalus	O
.	O

to	O
evaluate	O
role	O
of	O
three-dimensional	O
constructive	O
interference	O
in	O
steady-state	O
(	O
3D-CISS	O
)	O
sequences	O
and	O
phase-contrast	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	O
PC-MRI	B-P
)	O
in	O
patients	O
with	O
arrested	O
hydrocephalus	O
.	O

Prospective	O
study	O
was	O
conducted	O
on	O
20	O
patients	O
with	O
arrested	O
hydrocephalus	O
.	O

All	O
patients	O
underwent	O
PC-MRI	B-P
and	O
3D-CISS	O
for	O
assessment	O
of	O
the	O
aqueduct	O
.	O

Axial	O
(	O
through-plane	O
)	O
,	O
sagittal	O
(	O
in-plane	O
)	O
PC-MRI	B-P
and	O
sagittal	O
3D-CISS	O
were	O
applied	O
to	O
assess	O
the	O
cerebral	O
aqueduct	O
and	O
the	O
spontaneous	O
third	O
ventriculostomy	O
if	O
present	O
.	O

Aqueductal	O
patency	O
was	O
graded	O
using	O
3D-CISS	O
and	O
PC-MRI	B-P
.	O

Quantitative	B-P
analysis	I-P
of	O
flow	O
through	O
the	O
aqueduct	O
was	O
done	O
using	O
PC-MRI	B-P
.	O

The	O
causes	O
of	O
obstruction	O
were	O
aqueductal	O
obstruction	O
in	O
75	O
%	O
(	O
n=15	O
)	O
,	O
3rd	O
ventricular	O
obstruction	O
in	O
5	O
%	O
(	O
n=1	O
)	O
and	O
4th	O
ventricular	O
obstruction	O
in	O
20	O
%	O
(	O
n=4	O
)	O
.	O

The	O
cause	O
of	O
arrest	O
of	O
hydrocephalus	O
was	O
spontaneous	O
third	O
ventriculostomy	O
in	O
65	O
%	O
(	O
n=13	O
)	O
,	O
endoscopic	O
third	O
ventriculostomy	O
in	O
10	O
%	O
(	O
n=2	O
)	O
,	O
ventriculo-peritoneal	O
shunt	O
in	O
5	O
%	O
(	O
n=1	O
)	O
and	O
no	O
cause	O
could	O
be	O
detected	O
in	O
20	O
%	O
of	O
patients	O
(	O
n=4	O
)	O
.	O

There	O
is	O
a	O
positive	O
correlation	O
(	O
r=	O
0.80	O
)	O
and	O
moderate	O
agreement	O
(	O
κ=	O
0.509	O
)	O
of	O
grading	O
with	O
PC-MRI	B-P
and	O
3D-CISS	O
sequences	O
.	O

The	O
mean	O
peak	O
systolic	O
velocity	O
of	O
CSF	O
was	O
1.86	O
±	O
2.48	O
cm/sec	O
,	O
the	O
stroke	O
volume	O
was	O
6.43	O
±	O
13.81μl/cycle	O
,	O
and	O
the	O
mean	O
flow	O
was	O
0.21	O
±	O
0.32	O
ml/min	O
.	O

We	O
concluded	O
that	O
3D-CISS	O
and	O
PC-MRI	B-P
are	O
non-invasive	O
sequences	O
for	O
diagnosis	O
of	O
the	O
level	O
and	O
cause	O
of	O
arrested	O
hydrocephalus	O
.	O

Approximate	O
Bayesian	O
computation	O
for	O
estimating	O
number	O
concentrations	O
of	O
monodisperse	O
nanoparticles	O
in	O
suspension	O
by	O
optical	B-P
microscopy	I-P
.	O

We	O
present	O
an	O
approximate	O
Bayesian	O
computation	O
scheme	O
for	O
estimating	O
number	O
concentrations	O
of	O
monodisperse	O
diffusing	O
nanoparticles	O
in	O
suspension	O
by	O
optical	B-P
particle	I-P
tracking	I-P
microscopy	I-P
.	O

The	O
method	O
is	O
based	O
on	O
the	O
probability	O
distribution	O
of	O
the	O
time	O
spent	O
by	O
a	O
particle	O
inside	O
a	O
detection	O
region	O
.	O

We	O
validate	O
the	O
method	O
on	O
suspensions	O
of	O
well-controlled	O
reference	O
particles	O
.	O

We	O
illustrate	O
its	O
usefulness	O
with	O
an	O
application	O
in	O
gene	O
therapy	O
,	O
applying	O
the	O
method	O
to	O
estimate	O
number	O
concentrations	O
of	O
plasmid	O
DNA	O
molecules	O
and	O
the	O
average	O
number	O
of	O
DNA	O
molecules	O
complexed	O
with	O
liposomal	O
drug	O
delivery	O
particles	O
.	O

Albumin	O
-Bioinspired	O
Gd	O
:	O
CuS	O
Nanotheranostic	O
Agent	O
for	O
In	O
Vivo	O
Photoacoustic	B-P
/	O
Magnetic	B-P
Resonance	I-P
Imaging	I-P
-Guided	O
Tumor	O
-Targeted	O
Photothermal	O
Therapy	O
.	O

Photothermal	O
therapy	O
(	O
PTT	O
)	O
is	O
attracting	O
increasing	O
interest	O
and	O
becoming	O
more	O
widely	O
used	O
for	O
skin	O
cancer	O
therapy	O
in	O
the	O
clinic	O
,	O
as	O
a	O
result	O
of	O
its	O
noninvasiveness	O
and	O
low	O
systemic	O
adverse	O
effects	O
.	O

However	O
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
develop	O
biocompatible	O
PTT	O
agents	O
,	O
which	O
enable	O
accurate	O
imaging	B-P
,	O
monitoring	O
,	O
and	O
diagnosis	O
.	O

Herein	O
,	O
a	O
biocompatible	O
Gd	O
-integrated	O
CuS	O
nanotheranostic	O
agent	O
(	O
Gd	O
:	O
CuS	O
@	O
BSA	O
)	O
was	O
synthesized	O
via	O
a	O
facile	O
and	O
environmentally	O
friendly	O
biomimetic	O
strategy	O
,	O
using	O
bovine	O
serum	O
albumin	O
(	O
BSA	O
)	O
as	O
a	O
biotemplate	O
at	O
physiological	O
temperature	O
.	O

The	O
as-prepared	O
Gd	O
:	O
CuS	O
@	O
BSA	O
nanoparticles	O
(	O
NPs	O
)	O
with	O
ultrasmall	O
sizes	O
(	O
ca	O
.	O

9	O
nm	O
)	O
exhibited	O
high	O
photothermal	O
conversion	O
efficiency	O
and	O
good	O
photostability	O
under	O
near-infrared	O
(	O
NIR	O
)	O
laser	O
irradiation	O
.	O

With	O
doped	O
Gd	O
species	O
and	O
strong	O
tunable	O
NIR	O
absorbance	O
,	O
Gd	O
:	O
CuS	O
@	O
BSA	O
NPs	O
demonstrate	O
prominent	O
tumor-contrasted	B-P
imaging	I-P
performance	O
both	O
on	O
the	O
photoacoustic	B-P
and	O
magnetic	B-P
resonance	I-P
imaging	I-P
modalities	O
.	O

The	O
subsequent	O
Gd	O
:	O
CuS	O
@	O
BSA	O
-mediated	O
PTT	O
result	O
shows	O
high	O
therapy	O
efficacy	O
as	O
a	O
result	O
of	O
their	O
potent	O
NIR	O
absorption	O
and	O
high	O
photothermal	O
conversion	O
efficiency	O
.	O

The	O
immune	O
response	O
triggered	O
by	O
Gd	O
:	O
CuS	O
@	O
BSA	O
-mediated	O
PTT	O
is	O
preliminarily	O
explored	O
.	O

In	O
addition	O
,	O
toxicity	B-P
studies	I-P
in	O
vitro	O
and	O
in	O
vivo	O
verify	O
that	O
Gd	O
:	O
CuS	O
@	O
BSA	O
NPs	O
qualify	O
as	O
biocompatible	O
agents	O
.	O

A	O
biodistribution	O
study	O
demonstrated	O
that	O
the	O
NPs	O
can	O
undergo	O
hepatic	O
clearance	O
from	O
the	O
body	O
.	O

This	O
study	O
highlights	O
the	O
practicality	O
and	O
versatility	O
of	O
albumin	O
-mediated	O
biomimetic	O
mineralization	O
of	O
a	O
nanotheranostic	O
agent	O
and	O
also	O
suggests	O
that	O
bioinspired	O
Gd	O
:	O
CuS	O
@	O
BSA	O
NPs	O
possess	O
promising	O
imaging	O
guidance	O
and	O
effective	O
tumor	O
ablation	O
properties	O
,	O
with	O
high	O
spatial	O
resolution	O
and	O
deep	O
tissue	O
penetration	O
.	O

Quantitative	B-P
fetal	I-P
fibronectin	I-P
and	O
cervical	B-P
length	I-P
to	O
predict	O
preterm	O
birth	O
in	O
asymptomatic	O
women	O
with	O
previous	O
cervical	O
surgery	O
.	O

Quantitative	B-P
fetal	I-P
fibronectin	I-P
testing	I-P
has	O
demonstrated	B-P
accuracy	O
for	O
prediction	O
of	O
spontaneous	O
preterm	O
birth	O
in	O
asymptomatic	O
women	O
with	O
a	O
history	O
of	O
preterm	O
birth	O
.	O

Predictive	O
accuracy	O
in	O
women	O
with	O
previous	O
cervical	O
surgery	O
(	O
a	O
potentially	O
different	O
risk	O
mechanism	O
)	O
is	O
not	O
known	O
.	O

We	O
sought	O
to	O
compare	O
the	O
predictive	O
accuracy	O
of	O
cervicovaginal	O
fluid	O
quantitative	B-P
fetal	I-P
fibronectin	I-P
and	O
cervical	B-P
length	I-P
testing	I-P
in	O
asymptomatic	O
women	O
with	O
previous	O
cervical	O
surgery	O
to	O
that	O
in	O
women	O
with	O
1	O
previous	O
preterm	O
birth	O
.	O

We	O
conducted	O
a	O
prospective	O
blinded	O
secondary	O
analysis	O
of	O
a	O
larger	O
observational	O
study	O
of	O
cervicovaginal	O
fluid	O
quantitative	B-P
fetal	I-P
fibronectin	I-P
concentration	O
in	O
asymptomatic	O
women	O
measured	O
with	O
a	O
Hologic	O
10Q	O
system	O
(	O
Hologic	O
,	O
Marlborough	O
,	O
MA	O
)	O
.	O

Prediction	O
of	O
spontaneous	O
preterm	O
birth	O
(	O
<	O
30	O
,	O
<	O
34	O
,	O
and	O
<	O
37	O
weeks	O
)	O
with	O
cervicovaginal	O
fluid	O
quantitative	B-P
fetal	I-P
fibronectin	I-P
concentration	O
in	O
primiparous	O
women	O
who	O
had	O
undergone	O
at	O
least	O
1	O
invasive	O
cervical	B-P
procedure	I-P
(	O
n	O
=	O
473	O
)	O
was	O
compared	O
with	O
prediction	O
in	O
women	O
who	O
had	O
previous	O
spontaneous	O
preterm	O
birth	O
,	O
preterm	O
prelabor	O
rupture	O
of	O
membranes	O
,	O
or	O
late	O
miscarriage	O
(	O
n	O
=	O
821	O
)	O
.	O

Relationship	O
with	O
cervical	O
length	O
was	O
explored	O
.	O

The	O
rate	O
of	O
spontaneous	O
preterm	O
birth	O
<	O
34	O
weeks	O
in	O
the	O
cervical	O
surgery	O
group	O
was	O
3	O
%	O
compared	O
with	O
9	O
%	O
in	O
previous	O
spontaneous	O
preterm	O
birth	O
group	O
.	O

Receiver	O
operating	O
characteristic	O
curves	O
comparing	O
quantitative	B-P
fetal	I-P
fibronectin	I-P
for	O
prediction	O
at	O
all	O
3	O
gestational	O
end	O
points	O
were	O
comparable	O
between	O
the	O
cervical	O
surgery	O
and	O
previous	O
spontaneous	O
preterm	O
birth	O
groups	O
(	O
34	O
weeks	O
:	O
area	O
under	O
the	O
curve	O
,	O
0.78	O
[	O
95	O
%	O
confidence	O
interval	O
0.64-0.93	O
]	O
vs	O
0.71	O
[	O
95	O
%	O
confidence	O
interval	O
0.64-0.78	O
]	O
;	O
P	O
=	O
.39	O
)	O
.	O

Prediction	O
of	O
spontaneous	O
preterm	O
birth	O
using	O
cervical	B-P
length	I-P
compared	O
with	O
quantitative	B-P
fetal	I-P
fibronectin	I-P
for	O
prediction	O
of	O
preterm	O
birth	O
<	O
34	O
weeks	O
of	O
gestation	O
offered	O
similar	O
prediction	O
(	O
area	O
under	O
the	O
curve	O
,	O
0.88	O
[	O
95	O
%	O
confidence	O
interval	O
0.79-0.96	O
]	O
vs	O
0.77	O
[	O
95	O
%	O
confidence	O
interval	O
0.62-0.92	O
]	O
,	O
P	O
=	O
.12	O
in	O
the	O
cervical	O
surgery	O
group	O
;	O
and	O
0.77	O
[	O
95	O
%	O
confidence	O
interval	O
0.70-0.84	O
]	O
vs	O
0.74	O
[	O
95	O
%	O
confidence	O
interval	O
0.67-0.81	O
]	O
,	O
P	O
=	O
.32	O
in	O
the	O
previous	O
spontaneous	O
preterm	O
birth	O
group	O
)	O
.	O

Prediction	O
of	O
spontaneous	O
preterm	O
birth	O
using	O
cervicovaginal	O
fluid	O
quantitative	B-P
fetal	I-P
fibronectin	I-P
in	O
asymptomatic	O
women	O
with	O
cervical	O
surgery	O
is	O
valid	O
,	O
and	O
has	O
comparative	O
accuracy	O
to	O
that	O
in	O
women	O
with	O
a	O
history	O
of	O
spontaneous	O
preterm	O
birth	O
.	O

Probiotics	O
and	O
oral	O
health	O
:	O
A	O
systematic	O
review	O
.	O

Probiotics	O
are	O
microorganisms	O
,	O
mainly	O
bacteria	O
,	O
which	O
benefit	O
the	O
host	O
's	O
health	O
.	O

Many	O
studies	O
support	O
the	O
role	O
of	O
probiotics	O
as	O
a	O
contributor	O
to	O
gastrointestinal	O
health	O
,	O
and	O
nowadays	O
many	O
authors	O
are	O
trying	O
to	O
prove	O
its	O
influence	O
in	O
oral	O
health	O
maintenance	O
.	O

To	O
review	O
the	O
published	O
literature	O
with	O
the	O
purpose	O
of	O
knowing	O
the	O
importance	O
of	O
using	O
probiotics	O
as	O
a	O
preventive	O
and	O
therapeutic	O
method	O
for	O
oral	O
infectious	O
diseases	O
management	O
.	O

An	O
electronic	O
search	O
in	O
PubMed	O
database	O
with	O
the	O
keywords	O
``	O
oral	O
health	O
AND	O
probiotics	O
AND	O
dentistry	O
``	O
was	O
conducted	O
.	O

The	O
inclusion	O
criteria	O
were	O
:	O
randomized	O
clinical	O
trials	O
(	O
RCTs	O
)	O
that	O
assess	O
the	O
action	O
of	O
any	O
probiotic	O
strain	O
in	O
the	O
treatment	O
and	O
/	O
or	O
prevention	O
of	O
an	O
infectious	O
oral	O
disease	O
,	O
RCTs	O
that	O
assess	O
the	O
action	O
of	O
any	O
probiotic	O
strain	O
on	O
counting	B-P
colony	O
forming	O
units	O
(	O
CFU	O
)	O
of	O
oral	O
pathogens	O
,	O
systematic	O
reviews	O
and	O
meta-analysis	O
.	O

The	O
Jadad	O
scale	O
was	O
used	O
to	O
assess	O
the	O
high	O
quality	O
of	O
RCTs	O
.	O

Fifteen	O
articles	O
were	O
considered	O
for	O
this	O
review	O
.	O

Of	O
which	O
,	O
12	O
were	O
RCTs	O
of	O
good	O
/	O
high	O
quality	O
(	O
Jadad	O
scale	O
)	O
,	O
two	O
meta-analysis	O
and	O
one	O
systematic	O
review	O
.	O

The	O
literature	O
reviewed	O
suggests	O
probiotics	O
usage	O
could	O
be	O
beneficial	O
for	O
the	O
maintenance	O
of	O
oral	O
health	O
,	O
due	O
to	O
its	O
ability	O
to	O
decrease	O
the	O
colony	O
forming	O
units	O
(	O
CFU	O
)	O
counts	O
of	O
the	O
oral	O
pathogens	O
.	O

However	O
,	O
randomized	O
clinical	O
trials	O
with	O
long-term	O
follow-up	O
periods	O
are	O
needed	O
to	O
confirm	O
their	O
efficacy	O
in	O
reducing	O
the	O
prevalence/incidence	O
of	O
oral	O
infectious	O
diseases	O
.	O

Furthermore	O
,	O
the	O
recognition	O
of	O
specific	O
strains	O
with	O
probiotic	O
activity	O
for	O
each	O
infectious	O
oral	O
disease	O
is	O
required	O
,	O
in	O
order	O
to	O
determine	O
exact	O
dose	O
,	O
treatment	O
time	O
and	O
ideal	O
vehicles	O
.	O

Comparison	O
of	O
Leishmania	O
typing	B-P
results	O
obtained	O
from	O
16	O
European	O
clinical	O
laboratories	O
in	O
2014	O
.	O

Leishmaniasis	O
is	O
endemic	O
in	O
southern	O
Europe	O
,	O
and	O
in	O
other	O
European	O
countries	O
cases	O
are	O
diagnosed	O
in	O
travellers	O
who	O
have	O
visited	O
affected	O
areas	O
both	O
within	O
the	O
continent	O
and	O
beyond	O
.	O

Prompt	O
and	O
accurate	O
diagnosis	O
poses	O
a	O
challenge	O
in	O
clinical	O
practice	O
in	O
Europe	O
.	O

Different	O
methods	O
exist	O
for	O
identification	O
of	O
the	O
infecting	O
Leishmania	O
species	O
.	O

Sixteen	O
clinical	O
laboratories	O
in	O
10	O
European	O
countries	O
,	O
plus	O
Israel	O
and	O
Turkey	O
,	O
conducted	O
a	O
study	O
to	O
assess	O
their	O
genotyping	B-P
performance	O
.	O

DNA	O
from	O
21	O
promastigote	O
cultures	O
of	O
13	O
species	O
was	O
analysed	O
blindly	O
by	O
the	O
routinely	O
used	O
typing	B-P
method	O
.	O

Five	O
different	O
molecular	O
targets	O
were	O
used	O
,	O
which	O
were	O
analysed	O
with	O
PCR-based	O
methods	O
.	O

Different	O
levels	O
of	O
identification	O
were	O
achieved	O
,	O
and	O
either	O
the	O
Leishmania	O
subgenus	O
,	O
species	O
complex	O
,	O
or	O
actual	O
species	O
were	O
reported	O
.	O

The	O
overall	O
error	O
rate	O
of	O
strains	O
placed	O
in	O
the	O
wrong	O
complex	O
or	O
species	O
was	O
8.5	O
%	O
.	O

Various	O
reasons	O
for	O
incorrect	O
typing	B-P
were	O
identified	O
.	O

The	O
study	O
shows	O
there	O
is	O
considerable	O
room	O
for	O
improvement	O
and	O
standardisation	O
of	O
Leishmania	O
typing	B-P
.	O

The	O
use	O
of	O
well	O
validated	O
standard	O
operating	O
procedures	O
is	O
recommended	O
,	O
covering	O
testing	O
,	O
interpretation	O
,	O
and	O
reporting	O
guidelines	O
.	O

Application	O
of	O
the	O
internal	O
transcribed	O
spacer	O
1	O
of	O
the	O
rDNA	O
array	O
should	O
be	O
restricted	O
to	O
Old	O
World	O
samples	O
,	O
while	O
the	O
heat-shock	O
protein	O
70	O
gene	O
and	O
the	O
mini-exon	O
can	O
be	O
applied	O
globally	O
.	O

Immobilization	O
of	O
Lipase	O
from	O
Pseudomonas	O
fluorescens	O
on	O
Porous	O
Polyurea	O
and	O
Its	O
Application	O
in	O
Kinetic	B-P
Resolution	I-P
of	O
Racemic	O
1-Phenylethanol	O
.	O

A	O
porous	O
polyurea	O
(	O
PPU	O
)	O
was	O
prepared	O
through	O
a	O
simple	O
protocol	O
by	O
reacting	O
toluene	O
diisocyanate	O
with	O
water	O
in	O
binary	O
solvent	O
of	O
water	O
-	O
acetone	O
.	O

Its	O
amine	O
group	O
was	O
determined	O
through	O
spectrophotometric	B-P
absorbance	O
based	O
on	O
its	O
iminization	O
with	O
p-nitrobenzaldehyde	O
amines	O
.	O

PPU	O
was	O
then	O
used	O
as	O
a	O
novel	O
polymer	O
support	O
for	O
enzyme	O
immobilization	O
,	O
through	O
activation	O
by	O
glutaraldehyde	O
followed	O
by	O
immobilization	O
of	O
an	O
enzyme	O
,	O
lipase	O
from	O
Pseudomonas	O
fluorescens	O
(	O
PFL	O
)	O
,	O
via	O
covalent	O
bonding	O
with	O
the	O
amine	O
groups	O
of	O
lipase	O
molecules	O
.	O

Influences	O
of	O
glutaraldehyde	O
and	O
enzyme	O
concentration	O
and	O
pH	O
in	O
the	O
process	O
were	O
studied	O
.	O

The	O
results	O
revealed	O
that	O
the	O
activity	O
of	O
the	O
immobilized	O
PFL	O
reached	O
a	O
maximum	O
at	O
GA	O
concentration	O
of	O
0.17	O
mol/L	O
and	O
at	O
pH	O
8	O
.	O

Immobilization	O
rate	O
of	O
60	O
%	O
or	O
higher	O
for	O
PFL	O
was	O
obtained	O
under	O
optimized	O
condition	O
with	O
an	O
enzyme	O
activity	O
of	O
283	O
U/mg	O
.	O

The	O
porous	O
structure	O
of	O
PPU	O
,	O
prior	O
to	O
and	O
after	O
GA	O
activation	O
and	O
PFL	O
immobilization	O
,	O
was	O
characterized	O
.	O

The	O
activity	O
of	O
the	O
immobilized	O
PFL	O
at	O
different	O
temperature	O
and	O
pH	O
and	O
its	O
stability	O
at	O
40	O
°C	O
as	O
well	O
as	O
its	O
reusability	O
were	O
tested	O
.	O

The	O
immobilized	O
enzyme	O
was	O
finally	O
used	O
as	O
enantioselective	O
catalyst	O
in	O
kinetic	B-P
resolution	I-P
of	O
racemic	O
1-	O
ph	O
enylethanol	O
(	O
1-PEOH	O
)	O
,	O
and	O
its	O
performance	O
compared	O
with	O
the	O
free	O
PFL	O
.	O

The	O
results	O
demonstrate	O
that	O
the	O
enzyme	O
activity	O
and	O
stability	O
were	O
greatly	O
improved	O
for	O
the	O
immobilized	O
PFL	O
,	O
and	O
highly	O
pure	O
enantiomers	O
from	O
racemic	O
1-PEOH	O
were	O
effectively	O
achieved	O
using	O
the	O
immobilized	O
PFL	O
.	O

Noticeable	O
deactivation	O
of	O
PFL	O
in	O
the	O
resolution	B-P
was	O
observed	O
by	O
acetaldehyde	O
in	O
situ	O
formed	O
.	O

In	O
addition	O
,	O
the	O
immobilized	O
PFL	O
was	O
readily	O
recovered	O
from	O
the	O
reaction	O
system	O
for	O
reuse	O
.	O

A	O
total	O
of	O
73	O
%	O
of	O
the	O
initial	O
activity	O
was	O
retained	O
after	O
5	O
repeated	O
reuse	O
cycles	O
.	O

This	O
work	O
provides	O
a	O
novel	O
route	O
to	O
preparation	O
of	O
a	O
polyurea	O
porous	O
material	O
and	O
its	O
enzyme	O
immobilization	O
,	O
leading	O
to	O
a	O
novel	O
type	O
of	O
immobilized	O
enzyme	O
for	O
efficient	O
kinetic	B-P
resolution	I-P
of	O
racemic	O
molecules	O
.	O

Magnetic	B-P
Resonance	I-P
Imaging	I-P
Appearance	O
and	O
Mechanism	O
of	O
Action	O
of	O
Five	O
Hemostatic	O
Agents	O
Used	O
in	O
Neurosurgery	O
.	O

To	O
describe	O
the	O
magnetic	O
resonance	O
(	O
MR	O
)	O
image	O
appearance	O
of	O
5	O
hemostatic	O
agents	O
placed	O
in	O
the	O
brain	O
,	O
and	O
to	O
review	O
their	O
clinical	O
application	O
.	O

Descriptive	O
ex	O
vivo	O
and	O
in	O
vivo	O
study	O
.	O

Canine	O
cadavers	O
(	O
n=4	O
)	O
,	O
client-owned	O
dogs	O
(	O
n=4	O
)	O
.	O

Heads	O
from	O
4	O
canine	O
cadavers	O
were	O
used	O
,	O
each	O
with	O
5	O
hemostatic	O
agents	O
placed	O
in	O
specific	O
locations	O
in	O
the	O
brain	O
.	O

Hemostatic	O
agents	O
were	O
used	O
in	O
their	O
native	O
form	O
in	O
2	O
cadaveric	O
brains	O
,	O
and	O
in	O
2	O
others	O
the	O
materials	O
were	O
saturated	O
with	O
fresh	O
whole	O
blood	O
prior	O
to	O
placement	O
to	O
mimic	O
application	O
in	O
a	O
field	O
of	O
active	O
hemorrhage	O
.	O

The	O
heads	O
underwent	O
MR	B-P
imaging	I-P
and	O
the	O
images	O
were	O
reviewed	O
.	O

Postoperative	O
MRI	B-P
images	O
from	O
4	O
dogs	O
undergoing	O
brain	O
tumor	O
resection	O
were	O
retrospectively	O
reviewed	O
and	O
compared	O
to	O
the	O
images	O
from	O
the	O
cadavers	O
.	O

All	O
clinical	O
cases	O
and	O
cadaveric	O
specimens	O
underwent	O
surgical	O
closure	O
prior	O
to	O
MR	B-P
imaging	I-P
including	O
placement	O
of	O
titanium	O
mesh	O
over	O
the	O
craniotomy	O
defect	O
with	O
a	O
dural	O
graft	O
of	O
porcine	O
small	O
intestinal	O
submucosa	O
(	O
SIS	O
)	O
sealed	O
with	O
Tisseel	O
(	O
fibrin	O
sealant	O
)	O
.	O

The	O
SIS	O
and	O
Tisseel	O
used	O
in	O
the	O
dural	O
graft	O
were	O
consistently	O
indistinguishable	O
from	O
the	O
surrounding	O
tissues	O
on	O
MR	O
images	O
.	O

The	O
MR	B-P
imaging	I-P
appearance	O
of	O
the	O
remaining	O
4	O
hemostatic	O
agents	O
(	O
Gelfoam	O
,	O
Avitene	O
,	O
Surgicel	O
,	O
and	O
Floseal	O
)	O
placed	O
on	O
the	O
surface	O
or	O
in	O
the	O
parenchyma	O
of	O
canine	O
brain	O
,	O
varied	O
with	O
MR	O
sequence	O
weighting	O
and	O
blood	O
saturation	O
.	O

Accurate	O
evaluation	O
of	O
the	O
degree	O
of	O
brain	O
tumor	O
resection	O
on	O
postoperative	O
MR	O
images	O
requires	O
careful	O
differentiation	O
between	O
hemorrhage	O
,	O
residual	O
tumor	O
,	O
and	O
hemostatic	O
agents	O
implanted	O
.	O

Recombinant	O
MHC	O
Tetramers	O
for	O
Isolation	O
of	O
Virus	O
-	O
Specific	O
CD8	O
(	O
+	O
)	O
Cells	O
from	O
Healthy	O
Donors	O
:	O
Potential	O
Approach	O
for	O
Cell	O
Therapy	O
of	O
Posttransplant	O
Cytomegalovirus	O
Infection	O
.	O

Patients	O
undergoing	O
allogeneic	O
hematopoietic	O
stem	O
cell	O
transplantation	O
have	O
a	O
high	O
risk	O
of	O
cytomegalovirus	O
reactivation	O
,	O
which	O
in	O
the	O
absence	O
of	O
T-cell	O
immunity	O
can	O
result	O
in	O
the	O
development	O
of	O
an	O
acute	O
inflammatory	O
reaction	O
and	O
damage	O
of	O
internal	O
organs	O
.	O

Transfusion	O
of	O
the	O
virus-specific	O
donor	O
T-lymphocytes	O
represents	O
an	O
alternative	O
to	O
a	O
highly	O
toxic	O
and	O
often	O
ineffective	O
antiviral	O
therapy	O
.	O

Potentially	O
promising	O
cell	O
therapy	O
approach	O
comprises	O
transfusion	O
of	O
cytotoxic	O
T-lymphocytes	O
,	O
specific	O
to	O
the	O
viral	O
antigens	O
,	O
immediately	O
after	O
their	O
isolation	O
from	O
the	O
donor	O
's	O
blood	O
circulation	O
without	O
any	O
in	O
vitro	O
expansion	O
.	O

Specific	O
T-cells	O
could	O
be	O
separated	O
from	O
potentially	O
alloreactive	O
lymphocytes	O
using	O
recombinant	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
multimers	O
,	O
carrying	O
synthetic	O
viral	O
peptides	O
.	O

Rapid	O
transfusion	O
of	O
virus	O
-	O
specific	O
T-cells	O
to	O
patients	O
has	O
several	O
crucial	O
advantages	O
in	O
comparison	O
with	O
methods	O
based	O
on	O
the	O
in	O
vitro	O
expansion	O
of	O
the	O
cells	O
.	O

About	O
30	O
%	O
of	O
hematopoietic	O
stem	O
cell	O
donors	O
and	O
46	O
%	O
of	O
transplant	O
recipients	O
at	O
the	O
National	O
Research	O
Center	O
for	O
Hematology	O
were	O
carriers	O
of	O
the	O
HLA-A*02	O
allele	O
.	O

Moreover	O
,	O
94	O
%	O
of	O
Russian	O
donors	O
have	O
an	O
immune	O
response	O
against	O
the	O
cytomegalovirus	O
(	O
CMV	O
)	O
.	O

Using	O
recombinant	O
HLA-A*02	O
multimers	O
carrying	O
an	O
immunodominant	O
cytomegalovirus	O
peptide	O
(	O
NLV	O
)	O
,	O
we	O
have	O
shown	O
that	O
the	O
majority	O
of	O
healthy	O
donors	O
have	O
pronounced	O
T-cell	O
immunity	O
against	O
this	O
antigen	O
,	O
whereas	O
shortly	O
after	O
the	O
transplantation	O
the	O
patients	O
do	O
not	O
have	O
specific	O
T-lymphocytes	O
.	O

The	O
donor	O
cells	O
have	O
the	O
immune	O
phenotype	O
of	O
memory	O
cells	O
and	O
can	O
be	O
activated	O
and	O
proliferate	O
after	O
stimulation	O
with	O
the	O
specific	O
antigen	O
.	O

Donor	O
lymphocytes	O
can	O
be	O
substantially	O
enriched	O
to	O
significant	O
purity	O
by	O
magnetic	B-P
separation	I-P
with	O
recombinant	O
MHC	O
multimers	O
and	O
are	O
not	O
activated	O
upon	O
cocultivation	B-P
with	O
the	O
antigen	O
-presenting	O
cells	O
from	O
HLA	O
-	O
incompatible	O
donors	O
without	O
addition	O
of	O
the	O
specific	O
antigen	O
.	O

This	O
study	O
demonstrated	O
that	O
strong	O
immune	O
response	O
to	O
CMV	O
of	O
healthy	O
donors	O
and	O
prevalence	O
of	O
HLA-A*02	O
allele	O
in	O
the	O
Russian	O
population	O
make	O
it	O
possible	O
to	O
isolate	O
a	O
significant	O
number	O
of	O
virus-specific	O
cells	O
using	O
HLA-A*02-NLV	O
multimers	O
.	O

After	O
the	O
transfusion	O
,	O
these	O
cells	O
should	O
protect	O
patients	O
from	O
CMV	O
without	O
development	O
of	O
allogeneic	O
immune	O
response	O
.	O

Role	O
of	O
endoscopy	B-P
in	O
primary	O
sclerosing	O
cholangitis	O
:	O
European	O
Society	O
of	O
Gastrointestinal	O
Endoscopy	O
(	O
ESGE	O
)	O
and	O
European	O
Association	O
for	O
the	O
Study	O
of	O
the	O
Liver	O
(	O
EASL	O
)	O
Clinical	O
Guideline	O
.	O

1	O
ESGE	O
/	O
EASL	O
recommend	O
that	O
,	O
as	O
the	O
primary	O
diagnostic	B-P
modality	O
for	O
PSC	O
,	O
magnetic	B-P
resonance	I-P
cholangiography	I-P
(	O
MRC	B-P
)	O
should	O
be	O
preferred	O
over	O
endoscopic	B-P
retrograde	I-P
cholangiopancreatography	I-P
(	O
ERCP	B-P
)	O
.	O

Moderate	O
quality	O
evidence	O
,	O
strong	O
recommendation	O
.	O

2	O
ESGE	O
/	O
EASL	O
suggest	O
that	O
ERCP	B-P
can	O
be	O
considered	O
if	O
MRC	B-P
plus	O
liver	B-P
biopsy	I-P
is	O
equivocal	O
or	O
contraindicated	O
in	O
patients	O
with	O
persisting	O
clinical	O
suspicion	O
of	O
PSC	O
.	O

The	O
risks	O
of	O
ERCP	B-P
have	O
to	O
be	O
weighed	O
against	O
the	O
potential	O
benefit	O
with	O
regard	O
to	O
surveillance	O
and	O
treatment	O
recommendations	O
.	O

Low	O
quality	O
evidence	O
,	O
weak	O
recommendation	O
.	O

6	O
ESGE	O
/	O
EASL	O
suggest	O
that	O
,	O
in	O
patients	O
with	O
an	O
established	O
diagnosis	O
of	O
PSC	O
,	O
MRC	B-P
should	O
be	O
considered	O
before	O
therapeutic	O
ERCP	B-P
.	O

Weak	O
recommendation	O
,	O
low	O
quality	O
evidence	O
.	O

7	O
ESGE	O
/	O
EASL	O
suggest	O
performing	O
endoscopic	B-P
treatment	O
with	O
concomitant	O
ductal	O
sampling	O
(	O
brush	O
cytology	O
,	O
endobiliary	O
biopsies	O
)	O
of	O
suspected	O
significant	O
strictures	O
identified	O
at	O
MRC	B-P
in	O
PSC	O
patients	O
who	O
present	O
with	O
symptoms	O
likely	O
to	O
improve	O
following	O
endoscopic	B-P
treatment	O
.	O

Strong	O
recommendation	O
,	O
low	O
quality	O
evidence	O
.	O

9	O
ESGE	O
/	O
EASL	O
recommend	O
weighing	O
the	O
anticipated	O
benefits	O
of	O
biliary	O
papillotomy	O
/	O
sphincterotomy	O
against	O
its	O
risks	O
on	O
a	O
case-by-case	O
basis	O
.	O

Strong	O
recommendation	O
,	O
moderate	O
quality	O
evidence	O
.	O

Biliary	O
papillotomy	O
/	O
sphincterotomy	O
should	O
be	O
considered	O
especially	O
after	O
difficult	O
cannulation	O
.	O

Strong	O
recommendation	O
,	O
low	O
quality	O
evidence	O
.	O

16	O
ESGE	O
/	O
EASL	O
suggest	O
routine	O
administration	O
of	O
prophylactic	O
antibiotics	O
before	O
ERCP	B-P
in	O
patients	O
with	O
PSC	O
.	O

Strong	O
recommendation	O
,	O
low	O
quality	O
evidence	O
.	O

17	O
EASL	O
/	O
ESGE	O
recommend	O
that	O
cholangiocarcinoma	O
(	O
CCA	O
)	O
should	O
be	O
suspected	O
in	O
any	O
patient	O
with	O
worsening	O
cholestasis	O
,	O
weight	O
loss	O
,	O
raised	O
serum	O
CA19-9	B-P
,	O
and/or	O
new	O
or	O
progressive	O
dominant	O
stricture	O
,	O
particularly	O
with	O
an	O
associated	O
enhancing	O
mass	O
lesion	O
.	O

Strong	O
recommendation	O
,	O
moderate	O
quality	O
evidence	O
.	O

19	O
ESGE	O
/	O
EASL	O
recommend	O
ductal	O
sampling	O
(	O
brush	O
cytology	O
,	O
endobiliary	O
biopsies	O
)	O
as	O
part	O
of	O
the	O
initial	O
investigation	O
for	O
the	O
diagnosis	O
and	O
staging	B-P
of	O
suspected	O
CCA	O
in	O
patients	O
with	O
PSC	O
.	O

Strong	O
recommendation	O
,	O
high	O
quality	O
evidence	O
.	O

Severe	O
respiratory	O
depression	O
and	O
bradycardia	O
before	O
induction	O
of	O
anesthesia	O
and	O
onset	O
of	O
Takotsubo	O
cardiomyopathy	O
after	O
cardiopulmonary	O
resuscitation	O
.	O

A	O
69-	O
year	O
-old	O
woman	O
undergoing	O
treatment	O
for	O
hypertension	O
and	O
epilepsy	O
was	O
scheduled	O
to	O
undergo	O
cataract	O
surgery	O
.	O

All	O
preoperative	O
examination	O
results	O
were	O
within	O
normal	O
limits	O
.	O

Despite	O
being	O
tense	O
,	O
she	O
walked	O
to	O
the	O
operating	O
room	O
.	O

Approximately	O
2	O
minutes	O
after	O
an	O
intravenous	O
line	O
was	O
established	O
by	O
an	O
anesthesia	O
resident	O
,	O
severe	O
hypoxia	O
and	O
bradycardia	O
developed	O
,	O
and	O
she	O
lost	O
consciousness	O
.	O

Cardiopulmonary	O
resuscitation	O
was	O
initiated	O
immediately	O
,	O
and	O
after	O
1	O
minute	O
,	O
she	O
regained	O
consciousness	O
,	O
and	O
her	O
breathing	O
and	O
circulation	O
recovered	O
.	O

After	O
admission	O
to	O
the	O
intensive	O
care	O
unit	O
,	O
emergency	O
coronary	B-P
angiography	I-P
was	O
performed	O
.	O

The	O
blood	O
flow	O
in	O
all	O
the	O
coronary	O
arteries	O
was	O
normal	O
.	O

However	O
,	O
a	O
decrease	O
in	O
the	O
apical	O
left	O
ventricular	O
wall	O
motion	O
and	O
an	O
increase	O
in	O
the	O
basal	O
wall	O
motion	O
were	O
observed	O
.	O

Based	O
on	O
these	O
findings	O
,	O
Takotsubo	O
cardiomyopathy	O
was	O
diagnosed	O
.	O

The	O
wall	O
motion	O
gradually	O
improved	O
and	O
the	O
patient	O
was	O
discharged	O
from	O
the	O
hospital	O
on	O
postoperative	O
day	O
15	O
.	O

The	O
respiratory	O
depression	O
and	O
bradycardia	O
were	O
thought	O
to	O
be	O
due	O
to	O
an	O
inadvertent	O
bolus	O
of	O
remifentanil	O
.	O

We	O
surmised	O
that	O
the	O
patient	O
had	O
received	O
a	O
slight	O
amount	O
of	O
retained	O
medication	O
when	O
the	O
anesthesia	O
resident	O
established	O
the	O
intravenous	O
line	O
,	O
which	O
caused	O
severe	O
respiratory	O
depression	O
.	O

It	O
is	O
important	O
to	O
note	O
that	O
adverse	O
effects	O
such	O
as	O
severe	O
respiratory	O
depression	O
and	O
bradycardia	O
can	O
be	O
caused	O
by	O
even	O
small	O
doses	O
of	O
remifentanil	O
.	O

Alleviation	O
of	O
hepatic	O
fat	O
accumulation	O
by	O
betaine	O
involves	O
reduction	O
of	O
homocysteine	O
via	O
up-regulation	O
of	O
betaine-homocysteine	O
methyltransferase	O
(	O
BHMT	O
)	O
.	O

We	O
investigated	O
the	O
anti-lipogenic	O
effect	O
of	O
betaine	O
in	O
rats	O
fed	O
methionine	O
and	O
choline	O
-	O
deficient	O
diet	O
(	O
MCD	O
)	O
.	O

Intake	O
of	O
MCD	O
for	O
3	O
wk	O
resulted	O
in	O
a	O
significant	O
accumulation	O
of	O
hepatic	O
lipids	O
,	O
which	O
was	O
prevented	O
by	O
betaine	O
supplementation	O
in	O
drinking	O
water	O
(	O
1	O
%	O
)	O
.	O

Phosphorylation	O
of	O
AMP-activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
,	O
acetyl-CoA	O
carboxylase	O
(	O
ACC	O
)	O
,	O
sterol	O
regulatory	O
element-binding	O
protein	O
1c	O
(	O
SREBP-1c	O
)	O
,	O
and	O
liver	O
kinase	O
B1	O
(	O
LKB1	O
)	O
was	O
inhibited	O
by	O
MCD	O
intake	O
,	O
and	O
these	O
changes	O
were	O
all	O
inhibited	O
by	O
betaine	O
feeding	O
.	O

Meanwhile	O
,	O
betaine	O
supplementation	O
reversed	O
the	O
reduction	O
of	O
methionine	O
and	O
S-adenosylmethionine	O
(	O
SAM	O
)	O
,	O
and	O
the	O
elevation	O
of	O
homocysteine	B-P
levels	I-P
in	O
the	O
liver	O
,	O
which	O
could	O
be	O
attributable	O
to	O
the	O
induction	O
of	O
betaine-homocysteine	O
methyltransfease	O
(	O
BHMT	O
)	O
and	O
methionine	O
adenosyltransferase	O
(	O
MAT	O
)	O
.	O

Different	O
cell	O
lines	O
were	O
used	O
to	O
clarify	O
the	O
role	O
of	O
homocysteine	O
on	O
activation	O
of	O
the	O
AMPK	O
pathway	O
.	O

Homocysteine	O
treatment	O
decreased	O
pAMPK	O
,	O
pACC	O
,	O
pSREBP-1c	O
and	O
pLKB1	O
in	O
HepG2	O
cells	O
.	O

Metformin	O
-	O
induced	O
activation	O
of	O
AMPK	O
was	O
also	O
inhibited	O
by	O
homocysteine	O
.	O

Treatment	O
with	O
hydroxylamine	O
,	O
a	O
cystathionine	O
β-synthase	O
inhibitor	O
,	O
resulted	O
in	O
a	O
reduction	O
of	O
pAMPK	O
,	O
pACC	O
and	O
pSREBP-1c	O
,	O
accompanied	O
by	O
an	O
elevation	O
of	O
intracellular	O
homocysteine	O
.	O

Betaine	O
treatment	O
prevented	O
the	O
homocysteine	O
-	O
induced	O
reduction	O
of	O
pAMPK	O
,	O
pACC	O
,	O
pSREBP-1c	O
and	O
pLKB1	O
in	O
H4IIE	O
cells	O
,	O
but	O
not	O
in	O
HepG2	O
cells	O
.	O

Also	O
the	O
elevation	O
of	O
cellular	O
homocysteine	O
and	O
inhibition	O
of	O
protein	O
expression	O
of	O
BHMT	O
were	O
prevented	O
by	O
betaine	O
only	O
in	O
H4IIE	O
cells	O
which	O
express	O
BHMT	O
.	O

The	O
results	O
suggest	O
that	O
the	O
beneficial	O
effect	O
of	O
betaine	O
against	O
hepatic	O
lipid	O
accumulation	O
may	O
be	O
attributed	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
the	O
depletion	O
of	O
homocysteine	O
via	O
up-regulation	O
of	O
BHMT	O
in	O
hepatocytes	O
.	O

Safety	O
and	O
Efficacy	O
of	O
Flexible	O
Ureteroscopy	O
in	O
Combination	O
with	O
Holmium	O
Laser	O
Lithotripsy	O
for	O
the	O
Treatment	O
of	O
Bilateral	O
Upper	O
Urinary	O
Tract	O
Calculi	O
.	O

To	O
retrospectively	O
evaluate	O
the	O
safety	O
and	O
efficacy	O
of	O
flexible	O
ureteroscopy	O
(	O
FURS	O
)	O
in	O
combination	O
with	O
holmium	O
laser	O
lithotripsy	O
for	O
the	O
treatment	O
of	O
bilateral	O
upper	O
urinary	O
calculi	O
.	O

The	O
stone-free	O
status	O
was	O
defined	O
as	O
the	O
absence	O
of	O
any	O
stones	O
or	O
asymptomatic	O
status	O
,	O
or	O
the	O
presence	O
of	O
clinically	O
insignificant	O
residual	O
fragments	O
<	O
4	O
mm	O
,	O
and	O
was	O
assessed	O
by	O
plain	O
kidney	O
,	O
ureter	O
,	O
and	O
bladder	B-P
X-ray	I-P
.	O

The	O
operative	O
time	O
,	O
stone-free	O
rates	O
(	O
SFRs	O
)	O
,	O
serum	B-P
creatinine	I-P
(	O
SCr	B-P
)	O
,	O
and	O
complications	O
were	O
recorded	O
.	O

During	O
the	O
operation	O
,	O
there	O
was	O
no	O
bleeding	O
,	O
ureteral	O
perforation	O
,	O
avulsion	O
,	O
and	O
rupture	O
.	O

Postoperative	O
hematuria	O
was	O
observed	O
in	O
2	O
patients	O
.	O

SCr	B-P
increased	O
significantly	O
on	O
the	O
first	O
day	O
after	O
the	O
procedure	O
compared	O
with	O
the	O
preoperative	O
SCr	B-P
,	O
but	O
after	O
4	O
weeks	O
,	O
the	O
renal	O
function	O
significantly	O
improved	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
SFR	O
was	O
71.6	O
%	O
(	O
63/88	O
)	O
on	O
the	O
first	O
day	O
after	O
the	O
first	O
surgical	O
procedure	O
;	O
it	O
then	O
increased	O
to	O
86.4	O
%	O
(	O
76/88	O
)	O
in	O
the	O
fourth	O
week	O
,	O
and	O
rose	O
to	O
97.4	O
%	O
(	O
76/78	O
)	O
after	O
the	O
second	O
operation	O
.	O

The	O
results	O
demonstrated	O
that	O
FURS	O
in	O
combination	O
with	O
holmium	O
laser	O
lithotripsy	O
represented	O
a	O
favorable	O
less-invasive	O
alternative	O
with	O
high	O
SFR	O
and	O
acceptable	O
complication	O
rates	O
in	O
the	O
treatment	O
of	O
bilateral	O
upper	O
urinary	O
tract	O
calculi	O
.	O

Comprehensive	O
genetic	O
characterization	O
of	O
rosette-forming	O
glioneuronal	O
tumors	O
:	O
independent	O
component	O
analysis	O
by	O
tissue	O
microdissection	B-P
.	O

A	O
rosette-forming	O
glioneuronal	O
tumor	O
(	O
RGNT	O
)	O
is	O
a	O
rare	O
mixed	O
neuronal-glial	O
tumor	O
characterized	O
by	O
biphasic	O
architecture	O
of	O
glial	O
and	O
neurocytic	O
components	O
.	O

The	O
number	O
of	O
reports	O
of	O
genetic	B-P
analyses	I-P
of	O
RGNTs	O
is	O
few	O
.	O

Additionally	O
,	O
the	O
genetic	O
background	O
of	O
the	O
unique	O
biphasic	O
pathological	O
characteristics	O
of	O
such	O
mixed	O
neuronal-glial	O
tumors	O
remains	O
unclear	O
.	O

To	O
clarify	O
the	O
genetic	O
background	O
of	O
RGNTs	O
,	O
we	O
performed	O
separate	O
comprehensive	O
genetic	B-P
analyses	I-P
of	O
glial	O
and	O
neurocytic	O
components	O
of	O
five	O
RGNTs	O
,	O
by	O
tissue	O
microdissection	B-P
.	O

Two	O
missense	O
mutations	O
in	O
FGFR1	O
in	O
both	O
components	O
of	O
two	O
cases	O
,	O
and	O
one	O
mutation	O
in	O
PIK3CA	O
in	O
both	O
components	O
of	O
one	O
case	O
,	O
were	O
detected	O
.	O

In	O
the	O
latter	O
case	O
with	O
PIK3CA	O
mutation	O
,	O
the	O
additional	O
FGFR1	O
mutation	O
was	O
detected	O
only	O
in	O
the	O
glial	O
component	O
.	O

Moreover	O
,	O
the	O
loss	O
of	O
chromosome	O
13q	O
in	O
only	O
the	O
neurocytic	O
component	O
was	O
observed	O
in	O
one	O
other	O
case	O
.	O

Their	O
results	O
suggested	O
that	O
RGNTs	O
,	O
which	O
are	O
tumors	O
harboring	O
two	O
divergent	O
differentiations	O
that	O
arose	O
from	O
a	O
single	O
clone	O
,	O
have	O
a	O
diverse	O
genetic	O
background	O
.	O

Although	O
previous	O
studies	O
have	O
suggested	O
that	O
RGNTs	O
and	O
pilocytic	O
astrocytomas	O
(	O
PAs	O
)	O
represent	O
the	O
same	O
tumor	O
entity	O
,	O
their	O
results	O
confirm	O
that	O
the	O
genetic	O
background	O
of	O
RGNTs	O
is	O
not	O
identical	O
to	O
that	O
of	O
PA	O
.	O

Increase	O
in	O
acid	O
sphingomyelinase	O
level	O
in	O
human	O
retinal	O
endothelial	O
cells	O
and	O
CD34	O
(	O
+	O
)	O
circulating	O
angiogenic	O
cells	O
isolated	O
from	O
diabetic	O
individuals	O
is	O
associated	O
with	O
dysfunctional	O
retinal	O
vasculature	O
and	O
vascular	O
repair	O
process	O
in	O
diabetes	O
.	O

Diabetic	O
retinopathy	O
is	O
a	O
microvascular	O
disease	O
that	O
results	O
from	O
retinal	O
vascular	O
degeneration	O
and	O
defective	O
repair	O
due	O
to	O
diabetes	O
-	O
induced	O
endothelial	O
progenitor	O
dysfunction	O
.	O

Understanding	O
key	O
molecular	O
factors	O
involved	O
in	O
vascular	O
degeneration	O
and	O
repair	O
is	O
paramount	O
for	O
developing	O
effective	O
diabetic	O
retinopathy	O
treatment	O
strategies	O
.	O

We	O
propose	O
that	O
diabetes	O
-	O
induced	O
activation	O
of	O
acid	O
sphingomyelinase	O
(	O
ASM	O
)	O
plays	O
essential	O
role	O
in	O
retinal	O
endothelial	O
and	O
CD34	O
(	O
+	O
)	O
circulating	O
angiogenic	O
cell	O
(	O
CAC	O
)	O
dysfunction	O
in	O
diabetes	O
.	O

Human	O
retinal	O
endothelial	O
cells	O
(	O
HRECs	O
)	O
isolated	O
from	O
control	O
and	O
diabetic	O
donor	O
tissue	O
and	O
human	O
CD34	O
(	O
+	O
)	O
CACs	O
from	O
control	O
and	O
diabetic	O
patients	O
were	O
used	O
in	O
this	O
study	O
.	O

ASM	O
messenger	O
RNA	O
and	O
protein	O
expression	O
were	O
assessed	O
by	O
quantitative	O
polymerase	O
chain	O
reaction	O
and	O
enzyme-linked	B-P
immunosorbent	I-P
assay	I-P
,	O
respectively	O
.	O

To	O
evaluate	O
the	O
effect	O
of	O
diabetes	O
-	O
induced	O
ASM	O
on	O
HRECs	O
and	O
CD34	O
(	O
+	O
)	O
CACs	O
function	O
,	O
tube	O
formation	O
,	O
CAC	O
incorporation	O
into	O
endothelial	O
tubes	O
,	O
and	O
diurnal	O
release	O
of	O
CD34	O
(	O
+	O
)	O
CACs	O
in	O
diabetic	O
individuals	O
were	O
determined	O
.	O

ASM	O
expression	O
level	O
was	O
significantly	O
increased	O
in	O
HRECs	O
isolated	O
from	O
diabetic	O
compared	O
with	O
control	O
donor	O
tissue	O
,	O
as	O
well	O
as	O
CD34	O
(	O
+	O
)	O
CACs	O
and	O
plasma	O
of	O
diabetic	O
patients	O
.	O

A	O
significant	O
decrease	O
in	O
tube	O
area	O
was	O
observed	O
in	O
HRECs	O
from	O
diabetic	O
donors	O
compared	O
with	O
control	O
HRECs	O
.	O

The	O
tube	O
formation	O
deficiency	O
was	O
associated	O
with	O
increased	O
expression	O
of	O
ASM	O
in	O
diabetic	O
HRECs	O
.	O

Moreover	O
,	O
diabetic	O
CD34	O
(	O
+	O
)	O
CACs	O
with	O
high	O
ASM	O
showed	O
defective	O
incorporation	O
into	O
endothelial	O
tubes	O
.	O

Diurnal	O
release	O
of	O
CD34	O
(	O
+	O
)	O
CACs	O
was	O
disrupted	O
with	O
the	O
rhythmicity	O
lost	O
in	O
diabetic	O
patients	O
.	O

Collectively	O
,	O
these	O
findings	O
support	O
that	O
diabetes	O
-	O
induced	O
ASM	O
upregulation	O
has	O
a	O
marked	O
detrimental	O
effect	O
on	O
both	O
retinal	O
endothelial	O
cells	O
and	O
CACs	O
.	O

A	O
comparative	O
study	O
of	O
glycerol	O
and	O
sorbitol	O
as	O
co-substrates	O
in	O
methanol	O
-	O
induced	O
cultures	B-P
of	O
Pichia	O
pastoris	O
:	O
temperature	O
effect	O
and	O
scale-up	O
simulation	O
.	O

The	O
production	O
of	O
recombinant	O
proteins	O
by	O
Pichia	O
pastoris	O
under	O
AOX1	O
promoter	O
is	O
usually	O
performed	O
using	O
methanol	O
together	O
with	O
either	O
glycerol	O
or	O
sorbitol	O
as	O
co-substrate	O
.	O

Although	O
both	O
co-substrates	O
have	O
been	O
widely	O
used	O
,	O
comparative	O
studies	O
are	O
scarce	O
.	O

In	O
addition	O
,	O
these	O
comparisons	O
have	O
been	O
performed	O
at	O
different	O
specific	O
growth	O
rate	O
(	O
µ	O
)	O
that	O
it	O
is	O
well	O
known	O
that	O
has	O
an	O
important	O
effect	O
on	O
productivity	O
.	O

Thus	O
,	O
the	O
effect	O
of	O
using	O
these	O
co-substrates	O
on	O
the	O
production	O
of	O
Rhyzopus	O
oryzae	O
lipase	O
(	O
ROL	O
)	O
by	O
P.	O
pastoris	O
was	O
compared	O
in	O
continuous	O
cultures	B-P
growing	O
at	O
the	O
same	O
µ	O
at	O
either	O
22	O
or	O
30	O
°C	O
.	O

Results	O
show	O
that	O
using	O
glycerol	O
as	O
co-substrate	O
led	O
to	O
higher	O
volumetric	O
productivities	O
,	O
and	O
lower	O
specific	O
and	O
volumetric	O
methanol	O
consumption	O
rates	O
.	O

Scale-up	O
simulation	O
with	O
10-10,000	O
L	O
bioreactor	O
sizes	O
indicated	O
that	O
glycerol	O
produced	O
the	O
highest	O
volumetric	O
productivity	O
of	O
ROL	O
with	O
lower	O
aeration	O
requirements	O
.	O

Therefore	O
,	O
glycerol	O
rises	O
as	O
a	O
better	O
option	O
than	O
sorbitol	O
in	O
ROL	O
production	O
.	O

Structural	O
and	O
functional	O
characterization	O
of	O
the	O
TYW3	O
/	O
Taw3	O
class	O
of	O
SAM-dependent	O
methyltransferases	O
.	O

S-adenosylmethionine	O
(	O
SAM	O
)	O
-dependent	O
methyltransferases	O
regulate	O
a	O
wide	O
range	O
of	O
biological	O
processes	O
through	O
the	O
modification	O
of	O
proteins	O
,	O
nucleic	O
acids	O
,	O
polysaccharides	O
,	O
as	O
well	O
as	O
various	O
metabolites	O
.	O

TYW3	O
/	O
Taw3	O
is	O
a	O
SAM-dependent	O
methyltransferase	O
responsible	O
for	O
the	O
formation	O
of	O
a	O
tRNA	O
modification	O
known	O
as	O
wybutosine	O
and	O
its	O
derivatives	O
that	O
are	O
required	O
for	O
accurate	O
decoding	O
in	O
protein	O
synthesis	O
.	O

Here	O
,	O
we	O
report	O
the	O
crystal	O
structure	O
of	O
Taw3	O
,	O
a	O
homolog	O
of	O
TYW3	O
from	O
Sulfolobus	O
solfataricus	O
,	O
which	O
revealed	O
a	O
novel	O
α/β	O
fold	O
.	O

The	O
sequence	O
motif	O
(	O
S/T	O
)	O
xSSCxGR	O
and	O
invariant	O
aspartate	O
and	O
histidine	O
,	O
conserved	O
in	O
TYW3	O
/	O
Taw3	O
,	O
cluster	O
to	O
form	O
the	O
catalytic	O
center	O
.	O

These	O
structural	O
and	O
sequence	O
features	O
indicate	O
that	O
TYW3	O
/	O
Taw3	O
proteins	O
constitute	O
a	O
distinct	O
class	O
of	O
SAM-dependent	O
methyltransferases	O
.	O

Using	O
site-directed	O
mutagenesis	O
along	O
with	O
in	O
vivo	O
complementation	O
assays	O
combined	O
with	O
mass	B-P
spectrometry	I-P
as	O
well	O
as	O
ligand	O
docking	O
and	O
cofactor	O
binding	O
assays	B-P
,	O
we	O
have	O
identified	O
the	O
active	O
site	O
of	O
TYW3	O
and	O
residues	O
essential	O
for	O
cofactor	O
binding	O
and	O
methyltransferase	O
activity	O
.	O

Phase	O
I	O
Dose-Escalation	O
Study	O
of	O
Pilaralisib	O
(	O
SAR245408	O
,	O
XL147	O
)	O
in	O
Combination	O
with	O
Paclitaxel	O
and	O
Carboplatin	O
in	O
Patients	O
with	O
Solid	O
Tumors	O
.	O

Despite	O
involvement	O
of	O
PI3K	O
pathway	O
activation	O
in	O
tumorigenesis	O
of	O
solid	O
tumors	O
,	O
single-agent	O
PI3K	O
inhibitors	O
have	O
shown	O
modest	O
clinical	O
activity	O
.	O

Preclinical	O
evidence	O
suggests	O
that	O
combining	O
PI3K	O
pathway	O
inhibitors	O
and	O
chemotherapy	O
can	O
enhance	O
antitumor	O
effects	O
.In	O
patients	O
with	O
solid	O
tumors	O
,	O
the	O
PI3K	O
inhibitor	O
pilaralisib	O
had	O
a	O
favorable	O
safety	O
profile	B-P
but	O
did	O
not	O
enhance	O
the	O
antitumor	O
activity	O
of	O
paclitaxel	O
plus	O
carboplatin	O
.Further	O
clinical	O
evaluation	O
is	O
warranted	O
to	O
identify	O
effective	O
combination	O
strategies	O
with	O
PI3K	O
pathway	O
inhibitors	O
.	O

Pilaralisib	O
(	O
SAR245408	O
)	O
is	O
an	O
oral	O
,	O
pan-class	O
I	O
phosphoinositide	O
3-kinase	O
(	O
PI3K	O
)	O
inhibitor	O
.	O

This	O
phase	O
I	O
dose-escalation	O
study	O
evaluated	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
,	O
safety	O
,	O
pharmacokinetics	O
(	O
PK	O
)	O
,	O
and	O
pharmacodynamics	O
of	O
pilaralisib	O
in	O
capsule	O
and	O
tablet	O
formulations	O
,	O
administered	O
in	O
combination	O
with	O
paclitaxel	O
and	O
carboplatin	O
in	O
patients	O
with	O
advanced	O
solid	O
tumors	O
.	O

A	O
3	O
+	O
3	O
design	O
was	O
used	O
.	O

Pilaralisib	O
was	O
administered	O
once	O
daily	O
(	O
QD	O
)	O
;	O
paclitaxel	O
(	O
up	O
to	O
175	O
mg/m	O
(	O
2	O
)	O
)	O
and	O
carboplatin	O
(	O
up	O
to	O
area	O
under	O
the	O
curve	O
[	O
AUC	O
]	O
of	O
6	O
)	O
were	O
administered	O
on	O
day	O
1	O
of	O
21-day	O
cycles	O
.	O

An	O
MTD	O
expansion	O
cohort	O
of	O
patients	O
with	O
endometrial	O
carcinoma	O
was	O
included	O
.	O

Fifty-eight	O
patients	O
were	O
enrolled	O
.	O

Six	O
patients	O
(	O
10.3	O
%	O
)	O
had	O
dose-limiting	O
toxicities	O
,	O
of	O
which	O
only	O
rash	O
(	O
two	O
patients	O
,	O
3.4	O
%	O
)	O
occurred	O
in	O
more	O
than	O
one	O
patient	O
.	O

The	O
MTD	O
of	O
pilaralisib	O
tablets	O
in	O
combination	O
with	O
paclitaxel	O
and	O
carboplatin	O
was	O
determined	O
to	O
be	O
200	O
mg	O
QD	O
.	O

The	O
most	O
frequently	O
reported	O
adverse	O
events	O
(	O
AEs	O
)	O
of	O
any	O
grade	O
were	O
neutropenia	O
(	O
67.2	O
%	O
)	O
and	O
thrombocytopenia	O
(	O
67.2	O
%	O
)	O
.	O

PK	O
data	O
showed	O
no	O
interaction	O
between	O
pilaralisib	O
and	O
paclitaxel/carboplatin	O
.	O

Tumor	O
tissue	O
showed	O
moderate	O
inhibition	O
of	O
PI3K	O
and	O
mitogen-activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
pathways	O
.	O

Seven	O
of	O
52	O
evaluable	O
patients	O
had	O
a	O
partial	O
response	O
(	O
PR	O
;	O
13.5	O
%	O
)	O
.	O

Pilaralisib	O
had	O
a	O
favorable	O
safety	O
profile	B-P
but	O
did	O
not	O
enhance	O
the	O
antitumor	O
activity	O
of	O
paclitaxel	O
plus	O
carboplatin	O
in	O
solid	O
tumors	O
.	O

The	O
Oncologist	O
2017	O
;	O
22:377-378	O
.	O

Molecular	O
mechanisms	O
of	O
thermal	O
resistance	O
of	O
the	O
insect	O
trypanosomatid	O
Crithidia	O
thermophila	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
investigated	O
molecular	O
mechanisms	O
governing	O
thermal	O
resistance	O
of	O
a	O
monoxenous	O
trypanosomatid	O
Crithidia	O
luciliae	O
thermophila	O
,	O
which	O
we	O
reclassified	O
as	O
a	O
separate	O
species	O
C.	O
thermophila	O
.	O

We	O
analyzed	O
morphology	O
,	O
growth	O
kinetics	O
,	O
and	O
transcriptomic	O
profiles	O
of	O
flagellates	O
cultivated	O
at	O
low	O
(	O
23°C	O
)	O
and	O
elevated	O
(	O
34°C	O
)	O
temperature	O
.	O

When	O
maintained	O
at	O
high	O
temperature	O
,	O
they	O
grew	O
significantly	O
faster	O
,	O
became	O
shorter	O
,	O
with	O
genes	O
involved	O
in	O
sugar	B-P
metabolism	I-P
and	O
mitochondrial	O
stress	O
protection	O
significantly	O
upregulated	O
.	O

Comparison	O
with	O
another	O
thermoresistant	O
monoxenous	O
trypanosomatid	O
,	O
Leptomonas	O
seymouri	O
,	O
revealed	O
dramatic	O
differences	O
in	O
transcription	O
profiles	O
of	O
the	O
two	O
species	O
with	O
only	O
few	O
genes	O
showing	O
the	O
same	O
expression	O
pattern	O
.	O

This	O
disparity	O
illustrates	O
differences	O
in	O
the	O
biology	O
of	O
these	O
two	O
parasites	O
and	O
distinct	O
mechanisms	O
of	O
their	O
thermotolerance	O
,	O
a	O
prerequisite	O
for	O
living	O
in	O
warm-blooded	O
vertebrates	O
.	O

Renieramycin	O
M	O
Attenuates	O
Cancer	O
Stem	O
Cell	O
-like	O
Phenotypes	O
in	O
H460	O
Lung	O
Cancer	O
Cells	O
.	O

Cancer	O
stem	O
cells	O
(	O
CSCs	O
)	O
are	O
a	O
subpopulation	O
of	O
cancer	O
cells	O
that	O
possess	O
self-renewal	O
and	O
differentiation	O
capacities	O
.	O

CSCs	O
contribute	O
to	O
drug-resistance	O
,	O
cancer	O
recurrence	O
and	O
metastasis	O
,	O
thus	O
development	O
of	O
CSC	O
-targeted	O
therapeutic	O
strategies	O
has	O
recently	O
received	O
significant	O
attention	O
in	O
cancer	O
research	O
.	O

In	O
this	O
study	O
,	O
the	O
potential	O
efficacy	O
of	O
renieramycin	O
M	O
(	O
RM	O
)	O
isolated	O
from	O
the	O
sponge	O
Xestospongia	O
species	O
,	O
was	O
examined	O
against	O
lung	O
CSCs	O
.	O

Colony	B-P
and	I-P
spheroid	I-P
formation	I-P
assays	I-P
,	O
as	O
well	O
as	O
western	O
blotting	O
analysis	O
of	O
lung	O
CSC	O
protein	O
markers	O
were	O
employed	O
to	O
determine	O
the	O
CSC	O
-like	O
phenotypes	O
of	O
H460	O
lung	O
cancer	O
cells	O
after	O
treatment	O
with	O
RM	O
at	O
non-toxic	O
concentrations	O
.	O

RM	O
treatment	O
reduced	O
significantly	O
colony	B-P
and	I-P
spheroid	I-P
formation	I-P
of	O
H460	O
cells	O
.	O

Moreover	O
,	O
the	O
CSC	O
markers	O
CD133	O
,	O
CD44	O
and	O
ALDH1A1	O
of	O
CSC	O
-enriched	O
H460	O
cells	O
were	O
reduced	O
significantly	O
following	O
RM	O
treatment	O
.	O

RM	O
could	O
be	O
a	O
potent	O
anti-metastatic	O
agent	O
by	O
suppressing	O
lung	O
CSC	O
-like	O
phenotypes	O
in	O
H460	O
cells	O
.	O

EASL	O
Clinical	O
Practice	O
Guidelines	O
:	O
The	O
diagnosis	O
and	O
management	O
of	O
patients	O
with	O
primary	O
biliary	O
cholangitis	O
.	O

Primary	O
biliary	O
cholangitis	O
(	O
PBC	O
)	O
is	O
a	O
chronic	O
inflammatory	O
autoimmune	O
cholestatic	O
liver	O
disease	O
,	O
which	O
when	O
untreated	O
will	O
culminate	O
in	O
end-stage	O
biliary	O
cirrhosis	O
.	O

Diagnosis	O
is	O
usually	O
based	O
on	O
the	O
presence	O
of	O
serum	B-P
liver	I-P
tests	I-P
indicative	O
of	O
a	O
cholestatic	O
hepatitis	O
in	O
association	O
with	O
circulating	O
antimitochondrial	O
antibodies	O
.	O

Patient	O
presentation	O
and	O
course	O
can	O
be	O
diverse	O
and	O
risk	O
stratification	O
is	O
important	O
to	O
ensure	O
all	O
patients	O
receive	O
a	O
personalised	O
approach	O
to	O
their	O
care	O
.	O

The	O
goals	O
of	O
treatment	O
and	O
management	O
are	O
the	O
prevention	O
of	O
end-stage	O
liver	O
disease	O
,	O
and	O
the	O
amelioration	O
of	O
associated	O
symptoms	O
.	O

Pharmacologic	O
approaches	O
in	O
practice	O
,	O
to	O
reduce	O
the	O
impact	O
of	O
the	O
progressive	O
nature	O
of	O
disease	O
,	O
currently	O
include	O
licensed	O
therapies	O
(	O
ursodeoxycholic	O
acid	O
and	O
obeticholic	O
acid	O
)	O
and	O
off-label	O
therapies	O
(	O
fibric	O
acid	O
derivatives	O
,	O
budesonide	O
)	O
.	O

These	O
clinical	O
practice	O
guidelines	O
summarise	O
the	O
evidence	O
for	O
the	O
importance	O
of	O
a	O
structured	O
,	O
life-long	O
and	O
individualised	O
,	O
approach	O
to	O
the	O
care	O
of	O
patients	O
with	O
PBC	O
,	O
providing	O
a	O
framework	O
to	O
help	O
clinicians	O
diagnose	O
and	O
effectively	O
manage	O
patients	O
.	O

Who	O
contributes	O
more	O
to	O
N2O	O
emission	O
during	O
sludge	O
bio-drying	O
with	O
two	O
different	O
aeration	O
strategies	O
,	O
nitrifiers	O
or	O
denitrifiers	O
?	O
.	O

Global	O
warming	O
effects	O
have	O
drawn	O
more	O
and	O
more	O
attention	O
to	O
studying	O
all	O
sources	O
and	O
sinks	O
of	O
nitrous	O
oxide	O
(	O
N2O	O
)	O
.	O

Sludge	O
bio-drying	O
,	O
as	O
an	O
effective	O
sludge	O
treatment	O
technology	O
,	O
is	O
being	O
adopted	O
worldwide	O
.	O

In	O
this	O
study	O
,	O
two	O
aeration	O
strategies	O
(	O
piles	O
I	O
and	O
II	O
)	O
were	O
compared	O
to	O
investigate	O
the	O
primary	O
contributors	O
to	O
N2O	O
emission	O
during	O
sludge	O
bio-drying	O
through	O
studying	O
the	O
evolution	O
of	O
functional	O
genes	O
involved	O
in	O
nitrification	O
(	O
amoA	O
,	O
hao	O
,	O
and	O
nxrA	O
)	O
and	O
denitrification	O
(	O
narG	O
,	O
nirS	O
,	O
nirK	O
,	O
norB	O
,	O
and	O
nosZ	O
)	O
by	O
quantitative	B-P
PCR	I-P
(	O
qPCR	B-P
)	O
.	O

Results	O
showed	O
that	O
the	O
profile	O
of	O
N2O	O
emission	O
can	O
be	O
divided	O
into	O
three	O
stages	O
,	O
traditional	O
denitrification	O
contributed	O
largely	O
to	O
N2O	O
emission	O
at	O
stage	O
I	O
(	O
days	O
1-5	O
)	O
,	O
but	O
N2O	O
emission	O
mainly	O
happened	O
at	O
stage	O
II	O
(	O
days	O
5-14	O
)	O
due	O
to	O
nitrifier	O
denitrification	O
and	O
NH2OH	O
accumulation	O
by	O
ammonia-oxidizing	O
bacteria	O
(	O
AOB	O
)	O
,	O
accounting	O
for	O
51.4	O
%	O
and	O
58.2	O
%	O
of	O
total	O
N2O	O
emission	O
for	O
piles	O
I	O
and	O
II	O
,	O
respectively	O
.	O

At	O
stage	O
III	O
(	O
days	O
14-21	O
)	O
,	O
nitrifier	O
denitrification	O
was	O
inhibited	O
because	O
sludge	O
bio-drying	O
proceeded	O
mainly	O
by	O
the	O
physical	O
aeration	O
,	O
thus	O
N2O	O
emission	O
decreased	O
and	O
changed	O
little	O
.	O

The	O
improved	O
aeration	O
strategy	O
availed	O
pile	O
I	O
to	O
reduce	O
N2O	O
emission	O
much	O
especially	O
at	O
stages	O
II	O
and	O
III	O
,	O
respectively	O
.	O

These	O
results	O
indicated	O
that	O
nitrifier	O
denitrification	O
by	O
AOB	O
and	O
biological	O
NH2OH	O
oxidation	O
due	O
to	O
AOB	O
made	O
more	O
contribution	O
to	O
N2O	O
emission	O
,	O
and	O
aeration	O
strategy	O
was	O
crucial	O
to	O
mitigate	O
N2O	O
emission	O
during	O
sludge	O
bio-drying	O
.	O

Invasive	O
fungal	O
infections	O
in	O
renal	O
transplant	O
patients	O
:	O
a	O
single	O
center	O
study	O
.	O

Timely	O
diagnosis	O
of	O
invasive	O
fungal	O
infections	O
(	O
IFI	O
)	O
in	O
renal	O
transplant	O
(	O
RT	O
)	O
patients	O
on	O
immunosuppression	O
is	O
often	O
difficult	O
,	O
jeopardizing	O
their	O
life	O
and	O
graft	O
.	O

We	O
reported	O
IFI	O
and	O
their	O
causative	O
fungal	O
agents	O
in	O
post-	O
RT	O
patients	O
.	O

This	O
was	O
a	O
retrospective	O
6-year	O
clinical	O
study	O
carried	O
out	O
from	O
2010	O
to	O
2015	O
on	O
1900	O
RT	O
patients	O
.	O

Clinical	O
data	O
included	O
patient	O
-	O
donor	O
demographics	O
,	O
time	O
to	O
onset	O
of	O
infection	O
,	O
risk	O
factors	O
and	O
graft	O
function	O
in	O
terms	O
of	O
serum	B-P
creatinine	I-P
(	O
SCr	B-P
)	O
.	O

To	O
identify	O
IFI	O
,	O
we	O
examined	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
,	O
blood	O
,	O
tissue	O
,	O
and	O
wound	O
swab	O
samples	O
by	O
conventional	O
mycological	B-P
methods	I-P
.	O

IFI	O
were	O
diagnosed	O
in	O
30	O
(	O
1.56	O
%	O
)	O
patients	O
on	O
triple	O
immunosuppression	O
,	O
mainly	O
males	O
(	O
n	O
=	O
25	O
)	O
with	O
mean	O
age	O
of	O
36.57	O
±	O
11.9	O
years	O
at	O
13.12	O
±	O
18.35	O
months	O
post-	O
RT	O
.	O

Aspergillus	O
species	O
was	O
identified	O
in	O
11	O
BAL	O
,	O
one	O
tissue	O
,	O
and	O
one	O
wound	O
specimen	O
each	O
,	O
30.76	O
%	O
of	O
these	O
were	O
fatal	O
and	O
15.38	O
%	O
caused	O
graft	O
loss	O
;	O
Candida	O
albicans	O
was	O
in	O
nine	O
BAL	O
,	O
four	O
blood	O
,	O
two	O
wound	O
swab	O
,	O
and	O
one	O
tissue	O
specimens	O
,	O
25	O
%	O
of	O
these	O
were	O
fatal	O
and	O
25	O
%	O
had	O
graft	O
loss	O
and	O
one	O
mucor	O
in	O
BAL	O
which	O
was	O
fatal	O
.	O

Seven	O
patients	O
were	O
diabetic	O
,	O
10	O
had	O
superadded	O
cytomegalovirus	O
infection	O
,	O
and	O
15	O
were	O
anti-rejected	O
.	O

IFI	O
are	O
associated	O
with	O
increased	O
morbidity	O
and	O
mortality	O
in	O
RT	O
patients	O
.	O

Triple	O
immunosuppression	O
,	O
broad	O
spectrum	O
antibiotics	O
for	O
≥	O
two	O
weeks	O
,	O
diabetes	O
and	O
superadded	O
infection	O
are	O
added	O
risks	O
for	O
these	O
patients	O
.	O

Prevention	O
,	O
early	O
diagnosis	O
,	O
and	O
appropriate	O
management	O
are	O
necessary	O
to	O
improve	O
their	O
prognosis	O
.	O

microRNA-145	O
Mediates	O
the	O
Inhibitory	O
Effect	O
of	O
Adipose	O
Tissue	O
-Derived	O
Stromal	O
Cells	O
on	O
Prostate	O
Cancer	O
.	O

Adipose-derived	O
stromal	O
cell	O
(	O
ASC	O
)	O
,	O
known	O
as	O
one	O
of	O
the	O
mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
,	O
is	O
a	O
promising	O
tool	O
for	O
regenerative	O
medicine	O
;	O
however	O
,	O
the	O
effect	O
of	O
ASCs	O
on	O
tumor	O
growth	O
has	O
not	O
been	O
studied	O
sufficiently	O
.	O

We	O
investigated	O
the	O
hypothesis	O
that	O
ASCs	O
have	O
an	O
inhibitory	O
effect	O
on	O
metastatic	O
tumor	O
progression	O
.	O

To	O
evaluate	O
the	O
in	O
vitro	O
inhibitory	O
effect	O
of	O
ASCs	O
on	O
metastatic	O
prostate	O
cancer	O
(	O
PCa	O
)	O
,	O
direct	O
coculture	B-P
and	O
indirect	O
separate	O
culture	B-P
experiments	I-P
with	O
PC3M-luc2	O
cells	O
and	O
human	O
ASCs	O
were	O
performed	O
,	O
and	O
ASCs	O
were	O
administered	O
to	O
PC3M-luc2	O
cell	O
-derived	O
tumor	O
-bearing	O
nude	O
mice	O
for	O
in	O
vivo	O
experiment	O
.	O

We	O
also	O
performed	O
exosome	O
microRNA	O
(	O
miRNA	O
)	O
array	B-P
analysis	I-P
to	O
explore	O
a	O
mechanistic	O
insight	O
into	O
the	O
effect	O
of	O
ASCs	O
on	O
PCa	O
cell	O
proliferation	O
/	O
apoptosis	O
.	O

Both	O
in	O
vitro	O
and	O
in	O
vivo	O
experiments	O
exhibited	O
the	O
inhibitory	O
effect	O
of	O
ASCs	O
on	O
PC3M-luc2	O
cell	O
proliferation	O
,	O
inducing	O
apoptosis	O
and	O
PCa	O
growth	O
,	O
respectively	O
.	O

Among	O
upregulated	O
miRNAs	O
in	O
ASCs	O
compared	O
with	O
fibroblasts	O
,	O
we	O
focused	O
on	O
miR-145	O
,	O
which	O
was	O
known	O
as	O
a	O
tumor	O
suppressor	O
.	O

ASC	O
-derived	O
conditioned	O
medium	O
(	O
CM	O
)	O
significantly	O
inhibited	O
PC3M-luc2	O
cell	O
proliferation	O
,	O
inducing	O
apoptosis	O
,	O
but	O
the	O
effect	O
was	O
canceled	O
by	O
miR-145	O
knockdown	O
in	O
ASCs	O
.	O

ASC	O
miR-145	O
knockdown	O
CM	O
also	O
reduced	O
the	O
expression	O
of	O
Caspase	O
3	O
/	O
7	O
with	O
increased	O
antiapoptotic	O
protein	O
,	O
BclxL	O
,	O
expression	O
in	O
PC3M-luc2	O
cells	O
.	O

This	O
study	O
provides	O
preclinical	O
data	O
that	O
ASCs	O
inhibit	O
PCa	O
growth	O
,	O
inducing	O
PCa	O
cell	O
apoptosis	O
with	O
reduced	O
activity	O
of	O
BclxL	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
miR-145	O
,	O
including	O
exosomes	O
released	O
from	O
ASCs	O
,	O
suggesting	O
that	O
ASC	O
administration	O
could	O
be	O
a	O
novel	O
and	O
promising	O
therapeutic	O
strategy	O
in	O
patients	O
with	O
PCa	O
.	O

Toxicity	O
assessment	O
of	O
water-accommodated	O
fractions	O
from	O
two	O
different	O
oils	O
using	O
a	O
zebrafish	O
(	O
Danio	O
rerio	O
)	O
embryo	O
-	O
larval	O
bioassay	B-P
with	O
a	O
multilevel	O
approach	O
.	O

Petroleum	O
compounds	O
from	O
chronic	O
discharges	O
and	O
oil	O
spills	O
represent	O
an	O
important	O
source	O
of	O
environmental	O
pollution	O
.	O

To	O
better	O
understand	O
the	O
deleterious	O
effects	O
of	O
these	O
compounds	O
,	O
the	O
toxicity	O
of	O
water-accommodated	O
fractions	O
(	O
WAF	O
)	O
from	O
two	O
different	O
oils	O
(	O
brut	O
Arabian	O
Light	O
and	O
Erika	O
heavy	O
fuel	O
oils	O
)	O
were	O
used	O
in	O
this	O
study	O
.	O

Zebrafish	O
embryos	O
(	O
Danio	O
rerio	O
)	O
were	O
exposed	O
during	O
96	O
h	O
at	O
three	O
WAF	O
concentrations	O
(	O
1	O
,	O
10	O
and	O
100	O
%	O
for	O
Arabian	O
Light	O
and	O
10	O
,	O
50	O
and	O
100	O
%	O
for	O
Erika	O
)	O
in	O
order	O
to	O
cover	O
a	O
wide	O
range	O
of	O
polycyclic	O
aromatic	O
hydrocarbon	O
(	O
PAH	O
)	O
concentrations	O
,	O
representative	O
of	O
the	O
levels	O
found	O
after	O
environmental	O
oil	O
spills	O
.	O

Several	O
endpoints	O
were	O
recorded	O
at	O
different	O
levels	O
of	O
biological	O
organization	O
,	O
including	O
lethal	O
endpoints	O
,	O
morphological	O
abnormalities	O
,	O
photomotor	O
behavioral	O
responses	O
,	O
cardiac	O
activity	O
,	O
DNA	O
damage	O
and	O
exposure	O
level	O
measurements	O
(	O
EROD	O
activity	O
,	O
cyp1a	O
and	O
PAH	O
metabolites	O
)	O
.	O

Neither	O
morphological	O
nor	O
behavioral	O
or	O
physiological	O
alterations	O
were	O
observed	O
after	O
exposure	O
to	O
Arabian	O
Light	O
fractions	O
.	O

In	O
contrast	O
,	O
the	O
Erika	O
fractions	O
led	O
a	O
high	O
degree	O
of	O
toxicity	O
in	O
early	O
life	O
stages	O
of	O
zebrafish	O
.	O

Despite	O
of	O
defense	O
mechanisms	O
induced	O
by	O
oil	O
,	O
acute	O
toxic	O
effects	O
have	O
been	O
recorded	O
including	O
mortality	O
,	O
delayed	O
hatching	O
,	O
high	O
rates	O
of	O
developmental	O
abnormalities	O
,	O
disrupted	O
locomotor	O
activity	O
and	O
cardiac	O
failures	O
at	O
the	O
highest	O
PAH	O
concentrations	O
(	O
∑TPAHs=257,029±47,231ng·L	O
(	O
-1	O
)	O
)	O
.	O

Such	O
differences	O
in	O
toxicity	O
are	O
likely	O
related	O
to	O
the	O
oil	O
composition	O
.	O

The	O
use	O
of	O
developing	O
zebrafish	O
is	O
a	O
good	O
tool	O
to	O
identify	O
wide	O
range	O
of	O
detrimental	O
effects	O
and	O
elucidate	O
their	O
underlying	O
foundations	O
.	O

Our	O
work	O
highlights	O
once	O
more	O
,	O
the	O
cardiotoxic	O
action	O
(	O
and	O
potentially	O
neurotoxic	O
)	O
of	O
petroleum	O
-related	O
PAHs	O
.	O

Neuro-Behcet	O
disease	O
presenting	O
as	O
a	O
solitary	O
cerebellar	O
hemorrhagic	O
lesion	O
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

Behcet	O
's	O
disease	O
is	O
a	O
heterogeneous	O
,	O
multisystem	O
,	O
inflammatory	O
disorder	O
of	O
unknown	O
etiology	O
.	O

The	O
classic	O
triad	O
of	O
oral	O
and	O
genital	O
ulcerations	O
in	O
conjunction	O
with	O
uveitis	O
was	O
originally	O
described	O
by	O
the	O
Turkish	O
dermatologist	O
Hulusi	O
Behcet	O
in	O
1937	O
,	O
but	O
associated	O
symptoms	O
of	O
the	O
cardiovascular	O
,	O
central	O
nervous	O
,	O
pulmonary	O
,	O
and	O
gastrointestinal	O
systems	O
were	O
later	O
identified	O
.	O

In	O
fact	O
,	O
Behcet	O
's	O
disease	O
with	O
neurological	O
involvement	O
(	O
neuro-Behcet	O
's	O
disease	O
)	O
is	O
not	O
uncommon	O
.	O

Patients	O
with	O
neuro-Behcet	O
's	O
disease	O
typically	O
exhibit	O
a	O
diverse	O
array	O
of	O
symptoms	O
,	O
most	O
commonly	O
in	O
the	O
brainstem	O
and	O
diencephalic	O
regions	O
.	O

Herein	O
,	O
we	O
report	O
an	O
unusual	O
case	O
of	O
neuro-Behcet	O
's	O
disease	O
in	O
a	O
patient	O
who	O
presented	O
with	O
a	O
solitary	O
cerebellar	O
hemorrhage	O
.	O

A	O
39-year-old	O
Asian	O
woman	O
was	O
admitted	O
to	O
our	O
hospital	O
with	O
complaints	O
of	O
a	O
sudden	O
speech	O
difficulty	O
that	O
had	O
manifested	O
the	O
same	O
morning	O
,	O
and	O
dizziness	O
and	O
mild	O
vomiting	O
experienced	O
over	O
the	O
previous	O
3	O
days	O
.	O

Magnetic	O
resonance	O
images	O
revealed	O
target-like	O
hemorrhagic	O
lesions	O
in	O
the	O
right	O
hemisphere	O
of	O
the	O
cerebellum	O
.	O

Risk	O
factors	O
that	O
may	O
result	O
in	O
cerebellar	O
hemorrhage	O
,	O
such	O
as	O
high	O
blood	O
pressure	O
or	O
bleeding	O
diathesis	O
,	O
were	O
ruled	O
out	O
,	O
and	O
subsequent	O
brain	O
angiograms	B-P
were	O
normal	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
patient	O
's	O
cerebellar	O
hemorrhage	O
could	O
have	O
been	O
due	O
to	O
intracranial	O
vasculitis	O
in	O
a	O
rare	O
,	O
if	O
not	O
unique	O
,	O
complication	O
of	O
neuro-Behcet	O
's	O
disease	O
.	O

Relationship	O
between	O
fear	O
of	O
falling	O
and	O
functional	O
status	O
in	O
nursing	O
home	O
residents	O
aged	O
older	O
than	O
65	O
years	O
.	O

The	O
present	O
study	O
investigated	O
the	O
relationship	O
between	O
fear	O
of	O
falling	O
and	O
functional	O
status	O
,	O
and	O
sociodemographic	O
and	O
health-related	O
factors	O
in	O
nursing	O
home	O
residents	O
aged	O
older	O
than	O
65	O
years	O
.	O

The	O
cross-sectional	O
study	O
involved	O
100	O
participants	O
who	O
were	O
residents	O
of	O
a	O
nursing	O
home	O
and	O
aged	O
older	O
than	O
65	O
years	O
.	O

Fear	O
of	O
falling	O
was	O
assessed	O
using	O
the	O
Falls	O
Efficacy	O
Scale	O
.	O

Functional	O
status	O
was	O
assessed	O
by	O
four	O
performance-based	O
measures	O
.	O

Balance	O
was	O
assessed	O
by	O
the	O
Berg	O
Balance	O
Scale	O
,	O
mobility	O
by	O
the	O
Timed	B-P
Up	I-P
and	I-P
Go	I-P
test	I-P
,	I-P
lower	O
limbs	O
muscle	O
strength	O
by	O
the	O
Chair	O
Rising	O
Test	O
and	O
participants	O
'	O
functional	O
ability	O
by	O
the	O
motor	O
Functional	O
Independence	O
Measure	O
.	O

There	O
was	O
a	O
significant	O
negative	O
correlation	O
between	O
the	O
Falls	O
Efficacy	O
Scale	O
and	O
Berg	O
Balance	O
Scale	O
(	O
P	O
<	O
0.001	O
)	O
,	O
and	O
motor	O
Functional	O
Independence	O
Measure	O
(	O
P	O
<	O
0.001	O
)	O
scores	O
;	O
and	O
a	O
positive	O
correlation	O
with	O
the	O
Timed	B-P
Up	I-P
and	I-P
Go	I-P
test	I-P
(	O
P	O
<	O
0.001	O
)	O
and	O
Chair	O
Rising	O
Test	O
(	O
P	O
<	O
0.001	O
)	O
values	O
.	O

Falls	O
Efficacy	O
Scale	O
score	O
increase	O
is	O
associated	O
with	O
age	O
,	O
being	O
a	O
widower	O
/	O
widow	O
and	O
the	O
number	O
of	O
falls	O
in	O
the	O
previous	O
year	O
.	O

Higher	O
fear	O
of	O
falling	O
is	O
associated	O
with	O
an	O
increase	O
in	O
the	O
number	O
of	O
falls	O
in	O
the	O
previous	O
year	O
and	O
with	O
a	O
decrease	O
in	O
Berg	O
Balance	O
Scale	O
score	O
.	O

The	O
study	O
found	O
a	O
significant	O
associations	O
between	O
Falls	O
Efficacy	O
Scale	O
score	O
and	O
all	O
of	O
the	O
examined	O
parameters	O
of	O
functional	O
status	O
,	O
the	O
number	O
of	O
falls	O
in	O
the	O
previous	O
year	O
,	O
age	O
and	O
marital	O
status	O
of	O
widower	O
/	O
widow	O
.	O

The	O
major	O
finding	O
was	O
that	O
poor	O
balance	O
and	O
an	O
increase	O
in	O
the	O
number	O
of	O
falls	O
in	O
the	O
previous	O
year	O
are	O
independent	O
factors	O
significantly	O
associated	O
with	O
the	O
fear	O
of	O
falling	O
.	O

Geriatr	O
Gerontol	O
Int	O
2016	O
;	O
••	O
:	O
••-••	O
.	O

Safety	O
and	O
toxicology	O
of	O
the	O
intravenous	O
administration	O
of	O
Ang2	O
�€	O
‘	O
siRNA	O
plasmid	O
chitosan	O
magnetic	O
nanoparticles	O
.	O

This	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
safety	O
and	O
toxicology	O
of	O
intravenous	O
administration	O
of	O
angiopoietin�€	O
‘	O
2	O
(	O
Ang2	O
)	O
�€	O
‘	O
small	O
interfering	O
(	O
si	O
)	O
RNA	O
plasmid	O
�€	O
‘	O
chitosan	O
magnetic	O
nanoparticles	O
(	O
CMNPs	O
)	O
.	O

Ang2	O
�€	O
‘	O
CMNPs	O
were	O
constructed	O
and	O
subsequently	O
administered	O
at	O
different	O
doses	O
to	O
mice	O
and	O
rats	O
via	O
the	O
tail	O
vein	O
.	O

The	O
acute	O
(	O
in	O
mice	O
)	O
and	O
chronic	O
toxicity	O
(	O
in	O
rats	O
)	O
were	O
observed	O
.	O

The	O
results	O
of	O
the	O
acute	O
toxicity	B-P
assay	I-P
revealed	O
that	O
the	O
LD50	O
mice	O
was	O
>	O
707.0	O
mg·kg�€	O
‘	O
1·d�€	O
‘	O
1	O
,	O
and	O
the	O
general	O
condition	O
of	O
mice	O
revealed	O
no	O
obvious	O
abnormalities	O
.	O

With	O
the	O
exception	O
of	O
the	O
high	O
dose	O
group	O
(	O
254.6	O
mg·kg�€	O
‘	O
1·d�€	O
‘	O
1	O
)	O
,	O
which	O
exhibited	O
partial	O
lung	O
congestion	O
,	O
the	O
other	O
groups	O
exhibited	O
no	O
obvious	O
abnormalities	O
.	O

Results	O
of	O
the	O
chronic	O
toxicity	B-P
assay	I-P
demonstrated	O
that	O
the	O
non�€	O
‘	O
toxic	O
dose	O
of	O
Ang2	O
�€	O
‘	O
CMNPs	O
in	O
the	O
rat	O
was	O
>	O
35.35	O
mg·kg�€	O
‘	O
1·d�€	O
‘	O
1	O
for	O
14	O
days	O
.	O

The	O
rat	O
general	O
condition	O
and	O
blood	B-P
biochemistry	I-P
indexes	I-P
revealed	O
no	O
obvious	O
abnormality	O
.	O

The	O
blood	B-P
routine	I-P
indexes	I-P
and	O
lung/body	B-P
ratio	I-P
of	O
each	O
treatment	O
group	O
were	O
higher	O
when	O
compared	O
with	O
the	O
control	O
group	O
.	O

The	O
middle�€	O
‘	O
and	O
high�€	O
‘	O
dose	O
groups	O
exhibited	O
chronic	O
pulmonary	O
congestion	O
,	O
whilst	O
the	O
low�€	O
‘	O
dose	O
and	O
control	O
groups	O
exhibited	O
no	O
abnormality	O
.	O

Similarly	O
,	O
the	O
other	O
organs	O
revealed	O
no	O
obvious	O
abnormality	O
.	O

Ang2	O
�€	O
‘	O
CMNPs	O
have	O
good	O
safety	O
at	O
a	O
certain	O
dose	O
range	O
and	O
may	O
be	O
considered	O
as	O
the	O
target	O
drug	O
carrier	O
.	O

Trans-oral	O
fine	B-P
needle	I-P
aspiration	I-P
cytology	I-P
in	O
cervical	O
(	O
C1	O
and	O
C2	O
)	O
vertebral	O
lesions	O
:	O
a	O
novel	O
diagnostic	B-P
approach	I-P
.	O

Fine	B-P
needle	I-P
aspiration	I-P
(	I-P
FNA	I-P
)	I-P
cytology	I-P
is	O
a	O
relatively	O
non-invasive	O
method	O
for	O
diagnosing	O
both	O
superficial	O
and	O
deep-seated	O
neoplastic	O
and	O
non-neoplastic	O
lesions	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
diagnostic	O
utility	O
of	O
trans-oral	O
FNA	B-P
in	O
cervical	O
(	O
C1	O
and	O
C2	O
)	O
vertebral	O
and	O
paravertebral	O
lesions	O
.	O

Eighteen	O
FNA	B-P
cases	O
of	O
cervical	O
vertebral	O
and	O
paravertebral	O
lesions	O
performed	O
by	O
a	O
trans-oral	O
route	O
without	O
any	O
image-guidance	O
between	O
1995	O
and	O
2014	O
were	O
retrieved	O
from	O
the	O
archives	O
of	O
the	O
cytology	O
department	O
at	O
PGIMER	O
,	O
Chandigarh	O
and	O
reviewed	O
.	O

Out	O
of	O
18	O
cases	O
,	O
a	O
definite	O
diagnosis	O
was	O
given	O
in	O
15	O
cases	O
(	O
83.3	O
%	O
)	O
.	O

The	O
commonest	O
diagnosis	O
seen	O
was	O
granulomatous	O
inflammation	O
consistent	O
with	O
tuberculosis	O
(	O
33.3	O
%	O
)	O
.	O

Trans-oral	O
FNA	B-P
is	O
a	O
quick	O
,	O
inexpensive	O
and	O
relatively	O
safe	O
outpatient	O
procedure	O
for	O
sampling	O
C1	O
and	O
C2	O
vertebral	O
and	O
paravertebral	O
lesions	O
,	O
which	O
are	O
clinically	O
and	O
radiologically	O
difficult	O
to	O
approach	O
.	O

It	O
helps	O
in	O
the	O
early	B-P
diagnosis	I-P
and	O
management	O
of	O
these	O
patients	O
.	O

Association	O
between	O
OCT	B-P
-based	O
microangiography	B-P
perfusion	O
indices	O
and	O
diabetic	O
retinopathy	O
severity	O
.	O

To	O
evaluate	O
the	O
association	O
between	O
retinal	O
capillary	O
non-perfusion	O
and	O
diabetic	O
retinopathy	O
(	O
DR	O
)	O
severity	O
using	O
optical	B-P
coherence	I-P
tomography-based	I-P
microangiography	I-P
(	O
OMAG	B-P
)	O
.	O

33	O
patients	O
(	O
51	O
eyes	O
)	O
with	O
a	O
history	O
of	O
diabetes	O
underwent	O
imaging	B-P
with	O
a	O
68	O
kHz	O
Cirrus-5000	O
spectral	O
domain	O
OMAG	O
prototype	O
.	O

Demographic	O
and	O
clinical	O
characteristics	O
were	O
collected	O
.	O

The	O
perfusion	O
index	O
(	O
PI	O
)	O
was	O
defined	O
as	O
per	O
cent	O
coverage	O
of	O
area	O
by	O
retinal	O
vessels	O
with	O
flow	O
,	O
measured	O
within	O
a	O
minimum	O
of	O
6.8×6.8	O
mm	O
(	O
2	O
)	O
OMAG	B-P
scan	I-P
.	O

The	O
PI	O
in	O
each	O
ETDRS	O
zone	O
was	O
analysed	O
using	O
an	O
automated	O
algorithm	O
.	O

Univariate	O
and	O
multivariate	O
analyses	O
were	O
used	O
to	O
determine	O
the	O
degree	O
of	O
association	O
between	O
PI	O
and	O
DR	O
severity	O
.	O

51	O
eyes	O
with	O
different	O
DR	O
severities	O
were	O
imaged	B-P
.	O

More	O
severe	O
DR	O
was	O
significantly	O
associated	O
with	O
lower	O
PI	O
after	O
adjusting	O
for	O
logarithm	O
of	O
the	O
minimum	O
angle	O
of	O
resolution	O
best-corrected	O
visual	O
acuity	O
,	O
hyperlipidaemia	O
,	O
diabetes	O
type	O
and	O
ETDRS	O
ring	O
in	O
a	O
multivariate	O
mixed	O
linear	O
model	O
.	O

Compared	O
with	O
the	O
none-	O
mild	O
non-proliferative	O
diabetic	O
retinopathy	O
(	O
NPDR	O
)	O
group	O
,	O
the	O
moderate-severe	O
NPDR	O
group	O
had	O
2.7	O
lower	O
PI	O
(	O
p=0.03	O
)	O
and	O
proliferative	O
DR	O
group	O
had	O
4.3	O
lower	O
PI	O
(	O
p=0.003	O
)	O
.	O

All	O
ETDRS	O
zones	O
except	O
for	O
the	O
foveal	O
centre	O
showed	O
inverse	O
associations	O
between	O
PI	O
and	O
DR	O
severity	O
(	O
p	O
values	O
<	O
0.001	O
to	O
0.862	O
)	O
.	O

A	O
statistically	O
significant	O
inverse	O
association	O
exists	O
between	O
PI	O
and	O
DR	O
severity	O
.	O

Our	O
study	O
suggests	O
that	O
PI	O
may	O
become	O
a	O
useful	O
biomarker	O
in	O
evaluating	O
and	O
following	O
the	O
progression	O
of	O
DR	O
.	O

Differential	O
effects	O
of	O
crude	O
oil	O
on	O
denitrification	O
and	O
anammox	O
,	O
and	O
the	O
impact	O
on	O
N2O	O
production	O
.	O

Denitrification	O
and	O
anammox	O
are	O
key	O
processes	O
for	O
reducing	O
the	O
external	O
nitrogen	O
loads	O
delivered	O
to	O
coastal	O
ecosystems	O
,	O
and	O
these	O
processes	O
can	O
be	O
affected	O
by	O
pollutants	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
crude	O
oil	O
on	O
denitrification	O
and	O
anammox	O
.	O

Controlled	O
laboratory	O
experiments	O
were	O
performed	O
using	O
sediment	O
slurries	O
from	O
the	O
Lima	O
Estuary	O
(	O
NW	O
Portugal	O
)	O
.	O

Anammox	O
and	O
denitrification	O
rates	O
were	O
measured	O
using	O
(	O
15	O
)	O
N-labeled	O
NO3	O
(	O
-	O
)	O
,	O
and	O
the	O
production	O
of	O
(	O
29	O
)	O
N2	O
and	O
(	O
30	O
)	O
N2	O
quantified	O
by	O
membrane	B-P
inlet	I-P
mass	I-P
spectrometry	I-P
.	O

Results	O
revealed	O
that	O
while	O
denitrification	O
rates	O
were	O
stimulated	O
between	O
10	O
and	O
25	O
000	O
times	O
after	O
crude	O
oil	O
amendment	O
,	O
anammox	O
activity	O
was	O
partially	O
(	O
between	O
2	O
and	O
5	O
times	O
)	O
or	O
completely	O
inhibited	O
by	O
the	O
addition	O
of	O
crude	O
oil	O
when	O
comparing	O
to	O
rates	O
in	O
unamended	O
controls	O
.	O

Similar	O
results	O
were	O
observed	O
across	O
four	O
estuarine	O
sediment	O
types	O
,	O
despite	O
their	O
different	O
physical-chemical	O
characteristics	O
.	O

Moreover	O
,	O
N2O	O
production	O
was	O
reduced	O
by	O
2-36	O
times	O
following	O
crude	O
oil	O
addition	O
.	O

Further	O
work	O
is	O
required	O
to	O
fully	O
understand	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
the	O
observed	O
reduction	O
in	O
N2O	O
production	O
.	O

This	O
study	O
represents	O
one	O
of	O
the	O
first	O
contributions	O
to	O
the	O
understanding	O
of	O
the	O
impact	O
of	O
crude	O
oil	O
pollution	O
on	O
denitrification	O
and	O
anammox	O
,	O
with	O
profound	O
implications	O
for	O
the	O
management	O
of	O
aquatic	O
ecosystems	O
regarding	O
eutrophication	O
(	O
N-removal	O
)	O
.	O

Functional	O
analyses	O
of	O
OcRhS1	O
and	O
OcUER1	O
involved	O
in	O
UDP-L-rhamnose	O
biosynthesis	O
in	O
Ornithogalum	O
caudatum	O
.	O

UDP-L-rhamnose	O
(	O
UDP-Rha	O
)	O
is	O
an	O
important	O
sugar	O
donor	O
for	O
the	O
synthesis	O
of	O
rhamnose	O
-containing	O
compounds	O
in	O
plants	O
.	O

However	O
,	O
only	O
a	O
few	O
enzymes	O
and	O
their	O
encoding	O
genes	O
involved	O
in	O
UDP-Rha	O
biosynthesis	O
are	O
available	O
in	O
plants	O
.	O

Here	O
,	O
two	O
genes	O
encoding	O
rhamnose	O
synthase	O
(	O
RhS	O
)	O
and	O
bi-functional	O
UDP-4-keto-6-deoxy-D-glucose	O
(	O
UDP-4K6DG	O
)	O
3	O
,	O
5-epimerase/UDP-4-keto-L-rhamnose	O
(	O
UDP-4KR	O
)	O
4-keto-reductase	O
(	O
UER	O
)	O
were	O
isolated	O
from	O
Ornithogalum	O
caudatum	O
based	O
on	O
the	O
RNA	O
-	O
Seq	O
data	O
.	O

The	O
OcRhS1	O
gene	O
has	O
an	O
ORF	O
(	O
open	O
reading	O
frame	O
)	O
of	O
2019	O
bp	O
encoding	O
a	O
tri-functional	O
RhS	O
enzyme	O
.	O

In	O
vitro	O
enzymatic	B-P
assays	I-P
revealed	O
OcRhS1	O
can	O
really	O
convert	O
UDP-D-glucose	O
(	O
UDP-Glc	O
)	O
into	O
UDP-Rha	O
via	O
three	O
consecutive	O
reactions	O
.	O

Biochemical	O
evidences	O
indicated	O
that	O
the	O
recombinant	O
OcRhS1	O
was	O
active	O
in	O
the	O
pH	O
range	O
of	O
5-11	O
and	O
over	O
the	O
temperature	O
range	O
of	O
0-60	O
°C	O
.	O

The	O
Km	O
value	O
of	O
OcRhS1	O
for	O
UDP-Glc	O
was	O
determined	O
to	O
be	O
1.52	O
×	O
10	O
(	O
-4	O
)	O
M.	O
OcRhS1	O
is	O
a	O
multi-domain	O
protein	O
with	O
two	O
sets	O
of	O
cofactor-binding	O
motifs	O
.	O

The	O
cofactors	O
dependent	O
properties	O
of	O
OcRhS1	O
were	O
thus	O
characterized	O
in	O
this	O
research	O
.	O

Moreover	O
,	O
the	O
N-terminal	O
portion	O
of	O
OcRhS1	O
(	O
OcRhS1-N	O
)	O
was	O
observed	O
to	O
metabolize	O
UDP-Glc	O
to	O
form	O
intermediate	O
UDP-4K6DG	O
.	O

OcUER1	O
contains	O
an	O
ORF	O
of	O
906	O
bp	O
encoding	O
a	O
polypeptide	O
of	O
301	O
aa	O
.	O

OcUER1	O
shared	O
high	O
similarity	O
with	O
the	O
carboxy-terminal	O
domain	O
of	O
OcRhS1	O
(	O
OcRhS1-C	O
)	O
,	O
suggesting	O
its	O
intrinsic	O
ability	O
of	O
converting	O
UDP-4K6DG	O
into	O
UDP-Rha	O
.	O

It	O
was	O
thus	O
reasonably	O
inferred	O
that	O
UDP-Glc	O
could	O
be	O
bio-transformed	O
into	O
UDP-Rha	O
under	O
the	O
collaborating	O
action	O
of	O
OcRhS1-N	O
and	O
OcUER1	O
.	O

The	O
subsequently	O
biochemical	B-P
assay	I-P
verified	O
this	O
notion	O
.	O

Importantly	O
,	O
expression	O
profiles	O
of	O
OcRhS1	O
and	O
OcUER1	O
revealed	O
their	O
possible	O
involvement	O
in	O
the	O
biosynthesis	O
of	O
rhamnose	O
-containing	O
polysaccharides	O
in	O
O.	O
caudatum	O
.	O

Tongxinluo	O
improves	O
cognition	O
by	O
decreasing	O
β-amyloid	O
in	O
spontaneous	O
hypertensive	O
rats	O
.	O

β-Amyloid	O
(	O
Aβ	O
)	O
accumulation	O
in	O
the	O
brain	O
is	O
the	O
major	O
pathophysiology	O
of	O
Alzheimer	O
disease	O
(	O
AD	O
)	O
.	O

Hypertension	O
is	O
a	O
risk	O
factor	O
for	O
AD	O
by	O
promoting	O
Aβ	O
deposition	O
.	O

Traditional	O
Chinese	O
medicinal	O
compound	O
tongxinluo	O
(	O
TXL	O
)	O
can	O
improve	O
blood	O
circulation	O
and	O
endothelium	O
-dependent	O
vasodilation	O
.	O

This	O
study	O
investigates	O
the	O
effects	O
of	O
TXL	O
on	O
cognition	O
and	O
Aβ	O
using	O
spontaneously	O
hypertensive	O
rats	O
(	O
SHRs	O
)	O
.	O

TXL	O
was	O
intragastrically	O
administered	O
to	O
SHRs	O
at	O
low-dose	O
,	O
mid-	O
dose	O
and	O
high-dose	O
for	O
15	O
,	O
30	O
or	O
60	O
days	O
.	O

Cognition	O
was	O
evaluated	O
with	O
a	O
Morris	B-P
Water	I-P
Maze	I-P
(	O
MWM	B-P
)	O
.	O

Aβ	O
in	O
the	O
brain	O
was	O
detected	O
by	O
western	B-P
blot	I-P
,	O
ELISA	B-P
and	O
Thioflavin-S	O
staining	B-P
.	O

Western	B-P
blot	I-P
and	O
RT-PCR	O
were	O
employed	O
to	O
exam	O
the	O
expression	O
of	O
receptor	O
for	O
advanced	O
glycation	O
end	O
products	O
(	O
RAGE	O
)	O
,	O
low-density	O
lipoprotein	O
receptor-related	O
protein-1	O
(	O
LRP-1	O
)	O
and	O
amyloid	O
precursor	O
protein	O
(	O
APP	O
)	O
.	O

After	O
TXL	O
treatment	O
for	O
60	O
days	O
,	O
compared	O
with	O
the	O
vehicle	O
,	O
the	O
number	O
of	O
crossed	O
platform	O
and	O
the	O
time	O
spent	O
in	O
the	O
target	O
quadrant	O
increased	O
in	O
parallel	O
with	O
the	O
increasing	O
length	O
of	O
treatment	O
in	O
MWM	B-P
.	O

Moreover	O
,	O
the	O
Aβ	O
in	O
the	O
hippocampus	O
significantly	O
decreased	O
compared	O
to	O
the	O
vehicle	O
group	O
,	O
both	O
in	O
western	B-P
blot	I-P
and	O
ELISA	B-P
.	O

Additionally	O
,	O
TXL	O
reduced	O
RAGE	O
expression	O
in	O
a	O
dose	O
-	O
and	O
time	O
-depended	O
manner	O
,	O
but	O
LRP-1	O
expression	O
had	O
no	O
difference	O
between	O
TXL	O
groups	O
and	O
vehicle	O
groups	O
.	O

Furthermore	O
,	O
the	O
β-secretase	O
expression	O
was	O
significantly	O
decreased	O
compared	O
to	O
the	O
vehicle	O
group	O
,	O
but	O
APP	O
expression	O
had	O
no	O
difference	O
.	O

In	O
conclusion	O
,	O
TXL	O
improved	O
cognition	O
and	O
decreased	O
Aβ	O
in	O
SHRs	O
in	O
a	O
dose	O
-	O
and	O
time	O
-dependent	O
manner	O
,	O
the	O
underlying	O
mechanism	O
may	O
involved	O
in	O
inhibiting	O
RAGE	O
and	O
β-secretase	O
expression	O
.	O

Clinical	O
application	O
and	O
outcomes	O
of	O
sentinel	O
node	O
navigation	O
surgery	O
in	O
patients	O
with	O
early	O
gastric	O
cancer	O
.	O

Sentinel	O
node	O
navigation	O
surgery	O
(	O
SNNS	O
)	O
has	O
been	O
recognized	O
as	O
a	O
minimally	O
invasive	O
tool	O
for	O
individualized	O
lymphadenectomy	O
in	O
patients	O
with	O
early	O
gastric	O
cancer	O
(	O
EGC	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
clinicopathological	O
factors	O
,	O
adverse	O
events	O
,	O
and	O
clinical	O
outcomes	O
between	O
sentinel	B-P
node	I-P
mapping	I-P
(	O
SNM	B-P
)	O
and	O
SN	O
dissection	O
(	O
SND	O
)	O
groups	O
and	O
assess	O
the	O
clinical	O
utility	O
of	O
SNNS	O
in	O
patients	O
with	O
EGC	O
.	O

The	O
clinical	O
data	O
of	O
157	O
patients	O
with	O
EGC	O
,	O
diagnosed	O
as	O
clinical	O
T1N0M0	O
with	O
tumors	O
≤	O
40	O
mm	O
,	O
undergoing	O
SNNS	O
between	O
March	O
2004	O
and	O
April	O
2016	O
were	O
retrospectively	O
reviewed	O
.	O

Twenty-seven	O
patients	O
were	O
excluded	O
from	O
the	O
analysis	O
.	O

In	O
the	O
remaining	O
130	O
patients	O
,	O
59	O
and	O
71	O
patients	O
underwent	O
standard	O
lymphadenectomy	O
for	O
SNM	B-P
and	O
SND	O
,	O
respectively	O
.	O

The	O
sentinel	O
node	O
detection	O
rate	O
in	O
the	O
SNM	B-P
and	O
SND	O
groups	O
was	O
98.3	O
%	O
(	O
58/59	O
)	O
and	O
100	O
%	O
(	O
71/71	O
)	O
,	O
respectively	O
.	O

Two	O
(	O
3.5	O
%	O
)	O
,	O
15	O
(	O
25.9	O
%	O
)	O
,	O
and	O
41	O
(	O
70.7	O
%	O
)	O
patients	O
having	O
sentinel	O
nodes	O
underwent	O
total	O
gastrectomy	O
,	O
proximal	O
gastrectomy	O
(	O
PG	O
)	O
,	O
and	O
distal	O
gastrectomy	O
(	O
DG	O
)	O
,	O
respectively	O
,	O
in	O
the	O
SNM	B-P
group	O
.	O

One	O
(	O
1.4	O
%	O
)	O
,	O
5	O
(	O
7.0	O
%	O
)	O
,	O
10	O
(	O
14.1	O
%	O
)	O
,	O
39	O
(	O
54.9	O
%	O
)	O
,	O
and	O
16	O
(	O
22.5	O
%	O
)	O
patients	O
underwent	O
PG	O
,	O
DG	O
,	O
segmental	O
gastrectomy	O
,	O
local	O
resection	O
,	O
and	O
endoscopic	O
submucosal	O
dissection	O
,	O
respectively	O
,	O
in	O
the	O
SND	O
group	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
postoperative	O
complications	O
between	O
the	O
SNM	B-P
and	O
SND	O
groups	O
(	O
P	O
=	O
0.781	O
)	O
.	O

Survival	O
did	O
not	O
differ	O
between	O
the	O
both	O
groups	O
(	O
P	O
=	O
0.856	O
)	O
.	O

The	O
present	O
results	O
suggest	O
that	O
personalized	O
surgery	O
with	O
SND	O
provides	O
technical	O
safety	O
and	O
curability	O
related	O
with	O
a	O
favorable	O
survival	O
outcome	O
in	O
patients	O
with	O
EGC	O
.	O

Tips	O
and	O
Pitfalls	O
in	O
Direct	O
Ligation	O
of	O
Large	O
Spontaneous	O
Splenorenal	O
Shunt	O
during	O
Liver	O
Transplantation	O
.	O

Patients	O
with	O
large	O
spontaneous	O
splenorenal	O
shunt	O
(	O
SRS	O
)	O
prove	O
challenging	O
during	O
liver	O
transplantation	O
(	O
LT	O
)	O
,	O
irrespective	O
of	O
organizing	O
portal	O
vein	O
(	O
PV	O
)	O
thrombosis	O
.	O

Here	O
,	O
we	O
detail	O
the	O
clinical	O
outcomes	O
of	O
26	O
patients	O
who	O
underwent	O
direct	O
ligation	O
of	O
large	O
SRS	O
during	O
LT	O
.	O

Direct	O
ligation	O
of	O
large	O
SRS	O
was	O
applied	O
in	O
poor	O
portal	O
flow	O
during	O
LT.	O
We	O
performed	O
temporary	B-P
test	I-P
clamping	O
of	O
the	O
SRS	O
before	O
direct	O
ligation	O
and	O
applied	O
PV	O
pressure	O
monitoring	O
in	O
patients	O
who	O
showed	O
signs	O
of	O
portal	O
hypertension	O
,	O
such	O
as	O
bowel	O
edema	O
.	O

We	O
retrospectively	O
reviewed	O
and	O
evaluated	O
their	O
clinical	O
outcomes	O
.	O

Among	O
843	O
patients	O
who	O
underwent	O
LT	O
between	O
2010	O
and	O
2015	O
,	O
26	O
(	O
3.9	O
%	O
)	O
underwent	O
direct	O
ligation	O
of	O
SRS	O
without	O
any	O
intraoperative	O
event	O
.	O

Mean	O
preoperative	O
MELD	O
score	O
was	O
16.7±9.0	O
.	O

The	O
main	O
PV	O
diameter	O
on	O
preoperative	O
computed	B-P
tomography	I-P
was	O
8.3±3.4	O
mm	O
(	O
range	O
,	O
3.0-14.0	O
mm	O
)	O
.	O

SRS	O
was	O
easily	O
identified	O
at	O
just	O
below	O
the	O
distal	O
pancreas	O
and	O
beside	O
the	O
inferior	O
mesenteric	O
vein	O
in	O
all	O
patients	O
.	O

Accompanying	O
PV	O
thrombectomy	O
was	O
done	O
in	O
42.3	O
%	O
of	O
patients	O
.	O

Among	O
26	O
patients	O
,	O
massive	O
and	O
prolonged	O
ascites	O
was	O
evident	O
in	O
15.4	O
%	O
(	O
n	O
=	O
4	O
)	O
postoperatively	O
.	O

They	O
were	O
all	O
living	O
donor	O
LT	O
recipients	O
with	O
a	O
small	O
PV	O
diameter	O
(	O
4.0-6.7	O
mm	O
)	O
.	O

Except	O
for	O
one	O
patient	O
who	O
underwent	O
splenic	O
artery	O
embolization	O
,	O
ascites	O
was	O
tolerable	O
and	O
well	O
controlled	O
by	O
conservative	O
management	O
.	O

There	O
was	O
a	O
7.7	O
%	O
rate	O
of	O
major	O
complications	O
related	O
to	O
direct	O
ligation	O
,	O
including	O
reoperation	O
due	O
to	O
combined	O
ligation	O
of	O
SRS	O
along	O
with	O
a	O
left	O
renal	O
vein	O
at	O
the	O
confluence	O
.	O

Except	O
for	O
one	O
hospital	O
mortality	O
due	O
to	O
sepsis	O
,	O
25	O
patients	O
(	O
96.2	O
%	O
)	O
are	O
alive	O
with	O
no	O
evidence	O
of	O
further	O
PV	O
complications	O
.	O

In	O
conclusion	O
,	O
direct	O
ligation	O
of	O
large	O
SRS	O
during	O
LT	O
is	O
a	O
safe	O
and	O
feasible	O
method	O
to	O
overcome	O
the	O
effects	O
of	O
a	O
large	O
SRS	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Untypeable	O
hepatitis	O
C	O
virus	O
subtypes	O
in	O
Pakistan	O
:	O
A	O
neglected	O
section	O
.	O

Diagnostically	O
untypeable	O
subtypes	O
contribute	O
a	O
considerable	O
percent	O
of	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
subtypes	O
in	O
Pakistan	O
.	O

In	O
the	O
present	O
study	O
,	O
chronically	O
infected	O
HCV	O
patients	O
with	O
known	O
viremia	O
were	O
subjected	O
to	O
HCV	O
genotyping	B-P
.	O

Among	O
the	O
total	O
retrieved	O
samples	O
,	O
92.7	O
%	O
(	O
64/69	O
)	O
were	O
found	O
typeable	O
while	O
7.24	O
%	O
(	O
5/69	O
)	O
were	O
diagnostically	O
untypeable	O
.	O

In	O
conclusion	O
,	O
the	O
presence	O
of	O
large	O
number	O
of	O
untypeable	O
HCV	O
subtypes	O
emphasizes	O
the	O
need	O
of	O
an	O
updated	O
type	O
-	O
specific	O
genotyping	B-P
assay	B-P
and	O
consideration	O
of	O
primers	O
for	O
proportionally	O
rare	O
subtypes	O
to	O
minimize	O
the	O
number	O
of	O
untypeable	O
HCV	O
subtypes	O
.	O

Loss	O
of	O
Snf5	O
Induces	O
Formation	O
of	O
an	O
Aberrant	O
SWI/SNF	O
Complex	O
.	O

The	O
SWI/SNF	O
chromatin	O
remodeling	O
complex	O
is	O
highly	O
conserved	O
from	O
yeast	O
to	O
human	O
,	O
and	O
aberrant	O
SWI/SNF	O
complexes	O
contribute	O
to	O
human	O
disease	O
.	O

The	O
Snf5/SMARCB1/INI1	O
subunit	O
of	O
SWI/SNF	O
is	O
a	O
tumor	O
suppressor	O
frequently	O
lost	O
in	O
pediatric	O
rhabdoid	O
cancers	O
.	O

We	O
examined	O
the	O
effects	O
of	O
Snf5	O
loss	O
on	O
the	O
composition	O
,	O
nucleosome	O
binding	O
,	O
recruitment	O
,	O
and	O
remodeling	O
activities	O
of	O
yeast	O
SWI/SNF	O
.	O

The	O
Snf5	O
subunit	O
is	O
shown	O
by	O
crosslinking-mass	B-P
spectrometry	I-P
(	O
CX-MS	B-P
)	O
and	O
subunit	O
deletion	B-P
analysis	I-P
to	O
interact	O
with	O
the	O
ATPase	O
domain	O
of	O
Snf2	O
and	O
to	O
form	O
a	O
submodule	O
consisting	O
of	O
Snf5	O
,	O
Swp82	O
,	O
and	O
Taf14	O
.	O

Snf5	O
promotes	O
binding	O
of	O
the	O
Snf2	O
ATPase	O
domain	O
to	O
nucleosomal	O
DNA	O
and	O
enhances	O
the	O
catalytic	O
and	O
nucleosome	O
remodeling	O
activities	O
of	O
SWI/SNF	O
.	O

Snf5	O
is	O
also	O
required	O
for	O
SWI/SNF	O
recruitment	O
by	O
acidic	O
transcription	O
factors	O
.	O

RNA-seq	O
analysis	O
suggests	O
that	O
both	O
the	O
recruitment	O
and	O
remodeling	O
functions	O
of	O
Snf5	O
are	O
required	O
in	O
vivo	O
for	O
SWI/SNF	O
regulation	O
of	O
gene	O
expression	O
.	O

Thus	O
,	O
loss	O
of	O
SNF5	O
alters	O
the	O
structure	O
and	O
function	O
of	O
SWI/SNF	O
.	O

Pulmonary	O
homograft	O
stenosis	O
in	O
the	O
Ross	O
procedure	O
:	O
Incidence	O
,	O
clinical	O
impact	O
and	O
predictors	O
in	O
long-term	O
follow-up	O
.	O

The	O
Ross	O
procedure	O
is	O
used	O
in	O
the	O
treatment	O
of	O
selected	O
patients	O
with	O
aortic	O
valve	O
disease	O
.	O

Pulmonary	O
graft	O
stenosis	O
can	O
appear	O
in	O
the	O
long-term	O
follow-up	O
after	O
the	O
Ross	O
intervention	O
,	O
but	O
the	O
factors	O
involved	O
and	O
its	O
clinical	O
implications	O
are	O
not	O
fully	O
known	O
.	O

To	O
describe	O
the	O
incidence	O
,	O
clinical	O
impact	O
and	O
predictors	O
of	O
homograft	O
stenosis	O
and	O
reintervention	O
after	O
the	O
Ross	O
procedure	O
in	O
a	O
prospective	O
series	O
in	O
a	O
tertiary	O
referral	O
hospital	O
.	O

From	O
1997	O
to	O
2009	O
,	O
107	O
patients	O
underwent	O
the	O
Ross	O
procedure	O
(	O
mean	O
age	O
:	O
30±11	O
years	O
;	O
69	O
%	O
men	O
;	O
21	O
aged	O
<	O
18	O
years	O
)	O
,	O
and	O
were	O
followed	O
for	O
echocardiographic	B-P
homograft	O
stenosis	O
(	O
peak	O
gradient	O
>	O
36mmHg	O
)	O
and	O
surgical	O
or	O
percutaneous	O
homograft	O
reintervention	O
.	O

After	O
15	O
years	O
of	O
follow-up	O
(	O
median	O
:	O
11	O
years	O
)	O
,	O
echocardiographic	B-P
and	O
clinical	O
data	O
were	O
available	O
in	O
91	O
(	O
85	O
%	O
)	O
and	O
104	O
(	O
98	O
%	O
)	O
patients	O
,	O
respectively	O
:	O
26/91	O
(	O
29	O
%	O
)	O
patients	O
developed	O
homograft	O
stenosis	O
;	O
10/104	O
(	O
10	O
%	O
)	O
patients	O
underwent	O
13	O
homograft	O
reintervention	O
procedures	O
(	O
three	O
patients	O
underwent	O
surgical	O
replacement	O
,	O
three	O
received	O
a	O
percutaneous	O
pulmonary	O
valve	O
and	O
one	O
needed	O
stent	O
implantation	O
)	O
.	O

The	O
other	O
three	O
patients	O
underwent	O
two	O
consecutive	O
procedures	O
in	O
follow-up	O
;	O
one	O
died	O
because	O
of	O
a	O
procedure-related	O
myocardial	O
infarction	O
.	O

Rates	O
of	O
survival	O
free	O
from	O
homograft	O
stenosis	O
and	O
reintervention	O
at	O
1	O
,	O
5	O
and	O
10	O
years	O
were	O
96	O
%	O
,	O
82	O
%	O
and	O
75	O
%	O
and	O
99	O
%	O
,	O
94	O
%	O
and	O
91	O
%	O
,	O
respectively	O
.	O

Paediatric	O
patients	O
had	O
worse	O
survival	O
free	O
from	O
homograft	O
stenosis	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
3.50	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
1.56-7.90	O
;	O
P=0.002	O
)	O
,	O
although	O
there	O
were	O
no	O
significant	O
differences	O
regarding	O
reintervention	O
(	O
HR	O
:	O
2.01	O
,	O
95	O
%	O
CI	O
:	O
0.52-7.78	O
;	O
P=0.31	O
)	O
.	O

Younger	O
age	O
of	O
homograft	O
donor	O
was	O
also	O
a	O
stenosis	O
predictor	O
(	O
HR	O
:	O
0.97	O
,	O
95	O
%	O
CI	O
:	O
0.94-0.99	O
;	O
P=0.046	O
)	O
.	O

The	O
probabilities	O
of	O
homograft	O
stenosis	O
and	O
reintervention	O
10	O
years	O
after	O
the	O
Ross	O
procedure	O
were	O
29	O
%	O
and	O
10	O
%	O
,	O
respectively	O
;	O
only	O
one	O
patient	O
had	O
a	O
reintervention	O
-related	O
death	O
.	O

Younger	O
donor	O
and	O
recipient	O
age	O
were	O
associated	O
with	O
a	O
higher	O
rate	O
of	O
stenosis	O
.	O

Synthesis	O
and	O
In	O
Vitro	O
Cytotoxic	O
Properties	O
of	O
Polycarbo-Substituted	O
4-	O
(	O
Arylamino	O
)	O
quinazolines	O
.	O

Herein	O
,	O
we	O
describe	O
the	O
synthesis	O
of	O
novel	O
unsymmetrical	O
polycarbo-substituted	O
4-anilinoquinazolines	O
derived	O
from	O
the	O
2-aryl-6-bromo-8-iodoquinazolines	O
via	O
one-pot	O
three-step	O
reaction	O
sequences	O
involving	O
initial	O
amination	O
and	O
subsequent	O
double	O
cross-coupling	O
(	O
bis-Suzuki	O
,	O
Sonogashira/Stille	O
or	O
Sonogashira/Suzuki-Miyaura	O
)	O
reactions	O
with	O
different	O
cross	O
coupling	O
partners	O
for	O
the	O
two	O
carbon-carbon	O
bond	O
formation	O
steps	O
.	O

The	O
4-anilinoquinazolines	O
were	O
evaluated	O
for	O
potential	O
cytotoxicity	O
against	O
three	O
cancer	O
cell	O
lines	O
,	O
namely	O
,	O
human	O
breast	O
adenocarcinoma	O
(	O
MCF-7	O
)	O
cells	O
,	O
human	O
cervical	O
cancer	O
(	O
HeLa	O
)	O
and	O
human	O
lung	O
cancer	O
(	O
A549	O
)	O
cells	O
.	O

The	O
most	O
active	O
compounds	O
,	O
2b	O
,	O
2c	O
,	O
3c	O
,	O
4a	O
,	O
4c	O
and	O
5a	O
,	O
were	O
found	O
to	O
be	O
more	O
selective	O
against	O
the	O
MCF-7	O
and	O
HeLa	O
cell	O
lines	O
than	O
the	O
human	O
lung	O
carcinoma	O
(	O
A549	O
)	O
cells	O
.	O

We	O
selected	O
compounds	O
2c	O
,	O
3c	O
and	O
7a	O
as	O
representatives	O
for	O
further	O
evaluation	O
for	O
potential	O
to	O
induce	O
apoptosis	O
and/or	O
necrotic	O
properties	O
in	O
the	O
three	O
cancer	O
cell	O
lines	O
.	O

Compound	O
2c	O
induced	O
apoptosis	O
of	O
MCF-7	O
cells	O
through	O
cell	O
membrane	O
alteration	O
.	O

Treatment	O
of	O
Hela	O
and	O
A549	O
cell	O
lines	O
with	O
compounds	O
3c	O
and	O
7a	O
,	O
respectively	O
,	O
led	O
to	O
caspase-3	O
activation	O
in	O
both	O
cell	O
lines	O
.	O

Compound	O
3c	O
,	O
on	O
the	O
other	O
hand	O
,	O
caused	O
more	O
necrosis	O
than	O
apoptosis	O
induction	O
in	O
the	O
membrane	O
alteration	O
assay	B-P
.	O

Incidence	O
of	O
Complex	O
Regional	O
Pain	O
Syndrome	O
I	O
Following	O
Foot	O
and	O
Ankle	O
Fractures	O
Using	O
the	O
Budapest	O
Criteria	O
.	O

OBJECTIVE	O
:	O
Fractures	O
are	O
a	O
well-recognized	O
inciting	O
event	O
in	O
the	O
development	O
of	O
complex	O
regional	O
pain	O
syndrome	O
.	O

This	O
study	O
aimed	O
to	O
prospectively	O
determine	O
the	O
incidence	O
of	O
complex	O
regional	O
pain	O
syndrome	O
following	O
foot	O
and	O
ankle	O
fractures	O
.	O

METHODS	O
:	O
A	O
prospective	O
study	O
was	O
conducted	O
of	O
patients	O
presenting	O
to	O
two	O
metropolitan	O
hospitals	O
with	O
plain	B-P
radiograph	I-P
diagnosis	O
of	O
fractures	O
to	O
the	O
foot	O
or	O
ankle	O
.	O

Patients	O
were	O
initially	O
screened	O
by	O
phone	O
3	O
months	O
after	O
injury	O
using	O
the	O
validated	O
International	O
Association	O
for	O
the	O
Study	O
of	O
Pain	O
Budapest	O
criteria	O
.	O

Patients	O
who	O
fulfilled	O
the	O
screening	O
criteria	O
were	O
then	O
physically	O
examined	O
by	O
a	O
pain	O
specialist	O
to	O
assess	O
clinical	O
signs	O
as	O
part	O
of	O
the	O
Budapest	O
criteria	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
306	O
consecutive	O
eligible	O
patients	O
were	O
included	O
.	O

One	O
hundred	O
and	O
ten	O
patients	O
reported	O
at	O
least	O
one	O
symptom	O
of	O
complex	O
regional	O
pain	O
syndrome	O
;	O
however	O
,	O
only	O
three	O
fulfilled	O
the	O
minimum	O
requirements	O
to	O
necessitate	O
clinical	O
review	O
.	O

Of	O
these	O
three	O
,	O
only	O
one	O
patient	O
fulfilled	O
the	O
combination	O
of	O
symptom	O
and	O
sign	O
criteria	O
for	O
a	O
positive	O
diagnosis	O
according	O
to	O
the	O
validated	O
Budapest	O
criteria	O
.	O

The	O
incidence	O
of	O
complex	O
regional	O
pain	O
syndrome	O
following	O
foot	O
and	O
ankle	O
fracture	O
in	O
this	O
study	O
was	O
0.3	O
%	O
.	O

CONCLUSION	O
:	O
Although	O
many	O
patients	O
may	O
experience	O
vasomotor	O
,	O
sensory	O
,	O
and	O
sudomotor	O
disturbance	O
following	O
a	O
fracture	O
to	O
the	O
foot	O
and	O
ankle	O
,	O
the	O
observed	O
incidence	O
of	O
complex	O
regional	O
pain	O
syndrome	O
using	O
a	O
prospectively	O
collected	O
validated	O
criteria	O
is	O
significantly	O
lower	O
than	O
previously	O
published	O
.	O

A	O
Rational	O
Engineering	O
Strategy	O
for	O
Designing	O
Protein	O
A-Binding	O
Camelid	O
Single-Domain	O
Antibodies	O
.	O

Staphylococcal	O
protein	O
A	O
(	O
SpA	O
)	O
and	O
streptococcal	O
protein	O
G	O
(	O
SpG	O
)	O
affinity	B-P
chromatography	I-P
are	O
the	O
gold	O
standards	O
for	O
purifying	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
in	O
therapeutic	O
applications	O
.	O

However	O
,	O
camelid	O
VHH	O
single-domain	O
Abs	O
(	O
sdAbs	O
or	O
VHHs	O
)	O
are	O
not	O
bound	O
by	O
SpG	O
and	O
only	O
sporadically	O
bound	O
by	O
SpA	O
.	O

Currently	O
,	O
VHHs	O
require	O
affinity	O
tag-based	B-P
purification	I-P
,	O
which	O
limits	O
their	O
therapeutic	O
potential	O
and	O
adds	O
considerable	O
complexity	O
and	O
cost	O
to	O
their	O
production	O
.	O

Here	O
we	O
describe	O
a	O
simple	O
and	O
rapid	O
mutagenesis	B-P
-based	O
approach	O
designed	O
to	O
confer	O
SpA	O
binding	O
upon	O
a	O
priori	O
non-SpA-binding	O
VHHs	O
.	O

We	O
show	O
that	O
SpA	O
binding	O
of	O
VHHs	O
is	O
determined	O
primarily	O
by	O
the	O
same	O
set	O
of	O
residues	O
as	O
in	O
human	O
mAbs	O
,	O
albeit	O
with	O
an	O
unexpected	O
degree	O
of	O
tolerance	O
to	O
substitutions	O
at	O
certain	O
core	O
and	O
non-core	O
positions	O
and	O
some	O
limited	O
dependence	O
on	O
at	O
least	O
one	O
residue	O
outside	O
the	O
SpA	O
interface	O
,	O
and	O
that	O
SpA	O
binding	O
could	O
be	O
successfully	O
introduced	O
into	O
five	O
VHHs	O
against	O
three	O
different	O
targets	O
with	O
no	O
adverse	O
effects	O
on	O
expression	O
yield	O
or	O
antigen	O
binding	O
.	O

Next-generation	O
sequencing	O
of	O
llama	O
,	O
alpaca	O
and	O
dromedary	O
VHH	O
repertoires	O
suggested	O
that	O
species	O
differences	O
in	O
SpA	O
binding	O
may	O
result	O
from	O
frequency	O
variation	O
in	O
specific	O
deleterious	O
polymorphisms	O
,	O
especially	O
Ile57	O
.	O

Thus	O
,	O
the	O
SpA	O
binding	O
phenotype	O
of	O
camelid	O
VHHs	O
can	O
be	O
easily	O
modulated	O
to	O
take	O
advantage	O
of	O
tag-less	B-P
purification	I-P
techniques	O
,	O
although	O
the	O
frequency	O
with	O
which	O
this	O
is	O
required	O
may	O
depend	O
on	O
the	O
source	O
species	O
.	O

Bi-directional	O
DNA	O
Walking	O
Machine	O
and	O
Its	O
Application	O
in	O
an	O
Enzyme-Free	B-P
Electrochemiluminescence	I-P
Biosensor	O
for	O
Sensitive	O
Detection	O
of	O
MicroRNAs	O
.	O

Herein	O
,	O
a	O
dual	O
microRNA	O
(	O
miRNA	O
)	O
powered	O
bi-directional	O
DNA	O
walking	O
machine	O
with	O
precise	O
control	O
was	O
developed	O
to	O
fabricate	O
an	O
enzyme-free	O
biosensor	O
on	O
the	O
basis	O
of	O
distance-based	O
electrochemiluminescence	B-P
(	O
ECL	B-P
)	O
energy	O
transfer	O
for	O
multiple	O
detection	O
of	O
miRNAs	O
.	O

By	O
using	O
miRNA-21	O
as	O
the	O
driving	O
force	O
,	O
the	O
DNA	O
walker	O
could	O
move	O
forth	O
along	O
the	O
track	O
and	O
generated	O
quenching	O
of	O
ECL	B-P
response	O
due	O
to	O
the	O
proximity	O
between	O
Au	O
nanoparticles	O
(	O
AuNPs	O
)	O
and	O
Mn	O
(	O
2+	O
)	O
doped	O
CdS	O
nanocrystals	O
(	O
CdS	O
:	O
Mn	O
NCs	O
)	O
film	O
as	O
the	O
ECL	B-P
emitters	O
,	O
realizing	O
ultrasensitive	O
determination	B-P
of	O
miRNA-21	O
.	O

Impressively	O
,	O
once	O
miRNA-155	O
was	O
introduced	O
as	O
the	O
driving	O
force	O
,	O
the	O
walker	O
could	O
move	O
back	O
along	O
the	O
track	O
automatically	O
,	O
and	O
surface	O
plasmon	O
resonance	O
(	O
SPR	O
)	O
occurred	O
owing	O
to	O
the	O
appropriate	O
large	O
separation	O
between	O
AuNPs	O
and	O
CdS	O
:	O
Mn	O
NCs	O
,	O
achieving	O
an	O
ECL	B-P
enhancement	O
and	O
realizing	O
ultrasensitive	O
detection	O
of	O
miRNA-155	O
.	O

The	O
bi-directiona	O
l	O
movement	O
of	O
the	O
DNA	O
walker	O
on	O
the	O
track	O
led	O
to	O
continuous	O
distance-based	O
energy	O
transfer	O
from	O
CdS	O
:	O
Mn	O
NCs	O
film	O
by	O
AuNPs	O
,	O
which	O
resulted	O
in	O
significant	O
ECL	B-P
signal	O
variation	O
of	O
CdS	O
:	O
Mn	O
NCs	O
for	O
multiple	O
detection	O
of	O
miRNA-21	O
and	O
miRNA-155	O
down	O
to	O
1.51	O
fM	O
and	O
1.67	O
fM	O
,	O
respectively	O
.	O

Amazingly	O
,	O
the	O
elaborated	O
biosensor	O
provided	O
a	O
new	O
chance	O
for	O
constructing	O
controllable	O
molecular	O
nanomachines	O
in	O
biosensing	B-P
,	O
disease	O
diagnosis	O
,	O
and	O
clinical	O
analysis	O
.	O

Histopathology	O
of	O
the	O
filum	O
terminale	O
in	O
children	O
with	O
and	O
without	O
tethered	O
cord	O
syndrome	O
with	O
attention	O
to	O
the	O
elastic	O
tissue	O
within	O
the	O
filum	O
.	O

To	O
compare	O
histologically	O
transected	O
fila	O
from	O
pediatric	O
patients	O
with	O
tethered	O
cord	O
syndrome	O
(	O
TCS	O
)	O
,	O
with	O
and	O
without	O
a	O
low	O
conus	O
,	O
with	O
controls	O
,	O
focusing	O
on	O
collagenous	O
and	O
elastic	O
tissue	O
.	O

Thirty	O
fila	O
from	O
patients	O
with	O
TCS	O
,	O
including	O
5	O
where	O
minimal	O
cautery	O
was	O
used	O
prior	O
to	O
filum	O
section	B-P
,	O
were	O
compared	O
with	O
fila	O
from	O
27	O
pediatric	O
cadavers	O
without	O
TCS	O
(	O
controls	O
)	O
.	O

Sections	O
of	O
fila	O
were	O
stained	B-P
with	O
H	B-P
&	I-P
E	I-P
,	O
Masson	B-P
trichrome	I-P
and	O
Verhoeff	B-P
von	I-P
Gieson	I-P
elastic	I-P
stains	I-P
,	O
and	O
7	O
with	O
Gordon	B-P
and	I-P
Sweet	I-P
's	I-P
reticulin	I-P
stain	I-P
.	O

Fila	O
from	O
controls	O
showed	O
loose	O
fibrous	O
connective	O
tissue	O
(	O
FCT	O
)	O
with	O
thin	O
and	O
evenly	O
dispersed	O
elastic	O
fibers	O
(	O
EFs	O
)	O
.	O

Reticulin	O
fibers	O
(	O
RFs	O
)	O
were	O
seen	O
in	O
blood	O
vessel	O
walls	O
and	O
nerve	O
twigs	O
.	O

Fat	O
was	O
identified	O
microscopically	O
in	O
2	O
fila	O
.	O

All	O
fila	O
from	O
patients	O
with	O
TCS	O
had	O
dense	O
FCT	O
.	O

The	O
EFs	O
were	O
in	O
normal	O
numbers	O
in	O
17	O
,	O
and	O
focally	O
or	O
diffusely	O
decreased	O
in	O
13	O
.	O

All	O
25	O
patients	O
where	O
the	O
fila	O
were	O
cauterized	O
during	O
resection	O
had	O
thick	O
and	O
coiled	O
EFs	O
.	O

Coiling	O
was	O
not	O
seen	O
when	O
minimal	O
cautery	O
was	O
applied	O
.	O

RFs	O
were	O
seen	O
in	O
blood	O
vessel	O
walls	O
and	O
nerve	O
twigs	O
.	O

Fat	O
was	O
identified	O
in	O
19	O
patients	O
.	O

Findings	O
were	O
similar	O
,	O
whether	O
the	O
conus	O
termination	O
was	O
normal	O
or	O
low	O
.	O

The	O
fila	O
of	O
all	O
patients	O
with	O
TCS	O
,	O
whether	O
or	O
not	O
the	O
conus	O
was	O
low	O
,	O
showed	O
abnormal	O
FCT	O
.	O

EFs	O
were	O
decreased	O
in	O
48	O
%	O
of	O
patients	O
;	O
however	O
,	O
there	O
were	O
thick	O
and	O
coiled	O
EFs	O
in	O
all	O
patients	O
.	O

Coiling	O
of	O
EFs	O
,	O
initially	O
thought	O
to	O
be	O
an	O
abnormality	O
in	O
patients	O
,	O
is	O
considered	O
most	O
likely	O
to	O
be	O
a	O
result	O
of	O
cautery	O
(	O
i.e.	O
,	O
artifactual	O
/	O
iatrogenic	O
coiling	O
)	O
.	O

Structural	O
Insight	O
into	O
Recognition	O
of	O
Methylated	O
Histone	O
H3K4	O
by	O
Set3	O
.	O

The	O
plant	O
homeodomain	O
(	O
PHD	O
)	O
finger	O
of	O
Set3	O
binds	O
methylated	O
lysine	O
4	O
of	O
histone	O
H3	O
in	O
vitro	O
and	O
in	O
vivo	O
;	O
however	O
,	O
precise	O
selectivity	O
of	O
this	O
domain	O
has	O
not	O
been	O
fully	O
characterized	O
.	O

Here	O
,	O
we	O
explore	O
the	O
determinants	O
of	O
methyllysine	O
recognition	O
by	O
the	O
PHD	O
fingers	O
of	O
Set3	O
and	O
its	O
orthologs	O
.	O

We	O
use	O
X-ray	B-P
crystallographic	I-P
and	O
spectroscopic	B-P
approaches	I-P
to	O
show	O
that	O
the	O
Set3	O
PHD	O
finger	O
binds	O
di-	O
and	O
trimethylated	O
states	O
of	O
H3K4	O
with	O
comparable	O
affinities	O
and	O
employs	O
similar	O
molecular	O
mechanisms	O
to	O
form	O
complexes	O
with	O
either	O
mark	O
.	O

Composition	O
of	O
the	O
methyllysine	O
-	O
binding	O
pocket	O
plays	O
an	O
essential	O
role	O
in	O
determining	B-P
the	I-P
selectivity	I-P
of	O
the	O
PHD	O
fingers	O
.	O

The	O
finding	O
that	O
the	O
histone-binding	O
activity	O
is	O
not	O
conserved	O
in	O
the	O
PHD	O
finger	O
of	O
Set4	O
suggests	O
different	O
functions	O
for	O
the	O
Set3	O
and	O
Set4	O
paralogs	O
.	O

Cyclic	O
thrombocytopenia	O
synchronizing	O
with	O
the	O
menstrual	O
cycle	O
showing	O
periodic	O
phases	O
of	O
thrombocytopenia	O
and	O
rebound	O
thrombocytosis	O
.	O

A	O
37-	O
year	O
-old	O
woman	O
was	O
admitted	O
to	O
our	O
hospital	O
for	O
purpura	O
involving	O
the	O
extremities	O
and	O
thrombocytopenia	O
.	O

Prednisolone	O
(	O
PSL	O
)	O
was	O
administered	O
based	O
on	O
a	O
diagnosis	O
of	O
idiopathic	O
thrombocytopenic	O
purpura	O
(	O
ITP	O
)	O
,	O
but	O
was	O
not	O
effective	O
for	O
maintaining	O
her	O
platelet	B-P
count	I-P
within	O
the	O
normal	O
range	O
,	O
which	O
showed	O
cyclic	O
fluctuation	O
corresponding	O
to	O
the	O
menstrual	O
cycle	O
.	O

Therefore	O
,	O
we	O
discontinued	O
PSL	O
,	O
and	O
cyclic	O
thrombocytopenia	O
(	O
CTP	O
)	O
was	O
diagnosed	O
.	O

CTP	O
is	O
a	O
rare	O
disease	O
which	O
is	O
usually	O
treated	O
as	O
ITP	O
but	O
with	O
no	O
response	O
.	O

Although	O
the	O
exact	O
cause	O
of	O
CTP	O
is	O
uncertain	O
,	O
in	O
our	O
case	O
,	O
a	O
hormonal	O
mechanism	O
may	O
be	O
responsible	O
for	O
fluctuating	O
platelet	B-P
count	I-P
.	O

Intraoperative	O
ketamine	O
reduces	O
immediate	O
postoperative	O
opioid	O
consumption	O
after	O
spinal	O
fusion	O
surgery	O
in	O
chronic	O
pain	O
patients	O
with	O
opioid	O
dependency	O
:	O
a	O
randomized	O
,	O
blinded	O
trial	O
.	O

Perioperative	O
handling	O
of	O
surgical	O
patients	O
with	O
opioid	O
dependency	O
represents	O
an	O
important	O
clinical	O
problem	O
.	O

Animal	O
studies	O
suggest	O
that	O
ketamine	O
attenuates	O
central	O
sensitization	O
and	O
hyperalgesia	O
and	O
thereby	O
reduces	O
postoperative	O
opioid	O
tolerance	O
.	O

We	O
hypothesized	O
that	O
intraoperative	O
ketamine	O
would	O
reduce	O
immediate	O
postoperative	O
opioid	O
consumption	O
compared	O
with	O
placebo	O
in	O
chronic	O
pain	O
patients	O
with	O
opioid	O
dependency	O
undergoing	O
lumbar	O
spinal	O
fusion	O
surgery	O
.	O

Primary	O
outcome	O
was	O
morphine	O
consumption	O
0	O
to	O
24	O
hours	O
postoperatively	O
.	O

Secondary	O
outcomes	O
were	O
acute	O
pain	O
at	O
rest	O
and	O
during	O
mobilization	O
2	O
to	O
24	O
hours	O
postoperatively	O
(	O
visual	B-P
analogue	I-P
scale	I-P
)	O
,	O
adverse	O
events	O
,	O
and	O
persistent	O
pain	O
6	O
months	O
postoperatively	O
.	O

One	O
hundred	O
fifty	O
patients	O
were	O
randomly	O
assigned	O
to	O
intraoperative	O
S-ketamine	O
bolus	O
0.5	O
mg/kg	O
and	O
infusion	O
0.25	O
mg·kg·h	O
or	O
placebo	O
.	O

Postoperatively	O
,	O
patients	O
received	O
their	O
usual	O
opioids	O
,	O
paracetamol	O
and	O
IV	O
patient-controlled	O
analgesia	O
with	O
morphine	O
.	O

In	O
the	O
final	O
analyses	O
,	O
147	O
patients	O
were	O
included	O
.	O

Patient-controlled	O
analgesia	O
IV	O
morphine	O
consumption	O
0	O
to	O
24	O
hours	O
postoperatively	O
was	O
significantly	O
reduced	O
in	O
the	O
ketamine	O
group	O
compared	O
with	O
the	O
placebo	O
group	O
:	O
79	O
(	O
47	O
)	O
vs	O
121	O
(	O
53	O
)	O
mg	O
IV	O
,	O
mean	O
difference	O
42	O
mg	O
(	O
95	O
%	O
confidence	O
interval	O
-59	O
to	O
-25	O
)	O
,	O
P	O
<	O
0.001	O
.	O

Sedation	O
was	O
significantly	O
reduced	O
in	O
the	O
ketamine	O
group	O
6	O
and	O
24	O
hours	O
postoperatively	O
.	O

There	O
were	O
no	O
significant	O
differences	O
regarding	O
acute	O
pain	O
,	O
nausea	O
,	O
vomiting	O
,	O
hallucinations	O
,	O
or	O
nightmares	O
.	O

Back	O
pain	O
at	O
6	O
months	O
postoperatively	O
compared	O
with	O
preoperative	O
pain	O
was	O
significantly	O
more	O
improved	O
in	O
the	O
ketamine	O
group	O
compared	O
with	O
the	O
placebo	O
group	O
,	O
P	O
=	O
0.005	O
.	O

In	O
conclusion	O
,	O
intraoperative	O
ketamine	O
significantly	O
reduced	O
morphine	O
consumption	O
0	O
to	O
24	O
hours	O
after	O
lumbar	O
fusion	O
surgery	O
in	O
opioid	O
-	O
dependent	O
patients	O
.	O

The	O
trend	O
regarding	O
less	O
persistent	O
pain	O
6	O
months	O
postoperatively	O
needs	O
further	O
investigation	O
.	O

Structure	O
of	O
Carbon	O
Nanotube	O
Porins	O
in	O
Lipid	O
Bilayers	O
:	O
An	O
in	O
Situ	O
Small-Angle	B-P
X-ray	I-P
Scattering	I-P
(	O
SAXS	B-P
)	O
Study	O
.	O

Carbon	O
nanotube	O
porins	O
(	O
CNTPs	O
)	O
,	O
small	O
segments	O
of	O
carbon	O
nanotubes	O
capable	O
of	O
forming	O
defined	O
pores	O
in	O
lipid	O
membranes	O
,	O
are	O
important	O
future	O
components	O
for	O
bionanoelectronic	O
devices	O
as	O
they	O
could	O
provide	O
a	O
robust	O
analog	O
of	O
biological	O
membrane	O
channels	O
.	O

In	O
order	O
to	O
control	O
the	O
incorporation	O
of	O
these	O
CNT	O
channels	O
into	O
lipid	O
bilayers	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
structure	O
of	O
the	O
CNTPs	O
before	O
and	O
after	O
insertion	O
into	O
the	O
lipid	O
bilayer	O
as	O
well	O
as	O
the	O
impact	O
of	O
such	O
insertion	O
on	O
the	O
bilayer	O
structure	O
.	O

Here	O
we	O
employed	O
a	O
noninvasive	O
in	O
situ	O
probe	O
,	O
small-angle	B-P
X-ray	I-P
scattering	I-P
,	O
to	O
study	O
the	O
integration	O
of	O
CNT	O
porins	O
into	O
dioleoylphosphatidylcholine	O
bilayers	O
.	O

Our	O
results	O
show	O
that	O
CNTPs	O
in	O
solution	O
are	O
stabilized	O
by	O
a	O
monolayer	O
of	O
lipid	O
molecules	O
wrapped	O
around	O
their	O
outer	O
surface	O
.	O

We	O
also	O
demonstrate	O
that	O
insertion	O
of	O
CNTPs	O
into	O
the	O
lipid	O
bilayer	O
results	O
in	O
decreased	O
bilayer	O
thickness	O
with	O
the	O
magnitude	O
of	O
this	O
effect	O
increasing	O
with	O
the	O
concentration	O
of	O
CNTPs	O
.	O

Increase	O
in	O
average	O
foveal	O
thickness	O
after	O
internal	O
limiting	O
membrane	O
peeling	O
.	O

To	O
report	O
the	O
findings	O
in	O
three	O
cases	O
in	O
which	O
the	O
average	O
foveal	O
thickness	O
was	O
increased	O
after	O
a	O
thin	O
epiretinal	O
membrane	O
(	O
ERM	O
)	O
was	O
removed	O
by	O
vitrectomy	O
with	O
internal	O
limiting	O
membrane	O
(	O
ILM	O
)	O
peeling	O
.	O

The	O
foveal	O
contour	O
was	O
normal	O
preoperatively	O
in	O
all	O
eyes	O
.	O

All	O
cases	O
underwent	O
successful	O
phacovitrectomy	O
with	O
ILM	O
peeling	O
for	O
a	O
thin	O
ERM	O
.	O

The	O
optical	B-P
coherence	I-P
tomography	I-P
(	O
OCT	B-P
)	O
images	O
were	O
examined	O
before	O
and	O
after	O
the	O
surgery	O
.	O

The	O
changes	O
in	O
the	O
average	O
foveal	O
(	O
1	O
mm	O
)	O
thickness	O
and	O
the	O
foveal	O
areas	O
within	O
500	O
μm	O
from	O
the	O
foveal	O
center	O
were	O
measured	O
.	O

The	O
postoperative	O
changes	O
in	O
the	O
inner	O
and	O
outer	O
retinal	O
areas	O
determined	O
from	O
the	O
cross-sectional	O
OCT	B-P
images	O
were	O
analyzed	O
.	O

The	O
average	O
foveal	O
thickness	O
and	O
the	O
inner	O
and	O
outer	O
foveal	O
areas	O
increased	O
significantly	O
after	O
the	O
surgery	O
in	O
each	O
of	O
the	O
three	O
cases	O
.	O

The	O
percentage	O
increase	O
in	O
the	O
average	O
foveal	O
thickness	O
relative	O
to	O
the	O
baseline	O
thickness	O
was	O
26	O
%	O
in	O
Case	O
1	O
,	O
29	O
%	O
in	O
Case	O
2	O
,	O
and	O
31	O
%	O
in	O
Case	O
3	O
.	O

The	O
percentage	O
increase	O
in	O
the	O
foveal	O
inner	O
retinal	O
area	O
was	O
71	O
%	O
in	O
Case	O
1	O
,	O
113	O
%	O
in	O
Case	O
2	O
,	O
and	O
110	O
%	O
in	O
Case	O
3	O
,	O
and	O
the	O
percentage	O
increase	O
in	O
foveal	O
outer	O
retinal	O
area	O
was	O
8	O
%	O
in	O
Case	O
1	O
,	O
13	O
%	O
in	O
Case	O
2	O
,	O
and	O
18	O
%	O
in	O
Case	O
3	O
.	O

The	O
increase	O
in	O
the	O
average	O
foveal	O
thickness	O
and	O
the	O
inner	O
and	O
outer	O
foveal	O
areas	O
suggests	O
that	O
a	O
centripetal	O
movement	O
of	O
the	O
inner	O
and	O
outer	O
retinal	O
layers	O
toward	O
the	O
foveal	O
center	O
probably	O
occurred	O
due	O
to	O
the	O
ILM	O
peeling	O
.	O

Impact	O
of	O
systemic	O
alitretinoin	O
treatment	O
on	O
skin	O
barrier	O
gene	O
and	O
protein	O
expression	O
in	O
patients	O
with	O
chronic	O
hand	O
eczema	O
.	O

Chronic	O
hand	O
eczema	O
(	O
CHE	O
)	O
is	O
a	O
common	O
inflammatory	O
skin	O
disease	O
that	O
affects	O
approximately	O
10	O
%	O
of	O
the	O
population	O
.	O

Systemic	O
alitretinoin	O
has	O
been	O
shown	O
to	O
be	O
effective	O
in	O
patients	O
with	O
CHE	O
who	O
are	O
refractory	O
to	O
topical	O
corticosteroids	O
.	O

To	O
analyse	O
the	O
impact	O
of	O
alitretinoin	O
on	O
the	O
skin	O
barrier	O
genes	O
and	O
protein	O
expression	O
in	O
the	O
skin	O
lesions	O
of	O
patients	O
with	O
CHE	O
.	O

Fifteen	O
patients	O
with	O
CHE	O
were	O
treated	O
with	O
30	O
mg	O
daily	O
of	O
alitretinoin	O
for	O
up	O
to	O
27	O
weeks	O
.	O

Disease	O
severity	O
was	O
assessed	O
using	O
a	O
clinical	O
score	O
.	O

Skin	B-P
biopsies	I-P
from	O
all	O
the	O
patients	O
were	O
evaluated	O
before	O
and	O
after	O
therapy	O
for	O
the	O
expression	O
of	O
Ki-67	O
,	O
various	O
skin	O
barrier	O
genes	O
and	O
thymic	O
stromal	O
lymphopoietin	O
(	O
TSLP	O
)	O
by	O
real-time	O
quantitative	O
polymerase	O
chain	O
reaction	O
and	O
immunohistochemistry	B-P
.	O

After	O
alitretinoin	O
application	O
,	O
an	O
improvement	O
in	O
the	O
clinical	O
severity	O
of	O
CHE	O
was	O
observed	O
in	O
the	O
majority	O
of	O
patients	O
.	O

Analysis	O
of	O
skin	B-P
biopsies	I-P
before	O
treatment	O
showed	O
a	O
significant	O
increase	O
in	O
Ki-67	O
-	O
positive	O
cells	O
in	O
the	O
suprabasal	O
layer	O
and	O
a	O
dysregulated	O
expression	O
of	O
various	O
skin	O
barrier	O
genes	O
,	O
such	O
as	O
claudin	O
1	O
,	O
loricrin	O
,	O
filaggrin	O
and	O
cytokeratin	O
10	O
,	O
which	O
were	O
normalized	O
after	O
treatment	O
.	O

TSLP	O
was	O
significantly	O
upregulated	O
in	O
patients	O
with	O
CHE	O
and	O
also	O
normalized	O
after	O
alitretinoin	O
treatment	O
and	O
negatively	O
correlated	O
with	O
filaggrin	O
.	O

Our	O
data	O
indicate	O
that	O
the	O
expression	O
of	O
barrier	O
genes	O
and	O
proteins	O
was	O
normalized	O
following	O
treatment	O
with	O
alitretinoin	O
in	O
patients	O
with	O
CHE	O
.	O

The	O
change	O
in	O
expression	O
levels	O
of	O
these	O
genes	O
correlated	O
with	O
the	O
clinical	O
efficacy	O
,	O
suggesting	O
that	O
alitretinoin	O
exhibits	O
a	O
disease	O
-	O
modifying	O
activity	O
.	O

TSLP	O
is	O
upregulated	O
in	O
CHE	O
and	O
seems	O
to	O
counteract	O
filaggrin	O
expression	O
in	O
the	O
skin	O
.	O

Geometric	O
morphometrics	B-P
reveals	O
restrictions	O
on	O
the	O
shape	O
of	O
the	O
female	O
os	O
coxae	O
.	O

The	O
methodology	O
for	O
sex	O
determination	O
in	O
human	O
skeletal	O
remains	O
depends	O
on	O
the	O
different	O
bone	O
morphologies	O
presented	O
by	O
men	O
and	O
women	O
.	O

Due	O
to	O
their	O
direct	O
implications	O
in	O
reproduction	O
,	O
the	O
whole	O
pelvis	O
,	O
particularly	O
the	O
os	O
coxae	O
,	O
shows	O
different	O
characteristics	O
in	O
either	O
sex	O
.	O

The	O
sacrum	O
and	O
the	O
os	O
coxae	O
constitute	O
the	O
birth	O
cana	O
l.	O
In	O
this	O
research	O
study	O
,	O
the	O
os	O
coxae	O
shape	O
is	O
analyzed	O
using	O
geometric	O
morphometrics	B-P
,	O
providing	O
information	O
on	O
morphology	O
,	O
regardless	O
of	O
size	O
or	O
any	O
other	O
factor	O
beyond	O
the	O
geometry	O
itself	O
.	O

A	O
total	O
of	O
46	O
adult	O
ossa	O
coxae	O
from	O
a	O
Spanish	O
archaeological	O
collection	B-P
were	O
studied	O
using	O
geometric	O
morphometrics	B-P
.	O

The	O
results	O
show	O
that	O
there	O
is	O
a	O
restriction	O
on	O
the	O
shape	O
of	O
female	O
os	O
coxae	O
.	O

In	O
contrast	O
,	O
male	O
os	O
coxae	O
presents	O
a	O
greater	O
range	O
of	O
variation	O
.	O

The	O
biological	O
reason	O
for	O
this	O
difference	O
is	O
the	O
obstetrical	O
dilemma	O
;	O
a	O
concept	O
defined	O
as	O
the	O
anatomical	O
conflict	O
between	O
bipedalism	O
and	O
the	O
full-term	O
birth	O
of	O
a	O
neonate	O
whose	O
large	O
head	O
requires	O
greater	O
dimensions	O
in	O
the	O
pelvic	O
cavity	O
.	O

Our	O
experimental	O
data	O
reinforce	O
the	O
validity	O
of	O
the	O
obstetrical	O
dilemma	O
as	O
source	O
of	O
the	O
restriction	O
on	O
the	O
shape	O
of	O
female	O
ossa	O
coxae	O
.	O

Additionally	O
,	O
according	O
to	O
the	O
results	O
obtained	O
,	O
size	O
itself	O
does	O
not	O
represent	O
a	O
condition	O
for	O
belonging	O
to	O
one	O
sex	O
or	O
another	O
.	O

The	O
Heater	O
Cooler	O
as	O
a	O
Source	O
of	O
Infection	O
from	O
Nontuberculous	O
Mycobacteria	O
.	O

Nosocomial	O
infections	O
acquired	O
during	O
the	O
course	O
of	O
cardiac	O
surgery	O
and	O
hospitalization	O
can	O
have	O
devastating	O
patient	O
consequences	O
.	O

The	O
source	O
of	O
these	O
infections	O
is	O
often	O
difficult	O
to	O
determine	O
which	O
complicates	O
eradication	O
efforts	O
.	O

Recently	O
it	O
has	O
become	O
apparent	O
that	O
the	O
heater-cooler	O
devices	O
used	O
in	O
conjunction	O
with	O
cardiopulmonary	O
bypass	O
may	O
become	O
contaminated	O
with	O
bacteria	O
that	O
are	O
normally	O
found	O
in	O
hospital	O
water	O
sources	O
.	O

The	O
culprit	O
organisms	O
are	O
nontuberculous	O
mycobacteria	O
which	O
coat	O
the	O
intrinsic	O
surfaces	O
found	O
within	O
the	O
circuits	O
of	O
the	O
heater-coolers	O
.	O

Aerosolization	O
of	O
the	O
bacteria	O
occurs	O
during	O
normal	O
heater-cooler	O
operation	O
which	O
can	O
disperse	O
the	O
organisms	O
throughout	O
the	O
operating	O
room	O
.	O

The	O
bacteria	O
are	O
slow-growing	O
and	O
may	O
not	O
present	O
for	O
months	O
,	O
or	O
years	O
,	O
following	O
exposure	O
which	O
makes	O
epidemiological	O
determination	B-P
a	O
challenge	O
.	O

The	O
ensuing	O
report	O
summarizes	O
a	O
recent	O
outbreak	O
in	O
these	O
infections	O
that	O
have	O
been	O
reported	O
both	O
in	O
Europe	O
and	O
the	O
United	O
States	O
,	O
along	O
with	O
efforts	O
to	O
reduce	O
the	O
risk	O
for	O
patient	O
infection	O
.	O

Negative	O
Psychological	O
Consequences	O
of	O
Breast	O
Cancer	O
among	O
Recently	O
Diagnosed	O
Ethnically	O
Diverse	O
Women	O
.	O

Breast	O
cancer	O
has	O
psychological	O
consequences	O
that	O
impact	O
quality	O
of	O
life	O
(	O
QOL	O
)	O
.	O

We	O
examined	O
factors	O
associated	O
with	O
negative	O
psychological	O
consequences	O
of	O
a	O
breast	O
cancer	O
diagnosis	O
,	O
in	O
a	O
diverse	O
sample	O
of	O
910	O
recently	O
diagnosed	O
patients	O
(	O
378	O
African-American	O
,	O
372	O
White	O
,	O
and	O
160	O
Latina	O
)	O
.	O

Patients	O
completed	O
an	O
in-person	O
interview	O
as	O
part	O
of	O
the	O
Breast	O
Cancer	O
Care	O
in	O
Chicago	O
study	O
within	O
an	O
average	O
of	O
four	O
months	O
from	O
diagnosis	O
.	O

The	O
Cockburn	O
negative	O
psychological	O
consequences	O
of	O
breast	B-P
cancer	I-P
screening	I-P
scale	O
was	O
revised	O
to	O
focus	O
on	O
a	O
breast	O
cancer	O
diagnosis	O
.	O

Path	O
analysis	O
assessed	O
predictors	O
of	O
psychological	O
consequences	O
and	O
potential	O
mediators	O
between	O
race	O
/	O
ethnicity	O
and	O
psychological	O
consequences	O
.	O

Compared	O
to	O
White	O
counterparts	O
,	O
bivariate	O
analysis	O
showed	O
African-American	O
(	O
β	O
=	O
1.4	O
,	O
p	O
<	O
0.05	O
)	O
and	O
Latina	O
(	O
β	O
=	O
3.6	O
,	O
p	O
<	O
0.001	O
)	O
women	O
reported	O
greater	O
psychological	O
consequences	O
.	O

Strongest	O
predictors	O
(	O
P	O
<	O
0.05	O
for	O
all	O
)	O
included	O
unmet	O
social	O
support	O
(	O
β	O
=	O
0.38	O
)	O
,	O
and	O
provider	O
trust	O
(	O
β	O
=	O
0.12	O
)	O
,	O
followed	O
by	O
stage	O
at	O
diagnosis	O
(	O
β	O
=	O
0.10	O
)	O
and	O
perceived	O
neighborhood	O
social	O
disorder	O
(	O
β	O
=	O
0.09	O
)	O
.The	O
strongest	O
mediator	O
between	O
race	O
/	O
ethnicity	O
and	O
psychological	O
consequences	O
was	O
unmet	O
social	O
support	O
.	O

African-American	O
and	O
Latina	O
women	O
reported	O
greater	O
psychological	O
consequences	O
related	O
to	O
their	O
breast	O
cancer	O
diagnosis	O
;	O
this	O
disparity	O
was	O
mediated	O
by	O
differences	O
in	O
unmet	O
social	O
support	O
.	O

Social	O
support	O
represents	O
a	O
promising	O
point	O
of	O
intervention	O
.	O

Targeting	O
accuracy	O
of	O
single-isocenter	O
intensity-modulated	O
radiosurgery	O
for	O
multiple	O
lesions	O
.	O

To	O
investigate	O
the	O
targeting	O
accuracy	O
of	O
intensity-modulated	O
SRS	O
(	O
IMRS	O
)	O
plans	O
designed	O
to	O
simultaneously	O
treat	O
multiple	O
brain	O
metastases	O
with	O
a	O
single	O
isocenter	O
.	O

A	O
home-made	O
acrylic	O
phantom	O
able	O
to	O
support	O
a	O
film	O
(	O
EBT3	O
)	O
in	O
its	O
coronal	O
plane	O
was	O
used	O
.	O

The	O
phantom	O
was	O
CT	B-P
scanned	I-P
and	O
three	O
coplanar	O
small	O
targets	O
(	O
a	O
central	O
and	O
two	O
peripheral	O
)	O
were	O
outlined	O
in	O
the	O
Eclipse	O
system	O
.	O

Peripheral	O
targets	O
were	O
6	O
cm	O
apart	O
from	O
the	O
central	O
one	O
.	O

A	O
reference	O
IMRS	O
plan	O
was	O
designed	O
to	O
simultaneously	O
treat	O
the	O
three	O
targets	O
,	O
but	O
only	O
a	O
single	O
isocenter	O
located	O
at	O
the	O
center	O
of	O
the	O
central	O
target	O
was	O
used	O
.	O

After	O
positioning	O
the	O
phantom	O
on	O
the	O
linac	O
using	O
the	O
room	O
lasers	O
,	O
a	O
CBCT	B-P
scan	I-P
was	O
acquired	O
and	O
the	O
reference	O
plan	O
were	O
mapped	O
on	O
it	O
,	O
by	O
placing	O
the	O
planned	O
isocenter	O
at	O
the	O
intersection	O
of	O
the	O
landmarks	O
used	O
in	O
the	O
film	O
showing	O
the	O
linac	O
isocenter	O
.	O

The	O
mapped	O
plan	O
was	O
then	O
recalculated	O
and	O
delivered	O
.	O

The	O
film	O
dose	O
distribution	O
was	O
derived	O
using	O
a	O
cloud	O
computing	O
application	O
(	O
www.radiochromic.com	O
)	O
that	O
uses	O
a	O
triple-channel	O
dosimetry	B-P
algorithm	O
.	O

Comparison	O
of	O
dose	O
distributions	O
using	O
the	O
gamma	O
index	O
(	O
5	O
%	O
/1	O
mm	O
)	O
were	O
performed	O
over	O
a	O
5	O
×	O
5	O
cm	O
(	O
2	O
)	O
region	O
centered	O
over	O
each	O
target	O
.	O

2D	O
shifts	O
required	O
to	O
get	O
the	O
best	O
gamma	O
passing	O
rates	O
on	O
the	O
peripheral	O
target	O
regions	O
were	O
compared	O
with	O
the	O
reported	O
ones	O
for	O
the	O
central	O
target	O
.	O

The	O
experiment	O
was	O
repeated	O
ten	O
times	O
in	O
different	O
sessions	O
.	O

Average	O
2D	O
shifts	O
required	O
to	O
achieve	O
optimal	O
gamma	O
passing	O
rates	O
(	O
99	O
%	O
,	O
97	O
%	O
,	O
99	O
%	O
)	O
were	O
0.7	O
mm	O
(	O
SD	O
:	O
0.3	O
mm	O
)	O
,	O
0.8	O
mm	O
(	O
SD	O
:	O
0.4	O
mm	O
)	O
and	O
0.8	O
mm	O
(	O
SD	O
:	O
0.3	O
mm	O
)	O
,	O
for	O
the	O
central	O
and	O
the	O
two	O
peripheral	O
targets	O
,	O
respectively	O
.	O

No	O
statistical	O
differences	O
(	O
p	O
>	O
0.05	O
)	O
were	O
found	O
for	O
targeting	O
accuracy	O
between	O
the	O
central	O
and	O
the	O
two	O
peripheral	O
targets	O
.	O

The	O
study	O
revealed	O
a	O
targeting	O
accuracy	O
within	O
1	O
mm	O
for	O
off-	O
isocenter	O
targets	O
within	O
6	O
cm	O
of	O
the	O
linac	O
isocenter	O
,	O
when	O
a	O
single-isocenter	O
IMRS	O
plan	O
is	O
designed	O
.	O

Hydroxysafflor	O
yellow	O
A	O
attenuates	O
the	O
expression	O
of	O
inflammatory	O
cytokines	O
in	O
acute	O
soft	O
tissue	O
injury	O
.	O

We	O
examined	O
the	O
effect	O
of	O
hydroxysafflor	O
yellow	O
A	O
(	O
HSYA	O
)	O
on	O
the	O
inflammatory	O
response	O
to	O
strike	O
-	O
induced	O
acute	O
soft	O
tissue	O
injury	O
in	O
rats	O
.	O

Soft	O
tissue	O
injury	O
was	O
induced	O
in	O
rat	O
leg	O
muscles	O
using	O
a	O
strike	O
hammer	O
,	O
followed	O
by	O
intraperitoneal	O
administration	O
of	O
HSYA	O
at	O
16	O
,	O
32	O
,	O
or	O
64	O
mg/kg	O
.	O

After	O
24	O
h	O
,	O
the	O
rats	O
were	O
anaesthetized	O
,	O
blood	O
and	O
muscle	O
samples	O
were	O
taken	O
.	O

Plasma	O
levels	B-P
of	I-P
interleukin	I-P
(	I-P
IL	I-P
)	I-P
-6	I-P
,	O
IL-1β	B-P
,	O
and	O
tumour	B-P
necrosis	I-P
factor	I-P
(	I-P
TNF	I-P
)	I-P
-α	I-P
were	O
measured	O
by	O
enzyme-linked	B-P
immunosorbent	I-P
assay	I-P
.	O

Total	O
RNA	O
and	O
protein	O
were	O
isolated	O
from	O
muscle	O
tissue	O
to	O
determine	O
the	O
mRNA	O
levels	B-P
of	I-P
IL-6	I-P
,	O
IL-1β	B-P
,	O
TNF-α	B-P
,	O
vascular	B-P
cell	I-P
adhesion	I-P
molecule	I-P
(	I-P
VCAM	I-P
)	I-P
-1	I-P
,	O
and	O
intercellular	B-P
adhesion	I-P
molecule	I-P
(	I-P
ICAM	I-P
)	I-P
-1	I-P
,	O
and	O
the	O
protein	O
level	O
of	O
phosphorylated	O
p38	O
mitogen-activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
.	O

Nuclear	O
factor	O
(	O
NF	O
)	O
-κB	O
expression	O
was	O
determined	O
by	O
muscle	O
histopathology	B-P
and	O
immunohistochemistry	B-P
.	O

HSYA	O
attenuated	O
pathologic	O
changes	O
in	O
strike	O
-	O
induced	O
soft	O
tissue	O
inflammation	O
.	O

Treatment	O
with	O
HSYA	O
also	O
alleviated	O
strike	O
-	O
induced	O
increases	O
in	O
TNF-α	B-P
,	O
IL-1β	B-P
,	O
IL-6	B-P
,	O
VCAM-1	B-P
,	O
and	O
ICAM-1	B-P
mRNA	O
levels	O
and	O
inhibited	O
the	O
increased	O
activation	O
of	O
NF-κB	O
and	O
phosphorylation	O
of	O
p38	O
MAPK	O
in	O
muscle	O
tissue	O
.	O

These	O
findings	O
suggest	O
that	O
HSYA	O
effectively	O
inhibits	O
strike	O
-	O
induced	O
inflammatory	O
signal	O
transduction	O
in	O
rats	O
.	O

Influence	O
of	O
yeast	O
and	O
lactic	O
acid	O
bacterium	O
on	O
the	O
constituent	O
profile	B-P
of	O
soy	O
sauce	O
during	O
fermentation	O
.	O

Soy	O
sauce	O
is	O
a	O
Japanese	O
traditional	O
seasoning	O
composed	O
of	O
various	O
constituents	O
that	O
are	O
produced	O
by	O
various	O
microbes	O
during	O
a	O
long-term	O
fermentation	O
process	O
.	O

Due	O
to	O
the	O
complexity	O
of	O
the	O
process	O
,	O
the	O
investigation	O
of	O
the	O
constituent	O
profile	B-P
during	O
fermentation	O
is	O
difficult	O
.	O

Metabolomics	O
,	O
the	O
comprehensive	O
study	O
of	O
low	O
molecular	O
weight	O
compounds	O
in	O
biological	O
samples	O
,	O
is	O
thought	O
to	O
be	O
a	O
promising	O
strategy	O
for	O
deep	O
understanding	O
of	O
the	O
constituent	O
contribution	O
to	O
food	O
flavor	O
characteristics	O
.	O

Therefore	O
,	O
metabolomics	O
is	O
suitable	O
for	O
the	O
analysis	O
of	O
soy	O
sauce	O
fermentation	O
.	O

Unfortunately	O
,	O
only	O
few	O
and	O
unrefined	O
studies	O
of	O
soy	O
sauce	O
fermentation	O
using	O
metabolomics	O
approach	O
have	O
been	O
reported	O
.	O

Therefore	O
,	O
we	O
investigated	O
changes	O
in	O
low	O
molecular	O
weight	O
hydrophilic	O
and	O
volatile	O
compounds	O
of	O
soy	O
sauce	O
using	O
gas	B-P
chromatography/mass	I-P
spectrometry	I-P
(	O
GC/MS	B-P
)	O
-	O
based	O
non-targeted	O
metabolic	O
profiling	O
.	O

The	O
data	O
were	O
analyzed	O
by	O
statistical	O
analysis	O
to	O
evaluate	O
influences	O
of	O
yeast	O
and	O
lactic	O
acid	O
bacterium	O
on	O
the	O
constituent	O
profile	B-P
.	O

Consequently	O
,	O
our	O
results	O
suggested	O
a	O
novel	O
finding	O
that	O
lactic	O
acid	O
bacterium	O
affected	O
the	O
production	O
of	O
several	O
constituents	O
such	O
as	O
cyclotene	O
,	O
furfural	O
,	O
furfuryl	O
alcohol	O
and	O
methional	O
in	O
the	O
soy	O
sauce	O
fermentation	O
process	O
.	O

Vasopressin	O
regulates	O
the	O
growth	O
of	O
the	O
biliary	O
epithelium	O
in	O
polycystic	O
liver	O
disease	O
.	O

The	O
neurohypophysial	O
hormone	O
arginine	O
vasopressin	O
(	O
AVP	O
)	O
acts	O
by	O
three	O
distinct	O
receptor	O
subtypes	O
:	O
V1a	O
,	O
V1b	O
,	O
and	O
V2	O
.	O

In	O
the	O
liver	O
,	O
AVP	O
is	O
involved	O
in	O
ureogenesis	O
,	O
glycogenolysis	O
,	O
neoglucogenesis	O
and	O
regeneration	O
.	O

No	O
data	O
exist	O
about	O
the	O
presence	O
of	O
AVP	O
in	O
the	O
biliary	O
epithelium	O
.	O

Cholangiocytes	O
are	O
the	O
target	O
cells	O
in	O
a	O
number	O
of	O
animal	O
models	O
of	O
cholestasis	O
,	O
including	O
bile	O
duct	O
ligation	O
(	O
BDL	O
)	O
,	O
and	O
in	O
several	O
human	O
pathologies	O
,	O
such	O
as	O
polycystic	O
liver	O
disease	O
characterized	O
by	O
the	O
presence	O
of	O
cysts	O
that	O
bud	O
from	O
the	O
biliary	O
epithelium	O
.	O

In	O
vivo	O
,	O
liver	O
fragments	O
from	O
normal	O
and	O
BDL	O
mice	O
and	O
rats	O
as	O
well	O
as	O
liver	O
samples	O
from	O
normal	O
and	O
ADPKD	O
patients	O
were	O
collected	O
to	O
evaluate	O
:	O
(	O
i	O
)	O
intrahepatic	O
bile	O
duct	O
mass	O
by	O
immunohistochemistry	B-P
for	O
cytokeratin-19	O
;	O
and	O
(	O
ii	O
)	O
expression	O
of	O
V1a	O
,	O
V1b	O
and	O
V2	O
by	O
immunohistochemistry	B-P
,	O
immunofluorescence	B-P
and	O
real-time	O
PCR	O
.	O

In	O
vitro	O
,	O
small	O
and	O
large	O
mouse	O
cholangiocytes	O
,	O
H69	O
(	O
non-malignant	O
human	O
cholangiocytes	O
)	O
and	O
LCDE	O
(	O
human	O
cholangiocytes	O
from	O
the	O
cystic	O
epithelium	O
)	O
were	O
stimulated	O
with	O
vasopressin	O
in	O
the	O
absence/	O
presence	O
of	O
AVP	O
antagonists	O
such	O
as	O
OPC-31260	O
and	O
Tolvaptan	O
,	O
before	O
assessing	O
cellular	O
growth	O
by	O
MTT	B-P
assay	I-P
and	O
cAMP	O
levels	O
.	O

Cholangiocytes	O
express	O
V2	O
receptor	O
that	O
was	O
upregulated	O
following	O
BDL	O
and	O
in	O
ADPKD	O
liver	O
samples	O
.	O

Administration	O
of	O
AVP	O
increased	O
proliferation	O
and	O
cAMP	O
levels	O
of	O
small	O
cholangiocytes	O
and	O
LCDE	O
cells	O
.	O

We	O
found	O
no	O
effect	O
in	O
the	O
proliferation	O
of	O
large	O
mouse	O
cholangiocytes	O
and	O
H69	O
cells	O
.	O

Increases	O
were	O
blocked	O
by	O
preincubation	B-P
with	O
the	O
AVP	O
antagonists	O
.	O

These	O
results	O
showed	O
that	O
AVP	O
and	O
its	O
receptors	O
may	O
be	O
important	O
in	O
the	O
modulation	O
of	O
the	O
proliferation	O
rate	O
of	O
the	O
biliary	O
epithelium	O
.	O

Co-Folding	O
of	O
a	O
FliF	O
-	O
FliG	O
Split	O
Domain	O
Forms	O
the	O
Basis	O
of	O
the	O
MS	O
:	O
C	O
Ring	O
Interface	O
within	O
the	O
Bacterial	O
Flagellar	O
Motor	O
.	O

The	O
interface	O
between	O
the	O
membrane	O
(	O
MS	O
)	O
and	O
cytoplasmic	O
(	O
C	O
)	O
rings	O
of	O
the	O
bacterial	O
flagellar	O
motor	O
couples	O
torque	O
generation	O
to	O
rotation	O
within	O
the	O
membrane	O
.	O

The	O
structure	O
of	O
the	O
C-terminal	O
helices	O
of	O
the	O
integral	O
membrane	O
protein	O
FliF	O
(	O
FliFC	O
)	O
bound	O
to	O
the	O
N	O
terminal	O
domain	O
of	O
the	O
switch	O
complex	O
protein	O
FliG	O
(	O
FliGN	O
)	O
reveals	O
that	O
FliGN	O
folds	O
around	O
FliFC	O
to	O
produce	O
a	O
topology	O
that	O
closely	O
resembles	O
both	O
the	O
middle	O
and	O
C-terminal	O
domains	O
of	O
FliG	O
.	O

The	O
interface	O
is	O
consistent	O
with	O
solution-state	O
nuclear	O
magnetic	O
resonance	O
,	O
small-angle	B-P
X-ray	I-P
scattering	I-P
,	O
in	O
vivo	O
interaction	O
studies	O
,	O
and	O
cellular	B-P
motility	I-P
assays	I-P
.	O

Co-folding	O
with	O
FliFC	O
induces	O
substantial	O
conformational	O
changes	O
in	O
FliGN	O
and	O
suggests	O
that	O
FliF	O
and	O
FliG	O
have	O
the	O
same	O
stoichiometry	O
within	O
the	O
rotor	O
.	O

Modeling	O
the	O
FliFC	O
:	O
FliGN	O
complex	O
into	O
cryo-electron	B-P
microscopy	I-P
rotor	O
density	O
updates	O
the	O
architecture	O
of	O
the	O
middle	O
and	O
upper	O
switch	O
complex	O
and	O
shows	O
how	O
domain	O
shuffling	O
of	O
a	O
conserved	O
interaction	O
module	O
anchors	O
the	O
cytoplasmic	O
rotor	O
to	O
the	O
membrane	O
.	O

The	O
Peptidoglycan	O
Pattern	O
of	O
Staphylococcus	O
carnosus	O
TM300	O
-	O
Detailed	O
Analysis	O
and	O
Variations	O
Due	O
to	O
Genetic	O
and	O
Metabolic	O
Influences	O
.	O

The	O
Gram-positive	O
bacterium	O
Staphylococcus	O
carnosus	O
(	O
S.	O
carnosus	O
)	O
TM300	O
is	O
an	O
apathogenic	O
staphylococcal	O
species	O
commonly	O
used	O
in	O
meat	O
starter	B-P
cultures	I-P
.	O

As	O
with	O
all	O
Gram-positive	O
bacteria	O
,	O
its	O
cytoplasmic	O
membrane	O
is	O
surrounded	O
by	O
a	O
thick	O
peptidoglycan	O
(	O
PGN	O
)	O
or	O
murein	O
sacculus	O
consisting	O
of	O
several	O
layers	O
of	O
glycan	O
strands	O
cross-linked	O
by	O
peptides	O
.	O

In	O
contrast	O
to	O
pathogenic	O
staphylococci	O
,	O
mainly	O
Staphylococcus	O
aureus	O
(	O
S.	O
aureus	O
)	O
,	O
the	O
chemical	O
composition	O
of	O
S.	O
carnosus	O
PGN	O
is	O
not	O
well	O
studied	O
so	O
far	O
.	O

UPLC/MS	B-P
analysis	I-P
of	O
enzymatically	B-P
digested	I-P
S.	O
carnosus	O
TM300	O
PGN	O
revealed	O
substantial	O
differences	O
in	O
its	O
composition	O
compared	O
to	O
the	O
known	O
pattern	O
of	O
S.	O
aureus	O
.	O

While	O
in	O
S.	O
aureus	O
the	O
uncross-linked	O
stem	O
peptide	O
consists	O
of	O
a	O
pentapeptide	O
,	O
in	O
S.	O
carnosus	O
,	O
this	O
part	O
of	O
the	O
PGN	O
is	O
shortened	O
to	O
tripeptides	O
.	O

Furthermore	O
,	O
we	O
found	O
the	O
PGN	O
composition	O
to	O
vary	O
when	O
cells	O
were	O
incubated	B-P
under	O
certain	O
conditions	O
.	O

The	O
collective	O
overproduction	O
of	O
HlyD	O
,	O
FtsE	O
and	O
FtsX	O
-a	O
putative	O
protein	O
complex	O
interacting	O
with	O
penicillin-binding	O
protein	O
2	O
(	O
PBP2	O
)	O
-caused	O
the	O
reappearance	O
of	O
classical	O
penta	O
stem	O
peptides	O
.	O

In	O
addition	O
,	O
under	O
high	O
sugar	O
conditions	O
,	O
tetra	O
stem	O
peptides	O
occur	O
due	O
to	O
overflow	O
metabolism	O
.	O

This	O
indicates	O
that	O
S.	O
carnosus	O
TM300	O
cells	O
adapt	O
to	O
various	O
conditions	O
by	O
modification	O
of	O
their	O
PGN	O
.	O

Glomus	O
tumor	O
in	O
teen	O
and	O
repetition	O
pneumonia	O
:	O
Case	O
report	O
.	O

Glomus	O
tumors	O
are	O
uncommon	O
tumors	O
that	O
are	O
originated	O
from	O
smooth	O
muscle	O
cells	O
of	O
the	O
neuromioarterials	O
glomus	O
bodies	O
located	O
in	O
the	O
arteriovenous	O
anastomoses	O
subcutaneous	O
tissue	O
or	O
deep	O
dermis	O
of	O
the	O
extremities	O
,	O
mainly	O
in	O
the	O
palms	O
of	O
the	O
hands	O
,	O
wrists	O
and	O
subungual	O
areas	O
of	O
the	O
fingers	O
.	O

Carcinoid	O
tumor	O
,	O
as	O
the	O
glomus	O
tumor	O
,	O
can	O
show	O
an	O
organoid	O
pattern	O
,	O
increased	O
vascularity	O
,	O
and	O
uniform	O
,	O
round	O
cells	O
with	O
eosinophilic	O
cytoplasm	O
,	O
but	O
usually	O
are	O
positive	O
for	O
cytokeratin	O
and	O
always	O
stained	O
with	O
chromogranin	O
and	O
synaptophysin	O
showing	O
negative	O
for	O
smooth	O
muscle	O
markers	O
which	O
is	O
presented	O
in	O
our	O
case	O
.	O

Glomus	O
tumors	O
have	O
a	O
good	O
prognosis	O
and	O
surgical	O
resection	O
is	O
the	O
treatment	O
of	O
choice	O
.	O

In	O
our	O
case	O
,	O
the	O
patient	O
underwent	O
pulmonary	O
bilobectomy	O
because	O
of	O
the	O
location	O
of	O
the	O
tumor	O
in	O
the	O
transition	O
between	O
the	O
middle	O
lobe	O
and	O
the	O
basal	O
bronchial	O
trunk	O
right	O
lower	O
lobe	O
divisions	O
.	O

It	O
is	O
presented	O
thus	O
a	O
glomus	O
tumor	O
with	O
exceptional	O
localization	O
(	O
pulmonary	O
and	O
bronchial	O
)	O
of	O
benign	O
histological	O
features	O
,	O
according	O
to	O
most	O
of	O
the	O
cases	O
reported	O
in	O
the	O
literature	O
emphasizing	O
their	O
particular	O
rare	O
location	O
,	O
histological	O
,	O
and	O
immunohistochemical	B-P
profile	B-P
,	O
which	O
helps	O
the	O
differential	B-P
diagnosis	I-P
with	O
other	O
most	O
common	O
tumors	O
of	O
bronchial	O
location	O
.	O

Case	O
report	O
:	O
imaging	O
the	O
clinical	O
course	O
of	O
FOPE	O
-a	O
cause	O
of	O
adolescent	O
knee	O
pain	O
.	O

Focal	O
periphyseal	O
oedema	O
(	O
FOPE	O
)	O
is	O
a	O
rare	O
MRI	B-P
finding	O
associated	O
with	O
pain	O
in	O
adolescent	O
patients	O
with	O
very	O
few	O
reported	O
cases	O
.	O

We	O
present	O
a	O
case	O
of	O
FOPE	O
in	O
a	O
13-year-old	O
girl	O
and	O
the	O
only	O
follow-up	O
imaging	B-P
available	O
for	O
an	O
isolated	O
presentation	O
of	O
this	O
condition	O
.This	O
article	O
describes	O
a	O
clinical	O
course	O
that	O
correlates	O
well	O
with	O
the	O
imaging	B-P
obtained	O
.	O

This	O
article	O
describes	O
a	O
clinical	O
course	O
that	O
correlates	O
well	O
with	O
the	O
imaging	B-P
obtained	O
.	O

A	O
16	O
Yin	O
Yang	O
gene	O
expression	O
ratio	O
signature	O
for	O
ER+	O
/	O
node-	O
breast	O
cancer	O
.	O

Breast	O
cancer	O
is	O
one	O
of	O
the	O
leading	O
causes	O
of	O
cancer	O
death	O
in	O
women	O
.	O

It	O
is	O
a	O
complex	O
and	O
heterogeneous	O
disease	O
with	O
different	O
clinical	O
outcomes	O
.	O

Stratifying	O
patients	O
into	O
subgroups	O
with	O
different	O
outcomes	O
could	O
help	O
guide	O
clinical	B-P
decision	I-P
making	I-P
.	O

In	O
this	O
study	O
,	O
we	O
used	O
two	O
opposing	O
groups	O
of	O
genes	O
,	O
Yin	O
and	O
Yang	O
,	O
to	O
develop	O
a	O
prognostic	O
expression	O
ratio	O
signature	O
.	O

Using	O
the	O
METABRIC	O
cohort	O
we	O
identified	O
a16-	O
gene	O
signature	O
capable	O
of	O
stratifying	O
breast	O
cancer	O
patients	O
into	O
four	O
risk	O
levels	O
with	O
intention	O
that	O
low-risk	O
patients	O
would	O
not	O
undergo	O
adjuvant	O
systemic	O
therapy	O
,	O
intermediate	O
-	O
low-risk	O
patients	O
will	O
be	O
treated	O
with	O
hormonal	O
therapy	O
only	O
,	O
and	O
intermediate	O
-high-	O
and	O
high-risk	O
groups	O
will	O
be	O
treated	O
by	O
chemotherapy	O
in	O
addition	O
to	O
the	O
hormonal	O
therapy	O
.	O

The	O
16-	O
gene	O
signature	O
for	O
four	O
risk	O
level	O
stratifications	O
of	O
breast	O
cancer	O
patients	O
has	O
been	O
validated	O
using	O
14	O
independent	O
datasets	O
.	O

Notably	O
,	O
the	O
low-risk	O
group	O
(	O
n	O
=	O
51	O
)	O
of	O
205	O
estrogen	O
receptor-positive	O
and	O
node	O
negative	O
(	O
ER+	O
/	O
node-	O
)	O
patients	O
from	O
three	O
different	O
datasets	O
who	O
had	O
not	O
had	O
any	O
systemic	O
adjuvant	O
therapy	O
had	O
100	O
%	O
15-	O
year	O
disease-specific	O
survival	O
rate	O
.	O

The	O
Concordance	O
Index	O
of	O
YMR	B-P
for	O
ER+	O
/	O
node	O
negative	O
patients	O
is	O
close	O
to	O
the	O
commercially	O
available	O
signatures	O
.	O

However	O
,	O
YMR	B-P
showed	O
more	O
significance	O
(	O
HR	O
=	O
3.7	O
,	O
p	O
=	O
8.7e-12	O
)	O
in	O
stratifying	O
ER+	O
/	O
node-	O
subgroup	O
than	O
OncotypeDx	B-P
(	O
HR	O
=	O
2.7	O
,	O
p	O
=	O
1.3e-7	O
)	O
,	O
MammaPrint	B-P
(	O
HR	O
=	O
2.5	O
,	O
p	O
=	O
5.8e-7	O
)	O
,	O
rorS	B-P
(	O
HR	O
=	O
2.4	O
,	O
p	O
=	O
1.4e-6	O
)	O
,	O
and	O
NPI	B-P
(	O
HR	O
=	O
2.6	O
,	O
p	O
=	O
1.2e-6	O
)	O
.	O

YMR	B-P
signature	O
may	O
be	O
developed	O
as	O
a	O
clinical	O
tool	O
to	O
select	O
a	O
subgroup	O
of	O
low-risk	O
ER+	O
/	O
node-	O
patients	O
who	O
do	O
not	O
require	O
any	O
adjuvant	O
hormonal	O
therapy	O
(	O
AHT	O
)	O
.	O

Relationship	O
between	O
XspI	O
Site	O
Polymorphisms	O
of	O
LDL-R	O
Gene	O
and	O
Serum	O
IL-2	O
and	O
IL-10	O
in	O
Patients	O
with	O
Hypercholesterolemia	O
.	O

Relationship	O
has	O
been	O
identified	O
in	O
sporadic	O
reports	O
between	O
polymorphisms	O
and	O
hypercholesterolemia	O
.	O

However	O
,	O
the	O
relationship	O
between	O
inflammatory	O
cytokines	O
and	O
polymorphism	O
of	O
low-density	O
lipoprotein	O
receptor	O
(	O
LDL-R	O
)	O
gene	O
in	O
hypercholesterolemia	O
is	O
unclear	O
.	O

This	O
study	O
aimed	O
to	O
explore	O
the	O
relationship	O
and	O
significance	O
between	O
polymorphisms	O
of	O
LDL-R	O
gene	O
and	O
serum	O
Interleukin-2	O
(	O
IL-2	O
)	O
,	O
IL-10	O
in	O
patients	O
with	O
hypercholesterolemia	O
.	O

PCR-RFLP	B-P
and	O
direct	O
DNA	O
sequencing	O
assay	O
were	O
employed	O
to	O
determine	O
polymorphism	O
of	O
LDL-R	O
gene	O
in	O
900	O
patients	O
with	O
hypercholesterolemia	O
and	O
400	O
healthy	O
cases	O
.	O

ELISA	B-P
was	O
applied	O
to	O
assay	O
serum	O
concentration	O
of	O
IL-2	O
and	O
IL-10	O
.	O

Blood	O
lipid	O
indexes	O
were	O
tested	O
in	O
all	O
cases	O
.	O

Compared	O
with	O
the	O
healthy	O
controls	O
,	O
level	O
of	O
IL-2	O
increased	O
significantly	O
,	O
while	O
IL-10	O
decreased	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Correlation	O
analysis	O
showed	O
that	O
IL-2	O
was	O
positively	O
correlated	O
with	O
total	O
cholesterol	O
(	O
TC	O
)	O
,	O
LDL-c	O
,	O
and	O
genotype	O
(	O
r	O
=	O
0.542	O
,	O
0.410	O
,	O
0.598	O
,	O
P	O
<	O
0.05	O
)	O
and	O
negatively	O
correlated	O
with	O
HDL-c	O
(	O
r	O
=	O
-0.352	O
,	O
P	O
<	O
0.05	O
)	O
.	O

Negative	O
relationship	O
also	O
was	O
found	O
between	O
TC	O
,	O
LDL-c	O
,	O
genotype	O
,	O
and	O
IL-10	O
(	O
r	O
=	O
-0.452	O
,	O
-0.390	O
,	O
-0.613	O
,	O
P	O
<	O
0.05	O
)	O
,	O
and	O
positive	O
correlation	O
between	O
HDL-c	O
and	O
IL-10	O
(	O
r	O
=	O
0.398	O
,	O
P	O
<	O
0.05	O
)	O
.	O

Multiple	O
linear	O
regression	O
showed	O
that	O
genotypes	O
and	O
TC	O
were	O
independent	O
factors	O
affecting	O
the	O
levels	B-P
of	I-P
IL-2	I-P
and	O
IL-10	B-P
(	O
P	O
<	O
0.05	O
)	O
.	O

IL-2	O
and	O
IL-10	O
were	O
related	O
to	O
gene	O
polymorphisms	O
of	O
LDL-R	O
,	O
which	O
might	O
be	O
involved	O
in	O
the	O
development	O
and	O
progress	O
of	O
hypercholesterolemia	O
.	O

Severity	O
of	O
Gastric	O
Mucosal	O
Atrophy	O
Is	O
the	O
Major	O
Determinant	O
of	O
Plasma	O
Ghrelin	O
Level	O
in	O
Hemodialysis	O
Patients	O
.	O

Ghrelin	O
,	O
an	O
orexigenic	O
hormone	O
,	O
has	O
multiple	O
favorable	O
functions	O
including	O
protein	O
anabolism	O
enhancement	O
,	O
anti-inflammatory	O
actions	O
,	O
and	O
cardiovascular	O
protection	O
.	O

A	O
low	O
plasma	O
ghrelin	O
level	O
is	O
associated	O
with	O
increased	O
mortality	O
in	O
patients	O
treated	O
with	O
hemodialysis	O
(	O
HD	O
)	O
.	O

However	O
,	O
it	O
is	O
unclear	O
whether	O
the	O
plasma	O
ghrelin	O
level	O
in	O
HD	O
patients	O
correlates	O
with	O
the	O
severity	O
of	O
gastric	O
mucosal	O
atrophy	O
and	O
Helicobacter	O
pylori	O
status	O
.	O

Seventy-eight	O
maintenance	O
HD	O
patients	O
and	O
51	O
non-dialysis	O
patients	O
with	O
chronic	O
kidney	O
disease	O
were	O
evaluated	O
for	O
severity	O
of	O
gastric	O
mucosal	O
atrophy	O
by	O
gastroduodenoscopy	O
and	O
for	O
H.	O
pylori	O
status	O
using	O
an	O
anti-H.	B-P
pylori-antibody	I-P
and	O
rapid	O
urease	B-P
test	I-P
.	O

Plasma	O
acyl	O
and	O
des-acyl	O
ghrelin	O
levels	O
were	O
measured	O
and	O
their	O
associations	O
with	O
relevant	O
clinical	O
parameters	O
were	O
investigated	O
.	O

Des-acyl	O
ghrelin	O
level	O
in	O
HD	O
patients	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
patients	O
with	O
kidney	O
function	O
preserved	O
.	O

Although	O
acyl	O
and	O
des-acyl	O
ghrelin	O
levels	O
were	O
similar	O
between	O
current	O
H.	O
pylori	O
positive	O
and	O
negative	O
HD	O
patients	O
,	O
both	O
levels	O
decreased	O
significantly	O
with	O
the	O
progress	O
of	O
endoscopic	O
gastric	O
mucosal	O
atrophy	O
in	O
HD	O
patients	O
.	O

Serum	O
pepsinogen	O
(	O
PG	O
)	O
I	O
level	O
and	O
PG	O
I	O
/	O
II	O
ratio	O
decreased	O
significantly	O
according	O
to	O
the	O
severity	O
of	O
atrophy	O
in	O
HD	O
patients	O
and	O
positively	O
significantly	O
correlated	O
with	O
both	O
ghrelin	O
levels	O
.	O

Multiple	O
regression	O
analysis	O
showed	O
significant	O
positive	O
correlations	O
between	O
acyl	O
ghrelin	O
and	O
PG	O
I	O
levels	O
(	O
β	O
=	O
0.738	O
,	O
p	O
<	O
0.001	O
)	O
and	O
significant	O
negative	O
correlations	O
between	O
ghrelin	O
and	O
age	O
,	O
albumin	O
,	O
and	O
creatinine	O
levels	O
.	O

Gastric	O
atrophy	O
is	O
the	O
major	O
determinant	O
of	O
ghrelin	O
level	O
in	O
HD	O
patients	O
.	O

Management	O
practices	O
,	O
such	O
as	O
H.	O
pylori	O
eradication	O
,	O
before	O
advanced	O
atrophy	O
may	O
be	O
required	O
to	O
prevent	O
the	O
decrease	O
of	O
ghrelin	O
levels	O
and	O
improve	O
the	O
prognosis	O
of	O
HD	O
patients	O
.	O

Identification	O
of	O
low	O
micromolar	O
dual	O
inhibitors	O
for	O
aldose	O
reductase	O
(	O
ALR2	O
)	O
and	O
poly	O
(	O
ADP-ribose	O
)	O
polymerase	O
(	O
PARP-1	O
)	O
using	O
structure	O
based	O
design	O
approach	O
.	O

Clinical	O
studies	O
have	O
revealed	O
that	O
diabetic	O
retinopathy	O
is	O
a	O
multifactorial	O
disorder	O
.	O

Moreover	O
,	O
studies	O
also	O
suggest	O
that	O
ALR2	O
and	O
PARP-1	O
co-occur	O
in	O
retinal	O
cells	O
,	O
making	O
them	O
appropriate	O
targets	O
for	O
the	O
treatment	O
of	O
diabetic	O
retinopathy	O
.	O

To	O
find	O
the	O
dual	O
inhibitors	O
of	O
ALR2	O
and	O
PARP-1	O
,	O
the	O
structure	O
based	O
design	O
was	O
carried	O
out	O
in	O
parallel	O
for	O
both	O
the	O
target	O
proteins	O
.	O

A	O
series	O
of	O
novel	O
thiazolidine-2,4-dione	O
(	O
TZD	O
)	O
derivatives	O
were	O
therefore	O
rationally	O
designed	O
,	O
synthesized	O
and	O
their	O
in	O
vitro	O
inhibitory	O
activities	O
against	O
ALR2	O
and	O
PARP-1	O
were	O
evaluated	O
.	O

The	O
experimental	O
results	O
showed	O
that	O
compounds	O
5b	O
and	O
5f	O
,	O
with	O
2-chloro	O
and	O
4-fluoro	O
substitutions	O
,	O
showed	O
biochemical	O
activities	O
in	O
micromolar	O
and	O
submicromolar	O
range	O
(	O
IC50	O
1.34-5.03μM	O
)	O
against	O
both	O
the	O
targeted	O
enzymes	O
.	O

The	O
structure-activity	O
relationship	O
elucidated	O
for	O
these	O
novel	O
inhibitors	O
against	O
both	O
the	O
enzymes	O
provide	O
new	O
insight	O
into	O
the	O
binding	O
mode	O
of	O
the	O
inhibitors	O
to	O
the	O
active	O
sites	O
of	O
enzymes	O
.	O

The	O
positive	O
results	O
of	O
the	O
biochemical	O
assay	B-P
suggest	O
that	O
these	O
compounds	O
may	O
be	O
further	O
optimized	O
and	O
utilized	O
for	O
the	O
treatment	O
of	O
diabetic	O
retinopathy	O
.	O

Comparison	O
of	O
visual	O
outcomes	O
and	O
reading	O
performance	O
after	O
bilateral	O
implantation	O
of	O
multifocal	O
intraocular	O
lenses	O
with	O
bilateral	O
monofocal	O
intraocular	O
lenses	O
.	O

To	O
compare	O
the	O
visual	O
acuity	O
outcomes	O
,	O
contrast	O
sensitivity	O
function	O
(	O
CS	O
)	O
and	O
reading	O
ability	O
in	O
patients	O
with	O
bilateral	O
multifocal	O
intraocular	O
lenses	O
and	O
patients	O
with	O
bilateral	O
monofocal	O
lenses	O
.	O

Vizyon	O
Eye	O
Center	O
,	O
Denizli	O
,	O
Turkey	O
.	O

Comparative	O
case	O
series	O
.	O

Consecutive	O
bilateral	O
cataract	O
patients	O
having	O
implantation	O
of	O
Acriva	O
Reviol	O
MFM	O
611	O
multifocal	O
IOLs	O
(	O
Group	O
A	O
)	O
or	O
Acriva	O
BB	O
UD	O
613	O
monofocal	O
IOLs	O
(	O
Group	O
B	O
)	O
were	O
included	O
.	O

Parameters	O
analyzed	O
6	O
months	O
postoperatively	O
included	O
monocular	O
uncorrected	O
distance	O
(	O
UDVA	O
)	O
,	O
binocular	O
uncorrected	O
intermediate	O
(	O
UIVA	O
)	O
,	O
binocular	O
uncorrected	O
near	O
(	O
UNVA	O
)	O
,	O
CS	O
and	O
bilateral	O
reading	O
performance	O
using	O
MN	B-P
Read	I-P
.	O

The	O
study	O
evaluated	O
42	O
eyes	O
in	O
Group	O
A	O
and	O
40	O
eyes	O
in	O
Group	O
B	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
UDVA	O
between	O
two	O
groups	O
postoperatively	O
(	O
p	O
=	O
.39	O
)	O
.	O

Binocular	O
UIVA	O
and	O
binocular	O
UNVA	O
are	O
better	O
in	O
Group	O
A	O
(	O
p	O
=	O
.00	O
,	O
p	O
=	O
.00	O
)	O
.	O

Under	O
photopic	O
and	O
scotopic	O
conditions	O
,	O
contrast	O
sensitivity	O
results	O
were	O
decreased	O
in	O
Group	O
A	O
,	O
especially	O
at	O
high	O
spatial	O
frequencies	O
.	O

No	O
statistically	O
difference	O
were	O
found	O
in	O
reading	O
acuity	O
,	O
critical	O
print	O
size	O
and	O
maximum	O
reading	O
speed	O
between	O
two	O
groups	O
(	O
p	O
=	O
.57	O
,	O
p	O
=	O
.62	O
,	O
p	O
=	O
.22	O
)	O
.	O

This	O
study	O
concludes	O
that	O
multifocal	O
lenses	O
are	O
reliable	O
and	O
efficient	O
replacements	O
for	O
reading	O
glasses	O
since	O
they	O
significantly	O
improve	O
the	O
vision	O
for	O
near	O
or	O
intermediate	O
distance	O
activities	O
.	O

Epidemiological	O
patterns	O
of	O
bovine	O
besnoitiosis	O
in	O
an	O
endemic	O
beef	O
cattle	O
herd	O
reared	O
under	O
extensive	O
conditions	O
.	O

Bovine	O
besnoitiosis	O
is	O
a	O
parasitic	O
disease	O
caused	O
by	O
the	O
protozoan	O
Besnoitia	O
besnoiti	O
.	O

Described	O
many	O
decades	O
ago	O
,	O
recent	O
epidemiological	O
studies	O
reveal	O
its	O
important	O
spread	O
within	O
Europe	O
in	O
the	O
last	O
years	O
.	O

To	O
date	O
,	O
many	O
epidemiological	O
aspects	O
related	O
to	O
life	O
cycle	O
,	O
routes	O
of	O
transmission	O
,	O
incidence	O
rates	O
and	O
associated	O
risk	O
factors	O
are	O
lacking	O
;	O
hence	O
,	O
the	O
establishment	O
of	O
appropriate	O
disease	O
control	O
programmes	O
poses	O
an	O
important	O
challenge	O
.	O

Thus	O
,	O
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
epidemiological	O
pattern	O
of	O
the	O
disease	O
in	O
an	O
endemic	O
herd	O
reared	O
under	O
extensive	O
conditions	O
(	O
Spanish	O
Pyrenees	O
)	O
by	O
identifying	O
main	O
factors	O
associated	O
with	O
infection	O
and	O
clinical	O
disease	O
dynamics	O
.	O

The	O
study	O
population	O
consisted	O
of	O
276	O
Brown	O
Swiss	O
and	O
Pirenaica	O
adult	O
animals	O
and	O
145	O
calves	O
born	O
and	O
weaned	O
at	O
the	O
farm	O
during	O
the	O
study	O
.	O

Three	O
sampling	O
time	O
frames	O
were	O
used	O
:	O
January	O
2010	O
,	O
September	O
2010	O
and	O
February	O
2011	O
,	O
which	O
allowed	O
us	O
to	O
differentiate	O
two	O
periods	O
designated	O
as	O
mountain	O
and	O
valley	O
periods	O
.	O

The	O
data	O
related	O
to	O
animals	O
(	O
breed	O
,	O
sex	O
and	O
age	O
)	O
and	O
herd	O
management	O
(	O
animal	O
grouping	O
and	O
time	O
in	O
housing	O
)	O
were	O
recorded	O
.	O

The	O
data	O
collection	O
methodology	O
was	O
mainly	O
based	O
on	O
clinical	O
examinations	O
and	O
defining	O
the	O
serological	O
status	O
against	O
bovine	O
besnoitiosis	O
by	O
the	O
immunofluorescent	B-P
antibody	I-P
testing	I-P
of	O
blood	O
samples	O
.	O

The	O
total	O
prevalence	O
among	O
adult	O
animals	O
was	O
38.34	O
%	O
(	O
CI	O
95	O
%	O
:	O
34.53-42.07	O
)	O
,	O
with	O
18.54	O
%	O
of	O
seropositive	O
animals	O
showing	O
clinical	O
signs	O
.	O

In	O
regard	O
to	O
the	O
cumulative	O
incidence	O
,	O
34.57	O
%	O
of	O
new	O
infections	O
were	O
detected	O
during	O
the	O
mountain	O
period	O
,	O
in	O
contrast	O
to	O
the	O
24.59	O
%	O
observed	O
in	O
the	O
valley	O
period	O
.	O

The	O
incidence	O
density	O
was	O
0.058	O
and	O
0.061	O
new	O
infections	O
per	O
animal	O
-	O
month	O
for	O
the	O
mountain	O
and	O
valley	O
periods	O
,	O
respectively	O
.	O

According	O
to	O
the	O
seroepidemiological	O
study	O
,	O
the	O
seroconversion	O
probability	O
of	O
B.	O
besnoiti	O
infection	O
was	O
directly	O
associated	O
with	O
the	O
number	O
of	O
seropositive	O
cows	O
with	O
whom	O
an	O
animal	O
had	O
been	O
stabled	O
as	O
well	O
as	O
the	O
housing	O
period	O
duration	O
,	O
supporting	O
horizontal	O
transmission	O
by	O
close	O
contact	O
as	O
one	O
of	O
the	O
most	O
important	O
methods	O
of	O
disease	O
spread	O
.	O

In	O
addition	O
,	O
the	O
risk	O
of	O
developing	O
the	O
clinical	O
course	O
increased	O
with	O
age	O
,	O
and	O
the	O
presence	O
of	O
clinical	O
signs	O
was	O
related	O
to	O
higher	O
antibody	O
responses	O
.	O

Among	O
calves	O
(	O
from	O
3.1	O
to	O
7.1	O
months	O
old	O
)	O
sampled	O
once	O
at	O
weaning	O
,	O
the	O
total	O
seroprevalence	O
was	O
15.17	O
%	O
(	O
CI	O
95	O
%	O
:	O
9.36-21.04	O
)	O
,	O
and	O
the	O
chronic	O
stage	O
was	O
observed	O
in	O
three	O
animals	O
,	O
supporting	O
the	O
ability	O
of	O
B.	O
besnoiti	O
to	O
infect	O
and	O
even	O
cause	O
disease	O
in	O
animals	O
less	O
than	O
6	O
months	O
old	O
.	O

Finally	O
,	O
the	O
risk	O
of	O
calf	O
seroconversion	O
was	O
positively	O
related	O
to	O
the	O
serological	O
status	O
of	O
the	O
cows	O
,	O
suggesting	O
postnatal	O
transmission	O
between	O
dams	O
and	O
offspring	O
by	O
contact	O
during	O
the	O
suckling	O
period	O
.	O

Inter-observer	O
agreement	O
for	O
clinical	O
examinations	O
of	O
foot	O
lesions	O
of	O
sheep	O
.	O

In	O
sheep	O
,	O
the	O
diagnosis	O
of	O
foot	O
lesions	O
is	O
routinely	O
based	O
on	O
physical	O
examination	O
of	O
the	O
hoof	O
.	O

Correct	O
diagnosis	O
is	O
important	O
for	O
the	O
effective	O
treatment	O
,	O
prevention	O
and	O
control	O
of	O
both	O
infectious	O
and	O
non-infectious	O
causes	O
of	O
lameness	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
level	O
of	O
inter-observer	O
agreement	O
for	O
clinical	O
examination	O
of	O
ovine	O
foot	O
lesions	O
.	O

Eight	O
observers	O
of	O
varying	O
experience	O
,	O
training	O
and	O
occupation	O
performed	O
foot	B-P
examinations	I-P
on	O
a	O
total	O
of	O
1158	O
sheep	O
from	O
38	O
farms	O
across	O
North	O
England	O
and	O
Wales	O
.	O

On	O
each	O
farm	O
,	O
a	O
group	O
of	O
two	O
to	O
four	O
observers	O
independently	O
examined	O
a	O
sample	O
of	O
24	O
to	O
30	O
sheep	O
to	O
diagnose	O
the	O
presence	O
or	O
absence	O
of	O
specific	O
foot	O
lesions	O
including	O
white	O
line	O
lesions	O
(	O
WL	O
)	O
,	O
contagious	O
ovine	O
digital	O
dermatitis	O
(	O
CODD	O
)	O
,	O
footrot	O
(	O
FR	O
)	O
,	O
inter-digital	O
dermatitis	O
(	O
ID	O
)	O
and	O
toe	O
granuloma	O
(	O
TG	O
)	O
.	O

The	O
inter-observer	O
agreement	O
of	O
foot	O
lesion	O
assessments	O
was	O
examined	O
using	O
Fleiss	O
kappa	O
(	O
κ	O
)	O
,	O
and	O
Cohen	O
's	O
κ	O
examined	O
the	O
paired	O
agreement	O
between	O
the	O
test	O
standard	O
observer	O
(	O
TSO	O
)	O
and	O
each	O
observer	O
.	O

Scoring	O
differences	O
with	O
the	O
TSO	O
were	O
examined	O
as	O
the	O
percentage	O
of	O
scoring	O
errors	O
and	O
assessed	O
for	O
evidence	O
of	O
systematic	O
scoring	O
bias	O
.	O

With	O
the	O
exception	O
of	O
WL	O
(	O
maximum	O
error	O
rate	O
33.3	O
%	O
)	O
,	O
few	O
scoring	O
differences	O
with	O
the	O
TSO	O
occurred	O
(	O
maximum	O
error	O
rate	O
3.3	O
%	O
)	O
.	O

This	O
suggests	O
that	O
observers	O
can	O
achieve	O
good	O
levels	O
of	O
reliability	O
when	O
diagnosing	O
most	O
of	O
the	O
commonly	O
observed	O
foot	O
conditions	O
associated	O
with	O
lameness	O
in	O
sheep	O
.	O

Clinical	O
and	O
therapeutic	O
implications	O
of	O
BRAF	O
mutation	O
heterogeneity	O
in	O
metastatic	O
melanoma	O
.	O

Heterogeneity	O
of	O
BRAF	O
mutation	O
in	O
melanoma	O
has	O
been	O
a	O
controversial	O
subject	O
.	O

Quantitative	O
data	O
on	O
BRAF	O
allele	O
frequency	O
(	O
AF	O
)	O
are	O
sparse	O
,	O
and	O
the	O
potential	O
relationship	O
with	O
response	O
to	O
BRAF	O
inhibitors	O
(	O
BRAFi	O
)	O
in	O
patients	O
with	O
metastatic	O
melanoma	O
is	O
unknown	O
.	O

We	O
quantitatively	O
measured	O
BRAF	O
AF	O
in	O
a	O
cohort	O
of	O
treatment	O
naïve	O
metastatic	O
melanoma	O
samples	O
by	O
pyrosequencing	B-P
and	O
correlated	O
with	O
survival	O
data	O
in	O
patients	O
treated	O
with	O
BRAFi	O
as	O
part	O
of	O
their	O
clinical	O
care	O
.	O

Fifty-two	O
samples	O
from	O
50	O
patients	O
were	O
analysed	O
.	O

BRAF	O
V600E	O
mutations	O
were	O
detected	O
in	O
71.1	O
%	O
of	O
samples	O
followed	O
by	O
V600K	O
(	O
25	O
%	O
)	O
and	O
V600R	O
(	O
3.9	O
%	O
)	O
.	O

There	O
was	O
a	O
wide	O
range	O
of	O
AF	O
from	O
3.9	O
%	O
to	O
80.3	O
%	O
(	O
median	O
41.3	O
%	O
)	O
.	O

In	O
33	O
patients	O
treated	O
with	O
BRAFi	O
,	O
there	O
was	O
no	O
difference	O
in	O
overall	O
or	O
progression-free	O
survival	O
when	O
the	O
patients	O
were	O
categorized	O
into	O
high	O
or	O
low	O
AF	O
groups	O
.	O

There	O
was	O
no	O
correlation	O
between	O
AF	O
and	O
degree	O
of	O
response	O
,	O
and	O
no	O
difference	O
in	O
survival	O
based	O
on	O
genotype	O
.	O

Antibacterial	O
Activity	O
of	O
Polyaniline	O
Coated	O
Silver	O
Nanoparticles	O
Synthesized	O
from	O
Piper	O
Betle	O
Leaves	O
Extract	O
.	O

Plants	O
or	O
natural	O
resources	O
have	O
been	O
found	O
to	O
be	O
a	O
good	O
alternative	O
method	O
for	O
nanoparticles	O
synthesis	O
.	O

In	O
this	O
study	O
,	O
polyaniline	O
coated	O
silver	O
nanoparticles	O
(	O
AgNPs	O
)	O
synthesized	O
from	O
Piper	O
betle	O
leaves	O
extract	O
were	O
investigated	O
for	O
their	O
antibacterial	O
activity	O
.	O

Silver	O
nanoparticles	O
were	O
prepared	O
from	O
the	O
reduction	O
of	O
silver	O
nitrate	O
and	O
NaBH4	O
was	O
used	O
as	O
reducing	O
agent	O
.	O

Silver	O
nanoparticles	O
and	O
extracts	O
were	O
mixed	O
thoroughly	O
and	O
then	O
coated	O
by	O
polyaniline	O
.	O

Prepared	O
nanoparticles	O
were	O
characterized	O
by	O
Visual	O
inspection	O
,	O
Ultraviolet-visible	B-P
spectroscopy	I-P
(	O
UV	B-P
)	O
,	O
Fourier	O
transform	O
infrared	O
Spectroscopy	O
(	O
FT-IR	O
)	O
,	O
Transmission	B-P
Electron	I-P
Microscopy	I-P
(	I-P
TEM	I-P
)	I-P
techniques	I-P
.	O

Antibacterial	O
activities	O
of	O
the	O
synthesized	O
silver	O
nanoparticles	O
were	O
tested	O
against	O
Staphylococcus	O
aureus	O
ATCC	O
25923	O
,	O
Salmonella	O
typhi	O
ATCC	O
14028	O
,	O
Escherichia	O
coli	O
ATCC	O
25922	O
and	O
Pseudomonas	O
aeruginosa	O
ATCC	O
27853	O
.	O

UV-Vis	B-P
spectrum	I-P
of	O
reaction	O
mixture	O
showed	O
strong	O
absorption	O
peak	O
with	O
centering	O
at	O
400	O
nm	O
.	O

The	O
FT-IR	O
results	O
imply	O
that	O
Ag-NPs	O
were	O
successfully	O
synthesized	O
and	O
capped	O
with	O
bio-compounds	O
present	O
in	O
P.	O
betle	O
.	O

TEM	B-P
image	O
showed	O
that	O
Ag-NPs	O
formed	O
were	O
well	O
dispersed	O
with	O
a	O
spherical	O
structures	O
and	O
particle	O
size	O
ranging	O
from	O
10	O
to	O
30	O
nm	O
.	O

The	O
result	O
revealed	O
that	O
Ag-Extract	O
NPs	O
showed	O
32.78±0.64	O
mm	O
zone	O
of	O
inhibition	O
against	O
S.	O
aureus	O
,	O
whereas	O
norfloxacin	O
(	O
positive	O
control	O
)	O
showed	O
maximum	O
32.15±0.40	O
mm	O
zone	O
of	O
inhibition	O
for	O
S.	O
aureus	O
.	O

Again	O
,	O
maximum	O
zone	O
of	O
inhibition	O
29.55±0.45	O
mm	O
was	O
found	O
for	O
S.	O
typhi	O
,	O
27.12±0.38	O
mm	O
for	O
E.	O
coli	O
and	O
21.95±0.45	O
mm	O
for	O
P.	O
aeruginosa	O
.	O

The	O
results	O
obtained	O
by	O
this	O
study	O
ca	O
n't	O
be	O
directly	O
extrapolated	O
to	O
human	O
;	O
so	O
further	O
studies	O
should	O
be	O
undertaken	O
to	O
established	O
the	O
strong	O
antimicrobial	O
activity	O
of	O
Ag-Extract	O
NPs	O
for	O
drug	O
development	O
program	O
.	O

Transplacental	O
Passage	O
of	O
Acetaminophen	O
in	O
Term	O
Pregnancy	O
.	O

Objective	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
maternal	O
and	O
fetal	O
pharmacokinetic	O
(	O
PK	O
)	O
profiles	B-P
of	O
acetaminophen	O
after	O
administration	O
of	O
a	O
therapeutic	O
oral	O
dose	O
.	O

Study	O
Design	O
After	O
obtaining	O
Institutional	O
Review	O
Board	O
approval	O
and	O
their	O
written	O
informed	O
consent	O
,	O
pregnant	O
women	O
were	O
given	O
a	O
single	O
oral	O
dose	O
(	O
1,000	O
mg	O
)	O
of	O
acetaminophen	O
upon	O
admission	O
for	O
scheduled	O
cesarean	O
delivery	O
.	O

Maternal	O
venous	O
blood	O
and	O
fetal	O
cord	O
blood	O
were	O
obtained	O
at	O
the	O
time	O
of	O
delivery	O
and	O
acetaminophen	B-P
levels	I-P
were	O
measured	O
using	O
gas	B-P
chromatography-mass	I-P
spectroscopy	I-P
.	O

PK	O
parameters	O
were	O
calculated	O
by	O
noncompartmental	O
analysis	O
.	O

Nonparametric	O
correlation	O
of	O
maternal	O
/	O
fetal	O
acetaminophen	B-P
levels	I-P
and	O
PK	O
curves	O
were	O
calculated	O
.	O

Results	O
In	O
this	O
study	O
,	O
34	O
subjects	O
were	O
enrolled	O
(	O
median	O
,	O
32	O
years	O
;	O
range	O
,	O
25-39	O
years	O
)	O
.	O

The	O
median	O
maternal	O
weight	O
was	O
82	O
kg	O
(	O
range	O
,	O
62-100	O
kg	O
)	O
.	O

All	O
but	O
two	O
subjects	O
were	O
delivered	O
beyond	O
39	O
weeks	O
'	O
gestation	O
.	O

The	O
median	O
newborn	O
birth	O
weight	O
was	O
3,590	O
g	O
(	O
interquartile	O
range	O
,	O
3,403-3,848	O
g	O
)	O
.	O

Noncompartmental	O
analysis	O
described	O
similar	O
PK	O
parameters	O
in	O
the	O
maternal	O
(	O
T1/2	O
,	O
84	O
minutes	O
;	O
apparent	O
clearance	O
[	O
Cl/F	O
]	O
,	O
28.8	O
L/h	O
;	O
apparent	O
volume	O
of	O
distribution	O
[	O
Vd/F	O
]	O
,	O
57.5	O
L	O
)	O
and	O
fetal	O
compartments	O
(	O
T1/2	O
,	O
82	O
minutes	O
;	O
Cl/F	O
,	O
31.2	O
L/h	O
;	O
Vd/F	O
,	O
61.2	O
L	O
)	O
.	O

Paired	O
maternal	O
/	O
fetal	O
acetaminophen	B-P
levels	I-P
were	O
highly	O
correlated	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

Conclusion	O
Fetal	O
acetaminophen	O
PKs	O
in	O
the	O
fetus	O
parallels	O
that	O
in	O
the	O
mother	O
suggesting	O
that	O
placental	O
transfer	O
is	O
flow	O
limited	O
.	O

Maternal	O
acetaminophen	B-P
levels	I-P
can	O
be	O
used	O
as	O
a	O
surrogate	O
for	O
fetal	O
exposure	O
.	O

ACR	O
Appropriateness	O
Criteria	O
(	O
®	O
)	O
Radiologic	O
Management	O
of	O
Mesenteric	O
Ischemia	O
.	O

Mesenteric	O
vascular	O
insufficiency	O
is	O
a	O
serious	O
medical	O
condition	O
that	O
may	O
lead	O
to	O
bowel	O
infarction	O
,	O
morbidity	O
,	O
and	O
mortality	O
that	O
may	O
approach	O
50	O
%	O
.	O

Recommended	O
therapy	O
for	O
acute	O
mesenteric	O
ischemia	O
includes	O
aspiration	O
embolectomy	O
,	O
transcatheter	O
thrombolysis	O
,	O
and	O
angioplasty	O
with	O
or	O
without	O
stenting	O
for	O
the	O
treatment	O
of	O
underlying	O
arterial	O
stenosis	O
.	O

Nonocclusive	O
mesenteric	O
ischemia	O
may	O
respond	O
to	O
transarterial	O
infusion	O
of	O
vasodilators	O
such	O
as	O
nitroglycerin	O
,	O
papaverine	O
,	O
glucagon	O
,	O
and	O
prostaglandin	O
E1	O
.	O

Recommended	O
therapy	O
for	O
chronic	O
mesenteric	O
ischemia	O
includes	O
angioplasty	O
with	O
or	O
without	O
stent	O
placement	O
and	O
,	O
if	O
an	O
endovascular	O
approach	O
is	O
not	O
possible	O
,	O
surgical	O
bypass	O
or	O
endarterectomy	O
.	O

The	O
diagnosis	O
of	O
median	O
arcuate	O
ligament	O
syndrome	O
is	O
controversial	O
,	O
but	O
surgical	O
release	O
may	O
be	O
appropriate	O
depending	O
on	O
the	O
clinical	O
situation	O
.	O

Venous	O
mesenteric	O
ischemia	O
may	O
respond	O
to	O
systemic	O
anticoagulation	O
alone	O
.	O

Transhepatic	O
or	O
transjugular	O
superior	O
mesenteric	O
vein	O
catheterization	B-P
and	I-P
thrombolytic	I-P
infusion	I-P
can	O
be	O
offered	O
depending	O
on	O
the	O
severity	O
of	O
symptoms	O
,	O
condition	O
of	O
the	O
patient	O
,	O
and	O
response	O
to	O
systemic	O
anticoagulation	O
.	O

Adjunct	O
transjugular	O
intrahepatic	O
portosystemic	O
shunt	O
creation	O
can	O
be	O
considered	O
for	O
outflow	O
improvement	O
.	O

The	O
American	O
College	O
of	O
Radiology	O
Appropriateness	O
Criteria	O
are	O
evidence-based	O
guidelines	O
for	O
specific	O
clinical	O
conditions	O
that	O
are	O
reviewed	O
annually	O
by	O
a	O
multidisciplinary	O
expert	O
panel	O
.	O

The	O
guideline	O
development	O
and	O
revision	O
include	O
an	O
extensive	O
analysis	O
of	O
current	O
medical	O
literature	O
from	O
peer-reviewed	O
journals	O
and	O
the	O
application	O
of	O
well-established	O
methodologies	O
(	O
RAND	O
/	O
UCLA	O
Appropriateness	O
Method	O
and	O
Grading	O
of	O
Recommendations	O
Assessment	O
,	O
Development	O
,	O
and	O
Evaluation	O
or	O
GRADE	O
)	O
to	O
rate	O
the	O
appropriateness	O
of	O
imaging	B-P
and	O
treatment	O
procedures	O
for	O
specific	O
clinical	O
scenarios	O
.	O

In	O
those	O
instances	O
where	O
evidence	O
is	O
lacking	O
or	O
equivocal	O
,	O
expert	O
opinion	O
may	O
supplement	O
the	O
available	O
evidence	O
to	O
recommend	O
imaging	B-P
or	O
treatment	O
.	O

Cross-reactivity	O
features	O
of	O
deoxynivalenol	O
(	O
DON	O
)	O
-targeted	O
immunoaffinity	B-P
columns	O
aiming	O
to	O
achieve	O
simultaneous	O
analysis	B-P
of	O
DON	O
and	O
major	O
conjugates	O
in	O
cereal	O
samples	O
.	O

Immunoafﬁnity	B-P
columns	O
(	O
IACs	O
)	O
are	O
a	O
well-established	O
tool	O
in	O
the	O
determination	O
of	O
regulated	O
mycotoxins	O
in	O
food	O
and	O
feed	O
commodities	O
.	O

However	O
,	O
they	O
also	O
have	O
the	O
potential	O
to	O
become	O
attractive	O
pre-concentration	O
and	O
clean-up	O
materials	O
for	O
the	O
determination	O
of	O
masked	O
(	O
also	O
called	O
modified	O
)	O
mycotoxins	O
,	O
which	O
have	O
been	O
recognised	O
as	O
important	O
contributors	O
to	O
the	O
toxicological	O
hazard	O
deriving	O
from	O
fungal	O
spoilage	O
of	O
goods	O
.	O

However	O
,	O
the	O
information	O
available	O
in	O
the	O
literature	O
concerning	O
the	O
cross-reactivity	O
of	O
DON	O
-	O
IACs	O
against	O
the	O
major	O
conjugates	O
(	O
DON-3-G	O
,	O
15-AcDON	O
and	O
3-AcDON	O
)	O
is	O
incomplete	O
and	O
often	O
contradictory	O
.	O

We	O
have	O
carried	O
out	O
a	O
detailed	O
characterisation	O
of	O
the	O
cross-reactivity	O
of	O
the	O
four	O
main	O
IACs	O
brands	O
against	O
DON	O
and	O
its	O
conjugates	O
as	O
well	O
as	O
an	O
assessment	O
of	O
the	O
competition	O
among	O
the	O
analytes	O
.	O

Only	O
one	O
IAC	O
enabled	O
the	O
simultaneous	O
analysis	B-P
of	O
all	O
relevant	O
DON	O
forms	O
while	O
two	O
missed	O
15-AcDON	O
and	O
the	O
fourth	O
one	O
missed	O
DON-3-G	O
and	O
3-AcDON	O
.	O

In	O
the	O
case	O
of	O
the	O
multivalent	O
IAC	O
,	O
the	O
analytes	O
modified	O
at	O
the	O
C-3	O
position	O
compete	O
for	O
the	O
antibody	O
binding	O
with	O
preference	O
for	O
3-AcDON	O
(	O
less	O
spatially	O
hindered	O
)	O
while	O
DON-3-G	O
has	O
the	O
more-hindered	O
access	O
to	O
the	O
active	O
sites	O
.	O

Taking	O
into	O
consideration	O
the	O
levels	O
of	O
DON	O
conjugates	O
existing	O
in	O
real	O
samples	O
,	O
the	O
cross-reactivity	O
of	O
one	O
DON	O
-	O
IAC	O
allows	O
a	O
quantitative	O
analysis	O
of	O
all	O
of	O
these	O
analytes	O
.	O

Important	O
but	O
rather	O
neglected	O
aspects	O
such	O
as	O
the	O
continuous	O
supply	O
of	O
IACs	O
with	O
identical	O
characteristics	O
,	O
and	O
of	O
columns	O
which	O
are	O
strictly	O
blank	O
,	O
are	O
also	O
addressed	O
in	O
this	O
paper	O
.	O

Adenoviral	O
Delivery	O
of	O
Tumor	O
Necrosis	O
Factor-α	O
and	O
Interleukin-2	O
Enables	O
Successful	O
Adoptive	O
Cell	O
Therapy	O
of	O
Immunosuppressive	O
Melanoma	O
.	O

Adoptive	O
T-cell	O
transfer	O
is	O
a	O
promising	O
treatment	O
approach	O
for	O
metastatic	O
cancer	O
,	O
but	O
efficacy	O
in	O
solid	O
tumors	O
has	O
only	O
been	O
achieved	O
with	O
toxic	O
pre-	O
and	O
postconditioning	O
regimens	O
.	O

Thus	O
,	O
adoptive	O
T-cell	O
therapies	O
would	O
benefit	O
from	O
complementary	O
modalities	O
that	O
enable	O
their	O
full	O
potential	O
without	O
excessive	O
toxicity	O
.	O

We	O
aimed	O
to	O
improve	O
the	O
efficacy	O
and	O
safety	O
of	O
adoptive	O
T-cell	O
transfer	O
by	O
using	O
adenoviral	O
vectors	O
for	O
direct	O
delivery	O
of	O
immunomodulatory	O
murine	O
cytokines	O
into	O
B16.OVA	O
melanoma	O
tumors	O
with	O
concomitant	O
T-cell	O
receptor	O
transgenic	O
OT-I	O
T-cell	O
transfer	O
.	O

Armed	O
adenoviruses	O
expressed	O
high	O
local	O
and	O
low	O
systemic	O
levels	O
of	O
cytokine	O
when	O
injected	O
into	O
B16.OVA	O
tumors	O
,	O
suggesting	O
safety	O
of	O
virus-mediated	O
cytokine	O
delivery	O
.	O

Antitumor	O
efficacy	O
was	O
significantly	O
enhanced	O
with	O
adenoviruses	O
coding	O
for	O
murine	O
interleukin-2	O
(	O
mIL-2	O
)	O
and	O
tumor	O
necrosis	O
factor-α	O
(	O
mTNFα	O
)	O
when	O
compared	O
with	O
T-cell	O
transfer	O
alone	O
or	O
viruses	O
alone	O
.	O

Further	O
improvement	O
in	O
efficacy	O
was	O
achieved	O
with	O
a	O
triple	O
combination	O
of	O
mIL-2	O
,	O
mTNFα	O
,	O
and	O
OT-I	O
T-cells	O
.	O

Mechanistic	O
studies	O
suggest	O
that	O
mIL-2	O
has	O
an	O
important	O
role	O
in	O
activating	O
T-cells	O
at	O
the	O
tumor	O
,	O
while	O
mTNFα	O
induces	O
chemokine	O
expression	O
.	O

Furthermore	O
,	O
adenovirus	O
treatments	O
enhanced	O
tumor	O
-	O
infiltration	O
of	O
OT-I	O
T-cells	O
as	O
demonstrated	O
by	O
SPECT/CT	B-P
imaging	I-P
of	O
(	O
111	O
)	O
In-labeled	O
cells	O
.	O

Our	O
results	O
suggest	O
the	O
utility	O
of	O
cytokine-coding	O
adenoviruses	O
for	O
improving	O
the	O
efficacy	O
of	O
adoptive	O
T-cell	O
therapies	O
.	O

Cocaine	O
Use	O
Reverses	O
Striatal	O
Plasticity	O
Produced	O
During	O
Cocaine	O
Seeking	O
.	O

Relapse	O
is	O
a	O
two	O
-	O
component	O
process	O
consisting	O
of	O
a	O
highly	O
motivated	O
drug-seeking	O
phase	O
that	O
,	O
if	O
successful	O
,	O
is	O
followed	O
by	O
a	O
drug-using	O
phase	O
resulting	O
in	O
temporary	O
satiation	O
.	O

In	O
rodents	O
,	O
cue-induced	O
drug	O
seeking	O
requires	O
transient	O
synaptic	O
potentiation	O
(	O
t-SP	O
)	O
of	O
cortical	O
glutamatergic	O
synapses	O
on	O
nucleus	O
accumbens	O
core	O
medium	O
spiny	O
neurons	O
,	O
but	O
it	O
is	O
unknown	O
how	O
achieving	O
drug	O
use	O
affects	O
this	O
plasticity	O
.	O

We	O
modeled	O
the	O
two	O
phases	O
of	O
relapse	O
after	O
extinction	O
from	O
cocaine	O
self-administration	O
to	O
assess	O
how	O
cocaine	O
use	O
affects	O
t-SP	O
associated	O
with	O
cue-induced	O
drug	O
seeking	O
.	O

Rats	O
were	O
trained	O
to	O
self-administer	O
cocaine	O
(	O
n	O
=	O
96	O
)	O
or	O
were	O
used	O
as	O
yoked	O
-	O
saline	O
control	O
animals	O
(	O
n	O
=	O
21	O
)	O
.	O

After	O
extinction	O
,	O
reinstatement	O
was	O
initiated	O
by	O
10	O
minutes	O
of	O
cue-induced	O
drug	O
seeking	O
,	O
followed	O
by	O
45	O
minutes	O
with	O
contingent	O
cocaine	O
access	O
,	O
after	O
which	O
cocaine	O
was	O
discontinued	O
and	O
unreinforced	O
lever	O
pressing	O
ensued	O
.	O

Three	O
measures	O
of	O
t-SP	O
were	O
assayed	B-P
during	O
reinstatement	O
:	O
dendritic	O
spine	O
morphology	O
,	O
alpha-amino-3-hydroxy-5-methyl-4-isoxazole	O
propionic	O
acid	O
(	O
AMPA	O
)	O
to	O
N-methyl-D-aspartate	O
(	O
NMDA	O
)	O
ratios	O
,	O
and	O
matrix	O
metalloproteinase	O
activity	O
.	O

We	O
found	O
that	O
cocaine	O
use	O
for	O
10	O
minutes	O
collapsed	O
all	O
three	O
measures	O
of	O
cue-potentiated	O
t-SP	O
back	O
to	O
baseline	O
.	O

Moreover	O
,	O
when	O
cocaine	O
use	O
was	O
discontinued	O
45	O
minutes	O
later	O
,	O
dendritic	O
spine	O
morphology	O
and	O
AMPA	O
to	O
NMDA	O
ratios	O
were	O
restored	O
as	O
animals	O
became	O
motivated	O
to	O
engage	O
unrewarded	O
lever	O
pressing	O
.	O

Nonreinforced	O
drug	O
seeking	O
was	O
positively	O
correlated	O
with	O
changes	O
in	O
spine	O
morphology	O
,	O
and	O
cocaine	O
access	O
reversed	O
this	O
relationship	O
.	O

Using	O
a	O
novel	O
modification	O
of	O
the	O
reinstatement	O
paradigm	O
,	O
we	O
show	O
that	O
achieving	O
cocaine	O
use	O
reversed	O
the	O
synaptic	O
plasticity	O
underpinning	O
the	O
motivation	O
to	O
seek	O
the	O
drug	O
.	O

Cerebrospinal	O
fluid	O
biomarkers	O
as	O
a	O
measure	O
of	O
disease	O
activity	O
and	O
treatment	O
efficacy	O
in	O
relapsing-remitting	O
multiple	O
sclerosis	O
.	O

Cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
biomarkers	O
can	O
reflect	O
different	O
aspects	O
of	O
the	O
pathophysiology	O
of	O
relapsing-remitting	O
multiple	O
sclerosis	O
(	O
RRMS	O
)	O
.	O

Understanding	O
the	O
impact	O
of	O
different	O
disease	O
modifying	O
therapies	O
on	O
the	O
CSF	O
biomarker	O
profile	B-P
may	O
increase	O
their	O
implementation	O
in	O
clinical	O
practice	O
and	O
their	O
appropriateness	O
for	O
monitoring	O
treatment	O
efficacy	O
.	O

This	O
study	O
investigated	O
the	O
influence	O
of	O
first-line	O
(	O
interferon	O
beta	O
)	O
and	O
second-line	O
(	O
natalizumab	O
)	O
therapies	O
on	O
seven	O
CSF	O
biomarkers	O
in	O
RRMS	O
and	O
their	O
correlation	O
with	O
clinical	O
and	O
radiological	O
outcomes	O
.	O

We	O
included	O
59	O
RRMS	O
patients	O
and	O
39	O
healthy	O
controls	O
.	O

The	O
concentrations	O
of	O
C-X-C	O
motif	O
chemokine	O
13	O
(	O
CXCL13	O
)	O
,	O
C-C	O
motif	O
chemokine	O
ligand	O
2	O
(	O
CCL2	O
)	O
,	O
chitinase-3-like	O
protein	O
1	O
(	O
CHI3L1	O
)	O
,	O
glial	O
fibrillary	O
acidic	O
protein	O
,	O
neurofilament	O
light	O
protein	O
(	O
NFL	O
)	O
,	O
and	O
neurogranin	O
were	O
determined	O
by	O
ELISA	B-P
,	O
and	O
chitotriosidase	O
(	O
CHIT1	O
)	O
was	O
analyzed	O
by	O
spectrofluorometry	B-P
.	O

RRMS	O
patients	O
had	O
higher	O
levels	O
of	O
NFL	O
,	O
CXCL13	O
,	O
CHI3L1	O
,	O
and	O
CHIT1	O
than	O
controls	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Subgroup	O
analysis	O
revealed	O
higher	O
NFL	O
,	O
CXCL13	O
and	O
CHIT1	O
levels	O
in	O
patients	O
treated	O
with	O
first-line	O
therapy	O
compared	O
to	O
second-line	O
therapy	O
(	O
p	O
=	O
0.008	O
,	O
p	O
=	O
0.001	O
and	O
p	O
=	O
0.026	O
,	O
respectively	O
)	O
.	O

NFL	O
and	O
CHIT1	O
levels	O
correlated	O
with	O
relapse	O
status	O
,	O
and	O
NFL	O
and	O
CXCL13	O
levels	O
correlated	O
with	O
the	O
formation	O
of	O
new	O
magnetic	B-P
resonance	I-P
imaging	I-P
lesions	O
.	O

Furthermore	O
,	O
we	O
found	O
an	O
association	O
between	O
inflammatory	O
and	O
degenerative	O
biomarkers	O
.	O

The	O
results	O
indicate	O
that	O
CSF	O
levels	O
of	O
NFL	O
,	O
CXCL13	O
,	O
CHI3L1	O
,	O
and	O
CHIT1	O
correlate	O
with	O
the	O
clinical	O
and/or	O
radiological	O
disease	O
activity	O
,	O
providing	O
additional	O
dimensions	O
in	O
the	O
assessment	O
of	O
treatment	O
efficacy	O
.	O

Bone	O
Marrow	O
-Derived	O
Mesenchymal	O
Stem	O
Cells	O
-Derived	O
Exosomes	O
Promote	O
Survival	O
of	O
Retinal	O
Ganglion	O
Cells	O
Through	O
miRNA	O
-Dependent	O
Mechanisms	O
.	O

The	O
loss	O
of	O
retinal	O
ganglion	O
cells	O
(	O
RGC	O
)	O
and	O
their	O
axons	O
is	O
one	O
of	O
the	O
leading	O
causes	O
of	O
blindness	O
and	O
includes	O
traumatic	O
(	O
optic	O
neuropathy	O
)	O
and	O
degenerative	O
(	O
glaucoma	O
)	O
eye	O
diseases	O
.	O

Although	O
no	O
clinical	O
therapies	O
are	O
in	O
use	O
,	O
mesenchymal	O
stem	O
cells	O
(	O
MSC	O
)	O
have	O
demonstrated	O
significant	O
neuroprotective	O
and	O
axogenic	O
effects	O
on	O
RGC	O
in	O
both	O
of	O
the	O
aforementioned	O
models	O
.	O

Recent	O
evidence	O
has	O
shown	O
that	O
MSC	O
secrete	O
exosomes	O
,	O
membrane	O
enclosed	O
vesicles	O
(	O
30-100	O
nm	O
)	O
containing	O
proteins	O
,	O
mRNA	O
and	O
miRNA	O
which	O
can	O
be	O
delivered	O
to	O
nearby	O
cells	O
.	O

The	O
present	O
study	O
aimed	O
to	O
isolate	O
exosomes	O
from	O
bone	O
marrow	O
-derived	O
MSC	O
(	O
BMSC	O
)	O
and	O
test	O
them	O
in	O
a	O
rat	O
optic	O
nerve	O
crush	O
(	O
ONC	O
)	O
model	O
.	O

Treatment	O
of	O
primary	B-P
retinal	I-P
cultures	I-P
with	O
BMSC	O
-	O
exosomes	O
demonstrated	O
significant	O
neuroprotective	O
and	O
neuritogenic	O
effects	O
.	O

Twenty-one	O
days	O
after	O
ONC	O
and	O
weekly	O
intravitreal	O
exosome	O
injections	O
;	O
optical	B-P
coherence	I-P
tomography	I-P
,	O
electroretinography	B-P
,	O
and	O
immunohistochemistry	B-P
was	O
performed	O
.	O

BMSC	O
-derived	O
exosomes	O
promoted	O
statistically	O
significant	O
survival	O
of	O
RGC	O
and	O
regeneration	O
of	O
their	O
axons	O
while	O
partially	O
preventing	O
RGC	O
axonal	O
loss	O
and	O
RGC	O
dysfunction	O
.	O

Exosomes	O
successfully	O
delivered	O
their	O
cargo	O
into	O
inner	O
retinal	O
layers	O
and	O
the	O
effects	O
were	O
reliant	O
on	O
miRNA	O
,	O
demonstrated	O
by	O
the	O
diminished	O
therapeutic	O
effects	O
of	O
exosomes	O
derived	O
from	O
BMSC	O
after	O
knockdown	O
of	O
Argonaute-2	O
,	O
a	O
key	O
miRNA	O
effector	O
molecule	O
.	O

This	O
study	O
supports	O
the	O
use	O
of	O
BMSC	O
-derived	O
exosomes	O
as	O
a	O
cell-free	O
therapy	O
for	O
traumatic	O
and	O
degenerative	O
ocular	O
disease	O
.	O

Stem	O
Cells	O
Translational	O
Medicine	O
2017	O
;	O
6:1273-1285	O
.	O

MiR	O
221	O
/	O
222	O
as	O
new	O
players	O
in	O
tamoxifen	O
resistance	O
.	O

Breast	O
cancer	O
is	O
the	O
most	O
frequent	O
cancer	O
in	O
women	O
.	O

Despite	O
advances	O
in	O
early	B-P
detection	I-P
and	O
treatment	O
,	O
it	O
has	O
the	O
second	O
highest	O
mortality	O
rate	O
after	O
lung	O
cancer	O
.	O

Around	O
85	O
%	O
of	O
breast	O
carcinomas	O
are	O
ER+	O
;	O
thus	O
,	O
antiestrogens	O
like	O
tamoxifen	O
are	O
beneficial	O
.	O

Although	O
,	O
tamoxifen	O
is	O
useful	O
for	O
many	O
patients	O
,	O
plenty	O
of	O
patients	O
respond	O
poorly	O
to	O
initial	O
therapy	O
or	O
recurrence	O
occurs	O
in	O
about	O
30	O
%	O
of	O
cases	O
,	O
because	O
tamoxifen	O
resistance	O
happens	O
.	O

Drug	O
resistance	O
remains	O
a	O
major	O
clinical	O
obstacle	O
to	O
successful	O
treatment	O
of	O
breast	O
cancer	O
and	O
more	O
than	O
90	O
%	O
of	O
unsuccessful	O
treatments	O
are	O
because	O
of	O
acquired	O
resistance	O
and	O
MultiDrug	O
Resistance	O
(	O
MDR	O
)	O
is	O
a	O
major	O
contributor	O
.	O

MicroRNAs	O
are	O
members	O
of	O
a	O
novel	O
class	O
of	O
short	O
noncoding	O
RNAs	O
.	O

Besides	O
to	O
their	O
various	O
roles	O
in	O
gene	O
expression	O
,	O
miRNAs	O
are	O
considered	O
as	O
important	O
cancer	O
therapeutic	O
targets	O
and	O
biomarkers	O
.	O

Since	O
2005	O
,	O
when	O
miRNA	O
deregulation	O
was	O
first	O
reported	O
in	O
breast	O
cancer	O
,	O
more	O
than	O
1000	O
reports	O
have	O
been	O
published	O
about	O
miRNAs	O
.	O

Increasing	O
number	O
of	O
studies	O
showed	O
the	O
importance	O
of	O
miRNAs	O
in	O
antiestrogen	O
therapy	O
,	O
especially	O
on	O
tamoxifen	O
;	O
thus	O
,	O
it	O
is	O
not	O
surprising	O
that	O
these	O
tiny	O
molecules	O
are	O
involved	O
in	O
drug	O
resistance	O
.	O

Due	O
to	O
the	O
pivotal	O
role	O
of	O
these	O
known	O
RNA	O
molecules	O
,	O
in	O
this	O
review	O
,	O
we	O
tried	O
to	O
illustrate	O
the	O
importance	O
of	O
the	O
miRNAs	O
as	O
a	O
new	O
player	O
in	O
breast	O
cancer	O
pathogenesis	O
.	O

We	O
have	O
also	O
focused	O
on	O
cancer	O
drug	O
resistance	O
mechanisms	O
highlighting	O
the	O
role	O
of	O
important	O
oncomirs	O
,	O
miR	O
221	O
/	O
222	O
,	O
involved	O
in	O
cell	O
cycle	O
deregulation	O
in	O
breast	O
cancer	O
.	O

The	O
relationship	O
between	O
these	O
oncomiRs	O
with	O
resistance	O
to	O
tamoxifen	O
is	O
also	O
emphasized	O
.	O

Generalized	O
Epilepsy	O
and	O
Myoclonic	O
Seizures	O
in	O
22q11.2	O
Deletion	O
Syndrome	O
.	O

Prompted	O
by	O
the	O
observations	O
of	O
juvenile	O
myoclonic	O
epilepsy	O
(	O
JME	O
)	O
in	O
22q11.2	O
deletion	O
syndrome	O
(	O
22q11DS	O
)	O
and	O
recurrent	O
copy	O
number	O
variants	O
in	O
genetic	O
generalized	O
epilepsy	O
(	O
GGE	O
)	O
,	O
we	O
searched	O
for	O
further	O
evidence	O
supporting	O
a	O
possible	O
correlation	O
of	O
22q11DS	O
with	O
GGE	O
and	O
with	O
myoclonic	O
seizures	O
.	O

Through	O
routine	B-P
diagnostics	I-P
,	O
we	O
identified	O
3	O
novel	O
individuals	O
with	O
the	O
seemingly	O
uncommon	O
combination	O
of	O
22q11DS	O
and	O
JME	O
.	O

We	O
subsequently	O
screened	O
the	O
literature	O
for	O
reports	O
focussing	O
on	O
the	O
epilepsy	O
phenotype	O
in	O
22q11DS	O
.	O

We	O
additionally	O
screened	O
a	O
database	O
of	O
173	O
22q11DS	O
patients	O
and	O
identified	O
a	O
fourth	O
individual	O
with	O
JME	O
as	O
well	O
as	O
2	O
additional	O
cases	O
with	O
GGE	O
.	O

We	O
describe	O
6	O
novel	O
and	O
22	O
published	O
cases	O
with	O
co-occurrence	O
of	O
22q11DS	O
and	O
GGE	O
.	O

In	O
many	O
patients	O
,	O
GGE	O
was	O
associated	O
with	O
myoclonic	O
seizures	O
allowing	O
for	O
a	O
diagnosis	O
of	O
JME	O
in	O
at	O
least	O
6	O
individuals	O
.	O

Seventeen	O
of	O
the	O
173	O
22q11DS	O
cases	O
(	O
10	O
%	O
)	O
had	O
a	O
diagnosis	O
of	O
either	O
focal	O
or	O
generalized	O
epilepsy	O
.	O

In	O
these	O
cases	O
,	O
focal	O
epilepsy	O
could	O
often	O
be	O
attributed	O
to	O
syndrome-associated	O
hypocalcaemia	O
,	O
cerebral	O
bleeds	O
,	O
or	O
structural	O
brain	O
anomalies	O
.	O

However	O
,	O
the	O
cause	O
of	O
GGE	O
remained	O
unclear	O
.	O

In	O
this	O
study	O
,	O
we	O
describe	O
and	O
review	O
28	O
individuals	O
with	O
22q11DS	O
and	O
GGE	O
(	O
especially	O
JME	O
)	O
,	O
showing	O
that	O
both	O
disorders	O
frequently	O
co-occur	O
.	O

Compared	O
to	O
the	O
reported	O
prevalence	O
of	O
15-21	O
%	O
,	O
in	O
our	O
case	O
series	O
only	O
10	O
%	O
of	O
22q11DS	O
individuals	O
were	O
found	O
to	O
have	O
epilepsy	O
,	O
often	O
GGE	O
.	O

Since	O
22q11.2	O
does	O
not	O
contain	O
convincing	O
GGE	O
candidate	O
genes	O
,	O
we	O
discuss	O
the	O
possibility	O
of	O
an	O
aetiological	O
correlation	O
through	O
a	O
possibly	O
disturbed	O
interaction	O
with	O
the	O
GABAB	O
receptor	O
.	O

A	O
novel	O
role	O
for	O
poly	O
(	O
C	O
)	O
binding	O
proteins	O
in	O
programmed	O
ribosomal	O
frameshifting	O
.	O

Translational	O
control	O
through	O
programmed	O
ribosomal	O
frameshifting	O
(	O
PRF	O
)	O
is	O
exploited	O
widely	O
by	O
viruses	O
and	O
increasingly	O
documented	O
in	O
cellular	O
genes	O
.	O

Frameshifting	O
is	O
induced	O
by	O
mRNA	O
secondary	O
structures	O
that	O
compromise	O
ribosome	O
fidelity	O
during	O
decoding	O
of	O
a	O
heptanucleotide	O
'slippery	O
'	O
sequence	O
.	O

The	O
nsp2	O
PRF	O
signal	O
of	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
is	O
distinctive	O
in	O
directing	O
both	O
-2	O
and	O
-1	O
PRF	O
and	O
in	O
its	O
requirement	O
for	O
a	O
trans-acting	O
protein	O
factor	O
,	O
the	O
viral	O
replicase	O
subunit	O
nsp1β	O
.	O

Here	O
we	O
show	O
that	O
the	O
the	O
trans-activation	O
of	O
frameshifting	O
is	O
carried	O
out	O
by	O
a	O
protein	O
complex	O
composed	O
of	O
nsp1β	O
and	O
a	O
cellular	O
poly	O
(	O
C	O
)	O
binding	O
protein	O
(	O
PCBP	O
)	O
.	O

From	O
the	O
results	O
of	O
in	O
vitro	O
translation	O
and	O
electrophoretic	B-P
mobility	I-P
shift	I-P
assays	I-P
,	O
we	O
demonstrate	O
that	O
a	O
PCBP	O
/	O
nsp1β	O
complex	O
binds	O
to	O
a	O
C-rich	O
sequence	O
downstream	O
of	O
the	O
slippery	O
sequence	O
and	O
here	O
mimics	O
the	O
activity	O
of	O
a	O
structured	O
mRNA	O
stimulator	O
of	O
PRF	O
.	O

This	O
is	O
the	O
first	O
description	O
of	O
a	O
role	O
for	O
a	O
trans-acting	O
cellular	O
protein	O
in	O
PRF	O
.	O

The	O
discovery	O
broadens	O
the	O
repertoire	O
of	O
activities	O
associated	O
with	O
poly	O
(	O
C	O
)	O
binding	O
proteins	O
and	O
prototypes	O
a	O
new	O
class	O
of	O
virus	O
-	O
host	O
interactions	O
.	O

Individual	O
Leg	O
Muscle	O
Contributions	O
to	O
the	O
Cost	O
of	O
Walking	O
:	O
Effects	O
of	O
Age	O
and	O
Walking	O
Speed	O
.	O

This	O
study	O
examined	O
the	O
contributions	O
of	O
individual	O
muscles	O
to	O
changes	O
in	O
energetic	O
cost	O
of	O
transport	O
(	O
COT	O
)	O
over	O
seven	O
walking	O
speeds	O
,	O
and	O
compared	O
results	O
between	O
healthy	O
young	O
and	O
elderly	O
subjects	O
.	O

Twenty	O
six	O
participants	O
(	O
13	O
young	O
aged	O
18-30	O
;	O
13	O
old	O
aged	O
70-80	O
)	O
were	O
recruited	O
.	O

COT	O
(	O
O2/kg	O
body	O
mass/km	O
)	O
was	O
calculated	O
by	O
standardizing	O
the	O
mean	O
oxygen	O
consumption	O
recorded	O
during	O
steady	O
state	O
walking	O
.	O

Electromyography	B-P
signals	O
from	O
10	O
leg	O
muscles	O
were	O
used	O
to	O
calculate	O
the	O
cumulative	O
activity	O
required	O
to	O
traverse	O
a	O
unit	O
of	O
distance	O
(	O
CMAPD	O
)	O
for	O
each	O
muscle	O
at	O
each	O
speed	O
.	O

In	O
the	O
old	O
group	O
CMAPD	O
was	O
correlated	O
with	O
COT	O
,	O
presented	O
higher	O
and	O
more	O
variable	O
values	O
,	O
and	O
showed	O
greater	O
increases	O
around	O
optimal	O
speed	O
for	O
all	O
studied	O
muscles	O
.	O

Soleus	O
CMAPD	O
was	O
independent	O
of	O
speed	O
in	O
the	O
young	O
group	O
,	O
but	O
this	O
was	O
not	O
evident	O
with	O
aging	O
.	O

Greater	O
energy	O
cost	O
of	O
walking	O
in	O
older	O
individuals	O
seems	O
to	O
be	O
attributable	O
to	O
increased	O
energy	O
cost	O
of	O
all	O
lower	O
limb	O
muscles	O
.	O

Rapidly	O
Progressive	O
and	O
Almost	O
Lethal	O
Pneumonia	O
.	O

We	O
herein	O
describe	O
the	O
case	O
of	O
a	O
65-	O
year	O
-old	O
male	O
patient	O
who	O
presented	O
with	O
Osler	O
's	O
triad	O
,	O
which	O
is	O
the	O
combination	O
of	O
endocarditis	O
,	O
pneumonia	O
,	O
and	O
meningitis	O
.	O

This	O
report	O
is	O
even	O
more	O
unusual	O
since	O
the	O
pathogen	O
isolated	O
was	O
the	O
invasive	O
and	O
virulent	O
strain	O
of	O
Streptococcus	O
pneumoniae	O
serotype	O
3	O
.	O

The	O
clinical	O
entity	O
described	O
is	O
also	O
called	O
Austrian	O
syndrome	O
.	O

Even	O
though	O
rare	O
in	O
this	O
antibiotic	O
era	O
,	O
the	O
syndrome	O
remains	O
one	O
of	O
high	O
morbidity	O
and	O
mortality	O
.	O

This	O
particular	O
case	O
is	O
of	O
paramount	O
importance	O
for	O
the	O
clinician	O
reader	O
.	O

First	O
,	O
it	O
documents	O
the	O
clinical	O
features	O
associated	O
with	O
invasive	O
pneumococcal	O
disease	O
and	O
the	O
Austrian	O
syndrome	O
.	O

Second	O
,	O
and	O
equally	O
important	O
,	O
it	O
highlights	O
why	O
following	O
the	O
Surviving	O
Sepsis	O
Campaign	O
guidelines	O
saves	O
lives	O
.	O

For	O
this	O
case	O
,	O
the	O
following	O
steps	O
were	O
taken	O
:	O
1	O
.	O

As	O
a	O
surrogate	O
for	O
perfusion	O
,	O
early	O
and	O
aggressive	O
fluid	O
resuscitation	O
therapy	O
(	O
guided	O
by	O
lactic	B-P
acid	I-P
levels	I-P
)	O
was	O
instituted	O
;	O
2.	O
also	O
early	O
in	O
the	O
treatment	O
,	O
broad	O
spectrum	O
antibiotics	O
were	O
administered	O
;	O
3.	O
to	O
guide	O
antibiotic	O
therapy	O
,	O
microbiological	B-P
cultures	I-P
were	O
obtained	O
.	O

The	O
patient	O
subsequently	O
improved	O
and	O
was	O
transferred	O
to	O
the	O
internal	O
medicine	O
ward	O
to	O
complete	O
4	O
weeks	O
of	O
antibiotic	O
therapy	O
.	O

A	O
new	O
light	O
on	O
Alkaptonuria	O
:	O
A	O
Fourier-transform	B-P
infrared	I-P
microscopy	I-P
(	O
FTIRM	B-P
)	O
and	O
low	B-P
energy	I-P
X-ray	I-P
fluorescence	I-P
microscopy	I-P
(	O
LEXRF	B-P
)	O
correlative	O
study	O
on	O
a	O
rare	O
disease	O
.	O

Alkaptonuria	O
(	O
AKU	O
)	O
is	O
an	O
ultra-rare	O
disease	O
associated	O
to	O
the	O
lack	O
of	O
an	O
enzyme	O
involved	O
in	O
tyrosine	O
catabolism	O
.	O

This	O
deficiency	O
results	O
in	O
the	O
accumulation	O
of	O
homogentisic	O
acid	O
(	O
HGA	O
)	O
in	O
the	O
form	O
of	O
ochronotic	O
pigment	O
in	O
joint	O
cartilage	O
,	O
leading	O
to	O
a	O
severe	O
arthropathy	O
.	O

Secondary	O
amyloidosis	O
has	O
been	O
also	O
unequivocally	O
assessed	O
as	O
a	O
comorbidity	O
of	O
AKU	O
arthropathy	O
.	O

Composition	O
of	O
ochronotic	O
pigment	O
and	O
how	O
it	O
is	O
structurally	O
related	O
to	O
amyloid	O
is	O
still	O
unknown	O
.	O

We	O
exploited	O
Synchrotron	O
Radiation	O
Infrared	B-P
and	O
X-Ray	B-P
Fluorescence	I-P
microscopies	I-P
in	O
combination	O
with	O
conventional	O
bio-assays	B-P
and	O
analytical	O
tools	O
to	O
characterize	O
chemical	O
composition	O
and	O
morphology	O
of	O
AKU	O
cartilage	O
.	O

We	O
evinced	O
that	O
AKU	O
cartilage	O
is	O
characterized	O
by	O
proteoglycans	O
depletion	O
,	O
increased	O
Sodium	O
levels	O
,	O
accumulation	O
of	O
lipids	O
in	O
the	O
peri-lacunar	O
regions	O
and	O
amyloid	O
formation	O
.	O

We	O
also	O
highlighted	O
an	O
increase	O
of	O
aromatic	O
compounds	O
and	O
oxygen-containing	O
species	O
,	O
depletion	O
in	O
overall	O
Magnesium	O
content	O
(	O
although	O
localized	O
in	O
the	O
peri-lacunar	O
region	O
)	O
and	O
the	O
presence	O
of	O
calcium	O
carbonate	O
fragments	O
in	O
proximity	O
of	O
cartilage	O
lacunae	O
.	O

We	O
highlighted	O
common	O
features	O
between	O
AKU	O
and	O
arthropathy	O
,	O
but	O
also	O
specific	O
signatures	O
of	O
the	O
disease	O
,	O
like	O
presence	O
of	O
amyloids	O
and	O
peculiar	O
calcifications	O
.	O

Our	O
analyses	O
provide	O
a	O
unified	O
picture	O
of	O
AKU	O
cartilage	O
,	O
shedding	O
a	O
new	O
light	O
on	O
the	O
disease	O
and	O
opening	O
new	O
perspectives	O
.	O

Ochronotic	O
pigment	O
is	O
a	O
hallmark	O
of	O
AKU	O
and	O
responsible	O
of	O
tissue	O
degeneration	O
.	O

Conventional	O
bio-assays	B-P
have	O
not	O
yet	O
clarified	O
its	O
composition	O
and	O
its	O
structural	O
relationship	O
with	O
amyloids	O
.	O

The	O
present	O
work	O
proposes	O
new	O
strategies	O
for	O
filling	O
the	O
aforementioned	O
gap	O
that	O
encompass	O
the	O
integration	O
of	O
new	O
analytical	O
approaches	O
with	O
standardized	O
analyses	O
.	O

Harmonization	O
of	O
Clinical	O
Laboratory	O
Information	O
-	O
Current	O
and	O
Future	O
Strategies	O
.	O

According	O
to	O
a	O
patient	O
-centered	O
viewpoint	O
,	O
the	O
meaning	O
of	O
harmonization	O
in	O
the	O
context	O
of	O
laboratory	O
medicine	O
is	O
that	O
the	O
information	O
should	O
be	O
comparable	O
irrespective	O
of	O
the	O
measurement	O
procedure	O
used	O
and	O
where	O
and/or	O
when	O
a	O
measurement	O
is	O
made	O
.	O

Harmonization	O
represents	O
a	O
fundamental	O
aspect	O
of	O
quality	O
in	O
laboratory	O
medicine	O
as	O
its	O
ultimate	O
goal	O
is	O
to	O
improve	O
patient	O
outcomes	O
through	O
the	O
provision	O
of	O
an	O
accurate	O
and	O
actionable	O
laboratory	O
information	O
.	O

Although	O
the	O
initial	O
focus	O
has	O
to	O
a	O
large	O
extent	O
been	O
to	O
harmonize	O
and	O
standardize	O
analytical	O
processes	O
and	O
methods	O
,	O
the	O
scope	O
of	O
harmonization	O
goes	O
beyond	O
to	O
include	O
all	O
other	O
aspects	O
of	O
the	O
total	O
testing	O
process	O
(	O
TTP	O
)	O
,	O
such	O
as	O
terminology	O
and	O
units	O
,	O
report	O
formats	O
,	O
reference	O
intervals	O
and	O
decision	O
limits	O
,	O
as	O
well	O
as	O
tests	O
and	O
test	B-P
profiles	I-P
request	O
and	O
criteria	O
for	O
interpretation	O
.	O

Two	O
major	O
progresses	O
have	O
been	O
made	O
in	O
the	O
area	O
of	O
harmonization	O
in	O
laboratory	O
medicine	O
:	O
first	O
,	O
the	O
awareness	O
that	O
harmonization	O
should	O
take	O
into	O
consideration	O
not	O
only	O
the	O
analytical	O
phase	O
but	O
all	O
steps	O
of	O
the	O
TTP	O
,	O
thus	O
dealing	O
with	O
the	O
request	O
,	O
the	O
sample	O
,	O
the	O
measurement	O
,	O
and	O
the	O
report	O
.	O

Second	O
,	O
as	O
the	O
processes	O
required	O
to	O
achieve	O
harmonization	O
are	O
complicated	O
,	O
a	O
systematic	O
approach	O
is	O
needed	O
.	O

The	O
International	B-P
Federation	I-P
of	I-P
Clinical	I-P
Chemistry	I-P
and	I-P
Laboratory	I-P
Medicine	I-P
(	O
IFCC	B-P
)	O
has	O
played	O
a	O
fundamental	O
and	O
successful	O
role	O
in	O
the	O
development	O
of	O
standardized	O
and	O
harmonized	B-P
assays	I-P
,	O
and	O
now	O
it	O
should	O
continue	O
to	O
work	O
in	O
the	O
field	O
through	O
the	O
collaboration	O
and	O
cooperation	O
with	O
many	O
other	O
stakeholders	O
.	O

Radiolabeled	O
B9958	O
Derivatives	O
for	O
Imaging	B-P
Bradykinin	O
B1	O
Receptor	O
Expression	O
with	O
Positron	B-P
Emission	I-P
Tomography	I-P
:	O
Effect	O
of	O
the	O
Radiolabel	O
-	O
Chelator	O
Complex	O
on	O
Biodistribution	O
and	O
Tumor	O
Uptake	O
.	O

Bradykinin	O
B1	O
receptor	O
(	O
B1R	O
)	O
,	O
which	O
is	O
upregulated	O
in	O
a	O
variety	O
of	O
malignancies	O
,	O
is	O
an	O
attractive	O
cancer	B-P
imaging	I-P
biomarker	O
.	O

In	O
this	O
study	O
we	O
optimized	O
the	O
selection	O
of	O
radiolabel	O
-	O
chelator	O
complex	O
to	O
improve	O
tumor	O
uptake	O
and	O
tumor	O
-to-background	O
contrast	O
of	O
radiolabeled	O
analogues	O
of	O
B9958	O
(	O
Lys-Lys-Arg-Pro-Hyp-Gly-Cpg-Ser-d-Tic-Cpg	O
)	O
,	O
a	O
potent	O
B1R	O
antagonist	O
.	O

Peptide	O
sequences	O
were	O
assembled	O
on	O
solid	O
phase	O
.	O

Cold	O
standards	O
were	O
prepared	O
by	O
incubating	O
DOTA	O
-/	O
NODA	O
-	O
conjugated	O
peptides	O
with	O
GaCl3	O
,	O
and	O
by	O
incubating	O
AlOH	O
-	O
NODA	O
-conjugated	O
peptide	O
with	O
NaF	O
.	O

Binding	O
affinities	O
were	O
measured	O
via	O
in	B-P
vitro	I-P
competition	I-P
binding	I-P
assays	I-P
.	O

(	O
68	O
)	O
Ga	O
and	O
(	O
18	O
)	O
F	O
labeling	O
experiments	O
were	O
performed	O
in	O
acidic	O
buffer	O
and	O
purified	O
by	O
HPLC	B-P
.	O

Imaging	B-P
/	O
biodistribution	O
studies	O
were	O
performed	O
in	O
mice	O
bearing	O
both	O
B1R-positive	O
(	O
B1R+	O
)	O
HEK293T	O
:	O
:	O
hB1R	O
and	O
B1R-negative	O
(	O
B1R-	O
)	O
HEK293T	O
tumors	O
.	O

Z02176	O
(	O
Ga-DOTA-Pip-B9958	O
;	O
Pip	O
:	O
4-amino-	O
(	O
1-carboxymethyl	O
)	O
piperidine	O
)	O
,	O
Z02137	O
(	O
Ga-NODA-Mpaa-Pip-B9958	O
;	O
Mpaa	O
:	O
4-methylphenylacetic	O
acid	O
)	O
,	O
and	O
Z04139	O
(	O
AlF-NODA-Mpaa-Pip-B9958	O
)	O
bound	O
h	O
B1R	O
with	O
high	O
affinity	O
(	O
Ki	O
=	O
1.4-2.5	O
nM	O
)	O
.	O

(	O
68	O
)	O
Ga	O
-/	O
(	O
18	O
)	O
F	O
-	O
labeled	O
peptides	O
were	O
obtained	O
on	O
average	O
in	O
≥32	O
%	O
decay-corrected	O
radiochemical	O
yield	O
with	O
>	O
99	O
%	O
radiochemical	O
purity	O
and	O
100-261	O
GBq/μmol	O
specific	O
activity	O
.	O

Biodistribution	O
/	O
imaging	B-P
studies	O
at	O
1	O
h	O
postinjection	O
showed	O
that	O
all	O
tracers	O
cleared	O
rapidly	O
from	O
background	O
tissues	O
(	O
except	O
kidneys	O
)	O
and	O
were	O
excreted	O
predominantly	O
via	O
the	O
renal	O
pathway	O
.	O

Only	O
kidneys	O
,	O
bladders	O
,	O
and	O
B1R+	O
tumors	O
were	O
clearly	O
visualized	O
in	O
PET	B-P
images	O
.	O

Uptake	O
in	O
B1R+	O
tumor	O
was	O
higher	O
by	O
using	O
(	O
68	O
)	O
Ga	O
-	O
Z02176	O
(	O
28.9	O
±	O
6.21	O
%	O
ID/g	O
)	O
and	O
(	O
18	O
)	O
F	O
-	O
Z04139	O
(	O
22.6	O
±	O
3.41	O
%	O
ID/g	O
)	O
than	O
(	O
68	O
)	O
Ga	O
-	O
Z02137	O
(	O
14.0	O
±	O
4.86	O
%	O
ID/g	O
)	O
.	O

The	O
B1R+	O
tumor-to-blood	O
and	O
B1R+	O
tumor-to-muscle	O
contrast	O
ratios	O
were	O
also	O
higher	O
for	O
(	O
68	O
)	O
Ga	O
-	O
Z02176	O
(	O
56.1	O
±	O
17.3	O
and	O
167	O
±	O
57.6	O
)	O
and	O
(	O
18	O
)	O
F	O
-	O
Z04139	O
(	O
58.0	O
±	O
20.9	O
and	O
173	O
±	O
42.9	O
)	O
than	O
(	O
68	O
)	O
Ga	O
-	O
Z02137	O
(	O
34.3	O
±	O
15.2	O
and	O
103	O
±	O
30.2	O
)	O
.	O

With	O
improved	O
target-to-background	O
contrast	O
(	O
68	O
)	O
Ga	O
-	O
Z02176	O
and	O
(	O
18	O
)	O
F	O
-	O
Z04139	O
are	O
promising	O
for	O
imaging	B-P
B1R	O
expression	O
in	O
cancers	O
with	O
PET	B-P
.	O

Long-term	O
antibiofilm	O
activity	O
of	O
carboxymethyl	O
chitosan	O
on	O
mixed	O
biofilm	O
on	O
silicone	O
.	O

Silicone	O
voice	O
prostheses	O
are	O
most	O
frequently	O
used	O
in	O
voice	O
rehabilitation	O
of	O
laryngectomized	O
patients	O
.	O

However	O
,	O
the	O
functional	O
device	O
lifetimes	O
are	O
limited	O
due	O
to	O
formation	O
of	O
mixed	O
biofilms	O
.	O

Existing	O
in	O
vitro	O
models	O
simulating	O
biofilm	O
formation	O
are	O
restricted	O
to	O
only	O
short-term	O
periods	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
carboxymethyl	O
chitosan	O
on	O
mixed	O
biofilm	O
formation	O
of	O
fungi	O
and	O
bacteria	O
on	O
silicone	O
over	O
a	O
long-term	O
period	O
.	O

Mixed	O
species	O
biofilms	O
of	O
Candida	O
albicans	O
,	O
Candida	O
tropicalis	O
,	O
Lactobacillus	O
gasseri	O
,	O
Streptococcus	O
salivarius	O
,	O
Rothia	O
dentocariosa	O
,	O
and	O
Staphylococcus	O
epidermidis	O
were	O
cultivated	O
on	O
the	O
surfaces	O
of	O
medical-grade	O
silicone	O
with	O
and	O
without	O
addition	O
of	O
carboxymethyl	O
chitosan	O
.	O

Biofilm	O
kinetics	O
was	O
monitored	O
using	O
specially	O
designed	O
image	O
analysis	O
software	O
to	O
calculate	O
the	O
percentual	O
surface	O
covering	O
of	O
each	O
platelet	O
.	O

Biofilm	O
architecture	O
was	O
investigated	O
by	O
scanning	B-P
electron	I-P
microscopy	I-P
.	O

A	O
cover	O
of	O
living	O
mixed	O
biofilm	O
could	O
be	O
generated	O
over	O
22	O
days	O
on	O
silicone	O
and	O
the	O
maximum	O
of	O
22	O
%	O
biofilm	O
surface	O
covering	O
at	O
day	O
22	O
.	O

However	O
,	O
less	O
than	O
4	O
%	O
surface	O
coverage	O
was	O
observed	O
on	O
the	O
carboxymethyl	O
chitosan	O
-	O
treated	O
plates	O
in	O
the	O
testing	O
period	O
.	O

Scanning	B-P
electron	I-P
microscopy	I-P
confirms	O
that	O
,	O
on	O
surfaces	O
treated	O
by	O
carboxymethyl	O
chitosan	O
,	O
the	O
biofilm	O
was	O
less	O
dense	O
.	O

In	O
addition	O
,	O
there	O
were	O
fewer	O
layers	O
of	O
cells	O
and	O
profuse	O
cellular	O
debris	O
,	O
together	O
with	O
degrading	O
and	O
morphologically	O
altered	O
yeast	O
cells	O
.	O

Carboxymethyl	O
chitosan	O
may	O
serve	O
as	O
a	O
possible	O
antibiofilm	O
agent	O
to	O
limit	O
biofilm	O
formation	O
on	O
voice	O
prostheses	O
.	O

NA	O
Laryngoscope	O
,	O
126	O
:	O
E404-E408	O
,	O
2016	O
.	O

Molecular	O
profile	O
of	O
5-fluorouracil	O
pathway	O
genes	O
in	O
colorectal	O
carcinoma	O
.	O

This	O
study	O
addresses	O
involvement	O
of	O
major	O
5-fluorouracil	O
(	O
5-FU	O
)	O
pathway	O
genes	O
in	O
the	O
prognosis	O
of	O
colorectal	O
carcinoma	O
patients	O
.	O

Testing	O
set	O
and	O
two	O
validation	O
sets	O
comprising	O
paired	O
tumor	O
and	O
adjacent	O
mucosa	O
tissue	O
samples	O
from	O
151	O
patients	O
were	O
used	O
for	O
transcript	O
profiling	O
of	O
15	O
5-FU	O
pathway	O
genes	O
by	O
quantitative	O
real-time	O
PCR	O
and	O
DNA	O
methylation	O
profiling	O
by	O
high	O
resolution	O
melting	O
analysis	O
.	O

Intratumoral	O
molecular	O
profiles	O
were	O
correlated	O
with	O
clinical	O
data	O
of	O
patients	O
.	O

Protein	O
levels	O
of	O
two	O
most	O
relevant	O
candidate	O
markers	O
were	O
assessed	O
by	O
immunoblotting	B-P
.	O

Downregulation	O
of	O
DPYD	O
and	O
upregulation	O
of	O
PPAT	O
,	O
UMPS	O
,	O
RRM2	O
,	O
and	O
SLC29A1	O
transcripts	O
were	O
found	O
in	O
tumors	O
compared	O
to	O
adjacent	O
mucosa	O
in	O
testing	O
and	O
validation	O
sets	O
of	O
patients	O
.	O

Low	O
RRM2	O
transcript	O
level	O
significantly	O
associated	O
with	O
poor	O
response	O
to	O
the	O
first-line	O
palliative	O
5-FU	O
-based	O
chemotherapy	O
in	O
the	O
testing	O
set	O
and	O
with	O
poor	O
disease-free	O
interval	O
of	O
patients	O
in	O
the	O
validation	O
set	O
irrespective	O
of	O
5-FU	O
treatment	O
.	O

UPP2	O
was	O
strongly	O
methylated	O
while	O
its	O
transcript	O
absent	O
in	O
both	O
tumors	O
and	O
adjacent	O
mucosa	O
.	O

DPYS	O
methylation	O
level	O
was	O
significantly	O
higher	O
in	O
tumor	O
tissues	O
compared	O
to	O
adjacent	O
mucosa	O
samples	O
.	O

Low	O
intratumoral	O
level	O
of	O
UPB1	O
methylation	O
was	O
prognostic	O
for	O
poor	O
disease-free	O
interval	O
of	O
the	O
patients	O
(	O
P	O
=	O
0.0002	O
)	O
.	O

The	O
rest	O
of	O
the	O
studied	O
5-FU	O
genes	O
were	O
not	O
methylated	O
in	O
tumors	O
or	O
adjacent	O
mucosa	O
.	O

The	O
observed	O
overexpression	O
of	O
several	O
5-FU	O
activating	O
genes	O
and	O
DPYD	O
downregulation	O
deduce	O
that	O
chemotherapy	O
naïve	O
colorectal	O
tumors	O
share	O
favorable	O
gene	O
expression	O
profile	O
for	O
5-FU	O
therapy	O
.	O

Low	O
RRM2	O
transcript	O
and	O
UPB1	O
methylation	O
levels	O
present	O
separate	O
poor	O
prognosis	O
factors	O
for	O
colorectal	O
carcinoma	O
patients	O
and	O
should	O
be	O
further	O
investigated	O
.	O

Rate	O
-	O
equation	O
modelling	O
and	O
ensemble	O
approach	O
to	O
extraction	O
of	O
parameters	O
for	O
viral	O
infection	O
-	O
induced	O
cell	O
apoptosis	O
and	O
necrosis	O
.	O

We	O
develop	O
a	O
theoretical	O
approach	O
that	O
uses	O
physiochemical	O
kinetics	O
modelling	O
to	O
describe	O
cell	O
population	O
dynamics	O
upon	O
progression	O
of	O
viral	O
infection	O
in	O
cell	B-P
culture	I-P
,	O
which	O
results	O
in	O
cell	O
apoptosis	O
(	O
programmed	O
cell	O
death	O
)	O
and	O
necrosis	O
(	O
direct	O
cell	O
death	O
)	O
.	O

Several	O
model	O
parameters	O
necessary	O
for	O
computer	O
simulation	O
were	O
determined	O
by	O
reviewing	O
and	O
analyzing	O
available	O
published	O
experimental	O
data	O
.	O

By	O
comparing	O
experimental	O
data	O
to	O
computer	O
modelling	O
results	O
,	O
we	O
identify	O
the	O
parameters	O
that	O
are	O
the	O
most	O
sensitive	O
to	O
the	O
measured	O
system	O
properties	O
and	O
allow	O
for	O
the	O
best	O
data	O
fitting	O
.	O

Our	O
model	O
allows	O
extraction	O
of	O
parameters	O
from	O
experimental	O
data	O
and	O
also	O
has	O
predictive	O
power	O
.	O

Using	O
the	O
model	O
we	O
describe	O
interesting	O
time	O
-	O
dependent	O
quantities	O
that	O
were	O
not	O
directly	O
measured	O
in	O
the	O
experiment	O
and	O
identify	O
correlations	O
among	O
the	O
fitted	O
parameter	O
values	O
.	O

Numerical	O
simulation	O
of	O
viral	O
infection	O
progression	O
is	O
done	O
by	O
a	O
rate	O
-	O
equation	O
approach	O
resulting	O
in	O
a	O
system	O
of	O
``	O
stiff	O
''	O
equations	O
,	O
which	O
are	O
solved	O
by	O
using	O
a	O
novel	O
variant	O
of	O
the	O
stochastic	O
ensemble	O
modelling	O
approach	O
.	O

The	O
latter	O
was	O
originally	O
developed	O
for	O
coupled	O
chemical	O
reactions	O
.	O

Atmospheric	O
wet	O
deposition	O
of	O
dissolved	O
trace	O
elements	O
to	O
Jiaozhou	O
Bay	O
,	O
North	O
China	O
:	O
Fluxes	O
,	O
sources	O
and	O
potential	O
effects	O
on	O
aquatic	O
environments	O
.	O

To	O
analyze	O
the	O
fluxes	O
,	O
seasonal	O
variations	O
,	O
sources	O
and	O
potential	O
ecological	O
effects	O
of	O
dissolved	O
trace	O
elements	O
(	O
TEs	O
)	O
in	O
atmospheric	O
wet	O
deposition	O
(	O
AWD	O
)	O
,	O
one-year	O
wet	O
precipitation	O
samples	O
were	O
collected	O
and	O
determined	O
for	O
nine	O
TEs	O
in	O
Jiaozhou	O
Bay	O
(	O
JZB	O
)	O
between	O
June	O
2015	O
and	O
May	O
2016	O
.	O

Both	O
the	O
volume-weighted	B-P
mean	O
(	O
VWM	O
)	O
concentration	O
and	O
flux	O
sequence	O
for	O
the	O
measured	O
TEs	O
was	O
Al	O
>	O
Mn	O
>	O
Zn	O
>	O
Fe	O
>	O
Pb	O
>	O
Se	O
>	O
Cr	O
>	O
Cd	O
>	O
Co.	O
Al	O
was	O
the	O
most	O
abundant	O
TE	O
with	O
a	O
VWM	O
concentration	O
and	O
wet	O
flux	O
of	O
33.8	O
μg	O
L	O
(	O
-1	O
)	O
and	O
29.2	O
mg	O
m	O
(	O
-2	O
)	O
yr	O
(	O
-1	O
)	O
,	O
which	O
were	O
2	O
and	O
3	O
orders	O
of	O
magnitude	O
higher	O
than	O
those	O
of	O
Co	O
,	O
respectively	O
.	O

The	O
emission	O
intensities	O
of	O
pollutants	O
,	O
rainfall	O
amount	O
and	O
wind	O
speed	O
were	O
the	O
dominating	O
factors	O
influencing	O
seasonal	O
variations	O
of	O
TEs	O
in	O
AWD	O
.	O

Based	O
on	O
enrichment	O
factors	O
,	O
correlation	O
analysis	O
and	O
principal	O
component	O
analysis	O
,	O
most	O
of	O
the	O
TEs	O
in	O
AWD	O
were	O
primarily	O
originated	O
from	O
anthropogenic	O
activities	O
except	O
for	O
Al	O
and	O
Fe	O
,	O
which	O
are	O
typically	O
derived	O
from	O
re-suspended	O
soil	O
dusts	O
.	O

Although	O
the	O
TE	O
inputs	O
by	O
AWD	O
were	O
significantly	O
lower	O
than	O
those	O
by	O
rivers	O
,	O
the	O
TE	O
inputs	O
via	O
short-term	O
heavy	O
rains	O
would	O
distinctly	O
increase	O
surface	O
seawater	O
TE	O
concentrations	O
and	O
then	O
pollute	O
the	O
marine	O
environment	O
of	O
JZB	O
.	O

AWD	O
would	O
have	O
both	O
profound	O
impacts	O
on	O
the	O
biogeochemical	O
cycles	O
of	O
TEs	O
and	O
dual	O
ecological	O
effects	O
(	O
nutrient	O
and	O
toxicity	O
)	O
on	O
aquatic	O
organisms	O
.	O

P-glycoprotein	O
traffics	O
from	O
the	O
nucleus	O
to	O
the	O
plasma	O
membrane	O
in	O
rat	O
brain	O
endothelium	O
during	O
inflammatory	O
pain	O
.	O

P-glycoprotein	O
(	O
PgP	O
)	O
,	O
a	O
drug	O
efflux	O
pump	O
in	O
blood-brain	O
barrier	O
endothelial	O
cells	O
,	O
is	O
a	O
major	O
clinical	O
obstacle	O
for	O
effective	O
central	O
nervous	O
system	O
drug	O
delivery	O
.	O

Identifying	O
PgP	O
regulatory	O
pathways	O
that	O
can	O
be	O
exploited	O
clinically	O
is	O
critical	O
for	O
improving	O
central	O
nervous	O
system	O
drug	O
delivery	O
.	O

We	O
previously	O
found	O
that	O
PgP	O
activity	O
increases	O
in	O
rat	O
brain	O
microvessels	O
concomitant	O
with	O
decreased	O
central	O
nervous	O
system	O
drug	O
delivery	O
in	O
response	O
to	O
acute	O
peripheral	O
inflammatory	O
pain	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
PgP	O
traffics	O
to	O
the	O
luminal	O
plasma	O
membrane	O
of	O
the	O
microvessel	O
endothelial	O
cells	O
from	O
intracellular	O
stores	O
during	O
peripheral	O
inflammatory	O
pain	O
.	O

Using	O
immunofluorescence	B-P
microscopy	I-P
,	O
we	O
detected	O
PgP	O
in	O
endothelial	O
cell	O
nuclei	O
and	O
in	O
the	O
luminal	O
plasma	O
membrane	O
in	O
control	O
animals	O
.	O

Following	O
peripheral	O
inflammatory	O
pain	O
,	O
luminal	O
PgP	O
staining	B-P
increased	O
while	O
staining	B-P
in	O
the	O
nucleus	O
decreased	O
.	O

Biochemical	B-P
analysis	I-P
of	O
nuclear	O
PgP	O
content	O
confirmed	O
our	O
visual	O
observations	O
.	O

Peripheral	O
inflammatory	O
pain	O
also	O
increased	O
endothelial	O
cell	O
luminal	O
staining	B-P
of	O
polymerase	O
1	O
and	O
transcript	O
release	O
factor	O
/	O
cavin1	O
and	O
serum	O
deprivation	O
response	O
protein	O
/	O
cavin2	O
,	O
two	O
caveolar	O
scaffold	O
proteins	O
,	O
without	O
changing	O
caveolin1	O
or	O
protein	O
kinase	O
C	O
delta	O
binding	O
protein	O
/	O
cavin3	O
location	O
.	O

Our	O
data	O
(	O
a	O
)	O
indicate	O
that	O
PgP	O
traffics	O
from	O
stores	O
in	O
the	O
nucleus	O
to	O
the	O
endothelial	O
cell	O
luminal	O
membrane	O
in	O
response	O
to	O
peripheral	O
inflammatory	O
pain	O
;	O
(	O
b	O
)	O
provide	O
an	O
explanation	O
for	O
our	O
previous	O
observation	O
that	O
peripheral	O
inflammatory	O
pain	O
inhibits	O
central	O
nervous	O
system	O
drug	O
uptake	O
;	O
and	O
(	O
c	O
)	O
suggest	O
a	O
novel	O
regulatory	O
mechanism	O
for	O
PgP	O
activity	O
in	O
rat	O
brain	O
.	O

Breast	O
cancer	O
cells	O
and	O
bone	O
marrow	O
mesenchymal	O
stromal	O
cells	O
:	O
a	O
regulated	O
modulation	O
of	O
the	O
breast	O
tumor	O
in	O
the	O
context	O
of	O
immune	O
response	O
.	O

The	O
role	O
of	O
direct	O
cell-cell	O
interactions	O
mediating	O
selective	O
bone	O
metastasis	O
by	O
breast	O
cancer	O
cells	O
(	O
BCCs	O
)	O
niche	O
is	O
still	O
mostly	O
unknown	O
.	O

Conditioned	O
medium	O
and	O
direct	O
cell-cell	O
contacts	O
experiments	O
were	O
used	O
to	O
investigate	O
the	O
effect	O
of	O
bone	O
marrow	O
-derived	O
mesenchymal	O
stromal	O
cells	O
(	O
MSCs	O
)	O
,	O
osteoprogenitor-like	O
cells	O
(	O
MG-63	O
)	O
and	O
osteosarcoma	O
cells	O
(	O
SaOS-2	O
)	O
on	O
luminal-like	O
(	O
MCF-7	O
)	O
and	O
basal-like	O
(	O
MDA-MB-231	O
)	O
BCCs	O
flow	B-P
cytometry	I-P
was	O
used	O
to	O
assess	O
the	O
purity	O
of	O
isolated	O
BCCs	O
and	O
osteoblasts	O
.	O

Expression	O
of	O
osteoblastic	O
markers	O
was	O
investigated	O
by	O
semi-quantitative	O
RT-PCR	O
.	O

RANKL	O
and	O
OPG	O
levels	O
were	O
measured	O
by	O
ELISA	B-P
.	O

Conditioned	O
medium	O
from	O
MSCs	O
and	O
osteoblasts	O
induced	O
the	O
expression	O
of	O
osteoblastic	O
markers	O
in	O
BCCs	O
.	O

While	O
co-culture	B-P
assays	B-P
with	O
SaOS-2	O
increased	O
the	O
expression	O
of	O
osteoblastic	O
markers	O
in	O
MCF-7	O
cells	O
,	O
SaOS-2	O
cell	O
conditioned	O
medium	O
increased	O
the	O
expression	O
of	O
RANKL	O
,	O
PTHrP	O
,	O
VEGF	O
and	O
NOGGIN	O
in	O
MCF-7	O
cells	O
.	O

Co-cultures	B-P
with	O
either	O
MG-63	O
cells	O
or	O
MSCs	O
induced	O
OPG	O
and	O
MMP-2	O
in	O
both	O
tumor	O
cell	O
lines	O
.	O

Interestingly	O
,	O
conditioned	O
medium	O
from	O
co-cultures	B-P
of	O
MSCs	O
and	O
MDA-MB-231	O
cells	O
significantly	O
decreased	O
the	O
proliferation	O
of	O
activated	O
T	O
lymphocytes	O
which	O
was	O
reversed	O
by	O
addition	O
of	O
anti-OPG	O
antibodies	O
to	O
the	O
co-cultures	B-P
.	O

Our	O
data	O
suggest	O
that	O
MSCs	O
strongly	O
contribute	O
to	O
the	O
adaptation	O
and	O
invasiveness	O
of	O
breast	O
cancer	O
cells	O
in	O
skeletal	O
tissues	O
.	O

Blinking	O
Phase-Change	O
Nanocapsules	O
Enable	O
Background-Free	O
Ultrasound	B-P
Imaging	I-P
.	O

Microbubbles	O
are	O
widely	O
used	O
as	O
contrast	O
agents	O
to	O
improve	O
the	O
diagnostic	O
capability	O
of	O
conventional	O
,	O
highly	O
speckled	O
,	O
low-contrast	O
ultrasound	B-P
imaging	I-P
.	O

However	O
,	O
while	O
microbubbles	O
can	O
be	O
used	O
for	O
molecular	B-P
imaging	I-P
,	O
these	O
agents	O
are	O
limited	O
to	O
the	O
vascular	O
space	O
due	O
to	O
their	O
large	O
size	O
(	O
>	O
1	O
μm	O
)	O
.	O

Smaller	O
microbubbles	O
are	O
desired	O
but	O
their	O
ultrasound	O
visualization	O
is	O
limited	O
due	O
to	O
lower	O
echogenicity	O
or	O
higher	O
resonant	O
frequencies	O
.	O

Here	O
we	O
present	O
nanometer	O
scale	O
,	O
phase	O
changing	O
,	O
blinking	O
nanocapsules	O
(	O
BLInCs	O
)	O
,	O
which	O
can	O
be	O
repeatedly	O
optically	O
triggered	O
to	O
provide	O
transient	O
contrast	O
and	O
enable	O
background-free	B-P
ultrasound	I-P
imaging	I-P
.	O

In	O
response	O
to	O
irradiation	O
by	O
near-infrared	O
laser	O
pulses	O
,	O
the	O
BLInCs	O
undergo	O
cycles	O
of	O
rapid	O
vaporization	O
followed	O
by	O
recondensation	O
into	O
their	O
native	O
liquid	O
state	O
at	O
body	O
temperature	O
.	O

High	O
frame	O
rate	O
ultrasound	B-P
imaging	I-P
measures	O
the	O
dynamic	O
echogenicity	O
changes	O
associated	O
with	O
these	O
controllable	O
,	O
periodic	O
phase	O
transitions	O
.	O

Using	O
a	O
newly	O
developed	O
image	O
processing	O
algorithm	O
,	O
the	O
blinking	O
particles	O
are	O
distinguished	O
from	O
tissue	O
,	O
providing	O
a	O
background-free	O
image	O
of	O
the	O
BLInCs	O
while	O
the	O
underlying	O
B-mode	B-P
ultrasound	I-P
image	O
is	O
used	O
as	O
an	O
anatomical	O
reference	O
of	O
the	O
tissue	O
.	O

We	O
demonstrate	O
the	O
function	O
of	O
BLInCs	O
and	O
the	O
associated	O
imaging	B-P
technique	I-P
in	O
a	O
tissue	O
-mimicking	O
phantom	O
and	O
in	O
vivo	O
for	O
the	O
identification	O
of	O
the	O
sentinel	O
lymph	O
node	O
.	O

Our	O
studies	O
indicate	O
that	O
BLInCs	O
may	O
become	O
a	O
powerful	O
tool	O
to	O
identify	O
biological	O
targets	O
using	O
a	O
conventional	O
ultrasound	O
imaging	O
system	O
.	O

Total	O
synthesis	O
and	O
neuroprotective	O
effect	O
of	O
O-methylmurrayamine	O
A	O
and	O
7-methoxymurrayacine	O
.	O

O-Methylmurrayamine	O
A	O
(	O
7	O
)	O
and	O
7-methoxymurrayacine	O
(	O
8	O
)	O
are	O
natural	O
products	O
isolated	O
from	O
Murraya	O
koenigii	O
and	O
Murraya	O
siamensis	O
,	O
respectively	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
the	O
synthesis	O
of	O
7	O
and	O
8	O
which	O
are	O
featured	O
in	O
the	O
key	O
step	O
of	O
cyclization	O
to	O
form	O
carbazole	O
intermediate	O
5	O
with	O
mild	O
conditions	O
.	O

The	O
structures	O
were	O
confirmed	O
by	O
(	B-P
1	I-P
)	I-P
H	I-P
NMR	I-P
,	O
(	B-P
13	I-P
)	I-P
C	I-P
NMR	I-P
,	O
and	O
HR-ESI-MS	B-P
.	O

In	O
addition	O
,	O
compounds	O
7	O
and	O
8	O
were	O
tested	O
for	O
their	O
neuroprotective	O
effects	O
against	O
H2O2	O
-induced	O
PC12	O
cell	O
damage	O
.	O

The	O
results	O
showed	O
that	O
compounds	O
7	O
and	O
8	O
have	O
neuroprotective	O
effect	O
.	O

PUMILIO	O
/	O
FOXP1	O
signaling	O
drives	O
expansion	O
of	O
hematopoietic	O
stem/progenitor	O
and	O
leukemia	O
cells	O
.	O

RNA-binding	O
proteins	O
(	O
RBPs	O
)	O
have	O
emerged	O
as	O
important	O
regulators	O
of	O
invertebrate	O
adult	O
stem	O
cells	O
,	O
but	O
their	O
activities	O
remain	O
poorly	O
appreciated	O
in	O
mammals	O
.	O

Using	O
a	O
short	O
hairpin	O
RNA	O
strategy	O
,	O
we	O
demonstrate	O
here	O
that	O
the	O
2	O
mammalian	O
RBPs	O
,	O
PUMILIO	O
(	O
PUM	O
)	O
1	O
and	O
PUM2	O
,	O
members	O
of	O
the	O
PUF	O
family	O
of	O
posttranscriptional	O
regulators	O
,	O
are	O
essential	O
for	O
hematopoietic	O
stem/progenitor	O
cell	O
(	O
HSPC	O
)	O
proliferation	O
and	O
survival	O
in	O
vitro	O
and	O
in	O
vivo	O
upon	O
reconstitution	B-P
assays	I-P
.	O

Moreover	O
,	O
we	O
found	O
that	O
PUM1	O
/	O
2	O
sustain	O
myeloid	O
leukemic	O
cell	O
growth	O
.	O

Through	O
a	O
proteomic	O
approach	O
,	O
we	O
identified	O
the	O
FOXP1	O
transcription	O
factor	O
as	O
a	O
new	O
target	O
of	O
PUM1	O
/	O
2	O
.	O

Contrary	O
to	O
its	O
canonical	O
repressive	O
activity	O
,	O
PUM1	O
/	O
2	O
rather	O
promote	O
FOXP1	O
expression	O
by	O
a	O
direct	O
binding	O
to	O
2	O
canonical	O
PUM	O
responsive	O
elements	O
present	O
in	O
the	O
FOXP1	O
-	O
3	O
'	O
untranslated	O
region	O
(	O
UTR	O
)	O
.	O

Expression	O
of	O
FOXP1	O
strongly	O
correlates	O
with	O
PUM1	O
and	O
PUM2	O
levels	O
in	O
primary	O
HSPCs	O
and	O
myeloid	O
leukemia	O
cells	O
.	O

We	O
demonstrate	O
that	O
FOXP1	O
by	O
itself	O
supports	O
HSPC	O
and	O
leukemic	O
cell	O
growth	O
,	O
thus	O
mimicking	O
PUM	O
activities	O
.	O

Mechanistically	O
,	O
FOXP1	O
represses	O
the	O
expression	O
of	O
the	O
p21	O
(	O
-CIP1	O
)	O
and	O
p27	O
(	O
-KIP1	O
)	O
cell	O
cycle	O
inhibitors	O
.	O

Enforced	O
FOXP1	O
expression	O
reverses	O
shPUM	O
antiproliferative	O
and	O
proapoptotic	O
activities	O
.	O

Altogether	O
,	O
our	O
results	O
reveal	O
a	O
novel	O
regulatory	O
pathway	O
,	O
underscoring	O
a	O
previously	O
unknown	O
and	O
interconnected	O
key	O
role	O
of	O
PUM1	O
/	O
2	O
and	O
FOXP1	O
in	O
regulating	O
normal	O
HSPC	O
and	O
leukemic	O
cell	O
growth	O
.	O

Assessment	O
of	O
transient	B-P
elastography	I-P
in	O
Japanese	O
patients	O
with	O
non-alcoholic	O
fatty	O
liver	O
disease	O
.	O

Transient	B-P
elastography	I-P
(	O
TE	B-P
)	O
is	O
a	O
non-invasive	O
method	B-P
for	O
predicting	O
liver	O
fibrosis	O
.	O

However	O
,	O
there	O
are	O
limited	O
data	O
regarding	O
the	O
performance	O
of	O
TE	B-P
in	O
Japanese	O
patients	O
with	O
non-alcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFLD	O
)	O
.	O

We	O
aimed	O
to	O
evaluate	O
the	O
association	O
between	O
liver	O
stiffness	O
measurement	O
(	O
LSM	O
)	O
by	O
TE	B-P
and	O
liver	O
fibrosis	O
stage	O
,	O
and	O
define	O
a	O
cut-off	O
value	O
for	O
predicting	O
liver	O
fibrosis	O
.	O

A	O
total	O
of	O
171	O
Japanese	O
patients	O
with	O
biopsy	B-P
-	O
proven	O
NAFLD	O
underwent	O
LSM	O
using	O
TE	B-P
with	O
FibroScan	B-P
.	O

The	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
of	O
LSM	O
and	O
other	O
non-invasive	O
markers	O
of	O
liver	O
fibrosis	O
were	O
compared	O
to	O
determine	O
the	O
most	O
accurate	O
method	B-P
of	O
predicting	O
liver	O
fibrosis	O
.	O

Liver	O
stiffness	O
measurement	O
significantly	O
correlated	O
with	O
fibrosis	O
stage	O
(	O
P	O
<	O
0.001	O
)	O
.	O

The	O
areas	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
of	O
LSM	O
for	O
fibrosis	O
stage	O
≥1	O
and	O
≥3	O
was	O
0.85	O
and	O
0.91	O
,	O
respectively	O
and	O
were	O
higher	O
than	O
those	O
of	O
the	O
aspartate	O
aminotransferase	O
/	O
alanine	O
aminotransferase	O
ratio	O
,	O
aspartate	O
aminotransferase	O
to	O
platelet	O
ratio	O
index	O
,	O
fibrosis-4	O
index	O
,	O
and	O
NAFLD	O
fibrosis	O
score	O
.	O

The	O
best	O
cut-off	O
values	O
of	O
LSM	O
fibrosis	O
stage	O
≥1	O
and	O
≥3	O
were	O
7.2	O
kPa	O
(	O
sensitivity	O
78.5	O
%	O
,	O
specificity	O
78.3	O
%	O
)	O
and	O
10.0	O
kPa	O
(	O
sensitivity	O
89.5	O
%	O
,	O
specificity	O
87.6	O
%	O
)	O
,	O
respectively	O
.	O

The	O
combination	O
of	O
LSM	O
(	O
≥10	O
kPa	O
)	O
and	O
type	O
IV	O
collagen	O
7	O
s	O
(	O
≥6.0	O
ng/mL	O
)	O
had	O
a	O
specificity	O
of	O
97.6	O
%	O
for	O
advanced	O
fibrosis	O
.	O

The	O
LSM	O
in	O
patients	O
with	O
high	O
alanine	O
aminotransferase	O
levels	O
or	O
high	O
body	O
mass	O
index	O
was	O
associated	O
with	O
false	O
positive	O
results	O
regarding	O
advanced	O
fibrosis	O
.	O

In	O
NAFLD	O
patients	O
,	O
TE	B-P
has	O
excellent	O
utility	O
for	O
the	O
assessment	O
of	O
liver	O
fibrosis	O
,	O
particularly	O
for	O
advanced	O
stage	O
cases	O
.	O

The	O
cut-off	O
value	O
of	O
LSM	O
by	O
TE	B-P
for	O
predicting	O
liver	O
fibrosis	O
stage	O
≥3	O
is	O
10.0	O
kPa	O
in	O
Japanese	O
NAFLD	O
patients	O
.	O

Determination	B-P
of	O
eight	O
pesticides	O
in	O
Lycium	O
barbarum	O
by	O
LC-MS/MS	B-P
and	O
dietary	O
risk	O
assessment	O
.	O

A	O
LC-MS/MS	B-P
method	O
for	O
determination	B-P
of	O
eight	O
pesticides	O
(	O
triadimefon	O
,	O
sulfoxaflor	O
,	O
flusilazole	O
,	O
tebuconazole	O
,	O
difenoconazole	O
,	O
amitraz	O
,	O
azoxystrobin	O
,	O
and	O
thiophanate-methyl	O
)	O
in	O
Lycium	O
barbarum	O
was	O
established	O
.	O

The	O
samples	O
were	O
extracted	B-P
with	O
acetonitrile	O
,	O
and	O
then	O
cleaned	O
up	O
by	O
primary	O
secondary	O
amine	O
.	O

The	O
extracts	O
were	O
diluted	O
with	O
0.1	O
%	O
formic	O
acid	O
in	O
water	O
.	O

The	O
results	O
showed	O
that	O
at	O
the	O
fortified	O
levels	O
of	O
0.01-10mg/kg	O
,	O
the	O
average	O
recoveries	O
of	O
these	O
pesticides	O
ranged	O
from	O
82.1	O
%	O
to	O
96.2	O
%	O
with	O
the	O
relative	O
standard	O
deviations	O
lower	O
than	O
7	O
%	O
.	O

The	O
half-lives	O
of	O
eight	O
pesticides	O
were	O
1.3-5.0days	O
in	O
Lycium	O
barbarum	O
fruits	O
.	O

The	O
pre-harvest	O
interval	O
of	O
all	O
pesticides	O
mentioned	O
above	O
were	O
investigated	O
.	O

Tebuconazole	O
(	O
14days	O
)	O
,	O
sulfoxaflor	O
(	O
14days	O
)	O
and	O
flusilazole	O
(	O
28days	O
)	O
have	O
longer	O
pre-harvest	O
interval	O
than	O
the	O
others	O
which	O
have	O
7days	O
.	O

The	O
dietary	O
risks	O
,	O
assessed	O
as	O
hazard	O
quotients	O
,	O
were	O
far	O
below	O
100	O
%	O
.	O

The	O
results	O
showed	O
that	O
the	O
eight	O
pesticides	O
applied	O
to	O
Lycium	O
barbarum	O
were	O
comparably	O
safe	O
for	O
the	O
consumer	O
.	O

Dental	O
implants	O
and	O
bone	O
augmentation	O
in	O
HIV-infected	O
patients	O
under	O
HAART	O
:	O
Case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

The	O
present	O
study	O
reviewed	O
the	O
literature	O
regarding	O
dental	O
implants	O
in	O
HIV-infected	O
patients	O
and	O
reports	O
the	O
long-term	O
follow-up	O
of	O
three	O
clinical	O
cases	O
of	O
patients	O
under	O
HAART	O
that	O
received	O
bone	O
augmentation	O
and	O
dental	O
implants	O
.	O

The	O
first	O
case	O
presents	O
a	O
young	O
patient	O
with	O
a	O
large	O
defect	O
in	O
the	O
mandible	O
,	O
as	O
a	O
consequence	O
of	O
a	O
longitudinal	O
fracture	O
,	O
that	O
was	O
treated	O
with	O
guided	O
bone	O
regeneration	O
(	O
GBR	O
)	O
previously	O
to	O
implant	O
placement	O
.	O

The	O
second	O
case	O
reported	O
is	O
middle-aged	O
man	O
with	O
a	O
fractured	O
upper	O
lateral	O
incisor	O
treated	O
with	O
immediate	O
placement	O
and	O
simultaneous	O
GBR	O
to	O
repair	O
the	O
dehiscence	O
due	O
to	O
the	O
buccal	O
bone	O
resorption	O
.	O

The	O
third	O
case	O
shows	O
an	O
elderly	O
patient	O
that	O
underwent	O
sinus	O
lifting	O
with	O
the	O
simultaneous	O
placement	O
of	O
two	O
implants	O
.	O

All	O
cases	O
were	O
treated	O
after	O
patients	O
were	O
medically	O
controlled	O
and	O
followed	O
for	O
at	O
least	O
10	O
years	O
.	O

Controlled	O
HIV-infected	O
patients	O
undergoing	O
HAART	O
may	O
be	O
candidates	O
to	O
implant	O
rehabilitation	O
,	O
as	O
long	O
as	O
their	O
plasmatic	O
HIV	B-P
viral	I-P
load	I-P
and	O
CD4+	O
T	O
lymphocytes	O
count	O
are	O
within	O
the	O
parameters	O
that	O
indicate	O
immune	O
stability	O
.	O

Long-term	O
stability	O
of	O
soft	O
and	O
hard	O
tissues	O
can	O
be	O
obtained	O
maintaining	O
function	O
and	O
esthetics	O
.	O

However	O
,	O
stronger	O
evidence	O
,	O
based	O
on	O
prospective	O
,	O
controlled	O
clinical	O
trials	O
is	O
needed	O
to	O
provide	O
the	O
dental	O
and	O
medical	O
teams	O
with	O
conclusive	O
data	O
.	O

Is	O
UV	O
-	O
Induced	O
Electron-Driven	O
Proton	O
Transfer	O
Active	O
in	O
a	O
Chemically	O
Modified	O
A	O
·	O
T	O
DNA	O
Base	O
Pair	O
?	O
.	O

Transient	B-P
electronic	I-P
and	I-P
vibrational	I-P
absorption	I-P
spectroscopies	I-P
have	O
been	O
used	O
to	O
investigate	O
whether	O
UV	O
-	O
induced	O
electron-driven	O
proton	O
transfer	O
(	O
EDPT	O
)	O
mechanisms	O
are	O
active	O
in	O
a	O
chemically	O
modified	O
adenine	O
-	O
thymine	O
(	O
A	O
·	O
T	O
)	O
DNA	O
base	O
pair	O
.	O

To	O
enhance	O
the	O
fraction	O
of	O
biologically	O
relevant	O
Watson-Crick	O
(	O
WC	O
)	O
hydrogen-bonding	O
motifs	O
and	O
eliminate	O
undesired	O
Hoogsteen	O
structures	O
,	O
a	O
chemically	O
modified	O
derivative	O
of	O
A	O
was	O
synthesized	O
,	O
8-	O
(	O
tert-butyl	O
)	O
-9-ethyladenine	O
(	O
8tBA	O
)	O
.	O

Equimolar	O
solutions	O
of	O
8tBA	O
and	O
silyl-protected	O
T	O
nucleosides	O
in	O
chloroform	O
yield	O
a	O
mixture	O
of	O
WC	O
pairs	O
,	O
reverse	O
WC	O
pairs	O
,	O
and	O
residual	O
monomers	O
.	O

Unlike	O
previous	O
transient	B-P
absorption	I-P
studies	I-P
of	O
WC	O
guanine	O
-	O
cytosin	O
e	O
(	O
G	O
·	O
C	O
)	O
pairs	O
,	O
no	O
clear	O
spectroscopic	O
or	O
kinetic	O
evidence	O
was	O
identified	O
for	O
the	O
participation	O
of	O
EDPT	O
in	O
the	O
excited-state	O
relaxation	O
dynamics	O
of	O
8tBA	O
·	O
T	O
pairs	O
,	O
although	O
ultrafast	O
(	O
sub-100	O
fs	O
)	O
EDPT	O
can	O
not	O
be	O
discounted	O
.	O

Monomer-like	O
dynamics	O
are	O
proposed	O
to	O
dominate	O
in	O
8tBA	O
·	O
T	O
.	O

When	O
Is	O
a	O
Test	O
Score	O
Fair	O
for	O
the	O
Individual	O
Who	O
Is	O
Being	O
Tested	O
?	O

Effects	O
of	O
Different	O
Scoring	O
Procedures	O
across	O
Multiple	O
Attempts	O
When	O
Testing	O
a	O
Motor	O
Skill	O
Task	O
.	O

Tests	O
or	O
test	O
batteries	O
used	O
for	O
assessing	O
motor	O
skills	O
,	O
either	O
in	O
research	O
studies	O
or	O
in	O
clinical	O
settings	O
,	O
apply	O
a	O
variety	O
of	O
procedures	O
for	O
scoring	O
performances	O
,	O
including	O
everything	O
from	O
one	O
to	O
ten	O
attempts	O
,	O
of	O
which	O
the	O
best	O
is	O
scored	O
or	O
an	O
average	O
is	O
computed	B-P
.	O

The	O
rationale	O
behind	O
scoring	O
procedures	O
is	O
rarely	O
stated	O
,	O
and	O
it	O
seems	O
that	O
the	O
number	O
of	O
attempts	O
allowed	O
is	O
decided	O
without	O
much	O
qualification	O
from	O
research	O
.	O

It	O
is	O
uncertain	O
whether	O
procedures	O
fairly	O
capture	O
an	O
individual	O
's	O
skill	O
level	O
.	O

Thus	O
,	O
the	O
validity	O
of	O
the	O
tests	O
may	O
be	O
compromised	O
.	O

The	O
present	O
study	O
tested	O
24	O
young	O
female	O
soccer	O
players	O
on	O
the	O
juggling	O
of	O
a	O
soccer	O
ball	O
.	O

They	O
were	O
given	O
10	O
attempts	O
,	O
and	O
trials	O
were	O
scored	O
according	O
to	O
nine	O
different	O
procedures	O
including	O
the	O
'	O
best	O
of	O
'	O
or	O
'	O
mean	O
of	O
'	O
either	O
one	O
,	O
two	O
,	O
three	O
,	O
five	O
,	O
or	O
ten	O
attempts	O
.	O

Individual	O
raw	O
scores	O
differed	O
widely	O
across	O
trials	O
,	O
but	O
no	O
general	O
effect	O
of	O
trials	O
was	O
found	O
.	O

The	O
mean	O
(	O
SD	O
)	O
percentage	O
difference	O
between	O
the	O
lowest	O
and	O
highest	O
scores	O
was	O
27.7	O
(	O
9.9	O
)	O
%	O
,	O
with	O
17	O
players	O
(	O
71	O
%	O
)	O
demonstrating	O
a	O
significant	O
change	O
from	O
lowest	O
to	O
highest	O
score	O
.	O

Correlations	O
between	O
raw	O
scores	O
were	O
low	O
across	O
trials	O
,	O
while	O
they	O
were	O
generally	O
higher	O
across	O
scoring	O
procedures	O
.	O

The	O
first	O
trial	O
was	O
significantly	O
different	O
from	O
the	O
remaining	O
both	O
as	O
a	O
raw	O
score	O
and	O
as	O
scoring	O
procedure	O
.	O

The	O
mean	O
percentage	O
difference	O
between	O
best-of-two	O
and	O
best-of-ten	O
scores	O
was	O
95	O
%	O
,	O
with	O
50	O
%	O
of	O
the	O
players	O
demonstrating	O
a	O
significant	O
difference	O
between	O
the	O
two	O
scoring	O
procedures	O
.	O

No	O
significant	O
differences	O
were	O
found	O
across	O
mean-of-rule	O
scorings	O
.	O

Best-of-rule	O
and	O
mean-of-rule	O
scorings	O
were	O
significantly	O
different	O
except	O
for	O
the	O
best-of-two	O
vs.	O
mean-of-two	O
.	O

The	O
mean	O
difference	O
between	O
highest	O
and	O
lowest	O
rank	O
across	O
players	O
was	O
6.7	O
(	O
3.6	O
)	O
,	O
with	O
individual	O
rankings	O
within	O
the	O
group	O
varying	O
33	O
%	O
on	O
average	O
across	O
procedures	O
.	O

One	O
player	O
moved	O
from	O
3rd	O
to	O
23rd	O
place	O
because	O
of	O
procedural	O
differences	O
.	O

Therefore	O
,	O
it	O
is	O
concluded	O
that	O
scoring	O
procedures	O
affect	O
results	O
and	O
may	O
have	O
an	O
impact	O
on	O
test	O
outcomes	O
.	O

This	O
may	O
present	O
consequences	O
for	O
decision-making	O
from	O
test	O
results	O
,	O
such	O
as	O
diagnosing	O
and	O
selection	O
of	O
intervention	O
groups	O
.	O

We	O
hope	O
that	O
our	O
results	O
would	O
inspire	O
further	O
research	O
into	O
the	O
scoring	O
procedures	O
of	O
the	O
vast	O
amount	O
of	O
tests	O
and	O
tasks	O
in	O
common	O
use	O
.	O

Extracellular	O
Self-Assembly	O
of	O
Functional	O
and	O
Tunable	O
Protein	O
Conjugates	O
from	O
Bacillus	O
subtilis	O
.	O

The	O
ability	O
to	O
stably	O
and	O
specifically	O
conjugate	O
recombinant	O
proteins	O
to	O
one	O
another	O
is	O
a	O
powerful	O
approach	O
for	O
engineering	O
multifunctional	O
enzymes	O
,	O
protein	O
therapeutics	O
,	O
and	O
novel	O
biological	O
materials	O
.	O

While	O
many	O
of	O
these	O
applications	O
have	O
been	O
illustrated	O
through	O
in	O
vitro	O
and	O
in	O
vivo	O
intracellular	O
protein	O
conjugation	O
methods	O
,	O
extracellular	O
self-assembly	O
of	O
protein	O
conjugates	O
offers	O
unique	O
advantages	O
:	O
simplifying	O
purification	B-P
,	O
reducing	O
toxicity	O
and	O
burden	O
,	O
and	O
enabling	O
tunability	O
.	O

Exploiting	O
the	O
recently	O
described	O
SpyTag-SpyCatcher	B-P
system	I-P
,	O
we	O
describe	O
here	O
how	O
enzymes	O
and	O
structural	O
proteins	O
can	O
be	O
genetically	O
encoded	O
to	O
covalently	O
conjugate	O
in	O
culture	O
media	O
following	O
programmable	O
secretion	O
from	O
Bacillus	O
subtilis	O
.	O

Using	O
this	O
approach	O
,	O
we	O
demonstrate	O
how	O
self-conjugation	O
of	O
a	O
secreted	O
industrial	O
enzyme	O
,	O
XynA	O
,	O
dramatically	O
increases	O
its	O
resilience	O
to	O
boiling	O
,	O
and	O
we	O
show	O
that	O
cellular	O
consortia	O
can	O
be	O
engineered	O
to	O
self-assemble	O
functional	O
protein-protein	O
conjugates	O
with	O
tunable	O
composition	O
.	O

This	O
novel	O
genetically	O
encoded	O
modular	O
system	O
provides	O
a	O
flexible	O
strategy	O
for	O
protein	O
conjugation	O
harnessing	O
the	O
substantial	O
advantages	O
of	O
extracellular	O
self-assembly	O
.	O

Cytokine	O
IL-10	O
,	O
activators	O
of	O
PI3-kinase	O
,	O
agonists	O
of	O
α-2	O
adrenoreceptor	O
and	O
antioxidants	O
prevent	O
ischemia	O
-	O
induced	O
cell	O
death	O
in	O
rat	O
hippocampal	O
cultures	O
.	O

In	O
the	O
present	O
work	O
we	O
compared	O
the	O
protective	O
effect	O
of	O
anti-inflammatory	O
cytokine	O
IL-10	O
with	O
the	O
action	O
of	O
a	O
PI3-kinase	O
selective	O
activator	O
740	O
Y-P	O
,	O
selective	O
agonists	O
of	O
alpha-2	O
adrenoreceptor	O
,	O
guanfacine	O
and	O
UK-14,304	O
,	O
and	O
compounds	O
having	O
antioxidant	O
effect	O
:	O
recombinant	O
human	O
peroxiredoxin	O
6	O
and	O
B27	O
,	O
in	O
hippocampal	O
cell	O
culture	O
during	O
OGD	O
(	O
ischemia-like	O
conditions	O
)	O
.	O

It	O
has	O
been	O
shown	O
that	O
the	O
response	O
of	O
cells	O
to	O
OGD	O
in	O
the	O
control	O
includes	O
two	O
phases	O
.	O

The	O
first	O
phase	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
the	O
frequency	O
of	O
spontaneous	O
synchronous	O
Ca	O
(	O
2+	O
)	O
-oscillations	O
(	O
SSCO	O
)	O
in	O
neurons	O
and	O
Ca	O
(	O
2+	O
)	O
-	O
pulse	O
in	O
astrocytes	O
.	O

Spontaneous	O
Ca	O
(	O
2+	O
)	O
events	O
in	O
astrocytes	O
during	O
ischemia	O
in	O
control	O
experiments	O
disappeared	O
.	O

The	O
second	O
phase	O
started	O
after	O
a	O
few	O
minutes	O
of	O
OGD	O
and	O
looked	O
like	O
a	O
sharp/avalanche	O
,	O
global	O
synchronic	O
(	O
within	O
20	O
s	O
)	O
increase	O
in	O
[	O
Ca	O
(	O
2+	O
)	O
]	O
i	O
in	O
many	O
cells	O
.	O

Within	O
1	O
h	O
after	O
OGD	O
,	O
a	O
mass	O
death	O
of	O
cells	O
,	O
primarily	O
astrocytes	O
,	O
was	O
observed	O
.	O

To	O
study	O
the	O
protective	O
action	O
of	O
the	O
compounds	O
,	O
cells	O
were	O
incubated	B-P
in	O
the	O
presence	O
of	O
the	O
neuroprotective	O
agents	O
for	O
10-40	O
min	O
or	O
24	O
h	O
before	O
ischemia	O
.	O

All	O
the	O
neuroprotective	O
agents	O
delayed	O
a	O
global	O
[	O
Ca	O
(	O
2+	O
)	O
]	O
i	O
increase	O
during	O
OGD	O
or	O
completely	O
inhibited	O
this	O
process	O
and	O
increased	O
cell	O
survival	O
.	O

Optimization	O
of	O
Early	O
Response	O
Monitoring	O
and	O
Prediction	O
of	O
Cancer	O
Antiangiogenesis	O
Therapy	O
via	O
Noninvasive	O
PET	B-P
Molecular	I-P
Imaging	I-P
Strategies	O
of	O
Multifactorial	O
Bioparameters	O
.	O

Objective	O
:	O
Antiangiogenesis	O
therapy	O
(	O
AAT	O
)	O
has	O
provided	O
substantial	O
benefits	O
regarding	O
improved	O
outcomes	O
and	O
survival	O
for	O
suitable	O
patients	O
in	O
clinical	O
settings	O
.	O

Therefore	O
,	O
the	O
early	O
definition	O
of	O
therapeutic	O
effects	O
is	O
urgently	O
needed	O
to	O
guide	O
cancer	O
AAT	O
.	O

We	O
aimed	O
to	O
optimize	O
the	O
early	O
response	O
monitoring	O
and	O
prediction	O
of	O
AAT	O
efficacy	O
,	O
as	O
indicated	O
by	O
the	O
multi-targeted	O
anti-angiogenic	O
drug	O
sunitinib	O
in	O
U87MG	O
tumors	O
,	O
using	O
noninvasive	O
positron	B-P
emission	I-P
computed	I-P
tomography	I-P
(	I-P
PET	I-P
)	I-P
molecular	I-P
imaging	I-P
strategies	O
of	O
multifactorial	O
bioparameters	O
.	O

Methods	O
:	O
U87MG	O
tumor	O
mice	O
were	O
treated	O
via	O
intragastric	O
injections	O
of	O
sunitinib	O
(	O
80	O
mg/kg	O
)	O
or	O
vehicle	O
for	O
7	O
consecutive	O
days	O
.	O

Longitudinal	O
MicroPET/CT	B-P
scans	I-P
with	O
(	O
18	O
)	O
F-FDG	O
,	O
(	O
18	O
)	O
F-FMISO	O
,	O
(	O
18	O
)	O
F-ML-10	O
and	O
(	O
18	O
)	O
F-Alfatide	O
II	O
were	O
acquired	O
to	O
quantitatively	O
measure	O
metabolism	O
,	O
hypoxia	O
,	O
apoptosis	O
and	O
angiogenesis	O
on	O
days	O
0	O
,	O
1	O
,	O
3	O
,	O
7	O
and	O
13	O
following	O
therapy	O
initiation	O
.	O

Tumor	O
tissues	O
from	O
a	O
dedicated	O
group	O
of	O
mice	O
were	O
collected	O
for	O
immunohistochemical	B-P
(	O
IHC	B-P
)	O
analysis	O
of	O
key	O
biomarkers	O
(	O
Glut-1	O
,	O
CA-IX	O
,	O
TUNEL	O
,	O
ανβ3	O
and	O
CD31	O
)	O
at	O
the	O
time	O
points	O
of	O
PET	B-P
imaging	I-P
.	O

The	O
tumor	O
sizes	O
and	O
mouse	O
weights	O
were	O
measured	O
throughout	O
the	O
study	O
.	O

The	O
tumor	O
uptake	O
(	O
ID	O
%	O
/gmax	O
)	O
,	O
the	O
ratios	O
of	O
the	O
tumor	O
/	O
muscle	O
(	O
T	O
/	O
M	O
)	O
for	O
each	O
probe	O
,	O
and	O
the	O
tumor	O
growth	O
ratios	O
(	O
TGR	O
)	O
were	O
calculated	O
and	O
used	O
for	O
statistical	O
analyses	O
of	O
the	O
differences	O
and	O
correlations	O
.	O

Results	O
:	O
Sunitinib	O
successfully	O
inhibited	O
U87MG	O
tumor	O
growth	O
with	O
significant	O
differences	O
in	O
the	O
tumor	O
size	O
from	O
day	O
9	O
after	O
sunitinib	O
treatment	O
compared	O
with	O
the	O
control	O
group	O
(	O
P	O
<	O
0.01	O
)	O
.	O

The	O
uptakes	O
of	O
(	O
18	O
)	O
F-FMISO	O
(	O
reduced	O
hypoxia	O
)	O
,	O
(	O
18	O
)	O
F-ML-10	O
(	O
increased	O
apoptosis	O
)	O
and	O
(	O
18	O
)	O
F-Alfatide	O
II	O
(	O
decreased	O
angiogenesis	O
)	O
in	O
the	O
tumor	O
lesions	O
significantly	O
changed	O
during	O
the	O
early	O
stage	O
(	O
days	O
1	O
to	O
3	O
)	O
of	O
sunitinib	O
treatment	O
;	O
however	O
,	O
the	O
uptake	O
of	O
(	O
18	O
)	O
F-FDG	O
(	O
increased	O
glucose	O
metabolism	O
)	O
was	O
significantly	O
different	O
during	O
the	O
late	O
stage	O
.	O

The	O
PET	B-P
imaging	I-P
data	O
of	O
each	O
probe	O
were	O
all	O
confirmed	O
via	O
ex	O
vivo	O
IHC	B-P
of	O
the	O
relevant	O
biomarkers	O
.	O

Notably	O
,	O
the	O
PET	B-P
imaging	I-P
of	O
(	O
18	O
)	O
F-Alfatide	O
II	O
and	O
(	O
18	O
)	O
F-FMISO	O
was	O
significantly	O
correlated	O
(	O
all	O
P	O
<	O
0.05	O
)	O
with	O
TGR	O
,	O
whereas	O
the	O
imaging	O
of	O
(	O
18	O
)	O
F-FDG	O
and	O
(	O
18	O
)	O
F-ML-10	O
was	O
not	O
significantly	O
correlated	O
with	O
TGR	O
.	O

Conclusion	O
:	O
Based	O
on	O
the	O
tumor	O
uptake	O
of	O
the	O
PET	B-P
probes	O
and	O
their	O
correlations	O
with	O
MVD	O
and	O
TGR	O
,	O
(	O
18	O
)	O
F-Alfatide	O
II	O
PET	B-P
may	O
not	O
only	O
monitor	O
the	O
early	O
response	O
but	O
also	O
precisely	O
predict	O
the	O
therapeutic	O
efficacy	O
of	O
the	O
multi-targeted	O
,	O
anti-angiogenic	O
drug	O
sunitinib	O
in	O
U87MG	O
tumors	O
.	O

In	O
conclusion	O
,	O
it	O
is	O
feasible	O
to	O
optimize	O
the	O
early	O
response	O
monitoring	O
and	O
efficacy	O
prediction	O
of	O
cancer	O
AAT	O
using	O
noninvasive	O
PET	B-P
molecular	I-P
imaging	I-P
strategies	O
of	O
multifactorial	O
bioparameters	O
,	O
such	O
as	O
angiogenesis	O
imaging	B-P
with	O
(	O
18	O
)	O
F-Alfatide	O
II	O
,	O
which	O
represents	O
an	O
RGD	O
-based	O
probe	O
.	O

Biomarkers	O
for	O
predicting	O
spontaneous	O
preterm	O
birth	O
:	O
an	O
umbrella	O
systematic	O
review	O
.	O

To	O
identify	O
all	O
systematic	O
reviews	O
investigating	O
the	O
role	O
of	O
maternal	O
and	O
fetal	O
biomarkers	O
for	O
predicting	O
spontaneous	O
preterm	O
birth	O
(	O
SPTB	O
)	O
.	O

Medline	O
and	O
Web	O
of	O
Sciences	O
databases	O
were	O
searched	O
electronically	O
.	O

Studies	O
exploring	O
the	O
association	O
between	O
maternal	O
biomarkers	O
and	O
spontaneous	O
delivery	O
were	O
considered	O
suitable	O
for	O
inclusion	O
.	O

A	O
synthesis	O
of	O
the	O
systematic	O
reviews	O
was	O
performed	O
with	O
the	O
umbrella	O
methodology	O
.	O

Statistical	O
measures	O
of	O
association	O
(	O
Odd	O
ratio	O
,	O
OR	O
,	O
relative	O
risk	O
,	O
RR	O
)	O
and	O
predictive	O
accuracy	O
(	O
sensitivity	O
,	O
specificity	O
,	O
positive	O
and	O
negative	O
likelihood	O
ratios	O
were	O
used	O
to	O
synthesize	O
results	O
of	O
the	O
included	O
studies	O
.	O

21,614	O
articles	O
were	O
identified	O
,	O
542	O
were	O
assessed	O
with	O
respect	O
to	O
their	O
eligibility	O
for	O
inclusion	O
and	O
14	O
systematic	O
reviews	O
included	O
.	O

Cervical	O
fibronectin	O
was	O
the	O
biomarkers	O
which	O
showed	O
the	O
highest	O
strength	O
of	O
association	O
with	O
the	O
occurrence	O
of	O
SPTB	O
(	O
delivery	O
within	O
24	O
h	O
OR	O
7	O
,	O
95	O
%	O
CI	O
3-17	O
;	O
delivery	O
<	O
7	O
days	O
(	O
OR	O
12	O
,	O
95	O
%	O
CI	O
8-16	O
)	O
.	O

Maternal	B-P
serum	I-P
alpha	I-P
fetoprotein	I-P
,	O
was	O
associated	O
with	O
an	O
OR	O
of	O
4	O
and	O
3	O
for	O
early	O
and	O
late	O
SPTB	O
.	O

C-reactive	O
protein	O
had	O
an	O
OR	O
of	O
2	O
(	O
95	O
%	O
CI	O
1-2	O
)	O
and	O
8	O
(	O
95	O
%	O
CI	O
4-16	O
)	O
when	O
detected	O
in	O
maternal	O
plasma	O
and	O
amniotic	O
fluid	O
,	O
respectively	O
.	O

Among	O
cytokines	O
,	O
interleukin-6	O
had	O
an	O
OR	O
and	O
an	O
LR	O
+	O
for	O
SPTB	O
of	O
2	O
and	O
12	O
when	O
detected	O
in	O
maternal	O
serum	O
.	O

Cervical	O
fetal	O
fibronectin	O
,	O
alpha	O
fetoprotein	O
,	O
C-	O
reactive	O
protein	O
and	O
interleukin	O
6	O
can	O
have	O
an	O
overall	O
good	O
diagnostic	O
accuracy	O
in	O
identifying	O
pregnancies	O
at	O
risk	O
of	O
SPTB	O
.	O

Large	O
prospective	O
studies	O
in	O
different	O
sub-set	O
of	O
women	O
are	O
needed	O
to	O
ascertain	O
whether	O
the	O
combination	O
of	O
different	O
serological	O
and	O
imaging	O
marker	O
can	O
improve	O
antenatal	O
prediction	O
of	O
this	O
condition	O
.	O

Flexible	O
information	O
routing	O
by	O
transient	O
synchrony	B-P
.	O

Perception	O
,	O
cognition	O
and	O
behavior	O
rely	O
on	O
flexible	O
communication	O
between	O
microcircuits	O
in	O
distinct	O
cortical	O
regions	O
.	O

The	O
mechanisms	O
underlying	O
rapid	O
information	O
rerouting	O
between	O
such	O
microcircuits	O
are	O
still	O
unknown	O
.	O

It	O
has	O
been	O
proposed	O
that	O
changing	O
patterns	O
of	O
coherence	O
between	O
local	O
gamma	O
rhythms	O
support	O
flexible	O
information	O
rerouting	O
.	O

The	O
stochastic	O
and	O
transient	O
nature	O
of	O
gamma	O
oscillations	O
in	O
vivo	O
,	O
however	O
,	O
is	O
hard	O
to	O
reconcile	O
with	O
such	O
a	O
function	O
.	O

Here	O
we	O
show	O
that	O
models	O
of	O
cortical	O
circuits	O
near	O
the	O
onset	O
of	O
oscillatory	O
synchrony	B-P
selectively	O
route	O
input	O
signals	O
despite	O
the	O
short	O
duration	O
of	O
gamma	O
bursts	O
and	O
the	O
irregularity	O
of	O
neuronal	O
firing	O
.	O

In	O
canonical	O
multiarea	O
circuits	O
,	O
we	O
find	O
that	O
gamma	O
bursts	O
spontaneously	O
arise	O
with	O
matched	O
timing	O
and	O
frequency	O
and	O
that	O
they	O
organize	O
information	O
flow	O
by	O
large-scale	O
routing	O
states	O
.	O

Specific	O
self-organized	O
routing	O
states	O
can	O
be	O
induced	O
by	O
minor	O
modulations	O
of	O
background	O
activity	O
.	O

The	O
emerging	O
contribution	O
of	O
social	O
wasps	O
to	O
grape	O
rot	O
disease	O
ecology	O
.	O

Grape	O
sour	O
(	O
bunch	O
)	O
rot	O
is	O
a	O
polymicrobial	O
disease	O
of	O
vineyards	O
that	O
causes	O
millions	O
of	O
dollars	O
in	O
lost	O
revenue	O
per	O
year	O
due	O
to	O
decreased	O
quality	O
of	O
grapes	O
and	O
resultant	O
wine	O
.	O

The	O
disease	O
is	O
associated	O
with	O
damaged	O
berries	O
infected	O
with	O
a	O
community	O
of	O
acetic	O
acid	O
bacteria	O
,	O
yeasts	O
,	O
and	O
filamentous	O
fungi	O
that	O
results	O
in	O
rotting	O
berries	O
with	O
high	O
amounts	O
of	O
undesirable	O
volatile	O
acidity	O
.	O

Many	O
insect	O
species	O
cause	O
the	O
initial	O
grape	O
berry	O
damage	O
that	O
can	O
lead	O
to	O
this	O
disease	O
,	O
but	O
most	O
studies	O
have	O
focused	O
on	O
the	O
role	O
of	O
fruit	O
flies	O
in	O
facilitating	O
symptoms	O
and	O
vectoring	O
the	O
microorganisms	O
of	O
this	O
disease	O
complex	O
.	O

Like	O
fruit	O
flies	O
,	O
social	O
wasps	O
are	O
abundant	O
in	O
vineyards	O
where	O
they	O
feed	O
on	O
ripe	O
berries	O
and	O
cause	O
significant	O
damage	O
,	O
while	O
also	O
dispersing	O
yeasts	O
involved	O
in	O
wine	O
fermentation	O
.	O

Despite	O
this	O
,	O
their	O
possible	O
role	O
in	O
disease	O
facilitation	O
and	O
dispersal	O
of	O
grape	O
rots	O
has	O
not	O
been	O
explored	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
the	O
paper	O
wasp	O
Polistes	O
dominulus	O
could	O
facilitate	O
grape	O
sour	O
rot	O
in	O
the	O
absence	O
of	O
other	O
insect	O
vectors	O
.	O

Using	O
marker	B-P
gene	I-P
sequencing	I-P
we	O
characterized	O
the	O
bacterial	O
and	O
fungal	O
community	O
of	O
wild-caught	O
adults	O
.	O

We	O
used	O
a	O
sterilized	O
foraging	O
arena	O
to	O
determine	O
if	O
these	O
wasps	O
transfer	O
viable	O
microorganisms	O
when	O
foraging	O
.	O

We	O
then	O
tested	O
if	O
wasps	O
harboring	O
their	O
native	O
microbial	O
community	O
,	O
or	O
those	O
inoculated	O
with	O
sour	O
rot	O
,	O
had	O
an	O
effect	O
on	O
grape	O
sour	O
rot	O
incidence	O
and	O
severity	O
using	O
a	O
laboratory	O
foraging	O
arena	O
.	O

We	O
found	O
that	O
all	O
wasps	O
harbor	O
some	O
portion	O
of	O
the	O
sour	O
rot	O
microbial	O
community	O
and	O
that	O
they	O
have	O
the	O
ability	O
to	O
transfer	O
viable	O
microorganisms	O
when	O
foraging	O
.	O

Foraging	O
by	O
inoculated	O
and	O
uninoculated	O
wasps	O
led	O
to	O
an	O
increase	O
in	O
berry	O
rot	O
disease	O
symptom	O
severity	O
and	O
incidence	O
.	O

Our	O
results	O
indicate	O
that	O
paper	O
wasps	O
can	O
facilitate	O
sour	O
rot	O
diseases	O
in	O
the	O
absence	O
of	O
other	O
vectors	O
and	O
that	O
the	O
mechanism	O
of	O
this	O
facilitation	O
may	O
include	O
both	O
increasing	O
host	O
susceptibility	O
and	O
transmitting	O
these	O
microbial	O
communities	O
to	O
the	O
grapes	O
.	O

Social	O
wasps	O
are	O
understudied	O
but	O
relevant	O
players	O
in	O
the	O
sour	O
rot	O
ecology	O
of	O
vineyards	O
.	O

International	O
validation	O
of	O
a	O
urinary	O
biomarker	O
panel	B-P
for	O
identification	O
of	O
active	O
lupus	O
nephritis	O
in	O
children	O
.	O

Conventional	O
markers	O
of	O
juvenile-onset	O
systemic	O
lupus	O
erythematosus	O
(	O
JSLE	O
)	O
disease	B-P
activity	I-P
fail	O
to	O
adequately	O
identify	O
lupus	O
nephritis	O
(	O
LN	O
)	O
.	O

While	O
individual	O
novel	O
urine	O
biomarkers	O
are	O
good	O
at	O
detecting	O
LN	O
flares	O
,	O
biomarker	O
panels	B-P
may	O
improve	O
diagnostic	O
accuracy	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
performance	O
of	O
a	O
biomarker	O
panel	B-P
to	O
identify	O
active	O
LN	O
in	O
two	O
international	O
JSLE	O
cohorts	O
.	O

Novel	O
urinary	O
biomarkers	O
,	O
namely	O
vascular	O
cell	O
adhesion	O
molecule-1	O
(	O
VCAM-1	O
)	O
,	O
monocyte	O
chemoattractant	O
protein	O
1	O
(	O
MCP-1	O
)	O
,	O
lipocalin-like	O
prostaglandin	O
D	O
synthase	O
(	O
LPGDS	O
)	O
,	O
transferrin	O
(	O
TF	O
)	O
,	O
ceruloplasmin	O
,	O
alpha-1-acid	O
glycoprotein	O
(	O
AGP	O
)	O
and	O
neutrophil	O
gelatinase-associated	O
lipocalin	O
(	O
NGAL	O
)	O
,	O
were	O
quantified	O
in	O
a	O
cross-sectional	O
study	O
that	O
included	O
participants	O
of	O
the	O
UK	O
JSLE	O
Cohort	O
Study	O
(	O
Cohort	O
1	O
)	O
and	O
validated	O
within	O
the	O
Einstein	O
Lupus	O
Cohort	O
(	O
Cohort	O
2	O
)	O
.	O

Binary	O
logistic	O
regression	O
modelling	O
and	O
receiver	O
operating	O
characteristic	O
curve	O
analysis	O
[	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
]	O
were	O
used	O
to	O
identify	O
and	O
assess	O
combinations	O
of	O
biomarkers	O
for	O
diagnostic	O
accuracy	O
.	O

A	O
total	O
of	O
91	O
JSLE	O
patients	O
were	O
recruited	O
across	O
both	O
cohorts	O
,	O
of	O
whom	O
31	O
(	O
34	O
%	O
)	O
had	O
active	O
LN	O
and	O
60	O
(	O
66	O
%	O
)	O
had	O
no	O
LN	O
.	O

Urinary	O
AGP	O
,	O
ceruloplasmin	O
,	O
VCAM-1	O
,	O
MCP-1	O
and	O
LPGDS	O
levels	O
were	O
significantly	O
higher	O
in	O
those	O
patients	O
with	O
active	O
LN	O
than	O
in	O
non	O
-	O
LN	O
patients	O
[	O
all	O
corrected	O
p	O
values	O
(	O
p	O
c	O
)	O
<	O
0.05	O
]	O
across	O
both	O
cohorts	O
.	O

Urinary	O
TF	O
also	O
differed	O
between	O
patient	O
groups	O
in	O
Cohort	O
2	O
(	O
p	O
c	O
=	O
0.001	O
)	O
.	O

Within	O
Cohort	O
1	O
,	O
the	O
optimal	O
biomarker	O
panel	B-P
included	O
AGP	O
,	O
ceruloplasmin	O
,	O
LPGDS	O
and	O
TF	O
(	O
AUC	O
0.920	O
for	O
active	O
LN	O
identification	O
)	O
.	O

These	O
results	O
were	O
validated	O
in	O
Cohort	O
2	O
,	O
with	O
the	O
same	O
markers	O
resulting	O
in	O
the	O
optimal	O
urine	O
biomarker	O
panel	B-P
(	O
AUC	O
0.991	O
)	O
.	O

In	O
two	O
international	O
JSLE	O
cohorts	O
,	O
urinary	O
AGP	O
,	O
ceruloplasmin	O
,	O
LPGDS	O
and	O
TF	O
demonstrate	O
an	O
'excellent	O
'	O
ability	O
for	O
accurately	O
identifying	O
active	O
LN	O
in	O
children	O
.	O

22q11.2q13	O
duplication	O
including	O
SOX10	O
causes	O
sex-reversal	O
and	O
peripheral	O
demyelinating	O
neuropathy	O
,	O
central	O
dysmyelinating	O
leukodystrophy	O
,	O
Waardenburg	O
syndrome	O
,	O
and	O
Hirschsprung	O
disease	O
.	O

Diagnosis	O
of	O
genetic	O
syndromes	O
may	O
be	O
difficult	O
when	O
specific	O
components	O
of	O
a	O
disorder	O
manifest	O
at	O
a	O
later	O
age	O
.	O

We	O
present	O
a	O
follow	O
up	O
of	O
a	O
previous	O
report	O
[	O
Seeherunvong	O
et	O
al.	O
,	O
(	O
2004	O
)	O
;	O
AJMGA	O
127	O
:	O
149-151	O
]	O
,	O
of	O
an	O
individual	O
with	O
22q	O
duplication	O
and	O
sex-reversal	O
syndrome	O
.	O

The	O
subject	O
's	O
phenotype	O
evolved	O
to	O
include	O
peripheral	O
and	O
central	O
demyelination	O
,	O
Waardenburg	O
syndrome	O
type	O
IV	O
,	O
and	O
Hirschsprung	O
disease	O
(	O
PCWH	O
;	O
MIM	O
609136	O
)	O
.	O

DNA	O
microarray	O
analysis	O
defined	O
the	O
duplication	O
at	O
22q11.2q13	O
,	O
including	O
SOX10	O
.	O

Sequencing	B-P
of	O
the	O
coding	O
region	O
of	O
SOX10	O
did	O
not	O
reveal	O
any	O
mutations	O
.	O

Our	O
data	O
suggest	O
that	O
SOX10	O
duplication	O
can	O
cause	O
disorders	O
of	O
sex	O
development	O
and	O
PCWH	O
,	O
supporting	O
the	O
hypothesis	O
that	O
SOX10	O
toxic	O
gain	O
of	O
function	O
rather	O
than	O
dominant	O
negative	O
activity	O
underlies	O
PCWH	O
.	O

BAG3	O
is	O
involved	O
in	O
neuronal	O
differentiation	O
and	O
migration	O
.	O

Bcl2-associated	O
athanogene	O
3	O
(	O
BAG3	O
)	O
protein	O
belongs	O
to	O
the	O
family	O
of	O
co-chaperones	O
interacting	O
with	O
several	O
heat	O
shock	O
proteins	O
.	O

It	O
plays	O
a	O
key	O
role	O
in	O
protein	O
quality	O
control	O
and	O
mediates	O
the	O
clearance	O
of	O
misfolded	O
proteins	O
.	O

Little	O
is	O
known	O
about	O
the	O
expression	O
and	O
cellular	O
localization	O
of	O
BAG3	O
during	O
nervous	O
system	O
development	O
and	O
differentiation	O
.	O

Therefore	O
,	O
we	O
analyze	O
the	O
subcellular	O
distribution	O
and	O
expression	O
of	O
BAG3	O
in	O
nerve-growth-factor	O
-induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
and	O
in	O
developing	O
and	O
adult	O
cortex	O
of	O
mouse	O
brain	O
.	O

In	O
differentiated	O
PC12	O
cells	O
,	O
BAG3	O
was	O
localized	O
mainly	O
in	O
the	O
neuritic	O
domain	O
rather	O
than	O
the	O
cell	O
body	O
,	O
whereas	O
in	O
control	O
cells	O
,	O
it	O
appeared	O
to	O
be	O
confined	O
to	O
the	O
cytoplasm	O
near	O
the	O
nuclear	O
membrane	O
.	O

Interestingly	O
,	O
the	O
change	O
of	O
BAG3	O
localization	O
during	O
neuronal	O
differentiation	O
was	O
associated	O
only	O
with	O
a	O
slight	O
increase	O
in	O
total	O
BAG3	O
expression	O
.	O

These	O
data	O
were	O
coroborated	O
by	O
transmission	B-P
electron	I-P
microscopy	I-P
showing	O
that	O
BAG3	O
was	O
confined	O
mainly	O
within	O
large	O
dense-core	O
vesicles	O
of	O
the	O
axon	O
in	O
differentiated	O
PC12	O
cells	O
.	O

In	O
mouse	O
developing	O
cortex	O
,	O
BAG3	O
appeared	O
to	O
be	O
intensely	O
expressed	O
in	O
cellular	O
processes	O
of	O
migrating	O
cells	O
,	O
whereas	O
in	O
adult	O
brain	O
,	O
a	O
diffuse	O
expression	O
of	O
low	O
to	O
medium	O
intensity	O
was	O
detected	O
in	O
neuronal	O
cell	O
bodies	O
.	O

These	O
findings	O
suggest	O
that	O
BAG3	O
expression	O
is	O
required	O
for	O
neuronal	O
differentiation	O
and	O
migration	O
and	O
that	O
its	O
role	O
is	O
linked	O
to	O
a	O
change	O
in	O
its	O
distribution	O
pattern	O
rather	O
than	O
to	O
an	O
increase	O
in	O
its	O
protein	O
expression	O
levels	O
.	O

Long-range	O
interactions	O
between	O
protein	O
-	O
coated	O
particles	O
and	O
POEGMA	O
brush	O
layers	O
in	O
a	O
serum	O
environment	O
.	O

Hydrophilic	O
poly	O
[	O
oligo	O
(	O
ethylene	O
glycol	O
)	O
methyl	O
methacrylate	O
]	O
(	O
POEGMA	O
)	O
brush	O
layers	O
with	O
different	O
thickness	O
and	O
graft	O
densities	O
were	O
prepared	O
by	O
surface-initiated	O
atom	O
transfer	O
radical	O
polymerization	O
(	O
SI-ATRP	O
)	O
to	O
construct	O
a	O
model	O
surface	O
to	O
examine	O
protein	O
-	O
surface	O
interactions	O
in	O
a	O
serum	O
environment	O
.	O

The	O
thickness	O
of	O
the	O
POEGMA	O
brush	O
layers	O
could	O
be	O
well	O
controlled	O
by	O
the	O
polymerization	O
time	O
and	O
density	O
of	O
the	O
immobilized	O
initiators	O
.	O

The	O
interactions	O
between	O
these	O
brush	O
-	O
modified	O
surfaces	O
and	O
the	O
protein	O
-	O
coated	O
polystyrene	O
(	O
PS	O
)	O
particles	O
in	O
newborn	O
calf	O
serum	O
(	O
NBCS	O
)	O
environment	O
were	O
then	O
measured	O
by	O
total	B-P
internal	I-P
reflection	I-P
microscopy	I-P
(	O
TIRM	B-P
)	O
.	O

In	O
addition	O
,	O
protein	O
adsorption	O
properties	O
onto	O
the	O
polymer	O
brush	O
surface	O
layers	O
were	O
examined	O
by	O
atomic	B-P
force	I-P
microscopy	I-P
(	O
AFM	B-P
)	O
.	O

Relatively	O
large	O
amounts	O
of	O
protein	O
adsorbed	O
to	O
short	O
(	O
4nm	O
and	O
9nm-thick	O
)	O
POEGMA	O
-	O
coated	O
surfaces	O
or	O
surfaces	O
grafted	O
with	O
a	O
low	O
density	O
of	O
polymer	O
chains	O
.	O

It	O
was	O
considered	O
that	O
shorter	O
polymer	O
chains	O
or	O
chains	O
with	O
low	O
grafted	O
density	O
can	O
not	O
fully	O
cover	O
the	O
surfaces	O
,	O
proteins	O
in	O
serum	O
could	O
directly	O
interact	O
with	O
the	O
material	O
surface	O
and	O
then	O
deposited	O
to	O
form	O
an	O
adsorbed	O
layer	O
.	O

The	O
TIRM	B-P
measurements	O
showed	O
that	O
such	O
adsorbed	O
protein	O
layer	O
could	O
mediate	O
the	O
interactions	O
between	O
the	O
two	O
surfaces	O
by	O
generating	O
steric	O
or	O
bridging	O
forces	O
,	O
resulting	O
in	O
different	O
interaction	O
potentials	O
.	O

Some	O
particles	O
were	O
freely	O
diffusing	O
,	O
some	O
experienced	O
intermittent	O
diffusion	O
and	O
more	O
than	O
50	O
%	O
of	O
particles	O
were	O
irreversibly	O
deposited	O
to	O
the	O
surfaces	O
covered	O
by	O
short	O
polymer	O
brushes	O
.	O

However	O
,	O
for	O
longer	O
(	O
17	O
and	O
30nm-thick	O
)	O
POEGMA	O
brush	O
layer	O
surfaces	O
,	O
material	O
surface	O
would	O
be	O
sufficiently	O
covered	O
by	O
the	O
dense	O
coating	O
and	O
the	O
first	O
step	O
of	O
protein	O
adsorption	B-P
on	O
surface	O
was	O
avoided	O
.	O

TIRM	B-P
measurements	O
showed	O
that	O
around	O
95	O
%	O
of	O
the	O
protein	O
-	O
coated	O
particles	O
could	O
freely	O
move	O
in	O
the	O
serum	O
and	O
no	O
attractive	O
force	O
between	O
two	O
surfaces	O
was	O
detected	O
.	O

The	O
steric	O
repulsion	O
generated	O
from	O
the	O
long	O
POEGMA	O
brush	O
layer	O
in	O
the	O
swollen	O
state	O
was	O
long-range	O
and	O
strong	O
so	O
that	O
the	O
protein	O
adsorption	B-P
is	O
very	O
unlikely	O
.	O

These	O
results	O
concluded	O
that	O
the	O
adsorbed	O
protein	O
layer	O
on	O
POEGMA	O
surfaces	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
the	O
interaction	O
between	O
protein	O
-	O
coated	O
particles	O
and	O
POEGMA	O
surfaces	O
which	O
are	O
highly	O
repellent	O
toward	O
protein	O
adsorption	B-P
.	O

Visualization	B-P
of	O
the	O
Intimal	O
Flap	O
in	O
Intracranial	O
Arterial	O
Dissection	O
Using	O
High-Resolution	B-P
3T	B-P
MRI	I-P
.	O

Presence	O
of	O
an	O
intimal	O
flap	O
is	O
a	O
critical	O
imaging	O
finding	O
in	O
diagnosing	O
intracranial	O
artery	O
dissection	O
(	O
ICAD	O
)	O
.	O

Recent	O
reports	O
showed	O
that	O
high-resolution	B-P
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
was	O
better	O
at	O
identifying	O
intimal	O
flaps	O
as	O
compared	O
with	O
routine	O
MRI	B-P
techniques	I-P
used	O
in	O
clinical	O
settings	O
.	O

However	O
,	O
no	O
current	O
standardized	O
sequence	O
for	O
high-resolution	B-P
MRI	B-P
without	O
gadolinium	O
enhancement	O
produces	O
images	O
of	O
satisfactory	O
quality	O
with	O
clinically	O
tolerable	O
scanning	B-P
times	O
.	O

This	O
study	O
evaluated	O
a	O
nonenhanced	B-P
high-resolution	I-P
fast	I-P
spin	I-P
echo	I-P
(	I-P
HR-FSE	I-P
)	I-P
MRI	I-P
sequence	O
for	O
visualizing	O
intimal	O
flaps	O
in	O
patients	O
with	O
ICAD	O
.	O

Three	O
patients	O
with	O
ICAD	O
underwent	O
plain	O
MRI	B-P
examination	O
using	O
a	O
2-dimensional	O
T2-weighted	B-P
FSE	I-P
imaging	I-P
sequence	O
optimized	O
for	O
our	O
3T	O
system	O
(	O
in-plane	O
pixel	O
size	O
,	O
.23	O
mm	O
×	O
.23	O
mm	O
;	O
slice	O
thickness	O
3	O
mm	O
with	O
no	O
interslice	O
gap	O
)	O
,	O
as	O
well	O
as	O
scanning	B-P
with	O
conventional	O
modalities	O
,	O
including	O
CT	B-P
angiography	I-P
,	O
magnetic	B-P
resonance	I-P
angiography	I-P
,	O
and	O
digital	B-P
subtraction	I-P
angiography	I-P
.	O

We	O
assessed	O
whether	O
these	O
imaging	O
methods	O
could	O
visualize	O
an	O
intimal	O
flap	O
and/or	O
double	O
lumen	O
sign	O
in	O
the	O
participants	O
and	O
compared	O
the	O
results	O
between	O
HR-FSE	B-P
and	O
the	O
other	O
modalities	O
.	O

HR-FSE	B-P
images	O
clearly	O
showed	O
intimal	O
flaps	O
and	O
double	O
lumen	O
signs	O
in	O
all	O
3	O
patients	O
,	O
whereas	O
the	O
conventional	O
modalities	O
identified	O
a	O
double	O
lumen	O
sign	O
in	O
only	O
2	O
of	O
the	O
3	O
patients	O
.	O

The	O
present	O
method	O
of	O
optimized	O
HR-FSE	B-P
imaging	I-P
with	O
a	O
3T	O
system	O
improved	O
visualization	B-P
of	O
intimal	O
flaps	O
and	O
should	O
thus	O
be	O
considered	O
for	O
assessing	O
patients	O
with	O
suspected	O
ICAD	O
that	O
can	O
not	O
be	O
definitively	O
diagnosed	O
by	O
conventional	O
imaging	O
modalities	O
.	O

Family	O
Psychosocial	O
Risk	O
Screening	O
in	O
Infants	O
and	O
Older	O
Children	O
in	O
the	O
Acute	O
Pediatric	O
Hospital	O
Setting	O
Using	O
the	O
Psychosocial	O
Assessment	O
Tool	O
.	O

To	O
examine	O
the	O
validity	O
of	O
the	O
Psychosocial	O
Assessment	O
Tool	O
(	O
PAT	O
)	O
with	O
families	O
of	O
infants	O
(	O
<	O
2	O
years	O
)	O
and	O
children	O
admitted	O
to	O
hospital	O
with	O
acute	O
life-threatening	O
illnesses	O
.	O

METHODS	O
:	O
A	O
total	O
of	O
235	O
parents	O
of	O
177	O
children	O
admitted	O
to	O
oncology	O
,	O
cardiology	O
,	O
or	O
pediatric	O
intensive	O
care	O
completed	O
the	O
PAT	O
and	O
measures	O
of	O
acute	O
stress	O
,	O
trait	O
anxiety	O
,	O
family	O
functioning	O
,	O
and	O
quality	O
of	O
life	O
,	O
a	O
mean	O
3.7	O
weeks	O
following	O
diagnosis	O
.	O

A	O
modified	O
PAT	O
was	O
used	O
for	O
families	O
of	O
infants	O
,	O
rendering	O
two	O
forms	O
,	O
PAT	O
(	O
<	O
2	O
)	O
and	O
PAT	O
(	O
2+	O
)	O
.	O

RESULTS	O
:	O
Psychometrics	B-P
for	O
PAT	O
(	O
<	O
2	O
)	O
and	O
PAT	O
(	O
2+	O
)	O
were	O
acceptable	O
.	O

PAT	O
Total	O
and	O
Subscale	O
scores	O
for	O
each	O
version	O
were	O
significantly	O
correlated	O
with	O
validation	O
measures	O
.	O

Internal	O
consistency	O
for	O
PAT	O
subscales	O
was	O
variable	O
.	O

Receiver	O
Operating	O
Characteristics	O
provided	O
some	O
support	O
for	O
PAT	O
cutoffs	O
.	O

PAT	O
scores	O
across	O
illness	O
groups	O
were	O
comparable	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
provides	O
promising	O
support	O
for	O
the	O
PAT	O
as	O
a	O
psychosocial	O
screener	O
for	O
families	O
of	O
infants	O
and	O
older	O
children	O
across	O
illness	O
conditions	O
.	O

The	O
consummatory	O
and	O
motivational	O
behaviors	O
for	O
natural	O
rewards	O
following	O
long-term	O
withdrawal	O
from	O
morphine	O
:	O
no	O
anhedonia	O
but	O
persistent	O
maladaptive	O
behaviors	O
for	O
high-value	O
rewards	O
.	O

The	O
negative	O
affective	O
state	O
,	O
e.g.	O
,	O
anhedonia	O
,	O
emerges	O
after	O
abstinence	O
from	O
abused	O
drugs	O
may	O
be	O
linked	O
to	O
the	O
motivational	O
processes	O
of	O
drug	O
craving	O
and	O
relapse	O
.	O

Although	O
anhedonia	O
diminishes	O
over	O
time	O
with	O
drug	O
abstinence	O
,	O
it	O
is	O
not	O
yet	O
rather	O
explicit	O
whether	O
anhedonia	O
exists	O
or	O
not	O
following	O
protracted	O
withdrawal	O
.	O

The	O
behavioral	O
responses	O
to	O
natural	O
rewards	O
were	O
examined	O
after	O
2	O
to	O
3	O
weeks	O
withdrawal	O
from	O
morphine	O
.	O

Male	O
rats	O
were	O
pretreated	O
with	O
either	O
a	O
binge-like	O
morphine	O
paradigm	O
or	O
daily	O
saline	O
injection	O
for	O
5	O
days	O
.	O

The	O
consummatory	O
and	O
motivational	O
behaviors	O
for	O
three	O
natural	O
rewards	O
(	O
sucrose	O
solutions	O
4	O
,	O
15	O
,	O
and	O
60	O
%	O
,	O
social	O
stimulus	O
:	O
male	O
rat	O
,	O
and	O
sexual	O
stimulus	O
:	O
estrous	O
female	O
rat	O
)	O
were	O
examined	O
under	O
varied	O
testing	O
conditions	O
.	O

The	O
morphine	O
-	O
withdrawn	O
rats	O
significantly	O
increased	O
their	O
intake	O
of	O
15	O
%	O
sucrose	O
solution	O
during	O
the	O
1-h	O
consumption	B-P
test	I-P
and	O
their	O
operant	O
responding	O
for	O
15	O
%	O
sucrose	O
solution	O
under	O
a	O
progressive	O
ratio	O
(	O
PR	O
)	O
schedule	O
of	O
reinforcement	O
.	O

When	O
obtaining	O
a	O
reinforcer	O
was	O
associated	O
with	O
a	O
0.5	O
mA	O
foot	O
shock	O
under	O
a	O
PR-punishment	O
schedule	O
,	O
the	O
morphine	O
-	O
withdrawn	O
rats	O
showed	O
a	O
higher	O
performance	O
for	O
60	O
%	O
sucrose	O
solution	O
.	O

Meanwhile	O
,	O
the	O
morphine	O
-	O
withdrawn	O
rats	O
displayed	O
a	O
higher	O
motivation	O
to	O
sexual	O
stimulus	O
during	O
the	O
free-approach	B-P
test	I-P
and	O
more	O
approaching	O
behaviors	O
towards	O
sexual	O
stimulus	O
in	O
a	O
conflict-based	B-P
approach	I-P
test	I-P
(	O
concurrent	O
presence	O
of	O
reward	O
and	O
aversive	O
stimulus	O
)	O
.	O

No	O
anhedonia	O
-like	O
behavior	O
but	O
sensitized	O
behaviors	O
for	O
natural	O
rewards	O
were	O
found	O
after	O
long-term	O
morphine	O
withdrawal	O
.	O

Notably	O
,	O
the	O
morphine	O
-	O
withdrawn	O
rats	O
displayed	O
persistent	O
motivated	O
behaviors	O
for	O
high-value	O
rewards	O
(	O
60	O
%	O
sucrose	O
and	O
sexual	O
stimulus	O
)	O
in	O
the	O
conflict	B-P
tests	I-P
suggesting	O
impairments	O
in	O
inhibitory	O
control	O
in	O
morphine	O
-	O
treated	O
rats	O
.	O

Emergency	O
splenectomy	O
postelective	O
colonoscopy	B-P
.	O

Colonoscopy	B-P
is	O
the	O
gold	O
standard	O
for	O
investigation	O
of	O
colorectal	O
carcinoma	O
and	O
inflammatory	O
bowel	O
disease	O
.	O

Splenic	O
injury	O
is	O
a	O
rare	O
but	O
potentially	O
fatal	O
complication	O
of	O
colonoscopy	B-P
.	O

The	O
present	O
case	O
study	O
outlines	O
the	O
early	O
clinical	O
presentation	O
and	O
rapid	O
deterioration	O
of	O
a	O
patient	O
with	O
a	O
splenic	O
injury	O
after	O
an	O
elective	O
colonoscopy	B-P
.	O

A	O
70-year-old	O
female	O
underwent	O
a	O
colonoscopy	B-P
for	O
investigation	O
of	O
altered	O
bowel	O
habit	O
.	O

The	O
procedure	O
was	O
documented	O
as	O
difficult	O
due	O
to	O
the	O
presence	O
of	O
'	O
stiff	O
loopy	O
colon	O
'	O
.	O

In	O
recovery	O
,	O
patient	O
's	O
condition	O
deteriorated	O
and	O
she	O
was	O
moved	O
to	O
the	O
ward	O
for	O
further	O
assessment	O
.	O

She	O
gradually	O
became	O
haemodynamically	O
unstable	O
and	O
displayed	O
signs	O
of	O
peritoneal	O
irritation	O
.	O

Initial	O
attempts	O
of	O
fluid	O
resuscitation	O
failed	O
to	O
improve	O
patient	O
's	O
clinical	O
condition	O
.	O

Further	O
testing	O
revealed	O
a	O
significant	O
drop	O
in	O
haemoglobin	O
and	O
CT	B-P
confirmed	O
the	O
diagnosis	O
of	O
a	O
splenic	O
rupture	O
.	O

She	O
underwent	O
an	O
emergency	O
splenectomy	O
that	O
evening	O
.	O

Postoperatively	O
she	O
was	O
managed	O
in	O
the	O
high	O
dependency	O
unit	O
.	O

Investigating	O
Effects	O
of	O
Acidic	O
pH	O
on	O
Proliferation	O
,	O
Invasion	O
and	O
Drug	O
-	O
Induced	O
Apoptosis	O
in	O
Lymphoblastic	O
Leukemia	O
.	O

Some	O
studies	O
have	O
shown	O
that	O
extracellular	O
pH	O
in	O
tumors	O
,	O
which	O
results	O
in	O
tumor	O
progression	O
,	O
is	O
less	O
than	O
that	O
in	O
normal	O
tissues	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
extracellular	O
acidic	O
pH	O
on	O
proliferation	O
,	O
invasion	O
,	O
and	O
drug	O
-	O
induced	O
apoptosis	O
in	O
acute	O
lymphoblastic	O
cells	O
.	O

The	O
cells	O
were	O
cultured	O
in	O
different	O
pH	O
(	O
pH	O
6.6	O
and	O
pH	O
7.4	O
)	O
for	O
12	O
days	O
.	O

Cell	O
proliferation	O
was	O
assessed	O
by	O
MTT	O
assay	O
and	O
cell	O
invasion	O
was	O
assayed	O
by	O
invasion	B-P
assay	I-P
and	O
gene	O
expression	O
analysis	O
of	O
MMP-9	O
.	O

Drug	O
-	O
induced	O
apoptosis	O
was	O
evaluated	O
after	O
exposure	O
to	O
doxorubicin	O
for	O
24	O
hours	O
by	O
annexin	O
V	O
/	O
PI	O
staining	B-P
and	O
gene	O
expression	O
analysis	O
of	O
BAX	O
pro-apoptotic	O
protein	O
.	O

The	O
results	O
indicated	O
the	O
enhanced	O
growth	O
and	O
invasion	O
of	O
leukemic	O
cells	O
at	O
pH	O
6.6	O
(	O
P	O
≤	O
0.05	O
)	O
.	O

Furthermore	O
,	O
the	O
cells	O
at	O
pH	O
6.6	O
were	O
resistant	O
to	O
apoptosis	O
by	O
doxorubicin	O
(	O
P	O
≤	O
0.05	O
)	O
.	O

It	O
can	O
be	O
concluded	O
that	O
acidic	O
pH	O
increases	O
the	O
proliferation	O
,	O
invasion	O
and	O
reduces	O
the	O
drug	O
-	O
induced	O
apoptosis	O
in	O
acute	O
lymphoblastic	O
leukemia	O
.	O

Extracellular	O
acidity	O
can	O
influence	O
the	O
behavior	O
of	O
leukemic	O
cells	O
and	O
therefore	O
,	O
the	O
manipulation	O
of	O
extracellular	O
liquid	O
can	O
be	O
selected	O
as	O
a	O
therapeutic	O
strategy	O
for	O
leukemia	O
,	O
especially	O
for	O
acute	O
lymphoblastic	O
leukemia	O
.	O

Assessment	O
of	O
the	O
wish	O
to	O
hasten	O
death	O
in	O
patients	O
with	O
advanced	O
disease	O
:	O
A	O
systematic	O
review	O
of	O
measurement	O
instruments	O
.	O

Patients	O
with	O
advanced	O
conditions	O
may	O
present	O
a	O
wish	O
to	O
hasten	O
death	O
.	O

Assessing	O
this	O
wish	O
is	O
complex	O
due	O
to	O
the	O
nature	O
of	O
the	O
phenomenon	O
and	O
the	O
difficulty	O
of	O
conceptualising	O
it	O
.	O

To	O
identify	O
and	O
analyse	O
existing	O
instruments	O
for	O
assessing	O
the	O
wish	O
to	O
hasten	O
death	O
and	O
to	O
rate	O
their	O
reported	O
psychometric	B-P
properties	O
.	O

Systematic	O
review	O
based	O
on	O
PRISMA	O
guidelines	O
.	O

The	O
COnsensus-based	O
Standards	O
for	O
the	O
selection	O
of	O
health	O
Measurement	O
INstruments	O
checklist	O
was	O
used	O
to	O
evaluate	O
the	O
methodological	O
quality	O
of	O
validation	O
studies	O
and	O
the	O
measurement	O
properties	O
of	O
the	O
instrument	O
described	O
.	O

The	O
CINAHL	O
,	O
PsycINFO	O
,	O
Pubmed	O
and	O
Web	O
of	O
Science	O
databases	O
were	O
searched	O
from	O
inception	O
to	O
November	O
2015	O
.	O

A	O
total	O
of	O
50	O
articles	O
involving	O
assessment	O
of	O
the	O
wish	O
to	O
hasten	O
death	O
were	O
included	O
.	O

Eight	O
concerned	O
instrument	O
validation	O
and	O
were	O
evaluated	O
using	O
COnsensus-based	O
Standards	O
for	O
the	O
selection	O
of	O
health	O
Measurement	O
INstruments	O
criteria	O
.	O

They	O
reported	O
data	O
for	O
between	O
two	O
and	O
seven	O
measurement	O
properties	O
,	O
with	O
ratings	O
between	O
fair	O
and	O
excellent	O
.	O

Of	O
the	O
seven	O
instruments	O
identified	O
,	O
the	O
Desire	O
for	O
Death	O
Rating	O
Scale	O
or	O
the	O
Schedule	O
of	O
Attitudes	O
toward	O
Hastened	O
Death	O
feature	O
in	O
48	O
of	O
the	O
50	O
articles	O
.	O

The	O
Schedule	O
of	O
Attitudes	O
toward	O
Hastened	O
Death	O
is	O
the	O
most	O
widely	O
used	O
and	O
is	O
the	O
instrument	O
whose	O
psychometric	B-P
properties	O
have	O
been	O
most	O
often	O
analysed	O
.	O

Versions	O
of	O
the	O
Schedule	O
of	O
Attitudes	O
toward	O
Hastened	O
Death	O
are	O
available	O
in	O
five	O
languages	O
other	O
than	O
the	O
original	O
English	O
.	O

This	O
systematic	O
review	O
has	O
analysed	O
existing	O
instruments	O
for	O
assessing	O
the	O
wish	O
to	O
hasten	O
death	O
.	O

It	O
has	O
also	O
explored	O
the	O
methodological	O
quality	O
of	O
studies	O
that	O
have	O
examined	O
the	O
measurement	O
properties	O
of	O
these	O
instruments	O
and	O
offers	O
ratings	O
of	O
the	O
reported	O
properties	O
.	O

These	O
results	O
will	O
be	O
useful	O
to	O
clinicians	O
and	O
researchers	O
with	O
an	O
interest	O
in	O
a	O
phenomenon	O
of	O
considerable	O
relevance	O
to	O
advanced	O
patients	O
.	O

EEG	B-P
Monitoring	O
Technique	O
Influences	O
the	O
Management	O
of	O
Hypoxic-Ischemic	O
Seizures	O
in	O
Neonates	O
Undergoing	O
Therapeutic	O
Hypothermia	O
.	O

Electroencephalogram	O
(	O
EEG	O
)	O
monitoring	O
techniques	O
for	O
neonatal	O
hypoxia-ischemia	O
(	O
HI	O
)	O
are	O
evolving	O
over	O
time	O
,	O
and	O
the	O
specific	O
type	O
of	O
EEG	O
utilized	O
could	O
influence	O
seizure	O
diagnosis	O
and	O
management	O
.	O

We	O
examined	O
whether	O
the	O
type	O
of	O
EEG	B-P
performed	O
affected	O
seizure	O
treatment	O
decisions	O
(	O
e.g.	O
,	O
the	O
choice	O
and	O
number	O
of	O
antiseizure	O
drugs	O
[	O
ASDs	O
]	O
)	O
in	O
therapeutic	O
hypothermia-treated	O
neonates	O
with	O
HI	O
from	O
2007	O
to	O
2015	O
in	O
the	O
Johns	O
Hopkins	O
Hospital	O
Neonatal	O
Intensive	O
Care	O
Unit	O
.	O

During	O
this	O
period	O
,	O
3	O
different	O
EEG	O
monitoring	O
protocols	O
were	O
utilized	O
:	O
Period	O
1	O
(	O
2007-2009	O
)	O
,	O
single	O
,	O
brief	O
conventional	O
EEG	B-P
(	O
1	O
h	O
duration	O
)	O
at	O
a	O
variable	O
time	O
during	O
therapeutic	O
hypothermia	O
treatment	O
,	O
i.e.	O
,	O
ordered	O
when	O
a	O
seizure	O
was	O
suspected	O
;	O
Period	O
2	O
(	O
2009-2013	O
)	O
,	O
single	O
,	O
brief	O
conventional	O
EEG	B-P
followed	O
by	O
amplitude-integrated	B-P
EEG	I-P
for	O
the	O
duration	O
of	O
therapeutic	O
hypothermia	O
treatment	O
and	O
another	O
brief	O
conventional	O
EEG	B-P
after	O
rewarming	O
;	O
and	O
Period	O
3	O
(	O
2014-2015	O
)	O
,	O
continuous	B-P
video-EEG	I-P
(	O
cEEG	B-P
)	O
for	O
the	O
duration	O
of	O
therapeutic	O
hypothermia	O
treatment	O
(	O
72	O
h	O
)	O
plus	O
for	O
an	O
additional	O
12	O
h	O
during	O
and	O
after	O
rewarming	O
.	O

One	O
hundred	O
and	O
sixty-two	O
newborns	O
were	O
included	O
in	O
this	O
retrospective	O
cohort	O
study	O
.	O

As	O
a	O
function	O
of	O
the	O
type	O
and	O
duration	O
of	O
EEG	O
monitoring	O
,	O
we	O
assessed	O
the	O
risk	O
(	O
likelihood	O
)	O
of	O
receiving	O
no	O
ASD	O
,	O
at	O
least	O
1	O
ASD	O
,	O
or	O
≥2	O
ASDs	O
.	O

We	O
found	O
that	O
the	O
risk	O
of	O
a	O
neonate	O
being	O
prescribed	O
an	O
ASD	O
was	O
46	O
%	O
less	O
during	O
Period	O
3	O
(	O
cEEG	B-P
)	O
than	O
during	O
Period	O
1	O
(	O
brief	O
conventional	O
EEG	B-P
only	O
)	O
(	O
95	O
%	O
CI	O
6-69	O
%	O
,	O
p	O
=	O
0.03	O
)	O
.	O

After	O
adjusting	O
for	O
initial	O
EEG	B-P
and	O
MRI	B-P
results	O
,	O
compared	O
with	O
Period	O
1	O
,	O
there	O
was	O
a	O
38	O
%	O
lower	O
risk	O
of	O
receiving	O
an	O
ASD	O
during	O
Period	O
2	O
(	O
95	O
%	O
CI	O
:	O
9-58	O
%	O
,	O
p	O
=	O
0.02	O
)	O
and	O
a	O
67	O
%	O
lower	O
risk	O
during	O
Period	O
3	O
(	O
95	O
%	O
CI	O
:	O
23-86	O
%	O
,	O
p	O
=	O
0.01	O
)	O
.	O

The	O
risk	O
ratio	O
of	O
receiving	O
≥2	O
ASDs	O
was	O
not	O
significantly	O
different	O
across	O
the	O
3	O
periods	O
.	O

In	O
conclusion	O
,	O
in	O
addition	O
to	O
the	O
higher	O
sensitivity	O
and	O
specificity	O
of	O
continuous	B-P
video-EEG	I-P
monitoring	O
,	O
fewer	O
infants	O
are	O
prescribed	O
an	O
ASD	O
when	O
undergoing	O
continuous	O
forms	O
of	O
EEG	O
monitoring	O
(	O
aEEG	B-P
or	O
cEEG	B-P
)	O
than	O
those	O
receiving	O
conventional	O
EEG	B-P
.	O

We	O
recommend	O
that	O
use	O
of	O
continuous	B-P
video-EEG	I-P
be	O
considered	O
whenever	O
possible	O
,	O
both	O
to	O
treat	O
seizures	O
more	O
specifically	O
and	O
to	O
avoid	O
overtreatment	O
.	O

An	O
example	O
of	O
host	O
plant	O
expansion	O
of	O
host	O
-	O
specialized	O
Aphis	O
gossypii	O
Glover	O
in	O
the	O
field	O
.	O

The	O
host	O
plant	O
expansion	O
of	O
host	O
-	O
specialized	O
Aphis	O
gossypii	O
(	O
Glover	O
)	O
has	O
been	O
well	O
studied	O
in	O
the	O
laboratory	O
;	O
however	O
,	O
this	O
phenomenon	O
is	O
poorly	O
understood	O
in	O
the	O
field	O
.	O

Here	O
,	O
we	O
provide	O
a	O
series	O
of	O
laboratory	O
and	O
field	O
experiments	O
to	O
assess	O
the	O
role	O
of	O
zucchini	O
in	O
the	O
host	O
plant	O
expansion	O
of	O
cotton	O
-	O
specialized	O
aphids	O
.	O

We	O
observed	O
that	O
cotton	O
-	O
specialized	O
aphids	O
possessed	O
the	O
ability	O
to	O
expand	O
on	O
a	O
new	O
host	O
plant	O
(	O
cucumber	O
)	O
,	O
with	O
individuals	O
first	O
recorded	O
on	O
June	O
12	O
and	O
consequently	O
increasing	O
exponentially	O
in	O
number	O
in	O
a	O
field	O
cage	O
.	O

A	O
bioassay	B-P
experiment	O
showed	O
that	O
aphids	O
from	O
both	O
cotton	O
and	O
cucumber	O
preferred	O
their	O
natal	O
host	O
,	O
but	O
clones	O
from	O
zucchini	O
have	O
a	O
stronger	O
preference	O
for	O
cucumber	O
than	O
cotton	O
or	O
zucchini	O
.	O

A	O
total	O
of	O
1512	O
individuals	O
were	O
collected	O
from	O
a	O
cotton	O
field	O
(	O
mixed	O
cotton	O
and	O
cucurbit	O
plot	O
)	O
,	O
cotton	O
farmland	O
(	O
cotton	O
alone	O
)	O
and	O
a	O
field	O
cage	O
and	O
sequenced	B-P
to	O
identify	O
their	O
biotypes	O
.	O

The	O
results	O
for	O
apterous	O
individuals	O
from	O
the	O
cotton	O
field	O
showed	O
that	O
more	O
cucurbit	O
-	O
specialized	O
biotypes	O
occurred	O
on	O
cucumber	O
and	O
more	O
cotton	O
-	O
specialized	O
biotypes	O
occurred	O
on	O
cotton	O
and	O
zucchini	O
.	O

A	O
majority	O
(	O
>	O
97.0	O
%	O
)	O
of	O
aphids	O
from	O
both	O
the	O
field	O
cage	O
and	O
cotton	O
farmland	O
were	O
cotton	O
-	O
specialized	O
individuals	O
.	O

Consequently	O
,	O
eliminating	O
intermediate	O
host	O
plants	O
may	O
be	O
an	O
effective	O
measure	O
to	O
suppress	O
A.	O
gossypii	O
outbreaks	O
,	O
because	O
cotton	O
and	O
cucumber	O
are	O
often	O
grown	O
together	O
in	O
fields	O
and	O
greenhouses	O
.	O

Muscle	O
synergies	O
after	O
stroke	O
are	O
correlated	O
with	O
perilesional	O
high	O
gamma	O
.	O

Movements	O
can	O
be	O
factored	O
into	O
modules	O
termed	O
``	O
muscle	O
synergies	O
``	O
.	O

After	O
stroke	O
,	O
abnormal	O
synergies	O
are	O
linked	O
to	O
impaired	O
movements	O
;	O
however	O
,	O
their	O
neural	O
basis	O
is	O
not	O
understood	O
.	O

In	O
a	O
single	O
subject	O
,	O
we	O
examined	O
how	O
electrocorticography	B-P
signals	I-P
from	O
the	O
perilesional	O
cortex	O
were	O
associated	O
with	O
synergies	O
.	O

The	O
measured	O
synergies	O
contained	O
a	O
mix	O
of	O
both	O
normal	O
and	O
abnormal	O
patterns	O
and	O
were	O
remarkably	O
similar	O
to	O
those	O
described	O
in	O
past	O
work	O
.	O

Interestingly	O
,	O
we	O
found	O
that	O
both	O
normal	O
and	O
abnormal	O
synergies	O
were	O
correlated	O
with	O
perilesional	O
high	O
gamma	O
.	O

Given	O
the	O
link	O
between	O
high	O
gamma	O
and	O
cortical	O
spiking	O
,	O
our	O
results	O
suggest	O
that	O
perilesional	O
spiking	O
may	O
organize	O
synergies	O
after	O
stroke	O
.	O

Fragment	O
-Based	O
Discovery	O
of	O
5-Arylisatin	O
-Based	O
Inhibitors	O
of	O
Matrix	O
Metalloproteinases	O
2	O
and	O
13	O
.	O

Matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
are	O
well-established	O
targets	O
for	O
several	O
pathologies	O
.	O

In	O
particular	O
,	O
MMP-2	O
and	O
MMP-13	O
play	O
a	O
prominent	O
role	O
in	O
cancer	O
progression	O
.	O

In	O
this	O
study	O
,	O
a	O
structure-based	O
screening	O
campaign	O
was	O
applied	O
to	O
prioritize	O
metalloproteinase	O
-oriented	O
fragments	O
.	O

This	O
computational	O
model	O
was	O
applied	O
to	O
a	O
representative	O
fragment	O
set	O
from	O
the	O
publically	O
available	O
EDASA	O
Scientific	O
compound	O
library	O
.	O

These	O
fragments	O
were	O
prioritized	O
,	O
and	O
the	O
top-ranking	O
hits	O
were	O
tested	O
in	O
a	O
biological	B-P
assay	I-P
to	O
validate	O
the	O
model	O
.	O

Two	O
scaffolds	O
showed	O
consistent	O
activity	O
in	O
the	O
assay	B-P
,	O
and	O
the	O
isatin-based	O
compounds	O
were	O
the	O
most	O
interesting	O
.	O

These	O
latter	O
fragments	O
have	O
significant	O
potential	O
as	O
tools	O
for	O
the	O
design	O
and	O
realization	O
of	O
novel	O
MMP	O
inhibitors	O
.	O

In	O
addition	O
to	O
their	O
micromolar	O
activity	O
,	O
the	O
chemical	O
synthesis	O
affords	O
flexible	O
and	O
creative	O
access	O
to	O
their	O
analogues	O
.	O

Lignans	O
from	O
the	O
fruits	O
of	O
Schisandra	O
chinensis	O
(	O
Turcz	O
.	O
)	O

Baill	O
inhibit	O
proprotein	O
convertase	O
subtilisin/kexin	O
type	O
9	O
expression	O
.	O

Bioactivity-guided	B-P
fractionation	I-P
of	O
the	O
fruits	O
of	O
Schisandra	O
chinensis	O
,	O
using	O
the	O
proprotein	O
convertase	O
subtilisin-kexin	O
type	O
9	O
(	O
PCSK9	O
)	O
mRNA	O
expression	O
screening	B-P
assay	I-P
,	O
led	O
to	O
isolation	O
of	O
two	O
previously	O
unknown	O
lignans	O
,	O
14-tigloylschinlignan	O
D	O
and	O
rel-	O
(	O
7R	O
,	O
8R	O
,	O
7	O
'	O
R	O
,	O
8	O
'	O
R	O
)	O
-manglisin	O
E	O
,	O
along	O
with	O
28	O
known	O
compounds	O
.	O

All	O
structures	O
were	O
established	O
by	O
NMR	B-P
spectroscopic	I-P
data	O
as	O
well	O
as	O
CD	B-P
and	O
MS	B-P
analysis	O
.	O

All	O
isolates	O
were	O
tested	O
for	O
their	O
inhibitory	O
activities	O
on	O
the	O
mRNA	O
expression	O
of	O
PCSK9	O
.	O

Of	O
the	O
tested	O
compounds	O
,	O
four	O
of	O
the	O
compounds	O
rel-	O
(	O
7R	O
,	O
8R	O
,	O
7	O
'	O
R	O
,	O
8	O
'	O
R	O
)	O
-manglisin	O
E	O
,	O
(	O
-	O
)	O
-schisandrin	O
C	O
,	O
schinlignan	O
D	O
,	O
and	O
(	O
+	O
)	O
-schisandrol	O
B	O
potently	O
inhibited	O
PCSK9	O
mRNA	O
expression	O
with	O
IC50	O
values	O
of	O
3.15	O
,	O
3.85	O
,	O
0.36	O
,	O
and	O
1.10	O
μM	O
,	O
respectively	O
.	O

Furthermore	O
,	O
schinlignan	O
D	O
and	O
(	O
+	O
)	O
-schisandrol	O
B	O
were	O
found	O
to	O
suppress	O
PCSK9	O
protein	O
expressions	O
and	O
schinlignan	O
D	O
deemed	O
to	O
increase	O
low	O
density	O
lipoprotein	O
receptor	O
expression	O
.	O

Surface	O
Modification	O
of	O
Porous	O
Titanium	O
Granules	O
for	O
Improving	O
Bioactivity	O
.	O

The	O
highly	O
porous	O
titanium	O
granules	O
are	O
currently	O
being	O
used	O
as	O
bone	O
substitute	O
material	O
and	O
for	O
bone	O
tissue	O
augmentation	O
.	O

However	O
,	O
they	O
suffer	O
from	O
weak	O
bone	O
bonding	O
ability	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
create	O
a	O
nanostructured	O
surface	O
oxide	O
layer	O
on	O
irregularly	O
shaped	O
titanium	O
granules	O
to	O
improve	O
their	O
bioactivity	O
.	O

This	O
could	O
be	O
achieved	O
using	O
optimized	O
electrochemical	O
anodic	O
oxidation	O
(	O
anodizing	O
)	O
and	O
heat	O
treatment	O
processes	O
.	O

The	O
anodizing	O
process	O
was	O
done	O
in	O
an	O
ethylene	O
glycol	O
-based	O
electrolyte	O
at	O
an	O
optimized	O
condition	O
of	O
60	O
V	O
for	O
3	O
hours	O
.	O

The	O
anodized	O
granules	O
were	O
subsequently	O
annealed	O
at	O
450°C	O
for	O
1	O
hour	O
.	O

Scanning	B-P
electron	I-P
microscopy	I-P
(	O
SEM	B-P
)	O
,	O
energy-dispersive	B-P
x-ray	I-P
spectroscopy	I-P
(	O
EDS	B-P
)	O
,	O
and	O
x-ray	B-P
diffraction	I-P
(	O
XRD	B-P
)	O
were	O
used	O
to	O
characterize	O
the	O
surface	O
structure	O
and	O
morphology	O
of	O
the	O
granules	O
.	O

The	O
in	O
vitro	O
bioactivity	O
of	O
the	O
samples	O
was	O
evaluated	O
by	O
immersion	O
of	O
specimens	O
in	O
simulated	O
body	O
fluid	O
(	O
SBF	O
)	O
for	O
1	O
,	O
2	O
,	O
and	O
3	O
weeks	O
.	O

The	O
human	O
osteoblastic	O
sarcoma	O
cell	O
line	O
,	O
MG63	O
,	O
was	O
used	O
to	O
evaluate	O
cell	O
viability	O
on	O
the	O
samples	O
using	O
dimethylthiazol-diphenyl	O
tetrazolium	O
bromide	O
(	O
MTT	O
)	O
assay	O
.	O

The	O
results	O
demonstrated	O
the	O
formation	O
of	O
amorphous	O
nanostructured	O
titanium	O
oxide	O
after	O
anodizing	O
,	O
which	O
transformed	O
to	O
crystalline	O
anatase	O
and	O
rutile	O
phases	O
upon	O
heat	O
treatment	O
.	O

After	O
immersion	O
in	O
SBF	O
,	O
spherical	O
aggregates	O
of	O
amorphous	O
calcium	O
phosphate	O
were	O
formed	O
on	O
the	O
surface	O
of	O
the	O
anodized	O
sample	O
,	O
which	O
turned	O
into	O
crystalline	O
hydroxyapatite	O
on	O
the	O
surface	O
of	O
the	O
anodized	O
annealed	O
sample	O
.	O

No	O
cytotoxicity	O
was	O
detected	O
among	O
the	O
samples	O
.	O

It	O
is	O
suggested	O
that	O
anodic	O
oxidation	O
followed	O
by	O
heat	O
treatment	O
could	O
be	O
used	O
as	O
an	O
effective	O
surface	O
treatment	O
procedure	O
to	O
improve	O
bioactivity	O
of	O
titanium	O
granules	O
implemented	O
for	O
bone	O
tissue	O
repair	O
and	O
augmentation	O
.	O

Impact	O
of	O
antibiotic	O
de-escalation	O
on	O
clinical	O
outcomes	O
in	O
community-acquired	O
pneumococcal	O
pneumonia	O
.	O

Although	O
antibiotic	O
de-escalation	O
is	O
regarded	O
as	O
a	O
measure	O
that	O
reduces	O
selection	O
pressure	O
,	O
adverse	O
drug	O
effects	O
and	O
costs	O
,	O
evidence	O
supporting	O
this	O
practice	O
in	O
community-acquired	O
pneumococcal	O
pneumonia	O
(	O
CAPP	O
)	O
is	O
lacking	O
.	O

We	O
carried	O
out	O
a	O
retrospective	O
analysis	O
of	O
prospectively	O
collected	O
data	O
of	O
a	O
cohort	O
of	O
hospitalized	O
adults	O
with	O
CAPP	O
.	O

Pneumococcal	O
aetiology	O
was	O
established	O
in	O
patients	O
with	O
one	O
or	O
more	O
positive	O
cultures	O
for	O
Streptococcus	O
pneumoniae	O
obtained	O
from	O
blood	O
,	O
sterile	O
fluids	O
or	O
sputum	O
,	O
and/or	O
a	O
positive	O
urinary	B-P
antigen	I-P
test	I-P
.	O

De-escalation	O
therapy	O
was	O
considered	O
when	O
the	O
initial	O
antibiotic	O
therapy	O
was	O
narrowed	O
to	O
penicillin	O
,	O
amoxicillin	O
or	O
amoxicillin/clavulanate	O
within	O
the	O
first	O
72	O
h	O
after	O
admission	O
.	O

The	O
primary	O
outcomes	O
were	O
30	O
day	O
mortality	O
and	O
length	O
of	O
hospital	O
stay	O
(	O
LOS	O
)	O
.	O

Adjustment	O
for	O
confounders	O
was	O
performed	O
with	O
multivariate	O
and	O
propensity	O
score	O
analyses	O
.	O

Of	O
1410	O
episodes	O
of	O
CAPP	O
,	O
antibiotic	O
de-escalation	O
within	O
the	O
first	O
72	O
h	O
after	O
admission	O
was	O
performed	O
in	O
166	O
cases	O
.	O

After	O
adjustment	O
,	O
antibiotic	O
de-escalation	O
was	O
not	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
mortality	O
(	O
OR	O
=	O
0.83	O
,	O
95	O
%	O
CI	O
=	O
0.24-2.81	O
)	O
,	O
but	O
it	O
was	O
found	O
to	O
be	O
a	O
protective	O
factor	O
for	O
prolonged	O
LOS	O
(	O
above	O
the	O
median	O
)	O
(	O
OR	O
=	O
0.46	O
,	O
95	O
%	O
CI	O
=	O
0.30-0.70	O
)	O
.	O

Similar	O
results	O
were	O
found	O
in	O
patients	O
classified	O
into	O
high-risk	O
pneumonia	O
severity	O
index	O
classes	O
(	O
IV-V	O
)	O
,	O
those	O
with	O
clinical	O
instability	O
and	O
those	O
with	O
bacteraemia	O
.	O

No	O
significant	O
differences	O
were	O
documented	O
in	O
adverse	O
drug	O
reactions	O
or	O
readmission	O
(	O
<	O
30	O
days	O
)	O
.	O

Antibiotic	O
de-escalation	O
seems	O
to	O
be	O
safe	O
and	O
effective	O
in	O
reducing	O
the	O
duration	O
of	O
LOS	O
,	O
and	O
did	O
not	O
adversely	O
affect	O
outcomes	O
of	O
patients	O
with	O
CAPP	O
,	O
even	O
those	O
with	O
bacteraemia	O
and	O
severe	O
disease	O
,	O
and	O
those	O
who	O
were	O
clinically	O
unstable	O
.	O

Unusual	O
Salt	O
and	O
pH	O
Induced	O
Changes	O
in	O
Polyethylenimine	O
Solutions	O
.	O

Linear	O
PEI	O
is	O
a	O
cationic	O
polymer	O
commonly	O
used	O
for	O
complexing	O
DNA	O
into	O
nanoparticles	O
for	O
cell-transfection	O
and	O
gene-therapy	O
applications	O
.	O

The	O
polymer	O
has	O
closely-spaced	O
amines	O
with	O
weak-base	O
protonation	O
capacity	O
,	O
and	O
a	O
hydrophobic	O
backbone	O
that	O
is	O
kept	O
unaggregated	O
by	O
intra-chain	O
repulsion	O
.	O

As	O
a	O
result	O
,	O
in	O
solution	O
PEI	O
exhibits	O
multiple	O
buffering	O
mechanisms	O
,	O
and	O
polyelectrolyte	O
states	O
that	O
shift	O
between	O
aggregated	O
and	O
free	O
forms	O
.	O

We	O
studied	O
the	O
interplay	O
between	O
the	O
aggregation	O
and	O
protonation	O
behavior	O
of	O
2.5	O
kDa	O
linear	O
PEI	O
by	O
pH	O
probing	O
,	O
vapor	O
pressure	O
osmometry	O
,	O
dynamic	B-P
light	I-P
scattering	I-P
,	O
and	O
ninhydrin	O
assay	B-P
.	O

Our	O
results	O
indicate	O
that	O
:	O
At	O
neutral	O
pH	O
,	O
the	O
PEI	O
chains	O
are	O
associated	O
and	O
the	O
addition	O
of	O
NaCl	O
initially	O
reduces	O
and	O
then	O
increases	O
the	O
extent	O
of	O
association	O
.The	O
aggregate	O
form	O
is	O
uncollapsed	O
and	O
co-exists	O
with	O
the	O
free	O
chains	O
.	O

PEI	O
buffering	O
occurs	O
due	O
to	O
continuous	O
or	O
discontinuous	O
charging	O
between	O
stalled	O
states	O
.	O

Ninhydrin	O
assay	B-P
tracks	O
the	O
number	O
of	O
unprotonated	O
amines	O
in	O
PEI	O
.The	O
size	O
of	O
PEI	O
-	O
DNA	O
complexes	O
is	O
not	O
significantly	O
affected	O
by	O
the	O
free	O
vs.	O
aggregated	O
state	O
of	O
the	O
PEI	O
polymer	O
.	O

Despite	O
its	O
simple	O
chemical	O
structure	O
,	O
linear	O
PEI	O
displays	O
intricate	O
solution	O
dynamics	O
,	O
which	O
can	O
be	O
harnessed	O
for	O
environment	O
-	O
sensitive	O
biomaterials	O
and	O
for	O
overcoming	O
current	O
challenges	O
with	O
DNA	O
delivery	O
.	O

The	O
Shear	O
Bond	O
Strength	O
of	O
Porcelain	O
Laminate	O
to	O
Prepared	O
and	O
Unprepared	O
Anterior	O
Teeth	O
.	O

Porcelain	O
laminate	O
veneer	O
is	O
an	O
esthetic	O
restoration	O
used	O
as	O
an	O
alternative	O
to	O
full	O
veneer	O
crowns	O
and	O
requires	O
minimal	O
tooth	O
preparation	O
.	O

In	O
restoration	O
with	O
porcelain	O
laminate	O
veneers	O
,	O
both	O
the	O
longevity	O
of	O
the	O
laminate	O
and	O
conservation	O
of	O
the	O
sound	O
tooth	O
structure	O
are	O
imperative	O
.	O

The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
shear	O
bond	O
strength	O
of	O
porcelain	O
laminates	O
to	O
prepared	O
-	O
and	O
unprepared	O
-	O
anterior	O
teeth	O
in	O
order	O
to	O
compare	O
their	O
longevity	O
and	O
success	O
rate	O
.	O

Thirty	O
extracted	O
maxillary	O
central	O
incisors	O
were	O
randomly	O
divided	O
into	O
3	O
groups	O
regarding	O
their	O
preparation	O
methods	O
.	O

The	O
preparation	O
methods	O
were	O
full-preparation	O
in	O
group	O
A	O
,	O
full-preparation	O
and	O
finishing	O
with	O
fine	O
diamond	O
bur	O
in	O
group	O
B	O
,	O
and	O
no-preparation	O
,	O
only	O
grinding	O
with	O
diamond	O
bur	O
in	O
group	O
C.	O
After	O
conditioning	O
the	O
teeth	O
,	O
ceramic	O
veneers	O
(	O
IP	O
S	O
e.max	O
)	O
were	O
silanated	O
and	O
then	O
cemented	O
with	O
DuoLink	O
luting	O
cement	O
.	O

The	O
shear	O
bond	O
strength	O
was	O
measured	O
for	O
each	O
group	O
and	O
failure	O
mode	O
was	O
determined	O
by	O
stereomicroscopic	B-P
examination	I-P
.	O

Group	O
C	O
exhibited	O
the	O
highest	O
shear	O
bond	O
strength	O
.	O

The	O
shear	O
bond	O
strength	O
was	O
significantly	O
different	O
between	O
groups	O
C	O
and	O
B	O
(	O
p	O
<	O
0.05	O
)	O
.	O

However	O
,	O
the	O
difference	O
between	O
group	O
A	O
and	O
C	O
was	O
insignificant	O
,	O
as	O
was	O
the	O
difference	O
between	O
group	O
A	O
and	O
B	O
(	O
p	O
>	O
0.05	O
)	O
.	O

Adhesion	O
failure	O
mode	O
was	O
found	O
to	O
be	O
more	O
common	O
than	O
the	O
cohesive	O
mode	O
.	O

Regarding	O
the	O
shear	O
bond	O
strength	O
of	O
unprepared	O
anterior	O
teeth	O
to	O
porcelain	O
laminate	O
veneers	O
yielded	O
by	O
this	O
study	O
,	O
no-preparation	O
veneers	O
might	O
be	O
used	O
when	O
the	O
enamel	O
is	O
affected	O
by	O
wearing	O
,	O
trauma	O
,	O
or	O
abrasion	O
.	O

It	O
can	O
also	O
be	O
used	O
in	O
patients	O
who	O
refuse	O
the	O
treatments	O
which	O
involve	O
tooth	O
reduction	O
and	O
preparation	O
.	O

Translating	O
Neurocognitive	O
Models	O
of	O
Auditory-Verbal	O
Hallucinations	O
into	O
Therapy	O
:	O
Using	O
Real-time	O
fMRI	B-P
-	O
Neurofeedback	O
to	O
Treat	O
Voices	O
.	O

Auditory-verbal	O
hallucinations	O
(	O
AVHs	O
)	O
are	O
frequent	O
and	O
disabling	O
symptoms	O
,	O
which	O
can	O
be	O
refractory	O
to	O
conventional	O
psychopharmacological	O
treatment	O
in	O
more	O
than	O
25	O
%	O
of	O
the	O
cases	O
.	O

Recent	O
advances	O
in	O
brain	B-P
imaging	I-P
allow	O
for	O
a	O
better	O
understanding	O
of	O
the	O
neural	O
underpinnings	O
of	O
AVHs	O
.	O

These	O
findings	O
strengthened	O
transdiagnostic	O
neurocognitive	O
models	O
that	O
characterize	O
these	O
frequent	O
and	O
disabling	O
experiences	O
.	O

At	O
the	O
same	O
time	O
,	O
technical	O
improvements	O
in	O
real-time	O
functional	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	O
fMRI	B-P
)	O
enabled	O
the	O
development	O
of	O
innovative	O
and	O
non-invasive	O
methods	O
with	O
the	O
potential	O
to	O
relieve	O
psychiatric	O
symptoms	O
,	O
such	O
as	O
fMRI	B-P
-based	O
neurofeedback	O
(	O
fMRI	B-P
-	O
NF	O
)	O
.	O

During	O
fMRI	B-P
-	O
NF	O
,	O
brain	O
activity	O
is	O
measured	O
and	O
fed	O
back	O
in	O
real	O
time	O
to	O
the	O
participant	O
in	O
order	O
to	O
help	O
subjects	O
to	O
progressively	O
achieve	O
voluntary	O
control	O
over	O
their	O
own	O
neural	O
activity	O
.	O

Precisely	O
defining	O
the	O
target	O
brain	O
area	O
/	O
network	O
(	O
s	O
)	O
appears	O
critical	O
in	O
fMRI	B-P
-	O
NF	O
protocols	O
.	O

After	O
reviewing	O
the	O
available	O
neurocognitive	O
models	O
for	O
AVHs	O
,	O
we	O
elaborate	O
on	O
how	O
recent	O
findings	O
in	O
the	O
field	O
may	O
help	O
to	O
develop	O
strong	O
a	O
priori	O
strategies	O
for	O
fMRI	B-P
-	O
NF	O
target	O
localization	O
.	O

The	O
first	O
approach	O
relies	O
on	O
imaging	B-P
-based	O
``	O
trait	O
markers	O
``	O
(	O
i.e.	O
,	O
persistent	O
traits	O
or	O
vulnerability	O
markers	O
that	O
can	O
also	O
be	O
detected	O
in	O
the	O
presymptomatic	O
and	O
remitted	O
phases	O
of	O
AVHs	O
)	O
.	O

The	O
goal	O
of	O
such	O
strategies	O
is	O
to	O
target	O
areas	O
that	O
show	O
aberrant	O
activations	O
during	O
AVHs	O
or	O
are	O
known	O
to	O
be	O
involved	O
in	O
compensatory	O
activation	O
(	O
or	O
resilience	O
processes	O
)	O
.	O

Brain	O
regions	O
,	O
from	O
which	O
the	O
NF	O
signal	O
is	O
derived	O
,	O
can	O
be	O
based	O
on	O
structural	B-P
MRI	I-P
and	O
neurocognitive	O
knowledge	O
,	O
or	O
functional	B-P
MRI	I-P
information	O
collected	O
during	O
specific	O
cognitive	O
tasks	O
.	O

Because	O
hallucinations	O
are	O
acute	O
and	O
intrusive	O
symptoms	O
,	O
a	O
second	O
strategy	O
focuses	O
more	O
on	O
``	O
state	O
markers	O
.	O
''	O

In	O
this	O
case	O
,	O
the	O
signal	O
of	O
interest	O
relies	O
on	O
fMRI	B-P
capture	O
of	O
the	O
neural	O
networks	O
exhibiting	O
increased	O
activity	O
during	O
AVHs	O
occurrences	O
,	O
by	O
means	O
of	O
multivariate	O
pattern	O
recognition	O
methods	O
.	O

The	O
fine-grained	O
activity	O
patterns	O
concomitant	O
to	O
hallucinations	O
can	O
then	O
be	O
fed	O
back	O
to	O
the	O
patients	O
for	O
therapeutic	O
purpose	O
.	O

Considering	O
the	O
potential	O
cost	O
necessary	O
to	O
implement	O
fMRI	B-P
-	O
NF	O
,	O
proof-of-concept	O
studies	O
are	O
urgently	O
required	O
to	O
define	O
the	O
optimal	O
strategy	O
for	O
application	O
in	O
patients	O
with	O
AVHs	O
.	O

This	O
technique	O
has	O
the	O
potential	O
to	O
establish	O
a	O
new	O
brain	B-P
imaging	I-P
-guided	O
psychotherapy	O
for	O
patients	O
that	O
do	O
not	O
respond	O
to	O
conventional	O
treatments	O
and	O
take	O
functional	O
neuroimaging	O
to	O
therapeutic	O
applications	O
.	O

Moorean	O
and	O
Tahitian	O
Partula	O
tree	O
snail	O
survival	O
after	O
a	O
mass	O
extinction	O
:	O
New	O
genomic	O
insights	O
using	O
museum	O
specimens	O
.	O

Natural	O
history	O
museum	O
collections	O
provide	O
a	O
biodiversity	O
window	O
into	O
the	O
past	O
and	O
are	O
of	O
particular	O
importance	O
to	O
the	O
study	O
of	O
extinction	O
-impacted	O
clades	O
such	O
as	O
the	O
Pacific	O
Island	O
tree	O
snail	O
family	O
Partulidae	O
.	O

Deliberate	O
introduction	O
of	O
the	O
predatory	O
rosy	O
wolf	O
snail	O
Euglandina	O
rosea	O
in	O
the	O
late	O
20th	O
century	O
led	O
to	O
the	O
extinction	O
/	O
extirpation	O
of	O
55/61	O
Society	O
Island	O
Partulidae	O
species	O
.	O

In	O
this	O
study	O
,	O
we	O
phylogenomically	O
investigated	O
the	O
inter-relationships	O
of	O
the	O
three	O
surviving	O
Society	O
Island	O
valley	O
Partula	O
species	O
:	O
P.	O
taeniata	O
(	O
Moorea	O
)	O
,	O
P.	O
clara	O
and	O
P.	O
hyalina	O
(	O
Tahiti	O
)	O
.	O

All	O
three	O
formed	O
a	O
distinct	O
clade	O
in	O
earlier	O
mitochondrial	O
phylogenies	O
.	O

Using	O
Next	O
Generation	O
Sequencing	O
(	O
NGS	O
)	O
double	O
digested	O
Restriction	O
Associated	O
DNA	O
sequencing	O
(	O
ddRADseq	O
)	O
,	O
we	O
found	O
that	O
46-year-old	O
lyophilized	B-P
museum	O
specimens	O
produced	O
similar	O
numbers	O
of	O
reads	O
,	O
sequencing	O
depth	O
,	O
and	O
loci	O
as	O
10-year	O
old	O
ethanol	O
-preserved	O
collections	O
.	O

Phylogenomic	O
trees	O
indicated	O
that	O
Tahitian	O
P.	O
clara	O
and	O
P.	O
hyalina	O
are	O
the	O
result	O
of	O
a	O
single	O
founding	O
lineage	O
from	O
Moorea	O
,	O
contrasting	O
previous	O
mitochondrial	O
results	O
and	O
clarifying	O
the	O
enigmatic	O
taxonomic	O
status	O
of	O
P.	O
c.	O
incrassa	O
.	O

Our	O
study	O
highlights	O
the	O
utility	O
and	O
viability	O
of	O
NGS	O
techniques	O
for	O
museum	O
specimens	O
and	O
their	O
increased	O
resolution	O
of	O
evolutionary	O
patterns	O
.	O

Sampling	O
will	O
be	O
expanded	O
to	O
include	O
the	O
remaining	O
Society	O
Island	O
partulid	O
taxa	O
to	O
further	O
explore	O
the	O
evolutionary	O
history	O
of	O
this	O
radiation	O
.	O

The	O
four-component	O
aureocin	O
A70	O
as	O
a	O
promising	O
agent	O
for	O
food	O
biopreservation	O
.	O

Aureocin	O
A70	O
is	O
the	O
only	O
four-component	O
bacteriocin	O
described	O
to	O
date	O
.	O

As	O
it	O
inhibits	O
the	O
growth	O
of	O
a	O
wide	O
range	O
of	O
Gram-positive	O
bacteria	O
,	O
including	O
Listeria	O
monocytogenes	O
strains	O
isolated	O
from	O
food	O
,	O
its	O
potential	O
for	O
improving	O
food	O
safety	O
was	O
investigated	O
in	O
this	O
study	O
.	O

Aureocin	O
A70	O
(	O
10,240AU/mL	O
)	O
proved	O
to	O
be	O
bactericidal	O
,	O
but	O
not	O
extensively	O
lytic	O
,	O
against	O
listerial	O
strains	O
.	O

The	O
antibacterial	O
activity	O
of	O
aureocin	O
A70	O
(	O
16AU/mL	O
)	O
was	O
then	O
tested	O
in	O
UHT-treated	O
skimmed	O
milk	O
inoculated	B-P
with	O
the	O
food	O
-associated	O
L.	O
monocytogenes	O
L12	O
strain	O
(	O
4-log	O
CFU/mL	O
)	O
during	O
storage	O
at	O
4°C	O
for	O
one	O
week	O
.	O

Aureocin	O
A70	O
caused	O
a	O
time-dependent	O
reduction	O
in	O
the	O
listerial	O
viable	B-P
cell	I-P
counts	I-P
(	O
5.51-log	O
units	O
)	O
up	O
to	O
7days	O
of	O
incubation	B-P
.	O

Aureocin	O
A70	O
was	O
neither	O
toxic	O
to	O
the	O
Vero	O
and	O
the	O
L-929	O
cell	O
lines	O
nor	O
exhibited	O
a	O
hemolytic	O
activity	O
against	O
sheep	O
red	O
blood	O
cells	O
.	O

Aureocin	O
A70	O
proved	O
to	O
be	O
completely	O
stable	O
for	O
one	O
month	O
at	O
25°C	O
,	O
16weeks	O
at	O
4°C	O
and	O
20weeks	O
at	O
-20°C	O
.	O

Aureocin	O
A70	O
exhibited	O
a	O
time-dependent	O
susceptibility	O
to	O
simulated	O
gastric	O
juice	O
and	O
bile	O
salts	O
mimicking	O
gastrointestinal	O
conditions	O
.	O

The	O
entrapment	O
of	O
aureocin	O
A70	O
in	O
an	O
alginate	O
/	O
gelatin	O
matrix	O
revealed	O
that	O
this	O
bacteriocin	O
can	O
be	O
released	O
from	O
this	O
matrix	O
.	O

Moreover	O
,	O
it	O
remained	O
adsorbed	O
to	O
and	O
active	O
on	O
a	O
low-density	O
polyethylene	O
plastic	O
surface	O
suggesting	O
that	O
aureocin	O
A70	O
may	O
be	O
employed	O
in	O
bioactive	O
packaging	O
to	O
control	O
the	O
growth	O
of	O
undesirable	O
bacteria	O
.	O

Taken	O
together	O
these	O
results	O
suggest	O
that	O
aureocin	O
A70	O
is	O
a	O
promising	O
alternative	O
to	O
be	O
used	O
in	O
food	O
applications	O
.	O

Intracellular	O
Metabolism	O
of	O
α	O
,	O
β-Unsaturated	O
Carbonyl	O
Compounds	O
,	O
Acrolein	O
,	O
Crotonaldehyde	O
and	O
Methyl	O
Vinyl	O
Ketone	O
,	O
Active	O
Toxicants	O
in	O
Cigarette	O
Smoke	O
:	O
Participation	O
of	O
Glutathione	O
Conjugation	O
Ability	O
and	O
Aldehyde-Ketone	O
Sensitive	O
Reductase	O
Activity	O
.	O

The	O
major	O
toxicants	O
in	O
cigarette	O
smoke	O
,	O
α	O
,	O
β-unsaturated	O
aldehydes	O
,	O
such	O
as	O
acrolein	O
(	O
ACR	O
)	O
and	O
crotonaldehyde	O
(	O
CA	O
)	O
,	O
and	O
α	O
,	O
β-unsaturated	O
ketone	O
,	O
methyl	O
vinyl	O
ketone	O
(	O
MVK	O
)	O
,	O
are	O
known	O
to	O
form	O
Michael-type	O
adducts	O
with	O
glutathione	O
(	O
GSH	O
)	O
and	O
consequently	O
cause	O
intracellular	O
GSH	O
depletion	O
,	O
which	O
is	O
involved	O
in	O
cigarette	O
smoke	O
-	O
induced	O
cytotoxicity	O
.	O

We	O
have	O
previously	O
clarified	O
that	O
exposure	O
to	O
cigarette	O
smoke	O
extract	O
(	O
CSE	O
)	O
of	O
a	O
mouse	O
melanoma	O
cell	O
culture	O
medium	O
causes	O
rapid	O
reduction	O
of	O
intracellular	O
GSH	O
levels	O
,	O
and	O
that	O
the	O
GSH	O
-	O
MVK	O
adduct	O
can	O
be	O
detected	O
by	O
LC/MS	B-P
analysis	I-P
while	O
the	O
GSH	O
-	O
CA	O
adduct	O
is	O
hardly	O
detected	O
.	O

In	O
the	O
present	O
study	O
,	O
to	O
clarify	O
why	O
the	O
GSH	O
-	O
CA	O
adduct	O
is	O
difficult	O
to	O
detect	O
in	O
the	O
cell	O
medium	O
,	O
we	O
conducted	O
detailed	O
investigation	O
of	O
the	O
structures	O
of	O
the	O
reaction	O
products	O
of	O
ACR	O
,	O
CA	O
,	O
MVK	O
and	O
CSE	O
in	O
the	O
GSH	O
solution	O
or	O
the	O
cell	O
culture	O
medium	O
.	O

The	O
mass	B-P
spectra	I-P
indicated	O
that	O
in	O
the	O
presence	O
of	O
the	O
cells	O
,	O
the	O
GSH	O
-	O
CA	O
and	O
GSH	O
-	O
ACR	O
adducts	O
were	O
almost	O
not	O
detected	O
while	O
their	O
corresponding	O
alcohols	O
were	O
detected	O
.	O

On	O
the	O
other	O
hand	O
,	O
both	O
the	O
GSH	O
-	O
MVK	O
adducts	O
and	O
their	O
reduced	O
products	O
were	O
detected	O
.	O

In	O
the	O
absence	O
of	O
the	O
cells	O
,	O
the	O
reaction	O
of	O
GSH	O
with	O
all	O
α	O
,	O
β-unsaturated	O
carbonyls	O
produced	O
only	O
their	O
corresponding	O
adducts	O
.	O

These	O
results	O
show	O
that	O
the	O
GSH	O
adducts	O
of	O
α	O
,	O
β-unsaturated	O
aldehydes	O
,	O
CA	O
and	O
ACR	O
,	O
are	O
quickly	O
reduced	O
by	O
certain	O
intracellular	O
carbonyl	O
reductase	O
(	O
s	O
)	O
and	O
excreted	O
from	O
the	O
cells	O
,	O
unlike	O
the	O
GSH	O
adduct	O
of	O
α	O
,	O
β-unsaturated	O
ketone	O
,	O
MVK	O
.	O

Such	O
a	O
difference	O
in	O
reactivity	O
to	O
the	O
carbonyl	O
reductase	O
might	O
be	O
related	O
to	O
differences	O
in	O
the	O
cytotoxicity	O
of	O
α	O
,	O
β-unsaturated	O
aldehydes	O
and	O
ketones	O
.	O

Identification	O
of	O
a	O
novel	O
PSEN1	O
mutation	O
(	O
Leu232Pro	O
)	O
in	O
a	O
Korean	O
patient	O
with	O
early-onset	O
Alzheimer	O
's	O
disease	O
and	O
a	O
family	O
history	O
of	O
dementia	O
.	O

In	O
the	O
present	O
study	O
,	O
a	O
novel	O
mutation	O
in	O
exon	O
7	O
of	O
presenilin	O
1	O
(	O
Leu232Pro	O
)	O
was	O
discovered	O
in	O
a	O
Korean	O
patient	O
with	O
early-onset	O
Alzheimer	O
's	O
disease	O
,	O
who	O
represented	O
memory	O
decline	O
at	O
37	O
years	O
of	O
age	O
,	O
followed	O
by	O
impairment	O
in	O
spatial	O
activity	O
and	O
concentrations	O
and	O
personality	O
changes	O
.	O

Imaging	B-P
analyses	I-P
with	O
magnetic	B-P
resonance	I-P
scan	I-P
showed	O
diffuse	O
atrophy	O
in	O
the	O
frontoparietal	O
regions	O
.	O

Targeted	O
next	O
generation	O
sequencing	O
and	O
Sanger	O
sequencing	O
identified	O
a	O
heterozygous	O
T	O
to	O
C	O
transition	O
at	O
position	O
695	O
(	O
c.695T	O
>	O
C	O
)	O
of	O
in	O
presenilin	O
1	O
gene	O
(	O
PSEN1	O
)	O
,	O
resulting	O
in	O
a	O
novel	O
missense	O
mutation	O
at	O
codon	O
232	O
from	O
leucine	O
to	O
proline	O
(	O
L232P	O
)	O
.	O

Several	O
family	O
members	O
of	O
the	O
patient	O
developed	O
dementia	O
,	O
suggesting	O
an	O
autosomal	O
dominant	O
inheritance	O
;	O
however	O
,	O
we	O
were	O
unable	O
to	O
perform	O
a	O
segregation	O
analysis	O
to	O
confirm	O
this	O
.	O

Since	O
the	O
proline	O
may	O
play	O
a	O
role	O
as	O
a	O
helix	O
breaker	O
,	O
this	O
mutation	O
could	O
significantly	O
disturb	O
the	O
transmembrane	O
helix	O
domain-V	O
of	O
PSEN1	O
and	O
perturb	O
its	O
protein	O
functions	O
.	O

This	O
hypothesis	O
was	O
supported	O
by	O
the	O
results	O
from	O
the	O
in	O
silico	O
analyses	O
,	O
predicted	O
a	O
major	O
kink	O
on	O
this	O
helix	O
.	O

Several	O
leucine	O
>	O
proline	O
substitutions	O
in	O
other	O
PSEN1	O
transmembrane	O
helices	O
revealed	O
aggressive	O
AD	O
phenotypes	O
.	O

Future	O
functional	O
studies	O
would	O
be	O
needed	O
to	O
evaluate	O
the	O
pathogenicity	O
of	O
this	O
mutation	O
in	O
AD	O
.	O

Making	O
extra	O
teeth	O
:	O
Lessons	O
from	O
a	O
TRPS1	O
mutation	O
.	O

A	O
Thai	O
mother	O
and	O
her	O
two	O
daughters	O
were	O
affected	O
with	O
tricho-rhino-phalangeal	O
syndrome	O
type	O
I	O
.	O

The	O
daughters	O
had	O
15	O
and	O
18	O
supernumerary	O
teeth	O
,	O
respectively	O
.	O

The	O
mother	O
had	O
normal	O
dentition	O
.	O

Mutation	B-P
analysis	I-P
of	O
TRPS1	O
showed	O
a	O
novel	O
heterozygous	O
c.3809_3811del	O
ACTinsCATGTTGTG	O
mutation	O
in	O
all	O
.	O

This	O
mutation	O
is	O
predicted	O
to	O
cause	O
amino	O
acid	O
changes	O
in	O
the	O
Ikaros-like	O
zinc	O
finger	O
domain	O
near	O
the	O
C-terminal	O
end	O
of	O
TRPS1	O
,	O
which	O
is	O
important	O
for	O
repressive	O
protein	O
function	O
.	O

The	O
results	O
of	O
our	O
study	O
and	O
the	O
comprehensive	O
review	O
of	O
the	O
literature	O
show	O
that	O
pathways	O
of	O
forming	O
supernumerary	O
teeth	O
appear	O
to	O
involve	O
APC	O
and	O
RUNX2	O
,	O
the	O
genes	O
responsible	O
for	O
familial	O
adenomatous	O
polyposis	O
syndrome	O
and	O
cleidocranial	O
dysplasia	O
,	O
respectively	O
.	O

The	O
final	O
pathway	O
resulting	O
in	O
supernumerary	O
teeth	O
seems	O
to	O
involve	O
Wnt	O
,	O
a	O
morphogen	O
active	O
during	O
many	O
stages	O
of	O
development	O
.	O

©	O
2016	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

Outcomes	O
of	O
Subaortic	O
Obstruction	O
Resection	O
in	O
Children	O
.	O

Studies	O
of	O
long-term	O
outcomes	O
of	O
discrete	O
subaortic	O
stenosis	O
are	O
rare	O
.	O

Therefore	O
,	O
we	O
reviewed	O
the	O
long-term	O
outcomes	O
of	O
fibromuscular	O
resection	O
in	O
children	O
with	O
subaortic	O
stenosis	O
over	O
26	O
years	O
from	O
a	O
single	O
institution	O
.	O

We	O
conducted	O
a	O
retrospective	O
review	O
of	O
all	O
children	O
(	O
n=72	O
)	O
who	O
underwent	O
resection	O
of	O
subaortic	O
obstruction	O
for	O
discrete	O
subaortic	O
stenosis	O
between	O
1989	O
and	O
2015	O
.	O

Median	O
age	O
at	O
surgery	O
was	O
5.0	O
years	O
(	O
2.7-7.6	O
years	O
)	O
.	O

There	O
were	O
no	O
operative	O
deaths	O
but	O
three	O
late	O
deaths	O
(	O
4.2	O
%	O
,	O
3/72	O
)	O
.	O

Overall	O
Kaplan-Meier	O
survival	O
at	O
10	O
years	O
was	O
93.0	O
±	O
3.9	O
%	O
(	O
95	O
%	O
CI	O
:	O
79.6	O
,	O
97.7	O
)	O
.	O

Peak	O
instantaneous	O
left	O
ventricular	O
outflow	O
tract	O
Doppler	B-P
gradient	O
decreased	O
from	O
74.2±36.7mmHg	O
(	O
16.0-242.0mmHg	O
)	O
preoperatively	O
to	O
12.8±7.4mmHg	O
(	O
2.6-36.0mmHg	O
)	O
postoperatively	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Mean	O
left	O
ventricular	O
outflow	O
tract	O
Doppler	B-P
gradient	O
decreased	O
from	O
42.4±17.2mmHg	O
(	O
12.0-98.0	O
)	O
preoperatively	O
to	O
7.5±2.7mmHg	O
(	O
1.4-19.3mmHg	O
)	O
postoperatively	O
(	O
p	O
<	O
0.001	O
)	O
.	O

However	O
,	O
over	O
the	O
mean	O
follow-up	O
period	O
of	O
7.8±6.1	O
years	O
(	O
0.1-25.2	O
years	O
)	O
,	O
29.0	O
%	O
(	O
20/69	O
)	O
of	O
patients	O
had	O
recurrence	O
and	O
18.8	O
%	O
(	O
13/69	O
)	O
required	O
reoperation	O
at	O
median	O
time	O
of	O
4.8	O
years	O
(	O
3.1-9.1	O
years	O
)	O
after	O
the	O
initial	O
repair	O
.	O

Freedom	O
from	O
reoperation	O
at	O
10	O
years	O
was	O
71.1±7.1	O
%	O
(	O
95	O
%	O
CI	O
:	O
54.6	O
,	O
82.3	O
)	O
.	O

Risk	O
factors	O
for	O
reoperation	O
were	O
age	O
less	O
than	O
five	O
years	O
at	O
initial	O
repair	O
(	O
p=0.036	O
)	O
and	O
extension	O
of	O
the	O
membrane	O
to	O
the	O
aortic	O
valve	O
(	O
p=0.001	O
)	O
.	O

Aortic	O
insufficiency	O
was	O
present	O
in	O
54.2	O
%	O
(	O
39/72	O
)	O
of	O
patients	O
preoperatively	O
.	O

Progression	O
of	O
aortic	O
insufficiency	O
occurred	O
in	O
38.9	O
%	O
(	O
28/72	O
)	O
.	O

Involvement	O
of	O
the	O
aortic	O
valve	O
at	O
initial	O
repair	O
was	O
associated	O
with	O
need	O
for	O
subsequent	O
aortic	O
valve	O
repair	O
or	O
replacement	O
(	O
p=0.01	O
)	O
.	O

Resection	O
of	O
subaortic	O
obstruction	O
is	O
associated	O
with	O
low	O
mortality	O
and	O
morbidity	O
.	O

Recurrence	O
and	O
reoperation	O
rates	O
are	O
high	O
and	O
progression	O
of	O
aortic	O
insufficiency	O
following	O
subaortic	O
resection	O
is	O
common	O
.	O

Therefore	O
,	O
these	O
patients	O
warrant	O
close	O
follow-up	O
into	O
adult	O
life	O
.	O

Evidence	O
of	O
toothpick	O
groove	O
formation	O
in	O
Neandertal	O
anterior	O
and	O
posterior	O
teeth	O
.	O

During	O
the	O
microscopic	B-P
examination	I-P
of	O
the	O
Neandertal	O
dentitions	O
from	O
El	O
Sidrón	O
(	O
Spain	O
)	O
and	O
Hortus	O
(	O
France	O
)	O
,	O
we	O
found	O
unusual	O
fine	O
parallel	O
microstriations	O
on	O
the	O
mesial	O
and	O
distal	O
sides	O
of	O
all	O
tooth	O
types	O
,	O
near	O
the	O
cervix	O
.	O

As	O
its	O
appearance	O
was	O
similar	O
to	O
toothpick	O
grooves	O
described	O
in	O
other	O
Homo	O
species	O
,	O
it	O
could	O
correspond	O
to	O
early	O
stages	O
on	O
its	O
formation	O
.	O

To	O
test	O
this	O
hypothesis	O
we	O
developed	O
an	O
experimental	O
replication	O
of	O
a	O
groove	O
using	O
grass	O
stalks	O
.	O

Comparisons	O
between	O
204	O
isolated	O
Neandertal	O
teeth	O
and	O
the	O
two	O
experimental	O
dental	O
specimens	O
corroborate	O
that	O
the	O
marks	O
correspond	O
to	O
initial	O
stages	O
of	O
toothpick	O
groove	O
formation	O
,	O
and	O
we	O
propose	O
a	O
five-grade	O
recording	O
scale	O
that	O
summarized	O
the	O
groove	O
formation	O
process	O
.	O

Using	O
this	O
new	O
recording	O
procedure	O
,	O
we	O
found	O
that	O
Hortus	O
individuals	O
have	O
higher	O
incidence	O
of	O
this	O
trait	O
(	O
eight	O
individuals	O
out	O
of	O
nine	O
)	O
than	O
the	O
El	O
Sidrón	O
individuals	O
(	O
nine	O
out	O
of	O
11	O
)	O
.	O

Toothpick	O
grooves	O
from	O
El	O
Sidrón	O
show	O
the	O
earliest	O
stages	O
of	O
development	O
,	O
whereas	O
the	O
grooves	O
found	O
on	O
Hortus	O
Neandertals	O
were	O
well-developed	O
.	O

Toothpick	O
grooves	O
were	O
also	O
found	O
in	O
21	O
incisors	O
and	O
canines	O
.	O

These	O
differences	O
could	O
be	O
due	O
to	O
the	O
more	O
advanced	O
occlusal	O
dental	O
wear	O
in	O
Hortus	O
individuals	O
,	O
maybe	O
age	O
-related	O
and	O
with	O
a	O
more	O
meat	O
-based	O
diet	O
maybe	O
favoring	O
the	O
inclusion	O
of	O
food	O
debris	O
and	O
thus	O
probing	O
as	O
the	O
cleaning	O
methodology	O
.	O

Our	O
results	O
allow	O
the	O
identification	O
and	O
characterization	O
of	O
incipient	O
toothpick	O
grooves	O
on	O
the	O
human	O
fossil	O
record	O
and	O
contribute	O
to	O
increase	O
our	O
knowledge	O
on	O
Neandertals	O
behavioral	O
and	O
oral	O
care	O
habits	O
.	O

Update	O
on	O
the	O
Role	O
of	O
Cardiac	B-P
Magnetic	I-P
Resonance	I-P
in	O
Acquired	O
Nonischemic	O
Cardiomyopathies	O
.	O

Cardiomyopathies	O
refer	O
to	O
a	O
variety	O
of	O
myocardial	O
disorders	O
without	O
underlying	O
coronary	O
artery	O
disease	O
,	O
valvular	O
heart	O
disease	O
,	O
hypertension	O
,	O
or	O
congenital	O
heart	O
disease	O
.	O

Several	O
imaging	O
modalities	O
are	O
available	O
,	O
but	O
cardiac	B-P
magnetic	I-P
resonance	I-P
(	O
CMR	B-P
)	O
has	O
now	O
established	O
itself	O
as	O
a	O
crucial	O
imaging	B-P
technique	I-P
in	O
the	O
evaluation	O
of	O
several	O
cardiomyopathies	O
.	O

It	O
not	O
only	O
provides	O
comprehensive	O
information	O
on	O
structure	O
and	O
function	O
,	O
but	O
also	O
can	O
perform	O
tissue	O
characterization	O
,	O
which	O
helps	O
in	O
establishing	O
the	O
etiology	O
of	O
cardiomyopathy	O
.	O

CMR	B-P
is	O
also	O
useful	O
in	O
establishing	O
the	O
diagnosis	O
,	O
providing	O
guidance	O
for	O
endomyocardial	B-P
biopsy	I-P
,	O
accurate	O
quantification	O
of	O
function	O
,	O
volumes	O
,	O
and	O
fibrosis	O
,	O
prognostic	O
determination	O
,	O
risk	O
stratification	O
,	O
and	O
monitoring	O
response	O
to	O
therapy	O
.	O

In	O
this	O
article	O
,	O
we	O
review	O
the	O
current	O
role	O
of	O
CMR	B-P
in	O
the	O
evaluation	O
of	O
several	O
acquired	O
nonischemic	O
cardiomyopathies	O
,	O
particularly	O
focusing	O
on	O
recent	O
advances	O
in	O
knowledge	O
.	O

We	O
also	O
discuss	O
in	O
detail	O
a	O
select	O
group	O
of	O
common	O
acquired	O
nonischemic	O
cardiomyopathies	O
.	O

Co-infection	O
of	O
Acipenserid	O
herpesvirus	O
2	O
(	O
AciHV-2	O
)	O
and	O
Streptococcus	O
iniae	O
in	O
cultured	B-P
white	O
sturgeon	O
Acipenser	O
transmontanus	O
.	O

A	O
mortality	O
event	O
in	O
cultured	B-P
white	O
sturgeon	O
Acipenser	O
transmontanus	O
(	O
Richardson	O
,	O
1836	O
)	O
sub-adults	O
was	O
investigated	O
.	O

After	O
transfer	O
between	O
farms	O
,	O
high	O
mortality	O
was	O
observed	O
in	O
fish	O
,	O
associated	O
with	O
back	O
arching	O
,	O
abnormal	O
swimming	O
,	O
and	O
ulcerative	O
skin	O
lesions	O
.	O

Necropsy	B-P
of	O
moribund	O
individuals	O
revealed	O
hemorrhagic	O
ascites	O
and	O
petechial	O
hemorrhages	O
in	O
the	O
coelomic	O
peritoneum	O
and	O
serosa	O
of	O
internal	O
organs	O
.	O

Acipenserid	O
herpesvirus	O
2	O
(	O
AciHV-2	O
)	O
was	O
isolated	O
from	O
external	O
tissue	O
samples	O
,	O
then	O
identified	O
and	O
genotyped	O
by	O
sequencing	O
of	O
the	O
terminase	O
and	O
polymerase	O
genes	O
.	O

In	O
addition	O
,	O
Streptococcus	O
iniae	O
was	O
recovered	O
from	O
internal	O
organs	O
of	O
affected	O
fish	O
.	O

Histologic	O
changes	O
were	O
limited	O
to	O
interstitial	O
hematopoietic	O
areas	O
of	O
the	O
kidney	O
and	O
consisted	O
of	O
small	O
foci	O
of	O
necrosis	O
accompanied	O
by	O
fibrin	O
deposition	O
,	O
minimal	O
inflammatory	O
response	O
,	O
and	O
small	O
numbers	O
of	O
bacterial	O
cocci	O
compatible	O
with	O
streptococci	O
.	O

Identity	O
was	O
confirmed	O
by	O
partial	O
sequencing	B-P
of	O
the	O
16S	O
rRNA	O
,	O
rpoB	O
,	O
and	O
gyrB	O
genes	O
.	O

Genetic	O
fingerprinting	O
demonstrated	O
a	O
genetic	B-P
profile	I-P
distinct	O
from	O
S.	O
iniae	O
isolates	O
recovered	O
from	O
previous	O
outbreaks	O
in	O
wild	O
and	O
cultured	B-P
fish	O
in	O
North	O
America	O
,	O
South	O
America	O
,	O
and	O
the	O
Caribbean	O
.	O

Although	O
the	O
isolates	O
were	O
resistant	O
to	O
white	O
sturgeon	O
complement	O
in	O
serum	O
killing	B-P
assays	I-P
,	O
in	O
vivo	O
challenges	O
failed	O
to	O
fulfill	O
Koch	O
's	O
postulates	O
.	O

However	O
,	O
the	O
clinical	O
presentation	O
,	O
coupled	O
with	O
consistent	O
recovery	O
of	O
S.	O
iniae	O
and	O
AciHV-2	O
from	O
moribund	O
fish	O
,	O
suggests	O
viral	O
and	O
bacterial	O
co-infection	O
were	O
the	O
proximate	O
cause	O
of	O
death	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
represents	O
the	O
first	O
report	O
of	O
AciHV-2	O
and	O
S.	O
iniae	O
co-infection	O
in	O
cultured	B-P
white	O
sturgeon	O
.	O

Treatment	O
with	O
high	O
dose	O
of	O
atorvastatin	O
reduces	O
vascular	O
injury	O
in	O
diabetic	O
rats	O
.	O

Previous	O
reports	O
showed	O
conflicting	O
results	O
regarding	O
the	O
treatment	O
effects	O
of	O
statin	O
on	O
Diabetes	O
mellitus	O
(	O
DM	O
)	O
.	O

We	O
investigated	O
how	O
treatment	O
with	O
high	O
dose	O
of	O
atorvastatin	O
affects	O
the	O
impaired	O
vascular	O
function	O
in	O
diabetic	O
rats	O
.	O

Atorvastatin	O
(	O
80mg/kg/day	O
,	O
oral	O
gavage	O
,	O
4	O
weeks	O
)	O
or	O
its	O
vehicle	O
was	O
administered	O
to	O
male	O
control	O
or	O
streptozotocin	O
(	O
STZ	O
)	O
-induced	O
diabetic	O
rats	O
.	O

Aortic	O
segments	O
were	O
used	O
to	O
investigate	O
the	O
vascular	O
reactivity	O
,	O
protein	O
expression	O
of	O
cyclooxygenase-2	O
(	O
COX-2	O
)	O
and	O
nicotinamide	O
adenine	O
dinucleotide	O
phosphate	O
oxidase	O
(	O
NADPH	O
oxidase	O
)	O
1	O
(	O
NOX1	O
)	O
and	O
superoxide	O
anions	O
levels	O
.	O

Atorvastatin	O
treatment	O
did	O
not	O
affect	O
glycemia	B-P
levels	I-P
.	O

In	O
diabetic	O
rats	O
,	O
the	O
vascular	O
reactivity	O
to	O
phenylephrine	O
increased	O
compared	O
with	O
controls	O
and	O
the	O
atorvastatin	O
treatment	O
reduced	O
this	O
response	O
.	O

Removal	O
of	O
the	O
endothelium	O
increased	O
the	O
response	O
to	O
phenylephrine	O
in	O
control	O
rats	O
,	O
but	O
not	O
in	O
the	O
diabetic	O
group	O
.	O

Atorvastatin	O
increased	O
the	O
endothelial	O
modulation	O
in	O
diabetic	O
rats	O
.	O

L-NAME	O
(	O
100μM	O
)	O
increased	O
the	O
reactivity	O
in	O
all	O
groups	O
,	O
but	O
this	O
effect	O
was	O
greater	O
in	O
atorvastatin	O
-treated	O
diabetic	O
rats	O
.	O

Indomethacin	O
(	O
10μM	O
)	O
and	O
NS398	O
(	O
1μM	O
)	O
decreased	O
the	O
contractile	O
response	O
in	O
diabetic	O
rats	O
and	O
atorvastatin	O
reversed	O
these	O
effects	O
,	O
without	O
changing	O
COX-2	O
expression	O
.	O

Apocynin	O
(	O
30μM	O
)	O
decreased	O
the	O
phenylephrine	O
response	O
in	O
diabetic	O
rats	O
,	O
which	O
also	O
showed	O
increased	O
NOX1	O
and	O
superoxide	O
anions	O
;	O
these	O
effects	O
were	O
prevented	O
by	O
atorvastatin	O
treatment	O
.	O

The	O
results	O
suggest	O
that	O
treatment	O
with	O
high	O
dose	O
of	O
atorvastatin	O
,	O
independent	O
of	O
glycemia	O
,	O
improves	O
endothelial	O
function	O
in	O
aortas	O
from	O
diabetic	O
rats	O
by	O
reducing	O
the	O
constrictor	O
prostanoids	O
derived	O
from	O
COX-2	O
and	O
by	O
reducing	O
the	O
oxidative	O
stress	O
by	O
NADPH	O
oxidase	O
,	O
as	O
well	O
as	O
a	O
possible	O
increasing	O
of	O
nitric	O
oxide	O
participation	O
.	O

Synthesis	O
and	O
characterization	O
of	O
acetylated	O
amylose	O
and	O
development	O
of	O
inclusion	O
complexes	O
with	O
rifampicin	O
.	O

Amylose	O
(	O
AM	O
)	O
tends	O
to	O
form	O
single	O
helical	O
inclusion	O
complexes	O
with	O
suitable	O
agents	O
.	O

These	O
complexes	O
are	O
considered	O
promising	O
biomaterial	O
carrier	O
since	O
the	O
guest	O
molecules	O
can	O
be	O
released	O
later	O
,	O
leading	O
to	O
many	O
applications	O
,	O
especially	O
in	O
the	O
pharmaceutical	O
industry	O
.	O

Rifampicin	O
(	O
RIF	O
)	O
has	O
long	O
been	O
recognized	O
as	O
an	O
active	O
drug	O
against	O
Mycobacterium	O
tuberculosis	O
,	O
however	O
,	O
the	O
administration	O
of	O
RIF	O
in	O
high	O
dosages	O
can	O
originate	O
unwanted	O
side-effects	O
.	O

Due	O
to	O
the	O
fact	O
that	O
the	O
use	O
of	O
native	O
amylose	O
(	O
AM	O
)	O
in	O
the	O
formation	O
of	O
complexes	O
is	O
limited	O
by	O
their	O
low	O
water	O
solubility	O
,	O
it	O
was	O
acetylated	O
with	O
a	O
medium	O
degree	O
of	O
substitution	O
(	O
DS	O
)	O
,	O
allowing	O
solubilizing	O
(	O
0.5gL	O
(	O
-1	O
)	O
)	O
acetylated	O
amylose	O
(	O
AMA	O
)	O
in	O
water	O
at	O
neutral	O
pH	O
,	O
in	O
opposition	O
to	O
that	O
observed	O
with	O
native	O
amylose	O
(	O
trace	O
solubility	O
)	O
.	O

The	O
resulting	O
acetylated	O
amylose	O
was	O
characterized	O
by	O
means	O
of	O
Fourier	O
Transform	O
Infrared	O
(	O
FT-IR	O
)	O
spectroscopy	O
and	O
Scanning	B-P
Electron	I-P
Microscopy	I-P
(	O
SEM	B-P
)	O
.	O

FT-IR	O
results	O
indicated	O
that	O
the	O
acetylation	O
of	O
anhydroglucose	O
units	O
of	O
amylose	O
corresponds	O
to	O
a	O
low	O
DS	O
,	O
whereas	O
SEM	B-P
results	O
suggested	O
that	O
the	O
smooth	O
surfaces	O
of	O
amylose	O
granules	O
were	O
changed	O
into	O
rougher	O
surfaces	O
after	O
acetylation	O
.	O

Ultraviolet	B-P
absorption	I-P
spectroscopy	I-P
(	O
UV-vis	B-P
)	O
analysis	O
confirmed	O
the	O
formation	O
and	O
allowed	O
the	O
quantification	O
of	O
both	O
native	O
(	O
AM	O
-	O
RIF	O
)	O
and	O
acetylated	O
(	O
AMA	O
-	O
RIF	O
)	O
amylose	O
inclusion	O
complexes	O
.	O

Their	O
characterization	O
in	O
solution	O
was	O
performed	O
by	O
dynamic	B-P
light	I-P
scattering	I-P
(	O
DLS	B-P
)	O
and	O
zeta	O
potential	O
(	O
ZP	O
)	O
measurements	O
.	O

The	O
average	O
size	O
of	O
inclusion	O
complexes	O
as	O
determined	O
by	O
DLS	B-P
,	O
ranged	O
between	O
70	O
and	O
100nm	O
.	O

Besides	O
,	O
ZP	O
analysis	O
showed	O
that	O
both	O
complexes	O
are	O
more	O
stable	O
in	O
the	O
presence	O
of	O
RIF	O
.	O

This	O
study	O
may	O
lead	O
to	O
the	O
development	O
of	O
an	O
effective	O
method	O
for	O
the	O
preparation	O
of	O
amylose	O
inclusion	O
complexes	O
,	O
which	O
is	O
beneficial	O
to	O
their	O
further	O
application	O
in	O
drug	O
delivery	O
systems	O
.	O

Blubber	O
transcriptome	O
response	O
to	O
acute	O
stress	O
axis	O
activation	O
involves	O
transient	O
changes	O
in	O
adipogenesis	O
and	O
lipolysis	O
in	O
a	O
fasting	O
-adapted	O
marine	O
mammal	O
.	O

Stress	O
can	O
compromise	O
an	O
animal	O
's	O
ability	O
to	O
conserve	O
metabolic	O
stores	O
and	O
participate	O
in	O
energy	O
-demanding	O
activities	O
that	O
are	O
critical	O
for	O
fitness	O
.	O

Understanding	O
how	O
wild	O
animals	O
,	O
especially	O
those	O
already	O
experiencing	O
physiological	O
extremes	O
(	O
e.g	O
.	O

fasting	O
)	O
,	O
regulate	O
stress	O
responses	O
is	O
critical	O
for	O
evaluating	O
the	O
impacts	O
of	O
anthropogenic	O
disturbance	O
on	O
physiology	O
and	O
fitness	O
,	O
key	O
challenges	O
for	O
conservation	O
.	O

However	O
,	O
studies	O
of	O
stress	O
in	O
wildlife	O
are	O
often	O
limited	O
to	O
baseline	B-P
endocrine	I-P
measurements	I-P
and	O
few	O
have	O
investigated	O
stress	O
effects	O
in	O
fasting	O
-adapted	O
species	O
.	O

We	O
examined	O
downstream	B-P
molecular	I-P
consequences	I-P
of	O
hypothalamic-pituitary-adrenal	O
(	O
HPA	O
)	O
axis	O
activation	O
by	O
exogenous	O
adrenocorticotropic	O
hormone	O
(	O
ACTH	O
)	O
in	O
blubber	O
of	O
northern	O
elephant	O
seals	O
due	O
to	O
the	O
ease	O
of	O
blubber	O
sampling	O
and	O
its	O
key	O
role	O
in	O
metabolic	O
regulation	O
in	O
marine	O
mammals	O
.	O

We	O
report	O
the	O
first	O
phocid	O
blubber	O
transcriptome	O
produced	O
by	O
RNAseq	O
,	O
containing	O
over	O
140,000	O
annotated	O
transcripts	O
,	O
including	O
metabolic	O
and	O
adipocytokine	O
genes	O
of	O
interest	O
.	O

The	O
acute	O
response	O
of	O
blubber	O
to	O
stress	O
axis	O
activation	O
,	O
measured	O
2	O
hours	O
after	O
ACTH	O
administration	O
,	O
involved	O
highly	O
specific	O
,	O
transient	O
(	O
lasting	O
<	O
24	O
hours	O
)	O
induction	O
of	O
gene	O
networks	O
that	O
promote	O
lipolysis	O
and	O
adipogenesis	O
in	O
mammalian	O
adipocytes	O
.	O

Differentially	O
expressed	O
genes	O
included	O
key	O
adipogenesis	O
factors	O
which	O
can	O
be	O
used	O
as	O
blubber	O
-specific	O
markers	O
of	O
acute	O
stress	O
in	O
marine	O
mammals	O
of	O
concern	O
for	O
which	O
sampling	O
of	O
other	O
tissues	O
is	O
not	O
possible	O
.	O

Catheter	O
traction	O
and	O
gastric	O
outlet	O
obstruction	O
:	O
a	O
repeated	O
complication	O
of	O
using	O
a	O
Foley	O
catheter	O
for	O
gastrostomy	O
tube	O
replacement	O
.	O

Percutaneous	O
endoscopic	O
gastrostomy	O
(	O
PEG	O
)	O
is	O
a	O
safe	O
procedure	O
and	O
major	O
morbidity	O
is	O
unusual	O
.	O

However	O
,	O
the	O
number	O
of	O
PEG	O
fed	O
patients	O
is	O
increasing	O
all	O
over	O
the	O
world	O
and	O
complications	O
may	O
become	O
more	O
and	O
more	O
frequent	O
.	O

We	O
describe	O
a	O
73	O
years	O
old	O
woman	O
with	O
persistent	O
vomit	O
after	O
replacement	O
of	O
the	O
standard	O
PEG	O
tube	O
with	O
a	O
Foley	O
catheter	O
.	O

An	O
upper	B-P
GI	I-P
endoscopy	I-P
showed	O
the	O
catheter	O
pulled	O
into	O
the	O
duodenum	O
causing	O
gastric	O
outlet	O
obstruction	O
.	O

It	O
was	O
removed	O
and	O
replaced	O
by	O
a	O
suitable	O
standard	O
PEG	O
tube	O
,	O
allowing	O
PEG	O
feeding	O
to	O
be	O
resumed	O
.	O

Previous	O
reports	O
pointed	O
the	O
risk	O
of	O
this	O
complication	O
,	O
almost	O
always	O
associated	O
with	O
insertion	O
of	O
a	O
Foley-type	O
catheter	O
.	O

Replacement	O
of	O
PEG	O
tubes	O
should	O
be	O
performed	O
by	O
experienced	O
teams	O
using	O
standard	O
PEG	O
tubes	O
and	O
the	O
use	O
of	O
Foley-type	O
catheters	O
for	O
this	O
purpose	O
should	O
be	O
banned	O
from	O
routine	O
practice	O
.	O

Interferon	O
gamma	O
and	O
interleukin	O
10	O
polymorphisms	O
in	O
Chinese	O
children	O
with	O
hemophagocytic	O
lymphohistiocytosis	O
.	O

The	O
aim	O
of	O
the	O
study	O
is	O
to	O
investigate	O
the	O
association	O
of	O
interferon	O
gamma	O
(	O
IFN-γ	O
)	O
and	O
interleukin-10	O
(	O
IL-10	O
)	O
gene	O
single	O
nucleotide	O
polymorphisms	O
with	O
the	O
susceptibility	O
of	O
hemophagocytic	O
lymphohistiocytosis	O
(	O
HLH	O
)	O
in	O
Chinese	O
children	O
without	O
known	O
family	O
history	O
of	O
HLH	O
.	O

Forty	O
children	O
with	O
HLH	O
and	O
160	O
age	O
-	O
and	O
gender	O
-matched	O
healthy	O
controls	O
from	O
Xuzhou	O
Children	O
's	O
Hospital	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

Serum	O
IFN-γ	O
and	O
IL-10	O
levels	O
were	O
measured	O
by	O
enzyme	B-P
linked-immunosorbent	I-P
assay	I-P
.	O

Polymorphisms	O
of	O
the	O
IFN-γ	O
gene	O
at	O
position	O
+874	O
and	O
+2109	O
,	O
and	O
IL-10	O
at	O
position	O
-1082	O
were	O
analyzed	O
by	O
allele	O
-	O
specific	O
PCR	O
.	O

Median	O
serum	O
concentrations	O
of	O
IFN	O
-γ	O
and	O
IL-10	O
were	O
significantly	O
higher	O
in	O
children	O
with	O
HLH	O
compared	O
to	O
healthy	O
controls	O
.	O

The	O
frequencies	O
of	O
IFN-γ	O
+874	O
T/A	O
and	O
T/T	O
genotypes	O
,	O
as	O
well	O
as	O
T	O
allele	O
,	O
were	O
significantly	O
higher	O
in	O
the	O
HLH	O
group	O
compared	O
with	O
those	O
in	O
the	O
control	O
group	O
.	O

The	O
frequencies	O
of	O
IL-10	O
-1082	O
G/A	O
genotype	O
and	O
G	O
allele	O
were	O
significantly	O
increased	O
in	O
HLH	O
patients	O
compared	O
with	O
healthy	O
controls	O
.	O

No	O
significant	O
difference	O
was	O
found	O
in	O
the	O
distribution	O
of	O
IFN-γ	O
+2109	O
G/A	O
genotypes	O
between	O
children	O
with	O
HLH	O
and	O
controls	O
.	O

This	O
study	O
presents	O
preliminary	O
evidence	O
for	O
the	O
association	O
between	O
IFN	O
+874	O
T/A	O
,	O
T/T	O
,	O
IL-10	O
-1082	O
A/G	O
genotypes	O
,	O
and	O
HLH	O
susceptibility	O
in	O
Chinese	O
children	O
with	O
HLH	O
.	O

Triterpenoids	O
from	O
the	O
stems	O
of	O
Tripterygium	O
regelii	O
.	O

Three	O
new	O
triterpenoids	O
,	O
triregelolides	O
A	O
,	O
B	O
(	O
1	O
,	O
2	O
)	O
,	O
and	O
triregeloic	O
acid	O
(	O
3	O
)	O
,	O
were	O
isolated	O
from	O
the	O
stems	O
of	O
Tripterygium	O
regelii	O
along	O
with	O
twenty	O
known	O
triterpene	O
analogues	O
(	O
4-23	O
)	O
.	O

The	O
structures	O
of	O
three	O
new	O
compounds	O
were	O
identified	O
by	O
analyzing	O
their	O
NMR	B-P
spectroscopic	I-P
and	O
HRESIMS	B-P
data	O
.	O

Compounds	O
4	O
,	O
7	O
,	O
8	O
,	O
10	O
,	O
13	O
,	O
14	O
,	O
17	O
,	O
21-23	O
were	O
isolated	O
from	O
T.	O
regelii	O
for	O
the	O
first	O
time	O
.	O

Compounds	O
3	O
,	O
5	O
,	O
6	O
,	O
8	O
,	O
9	O
,	O
10	O
,	O
14	O
and	O
16	O
showed	O
inhibitory	O
effects	O
on	O
the	O
proliferation	O
of	O
human	O
breast	O
cancer	O
cells	O
MCF-7	O
by	O
24.1	O
%	O
,	O
69.6	O
%	O
,	O
72.8	O
%	O
,	O
21.6	O
%	O
,	O
23.1	O
%	O
,	O
43.3	O
%	O
,	O
25.5	O
%	O
and	O
23.5	O
%	O
(	O
p	O
<	O
0.05	O
)	O
at	O
a	O
concentration	O
of	O
10μM	O
,	O
respectively	O
.	O

Increased	O
childhood	O
body	O
mass	O
index	O
is	O
associated	O
with	O
young	O
adult	O
serum	B-P
uric	I-P
acid	I-P
levels	I-P
:	O
a	O
linkage	O
study	O
from	O
Japan	O
.	O

Growth	O
pattern	O
in	O
early	O
life	O
is	O
one	O
of	O
the	O
most	O
important	O
factors	O
affecting	O
the	O
pathogenesis	O
of	O
metabolic-associated	O
diseases	O
.	O

The	O
associations	O
between	O
serum	O
uric	O
acid	O
(	O
SUA	O
)	O
and	O
hypertension	O
,	O
kidney	O
disease	O
,	O
and	O
coronary	O
heart	O
disease	O
have	O
been	O
recognized	O
.	O

We	O
investigated	O
the	O
association	O
between	O
increased	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
during	O
childhood	O
and	O
adult	O
SUA	B-P
levels	I-P
in	O
Japan	O
.MethodsWe	O
included	O
298	O
children	O
with	O
health	O
examination	O
data	O
between	O
1981	O
and	O
2002	O
who	O
had	O
also	O
undergone	O
physical	O
examinations	O
after	O
reaching	O
early	O
adulthood	O
(	O
approximately	O
27	O
years	O
old	O
)	O
.	O

Subjects	O
were	O
divided	O
into	O
sex-specific	O
tertiles	O
based	O
on	O
the	O
difference	O
in	O
their	O
BMI	O
(	O
DBMI	O
)	O
over	O
a	O
6-	O
year	O
period	O
(	O
6-12	O
years	O
of	O
age	O
)	O
.	O

The	O
association	O
between	O
the	O
three	O
DBMI	O
groups	O
and	O
SUA	O
in	O
adults	O
was	O
analyzed	O
.	O

The	O
predicted	O
average	O
SUA	B-P
level	I-P
in	O
adults	O
from	O
the	O
high	O
DBMI	O
group	O
was	O
5.32	O
mg/dl	O
after	O
adjustment	O
for	O
related	O
factors	O
in	O
a	O
combined	O
sex	O
analysis	O
.	O

This	O
was	O
significantly	O
higher	O
than	O
among	O
the	O
low	O
DBMI	O
group	O
.	O

Excessive	O
BMI	O
increases	O
during	O
childhood	O
led	O
to	O
young	O
adult	O
SUA	O
elevation	O
even	O
after	O
adjusting	O
for	O
several	O
factors	O
.	O

Lifestyle	O
in	O
early	O
life	O
may	O
be	O
a	O
strong	O
predictor	O
of	O
future	O
uric	O
acid	O
metabolism	O
and	O
the	O
resulting	O
disease	O
risk	O
.	O

Synthesis	O
,	O
characterization	O
and	O
drug	O
loading	O
property	O
of	O
Monomethoxy-Poly	O
(	O
ethylene	O
glycol	O
)	O
-Poly	O
(	O
ε-caprolactone	O
)	O
-Poly	O
(	O
D	O
,	O
L-lactide	O
)	O
(	O
MPEG-PCLA	O
)	O
copolymers	O
.	O

Amphiphilic	O
block	O
copolymers	O
have	O
attracted	O
a	O
great	O
deal	O
of	O
attention	O
in	O
drug	O
delivery	O
systems	O
.	O

In	O
this	O
work	O
,	O
a	O
series	O
of	O
monomethoxy-poly	O
(	O
ethylene	O
glycol	O
)	O
-poly	O
(	O
ε-caprolactone-co-D	O
,	O
L-lactide	O
)	O
(	O
MPEG-PCLA	O
)	O
copolymers	O
with	O
variable	O
composition	O
of	O
poly	O
(	O
ε-caprolactone	O
)	O
(	O
PCL	O
)	O
and	O
poly	O
(	O
D	O
,	O
L-lactide	O
)	O
(	O
PDLLA	O
)	O
were	O
prepared	O
via	O
ring-opening	O
copolymerization	O
of	O
ε-CL	O
and	O
D	O
,	O
L-LA	O
in	O
the	O
presence	O
of	O
MPEG	O
and	O
stannous	O
octoate	O
.	O

The	O
structure	O
and	O
molecular	O
weight	O
were	O
characterized	O
by	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
and	O
gel	B-P
permeation	I-P
chromatography	I-P
(	O
GPC	B-P
)	O
.	O

The	O
crystallinity	O
,	O
hydrophilicity	O
,	O
thermal	O
stability	O
and	O
hydrolytic	O
degradation	O
behavior	O
were	O
investigated	O
in	O
detail	O
,	O
respectively	O
.	O

The	O
results	O
showed	O
that	O
the	O
prepared	O
amphiphilic	O
MPEG-PCLA	O
copolymers	O
have	O
adjustable	O
properties	O
by	O
altering	O
the	O
composition	O
of	O
PCLA	O
,	O
which	O
make	O
it	O
convenient	O
for	O
clinical	O
applications	O
.	O

Besides	O
,	O
the	O
drug	O
loading	O
properties	O
were	O
also	O
studied	O
.	O

Docetaxel	O
(	O
DTX	O
)	O
could	O
be	O
entrapped	O
in	O
MPEG-PCLA	O
micelles	O
with	O
high	O
loading	O
capacity	O
and	O
encapsulation	O
efficiency	O
.	O

And	O
all	O
lyophilized	O
DTX	O
-loaded	O
MPEG-PCLA	O
micelles	O
except	O
MPEG-PCL	O
micelles	O
were	O
readily	O
re-dissolved	O
in	O
normal	O
saline	O
at	O
25	O
°C	O
.	O

In	O
addition	O
,	O
DTX	O
-loaded	O
MPEG-PCLA	O
micelles	O
showed	O
a	O
slightly	O
enhanced	O
antitumor	O
activity	O
compared	O
with	O
free	O
DTX	O
.	O

Furthermore	O
,	O
DTX	O
micelles	O
exhibited	O
a	O
slower	O
and	O
sustained	O
release	O
behavior	O
in	O
vitro	O
,	O
and	O
higher	O
DTX	O
concentration	O
and	O
longer	O
retention	O
time	O
in	O
vivo	O
.	O

The	O
results	O
suggested	O
that	O
the	O
MPEG-PCLA	O
copolymer	O
with	O
the	O
adjustable	O
ratio	O
of	O
PCL	O
to	O
PDLLA	O
may	O
be	O
a	O
promising	O
drug	O
delivery	O
carrier	O
for	O
DTX	O
.	O

Outcomes	O
With	O
Cerclage	O
Alone	O
Compared	O
With	O
Cerclage	O
Plus	O
17α-Hydroxyprogesterone	O
Caproate	O
.	O

To	O
examine	O
the	O
differences	O
in	O
perinatal	O
outcomes	O
among	O
women	O
with	O
a	O
prior	O
preterm	O
birth	O
who	O
received	O
cerclage	O
compared	O
with	O
cerclage	O
plus	O
17α-hydroxyprogesterone	O
caproate	O
.	O

Women	O
with	O
transvaginal	O
cerclage	O
placement	O
and	O
a	O
prior	O
delivery	O
between	O
16	O
and	O
36	O
weeks	O
of	O
gestation	O
were	O
identified	O
over	O
a	O
10-	O
year	O
period	O
(	O
July	O
2002	O
to	O
May	O
2012	O
)	O
in	O
this	O
retrospective	O
cohort	O
study	O
.	O

Exclusion	O
criteria	O
were	O
delivery	O
at	O
another	O
institution	O
,	O
abdominal	O
cerclage	O
,	O
multiple	O
gestations	O
,	O
and	O
major	O
fetal	O
anomalies	O
.	O

Maternal	O
demographics	O
,	O
gestational	O
age	O
at	O
cerclage	O
,	O
gestational	O
age	O
at	O
delivery	O
,	O
preterm	O
prelabor	O
rupture	O
of	O
membranes	O
(	O
PROM	O
)	O
,	O
and	O
birth	O
weight	O
were	O
compared	O
between	O
women	O
with	O
a	O
cerclage	O
and	O
cerclage	O
plus	O
17α-hydroxyprogesterone	O
caproate	O
.	O

The	O
primary	O
outcome	O
was	O
delivery	O
at	O
less	O
than	O
24	O
weeks	O
of	O
gestation	O
.	O

Of	O
the	O
411	O
women	O
who	O
had	O
a	O
cerclage	O
,	O
260	O
met	O
inclusion	O
criteria	O
.	O

Of	O
these	O
,	O
171	O
received	O
a	O
cerclage	O
alone	O
and	O
89	O
received	O
cerclage	O
plus	O
17α-hydroxyprogesterone	O
caproate	O
.	O

The	O
two	O
groups	O
were	O
not	O
different	O
with	O
respect	O
to	O
maternal	O
demographics	O
and	O
gestational	O
age	O
at	O
cerclage	O
.	O

There	O
was	O
a	O
significant	O
difference	O
among	O
those	O
who	O
received	O
indomethacin	O
at	O
the	O
time	O
of	O
cerclage	O
,	O
betamethasone	O
administration	O
,	O
and	O
history	O
of	O
a	O
loop	O
electrosurgical	O
excision	O
procedure	O
-	O
cold	B-P
knife	I-P
cone	I-P
and	O
cerclage	O
.	O

Delivery	O
at	O
less	O
than	O
24	O
weeks	O
of	O
gestation	O
occurred	O
in	O
6	O
%	O
of	O
women	O
receiving	O
both	O
17α-hydroxyprogesterone	O
caproate	O
and	O
cerclage	O
compared	O
with	O
16	O
%	O
in	O
the	O
cerclage	O
only	O
group	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
0.31	O
,	O
95	O
%	O
confidence	O
interval	O
0.10-0.78	O
,	O
P=.01	O
)	O
.	O

In	O
the	O
multivariate	O
analysis	O
controlling	O
for	O
indomethacin	O
use	O
,	O
prior	O
cerclage	O
,	O
and	O
loop	O
electrosurgical	O
excision	O
procedure	O
-	O
cold	B-P
knife	I-P
cone	I-P
there	O
was	O
a	O
73	O
%	O
reduction	O
in	O
delivery	O
in	O
the	O
combined	O
treatment	O
group	O
compared	O
with	O
cerclage	O
alone	O
(	O
adjusted	O
OR	O
0.26	O
,	O
P=.02	O
)	O
.	O

A	O
multivariant	O
analysis	O
was	O
conducted	O
with	O
correction	O
for	O
indomethacin	O
at	O
the	O
time	O
of	O
cerclage	O
,	O
prior	O
cerclage	O
,	O
and	O
loop	O
electrosurgical	O
excision	O
procedure	O
-	O
cold	B-P
knife	I-P
cone	I-P
and	O
cerclage	O
surgery	O
.	O

Even	O
after	O
controlling	O
for	O
significant	O
variables	O
,	O
there	O
remained	O
a	O
73	O
%	O
reduction	O
in	O
delivery	O
at	O
less	O
than	O
24	O
weeks	O
of	O
gestation	O
in	O
the	O
cerclage	O
plus	O
17α-hydroxyprogesterone	O
caproate	O
cohort	O
(	O
adjusted	O
OR	O
0.26	O
,	O
P=.02	O
)	O
.	O

Women	O
receiving	O
transvaginal	O
cerclage	O
plus	O
17α-hydroxyprogesterone	O
caproate	O
had	O
a	O
69	O
%	O
relative	O
reduction	O
in	O
delivery	O
at	O
less	O
than	O
24	O
weeks	O
of	O
gestation	O
when	O
compared	O
with	O
women	O
receiving	O
cerclage	O
alone	O
.	O

We	O
found	O
no	O
difference	O
in	O
overall	O
preterm	O
delivery	O
or	O
preterm	O
PROM	O
.	O

In	O
this	O
cohort	O
,	O
compared	O
with	O
cerclage	O
alone	O
,	O
the	O
likelihood	O
of	O
a	O
viable	O
neonate	O
improves	O
with	O
both	O
treatments	O
.	O

Sensitive	O
fluorescent	O
detection	O
of	O
DNA	O
methyltransferase	O
using	O
nicking	O
endonuclease	O
-mediated	O
multiple	O
primers	O
-like	O
rolling	O
circle	O
amplification	O
.	O

Sensitive	O
and	O
reliable	O
detection	O
of	O
DNA	O
methyltransferase	O
(	O
MTase	O
)	O
is	O
of	O
great	O
significance	O
for	O
both	O
early	O
tumor	O
diagnosis	O
and	O
therapy	O
.	O

In	O
this	O
study	O
,	O
a	O
simple	O
,	O
label	O
-free	O
and	O
sensitive	O
DNA	O
MTase	O
-	O
sensing	B-P
method	I-P
was	O
developed	O
on	O
the	O
basis	O
of	O
a	O
nicking	O
endonuclease	O
-mediated	O
multiple	O
primers	O
-like	O
rolling	O
circle	O
amplification	O
(	O
RCA	O
)	O
strategy	B-P
.	O

In	O
this	O
method	B-P
,	O
a	O
dumbbell	O
RCA	O
template	O
was	O
prepared	O
by	O
blunt-end	O
ligation	O
of	O
two	O
molecules	O
of	O
hairpin	O
DNA	O
.	O

In	O
addition	O
to	O
the	O
primer	O
-	O
binding	O
sequence	O
,	O
the	O
dumbbell	O
template	O
contained	O
another	O
three	O
important	O
parts	O
:	O
5'-CCGG-3	O
'	O
sequences	O
in	O
double-stranded	O
stems	O
,	O
nicking	O
endonuclease	O
recognition	O
sites	O
and	O
C-rich	O
sequences	O
in	O
single-stranded	O
loops	O
.	O

The	O
introduction	O
of	O
5'-CCGG-3	O
'	O
sequences	O
allows	O
the	O
dumbbell	O
template	O
to	O
be	O
destroyed	O
by	O
the	O
restriction	O
endonuclease	O
,	O
HpaII	O
,	O
but	O
is	O
not	O
destroyed	O
in	O
the	O
presence	O
of	O
the	O
target	O
MTase	O
-	O
M.SssI	O
MTase	O
.	O

The	O
introduction	O
of	O
nicking	O
endonuclease	O
recognition	O
sites	O
makes	O
the	O
M.SssI	O
MTase	O
-protected	O
dumbbell	O
template	O
-mediated	O
RCA	O
proceed	O
in	O
a	O
multiple	O
primers	O
-like	O
exponential	O
mode	O
,	O
thus	O
providing	O
the	O
RCA	O
with	O
high	O
amplification	O
efficiency	O
.	O

The	O
introduction	O
of	O
C-rich	O
sequences	O
may	O
promote	O
the	O
folding	O
of	O
amplification	O
products	O
into	O
a	O
G-quadruplex	O
structure	O
,	O
which	O
is	O
specifically	O
recognized	O
by	O
the	O
commercially	O
available	O
fluorescent	O
probe	O
thioflavin	O
T.	O
Improved	O
RCA	O
amplification	O
efficiency	O
and	O
specific	O
fluorescent	O
recognition	O
of	O
RCA	O
products	O
provide	O
the	O
M.SssI	O
MTase	O
-	O
sensing	B-P
platform	O
with	O
high	O
sensitivity	O
.	O

When	O
a	O
dumbbell	O
template	O
containing	O
four	O
nicking	O
endonuclease	O
sites	O
is	O
used	O
,	O
highly	O
specific	O
M.SssI	O
MTase	O
activity	O
detection	O
can	O
be	O
achieved	O
in	O
the	O
range	O
of	O
0.008-50U/mL	O
with	O
a	O
detection	O
limit	O
as	O
low	O
as	O
0.0011U/mL	O
.	O

Simple	O
experimental	B-P
operation	I-P
and	O
mix-and-detection	O
fluorescent	O
sensing	O
mode	O
ensures	O
that	O
M.SssI	O
MTase	O
quantitation	O
works	O
well	O
in	O
a	O
real-time	O
RCA	O
mode	O
,	O
thus	O
further	O
simplifying	O
the	O
sensing	O
performance	O
and	O
making	O
high	O
throughput	O
detection	O
possible	O
.	O

The	O
proposed	O
MTase	O
-	O
sensing	B-P
strategy	I-P
was	O
also	O
demonstrated	O
to	O
be	O
applicable	O
for	O
screening	O
and	O
evaluating	O
the	O
inhibitory	O
activity	O
of	O
MTase	O
inhibitors	O
.	O

Identification	O
and	O
Quantification	O
of	O
Human	O
Brown	O
Adipose	O
Tissue	O
.	O

Brown	O
adipose	O
tissue	O
(	O
BAT	O
)	O
has	O
attracted	O
significant	O
interest	O
as	O
a	O
potential	O
target	O
tissue	O
against	O
obesity	O
and	O
its	O
associated	O
metabolic	O
perturbations	O
.	O

The	O
purpose	O
of	O
this	O
chapter	O
is	O
to	O
provide	O
an	O
overview	O
of	O
some	O
of	O
the	O
methodological	O
approaches	O
that	O
can	O
be	O
used	O
to	O
identify	O
and	O
quantify	O
BAT	O
in	O
people	O
.	O

Specifically	O
,	O
we	O
will	O
provide	O
a	O
step-by-step	O
description	O
of	O
the	O
following	O
procedures	O
:	O
quantification	O
of	O
BAT	O
in	O
vivo	O
using	O
positron	B-P
emission	I-P
tomography-computed	I-P
tomography	I-P
(	O
PET/CT	B-P
)	O
with	O
2-deoxy-2-	O
[	O
(	O
18	O
)	O
F	O
]	O
fluoroglucose	O
(	O
(	O
18	O
)	O
F-FDG	O
)	O
as	O
a	O
tracer	O
,	O
mitochondrial	O
respiration	O
,	O
and	O
uncoupling	O
protein	O
1	O
(	O
UCP1	O
)	O
gene	O
and	O
protein	O
expression	O
.	O

Evaluation	O
of	O
the	O
VIDAS	B-P
Anti-HCV	I-P
Assay	I-P
for	O
Detection	O
of	O
Hepatitis	O
C	O
Virus	O
Infection	O
.	O

Anti-hepatitis	O
C	O
virus	O
antibody	O
(	O
anti-HCV	O
)	O
assays	B-P
are	O
recommended	O
for	O
screening	O
HCV	O
-infected	O
persons	O
.	O

The	O
VIDAS	B-P
Anti-HCV	I-P
Assay	I-P
(	O
bioMérieux	O
,	O
France	O
)	O
,	O
based	O
on	O
the	O
enzyme-linked	B-P
fluorescence	I-P
test	I-P
principle	O
,	O
was	O
recently	O
introduced	O
in	O
Korea	O
.	O

We	O
evaluated	O
the	O
clinical	O
performance	O
of	O
the	O
VIDAS	B-P
assay	I-P
.	O

One	O
hundred	O
HCV-positive	O
and	O
1,002	O
HCV-negative	O
blood	O
samples	O
confirmed	O
by	O
Architect	B-P
anti-HCV	I-P
(	O
Abbott	O
Laboratories	O
,	O
USA	O
)	O
and	O
COBAS	O
TaqMan	O
HCV	O
real-time	O
PCR	O
(	O
Roche	O
Diagnostics	O
,	O
USA	O
)	O
or	O
the	O
Procleix	B-P
Ultrio	I-P
Plus	I-P
Assay	I-P
(	O
Gen-Probe	O
Incorporated	O
,	O
USA	O
)	O
were	O
obtained	O
from	O
the	O
Human	O
Serum	O
Bank	O
(	O
HSB	O
)	O
and	O
tested	O
by	O
VIDAS	B-P
.	O

In	O
case	O
of	O
discrepant	O
results	O
,	O
we	O
conducted	O
a	O
recombinant	B-P
immunoblot	I-P
assay	I-P
(	O
RIBA	B-P
)	O
.	O

The	O
agreement	O
rates	O
for	O
known	O
HCV-positive	O
and	O
HCV-negative	O
samples	O
between	O
the	O
VIDAS	B-P
assay	I-P
and	O
the	O
HSB	O
testing	O
were	O
100	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
96.4-100	O
%	O
)	O
and	O
99.5	O
%	O
(	O
95	O
%	O
CI	O
:	O
98.8-99.8	O
%	O
)	O
,	O
respectively	O
.	O

One	O
of	O
the	O
five	O
discrepant	O
samples	O
was	O
positive	O
for	O
Core	O
2+	O
and	O
NS3-2	O
2+	O
reactivity	O
,	O
two	O
samples	O
were	O
negative	O
,	O
and	O
the	O
other	O
two	O
were	O
indeterminate	O
regarding	O
NS4	O
2+	O
reactivity	O
in	O
RIBA	B-P
.	O

We	O
observed	O
a	O
significant	O
but	O
weak	O
positive	O
correlation	O
between	O
the	O
titers	O
of	O
VIDAS	B-P
and	O
Architect	B-P
assays	I-P
(	O
r=0.315	O
,	O
P	O
<	O
0.001	O
)	O
.	O

The	O
VIDAS	B-P
anti-HCV	I-P
assay	I-P
,	O
developed	O
on	O
the	O
VIDAS	B-P
automated	B-P
immunoassay	I-P
platform	I-P
based	O
on	O
the	O
ready-to-use	O
,	O
single-sample	O
test	O
concept	O
may	O
be	O
useful	O
in	O
small-to-medium-sized	O
laboratories	O
.	O

It	O
showed	O
good	O
agreement	O
with	O
Architect	B-P
anti-HCV	I-P
and	O
COBAS	O
PCR	O
assays	O
and	O
is	O
therefore	O
useful	O
for	O
detection	O
of	O
HCV	O
infection	O
.	O

Weakly	O
test-positive	O
(	O
ambiguous	O
)	O
samples	O
require	O
additional	O
testing	O
by	O
another	O
anti-HCV	O
,	O
RIBA	B-P
,	O
or	O
HCV	B-P
RNA	I-P
assay	I-P
.	O

Electrochemically	O
assisted	O
deposition	O
of	O
strontium	O
modified	O
magnesium	O
phosphate	O
on	O
titanium	O
surfaces	O
.	O

Electrochemically	O
assisted	O
deposition	O
was	O
utilized	O
to	O
produce	O
ceramic	O
coatings	O
on	O
the	O
basis	O
of	O
magnesium	O
ammonium	O
phosphate	O
(	O
struvite	O
)	O
on	O
corundum	O
-	O
blasted	O
titanium	O
surfaces	O
.	O

By	O
the	O
addition	O
of	O
defined	O
concentrations	O
of	O
strontium	O
nitrate	O
to	O
the	O
coating	O
electrolyte	O
Sr	O
(	O
2+	O
)	O
ions	O
were	O
successfully	O
incorporated	O
into	O
the	O
struvite	O
matrix	O
.	O

By	O
variation	O
of	O
deposition	O
parameters	O
it	O
was	O
possible	O
to	O
fabricate	O
coatings	O
with	O
different	O
kinetics	O
of	O
Sr	O
(	O
2+	O
)	O
into	O
physiological	O
media	O
,	O
whereas	O
the	O
release	O
of	O
therapeutically	O
relevant	O
strontium	O
doses	O
could	O
be	O
sustained	O
over	O
several	O
weeks	O
.	O

Morphological	O
and	O
crystallographic	B-P
examinations	I-P
of	O
the	O
immersed	O
coatings	O
revealed	O
that	O
the	O
degradation	O
of	O
struvite	O
and	O
the	O
release	O
of	O
Sr	O
(	O
2+	O
)	O
ions	O
were	O
accompanied	O
by	O
a	O
transformation	O
of	O
the	O
coating	O
to	O
a	O
calcium	O
phosphate	O
based	O
phase	O
similar	O
to	O
low-crystalline	O
hydroxyapatite	O
.	O

These	O
findings	O
showed	O
that	O
strontium	O
doped	O
struvite	O
coatings	O
may	O
provide	O
a	O
promising	O
degradable	O
coating	O
system	O
for	O
the	O
local	O
application	O
of	O
strontium	O
or	O
other	O
biologically	O
active	O
metal	O
ions	O
in	O
the	O
implant-bone	O
interface	O
.	O

Isolation	B-P
,	O
structural	B-P
analysis	I-P
,	O
and	O
expression	O
characteristics	O
of	O
the	O
maize	O
nuclear	O
factor	O
Y	O
gene	O
families	O
.	O

NUCLEAR	O
FACTOR-Y	O
(	O
NF-Y	O
)	O
has	O
been	O
shown	O
to	O
play	O
an	O
important	O
role	O
in	O
growth	O
,	O
development	O
,	O
and	O
response	O
to	O
environmental	O
stress	O
.	O

A	O
NF-Y	O
complex	O
,	O
which	O
consists	O
of	O
three	O
subunits	O
,	O
NF-YA	O
,	O
NF-YB	O
,	O
and	O
,	O
NF-YC	O
,	O
binds	O
to	O
CCAAT	O
sequences	O
in	O
a	O
promoter	O
to	O
control	O
the	O
expression	O
of	O
target	O
genes	O
.	O

Although	O
NF-Y	O
proteins	O
have	O
been	O
reported	O
in	O
Arabidopsis	O
and	O
rice	O
,	O
a	O
comprehensive	O
and	O
systematic	O
analysis	O
of	O
ZmNF-Y	O
genes	O
has	O
not	O
yet	O
been	O
performed	O
.	O

To	O
examine	O
the	O
functions	O
of	O
ZmNF-Y	O
genes	O
in	O
this	O
family	O
,	O
we	O
isolated	O
and	O
characterized	O
50	O
ZmNF-Y	O
(	O
14	O
ZmNF-YA	O
,	O
18	O
ZmNF-YB	O
,	O
and	O
18	O
ZmNF-YC	O
)	O
genes	O
in	O
an	O
analysis	O
of	O
the	O
maize	O
genome	O
.	O

The	O
50	O
ZmNF-Y	O
genes	O
were	O
distributed	O
on	O
all	O
10	O
maize	O
chromosomes	O
,	O
and	O
12	O
paralogs	O
were	O
identified	O
.	O

Multiple	O
alignments	O
showed	O
that	O
maize	O
ZmNF-Y	O
family	O
proteins	O
had	O
conserved	O
regions	O
and	O
relatively	O
variable	O
N-terminal	O
or	O
C-terminal	O
domains	O
.	O

The	O
comparative	O
syntenic	O
map	O
illustrated	O
40	O
paralogous	O
NF-Y	O
gene	O
pairs	O
among	O
the	O
10	O
maize	O
chromosomes	O
.	O

Microarray	B-P
data	O
showed	O
that	O
the	O
ZmNF-Y	O
genes	O
had	O
tissue-specific	O
expression	O
patterns	O
in	O
various	O
maize	O
developmental	O
stages	O
and	O
in	O
response	O
to	O
biotic	O
and	O
abiotic	O
stresses	O
.	O

The	O
results	O
suggested	O
that	O
ZmNF-YB2	O
,	O
4	O
,	O
8	O
,	O
10	O
,	O
13	O
,	O
and	O
16	O
and	O
ZmNF-YC6	O
,	O
8	O
,	O
and	O
15	O
were	O
induced	O
,	O
while	O
ZmNF-YA1	O
,	O
3	O
,	O
4	O
,	O
6	O
,	O
7	O
,	O
10	O
,	O
12	O
,	O
and	O
13	O
,	O
ZmNF-YB15	O
,	O
and	O
ZmNF-YC3	O
and	O
9	O
were	O
suppressed	O
by	O
drought	O
stress	O
.	O

ZmNF-YA3	O
,	O
ZmNF-YA8	O
and	O
ZmNF-YA12	O
were	O
upregulated	O
after	O
infection	O
by	O
the	O
three	O
pathogens	O
,	O
while	O
ZmNF-YA1	O
and	O
ZmNF-YB2	O
were	O
suppressed	O
.	O

These	O
results	O
indicate	O
that	O
the	O
ZmNF-Ys	O
may	O
have	O
significant	O
roles	O
in	O
the	O
response	O
to	O
abiotic	O
and	O
biotic	O
stresses	O
.	O

Corn	O
oil	O
intake	O
favorably	O
impacts	O
lipoprotein	O
cholesterol	O
,	O
apolipoprotein	B-P
and	O
lipoprotein	B-P
particle	O
levels	O
compared	O
with	O
extra-virgin	O
olive	O
oil	O
.	O

Corn	O
oil	O
(	O
CO	O
)	O
and	O
extra-virgin	O
olive	O
oil	O
(	O
EVOO	O
)	O
are	O
rich	O
sources	O
of	O
unsaturated	O
fatty	O
acids	O
(	O
UFA	O
)	O
,	O
but	O
UFA	O
profiles	O
differ	O
among	O
oils	O
,	O
which	O
may	O
affect	O
lipoprotein	B-P
levels	I-P
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
effects	O
of	O
CO	O
versus	O
EVOO	O
intake	O
on	O
fasting	O
lipoprotein	B-P
and	O
subfraction	O
cholesterol	B-P
levels	I-P
,	O
apolipoprotein	B-P
(	I-P
apo	I-P
)	I-P
A1	I-P
,	O
apo	B-P
B	I-P
,	O
and	O
low-density	B-P
lipoprotein	I-P
particle	O
concentrations	O
in	O
men	O
and	O
women	O
.	O

As	O
part	O
of	O
a	O
weight	O
maintenance	O
diet	O
,	O
men	O
and	O
women	O
were	O
provided	O
with	O
food	O
items	O
prepared	O
with	O
54	O
g	O
per	O
day	O
of	O
CO	O
or	O
EVOO	O
(	O
21-day	O
treatment	O
,	O
21-day	O
washout	O
)	O
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
controlled-feeding	O
,	O
crossover	O
trial	O
.	O

Fasting	O
lipoprotein	O
cholesterol	O
and	O
related	O
variables	O
were	O
determined	O
with	O
density	B-P
gradient	I-P
ultracentrifugation	I-P
.	O

Among	O
the	O
54	O
completers	O
,	O
CO	O
reduced	O
total	O
cholesterol	O
,	O
low-density	B-P
lipoprotein	I-P
cholesterol	I-P
(	O
LDL-C	B-P
)	O
,	O
very	B-P
low-density	I-P
lipoprotein	I-P
cholesterol	I-P
(	O
VLDL-C	B-P
)	O
,	O
non-high-density	B-P
lipoprotein	I-P
cholesterol	I-P
(	O
non-HDL-C	B-P
)	O
,	O
apo	B-P
B	I-P
and	O
LDL	B-P
particle	O
concentration	O
to	O
a	O
greater	O
extent	O
compared	O
with	O
EVOO	O
intake	O
.	O

Changes	O
in	O
LDL-C	B-P
and	O
VLDL-C	B-P
contributed	O
to	O
the	O
larger	O
reduction	O
in	O
non-HDL-C	B-P
with	O
CO	O
compared	O
with	O
EVOO	O
intake	O
(	O
-0.39	O
mmol/l	O
vs	O
-0.04	O
mmol/l	O
;	O
P	O
<	O
0.001	O
)	O
.	O

The	O
larger	O
reduction	O
in	O
LDL-C	B-P
by	O
CO	O
intake	O
was	O
attributable	O
to	O
changes	O
(	O
P	O
<	O
0.05	O
)	O
caused	O
by	O
CO	O
vs	O
EVOO	O
in	O
large	O
LDL1+2-C	B-P
(	O
-0.22	O
mmol/l	O
)	O
and	O
intermediate-density	B-P
lipoprotein	I-P
cholesterol	I-P
(	O
-0.12	O
mmol/l	O
)	O
.	O

HDL-C	B-P
responses	O
did	O
not	O
differ	O
between	O
treatments	O
,	O
but	O
apo	B-P
A1	I-P
increased	O
more	O
with	O
EVOO	O
compared	O
with	O
CO	O
intake	O
(	O
4.6	O
versus	O
0.7	O
mg/dl	O
,	O
respectively	O
,	O
P=0.016	O
)	O
.	O

CO	O
intake	O
reduced	O
atherogenic	O
lipoprotein	O
cholesterol	O
and	O
particle	O
concentrations	O
to	O
a	O
larger	O
extent	O
than	O
did	O
EVOO	O
,	O
which	O
may	O
have	O
implications	O
for	O
cardiovascular	O
disease	O
risk	O
.	O

Impact	O
of	O
SPARC	O
expression	O
on	O
outcome	O
in	O
patients	O
with	O
advanced	O
pancreatic	O
cancer	O
not	O
receiving	O
nab-paclitaxel	O
:	O
a	O
pooled	O
analysis	O
from	O
prospective	O
clinical	O
and	O
translational	O
trials	O
.	O

Conflicting	O
results	O
on	O
the	O
role	O
of	O
secreted	O
protein	O
acidic	O
and	O
rich	O
in	O
cysteins	O
(	O
SPARC	O
)	O
expression	O
have	O
been	O
reported	O
in	O
resected	O
pancreatic	O
ductal	O
adenocarcinoma	O
(	O
PDAC	O
)	O
,	O
and	O
its	O
prognostic	O
and/or	O
predictive	O
role	O
in	O
advanced	O
PDAC	O
(	O
aPDAC	O
)	O
has	O
not	O
been	O
extensively	O
investigated	O
yet	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
SPARC	O
expression	O
as	O
a	O
biomarker	O
in	O
aPDAC	O
patients	O
(	O
pts	O
)	O
not	O
receiving	O
nab-paclitaxel	O
.	O

Using	O
immunohistochemistry	B-P
,	O
we	O
examined	O
the	O
stromal	O
as	O
well	O
as	O
the	O
tumoral	O
(	O
i.e.	O
,	O
cytoplasmic	O
)	O
SPARC	O
expression	O
in	O
tumour	O
tissue	O
(	O
primary	O
tumours	O
and	O
metastases	O
)	O
of	O
134	O
aPDAC	O
pts	O
participating	O
in	O
completed	O
prospective	O
clinical	O
and	O
biomarker	O
trials	O
.	O

The	O
SPARC	O
expression	O
levels	O
were	O
correlated	O
to	O
the	O
pts	O
'	O
clinicopathological	O
parameters	O
and	O
survival	O
times	O
.	O

Sixty-seven	O
per	O
cent	O
of	O
the	O
analysed	O
tumours	O
showed	O
high	O
stromal	O
SPARC	O
expression	O
,	O
which	O
was	O
not	O
associated	O
with	O
overall	O
survival	O
(	O
OS	O
,	O
median	O
9.1	O
vs	O
7.6	O
months	O
,	O
P=0.316	O
)	O
.	O

A	O
positive	O
cytoplasmic	O
SPARC	O
expression	O
was	O
detected	O
in	O
55	O
%	O
of	O
the	O
tumours	O
and	O
correlated	O
significantly	O
with	O
inferior	O
progression-free	O
survival	O
(	O
PFS	O
,	O
6.2	O
vs	O
8.6	O
months	O
,	O
P=0.004	O
)	O
and	O
OS	O
(	O
7.8	O
vs	O
8.4	O
months	O
,	O
P=0.032	O
)	O
.	O

This	O
association	O
was	O
strongest	O
for	O
pts	O
,	O
where	O
primary	O
tumour	O
tissue	O
was	O
examined	O
(	O
PFS	O
:	O
6.7	O
vs	O
10.8	O
months	O
,	O
P=0.004	O
;	O
OS	O
:	O
7.9	O
vs	O
11.9	O
months	O
,	O
P=0.030	O
)	O
,	O
whereas	O
no	O
significant	O
correlation	O
was	O
detected	O
for	O
pts	O
,	O
where	O
only	O
metastatic	O
tissue	O
was	O
available	O
(	O
PFS	O
:	O
5.8	O
vs	O
6.6	O
months	O
,	O
P=0.502	O
;	O
OS	O
:	O
7.0	O
vs	O
7.8	O
months	O
,	O
P=0.452	O
)	O
.	O

In	O
pts	O
receiving	O
gemcitabine	O
-based	O
chemotherapy	O
cytoplasmic	O
SPARC	O
expression	O
was	O
significantly	O
associated	O
with	O
an	O
inferior	O
PFS	O
and	O
OS	O
(	O
PFS	O
:	O
6.2	O
vs	O
9.2	O
months	O
,	O
P=0.002	O
;	O
OS	O
7.3	O
vs	O
9.9	O
months	O
,	O
P=0.012	O
)	O
,	O
whereas	O
no	O
such	O
association	O
was	O
detected	O
for	O
stromal	O
SPARC	O
expression	O
or	O
for	O
pts	O
receiving	O
fluoropyrimidine	O
-based	O
chemotherapy	O
.	O

We	O
identified	O
cytoplasmic	O
SPARC	O
expression	O
in	O
the	O
primary	O
tumour	O
as	O
a	O
biomarker	O
associated	O
with	O
inferior	O
PFS	O
and	O
OS	O
in	O
aPDAC	O
.	O

Cytoplasmic	O
SPARC	O
expression	O
may	O
furthermore	O
act	O
as	O
a	O
negative	O
predictive	O
biomarker	O
in	O
pts	O
treated	O
with	O
gemcitabine	O
-based	O
chemotherapy	O
.	O

Far-infrared	O
protects	O
vascular	O
endothelial	O
cells	O
from	O
advanced	O
glycation	O
end	O
products	O
-	O
induced	O
injury	O
via	O
PLZF	O
-mediated	O
autophagy	O
in	O
diabetic	O
mice	O
.	O

The	O
accumulation	O
of	O
advanced	O
glycation	O
end	O
products	O
(	O
AGEs	O
)	O
in	O
diabetic	O
patients	O
induces	O
vascular	O
endothelial	O
injury	O
.	O

Promyelocytic	O
leukemia	O
zinc	O
finger	O
protein	O
(	O
PLZF	O
)	O
is	O
a	O
transcription	O
factor	O
that	O
can	O
be	O
activated	O
by	O
low-temperature	O
far-infrared	O
(	O
FIR	O
)	O
irradiation	O
to	O
exert	O
beneficial	O
effects	O
on	O
the	O
vascular	O
endothelium	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
influence	O
of	O
FIR	O
-	O
induced	O
PLZF	O
activation	O
on	O
AGE	O
-	O
induced	O
endothelial	O
injury	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

FIR	O
irradiation	O
inhibited	O
AGE	O
-	O
induced	O
apoptosis	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
.	O

PLZF	O
activation	O
increased	O
the	O
expression	O
of	O
phosphatidylinositol-3	O
kinases	O
(	O
PI3K	O
)	O
,	O
which	O
are	O
important	O
kinases	O
in	O
the	O
autophagic	O
signaling	O
pathway	O
.	O

FIR	O
-	O
induced	O
PLZF	O
activation	O
led	O
to	O
autophagy	O
in	O
HUVEC	O
,	O
which	O
was	O
mediated	O
through	O
the	O
upregulation	O
of	O
PI3K	O
.	O

Immunofluorescence	B-P
staining	B-P
showed	O
that	O
AGEs	O
were	O
engulfed	O
by	O
HUVECs	O
and	O
localized	O
to	O
lysosomes	O
.	O

FIR	O
-	O
induced	O
autophagy	O
promoted	O
AGEs	O
degradation	O
in	O
HUVECs	O
.	O

In	O
nicotinamide	O
/	O
streptozotocin	O
-	O
induced	O
diabetic	O
mice	O
,	O
FIR	O
therapy	O
reduced	O
serum	O
AGEs	O
and	O
AGEs	O
deposition	O
at	O
the	O
vascular	O
endothelium	O
.	O

FIR	O
therapy	O
also	O
reduced	O
diabetes	O
-	O
induced	O
inflammatory	O
markers	O
in	O
the	O
vascular	O
endothelium	O
and	O
improved	O
vascular	O
endothelial	O
function	O
.	O

These	O
protective	O
effects	O
of	O
FIR	O
therapy	O
were	O
not	O
found	O
in	O
PLZF	O
-	O
knockout	O
mice	O
.	O

Our	O
data	O
suggest	O
that	O
FIR	O
-	O
induced	O
PLZF	O
activation	O
in	O
vascular	O
endothelial	O
cells	O
protects	O
the	O
vascular	O
endothelium	O
in	O
diabetic	O
mice	O
from	O
AGE	O
-	O
induced	O
injury	O
.	O

Minor	O
physical	O
anomalies	O
and	O
dermatoglyphic	O
signs	O
in	O
affective	O
disorders	O
:	O
A	O
systematic	O
review	O
.	O

The	O
increased	O
prevalence	O
of	O
minor	O
physical	O
anomalies	O
(	O
MPAs	O
)	O
and	O
the	O
abnormalities	O
of	O
dermatoglyphic	O
patterns	O
may	O
be	O
physical	O
manifestations	O
of	O
neurodevelopmental	O
disruption	O
in	O
affective	O
disorders	O
.	O

This	O
paper	O
aims	O
to	O
review	O
the	O
current	O
state	O
of	O
knowledge	O
on	O
the	O
frequency	O
of	O
MPAs	O
and	O
dermatoglyphic	O
abnormalities	O
in	O
mood	O
disorders	O
.	O

A	O
MEDLINE	O
,	O
PsychInfo	O
and	O
Web	O
of	O
Science	O
search	O
was	O
carried	O
out	O
to	O
collect	O
all	O
publications	O
on	O
the	O
frequency	O
of	O
MPAs	O
and	O
on	O
dermatoglyphic	O
traits	O
in	O
bipolar	O
disorder	O
and	O
unipolar	O
depression	O
.	O

24	O
studies	O
on	O
MPAs	O
,	O
19	O
on	O
dermatoglyphics	B-P
,	O
and	O
5	O
dealing	O
with	O
both	O
were	O
found	O
with	O
discrepant	O
findings	O
.	O

The	O
relative	O
contribution	O
of	O
neurodevelopmental	O
retardation	O
to	O
the	O
aetiology	O
of	O
affective	O
disorders	O
remains	O
undetermined	O
,	O
the	O
field	O
is	O
open	O
for	O
further	O
research	O
.	O

Increased	O
recognition	O
of	O
neurodevelopmental	O
processes	O
in	O
the	O
origin	O
of	O
affective	O
disorders	O
may	O
allow	O
for	O
earlier	O
and	O
more	O
effective	O
intervention	O
and	O
prevention	O
.	O

Does	O
adenomatous	O
polyposis	O
coli	O
gene	O
promoter	O
1A	O
methylation	B-P
increase	O
non-small	O
cell	O
lung	O
cancer	O
risk	O
?	O

A	O
meta-analysis	O
.	O

The	O
promoter	O
region	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
gene	O
is	O
hypermethylated	O
in	O
several	O
types	O
of	O
cancers	O
,	O
including	O
non-small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
.	O

The	O
prevalence	O
of	O
methylation	B-P
in	O
the	O
promoter	O
region	O
of	O
this	O
gene	O
in	O
tumor	O
tissues	O
and	O
autologous	B-P
controls	I-P
has	O
not	O
been	O
consistent	O
in	O
previous	O
studies	O
.	O

We	O
evaluated	O
the	O
frequency	O
of	O
APC	O
gene	O
promoter	O
1A	O
methylation	B-P
between	O
tumor	O
tissues	O
and	O
autologous	B-P
controls	I-P
in	O
NSCLC	O
patients	O
by	O
meta-analysis	O
.	O

Open	O
published	O
studies	O
of	O
APC	O
gene	O
promoter	O
1A	O
methylation	B-P
between	O
tumor	O
tissues	O
and	O
autologous	O
samples	O
in	O
NSCLC	O
patients	O
were	O
identified	O
using	O
a	O
systematic	O
search	O
.	O

Odds	O
ratios	O
(	O
OR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
of	O
APC	O
gene	O
promoter	O
1A	O
methylation	B-P
in	O
lung	O
cancer	O
tissues	O
versus	O
autologous	B-P
controls	I-P
were	O
calculated	O
.	O

Fourteen	O
studies	O
,	O
involving	O
a	O
total	O
of	O
1345	O
patients	O
and	O
2182	O
samples	O
,	O
were	O
finally	O
included	O
.	O

The	O
pooled	O
proportion	O
of	O
APC	O
promoter	O
1A	O
methylation	B-P
was	O
0.62	O
(	O
95	O
%	O
CI	O
0.52-072	O
)	O
and	O
0.34	O
(	O
95	O
%	O
CI	O
0.21-0.50	O
)	O
in	O
cancer	O
tissues	O
and	O
autologous	B-P
controls	I-P
,	O
respectively	O
.	O

The	O
APC	O
gene	O
promoter	O
1A	O
methylation	B-P
rate	O
in	O
cancer	O
tissues	O
was	O
much	O
higher	O
than	O
in	O
autologous	B-P
controls	I-P
,	O
with	O
a	O
pooled	O
OR	O
of	O
3.66	O
(	O
95	O
%	O
CI	O
2.12-6.33	O
)	O
.	O

A	O
strong	O
and	O
significant	O
correlation	O
of	O
APC	O
gene	O
promoter	O
1A	O
methylation	B-P
between	O
tumor	O
tissues	O
and	O
autologous	B-P
controls	I-P
was	O
detected	O
(	O
correlation	O
coefficient	O
rpearson	O
=	O
0.77	O
;	O
P	O
=	O
0.0013	O
)	O
.	O

The	O
proportion	O
of	O
APC	O
promoter	O
1A	O
methylation	B-P
in	O
lung	O
cancer	O
tissues	O
was	O
higher	O
than	O
in	O
autologous	B-P
controls	I-P
,	O
indicating	O
that	O
promoter	O
1A	O
methylation	B-P
of	O
the	O
APC	O
gene	O
may	O
play	O
an	O
important	O
role	O
in	O
NSCLC	O
carcinogenesis	O
.	O

Dynamic	O
Cross-Entropy	O
.	O

Complexity	O
measures	O
for	O
time	O
series	O
have	O
been	O
used	O
in	O
many	O
applications	O
to	O
quantify	O
the	O
regularity	O
of	O
one	O
dimensional	O
time	O
series	O
,	O
however	O
many	O
dynamical	O
systems	O
are	O
spatially	O
distributed	O
multidimensional	O
systems	O
.	O

We	O
introduced	O
Dynamic	O
Cross-Entropy	O
(	O
DCE	O
)	O
a	O
novel	O
multidimensional	O
complexity	O
measure	O
that	O
quantifies	O
the	O
degree	O
of	O
regularity	O
of	O
EEG	B-P
signals	O
in	O
selected	O
frequency	O
bands	O
.	O

Time	O
series	O
generated	O
by	O
discrete	O
logistic	O
equations	O
with	O
varying	O
control	O
parameter	O
r	O
are	O
used	O
to	O
test	O
DCE	O
measures	O
.	O

Sliding	O
window	O
DCE	O
analyses	O
are	O
able	O
to	O
reveal	O
specific	O
period	O
doubling	O
bifurcations	O
that	O
lead	O
to	O
chaos	O
.	O

A	O
similar	O
behavior	O
can	O
be	O
observed	O
in	O
seizures	O
triggered	O
by	O
electroconvulsive	O
therapy	O
(	O
ECT	O
)	O
.	O

Sample	O
entropy	O
data	O
show	O
the	O
level	O
of	O
signal	O
complexity	O
in	O
different	O
phases	O
of	O
the	O
ictal	O
ECT	O
.	O

The	O
transition	O
to	O
irregular	O
activity	O
is	O
preceded	O
by	O
the	O
occurrence	O
of	O
cyclic	O
regular	O
behavior	O
.	O

A	O
significant	O
increase	O
of	O
DCE	O
values	O
in	O
successive	O
order	O
from	O
high	O
frequencies	O
in	O
gamma	O
to	O
low	O
frequencies	O
in	O
delta	O
band	O
reveals	O
several	O
phase	O
transitions	O
into	O
less	O
ordered	O
states	O
,	O
possible	O
chaos	O
in	O
the	O
human	O
brain	O
.	O

To	O
our	O
knowledge	O
there	O
are	O
no	O
reliable	O
techniques	O
able	O
to	O
reveal	O
the	O
transition	O
to	O
chaos	O
in	O
case	O
of	O
multidimensional	O
times	O
series	O
.	O

In	O
addition	O
,	O
DCE	O
based	O
on	O
sample	O
entropy	O
appears	O
to	O
be	O
robust	O
to	O
EEG	O
artifacts	O
compared	O
to	O
DCE	O
based	O
on	O
Shannon	O
entropy	O
.	O

The	O
applied	O
technique	O
may	O
offer	O
new	O
approaches	O
to	O
better	O
understand	O
nonlinear	O
brain	O
activity	O
.	O

Methylation	O
status	O
of	O
the	O
promoter	O
region	O
of	O
the	O
human	O
frizzled	O
9	O
gene	O
in	O
acute	O
myeloid	O
leukemia	O
.	O

The	O
FZD9	O
gene	O
is	O
located	O
at	O
chromosome	O
7q11.23	O
,	O
and	O
has	O
been	O
indicated	O
to	O
be	O
a	O
tumor	O
suppressor	O
gene	O
.	O

The	O
present	O
study	O
examined	O
the	O
involvement	O
of	O
FZD9	O
promoter	O
methylation	O
in	O
the	O
downregulation	O
of	O
FZD9	O
expression	O
in	O
leukemia	O
cells	O
.	O

The	O
expression	O
of	O
the	O
FZD9	O
gene	O
was	O
absent	O
in	O
various	O
leukemic	O
cell	O
lines	O
,	O
while	O
it	O
was	O
restored	O
following	O
treatment	O
with	O
DNA	O
demethylating	O
agent	O
5-aza-2'-deoxycytidine	O
.	O

Bisulfite	O
sequencing	O
analysis	O
of	O
the	O
FZD9	O
promoter	O
region	O
showed	O
that	O
it	O
was	O
partially	O
methylated	O
in	O
cell	O
lines	O
in	O
which	O
FZD9	O
gene	O
was	O
not	O
expressed	O
.	O

Thus	O
,	O
DNA	O
methylation	O
in	O
the	O
promoter	O
region	O
may	O
lead	O
to	O
inactivation	O
of	O
the	O
FZD9	O
gene	O
,	O
which	O
may	O
represent	O
and	O
aberration	O
associated	O
with	O
leukemia	O
,	O
since	O
DNA	O
was	O
not	O
methylated	O
in	O
normal	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

Methylation	O
-specific	O
polymerase	O
chain	O
reaction	O
analysis	O
revealed	O
that	O
the	O
promoter	O
region	O
of	O
the	O
FZD9	O
gene	O
was	O
frequently	O
methylated	O
in	O
primary	O
or	O
relapse	O
acute	O
myeloid	O
leukemia	O
(	O
52.9	O
%	O
;	O
excluding	O
acute	O
promyelocytic	O
leukemia	O
)	O
;	O
however	O
,	O
methylation	O
was	O
infrequent	O
in	O
B-cell	O
acute	O
lymphocytic	O
leukemia	O
(	O
5.6	O
%	O
)	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	O
indicated	O
that	O
the	O
methylation	O
profile	B-P
of	O
the	O
FZD9	O
gene	O
corresponded	O
to	O
that	O
of	O
a	O
candidate	O
tumor-suppressor	O
gene	O
in	O
acute	O
myeloid	O
leukemia	O
.	O

Metalloproteinase	O
meprin	O
α	O
regulates	O
migration	O
and	O
invasion	O
of	O
human	O
hepatocarcinoma	O
cells	O
and	O
is	O
a	O
mediator	O
of	O
the	O
oncoprotein	O
Reptin	O
.	O

Hepatocellular	O
carcinoma	O
is	O
associated	O
with	O
a	O
high	O
rate	O
of	O
intra-hepatic	O
invasion	O
that	O
carries	O
a	O
poor	O
prognosis	O
.	O

Meprin	O
alpha	O
(	O
Mep1A	O
)	O
is	O
a	O
secreted	O
metalloproteinase	O
with	O
many	O
substrates	O
relevant	O
to	O
cancer	O
invasion	O
.	O

We	O
found	O
that	O
Mep1A	O
was	O
a	O
target	O
of	O
Reptin	O
,	O
a	O
protein	O
that	O
is	O
oncogenic	O
in	O
HCC	O
.	O

We	O
studied	O
Mep1A	O
regulation	O
by	O
Reptin	O
,	O
its	O
role	O
in	O
HCC	O
,	O
and	O
whether	O
it	O
mediates	O
Reptin	O
oncogenic	O
effects	O
.	O

MepA	O
and	O
Reptin	O
expression	O
was	O
measured	O
in	O
human	O
HCC	O
by	O
qRT-PCR	O
and	O
in	O
cultured	O
cells	O
by	O
PCR	O
,	O
western	B-P
blot	I-P
and	O
enzymatic	O
activity	O
measurements	O
.	O

Cell	O
growth	O
was	O
assessed	O
by	O
counting	B-P
and	O
MTS	O
assay	O
.	O

Cell	O
migration	O
was	O
measured	O
in	O
Boyden	O
chambers	O
and	O
wound	O
healing	O
assays	B-P
,	O
and	O
cell	O
invasion	O
in	O
Boyden	O
chambers	O
.	O

Silencing	O
Reptin	O
decreased	O
Mep1A	O
expression	O
and	O
activity	O
,	O
without	O
affecting	O
meprin	O
β.	O
Mep1A	O
,	O
but	O
not	O
meprin	O
β	O
,	O
was	O
overexpressed	O
in	O
a	O
series	O
of	O
242	O
human	O
HCC	O
(	O
2.04	O
fold	O
,	O
p	O
<	O
0.0001	O
)	O
,	O
and	O
a	O
high	O
expression	O
correlated	O
with	O
a	O
poor	O
prognosis	O
.	O

Mep1A	O
and	O
Reptin	O
expressions	O
were	O
positively	O
correlated	O
(	O
r	O
=	O
0.39	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

Silencing	O
Mep1A	O
had	O
little	O
effect	O
on	O
cell	O
proliferation	O
,	O
but	O
decreased	O
cell	O
migration	O
and	O
invasion	O
of	O
HuH7	O
and	O
Hep3B	O
cells	O
.	O

Conversely	O
,	O
overexpression	O
of	O
Mep1A	O
or	O
addition	O
of	O
recombinant	O
Mep1A	O
increased	O
migration	O
and	O
invasion	O
.	O

Finally	O
,	O
overexpression	O
of	O
Mep1A	O
restored	O
a	O
normal	O
cell	O
migration	O
in	O
cells	O
where	O
Reptin	O
was	O
depleted	O
.	O

Mep1A	O
is	O
overexpressed	O
in	O
most	O
HCC	O
and	O
induces	O
HCC	O
cell	O
migration	O
and	O
invasion	O
.	O

Mep1A	O
expression	O
is	O
regulated	O
by	O
Reptin	O
,	O
and	O
Mep1A	O
mediates	O
Reptin	O
-	O
induced	O
migration	O
.	O

Overall	O
,	O
we	O
suggest	O
that	O
Mep1A	O
may	O
be	O
a	O
useful	O
target	O
in	O
HCC	O
.	O

Prospective	O
study	O
of	O
dietary	O
Non	B-P
Enzymatic	I-P
Antioxidant	I-P
Capacity	I-P
on	O
the	O
risk	O
of	O
hip	O
fracture	O
in	O
the	O
elderly	O
.	O

Dietary	O
antioxidants	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
prevention	O
of	O
bone	O
loss	O
and	O
associated	O
fractures	O
by	O
reducing	O
levels	O
of	O
oxidative	O
stress	O
.	O

We	O
prospectively	O
investigated	O
the	O
association	O
between	O
dietary	O
Non	B-P
Enzymatic	I-P
Antioxidant	I-P
Capacity	I-P
(	O
NEAC	B-P
)	O
and	O
the	O
risk	O
of	O
hip	O
fracture	O
and	O
whether	O
this	O
effect	O
was	O
modified	O
by	O
smoking	O
.	O

In	O
the	O
Swedish	O
National	O
March	O
Cohort	O
13,409	O
men	O
and	O
women	O
over	O
the	O
age	O
of	O
55	O
who	O
had	O
not	O
experienced	O
cancer	O
,	O
cardiovascular	O
disease	O
or	O
hip	O
fracture	O
,	O
were	O
followed	O
through	O
record-linkages	O
from	O
1997	O
through	O
2010	O
.	O

NEAC	B-P
was	O
assessed	O
by	O
a	O
validated	O
food	O
frequency	O
questionnaire	O
collected	O
at	O
baseline	O
.	O

We	O
categorized	O
the	O
distribution	O
of	O
NEAC	B-P
into	O
sex	O
-	O
specific	O
quartiles	O
and	O
used	O
multivariable	O
adjusted	O
Cox	O
proportional	O
hazards	O
regression	O
models	O
to	O
estimate	O
hazard	O
ratios	O
(	O
HRs	O
)	O
with	O
95	O
%	O
confidence	O
intervals	O
(	O
95	O
%	O
CI	O
)	O
.	O

During	O
a	O
mean	O
follow-up	O
time	O
of	O
12.4years	O
,	O
we	O
identified	O
491	O
incident	O
cases	O
of	O
first	O
hip	O
fracture	O
.	O

Subjects	O
in	O
the	O
highest	O
quartile	O
of	O
dietary	O
NEAC	B-P
had	O
a	O
39	O
%	O
lower	O
risk	O
of	O
incident	O
hip	O
fracture	O
compared	O
to	O
those	O
in	O
the	O
lowest	O
quartile	O
(	O
HR	O
:	O
0.61	O
;	O
95	O
%	O
CI	O
:	O
0.44-0.85	O
)	O
.	O

The	O
association	O
was	O
non-linear	O
(	O
p	O
for	O
non-linearity	O
:	O
0.004	O
)	O
with	O
a	O
potential	O
threshold	O
between	O
the	O
first	O
and	O
the	O
second	O
quartile	O
and	O
no	O
further	O
risk	O
reduction	O
at	O
higher	O
levels	O
of	O
dietary	O
NEAC	B-P
.	O

Due	O
to	O
a	O
low	O
smoking	O
prevalence	O
in	O
our	O
study	O
population	O
,	O
we	O
had	O
limited	O
power	O
to	O
detect	O
effect	O
modification	O
between	O
dietary	O
NEAC	B-P
and	O
smoking	O
on	O
a	O
multiplicative	O
or	O
additive	O
scale	O
.	O

Higher	O
dietary	O
NEAC	B-P
intake	O
is	O
associated	O
with	O
lower	O
risk	O
of	O
hip	O
fracture	O
in	O
the	O
elderly	O
.	O

An	O
Encapsulation	O
of	O
Gene	O
Signatures	O
for	O
Hepatocellular	O
Carcinoma	O
,	O
MicroRNA-132	O
Predicted	O
Target	O
Genes	O
and	O
the	O
Corresponding	O
Overlaps	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
microRNA-132	O
plays	O
a	O
vital	O
part	O
in	O
and	O
is	O
actively	O
associated	O
with	O
several	O
cancers	O
,	O
with	O
its	O
tumor-suppressive	O
role	O
in	O
hepatocellular	O
carcinoma	O
confirmed	O
.	O

The	O
current	O
study	O
employed	O
multiple	O
bioinformatics	O
techniques	O
to	O
establish	O
gene	O
signatures	O
for	O
hepatocellular	O
carcinoma	O
,	O
microRNA-132	O
predicted	O
target	O
genes	O
and	O
the	O
corresponding	O
overlaps	O
.	O

Various	O
assays	B-P
were	O
performed	O
to	O
explore	O
the	O
role	O
and	O
cellular	O
functions	O
of	O
miR-132	O
in	O
HCC	O
and	O
a	O
successive	O
panel	O
of	O
tasks	O
was	O
completed	O
,	O
including	O
NLP	O
analysis	O
,	O
miR-132	O
target	O
genes	O
prediction	O
,	O
comprehensive	O
analyses	O
(	O
gene	O
ontology	O
analysis	O
,	O
pathway	O
analysis	O
,	O
network	O
analysis	O
and	O
connectivity	O
analysis	O
)	O
,	O
and	O
analytical	O
integration	O
.	O

Later	O
,	O
HCC	O
-	O
related	O
and	O
miR-132	O
-	O
related	O
potential	O
targets	O
,	O
pathways	O
,	O
networks	O
and	O
highlighted	O
hub	O
genes	O
were	O
revealed	O
as	O
well	O
as	O
those	O
of	O
the	O
overlapped	O
section	O
.	O

MiR-132	O
was	O
effective	O
in	O
both	O
impeding	O
cell	O
growth	O
and	O
boosting	O
apoptosis	O
in	O
HCC	O
cell	O
lines	O
.	O

A	O
total	O
of	O
fifty-nine	O
genes	O
were	O
obtained	O
from	O
the	O
analytical	O
integration	O
,	O
which	O
were	O
considered	O
to	O
be	O
both	O
HCC	O
-	O
and	O
miR-132	O
-	O
related	O
.	O

Moreover	O
,	O
four	O
specific	O
pathways	O
were	O
unveiled	O
in	O
the	O
network	O
analysis	O
of	O
the	O
overlaps	O
,	O
i.e	O
.	O

adherens	O
junction	O
,	O
VEGF	O
signaling	O
pathway	O
,	O
neurotrophin	O
signaling	O
pathway	O
,	O
and	O
MAPK	O
signaling	O
pathway	O
.	O

The	O
tumor-suppressive	O
role	O
of	O
miR-132	O
in	O
HCC	O
has	O
been	O
further	O
confirmed	O
by	O
in	O
vitro	O
experiments	O
.	O

Gene	O
signatures	O
in	O
the	O
study	O
identified	O
the	O
potential	O
molecular	O
mechanisms	O
of	O
HCC	O
,	O
miR-132	O
and	O
their	O
established	O
associations	O
,	O
which	O
might	O
be	O
effective	O
for	O
diagnosis	O
,	O
individualized	O
treatments	O
and	O
prognosis	O
of	O
HCC	O
patients	O
.	O

However	O
,	O
combined	O
detections	O
of	O
miR-132	O
with	O
other	O
bio-indicators	O
in	O
clinical	O
practice	O
and	O
further	O
in	O
vitro	O
experiments	O
are	O
needed	O
.	O

Does	O
orthodontic	O
debonding	O
lead	O
to	O
tooth	O
sensitivity	O
?	O

Comparison	O
of	O
teeth	O
with	O
and	O
without	O
visible	O
enamel	O
microcracks	O
.	O

Our	O
aim	O
was	O
to	O
assess	O
the	O
possible	O
changes	O
in	O
sensitivity	O
of	O
teeth	O
with	O
and	O
without	O
visible	O
enamel	O
microcracks	O
(	O
EMCs	O
)	O
up	O
to	O
1	O
week	O
after	O
the	O
removal	O
of	O
metal	O
brackets	O
.	O

After	O
debonding	O
,	O
15	O
patients	O
possessing	O
teeth	O
with	O
visible	O
EMCs	O
and	O
15	O
subjects	O
whose	O
teeth	O
were	O
free	O
of	O
EMCs	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

For	O
each	O
experimental	O
group	O
,	O
a	O
control	O
group	O
was	O
formed	O
.	O

The	O
assessments	O
of	O
tooth	O
sensitivity	O
elicited	O
by	O
compressed	O
air	O
and	O
cold	O
testing	O
were	O
performed	O
5	O
times	O
:	O
just	O
before	O
debonding	O
,	O
immediately	O
after	O
debonding	O
,	O
and	O
at	O
1	O
,	O
3	O
,	O
and	O
7	O
days	O
after	O
debonding	O
.	O

Tooth	O
sensitivity	O
was	O
recorded	O
on	O
a	O
100-mm	O
visual	B-P
analog	I-P
scale	I-P
.	O

For	O
the	O
patients	O
without	O
visible	O
EMCs	O
,	O
discomfort	O
peaked	O
immediately	O
after	O
debonding	O
and	O
started	O
to	O
decrease	O
on	O
day	O
1	O
;	O
at	O
1	O
week	O
after	O
debonding	O
,	O
the	O
visual	B-P
analog	I-P
scale	I-P
scores	O
were	O
lower	O
than	O
just	O
before	O
debonding	O
and	O
immediately	O
after	O
debonding	O
.	O

For	O
the	O
subjects	O
possessing	O
teeth	O
with	O
visible	O
EMCs	O
,	O
the	O
pattern	O
of	O
sensitivity	O
dynamic	O
was	O
inherently	O
the	O
same	O
.	O

However	O
,	O
the	O
patients	O
with	O
visible	O
EMCs	O
showed	O
higher	O
visual	B-P
analog	I-P
scale	I-P
values	O
at	O
each	O
time	O
interval	O
.	O

Debonding	O
leads	O
to	O
a	O
short-term	O
increase	O
in	O
tooth	O
sensitivity	O
.	O

EMCs	O
,	O
a	O
form	O
of	O
enamel	O
damage	O
,	O
do	O
not	O
predispose	O
to	O
greater	O
sensitivity	O
perception	O
in	O
relation	O
to	O
bracket	O
removal	O
.	O

Pharmacogenomic	B-P
identification	I-P
of	O
small	O
molecules	O
for	O
lineage	O
specific	O
manipulation	O
of	O
subventricular	O
zone	O
germinal	O
activity	O
.	O

Strategies	O
for	O
promoting	O
neural	O
regeneration	O
are	O
hindered	O
by	O
the	O
difficulty	O
of	O
manipulating	O
desired	O
neural	O
fates	O
in	O
the	O
brain	O
without	O
complex	O
genetic	B-P
methods	I-P
.	O

The	O
subventricular	O
zone	O
(	O
SVZ	O
)	O
is	O
the	O
largest	O
germinal	O
zone	O
of	O
the	O
forebrain	O
and	O
is	O
responsible	O
for	O
the	O
lifelong	O
generation	O
of	O
interneuron	O
subtypes	O
and	O
oligodendrocytes	O
.	O

Here	O
,	O
we	O
have	O
performed	O
a	O
bioinformatics	O
analysis	O
of	O
the	O
transcriptome	O
of	O
dorsal	O
and	O
lateral	O
SVZ	O
in	O
early	O
postnatal	O
mice	O
,	O
including	O
neural	O
stem	O
cells	O
(	O
NSCs	O
)	O
and	O
their	O
immediate	O
progenies	O
,	O
which	O
generate	O
distinct	O
neural	O
lineages	O
.	O

We	O
identified	O
multiple	O
signaling	O
pathways	O
that	O
trigger	O
distinct	O
downstream	O
transcriptional	O
networks	O
to	O
regulate	O
the	O
diversity	O
of	O
neural	O
cells	O
originating	O
from	O
the	O
SVZ	O
.	O

Next	O
,	O
we	O
used	O
a	O
novel	O
in	O
silico	O
genomic	O
analysis	O
,	O
searchable	O
platform-independent	O
expression	O
database	O
/	O
connectivity	O
map	O
(	O
SPIED	O
/	O
CMAP	O
)	O
,	O
to	O
generate	O
a	O
catalogue	O
of	O
small	O
molecules	O
that	O
can	O
be	O
used	O
to	O
manipulate	O
SVZ	O
microdomain-specific	O
lineages	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
compounds	O
identified	O
in	O
this	O
analysis	O
promote	O
the	O
generation	O
of	O
specific	O
cell	O
lineages	O
from	O
NSCs	O
in	O
vivo	O
,	O
during	O
postnatal	O
life	O
and	O
adulthood	O
,	O
as	O
well	O
as	O
in	O
regenerative	O
contexts	O
.	O

This	O
study	O
unravels	O
new	O
strategies	O
for	O
using	O
small	O
bioactive	O
molecules	O
to	O
direct	O
germinal	O
activity	O
in	O
the	O
SVZ	O
,	O
which	O
has	O
therapeutic	O
potential	O
in	O
neurodegenerative	O
diseases	O
.	O

Development	O
of	O
a	O
liquid	B-P
chromatography-tandem	I-P
mass	I-P
spectrometry	I-P
method	O
for	O
quantitative	O
analysis	O
of	O
trace	O
d-amino	O
acids	O
.	O

d-Amino	O
acids	O
have	O
recently	O
attracted	O
much	O
attention	O
in	O
various	O
research	O
fields	O
including	O
medical	O
,	O
clinical	O
and	O
food	O
industry	O
due	O
to	O
their	O
important	O
biological	O
functions	O
that	O
differ	O
from	O
l-amino	O
acid	O
.	O

Most	O
chiral	O
amino	O
acid	O
separation	B-P
techniques	O
require	O
complicated	O
derivatization	O
procedures	O
in	O
order	O
to	O
achieve	O
the	O
desirable	O
chromatographic	O
behavior	O
and	O
detectability	O
.	O

Thus	O
,	O
the	O
aim	O
of	O
this	O
research	O
is	O
to	O
develop	O
a	O
highly	O
sensitive	O
analytical	O
method	O
for	O
the	O
enantioseparation	B-P
of	O
chiral	O
amino	O
acids	O
without	O
any	O
derivatization	O
process	O
using	O
liquid	B-P
chromatography-tandem	I-P
mass	I-P
spectrometry	I-P
(	O
LC-MS/MS	B-P
)	O
.	O

By	O
optimizing	O
MS/MS	B-P
parameters	O
,	O
we	O
established	O
a	O
quantification	O
method	O
that	O
allowed	O
the	O
simultaneous	O
analysis	O
of	O
18	O
d-amino	O
acids	O
with	O
high	O
sensitivity	O
and	O
reproducibility	O
.	O

Additionally	O
,	O
we	O
applied	O
the	O
method	O
to	O
food	O
sample	O
(	O
vinegar	O
)	O
for	O
the	O
validation	O
,	O
and	O
successfully	O
quantified	O
trace	O
levels	O
of	O
d-amino	O
acids	O
in	O
samples	O
.	O

These	O
results	O
demonstrated	O
the	O
applicability	O
and	O
feasibility	O
of	O
the	O
LC-MS/MS	B-P
method	O
as	O
a	O
novel	O
,	O
effective	O
tool	O
for	O
d-amino	O
acid	O
measurement	O
in	O
various	O
biological	O
samples	O
.	O

Improvement	O
in	O
Exercise	O
Capacity	O
by	O
Exercise	O
Training	O
Associated	O
With	O
Favorable	O
Clinical	O
Outcomes	O
in	O
Advanced	O
Heart	O
Failure	O
With	O
High	O
B-Type	O
Natriuretic	O
Peptide	O
Level	O
.	O

The	O
efficacy	O
of	O
exercise	O
training	O
(	O
ET	O
)	O
programs	O
and	O
its	O
relationship	O
with	O
long-term	O
clinical	O
outcomes	O
in	O
advanced	O
heart	O
failure	O
(	O
HF	O
)	O
patients	O
with	O
high	O
levels	O
of	O
B-type	O
natriuretic	O
peptide	O
(	O
BNP	O
)	O
remain	O
uncertain.Methods	O
and	O
Results	O
:	O
We	O
studied	O
340	O
consecutive	O
HF	O
patients	O
with	O
ejection	B-P
fraction	I-P
(	O
EF	B-P
)	O
<	O
45	O
%	O
who	O
completed	O
a	O
3-	O
month	O
ET	O
program	O
.	O

Patients	O
with	O
BNP	O
≥200	O
pg/mL	O
(	O
High	O
-	O
BNP	O
,	O
n=170	O
)	O
had	O
more	O
advanced	O
HF	O
characteristics	O
,	O
including	O
lower	O
EF	O
(	O
25.0±8.6	O
%	O
vs.	O
28.1±8.0	O
%	O
,	O
P=0.0008	O
)	O
,	O
than	O
those	O
with	O
BNP	O
<	O
200	O
pg/mL	O
.	O

In	O
the	O
High	O
-	O
BNP	O
patients	O
,	O
peak	O
oxygen	O
uptake	O
(	O
V̇O2	O
)	O
was	O
significantly	O
increased	O
by	O
8.3±16.2	O
%	O
during	O
the	O
ET	O
program	O
,	O
and	O
changes	O
in	O
peak	O
V̇O2	O
inversely	O
correlated	O
with	O
changes	O
in	O
BNP	O
(	O
R=-0.453	O
,	O
P	O
<	O
0.0001	O
)	O
and	O
changes	O
in	O
ventilatory	O
efficiency	O
(	O
V̇E	O
/	O
V̇CO2	O
slope	O
)	O
(	O
R=-0.439	O
,	O
P	O
<	O
0.0001	O
)	O
.	O

During	O
a	O
median	O
follow-up	O
of	O
46	O
months	O
,	O
patients	O
in	O
the	O
upper	O
tertile	O
of	O
changes	O
in	O
peak	O
V̇O2	O
(	O
≥13.0	O
%	O
)	O
,	O
compared	O
with	O
those	O
in	O
the	O
lower	O
tertile	O
(	O
<	O
1.0	O
%	O
)	O
,	O
had	O
lower	O
rates	O
of	O
the	O
composite	O
of	O
all-cause	O
death	O
or	O
HF	O
hospitalization	O
(	O
37.9	O
%	O
vs.	O
54.4	O
%	O
,	O
P=0.036	O
)	O
and	O
all-cause	O
death	O
(	O
8.6	O
%	O
vs.	O
24.6	O
%	O
,	O
P=0.056	O
)	O
.	O

In	O
the	O
multivariate	O
analysis	O
,	O
change	O
in	O
peak	O
V̇O2	O
was	O
a	O
significant	O
independent	O
predictor	O
of	O
the	O
composite	O
outcome	O
and	O
all-cause	O
death	O
.	O

Even	O
among	O
advanced	O
HF	O
p	O
atient	O
s	O
with	O
high	O
BNP	O
level	O
,	O
an	O
ET	O
program	O
significantly	O
improved	O
exercise	O
capacity	O
,	O
and	O
a	O
greater	O
improvement	O
in	O
exercise	O
capacity	O
was	O
associated	O
with	O
greater	O
decreases	O
in	O
BNP	O
level	O
and	O
V̇E	O
/	O
V̇CO2	O
slope	O
and	O
more	O
favorable	O
long-term	O
clinical	O
outcomes	O
.	O

Skeletal	O
muscle	O
metabolic	O
adaptations	O
to	O
endurance	O
exercise	O
training	O
are	O
attainable	O
in	O
mice	O
with	O
simvastatin	O
treatment	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
a	O
6-week	O
regimen	O
of	O
simvastatin	O
would	O
attenuate	O
skeletal	O
muscle	O
adaptation	O
to	O
low-intensity	O
exercise	O
.	O

Male	O
C57BL/6J	O
wildtype	O
mice	O
were	O
subjected	O
to	O
6-weeks	O
of	O
voluntary	O
wheel	O
running	O
or	O
normal	O
cage	O
activities	O
with	O
or	O
without	O
simvastatin	O
treatment	O
(	O
20	O
mg/kg/d	O
,	O
n	O
=	O
7-8	O
per	O
group	O
)	O
.	O

Adaptations	O
in	O
in	O
vivo	O
fatigue	O
resistance	O
were	O
determined	O
by	O
a	O
treadmill	B-P
running	I-P
test	I-P
,	O
and	O
by	O
ankle	O
plantarflexor	O
contractile	O
assessment	O
.	O

The	O
tibialis	O
anterior	O
,	O
gastrocnemius	O
,	O
and	O
plantaris	O
muscles	O
were	O
evaluated	O
for	O
exercised	O
-induced	O
mitochondrial	O
adaptations	O
(	O
i.e.	O
,	O
biogenesis	O
,	O
function	O
,	O
autophagy	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
weekly	O
wheel	O
running	O
distance	O
between	O
control	O
and	O
simvastatin	O
-	O
treated	O
mice	O
(	O
P	O
=	O
0.51	O
)	O
.	O

Trained	O
mice	O
had	O
greater	O
treadmill	O
running	O
distance	O
(	O
296	O
%	O
,	O
P	O
<	O
0.001	O
)	O
,	O
and	O
ankle	O
plantarflexor	O
contractile	O
fatigue	O
resistance	O
(	O
9	O
%	O
,	O
P	O
<	O
0.05	O
)	O
compared	O
to	O
sedentary	O
mice	O
,	O
independent	O
of	O
simvastatin	O
treatment	O
.	O

At	O
the	O
cellular	O
level	O
,	O
trained	O
mice	O
had	O
greater	O
mitochondrial	O
biogenesis	O
(	O
e.g.	O
,	O
~2-fold	O
greater	O
PGC1α	O
expression	O
,	O
P	O
<	O
0.05	O
)	O
and	O
mitochondrial	O
content	O
(	O
e.g.	O
,	O
25	O
%	O
greater	O
citrate	O
synthase	O
activity	O
,	O
P	O
<	O
0.05	O
)	O
,	O
independent	O
of	O
simvastatin	O
treatment	O
.	O

Mitochondrial	O
autophagy	O
-related	O
protein	O
contents	O
were	O
greater	O
in	O
trained	O
mice	O
(	O
e.g.	O
,	O
40	O
%	O
greater	O
Bnip3	O
,	O
P	O
<	O
0.05	O
)	O
,	O
independent	O
of	O
simvastatin	O
treatment	O
.	O

However	O
,	O
Drp1	O
,	O
a	O
marker	O
of	O
mitochondrial	O
fission	O
,	O
was	O
less	O
in	O
simvastatin	O
treated	O
mice	O
,	O
independent	O
of	O
exercise	O
training	O
,	O
and	O
there	O
was	O
a	O
significant	O
interaction	O
between	O
training	O
and	O
statin	O
treatment	O
(	O
P	O
<	O
0.022	O
)	O
for	O
LC3-II	O
protein	O
content	O
,	O
a	O
marker	O
of	O
autophagy	O
flux	O
.	O

These	O
data	O
indicate	O
that	O
whole	O
body	O
and	O
skeletal	O
muscle	O
adaptations	O
to	O
endurance	O
exercise	O
training	O
are	O
attainable	O
with	O
simvastatin	O
treatment	O
,	O
but	O
simvastatin	O
may	O
have	O
side	O
effects	O
on	O
muscle	O
mitochondrial	O
maintenance	O
via	O
autophagy	O
,	O
which	O
could	O
have	O
long-term	O
implications	O
on	O
muscle	O
health	O
.	O

Assessing	O
the	O
learning	O
potential	O
of	O
an	O
interactive	O
digital	O
game	O
versus	O
an	O
interactive-style	O
didactic	O
lecture	O
:	O
the	O
continued	O
importance	O
of	O
didactic	O
teaching	O
in	O
medical	O
student	O
education	O
.	O

Games	O
with	O
educational	O
intent	O
offer	O
a	O
possible	O
advantage	O
of	O
being	O
more	O
interactive	O
and	O
increasing	O
learner	O
satisfaction	O
.	O

We	O
conducted	O
a	O
two-armed	O
experiment	O
to	O
evaluate	O
student	O
satisfaction	O
and	O
content	O
mastery	O
for	O
an	O
introductory	O
pediatric	O
radiology	O
topic	O
,	O
taught	O
by	O
either	O
an	O
interactive	O
digital	O
game	O
or	O
with	O
a	O
traditional	O
didactic	O
lecture	O
.	O

Medical	O
students	O
participating	O
in	O
a	O
fourth-year	O
radiology	O
elective	O
were	O
invited	O
to	O
participate	O
.	O

Student	O
cohorts	O
were	O
alternatively	O
given	O
a	O
faculty	O
-	O
supervised	O
1h	O
session	O
playing	O
a	O
simple	O
interactive	O
digital	O
Tic-tac-toe	O
quiz	O
module	O
on	O
pediatric	B-P
gastrointestinal	I-P
radiology	I-P
or	O
a	O
1h	O
didactic	O
introductory	O
lecture	O
on	O
the	O
same	O
topic	O
.	O

Survey	O
questions	O
assessed	O
the	O
learners	O
'	O
perceived	O
ability	O
to	O
recall	O
the	O
material	O
as	O
well	O
as	O
their	O
satisfaction	O
with	O
the	O
educational	O
experience	O
.	O

Results	O
of	O
an	O
end-of-rotation	O
exam	O
were	O
reviewed	O
to	O
evaluate	O
a	O
quantitative	O
measure	O
of	O
learning	O
between	O
groups	O
.	O

Survey	O
responses	O
were	O
analyzed	O
with	O
a	O
chi-squared	O
test	O
.	O

Exam	O
results	O
for	O
both	O
groups	O
were	O
analyzed	O
with	O
a	O
paired	O
Student	O
's	O
t-test	O
.	O

Students	O
in	O
the	O
lecture	O
group	O
had	O
higher	O
test	O
scores	O
compared	O
to	O
students	O
in	O
the	O
game	O
group	O
(	O
4.0/5	O
versus	O
3.6/5	O
,	O
P	O
=	O
0.045	O
)	O
.	O

Students	O
in	O
the	O
lecture	O
group	O
reported	O
greater	O
understanding	O
and	O
recall	O
of	O
the	O
material	O
than	O
students	O
in	O
the	O
game	O
group	O
(	O
P	O
<	O
0.001	O
and	O
P	O
=	O
0.004	O
,	O
respectively	O
)	O
.	O

Students	O
in	O
the	O
lecture	O
group	O
perceived	O
the	O
lecture	O
to	O
be	O
more	O
enjoyable	O
and	O
a	O
better	O
use	O
of	O
their	O
time	O
compared	O
to	O
those	O
in	O
the	O
game	O
group	O
(	O
P	O
=	O
0.04	O
and	O
P	O
<	O
0.001	O
,	O
respectively	O
)	O
.	O

There	O
was	O
no	O
statistically	O
significant	O
difference	O
between	O
the	O
lecture	O
and	O
game	O
group	O
in	O
ability	O
to	O
maintain	O
interest	O
(	O
P	O
=	O
0.187	O
)	O
.	O

In	O
comparison	O
to	O
pre-survey	O
results	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
decrease	O
in	O
interest	O
for	O
further	O
digital	O
interactive	O
materials	O
reported	O
by	O
students	O
in	O
the	O
game	O
group	O
(	O
P	O
=	O
0.146	O
)	O
.	O

Our	O
experience	O
supported	O
the	O
use	O
of	O
a	O
traditional	O
lecture	O
over	O
a	O
digital	O
game	O
module	O
.	O

While	O
these	O
results	O
might	O
be	O
affected	O
by	O
the	O
specific	O
lecture	O
and	O
digital	O
content	O
in	O
any	O
given	O
comparison	O
,	O
a	O
digital	O
module	O
is	O
not	O
always	O
the	O
superior	O
option	O
.	O

A	O
Strategy	O
to	O
Establish	O
a	O
Quality	O
Assurance	O
/	O
Quality	O
Control	O
Plan	O
for	O
the	O
Application	O
of	O
Biosensors	O
for	O
the	O
Detection	O
of	O
E.	O
coli	O
in	O
Water	O
.	O

Rapid	O
bacterial	O
detection	O
using	O
biosensors	O
is	O
a	O
novel	O
approach	O
for	O
microbiological	B-P
testing	I-P
applications	O
.	O

Validation	O
of	O
such	O
methods	O
is	O
an	O
obstacle	O
in	O
the	O
adoption	O
of	O
new	O
bio-sensing	B-P
technologies	I-P
for	O
water	O
testing	O
.	O

Therefore	O
,	O
establishing	O
a	O
quality	O
assurance	O
and	O
quality	O
control	O
(	O
QA	O
/	O
QC	O
)	O
plan	O
is	O
essential	O
to	O
demonstrate	O
accuracy	O
and	O
reliability	O
of	O
the	O
biosensor	O
method	O
for	O
the	O
detection	O
of	O
E.	O
coli	O
in	O
drinking	O
water	O
samples	O
.	O

In	O
this	O
study	O
,	O
different	O
reagents	O
and	O
assay	B-P
conditions	O
including	O
temperatures	O
,	O
holding	O
time	O
,	O
E.	O
coli	O
strains	O
and	O
concentrations	O
,	O
dissolving	O
agents	O
,	O
salinity	O
and	O
pH	O
effects	O
,	O
quality	O
of	O
substrates	O
of	O
various	O
suppliers	O
of	O
4-methylumbelliferyl	O
glucuronide	O
(	O
MUG	O
)	O
,	O
and	O
environmental	O
water	O
samples	O
were	O
included	O
in	O
the	O
QA	O
/	O
QC	O
plan	O
and	O
used	O
in	O
the	O
assay	B-P
optimization	O
and	O
documentation	O
.	O

Furthermore	O
,	O
the	O
procedural	O
QA	O
/	O
QC	O
for	O
the	O
monitoring	O
of	O
drinking	O
water	O
samples	O
was	O
established	O
to	O
validate	O
the	O
performance	O
of	O
the	O
biosensor	O
platform	O
for	O
the	O
detection	O
of	O
E.	O
coli	O
using	O
a	O
culture	B-P
-based	O
standard	O
technique	O
.	O

Implementing	O
the	O
developed	O
QA	O
/	O
QC	O
plan	O
,	O
the	O
same	O
level	O
of	O
precision	O
and	O
accuracy	O
was	O
achieved	O
using	O
both	O
the	O
standard	O
and	O
the	O
biosensor	O
methods	O
.	O

The	O
established	O
procedural	O
QA	O
/	O
QC	O
for	O
the	O
biosensor	O
will	O
provide	O
a	O
reliable	O
tool	O
for	O
a	O
near	O
real-time	O
monitoring	O
of	O
E.	O
coli	O
in	O
drinking	O
water	O
samples	O
to	O
both	O
industry	O
and	O
regulatory	O
authorities	O
.	O

Reference	O
data	O
for	O
jumping	B-P
mechanography	I-P
in	O
Canadian	O
children	O
,	O
adolescents	O
and	O
young	O
adults	O
.	O

To	O
provide	O
age	O
-	O
and	O
sex	O
-	O
specific	O
reference	O
data	O
for	O
mechanography	B-P
-derived	O
parameters	O
of	O
muscle	O
function	O
in	O
Canadian	O
children	O
and	O
youth	O
using	O
the	O
single	O
two-legged	O
jump	O
(	O
S2LJ	O
)	O
with	O
hands-on-waist	O
.	O

Our	O
sample	O
included	O
2017	O
observations	O
from	O
715	O
participants	O
(	O
9-21	O
years	O
;	O
338	O
girls	O
)	O
.	O

Participants	O
performed	O
three	O
S2LJ	O
with	O
hands-on-waist	O
on	O
a	O
force	O
platform	O
(	O
Leonardo	O
Mechanograph	O
,	O
Novotec	O
)	O
.	O

Outcomes	O
were	O
maximum	O
peak	O
power	O
(	O
Pmax	O
)	O
,	O
Pmax	O
/	O
mass	O
,	O
peak	O
force	O
/	O
body	O
weight	O
(	O
Fmax	O
/	O
BW	O
)	O
,	O
force	O
efficiency	O
,	O
maximum	O
jump	O
height	O
(	O
Hmax	O
)	O
,	O
and	O
velocity	O
(	O
Vmax	O
)	O
.	O

We	O
used	O
the	O
LMS	O
method	O
to	O
construct	O
age	O
-	O
and	O
sex	O
-	O
specific	O
percentile	O
curves	O
and	O
mixed	O
effects	O
models	O
to	O
examine	O
sex	O
and	O
ethnic	O
differences	O
.	O

With	O
the	O
exception	O
of	O
Efficiency	O
,	O
mechanography	B-P
outcomes	O
were	O
greater	O
in	O
girls	O
(	O
4-40	O
%	O
,	O
p	O
<	O
0.05	O
)	O
than	O
boys	O
at	O
age	O
9	O
.	O

Boys	O
'	O
advantage	O
in	O
mechanography	B-P
parameters	O
emerged	O
in	O
adolescence	O
(	O
age	O
11-13	O
years	O
;	O
3-65	O
%	O
,	O
p	O
<	O
0.05	O
)	O
and	O
persisted	O
into	O
young	O
adulthood	O
,	O
except	O
for	O
Fmax	O
/	O
BW	O
which	O
was	O
not	O
greater	O
in	O
boys	O
until	O
age	O
17	O
(	O
4-10	O
%	O
,	O
p	O
<	O
0.05	O
)	O
.	O

Mechanography	B-P
outcomes	O
were	O
3-9	O
%	O
(	O
p	O
<	O
0.05	O
)	O
greater	O
in	O
Asian	O
compared	O
with	O
white	O
participants	O
.	O

We	O
provide	O
the	O
first	O
reference	O
data	O
for	O
the	O
S2LJ	O
using	O
the	O
hands-on-waist	O
protocol	O
in	O
children	O
,	O
youth	O
and	O
young	O
adults	O
.	O

These	O
data	O
support	O
previous	O
findings	O
using	O
freely	O
moving	O
arms	O
and	O
can	O
be	O
used	O
when	O
evaluating	O
muscle	O
function	O
in	O
pediatric	O
studies	O
.	O

Evaluation	O
of	O
the	O
Prostate	O
Imaging	O
Reporting	O
and	O
Data	O
System	O
for	O
Magnetic	B-P
Resonance	I-P
Imaging	I-P
Diagnosis	O
of	O
Prostate	O
Cancer	O
in	O
Patients	O
with	O
Prostate-specific	O
Antigen	O
<	O
20	O
ng/ml	O
.	O

The	O
European	O
Society	O
of	O
Urogenital	O
Radiology	O
has	O
built	O
the	O
Prostate	O
Imaging	O
Reporting	O
and	O
Data	O
System	O
(	O
PI-RADS	O
)	O
for	O
standardizing	O
the	O
diagnosis	O
of	O
prostate	O
cancer	O
(	O
PCa	O
)	O
.	O

This	O
study	O
evaluated	O
the	O
PI-RADS	O
diagnosis	B-P
method	I-P
in	O
patients	O
with	O
prostate-specific	O
antigen	O
(	O
PSA	O
)	O
<	O
20	O
ng/ml	O
.	O

A	O
total	O
of	O
133	O
patients	O
with	O
PSA	O
<	O
20	O
ng/ml	O
were	O
prospectively	O
recruited	O
.	O

T2-weighted	B-P
(	O
T2WI	B-P
)	O
and	O
diffusion-weighted	B-P
(	I-P
DWI	I-P
)	I-P
magnetic	I-P
resonance	I-P
images	I-P
of	O
the	O
prostate	O
were	O
acquired	O
before	O
a	O
12-core	B-P
transrectal	I-P
prostate	I-P
biopsy	I-P
.	O

Each	O
patient	O
's	O
peripheral	O
zone	O
was	O
divided	O
into	O
six	O
regions	O
on	O
the	O
images	O
;	O
each	O
region	O
corresponded	O
to	O
two	O
of	O
the	O
12	O
biopsy	B-P
cores	I-P
.	O

T2WI	B-P
,	O
DWI	B-P
,	O
and	O
T2WI	B-P
+	O
DWI	B-P
scores	O
were	O
computed	O
according	O
to	O
PI-RADS	O
.	O

The	O
diagnostic	O
accuracy	O
of	O
the	O
PI-RADS	O
score	O
was	O
evaluated	O
using	O
histopathology	O
of	O
prostate	B-P
biopsies	I-P
as	O
the	O
reference	O
standard	O
.	O

PCa	O
was	O
histologically	O
diagnosed	O
in	O
169	O
(	O
21.2	O
%	O
)	O
regions	O
.	O

Increased	O
PI-RADS	O
score	O
correlated	O
positively	O
with	O
increased	O
cancer	O
detection	O
rate	O
.	O

The	O
cancer	O
detection	O
rate	O
for	O
scores	O
1	O
to	O
5	O
was	O
2.8	O
%	O
,	O
15.0	O
%	O
,	O
34.6	O
%	O
,	O
52.6	O
%	O
,	O
and	O
88.9	O
%	O
,	O
respectively	O
,	O
using	O
T2WI	B-P
and	O
12.0	O
%	O
,	O
20.2	O
%	O
,	O
48.0	O
%	O
,	O
85.7	O
%	O
,	O
and	O
93.3	O
%	O
,	O
respectively	O
,	O
using	O
DWI	B-P
.	O

For	O
T2WI	B-P
+	O
DWI	B-P
,	O
the	O
cancer	O
detection	O
rate	O
was	O
1.5	O
%	O
(	O
score	O
2	O
)	O
,	O
13.5	O
%	O
(	O
scores	O
3-4	O
)	O
,	O
41.3	O
%	O
(	O
scores	O
5-6	O
)	O
,	O
75.9	O
%	O
(	O
scores	O
7-8	O
)	O
,	O
and	O
92.3	O
%	O
(	O
scores	O
9-10	O
)	O
.	O

The	O
area	O
under	O
the	O
curve	O
for	O
cancer	O
detection	O
was	O
0.700	O
(	O
T2WI	B-P
)	O
,	O
0.735	O
(	O
DWI	B-P
)	O
and	O
0.749	O
(	O
T2WI	B-P
+	O
DWI	B-P
)	O
.	O

The	O
sensitivity	O
and	O
specificity	O
were	O
53.8	O
%	O
and	O
89.2	O
%	O
,	O
respectively	O
,	O
when	O
using	O
scores	O
5-6	O
as	O
the	O
cutoff	O
value	O
for	O
T2WI	B-P
+	O
DWI	B-P
.	O

The	O
PI-RADS	O
score	O
correlates	O
with	O
the	O
PCa	O
detection	O
rate	O
in	O
patients	O
with	O
PSA	O
<	O
20	O
ng/ml	O
.	O

The	O
summed	O
score	O
of	O
T2WI	B-P
+	O
DWI	B-P
has	O
the	O
highest	O
accuracy	O
in	O
detection	O
of	O
PCa	O
.	O

However	O
,	O
the	O
sensitivity	O
should	O
be	O
further	O
improved	O
.	O

An	O
efficient	O
approach	O
to	O
identify	O
different	O
chemical	O
markers	O
between	O
fibrous	O
root	O
and	O
rhizome	O
of	O
Anemarrhena	O
asphodeloides	O
by	O
ultra	B-P
high-performance	I-P
liquid	I-P
chromatography	I-P
quadrupole	I-P
time-of-flight	I-P
tandem	I-P
mass	I-P
spectrometry	I-P
with	O
multivariate	O
statistical	O
analysis	O
.	O

An	O
ultra	B-P
high-performance	I-P
liquid	I-P
chromatography	I-P
quadrupole	I-P
time-of-flight	I-P
tandem	I-P
mass	I-P
spectrometry	I-P
approach	O
coupled	O
with	O
multivariate	O
statistical	O
analysis	O
was	O
established	O
and	O
applied	O
to	O
rapidly	O
distinguish	O
the	O
chemical	O
differences	O
between	O
fibrous	O
root	O
and	O
rhizome	O
of	O
Anemarrhena	O
asphodeloides	O
.	O

The	O
datasets	O
of	O
tR-m/z	O
pairs	O
,	O
ion	O
intensity	O
and	O
sample	O
code	O
were	O
processed	O
by	O
principal	O
component	O
analysis	O
and	O
orthogonal	O
partial	O
least	O
squares	O
discriminant	O
analysis	O
.	O

Chemical	O
markers	O
could	O
be	O
identified	O
based	O
on	O
their	O
exact	O
mass	O
data	O
,	O
fragmentation	O
characteristics	O
,	O
and	O
retention	O
times	O
.	O

And	O
the	O
new	O
compounds	O
among	O
chemical	O
markers	O
could	O
be	O
isolated	O
rapidly	O
guided	O
by	O
the	O
ultra	B-P
high-performance	I-P
liquid	I-P
chromatography	I-P
quadrupole	I-P
time-of-flight	I-P
tandem	I-P
mass	I-P
spectrometry	I-P
and	O
their	O
definitive	O
structures	O
would	O
be	O
further	O
elucidated	O
by	O
NMR	B-P
spectra	I-P
.	O

Using	O
this	O
approach	O
,	O
twenty-four	O
markers	O
were	O
identified	O
on	O
line	O
including	O
nine	O
new	O
saponins	O
and	O
five	O
new	O
steroidal	O
saponins	O
of	O
them	O
were	O
obtained	O
in	O
pure	O
form	O
.	O

The	O
study	O
validated	O
this	O
proposed	O
approach	O
as	O
a	O
suitable	O
method	B-P
for	O
identification	O
of	O
the	O
chemical	O
differences	O
between	O
various	O
medicinal	O
parts	O
in	O
order	O
to	O
expand	O
medicinal	O
parts	O
and	O
increase	O
the	O
utilization	O
rate	O
of	O
resources	O
.	O

Multimodality	B-P
imaging	I-P
approach	O
in	O
the	O
diagnosis	O
of	O
chronic	O
myocarditis	O
with	O
preserved	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
MCpEF	O
)	O
:	O
The	O
role	O
of	O
2D	B-P
speckle-tracking	I-P
echocardiography	I-P
.	O

Up	O
to	O
one	O
third	O
of	O
patients	O
with	O
chronic	O
myocarditis	O
(	O
MC	O
)	O
have	O
preserved	O
left	O
ventricular	O
(	O
LV	O
)	O
ejection	O
fraction	O
(	O
MCpEF	O
)	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
role	O
of	O
adding	O
2D	B-P
speckle-tracking	I-P
echocardiography	I-P
(	O
STE	B-P
)	O
to	O
cardiac	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
(	O
cMRI	B-P
)	O
in	O
the	O
diagnosis	O
of	O
patients	O
with	O
MCpEF	O
.	O

We	O
analyzed	O
67	O
patients	O
with	O
suspected	O
MCpEF	O
who	O
underwent	O
endomyocardial	B-P
biopsy	I-P
(	O
EMB	B-P
)	O
.	O

Thirty-two	O
patients	O
with	O
confirmed	O
chronic	O
myocardial	O
inflammation	O
by	O
EMB	B-P
served	O
as	O
study	O
group	O
(	O
MCpEF	O
)	O
and	O
the	O
remaining	O
patients	O
(	O
n=35	O
)	O
served	O
as	O
control	O
group	O
.	O

In	O
all	O
patients	O
,	O
2D	B-P
STE	I-P
and	O
cMRI	B-P
were	O
performed	O
within	O
48h	O
before	O
EMB	B-P
.	O

Patients	O
with	O
MCpEF	O
had	O
significantly	O
lower	O
LV	O
global	O
longitudinal	O
systolic	O
strain	O
(	O
GLS	O
)	O
than	O
controls	O
(	O
GLS	O
:	O
-17.01±2.42	O
%	O
vs.	O
-19.39±3.81	O
%	O
,	O
p	O
<	O
0.001	O
;	O
respectively	O
)	O
.	O

In	O
line	O
,	O
an	O
abnormal	O
GLS	O
had	O
adequate	O
diagnostic	O
performance	O
to	O
detect	O
MCpEF	O
(	O
sensitivity	O
,	O
specificity	O
,	O
and	O
accuracy	O
of	O
82	O
%	O
,	O
70	O
%	O
,	O
and	O
76	O
%	O
,	O
respectively	O
)	O
,	O
which	O
was	O
superior	O
to	O
cMRI	B-P
based	O
on	O
the	O
Lake-Louise	O
criteria	O
(	O
sensitivity	O
,	O
specificity	O
,	O
and	O
accuracy	O
54	O
%	O
,	O
71	O
%	O
,	O
and	O
67	O
%	O
,	O
respectively	O
)	O
.	O

In	O
addition	O
,	O
adding	O
GLS	O
to	O
the	O
Lake-Louise	O
criteria	O
improved	O
significantly	O
the	O
diagnostic	O
performance	O
of	O
cMRI	B-P
to	O
detect	O
MCpEF	O
(	O
sensitivity	O
,	O
specificity	O
,	O
and	O
accuracy	O
96	O
%	O
,	O
55	O
%	O
,	O
and	O
75	O
%	O
,	O
respectively	O
)	O
.	O

The	O
findings	O
of	O
this	O
study	O
suggest	O
that	O
GLS	O
using	O
2D	B-P
STE	I-P
could	O
play	O
an	O
important	O
role	O
in	O
the	O
diagnostic	O
evaluation	O
of	O
patients	O
with	O
suspected	O
chronic	O
myocarditis	O
with	O
preserved	O
LV	O
ejection	O
fraction	O
(	O
MCpEF	O
)	O
.	O

Snack	O
intake	O
is	O
reduced	O
using	O
an	O
implicit	O
,	O
high-level	O
construal	O
cue	O
.	O

Priming	O
a	O
high	O
level	O
construal	O
has	O
been	O
shown	O
to	O
enhance	O
self-control	O
and	O
reduce	O
preference	O
for	O
indulgent	O
food	O
.	O

Subtle	O
visual	O
cues	O
have	O
been	O
shown	O
to	O
enhance	O
the	O
effects	O
of	O
a	O
priming	O
procedure	O
.	O

The	O
current	O
study	O
therefore	O
examined	O
the	O
combined	O
impact	O
of	O
construal	O
level	O
and	O
a	O
visual	O
cue	O
reminder	O
on	O
the	O
consumption	O
of	O
energy-dense	O
snack	O
s.	O
A	O
student	O
and	O
community-based	O
adult	O
sample	O
with	O
a	O
wide	O
age	O
and	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
range	O
(	O
N	O
=	O
176	O
)	O
were	O
randomly	O
assigned	O
to	O
a	O
high	O
or	O
low	O
construal	O
condition	O
in	O
which	O
a	O
novel	O
symbol	O
was	O
embedded	O
.	O

Afterward	O
participants	O
completed	O
a	O
taste	O
test	B-P
of	O
ad	O
libitum	O
snack	O
foods	O
in	O
the	O
presence	O
or	O
absence	O
of	O
the	O
symbol	O
.	O

The	O
high	O
(	O
vs.	O
the	O
low	O
)	O
construal	O
level	O
prime	O
successfully	O
generated	O
more	O
abstract	O
responses	O
(	O
p	O
<	O
.0001	O
)	O
and	O
reduced	O
intake	O
when	O
the	O
cue	O
-	O
reminder	O
was	O
present	O
(	O
p	O
=	O
.02	O
)	O
but	O
not	O
when	O
it	O
was	O
absent	O
(	O
p	O
=	O
.40	O
)	O
.	O

Priming	O
high	O
construal	O
level	O
thinking	O
reduces	O
consumption	O
of	O
high	O
energy	O
dense	O
snacks	O
in	O
the	O
presence	O
of	O
a	O
visual	O
cue	O
-	O
reminder	O
.	O

This	O
may	O
be	O
a	O
practical	O
technique	O
for	O
reducing	O
overeating	O
and	O
has	O
the	O
potential	O
to	O
be	O
extended	O
to	O
other	O
unhealthy	O
behaviors	O
.	O

(	O
PsycINFO	O
Database	O
Record	O

Transition	O
From	O
Hospital	O
to	O
Home	O
in	O
Preterm	O
Infants	O
and	O
Their	O
Families	O
.	O

When	O
the	O
day	O
of	O
discharge	O
from	O
a	O
neonatal	O
intensive	O
care	O
unit	O
(	O
NICU	O
)	O
comes	O
for	O
the	O
parents	O
of	O
newborn	O
infants	O
,	O
they	O
are	O
filled	O
with	O
long-awaited	O
joy	O
and	O
happiness	O
.	O

They	O
go	O
home	O
feeling	O
as	O
parents	O
,	O
away	O
from	O
scheduled	O
routines	O
of	O
the	O
hospital	O
,	O
monitor	O
alarms	O
,	O
clinical	O
rounds	O
,	O
numerous	O
tests	B-P
,	O
and	O
so	O
on	O
.	O

What	O
do	O
we	O
know	O
about	O
what	O
happens	O
after	O
these	O
little	O
patients	O
and	O
their	O
families	O
leave	O
the	O
NICU	O
?	O

What	O
happens	O
from	O
the	O
point	O
of	O
leaving	O
the	O
hospital	O
until	O
when	O
things	O
get	O
settled	O
and	O
life	O
becomes	O
perceived	O
as	O
normal	O
?	O

This	O
article	O
presents	O
a	O
short	O
summary	O
of	O
research	O
conducted	O
with	O
the	O
vulnerable	O
population	O
of	O
high-risk	O
and	O
preterm	O
infants	O
and	O
their	O
families	O
postdischarge	O
.	O

Available	O
evidence	O
suggests	O
that	O
transition	O
to	O
home	O
after	O
hospital	O
discharge	O
,	O
a	O
phenomenon	O
that	O
many	O
families	O
experience	O
,	O
is	O
challenging	O
and	O
requires	O
attention	O
from	O
clinicians	O
and	O
researchers	O
if	O
we	O
are	O
to	O
provide	O
effective	O
,	O
efficient	O
,	O
and	O
high-quality	O
care	O
.	O

Mechanisms	O
of	O
Improved	O
Exercise	O
Performance	O
under	O
Hyperoxia	O
.	O

The	O
impact	O
of	O
hyperoxia	O
on	O
exercise	O
limitation	O
is	O
still	O
incompletely	O
understood	O
.	O

We	O
investigated	O
to	O
which	O
extent	O
breathing	O
hyperoxia	O
enhances	O
the	O
exercise	O
performance	O
of	O
healthy	O
subjects	O
and	O
which	O
physiologic	O
mechanisms	O
are	O
involved	O
.	O

A	O
total	O
of	O
32	O
healthy	O
volunteers	O
(	O
43	O
±	O
15	O
years	O
,	O
12	O
women	O
)	O
performed	O
4	O
bicycle	O
exercise	O
tests	O
to	O
exhaustion	O
with	O
ramp	O
and	O
constant-load	O
protocols	O
(	O
at	O
75	O
%	O
of	O
the	O
maximal	O
workload	O
[	O
Wmax	O
]	O
on	O
FiO2	O
0.21	O
)	O
on	O
separate	O
occasions	O
while	O
breathing	O
ambient	O
(	O
FiO2	O
0.21	O
)	O
or	O
oxygen-enriched	O
air	O
(	O
FiO2	O
0.50	O
)	O
in	O
a	O
random	O
,	O
blinded	O
order	O
.	O

Workload	O
,	O
endurance	O
,	O
gas	O
exchange	O
,	O
pulse	B-P
oximetry	I-P
(	O
SpO2	B-P
)	O
,	O
and	O
cerebral	O
(	O
CTO	O
)	O
and	O
quadriceps	O
muscle	O
tissue	O
oxygenation	O
(	O
QMTO	O
)	O
were	O
measured	O
.	O

During	O
the	O
final	O
15	O
s	O
of	O
ramp	O
exercising	O
with	O
FiO2	O
0.50	O
,	O
Wmax	O
(	O
mean	O
±	O
SD	O
270	O
±	O
80	O
W	O
)	O
,	O
SpO2	B-P
(	O
99	O
±	O
1	O
%	O
)	O
,	O
and	O
CTO	O
(	O
67	O
±	O
9	O
%	O
)	O
were	O
higher	O
and	O
the	O
Borg	O
CR10	O
Scale	O
dyspnea	O
score	O
was	O
lower	O
(	O
4.8	O
±	O
2.2	O
)	O
than	O
the	O
corresponding	O
values	O
with	O
FiO2	O
0.21	O
(	O
Wmax	O
257	O
±	O
76	O
W	O
,	O
SpO2	B-P
96	O
±	O
3	O
%	O
,	O
CTO	O
61	O
±	O
9	O
%	O
,	O
and	O
Borg	O
CR10	O
Scale	O
dyspnea	O
score	O
5.7	O
±	O
2.6	O
,	O
p	O
<	O
0.05	O
,	O
all	O
comparisons	O
)	O
.	O

In	O
constant-load	O
exercising	O
with	O
FiO2	O
0.50	O
,	O
endurance	O
was	O
longer	O
than	O
with	O
FiO2	O
0.21	O
(	O
16	O
min	O
22	O
s	O
±	O
7	O
min	O
39	O
s	O
vs.	O
10	O
min	O
47	O
s	O
±	O
5	O
min	O
58	O
s	O
)	O
.	O

With	O
FiO2	O
0.50	O
,	O
SpO2	B-P
(	O
99	O
±	O
0	O
%	O
)	O
and	O
QMTO	O
(	O
69	O
±	O
8	O
%	O
)	O
were	O
higher	O
than	O
the	O
corresponding	O
isotime	O
values	O
to	O
end-exercise	O
with	O
FiO2	O
0.21	O
(	O
SpO2	B-P
96	O
±	O
4	O
%	O
,	O
QMTO	O
66	O
±	O
9	O
%	O
)	O
,	O
while	O
minute	O
ventilation	O
was	O
lower	O
in	O
hyperoxia	O
(	O
82	O
±	O
18	O
vs.	O
93	O
±	O
23	O
L/min	O
,	O
p	O
<	O
0.05	O
,	O
all	O
comparisons	O
)	O
.	O

In	O
healthy	O
subjects	O
,	O
hyperoxia	O
increased	O
maximal	O
power	O
output	O
and	O
endurance	O
.	O

It	O
improved	O
arterial	O
,	O
cerebral	O
,	O
and	O
muscle	O
tissue	O
oxygenation	O
,	O
while	O
minute	O
ventilation	O
and	O
dyspnea	O
perception	O
were	O
reduced	O
.	O

The	O
findings	O
suggest	O
that	O
hyperoxia	O
enhanced	O
cycling	O
performance	O
through	O
a	O
more	O
efficient	O
pulmonary	O
gas	O
exchange	O
and	O
a	O
greater	O
availability	O
of	O
oxygen	O
to	O
muscles	O
and	O
the	O
brain	O
(	O
cerebral	O
motor	O
and	O
sensory	O
neurons	O
)	O
.	O

Engineering	O
and	O
In	O
Vivo	O
Applications	O
of	O
Riboswitches	O
.	O

Riboswitches	O
are	O
common	O
gene	O
regulatory	O
units	O
mostly	O
found	O
in	O
bacteria	O
that	O
are	O
capable	O
of	O
altering	O
gene	O
expression	O
in	O
response	O
to	O
a	O
small	O
molecule	O
.	O

These	O
structured	O
RNA	O
elements	O
consist	O
of	O
two	O
modular	O
subunits	O
:	O
an	O
aptamer	O
domain	O
that	O
binds	O
with	O
high	O
specificity	O
and	O
affinity	O
to	O
a	O
target	O
ligand	O
and	O
an	O
expression	O
platform	O
that	O
transduces	O
ligand	O
binding	O
to	O
a	O
gene	O
expression	O
output	O
.	O

Significant	O
progress	O
has	O
been	O
made	O
in	O
engineering	O
novel	O
aptamer	O
domains	O
for	O
new	O
small	O
molecule	O
inducers	O
of	O
gene	O
expression	O
.	O

Modified	O
expression	O
platforms	O
have	O
also	O
been	O
optimized	O
to	O
function	O
when	O
fused	O
with	O
both	O
natural	O
and	O
synthetic	O
aptamer	O
domains	O
.	O

As	O
this	O
field	O
expands	O
,	O
the	O
use	O
of	O
these	O
privileged	O
scaffolds	O
has	O
permitted	O
the	O
development	O
of	O
tools	O
such	O
as	O
RNA	O
-based	O
fluorescent	O
biosensors	O
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
the	O
methods	O
that	O
have	O
been	O
developed	O
to	O
engineer	O
new	O
riboswitches	O
and	O
highlight	O
applications	O
of	O
natural	O
and	O
synthetic	O
riboswitches	O
in	O
enzyme	O
and	O
strain	O
engineering	O
,	O
in	O
controlling	O
gene	O
expression	O
and	O
cellular	O
physiology	O
,	O
and	O
in	O
real-time	B-P
imaging	I-P
of	O
cellular	O
metabolites	O
and	O
signals	O
.	O

Expected	O
final	O
online	O
publication	O
date	O
for	O
the	O
Annual	O
Review	O
of	O
Biochemistry	O
Volume	O
86	O
is	O
June	O
20	O
,	O
2017	O
.	O

Please	O
see	O
http	O
:	O
//www.annualreviews.org/page/journal/pubdates	O
for	O
revised	O
estimates	O
.	O

Three-dimensional	O
functional	O
human	O
neuronal	O
networks	O
in	O
uncompressed	O
low-density	O
electrospun	O
fiber	O
scaffolds	O
.	O

We	O
demonstrate	O
an	O
artificial	O
three-dimensional	O
(	O
3D	O
)	O
electrical	O
active	O
human	O
neuronal	O
network	O
system	O
,	O
by	O
the	O
growth	O
of	O
brain	O
neural	O
progenitors	O
in	O
highly	O
porous	O
low	O
density	O
electrospun	O
poly-ε-caprolactone	O
(	O
PCL	O
)	O
fiber	O
scaffolds	O
.	O

In	O
neuroscience	O
research	O
cell-based	B-P
assays	I-P
are	O
important	O
experimental	O
instruments	O
for	O
studying	O
neuronal	O
function	O
in	O
health	O
and	O
disease	O
.	O

Traditional	O
cell	B-P
culture	I-P
at	O
2D	O
-	O
surfaces	O
induces	O
abnormal	O
cell	O
-	O
cell	O
contacts	O
and	O
network	O
formation	O
.	O

Hence	O
,	O
there	O
is	O
a	O
tremendous	O
need	O
to	O
explore	O
in	O
vivo	O
-	O
resembling	O
3D	O
neural	O
cell	B-P
culture	I-P
approaches	O
.	O

We	O
present	O
an	O
improved	O
electrospinning	O
method	O
for	O
fabrication	O
of	O
scaffolds	O
that	O
promote	O
neuronal	O
differentiation	O
into	O
highly	O
3D	O
integrated	O
networks	O
,	O
formation	O
of	O
inhibitory	O
and	O
excitatory	O
synapses	O
and	O
extensive	O
neurite	O
growth	O
.	O

Notably	O
,	O
in	O
3D	O
scaffolds	O
in	O
vivo	O
-	O
resembling	O
intermixed	O
neuronal	O
and	O
glial	O
cell	O
network	O
were	O
formed	O
,	O
whereas	O
in	O
parallel	O
2D	O
cultures	B-P
a	O
neuronal	O
cell	O
layer	O
grew	O
separated	O
from	O
an	O
underlying	O
glial	O
cell	O
layer	O
.	O

Hence	O
,	O
the	O
use	O
of	O
the	O
3D	O
cell	B-P
assay	I-P
presented	O
will	O
most	O
likely	O
provide	O
more	O
physiological	O
relevant	O
results	O
.	O

Evaluation	O
and	O
Treatment	O
of	O
Anemia	O
in	O
Premature	O
Infants	O
.	O

Anemia	O
in	O
preterm	O
infants	O
is	O
the	O
pathophysiological	O
process	O
with	O
greater	O
and	O
more	O
rapid	O
decline	O
in	O
hemoglobin	O
compared	O
to	O
the	O
physiological	O
anemia	O
in	O
infants	O
.	O

There	O
is	O
a	O
need	O
for	O
transfusions	O
and	O
administration	O
of	O
human	O
recombinant	O
erythropoietin	O
.	O

To	O
determine	O
the	O
frequency	O
of	O
anemia	O
in	O
premature	O
infants	O
at	O
the	O
Pediatric	O
Clinic	O
,	O
University	O
Clinical	O
Center	O
Sarajevo	O
,	O
as	O
well	O
as	O
parameter	O
values	O
in	O
the	O
blood	B-P
count	I-P
of	O
premature	O
infants	O
and	O
to	O
explore	O
a	O
relationship	O
between	O
blood	O
transfusions	O
with	O
the	O
advent	O
of	O
intraventricular	O
hemorrhage	O
(	O
determine	O
treatment	O
outcome	O
in	O
preterm	O
infants	O
)	O
.	O

Research	O
is	O
retrospective	O
study	O
and	O
it	O
included	O
the	O
period	O
of	O
six	O
months	O
in	O
year	O
2014	O
.	O

Research	O
included	O
100	O
patients	O
,	O
gestational	O
age	O
<	O
37	O
weeks	O
(	O
premature	O
infants	O
)	O
.	O

Data	O
were	O
collected	O
by	O
examining	O
the	O
medical	O
records	O
of	O
patients	O
at	O
the	O
Pediatric	O
Clinic	O
,	O
UCCS	O
.	O

The	O
first	O
group	O
of	O
patients	O
were	O
premature	O
infants	O
of	O
gestational	O
age	O
≤	O
32	O
weeks	O
(	O
62/100	O
)	O
and	O
the	O
second	O
group	O
were	O
premature	O
infants	O
of	O
gestational	O
age	O
33-37	O
weeks	O
(	O
38/100	O
)	O
.	O

Among	O
the	O
patients	O
,	O
5	O
%	O
were	O
boys	O
and	O
46	O
%	O
girls	O
.	O

There	O
was	O
significant	O
difference	O
in	O
birth	O
weight	O
and	O
APGAR	O
score	O
among	O
the	O
groups	O
.	O

In	O
the	O
first	O
group	O
,	O
there	O
were	O
27.42	O
%	O
of	O
deaths	O
,	O
while	O
in	O
the	O
second	O
group	O
,	O
there	O
were	O
only	O
10.53	O
%	O
of	O
deaths	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
the	O
length	O
of	O
treatment	O
.	O

There	O
was	O
a	O
statistically	O
significant	O
difference	O
in	O
the	O
need	O
for	O
transfusion	O
among	O
the	O
groups	O
.	O

18	O
patients	O
in	O
the	O
first	O
group	O
required	O
a	O
transfusion	O
,	O
while	O
in	O
the	O
second	O
group	O
only	O
3	O
patients	O
.	O

Preterm	O
infants	O
of	O
gestational	O
age	O
≤	O
32	O
weeks	O
are	O
likely	O
candidates	O
for	O
blood	O
transfusion	O
during	O
treatment	O
.	O

Preterm	O
infants	O
of	O
gestational	O
age	O
≤	O
32	O
weeks	O
have	O
the	O
risk	O
of	O
intracranial	O
bleeding	O
associated	O
with	O
the	O
application	O
of	O
blood	O
transfusion	O
in	O
the	O
first	O
week	O
of	O
life	O
.	O

Bilateral	O
Vertebral	O
Venous	O
Sinus	O
Thrombosis	O
Causing	O
Cervical	O
Spinal	O
Cord	O
Compression	O
in	O
a	O
Dog	O
.	O

A	O
10-year-old	O
male	O
neutered	O
mixed	O
breed	O
dog	O
was	O
evaluated	O
for	O
cervical	O
hyperesthesia	O
and	O
tetraparesis	O
.	O

Magnetic	B-P
resonance	I-P
imaging	I-P
of	O
the	O
brain	O
and	O
cervical	O
spinal	O
cord	O
identified	O
an	O
extradural	O
compressive	O
lesion	O
over	O
the	O
body	O
of	O
C2	O
caused	O
by	O
marked	O
dilation	O
of	O
the	O
vertebral	O
venous	O
sinuses	O
.	O

Following	O
intravenous	O
contrast	O
administration	O
both	O
vertebral	O
sinuses	O
had	O
heterogeneous	O
contrast	O
enhancement	O
consistent	O
with	O
incomplete	O
thrombi	O
formation	O
.	O

An	O
abdominal	B-P
ultrasound	I-P
also	O
showed	O
a	O
distal	O
aortic	O
thrombus	O
.	O

A	O
definitive	O
cause	O
for	O
the	O
thrombi	O
formation	O
was	O
not	O
identified	O
,	O
but	O
the	O
patient	O
had	O
several	O
predisposing	O
factors	O
which	O
may	O
have	O
contributed	O
.	O

The	O
patient	O
was	O
treated	O
with	O
a	O
combination	O
of	O
warfarin	O
,	O
clopidogrel	O
,	O
and	O
enoxaparin	O
as	O
well	O
as	O
analgesics	O
.	O

Within	O
48	O
h	O
of	O
initiation	O
of	O
warfarin	O
therapy	O
,	O
the	O
tetraparesis	O
and	O
hyperesthesia	O
were	O
markedly	O
improved	O
.	O

Repeat	O
abdominal	B-P
ultrasound	I-P
3	O
weeks	O
after	O
discharge	O
showed	O
reduction	O
in	O
size	O
of	O
aortic	O
thrombus	O
.	O

Neurologic	O
function	O
remained	O
normal	O
for	O
6	O
weeks	O
following	O
initiation	O
of	O
treatment	O
.	O

Seventy-four	O
days	O
following	O
initial	O
diagnosis	O
the	O
patient	O
rapidly	O
declined	O
and	O
passed	O
away	O
at	O
home	O
.	O

Necropsy	B-P
was	O
declined	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
vertebral	O
venous	O
sinus	O
enlargement	O
leading	O
to	O
spinal	O
cord	O
compression	O
and	O
tetraparesis	O
in	O
a	O
dog	O
.	O

Additionally	O
,	O
warfarin	O
in	O
combination	O
with	O
clopidogrel	O
and	O
enoxaparin	O
appeared	O
to	O
be	O
a	O
safe	O
and	O
effective	O
treatment	O
for	O
the	O
suspected	O
thrombi	O
reported	O
in	O
this	O
case	O
.	O

Vertebral	O
sinus	O
enlargement	O
secondary	O
to	O
thrombi	O
should	O
be	O
considered	O
as	O
a	O
differential	O
diagnosis	O
in	O
patients	O
presenting	O
with	O
tetraparesis	O
and	O
cervical	O
hyperesthesia	O
.	O

Preoperative	O
ultrasonographic	B-P
findings	O
of	O
internal	O
jugular	O
veins	O
and	O
carotid	O
arteries	O
in	O
kidney	O
transplant	O
recipients	O
.	O

Hemodialysis	O
via	O
the	O
internal	O
jugular	O
vein	O
(	O
IJV	O
)	O
has	O
been	O
widely	O
used	O
for	O
patients	O
with	O
end	O
stage	O
renal	O
disease	O
(	O
ESRD	O
)	O
patients	O
,	O
as	O
they	O
have	O
a	O
higher	O
risk	O
of	O
arterial	O
diseases	O
.	O

We	O
investigated	O
the	O
ultrasonographic	B-P
findings	O
of	O
the	O
IJV	O
and	O
carotid	O
artery	O
(	O
CA	O
)	O
in	O
recipients	O
of	O
kidney	O
transplantation	O
(	O
KT	O
)	O
and	O
identified	O
factors	O
influencing	O
IJV	O
/	O
CA	O
abnormalities	O
.	O

We	O
enrolled	O
120	O
adult	O
KT	O
recipients	O
.	O

Patients	O
in	O
group	O
A	O
(	O
n	O
=	O
57	O
)	O
had	O
a	O
history	O
of	O
IJV	O
hemodialysis	O
,	O
while	O
those	O
in	O
group	O
B	O
(	O
n	O
=	O
63	O
)	O
were	O
not	O
yet	O
on	O
dialysis	O
or	O
undergoing	O
dialysis	O
methods	O
not	O
involving	O
the	O
IJV	O
.	O

The	O
day	O
before	O
surgery	O
,	O
we	O
evaluated	O
the	O
state	O
of	O
the	O
IJV	O
and	O
CA	O
using	O
ultrasonography	B-P
.	O

We	O
followed	O
patients	O
with	O
IJV	O
stenosis	O
for	O
six	O
months	O
after	O
KT	O
.	O

Ultrasonography	B-P
revealed	O
that	O
four	O
patients	O
(	O
7	O
%	O
)	O
in	O
group	O
A	O
had	O
IJV	O
abnormalities	O
,	O
while	O
no	O
patients	O
in	O
group	O
B	O
had	O
abnormalities	O
(	O
P	O
=	O
0.118	O
)	O
.	O

Of	O
the	O
four	O
patients	O
with	O
abnormalities	O
,	O
one	O
with	O
57.4	O
%	O
stenosis	O
normalized	O
during	O
follow-	O
up	O
.	O

However	O
,	O
another	O
patient	O
with	O
90.1	O
%	O
stenosis	O
progressed	O
to	O
occlusion	O
,	O
while	O
the	O
two	O
patients	O
with	O
total	O
occlusion	O
remained	O
the	O
same	O
.	O

Twenty	O
patients	O
in	O
group	O
A	O
(	O
n	O
=	O
11	O
)	O
and	O
B	O
(	O
n	O
=	O
9	O
)	O
had	O
several	O
CA	O
abnormalities	O
(	O
P	O
=	O
0.462	O
)	O
.	O

Upon	O
multivariate	O
analysis	O
with	O
stepwise	O
selection	O
,	O
height	O
and	O
age	O
were	O
significantly	O
correlated	O
with	O
IJV	O
stenosis	O
(	O
P	O
=	O
0.043	O
,	O
odds	O
ratio	O
=	O
0.9	O
)	O
and	O
CA	O
abnormality	O
(	O
P	O
=	O
0.012	O
,	O
odds	O
ratio	O
=	O
1.1	O
)	O
,	O
respectively	O
.	O

IJV	O
abnormalities	O
(	O
especially	O
with	O
a	O
history	O
of	O
IJV	O
hemodialysis	O
)	O
and	O
CA	O
abnormalities	O
may	O
be	O
present	O
in	O
ESRD	O
patients	O
.	O

Therefore	O
,	O
we	O
recommend	O
ultrasonographic	B-P
evaluation	O
before	O
catheterization	O
.	O

RATIONAL	O
DESIGN	O
OF	O
NANOBODY80	O
LOOP	O
PEPTIDOMIMETICS	O
:	O
TOWARDS	O
BIASED	O
β2	O
ADRENERGIC	O
RECEPTOR	O
LIGANDS	O
.	O

G	O
protein-coupled	O
receptors	O
(	O
GPCRs	O
)	O
play	O
an	O
important	O
role	O
for	O
many	O
cellular	O
responses	O
,	O
and	O
as	O
such	O
their	O
mechanism	O
of	O
action	O
is	O
of	O
utmost	O
interest	O
.	O

To	O
gain	O
insight	O
into	O
the	O
active	O
conformation	O
of	O
GPCRs	O
,	O
the	O
X-ray	O
crystal	O
structures	O
of	O
Nanobody	O
(	O
Nb	O
)	O
-stabilized	O
β2-adrenergic	O
receptor	O
(	O
β2AR	O
)	O
have	O
been	O
reported	O
.	O

Nb80	O
in	O
particular	O
is	O
able	O
to	O
bind	O
the	O
intracellular	O
G	O
protein	O
binding	O
site	O
of	O
β2AR	O
and	O
stabilize	O
the	O
receptors	O
in	O
an	O
active	O
conformation	O
.	O

Within	O
Nb80	O
,	O
the	O
complementarity-determining	O
region	O
3	O
(	O
CDR3	O
)	O
is	O
responsible	O
for	O
most	O
of	O
the	O
binding	O
interactions	O
.	O

Hence	O
we	O
hypothesized	O
that	O
peptidomimetics	O
of	O
the	O
CDR3	O
loop	O
might	O
be	O
sufficient	O
for	O
binding	O
to	O
the	O
receptor	O
,	O
inhibiting	O
the	O
interaction	O
of	O
β2AR	O
with	O
intracellular	O
GPCR	O
interacting	O
proteins	O
(	O
e.g	O
.	O

G	O
proteins	O
)	O
.	O

Based	O
on	O
previous	O
crystallographic	B-P
data	I-P
,	O
a	O
set	O
of	O
peptidomimetics	O
were	O
synthesized	O
which	O
,	O
similarly	O
to	O
the	O
Nb80	O
CDR3	O
loop	O
,	O
adopt	O
a	O
	O
-hairpin	O
conformation	O
.	O

Syntheses	O
,	O
conformationa	O
l	O
analysis	O
,	O
binding	O
and	O
functional	O
in	O
vitro	O
assays	O
,	O
as	O
well	O
as	O
internalization	O
experiments	O
were	O
performed	O
.	O

We	O
demonstrate	O
that	O
peptidomimetics	O
can	O
structurally	O
mimic	O
the	O
CDR3	O
loop	O
of	O
a	O
Nanobody	O
and	O
its	O
function	O
by	O
inhibiting	O
G	O
protein	O
coupling	O
as	O
measured	O
by	O
partial	O
inhibition	O
of	O
cAMP	O
production	O
.	O

Dysplasia	O
discrimination	O
in	O
intestinal	O
-	O
type	O
neoplasia	O
of	O
the	O
esophagus	O
and	O
colon	O
via	O
digital	B-P
image	I-P
analysis	I-P
.	O

Determining	O
gastrointestinal	O
tract	O
dysplasia	O
level	O
is	O
clinically	O
important	O
but	O
can	O
be	O
difficult	O
,	O
and	O
given	O
this	O
challenge	O
,	O
we	O
investigated	O
colonic	O
and	O
esophageal	O
dysplastic	O
progression	O
using	O
digital	B-P
image	I-P
analysis	I-P
(	O
IA	B-P
)	O
.	O

Whole	O
slide	O
images	O
were	O
obtained	O
for	O
colonic	O
normal	O
mucosa	O
(	O
NCM	O
)	O
,	O
hyperplastic	O
polyps	O
(	O
HP	O
)	O
,	O
conventional	O
tubular	O
adenomas	O
(	O
TA	O
)	O
,	O
and	O
adenomas	O
with	O
high-grade	O
dysplasia	O
(	O
HGD	O
)	O
,	O
and	O
esophageal	O
intestinal	O
metaplasia	O
negative	O
for	O
dysplasia	O
(	O
IM	O
)	O
,	O
indefinite	O
for	O
dysplasia	O
(	O
IFD	O
)	O
,	O
low-grade	O
dysplasia	O
(	O
LGD	O
)	O
,	O
and	O
HGD	O
.	O

Characteristic	O
nuclei	O
were	O
circumscribed	O
,	O
and	O
parameters	O
discriminating	O
groups	O
included	O
nuclear	O
circumference	O
(	O
μm	O
)	O
,	O
area	O
(	O
μm	O
(	O
2	O
)	O
)	O
,	O
and	O
15	O
positive	B-P
pixel	I-P
count	I-P
(	I-P
PPC	I-P
)	I-P
algorithm	I-P
IA	I-P
measurements	O
.	O

In	O
colon	O
polyps	O
and	O
esophageal	O
lesions	O
,	O
average	O
nuclear	O
area	O
and	O
circumference	O
ranged	O
30-108.6	O
μm	O
(	O
2	O
)	O
and	O
27.5-48.9	O
μm	O
,	O
respectively	O
.	O

Differences	O
for	O
average	O
nuclear	O
area	O
and	O
circumference	O
met	O
statistical	O
significance	O
(	O
p	O
<	O
0.05	O
)	O
between	O
diagnostic	O
groups	O
in	O
the	O
esophagus	O
and	O
colon	O
,	O
except	O
for	O
IM	O
versus	O
IFD	O
nuclear	O
area	O
.	O

Pixel	O
intensity	O
(	O
brightness	O
)	O
separated	O
lesions	O
within	O
both	O
groups	O
with	O
statistical	O
significance	O
except	O
for	O
colonic	O
TAs	O
versus	O
HPs	O
and	O
esophageal	O
LGD	O
versus	O
IM	O
.	O

HGD	O
nuclei	O
in	O
both	O
groups	O
demonstrated	O
more	O
pixel	O
staining	O
heterogeneity	O
than	O
other	O
lesions	O
.	O

Hierarchical	O
clustering	O
and	O
principal	O
component	O
analysis	O
demonstrated	O
that	O
lesions	O
with	O
similar	O
diagnoses	O
tended	O
to	O
cluster	O
together	O
on	O
a	O
low-	O
to	O
high-grade	O
spectrum	O
.	O

Our	O
results	O
confirm	O
that	O
quantitative	B-P
IA	I-P
is	O
an	O
effective	O
adjunct	O
reflecting	O
dysplasia	O
in	O
colon	O
polyps	O
and	O
Barrett	O
esophagus	O
lesions	O
.	O

Nuclear	O
area	O
,	O
circumference	O
,	O
and	O
PPC	O
algorithm	O
findings	O
distinguished	O
lesions	O
in	O
a	O
statistically	O
significant	O
manner	O
.	O

This	O
suggests	O
utility	O
for	O
future	O
studies	O
on	O
similar	O
methods	O
,	O
which	O
may	O
provide	O
an	O
adjunctive	O
ancillary	O
technique	O
for	O
pathologists	O
and	O
enhance	O
patient	O
care	O
.	O

Determination	B-P
of	O
Deoxynivalenol	O
in	O
the	O
Urine	O
of	O
Pregnant	O
Women	O
in	O
the	O
UK	O
.	O

Deoxynivalenol	O
(	O
DON	O
)	O
is	O
one	O
of	O
the	O
most	O
commonly	O
occurring	O
trichothecenes	O
,	O
produced	O
mainly	O
by	O
Fusarium	O
graminearum	O
.	O

Little	O
is	O
known	O
about	O
the	O
effect	O
of	O
DON	O
exposure	O
or	O
the	O
levels	O
of	O
DON	O
exposure	O
that	O
occur	O
during	O
pregnancy	O
.	O

The	O
project	O
aimed	O
to	O
provide	O
data	O
on	O
levels	O
of	O
total	O
DON	O
and	O
de-epoxi	O
Deoxynivalenol	O
(	O
DOM-1	O
)	O
in	O
pregnant	O
human	O
urine	O
samples	O
analysed	O
by	O
liquid	B-P
chromatography-mass	I-P
spectrometry	I-P
(	O
LC-MS	B-P
)	O
.	O

Morning	O
urine	O
samples	O
were	O
collected	O
over	O
two	O
consecutive	O
days	O
from	O
42	O
volunteers	O
and	O
associated	O
food	O
consumption	O
was	O
recorded	O
for	O
the	O
24	O
h	O
prior	O
to	O
the	O
sample	O
.	O

Spearman	O
's	O
rho	O
non-parametric	O
test	O
for	O
correlation	O
was	O
used	O
to	O
assess	O
the	O
data	O
.	O

Levels	O
of	O
DON	O
did	O
not	O
differ	O
significantly	O
between	O
day	O
1	O
(	O
mean	O
29.7	O
ng/mL	O
urine	O
or	O
40.1	O
ng	O
DON	O
/mg	O
creatinine	O
)	O
and	O
day	O
2	O
(	O
mean	O
28.7	O
ng/mL	O
urine	O
or	O
38.8	O
ng	O
DON	O
/mg	O
creatinine	O
ng/mL/	O
day	O
)	O
urine	O
samples	O
.	O

The	O
only	O
significant	O
positive	O
correlation	O
was	O
found	O
between	O
total	O
ng	O
DON	O
/mg	O
creatinine	O
and	O
parity	O
(	O
rho	O
=	O
0.307	O
,	O
n	O
=	O
42	O
,	O
p	O
<	O
0.005	O
two-tailed	O
)	O
and	O
total	O
ng	O
DON	O
/mg	O
creatinine	O
with	O
baked	O
goods	O
on	O
day	O
1	O
(	O
rho	O
=	O
0.532	O
,	O
n	O
=	O
42	O
,	O
p	O
<	O
0.0005	O
two-tailed	O
)	O
.	O

This	O
study	O
provides	O
data	O
on	O
the	O
DON	O
levels	O
in	O
pregnancy	O
in	O
this	O
suburban	O
population	O
and	O
reassurance	O
that	O
those	O
levels	O
are	O
within	O
acceptable	O
limits	O
.	O

Mesenchymal	O
stromal	O
cell	O
-	O
secreted	O
chemerin	O
is	O
a	O
novel	O
immunomodulatory	O
molecule	O
driving	O
the	O
migration	O
of	O
ChemR23	O
-	O
expressing	O
cells	O
.	O

Mesenchymal	O
stromal	O
cells	O
(	O
MSCs	O
)	O
are	O
multipotent	O
cells	O
characterized	O
by	O
broad	O
immunomodulatory	O
properties	O
exploited	O
for	O
the	O
treatment	O
of	O
inflammatory	O
disorders	O
.	O

However	O
,	O
the	O
efficacy	O
of	O
MSC	O
-based	O
therapy	O
is	O
highly	O
variable	O
and	O
tightly	O
linked	O
to	O
MSC	O
culture	B-P
conditions	I-P
and	O
treatment	O
schedule	O
.	O

Thus	O
,	O
the	O
identification	O
of	O
novel	O
key	O
molecules	O
regulating	O
MSC	O
immunomodulatory	O
activities	O
in	O
vivo	O
might	O
constitute	O
a	O
crucial	O
step	O
toward	O
the	O
optimization	O
of	O
currently	O
available	O
clinical	O
protocols	O
.	O

In	O
this	O
regard	O
,	O
herein	O
,	O
we	O
sought	O
to	O
determine	O
whether	O
the	O
newly	O
identified	O
chemotactic	O
protein	O
,	O
chemerin	O
,	O
plays	O
a	O
role	O
in	O
MSC	O
-mediated	O
regulation	O
of	O
inflammation	O
.	O

Chemerin	O
production	O
by	O
human	O
MSCs	O
was	O
investigated	O
under	O
different	O
culture	B-P
conditions	I-P
using	O
enzyme-linked	B-P
immunosorbent	I-P
assay	I-P
(	O
ELISA	B-P
)	O
.	O

After	O
purification	O
,	O
MSC	O
-	O
secreted	O
chemerin	O
was	O
identified	O
using	O
mass	B-P
spectrometry	I-P
analysis	O
and	O
the	O
biological	O
activity	O
of	O
secreted	O
isoforms	O
was	O
evaluated	O
using	O
migration	B-P
assay	I-P
.	O

Bone	O
marrow	O
-	O
derived	O
MSCs	O
secrete	O
chemerin	O
and	O
express	O
its	O
receptors	O
ChemR23	O
and	O
CCRL2	O
.	O

Chemerin	O
production	O
is	O
dependent	O
on	O
culture	B-P
conditions	I-P
and	O
increases	O
upon	O
stimulation	O
with	O
inflammatory	O
cytokines	O
.	O

In	O
particular	O
,	O
platelet	O
lysate	O
(	O
PL	O
)	O
-	O
MSCs	O
produce	O
higher	O
levels	O
of	O
chemerin	O
compared	O
with	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
)	O
-	O
MSCs	O
.	O

Furthermore	O
,	O
chemerin	O
is	O
secreted	O
by	O
MSCs	O
as	O
an	O
inactive	O
precursor	O
,	O
which	O
can	O
be	O
converted	O
into	O
its	O
active	O
form	O
by	O
exogenous	O
chemerin	O
-	O
activating	O
serine	O
and	O
cysteine	O
proteases	O
.	O

Our	O
data	O
indicate	O
that	O
,	O
in	O
response	O
to	O
various	O
inflammatory	O
stimuli	O
,	O
MSCs	O
secrete	O
high	O
amounts	O
of	O
inactive	O
chemerin	O
,	O
which	O
can	O
then	O
be	O
activated	O
by	O
inflammation	O
-	O
induced	O
tissue	O
proteases	O
.	O

In	O
light	O
of	O
these	O
initial	O
findings	O
,	O
we	O
propose	O
that	O
further	O
analysis	O
of	O
chemerin	O
functions	O
in	O
vivo	O
might	O
constitute	O
a	O
crucial	O
step	O
toward	O
optimizing	O
MSC	O
-based	O
therapy	O
for	O
inflammatory	O
diseases	O
.	O

The	O
relationship	O
between	O
anthropometry	O
and	O
body	O
composition	O
from	O
computed	B-P
tomography	I-P
:	O
The	O
Mediators	O
of	O
Atherosclerosis	O
in	O
South	O
Asians	O
Living	O
in	O
America	O
Study	O
.	O

Few	O
studies	O
examine	O
the	O
relationships	O
between	O
anthropometry	O
and	O
the	O
body	O
composition	O
measures	O
they	O
approximate	O
,	O
or	O
whether	O
they	O
differ	O
by	O
sex	O
,	O
and	O
no	O
studies	O
have	O
examined	O
these	O
relationships	O
in	O
South	O
Asians	O
living	O
in	O
the	O
US	O
.	O

We	O
conducted	O
a	O
cross-sectional	O
study	O
of	O
871	O
participants	O
in	O
the	O
Mediators	O
of	O
Atherosclerosis	O
in	O
South	O
Asians	O
Living	O
in	O
America	O
(	O
MASALA	O
)	O
Study	O
who	O
had	O
BMI	O
<	O
40	O
kg/m	O
(	O
2	O
)	O
and	O
underwent	O
abdominal	B-P
CT	I-P
scans	I-P
for	O
measurement	O
of	O
visceral	O
and	O
subcutaneous	O
fat	O
.	O

Linear	O
regression	O
was	O
used	O
to	O
model	O
the	O
associations	O
between	O
anthropometric	O
measures	O
and	O
naturally	O
log-transformed	O
body	O
composition	O
measures	O
.	O

All	O
measures	O
of	O
anthropometry	O
,	O
except	O
height	O
,	O
were	O
significantly	O
associated	O
with	O
visceral	O
fat	O
and	O
had	O
a	O
significant	O
non-linear	O
component	O
(	O
p	O
<	O
.05	O
)	O
.	O

The	O
only	O
associations	O
for	O
visceral	O
fat	O
that	O
exhibited	O
significant	O
heterogeneity	O
by	O
sex	O
were	O
waist	O
circumference	O
(	O
%	O
difference	O
in	O
visceral	O
fat	O
slope	O
:	O
women	O
1.92	O
,	O
men	O
2.74	O
,	O
p	O
=	O
.007	O
for	O
interaction	O
)	O
and	O
waist-to-hip	O
ratio	O
(	O
women	O
25.9	O
,	O
men	O
717.4	O
,	O
p	O
<	O
.001	O
)	O
.	O

Except	O
for	O
height	O
,	O
all	O
measures	O
of	O
anthropometry	O
were	O
significantly	O
associated	O
with	O
subcutaneous	O
fat	O
,	O
had	O
a	O
significant	O
quadratic	O
component	O
,	O
and	O
significant	O
heterogeneity	O
by	O
sex	O
(	O
weight	O
(	O
kg	O
)	O
:	O
2.74	O
for	O
women	O
,	O
4.08	O
for	O
men	O
;	O
BMI	O
(	O
kg/m	O
(	O
2	O
)	O
)	O
:	O
10.3	O
,	O
14.0	O
;	O
waist	O
circumference	O
(	O
cm	O
)	O
:	O
1.51	O
,	O
3.36	O
;	O
hip	O
circumference	O
(	O
cm	O
)	O
:	O
2.53	O
,	O
4.50	O
)	O
with	O
p	O
<	O
.001	O
for	O
each	O
.	O

In	O
MASALA	O
participants	O
,	O
the	O
relationships	O
of	O
anthropometric	O
measures	O
with	O
visceral	O
and	O
subcutaneous	O
fat	O
appear	O
similar	O
to	O
other	O
race	O
/	O
ethnic	O
groups	O
,	O
but	O
with	O
weaker	O
non-linearity	O
and	O
heterogeneity	O
by	O
sex	O
.	O

Given	O
these	O
results	O
,	O
researchers	O
should	O
consider	O
separate	O
models	O
by	O
sex	O
for	O
US	O
South	O
Asians	O
when	O
approximating	O
subcutaneous	O
fat	O
or	O
when	O
using	O
waist	O
circumference	O
to	O
approximate	O
visceral	O
fat	O
.	O

Effect	O
of	O
oral	O
carbohydrate	O
with	O
amino	O
acid	O
solution	O
on	O
serum	O
oxidative/anti-oxidative	O
status	O
in	O
healthy	O
volunteers	O
.	O

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
oral	O
carbohydrate	O
with	O
amino	O
acid	O
[	O
oral	O
nutritional	O
supplement	O
(	O
ONS	O
)	O
]	O
solution	O
on	O
oxidative	O
stress	O
in	O
healthy	O
persons	O
.	O

Fourteen	O
healthy	O
volunteers	O
were	O
segregated	O
into	O
control	O
and	O
ONS	O
groups	O
.	O

Volunteers	O
in	O
the	O
ONS	O
group	O
ingested	O
250	O
ml	O
of	O
Arginaid	O
Water	O
(	O
Nestle	O
Japan	O
,	O
Tokyo	O
,	O
Japan	O
)	O
in	O
the	O
evening	O
before	O
the	O
experiment	O
and	O
at	O
7:00	O
am	O
on	O
the	O
day	O
of	O
the	O
experiment	O
.	O

Volunteers	O
in	O
the	O
control	O
group	O
fasted	O
after	O
dinner	O
and	O
drank	O
only	O
water	O
until	O
7:00	O
am	O
on	O
the	O
day	O
of	O
the	O
experiment	O
.	O

In	O
both	O
groups	O
,	O
blood	O
was	O
collected	O
at	O
9:00	O
am	O
.	O

The	O
serum	O
total	O
oxidant	O
levels	O
and	O
antioxidant	O
capacity	O
were	O
assessed	O
by	O
d-ROMs	B-P
(	I-P
derivatives	I-P
of	I-P
reactive	I-P
oxygen	I-P
metabolites	I-P
)	I-P
test	I-P
and	O
BAP	B-P
(	I-P
biological	I-P
antioxidant	I-P
potential	I-P
)	I-P
test	I-P
,	O
respectively	O
.	O

In	O
the	O
ONS	O
group	O
,	O
the	O
serum	O
d-ROMs	B-P
level	I-P
was	O
significantly	O
lower	O
than	O
in	O
the	O
control	O
group	O
(	O
297	O
±	O
43	O
and	O
327	O
±	O
41	O
U.CARR	O
,	O
respectively	O
,	O
p	O
=	O
0.018	O
)	O
,	O
while	O
the	O
serum	O
BAP	B-P
level	I-P
was	O
significantly	O
higher	O
than	O
the	O
control	O
group	O
(	O
2410	O
±	O
432	O
and	O
1979	O
±	O
397	O
µmol/l	O
,	O
respectively	O
,	O
p	O
=	O
0.005	O
)	O
.	O

The	O
OXY	O
level	O
of	O
Arginaid	O
Water	O
was	O
much	O
higher	O
than	O
preOp	O
drink	O
(	O
Nutricia	O
,	O
Ireland	O
)	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
showed	O
that	O
an	O
ONS	O
with	O
arginine	O
loading	O
could	O
decrease	O
oxidative	O
stress	O
and	O
increase	O
antioxidant	O
capacity	O
in	O
healthy	O
volunteers	O
.	O

Vaginal	O
Infections	O
of	O
Albanian	O
women	O
Infected	O
with	O
HPV	O
and	O
their	O
impact	O
in	O
intraepithelial	O
cervical	O
lesions	O
evidenced	O
by	O
Pap	B-P
test	I-P
.	O

Cervical	B-P
cytology	I-P
is	O
the	O
best	O
single	O
method	O
for	O
large	O
screening	B-P
of	O
the	O
population	O
in	O
identifying	O
precancerous	O
lesions	O
of	O
the	O
uterine	O
cervix	O
.	O

To	O
estimate	O
the	O
frequency	O
of	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
positivity	O
in	O
a	O
group	O
of	O
Albanian	O
women	O
,	O
the	O
prevalence	O
of	O
vaginal	O
coinfections	O
,	O
and	O
the	O
relationship	O
of	O
coinfections	O
with	O
HPV	O
,	O
as	O
well	O
as	O
their	O
role	O
in	O
metaplasia	O
or	O
cervical	O
intraepithelial	O
lesions	O
(	O
CIN	O
)	O
.	O

In	O
this	O
retrospective	O
study	O
,	O
2075	O
vaginal	B-P
smears	I-P
were	O
examined	O
.	O

The	O
Papanicolaou	B-P
stain	I-P
was	O
used	O
for	O
all	O
slides	O
.	O

The	O
New	B-P
Bethesda	I-P
System	I-P
2001	O
was	O
used	O
for	O
the	O
interpretations	B-P
of	I-P
the	I-P
smears	I-P
.	O

Data	O
analysis	O
was	O
completed	O
using	O
the	O
Statistical	O
Package	O
for	O
the	O
Social	O
Sciences	O
version	O
19.0	O
.	O

Prevalence	O
of	O
HPV	O
positivity	O
was	O
43.9	O
%	O
with	O
an	O
average	O
age	O
of	O
35.48	O
±	O
9.27	O
years	O
.	O

Candida	O
coinfection	O
resulted	O
in	O
57.8	O
%	O
of	O
HPV	O
positive	O
women	O
with	O
a	O
significant	O
relationship	O
between	O
them	O
.	O

Gardnerella	O
coinfection	O
resulted	O
in	O
36	O
(	O
23	O
%	O
)	O
,	O
mixed	O
flora	O
in	O
34	O
(	O
8	O
%	O
)	O
,	O
and	O
Trichomonas	O
vaginalis	O
in	O
50	O
%	O
of	O
HPV	O
positive	O
woman	O
.	O

Among	O
the	O
women	O
with	O
positive	O
HPV	O
,	O
19	O
%	O
had	O
CIN	O
,	O
8	O
%	O
had	O
metaplasia	O
,	O
and	O
1	O
%	O
had	O
metaplasia	O
and	O
CIN	O
;	O
9	O
%	O
of	O
the	O
women	O
with	O
HPV	O
had	O
CIN1	O
and	O
one	O
of	O
the	O
coinfections	O
.	O

There	O
is	O
a	O
strong	O
relationship	O
between	O
CIN1	O
and	O
HPV	O
positivity	O
as	O
well	O
as	O
between	O
CIN1	O
and	O
coinfections	O
.	O

HPV	O
infection	O
is	O
a	O
major	O
factor	O
contributing	O
to	O
metaplasia	O
,	O
and	O
bacterial	O
coinfections	O
in	O
HPV	O
positive	O
women	O
have	O
a	O
statistically	O
significant	O
impact	O
in	O
the	O
development	O
of	O
metaplasia	O
.	O

The	O
role	O
of	O
IGF-1	O
and	O
the	O
distribution	O
of	O
body	O
fat	O
in	O
decreasing	O
the	O
number	O
of	O
prostate	B-P
rebiopsies	I-P
.	O

To	O
assess	O
the	O
usefulness	O
of	O
IGF-1	O
and	O
internal	O
organ	O
fat	O
measured	O
by	O
bioelectrical	O
impedance	O
audiometry	B-P
to	O
avoid	O
rebiopsies	B-P
in	O
patients	O
with	O
persistently	O
high	O
prostate-specific	O
antigen	O
(	O
PSA	O
)	O
levels	O
.	O

A	O
prospective	O
study	O
was	O
conducted	O
with	O
92	O
patients	O
who	O
underwent	O
prostate	B-P
rebiopsy	I-P
due	O
to	O
high	O
PSA	O
levels	O
with	O
negative	O
results	O
in	O
the	O
rectal	B-P
examination	I-P
and	O
a	O
lack	O
of	O
preneoplastic	O
lesions	O
.	O

The	O
patients	O
previously	O
had	O
their	O
IGF-1	O
levels	O
measured	O
and	O
had	O
undergone	O
an	O
impedance	B-P
audiometry	I-P
test	I-P
using	O
the	O
abdominal	O
Fat	O
Analyser	O
AB-140	O
TANITA	O
system	O
.	O

We	O
calculated	O
the	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curves	O
for	O
the	O
PSA	O
levels	O
,	O
%	O
PSA	O
,	O
internal	O
organ	O
fat	O
and	O
IGF-1	O
and	O
PSA	O
density	O
.	O

Twenty-five	O
patients	O
were	O
diagnosed	O
with	O
prostate	O
cancer	O
.	O

These	O
patients	O
had	O
significantly	O
higher	O
PSA	O
,	O
PSAd	O
and	O
IGF-1	O
values	O
and	O
a	O
tendency	O
towards	O
higher	O
internal	O
organ	O
fat	O
levels	O
and	O
lower	O
%	O
PSA	O
readings	O
(	O
p=.001	O
,	O
p=.003	O
,	O
p=.001	O
,	O
p=.24	O
and	O
P=0.28	O
,	O
respectively	O
)	O
.	O

The	O
ROC	O
curve	O
showed	O
an	O
area	O
under	O
the	O
curve	O
for	O
IGF-1	O
and	O
PSA	O
of	O
.82	O
and	O
.81	O
,	O
respectively	O
.	O

Using	O
the	O
cutoff	O
points	O
for	O
95	O
%	O
sensitivity	O
and	O
using	O
the	O
3	O
criteria	O
as	O
an	O
indication	O
of	O
rebiopsy	B-P
,	O
74	O
%	O
of	O
the	O
biopsies	B-P
would	O
have	O
been	O
spared	O
,	O
leaving	O
undiagnosed	O
only	O
1	O
patient	O
with	O
clinically	O
significant	O
cancer	O
-	O
Gleason	O
score	O
>	O
7	O
(	O
4+3	O
)	O
-	O
.	O

The	O
positive	O
and	O
negative	O
predictive	O
values	O
for	O
the	O
set	O
of	O
variables	O
were	O
higher	O
than	O
for	O
each	O
one	O
separately	O
(	O
PPV	O
:	O
66/NPV	O
:	O
63	O
)	O
.	O

The	O
cost	O
of	O
both	O
determinations	B-P
was	O
82	O
euros	O
.	O

Our	O
results	O
suggest	O
that	O
measuring	O
IGF-1	O
could	O
significantly	O
decrease	O
the	O
number	O
of	O
unnecessary	O
rebiopsies	B-P
in	O
an	O
inexpensive	O
and	O
safe	O
manner	O
.	O

Cardiac	O
protective	O
effects	O
of	O
remote	O
ischaemic	O
preconditioning	O
in	O
children	O
undergoing	O
tetralogy	O
of	O
fallot	O
repair	O
surgery	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

Remote	O
ischaemic	O
preconditioning	O
(	O
RIPC	O
)	O
by	O
inducing	O
brief	O
ischaemia	O
in	O
distant	O
tissues	O
protects	O
the	O
heart	O
against	O
myocardial	O
ischaemia-reperfusion	O
injury	O
(	O
IRI	O
)	O
in	O
children	O
undergoing	O
open-heart	O
surgery	O
,	O
although	O
its	O
effectiveness	O
in	O
adults	O
with	O
comorbidities	O
is	O
controversial	O
.	O

The	O
effectiveness	O
and	O
mechanism	O
of	O
RIPC	O
with	O
respect	O
to	O
myocardial	O
IRI	O
in	O
children	O
with	O
tetralogy	O
of	O
Fallot	O
(	O
ToF	O
)	O
,	O
a	O
severe	O
cyanotic	O
congenital	O
cardiac	O
disease	O
,	O
undergoing	O
open	O
heart	O
surgery	O
are	O
unclear	O
.	O

We	O
hypothesized	O
that	O
RIPC	O
can	O
confer	O
cardioprotection	O
in	O
children	O
undergoing	O
ToF	O
repair	O
surgery	O
.	O

Overall	O
,	O
112	O
ToF	O
children	O
undergoing	O
radical	O
open	O
cardiac	O
surgery	O
using	O
cardiopulmonary	O
bypass	O
(	O
CPB	O
)	O
were	O
randomized	O
to	O
either	O
a	O
RIPC	O
group	O
(	O
n	O
=	O
55	O
)	O
or	O
a	O
control	O
group	O
(	O
n	O
=	O
57	O
)	O
.	O

The	O
RIPC	O
protocol	O
consisted	O
of	O
three	O
cycles	O
of	O
5-min	O
lower	O
limb	O
occlusion	O
and	O
5-min	O
reperfusion	O
using	O
a	O
cuff-inflator	O
.	O

Serum	O
inflammatory	O
cytokines	O
and	O
cardiac	O
injury	O
markers	O
were	O
measured	O
before	O
surgery	O
and	O
after	O
CPB	O
.	O

Right	O
ventricle	O
outflow	O
tract	O
(	O
RVOT	O
)	O
tissues	O
were	O
collected	O
during	O
the	O
surgery	O
to	O
assess	O
hypoxia-inducible	O
factor	O
(	O
Hif	O
)	O
-1α	O
and	O
other	O
signalling	O
proteins	O
.	O

Cardiac	O
mitochondrial	O
injury	O
was	O
assessed	O
by	O
electron	B-P
microscopy	I-P
.	O

The	O
primary	O
results	O
showed	O
that	O
the	O
length	O
of	O
stay	O
in	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
was	O
longer	O
in	O
the	O
control	O
group	O
than	O
in	O
the	O
RIPC	O
group	O
(	O
52.30	O
±	O
13.43	O
h	O
vs.	O
47.55	O
±	O
10.34	O
h	O
,	O
respectively	O
,	O
P	O
=	O
0.039	O
)	O
.	O

Patients	O
in	O
the	O
control	O
group	O
needed	O
longer	O
post-operative	O
ventilation	O
time	O
compared	O
to	O
the	O
RIPC	O
group	O
(	O
35.02	O
±	O
6.56	O
h	O
vs.	O
31.96	O
±	O
6.60	O
h	O
,	O
respectively	O
,	O
P	O
=	O
0.016	O
)	O
.	O

The	O
levels	O
of	O
post-operative	O
serum	O
troponin-T	O
at	O
12	O
and	O
18	O
h	O
,	O
CK-MB	B-P
at	O
24	O
h	O
,	O
as	O
well	O
as	O
the	O
serum	O
h-FABP	O
levels	O
at	O
6	O
h	O
,	O
after	O
CPB	O
were	O
significantly	O
lower	O
,	O
which	O
was	O
coincident	O
with	O
significantly	O
higher	O
protein	O
expression	O
of	O
cardiac	O
Hif-1α	O
,	O
p-Akt	O
,	O
p-STAT3	O
,	O
p-STAT5	O
,	O
and	O
p-eNOS	O
and	O
less	O
vacuolization	O
of	O
mitochondria	O
in	O
the	O
RIPC	O
group	O
compared	O
to	O
the	O
control	O
group	O
.	O

In	O
ToF	O
children	O
undergoing	O
open	O
heart	O
surgery	O
,	O
RIPC	O
attenuates	O
myocardial	O
IRI	O
and	O
improves	O
the	O
short-term	O
prognosis	O
.	O

Meta-Analysis	O
of	O
29	O
Experiments	O
Evaluating	O
the	O
Effects	O
of	O
Rapamycin	O
on	O
Life	O
Span	O
in	O
the	O
Laboratory	O
Mouse	O
.	O

Rapamycin	O
has	O
favorable	O
effects	O
on	O
aging	O
in	O
mice	O
and	O
may	O
eventually	O
be	O
applied	O
to	O
encourage	O
``	O
healthy	O
aging	O
``	O
in	O
humans	O
.	O

This	O
study	O
analyzed	O
raw	O
data	O
from	O
29	O
survival	O
studies	O
of	O
rapamycin	O
-	O
and	O
control	O
-	O
treated	O
mice	O
,	O
with	O
the	O
goals	O
of	O
estimating	O
summary	O
statistics	O
and	O
identifying	O
factors	O
associated	O
with	O
effect	O
size	O
heterogeneity	O
.	O

Meta-analysis	O
demonstrated	O
significant	O
heterogeneity	O
across	O
studies	B-P
,	O
with	O
hazard	O
ratio	O
(	O
HR	O
)	O
estimates	O
ranging	O
from	O
0.22	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
0.06-0.82	O
)	O
to	O
0.92	O
(	O
95	O
%	O
CI	O
:	O
0.65-1.28	O
)	O
.	O

Sex	O
was	O
the	O
major	O
factor	O
accounting	O
for	O
effect	O
size	O
variation	O
,	O
and	O
mortality	O
was	O
decreased	O
more	O
in	O
females	O
(	O
HR	O
=	O
0.41	O
;	O
95	O
%	O
CI	O
:	O
0.35-0.48	O
)	O
as	O
compared	O
with	O
males	O
(	O
HR	O
=	O
0.63	O
;	O
95	O
%	O
CI	O
:	O
0.55-0.71	O
)	O
.	O

Rapamycin	O
effects	O
were	O
also	O
genotype	O
dependent	O
,	O
however	O
,	O
with	O
stronger	O
survivorship	O
increases	O
in	O
hybrid	O
mice	O
(	O
14.4	O
%	O
;	O
95	O
%	O
CI	O
:	O
12.5-16.3	O
%	O
)	O
relative	O
to	O
pure	O
inbred	O
strains	O
(	O
8.8	O
%	O
;	O
95	O
%	O
CI	O
:	O
6.2-11.6	O
%	O
)	O
.	O

Number	O
needed	O
to	O
treat	O
was	O
applied	O
as	O
an	O
effect	O
size	O
metric	O
,	O
which	O
consistently	O
identified	O
early	O
senescence	O
as	O
the	O
age	O
of	O
peak	O
treatment	O
benefit	O
.	O

These	O
results	O
provide	O
synthesis	O
of	O
existing	O
data	O
to	O
support	O
the	O
potential	O
translation	O
of	O
findings	O
from	O
mouse	O
to	O
primate	O
species	O
.	O

Because	O
rapamycin	O
's	O
effect	O
on	O
survival	O
depends	O
on	O
sex	O
and	O
genotype	O
,	O
further	O
work	O
is	O
justified	O
to	O
understand	O
how	O
these	O
factors	O
shape	O
treatment	O
response	O
.	O

Hypo-Vascular	O
Liver	O
Metastases	O
Treated	O
with	O
Transarterial	O
chemoembolization	O
:	O
Assessment	O
of	O
Early	O
Response	O
by	O
Volumetric	O
Contrast-Enhanced	B-P
and	O
Diffusion-Weighted	B-P
Magnetic	I-P
Resonance	I-P
Imaging	I-P
.	O

To	O
evaluate	O
the	O
value	O
of	O
anatomic	O
and	O
volumetric	O
functional	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
in	O
early	O
assessment	O
of	O
response	O
to	O
trans-arterial	O
chemoembolization	O
(	O
TACE	O
)	O
in	O
hypovascular	O
liver	O
metastases	O
.	O

This	O
retrospective	O
study	O
included	O
52	O
metastatic	O
lesions	O
(	O
42	O
targeted	O
and	O
10	O
non-targeted	O
)	O
in	O
17	O
patients	O
who	O
underwent	O
MRI	B-P
before	O
and	O
early	O
after	O
TACE	O
.	O

Two	O
reviewers	O
reported	O
response	O
by	O
anatomic	O
criteria	O
(	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	O
Tumor	O
[	O
RECIST	O
]	O
,	O
modified	O
RECIST	O
[	O
mRECIST	O
]	O
,	O
and	O
European	O
Association	O
for	O
the	O
Study	O
of	O
Liver	O
Disease	O
[	O
EASL	O
]	O
)	O
and	O
functional	O
criteria	O
(	O
volumetric	O
apparent	O
diffusion	O
coefficient	O
and	O
contrast	O
enhancement	O
)	O
.	O

treatment	O
endpoint	O
was	O
RECIST	O
at	O
6	O
months	O
.	O

A	O
2-sample	O
paired	O
t	O
test	O
was	O
used	O
to	O
compare	O
the	O
mean	O
changes	O
after	O
intra-arterial	O
therapy	O
.	O

P	O
<	O
.05	O
was	O
considered	O
statistically	O
significant	O
.	O

Reduction	O
in	O
mRECIST	O
and	O
EASL	O
at	O
1	O
month	O
was	O
significant	O
in	O
the	O
whole	O
cohort	O
as	O
well	O
as	O
in	O
responders	O
by	O
RECIST	O
at	O
6	O
months	O
,	O
and	O
the	O
changes	O
fulfilled	O
partial	O
response	O
criteria	O
for	O
both	O
metrics	O
in	O
responders	O
.	O

Responders	O
also	O
had	O
significant	O
changes	O
in	O
volumetric	O
apparent	O
diffusion	O
coefficient	O
(	O
P	O
=	O
.01	O
and	O
P	O
=	O
.03	O
)	O
and	O
contrast	O
enhancement	O
(	O
P	O
<	O
.0001	O
and	O
P	O
<	O
.0001	O
)	O
at	O
1	O
month	O
for	O
both	O
readers	O
,	O
respectively	O
.	O

At	O
1	O
month	O
post	O
treatment	O
,	O
responders	O
did	O
not	O
fulfill	O
RECIST	O
criteria	O
but	O
fulfilled	O
mRECIST	O
and	O
EASL	O
criteria	O
.	O

In	O
addition	O
,	O
volumetric	O
contrast-enhanced	B-P
and	O
diffusion-weighted	B-P
MRI	I-P
may	O
be	O
helpful	O
in	O
evaluating	O
early	O
treatment	O
response	O
after	O
TACE	O
in	O
hypovascular	O
liver	O
metastases	O
in	O
patients	O
who	O
have	O
failed	O
to	O
respond	O
to	O
initial	O
chemotherapy	O
.	O

Variation	O
in	O
the	O
Use	O
of	O
Vestibular	B-P
Diagnostic	I-P
Testing	I-P
for	O
Patients	O
Presenting	O
to	O
Otolaryngology	O
Clinics	O
with	O
Dizziness	O
.	O

We	O
used	O
a	O
national	O
otolaryngology	O
practice-based	O
research	O
network	O
database	O
to	O
characterize	O
the	O
utilization	O
of	O
vestibular	B-P
function	I-P
testing	I-P
in	O
patients	O
diagnosed	O
with	O
dizziness	O
and/or	O
a	O
vestibular	O
disorder	O
.	O

Database	O
review	O
.	O

The	O
Creating	O
Healthcare	O
Excellence	O
through	O
Education	O
and	O
Research	O
(	O
CHEER	O
)	O
practice-based	O
research	O
network	O
of	O
academic	O
and	O
community	O
providers	O
Dizzy	O
patients	O
in	O
the	O
CHEER	O
retrospective	O
database	O
were	O
identified	O
through	O
ICD-9	O
codes	O
;	O
vestibular	B-P
testing	I-P
procedures	I-P
were	O
identified	O
with	O
CPT	O
codes	O
.	O

Demographics	O
and	O
procedures	B-P
per	I-P
patient	I-P
were	O
tabulated	O
.	O

Analysis	O
included	O
number	O
and	O
type	O
of	O
vestibular	B-P
tests	I-P
ordered	O
,	O
stratified	O
by	O
individual	O
clinic	O
and	O
by	O
practice	O
type	O
(	O
community	O
vs	O
academic	O
)	O
.	O

Chi-square	O
tests	O
were	O
performed	O
to	O
assess	O
if	O
the	O
percentage	O
of	O
patients	O
receiving	O
testing	O
was	O
statistically	O
significant	O
across	O
clinics	O
.	O

A	O
logistic	O
regression	O
model	O
was	O
used	O
to	O
examine	O
the	O
association	O
between	O
receipt	O
of	O
testing	O
and	O
being	O
tested	O
on	O
initial	O
visit	O
.	O

A	O
total	O
of	O
12,468	O
patients	O
diagnosed	O
with	O
dizziness	O
and/or	O
a	O
vestibular	O
disorder	O
were	O
identified	O
from	O
7	O
community	O
and	O
5	O
academic	O
CHEER	O
network	O
clinics	O
across	O
the	O
country	O
.	O

One-fifth	O
of	O
these	O
patients	O
had	O
at	O
least	O
1	O
vestibular	B-P
function	I-P
test	I-P
.	O

The	O
percentage	O
of	O
patients	O
tested	O
varied	O
widely	O
by	O
site	O
,	O
from	O
3	O
%	O
to	O
72	O
%	O
;	O
academic	O
clinics	O
were	O
twice	O
as	O
likely	O
to	O
test	O
.	O

Initial	O
visit	O
vestibular	B-P
testing	I-P
also	O
varied	O
,	O
from	O
0	O
%	O
to	O
96	O
%	O
of	O
dizzy	O
patients	O
,	O
and	O
was	O
15	O
times	O
more	O
likely	O
in	O
academic	O
clinics	O
.	O

There	O
is	O
significant	O
variation	O
in	O
use	O
and	O
timing	O
of	O
vestibular	B-P
diagnostic	I-P
testing	I-P
across	O
otolaryngology	O
clinics	O
.	O

The	O
CHEER	O
network	O
research	O
database	O
does	O
not	O
contain	O
outcome	O
data	O
.	O

These	O
results	O
illustrate	O
the	O
critical	O
need	O
for	O
research	O
that	O
examines	O
outcomes	O
as	O
related	O
to	O
vestibular	B-P
testing	I-P
.	O

Skin	O
Conductance	O
Responses	O
and	O
Neural	O
Activations	O
During	O
Fear	O
Conditioning	O
and	O
Extinction	O
Recall	O
Across	O
Anxiety	O
Disorders	O
.	O

The	O
fear	O
conditioning	O
and	O
extinction	O
neurocircuitry	O
has	O
been	O
extensively	O
studied	O
in	O
healthy	O
and	O
clinical	O
populations	O
,	O
with	O
a	O
particular	O
focus	O
on	O
posttraumatic	O
stress	O
disorder	O
.	O

Despite	O
significant	O
overlap	O
of	O
symptoms	O
between	O
posttraumatic	O
stress	O
disorder	O
and	O
anxiety	O
disorders	O
,	O
the	O
latter	O
has	O
received	O
less	O
attention	O
.	O

Given	O
that	O
dysregulated	O
fear	O
levels	O
characterize	O
anxiety	O
disorders	O
,	O
examining	O
the	O
neural	O
correlates	O
of	O
fear	O
and	O
extinction	O
learning	O
may	O
shed	O
light	O
on	O
the	O
pathogenesis	O
of	O
underlying	O
anxiety	O
disorders	O
.	O

To	O
investigate	O
the	O
psychophysiological	O
and	O
neural	O
correlates	O
of	O
fear	O
conditioning	O
and	O
extinction	O
recall	O
in	O
anxiety	O
disorders	O
and	O
to	O
document	O
how	O
these	O
features	O
differ	O
as	O
a	O
function	O
of	O
multiple	O
diagnoses	O
or	O
anxiety	O
severity	O
.	O

This	O
investigation	O
was	O
a	O
cross-sectional	O
,	O
case-control	O
,	O
functional	B-P
magnetic	I-P
resonance	I-P
imaging	I-P
study	O
at	O
an	O
academic	O
medical	O
center	O
.	O

Participants	O
were	O
healthy	O
controls	O
and	O
individuals	O
with	O
at	O
least	O
1	O
of	O
the	O
following	O
anxiety	O
disorders	O
:	O
generalized	O
anxiety	O
disorder	O
,	O
social	O
anxiety	O
disorder	O
,	O
specific	O
phobia	O
,	O
and	O
panic	O
disorder	O
.	O

The	O
study	O
dates	O
were	O
between	O
March	O
2013	O
and	O
May	O
2015	O
.	O

Two-day	O
fear	O
conditioning	O
and	O
extinction	O
paradigm	O
.	O

Skin	O
conductance	O
responses	O
,	O
blood	O
oxygenation	O
level-dependent	O
responses	O
,	O
trait	O
anxiety	O
scores	O
from	O
the	O
State	O
Trait	O
Anxiety	O
Inventory	O
-	O
Trait	O
Form	O
,	O
and	O
functiona	O
l	O
connectivity	O
.	O

This	O
study	O
included	O
21	O
healthy	O
controls	O
(	O
10	O
women	O
)	O
and	O
61	O
individuals	O
with	O
anxiety	O
disorders	O
(	O
36	O
women	O
)	O
.	O

P	O
values	O
reported	O
for	O
the	O
neuroimaging	B-P
results	O
are	O
all	O
familywise	O
error	O
corrected	O
.	O

Skin	O
conductance	O
responses	O
during	O
extinction	O
recall	O
did	O
not	O
differ	O
between	O
individuals	O
with	O
anxiety	O
disorders	O
and	O
healthy	O
controls	O
(	O
ηp2	O
=	O
0.001	O
,	O
P	O
=	O
.79	O
)	O
,	O
where	O
ηp2	O
is	O
partial	O
eta	O
squared	O
.	O

The	O
anxiety	O
group	O
had	O
lower	O
activation	O
of	O
the	O
ventromedial	O
prefrontal	O
cortex	O
(	O
vmPFC	O
)	O
during	O
extinction	O
recall	O
(	O
ηp2	O
=	O
0.178	O
,	O
P	O
=	O
.02	O
)	O
.	O

A	O
similar	O
hypoactive	O
pattern	O
was	O
found	O
during	O
early	O
conditioning	O
(	O
ηp2	O
=	O
0.106	O
,	O
P	O
=	O
.009	O
)	O
.	O

The	O
vmPFC	O
hypoactivation	O
was	O
associated	O
with	O
anxiety	O
symptom	O
severity	O
(	O
r	O
=	O
-0.420	O
,	O
P	O
=	O
.01	O
for	O
conditioning	O
and	O
r	O
=	O
-0.464	O
,	O
P	O
=	O
.004	O
for	O
extinction	O
recall	O
)	O
and	O
the	O
number	O
of	O
co-occuring	O
anxiety	O
disorders	O
diagnosed	O
(	O
ηp2	O
=	O
0.137	O
,	O
P	O
=	O
.009	O
for	O
conditioning	O
and	O
ηp2	O
=	O
0.227	O
,	O
P	O
=	O
.004	O
for	O
extinction	O
recall	O
)	O
.	O

Psychophysiological	O
interaction	O
analyses	O
revealed	O
that	O
the	O
fear	O
network	O
connectivity	O
differed	O
between	O
healthy	O
controls	O
and	O
the	O
anxiety	O
group	O
during	O
fear	O
learning	O
(	O
ηp2	O
range	O
between	O
0.088	O
and	O
0.176	O
and	O
P	O
range	O
between	O
0.02	O
and	O
0.003	O
)	O
and	O
extinction	O
recall	O
(	O
ηp2	O
range	O
between	O
0.111	O
and	O
0.235	O
and	O
P	O
range	O
between	O
0.02	O
and	O
0.002	O
)	O
.	O

Despite	O
no	O
skin	O
conductance	O
response	O
group	O
differences	O
during	O
extinction	O
recall	O
,	O
brain	O
activation	O
patterns	O
between	O
anxious	O
and	O
healthy	O
individuals	O
differed	O
.	O

These	O
findings	O
encourage	O
future	O
studies	O
to	O
examine	O
the	O
conditions	O
longitudinally	O
and	O
in	O
the	O
context	O
of	O
treatment	O
trials	O
to	O
improve	O
and	O
guide	O
therapeutics	O
via	O
advanced	O
neurobiological	O
understanding	O
of	O
each	O
disorder	O
.	O

Prenatal	B-P
Diagnosis	I-P
of	O
Lysosomal	O
Storage	O
Disorders	O
Using	O
Chorionic	O
Villi	O
.	O

Prenatal	B-P
enzymatic	I-P
diagnosis	I-P
for	O
an	O
array	O
of	O
lysosomal	O
storage	O
disorders	O
(	O
LSDs	O
)	O
can	O
be	O
performed	O
accurately	O
,	O
provided	O
that	O
a	O
confirmed	O
diagnosis	O
by	O
biochemical/molecular	O
study	O
in	O
the	O
index	O
case	O
is	O
available	O
and	O
a	O
strict	O
defined	O
protocol	O
,	O
specific	O
to	O
each	O
individual	O
disorder	O
is	O
followed	O
.	O

The	O
present	O
chapter	O
describes	O
the	O
protocols	O
for	O
reliable	O
and	O
accurate	O
prenatal	B-P
enzymatic	I-P
diagnoses	I-P
by	O
fluorometric	B-P
and	O
spectrophotometric	B-P
methods	I-P
of	O
lysosomal	O
storage	O
disorders	O
:	O
Gaucher	O
,	O
Fabry	O
,	O
Pompe	O
,	O
Niemann	O
Pick	O
A/B	O
,	O
Tay	O
Sach	O
,	O
Sandhoff	O
,	O
GM1	O
,	O
Mucoplysaccharidoses	O
,	O
Wolman	O
,	O
Krabbe	O
,	O
Metachromatic	O
leukodystrophy	O
,	O
and	O
Batten	O
diseases	O
using	O
uncultured	O
chorionic	O
villi	O
samples	O
.	O

The	O
biological	O
reference	O
intervals	O
for	O
enzyme	B-P
levels	I-P
in	O
normal	O
and	O
affected	O
fetuses	O
are	O
given	O
for	O
interpretation	O
of	O
prenatal	O
results	O
.	O

It	O
is	O
imperative	O
to	O
establish	O
normal	O
reference	O
interval	O
in	O
each	O
laboratory	O
to	O
take	O
into	O
account	O
the	O
local	O
environment	O
,	O
technical	O
variations	O
,	O
and	O
different	O
ethnicities	O
.	O

Besides	O
,	O
enzyme	O
activity	O
in	O
the	O
fetus	O
should	O
be	O
represented	O
as	O
percentage	O
of	O
the	O
mean	O
activity	O
of	O
enzyme	O
of	O
normal	O
fetuses	O
.	O

The	O
pitfalls	O
and	O
challenges	O
in	O
prenatal	B-P
diagnosis	I-P
as	O
well	O
as	O
technical	O
problems	O
in	O
performing	O
enzyme	B-P
assays	I-P
are	O
also	O
discussed	O
to	O
help	O
the	O
reader	O
in	O
standardization	O
and	O
performing	O
the	O
assays	B-P
for	O
correct	O
diagnosis	O
.	O

Toxicity	O
mechanism	O
of	O
titanium	O
dioxide	O
and	O
zinc	O
oxide	O
nanoparticles	O
against	O
food	O
pathogens	O
.	O

Food	O
preservation	O
is	O
an	O
important	O
field	O
of	O
research	O
.	O

It	O
extends	O
the	O
shelf	O
life	O
of	O
major	O
food	O
products	O
.	O

Our	O
current	O
study	O
is	O
based	O
on	O
food	O
preservation	O
through	O
TiO2	O
and	O
ZnO	O
nanoparticles	O
.	O

TiO2	O
and	O
ZnO	O
are	O
biocompatible	O
nanomaterial	O
.	O

The	O
biocompatibility	O
of	O
the	O
materials	O
were	O
established	O
through	O
toxicity	O
studies	O
on	O
cell	O
lines	O
.	O

Titanium	O
dioxide	O
and	O
Zinc	O
Oxide	O
nanoparticle	O
were	O
synthesized	O
by	O
wet	O
chemical	O
process	O
.	O

They	O
are	O
characterized	O
by	O
X-Ray	B-P
diffraction	I-P
and	O
TEM	B-P
.	O

The	O
antibacterial	O
activities	O
of	O
both	O
the	O
materials	O
were	O
analysed	O
to	O
ensure	O
their	O
effectiveness	O
as	O
food	O
preservative	O
against	O
Salmonella	O
typhi	O
,	O
Klebsiella	O
pneumoniae	O
and	O
Shigella	O
flexneri	O
.	O

The	O
results	O
indicates	O
that	O
TiO2	O
and	O
ZnO	O
nanoparticle	O
inhibits	O
Salmonella	O
,	O
Klebsiella	O
and	O
Shigella	O
.	O

The	O
mode	O
of	O
action	O
is	O
by	O
the	O
generation	O
of	O
ROS	O
in	O
cases	O
of	O
Salmonella	O
,	O
Klebsiella	O
.	O

Mode	O
of	O
action	O
in	O
Shigella	O
is	O
still	O
unclear	O
.	O

It	O
was	O
also	O
proved	O
that	O
TiO2	O
and	O
ZnO	O
nanoparticle	O
are	O
biocompatible	O
materials	O
.	O

Nat1	O
promotes	O
translation	O
of	O
specific	O
proteins	O
that	O
induce	O
differentiation	O
of	O
mouse	O
embryonic	O
stem	O
cells	O
.	O

Novel	O
APOBEC1	O
target	O
1	O
(	O
Nat1	O
)	O
(	O
also	O
known	O
as	O
``	O
p97	O
,	O
''	O
``	O
Dap5	O
,	O
''	O
and	O
``	O
Eif4g2	O
``	O
)	O
is	O
a	O
ubiquitously	O
expressed	O
cytoplasmic	O
protein	O
that	O
is	O
homologous	O
to	O
the	O
C-terminal	O
two	O
thirds	O
of	O
eukaryotic	O
translation	O
initiation	O
factor	O
4G	O
(	O
Eif4g1	O
)	O
.	O

We	O
previously	O
showed	O
that	O
Nat1	O
-	O
null	O
mouse	O
embryonic	O
stem	O
cells	O
(	O
mES	O
cells	O
)	O
are	O
resistant	O
to	O
differentiation	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
found	O
that	O
NAT1	O
and	O
eIF4G1	O
share	O
many	O
binding	O
proteins	O
,	O
such	O
as	O
the	O
eukaryotic	O
translation	O
initiation	O
factors	O
eIF3	O
and	O
eIF4A	O
and	O
ribosomal	O
proteins	O
.	O

However	O
,	O
NAT1	O
did	O
not	O
bind	O
to	O
eIF4E	O
or	O
poly	O
(	O
A	O
)	O
-binding	O
proteins	O
,	O
which	O
are	O
critical	O
for	O
cap-dependent	O
translation	O
initiation	O
.	O

In	O
contrast	O
,	O
compared	O
with	O
eIF4G1	O
,	O
NAT1	O
preferentially	O
interacted	O
with	O
eIF2	O
,	O
fragile	O
X	O
mental	O
retardation	O
proteins	O
(	O
FMR	O
)	O
,	O
and	O
related	O
proteins	O
and	O
especially	O
with	O
members	O
of	O
the	O
proline-rich	O
and	O
coiled-coil-containing	O
protein	O
2	O
(	O
PRRC2	O
)	O
family	O
.	O

We	O
also	O
found	O
that	O
Nat1	O
-	O
null	O
mES	O
cells	O
possess	O
a	O
transcriptional	O
profile	O
similar	O
,	O
although	O
not	O
identical	O
,	O
to	O
the	O
ground	O
state	O
,	O
which	O
is	O
established	O
in	O
wild-type	O
mES	O
cells	O
when	O
treated	O
with	O
inhibitors	O
of	O
the	O
ERK	O
and	O
glycogen	O
synthase	O
kinase	O
3	O
(	O
GSK3	O
)	O
signaling	O
pathways	O
.	O

In	O
Nat1	O
-	O
null	O
mES	O
cells	O
,	O
the	O
ERK	O
pathway	O
is	O
suppressed	O
even	O
without	O
inhibitors	O
.	O

Ribosome	O
profiling	B-P
revealed	O
that	O
translation	O
of	O
mitogen-activated	O
protein	O
kinase	O
kinase	O
kinase	O
3	O
(	O
Map3k3	O
)	O
and	O
son	O
of	O
sevenless	O
homolog	O
1	O
(	O
Sos1	O
)	O
is	O
suppressed	O
in	O
the	O
absence	O
of	O
Nat1	O
Forced	O
expression	O
of	O
Map3k3	O
induced	O
differentiation	O
of	O
Nat1	O
-	O
null	O
mES	O
cells	O
.	O

These	O
data	O
collectively	O
show	O
that	O
Nat1	O
is	O
involved	O
in	O
the	O
translation	O
of	O
proteins	O
that	O
are	O
required	O
for	O
cell	O
differentiation	O
.	O

Blood	O
Collection	O
Tubes	O
and	O
Storage	O
Temperature	O
Should	O
Be	O
Evaluated	O
when	O
Using	O
the	O
Siemens	O
ADVIA	O
Centaur	O
XP	O
for	O
Measuring	B-P
25-Hydroxyvitamin	I-P
D.	I-P
A	O
significant	O
bias	O
was	O
found	O
when	O
using	O
the	O
Siemens	O
ADVIA	O
Centaur	O
XP	O
system	O
for	O
measurement	O
of	O
25-hydroxyvitamin	O
D	O
(	O
25OHD	O
)	O
with	O
VACUETTE®	O
tubes	O
with	O
Serum	O
Clot	O
Activator	O
and	O
Gel	O
.	O

Here	O
,	O
we	O
examined	O
whether	O
other	O
commonly	O
used	O
tubes	O
or	O
temperatures	O
affected	O
25OHD	B-P
results	I-P
obtained	O
with	O
the	O
Siemens	O
ADVIA	O
Centaur	O
XP	O
system	O
.	O

Serum	O
was	O
collected	O
into	O
five	O
types	O
of	O
vacuum	O
blood	O
collection	O
tubes	O
from	O
three	O
manufacturers	O
,	O
and	O
25OHD	B-P
was	I-P
analyzed	I-P
using	O
the	O
Siemens	O
ADVIA	O
Centaur	O
XP	O
system	O
and	O
liquid	B-P
chromatography	I-P
tandem	I-P
mass	I-P
spectrometry	I-P
(	O
LC-MS/MS	B-P
)	O
immediately	O
or	O
after	O
storage	O
at	O
4°C	O
or	O
-80°C	O
for	O
48	O
h.	O
Significantly	O
higher	O
25OHD	B-P
values	I-P
were	O
found	O
when	O
using	O
the	O
Siemens	O
ADVIA	O
Centaur	O
XP	O
system	O
with	O
VACUETTE®	O
tubes	O
with	O
serum	O
clot	O
activator	O
and	O
gel	O
and	O
VACUETTE®	O
tubes	O
with	O
clot	O
activator	O
but	O
no	O
gel	O
compared	O
with	O
VACUETTE®	O
tubes	O
with	O
no	O
additives	O
.	O

The	O
25OHD	B-P
values	I-P
in	O
all	O
of	O
these	O
tubes	O
were	O
not	O
significantly	O
different	O
from	O
those	O
obtained	O
by	O
LC-MS/MS	B-P
.	O

Moreover	O
,	O
after	O
storage	O
at	O
-80°C	O
for	O
48	O
h	O
,	O
the	O
values	O
obtained	O
in	O
IMPROVEVACUTER®	O
tubes	O
with	O
serum	O
clot	O
activator	O
and	O
ge	O
l	O
significantly	O
increased	O
,	O
with	O
a	O
mean	O
bias	O
of	O
74.6	O
%	O
compared	O
with	O
the	O
values	O
before	O
storage	O
,	O
on	O
analysis	O
with	O
the	O
Siemens	O
ADVIA	O
Centaur	O
XP	O
system	O
.	O

VACUETTE®	O
tubes	O
containing	O
additives	O
significantly	O
affect	O
the	O
accuracy	O
of	O
25OHD	B-P
results	I-P
obtained	O
using	O
the	O
Siemens	O
ADVIA	O
Centaur	O
XP	O
system	O
.	O

Additionally	O
,	O
the	O
composition	O
of	O
serum	O
collected	O
in	O
IMPROVEVACUTER®	O
tubes	O
was	O
affected	O
by	O
freezing	O
,	O
resulting	O
in	O
different	O
measurements	O
when	O
using	O
the	O
Siemens	O
25OHD	O
assay	O
platform	O
.	O

Genomic	O
characterization	O
of	O
a	O
wild-bird	O
-	O
origin	O
pigeon	O
paramyxovirus	O
type	O
1	O
(	O
PPMV-1	O
)	O
first	O
isolated	O
in	O
the	O
northwest	O
region	O
of	O
China	O
.	O

Pigeon	O
paramyxovirus	O
type-1	O
(	O
PPMV-1	O
)	O
is	O
an	O
enzootic	O
in	O
pigeon	O
flocks	O
and	O
causes	O
severe	O
economic	O
losses	O
in	O
the	O
poultry	O
industry	O
in	O
many	O
countries	O
.	O

A	O
PPMV-1	O
isolate	O
,	O
abbreviated	O
as	O
PPMV-1/QL-01/CH/15	O
,	O
was	O
isolated	O
from	O
a	O
great	O
spotted	O
woodpecker	O
in	O
the	O
northwest	O
region	O
of	O
China	O
in	O
2015	O
.	O

The	O
complete	O
genome	O
was	O
sequenced	B-P
,	O
and	O
the	O
results	O
showed	O
that	O
the	O
virus	O
genome	O
was	O
15,192	O
nt	O
in	O
length	O
,	O
in	O
the	O
gene	O
arrangement	O
3'-NP-P-M-F-HN-L-5	O
'	O
.	O

Several	O
amino	O
acid	O
mutations	O
were	O
identified	O
in	O
the	O
functional	O
domains	O
of	O
the	O
F	O
and	O
HN	O
proteins	O
.	O

The	O
pathogenicity	O
index	O
of	O
the	O
isolate	O
was	O
evaluated	O
,	O
and	O
the	O
mean	O
death	O
time	O
(	O
MDT	O
)	O
was	O
72	O
h	O
and	O
the	O
intracerebral	O
pathogenicity	O
index	O
(	O
ICPI	O
)	O
was	O
0.925	O
,	O
indicating	O
that	O
this	O
isolate	O
was	O
mesogenic	O
.	O

Sequencing	B-P
results	O
showed	O
that	O
it	O
had	O
a	O
virulent	O
Newcastle	O
disease	O
virus	O
cleavage	O
motif	O
(	O
112	O
)	O
R-R-Q-K-R-F	O
(	O
117	O
)	O
at	O
the	O
fusion	O
protein	O
cleavage	O
site	O
.	O

Morbidity	O
and	O
mortality	O
were	O
70	O
%	O
and	O
50	O
%	O
,	O
after	O
inoculation	O
of	O
pigeons	O
,	O
whereas	O
this	O
virus	O
was	O
nonpathogenic	O
in	O
chickens	O
.	O

Different	O
immune	O
responses	O
of	O
pigeons	O
and	O
chickens	O
were	O
induced	O
in	O
vivo	O
,	O
which	O
led	O
to	O
different	O
HI	B-P
serum	I-P
antibody	I-P
titers	I-P
.	O

The	O
results	O
of	O
phylogenetic	O
and	O
evolutionary	O
distance	O
analysis	O
showed	O
that	O
this	O
PPMV-1	O
strain	O
belonged	O
to	O
sub-genotype	O
VIa	O
in	O
class	O
II	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
identification	B-P
and	O
analysis	O
of	O
PPMV-1	O
co-circulation	O
among	O
wild	O
birds	O
and	O
domestic	O
pigeon	O
flocks	O
in	O
China	O
.	O

The	O
data	O
from	O
this	O
study	O
highlight	O
the	O
important	O
role	O
of	O
wild	O
birds	O
in	O
the	O
dissemination	O
of	O
PPMV-1	O
and	O
provide	O
useful	O
references	O
for	O
improving	O
our	O
understanding	O
of	O
the	O
distribution	O
and	O
evolution	O
of	O
PPMV-1	O
in	O
China	O
.	O

Environmental	O
fate	O
and	O
effects	O
of	O
novel	O
quorum	O
sensing	O
inhibitors	O
that	O
can	O
control	O
biofilm	O
formation	O
.	O

The	O
formation	O
of	O
bacterial	O
biofilms	O
can	O
have	O
negative	O
impacts	O
on	O
industrial	O
processes	O
and	O
are	O
typically	O
difficult	O
to	O
control	O
.	O

The	O
increase	O
of	O
antibiotic	O
resistance	O
,	O
in	O
combination	O
with	O
the	O
requirement	O
for	O
more	O
environmentally	O
focused	O
approaches	O
,	O
has	O
placed	O
pressure	O
on	O
industry	O
and	O
the	O
scientific	O
community	O
to	O
reassess	O
biofilm	O
control	O
strategies	O
.	O

The	O
discovery	O
of	O
bacterial	O
quorum	O
sensing	O
,	O
as	O
an	O
important	O
mechanism	O
in	O
biofilm	O
formation	O
,	O
has	O
led	O
to	O
the	O
development	O
of	O
new	O
substances	O
(	O
such	O
as	O
halogenated	O
thiophenones	O
)	O
to	O
inhibit	O
the	O
quorum	O
sensing	O
process	O
.	O

However	O
,	O
there	O
are	O
currently	O
limited	O
data	O
regarding	O
the	O
biodegradability	O
or	O
ecotoxicity	O
of	O
these	O
substances	O
.	O

To	O
assess	O
the	O
environmental	O
fate	O
and	O
effects	O
of	O
thiophenones	O
capable	O
of	O
quorum	O
sensing	O
inhibition	O
,	O
candidate	O
substances	O
were	O
first	O
identified	O
that	O
have	O
potentially	O
high	O
biodegradability	O
and	O
low	O
ecotoxicity	O
using	O
quantitative	O
structure	O
activity	O
relationships	O
.	O

Subsequent	O
confirmatory	O
hazard	O
assessment	O
of	O
these	O
substances	O
,	O
using	O
a	O
marine	O
alga	O
and	O
a	O
marine	O
crustacean	O
,	O
indicated	O
that	O
these	O
estimates	O
were	O
significantly	O
under	O
predicted	O
with	O
acute	B-P
toxicity	I-P
values	O
more	O
than	O
three	O
orders	O
of	O
magnitude	O
lower	O
than	O
anticipated	O
combined	O
with	O
limited	O
biodegradability	O
.	O

Therefore	O
,	O
although	O
these	O
quorum	O
sensing	O
inhibitors	O
appear	O
a	O
promising	O
approach	O
to	O
control	O
biofilms	O
,	O
they	O
may	O
also	O
have	O
environmental	O
impacts	O
on	O
certain	O
aquatic	O
organisms	O
.	O

Primitive	O
Neuroectodermal	O
Tumors	O
of	O
the	O
Female	O
Genital	O
Tract	O
:	O
A	O
Morphologic	O
,	O
Immunohistochemical	B-P
,	O
and	O
Molecular	O
Study	O
of	O
19	O
Cases	O
.	O

Primary	O
primitive	O
neuroectodermal	O
tumor	O
(	O
PNET	O
)	O
of	O
the	O
female	O
genital	O
tract	O
is	O
rare	O
,	O
and	O
its	O
proper	O
classification	O
remains	O
unclear	O
.	O

The	O
clinical	O
,	O
histologic	O
,	O
and	O
immunophenotypic	B-P
features	O
as	O
well	O
as	O
EWSR1	O
rearrangement	O
status	O
of	O
19	O
gynecologic	O
PNETs	O
,	O
including	O
10	O
ovarian	O
,	O
8	O
uterine	O
,	O
and	O
1	O
vulvar	O
tumors	O
,	O
are	O
herein	O
reported	O
.	O

Patient	O
age	O
ranged	O
from	O
12	O
to	O
68	O
years	O
,	O
with	O
a	O
median	O
age	O
of	O
20	O
and	O
51	O
years	O
among	O
those	O
with	O
ovarian	O
and	O
uterine	O
PNETs	O
,	O
respectively	O
.	O

Morphologic	O
features	O
of	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
tumors	O
were	O
seen	O
in	O
15	O
PNETs	O
,	O
including	O
9	O
medulloblastomas	O
,	O
3	O
ependymomas	O
,	O
2	O
medulloepitheliomas	O
,	O
and	O
1	O
glioblastoma	O
,	O
consistent	O
with	O
central	O
PNET	O
.	O

The	O
remaining	O
4	O
PNETs	O
were	O
composed	O
entirely	O
of	O
undifferentiated	O
small	O
round	O
blue	O
cells	O
and	O
were	O
classified	O
as	O
Ewing	O
sarcoma/peripheral	O
PNET	O
.	O

Eight	O
PNETs	O
were	O
associated	O
with	O
another	O
tumor	O
type	O
,	O
including	O
5	O
ovarian	O
mature	O
cystic	O
teratomas	O
,	O
2	O
endometrial	O
low-grade	O
endometrioid	O
carcinomas	O
,	O
and	O
a	O
uterine	O
carcinosarcoma	O
.	O

By	O
immunohistochemistry	B-P
,	O
17	O
PNETs	O
expressed	O
at	O
least	O
1	O
marker	O
of	O
neuronal	O
differentiation	O
,	O
including	O
synaptophysin	O
,	O
NSE	O
,	O
CD56	O
,	O
S100	O
,	O
and	O
chromogranin	O
in	O
10	O
,	O
8	O
,	O
14	O
,	O
8	O
,	O
and	O
1	O
tumors	O
,	O
respectively	O
.	O

GFAP	O
was	O
positive	O
in	O
4	O
PNETs	O
,	O
all	O
of	O
which	O
were	O
of	O
central	O
type	O
.	O

Membranous	O
CD99	O
and	O
nuclear	O
Fli-1	O
staining	B-P
was	O
seen	O
in	O
10	O
and	O
16	O
tumors	O
,	O
respectively	O
,	O
and	O
concurrent	O
expression	O
of	O
both	O
markers	O
was	O
seen	O
in	O
both	O
central	O
and	O
Ewing	O
sarcoma/peripheral	O
PNET	O
s.	O
All	O
tumors	O
expressed	O
vimentin	O
,	O
whereas	O
keratin	O
cocktail	O
(	O
CAM5.2	O
,	O
AE1/AE3	O
)	O
staining	B-P
was	O
only	O
focally	O
present	O
in	O
4	O
PNETs	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
was	O
successful	O
in	O
all	O
cases	O
and	O
confirmed	O
EWSR1	O
rearrangement	O
in	O
2	O
of	O
4	O
tumors	O
demonstrating	O
morphologic	O
features	O
of	O
Ewing	O
sarcoma/peripheral	O
PNET	O
and	O
concurrent	O
CD99	O
and	O
Fli-1	O
expression	O
.	O

In	O
conclusion	O
,	O
central	O
and	O
Ewing	O
sarcoma/peripheral	O
PNETs	O
may	O
be	O
encountered	O
in	O
the	O
female	O
genital	O
tract	O
with	O
central	O
PNETs	O
being	O
more	O
common	O
.	O

Central	O
PNETs	O
show	O
a	O
spectrum	O
of	O
morphologic	O
features	O
that	O
overlaps	O
with	O
CNS	O
tumors	O
but	O
lack	O
EWSR1	O
rearrangement	O
s.	O
GFAP	O
expression	O
supports	O
a	O
morphologic	O
impression	O
of	O
central	O
PNET	O
and	O
is	O
absent	O
in	O
Ewing	O
sarcoma/peripheral	O
PNET	O
.	O

Ewing	O
sarcoma/peripheral	O
PNETs	O
lack	O
morphologic	O
features	O
of	O
CNS	O
tumors	O
.	O

Evolution	O
of	O
imidacloprid	O
resistance	O
in	O
Myzus	O
persicae	O
in	O
Greece	O
and	O
susceptibility	O
data	O
for	O
spirotetramat	O
.	O

Myzus	O
persicae	O
s.l	O
.	O

is	O
a	O
major	O
crop	O
pest	O
globally	O
and	O
has	O
evolved	O
resistance	O
to	O
a	O
range	O
of	O
insecticide	O
classes	O
making	O
it	O
increasingly	O
difficult	O
to	O
control	O
in	O
some	O
areas	O
.	O

Here	O
we	O
compare	O
bioassay	B-P
monitoring	O
data	O
for	O
two	O
important	O
compounds	O
,	O
imidacloprid	O
and	O
spirotetramat	O
,	O
on	O
field	O
samples	O
/	O
clones	O
collected	O
in	O
Greece	O
.	O

A	O
total	O
of	O
122	O
aphid	O
samples	O
/	O
clones	O
from	O
central	O
and	O
northern	O
Greece	O
were	O
examined	O
in	O
dose-response	O
bioassays	B-P
with	O
imidacloprid	O
.	O

There	O
was	O
an	O
overall	O
increase	O
in	O
the	O
level	O
of	O
resistance	O
(	O
resistance	O
factor	O
=	O
15-40	O
)	O
within	O
tobacco	O
-	O
collected	O
samples	O
from	O
78.7	O
%	O
in	O
2007	O
to	O
86.7	O
%	O
in	O
2015	O
.	O

The	O
corresponding	O
frequencies	O
for	O
peach	O
samples	O
were	O
13.3	O
%	O
and	O
6.7	O
%	O
.	O

These	O
results	O
were	O
confounded	O
however	O
by	O
the	O
first	O
identification	O
of	O
the	O
R81T	O
target	O
mutation	O
in	O
Greece	O
during	O
2015	O
(	O
4.3	O
%	O
as	O
heterozygotes	O
in	O
peach	O
)	O
and	O
2016	O
(	O
21.3	O
%	O
as	O
heterozygotes	O
in	O
peach	O
)	O
.	O

No	O
resistance	O
to	O
spirotetramat	O
was	O
found	O
at	O
the	O
60	O
clones	O
collected	O
in	O
2015	O
.	O

Resistance	O
to	O
imidacloprid	O
is	O
continuing	O
to	O
increase	O
within	O
Greek	O
M.	O
persicae	O
s.l	O
.	O

populations	O
and	O
the	O
situation	O
is	O
likely	O
to	O
deteriorate	O
further	O
with	O
the	O
recent	O
identification	O
of	O
the	O
R81T	O
resistance	O
mutation	O
.	O

Resistance	O
to	O
spirotetramat	O
has	O
not	O
been	O
found	O
and	O
is	O
therefore	O
a	O
good	O
alternative	O
to	O
neonicotinoids	O
for	O
resistance	O
management	O
.	O

©	O
2017	O
Society	O
of	O
Chemical	O
Industry	O
.	O

Why	O
being	O
an	O
expert	O
-	O
despite	O
xpert	B-P
-remains	O
crucial	O
for	O
children	O
in	O
high	O
TB	O
burden	O
settings	O
.	O

As	O
access	O
to	O
Xpert	B-P
expands	O
in	O
high	O
TB-burden	O
settings	O
,	O
its	O
performance	O
against	O
clinically	B-P
diagnosed	I-P
TB	O
as	O
a	O
reference	O
standard	O
provides	O
important	O
insight	O
as	O
the	O
majority	O
of	O
childhood	O
TB	O
is	O
bacteriologically	O
unconfirmed	O
.	O

We	O
aim	O
to	O
describe	O
the	O
characteristics	O
and	O
outcomes	O
of	O
children	O
with	O
presumptive	O
TB	O
and	O
TB	O
disease	O
,	O
and	O
assess	O
performance	O
of	O
Xpert	B-P
under	O
programmatic	O
conditions	O
against	O
a	O
clinical	B-P
diagnosis	I-P
of	O
TB	O
as	O
a	O
reference	O
standard	O
.	O

Retrospective	O
review	O
of	O
children	O
evaluated	O
for	O
presumptive	O
TB	O
in	O
Mbeya	O
,	O
Tanzania	O
.	O

Baseline	O
characteristics	O
were	O
compared	O
by	O
TB	O
disease	O
status	O
and	O
,	O
for	O
patients	O
diagnosed	B-P
with	O
TB	O
,	O
by	O
TB	O
confirmation	O
status	O
using	O
Wilcoxon	O
rank	O
sum	O
test	O
for	O
continuous	O
variables	O
and	O
the	O
Chi-square	O
test	O
for	O
categorical	O
variables	O
.	O

Sensitivity	O
and	O
specificity	O
were	O
calculated	O
to	O
assess	O
the	O
performance	O
of	O
Xpert	B-P
,	O
smear	B-P
,	O
and	O
culture	B-P
against	O
clinical	O
TB	O
.	O

Kappa	O
statistics	O
were	O
calculated	O
to	O
assess	O
agreement	O
between	O
Xpert	B-P
and	O
smear	B-P
to	O
culture	B-P
.	O

Among	O
children	O
(	O
N	O
=	O
455	O
)	O
evaluated	O
for	O
presumptive	O
TB	O
,	O
70.3	O
%	O
(	O
320/455	O
)	O
had	O
Xpert	B-P
and	O
62.8	O
%	O
(	O
286/455	O
)	O
had	O
culture	B-P
performed	O
on	O
sputa	O
.	O

34.5	O
%	O
(	O
157/455	O
)	O
were	O
diagnosed	B-P
with	O
TB	O
:	O
80.3	O
%	O
(	O
126/157	O
)	O
pulmonary	O
TB	O
,	O
13.4	O
%	O
(	O
21/157	O
)	O
bacteriologically	O
confirmed	O
,	O
53.5	O
%	O
(	O
84/157	O
)	O
HIV	O
positive	O
,	O
and	O
48.4	O
%	O
(	O
76/157	O
)	O
inpatients	O
.	O

Compared	O
to	O
the	O
reference	O
standard	O
of	O
clinical	B-P
diagnosis	I-P
,	O
sensitivity	O
of	O
Xpert	B-P
was	O
8	O
%	O
(	O
95	O
%	O
CI	O
4-15	O
)	O
,	O
smear	B-P
6	O
%	O
(	O
95	O
%	O
CI	O
3-12	O
)	O
and	O
culture	B-P
16	O
%	O
(	O
95	O
%	O
CI	O
9-24	O
)	O
,	O
and	O
did	O
not	O
differ	O
based	O
on	O
patient	O
disposition	O
,	O
nutrition	O
or	O
HIV	O
status	O
.	O

Despite	O
access	O
to	O
Xpert	B-P
,	O
the	O
majority	O
of	O
children	O
with	O
presumptive	O
TB	O
were	O
treated	O
based	O
on	O
clinical	B-P
diagnosis	I-P
.	O

Reflecting	O
the	O
reality	O
of	O
clinical	O
practice	O
in	O
resource	O
limited	O
settings	O
,	O
new	O
diagnostics	B-P
such	O
as	O
Xpert	B-P
serve	O
as	O
important	O
adjunctive	O
tests	O
but	O
will	O
not	O
obviate	O
the	O
need	O
for	O
astute	O
clinicians	O
and	O
comprehensive	O
diagnostic	O
algorithms	O
.	O

Effect	O
of	O
Core	O
Stability	O
Training	O
on	O
Trunk	O
Function	O
,	O
Standing	O
Balance	O
,	O
and	O
Mobility	O
in	O
Stroke	O
Patients	O
.	O

Trunk	O
function	O
is	O
important	O
for	O
standing	O
balance	O
,	O
mobility	O
,	O
and	O
functional	O
outcome	O
after	O
stroke	O
,	O
but	O
few	O
studies	O
have	O
evaluated	O
the	O
effects	O
of	O
exercises	O
aimed	O
at	O
improving	O
core	O
stability	O
in	O
stroke	O
patients	O
.	O

To	O
investigate	O
the	O
effectiveness	O
of	O
core	O
stability	O
training	O
on	O
trunk	O
function	O
,	O
standing	O
balance	O
,	O
and	O
mobility	O
in	O
stroke	O
patients	O
.	O

An	O
assessor-blinded	O
,	O
randomized	O
controlled	O
trial	O
was	O
undertaken	O
in	O
a	O
stroke	O
rehabilitation	O
ward	O
,	O
with	O
32	O
participants	O
randomly	O
assigned	O
to	O
an	O
experimental	O
group	O
or	O
a	O
control	O
group	O
(	O
n	O
=	O
16	O
each	O
)	O
.	O

The	O
experimental	O
group	O
received	O
400	O
minutes	O
of	O
core	O
stability	O
training	O
in	O
place	O
of	O
conventional	O
programs	O
within	O
total	O
training	O
time	O
,	O
while	O
the	O
control	O
group	O
received	O
only	O
conventional	O
programs	O
.	O

Primary	O
outcome	O
measures	O
were	O
evaluated	O
using	O
the	O
Trunk	O
Impairment	O
Scale	O
(	O
TIS	O
)	O
,	O
which	O
reflects	O
trunk	O
function	O
.	O

Secondary	O
outcome	O
measures	O
were	O
evaluated	O
by	O
pelvic	O
tilt	O
active	O
range	O
of	O
motion	O
in	O
the	O
sagittal	O
plane	O
,	O
the	O
Balance	O
Evaluation	O
Systems	O
Test-brief	O
version	O
(	O
Brief-BESTest	O
)	O
,	O
Functional	B-P
Reach	I-P
test	I-P
,	O
Timed	B-P
Up-and-Go	I-P
test	I-P
(	O
TUG	B-P
)	O
,	O
and	O
Functional	O
Ambulation	O
Categories	O
(	O
FAC	O
)	O
.	O

A	O
general	O
linear	O
repeated-measures	O
model	O
was	O
used	O
to	O
analyze	O
the	O
results	O
.	O

A	O
treatment	O
effect	O
was	O
found	O
for	O
the	O
experimental	O
group	O
on	O
the	O
dynamic	O
balance	O
subscale	O
and	O
total	O
score	O
of	O
the	O
TIS	O
(	O
P	O
=	O
.002	O
and	O
P	O
<	O
.001	O
,	O
respectively	O
)	O
,	O
pelvic	O
tilt	O
active	O
range	O
of	O
motion	O
(	O
P	O
<	O
.001	O
)	O
,	O
Brief-BESTest	O
(	O
P	O
<	O
.001	O
)	O
,	O
TUG	B-P
(	O
P	O
=	O
.008	O
)	O
,	O
and	O
FAC	O
(	O
P	O
=	O
.022	O
)	O
.	O

Core	O
stability	O
training	O
has	O
beneficial	O
effects	O
on	O
trunk	O
function	O
,	O
standing	O
balance	O
,	O
and	O
mobility	O
in	O
stroke	O
patients	O
.	O

Our	O
findings	O
might	O
provide	O
support	O
for	O
introducing	O
core	O
stability	O
training	O
in	O
stroke	O
rehabilitation	O
.	O

Co-ChIP	B-P
enables	O
genome-wide	O
mapping	O
of	O
histone	O
mark	O
co-occurrence	O
at	O
single-molecule	O
resolution	O
.	O

Histone	O
modifications	O
play	O
an	O
important	O
role	O
in	O
chromatin	O
organization	O
and	O
transcriptional	O
regulation	O
,	O
but	O
despite	O
the	O
large	O
amount	O
of	O
genome-wide	O
histone	O
modification	O
data	O
collected	O
in	O
different	O
cells	O
and	O
tissues	O
,	O
little	O
is	O
known	O
about	O
co-occurrence	O
of	O
modifications	O
on	O
the	O
same	O
nucleosome	O
.	O

Here	O
we	O
present	O
a	O
genome-wide	O
quantitative	O
method	O
for	O
combinatorial	O
indexed	O
chromatin	B-P
immunoprecipitation	I-P
(	O
co-ChIP	B-P
)	O
to	O
characterize	O
co-occurrence	O
of	O
histone	O
modifications	O
on	O
nucleosomes	O
.	O

Using	O
co-ChIP	B-P
,	O
we	O
study	O
the	O
genome-wide	O
co-occurrence	O
of	O
14	O
chromatin	O
marks	O
(	O
70	O
pairwise	O
combinations	O
)	O
,	O
and	O
find	O
previously	O
undescribed	O
co-occurrence	O
patterns	O
,	O
including	O
the	O
co-occurrence	O
of	O
H3K9me1	O
and	O
H3K27ac	O
in	O
super-enhancers	O
.	O

Finally	O
,	O
we	O
apply	O
co-ChIP	B-P
to	O
measure	O
the	O
distribution	O
of	O
the	O
bivalent	O
H3K4me3	O
-	O
H3K27me3	O
domains	O
in	O
two	O
distinct	O
mouse	O
embryonic	O
stem	O
cell	O
(	O
mESC	O
)	O
states	O
and	O
in	O
four	O
adult	O
tissues	O
.	O

We	O
observe	O
dynamic	O
changes	O
in	O
5,786	O
regions	O
and	O
discover	O
both	O
loss	O
and	O
de	O
novo	O
gain	O
of	O
bivalency	O
in	O
key	O
tissue-specific	O
regulatory	O
genes	O
,	O
suggesting	O
a	O
functional	O
role	O
for	O
bivalent	O
domains	O
during	O
different	O
stages	O
of	O
development	O
.	O

These	O
results	O
show	O
that	O
co-ChIP	B-P
can	O
reveal	O
the	O
complex	O
interactions	O
between	O
histone	O
modifications	O
.	O

Assessment	O
of	O
Residual	O
Disease	O
With	O
Molecular	B-P
Breast	I-P
Imaging	I-P
in	O
Patients	O
Undergoing	O
Neoadjuvant	O
Therapy	O
:	O
Association	O
With	O
Molecular	O
Subtypes	O
.	O

Assessment	O
of	O
residual	O
disease	O
after	O
neoadjuvant	O
therapy	O
for	O
breast	O
cancer	O
is	O
an	O
ongoing	O
challenge	O
of	O
breast	O
imaging	B-P
.	O

This	O
study	O
evaluates	O
the	O
accuracy	O
of	O
a	O
novel	O
dedicated	O
system	O
for	O
molecular	B-P
breast	I-P
imaging	I-P
(	O
MBI	B-P
)	O
composed	O
of	O
the	O
new	O
generation	O
of	O
cadmium	O
zinc	O
telluride	O
detectors	O
in	O
assessing	O
residual	O
disease	O
after	O
neoadjuvant	O
therapy	O
in	O
patients	O
with	O
breast	O
cancer	O
.	O

Clinical	O
data	O
,	O
imaging	B-P
,	O
surgical	O
,	O
and	O
pathological	O
findings	O
of	O
51	O
women	O
with	O
breast	O
cancer	O
undergoing	O
neoadjuvant	O
therapy	O
were	O
recorded	O
.	O

MBI	B-P
findings	O
were	O
correlated	O
with	O
surgical	O
pathology	O
results	O
.	O

Accuracy	O
of	O
MBI	B-P
in	O
predicting	O
complete	O
pathological	O
response	O
and	O
size	O
of	O
residual	O
disease	O
was	O
assessed	O
according	O
to	O
molecular	O
subtypes	O
.	O

The	O
size	O
of	O
the	O
largest	O
focus	O
of	O
uptake	O
on	O
MBI	B-P
correlated	O
with	O
the	O
largest	O
dimension	O
measured	O
on	O
pathology	O
(	O
r	O
=	O
0.55	O
;	O
P	O
<	O
.001	O
)	O
.	O

This	O
correlation	O
was	O
stronger	O
for	O
triple	O
negative	O
and	O
HER2/neu	O
positive	O
subtypes	O
(	O
r	O
=	O
0.92	O
and	O
0.62	O
,	O
respectively	O
)	O
.	O

Sixteen	O
patients	O
(	O
31	O
%	O
)	O
had	O
complete	O
pathological	O
response	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
MBI	B-P
for	O
detecting	O
residual	O
disease	O
were	O
83	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
66-93	O
)	O
and	O
69	O
%	O
(	O
95	O
%	O
CI	O
,	O
42-88	O
)	O
,	O
respectively	O
.	O

For	O
triple	O
negative	O
or	O
HER2/neu	O
positive	O
disease	O
the	O
sensitivity	O
and	O
specificity	O
were	O
88	O
%	O
(	O
95	O
%	O
CI	O
,	O
62-98	O
)	O
and	O
75	O
%	O
(	O
95	O
%	O
CI	O
,	O
43-93	O
)	O
,	O
respectively	O
.	O

The	O
accuracy	O
of	O
MBI	B-P
in	O
assessing	O
residual	O
disease	O
after	O
neoadjuvant	O
treatment	O
might	O
be	O
related	O
to	O
the	O
molecular	O
subtype	O
.	O

Accuracy	O
is	O
highest	O
in	O
the	O
triple	O
negative	O
and	O
HER2/neu	O
positive	O
subtypes	O
.	O

Production	O
of	O
Laccase	O
by	O
Cochliobolus	O
sp	O
.	O

Isolated	O
from	O
Plastic	O
Dumped	O
Soils	O
and	O
Their	O
Ability	O
to	O
Degrade	O
Low	O
Molecular	O
Weight	O
PVC	O
.	O

One	O
of	O
the	O
utmost	O
man-made	O
problems	O
faced	O
today	O
has	O
been	O
the	O
ever	O
-	O
increasing	O
plastic	O
waste	O
filling	O
the	O
world	O
.	O

It	O
accounts	O
for	O
an	O
estimated	O
20-30	O
%	O
(	O
by	O
volume	O
)	O
of	O
municipal	O
solid	O
waste	O
in	O
landfill	O
sites	O
worldwide	O
.	O

Research	O
on	O
plastic	O
biodegradation	O
has	O
been	O
steadily	O
growing	O
over	O
the	O
past	O
four	O
decades	O
.	O

Several	O
fungi	O
have	O
been	O
identified	O
that	O
produce	O
enzymes	O
capable	O
of	O
plastic	O
degradation	O
in	O
various	O
laboratory	O
conditions	O
.	O

This	O
paper	O
presents	O
a	O
study	O
that	O
determined	O
the	O
ability	O
of	O
fungi	O
to	O
degrade	O
low	O
molecular	O
weight	O
polyvinyl	O
chloride	O
(	O
PVC	O
)	O
by	O
the	O
enzyme	O
laccase	O
.	O

We	O
have	O
isolated	O
a	O
fungal	O
species	O
,	O
Cochliobolus	O
sp.	O
,	O
from	O
plastic	O
dumped	O
soils	O
and	O
they	O
were	O
cultured	B-P
on	O
Czapek	O
Dox	O
Agar	O
slants	O
at	O
30°C	O
.	O

The	O
effectiveness	O
of	O
this	O
fungal	O
species	O
on	O
the	O
degradation	O
of	O
commercial	O
low	O
molecular	O
weight	O
polyvinyl	O
chloride	O
(	O
PVC	O
)	O
was	O
studied	O
under	O
laboratory	O
conditions	O
.	O

Significant	O
differences	O
were	O
observed	O
from	O
the	O
FTIR	O
,	O
GC-MS	B-P
,	O
and	O
SEM	B-P
results	O
in	O
between	O
control	O
and	O
Cochliobolus	O
sp	O
.	O

treated	O
PVC	O
.	O

Dynamin-related	O
protein	O
1	O
mediates	O
low	O
glucose	O
-	O
induced	O
endothelial	O
dysfunction	O
in	O
human	O
arterioles	O
.	O

Intensive	O
glycemic	O
regulation	O
has	O
resulted	O
in	O
an	O
increased	O
incidence	O
of	O
hypoglycemia	O
.	O

Hypoglycemic	O
burden	O
correlates	O
with	O
adverse	O
cardiovascular	O
complications	O
and	O
contributes	O
acutely	O
and	O
chronically	O
to	O
endothelial	O
dysfunction	O
.	O

Prior	O
data	O
indicate	O
that	O
mitochondrial	O
dysfunction	O
contributes	O
to	O
hypoglycemia	O
-	O
induced	O
endothelial	O
dysfunction	O
,	O
but	O
the	O
mechanisms	O
behind	O
this	O
linkage	O
remain	O
unknown	O
.	O

We	O
attempt	O
to	O
determine	O
whether	O
clinically	O
relevant	O
low-glucose	O
(	O
LG	O
)	O
exposures	O
acutely	O
induce	O
endothelial	O
dysfunction	O
through	O
activation	O
of	O
the	O
mitochondrial	O
fission	O
process	O
.	O

Characterization	O
of	O
mitochondrial	O
morphology	O
was	O
carried	O
out	O
in	O
cultured	O
endothelial	O
cells	O
by	O
using	O
confocal	B-P
microscopy	I-P
.	O

Isolated	O
human	O
arterioles	O
were	O
used	O
to	O
explore	O
the	O
effect	O
LG	O
-	O
induced	O
mitochondrial	O
fission	O
has	O
on	O
the	O
formation	O
of	O
detrimental	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
,	O
bioavailability	O
of	O
nitric	O
oxide	O
(	O
NO	O
)	O
,	O
and	O
endothelial-dependent	O
vascular	O
relaxation	O
.	O

Fluorescence	B-P
microscopy	I-P
was	O
employed	O
to	O
visualize	O
changes	O
in	O
mitochondrial	O
ROS	O
and	O
NO	O
levels	O
and	O
videomicroscopy	B-P
applied	O
to	O
measure	O
vasodilation	O
response	O
.	O

Pharmacological	O
disruption	O
of	O
the	O
profission	O
protein	O
Drp1	O
with	O
Mdivi-1	O
during	O
LG	O
exposure	O
reduced	O
mitochondrial	O
fragmentation	O
among	O
vascular	O
endothelial	O
cells	O
(	O
LG	O
:	O
0.469	O
;	O
LG	O
+	O
Mdivi-1	O
:	O
0.276	O
;	O
P	O
=	O
0.003	O
)	O
,	O
prevented	O
formation	O
of	O
vascular	O
ROS	O
(	O
LG	O
:	O
2.036	O
;	O
LG	O
+	O
Mdivi-1	O
:	O
1.774	O
;	O
P	O
=	O
0.005	O
)	O
,	O
increased	O
the	O
presence	O
of	O
NO	O
(	O
LG	O
:	O
1.352	O
;	O
LG	O
+	O
Mdivi-1	O
:	O
1.502	O
;	O
P	O
=	O
0.048	O
)	O
,	O
and	O
improved	O
vascular	O
dilation	O
response	O
to	O
acetylcholine	O
(	O
LG	O
:	O
31.6	O
%	O
;	O
LG	O
+	O
Mdivi-1	O
;	O
78.5	O
%	O
at	O
maximum	O
dose	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Additionally	O
,	O
decreased	O
expression	O
of	O
Drp1	O
via	O
siRNA	O
knockdown	O
during	O
LG	O
conditions	O
also	O
improved	O
vascular	O
relaxation	O
.	O

Exposure	O
to	O
LG	O
imparts	O
endothelial	O
dysfunction	O
coupled	O
with	O
altered	O
mitochondrial	O
phenotypes	O
among	O
isolated	O
human	O
arterioles	O
.	O

Disruption	O
of	O
Drp1	O
and	O
subsequent	O
mitochondrial	O
fragmentation	O
events	O
prevents	O
impaired	O
vascular	O
dilation	O
,	O
restores	O
mitochondrial	O
phenotype	O
,	O
and	O
implicates	O
mitochondrial	O
fission	O
as	O
a	O
primary	O
mediator	O
of	O
LG	O
-	O
induced	O
endothelial	O
dysfunction	O
.NEW	O
&	O
NOTEWORTHY	O
Acute	O
low-glucose	O
exposure	O
induces	O
mitochondrial	O
fragmentation	O
in	O
endothelial	O
cells	O
via	O
Drp1	O
and	O
is	O
associated	O
with	O
impaired	O
endothelial	O
function	O
in	O
human	O
arterioles	O
.	O

Targeting	O
of	O
Drp1	O
prevents	O
fragmentation	O
,	O
improves	O
vasofunction	O
,	O
and	O
may	O
provide	O
a	O
therapeutic	O
target	O
for	O
improving	O
cardiovascular	O
complications	O
among	O
diabetics	O
.Listen	O
to	O
this	O
article	O
's	O
corresponding	O
podcast	O
@	O
http	O
:	O
//ajpheart.podbean.com/e/mitochondrial-dynamics-impact-endothelial-function/	O
.	O

Cerebromicrovascular	O
dysfunction	O
predicts	O
cognitive	O
decline	O
and	O
gait	O
abnormalities	O
in	O
a	O
mouse	O
model	O
of	O
whole	O
brain	O
irradiation	O
-induced	O
accelerated	O
brain	O
senescence	O
.	O

Whole	O
brain	O
irradiation	O
(	O
WBI	O
)	O
is	O
a	O
mainstream	O
therapy	O
for	O
patients	O
with	O
both	O
identifiable	O
brain	O
metastases	O
and	O
prophylaxis	O
for	O
microscopic	O
malignancies	O
.	O

However	O
,	O
it	O
also	O
promotes	O
accelerated	O
senescence	O
in	O
healthy	O
tissues	O
and	O
leads	O
to	O
progressive	O
cognitive	O
dysfunction	O
in	O
up	O
to	O
50	O
%	O
of	O
tumor	O
patients	O
surviving	O
long	O
term	O
after	O
treatment	O
,	O
due	O
to	O
γ-irradiation	O
-induced	O
cerebromicrovascular	O
injury	O
.	O

Moment-to-moment	O
adjustment	O
of	O
cerebral	O
blood	O
flow	O
(	O
CBF	O
)	O
via	O
neuronal	O
activity	O
-dependent	O
cerebromicrovascular	O
dilation	O
(	O
functional	O
hyperemia	O
)	O
has	O
a	O
critical	O
role	O
in	O
maintenance	O
of	O
healthy	O
cognitive	O
function	O
.	O

To	O
determine	O
whether	O
cognitive	O
decline	O
induced	O
by	O
WBI	O
associates	O
with	O
impaired	O
cerebromicrovascular	O
function	O
,	O
C56BL/6	O
mice	O
(	O
3	O
months	O
)	O
subjected	O
to	O
a	O
clinically	O
relevant	O
protocol	O
of	O
fractionated	O
WBI	O
(	O
5	O
Gy	O
twice	O
weekly	O
for	O
4	O
weeks	O
)	O
and	O
control	O
mice	O
were	O
compared	O
.	O

Mice	O
were	O
tested	O
for	O
spatial	O
memory	O
performance	O
(	O
radial	O
arm	O
water	O
maze	O
)	O
,	O
sensorimotor	O
coordination	O
(	O
computerized	B-P
gait	I-P
analysis	I-P
,	O
CatWalk	O
)	O
,	O
and	O
cerebromicrovascular	O
function	O
(	O
whisker	O
-	O
stimulation	O
-induced	O
increases	O
in	O
CBF	O
,	O
measured	O
by	O
laser	B-P
Doppler	I-P
flowmetry	I-P
)	O
at	O
3	O
to	O
6	O
months	O
post	O
-	O
irradiation	O
.	O

We	O
found	O
that	O
mice	O
with	O
WBI	O
exhibited	O
impaired	O
cerebromicrovascular	O
function	O
at	O
3	O
months	O
post	O
-	O
irradiation	O
,	O
which	O
was	O
associated	O
with	O
impaired	O
performance	O
in	O
the	O
radial	O
arm	O
water	O
maze	O
.	O

At	O
6	O
months	O
,	O
post	O
-	O
irradiation	O
progressive	O
impairment	O
in	O
gait	O
coordination	O
(	O
including	O
changes	O
in	O
the	O
regularity	O
index	O
and	O
phase	O
dispersion	O
)	O
was	O
also	O
evident	O
.	O

Collectively	O
,	O
our	O
findings	O
provide	O
evidence	O
for	O
early	O
and	O
persisting	O
neurovascular	O
impairment	O
after	O
a	O
clinically	O
relevant	O
protocol	O
of	O
fractionated	O
WBI	O
,	O
which	O
predict	O
early	O
manifestations	O
of	O
cognitive	O
impairment	O
.	O

Partial	O
tetrasomy	O
11q	O
resulting	O
from	O
an	O
intrachromosomal	O
triplication	O
of	O
a	O
22	O
Mb	O
region	O
of	O
chromosome	O
11	O
.	O

Intrachromosomal	O
triplications	O
are	O
complex	O
chromosomal	O
rearrangements	O
which	O
arise	O
during	O
meiosis	O
or	O
mitosis	O
and	O
lead	O
to	O
a	O
tetrasomic	O
dose	O
of	O
the	O
affected	O
genomic	O
regions	O
.	O

We	O
describe	O
a	O
female	O
patient	O
harboring	O
an	O
intrachromosomal	O
triplication	O
who	O
presented	O
to	O
the	O
Genetics	O
clinic	O
with	O
dysmorphic	O
features	O
,	O
including	O
telecanthus	O
,	O
flat	O
facial	O
profile	O
,	O
and	O
prognathism	O
,	O
short	O
stature	O
,	O
widely	O
spaced	O
nipples	O
,	O
multiple	O
allergy	O
complaints	O
,	O
loose	O
bowel	O
movements	O
,	O
and	O
mild	O
speech	O
delay	O
.	O

Microarray	B-P
analysis	I-P
showed	O
a	O
copy	O
number	O
gain	O
of	O
a	O
22.37	O
Mb	O
region	O
of	O
chromosome	O
11	O
between	O
bands	O
11q14.1	O
and	O
11q22.1	O
.	O

This	O
region	O
contains	O
95	O
genes	O
and	O
seven	O
microRNAs	O
,	O
none	O
of	O
which	O
have	O
been	O
implicated	O
in	O
a	O
disease	O
resulting	O
from	O
increased	O
gene	O
dosage	O
.	O

FISH	B-P
analysis	I-P
using	O
a	O
probe	O
targeted	O
to	O
the	O
middle	O
of	O
the	O
segment	O
of	O
the	O
copy	O
number	O
gain	O
yielded	O
a	O
pattern	O
indicative	O
of	O
a	O
tetrasomy	O
via	O
an	O
intrachromosomal	O
triplication	O
,	O
with	O
three	O
signals	O
on	O
the	O
long	O
arm	O
of	O
one	O
homologue	O
of	O
chromosome	O
11	O
and	O
the	O
fourth	O
on	O
the	O
other	O
homologue	O
.	O

Subsequent	O
FISH	B-P
analysis	I-P
showed	O
that	O
the	O
middle	O
triplicated	O
fragment	O
was	O
positioned	O
in	O
an	O
inverted	O
orientation	O
relative	O
to	O
the	O
outer	O
fragments	O
.	O

To	O
investigate	O
the	O
mechanism	O
by	O
which	O
the	O
intrachromosomal	O
triplication	O
occurred	O
,	O
SNP	B-P
microarray	I-P
analysis	I-P
was	O
performed	O
.	O

These	O
results	O
were	O
consistent	O
with	O
the	O
presence	O
of	O
multiple	O
haplotypes	O
in	O
the	O
tetrasomic	O
region	O
and	O
suggest	O
that	O
the	O
intrachromosomal	O
triplication	O
in	O
our	O
patient	O
arose	O
in	O
one	O
parent	O
during	O
meiosis	O
.	O

©	O
2017	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

Sedation	O
of	O
Patients	O
With	O
Disorders	O
of	O
Consciousness	O
During	O
Neuroimaging	B-P
:	O
Effects	O
on	O
Resting	B-P
State	I-P
Functional	I-P
Brain	I-P
Connectivity	I-P
.	O

To	O
reduce	O
head	O
movement	O
during	O
resting	B-P
state	I-P
functional	I-P
magnetic	I-P
resonance	I-P
imaging	I-P
,	O
post-coma	O
patients	O
with	O
disorders	O
of	O
consciousness	O
(	O
DOC	O
)	O
are	O
frequently	O
sedated	O
with	O
propofol	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
effects	O
of	O
this	O
sedation	O
on	O
the	O
brain	O
connectivity	O
patterns	O
in	O
the	O
damaged	O
brain	O
essential	O
for	O
differential	B-P
diagnosis	I-P
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
assess	O
these	O
effects	O
.	O

Using	O
resting	B-P
state	I-P
functional	I-P
magnetic	I-P
resonance	I-P
imaging	I-P
3T	O
data	O
obtained	O
over	O
several	O
years	O
of	O
scanning	B-P
patients	O
for	O
diagnostic	O
and	O
research	O
purposes	O
,	O
we	O
employed	O
a	O
seed-based	O
approach	O
to	O
examine	O
resting	O
state	O
connectivity	O
in	O
higher-order	O
(	O
default	O
mode	O
,	O
bilateral	O
external	O
control	O
,	O
and	O
salience	O
)	O
and	O
lower-order	O
(	O
auditory	O
,	O
sensorimotor	O
,	O
and	O
visual	O
)	O
resting	O
state	O
networks	O
and	O
connectivity	O
with	O
the	O
thalamus	O
,	O
in	O
20	O
healthy	O
unsedated	O
controls	O
,	O
8	O
unsedated	O
patients	O
with	O
DOC	O
,	O
and	O
8	O
patients	O
with	O
DOC	O
sedated	O
with	O
propofol	O
.	O

The	O
DOC	O
groups	O
were	O
matched	O
for	O
age	O
at	O
onset	O
,	O
etiology	O
,	O
time	O
spent	O
in	O
DOC	O
,	O
diagnosis	O
,	O
standardized	O
behavioral	O
assessment	O
scores	O
,	O
movement	O
intensities	O
,	O
and	O
pattern	O
of	O
structural	O
brain	O
injury	O
(	O
as	O
assessed	O
with	O
T1-based	B-P
voxel-based	I-P
morphometry	I-P
)	O
.	O

DOC	O
were	O
associated	O
with	O
severely	O
impaired	O
resting	O
state	O
network	O
connectivity	O
in	O
all	O
but	O
the	O
visual	O
network	O
.	O

Thalamic	O
connectivity	O
to	O
higher-order	O
network	O
regions	O
was	O
also	O
reduced	O
.	O

Propofol	O
administration	O
to	O
patients	O
was	O
associated	O
with	O
minor	O
further	O
decreases	O
in	O
thalamic	O
and	O
insular	O
connectivity	O
.	O

Our	O
findings	O
indicate	O
that	O
connectivity	O
decreases	O
associated	O
with	O
propofol	O
sedation	O
,	O
involving	O
the	O
thalamus	O
and	O
insula	O
,	O
are	O
relatively	O
small	O
compared	O
with	O
those	O
already	O
caused	O
by	O
DOC	O
-associated	O
structural	O
brain	O
injury	O
.	O

Nonetheless	O
,	O
given	O
the	O
known	O
importance	O
of	O
the	O
thalamus	O
in	O
brain	O
arousal	O
,	O
its	O
disruption	O
could	O
well	O
reflect	O
the	O
diminished	O
movement	O
obtained	O
in	O
these	O
patients	O
.	O

However	O
,	O
more	O
research	O
is	O
needed	O
on	O
this	O
topic	O
to	O
fully	O
address	O
the	O
research	O
question	O
.	O

From	O
Homology	O
Models	O
to	O
a	O
Set	O
of	O
Predictive	O
Binding	O
Pockets	O
-a	O
5-HT1A	O
Receptor	O
Case	O
Study	O
.	O

Despite	O
its	O
remarkable	O
importance	O
in	O
the	O
arena	O
of	O
drug	O
design	O
,	O
serotonin	O
1A	O
receptor	O
(	O
5-HT1A	O
)	O
has	O
been	O
elusive	O
to	O
the	O
X-ray	B-P
crystallography	I-P
community	O
.	O

This	O
lack	O
of	O
direct	O
structural	O
information	O
not	O
only	O
hampers	O
our	O
knowledge	O
regarding	O
the	O
binding	O
modes	O
of	O
many	O
popular	O
ligands	O
(	O
including	O
the	O
endogenous	O
neurotransmitter	O
-	O
serotonin	O
)	O
,	O
but	O
also	O
limits	O
the	O
search	O
for	O
more	O
potent	O
compounds	O
.	O

In	O
this	O
paper	O
we	O
shed	O
new	O
light	O
on	O
the	O
3D	O
pharmacological	O
properties	O
of	O
the	O
5-HT1A	O
receptor	O
by	O
using	O
a	O
ligand-guided	O
approach	O
(	O
ALiBERO	O
)	O
grounded	O
in	O
the	O
Internal	O
Coordinate	O
Mechanics	O
(	O
ICM	O
)	O
docking	O
platform	O
.	O

Starting	O
from	O
a	O
homology	O
template	O
and	O
set	O
of	O
known	O
actives	O
,	O
the	O
method	O
introduces	O
receptor	O
flexibility	O
via	O
Normal	O
Mode	O
Analysis	O
and	O
Monte	O
Carlo	O
sampling	O
,	O
to	O
generate	O
a	O
subset	O
of	O
pockets	O
that	O
display	O
enriched	O
discrimination	O
of	O
actives	O
from	O
inactives	O
in	O
retrospective	O
docking	O
.	O

Here	O
,	O
we	O
thoroughly	O
investigated	O
the	O
repercussions	O
of	O
using	O
different	O
protein	O
templates	O
and	O
the	O
effect	O
of	O
compound	O
selection	O
on	O
screening	O
performance	O
.	O

Finally	O
,	O
the	O
best	O
resulting	O
protein	O
models	O
were	O
applied	O
prospectively	O
in	O
a	O
large	O
virtual	O
screening	O
campaign	O
,	O
in	O
which	O
two	O
new	O
active	O
compounds	O
were	O
identified	O
that	O
were	O
chemically	O
distinct	O
from	O
those	O
described	O
in	O
the	O
literature	O
.	O

Stem	O
cells	O
and	O
their	O
role	O
in	O
pituitary	O
tumorigenesis	O
.	O

The	O
presence	O
of	O
adult	O
pituitary	O
stem	O
cells	O
(	O
PSCs	O
)	O
has	O
been	O
described	O
in	O
murine	O
systems	O
by	O
comprehensive	O
cellular	O
profiling	O
and	O
genetic	O
lineage	O
tracing	O
experiments	O
.	O

PSCs	O
are	O
thought	O
to	O
maintain	O
multipotent	O
capacity	O
throughout	O
life	O
and	O
give	O
rise	O
to	O
all	O
hormone	O
-producing	O
cell	O
lineages	O
,	O
playing	O
a	O
role	O
in	O
pituitary	O
gland	O
homeostasis	O
.	O

Additionally	O
,	O
PSCs	O
have	O
been	O
proposed	O
to	O
play	O
a	O
role	O
in	O
pituitary	O
tumorigenesis	O
,	O
in	O
both	O
adenomas	O
and	O
adamantinomatous	O
craniopharyngiomas	O
.	O

In	O
this	O
manuscript	O
,	O
we	O
discuss	O
the	O
different	O
approaches	O
used	O
to	O
demonstrate	O
the	O
presence	O
of	O
PSCs	O
in	O
the	O
murine	O
adult	O
pituitary	O
,	O
from	O
marker	B-P
analyses	I-P
to	O
genetic	B-P
tracing	I-P
.	O

In	O
addition	O
,	O
we	O
review	O
the	O
published	O
literature	O
suggesting	O
the	O
existence	O
of	O
tumor	O
stem	O
cells	O
in	O
mouse	O
and	O
human	O
pituitary	O
tumors	O
.	O

Finally	O
,	O
we	O
discuss	O
the	O
potential	O
role	O
of	O
PSCs	O
in	O
pituitary	O
tumorigenesis	O
in	O
the	O
context	O
of	O
current	O
models	O
of	O
carcinogenesis	O
and	O
present	O
evidence	O
showing	O
that	O
in	O
contrast	O
to	O
pituitary	O
adenoma	O
,	O
which	O
follows	O
a	O
classical	O
cancer	O
stem	O
cell	O
paradigm	O
,	O
a	O
novel	O
mechanism	O
has	O
been	O
revealed	O
for	O
paracrine	O
,	O
non-cell	O
autonomous	O
tumor	O
initiation	O
in	O
adamantinomatous	O
craniopharyngioma	O
,	O
a	O
benign	O
but	O
clinically	O
aggressive	O
pediatric	O
tumor	O
.	O

Primary	O
neuroendocrine	O
carcinoma	O
of	O
the	O
breast	O
A	O
single	O
Center	O
experience	O
and	O
review	O
of	O
the	O
literature	O
.	O

Neuroendocrine	O
carcinoma	O
of	O
the	O
breast	O
is	O
an	O
extremely	O
rare	O
tumor	O
.	O

A	O
standard	O
treatment	O
has	O
yet	O
to	O
be	O
established	O
because	O
only	O
a	O
few	O
cases	O
have	O
been	O
reported	O
in	O
literature	O
.	O

The	O
authors	O
report	O
five	O
cases	O
observed	O
from	O
January	O
2007	O
to	O
December	O
2014	O
and	O
a	O
review	O
of	O
literature	O
.	O

Four	O
patients	O
underwent	O
quadrantectomy	O
and	O
in	O
two	O
cases	O
axillary	O
nodal	O
dissection	O
and	O
only	O
one	O
to	O
mastectomy	O
with	O
axillary	O
nodal	O
dissection	O
.	O

Tumor	O
size	O
was	O
from	O
T1	O
to	O
T2	O
with	O
N0	O
to	O
N1	O
,	O
according	O
TNM	O
classification	O
.	O

Pathological	O
specimens	O
were	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
and	O
an	O
immunohistochemical	B-P
panel	O
of	O
antibodies	O
(	O
Neuron-specific	O
enolase	O
,	O
Chromogranin	O
,	O
Synaptophysin	O
,	O
Estrogen	O
and	O
Progesterone	O
receptors	O
,	O
c-erb	O
and	O
Ki-67	O
)	O
.	O

All	O
cases	O
showed	O
markers	O
positivity	O
to	O
Neuron-specific	O
enolase	O
,	O
Chromogranin	O
,	O
Synaptophysin	O
and	O
Estrogen	O
and	O
Progesterone	O
receptors	O
were	O
found	O
.	O

Ki-67	O
was	O
higher	O
than	O
40	O
%	O
in	O
four	O
patients	O
.	O

Adjuvant	O
chemotherapy	O
was	O
administrated	O
in	O
patients	O
with	O
Ki-67	O
>	O
10	O
%	O
;	O
every	O
patients	O
were	O
treated	O
with	O
radiotherapy	O
and	O
with	O
hormonal	O
therapy	O
too	O
.	O

Although	O
Neuroendocrine	O
breast	O
tumor	O
is	O
considered	O
a	O
distinct	O
entity	O
,	O
the	O
best	O
treatment	O
seems	O
to	O
be	O
correlate	O
to	O
the	O
size	O
of	O
tumor	O
and	O
to	O
the	O
lymph	O
node	O
status	O
and	O
to	O
Ki-67	O
index	O
like	O
the	O
common	O
breast	O
cancer	O
.	O

Diagnosis	O
,	O
Neuroendocrine	O
breast	O
carcinoma	O
.	O

The	O
number	O
of	O
tumorspheres	O
cultured	O
from	O
peripheral	O
blood	O
is	O
a	O
predictor	O
for	O
presence	O
of	O
metastasis	O
in	O
patients	O
with	O
breast	O
cancer	O
.	O

Tumor	O
metastases	O
are	O
the	O
major	O
cause	O
of	O
cancer	O
morbidity	O
and	O
mortality	O
.	O

A	O
subpopulation	O
of	O
tumor	O
cells	O
with	O
stem-like	O
properties	O
is	O
assumed	O
to	O
be	O
responsible	O
for	O
tumor	O
invasion	O
,	O
metastasis	O
,	O
heterogeneity	O
and	O
therapeutic	O
resistance	O
.	O

This	O
population	O
is	O
termed	O
cancer	O
stem	O
cells	O
(	O
CSCs	O
)	O
.	O

We	O
have	O
developed	O
a	O
simple	O
method	O
for	O
identification	O
and	O
characterization	O
of	O
circulating	O
cancer	O
stem	O
cells	O
among	O
circulating	O
epithelial	O
tumor	O
cells	O
(	O
CETCs	O
)	O
.	O

CETCs	O
were	O
cultured	O
under	O
conditions	O
favoring	O
growth	O
of	O
tumorspheres	O
from	O
72	O
patients	O
with	O
breast	O
cancer	O
,	O
including	O
a	O
subpopulation	O
of	O
23	O
patients	O
with	O
metastatic	O
disease	O
.	O

CETCs	O
were	O
determined	O
using	O
the	O
maintrac®	B-P
method	I-P
.	O

Gene	O
expression	O
profiles	O
of	O
single	O
CETCs	O
and	O
tumorspheres	O
of	O
the	O
same	O
patients	O
were	O
analyzed	O
using	O
qRT-PCR	O
.	O

Sphere	O
formation	O
was	O
observed	O
in	O
79	O
%	O
of	O
patients	O
.	O

We	O
found	O
that	O
the	O
number	O
of	O
tumorspheres	O
depended	O
on	O
stage	B-P
of	I-P
disease	I-P
.	O

Furthermore	O
,	O
the	O
most	O
important	O
factor	O
for	O
growing	O
of	O
tumorspheres	O
is	O
obtaining	O
chemotherapy	O
.	O

Patients	O
with	O
chemotherapy	O
treatment	O
had	O
lower	O
numbers	O
of	O
tumorspheres	O
compared	O
to	O
patients	O
without	O
chemotherapy	O
.	O

Patients	O
with	O
HER2	O
positive	O
primary	O
tumor	O
had	O
higher	O
number	O
of	O
tumorspheres	O
.	O

Analysis	O
of	O
surface	O
marker	O
expression	O
profile	O
of	O
tumorspheres	O
showed	O
that	O
cells	O
in	O
the	O
spheres	O
had	O
typical	O
phenotype	O
of	O
cancer	O
stem	O
cells	O
.	O

There	O
was	O
no	O
sphere	O
formation	O
in	O
a	O
control	O
group	O
with	O
50	O
healthy	O
donors	O
.	O

This	O
study	O
demonstrates	O
that	O
a	O
small	O
fraction	O
of	O
CETCs	O
has	O
proliferative	O
activity	O
.	O

Identifying	O
the	O
CETC	O
subset	O
with	O
cancer	O
stem	O
cell	O
properties	O
may	O
provide	O
more	O
clinically	O
useful	O
prognostic	O
information	O
.	O

Chemotherapy	O
is	O
the	O
most	O
important	O
component	O
in	O
cancer	O
therapy	O
because	O
it	O
frequently	O
reduces	O
the	O
number	O
of	O
tumorspheres	O
.	O

Evaluation	O
of	O
function	O
and	O
recovery	B-P
of	O
adipose	O
-derived	O
stem	O
cells	O
after	O
exposure	O
to	O
paclitaxel	O
.	O

Adipose	O
-derived	O
stem	O
cells	O
(	O
ASCs	O
)	O
are	O
considered	O
to	O
play	O
a	O
positive	O
role	O
in	O
wound	O
healing	O
as	O
evidenced	O
by	O
their	O
increasing	O
use	O
in	O
breast	O
reconstructive	O
procedures	O
.	O

After	O
chemotherapy	O
for	O
breast	O
cancer	O
,	O
poor	O
soft	O
tissue	O
wound	O
healing	O
is	O
a	O
major	O
problem	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
functional	O
capabilities	O
and	O
recovery	B-P
of	O
ASCs	O
after	O
exposure	O
to	O
chemotherapeutic	O
agent	O
paclitaxel	O
(	O
PTX	O
)	O
using	O
in	O
vitro	O
and	O
ex	O
vivo	O
models	O
were	O
demonstrated	O
.	O

Human	O
ASCs	O
were	O
isolated	O
from	O
periumbilical	O
fat	O
tissue	O
and	O
treated	O
with	O
PTX	O
at	O
various	O
concentrations	O
.	O

Adult	O
Sprague-Dawley	O
rats	O
were	O
given	O
intravenous	O
injections	O
with	O
PTX	O
.	O

Two	O
and	O
four	O
weeks	O
after	O
the	O
initial	O
PTX	O
treatment	O
,	O
ASCs	O
were	O
isolated	O
from	O
rat	O
adipose	O
tissue	O
.	O

Proliferation	O
,	O
cell	O
viability	O
,	O
apoptosis	O
and	O
cell	O
migration	O
rates	O
were	O
measured	O
by	O
growth	O
curves	O
,	O
MTT	O
assays	O
,	O
flow	B-P
cytometry	I-P
and	O
scratch	B-P
assays	I-P
.	O

ASCs	O
were	O
cultured	O
in	O
derivative-specific	O
differentiation	O
media	O
with	O
or	O
without	O
PTX	O
for	O
3	O
weeks	O
.	O

Adipogenic	O
,	O
osteogenic	O
and	O
endothelial	O
differentiation	O
levels	O
were	O
measured	O
by	O
quantitative	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
and	O
histological	B-P
staining	B-P
.	O

PTX	O
induced	O
apoptosis	O
,	O
decreased	O
the	O
proliferation	O
and	O
cell	O
migration	O
rates	O
of	O
ASCs	O
and	O
inhibited	O
ASCs	O
multipotent	O
differentiation	O
in	O
both	O
in	O
vitro	O
human	O
ASC	O
populations	O
and	O
ex	O
vivo	O
rat	O
ASC	O
populations	O
with	O
PTX	O
treatment	O
.	O

Furthermore	O
,	O
after	O
cessation	O
of	O
PTX	O
,	O
ASCs	O
exhibited	O
recovery	B-P
potential	O
of	O
differentiation	O
capacity	O
in	O
both	O
in	O
vitro	O
and	O
animal	O
studies	O
.	O

Our	O
results	O
provide	O
insight	O
into	O
poor	O
soft	O
tissue	O
wound	O
healing	O
and	O
promote	O
further	O
understanding	O
of	O
the	O
potential	O
capability	O
of	O
ASCs	O
to	O
serve	O
as	O
a	O
cell	O
source	O
for	O
fat	O
grafting	O
and	O
reconstruction	O
in	O
cancer	O
patients	O
undergoing	O
chemotherapy	O
treatment	O
.	O

DNA	O
annealing	O
by	O
Redβ	O
is	O
insufficient	O
for	O
homologous	O
recombination	O
and	O
the	O
additional	O
requirements	O
involve	O
intra-	O
and	O
inter-molecular	O
interactions	O
.	O

Single	O
strand	O
annealing	O
proteins	O
(	O
SSAPs	O
)	O
like	O
Redβ	O
initiate	O
homologous	O
recombination	O
by	O
annealing	O
complementary	O
DNA	O
strands	O
.	O

We	O
show	O
that	O
C-terminally	O
truncated	O
Redβ	O
,	O
whilst	O
still	O
able	O
to	O
promote	O
annealing	O
and	O
nucleoprotein	O
filament	O
formation	O
,	O
is	O
unable	O
to	O
mediate	O
homologous	O
recombination	O
.	O

Mutations	O
of	O
the	O
C-terminal	O
domain	O
were	O
evaluated	O
using	O
both	O
single	O
-	O
and	O
double	O
stranded	O
(	O
ss	O
and	O
ds	O
)	O
substrates	O
in	O
recombination	O
assays	B-P
.	O

Mutations	O
of	O
critical	O
amino	O
acids	O
affected	O
either	O
dsDNA	O
recombination	O
or	O
both	O
ssDNA	O
and	O
dsDNA	O
recombination	O
indicating	O
two	O
separable	O
functions	O
,	O
one	O
of	O
which	O
is	O
critical	O
for	O
dsDNA	O
recombination	O
and	O
the	O
second	O
for	O
recombination	O
per	O
se	O
.	O

As	O
evaluated	O
by	O
co-immunoprecipitation	B-P
experiments	I-P
,	O
the	O
dsDNA	O
recombination	O
function	O
relates	O
to	O
the	O
Redα	O
-	O
Redβ	O
protein-protein	O
interaction	O
,	O
which	O
requires	O
not	O
only	O
contacts	O
in	O
the	O
C-terminal	O
domain	O
but	O
also	O
a	O
region	O
near	O
the	O
N-terminus	O
.	O

Because	O
the	O
nucleoprotein	O
filament	O
formed	O
with	O
C-terminally	O
truncated	O
Redβ	O
has	O
altered	O
properties	O
,	O
the	O
second	O
C-terminal	O
function	O
could	O
be	O
due	O
to	O
an	O
interaction	O
required	O
for	O
functional	O
filaments	O
.	O

Alternatively	O
the	O
second	O
C-terminal	O
function	O
could	O
indicate	O
a	O
requirement	O
for	O
a	O
Redβ	O
-	O
host	O
factor	O
interaction	O
.	O

These	O
data	O
further	O
advance	O
the	O
model	O
for	O
Red	O
recombination	O
and	O
the	O
proposition	O
that	O
Redβ	O
and	O
RAD52	O
SSAPs	O
share	O
ancestral	O
and	O
mechanistic	O
roots	O
.	O

Evaluation	O
of	O
changes	O
in	O
anthropometric	O
indexes	O
due	O
to	O
intermaxillary	O
fixation	O
following	O
facial	O
fractures	O
.	O

Background	O
.	O

One	O
of	O
the	O
treatment	O
modalities	O
for	O
facial	O
fractures	O
is	O
closed	O
reduction	O
technique	O
,	O
but	O
treatment	O
with	O
intermaxillary	O
fixation	O
(	O
IMF	O
)	O
interferes	O
with	O
normal	O
nutrition	O
,	O
and	O
malnutrition	O
can	O
affect	O
the	O
patient	O
's	O
recovery	O
.	O

Anthropometric	O
measurements	O
such	O
as	O
skinfold	B-P
thickness	I-P
and	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
are	O
universal	O
indexes	O
for	O
diagnosing	O
malnutrition	O
.	O

Therefore	O
,	O
in	O
this	O
study	O
we	O
explain	O
how	O
treatment	O
with	O
IMF	O
changes	O
the	O
anthropometric	O
indexes	O
.	O

Methods	O
.	O

In	O
this	O
study	O
60	O
patients	O
were	O
treated	O
with	O
4	O
weeks	O
of	O
IMF	O
.	O

Skinfold	B-P
thickness	I-P
and	O
BMI	O
of	O
these	O
patients	O
were	O
measured	O
and	O
compared	O
before	O
and	O
after	O
the	O
treatment	O
.	O

Results	O
.	O

Patients	O
'	O
weight	O
,	O
BMI	O
and	O
skinfold	B-P
thickness	I-P
decreased	O
during	O
the	O
IMF	O
period	O
,	O
and	O
this	O
decrease	O
was	O
statistically	O
significant	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Conclusion	O
.	O

Although	O
no	O
severe	O
and	O
acute	O
malnutrition	O
was	O
seen	O
among	O
our	O
patients	O
,	O
IMF	O
led	O
to	O
mild	O
to	O
moderate	O
malnutrition	O
in	O
some	O
cases	O
,	O
making	O
it	O
necessary	O
to	O
use	O
nutritional	O
supplements	O
.	O

Thaw	B-P
-and-use	O
target	O
cells	O
pre-labeled	O
with	O
calcein	O
AM	O
for	O
antibody-dependent	B-P
cell-mediated	I-P
cytotoxicity	I-P
assays	I-P
.	O

In	O
vitro	O
antibody-dependent	B-P
cell-mediated	I-P
cytotoxicity	I-P
(	I-P
ADCC	I-P
)	I-P
assays	I-P
are	O
routinely	O
performed	O
to	O
support	O
the	O
research	O
and	O
development	O
of	O
therapeutic	O
antibodies	O
.	O

In	O
ADCC	B-P
assays	I-P
,	O
target	O
cells	O
bound	O
by	O
the	O
antibodies	O
are	O
lysed	O
by	O
activated	O
effector	O
cells	O
following	O
interactions	O
between	O
the	O
Fc	O
region	O
of	O
the	O
bound	O
antibody	O
and	O
Fcγ	O
receptors	O
on	O
effector	O
cells	O
.	O

Target	O
cell	O
lysis	O
is	O
typically	O
measured	O
by	O
quantification	O
of	O
released	O
endogenous	O
enzymes	O
,	O
e.g.	O
,	O
lactate	O
dehydrogenase	O
,	O
or	O
measurement	O
of	O
released	O
exogenous	O
labels	O
,	O
e.g.	O
,	O
(	O
51	O
)	O
Cr	O
,	O
europium	O
or	O
calcein	O
.	O

ADCC	B-P
assays	I-P
based	O
on	O
the	O
detection	O
of	O
exogenous	O
labels	O
released	O
from	O
lysed	O
target	O
cells	O
generally	O
show	O
higher	O
sensitivity	O
and	O
require	O
shorter	O
incubation	O
times	O
.	O

However	O
,	O
target	O
cells	O
are	O
usually	O
labeled	O
immediately	O
prior	O
to	O
assay	B-P
,	O
which	O
inadvertently	O
introduces	O
additional	O
assay	B-P
variations	O
due	O
to	O
differences	O
in	O
target	O
cell	O
conditions	O
and	O
labeling	B-P
/	O
handling	B-P
processes	I-P
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
use	O
of	O
thaw	B-P
-and-use	O
pre-labeled	O
target	O
cells	O
for	O
ADCC	B-P
assays	I-P
.	O

Thaw	B-P
-and-use	O
target	O
cells	O
in	O
our	O
experiments	O
were	O
pre-labeled	O
with	O
the	O
fluorescent	O
dye	O
calcein	O
AM	O
,	O
cryopreserved	B-P
in	O
single-use	O
aliquots	O
and	O
used	O
directly	O
in	O
assays	B-P
after	O
thawing	B-P
.	O

Upon	O
thaw	B-P
,	O
the	O
pre-labeled	O
cells	O
displayed	O
viability	O
and	O
label	O
retention	O
comparable	O
to	O
freshly	O
labeled	O
cells	O
,	O
responded	O
to	O
ADCC	O
mediated	O
by	O
both	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
engineered	O
natural	O
killer	O
cells	O
,	O
performed	O
stably	O
for	O
at	O
least	O
3	O
years	O
and	O
provided	O
favorable	O
precision	O
and	O
accuracy	O
to	O
ADCC	B-P
assays	I-P
.	O

Implementation	O
of	O
thaw	B-P
-and-use	O
pre-labeled	O
target	O
cells	O
in	O
ADCC	B-P
assays	I-P
can	O
help	O
to	O
alleviate	O
both	O
cell	B-P
culture	I-P
and	O
dye	B-P
labeling	I-P
derived	O
variability	O
,	O
increase	O
the	O
flexibility	O
of	O
assay	B-P
scheduling	O
and	O
improve	O
assay	O
consistency	O
and	O
robustness	O
.	O

Bacteriology	B-P
of	O
Urine	O
Specimens	O
Obtained	O
from	O
Men	O
with	O
Symptomatic	O
Benign	O
Prostatic	O
Hyperplasia	O
.	O

Bacteriuria	O
and	O
urinary	O
tract	O
infections	O
are	O
common	O
sequelae	O
of	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
.	O

Thus	O
,	O
the	O
knowledge	O
of	O
urine	O
bacteriology	B-P
in	O
men	O
with	O
symptomatic	O
BPH	O
in	O
our	O
environment	O
may	O
play	O
a	O
complementary	O
role	O
in	O
management	O
.	O

To	O
determine	O
the	O
incidence	O
of	O
bacteriuria	O
and	O
the	O
antibiotic	O
sensitivity	O
pattern	O
of	O
bacterial	O
isolates	O
in	O
cultured	B-P
urine	I-P
samples	O
of	O
men	O
with	O
symptomatic	O
BPH	O
.	O

This	O
was	O
a	O
1	O
year	O
prospective	O
study	O
.	O

All	O
patients	O
who	O
presented	O
with	O
lower	O
urinary	O
tract	O
symptoms	O
due	O
to	O
BPH	O
and	O
who	O
met	O
the	O
inclusion	O
criteria	O
were	O
studied	O
.	O

Urine	O
samples	O
were	O
obtained	O
from	O
the	O
patients	O
for	O
microscopy	B-P
,	O
culture	B-P
,	O
and	O
sensitivity	O
following	O
standard	O
protocol	O
.	O

Ninety-four	O
patients	O
were	O
studied	O
.	O

The	O
age	O
range	O
was	O
53-80	O
years	O
with	O
a	O
mean	O
of	O
65.5	O
±	O
7.8	O
years	O
.	O

Bacterial	O
isolates	O
were	O
noted	O
in	O
42	O
(	O
44.7	O
%	O
)	O
patients	O
.	O

Six	O
of	O
these	O
had	O
two	O
different	O
species	O
of	O
bacterial	O
organisms	O
isolated	O
.	O

Escherichia	O
coli	O
noted	O
in	O
20	O
(	O
47.6	O
%	O
)	O
specimens	O
was	O
the	O
most	O
common	O
organism	O
isolated	O
while	O
the	O
least	O
common	O
,	O
Providencia	O
species	O
,	O
was	O
noted	O
in	O
1	O
(	O
2.4	O
%	O
)	O
.	O

The	O
bacterial	O
isolates	O
were	O
mostly	O
sensitive	O
to	O
imipenem	O
,	O
meropenem	O
,	O
and	O
nitrofurantoin	O
,	O
but	O
showed	O
greater	O
resistance	O
to	O
cefuroxime	O
,	O
gentamicin	O
,	O
and	O
ofloxacin	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
means	O
for	O
age	O
(	O
P	O
=	O
0.80	O
)	O
,	O
duration	O
of	O
symptoms	O
(	O
P	O
=	O
0.09	O
)	O
,	O
and	O
prostate	O
size	O
(	O
P	O
=	O
0.52	O
)	O
in	O
the	O
patients	O
with	O
and	O
those	O
without	O
bacteriuria	O
.	O

Bacteriuria	O
is	O
a	O
common	O
finding	O
in	O
patients	O
with	O
symptomatic	O
BPH	O
in	O
our	O
setting	O
.	O

The	O
bacterial	O
isolates	O
showed	O
high	O
level	O
of	O
resistance	O
to	O
oral	O
cephalosporins	O
and	O
fluoroquinolones	O
.	O

There	O
is	O
a	O
need	O
to	O
update	O
guidelines	O
in	O
empiric	O
use	O
of	O
antibiotics	O
in	O
this	O
group	O
of	O
patients	O
.	O

Activation	O
of	O
ephrinB-EphB	O
receptor	O
signalling	O
in	O
rat	O
spinal	O
cord	O
contributes	O
to	O
maintenance	O
of	O
diabetic	O
neuropathic	O
pain	O
.	O

Diabetic	O
neuropathic	O
pain	O
(	O
DNP	O
)	O
is	O
severe	O
and	O
intractable	O
in	O
clinic	O
.	O

The	O
specific	O
cellular	O
and	O
molecular	O
mechanisms	O
underlying	O
DNP	O
remain	O
elusive	O
and	O
its	O
treatment	O
are	O
limited	O
.	O

We	O
investigated	O
roles	O
of	O
EphB1	O
receptor	O
in	O
the	O
development	O
of	O
DNP	O
.	O

Diabetic	O
neuropathic	O
pain	O
was	O
produced	O
in	O
male	O
,	O
adult	O
,	O
Sprague-Dawley	O
rats	O
by	O
a	O
single	O
i.p	O
.	O

streptozotocin	O
(	O
STZ	O
)	O
or	O
alloxan	O
.	O

Western	B-P
blot	I-P
analysis	I-P
and	O
immunohistochemistry	B-P
were	O
used	O
to	O
analyse	O
expression	O
of	O
EphB1	O
receptor	O
as	O
well	O
as	O
the	O
activation	O
of	O
the	O
glial	O
cells	O
and	O
the	O
pro-inflammatory	O
cytokines	O
in	O
the	O
spinal	O
cord	O
.	O

DNP	O
manifested	O
as	O
mechanical	O
allodynia	O
,	O
which	O
was	O
determined	O
by	O
measuring	O
incidence	O
of	O
foot	O
withdrawal	O
in	O
response	O
to	O
mechanical	O
indentation	O
of	O
the	O
hind	O
paw	O
by	O
an	O
electro	O
von	O
Frey	O
filament	O
.	O

Diabetic	O
neuropathic	O
pain	O
and	O
high	O
blood	O
glucose	O
were	O
exhibited	O
simultaneously	O
in	O
around	O
70	O
%	O
of	O
animals	O
that	O
received	O
i.p	O
.	O

STZ	O
or	O
alloxan	O
.	O

Phosphorylation	O
of	O
EphB1	O
,	O
activation	O
of	O
the	O
astrocytes	O
and	O
microglial	O
cells	O
,	O
and	O
level	O
of	O
tumour	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-α	O
and	O
interleukin	O
(	O
IL	O
)	O
-1β	O
in	O
the	O
spinal	O
cord	O
were	O
significantly	O
increased	O
in	O
rats	O
with	O
DNP	O
.	O

Spinal	O
blocking	O
EphB1	O
receptor	O
activation	O
in	O
the	O
late	O
phase	O
after	O
STZ	O
injection	O
significantly	O
suppressed	O
the	O
established	O
mechanical	O
allodynia	O
as	O
well	O
as	O
activation	O
of	O
the	O
astrocytes	O
and	O
microglial	O
cells	O
and	O
activity	O
of	O
TNF-α	O
and	O
IL-1β	O
.	O

However	O
,	O
spinal	O
treatment	O
of	O
EphB1	O
-	O
Fc	O
in	O
the	O
early	O
phase	O
after	O
STZ	O
injection	O
did	O
not	O
prevent	O
the	O
induction	O
of	O
DNP	O
.	O

EphB1	O
receptor	O
activation	O
in	O
the	O
spinal	O
cord	O
is	O
critical	O
to	O
the	O
maintenance	O
,	O
but	O
not	O
induction	O
of	O
diabetic	O
pain	O
.	O

EphB1	O
receptor	O
may	O
be	O
a	O
potential	O
target	O
for	O
relieving	O
the	O
established	O
diabetic	O
pain	O
.	O

Activation	O
of	O
EphB1	O
receptor	O
in	O
the	O
spinal	O
cord	O
is	O
critical	O
to	O
maintaining	O
the	O
established	O
diabetic	O
neuropathic	O
pain	O
,	O
but	O
not	O
to	O
diabetic	O
pain	O
induction	O
.	O

Spinal	O
blocking	O
EphB1	O
receptor	O
activation	O
suppresses	O
ongoing	O
diabetic	O
neuropathic	O
pain	O
.	O

Histological	O
variability	O
and	O
consequences	O
in	O
chronic	O
bird-related	O
hypersensitivity	O
pneumonitis	O
.	O

Lobar	O
and	O
temporal	O
histological	O
variability	O
in	O
chronic	O
bird-related	O
hypersensitivity	O
pneumonitis	O
(	O
BRHP	O
)	O
has	O
not	O
been	O
clearly	O
elucidated	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
spatio-temporal	O
histopathological	O
variability	O
in	O
chronic	O
BRHP	O
.	O

Fifty-two	O
patients	O
with	O
chronic	O
BRHP	O
who	O
underwent	O
a	O
surgical	O
lung	B-P
biopsy	I-P
(	O
SLB	B-P
)	O
between	O
1992	O
and	O
2008	O
were	O
evaluated	O
.	O

The	O
histopathological	O
characteristics	O
of	O
the	O
lung	O
biopsy	O
specimens	O
were	O
classified	O
by	O
the	O
2002	O
American	O
Thoracic	O
Society	O
/	O
European	O
Respiratory	O
Society	O
(	O
ATS/ERS	O
)	O
consensus	O
classification	O
of	O
idiopathic	O
interstitial	O
pneumonias	O
(	O
IIPs	O
)	O
.	O

Autopsy	B-P
specimens	O
from	O
seven	O
patients	O
were	O
also	O
evaluated	O
to	O
examine	O
the	O
serial	O
changes	O
from	O
SLB	B-P
to	O
autopsy	B-P
.	O

In	O
a	O
study	O
of	O
lobar	O
histological	O
variability	O
based	O
on	O
the	O
findings	O
of	O
SLB	B-P
,	O
7	O
patients	O
were	O
diagnosed	O
with	O
cellular	O
nonspecific	O
interstitial	O
pneumonia	O
(	O
NSIP	O
)	O
pattern	O
,	O
16	O
with	O
fibrotic	O
NSIP	O
pattern	O
,	O
20	O
with	O
fibrotic	O
NSIP	O
pattern	O
and	O
usual	O
interstitial	O
pneumonia	O
(	O
UIP	O
)	O
(	O
discordant	O
UIP	O
)	O
pattern	O
and	O
9	O
with	O
UIP	O
(	O
concordant	O
UIP	O
)	O
pattern	O
.	O

In	O
a	O
study	O
of	O
sequential	O
changes	O
,	O
specimens	O
of	O
SLBs	B-P
with	O
fibrotic	O
NSIP	O
pattern	O
changed	O
to	O
a	O
bronchiolocentric	O
interstitial	O
pneumonia	O
(	O
BIP	O
)	O
pattern	O
or	O
UIP	O
pattern	O
.	O

Interlobar	O
and	O
intralobar	O
histological	O
variability	O
is	O
present	O
in	O
chronic	O
BRHP	O
.	O

In	O
several	O
patients	O
with	O
chronic	O
BRHP	O
,	O
a	O
fibrotic	O
NSIP	O
pattern	O
may	O
be	O
an	O
early	O
lesion	O
that	O
progresses	O
to	O
a	O
UIP	O
pattern	O
.	O

Engagement	O
of	O
cellular	O
prion	O
protein	O
with	O
the	O
co-chaperone	O
Hsp70	O
/	O
90	O
organizing	O
protein	O
regulates	O
the	O
proliferation	O
of	O
glioblastoma	O
stem-like	O
cells	O
.	O

Glioblastoma	O
(	O
GBM	O
)	O
,	O
a	O
highly	O
aggressive	O
brain	O
tumor	O
,	O
contains	O
a	O
subpopulation	O
of	O
glioblastoma	O
stem-like	O
cells	O
(	O
GSCs	O
)	O
that	O
play	O
roles	O
in	O
tumor	O
maintenance	O
,	O
invasion	O
,	O
and	O
therapeutic	O
resistance	O
.	O

GSCs	O
are	O
therefore	O
a	O
promising	O
target	O
for	O
GBM	O
treatment	O
.	O

Our	O
group	O
identified	O
the	O
cellular	O
prion	O
protein	O
(	O
PrP	O
(	O
C	O
)	O
)	O
and	O
its	O
partner	O
,	O
the	O
co-chaperone	O
Hsp70	O
/	O
90	O
organizing	O
protein	O
(	O
HOP	O
)	O
,	O
as	O
potential	O
target	O
candidates	O
due	O
to	O
their	O
role	O
in	O
GBM	O
tumorigenesis	O
and	O
in	O
neural	O
stem	O
cell	O
maintenance	O
.	O

GSCs	O
expressing	O
different	O
levels	O
of	O
PrP	O
(	O
C	O
)	O
were	O
cultured	B-P
as	O
neurospheres	O
with	O
growth	O
factors	O
,	O
and	O
characterized	O
with	O
stem	O
cells	O
markers	O
and	O
adhesion	O
molecules	O
markers	O
through	O
immunofluorescence	B-P
and	O
flow	B-P
cytometry	I-P
.	O

We	O
than	O
evaluated	O
GSC	O
self-renewal	O
and	O
proliferation	O
by	O
clonal	B-P
density	I-P
assays	I-P
and	O
BrdU	B-P
incorporation	I-P
,	O
respectively	O
,	O
in	O
front	O
of	O
recombinant	O
HOP	O
treatment	O
,	O
combined	O
or	O
not	O
with	O
a	O
HOP	O
peptide	O
which	O
mimics	O
the	O
PrP	O
(	O
C	O
)	O
binding	O
site	O
.	O

Stable	O
silencing	O
of	O
HOP	O
was	O
also	O
performed	O
in	O
parental	O
and/or	O
PrP	O
(	O
C	O
)	O
-depleted	O
cell	O
populations	O
,	O
and	O
proliferation	O
in	O
vitro	O
and	O
tumor	O
growth	O
in	O
vivo	O
were	O
evaluated	O
.	O

Migration	B-P
assays	I-P
were	O
performed	O
on	O
laminin-1	O
pre-coated	O
glass	O
.	O

We	O
observed	O
that	O
,	O
when	O
GBM	O
cells	O
are	O
cultured	B-P
as	O
neurospheres	O
,	O
they	O
express	O
specific	O
stemness	O
markers	O
such	O
as	O
CD133	O
,	O
CD15	O
,	O
Oct4	O
,	O
and	O
SOX2	O
;	O
PrP	O
(	O
C	O
)	O
is	O
upregulated	O
compared	O
to	O
monolayer	B-P
culture	I-P
and	O
co-localizes	O
with	O
CD133	O
.	O

PrP	O
(	O
C	O
)	O
silencing	O
downregulates	O
the	O
expression	O
of	O
molecules	O
associated	O
with	O
cancer	O
stem	O
cells	O
,	O
upregulates	O
markers	O
of	O
cell	O
differentiation	O
and	O
affects	O
GSC	O
self-renewal	O
,	O
pointing	O
to	O
a	O
pivotal	O
role	O
for	O
PrP	O
(	O
C	O
)	O
in	O
the	O
maintenance	O
of	O
GSCs	O
.	O

Exogenous	O
HOP	O
treatment	O
increases	O
proliferation	O
and	O
self-renewal	O
of	O
GSCs	O
in	O
a	O
PrP	O
(	O
C	O
)	O
-dependent	O
manner	O
while	O
HOP	O
knockdown	O
disturbs	O
the	O
proliferation	O
process	O
.	O

In	O
vivo	O
,	O
PrP	O
(	O
C	O
)	O
and/or	O
HOP	O
knockdown	O
potently	O
inhibits	O
the	O
growth	O
of	O
subcutaneously	O
implanted	O
glioblastoma	O
cells	O
.	O

In	O
addition	O
,	O
disruption	O
of	O
the	O
PrP	O
(	O
C	O
)	O
-	O
HOP	O
complex	O
by	O
a	O
HOP	O
peptide	O
,	O
which	O
mimics	O
the	O
PrP	O
(	O
C	O
)	O
binding	O
site	O
,	O
affects	O
GSC	O
self-renewal	O
and	O
proliferation	O
indicating	O
that	O
the	O
HOP	O
-	O
PrP	O
(	O
C	O
)	O
complex	O
is	O
required	O
for	O
GSC	O
stemness	O
.	O

Furthermore	O
,	O
PrP	O
(	O
C	O
)	O
-depleted	O
GSCs	O
downregulate	O
cell	O
adhesion-related	O
proteins	O
and	O
impair	O
cell	O
migration	O
indicating	O
a	O
putative	O
role	O
for	O
PrP	O
(	O
C	O
)	O
in	O
the	O
cell	O
surface	O
stability	O
of	O
cell	O
adhesion	O
molecules	O
and	O
GBM	O
cell	O
invasiveness	O
,	O
respectively	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
show	O
that	O
the	O
modulation	O
of	O
HOP	O
-	O
PrP	O
(	O
C	O
)	O
engagement	O
or	O
the	O
decrease	O
of	O
PrP	O
(	O
C	O
)	O
and	O
HOP	O
expression	O
may	O
represent	O
a	O
potential	O
therapeutic	O
intervention	O
in	O
GBM	O
,	O
regulating	O
glioblastoma	O
stem-like	O
cell	O
self-renewal	O
,	O
proliferation	O
,	O
and	O
migration	O
.	O

Targeting	O
brain	O
and	O
peripheral	O
plasticity	O
of	O
the	O
lipidome	O
in	O
acute	O
kainic	O
acid	O
-	O
induced	O
epileptic	O
seizures	O
in	O
mice	O
via	O
quantitative	B-P
mass	I-P
spectrometry	I-P
.	O

Epilepsy	O
is	O
a	O
highly	O
common	O
chronic	O
neurological	O
disorder	O
,	O
manifested	O
in	O
many	O
different	O
types	O
,	O
affecting	O
~1	O
%	O
of	O
the	O
worldwide	O
human	O
population	O
.	O

The	O
molecular	O
mechanisms	O
of	O
epileptogenesis	O
have	O
not	O
yet	O
been	O
clarified	O
,	O
and	O
pharmacoresistance	O
exhibited	O
by	O
30-40	O
%	O
of	O
epilepsy	O
patients	O
remains	O
a	O
major	O
obstacle	O
in	O
medical	O
care	O
.	O

Growing	O
evidence	O
indicates	O
a	O
role	O
of	O
lipid	O
signalling	O
pathways	O
in	O
epileptogenesis	O
,	O
thus	O
lipid	O
signals	O
emerge	O
as	O
potential	O
biomarkers	O
for	O
the	O
onset	O
and	O
evolving	O
course	O
of	O
the	O
epileptic	O
disorder	O
,	O
as	O
well	O
as	O
potential	O
therapeutic	O
agents	O
and	O
targets	O
.	O

For	O
this	O
purpose	O
,	O
we	O
applied	O
a	O
lipidomic	O
strategy	O
to	O
unravel	O
lipid	O
alterations	O
in	O
brain	O
regions	O
,	O
periphery	O
tissues	O
and	O
plasma	O
that	O
are	O
specific	O
for	O
acute	O
epileptic	O
seizures	O
in	O
mice	O
at	O
1h	O
after	O
seizure	O
induction	O
by	O
systemic	O
kainic	O
acid	O
injection	O
as	O
compared	O
to	O
vehicle	O
controls	O
.	O

Specifically	O
,	O
levels	O
of	O
(	O
i	O
)	O
selected	O
phospholipids	O
and	O
sphingomyelins	O
,	O
(	O
ii	O
)	O
the	O
endocannabinoids	O
anandamide	O
(	O
AEA	O
)	O
and	O
2-arachidonoyl	O
glycerol	O
(	O
2-AG	O
)	O
,	O
and	O
the	O
endocannabinoid	O
-related	O
compounds	O
oleoylethanolamide	O
(	O
OEA	O
)	O
and	O
palmitoylethanolamide	O
(	O
PEA	O
)	O
,	O
(	O
iii	O
)	O
arachidonic	O
acid	O
(	O
AA	O
)	O
,	O
(	O
iv	O
)	O
selected	O
eicosanoids	O
,	O
and	O
(	O
v	O
)	O
fatty	O
acyl	O
content	O
of	O
lipidome	O
were	O
determined	O
in	O
pulverized	O
tissues	O
from	O
six	O
brain	O
regions	O
of	O
kainic	O
acid	O
induced	O
epileptic	O
seizure	O
models	O
and	O
vehicle	O
controls	O
:	O
hypothalamus	O
,	O
hippocampus	O
,	O
thalamus	O
,	O
striatum	O
,	O
cerebellum	O
and	O
cerebral	O
cortex	O
,	O
and	O
from	O
peripheral	O
organs	O
,	O
such	O
as	O
heart	O
and	O
lungs	O
,	O
and	O
in	O
plasma	O
.	O

Alterations	O
in	O
lipid	O
levels	O
after	O
acute	O
epileptic	O
seizures	O
as	O
compared	O
to	O
non-seizure	O
controls	O
were	O
found	O
to	O
be	O
brain	O
region	O
-	O
and	O
periphery	O
tissue	O
-	O
specific	O
,	O
including	O
specific	O
plasma	O
lipid	O
correlates	O
,	O
highlighting	O
their	O
value	O
as	O
marker	O
candidates	O
in	O
translational	O
research	O
studies	O
,	O
and/or	O
drug	O
discovery	O
and	O
response	O
monitoring	O
.	O

Radiosensitization	O
of	O
non-small-cell	O
lung	O
cancer	O
cells	O
and	O
xenografts	O
by	O
the	O
interactive	O
effects	O
of	O
pemetrexed	O
and	O
methoxyamine	O
.	O

The	O
anti-folate	O
pemetrexed	O
is	O
a	O
radiosensitizer	O
.	O

In	O
pre-clinical	O
models	O
,	O
pemetrexed	O
is	O
more	O
effective	O
along	O
with	O
the	O
base-excision-repair	O
inhibitor	O
methoxyamine	O
.	O

We	O
tested	O
whether	O
methoxyamine	O
enhances	O
pemetrexed	O
-mediated	O
radiosensitization	O
of	O
lung	O
adenocarcinoma	O
cells	O
and	O
xenografts	O
.	O

A549	O
and	O
H1299	O
cells	O
were	O
evaluated	O
for	O
cell	O
cycle	O
distribution	O
by	O
flow	B-P
cytometry	I-P
,	O
radiosensitization	O
by	O
clonogenic	B-P
assay	I-P
,	O
and	O
DNA	O
repair	O
by	O
neutral	O
comet	O
assay	O
and	O
repair	O
protein	O
activation	O
.	O

H460	O
cells	O
were	O
included	O
in	O
some	O
studies	O
.	O

Xenografts	O
in	O
nude	O
mice	O
received	O
drug	O
(	O
s	O
)	O
and/or	O
radiation	O
,	O
and	O
tumor	O
growth	O
was	O
monitored	O
by	O
caliper	O
and	O
in	O
vivo	O
toxicity	O
by	O
animal	O
weight	O
.	O

Exposure	O
to	O
pemetrexed	O
/	O
methoxyamine	O
for	O
24	O
(	O
H1299	O
,	O
H460	O
)	O
or	O
48	O
(	O
A549	O
)	O
hours	O
before	O
irradiation	O
resulted	O
in	O
accumulation	O
of	O
cells	O
near	O
the	O
radiosensitive	O
G1/S	O
border	O
;	O
dose	O
-	O
enhancement	O
factors	O
of	O
1.62±0.19	O
,	O
1.97±0.25	O
,	O
and	O
1.67±0.30	O
,	O
respectively	O
;	O
reduction	O
of	O
mean	O
inactivation	O
dose	O
by	O
32	O
%	O
,	O
30	O
%	O
,	O
and	O
46	O
%	O
,	O
respectively	O
;	O
and	O
significant	O
reductions	O
of	O
SF2	O
and	O
SF4	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Radiosensitization	O
was	O
associated	O
with	O
rapid	O
DNA	O
double-strand-break	O
rejoining	O
and	O
increased	O
levels	O
of	O
DNA-PKcs	O
.	O

Both	O
tumor-growth	O
rate	O
and	O
tumor-growth	O
delay	O
were	O
significantly	O
improved	O
by	O
adding	O
methoxyamine	O
to	O
pemetrexed	O
pre-irradiation	O
(	O
p	O
<	O
0.0001	O
)	O
;	O
no	O
mice	O
lost	O
weight	O
during	O
treatment	O
.	O

Addition	O
of	O
methoxyamine	O
to	O
pemetrexed	O
and	O
fractionated	O
radiotherapy	O
may	O
improve	O
outcome	O
for	O
patients	O
with	O
locally	O
advanced	O
non-squamous	O
non-small-cell	O
lung	O
cancer	O
.	O

Investigating	O
Synthetic	O
Oligonucleotide	O
Targeting	O
of	O
Mir31	O
in	O
Duchenne	O
Muscular	O
Dystrophy	O
.	O

Exon-skipping	O
via	O
synthetic	O
antisense	O
oligonucleotides	O
represents	O
one	O
of	O
the	O
most	O
promising	O
potential	O
therapies	O
for	O
Duchenne	O
muscular	O
dystrophy	O
(	O
DMD	O
)	O
,	O
yet	O
this	O
approach	O
is	O
highly	O
sequence-specific	O
and	O
thus	O
each	O
oligonucleotide	O
is	O
of	O
benefit	O
to	O
only	O
a	O
subset	O
of	O
patients	O
.	O

The	O
discovery	O
that	O
dystrophin	O
mRNA	O
is	O
subject	O
to	O
translational	O
suppression	O
by	O
the	O
microRNA	O
miR31	O
,	O
and	O
that	O
miR31	O
is	O
elevated	O
in	O
the	O
muscle	O
of	O
DMD	O
patients	O
,	O
raises	O
the	O
possibility	O
that	O
the	O
same	O
oligonucleotide	O
chemistries	O
employed	O
for	O
exon	O
skipping	O
could	O
be	O
directed	O
toward	O
relieving	O
this	O
translational	O
block	O
.	O

This	O
approach	O
would	O
act	O
synergistically	O
with	O
exon	O
skipping	O
where	O
possible	O
,	O
but	O
by	O
targeting	O
the	O
3'UTR	O
it	O
would	O
further	O
be	O
of	O
benefit	O
to	O
the	O
many	O
DMD	O
patients	O
who	O
express	O
low	O
levels	O
of	O
in-frame	O
transcript	O
.	O

We	O
here	O
present	O
investigations	O
into	O
the	O
feasibility	O
of	O
combining	O
exon	O
skipping	O
with	O
several	O
different	O
strategies	O
for	O
miR31	O
-	O
modulation	O
,	O
using	O
both	O
in	O
vitro	O
models	O
and	O
the	O
mdx	O
mouse	O
(	O
the	O
classical	O
animal	O
model	O
of	O
DMD	O
)	O
,	O
and	O
monitoring	O
effects	O
on	O
dystrophin	O
at	O
the	O
transcriptional	O
and	O
translational	O
level	O
.	O

We	O
show	O
that	O
despite	O
promising	O
results	O
from	O
our	O
cell	B-P
culture	I-P
model	O
,	O
our	O
in	O
vivo	O
data	O
failed	O
to	O
demonstrate	O
similarly	O
reproducible	O
enhancement	O
of	O
dystrophin	O
translation	O
,	O
suggesting	O
that	O
miR31	O
-	O
modulation	O
may	O
not	O
be	O
practical	O
under	O
current	O
oligonucleotide	O
approaches	O
.	O

Possible	O
explanations	O
for	O
this	O
disappointing	O
outcome	O
are	O
discussed	O
,	O
along	O
with	O
suggestions	O
for	O
future	O
investigations	O
.	O

Risk	O
stratification	O
for	O
major	O
adverse	O
cardiac	O
events	O
and	O
ventricular	O
tachyarrhythmias	O
by	O
cardiac	B-P
MRI	I-P
in	O
patients	O
with	O
cardiac	O
sarcoidosis	O
.	O

The	O
presence	O
of	O
myocardial	O
fibrosis	O
by	O
cardiac	B-P
MRI	I-P
has	O
prognostic	O
value	O
in	O
cardiac	O
sarcoidosis	O
,	O
and	O
localisation	O
may	O
be	O
equally	O
relevant	O
to	O
clinical	O
outcomes	O
.	O

We	O
aimed	O
to	O
analyse	O
cardiac	O
damage	O
and	O
function	O
in	O
detail	O
and	O
explore	O
the	O
relationship	O
with	O
clinical	O
outcomes	O
in	O
patients	O
with	O
cardiac	O
sarcoidosis	O
using	O
cardiac	B-P
MRI	I-P
.	O

We	O
included	O
81	O
consecutive	O
patients	O
with	O
cardiac	O
sarcoidosis	O
undergoing	O
cardiac	B-P
MR.	I-P
Left	O
ventricular	O
mass	O
and	O
fibrosis	O
mass	O
were	O
calculated	O
,	O
and	O
localisation	O
was	O
analysed	O
using	O
a	O
17-segment	O
model	O
.	O

Participants	O
underwent	O
follow-up	O
through	O
2015	O
,	O
and	O
the	O
development	O
of	O
major	O
adverse	O
cardiac	O
events	O
including	O
ventricular	O
tachyarrhythmias	O
was	O
recorded	O
.	O

Increased	O
left	O
ventricular	O
fibrosis	O
mass	O
was	O
associated	O
with	O
increased	O
prevalence	O
of	O
ventricular	O
tachyarrhythmias	O
(	O
p	O
<	O
0.001	O
)	O
.	O

When	O
localisation	O
was	O
defined	O
as	O
the	O
sum	O
of	O
late	O
gadolinium	O
enhancement	O
in	O
the	O
left	O
ventricular	O
basal	O
anterior	O
and	O
basal	O
anteroseptal	O
area	O
s	O
,	O
or	O
the	O
right	O
ventricular	O
area	O
,	O
it	O
was	O
associated	O
with	O
ventricular	O
tachyarrhythmias	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Kaplan-Meier	O
analysis	O
during	O
a	O
median	O
follow-up	O
of	O
22.1	O
months	O
showed	O
that	O
both	O
the	O
mass	O
and	O
localisation	O
groupings	O
for	O
fibrosis	O
were	O
significantly	O
associated	O
with	O
major	O
adverse	O
cardiac	O
events	O
or	O
ventricular	O
tachyarrhythmias	O
and	O
that	O
when	O
combined	O
,	O
the	O
risk	O
stratification	O
was	O
better	O
than	O
for	O
each	O
variable	O
alone	O
(	O
p	O
<	O
0.001	O
,	O
respectively	O
)	O
.	O

By	O
Cox-proportional	O
hazard	O
risk	O
analysis	O
,	O
the	O
localisation	O
grouping	O
was	O
an	O
independent	O
predictor	O
for	O
the	O
both	O
.	O

In	O
patients	O
with	O
cardiac	O
sarcoidosis	O
,	O
both	O
fibrosis	O
mass	O
and	O
its	O
localisation	O
to	O
the	O
basal	O
anterior	O
/	O
anteroseptal	O
left	O
ventricle	O
,	O
or	O
right	O
ventricle	O
was	O
associated	O
with	O
the	O
development	O
of	O
major	O
adverse	O
cardiac	O
events	O
or	O
ventricular	O
tachyarrhythmias	O
.	O

Cardiac	B-P
MR	I-P
with	O
late	O
gadolinium	O
enhancement	O
may	O
be	O
useful	O
for	O
improving	O
risk	O
stratification	O
in	O
patients	O
with	O
cardiac	O
sarcoidosis	O
.	O

Psychological	O
Stress	O
in	O
Pathogenesis	O
of	O
Essential	O
Hypertension	O
.	O

The	O
article	O
represents	O
literature	O
review	O
and	O
provides	O
evidence	O
for	O
psychological	O
stress	O
to	O
play	O
essential	O
role	O
in	O
the	O
development	O
of	O
arterial	O
hypertension	O
.	O

The	O
pathogenesis	O
of	O
hypertension	O
is	O
complex	O
with	O
a	O
significant	O
diversity	O
and	O
variability	O
of	O
the	O
mechanisms	O
involved	O
in	O
individual	O
patient	O
.	O

In	O
this	O
regard	O
,	O
the	O
determination	B-P
of	O
specific	O
pathogenic	O
pathways	O
underlying	O
sustained	O
blood	O
pressure	O
elevation	O
in	O
each	O
patient	O
would	O
substantially	O
individualize	O
therapeutic	O
approaches	O
,	O
and	O
hence	O
increase	O
the	O
effectiveness	O
of	O
treatment	O
.	O

Psychological	O
stress	O
is	O
proposed	O
as	O
a	O
significant	O
factor	O
contributing	O
to	O
the	O
development	O
of	O
hypertension	O
.	O

Global	O
urbanization	O
,	O
sedentary	O
lifestyle	O
,	O
daily	O
stress	O
at	O
workplace	O
,	O
lack	O
of	O
physical	O
activity	O
and	O
social	O
support	O
lead	O
to	O
increased	O
anxiety	O
,	O
uncertainty	O
,	O
and	O
finally	O
to	O
chronic	O
mental	O
and	O
emotional	O
stress	O
.	O

This	O
review	O
provides	O
information	O
about	O
alterations	O
in	O
neuroendocrine	O
and	O
immune	O
systems	O
as	O
the	O
main	O
pathogenic	O
pathways	O
linking	O
psychological	O
stress	O
and	O
hypertension	O
.	O

Endothelial	O
dysfunction	O
is	O
considered	O
not	O
only	O
as	O
a	O
consequence	O
but	O
also	O
a	O
primary	O
factor	O
causing	O
prohypertensive	O
state	O
.	O

Moreover	O
,	O
physical	O
inactivity	O
is	O
discussed	O
as	O
one	O
of	O
the	O
plausible	O
mechanisms	O
playing	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
hypertension	O
in	O
modern	O
lifestyle	O
conditions	O
.	O

Particularly	O
the	O
loss	O
of	O
connection	O
between	O
psychosocial	O
strain	O
and	O
physical	O
activity	O
may	O
underlie	O
the	O
deleterious	O
effect	O
of	O
stress	O
on	O
cardiovascular	O
and	O
metabolic	O
health	O
.	O

Spectrum	O
and	O
prevalence	O
of	O
thyroid	O
diseases	O
seen	O
at	O
a	O
tertiary	O
health	O
facility	O
in	O
Sagamu	O
,	O
South-West	O
Nigeria	O
.	O

The	O
prevalence	O
of	O
goitrous	O
swelling	O
has	O
reduced	O
in	O
Nigeria	O
since	O
the	O
introduction	O
of	O
salt	O
iodisation	O
programme	O
.	O

Thyroid	O
disorders	O
are	O
the	O
second	O
most	O
common	O
endocrine	O
disorder	O
after	O
diabetes	O
mellitus	O
worldwide	O
.	O

They	O
present	O
to	O
general	O
outpatient	O
,	O
medical	O
and	O
surgical	O
clinics	O
accompanied	O
by	O
great	O
anxiety	O
and	O
poor	O
health-related	O
quality	O
of	O
life	O
.	O

The	O
study	O
aimed	O
to	O
determine	O
and	O
describe	O
the	O
spectrum	O
of	O
thyroid	O
disorders	O
seen	O
at	O
Olabisi	O
Onabanjo	O
University	O
Teaching	O
Hospital	O
over	O
a	O
10-	O
year	O
period	O
.	O

This	O
was	O
a	O
retrospective	O
analysis	O
of	O
records	O
of	O
patients	O
who	O
presented	O
to	O
the	O
hospital	O
with	O
thyroid	O
swellings	O
over	O
a	O
10-	O
year	O
period	O
(	O
June	O
2004	O
to	O
June	O
2014	O
)	O
.	O

Clinicopathological	O
and	O
demographic	O
data	O
obtained	O
from	O
hospital	O
records	O
in	O
175	O
patients	O
diagnosed	O
by	O
clinical	O
examination	O
,	O
thyroid	B-P
ultrasound	I-P
,	O
hormone	B-P
profile	I-P
and	O
histological	O
confirmation	O
in	O
cases	O
that	O
had	O
surgery	O
were	O
analysed	O
for	O
this	O
study	O
.	O

The	O
records	O
of	O
175	O
patients	O
were	O
obtained	O
comprising	O
151	O
(	O
86.3	O
%	O
)	O
females	O
and	O
24	O
(	O
13.7	O
%	O
)	O
males	O
(	O
female	O
to	O
male	O
ratio	O
of	O
6.3:1	O
)	O
with	O
age	O
range	O
from	O
18	O
to	O
76	O
years	O
and	O
mean	O
age	O
of	O
42.3	O
years	O
,	O
standard	O
deviation	O
13.5	O
.	O

With	O
clinical	B-P
diagnosis	I-P
,	O
distribution	O
of	O
thyroid	O
diseases	O
was	O
simple	O
goitre	O
103	O
(	O
58.9	O
%	O
)	O
,	O
toxic	O
goitre	O
64	O
(	O
36.6	O
%	O
)	O
,	O
hypothyroidism	O
3	O
(	O
1.7	O
%	O
)	O
,	O
malignant	O
goitre	O
4	O
(	O
2.3	O
%	O
)	O
and	O
thyroiditis	O
1	O
(	O
0.6	O
%	O
)	O
.	O

The	O
age	O
group	O
of	O
30-49	O
years	O
had	O
the	O
highest	O
prevalence	O
of	O
the	O
thyroid	O
diseases	O
100	O
(	O
57.2	O
%	O
)	O
while	O
the	O
extremes	O
of	O
age	O
,	O
below	O
20	O
and	O
over	O
70	O
years	O
had	O
the	O
least	O
(	O
5.1	O
and	O
2.9	O
%	O
,	O
respectively	O
)	O
.	O

The	O
prevalent	O
form	O
of	O
thyroid	O
diseases	O
seen	O
at	O
Olabisi	O
Onabanjo	O
University	O
Teaching	O
Hospital	O
was	O
simple	O
goitre	O
and	O
most	O
common	O
in	O
females	O
.	O

Studies	O
on	O
autoimmunity	O
and	O
other	O
goitrogens	O
are	O
required	O
to	O
further	O
elucidate	O
the	O
cause	O
of	O
this	O
high	O
prevalence	O
.	O

Comparative	O
Evaluation	O
for	O
Brain	O
Structural	O
Connectivity	O
Approaches	O
:	O
Towards	O
Integrative	O
Neuroinformatics	O
Tool	O
for	O
Epilepsy	O
Clinical	O
Research	O
.	O

Recent	O
advances	O
in	O
brain	O
fiber	O
tractography	O
algorithms	O
and	O
diffusion	B-P
Magnetic	I-P
Resonance	I-P
Imaging	I-P
(	O
MRI	B-P
)	O
data	O
collection	O
techniques	O
are	O
providing	O
new	O
approaches	O
to	O
study	O
brain	O
white	O
matter	O
connectivity	O
,	O
which	O
play	O
an	O
important	O
role	O
in	O
complex	O
neurological	O
disorders	O
such	O
as	O
epilepsy	O
.	O

Epilepsy	O
affects	O
approximately	O
50	O
million	O
persons	O
worldwide	O
and	O
it	O
is	O
often	O
described	O
as	O
a	O
disorder	O
of	O
the	O
cortical	O
network	O
organization	O
.	O

There	O
is	O
growing	O
recognition	O
of	O
the	O
need	O
to	O
better	O
understand	O
the	O
role	O
of	O
brain	O
structural	O
networks	O
in	O
the	O
onset	O
and	O
propagation	O
of	O
seizures	O
in	O
epilepsy	O
using	O
high	B-P
resolution	I-P
non-invasive	I-P
imaging	I-P
technologies	I-P
.	O

In	O
this	O
paper	O
,	O
we	O
perform	O
a	O
comparative	O
evaluation	O
of	O
two	O
techniques	B-P
to	O
compute	O
structural	O
connectivity	O
,	O
namely	O
probabilistic	O
fiber	O
tractography	O
and	O
statistics	O
derived	O
from	O
fractional	B-P
anisotropy	I-P
(	O
FA	B-P
)	O
,	O
using	O
diffusion	B-P
MRI	I-P
data	O
from	O
a	O
patient	O
with	O
rare	O
case	O
of	O
medically	O
intractable	O
insular	O
epilepsy	O
.	O

The	O
results	O
of	O
our	O
evaluation	O
demonstrate	O
that	O
probabilistic	O
fiber	O
tractography	O
provides	O
a	O
more	O
accurate	O
map	O
of	O
structural	O
connectivity	O
and	O
may	O
help	O
address	O
inherent	O
complexities	O
of	O
neural	O
fiber	O
layout	O
in	O
the	O
brain	O
,	O
such	O
as	O
fiber	O
crossings	O
.	O

This	O
work	O
provides	O
an	O
initial	O
result	O
towards	O
building	O
an	O
integrative	O
informatics	O
tool	O
for	O
neuroscience	O
that	O
can	O
be	O
used	O
to	O
accurately	O
characterize	O
the	O
role	O
of	O
fiber	O
tract	O
connectivity	O
in	O
neurological	O
disorders	O
such	O
as	O
epilepsy	O
.	O

Does	O
Video	O
Laryngoscopy	O
Offer	O
Advantages	O
over	O
Direct	B-P
Laryngoscopy	I-P
during	O
Cardiopulmonary	O
Resuscitation	O
?	O
.	O

Interruption	O
of	O
chest	O
compressions	O
should	O
be	O
minimized	O
because	O
of	O
its	O
negative	O
effects	O
on	O
survival	O
.	O

This	O
randomized	O
,	O
controlled	O
,	O
cross-over	O
study	O
aimed	O
to	O
analyze	O
the	O
effectiveness	O
of	O
Macintosh	O
,	O
Miller	O
,	O
McCoy	O
and	O
McGrath	O
laryngoscopes	O
during	O
with	O
or	O
without	O
chest	O
compressions	O
in	O
the	O
scope	O
of	O
a	O
simulated	O
cardiopulmonary	O
resuscitation	O
scenario	O
.	O

The	O
time	O
required	O
for	O
successful	O
tracheal	O
intubation	O
,	O
number	O
of	O
attempts	O
,	O
dental	O
trauma	O
severity	O
and	O
the	O
need	O
for	O
optimization	O
manoeuvres	O
were	O
recorded	O
during	O
cardiopulmonary	O
resuscitation	O
with	O
and	O
without	O
chest	O
compressions	O
.	O

The	O
experience	O
with	O
computer	O
games	O
during	O
the	O
last	O
10	O
years	O
were	O
asked	O
to	O
the	O
participants	O
and	O
recorded	O
.	O

McCoy	O
laryngoscope	O
yielded	O
the	O
shortest	O
time	O
for	O
successful	O
tracheal	O
intubation	O
both	O
in	O
the	O
presence	O
of	O
and	O
without	O
chest	O
compressions	O
.	O

During	O
the	O
use	O
of	O
McCoy	O
laryngoscopes	O
,	O
fewer	O
tracheal	O
intubation	O
attempts	O
,	O
lower	O
incidence	O
of	O
dental	O
trauma	O
and	O
lower	O
visual	O
analogue	O
scale	O
scores	O
on	O
the	O
ease	O
of	O
intubation	O
were	O
recorded	O
.	O

Participants	O
who	O
are	O
experienced	O
computer	O
game	O
players	O
using	O
Macintosh	O
,	O
McCoy	O
and	O
McGrath	O
achieved	O
successful	O
tracheal	O
intubation	O
in	O
a	O
significantly	O
shorter	O
time	O
during	O
resuscitation	O
without	O
chest	O
compressions	O
.	O

Dental	O
trauma	O
incidence	O
and	O
number	O
of	O
tracheal	O
intubation	O
attempts	O
did	O
not	O
show	O
any	O
significant	O
difference	O
between	O
the	O
four	O
laryngoscopes	O
being	O
related	O
to	O
the	O
rate	O
of	O
playing	O
computer	O
games	O
.	O

McGrath	O
video	O
laryngoscopes	O
do	O
not	O
appear	O
to	O
have	O
advantages	O
over	O
direct	B-P
laryngoscopes	I-P
for	O
securing	O
a	O
smooth	O
and	O
successful	O
tracheal	O
intubation	O
during	O
rhythmic	O
chest	O
compressions	O
.	O

We	O
believe	O
that	O
as	O
McCoy	O
laryngoscope	O
provided	O
tracheal	O
intubation	O
in	O
a	O
shorter	O
time	O
and	O
with	O
fewer	O
attempts	O
,	O
this	O
laryngoscope	O
may	O
increase	O
the	O
success	O
rate	O
of	O
resuscitation	O
.	O

Risk	O
Factors	O
of	O
Neurological	O
Deterioration	O
in	O
Patients	O
with	O
Cerebral	O
Infarction	O
due	O
to	O
Large-Artery	O
Atherosclerosis	O
.	O

In	O
some	O
patients	O
with	O
acute	O
ischemic	O
stroke	O
,	O
neurological	O
deterioration	O
(	O
ND	O
)	O
is	O
observed	O
,	O
and	O
it	O
is	O
difficult	O
to	O
predict	O
at	O
the	O
time	O
of	O
admission	O
.	O

Especially	O
in	O
some	O
patients	O
with	O
large-artery	O
atherosclerosis	O
(	O
LAA	O
)	O
,	O
aggressive	O
medical	O
treatments	O
and	O
surgical	O
interventions	O
might	O
be	O
helpful	O
to	O
prevent	O
ND	O
.	O

Therefore	O
,	O
we	O
investigated	O
factors	O
associated	O
with	O
ND	O
in	O
patients	O
with	O
LAA	O
.	O

We	O
studied	O
patients	O
with	O
LAA	O
who	O
were	O
admitted	O
to	O
our	O
hospital	O
.	O

We	O
divided	O
them	O
into	O
2	O
groups	O
with	O
(	O
group	O
1	O
)	O
and	O
without	O
deterioration	O
(	O
group	O
2	O
)	O
,	O
and	O
evaluated	O
their	O
medical	O
records	O
,	O
risk	O
factors	O
,	O
and	O
radiological	O
findings	O
,	O
such	O
as	O
number	O
of	O
diffusion	O
-	O
positive	O
lesion	O
and	O
degree	O
of	O
stenosis	O
.	O

Our	O
study	O
population	O
consisted	O
of	O
171	O
patients	O
;	O
71	O
(	O
41.5	O
%	O
)	O
did	O
and	O
100	O
(	O
58.5	O
%	O
)	O
did	O
not	O
suffer	O
deterioration	O
.	O

By	O
univariate	O
analysis	O
,	O
blood	O
pressure	O
(	O
BP	O
)	O
,	O
heart	O
rate	O
,	O
National	O
Institutes	O
of	O
Health	O
Stroke	O
Scale	O
(	O
NIHSS	O
)	O
score	O
,	O
number	O
of	O
diffusion	O
-	O
positive	O
lesion	O
,	O
count	B-P
of	I-P
red	I-P
blood	I-P
cell	I-P
,	O
high-density	O
lipoprotein	O
,	O
and	O
degree	O
of	O
stenosis	O
differed	O
significantly	O
between	O
the	O
2	O
groups	O
.	O

By	O
multivariate	O
analysis	O
,	O
systolic	O
BP	O
(	O
≥170	O
mm	O
Hg	O
,	O
odds	O
ratio	O
:	O
7.20	O
,	O
P	O
<	O
.001	O
)	O
was	O
associated	O
with	O
ND	O
.	O

Furthermore	O
,	O
number	O
of	O
diffusion-weighted	B-P
image	I-P
(	O
DWI	B-P
)	O
-	O
positive	O
lesion	O
(	O
≥8	O
)	O
,	O
degree	O
of	O
stenosis	O
(	O
>	O
80.0	O
%	O
)	O
,	O
and	O
NIHSS	O
score	O
(	O
≥4	O
)	O
were	O
also	O
independent	O
factors	O
associated	O
with	O
ND	O
.	O

High	O
BP	O
,	O
severity	O
of	O
neurological	O
deficit	O
at	O
the	O
time	O
of	O
admission	O
,	O
and	O
radiological	O
findings	O
,	O
such	O
as	O
degree	O
of	O
stenosis	O
and	O
number	O
of	O
DWI	B-P
-	O
positive	O
lesion	O
,	O
are	O
independently	O
associated	O
with	O
ND	O
in	O
patients	O
with	O
LAA	O
.	O

Hounsfield	O
unit	O
recovery	O
in	O
clinical	O
cone	B-P
beam	I-P
CT	I-P
images	O
of	O
the	O
thorax	O
acquired	O
for	O
image	O
guided	O
radiation	O
therapy	O
.	O

A	O
comprehensive	O
artefact	O
correction	O
method	O
for	O
clinical	O
cone	B-P
beam	I-P
CT	I-P
(	O
CBCT	B-P
)	O
images	O
acquired	O
for	O
image	O
guided	O
radiation	O
therapy	O
(	O
IGRT	O
)	O
on	O
a	O
commercial	O
system	O
is	O
presented	O
.	O

The	O
method	O
is	O
demonstrated	O
to	O
reduce	O
artefacts	O
and	O
recover	O
CT	B-P
-like	O
Hounsfield	O
units	O
(	O
HU	O
)	O
in	O
reconstructed	O
CBCT	B-P
images	O
of	O
five	O
lung	O
cancer	O
patients	O
.	O

Projection	O
image	O
based	O
artefact	O
corrections	O
of	O
image	O
lag	O
,	O
detector	O
scatter	O
,	O
body	O
scatter	O
and	O
beam	O
hardening	O
are	O
described	O
and	O
applied	O
to	O
CBCT	B-P
images	O
of	O
five	O
lung	O
cancer	O
patients	O
.	O

Image	O
quality	O
is	O
evaluated	O
through	O
visual	O
appearance	O
of	O
the	O
reconstructed	O
images	O
,	O
HU	O
-correspondence	O
with	O
the	O
planning	O
CT	B-P
images	O
,	O
and	O
total	O
volume	O
HU	O
error	O
.	O

Artefacts	O
are	O
reduced	O
and	O
CT	B-P
-like	O
HUs	O
are	O
recovered	O
in	O
the	O
artefact	O
corrected	O
CBCT	B-P
images	O
.	O

Visual	O
inspection	O
confirms	O
that	O
artefacts	O
are	O
indeed	O
suppressed	O
by	O
the	O
proposed	O
method	O
,	O
and	O
the	O
HU	O
root	O
mean	O
square	O
difference	O
between	O
reconstructed	O
CBCTs	B-P
and	O
the	O
reference	O
CT	B-P
images	O
are	O
reduced	O
by	O
31	O
%	O
when	O
using	O
the	O
artefact	O
corrections	O
compared	O
to	O
the	O
standard	O
clinical	O
CBCT	B-P
reconstruction	O
.	O

A	O
versatile	O
artefact	O
correction	O
method	O
for	O
clinical	O
CBCT	B-P
images	O
acquired	O
for	O
IGRT	O
has	O
been	O
developed	O
.	O

HU	O
values	O
are	O
recovered	O
in	O
the	O
corrected	O
CBCT	B-P
images	O
.	O

The	O
proposed	O
method	O
relies	O
on	O
post	O
processing	O
of	O
clinical	O
projection	O
images	O
,	O
and	O
does	O
not	O
require	O
patient	O
specific	O
optimisation	O
.	O

It	O
is	O
thus	O
a	O
powerful	O
tool	O
for	O
image	O
quality	O
improvement	O
of	O
large	O
numbers	O
of	O
CBCT	B-P
images	O
.	O

Bone	O
Degeneration	O
and	O
Its	O
Recovery	O
in	O
SMP30/GNL	O
-	O
Knockout	O
Mice	O
.	O

Senescence	O
marker	O
protein-30	O
(	O
SMP30	O
)	O
decreases	O
androgen	O
-independently	O
with	O
aging	O
and	O
is	O
a	O
lactone	O
-	O
hydrolyzing	O
enzyme	O
gluconolactonase	O
(	O
GNL	O
)	O
that	O
is	O
involved	O
in	O
vitamin	O
C	O
biosynthesis	O
.	O

In	O
the	O
present	O
study	O
,	O
bone	O
properties	O
of	O
SMP30/GNL	O
knockout	O
(	O
KO	O
)	O
mice	O
with	O
deficiency	O
in	O
vitamin	O
C	O
synthesis	O
were	O
investigated	O
to	O
reveal	O
the	O
effects	O
of	O
SMP30/GNL	O
and	O
exogenous	O
vitamin	O
C	O
supplementation	O
on	O
bone	O
formation	O
.	O

Mineral	O
content	O
(	O
BMC	O
)	O
and	O
mineral	O
density	O
(	O
BMD	O
)	O
of	O
the	O
mandible	O
and	O
femur	O
of	O
SMP30/GNL	O
KO	O
and	O
wild-type	O
mice	O
at	O
2	O
and	O
3	O
months	O
of	O
age	O
with	O
or	O
without	O
vitamin	O
C	O
supplementation	O
were	O
measured	O
by	O
dual-energy	B-P
X-ray	I-P
absorptiometry	I-P
.	O

Body	O
and	O
bone	O
weight	O
of	O
both	O
age	O
groups	O
decreased	O
and	O
became	O
significantly	O
lower	O
than	O
those	O
of	O
wild-type	O
mice	O
.	O

The	O
bones	O
of	O
SMP30/GNL	O
KO	O
mice	O
were	O
rough	O
and	O
porous	O
,	O
with	O
BMC	O
and	O
BMD	O
significantly	O
below	O
wild-type	O
.	O

Oral	O
supplementation	O
with	O
vitamin	O
C	O
eliminated	O
differences	O
in	O
body	O
weight	O
,	O
bone	O
weight	O
,	O
BMC	O
,	O
and	O
BMD	O
between	O
SMP30/GNL	O
KO	O
and	O
wild-type	O
mice	O
at	O
each	O
age	O
.	O

These	O
results	O
indicate	O
that	O
bone	O
degeneration	O
in	O
SMP30/GNL	O
KO	O
mice	O
was	O
caused	O
by	O
lack	O
of	O
vitamin	O
C	O
,	O
and	O
that	O
this	O
mouse	O
strain	O
is	O
an	O
appropriate	O
model	O
for	O
bone	O
metabolism	O
in	O
humans	O
,	O
which	O
have	O
no	O
ability	O
to	O
synthesize	O
vitamin	O
C	O
.	O

A	O
New	O
Intraoperative	O
Protocol	O
for	O
Reducing	O
Perioperative	O
Transfusions	O
in	O
Cardiac	O
Surgery	O
.	O

Perioperative	O
anemia	O
and	O
blood	O
product	O
transfusion	O
increases	O
short-term	O
and	O
long-term	O
morbidity	O
and	O
mortality	O
during	O
cardiac	O
surgery	O
.	O

We	O
hypothesized	O
that	O
streamlined	O
cardiopulmonary	O
bypass	O
circuit	O
and	O
rotational	B-P
thromboelastometry	I-P
(	O
ROTEM	B-P
)	O
would	O
reduce	O
blood	O
product	O
usage	O
and	O
improve	O
outcomes	O
.	O

All	O
patients	O
with	O
Society	O
of	O
Thoracic	O
Surgeons	O
risk	O
scores	O
at	O
our	O
institution	O
from	O
January	O
2013	O
to	O
June	O
2015	O
were	O
included	O
.	O

Individuals	O
were	O
chronologically	O
stratified	O
into	O
2	O
groups	O
according	O
to	O
institutional	O
changes	O
to	O
a	O
streamlined	O
bypass	O
circuit	O
and	O
ROTEM	B-P
-guided	O
transfusion	O
.	O

Blood	O
product	O
transfusion	O
,	O
hematocrit	O
,	O
and	O
observed	O
to	O
expected	O
outcomes	O
(	O
O/E	O
)	O
were	O
compared	O
between	O
the	O
groups	O
.	O

Patients	O
were	O
defined	O
as	O
either	O
control	O
group	O
(	O
533	O
patients	O
,	O
12	O
months	O
)	O
or	O
intervention	O
group	O
(	O
804	O
patients	O
,	O
18	O
months	O
)	O
.	O

The	O
intervention	O
group	O
was	O
further	O
subdivided	O
into	O
streamlined	O
circuit	O
(	O
290	O
patients	O
,	O
6	O
months	O
)	O
and	O
ROTEM	B-P
(	O
514	O
patients	O
,	O
12	O
months	O
)	O
.	O

Use	O
of	O
streamlined	O
bypass	O
circuit	O
correlated	O
with	O
significantly	O
reduced	O
intraoperative	O
transfusion	O
of	O
packed	O
red	O
blood	O
cells	O
(	O
pRBCs	O
)	O
(	O
23.8	O
%	O
versus	O
17.9	O
%	O
;	O
p	O
=	O
0.05	O
)	O
and	O
platelets	O
(	O
28.0	O
%	O
versus	O
19.3	O
;	O
p	O
=	O
0.01	O
)	O
with	O
improvement	O
in	O
lowest	O
intraoperative	O
hematocrit	O
(	O
26.0	O
versus	O
26.9	O
;	O
p	O
=	O
0.02	O
)	O
.	O

ROTEM	B-P
was	O
associated	O
with	O
a	O
further	O
reduction	O
in	O
intraoperative	O
pRBCs	O
(	O
17.9	O
%	O
versus	O
11.28	O
%	O
;	O
p	O
=	O
0.01	O
)	O
and	O
postoperative	O
transfusion	O
pRBCs	O
(	O
38.3	O
%	O
versus	O
23.5	O
%	O
;	O
p	O
=	O
0.02	O
)	O
.	O

The	O
combination	O
was	O
associated	O
with	O
reduced	O
intraoperative	O
(	O
44.6	O
%	O
versus	O
34.1	O
;	O
p	O
<	O
0.001	O
)	O
and	O
postoperative	O
transfusions	O
(	O
45.6	O
%	O
versus	O
40.1	O
;	O
p	O
<	O
0.001	O
)	O
in	O
the	O
intervention	O
group	O
,	O
while	O
maintaining	O
a	O
higher	O
hematocrit	O
at	O
discharge	O
(	O
28.1	O
versus	O
29.1	O
;	O
p	O
<	O
0.001	O
)	O
.	O

Finally	O
,	O
the	O
intervention	O
was	O
associated	O
with	O
a	O
statistically	O
significant	O
reduction	O
in	O
the	O
O/E	O
for	O
reoperation	O
(	O
p	O
=	O
0.003	O
)	O
.	O

Use	O
of	O
streamlined	O
cardiopulmonary	O
bypass	O
circuit	O
and	O
ROTEM	B-P
may	O
reduce	O
transfusion	O
and	O
reoperation	O
rates	O
and	O
improve	O
perioperative	O
anemia	O
in	O
cardiac	O
surgical	O
patients	O
.	O

This	O
study	O
demonstrates	O
reproducible	O
intraoperative	O
methods	O
for	O
reducing	O
blood	O
product	O
usage	O
and	O
improving	O
outcomes	O
.	O

Tissue-engineered	O
cardiac	O
patch	O
seeded	B-P
with	O
human	O
induced	O
pluripotent	O
stem	O
cell	O
derived	O
cardiomyocytes	O
promoted	O
the	O
regeneration	O
of	O
host	O
cardiomyocytes	O
in	O
a	O
rat	O
model	O
.	O

Thousands	O
of	O
babies	O
are	O
born	O
with	O
congenital	O
heart	O
defects	O
that	O
require	O
surgical	O
repair	O
involving	O
a	O
prosthetic	O
implant	O
.	O

Lack	O
of	O
growth	O
in	O
prosthetic	O
grafts	O
is	O
especially	O
detrimental	O
in	O
pediatric	O
surgery	O
.	O

Cell	O
seeded	B-P
biodegradable	O
tissue	O
engineered	O
grafts	O
are	O
a	O
novel	O
solution	O
to	O
this	O
problem	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
is	O
to	O
evaluate	O
the	O
feasibility	O
of	O
seeding	B-P
human	O
induced	O
pluripotent	O
stem	O
cell	O
derived	O
cardiomyocytes	O
(	O
hiPS-CMs	O
)	O
onto	O
a	O
biodegradable	O
cardiac	O
patch	O
.	O

The	O
hiPS-CMs	O
were	O
cultured	B-P
on	O
a	O
biodegradable	O
patch	O
composed	O
of	O
a	O
polyglycolic	O
acid	O
(	O
PGA	O
)	O
and	O
a	O
50:50	O
poly	O
(	O
l-lactic-co-ε-caprolactone	O
)	O
copolymer	O
(	O
PLCL	O
)	O
for	O
1	O
week	O
.	O

Male	O
athymic	O
rats	O
were	O
randomly	O
divided	O
into	O
2	O
groups	O
of	O
10	O
animals	O
each	O
:	O
1.	O
hiPS-CM	O
seeded	B-P
group	O
,	O
and	O
2	O
.	O

Unseeded	O
group	O
.	O

After	O
culture	B-P
,	O
the	O
cardiac	O
patch	O
was	O
implanted	O
to	O
repair	O
a	O
defect	O
with	O
a	O
diameter	O
of	O
2	O
mm	O
created	O
in	O
the	O
right	O
ventricular	O
outflow	O
tract	O
(	O
RVOT	O
)	O
wall	O
.	O

Hearts	O
were	O
explanted	O
at	O
4	O
(	O
n	O
=	O
2	O
)	O
,	O
8	O
(	O
n	O
=	O
2	O
)	O
,	O
and	O
16	O
(	O
n	O
=	O
6	O
)	O
weeks	O
after	O
patch	O
implantation	O
.	O

Explanted	O
patches	O
were	O
assessed	O
immunohistochemically	B-P
.	O

Seeded	B-P
patch	O
explants	O
did	O
not	O
stain	O
positive	O
for	O
α-actinin	O
(	O
marker	O
of	O
cardiomyocytes	O
)	O
at	O
the	O
4	O
week	O
time	O
point	O
,	O
suggesting	O
that	O
the	O
cultured	B-P
hiPS-CMs	O
evacuated	O
the	O
patch	O
in	O
the	O
early	O
phase	O
of	O
tissue	O
remodeling	O
.	O

However	O
,	O
after	O
16	O
weeks	O
implantation	O
,	O
the	O
area	O
fraction	O
of	O
positively	O
stained	O
α-actinin	O
cells	O
was	O
significantly	O
higher	O
in	O
the	O
seeded	B-P
group	O
than	O
in	O
the	O
unseeded	O
group	O
(	O
Seeded	B-P
group	O
:	O
6.1	O
±	O
2.8	O
%	O
vs.	O
Unseeded	O
group	O
:	O
0.95	O
±	O
0.50	O
%	O
,	O
p	O
=	O
0.004	O
)	O
,	O
suggesting	O
cell	O
seeding	B-P
promoted	O
regenerative	O
proliferation	O
of	O
host	O
cardiomyocytes	O
.	O

Seeded	B-P
hiPS-CMs	O
were	O
not	O
present	O
in	O
the	O
patch	O
after	O
4	O
weeks	O
.	O

However	O
,	O
we	O
surmise	O
that	O
they	O
influenced	O
the	O
regeneration	O
of	O
host	O
cardiomyocytes	O
via	O
a	O
paracrine	O
mechanism	O
.	O

Tissue-engineered	O
hiPS-CMs	O
seeded	B-P
cardiac	O
patches	O
warrant	O
further	O
investigation	O
for	O
use	O
in	O
the	O
repair	O
of	O
congenital	O
heart	O
diseases	O
.	O

Peptide	O
-Mediated	O
Interference	O
of	O
PB2	O
-	O
eIF4G1	O
Interaction	O
Inhibits	O
Influenza	O
A	O
Viruses	O
'	O
Replication	O
in	O
Vitro	O
and	O
in	O
Vivo	O
.	O

Influenza	O
viruses	O
are	O
obligate	O
parasites	O
that	O
hijack	O
the	O
host	O
cellular	O
system	O
.	O

Previous	O
results	O
have	O
shown	O
that	O
the	O
influenza	O
virus	O
PB2	O
subunit	O
confers	O
a	O
dependence	O
of	O
host	O
eukaryotic	O
translation	O
initiation	O
factor	O
4-γ	O
1	O
(	O
eIF4G1	O
)	O
for	O
viral	O
mRNA	O
translation	O
.	O

Here	O
,	O
we	O
demonstrated	O
that	O
peptide	O
-mediated	O
interference	O
of	O
the	O
PB2	O
-	O
eIF4G1	O
interaction	O
inhibited	O
virus	O
replication	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Remarkably	O
,	O
intranasal	O
administration	O
of	O
the	O
peptide	O
provided	O
100	O
%	O
protection	O
against	O
lethal	O
challenges	O
of	O
influenza	O
A	O
viruses	O
in	O
BALB/c	O
mice	O
,	O
including	O
H1N1	O
,	O
H5N1	O
,	O
and	O
H7N9	O
influenza	O
virus	O
subtypes	O
.	O

Mapping	O
of	O
the	O
PB2	O
protein	O
indicated	O
that	O
the	O
eIF4G1	O
binding	O
sites	O
resided	O
within	O
the	O
PB2	O
cap	O
-	O
binding	O
domain	O
.	O

Virtual	O
docking	O
analysis	O
suggested	O
that	O
the	O
inhibitory	O
peptide	O
associated	O
with	O
the	O
conserved	O
amino	O
acid	O
residues	O
that	O
were	O
essential	O
to	O
PB2	O
cap-binding	B-P
activity	I-P
.	O

Overall	O
,	O
our	O
results	O
identified	O
the	O
PB2	O
-	O
eIF4G1	O
interactive	O
site	O
as	O
a	O
druggable	O
target	O
for	O
influenza	O
therapeutics	O
.	O

Accuracy	O
of	O
FDG-PET/CT	B-P
for	O
Detection	O
of	O
Incidental	O
Pre-Malignant	O
and	O
Malignant	O
Colonic	O
Lesions	O
-	O
Correlation	O
with	O
Colonoscopic	B-P
and	O
Histopathologic	O
Findings	O
.	O

We	O
evaluated	O
all	O
PET/CTs	B-P
acquired	O
for	O
patients	O
without	O
a	O
primary	O
diagnosis	O
of	O
colorectal	O
cancer	O
,	O
and	O
compared	O
results	O
for	O
those	O
who	O
had	O
subsequent	O
colonoscopy	B-P
within	O
6	O
months	O
,	O
to	O
assess	O
the	O
accuracy	O
of	O
FDG	B-P
PET/CT	I-P
for	O
detection	O
of	O
incidental	O
pre-malignant	O
polyps	O
and	O
malignant	O
colon	O
cancers	O
.	O

Medical	O
records	O
of	O
9,545	O
patients	O
who	O
underwent	O
F-18	O
FDG	O
PET/CT	O
studies	O
over	O
3.5	O
years	O
were	O
retrospectively	O
reviewed	O
.	O

Due	O
to	O
pre-existing	O
diagnosis	O
of	O
colorectal	O
cancer	O
,	O
818	O
patients	O
were	O
excluded	O
.	O

Of	O
the	O
remainder	O
,	O
157	O
patients	O
had	O
colonoscopy	B-P
within	O
6	O
months	O
(	O
79	O
males	O
;	O
mean	O
age	O
61	O
)	O
.	O

We	O
divided	O
the	O
colon	O
into	O
4	O
regions	O
and	O
compared	O
PET/CT	B-P
results	O
for	O
each	O
region	O
with	O
colonoscopy	B-P
and	O
histopathologic	O
findings	O
.	O

True	O
positive	O
lesions	O
included	O
colorectal	O
cancer	O
,	O
villous	O
adenoma	O
,	O
tubulovillous	O
adenoma	O
,	O
tubular	O
adenoma	O
and	O
serrated	O
hyperplastic	O
polyp	O
/	O
hyperplastic	O
polyposis	O
.	O

Of	O
157	O
patients	O
,	O
44	O
had	O
incidental	O
colonic	O
uptake	O
on	O
PET/CT	B-P
(	O
28	O
%	O
)	O
.	O

Of	O
those	O
,	O
25	O
had	O
true	O
positive	O
(	O
TP	O
)	O
uptake	O
,	O
yielding	O
a	O
48	O
%	O
positive	O
predictive	O
value	O
(	O
PPV	O
)	O
;	O
9	O
%	O
(	O
4/44	O
)	O
were	O
adenocarcinoma	O
.	O

There	O
were	O
23	O
false	O
positive	O
(	O
FP	O
)	O
lesions	O
of	O
which	O
4	O
were	O
hyperplastic	O
polyps	O
,	O
one	O
was	O
a	O
juvenile	O
polyp	O
and	O
7	O
were	O
explained	O
by	O
diverticulitis	O
.	O

Fifty	O
eight	O
patients	O
had	O
false	O
negative	O
PET	B-P
scans	I-P
but	O
colonoscopy	B-P
revealed	O
true	O
pre-malignant	O
and	O
malignant	O
pathology	O
,	O
yielding	O
23	O
%	O
sensitivity	O
.	O

The	O
specificity	O
,	O
negative	O
predictive	O
value	O
(	O
NPV	O
)	O
and	O
accuracy	O
were	O
96	O
%	O
,	O
90	O
%	O
and	O
87	O
%	O
,	O
respectively	O
.	O

The	O
average	O
SUVmax	O
values	O
of	O
TP	O
,	O
FP	O
and	O
FN	O
lesions	O
were	O
7.25	O
,	O
6.11	O
and	O
2.76	O
,	O
respectively	O
.	O

There	O
were	O
no	O
significant	O
difference	O
between	O
SUVmax	O
of	O
TP	O
lesions	O
and	O
FP	O
lesions	O
(	O
p	O
>	O
0.95	O
)	O
but	O
significantly	O
higher	O
than	O
in	O
FN	O
lesions	O
(	O
p	O
<	O
0.001	O
)	O
.	O

The	O
average	O
size	O
(	O
by	O
histopathology	O
and	O
colonoscopy	B-P
)	O
of	O
TP	O
lesion	O
s	O
was	O
18.1	O
mm	O
,	O
statistically	O
different	O
from	O
that	O
of	O
FN	O
lesions	O
which	O
was	O
5.9	O
mm	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Fifty-one	O
percent	O
of	O
FN	O
lesion	O
s	O
were	O
smaller	O
than	O
5	O
mm	O
(	O
29/57	O
)	O
and	O
88	O
%	O
smaller	O
than	O
10	O
mm	O
(	O
50/57	O
)	O
.	O

The	O
high	O
positive	O
predictive	O
value	O
of	O
incidental	O
focal	O
colonic	O
FDG	O
uptake	O
of	O
48	O
%	O
for	O
colonic	O
neoplasia	O
suggests	O
that	O
colonoscopy	B-P
follow-up	O
is	O
warranted	O
with	O
this	O
finding	O
.	O

We	O
observed	O
a	O
low	O
sensitivity	O
of	O
standardly	O
acquired	O
FDG-PET/CT	B-P
for	O
detecting	O
small	O
polyps	O
,	O
especially	O
those	O
less	O
than	O
5	O
mm	O
.	O

Clinicians	O
and	O
radiologists	O
should	O
be	O
aware	O
of	O
the	O
high	O
PPV	O
of	O
focal	O
colonic	O
uptake	O
reflecting	O
pre-malignant	O
and	O
malignant	O
lesion	O
s	O
,	O
and	O
the	O
need	O
for	O
appropriate	O
follow	O
up	O
.	O

Leveraging	O
sequence	O
-based	O
faecal	O
microbial	O
community	O
survey	O
data	O
to	O
identify	O
a	O
composite	O
biomarker	O
for	O
colorectal	O
cancer	O
.	O

Colorectal	O
cancer	O
(	O
CRC	O
)	O
is	O
the	O
second	O
leading	O
cause	O
of	O
cancer-associated	O
mortality	O
in	O
the	O
USA	O
.	O

The	O
faecal	O
microbiome	O
may	O
provide	O
non-invasive	O
biomarkers	O
of	O
CRC	O
and	O
indicate	O
transition	O
in	O
the	O
adenoma-carcinoma	O
sequence	O
.	O

Re-analysing	O
raw	O
sequence	O
and	O
metadata	O
from	O
several	O
studies	B-P
uniformly	O
,	O
we	O
sought	O
to	O
identify	O
a	O
composite	O
and	O
generalisable	O
microbial	O
marker	O
for	O
CRC	O
.	O

Raw	O
16S	O
rRNA	O
gene	O
sequence	O
data	O
sets	O
from	O
nine	O
studies	B-P
were	O
processed	O
with	O
two	O
pipelines	O
,	O
(	O
1	O
)	O
QIIME	O
closed	O
reference	O
(	O
QIIME-CR	O
)	O
or	O
(	O
2	O
)	O
a	O
strain-specific	O
method	O
herein	O
termed	O
SS-UP	O
(	O
Strain	O
Select	O
,	O
UPARSE	O
bioinformatics	O
pipeline	O
)	O
.	O

A	O
total	O
of	O
509	O
samples	O
(	O
79	O
colorectal	O
adenoma	O
,	O
195	O
CRC	O
and	O
235	O
controls	O
)	O
were	O
analysed	O
.	O

Differential	O
abundance	O
,	O
meta-analysis	O
random	O
effects	O
regression	O
and	O
machine	O
learning	O
analyses	O
were	O
carried	O
out	O
to	O
determine	O
the	O
consistency	O
and	O
diagnostic	O
capabilities	O
of	O
potential	O
microbial	O
biomarkers	O
.	O

Definitive	O
taxa	O
,	O
including	O
Parvimonas	O
micra	O
ATCC	O
33270	O
,	O
Streptococcus	O
anginosus	O
and	O
yet-to-be-cultured	O
members	O
of	O
Proteobacteria	O
,	O
were	O
frequently	O
and	O
significantly	O
increased	O
in	O
stools	O
from	O
patients	O
with	O
CRC	O
compared	O
with	O
controls	O
across	O
studies	O
and	O
had	O
high	O
discriminatory	O
capacity	O
in	O
diagnostic	O
classification	O
.	O

Microbiome	O
-based	O
CRC	O
versus	O
control	O
classification	O
produced	O
an	O
area	O
under	O
receiver	O
operator	O
characteristic	O
(	O
AUROC	O
)	O
curve	O
of	O
76.6	O
%	O
in	O
QIIME-CR	O
and	O
80.3	O
%	O
in	O
SS-UP	O
.	O

Combining	O
clinical	O
and	O
microbiome	O
markers	O
gave	O
a	O
diagnostic	O
AUROC	O
of	O
83.3	O
%	O
for	O
QIIME-CR	O
and	O
91.3	O
%	O
for	O
SS-UP	O
.	O

Despite	O
technological	O
differences	O
across	O
studies	O
and	O
methods	O
,	O
key	O
microbial	O
markers	O
emerged	O
as	O
important	O
in	O
classifying	O
CRC	O
cases	O
and	O
such	O
could	O
be	O
used	O
in	O
a	O
universal	O
diagnostic	O
for	O
the	O
disease	O
.	O

The	O
choice	O
of	O
bioinformatics	O
pipeline	O
influenced	O
accuracy	O
of	O
classification	O
.	O

Strain	O
-	O
resolved	O
microbial	O
markers	O
might	O
prove	O
crucial	O
in	O
providing	O
a	O
microbial	O
diagnostic	O
for	O
CRC	O
.	O

Development	O
of	O
delineation	O
for	O
the	O
left	O
anterior	O
descending	O
coronary	O
artery	O
region	O
in	O
left	O
breast	O
cancer	O
radiotherapy	O
:	O
An	O
optimized	O
organ	O
at	O
risk	O
.	O

The	O
left	O
anterior	O
descending	O
coronary	O
artery	O
(	O
LAD	O
)	O
and	O
diagonal	O
branches	O
(	O
DBs	O
)	O
are	O
blurred	O
on	O
computed	B-P
tomography	I-P
(	O
CT	B-P
)	O
.	O

We	O
aimed	O
to	O
define	O
the	O
LAD	O
region	O
(	O
LADR	O
)	O
with	O
adequate	O
inclusion	O
of	O
the	O
LAD	O
and	O
DBs	O
and	O
contouring	O
consistency	O
.	O

The	O
LADR	O
was	O
defined	O
using	O
coronary	O
CT	B-P
angiograms	I-P
.	O

The	O
inclusion	O
ratio	O
was	O
used	O
to	O
assess	O
the	O
LAD	O
and	O
DBs	O
inclusion	O
by	O
the	O
LADR	O
.	O

Four	O
radiation	O
oncologists	O
delineated	O
the	O
LAD	O
and	O
LADR	O
,	O
using	O
contrast-enhanced	B-P
CT	I-P
of	O
15	O
patients	O
undergoing	O
left	O
breast	O
radiotherapy	O
.	O

The	O
Sørensen-Dice	O
similarity	O
index	O
(	O
DSI	O
)	O
,	O
Jaccard	O
similarity	O
index	O
(	O
JSI	O
)	O
,	O
and	O
Hausdorff	O
distance	O
(	O
HD	O
)	O
were	O
calculated	O
to	O
assess	O
similarity	O
.	O

The	O
mean	O
dose	O
(	O
Dmean	O
)	O
and	O
maximum	O
dose	O
(	O
Dmax	O
)	O
to	O
the	O
LAD	O
and	O
LADR	O
were	O
calculated	O
to	O
compare	O
consistency	O
.	O

Correlations	O
were	O
evaluated	O
using	O
Pearson	O
's	O
correlation	O
coefficient	O
.	O

The	O
inclusion	O
ratio	O
of	O
the	O
LAD	O
by	O
the	O
LADR	O
was	O
96	O
%	O
.	O

The	O
mean	O
DSI	O
,	O
JSI	O
,	O
and	O
HD	O
values	O
were	O
respectively	O
27.9	O
%	O
,	O
16.7	O
%	O
,	O
and	O
0.42mm	O
for	O
the	O
LAD	O
,	O
and	O
83.1	O
%	O
,	O
73.0	O
%	O
,	O
and	O
0.18mm	O
for	O
the	O
LADR	O
.	O

The	O
Dmean	O
between	O
the	O
LAD	O
and	O
LADR	O
were	O
strongly	O
correlated	O
(	O
r=0.93	O
)	O
.	O

Delineation	O
of	O
the	O
LADR	O
significantly	O
improved	O
contouring	O
similarity	O
and	O
consistency	O
for	O
dose	O
reporting	O
.	O

This	O
could	O
optimize	O
dose	O
estimation	O
for	O
breast	O
radiotherapy	O
.	O

Effects	O
of	O
Cerium	O
and	O
Titanium	O
Oxide	O
Nanoparticles	O
in	O
Soil	O
on	O
the	O
Nutrient	O
Composition	O
of	O
Barley	O
(	O
Hordeum	O
vulgare	O
L	O
.	O
)	O

Kernels	O
.	O

The	O
implications	O
of	O
metal	O
nanoparticles	O
(	O
MeNPs	O
)	O
are	O
still	O
unknown	O
for	O
many	O
food	O
crops	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
cerium	O
oxide	O
(	O
nCeO₂	O
)	O
and	O
titanium	O
oxide	O
(	O
nTiO₂	O
)	O
nanoparticles	O
in	O
soil	O
at	O
0	O
,	O
500	O
and	O
1000	O
mg·kg	O
(	O
-1	O
)	O
on	O
the	O
nutritional	O
parameters	O
of	O
barley	O
(	O
Hordeum	O
vulgare	O
L.	O
)	O
kernels	O
.	O

Mineral	O
nutrients	O
,	O
amylose	O
,	O
β-glucans	O
,	O
amino	O
acid	O
and	O
crude	O
protein	O
(	O
CP	O
)	O
concentrations	O
were	O
measured	O
in	O
kernels	O
.	O

Whole	O
flour	O
samples	O
were	O
analyzed	O
by	O
ICP-AES/MS	B-P
,	O
HPLC	B-P
and	O
Elemental	O
CHNS	O
Analyzer	O
.	O

Results	O
showed	O
that	O
Ce	O
and	O
Ti	O
accumulation	O
under	O
MeNPs	O
treatments	O
did	O
not	O
differ	O
from	O
the	O
control	O
treatment	O
.	O

However	O
,	O
nCeO₂	O
and	O
nTiO₂	O
had	O
an	O
impact	O
on	O
composition	O
and	O
nutritional	O
quality	O
of	O
barley	O
kernels	O
in	O
contrasting	O
ways	O
.	O

Both	O
MeNPs	O
left	O
β-glucans	O
unaffected	O
but	O
reduced	O
amylose	O
content	O
by	O
approximately	O
21	O
%	O
.	O

Most	O
amino	O
acids	O
and	O
CP	O
increased	O
.	O

Among	O
amino	O
acids	O
,	O
lysine	O
followed	O
by	O
proline	O
saw	O
the	O
largest	O
increase	O
(	O
51	O
%	O
and	O
37	O
%	O
,	O
respectively	O
)	O
.	O

Potassium	O
and	O
S	O
were	O
both	O
negatively	O
impacted	O
by	O
MeNPs	O
,	O
while	O
B	O
was	O
only	O
affected	O
by	O
500	O
mg	O
nCeO₂	O
·kg	O
(	O
-1	O
)	O
.	O

On	O
the	O
contrary	O
Zn	B-P
and	O
Mn	B-P
concentrations	I-P
were	O
improved	O
by	O
500	O
mg	O
nTiO₂	O
·kg	O
(	O
-1	O
)	O
,	O
and	O
Ca	O
by	O
both	O
nTiO₂	O
treatments	O
.	O

Generally	O
,	O
our	O
findings	O
demonstrated	O
that	O
kernels	O
are	O
negatively	O
affected	O
by	O
nCeO₂	O
while	O
nTiO₂	O
can	O
potentially	O
have	O
beneficial	O
effects	O
.	O

However	O
,	O
both	O
MeNPs	O
have	O
the	O
potential	O
to	O
negatively	O
impact	O
malt	O
and	O
feed	O
production	O
.	O

Characterization	O
and	O
Ectopic	O
Expression	O
of	O
CoWRI1	O
,	O
an	O
AP2/EREBP	O
Domain-Containing	O
Transcription	O
Factor	O
from	O
Coconut	O
(	O
Cocos	O
nucifera	O
L	O
.	O
)	O

Endosperm	O
,	O
Changes	O
the	O
Seeds	O
Oil	O
Content	O
in	O
Transgenic	O
Arabidopsis	O
thaliana	O
and	O
Rice	O
(	O
Oryza	O
sativa	O
L	O
.	O
)	O
.	O

Coconut	O
(	O
Cocos	O
nucifera	O
L.	O
)	O
is	O
a	O
key	O
tropical	O
crop	O
and	O
a	O
member	O
of	O
the	O
monocotyledonous	O
family	O
Arecaceae	O
(	O
Palmaceae	O
)	O
.	O

Few	O
genes	O
and	O
related	O
metabolic	O
processes	O
involved	O
in	O
coconut	O
endosperm	O
development	O
have	O
been	O
investigated	O
.	O

In	O
this	O
study	O
,	O
a	O
new	O
member	O
of	O
the	O
WRI1	O
gene	O
family	O
was	O
isolated	O
from	O
coconut	O
endosperm	O
and	O
was	O
named	O
CoWRI1	O
.	O

Its	O
transcriptional	O
activities	O
and	O
interactions	O
with	O
the	O
acetyl-CoA	O
carboxylase	O
(	O
BCCP2	O
)	O
promoter	O
of	O
CoWRI1	O
were	O
confirmed	O
by	O
the	O
yeast	O
two-hybrid	O
and	O
yeast	O
one-hybrid	O
approaches	O
,	O
respectively	O
.	O

Functional	O
characterization	O
was	O
carried	O
out	O
through	O
seed	O
-specific	O
expression	O
in	O
Arabidopsis	O
and	O
endosperm	O
-specific	O
expression	O
in	O
rice	O
.	O

In	O
transgenic	O
Arabidopsis	O
,	O
high	O
over-expressions	O
of	O
CoWRI1	O
in	O
seven	O
independent	O
T2	O
lines	O
were	O
detected	O
by	O
quantitative	O
real-time	O
PCR	O
.	O

The	O
relative	O
mRNA	O
accumulation	O
of	O
genes	O
encoding	O
enzymes	O
involved	O
in	O
either	O
fatty	O
acid	O
biosynthesis	O
or	O
triacylglycerols	O
assembly	O
(	O
BCCP2	O
,	O
KASI	O
,	O
MAT	O
,	O
ENR	O
,	O
FATA	O
,	O
and	O
GPDH	O
)	O
were	O
also	O
assayed	B-P
in	O
mature	O
seeds	O
.	O

Furthermore	O
,	O
lipid	O
and	O
fatty	O
acids	O
C16:0	O
and	O
C18:0	O
significantly	O
increased	O
.	O

In	O
two	O
homozygous	O
T2	O
transgenic	O
rice	O
lines	O
(	O
G5	O
and	O
G2	O
)	O
,	O
different	O
CoWRI1	O
expression	O
levels	O
were	O
detected	O
,	O
but	O
no	O
CoWRI1	O
transcripts	O
were	O
detected	O
in	O
the	O
wild	O
type	O
.	O

Analyses	O
of	O
the	O
seed	O
oil	O
content	O
,	O
starch	O
content	O
,	O
and	O
total	O
protein	O
content	O
indicated	O
that	O
the	O
two	O
T2	O
transgenic	O
lines	O
showed	O
a	O
significant	O
increase	O
(	O
P	O
<	O
0.05	O
)	O
in	O
seed	O
oil	O
content	O
.	O

The	O
transgenic	O
lines	O
also	O
showed	O
a	O
significant	O
increase	O
in	O
starch	O
content	O
,	O
whereas	O
total	O
protein	O
content	O
decreased	O
significantly	O
.	O

Further	O
analysis	O
of	O
the	O
fatty	O
acid	O
composition	O
revealed	O
that	O
palmitic	O
acid	O
(	O
C16:0	O
)	O
and	O
linolenic	O
acid	O
(	O
C18:3	O
)	O
increased	O
significantly	O
in	O
the	O
seeds	O
of	O
the	O
transgenic	O
rice	O
lines	O
,	O
but	O
oleic	O
acid	O
(	O
C18:1	O
)	O
levels	O
significantly	O
declined	O
.	O

Entropy-driven	O
reactions	O
in	O
living	O
cells	O
for	O
assay	B-P
let-7a	O
microRNA	O
.	O

Imaging	B-P
of	O
microRNA	O
(	O
miRNA	O
)	O
in	O
living	O
cells	O
could	O
facilitate	O
the	O
monitoring	O
of	O
the	O
expression	O
and	O
distribution	O
of	O
miRNA	O
and	O
research	O
on	O
miRNA	O
-related	O
diseases	O
.	O

Given	O
the	O
low	O
expression	O
levels	O
and	O
even	O
down-regulation	O
of	O
cellular	O
miRNA	O
that	O
is	O
associated	O
with	O
some	O
diseases	O
,	O
enzyme	O
-	O
free	O
amplification	O
strategies	O
are	O
imperative	O
for	O
intracellular	O
miRNA	O
assay	B-P
.	O

In	O
this	O
work	O
,	O
we	O
report	O
an	O
entropy-driven	O
reaction	O
for	O
amplification	O
assay	B-P
miRNA	O
with	O
a	O
detection	O
limit	O
of	O
0.27	O
pM	O
.	O

The	O
resulting	O
signal	O
amplification	O
provides	O
excellent	O
recognition	O
and	O
signal	O
enhancement	O
of	O
specific	O
miRNA	O
s	O
in	O
living	O
cells	O
.	O

This	O
method	O
supplies	O
accurate	O
information	O
regarding	O
cellular	O
miRNA	O
-related	O
biological	O
events	O
and	O
provides	O
a	O
new	O
tool	O
for	O
highly	O
sensitive	O
and	O
simultaneous	O
imaging	B-P
of	O
multiple	O
low-level	O
biomarkers	O
,	O
thereby	O
improving	O
the	O
accuracy	O
of	O
early	B-P
disease	I-P
diagnosis	I-P
.	O

Technical	O
Note	O
:	O
Bone	B-P
mineral	I-P
density	I-P
measurements	I-P
of	O
strontium	O
-rich	O
trabecular	O
bone	O
-	O
mimicking	O
phantoms	O
using	O
quantitative	O
ultrasound	O
.	O

Bone	O
quantity	O
,	O
as	O
determined	O
by	O
the	O
current	O
gold	O
standard	O
,	O
dual	B-P
energy	I-P
X-ray	I-P
absorptiometry	I-P
(	O
DXA	B-P
)	O
,	O
through	O
measured	B-P
areal	I-P
bone	I-P
mineral	I-P
density	I-P
(	O
aBMD	O
)	O
,	O
is	O
subject	O
to	O
positive	O
biases	O
if	O
bone	O
strontium	B-P
levels	I-P
are	O
high	O
.	O

This	O
is	O
of	O
particular	O
concern	O
for	O
populations	O
administered	O
strontium-based	O
compounds	O
for	O
the	O
treatment	O
of	O
osteoporosis	O
.	O

This	O
study	O
investigated	O
the	O
dependence	O
of	O
bone	B-P
mineral	I-P
density	I-P
(	I-P
BMD	I-P
)	I-P
determinations	I-P
,	O
and	O
associated	O
ultrasound	B-P
-determined	O
indices	O
,	O
obtained	O
by	O
quantitative	O
ultrasound	O
(	O
QUS	O
)	O
,	O
on	O
bone	O
strontium	O
content	O
using	O
a	O
new	O
generation	O
of	O
trabecular	O
bone	O
-	O
mimicking	O
phantoms	O
.	O

A	O
new	O
generation	O
of	O
bone	O
-	O
mimicking	O
phantoms	O
,	O
consisting	O
of	O
hydroxyapatite	O
(	O
HA	O
)	O
and	O
gelatin	O
,	O
was	O
developed	O
.	O

Castor	O
oil	O
layers	O
were	O
included	O
in	O
these	O
phantoms	O
to	O
create	O
a	O
multilayer	O
bone	O
-	O
mimicking	O
phantom	O
.	O

These	O
phantoms	O
were	O
prepared	O
using	O
a	O
bone	O
mineral	O
fraction	O
consisting	O
of	O
varying	O
strontium	B-P
concentrations	I-P
in	O
the	O
range	O
of	O
0-2.5	O
%	O
mol/mol	O
as	O
strontium-substituted	O
HA	O
.	O

The	O
effect	O
of	O
varying	O
bone	O
strontium	O
content	O
on	O
determined	O
quality	O
indices	O
was	O
evaluated	O
based	O
on	O
determined	O
speed	O
of	O
sound	O
(	O
SOS	O
)	O
,	O
broadband	O
ultrasound	O
attenuation	O
(	O
BUA	O
)	O
and	O
determined	O
quantitative	O
ultrasound	O
index	O
(	O
QUI	O
)	O
for	O
phantoms	O
with	O
varying	O
BMD	O
values	O
and	O
varying	O
strontium	B-P
concentration	I-P
using	O
two	O
QUS	O
systems	O
:	O
a	O
clinical	B-P
Sahara®	I-P
system	I-P
and	O
an	O
in-house	O
research	O
system	O
with	O
two	O
identical	O
transducers	O
with	O
center	O
frequency	O
of	O
1	O
MHz	O
.	O

The	O
two	O
QUS	O
systems	O
were	O
also	O
compared	O
through	O
a	O
Bland-Altman	O
analysis	O
.	O

Both	O
the	O
clinical	B-P
system	I-P
and	O
the	O
research	O
QUS	O
systems	O
showed	O
a	O
strong	O
dependency	O
between	O
BMD	O
and	O
BUA	O
,	O
indicating	O
a	O
potential	O
for	O
QUS	O
to	O
be	O
used	O
as	O
a	O
means	O
of	O
estimating	O
BMD	O
(	O
p	O
=	O
0.001	O
)	O
.	O

SOS	O
was	O
found	O
to	O
have	O
no	O
correlation	O
to	O
BMD	O
(	O
p	O
=	O
0.546	O
)	O
.	O

There	O
was	O
no	O
correlation	O
observed	O
between	O
BUA	O
and	O
increasing	O
bone	O
strontium	B-P
concentrations	I-P
for	O
the	O
research	O
(	O
p	O
=	O
0.749	O
)	O
and	O
clinical	O
(	O
p	O
=	O
0.609	O
)	O
QUS	O
systems	O
.	O

Similarly	O
,	O
no	O
dependency	O
was	O
observed	O
between	O
the	O
SOS	O
and	O
bone	O
strontium	B-P
levels	I-P
up	O
to	O
2.5	O
mol/mol	O
[	O
Sr	O
/	O
(	O
Sr	O
+	O
Ca	O
)	O
]	O
%	O
for	O
the	O
research	O
(	O
p	O
=	O
0.862	O
)	O
and	O
clinical	O
(	O
p	O
=	O
0.481	O
)	O
QUS	O
systems	O
.	O

No	O
effect	O
on	O
the	O
QUI	O
values	O
was	O
observed	O
with	O
changing	O
strontium	B-P
levels	I-P
with	O
either	O
research	O
(	O
p	O
=	O
0.939	O
)	O
or	O
clinical	B-P
QUS	I-P
systems	I-P
(	O
p	O
=	O
0.931	O
)	O
.	O

A	O
Bland-Altman	O
analysis	O
showed	O
that	O
there	O
was	O
a	O
clear	O
offset	O
in	O
determined	O
QUI	O
values	O
for	O
both	O
systems	O
but	O
they	O
are	O
in	O
agreement	O
with	O
one	O
another	O
.	O

Bone	O
quality	O
can	O
be	O
assessed	O
through	O
the	O
use	O
of	O
QUS	O
while	O
increasing	O
bone	O
strontium	B-P
concentration	I-P
was	O
found	O
to	O
have	O
no	O
effect	O
on	O
QUS	O
-determined	O
quality	O
indices	O
.	O

This	O
study	O
concludes	O
that	O
QUS	O
can	O
potentially	O
be	O
used	O
for	O
the	O
determination	O
of	O
bone	O
quality	O
without	O
introducing	O
biases	O
due	O
to	O
bone	O
strontium	B-P
levels	I-P
as	O
is	O
known	O
to	O
be	O
the	O
case	O
with	O
DXA	B-P
determined	O
aBMD	O
.	O

High-Throughput	B-P
Analysis	I-P
of	O
the	O
IgG	O
N-Glycome	O
by	O
UPLC	B-P
-	O
FLR	O
.	O

As	O
biological	O
and	O
clinical	O
relevance	O
of	O
glycosylation	O
is	O
becoming	O
more	O
apparent	O
,	O
interest	O
in	O
large	O
scale	O
studies	O
of	O
the	O
glycome	O
is	O
growing	O
.	O

Glycans	O
attached	O
to	O
immunoglobulin	O
G	O
(	O
IgG	O
)	O
were	O
shown	O
to	O
be	O
essential	O
for	O
its	O
function	O
and	O
IgG	O
glycosylation	O
was	O
shown	O
to	O
change	O
with	O
various	O
processes	O
,	O
making	O
IgG	O
one	O
of	O
the	O
most	O
studied	O
glycoproteins	O
.	O

Many	O
approaches	O
including	O
liquid	B-P
chromatography	I-P
,	O
capillary	B-P
gel	I-P
electrophoresis	I-P
,	O
and	O
mass	B-P
spectrometry	I-P
were	O
developed	O
to	O
study	O
IgG	O
glycosylation	O
.	O

Generation	O
of	O
high-quality	O
glycomics	O
data	O
in	O
a	O
high-throughput	O
fashion	O
requires	O
reproducible	O
and	O
robust	O
sample	B-P
preparation	I-P
and	O
accurate	O
and	O
reliable	O
quantitative	O
analysis	O
.	O

This	O
chapter	O
presents	O
a	O
protocol	O
for	O
an	O
optimized	O
and	O
high-throughput	O
IgG	O
N-glycan	O
release	O
,	O
fluorescent	B-P
labeling	I-P
and	O
cleanup	O
,	O
and	O
analysis	O
of	O
fluorescently	O
labeled	O
IgG	O
N-glycans	O
by	O
hydrophilic	B-P
interaction	I-P
liquid	I-P
chromatography	I-P
(	O
HILIC	B-P
)	O
on	O
an	O
ultra	B-P
performance	I-P
liquid	I-P
chromatography	I-P
(	O
UPLC	B-P
)	O
system	O
with	O
fluorescence	O
(	O
FLR	O
)	O
detection	O
.	O

Curcumin	O
synergistically	O
increases	O
effects	O
of	O
β-interferon	O
and	O
retinoic	O
acid	O
on	O
breast	O
cancer	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
by	O
up-regulation	O
of	O
GRIM-19	O
through	O
STAT3	O
-	O
dependent	O
and	O
STAT3	O
-	O
independent	O
pathways	O
.	O

The	O
study	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
combination	O
treatment	O
of	O
curcumin	O
and	O
β-interferon	O
(	O
IFN-β	O
)	O
/	O
retinoic	O
acid	O
(	O
RA	O
)	O
on	O
breast	O
cancer	O
cells	O
,	O
including	O
cell	O
viability	O
,	O
apoptosis	O
and	O
migration	O
,	O
and	O
to	O
determine	B-P
the	O
mechanisms	O
related	O
to	O
GRIM-19	O
through	O
STAT3	O
-	O
dependent	O
and	O
STAT3	O
-	O
independent	O
pathways	O
.	O

The	O
following	O
groups	O
were	O
used	O
for	O
the	O
in	O
vitro	O
experiment	O
:	O
control	O
siRNA	O
,	O
GRIM-19	O
siRNA	O
,	O
IFN-β	O
/	O
RA	O
and	O
IFN-β	O
/	O
RA	O
+	O
curcumin	O
.	O

Cell	O
viability	O
is	O
by	O
the	O
MTT	O
method	O
,	O
cell	O
apoptosis	O
by	O
flow	B-P
cytometry	I-P
and	O
cell	O
migration	O
by	O
wound	O
healing	O
experiment	O
;	O
GRIM-19	O
,	O
STAT3	O
,	O
survivin	O
,	O
Bcl-2	O
,	O
GADD153	O
and	O
COX-2	O
expression	O
was	O
measured	O
by	O
Western	B-P
blot	I-P
.	O

In	O
vivo	O
experiment	O
,	O
MCF-7	O
cells	O
were	O
subcutaneously	O
injected	O
into	O
nude	O
mice	O
.	O

GRIM-19	O
siRNA	O
promoted	O
MCF-7	O
cell	O
proliferation	O
and	O
migration	O
;	O
inhibited	O
cell	O
apoptosis	O
;	O
and	O
promoted	O
the	O
expression	O
of	O
STAT3	O
,	O
survivin	O
,	O
Bcl-2	O
and	O
MMP-9	O
.	O

IFN-β	O
/	O
RA	O
inhibited	O
cell	O
proliferation	O
and	O
migration	O
;	O
promoted	O
cell	O
apoptosis	O
;	O
up-regulated	O
GRIM-19	O
;	O
and	O
inhibited	O
the	O
expression	O
of	O
STAT3	O
,	O
survivin	O
,	O
Bcl-2	O
and	O
MMP-9	O
.	O

Combination	O
treatment	O
of	O
curcumin	O
and	O
IFN-β	O
/	O
RA	O
had	O
a	O
stronger	O
effect	O
than	O
that	O
of	O
the	O
IFN-β	O
/	O
RA	O
group	O
.	O

In	O
addition	O
,	O
curcumin	O
and	O
IFN-β	O
/	O
RA	O
combination	O
inhibited	O
the	O
expression	O
of	O
COX-2	O
and	O
up-regulated	O
GADD153	O
.	O

Curcumin	O
synergistically	O
increases	O
the	O
effects	O
of	O
IFN-β	O
/	O
RA	O
on	O
breast	O
cancer	O
cells	O
.	O

The	O
mechanism	O
may	O
be	O
related	O
to	O
the	O
up-regulation	O
of	O
GRIM-19	O
through	O
STAT3	O
-	O
dependent	O
and	O
STAT3	O
-	O
independent	O
pathways	O
.	O

CT	B-P
angiography	I-P
for	O
planning	O
transcatheter	O
aortic	O
valve	O
replacement	O
using	O
automated	O
tube	O
voltage	O
selection	O
:	O
Image	O
quality	O
and	O
radiation	O
exposure	O
.	O

To	O
assess	O
image	O
quality	O
and	O
accuracy	O
of	O
CT	B-P
angiography	I-P
(	O
CTA	B-P
)	O
for	O
transcatheter	O
aortic	O
valve	O
replacement	O
(	O
TAVR	O
)	O
planning	O
performed	O
with	O
3rd	B-P
generation	I-P
dual-source	I-P
CT	I-P
(	O
DSCT	B-P
)	O
.	O

We	O
evaluated	O
125	O
patients	O
who	O
underwent	O
TAVR	O
-	O
planning	O
CTA	B-P
on	O
3rd	B-P
generation	I-P
DSCT	I-P
.	O

A	O
two-part	O
protocol	O
was	O
performed	O
including	O
retrospectively	O
ECG-gated	B-P
coronary	I-P
CTA	I-P
(	O
CCTA	B-P
)	O
and	O
prospectively	O
ECG-triggered	B-P
aortoiliac	I-P
CTA	I-P
using	O
60mL	O
of	O
contrast	O
medium	O
.	O

Automated	O
tube	O
voltage	O
selection	O
and	O
advanced	B-P
iterative	I-P
reconstruction	I-P
were	O
applied	O
.	O

Effective	O
dose	O
(	O
ED	O
)	O
,	O
signal-to-noise	O
(	O
SNR	O
)	O
and	O
contrast-to-noise	O
ratios	O
(	O
CNR	O
)	O
were	O
calculated	O
.	O

Five-point	O
scales	O
were	O
used	O
for	O
subjective	O
image	B-P
quality	I-P
analysis	I-P
.	O

In	O
patients	O
who	O
underwent	O
TAVR	O
,	O
sizing	O
parameters	O
were	O
obtained	O
.	O

Image	O
quality	O
was	O
rated	O
good	O
to	O
excellent	O
in	O
97.6	O
%	O
of	O
CCTA	B-P
and	O
100	O
%	O
of	O
aortoiliac	B-P
CTAs	I-P
.	O

CTA	B-P
studies	O
at	O
>	O
100kV	O
showed	O
decreased	O
objective	O
image	O
quality	O
compared	O
to	O
70-100kV	O
(	O
SNR	O
,	O
all	O
p≤0.0459	O
;	O
CNR	O
,	O
all	O
p≤0.0462	O
)	O
.	O

Mean	O
ED	O
increased	O
continuously	O
from	O
70	O
to	O
>	O
100kV	O
(	O
CCTA	B-P
:	O
4.5±1.7mSv-13.6±2.9mSv	O
,	O
all	O
p≤0.0233	O
;	O
aortoiliac	B-P
CTA	I-P
:	O
2.4±0.9mSv-6.8±2.7mSv	O
,	O
all	O
p≤0.0414	O
)	O
.	O

In	O
39	O
patients	O
TAVR	O
was	O
performed	O
and	O
annulus	O
diameter	O
was	O
within	O
the	O
recommended	O
range	O
in	O
all	O
patients	O
.	O

No	O
severe	O
cardiac	O
or	O
vascular	O
complications	O
were	O
noted	O
.	O

3rd	B-P
generation	I-P
DSCT	I-P
provides	O
diagnostic	O
image	O
quality	O
in	O
TAVR	O
-	O
planning	O
CTA	B-P
and	O
facilitates	O
reliable	O
assessment	O
of	O
TAVR	O
device	O
and	O
delivery	O
option	O
while	O
reducing	O
radiation	O
dose	O
.	O

Consistent	O
tracer	O
administration	O
profile	O
improves	O
test-retest	O
repeatability	O
of	O
myocardial	O
blood	O
flow	O
quantification	O
with	O
(	O
82	O
)	O
Rb	O
dynamic	B-P
PET	I-P
imaging	B-P
.	O

Quantification	O
of	O
myocardial	O
blood	O
flow	O
(	O
MBF	O
)	O
and	O
stress	O
/	O
rest	O
flow	O
reserve	O
is	O
used	O
increasingly	O
to	O
diagnose	O
multi-vessel	O
coronary	O
artery	O
disease	O
and	O
micro-vascular	O
disease	O
with	O
PET	B-P
imaging	B-P
.	O

However	O
,	O
variability	O
in	O
the	O
measurements	O
may	O
limit	O
physician	O
confidence	O
to	O
direct	O
revascularization	O
therapies	O
based	O
on	O
specific	O
threshold	O
values	O
.	O

This	O
study	O
evaluated	O
the	O
effects	O
of	O
rubidium-82	O
(	O
(	O
82	O
)	O
Rb	O
)	O
tracer	O
injection	O
profile	O
using	O
a	O
constant	O
-	O
activity-rate	O
(	O
CA	O
)	O
vs	O
a	O
constant	O
-	O
flow-rate	O
(	O
CF	O
)	O
infusion	O
to	O
improve	O
test-retest	O
repeatability	O
of	O
MBF	O
measurements	O
.	O

22	O
participants	O
underwent	O
single-session	O
(	O
82	O
)	O
Rb	O
dynamic	B-P
PET	I-P
imaging	B-P
during	O
rest	O
and	O
dipyridamole	B-P
stress	I-P
using	O
one	O
of	O
2	O
test-retest	O
infusion	O
protocols	O
:	O
CA	O
-	O
CA	O
(	O
n	O
=	O
12	O
)	O
or	O
CA	O
-	O
CF	O
(	O
n	O
=	O
10	O
)	O
.	O

MBF	O
was	O
quantified	O
using	O
a	O
single-tissue-compartment	O
model	O
(	O
1TCM	O
)	O
and	O
a	O
simplified	O
retention	O
model	O
(	O
SRM	O
)	O
.	O

Non-parametric	O
test-retest	O
repeatability	O
coefficients	O
(	O
RPCnp	O
)	O
were	O
compared	O
between	O
groups	O
.	O

Myocardium-to-blood	O
contrast	O
and	O
signal-to-noise	O
ratios	O
of	O
the	O
late	O
uptake	O
images	O
(	O
2	O
to	O
6	O
minutes	O
)	O
were	O
also	O
compared	O
to	O
evaluate	O
standard	O
myocardial	O
perfusion	O
image	O
(	O
MPI	O
)	O
quality	O
.	O

MBF	O
values	O
in	O
the	O
CA	O
-	O
CA	O
group	O
were	O
more	O
repeatable	O
(	O
smaller	O
RPCnp	O
)	O
than	O
the	O
CA	O
-	O
CF	O
group	O
using	O
the	O
1TCM	O
at	O
rest	O
alone	O
,	O
rest	O
and	O
stress	O
combined	O
,	O
and	O
stress	O
/	O
rest	O
reserve	O
(	O
21	O
%	O
vs	O
36	O
%	O
,	O
16	O
%	O
vs	O
19	O
%	O
,	O
and	O
20	O
%	O
vs	O
27	O
%	O
,	O
P	O
<	O
0.05	O
,	O
respectively	O
)	O
,	O
and	O
using	O
the	O
SRM	O
at	O
Rest	O
and	O
Stress	O
alone	O
,	O
Rest	O
and	O
Stress	O
combined	O
,	O
and	O
stress	O
/	O
rest	O
reserve	O
(	O
21	O
%	O
vs	O
38	O
%	O
,	O
15	O
%	O
vs	O
25	O
%	O
,	O
22	O
%	O
vs	O
38	O
%	O
,	O
and	O
23	O
%	O
vs	O
49	O
%	O
,	O
P	O
<	O
0.05	O
,	O
respectively	O
)	O
.	O

In	O
terms	O
of	O
image	O
quality	O
,	O
myocardium-to-blood	O
contrast	O
and	O
signal-to-noise	O
ratios	O
were	O
not	O
significantly	O
different	O
between	O
groups	O
.	O

Constant	O
-	O
activity-rate	O
'square-wave	O
'	O
infusion	O
of	O
(	O
82	O
)	O
Rb	O
produces	O
more	O
repeatable	O
tracer	O
injection	O
profiles	O
and	O
decreases	O
the	O
test-retest	O
variability	O
of	O
MBF	O
measurements	O
,	O
when	O
compared	O
to	O
a	O
constant-	O
flow-rate	O
'bolus	O
'	O
administration	O
of	O
(	O
82	O
)	O
Rb	O
,	O
especially	O
with	O
SRM	O
,	O
and	O
without	O
compromising	O
standard	O
MPI	O
quality	O
.	O

The	O
NCAM1	O
gene	O
set	O
is	O
linked	O
to	O
depressive	O
symptoms	O
and	O
their	O
brain	O
structural	O
correlates	O
in	O
healthy	O
individuals	O
.	O

Depressive	O
symptoms	O
exist	O
on	O
a	O
continuum	O
,	O
the	O
far	O
end	O
of	O
which	O
is	O
found	O
in	O
depressive	O
disorders	O
.	O

Utilizing	O
the	O
continuous	B-P
spectrum	I-P
of	O
depressive	O
symptoms	O
may	O
therefore	O
contribute	O
to	O
the	O
understanding	O
of	O
the	O
biological	O
underpinnings	O
of	O
depression	O
.	O

Gene	B-P
set	I-P
enrichment	I-P
analysis	I-P
(	O
GSEA	B-P
)	O
is	O
an	O
important	O
tool	O
for	O
the	O
identification	O
of	O
gene	O
groups	O
linked	O
to	O
complex	O
traits	O
,	O
and	O
was	O
applied	O
in	O
the	O
present	O
study	O
on	O
genome-wide	O
association	O
study	O
(	O
GWAS	O
)	O
data	O
of	O
depression	O
scores	O
and	O
their	O
brain-level	O
structural	O
correlates	O
in	O
healthy	O
young	O
individuals	O
.	O

On	O
symptom	O
level	O
(	O
i.e	O
.	O

depression	O
scores	O
)	O
,	O
robust	O
enrichment	O
was	O
identified	O
for	O
two	O
gene	O
sets	O
:	O
NCAM1	O
Interactions	O
and	O
Collagen	O
Formation	O
.	O

Depression	O
scores	O
were	O
also	O
associated	O
with	O
decreased	O
fractional	O
anisotropy	O
(	O
FA	O
)	O
-	O
a	O
brain	O
white	O
matter	O
property	O
-	O
within	O
the	O
forceps	O
minor	O
and	O
the	O
left	O
superior	O
temporal	O
longitudinal	O
fasciculus	O
.	O

Within	O
each	O
of	O
these	O
tracts	O
,	O
mean	O
FA	O
value	O
of	O
depression	O
score	O
-	O
associated	O
voxels	O
was	O
used	O
as	O
a	O
phenotype	O
in	O
a	O
subsequent	O
GSEA	B-P
.	O

The	O
NCAM1	O
Interactions	O
gene	O
set	O
was	O
significantly	O
enriched	O
in	O
these	O
tracts	O
.	O

By	O
linking	O
the	O
NCAM1	O
Interactions	O
gene	O
set	O
to	O
depression	O
scores	O
and	O
their	O
structural	O
brain	O
correlates	O
in	O
healthy	O
participants	O
,	O
the	O
current	O
study	O
contributes	O
to	O
the	O
understanding	O
of	O
the	O
molecular	O
underpinnings	O
of	O
depressive	O
symptomatology	O
.	O

Novel	O
protein	O
-	O
inhibitor	O
interactions	O
in	O
site	O
3	O
of	O
Ca	O
(	O
2+	O
)	O
-bound	O
S100B	O
as	O
discovered	O
by	O
X-ray	B-P
crystallography	I-P
.	O

Structure-based	O
drug	O
discovery	O
is	O
under	O
way	O
to	O
identify	O
and	O
develop	O
small-molecule	O
S100B	O
inhibitors	O
(	O
SBiXs	O
)	O
.	O

Such	O
inhibitors	O
have	O
therapeutic	O
potential	O
for	O
treating	O
malignant	O
melanoma	O
,	O
since	O
high	O
levels	O
of	O
S100B	O
downregulate	O
wild-type	O
p53	O
tumor	O
suppressor	O
function	O
in	O
this	O
cancer	O
.	O

Computational	B-P
and	O
X-ray	B-P
crystallographic	I-P
studies	I-P
of	O
two	O
S100B	O
-	O
SBiX	O
complexes	O
are	O
described	O
,	O
and	O
both	O
compounds	O
(	O
apomorphine	O
hydrochloride	O
and	O
ethidium	O
bromide	O
)	O
occupy	O
an	O
area	O
of	O
the	O
S100B	O
hydrophobic	O
cleft	O
which	O
is	O
termed	O
site	O
3	O
.	O

These	O
data	O
also	O
reveal	O
novel	O
protein	O
-	O
inhibitor	O
interactions	O
which	O
can	O
be	O
used	O
in	O
future	O
drug-design	O
studies	O
to	O
improve	O
SBiX	O
affinity	O
and	O
specificity	O
.	O

Of	O
particular	O
interest	O
,	O
apomorphine	O
hydrochloride	O
showed	O
S100B	O
-dependent	O
killing	O
in	O
melanoma	O
cell	O
assays	B-P
,	O
although	O
the	O
efficacy	O
exceeds	O
its	O
affinity	O
for	O
S100B	O
and	O
implicates	O
possible	O
off-target	O
contributions	O
.	O

Because	O
there	O
are	O
no	O
structural	O
data	O
available	O
for	O
compounds	O
occupying	O
site	O
3	O
alone	O
,	O
these	O
studies	O
contribute	O
towards	O
the	O
structure-based	O
approach	O
to	O
targeting	O
S100B	O
by	O
including	O
interactions	O
with	O
residues	O
in	O
site	O
3	O
of	O
S100B	O
.	O

Fluoride	O
concentration	O
in	O
saliva	O
and	O
biofilm	O
fluid	O
following	O
the	O
application	O
of	O
three	O
fluoride	O
varnishes	O
.	O

Most	O
of	O
the	O
commercially	O
available	O
fluoride	O
varnishes	O
(	O
FV	O
)	O
have	O
not	O
been	O
evaluated	O
for	O
their	O
cariostatic	O
properties	O
.	O

Consequently	O
,	O
the	O
aim	O
of	O
this	O
in	O
vivo	O
study	O
was	O
to	O
investigate	O
intra	O
-	O
oral	O
fluoride	O
retention	O
and	O
clearance	O
patterns	O
from	O
three	O
different	O
FV	O
.	O

Eighteen	O
subjects	O
(	O
7-11	O
years	O
)	O
participated	O
in	O
a	O
laboratory	O
analyst	O
-	O
blinded	O
,	O
randomized	O
,	O
crossover	O
study	O
comparing	O
the	O
ability	O
of	O
5	O
%	O
sodium	O
fluoride	O
varnishes	O
(	O
CavityShield-CS	O
,	O
Enamel	O
Pro-EP	O
,	O
Vanish-V	O
)	O
to	O
enhance	O
fluoride	O
concentrations	O
in	O
biofilm	O
fluid	O
,	O
centrifuged	O
and	O
whole	O
saliva	O
over	O
a	O
period	O
of	O
48h	O
after	O
a	O
single	O
FV	O
application	O
.	O

Similar	O
fluoride	O
concentration	O
×	O
time	O
patterns	O
were	O
noted	O
for	O
all	O
investigated	O
FV	O
and	O
studied	O
variables	O
,	O
with	O
the	O
highest	O
fluoride	O
concentrations	O
observed	O
for	O
the	O
first	O
biological	O
sample	O
collected	O
after	O
FV	O
application	O
(	O
30min	O
)	O
.	O

Mean±SE	O
(	O
area	O
under	O
fluoride	O
clearance	O
curve	O
)	O
values	O
were	O
(	O
μg	O
F/g	O
or	O
ml×min	O
)	O
:	O
biofilm	O
fluid	O
-	O
CS	O
(	O
472±191	O
)	O
,	O
EP	O
(	O
423±75	O
)	O
,	O
V	O
(	O
1264±279	O
)	O
;	O
centrifuged	O
saliva	O
-	O
CS	O
(	O
42±7	O
)	O
,	O
EP	O
(	O
19±3	O
)	O
,	O
V	O
(	O
41±8	O
)	O
;	O
whole	O
saliva	O
-	O
CS	O
(	O
68±11	O
)	O
,	O
EP	O
(	O
64±10	O
)	O
,	O
V	O
(	O
60±7	O
)	O
.	O

V	O
delivered	O
more	O
fluoride	O
to	O
biofilm	O
fluid	O
than	O
CS	O
(	O
p=0.0116	O
)	O
and	O
EP	O
(	O
p=0.0065	O
)	O
,	O
which	O
did	O
not	O
differ	O
(	O
p=0.27	O
)	O
.	O

For	O
centrifuged	O
saliva	O
,	O
CS	O
and	O
V	O
were	O
not	O
significantly	O
different	O
(	O
p=0.86	O
)	O
,	O
but	O
resulted	O
in	O
higher	O
fluoride	O
retention	O
than	O
EP	O
(	O
p	O
<	O
0.0008	O
)	O
.	O

No	O
significant	O
differences	O
among	O
FV	O
were	O
observed	O
for	O
whole	O
saliva	O
(	O
p=0.79	O
)	O
.	O

The	O
present	O
study	O
has	O
shown	O
that	O
FV	O
vary	O
in	O
their	O
ability	O
to	O
deliver	O
fluoride	O
intra	O
-	O
orally	O
potentially	O
related	O
to	O
formulation	O
differences	O
.	O

To	O
what	O
extent	O
the	O
present	O
findings	O
relate	O
to	O
clinical	O
efficacy	O
remains	O
,	O
however	O
,	O
to	O
be	O
determined	B-P
.	O

Clinical	O
research	O
that	O
investigates	O
fluoride	O
release	O
patterns	O
into	O
saliva	O
and	O
biofilm	O
fluid	O
from	O
different	O
FV	O
products	O
is	O
insufficient	O
.	O

More	O
research	O
is	O
needed	O
to	O
investigate	O
different	O
FV	O
formulations	O
for	O
their	O
efficacy	O
in	O
order	O
to	O
help	O
clinicians	O
make	O
better	O
evidence	O
based	O
treatment	O
choices	O
.	O

Semi-preparative	B-P
HPLC	I-P
separation	I-P
followed	O
by	O
HPLC/UV	B-P
and	O
tandem	O
mass	O
spectrometric	O
analysis	O
of	O
phorbol	O
esters	O
in	O
Jatropha	O
seed	O
.	O

Phorbol	O
esters	O
(	O
PEs	O
)	O
are	O
well	O
known	O
as	O
the	O
main	O
toxic	O
compounds	O
in	O
Jatropha	O
curcas	O
Linnaeus	O
(	O
JCL	O
)	O
,	O
the	O
seed	O
oil	O
of	O
which	O
has	O
been	O
considered	O
as	O
a	O
major	O
feedstock	O
for	O
the	O
production	O
of	O
biodiesel	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
a	O
series	O
of	O
PEs	O
extracted	O
from	O
JCL	O
seed	O
kernels	O
with	O
methanol	O
(	O
MeOH	O
)	O
,	O
and	O
identified	O
more	O
than	O
seven	O
components	O
contained	O
in	O
the	O
PEs	O
.	O

The	O
isolation	O
of	O
main	O
five	O
components	O
of	O
a	O
series	O
of	O
PEs	O
was	O
revised	O
using	O
a	O
semi-preparative	B-P
reversed	I-P
phase	I-P
HPLC	I-P
analysis	I-P
of	O
ODS-3	O
column	O
.	O

The	O
five	O
peaks	O
of	O
components	O
were	O
successfully	O
isolated	O
,	O
and	O
peaks	O
of	O
J2	O
,	O
J3	O
,	O
J5	O
,	O
and	O
J7	O
were	O
assigned	O
to	O
be	O
Jatropha	O
factors	O
C1	O
,	O
C2	O
,	O
C3	O
,	O
and	O
C4/5	O
,	O
but	O
J6	O
was	O
a	O
mixture	O
of	O
Jatropha	O
factor	O
C6	O
and	O
its	O
isomer	O
based	O
on	O
the	O
data	O
of	O
UV	B-P
and	O
LC-MS	B-P
/	O
MS	B-P
,	O
and	O
J2	O
was	O
identified	O
using	O
(	B-P
1	I-P
)	I-P
H	I-P
NMR	I-P
analysis	I-P
.	O

By	O
characterization	O
using	O
LC-MS	B-P
/	O
MS	B-P
analysis	I-P
,	O
all	O
components	O
of	O
a	O
series	O
of	O
PEs	O
were	O
elucidated	O
to	O
be	O
the	O
12-deoxy-16-hydroxyphorbol	O
esters	O
composed	O
of	O
isomeric	O
form	O
of	O
dicarboxylic	O
groups	O
with	O
same	O
m/z	O
value	O
of	O
380	O
.	O

A	O
Necrotizing	O
Fasciitis	O
Fake	O
Out	O
on	O
Point-of-Care	O
Ultrasound	O
-Watch	O
the	O
Shadow	O
.	O

Point-of-care	O
ultrasound	O
has	O
an	O
increasing	O
role	O
in	O
characterizing	O
soft-tissue	O
infections	O
and	O
has	O
been	O
described	O
previously	O
in	O
the	O
evaluation	O
of	O
necrotizing	O
fasciitis	O
(	O
NF	O
)	O
.	O

The	O
identification	O
of	O
air	O
within	O
the	O
soft	O
tissues	O
can	O
be	O
very	O
suggestive	O
of	O
NF	O
in	O
the	O
correct	O
clinical	O
context	O
.	O

A	O
78-year-old	O
male	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
extensive	O
lower-extremity	O
redness	O
and	O
edema	O
.	O

A	O
point-of-care	O
ultrasound	O
revealed	O
hyperechoic	O
areas	O
within	O
the	O
soft	O
tissues	O
consistent	O
with	O
air	O
,	O
and	O
the	O
patient	O
was	O
taken	O
to	O
surgery	O
and	O
found	O
to	O
have	O
NF	O
.	O

A	O
60-year-old	O
female	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
physical	O
examination	O
findings	O
consistent	O
with	O
severe	O
cellulitis	O
and	O
associated	O
sepsis	O
.	O

A	O
point-of-care	O
ultrasound	O
revealed	O
hyperechoic	O
areas	O
within	O
the	O
soft	O
tissue	O
that	O
were	O
very	O
similar	O
to	O
the	O
prior	O
case	O
.	O

An	O
emergent	O
surgical	O
consultation	O
was	O
placed	O
due	O
to	O
concern	O
for	O
soft-tissue	O
air	O
and	O
NF	O
.	O

However	O
,	O
these	O
hyperechoic	O
areas	O
were	O
found	O
to	O
be	O
subcutaneous	O
calcifications	O
on	O
subsequent	O
imaging	B-P
.	O

WHY	O
SHOULD	O
AN	O
EMERGENCY	O
PHYSICIAN	O
BE	O
AWARE	O
OF	O
THIS	O
?	O

:	O
Air	O
within	O
the	O
soft	O
tissue	O
is	O
easy	O
to	O
identify	O
on	O
point-of-care	O
ultrasound	O
and	O
can	O
expedite	O
surgical	O
evaluation	O
in	O
cases	O
of	O
suspected	O
NF	O
.	O

Calcifications	O
can	O
mimic	O
the	O
appearance	O
of	O
air	O
on	O
ultrasound	O
and	O
the	O
distinction	O
between	O
these	O
objects	O
can	O
often	O
be	O
made	O
based	O
on	O
the	O
echotexture	O
of	O
the	O
posterior	O
acoustic	O
shadow	O
.	O

Attention	O
to	O
the	O
posterior	O
acoustic	O
shadow	O
can	O
facilitate	O
correct	O
identification	O
of	O
various	O
structures	O
and	O
pathologies	O
in	O
a	O
variety	O
of	O
clinical	O
settings	O
.	O

Phototoxic	O
action	O
of	O
a	O
zinc	O
(	O
II	O
)	O
phthalocyanine	O
encapsulated	O
into	O
poloxamine	O
polymeric	O
micelles	O
in	O
2D	O
and	O
3D	O
colon	O
carcinoma	O
cell	B-P
cultures	I-P
.	O

Photodynamic	O
therapy	O
is	O
emerging	O
as	O
a	O
hopeful	O
method	O
for	O
the	O
treatment	O
of	O
oncological	O
diseases	O
.	O

In	O
the	O
search	O
of	O
novel	O
therapeutic	O
strategies	O
for	O
colorectal	O
cancer	O
,	O
in	O
this	O
work	O
we	O
reported	O
the	O
photocytotoxic	O
activity	O
of	O
a	O
lipophilic	O
zinc	O
(	O
II	O
)	O
phthalocyanine	O
on	O
a	O
murine	O
colon	O
adenocarcinoma	O
cell	O
line	O
(	O
CT26	O
cells	O
)	O
.	O

The	O
2,9	O
(	O
10	O
)	O
,16	O
(	O
17	O
)	O
,23	O
(	O
24	O
)	O
tetrakis	O
[	O
(	O
2-dimethylamino	O
)	O
ethylsulfanyl	O
]	O
phthalocyaninatozinc	O
(	O
II	O
)	O
,	O
named	O
Pc9	O
,	O
was	O
encapsulated	O
into	O
Tetronic®	O
1107	O
polymeric	O
poloxamine	O
micelles	O
(	O
T1107	O
)	O
and	O
assayed	O
in	O
2D	O
and	O
3D	O
cell	B-P
cultures	I-P
.	O

We	O
showed	O
that	O
the	O
formulation	O
Pc9	O
-	O
T1107	O
was	O
efficient	O
to	O
reduce	O
cell	O
viability	O
after	O
photodynamic	O
treatment	O
both	O
in	O
2D	O
cultures	B-P
(	O
IC50	O
10±2nM	O
)	O
as	O
well	O
as	O
in	O
CT26	O
spheroids	O
(	O
IC50	O
370±11nM	O
)	O
.	O

Cellular	O
uptake	O
of	O
Pc9	O
-	O
T1107	O
was	O
a	O
time-	O
and	O
concentration-dependent	O
process	O
,	O
being	O
the	O
phthalocyanine	O
formulation	O
mainly	O
incorporated	O
into	O
lysosomal	O
vesicles	O
and	O
endoplasmic	O
reticulum	O
cisterns	O
,	O
but	O
not	O
in	O
mitochondria	O
.	O

Pc9	O
-	O
T1107	O
also	O
induced	O
the	O
formation	O
of	O
reactive	O
oxygen	O
species	O
immediately	O
after	O
cell	O
irradiation	O
.	O

We	O
also	O
found	O
that	O
the	O
phototoxic	O
action	O
of	O
Pc9	O
-	O
T1107	O
was	O
partially	O
reversed	O
in	O
the	O
presence	O
of	O
antioxidants	O
,	O
such	O
as	O
TROLOX	O
and	O
N-acetyl-cysteine	O
.	O

In	O
addition	O
,	O
we	O
showed	O
that	O
Pc9	O
-	O
T1107	O
treatment	O
triggered	O
an	O
apoptotic	O
cell	O
death	O
,	O
as	O
suggested	O
by	O
the	O
detection	O
of	O
pyknotic	O
nuclei	O
,	O
the	O
reduction	O
in	O
the	O
expression	O
levels	O
of	O
procaspase-3	O
and	O
the	O
increase	O
in	O
caspase-3	O
enzymatic	O
activity	O
.	O

Human	O
Immunoglobulin	O
Heavy	O
Gamma	O
Chain	O
Polymorphisms	O
:	O
Molecular	O
Confirmation	O
Of	O
Proteomic	O
Assessment	O
.	O

Immunoglobulin	O
G	O
(	O
IgG	O
)	O
proteins	O
are	O
known	O
for	O
the	O
huge	O
diversity	O
of	O
the	O
variable	O
domains	O
of	O
their	O
heavy	O
and	O
light	O
chains	O
,	O
aimed	O
at	O
protecting	O
each	O
individual	O
against	O
foreign	O
antigens	O
.	O

The	O
IgG	O
also	O
harbor	O
specific	O
polymorphism	O
concentrated	O
in	O
the	O
CH2	O
and	O
CH3-CHS	O
constant	O
regions	O
located	O
on	O
the	O
Fc	O
fragment	O
of	O
their	O
heavy	O
chains	O
.	O

But	O
this	O
individual	O
particularity	O
relies	O
only	O
on	O
a	O
few	O
amino	O
acids	O
among	O
which	O
some	O
could	O
make	O
accurate	O
sequence	O
determination	O
a	O
challenge	O
for	O
mass	B-P
spectrometry	I-P
-	O
based	O
techniques	O
.The	O
purpose	O
of	O
the	O
study	O
was	O
to	O
bring	O
a	O
molecular	O
validation	O
of	O
proteomic	O
results	O
by	O
the	O
sequencing	B-P
of	O
encoding	O
DNA	O
fragments	O
.	O

It	O
was	O
performed	O
using	O
ten	O
individual	O
samples	O
(	O
DNA	O
and	O
sera	O
)	O
selected	O
on	O
the	O
basis	O
of	O
their	O
Gm	O
(	O
gamma	O
marker	O
)	O
allotype	O
polymorphism	O
in	O
order	O
to	O
cover	O
the	O
main	O
immunoglobulin	O
heavy	O
gamma	O
(	O
IGHG	O
)	O
gene	O
diversity	O
.	O

Gm	O
allotypes	O
,	O
reflecting	O
part	O
of	O
this	O
diversity	O
,	O
were	O
determined	O
by	O
a	O
serological	B-P
method	I-P
.	O

On	O
its	O
side	O
,	O
the	O
IGH	O
locus	O
comprises	O
four	O
functional	O
IGHG	O
genes	O
totalizing	O
34	O
alleles	O
and	O
encoding	O
the	O
four	O
IgG	O
subclasses	O
.	O

The	O
genomic	O
study	O
focused	O
on	O
the	O
nucleotide	O
polymorphism	O
of	O
the	O
CH2	O
and	O
CH3-CHS	O
exons	O
and	O
of	O
the	O
intron	O
.	O

Despite	O
strong	O
sequence	O
identity	O
,	O
four	O
pairs	O
of	O
specific	O
gene	O
amplification	O
primers	O
could	O
be	O
designed	O
.	O

Additional	O
primers	O
were	O
identified	O
to	O
perform	O
the	O
subsequent	O
sequencing	B-P
.	O

The	O
nucleotide	O
sequences	O
obtained	O
were	O
first	O
assigned	O
to	O
a	O
specific	O
IGHG	O
gene	O
,	O
and	O
then	O
IGHG	O
alleles	O
were	O
deduced	O
using	O
a	O
home-made	O
decision	O
tree	O
reading	O
of	O
the	O
nucleotide	O
sequences	O
.	O

IGHG	O
amino	O
acid	O
(	O
AA	O
)	O
alleles	O
were	O
determined	O
by	O
mass	B-P
spectrometry	I-P
.	O

Identical	O
results	O
were	O
found	O
at	O
95	O
%	O
between	O
alleles	O
identified	O
by	O
proteomics	B-P
and	O
those	O
deduced	O
from	O
genomics	O
.	O

These	O
results	O
validate	O
the	O
proteomic	O
approach	O
which	O
could	O
be	O
used	O
for	O
diagnostic	O
purposes	O
,	O
namely	O
for	O
a	O
mother-and-child	O
differential	O
IGHG	O
detection	O
in	O
a	O
context	O
of	O
suspicion	O
of	O
congenital	O
infection	O
.	O

A	O
study	O
of	O
acute	O
muscle	O
dysfunction	O
with	O
particular	O
reference	O
to	O
dengue	O
myopathy	O
.	O

Acute	O
myopathy	O
is	O
a	O
common	O
cause	O
of	O
acute	O
motor	O
quadriparesis	O
which	O
has	O
various	O
etiologies	O
with	O
different	O
courses	O
of	O
illness	O
and	O
prognosis	O
depending	O
on	O
the	O
cause	O
.	O

Understanding	O
this	O
diversity	O
helps	O
us	O
in	O
proper	O
approach	O
toward	O
diagnosis	O
,	O
predicting	O
the	O
prognosis	O
,	O
and	O
possible	O
complications	O
and	O
in	O
improving	O
the	O
treatments	O
that	O
are	O
being	O
provided	O
.	O

This	O
study	O
was	O
planned	O
to	O
study	O
the	O
clinical	O
,	O
electrophysiological	B-P
,	O
and	O
etiological	O
profile	O
of	O
patients	O
presenting	O
with	O
acute	O
myopathy	O
.	O

We	O
also	O
studied	O
how	O
dengue	O
-related	O
acute	O
myopathy	O
differs	O
from	O
other	O
causes	O
and	O
also	O
difference	O
between	O
myopathy	O
due	O
to	O
myositis	O
and	O
hypokalemia	O
in	O
cases	O
of	O
dengue	O
.	O

This	O
was	O
a	O
prospective	O
,	O
observational	O
study	O
involving	O
all	O
clinically	O
suspected	O
cases	O
of	O
acute	O
myopathy	O
of	O
not	O
more	O
than	O
4	O
weeks	O
duration	O
with	O
raised	O
serum	O
creatine	O
kinase	O
(	O
CK	O
)	O
level	O
.	O

They	O
were	O
subjected	O
to	O
detailed	O
clinical	O
evaluation	O
along	O
with	O
hematological	O
,	O
biochemical	O
,	O
microbiological	O
,	O
and	O
electrophysiological	B-P
studies	I-P
and	O
followed-up	O
for	O
outcome	O
at	O
1	O
and	O
3	O
months	O
.	O

Muscle	B-P
biopsy	I-P
and	O
histopathological	O
examination	O
were	O
done	O
in	O
selected	O
patients	O
after	O
taking	O
informed	O
consent	O
.	O

Statistical	O
analysis	O
was	O
performed	O
by	O
appropriate	O
methods	O
using	O
SPSS	O
version	O
16.0	O
(	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
.	O

We	O
evaluated	O
thirty	O
patients	O
of	O
acute	O
myopathy	O
with	O
raised	O
CK	O
level	O
.	O

Seventeen	O
patients	O
had	O
fever	O
,	O
11	O
had	O
myalgia	O
,	O
and	O
5	O
had	O
skin	O
lesions	O
.	O

All	O
presented	O
with	O
symmetric	O
weakness	O
,	O
17	O
(	O
56.7	O
%	O
)	O
patients	O
having	O
predominantly	O
proximal	O
weakness	O
,	O
neck	O
or	O
truncal	O
weakness	O
in	O
6	O
(	O
20	O
%	O
)	O
,	O
hyporeflexia	O
in	O
12	O
(	O
40	O
%	O
)	O
,	O
with	O
mean	O
Medical	O
Research	O
Council	O
(	O
MRC	O
)	O
sum	O
score	O
of	O
46.67	O
±	O
6.0	O
.	O

Eight	O
(	O
mean	O
modified	O
Barthel	O
index	O
[	O
MBI	O
]	O
at	O
presentation	O
-	O
15	O
±	O
3.7	O
)	O
patients	O
had	O
poor	O
functional	O
status	O
according	O
to	O
MBI	O
and	O
15	O
according	O
to	O
modified	O
Rankin	O
scale	O
(	O
MRS	O
)	O
(	O
mean	O
MRS	O
score	O
-	O
2.5	O
±	O
1.2	O
)	O
.	O

Etiology	O
was	O
dengue	O
viral	O
infection	O
in	O
14	O
patients	O
;	O
hypokalemia	O
due	O
to	O
various	O
causes	O
other	O
than	O
dengue	O
in	O
8	O
;	O
pyomyositis	O
in	O
3	O
;	O
dermatomyositis	O
,	O
polymyositis	O
,	O
thyrotoxicosis	O
,	O
systemic	O
lupus	O
erythematosus	O
,	O
and	O
unknown	O
etiology	O
in	O
one	O
each	O
.	O

Only	O
eight	O
patients	O
had	O
abnormal	O
electrophysiology	B-P
and	O
seven	O
among	O
nine	O
biopsies	B-P
done	O
were	O
abnormal	O
.	O

At	O
1	O
month	O
,	O
24	O
(	O
80.0	O
%	O
)	O
and	O
23	O
(	O
76.7	O
%	O
)	O
patients	O
had	O
achieved	O
normal	O
MBI	O
and	O
MRS	O
scores	O
with	O
28	O
(	O
93.3	O
)	O
and	O
27	O
(	O
90	O
%	O
)	O
patients	O
,	O
respectively	O
,	O
at	O
3	O
months	O
.	O

Dengue	O
with	O
hypokalemia	O
had	O
less	O
myalgia	O
,	O
more	O
of	O
hyporeflexia	O
,	O
and	O
lower	O
serum	O
CK	O
compared	O
to	O
those	O
without	O
hypokalemia	O
.	O

Dengue	O
infection	O
and	O
hypokalemia	O
due	O
to	O
various	O
causes	O
are	O
the	O
most	O
common	O
causes	O
of	O
acute	O
myopathy	O
and	O
are	O
associated	O
with	O
rapid	O
and	O
complete	O
recovery	O
within	O
1	O
month	O
.	O

Shorter	O
duration	O
of	O
illness	O
,	O
higher	O
MRC	O
sum	O
score	O
,	O
better	O
disability	O
status	O
at	O
presentation	O
,	O
lower	O
serum	O
CK	O
correlate	O
with	O
better	O
outcome	O
.	O

Biopsy	B-P
was	O
decisive	O
in	O
<	O
20	O
%	O
cases	O
;	O
hence	O
,	O
it	O
is	O
not	O
primary	O
investigation	O
in	O
acute	O
myopathy	O
.	O

Interlinking	O
Periodontitis	O
and	O
Type	O
2	O
Diabetes	O
Mellitus	O
by	O
Assessment	O
of	O
Crevicular	O
Visfatin	O
Levels	O
in	O
Health	O
and	O
in	O
Disease	O
Before	O
and	O
After	O
Initial	O
Periodontal	O
Therapy	O
.	O

Visfatin	O
is	O
a	O
new	O
adipocytokine	O
associated	O
with	O
both	O
chronic	O
periodontitis	O
and	O
type	O
2	O
diabetes	O
mellitus	O
independently	O
.	O

We	O
aimed	O
to	O
estimate	O
and	O
compare	O
the	O
changes	O
in	O
the	O
levels	O
of	O
visfatin	O
in	O
the	O
Gingival	O
Crevicular	O
Fluid	O
(	O
GCF	O
)	O
of	O
healthy	O
subjects	O
and	O
in	O
subjects	O
with	O
periodontitis	O
with	O
or	O
without	O
controlled	O
Type	O
2	O
Diabetes	O
Mellitus	O
(	O
T2DM	O
)	O
after	O
administration	O
of	O
non-surgical	O
periodontal	O
therapy	O
.	O

Forty	O
two	O
subjects	O
were	O
equally	O
divided	O
into	O
Group	O
1	O
(	O
healthy	O
)	O
,	O
Group	O
2	O
(	O
systemically	O
healthy	O
with	O
chronic	O
periodontitis	O
)	O
,	O
Group	O
3	O
(	O
subjects	O
with	O
chronic	O
periodontitis	O
having	O
controlled	O
T2DM	O
)	O
.	O

Defined	O
clinical	O
parameters	O
were	O
recorded	O
at	O
baseline	O
and	O
at	O
one	O
month	O
follow-up	O
period	O
.	O

Visfatin	O
was	O
assessed	O
using	O
enzyme	B-P
linked	I-P
immunosorbent	I-P
assay	I-P
.	O

One	O
way	O
ANOVA	O
and	O
Tukey	O
's	O
multiple	O
post	O
hoc	O
procedures	O
were	O
used	O
.	O

Pearson	O
's	O
correlation	O
coefficient	O
was	O
used	O
for	O
correlation	O
.	O

Significant	O
increase	O
in	O
the	O
visfatin	O
levels	O
was	O
seen	O
with	O
the	O
highest	O
values	O
observed	O
in	O
diabetes	O
with	O
periodontal	O
disease	O
.	O

Visfatin	O
responded	O
to	O
non-surgical	O
periodontal	O
therapy	O
as	O
observed	O
by	O
significant	O
decrease	O
in	O
levels	O
after	O
one	O
month	O
but	O
even	O
at	O
this	O
period	O
diabetics	O
showed	O
the	O
highest	O
levels	O
.	O

Visfatin	O
levels	O
are	O
highest	O
in	O
individuals	O
with	O
both	O
periodontal	O
disease	O
and	O
diabetes	O
even	O
after	O
periodontal	O
therapy	O
.	O

Individuals	O
with	O
T2DM	O
may	O
be	O
at	O
higher	O
risk	O
of	O
developing	O
periodontal	O
disease	O
.	O

Association	O
of	O
vitamin	O
D	O
deficiency	O
with	O
poor	O
glycaemic	O
control	O
in	O
diabetic	O
patients	O
.	O

An	O
association	O
between	O
serum	B-P
levels	I-P
of	I-P
vitamin	I-P
D	I-P
and	O
glycaemic	O
control	O
in	O
type-2	O
diabetes	O
mellitus	O
(	O
DM	O
)	O
patients	O
has	O
been	O
reported	O
in	O
some	O
of	O
the	O
studies	O
carried	O
out	O
in	O
the	O
West	O
.	O

However	O
,	O
there	O
are	O
no	O
reports	O
on	O
this	O
relationship	O
in	O
Pakistani	O
diabetic	O
patients	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
ascertain	O
whether	O
vitamin	B-P
D	I-P
levels	I-P
have	O
any	O
influence	O
on	O
glycaemic	O
control	O
in	O
Pakistani	O
patients	O
with	O
type-2	O
DM	O
.	O

In	O
a	O
cross-sectional	O
survey	O
,	O
relationship	O
between	O
serum	O
levels	B-P
of	I-P
25-hydroxy	I-P
vitamin	I-P
D	I-P
(	O
25	O
(	O
OH	O
)	O
D	O
)	O
and	O
glycated	B-P
haemoglobin	I-P
(	O
HbA1C	O
)	O
was	O
examined	O
in	O
141	O
type-2	O
diabetic	O
patients	O
including	O
102	O
males	O
and	O
39	O
females	O
;	O
age	O
range	O
22	O
to	O
70	O
years	O
,	O
visiting	O
the	O
Aga	O
Khan	O
University	O
Hospital	O
during	O
July	O
2013-	O
April	O
2014	O
.	O

Venous	O
blood	O
was	O
collected	O
and	O
analyzed	O
for	O
serum	O
/	O
plasma	O
levels	B-P
of	I-P
25	I-P
(	I-P
OH	I-P
)	I-P
D	I-P
and	O
related	O
biomarkers	O
using	O
kit	B-P
methods	I-P
.	O

HbA1C	B-P
levels	I-P
<	O
7.0	O
%	O
and	O
>	O
7.0	O
%	O
were	O
taken	O
as	O
indicators	O
of	O
good	O
and	O
poor	O
glycaemic	O
control	O
,	O
respectively	O
.	O

An	O
association	O
between	O
25	O
(	O
OH	O
)	O
D	O
and	O
HbA1C	O
was	O
investigated	O
using	O
regression	O
analysis	O
.	O

Percent	O
vitamin	O
D	O
deficiency	O
(	O
serum	O
level	B-P
of	I-P
25	I-P
(	I-P
OH	I-P
)	I-P
D	I-P
<	O
20	O
ng/ml	O
)	O
was	O
significantly	O
higher	O
in	O
patients	O
with	O
poor	O
glycaemic	O
control	O
compared	O
to	O
patients	O
with	O
good	O
glycaemic	O
control	O
(	O
58.7	O
%	O
vs.	O
30.6	O
%	O
;	O
p-value=0.006	O
)	O
.	O

Binary	O
logistic	O
regression	O
analysis	O
revealed	O
positive	O
association	O
between	O
vitamin	O
D	O
deficiency	O
and	O
poor	O
glycaemic	O
control	O
while	O
adjusting	O
for	O
BMI	O
,	O
serum	O
levels	O
of	O
albumin	O
,	O
alanine	B-P
aminotransferase	I-P
and	O
alkaline	B-P
phosphatase	I-P
(	O
OR	O
,	O
4.86	O
(	O
95	O
%	O
CI	O
,	O
1.9-11.9	O
;	O
p-value	O
<	O
0.001	O
)	O
.	O

The	O
association	O
between	O
vitamin	O
D	O
deficiency	O
and	O
abnormal	O
HbA1C	O
in	O
Pakistani	O
diabetic	O
patients	O
is	O
suggestive	O
that	O
patients	O
with	O
hypovitaminosis	O
D	O
could	O
benefit	O
from	O
vitamin	O
D	O
supplementation	O
.	O

Carbon	O
nanotube	O
-based	O
self-adhesive	O
polymer	O
electrodes	O
for	O
wireless	O
long-term	O
recording	O
of	O
electrocardiogram	O
signals	O
.	O

In	O
this	O
study	O
,	O
the	O
concept	O
of	O
polymer	O
electrodes	O
integrated	O
with	O
a	O
wireless	O
electrocardiogram	O
(	O
ECG	O
)	O
system	O
was	O
described	O
.	O

Polymer	O
electrodes	O
for	O
long-term	O
ECG	O
measurements	O
were	O
fabricated	O
by	O
loading	O
high	O
content	O
of	O
carbon	O
nanotubes	O
(	O
CNTs	O
)	O
in	O
polydimethylsiloxane	O
.	O

Silver	O
nanoparticles	O
(	O
Ag	O
NPs	O
)	O
were	O
added	O
to	O
increase	O
the	O
flexibility	O
of	O
the	O
polymer	O
and	O
the	O
conductivity	O
of	O
the	O
electrode	O
.	O

An	O
ECG	O
electrode	O
patch	O
was	O
fabricated	O
by	O
integrating	O
the	O
electrodes	O
with	O
an	O
adhesive	O
polydimethylsiloxane	O
(	O
aPDMS	O
)	O
layer	O
.	O

Holes	O
in	O
the	O
electrode	O
filled	O
with	O
aPDMS	O
can	O
enable	O
robust	O
contact	O
between	O
the	O
electrode	O
and	O
skin	O
,	O
reducing	O
motion	O
artifacts	O
.	O

A	O
wireless	O
ECG	O
measurement	O
system	O
was	O
developed	O
and	O
adapted	O
to	O
the	O
polymer	O
electrodes	O
.	O

The	O
polymer	O
electrodes	O
combined	O
with	O
the	O
measurement	O
system	O
were	O
successfully	O
applied	O
in	O
wireless	O
,	O
long-term	O
recording	O
of	O
ECG	B-P
signals	I-P
.	O

An	O
eleven-	O
day	O
continuous	O
test	O
showed	O
that	O
the	O
ECG	B-P
signal	I-P
did	O
not	O
degrade	O
over	O
time	O
.	O

The	O
results	O
of	O
attach/detach	O
tests	O
demonstrated	O
that	O
the	O
ECG	B-P
signal	I-P
was	O
affected	O
by	O
motion	O
artifacts	O
after	O
six	O
attach/detach	O
cycles	O
.	O

The	O
electrodes	O
produced	O
are	O
flexible	O
and	O
exhibit	O
good	O
ECG	O
performance	O
,	O
and	O
therefore	O
can	O
be	O
used	O
in	O
wearable	O
medical	O
monitoring	O
systems	O
.	O

The	O
approach	O
proposed	O
in	O
this	O
study	O
holds	O
significant	O
promise	O
for	O
commercial	O
application	O
in	O
medical	O
fields	O
.	O

Synthesis	O
of	O
Some	O
Unique	O
Carbamate	O
Derivatives	O
bearing	O
2-Furoyl-1-piperazine	O
as	O
a	O
Valuable	O
Therapeutic	O
Agents	O
.	O

The	O
aim	O
of	O
the	O
research	O
work	O
was	O
to	O
synthesize	O
different	O
biologically	O
active	O
carbamate	O
derivatives	O
bearing	O
2-furoyl-1-piperazine	O
and	O
having	O
modest	O
toxicity	O
.	O

The	O
synthesis	O
was	O
completed	O
as	O
a	O
multiple	O
sequence	O
.	O

The	O
structural	O
confirmation	O
of	O
all	O
the	O
synthesized	O
compounds	O
was	O
obtained	O
by	O
EI-MS	B-P
,	O
IR	B-P
and	O
1H-NMR	B-P
spectral	O
data	O
.	O

The	O
enzyme	O
inhibition	O
and	O
antibacterial	O
potential	O
of	O
the	O
synthesized	O
compounds	O
was	O
evaluated	O
.	O

To	O
find	O
the	O
utility	O
of	O
the	O
prepared	O
compounds	O
as	O
possible	O
therapeutic	O
agents	O
their	O
cytotoxicity	O
was	O
also	O
checked	O
.	O

All	O
the	O
compounds	O
were	O
active	O
against	O
acetylcholinesterase	O
enzyme	O
,	O
especially	O
12	O
and	O
14	O
showed	O
very	O
good	O
inhibitory	O
potential	O
relative	O
to	O
Eserine	O
,	O
a	O
reference	O
standard	O
.	O

Almost	O
all	O
the	O
compounds	O
showed	O
good	O
activities	O
against	O
both	O
Gram-positive	O
and	O
Gram-negative	O
bacterial	O
strains	O
.	O

Secondary	O
Ossification	O
Center	O
Appearance	O
and	O
Closure	O
in	O
the	O
Pelvis	O
and	O
Proximal	O
Femur	O
.	O

Variable	O
ossification	O
patterns	O
of	O
the	O
pelvis	O
in	O
skeletally	O
immature	O
patients	O
can	O
make	O
the	O
interpretation	O
of	O
pelvic	O
radiographs	B-P
challenging	O
.	O

Inconsistencies	O
among	O
prior	O
studies	O
and	O
lack	O
of	O
sex	O
comparisons	O
underscore	O
the	O
need	O
for	O
a	O
more	O
comprehensive	O
characterization	O
of	O
the	O
secondary	O
ossification	O
centers	O
.	O

This	O
study	O
evaluates	O
the	O
chronology	O
and	O
sex	O
differences	O
for	O
appearance	O
and	O
closure	O
of	O
pelvic	O
and	O
proximal	O
femoral	O
secondary	O
ossification	O
centers	O
using	O
computed	B-P
tomography	I-P
(	O
CT	B-P
)	O
.	O

Patients	O
who	O
underwent	O
abdominal	B-P
and	O
pelvic	B-P
CT	I-P
scans	I-P
between	O
January	O
2009	O
and	O
December	O
2014	O
at	O
2	O
tertiary	O
level	O
1	O
trauma	O
centers	O
were	O
retrospectively	O
reviewed	O
.	O

Patients	O
between	O
the	O
ages	O
of	O
2	O
and	O
32	O
years	O
with	O
adequate	O
imaging	B-P
of	O
the	O
pelvis	O
and	O
proximal	O
femurs	O
were	O
included	O
.	O

Patients	O
with	O
a	O
history	O
of	O
orthopaedic	O
trauma	O
or	O
pathology	O
affecting	O
ossification	O
were	O
excluded	O
.	O

CT	B-P
scans	I-P
were	O
assessed	O
for	O
the	O
appearance	O
and	O
closure	O
of	O
the	O
following	O
secondary	O
ossification	O
centers	O
:	O
anterior	O
inferior	O
iliac	O
spine	O
(	O
AIIS	O
)	O
,	O
anterior	O
superior	O
iliac	O
spine	O
(	O
ASIS	O
)	O
,	O
femoral	O
head	O
(	O
FH	O
)	O
,	O
greater	O
trochanter	O
(	O
GT	O
)	O
,	O
iliac	O
crest	O
(	O
IC	O
)	O
,	O
ischial	O
tuberosity	O
(	O
IT	O
)	O
,	O
lesser	O
trochanter	O
(	O
LT	O
)	O
,	O
posterior	O
superior	O
iliac	O
spine	O
(	O
PSIS	O
)	O
,	O
symphysis	O
pubis	O
(	O
SP	O
)	O
,	O
and	O
triradiate	O
cartilage	O
(	O
TRC	O
)	O
.	O

Basic	O
descriptive	O
statistics	O
are	O
reported	O
.	O

A	O
total	O
of	O
496	O
CT	B-P
scans	I-P
met	O
inclusion	O
criteria	O
(	O
240	O
males	O
and	O
256	O
females	O
)	O
.	O

The	O
order	O
of	O
appearance	O
of	O
the	O
secondary	O
ossification	O
centers	O
was	O
:	O
(	O
male	O
)	O
GT	O
,	O
LT	O
,	O
AIIS	O
,	O
IT	O
,	O
ASIS	O
,	O
PSIS	O
,	O
IC	O
,	O
and	O
SP	O
;	O
(	O
female	O
)	O
GT	O
,	O
LT	O
,	O
IT	O
,	O
AIIS	O
,	O
PSIS	O
,	O
IC	O
,	O
ASIS	O
,	O
and	O
SP	O
.	O

The	O
order	O
of	O
closure	O
was	O
similar	O
:	O
(	O
male	O
)	O
TRC	O
,	O
LT	O
,	O
FH	O
,	O
AIIS	O
,	O
GT	O
,	O
ASIS	O
,	O
PSIS	O
,	O
IT	O
,	O
IC	O
,	O
and	O
SP	O
;	O
(	O
female	O
)	O
LT	O
,	O
TRC	O
,	O
AIIS	O
,	O
FH	O
,	O
GT	O
,	O
ASIS	O
,	O
PSIS	O
,	O
IT	O
,	O
IC	O
,	O
and	O
SP	O
.	O

Female	O
ossification	O
centers	O
appeared	O
~1	O
to	O
2	O
years	O
before	O
males	O
in	O
all	O
locations	O
.	O

Female	O
ossification	O
centers	O
closed	O
~1	O
to	O
2	O
years	O
before	O
males	O
in	O
all	O
locations	O
except	O
TRC	O
,	O
IC	O
,	O
and	O
SP	O
.	O

The	O
appearance	O
and	O
closure	O
of	O
the	O
pelvis	O
and	O
proximal	O
femur	O
secondary	O
ossification	O
centers	O
follow	O
a	O
predictable	O
pattern	O
of	O
development	O
,	O
occurring	O
slightly	O
earlier	O
in	O
females	O
than	O
males	O
.	O

Knowledge	O
of	O
more	O
precise	O
ages	O
of	O
developmen	O
t	O
and	O
sex	O
differences	O
better	O
characterize	O
this	O
complex	O
skeletal	O
development	O
.	O

Future	O
studies	O
may	O
use	O
secondary	O
ossification	O
centers	O
to	O
further	O
evaluate	O
skeletal	B-P
maturity	I-P
,	O
assess	O
pediatric	O
pathology	O
,	O
and	O
aid	O
surgical	O
management	O
.	O

Level	O
III	O
.	O

Biochemical	O
studies	O
of	O
amylase	O
,	O
lipase	O
and	O
protease	O
in	O
Callosobruchus	O
maculatus	O
(	O
Coleoptera	O
:	O
Chrysomelidae	O
)	O
populations	O
fed	O
with	O
Vigna	O
unguiculata	O
grain	O
cultivated	O
with	O
diazotrophic	O
bacteria	O
strains	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
enzymatic	O
activity	O
of	O
homogenates	O
of	O
insects	O
fed	O
on	O
grain	O
of	O
cowpea	O
,	O
Vigna	O
unguiculata	O
(	O
L.	O
)	O
,	O
cultivars	O
grown	O
with	O
different	O
nitrogen	O
sources	O
.	O

For	O
the	O
experiment	O
we	O
used	O
aliquots	O
of	O
the	O
homogenate	O
of	O
100	O
unsexed	O
adult	O
insects	O
,	O
emerged	O
from	O
10	O
g	O
of	O
grain	O
obtained	O
from	O
four	O
cowpea	O
cultivars	O
:	O
'	O
BRS	O
Acauã	O
'	O
,	O
'	O
BRS	O
Carijó	O
'	O
,	O
'	O
BRS	O
Pujante	O
'	O
,	O
and	O
'	O
BRS	O
Tapaihum	O
'	O
grown	O
under	O
different	O
regimes	O
of	O
nitrogen	O
sources	O
:	O
mineral	O
fertilizer	O
,	O
inoculation	B-P
with	O
strains	O
of	O
diazotrophs	O
(	O
BR	O
3267	O
,	O
BR	O
3262	O
,	O
BR	O
3299	O
;	O
INPA	O
03-11B	O
,	O
03-84	O
UFLA	O
,	O
as	O
well	O
as	O
the	O
control	O
(	O
with	O
soil	O
nitrogen	O
)	O
.	O

The	O
parameters	O
evaluated	O
were	O
enzymatic	O
activities	O
of	O
insect	O
protease	O
,	O
amylase	O
and	O
lipase	O
and	O
the	O
starch	O
content	O
of	O
the	O
grains	O
.	O

There	O
were	O
differences	O
in	O
the	O
enzymatic	O
activity	O
of	O
amylase	O
,	O
lipase	O
and	O
protease	O
of	O
insect	O
homogenate	O
according	O
to	O
the	O
food	O
source	O
.	O

A	O
lower	O
activity	O
of	O
the	O
enzyme	O
amylase	O
from	O
C.	O
maculatus	O
homogenate	O
was	O
observed	O
when	O
insects	O
were	O
fed	O
grain	O
of	O
the	O
cultivar	O
BRS	O
Carijó	O
.	O

A	O
lower	O
activity	O
of	O
lipase	O
enzyme	O
from	O
C.	O
maculatus	O
homogenate	O
was	O
observed	O
when	O
the	O
insects	O
fed	O
on	O
grain	O
from	O
the	O
interaction	O
of	O
the	O
cultivar	O
Tapaihum	O
inoculated	O
with	O
BR	O
3262	O
diazotrophs	O
.	O

The	O
lowest	O
proteolytic	O
activity	O
was	O
observed	O
in	O
homogenate	O
of	O
insects	O
fed	O
on	O
interaction	O
of	O
'	O
BRS	O
Carijó	O
'	O
inoculated	O
with	O
BR	O
3262	O
diazotroph	O
s.	O
Starch	O
content	O
correlated	O
positively	O
with	O
the	O
amylase	O
activity	O
of	O
C.	O
maculatus	O
homogenate	O
.	O

The	O
cultivar	O
BRS	O
Carijó	O
had	O
a	O
different	O
behavior	O
from	O
the	O
other	O
cultivars	O
,	O
according	O
to	O
the	O
cluster	O
analysis	O
.	O

Narcolepsy	O
Following	O
Yellow	O
Fever	O
Vaccination	O
:	O
A	O
Case	O
Report	O
.	O

Narcolepsy	O
with	O
cataplexy	O
is	O
a	O
rare	O
,	O
but	O
important	O
differential	B-P
diagnosis	I-P
for	O
daytime	O
sleepiness	O
and	O
atonic	O
paroxysms	O
in	O
an	O
adolescent	O
.	O

A	O
recent	O
increase	O
in	O
incidence	O
in	O
the	O
pediatric	O
age	O
group	O
probably	O
linked	O
to	O
the	O
use	O
of	O
the	O
Pandemrix	O
influenza	O
vaccine	O
in	O
2009	O
,	O
has	O
increased	O
awareness	O
that	O
different	O
environmental	O
factors	O
can	O
``	O
trigger	O
''	O
narcolepsy	O
with	O
cataplexy	O
in	O
a	O
genetically	O
susceptible	O
population	O
.	O

Here	O
,	O
we	O
describe	O
the	O
case	O
of	O
a	O
13-year-old	O
boy	O
with	O
narcolepsy	O
following	O
yellow	O
fever	O
vaccination	O
.	O

He	O
carries	O
the	O
HLA	O
DQB1*0602	O
haplotype	O
strongly	O
associated	O
with	O
narcolepsy	O
and	O
cataplexy	O
.	O

Polysomnography	B-P
showed	O
rapid	O
sleep	O
onset	O
with	O
rapid	O
eye	O
movement	O
(	O
REM	O
)	O
latency	O
of	O
47	O
min	O
,	O
significant	O
sleep	O
fragmentation	O
and	O
a	O
mean	O
sleep	O
latency	O
of	O
1.6	O
min	O
with	O
sleep	O
onset	O
REM	O
in	O
four	O
out	O
of	O
four	O
nap	O
periods	O
.	O

Together	O
with	O
the	O
clinical	O
history	O
,	O
these	O
findings	O
are	O
diagnostic	O
of	O
narcolepsy	O
type	O
1	O
.	O

The	O
envelope	O
protein	O
E	O
of	O
the	O
yellow	O
fever	O
vaccine	O
strain	O
17D	O
has	O
significant	O
amino	O
acid	O
sequence	O
overlap	O
with	O
both	O
hypocretin	O
and	O
the	O
hypocretin	O
receptor	O
2	O
receptors	O
in	O
protein	O
regions	O
that	O
are	O
predicted	O
to	O
act	O
as	O
epitopes	O
for	O
antibody	O
production	O
.	O

These	O
findings	O
raise	O
the	O
question	O
whether	O
the	O
yellow	O
fever	O
vaccine	O
strain	O
may	O
,	O
through	O
a	O
potential	O
molecular	O
mimicry	O
mechanism	O
,	O
be	O
another	O
infectious	O
trigger	O
for	O
this	O
neuro-immunological	O
disorder	O
.	O

Cannabis	O
use	O
is	O
associated	O
with	O
reduced	O
prevalence	O
of	O
non-alcoholic	O
fatty	O
liver	O
disease	O
:	O
A	O
cross-sectional	O
study	O
.	O

Cannabis	O
use	O
is	O
associated	O
with	O
reduced	O
prevalence	O
of	O
obesity	O
and	O
diabetes	O
mellitus	O
(	O
DM	O
)	O
in	O
humans	O
and	O
mouse	O
disease	O
models	O
.	O

Obesity	O
and	O
DM	O
are	O
a	O
well-established	O
independent	O
risk	O
factor	O
for	O
non-alcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFLD	O
)	O
,	O
the	O
most	O
prevalent	O
liver	O
disease	O
globally	O
.	O

The	O
effects	O
of	O
cannabis	O
use	O
on	O
NAFLD	O
prevalence	O
in	O
humans	O
remains	O
ill-defined	O
.	O

Our	O
objective	O
is	O
to	O
determine	O
the	O
relationship	O
between	O
cannabis	O
use	O
and	O
the	O
prevalence	O
of	O
NAFLD	O
in	O
humans	O
.	O

We	O
conducted	O
a	O
population-based	O
case-control	O
study	O
of	O
5,950,391	O
patients	O
using	O
the	O
2014	O
Healthcare	O
Cost	O
and	O
Utilization	O
Project	O
(	O
HCUP	O
)	O
,	O
Nationwide	O
Inpatient	O
Survey	O
(	O
NIS	O
)	O
discharge	O
records	O
of	O
patients	O
18	O
years	O
and	O
older	O
.	O

After	O
identifying	O
patients	O
with	O
NAFLD	O
(	O
1	O
%	O
of	O
all	O
patients	O
)	O
,	O
we	O
next	O
identified	O
three	O
exposure	O
groups	O
:	O
non-cannabis	O
users	O
(	O
98.04	O
%	O
)	O
,	O
non-dependent	O
cannabis	O
users	O
(	O
1.74	O
%	O
)	O
,	O
and	O
dependent	O
cannabis	O
users	O
(	O
0.22	O
%	O
)	O
.	O

We	O
adjusted	O
for	O
potential	O
demographics	O
and	O
patient	O
related	O
confounders	O
and	O
used	O
multivariate	O
logistic	O
regression	O
(	O
SAS	O
9.4	O
)	O
to	O
determine	O
the	O
odds	O
of	O
developing	O
NAFLD	O
with	O
respects	O
to	O
cannabis	O
use	O
.	O

Our	O
findings	O
revealed	O
that	O
cannabis	O
users	O
(	O
dependent	O
and	O
non-dependent	O
)	O
showed	O
significantly	O
lower	O
NAFLD	O
prevalence	O
compared	O
to	O
non-users	O
(	O
AOR	O
:	O
0.82	O
[	O
0.76-0.88	O
]	O
;	O
p	O
<	O
0.0001	O
)	O
.	O

The	O
prevalence	O
of	O
NAFLD	O
was	O
15	O
%	O
lower	O
in	O
non-dependent	O
users	O
(	O
AOR	O
:	O
0.85	O
[	O
0.79-0.92	O
]	O
;	O
p	O
<	O
0.0001	O
)	O
and	O
52	O
%	O
lower	O
in	O
dependent	O
users	O
(	O
AOR	O
:	O
0.49	O
[	O
0.36-0.65	O
]	O
;	O
p	O
<	O
0.0001	O
)	O
.	O

Among	O
cannabis	O
users	O
,	O
dependent	O
patients	O
had	O
43	O
%	O
significantly	O
lower	O
prevalence	O
of	O
NAFLD	O
compared	O
to	O
non-dependent	O
patients	O
(	O
AOR	O
:	O
0.57	O
[	O
0.42-0.77	O
]	O
;	O
p	O
<	O
0.0001	O
)	O
.	O

Our	O
observations	O
suggest	O
that	O
cannabis	O
use	O
is	O
associated	O
with	O
lower	O
prevalence	O
of	O
NAFLD	O
in	O
patients	O
.	O

These	O
novel	O
findings	O
suggest	O
additional	O
molecular	B-P
mechanistic	I-P
studies	I-P
to	O
explore	O
the	O
potential	O
role	O
of	O
cannabis	O
use	O
in	O
NAFLD	O
development	O
.	O

The	O
Effect	O
of	O
Image	O
Review	O
before	O
Patient	O
Discharge	O
on	O
Study	O
Completeness	O
and	O
Sonographer	O
Job	O
Satisfaction	O
in	O
a	O
Pediatric	B-P
Echocardiographic	I-P
Laboratory	O
.	O

Incomplete	O
echocardiographic	B-P
assessment	O
accounts	O
for	O
approximately	O
10	O
%	O
of	O
preventable	O
diagnostic	O
errors	O
and	O
may	O
place	O
children	O
at	O
risk	O
for	O
adverse	O
outcomes	O
or	O
increased	O
testing	B-P
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
physician	O
review	O
of	O
images	O
improves	O
study	O
completeness	O
.	O

A	O
prospective	O
quality	O
improvement	O
(	O
QI	O
)	O
study	O
initiated	O
physician	O
review	O
of	O
first-time	O
echocardiographic	B-P
studies	O
for	O
completeness	O
before	O
patient	O
discharge	O
.	O

Studies	O
were	O
incomplete	O
if	O
not	O
all	O
anatomic	O
structures	O
were	O
diagnostically	O
demonstrated	O
.	O

QI	O
examinations	O
were	O
compared	O
with	O
controls	O
obtained	O
before	O
study	O
initiation	O
.	O

Demographic	O
and	O
clinical	O
information	O
and	O
duration	O
of	O
scan	B-P
were	O
collected	O
during	O
the	O
control	O
and	O
QI	O
periods	O
.	O

An	O
anonymous	O
survey	O
was	O
administered	O
to	O
the	O
sonographers	O
to	O
assess	O
perceptions	O
of	O
the	O
intervention	O
.	O

There	O
were	O
no	O
differences	O
between	O
the	O
QI	O
(	O
n	O
=	O
63	O
)	O
and	O
control	O
(	O
n	O
=	O
63	O
)	O
groups	O
in	O
age	O
,	O
height	O
,	O
weight	O
,	O
and	O
technical	O
barriers	O
.	O

After	O
study	O
completion	O
,	O
35	O
%	O
of	O
control	O
scans	B-P
versus	O
5	O
%	O
of	O
QI	O
scans	B-P
were	O
incomplete	O
(	O
P	O
<	O
.001	O
)	O
.	O

In	O
the	O
QI	O
group	O
,	O
the	O
sonographer	O
,	O
physician	O
,	O
or	O
both	O
returned	O
to	O
scan	B-P
in	O
12	O
(	O
19	O
%	O
)	O
,	O
nine	O
(	O
14	O
%	O
)	O
,	O
and	O
two	O
(	O
3	O
%	O
)	O
studies	O
,	O
respectively	O
.	O

QI	O
studies	O
were	O
longer	O
than	O
control	O
studies	O
(	O
44	O
vs	O
36	O
min	O
,	O
P	O
=	O
.003	O
)	O
before	O
review	O
.	O

Physician	O
review	O
added	O
a	O
median	O
of	O
6	O
min	O
(	O
range	O
,	O
1-28	O
min	O
)	O
.	O

The	O
majority	O
of	O
sonographers	O
believed	O
that	O
immediate	O
review	O
improved	O
communication	O
,	O
and	O
50	O
%	O
believed	O
that	O
it	O
improved	O
their	O
job	O
satisfaction	O
.	O

Review	O
of	O
initial	O
outpatient	O
echocardiographic	B-P
examinations	O
before	O
patient	O
discharge	O
significantly	O
improves	O
study	O
completeness	O
.	O

Review	O
adds	O
a	O
nominal	O
amount	O
of	O
time	O
to	O
total	O
study	O
duration	O
,	O
improves	O
sonographer	O
-	O
physician	O
communication	O
,	O
and	O
may	O
prevent	O
unnecessary	O
testing	B-P
,	O
potentially	O
reducing	O
the	O
cost	O
of	O
care	O
.	O

L-asparaginase	O
-	O
induced	O
abnormality	O
in	O
plasma	O
glucose	O
level	O
in	O
patients	O
of	O
acute	O
lymphoblastic	O
leukemia	O
admitted	O
to	O
a	O
tertiary	O
care	O
hospital	O
of	O
Odisha	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
any	O
abnormal	O
change	O
in	O
plasma	O
glucose	O
levels	O
in	O
patients	O
treated	O
with	O
L-asparaginase	O
(	O
L-Asp	O
)	O
-based	O
chemotherapy	O
regimen	O
in	O
patients	O
of	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
.	O

This	O
retrospective	O
,	O
hospital-based	O
study	O
was	O
conducted	O
in	O
patients	O
of	O
ALL	O
,	O
admitted	O
to	O
the	O
Clinical	O
Haematology	O
Department	O
of	O
a	O
tertiary	O
care	O
hospital	O
of	O
Odisha	O
from	O
August	O
2014	O
to	O
July	O
2015	O
.	O

Indoor	O
records	O
of	O
146	O
patients	O
on	O
multi-centered	O
protocol-841	O
were	O
evaluated	O
for	O
any	O
alteration	O
in	O
plasma	O
glucose	O
level	O
,	O
time	O
of	O
onset	O
of	O
hypo	O
/	O
hyperglycemia	O
,	O
and	O
persistence	O
of	O
plasma	B-P
glucose	I-P
alteration	O
.	O

Twenty-one	O
percent	O
of	O
patients	O
showed	O
abnormal	O
plasma	O
glucose	O
level	O
.	O

Most	O
of	O
these	O
patients	O
developed	O
hypoglycemia	O
and	O
were	O
of	O
lower	O
age	O
group	O
.	O

Most	O
of	O
these	O
patients	O
developed	O
hypoglycemia	O
and	O
were	O
of	O
lower	O
age	O
group	O
,	O
whereas	O
a	O
majority	O
of	O
higher	O
age	O
group	O
patients	O
developed	O
hyperglycemia	O
.	O

In	O
majority	O
of	O
the	O
cases	O
,	O
abnormal	O
glucose	O
developed	O
after	O
three	O
doses	O
of	O
L-Asp	O
.	O

Hypoglycemia	O
subsided	O
whereas	O
hyperglycemia	O
persisted	O
till	O
the	O
end	O
of	O
our	O
observation	O
period	O
.	O

L-Asp	O
produces	O
more	O
incidences	O
of	O
hypoglycemia	O
than	O
hyperglycemia	O
in	O
a	O
good	O
number	O
of	O
ALL	O
patients	O
towards	O
which	O
clinicians	O
should	O
be	O
more	O
vigilant	O
.	O

However	O
,	O
hyperglycemia	O
persists	O
for	O
a	O
longer	O
duration	O
than	O
hypoglycemia	O
.	O

Clinical	O
course	O
and	O
therapeutic	O
outcomes	O
of	O
operatively	O
and	O
non-operatively	O
managed	O
patients	O
with	O
denosumab	O
-related	O
osteonecrosis	O
of	O
the	O
jaw	O
(	O
DRONJ	O
)	O
.	O

Details	O
regarding	O
risk	O
factors	O
,	O
onset	O
,	O
and	O
outcomes	O
for	O
denosumab	O
-related	O
osteonecrosis	O
(	O
DRONJ	O
)	O
are	O
sparse	O
.	O

This	O
study	O
examines	O
the	O
clinical	O
characteristics	O
and	O
operative	O
and	O
non-operative	O
therapeutic	O
outcomes	O
in	O
patients	O
with	O
DRONJ	O
not	O
previously	O
exposed	O
to	O
other	O
antiresorptives	O
.	O

A	O
retrospective	O
medical	O
record	O
review	O
was	O
conducted	O
,	O
and	O
data	O
were	O
collected	O
,	O
including	O
clinical	O
findings	O
,	O
management	O
,	O
healing	O
outcomes	O
,	O
and	O
radiologic	O
,	O
histologic	O
,	O
and	O
micro-computed	B-P
tomography	I-P
(	O
CT	B-P
)	O
analyses	O
.	O

Seventeen	O
patients	O
were	O
treated	O
with	O
denosumab	O
,	O
with	O
14.1	O
±	O
8.3	O
doses	O
before	O
DRONJ	O
onset	O
.	O

The	O
majority	O
of	O
lesions	O
were	O
observed	O
at	O
sites	O
of	O
dental	O
prostheses	O
(	O
41	O
%	O
)	O
and	O
dental	O
extractions	O
(	O
35	O
%	O
)	O
.	O

Sixteen	O
patients	O
were	O
managed	O
non-operatively	O
(	O
10/16	O
)	O
or	O
operatively	O
(	O
6/16	O
)	O
with	O
either	O
major	O
(	O
5/6	O
)	O
or	O
minor	O
surgery	O
(	O
1/6	O
)	O
and	O
included	O
in	O
the	O
follow-up	O
analysis	O
.	O

Complete	O
healing	O
was	O
significant	O
in	O
patients	O
treated	O
with	O
major	O
surgery	O
(	O
80	O
%	O
)	O
compared	O
to	O
the	O
non-operative	O
group	O
(	O
20	O
%	O
;	O
p	O
<	O
0.035	O
)	O
.	O

Denosumab	O
was	O
discontinued	O
in	O
60	O
%	O
of	O
non-operative	O
patients	O
and	O
major	O
surgery	O
patients	O
with	O
no	O
effect	O
on	O
healing	O
.	O

Histologic	O
findings	O
of	O
4	O
patients	O
analyzed	O
exhibited	O
a	O
decreased	O
number	O
of	O
osteocyte	O
lacunae	O
,	O
and	O
micro-CT	B-P
of	O
3	O
patients	O
scanned	B-P
revealed	O
trabecular	O
thickening	O
.	O

DRONJ	O
lesions	O
occurred	O
mostly	O
at	O
sites	O
of	O
prostheses	O
sores	O
after	O
a	O
mean	O
of	O
14	O
doses	O
of	O
denosumab	O
.	O

Major	O
surgery	O
demonstrated	O
more	O
complete	O
healing	O
than	O
non-operative	O
management	O
,	O
and	O
denosumab	O
cessation	O
did	O
not	O
improve	O
healing	O
outcomes	O
.	O

Xylan-based	O
temperature	O
/	O
pH	O
sensitive	O
hydrogels	O
for	O
drug	O
controlled	O
release	O
.	O

Xylan-based	O
temperature	O
/	O
pH	O
sensitive	O
hydrogels	O
were	O
prepared	O
by	O
the	O
crosslinking	O
copolymerization	O
of	O
xylan	O
with	O
N-isopropylacrylamide	O
(	O
NIPAm	O
)	O
and	O
acrylic	O
acid	O
(	O
AA	O
)	O
using	O
N	O
,	O
Ń-methylenebis-acrylamide	O
(	O
MBA	O
)	O
as	O
a	O
cross-linker	O
and	O
2,2-dimethoxy-2-phenylacetophenone	O
as	O
a	O
photoinitiator	O
via	O
ultraviolet	O
irradiation	O
.	O

The	O
influence	O
of	O
the	O
NIPAm	O
,	O
AA	O
and	O
MBA	O
amount	O
on	O
properties	O
of	O
xylan-based	O
hydrogels	O
was	O
discussed	O
.	O

The	O
morphology	O
and	O
interactions	O
of	O
hydrogels	O
were	O
characterized	O
by	O
SEM	B-P
and	O
FTIR	O
.	O

The	O
lower	O
critical	O
solution	O
temperature	O
(	O
LCST	O
)	O
of	O
hydrogels	O
was	O
investigated	O
by	O
DSC	B-P
.	O

The	O
results	O
indicated	O
that	O
the	O
LCST	O
of	O
hydrogels	O
emerged	O
at	O
around	O
34°C	O
and	O
increased	O
with	O
increasing	O
the	O
AA	O
content	O
.	O

The	O
drug	O
encapsulation	O
efficiency	O
of	O
as-prepared	O
hydrogels	O
reached	O
to	O
97.60	O
%	O
and	O
the	O
cumulative	O
release	O
rate	O
of	O
acetylsalicylic	O
acid	O
was	O
90.12	O
%	O
and	O
26.35	O
%	O
in	O
the	O
intestinal	O
and	O
gastric	O
fluid	O
,	O
respectively	O
.	O

Xylan-based	O
hydrogels	O
were	O
proved	O
to	O
be	O
biocompatible	O
with	O
NIH3T3	O
cell	O
by	O
MTT	O
assay	O
and	O
showed	O
the	O
promising	O
application	O
as	O
drug	O
carriers	O
for	O
the	O
intestinal	O
-	O
targeted	O
oral	O
drug	O
delivery	O
.	O

The	O
relationship	O
between	O
social	O
functioning	O
and	O
subjective	O
memory	O
complaints	O
in	O
older	O
persons	O
:	O
a	O
population	O
-based	O
longitudinal	O
cohort	O
study	O
.	O

Poor	O
social	O
functioning	O
is	O
associated	O
with	O
cognitive	O
decline	O
in	O
older	O
adults	O
.	O

It	O
is	O
unclear	O
whether	O
social	O
functioning	O
is	O
also	O
associated	O
with	O
subjective	O
memory	O
complaints	O
(	O
SMC	O
)	O
.	O

We	O
investigated	O
the	O
association	O
between	O
social	O
functioning	O
and	O
incident	O
SMC	O
and	O
SMC	O
recovery	O
.	O

A	O
population	O
-based	O
sample	O
of	O
8762	O
older	O
adults	O
(	O
aged	O
≥65	O
years	O
)	O
with	O
good	O
objective	O
cognitive	O
functioning	O
at	O
baseline	O
(	O
MMSE	B-P
≥26	O
)	O
from	O
the	O
LifeLines	O
Cohort	O
Study	O
were	O
followed	O
for	O
1.5	O
years	O
.	O

Self-reported	O
SMC	O
were	O
measured	O
at	O
baseline	O
and	O
after	O
1.5	O
years	O
follow-up	O
.	O

Aspects	O
of	O
social	O
functioning	O
included	O
marital	O
status	O
,	O
household	O
composition	O
,	O
social	O
network	O
size	O
,	O
social	O
activity	O
,	O
quality	O
of	O
social	O
relationships	O
,	O
social	O
support	O
,	O
affection	O
,	O
behavioral	O
confirmation	O
,	O
and	O
status	O
.	O

Thirteen	O
percent	O
(	O
513/3963	O
)	O
developed	O
SMC	O
during	O
follow-up	O
(	O
incident	O
SMC	O
)	O
.	O

Multivariate	O
logistic	O
regression	O
analyses	O
(	O
adjusted	O
for	O
age	O
,	O
gender	O
,	O
education	O
level	O
,	O
physical	O
activity	O
,	O
alcohol	O
use	O
,	O
smoking	O
status	O
,	O
depression	O
,	O
arrhythmia	O
,	O
myocardial	O
infarction	O
,	O
heart	O
failure	O
,	O
stroke	O
)	O
showed	O
that	O
participants	O
with	O
better	O
feelings	O
of	O
affection	O
,	O
behavioral	O
confirmation	O
and	O
stable	O
good	O
social	O
support	O
had	O
a	O
lower	O
risk	O
of	O
incident	O
SMC	O
.	O

Thirty-four	O
percent	O
(	O
1632/4799	O
)	O
reported	O
recovery	O
.	O

Participants	O
with	O
good	O
social	O
functioning	O
at	O
baseline	O
on	O
all	O
determinants	O
reported	O
more	O
SMC	O
recovery	O
.	O

People	O
who	O
remained	O
stable	O
in	O
a	O
relationship	O
,	O
stable	O
in	O
good	O
quality	O
of	O
social	O
relationships	O
or	O
increased	O
in	O
quality	O
of	O
social	O
relationships	O
more	O
often	O
report	O
SMC	O
recovery	O
.	O

Good	O
social	O
functioning	O
is	O
associated	O
with	O
less	O
incident	O
SMC	O
and	O
more	O
SMC	O
recovery	O
over	O
a	O
follow-up	O
period	O
of	O
1.5	O
years	O
.	O

Albeit	O
future	O
confirmative	O
studies	O
are	O
needed	O
,	O
we	O
argue	O
for	O
targeting	O
also	O
social	O
functioning	O
when	O
designing	O
multidomain	O
interventions	O
to	O
prevent	O
or	O
slow	O
down	O
cognitive	O
decline	O
.	O

Copyright	O
©	O
2016	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

Straight	O
configuration	O
saphenous	O
vein	O
transposition	O
to	O
popliteal	O
artery	O
for	O
vascular	O
access	O
.	O

The	O
saphenous	O
vein	O
is	O
commonly	O
used	O
as	O
a	O
vascular	O
graft	O
in	O
peripheral	O
artery	O
surgery	O
but	O
rarely	O
used	O
for	O
vascular	O
access	O
.	O

The	O
literature	O
on	O
straight	O
configuration	O
saphenous	O
vein	O
transposition	O
to	O
the	O
popliteal	O
artery	O
is	O
scarce	O
.	O

Here	O
we	O
present	O
two	O
cases	O
of	O
straight	O
configuration	O
saphenous	O
vein	O
transposition	O
to	O
the	O
popliteal	O
artery	O
for	O
vascular	O
access	O
,	O
the	O
surgical	B-P
technique	I-P
and	O
respective	O
follow-up	O
.	O

Two	O
young	O
men	O
,	O
aged	O
29	O
and	O
36	O
years	O
,	O
were	O
chosen	O
for	O
lower-limb	O
vascular	O
access	O
for	O
hemodialysis	O
.	O

The	O
first	O
patient	O
was	O
paraplegic	O
since	O
birth	O
.	O

He	O
used	O
his	O
arms	O
to	O
move	O
so	O
upper	O
extremity	O
vascular	O
access	O
was	O
avoided	O
.	O

The	O
second	O
patient	O
presented	O
with	O
an	O
infected	O
upper	O
extremity	O
arteriovenous	O
graft	O
(	O
AVG	O
)	O
and	O
after	O
multiple	O
closed	O
AVFs	O
he	O
had	O
no	O
more	O
available	O
arm	O
veins	O
.	O

Both	O
patients	O
received	O
autologous	O
lower	O
extremity	O
straight	O
configuration	O
saphenous	O
vein	O
transpositions	O
to	O
the	O
popliteal	O
artery	O
under	O
spinal	O
anesthesia	O
in	O
May	O
and	O
October	O
2012	O
,	O
respectively	O
.	O

Cannulation	O
of	O
the	O
fistula	O
was	O
allowed	O
after	O
one	O
month	O
.	O

There	O
were	O
no	O
early	O
complications	O
.	O

Slight	O
swelling	O
on	O
the	O
leg	O
appeared	O
in	O
one	O
of	O
the	O
patients	O
.	O

Both	O
fistulas	O
were	O
still	O
functional	O
after	O
36	O
and	O
32	O
months	O
,	O
respectively	O
.	O

The	O
straight	O
configuration	O
saphenous	O
vein	O
transposition	O
to	O
popliteal	O
artery	O
is	O
simple	O
to	O
perform	O
,	O
offers	O
a	O
long	O
and	O
straight	O
segment	O
for	O
cannulation	O
and	O
may	O
be	O
a	O
suitable	O
autologous	O
vascular	O
access	O
in	O
selected	O
patients	O
.	O

Prolyl-4-hydroxylase	O
2	O
and	O
3	O
coregulate	O
murine	O
erythropoietin	O
in	O
brain	O
pericytes	O
.	O

A	O
classic	O
response	O
to	O
systemic	O
hypoxia	O
is	O
the	O
increased	O
production	O
of	O
red	O
blood	O
cells	O
due	O
to	O
hypoxia-inducible	O
factor	O
(	O
HIF	O
)	O
-mediated	O
induction	O
of	O
erythropoietin	O
(	O
EPO	O
)	O
.	O

EPO	O
is	O
a	O
glycoprotein	O
hormone	O
that	O
is	O
essential	O
for	O
normal	O
erythropoiesis	O
and	O
is	O
predominantly	O
synthesized	O
by	O
peritubular	O
renal	O
interstitial	O
fibroblast-like	O
cells	O
,	O
which	O
express	O
cellular	O
markers	O
characteristic	O
of	O
neuronal	O
cells	O
and	O
pericytes	O
.	O

To	O
investigate	O
whether	O
the	O
ability	O
to	O
synthesize	O
EPO	O
is	O
a	O
general	O
functional	O
feature	O
of	O
pericytes	O
,	O
we	O
used	O
conditional	O
gene	O
targeting	O
to	O
examine	O
the	O
von	O
Hippel-Lindau	O
/	O
prolyl-4-hydroxylase	O
domain	O
(	O
PHD	O
)	O
/HIF	O
axis	O
in	O
cell	O
-	O
expressing	O
neural	O
glial	O
antigen	O
2	O
,	O
a	O
known	O
molecular	O
marker	O
of	O
pericytes	O
in	O
multiple	O
organs	O
.	O

We	O
found	O
that	O
pericytes	O
in	O
the	O
brain	O
synthesized	O
EPO	O
in	O
mice	O
with	O
genetic	O
HIF	O
activation	O
and	O
were	O
capable	O
of	O
responding	O
to	O
systemic	O
hypoxia	O
with	O
the	O
induction	O
of	O
Epo	O
.	O

Using	O
high-resolution	B-P
multiplex	O
in	O
situ	O
hybridization	O
,	O
we	O
determined	O
that	O
brain	O
pericytes	O
represent	O
an	O
important	O
cellular	O
source	O
of	O
Epo	O
in	O
the	O
hypoxic	O
brain	O
(	O
up	O
to	O
70	O
%	O
of	O
all	O
Epo	O
-	O
expressing	O
cells	O
)	O
.	O

We	O
furthermore	O
determined	O
that	O
Epo	O
transcription	O
in	O
brain	O
pericytes	O
was	O
HIF-2	O
dependent	O
and	O
cocontrolled	O
by	O
PHD2	O
and	O
PHD3	O
,	O
oxygen	O
-	O
and	O
2-oxoglutarate	O
-dependent	O
prolyl-4-hydroxylases	O
that	O
regulate	O
HIF	O
activity	O
.	O

In	O
summary	O
,	O
our	O
studies	O
provide	O
experimental	O
evidence	O
that	O
pericytes	O
in	O
the	O
brain	O
have	O
the	O
ability	O
to	O
function	O
as	O
oxygen	O
sensors	O
and	O
respond	O
to	O
hypoxia	O
with	O
EPO	O
synthesis	O
.	O

Our	O
findings	O
furthermore	O
suggest	O
that	O
the	O
ability	O
to	O
synthesize	O
EPO	O
may	O
represent	O
a	O
functional	O
feature	O
of	O
pericytes	O
in	O
the	O
brain	O
and	O
kidney	O
.	O

Combination	O
of	O
diagnostic	B-P
laparoscopy	I-P
and	O
intraoperative	O
indocyanine	B-P
green	I-P
fluorescence	I-P
angiography	I-P
for	O
the	O
early	B-P
detection	I-P
of	O
intestinal	O
ischemia	O
not	O
detectable	O
at	O
CT	B-P
scan	I-P
.	O

Acute	O
mesenteric	O
ischemia	O
is	O
the	O
most	O
severe	O
gastrointestinal	O
complication	O
of	O
acute	O
aortic	O
dissection	O
.	O

The	O
timing	O
of	O
diagnosis	O
is	O
of	O
major	O
importance	O
,	O
in	O
fact	O
the	O
recognition	O
of	O
acute	O
mesenteric	O
ischemia	O
often	O
occurs	O
too	O
late	O
due	O
to	O
the	O
presence	O
of	O
unspecific	O
symptoms	O
and	O
lack	O
of	O
reliable	O
exams	O
.	O

Recently	O
,	O
indocyanine	B-P
green	I-P
fluorescence	I-P
angiography	I-P
has	O
been	O
adopted	O
in	O
order	O
to	O
measure	O
blood	O
perfusion	O
and	O
microcirculation	O
.	O

We	O
decided	O
to	O
perform	O
a	O
diagnostic	B-P
laparoscopy	I-P
with	O
the	O
support	O
of	O
intra-operative	O
near-infrared	O
indocyanine	B-P
green	I-P
fluorescence	I-P
angiography	I-P
,	O
in	O
order	O
to	O
detect	O
an	O
initial	O
intestinal	O
ischemia	O
in	O
a	O
68-year-old	O
patient	O
previously	O
treated	O
with	O
a	O
TEVAR	O
procedure	O
for	O
a	O
type-B	O
aortic	O
dissection	O
.	O

The	O
fluorescence	B-P
system	I-P
demonstrated	O
an	O
hypoperfused	O
area	O
in	O
the	O
ascending	O
colon	O
,	O
therefore	O
an	O
ileocholic	O
resection	O
was	O
thus	O
performed	O
.	O

Opening	O
the	O
operatory	O
specimen	O
,	O
the	O
mucosa	O
of	O
the	O
colon	O
appeared	O
totally	O
ischemic	O
,	O
whilst	O
the	O
serosa	O
was	O
normal	O
.	O

When	O
ischemia	O
occurs	O
,	O
the	O
oxygen	O
supply	O
is	O
interrupted	O
,	O
hence	O
the	O
necrosis	O
of	O
the	O
enteral	O
mucosa	O
occurs	O
within	O
3h	O
,	O
whilst	O
the	O
necrosis	O
of	O
the	O
full	O
thickness	O
of	O
the	O
bowel	O
wall	O
occurs	O
within	O
6h	O
.	O

A	O
diagnosis	O
during	O
these	O
``	O
golden	O
hours	O
``	O
is	O
of	O
major	O
importance	O
for	O
a	O
successful	O
treatment	O
.	O

The	O
combination	O
of	O
laparoscopy	B-P
and	O
UV	O
light	O
and	O
fluorescein	O
dye	O
should	O
be	O
considered	O
as	O
an	O
invaluable	O
diagnostic	B-P
procedure	I-P
for	O
the	O
diagnosis	O
of	O
early	O
stage	O
acute	O
bowel	O
ischemia	O
which	O
is	O
not	O
visible	O
at	O
instrumental	O
examinations	O
nor	O
with	O
diagnostic	B-P
laparoscopy	I-P
.	O

Influence	O
of	O
Sinus	O
Floor	O
Configuration	O
on	O
the	O
Grafted	O
Bone	O
Remodeling	O
Following	O
Osteotome	O
Sinus	O
Floor	O
Elevation	O
.	O

This	O
study	O
investigated	O
the	O
influence	O
of	O
the	O
sinus	O
floor	O
configuration	O
on	O
the	O
dimensional	O
stability	O
of	O
grafted	O
bone	O
height	O
following	O
the	O
osteotome	O
sinus	O
grafting	O
procedure	O
.	O

Forty	O
single	O
tooth	O
dental	O
implants	O
inserted	O
following	O
the	O
placement	O
of	O
bioglass	O
and/or	O
allograft	O
into	O
the	O
sinus	O
area	O
using	O
an	O
osteotome	O
technique	O
in	O
37	O
patients	O
were	O
evaluated	O
in	O
this	O
retrospective	O
study	O
.	O

Periapical	B-P
radiographs	I-P
were	O
taken	O
using	O
the	O
long-cone	O
technique	O
before	O
and	O
after	O
implant	O
placement	O
.	O

Specifically	O
,	O
radiographic	B-P
measurements	O
of	O
grafted	O
bone	O
height	O
at	O
the	O
mesial	O
and	O
distal	O
side	O
of	O
each	O
implant	O
were	O
taken	O
,	O
and	O
the	O
sinus	O
floor	O
configuration	O
was	O
classified	O
into	O
concave	O
,	O
angle	O
,	O
and	O
flat	O
according	O
to	O
the	O
sinus	O
floor	O
profile	O
at	O
the	O
implant	O
site	O
.	O

Further	O
,	O
the	O
intruding	O
angle	O
,	O
which	O
was	O
defined	O
as	O
the	O
angle	O
between	O
the	O
implant	O
axis	O
and	O
the	O
sinus	O
floor	O
,	O
was	O
measured	O
.	O

All	O
of	O
the	O
implants	O
were	O
clinically	O
stable	O
during	O
a	O
mean	O
follow-up	O
period	O
of	O
39.2	O
months	O
.	O

The	O
mean	O
initial	O
gain	O
of	O
the	O
sinus	O
grafted	O
bone	O
height	O
was	O
7.0	O
±	O
1.9	O
mm	O
,	O
and	O
it	O
later	O
reduced	O
to	O
4.6	O
±	O
1.9	O
mm	O
after	O
follow-up	O
(	O
p	O
<	O
0.001	O
)	O
.	O

A	O
greater	O
reduction	O
in	O
grafted	O
bone	O
height	O
was	O
revealed	O
in	O
the	O
flat	O
sinus	O
group	O
compared	O
to	O
the	O
concave	O
group	O
(	O
p	O
<	O
0.001	O
)	O
.	O

The	O
results	O
from	O
the	O
linear	O
regression	O
showed	O
that	O
larger	O
intruding	O
angles	O
were	O
statistically	O
significantly	O
associated	O
with	O
a	O
greater	O
reduction	O
in	O
grafted	O
bone	O
height	O
(	O
r	O
(	O
2	O
)	O
=	O
0.55	O
,	O
p	O
<	O
0.001	O
)	O
.	O

All	O
bioglass	O
and/or	O
allograft	O
placed	O
in	O
the	O
maxillary	O
sinus	O
following	O
the	O
osteotome	O
technique	O
underwent	O
remodeling	O
and	O
shrinkage	O
,	O
while	O
the	O
outcome	O
of	O
the	O
procedure	O
was	O
more	O
predictable	O
in	O
sinuses	O
with	O
a	O
concave	O
floor	O
and	O
small	O
implant	O
intruding	O
angles	O
.	O

Subsolid	O
pulmonary	O
nodule	O
morphology	O
and	O
associated	O
patient	O
characteristics	O
in	O
a	O
routine	O
clinical	O
population	O
.	O

To	O
determine	O
the	O
presence	O
and	O
morphology	O
of	O
subsolid	O
pulmonary	O
nodules	O
(	O
SSNs	O
)	O
in	O
a	O
non-screening	O
setting	O
and	O
relate	O
them	O
to	O
clinical	O
and	O
patient	O
characteristics	O
.	O

A	O
total	O
of	O
16,890	O
reports	O
of	O
clinically	O
obtained	O
chest	B-P
CT	I-P
(	O
06/2011	O
to	O
11/2014	O
,	O
single-centre	O
)	O
were	O
searched	O
describing	O
an	O
SSN	O
.	O

Subjects	O
with	O
a	O
visually	O
confirmed	O
SSN	O
and	O
at	O
least	O
two	O
thin-slice	B-P
CTs	I-P
were	O
included	O
.	O

Nodule	O
volumes	O
were	O
measured	O
.	O

Progression	O
was	O
defined	O
as	O
volume	O
increase	O
exceeding	O
the	O
software	B-P
interscan	I-P
variation	O
.	O

Nodule	O
morphology	O
,	O
location	O
,	O
and	O
patient	O
characteristics	O
were	O
evaluated	O
.	O

Fifteen	O
transient	O
and	O
74	O
persistent	O
SSNs	O
were	O
included	O
(	O
median	O
follow-up	O
19.6	O
[	O
8.3-36.8	O
]	O
months	O
)	O
.	O

Subjects	O
with	O
an	O
SSN	O
were	O
slightly	O
older	O
than	O
those	O
without	O
(	O
62	O
vs.	O
58	O
years	O
;	O
p	O
=	O
0.01	O
)	O
,	O
but	O
no	O
gender	O
predilection	O
was	O
found	O
.	O

SSNs	O
were	O
mostly	O
located	O
in	O
the	O
upper	O
lobes	O
.	O

Women	O
showed	O
significantly	O
more	O
often	O
persistent	O
lesions	O
than	O
men	O
(	O
94	O
%	O
vs.	O
69	O
%	O
;	O
p	O
=	O
0.002	O
)	O
.	O

Part-solid	O
lesions	O
were	O
larger	O
(	O
1638	O
vs.	O
383	O
mm	O
(	O
3	O
)	O
;	O
p	O
<	O
0.001	O
)	O
and	O
more	O
often	O
progressive	O
(	O
68	O
%	O
vs.	O
38	O
%	O
;	O
p	O
=	O
0.02	O
)	O
,	O
compared	O
to	O
pure	O
ground-glass	O
nodules	O
.	O

Progressive	O
SSNs	O
were	O
rare	O
under	O
the	O
age	O
of	O
50	O
years	O
.	O

Logistic	O
regression	O
analysis	O
did	O
not	O
identify	O
additional	O
nodule	O
parameters	O
of	O
future	O
progression	O
,	O
apart	O
from	O
part-solid	O
nature	O
.	O

This	O
study	O
confirms	O
previously	O
reported	O
characteristics	O
of	O
SSNs	O
and	O
associated	O
factors	O
in	O
a	O
European	O
,	O
routine	O
clinical	O
population	O
.	O

•	O
SSNs	O
in	O
women	O
are	O
significantly	O
more	O
often	O
persistent	O
compared	O
to	O
men	O
.	O

•	O
SSN	O
persistence	O
is	O
not	O
associated	O
with	O
age	O
or	O
prior	O
malignancy	O
.	O

•	O
The	O
majority	O
of	O
(	O
persistent	O
)	O
SSNs	O
are	O
located	O
in	O
the	O
upper	O
lung	O
lobes	O
.	O

•	O
A	O
part-solid	O
nature	O
is	O
associated	O
with	O
future	O
nodule	O
growth	O
.	O

•	O
Progressive	O
solitary	O
SSNs	O
are	O
rare	O
under	O
the	O
age	O
of	O
50	O
years	O
.	O

Pupil	O
Sizes	O
Scale	O
with	O
Attentional	O
Load	O
and	O
Task	O
Experience	O
in	O
a	O
Multiple	O
Object	O
Tracking	O
Task	O
.	O

Previous	O
studies	O
have	O
related	O
changes	O
in	O
attentional	O
load	O
to	O
pupil	O
size	O
modulations	O
.	O

However	O
,	O
studies	O
relating	O
changes	O
in	O
attentional	O
load	O
and	O
task	O
experience	O
on	O
a	O
finer	O
scale	O
to	O
pupil	O
size	O
modulations	O
are	O
scarce	O
.	O

Here	O
,	O
we	O
investigated	O
how	O
these	O
changes	O
affect	O
pupil	O
sizes	O
.	O

To	O
manipulate	O
attentional	O
load	O
,	O
participants	O
covertly	O
tracked	O
between	O
zero	O
and	O
five	O
objects	O
among	O
several	O
randomly	O
moving	O
objects	O
on	O
a	O
computer	O
screen	O
.	O

To	O
investigate	O
effects	O
of	O
task	O
experience	O
,	O
the	O
experiment	O
was	O
conducted	O
on	O
three	O
consecutive	O
days	O
.	O

We	O
found	O
that	O
pupil	O
sizes	O
increased	O
with	O
each	O
increment	O
in	O
attentional	O
load	O
.	O

Across	O
days	O
,	O
we	O
found	O
systematic	O
pupil	O
size	O
reductions	O
.	O

We	O
compared	O
the	O
model	O
fit	O
for	O
predicting	O
pupil	O
size	O
modulations	O
using	O
attentional	O
load	O
,	O
task	O
experience	O
,	O
and	O
task	O
performance	O
as	O
predictors	O
.	O

We	O
found	O
that	O
a	O
model	O
which	O
included	O
attentional	O
load	O
and	O
task	O
experience	O
as	O
predictors	O
had	O
the	O
best	O
model	O
fit	O
while	O
adding	O
performance	O
as	O
a	O
predictor	O
to	O
this	O
model	O
reduced	O
the	O
overall	O
model	O
fit	O
.	O

Overall	O
,	O
results	O
suggest	O
that	O
pupillometry	B-P
provides	O
a	O
viable	O
metric	O
for	O
precisely	O
assessing	O
attentional	O
load	O
and	O
task	O
experience	O
in	O
visuospatial	O
tasks	O
.	O

Truncated	O
Bovine	O
Integrin	O
Alpha-v/Beta-6	O
as	O
a	O
Universal	O
Capture	O
Ligand	O
for	O
FMD	O
Diagnosis	O
.	O

Foot-and-mouth	O
disease	O
(	O
FMD	O
)	O
is	O
endemic	O
in	O
many	O
regions	O
of	O
the	O
world	O
and	O
is	O
one	O
of	O
the	O
most	O
prevalent	O
epizootic	O
animal	O
diseases	O
.	O

FMD	O
affects	O
livestock	O
,	O
such	O
as	O
cattle	O
,	O
sheep	O
,	O
goats	O
and	O
pigs	O
,	O
and	O
causes	O
enormous	O
economic	O
losses	O
due	O
to	O
reduced	O
productivity	O
and	O
trade	O
restrictions	O
.	O

Preparedness	O
and	O
early	B-P
diagnosis	I-P
are	O
essential	O
for	O
effective	O
control	O
of	O
FMD	O
.	O

Many	O
diagnostic	B-P
assays	I-P
are	O
dependent	O
on	O
raising	O
high-affinity	O
,	O
anti-FMD	O
virus	O
(	O
FMDV	O
)	O
serotype-specific	O
antibodies	O
in	O
small	O
animals	O
(	O
rabbits	O
and	O
guinea	O
pigs	O
)	O
that	O
give	O
broad	O
virus	O
coverage	O
.	O

Here	O
we	O
show	O
that	O
soluble	O
,	O
truncated	O
forms	O
of	O
bovine	O
αvβ6	O
bind	O
FMDV	O
in	O
an	O
authentic	O
RGD	O
and	O
divalent	O
cation	O
dependent	O
interaction	O
and	O
can	O
be	O
used	O
as	O
the	O
trapping	O
reagent	O
in	O
a	O
FMDV	O
sandwich	B-P
ELISA	I-P
.	O

In	O
addition	O
,	O
inclusion	O
of	O
FLAG	O
or	O
His	O
tags	O
facilitates	O
simple	O
purification	B-P
without	O
the	O
loss	O
of	O
virus	O
binding	O
.	O

We	O
also	O
provide	O
evidence	O
that	O
when	O
combined	O
with	O
a	O
guinea	O
pig	O
polyclonal	O
serum	O
,	O
or	O
serotype-specific	O
monoclonal	O
antibodies	O
,	O
the	O
integrin	O
can	O
be	O
used	O
to	O
detect	O
viruses	O
representative	O
of	O
all	O
FMDV	O
serotypes	O
.	O

We	O
also	O
show	O
that	O
recombinant	O
FMDV	O
empty	O
capsids	O
,	O
with	O
stabilising	O
disulphide	O
bonds	O
,	O
can	O
serve	O
as	O
an	O
antigen	O
in	O
the	O
ELISA	B-P
and	O
can	O
therefore	O
replace	O
inactivated	O
virus	O
antigen	O
as	O
a	O
positive	O
control	O
for	O
the	O
assay	B-P
.	O

Our	O
results	O
demonstrate	O
the	O
potential	O
use	O
of	O
bovine	O
αvβ6	O
and	O
FMDV	O
empty	O
capsids	O
in	O
FMD	O
diagnostic	B-P
assays	I-P
.	O

Laparoscopic	B-P
Approach	I-P
for	O
Thermoablation	O
Microwave	O
in	O
the	O
Treatment	O
of	O
Hepatocellular	O
Carcinoma	O
:	O
A	O
Single	O
Center	O
Experience	O
.	O

The	O
surgical	O
therapy	O
of	O
choice	O
for	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
is	O
liver	O
transplantation	O
(	O
LT	O
)	O
or	O
hepatic	O
resection	O
,	O
although	O
only	O
a	O
small	O
percentage	O
of	O
patients	O
can	O
undergo	O
these	O
procedures	O
.	O

Microwave	O
thermal	O
ablation	O
(	O
MWTA	O
)	O
can	O
be	O
an	O
effective	O
alternative	O
treatment	O
for	O
HCC	O
that	O
complicates	O
a	O
cirrhotic	O
liver	O
disease	O
,	O
either	O
as	O
a	O
final	O
procedure	O
or	O
for	O
downstaging	B-P
patients	O
on	O
the	O
waiting	O
list	O
for	O
LT	O
,	O
or	O
in	O
combination	O
with	O
resective	O
surgery	O
to	O
achieve	O
oncological	O
radicality	O
.	O

The	O
purpose	O
of	O
this	O
retrospective	O
study	O
was	O
to	O
evaluate	O
experience	O
with	O
the	O
laparoscopic	B-P
approach	I-P
of	O
MWTA	O
at	O
our	O
center	O
.	O

In	O
a	O
cohort	O
of	O
35	O
consecutive	O
patients	O
undergoing	O
MWTA	O
with	O
laparoscopic	B-P
approach	I-P
between	O
January	O
,	O
2013	O
and	O
May	O
,	O
2016	O
,	O
we	O
reviewed	O
the	O
demographic	O
data	O
,	O
the	O
Barcelona	O
clinic	O
liver	O
cancer	O
stage	O
,	O
the	O
severity	O
of	O
cirrhotic	O
liver	O
disease	O
,	O
the	O
size	O
of	O
the	O
ablated	O
lesion	O
,	O
the	O
duration	O
of	O
the	O
procedure	O
,	O
and	O
complications	O
occurring	O
within	O
90	O
days	O
of	O
surgery	O
.	O

MWTA	O
was	O
performed	O
by	O
applying	O
one	O
to	O
three	O
hepatic	O
parenchymal	O
insertions	O
(	O
mean	O
1.8	O
)	O
per	O
patient	O
.	O

The	O
mean	O
duration	O
of	O
surgery	O
was	O
163	O
±	O
18	O
minutes	O
.	O

There	O
was	O
no	O
blood	O
loss	O
in	O
any	O
of	O
the	O
procedures	O
.	O

Complete	O
necrosis	O
on	O
CT	B-P
scan	I-P
was	O
achieved	O
in	O
26/35	O
patients	O
(	O
75	O
%	O
)	O
.	O

The	O
mean	O
hospital	O
stay	O
was	O
4.6	O
(	O
range	O
2-7	O
)	O
days	O
;	O
major	O
complications	O
were	O
postablation	O
syndrome	O
in	O
2/35	O
(	O
5.7	O
%	O
)	O
,	O
peritoneal	O
fluid	O
in	O
4/35	O
(	O
11.4	O
%	O
)	O
,	O
and	O
transient	O
jaundice	O
in	O
1/35	O
(	O
2.8	O
%	O
)	O
patients	O
.	O

There	O
was	O
no	O
mortality	O
.	O

Laparoscopic	B-P
MWTA	O
is	O
a	O
safe	O
and	O
effective	O
treatment	O
for	O
unresectable	O
HCC	O
and	O
when	O
a	O
percutaneous	O
procedure	O
is	O
not	O
feasible	O
.	O

Neospora	O
caninum	O
in	O
Axis	O
Deer	O
(	O
Axis	O
axis	O
)	O
and	O
Fallow	O
Deer	O
(	O
Dama	O
dama	O
)	O
in	O
Northern	O
Mexico	O
.	O

Serum	O
samples	O
from	O
18	O
axis	O
deer	O
(	O
Axis	O
axis	O
)	O
and	O
19	O
fallow	O
deer	O
(	O
Dama	O
dama	O
)	O
were	O
analyzed	O
with	O
an	O
enzyme-linked	B-P
immunosorbent	I-P
assay	I-P
for	O
Neospora	O
caninum	O
antibodies	O
.	O

Two	O
axis	O
(	O
11	O
%	O
)	O
and	O
two	O
fallow	O
deer	O
(	O
11	O
%	O
)	O
were	O
positive	O
for	O
N.	O
caninum	O
antibodies	O
.	O

Regional	O
Odontodysplasia	O
with	O
Generalised	O
Enamel	O
Defect	O
.	O

Regional	O
odontodysplasia	O
(	O
ROD	O
)	O
is	O
uncommon	O
developmental	O
anomaly	O
,	O
which	O
tends	O
to	O
be	O
localised	O
and	O
involves	O
the	O
ectodermal	O
and	O
mesodermal	O
tooth	O
components	O
.	O

A	O
five-year-old	O
female	O
was	O
referred	O
to	O
Department	O
of	O
Child	O
Dental	O
Health	O
at	O
the	O
Leeds	O
Dental	O
Institute	O
regarding	O
malformed	O
primary	O
teeth	O
.	O

On	O
examination	O
64	O
,	O
74	O
,	O
and	O
72	O
had	O
localised	O
hypomineralized	O
enamel	O
defect	O
.	O

The	O
crown	O
of	O
55	O
was	O
broken	O
down	O
with	O
only	O
the	O
root	O
remaining	O
below	O
the	O
gingival	O
level	O
.	O

54	O
has	O
a	O
yellowish	O
brown	O
discolouration	O
with	O
rough	O
irregular	O
surface	O
.	O

The	O
upper	O
anterior	O
teeth	O
show	O
mild	O
enamel	O
opacity	O
.	O

Radiographically	B-P
,	O
55	O
and	O
54	O
had	O
thin	O
radioopaque	O
contour	O
,	O
showing	O
poor	O
distinction	O
between	O
the	O
enamel	O
and	O
dentine	O
and	O
the	O
classic	O
feature	O
of	O
a	O
wide	O
pulp	O
chamber	O
.	O

15	O
,	O
16	O
,	O
and	O
17	O
were	O
developmentally	O
delayed	O
and	O
were	O
displaying	O
the	O
characteristic	O
``	O
ghost	O
appearance	O
.	O
''	O

Comprehensive	O
dental	O
care	O
was	O
done	O
under	O
local	O
anaesthesia	O
and	O
it	O
included	O
extraction	O
of	O
the	O
primary	O
molars	O
affected	O
by	O
ROD	O
,	O
stainless	O
steel	O
crown	O
on	O
64	O
,	O
and	O
caries	O
prevention	O
program	O
.	O

Fifteen	O
months	O
following	O
the	O
initial	O
assessment	O
the	O
patient	O
's	O
oral	O
condition	O
remains	O
stable	O
and	O
she	O
is	O
under	O
regular	O
follow-up	O
at	O
the	O
department	O
.	O

Paediatric	O
dentists	O
should	O
be	O
aware	O
of	O
this	O
anomaly	O
as	O
it	O
involves	O
both	O
dentitions	O
and	O
usually	O
requires	O
multidisciplinary	O
care	O
.	O

A	O
Case	O
Presenting	O
with	O
Splenic	O
Infarct	O
Diagnosed	O
as	O
Primary	O
Bone	O
Marrow	O
CD5	O
Positive	O
DLBCL	O
:	O
A	O
Clinicopathological	O
Correlation	O
.	O

De	O
novo	O
CD5+	O
Diffuse	O
large	O
B	O
cell	O
lymphoma	O
(	O
DLBCL	O
)	O
is	O
a	O
rare	O
and	O
aggressive	O
subtype	O
of	O
DLBCL	O
.	O

It	O
is	O
a	O
distinct	O
clinicopathologic	O
entity	O
with	O
complex	O
molecular	O
profile	O
and	O
poor	O
prognosis	O
.	O

A	O
59	O
year	O
old	O
female	O
presented	O
with	O
pyrexia	O
of	O
unknown	O
origin	O
since	O
1	O
month	O
.	O

On	O
examination	O
,	O
there	O
was	O
severe	O
pallor	O
,	O
hepatosplenomegaly	O
and	O
no	O
palpable	O
lymphadenopathy	O
.	O

Complete	B-P
blood	I-P
count	I-P
revealed	O
bicytopenia	O
with	O
normal	O
total	O
leucocyte	O
count	O
.	O

Liver	B-P
and	O
renal	B-P
function	I-P
tests	I-P
were	O
normal	O
.	O

Ultrasonography	B-P
abdomen	I-P
revealed	O
splenic	O
enlargement	O
with	O
two	O
focal	O
lesions	O
attributed	O
to	O
either	O
splenic	O
abscess	O
or	O
infarcts	O
.	O

Patient	O
was	O
being	O
managed	O
as	O
splenic	O
infarct	O
but	O
continued	O
to	O
have	O
bicytopenia	O
.	O

Further	O
investigation	O
showed	O
elevated	O
serum	O
ferritin	O
,	O
triglycerides	O
and	O
LDH	O
.	O

With	O
a	O
clinical	O
suspicion	O
of	O
infection	O
and	O
haemophagocytic	O
lymphohistiocytosis	O
bone	B-P
bone	B-P
marrow	I-P
aspiration	I-P
(	I-P
BMA	B-P
)	I-P
and	I-P
biopsy	B-P
(	I-P
BMBx	I-P
)	I-P
was	O
done	O
.	O

BMA	O
showed	O
extensive	O
haemophagocytosis	O
and	O
~7.4	O
%	O
large	O
lymphoma-like	O
cells	O
.	O

On	O
this	O
basis	O
PET-CT	B-P
was	O
suggested	O
which	O
showed	O
enlarged	O
spleen	O
with	O
diffuse	O
uptake	O
.	O

BMBx	B-P
showed	O
nodular	O
and	O
intrasinusoidal	O
collection	O
of	O
abnormal	O
lymphoid	O
cells	O
.	O

On	O
immunohistochemistry	B-P
,	O
these	O
cells	O
were	O
positive	O
for	O
CD20	O
,	O
CD5	O
,	O
MUM1	O
,	O
BCL-2	O
,	O
BCL-6	O
and	O
negative	O
for	O
CD3	O
,	O
CD10	O
and	O
CD23	O
.	O

CD34	O
highlighted	O
focal	O
intrasinusoidal	O
pattern	O
.	O

The	O
complete	O
clinicopathological	O
profile	O
suggested	O
the	O
diagnosis	O
of	O
de	O
novo	O
CD5+	O
DLBCL	O
,	O
with	O
primary	O
hepatosplenic	O
pattern	O
of	O
involvement	O
.	O

CD5+	O
DLBCL	O
presenting	O
as	O
splenic	O
infarct	O
is	O
very	O
rare	O
.	O

This	O
case	O
was	O
unusual	O
as	O
the	O
diagnosis	O
of	O
a	O
primary	O
aggressive	O
lymphoma	O
with	O
haemophagocytosis	O
was	O
established	O
in	O
a	O
patient	O
who	O
presented	O
with	O
fever	O
and	O
splenic	O
infarct	O
without	O
lymphadenopathy	O
.	O

This	O
indicates	O
the	O
importance	O
of	O
good	O
morphological	O
assessment	O
of	O
a	O
bone	O
marrow	O
aspirate	O
and	O
biopsy	B-P
to	O
make	O
a	O
correct	O
diagnosis	O
.	O

Assessment	O
of	O
demographic	O
and	O
pathoanatomic	O
risk	O
factors	O
in	O
recurrent	O
patellofemoral	O
instability	O
.	O

The	O
WARPS/STAID	O
classification	O
employs	O
clinical	O
assessment	O
of	O
presenting	O
features	O
and	O
anatomic	O
characteristics	O
to	O
identify	O
two	O
distinct	O
subsets	O
of	O
patients	O
within	O
the	O
patellofemoral	O
instability	O
population	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
further	O
define	O
the	O
specific	O
demographics	O
and	O
the	O
prevalence	O
of	O
risky	O
pathoanatomies	O
in	O
patients	O
classified	O
as	O
either	O
WARPS	O
or	O
STAID	O
presenting	O
with	O
recurrent	O
patellofemoral	O
instability	O
.	O

A	O
secondary	O
purpose	O
was	O
to	O
further	O
validate	O
the	O
WARPS/STAID	O
classification	O
with	O
the	O
Banff	O
Patella	O
Instability	O
Instrument	O
(	O
BPII	O
)	O
,	O
the	O
Marx	O
activity	O
scale	O
and	O
the	O
Patellar	O
Instability	O
Severity	O
Score	O
(	O
ISS	O
)	O
.	O

A	O
convenience	O
sample	O
of	O
50	O
patients	O
with	O
recurrent	O
patellofemoral	O
instability	O
,	O
including	O
25	O
WARPS	O
and	O
25	O
STAID	O
subtype	O
patients	O
,	O
were	O
assessed	O
.	O

Clinical	O
data	O
were	O
collected	O
including	O
assessment	O
of	O
demographic	O
risk	O
factors	O
(	O
sex	O
,	O
BMI	O
,	O
bilaterality	O
of	O
symptoms	O
,	O
affected	O
limb	O
side	O
and	O
age	O
at	O
first	O
dislocation	O
)	O
and	O
pathoanatomic	O
risk	O
factors	O
(	O
TT-TG	O
distance	O
,	O
patella	O
height	O
,	O
patellar	O
tilt	O
,	O
grade	O
of	O
trochlear	O
dysplasia	O
,	O
Beighton	O
score	O
and	O
rotational	O
abnormalities	O
of	O
the	O
tibia	O
or	O
femur	O
)	O
.	O

Patients	O
completed	O
the	O
BPII	O
and	O
the	O
Marx	O
activity	O
scale	O
.	O

The	O
ISS	O
was	O
calculated	B-P
from	O
the	O
clinical	O
assessment	O
data	O
.	O

Patients	O
were	O
stratified	O
into	O
the	O
WARPS	O
or	O
STAID	O
subtypes	O
for	O
comparative	O
analysis	O
.	O

An	O
independent	O
t	O
test	O
was	O
used	O
to	O
compare	O
demographics	O
,	O
the	O
pathoanatomic	O
risk	O
factors	O
and	O
subjective	O
measures	O
between	O
the	O
groups	O
.	O

Convergent	O
validity	O
was	O
tested	O
with	O
a	O
Pearson	O
r	O
correlation	O
coefficient	O
between	O
the	O
WARPS/STAID	O
and	O
ISS	O
scores	O
.	O

Demographic	O
risk	O
factors	O
statistically	O
associated	O
with	O
a	O
WARPS	O
subtype	O
included	O
female	O
sex	O
,	O
age	O
at	O
first	O
dislocation	O
and	O
bilaterality	O
.	O

Pathoanatomic	O
risk	O
factors	O
statistically	O
associated	O
with	O
a	O
WARPS	O
subtype	O
included	O
trochlear	O
dysplasia	O
,	O
TT-TG	O
distance	O
,	O
generalized	O
ligamentous	O
laxity	O
,	O
patellar	O
tilt	O
and	O
rotational	O
abnormalities	O
.	O

The	O
independent	O
t	O
test	O
revealed	O
a	O
significant	O
difference	O
between	O
the	O
ISS	O
scores	O
:	O
WARPS	O
subtype	O
(	O
M	O
=	O
4.4	O
,	O
SD	O
=	O
1.1	O
)	O
and	O
STAID	O
subtype	O
(	O
M	O
=	O
2.5	O
,	O
SD	O
=	O
1.5	O
)	O
;	O
t	O
(	O
48	O
)	O
=	O
5.2	O
,	O
p	O
<	O
0.001	O
.	O

The	O
relationship	O
between	O
the	O
WARPS/STAID	O
and	O
the	O
ISS	O
scores	O
,	O
measured	O
using	O
a	O
Pearson	O
r	O
correlation	O
coefficient	O
,	O
demonstrated	O
a	O
strong	O
relationship	O
:	O
r	O
=	O
-0.61	O
,	O
n	O
=	O
50	O
,	O
p	O
<	O
0.001	O
.	O

This	O
study	O
has	O
demonstrated	O
statistically	O
significant	O
evidence	O
that	O
certain	O
demographics	O
and	O
pathoanatomies	O
are	O
more	O
prevalent	O
in	O
each	O
of	O
the	O
WARPS	O
and	O
STAID	O
patellofemoral	O
instability	O
subtypes	O
.	O

There	O
was	O
no	O
difference	O
in	O
quality-of-life	O
or	O
activity	O
level	O
between	O
the	O
subtypes	O
.	O

The	O
WARPS/STAID	O
score	O
demonstrated	O
convergent	O
validity	O
to	O
the	O
ISS	O
and	O
divergent	O
validity	O
to	O
the	O
BPII	O
score	O
and	O
the	O
Marx	O
activity	O
scale	O
.	O

This	O
study	O
has	O
further	O
validated	O
both	O
the	O
WARPS/STAID	O
classification	O
and	O
the	O
ISS	O
of	O
patients	O
that	O
present	O
with	O
recurrent	O
patellofemoral	O
instability	O
.	O

III	O
.	O

A	O
pH	O
-	O
Sensitive	O
Nanocarrier	O
for	O
Tumor	O
Targeting	O
:	O
Delivery	O
of	O
Ruthenium	O
Complex	O
for	O
Tumor	O
Theranostic	O
by	O
pH	O
-	O
Sensitive	O
Nanocapsule	O
.	O

Ruthenium	O
complex	O
is	O
a	O
potentially	O
theranostic	O
agent	O
for	O
cancer	B-P
imaging	I-P
and	O
therapy	O
,	O
however	O
its	O
application	O
is	O
limited	O
due	O
to	O
poor	O
water-solubility	O
and	O
lack	O
of	O
tumor	O
selectivity	O
.	O

To	O
overcome	O
the	O
above	O
drawbacks	O
,	O
pH	O
-	O
sensitive	O
nanocapsule	O
as	O
a	O
novel	O
targeting	O
carrier	O
was	O
designed	O
to	O
deliver	O
ruthenium	O
complex	O
for	O
treating	O
xenograft	O
tumor	O
of	O
mice	O
.	O

The	O
core	O
/	O
shell	O
structured	O
nanocapsule	O
with	O
ruthenium	O
complex	O
tris	O
(	O
1,10-phenanthroline	O
)	O
ruthenium	O
(	O
II	O
)	O
complex	O
(	O
3P-Ru	O
)	O
as	O
the	O
core	O
and	O
a	O
pH	O
-	O
sensitive	O
polymeric	O
material	O
poly	O
(	O
2-diisopropylaminoethyl	O
methacrylate	O
)	O
-block	O
poly	O
(	O
2-aminoethyl	O
methacrylate	O
hydrochloride	O
)	O
(	O
PbPS	O
)	O
as	O
the	O
shell	O
was	O
synthesized	O
and	O
characterized	O
.	O

Meanwhile	O
,	O
the	O
nanocapsule	O
was	O
used	O
to	O
investigate	O
cell	O
viability	O
and	O
evaluate	O
tissue	O
distribution	O
as	O
well	O
as	O
preventing	O
tumor	O
growth	O
efficacy	O
in	O
U251	O
stem	O
cells	O
tumor	O
-bearing	O
mouse	O
model	O
.	O

The	O
nanocapsule	O
had	O
a	O
size	O
of	O
103.1	O
±	O
11.3	O
nm	O
,	O
zeta	O
potential	O
of	O
-40	O
±	O
5.3	O
mV	O
,	O
EE	O
of	O
76.7	O
±	O
0.9	O
%	O
,	O
LE	O
of	O
25.4	O
±	O
0.6	O
%	O
and	O
it	O
could	O
control	O
drug	O
release	O
under	O
different	O
pH	O
conditions	O
.	O

The	O
results	O
of	O
cell	O
uptake	O
showed	O
that	O
the	O
fluorescent	O
3P-Ru	O
loaded	O
in	O
the	O
nanocapsule	O
could	O
be	O
delivered	O
into	O
cells	O
with	O
high	O
efficiency	O
,	O
and	O
then	O
significantly	O
inhibited	O
U251	O
proliferation	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

After	O
U251	O
stem	O
cells	O
were	O
transplanted	O
subcutaneously	O
into	O
mice	O
,	O
the	O
3P-Ru	O
/	O
PbPS	O
nanocapsule	O
(	O
PbPS	O
-	O
Ru	O
-	O
NC	O
)	O
via	O
intravenous	O
administration	O
could	O
concentrate	O
in	O
tumor	O
area	O
and	O
obviously	O
prevent	O
tumor	O
growth	O
.	O

The	O
pH	O
-	O
sensitive	O
nanocapsule	O
as	O
a	O
antitumor	O
agent	O
carrier	O
was	O
able	O
to	O
effectively	O
deliver	O
3P-Ru	O
into	O
gliomas	O
cells	O
,	O
and	O
cell	O
growth	O
was	O
significantly	O
inhibited	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Such	O
pH	O
-	O
sensitive	O
nanocapsule	O
for	O
ruthenium	O
complex	O
delivery	O
would	O
have	O
great	O
potential	O
application	O
in	O
tumor	O
theranostics	O
.	O

Pupillary	O
response	O
abnormalities	O
in	O
depressive	O
disorders	O
.	O

Depressive	O
disorders	O
lack	O
objective	O
physiological	O
measurements	O
to	O
characterize	O
the	O
affected	O
population	O
and	O
facilitate	O
study	O
of	O
relevant	O
mechanisms	O
.	O

The	O
melanopsin	O
-	O
mediated	O
light	O
signaling	O
pathway	O
may	O
contribute	O
to	O
seasonal	O
variation	O
and	O
can	O
be	O
measured	O
non-invasively	O
by	O
pupillometry	B-P
.	O

We	O
prospectively	O
studied	O
changes	O
in	O
melanopsin	O
-	O
mediated	O
pupillary	O
constriction	O
in	O
19	O
participants	O
with	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
and	O
10	O
control	O
across	O
the	O
summer	O
and	O
winter	O
solstices	O
.	O

The	O
melanopsin	O
-	O
mediated	O
response	O
,	O
as	O
measured	O
by	O
the	O
pupil	O
's	O
sustained	O
constriction	O
six	O
s	O
after	O
a	O
high	O
intensity	O
blue	O
light	O
stimulus	O
,	O
was	O
marginally	O
attenuated	O
in	O
those	O
with	O
MDD	O
relative	O
to	O
controls	O
(	O
p	O
=0.071	O
)	O
.	O

The	O
participants	O
with	O
MDD	O
unexpectedly	O
showed	O
a	O
significantly	O
reduced	O
transient	O
pupillary	O
response	O
to	O
low	O
intensity	O
red	O
(	O
p	O
=0.011	O
)	O
and	O
blue	O
light	O
(	O
p	O
=0.013	O
)	O
,	O
but	O
not	O
high	O
intensity	O
red	O
and	O
blue	O
light	O
.	O

Sustained	O
pupillary	O
constriction	O
in	O
response	O
to	O
high	O
intensity	O
blue	O
light	O
was	O
more	O
pronounced	O
with	O
increasing	O
daylight	O
hours	O
(	O
p	O
=0.037	O
)	O
and	O
was	O
more	O
strongly	O
related	O
to	O
objectively	O
measured	O
versus	O
estimated	O
light	O
exposure	O
.	O

Melanopsin	O
-	O
mediated	O
impairments	O
in	O
pupil	O
response	O
may	O
serve	O
as	O
a	O
biological	O
marker	O
for	O
vulnerability	O
to	O
depression	O
in	O
low	O
light	O
conditions	O
.	O

Assessment	O
of	O
these	O
and	O
other	O
responses	O
to	O
light	O
stimuli	O
,	O
such	O
as	O
response	O
to	O
low	O
intensity	O
light	O
,	O
may	O
be	O
useful	O
for	O
the	O
study	O
of	O
the	O
neurobiology	O
of	O
MDD	O
and	O
related	O
mood	O
disorders	O
.	O

The	O
Origin	O
of	O
Selectivity	O
in	O
the	O
Complexation	O
of	O
N-Methyl	O
Amino	O
Acids	O
by	O
Tetraphosphonate	O
Cavitands	O
.	O

We	O
report	O
on	O
the	O
eligibility	O
of	O
tetraphosphonate	O
resorcinarene	O
cavitands	O
for	O
the	O
molecular	O
recognition	O
of	O
amino	O
acids	O
.	O

We	O
determined	O
the	O
crystal	O
structure	O
of	O
13	O
complexes	O
of	O
the	O
tetraphosphonate	O
cavitand	O
Tiiii	O
[	O
H	O
,	O
CH3	O
,	O
CH3	O
]	O
with	O
amino	O
acids	O
.	O

(	O
1	O
)	O
H	O
NMR	O
and	O
(	O
31	O
)	O
P	O
NMR	O
experiments	O
and	O
ITC	O
analysis	O
were	O
performed	O
to	O
probe	B-P
the	O
binding	O
between	O
cavitand	O
Tiiii	O
[	O
C3H7	O
,	O
CH3	O
,	O
C2H5	O
]	O
or	O
the	O
water	O
-	O
soluble	O
counterpart	O
Tiiii	O
[	O
C3H6Py	O
(	O
+	O
)	O
Cl	O
(	O
-	O
)	O
,	O
CH3	O
,	O
C2H5	O
]	O
and	O
a	O
selection	O
of	O
representative	O
amino	O
acids	O
.	O

The	O
reported	O
studies	O
and	O
results	O
allowed	O
us	O
(	O
i	O
)	O
to	O
highlight	O
the	O
noncovalent	O
interactions	O
involved	O
in	O
the	O
binding	O
event	O
in	O
each	O
case	O
;	O
(	O
ii	O
)	O
to	O
investigate	O
the	O
ability	O
of	O
tetraphosphonate	O
cavitand	O
receptors	O
to	O
discriminate	O
between	O
the	O
different	O
amino	O
acids	O
;	O
(	O
iii	O
)	O
to	O
calculate	O
the	O
Ka	O
values	O
of	O
the	O
different	O
complexes	O
formed	O
and	O
evaluate	O
the	O
thermodynamic	O
parameters	O
of	O
the	O
complexation	O
process	O
,	O
dissecting	O
the	O
entropic	O
and	O
enthalpic	O
contributions	O
;	O
and	O
(	O
iv	O
)	O
to	O
determine	B-P
the	O
solvent	O
influence	O
on	O
the	O
complexation	O
selectivity	O
.	O

By	O
moving	O
from	O
methanol	O
to	O
water	O
,	O
the	O
complexation	O
changed	O
from	O
entropy	O
driven	O
to	O
entropy	O
opposed	O
,	O
leading	O
to	O
a	O
drop	O
of	O
almost	O
three	O
orders	O
in	O
the	O
magnitude	O
of	O
the	O
Ka	O
.	O

However	O
,	O
this	O
reduction	O
in	O
binding	O
affinity	O
is	O
associated	O
with	O
a	O
dramatic	O
increase	O
in	O
selectivity	O
,	O
since	O
in	O
aqueous	O
solutions	O
only	O
N-methylated	O
amino	O
acids	O
are	O
effectively	O
recognized	O
.	O

The	O
thermodynamic	O
profile	B-P
of	O
the	O
binding	O
does	O
not	O
change	O
in	O
PBS	O
solution	O
.	O

The	O
pivotal	O
role	O
played	O
by	O
cation-π	O
interactions	O
is	O
demonstrated	O
by	O
the	O
linear	O
correlation	O
found	O
between	O
the	O
log	O
Ka	O
in	O
methanol	O
solution	O
and	O
the	O
depth	O
of	O
(	O
+	O
)	O
N-CH3	O
cavity	O
inclusion	O
in	O
the	O
molecular	O
structures	O
.	O

These	O
findings	O
are	O
relevant	O
for	O
the	O
potential	O
use	O
of	O
phosphonate	O
cavitands	O
as	O
synthetic	O
receptors	O
for	O
the	O
detection	O
of	O
epigenetic	O
modifications	O
of	O
histones	O
in	O
physiological	O
media	O
.	O

Targeting	O
Conserved	O
Genes	O
in	O
Alternaria	O
Species	O
.	O

Real-time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
is	O
a	O
molecular	B-P
biology	I-P
technique	I-P
based	O
on	O
the	O
detection	O
of	O
the	O
fluorescence	O
produced	O
by	O
a	O
reporter	O
molecule	O
,	O
which	O
increases	O
as	O
the	O
reaction	O
proceeds	O
proportionally	O
to	O
the	O
accumulation	O
of	O
the	O
PCR	O
product	O
within	O
each	O
amplification	O
cycle	O
.	O

The	O
fluorescent	O
reporter	O
molecules	O
include	O
dyes	O
that	O
bind	O
to	O
the	O
double-stranded	O
DNA	O
(	O
i.e.	O
,	O
SYBR	O
(	O
®	O
)	O
Green	O
)	O
or	O
sequence-specific	O
probes	O
(	O
i.e.	O
,	O
Molecular	O
Beacons	O
or	O
TaqMan	O
(	O
®	O
)	O
Probes	O
)	O
.	O

Real-time	O
PCR	O
provides	O
a	O
tool	O
for	O
accurate	O
and	O
sensitive	O
quantification	O
of	O
target	O
fungal	O
DNA	O
.	O

Here	O
,	O
we	O
describe	O
a	O
TaqMan	O
real-time	O
PCR	O
method	O
for	O
specific	O
detection	O
and	O
quantification	O
of	O
Alternaria	O
spp	O
.	O

The	O
method	B-P
uses	O
Alternaria-specific	O
primers	O
and	O
probe	O
,	O
targeting	O
the	O
internal	O
transcribed	O
spacer	O
regions	O
ITS1	O
and	O
ITS2	O
of	O
the	O
rRNA	O
gene	O
,	O
and	O
a	O
positive	O
amplification	O
control	O
based	O
on	O
18S	O
rRNA	O
gene	O
.	O

Locating	O
the	O
Seventh	O
Cervical	O
Spinous	O
Process	O
:	O
Development	O
and	O
Validation	O
of	O
a	O
Multivariate	O
Model	O
Using	O
Palpation	B-P
and	O
Personal	O
Information	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
develop	O
and	O
validate	O
a	O
multivariate	O
prediction	O
model	O
,	O
guided	O
by	O
palpation	B-P
and	O
personal	O
information	O
,	O
for	O
locating	O
the	O
seventh	O
cervical	O
spinous	O
process	O
(	O
C7SP	O
)	O
.	O

A	O
single-blinded	O
,	O
cross-sectional	O
study	O
at	O
a	O
primary	O
to	O
tertiary	O
health	O
care	O
center	O
was	O
conducted	O
for	O
model	O
development	O
and	O
temporal	O
validation	O
.	O

One-hundred	O
sixty	O
participants	O
were	O
prospectively	O
included	O
for	O
model	O
development	O
(	O
n	O
=	O
80	O
)	O
and	O
time-split	O
validation	O
stages	O
(	O
n	O
=	O
80	O
)	O
.	O

The	O
C7SP	O
was	O
located	O
using	O
the	O
thorax-rib	B-P
static	I-P
method	I-P
(	O
TRSM	B-P
)	O
.	O

Participants	O
underwent	O
chest	B-P
radiography	I-P
for	O
assessment	O
of	O
the	O
inner	O
body	O
structure	O
located	O
with	O
TRSM	B-P
and	O
using	O
radio-opaque	O
markers	O
placed	O
over	O
the	O
skin	O
.	O

Age	O
,	O
sex	O
,	O
height	O
,	O
body	O
mass	O
,	O
body	O
mass	O
index	O
,	O
and	O
vertex-marker	O
distanc	O
e	O
(	O
DV-M	O
)	O
were	O
used	O
to	O
predict	O
the	O
distance	O
from	O
the	O
C7SP	O
to	O
the	O
vertex	O
(	O
DV-C7	O
)	O
.	O

Multivariate	O
linear	O
regression	O
modeling	O
,	O
limits	O
of	O
agreement	O
plot	O
,	O
histogram	O
of	O
residues	O
,	O
receiver	O
operating	O
characteristic	O
curves	O
,	O
and	O
confusion	O
tables	O
were	O
analyzed	O
.	O

The	O
multivariate	O
linear	O
prediction	O
model	O
for	O
DV-C7	O
(	O
in	O
centimeters	O
)	O
was	O
DV-C7	O
=	O
0.986DV-M	O
+	O
0.018	O
(	O
mass	O
)	O
+	O
0.014	O
(	O
age	O
)	O
-	O
1.008	O
.	O

Receiver	O
operating	O
characteristic	O
curves	O
had	O
better	O
discrimination	O
of	O
DV-C7	O
(	O
area	O
under	O
the	O
curve	O
=	O
0.661	O
;	O
95	O
%	O
confidence	O
interval	O
=	O
0.541-0.782	O
;	O
P	O
=	O
.015	O
)	O
than	O
DV-M	O
(	O
area	O
under	O
the	O
curve	O
=	O
0.480	O
;	O
95	O
%	O
confidence	O
interval	O
=	O
0.345-0.614	O
;	O
P	O
=	O
.761	O
)	O
,	O
with	O
respective	O
cutoff	O
points	O
at	O
23.40	O
cm	O
(	O
sensitivity	O
=	O
41	O
%	O
,	O
specificity	O
=	O
63	O
%	O
)	O
and	O
24.75	O
cm	O
(	O
sensitivity	O
=	O
69	O
%	O
,	O
specificity	O
=	O
52	O
%	O
)	O
.	O

The	O
C7SP	O
was	O
correctly	O
located	O
more	O
often	O
when	O
using	O
predicted	O
DV-C7	O
in	O
the	O
validation	O
sample	O
than	O
when	O
using	O
the	O
TRSM	B-P
in	O
the	O
development	O
sample	O
:	O
n	O
=	O
53	O
(	O
66	O
%	O
)	O
vs	O
n	O
=	O
32	O
(	O
40	O
%	O
)	O
,	O
P	O
<	O
.001	O
.	O

Better	O
accuracy	O
was	O
obtained	O
when	O
locating	O
the	O
C7SP	O
by	O
use	O
of	O
a	O
multivariate	O
model	O
that	O
incorporates	O
palpation	B-P
and	O
personal	O
information	O
.	O

A	O
randomized	O
trial	O
of	O
TLR-2	O
agonist	O
CADI-05	O
targeting	O
desmocollin-3	O
for	O
advanced	O
non-small-cell	O
lung	O
cancer	O
.	O

Randomized	O
controlled	O
trial	O
to	O
evaluate	O
synergy	O
between	O
taxane	O
plus	O
platinum	O
chemotherapy	O
and	O
CADI-05	O
,	O
a	O
Toll	O
like	O
receptor-2	O
agonist	O
targeting	O
desmocollin-3	O
as	O
a	O
first-line	O
therapy	O
in	O
advanced	O
non-small-cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
.	O

Patients	O
with	O
advanced	O
NSCLC	O
(	O
stage	O
IIIB	O
or	O
IV	O
)	O
were	O
randomized	O
to	O
cisplatin-paclitaxel	O
(	O
chemotherapy	O
group	O
,	O
N	O
=	O
112	O
)	O
or	O
cisplatin-paclitaxel	O
plus	O
CADI-05	O
(	O
chemoimmunotherapy	O
group	O
,	O
N	O
=	O
109	O
)	O
.	O

CADI-05	O
was	O
administered	O
a	O
week	O
before	O
chemotherapy	O
and	O
on	O
days	O
8	O
and	O
15	O
of	O
each	O
cycle	O
and	O
every	O
month	O
subsequently	O
for	O
12	O
months	O
or	O
disease	O
progression	O
.	O

Overall	O
survival	O
was	O
compared	O
using	O
a	O
log-rank	O
test	O
.	O

Computed	B-P
tomography	I-P
was	O
carried	O
out	O
at	O
baseline	O
,	O
end	O
of	O
two	O
cycles	O
and	O
four	O
cycles	O
.	O

Response	O
rate	O
was	O
evaluated	O
using	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	O
Tumors	O
criteria	O
by	O
an	O
independent	O
radiologist	O
.	O

As	O
per	O
intention-to-treat	O
analysis	O
,	O
no	O
survival	O
benefit	O
was	O
observed	O
between	O
two	O
groups	O
[	O
208	O
versus	O
196	O
days	O
;	O
hazard	O
ratio	O
,	O
0.86	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0.63-1.19	O
;	O
P	O
=	O
0.3804	O
]	O
.	O

In	O
a	O
subgroup	O
analysis	O
,	O
improvement	O
in	O
median	O
survival	O
by	O
127	O
days	O
was	O
observed	O
in	O
squamous	O
NSCC	O
with	O
chemoimmunotherapy	O
(	O
hazard	O
ratio	O
,	O
0.55	O
;	O
95	O
%	O
CI	O
0.32-0.95	O
;	O
P	O
=	O
0.046	O
)	O
.	O

In	O
patients	O
receiving	O
planned	O
four	O
cycles	O
of	O
chemotherapy	O
,	O
there	O
was	O
improved	O
median	O
overall	O
survival	O
by	O
66	O
days	O
(	O
299	O
versus	O
233	O
days	O
;	O
hazard	O
ratio	O
,	O
0.64	O
;	O
95	O
%	O
CI	O
0.41	O
to	O
0.98	O
;	O
P	O
=	O
0.04	O
)	O
in	O
the	O
chemoimmunotherapy	O
group	O
compared	O
with	O
the	O
chemotherapy	O
group	O
.	O

This	O
was	O
associated	O
with	O
the	O
improved	O
survival	O
by	O
17.48	O
%	O
at	O
the	O
end	O
of	O
1	O
year	O
,	O
in	O
the	O
chemoimmunotherapy	O
group	O
.	O

Systemic	O
adverse	O
events	O
were	O
identical	O
in	O
both	O
the	O
group	O
s.	O
There	O
was	O
no	O
survival	O
benefit	O
with	O
the	O
addition	O
of	O
CADI-05	O
to	O
the	O
combination	O
of	O
cisplatin-paclitaxel	O
in	O
patients	O
with	O
advanced	O
NSCLC	O
;	O
however	O
,	O
the	O
squamous	O
cell	O
subset	O
did	O
demonstrate	O
a	O
survival	O
advantage	O
.	O

Dysphagia	O
-optimised	O
Intensity-modulated	O
Radiotherapy	O
Techniques	O
in	O
Pharyngeal	O
Cancers	O
:	O
Is	O
Anyone	O
Going	O
to	O
Swallow	O
it	O
?	O
.	O

Dysphagia	O
after	O
primary	O
chemoradiotherapy	O
or	O
radiation	O
alone	O
in	O
pharyngeal	O
cancers	O
can	O
have	O
a	O
devastating	O
impact	O
on	O
a	O
patient	O
's	O
physical	O
,	O
social	O
and	O
emotional	O
state	O
.	O

Establishing	O
and	O
validating	O
efficient	O
dysphagia	O
-	O
optimised	O
radiotherapy	O
techniques	O
is	O
,	O
therefore	O
,	O
of	O
paramount	O
importance	O
in	O
an	O
era	O
where	O
health-related	O
quality	O
of	O
life	O
measures	O
are	O
increasingly	O
influential	O
determinants	O
of	O
curative	O
management	O
strategies	O
,	O
particularly	O
as	O
the	O
incidence	O
of	O
good	O
prognosis	O
,	O
human	O
papillomavirus	O
-driven	O
pharyngeal	O
cancer	O
in	O
younger	O
patients	O
continues	O
to	O
rise	O
.	O

The	O
preferential	O
sparing	O
achievable	O
with	O
intensity-modulated	O
radiotherapy	O
(	O
IMRT	O
)	O
of	O
key	O
swallowing	O
structures	O
implicated	O
in	O
post-radiation	O
dysfunction	O
,	O
such	O
as	O
the	O
pharyngeal	O
constrictor	O
muscles	O
(	O
PCM	O
)	O
,	O
has	O
generated	O
significant	O
research	O
into	O
toxicity	O
-	O
mitigating	O
strategies	O
.	O

The	O
lack	O
of	O
randomised	O
evidence	O
,	O
however	O
,	O
means	O
that	O
there	O
remains	O
uncertainty	O
about	O
the	O
true	O
clinical	O
benefits	O
of	O
the	O
dosimetric	B-P
gains	O
offered	O
by	O
technological	O
advances	O
in	O
radiotherapy	O
.	O

As	O
a	O
result	O
,	O
we	O
feel	O
that	O
IMRT	O
techniques	O
that	O
spare	O
PCM	O
can	O
not	O
be	O
incorporated	O
into	O
routine	O
practice	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
swallowing	O
structures	O
responsible	O
for	O
functional	O
impairment	O
,	O
analyse	O
the	O
studies	O
that	O
have	O
explored	O
the	O
dose-response	O
relationship	O
between	O
these	O
critical	O
structures	O
and	O
late	O
dysphagia	O
,	O
and	O
consider	O
the	O
merits	O
of	O
reported	O
dysphagia	O
-	O
optimised	O
IMRT	O
(	O
Do-IMRT	O
)	O
approaches	O
,	O
thus	O
far	O
.	O

Finally	O
,	O
we	O
discuss	O
the	O
dysphagia	O
/	O
aspiration	O
-related	O
structures	O
(	O
DARS	O
)	O
study	O
(	O
ISRCTN	O
25458988	O
)	O
,	O
which	O
is	O
the	O
first	O
phase	O
III	O
randomised	O
controlled	O
trial	O
designed	O
to	O
investigate	O
the	O
impact	O
of	O
swallow	O
-sparing	O
strategies	O
on	O
improving	O
long-term	O
function	O
.	O

To	O
maximise	O
patient	O
benefits	O
,	O
improvements	O
in	O
radiation	O
delivery	O
will	O
need	O
to	O
integrate	O
with	O
novel	O
treatment	O
paradigms	O
and	O
comprehensive	O
rehabilitation	O
strategies	O
to	O
eventually	O
provide	O
a	O
patient	O
-centric	O
,	O
personalised	O
treatment	O
plan	O
.	O

Medication	O
Overuse	O
Headache	O
:	O
Pathophysiological	O
Insights	O
from	O
Structural	O
and	O
Functional	O
Brain	O
MRI	B-P
Research	O
.	O

Research	O
imaging	B-P
of	O
brain	O
structure	O
and	O
function	O
has	O
helped	O
to	O
elucidate	O
the	O
pathophysiology	O
of	O
medication	O
overuse	O
headache	O
(	O
MOH	O
)	O
.	O

This	O
is	O
a	O
narrative	O
review	O
of	O
imaging	B-P
research	O
studies	O
that	O
have	O
investigated	O
brain	O
structural	O
and	O
functional	O
alterations	O
associated	O
with	O
MOH	O
.	O

Studies	O
included	O
in	O
this	O
review	O
have	O
investigated	O
abnormal	O
structure	O
and	O
function	O
of	O
pain	O
processing	O
regions	O
in	O
people	O
with	O
MOH	O
,	O
functional	O
patterns	O
that	O
might	O
predispose	O
individuals	O
to	O
development	O
of	O
MOH	O
,	O
similarity	O
of	O
brain	O
functional	O
patterns	O
in	O
patients	O
with	O
MOH	O
to	O
those	O
found	O
in	O
people	O
with	O
addiction	O
,	O
brain	O
structure	O
that	O
could	O
predict	O
headache	O
improvement	O
following	O
discontinuation	O
of	O
the	O
overused	O
medication	O
,	O
and	O
changes	O
in	O
brain	O
structure	O
and	O
function	O
after	O
discontinuation	O
of	O
medication	O
overuse	O
.	O

MOH	O
is	O
associated	O
with	O
atypical	O
structure	O
and	O
function	O
of	O
brain	O
regions	O
responsible	O
for	O
pain	O
processing	O
as	O
well	O
as	O
brain	O
regions	O
that	O
are	O
commonly	O
implicated	O
in	O
addiction	O
.	O

Several	O
studies	O
have	O
shown	O
``	O
normalization	O
''	O
of	O
structure	O
and	O
function	O
in	O
pain	O
processing	O
regions	O
following	O
discontinuation	O
of	O
the	O
overused	O
medication	O
and	O
resolution	O
of	O
MOH	O
.	O

However	O
,	O
some	O
of	O
the	O
abnormalities	O
in	O
regions	O
also	O
implicated	O
in	O
addiction	O
tend	O
to	O
persist	O
following	O
discontinuation	O
of	O
the	O
overused	O
medication	O
,	O
suggesting	O
that	O
they	O
are	O
a	O
brain	O
trait	O
that	O
predisposes	O
certain	O
individuals	O
to	O
medication	O
overuse	O
and	O
MOH	O
.	O

Identification	O
and	O
SAR	O
Evaluation	O
of	O
Hemozoin	O
-	O
Inhibiting	O
Benzamides	O
Active	O
against	O
Plasmodium	O
falciparum	O
.	O

Quinoline	O
antimalarials	O
target	O
hemozoin	O
formation	O
causing	O
a	O
cytotoxic	O
accumulation	O
of	O
ferriprotoporphyrin	O
IX	O
(	O
Fe	O
(	O
III	O
)	O
PPIX	O
)	O
.	O

Well-developed	O
SAR	O
models	O
exist	O
for	O
β-hematin	O
inhibition	O
,	O
parasite	O
activity	O
,	O
and	O
cellular	O
mechanisms	O
for	O
this	O
compound	O
class	O
,	O
but	O
no	O
comparably	O
detailed	O
investigations	O
exist	O
for	O
other	O
hemozoin	O
inhibiting	O
chemotypes	O
.	O

Here	O
,	O
benzamide	O
analogues	O
based	O
on	O
previous	O
HTS	B-P
hits	O
have	O
been	O
purchased	O
or	O
synthesized	O
.	O

Only	O
derivatives	O
containing	O
an	O
electron	O
deficient	O
aromatic	O
ring	O
and	O
capable	O
of	O
adopting	O
flat	O
conformations	O
,	O
optimal	O
for	O
π-π	O
interactions	O
with	O
Fe	O
(	O
III	O
)	O
PPIX	O
,	O
inhibited	O
β-hematin	O
formation	O
.	O

The	O
two	O
most	O
potent	O
analogues	O
showed	O
nanomolar	O
parasite	O
activity	O
,	O
with	O
little	O
CQ	O
cross-resistance	O
,	O
low	O
cytotoxicity	O
,	O
and	O
high	O
in	O
vitro	O
microsomal	O
stability	O
.	O

Selected	O
analogues	O
inhibited	O
hemozoin	O
formation	O
in	O
Plasmodium	O
falciparum	O
causing	O
high	O
levels	O
of	O
free	O
heme	O
.	O

In	O
contrast	O
to	O
quinolines	O
,	O
introduction	O
of	O
amine	O
side	O
chains	O
did	O
not	O
lead	O
to	O
benzamide	O
accumulation	O
in	O
the	O
parasite	O
.	O

These	O
data	O
reveal	O
complex	O
relationships	O
between	O
heme	O
binding	O
,	O
free	O
heme	O
levels	O
,	O
cellular	O
accumulation	O
,	O
and	O
in	O
vitro	O
activity	O
of	O
potential	O
novel	O
antimalarials	O
.	O

A	O
Giant	O
Intra	O
Abdominal	O
Mass	O
Mimicking	O
Renal	O
Cell	O
Carcinoma	O
:	O
A	O
Rare	O
Presentation	O
of	O
Renal	O
Angiomyolipoma	O
.	O

Angiomyolipoma	O
(	O
AML	O
)	O
is	O
a	O
benign	O
tumor	O
commonly	O
found	O
in	O
kidney	O
than	O
extra	O
renal	O
sites	O
.	O

Most	O
of	O
the	O
small	O
renal	O
angiomyolipomas	O
are	O
diagnosed	O
incidentally	O
on	O
ultrasound	B-P
and	O
other	O
imaging	B-P
studies	I-P
.	O

Some	O
renal	O
AMLs	O
present	O
clinically	O
when	O
become	O
very	O
big	O
,	O
giant	O
renal	O
angiomyolipoma	O
.	O

Although	O
almost	O
all	O
cases	O
are	O
benign	O
,	O
a	O
relatively	O
rare	O
variant	O
of	O
epitheloid	O
angiomyolipoma	O
has	O
got	O
malignant	O
potential	O
and	O
can	O
even	O
metastasize	O
.	O

Ultrasonography	B-P
,	O
CT	B-P
and	O
MRI	B-P
scan	I-P
are	O
usually	O
used	O
for	O
diagnosis	O
of	O
angiomyolipoma	O
with	O
high	O
level	O
of	O
accuracy	O
;	O
even	O
though	O
some	O
lesions	O
may	O
be	O
confused	O
as	O
renal	O
cell	O
carcinoma	O
on	O
imaging	B-P
studies	I-P
.	O

Here	O
,	O
a	O
48	O
year	O
old	O
man	O
presented	O
with	O
a	O
large	O
intra-abdominal	O
mass	O
preoperatively	O
diagnosed	O
as	O
a	O
case	O
of	O
right	O
renal	O
cell	O
carcinoma	O
and	O
radical	O
nephrectomy	O
was	O
performed	O
.	O

Histopathology	O
revealed	O
epitheloid	O
angiomyolipoma	O
(	O
EAML	O
)	O
.	O

Chitinibacter	O
fontanus	O
sp	O
.	O

nov.	O
,	O
isolated	O
from	O
a	O
spring	O
.	O

A	O
bacterial	O
strain	O
,	O
designated	O
STM-7T	O
,	O
was	O
isolated	O
from	O
a	O
spring	O
in	O
Taiwan	O
and	O
characterized	O
using	O
a	O
polyphasic	O
taxonomy	O
approach	O
.	O

Cells	O
of	O
strain	O
STM-7T	O
were	O
Gram-staining-negative	O
,	O
aerobic	O
,	O
poly--hydroxybutyrate	O
-accumulating	O
,	O
motile	O
by	O
a	O
single	O
polar	O
flagellum	O
,	O
rod-shaped	O
that	O
were	O
surrounded	O
by	O
a	O
thick	O
capsule	O
and	O
forming	O
milky	O
white	O
colored	O
colonies	O
.	O

Growth	O
occurred	O
at	O
15-37	O
oC	O
(	O
optimum	O
,	O
25-30	O
°C	O
)	O
,	O
at	O
pH	O
6-8	O
(	O
optimum	O
,	O
pH	O
6-7	O
)	O
and	O
with	O
0-2	O
%	O
NaCl	O
(	O
optimum	O
,	O
0-1	O
%	O
)	O
.	O

Phylogenetic	O
analyses	O
based	O
on	O
16S	O
rRNA	O
gene	O
sequences	O
showed	O
that	O
strain	O
STM-7T	O
belonged	O
to	O
the	O
genus	O
Chitinibacter	O
and	O
was	O
most	O
closely	O
related	O
to	O
Chitinibacter	O
tainanensis	O
S1T	O
with	O
sequence	O
similarity	O
of	O
97.3	O
%	O
.	O

Strain	O
STM-7T	O
contained	O
summed	O
feature	O
3	O
(	O
comprising	O
C16:17c	O
and/or	O
C16:16c	O
)	O
and	O
C	O
16:0	O
as	O
the	O
predominant	O
f	O
atty	O
acids	O
.	O

The	O
major	O
h	O
ydroxyl	O
fatty	O
acids	O
were	O
C12:0	O
3-OH	O
and	O
C16:0	O
3-OH	O
.	O

The	O
polar	B-P
lipid	I-P
profile	I-P
consisted	O
of	O
phosphatidylethanolamine	O
,	O
phosphatidylglycerol	O
,	O
diphosphatidylglycerol	O
,	O
an	O
uncharacterized	O
aminophospholipid	O
,	O
an	O
uncharacterized	O
glycolipid	O
and	O
an	O
uncharacterized	O
phospholipid	O
.	O

The	O
major	O
isoprenoid	O
quinone	O
was	O
Q-8	O
.	O

The	O
DNA	O
G+C	O
content	O
of	O
the	O
genomic	O
DNA	O
was	O
52.4	O
mol	O
%	O
.	O

The	O
DNA-DNA	O
hybridization	O
value	O
for	O
strain	O
STM-7T	O
with	O
Chitinibacter	O
tainanensis	O
S1T	O
was	O
less	O
than	O
47	O
%	O
.	O

On	O
the	O
basis	O
of	O
the	O
phylogenetic	O
inference	O
and	O
phenotypic	O
data	O
,	O
strain	O
STM-7T	O
should	O
be	O
classified	O
as	O
a	O
novel	O
species	O
,	O
for	O
which	O
the	O
name	O
Chitinibacter	O
fontanus	O
sp	O
.	O

nov.	O
is	O
proposed	O
.	O

The	O
type	O
strain	O
is	O
STM-7T	O
(	O
=BCRC	O
80923T	O
=LMG	O
29289T	O
=KCTC	O
42982T	O
)	O
.	O

Lack	O
of	O
evidence	O
of	O
lower	O
30-day	O
all-cause	O
readmission	O
in	O
Medicare	O
beneficiaries	O
with	O
heart	O
failure	O
and	O
reduced	O
ejection	O
fraction	O
discharged	O
on	O
spironolactone	O
.	O

Therapy	O
with	O
evidence	O
-based	O
heart	O
failure	O
(	O
HF	O
)	O
medications	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
lower	O
risk	O
of	O
30-day	O
all-cause	O
readmission	O
in	O
patients	O
with	O
HF	O
and	O
reduced	O
ejection	O
fraction	O
(	O
HFrEF	O
)	O
.	O

We	O
examined	O
the	O
association	O
of	O
aldosterone	O
antagonist	O
use	O
with	O
30-day	O
all-cause	O
readmission	O
in	O
this	O
population	O
.	O

Of	O
the	O
2443	O
Medicare	O
beneficiaries	O
with	O
HF	O
and	O
left	O
ventricular	O
EF	O
≤35	O
%	O
discharged	O
home	O
from	O
106	O
Alabama	O
hospitals	O
during	O
1998-2001	O
,	O
2060	O
were	O
eligible	O
for	O
spironolactone	O
therapy	O
(	O
serum	O
creatinine	O
≤2.5	O
for	O
men	O
and	O
≤2mg/dl	O
for	O
women	O
,	O
and	O
serum	B-P
potassium	I-P
<	O
5mEq/L	O
)	O
.	O

After	O
excluding	O
186	O
patients	O
already	O
receiving	O
spironolactone	O
on	O
admission	O
,	O
the	O
inception	O
cohort	O
consisted	O
of	O
1874	O
patients	O
eligible	O
for	O
a	O
new	O
discharge	O
prescription	O
for	O
spironolactone	O
,	O
of	O
which	O
329	O
received	O
one	O
.	O

Using	O
propensity	O
scores	O
for	O
initiation	O
of	O
spironolactone	O
therapy	O
,	O
we	O
assembled	O
a	O
matched	O
cohort	O
of	O
324	O
pairs	O
of	O
patients	O
receiving	O
and	O
not	O
receiving	O
spironolactone	O
balanced	O
on	O
34	O
baseline	O
characteristics	O
(	O
mean	O
age	O
72years	O
,	O
42	O
%	O
women	O
,	O
33	O
%	O
African	O
American	O
)	O
.	O

Thirty-day	O
all-cause	O
readmission	O
occurred	O
in	O
17	O
%	O
and	O
19	O
%	O
of	O
matched	O
patients	O
receiving	O
and	O
not	O
receiving	O
spironolactone	O
,	O
respectively	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
0.92	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.64-1.32	O
;	O
p=0.650	O
)	O
.	O

Spironolactone	O
had	O
no	O
association	O
with	O
30-day	O
all-cause	O
mortality	O
(	O
HR	O
,	O
0.84	O
;	O
95	O
%	O
CI	O
,	O
0.38-1.88	O
;	O
p=0.678	O
)	O
or	O
HF	O
readmission	O
(	O
HR	O
,	O
0.74	O
;	O
95	O
%	O
CI	O
,	O
0.41	O
1.31	O
;	O
p=0.301	O
)	O
.	O

These	O
associations	O
remained	O
unchanged	O
during	O
12months	O
of	O
post-discharge	O
follow-up	O
.	O

A	O
discharge	O
prescription	O
for	O
spironolactone	O
had	O
no	O
association	O
with	O
30-day	O
all-cause	O
readmission	O
among	O
older	O
,	O
hospitalized	O
Medicare	O
beneficiaries	O
with	O
HFrEF	O
eligible	O
for	O
spironolactone	O
therapy	O
.	O

Perioperative	O
Transfusion	O
of	O
Leukocyte	O
-	O
depleted	O
Blood	O
Products	O
in	O
Contemporary	O
Radical	O
Cystectomy	O
Cohort	O
Does	O
Not	O
Adversely	O
Impact	O
Short-term	O
Survival	O
.	O

To	O
evaluate	O
the	O
effect	O
of	O
leukoreduced	O
-only	O
perioperative	O
blood	O
transfusion	O
(	O
PBT	O
)	O
and	O
corresponding	O
survival	O
outcomes	O
in	O
a	O
radical	O
cystectomy	O
cohort	O
of	O
patients	O
.	O

We	O
analyzed	O
data	O
from	O
1026	O
patients	O
who	O
underwent	O
radical	O
cystectomy	O
at	O
our	O
institution	O
.	O

PBT	O
was	O
defined	O
as	O
transfusion	O
in	O
the	O
intraoperative	O
or	O
within	O
the	O
postoperative	O
hospitalization	O
period	O
.	O

Multivariable	O
analyses	O
using	O
Cox	O
proportional	O
hazards	O
were	O
performed	O
to	O
measure	O
the	O
association	O
between	O
PBT	O
,	O
patient	O
variables	O
,	O
and	O
3	O
primary	O
end	O
points	O
:	O
recurrence-free	O
survival	O
,	O
disease-specific	O
survival	O
,	O
and	O
overall	O
survival	O
.	O

Kaplan-Meier	O
curves	O
estimated	O
survival	O
times	O
and	O
were	O
compared	O
with	O
log-rank	B-P
test	I-P
.	O

Overall	O
,	O
of	O
a	O
total	O
of	O
1026	O
patients	O
,	O
341	O
(	O
33.2	O
%	O
)	O
received	O
leukoreduced	O
PBT	O
.	O

The	O
median	O
follow-up	O
was	O
27.5	O
months	O
.	O

Transfused	O
patients	O
were	O
more	O
likely	O
to	O
be	O
female	O
,	O
had	O
higher	O
estimated	O
blood	O
loss	O
,	O
lower	O
preoperative	O
hemoglobin	O
,	O
were	O
more	O
likely	O
to	O
have	O
received	O
neoadjuvant	O
chemotherapy	O
,	O
or	O
had	O
undergone	O
a	O
continent	O
urinary	O
diversion	O
.	O

Higher	O
pathologic	O
tumor	O
and	O
nodal	O
stage	O
were	O
observed	O
more	O
frequently	O
in	O
patients	O
who	O
received	O
PBT	O
.	O

On	O
multivariable	O
analysis	O
,	O
PBT	O
was	O
not	O
associated	O
with	O
worse	O
recurrence-free	O
survival	O
,	O
disease-specific	O
survival	O
,	O
and	O
overall	O
survival	O
(	O
all	O
P	O
>	O
.05	O
)	O
.	O

Kaplan-Meier	O
curves	O
did	O
not	O
show	O
any	O
significant	O
differences	O
(	O
all	O
P	O
>	O
.05	O
)	O
between	O
the	O
transfused	O
and	O
nontransfused	O
groups	O
.	O

In	O
addition	O
,	O
no	O
differences	O
were	O
found	O
in	O
regard	O
to	O
timing	O
of	O
transfusion	O
,	O
that	O
is	O
,	O
intraoperative	O
vs	O
postoperative	O
,	O
in	O
distinct	O
analysis	O
.	O

No	O
significant	O
association	O
was	O
found	O
between	O
leukoreduced	O
PBT	O
and	O
worse	O
survival	O
outcomes	O
at	O
short-term	O
follow-up	O
in	O
a	O
contemporary	O
cohort	O
of	O
cystectomy	O
patients	O
.	O

Prospective	O
long-term	O
follow-up	O
is	O
warranted	O
.	O

Generation	O
of	O
a	O
Three-Dimensional	O
Retinal	O
Tissue	O
from	O
Self-Organizing	O
Human	O
ESC	O
Culture	O
.	O

A	O
three-dimensional	O
(	O
3D	O
)	O
tissue	O
generated	O
in	O
vitro	O
is	O
a	O
promising	O
source	O
to	O
study	O
developmental	O
biology	O
and	O
regenerative	O
medicine	O
.	O

In	O
the	O
last	O
decade	O
,	O
Yoshiki	O
Sasai	O
's	O
group	O
have	O
developed	O
a	O
3D	O
stem	O
cell	O
culture	B-P
technique	I-P
known	O
as	O
SFEBq	B-P
and	O
demonstrated	O
that	O
embryonic	O
stem	O
cells	O
(	O
ESCs	O
)	O
have	O
an	O
ability	O
to	O
self-organize	O
stratified	O
neural	O
tissue	O
including	O
3D	O
-	O
retina	O
.	O

Furthermore	O
,	O
we	O
have	O
reported	O
that	O
ESC-derived	O
retinal	O
tissue	O
can	O
form	O
an	O
optic	O
cup	O
and	O
a	O
ciliary	O
margin	O
,	O
which	O
are	O
unique	O
structures	O
in	O
the	O
developing	O
retina	O
.	O

In	O
this	O
review	O
,	O
we	O
focus	O
on	O
self-organizing	O
culture	B-P
technique	I-P
to	O
generate	O
3D	O
-	O
retina	O
from	O
human	O
ESCs	O
.	O

Targeting	O
postprandial	B-P
blood	I-P
sugar	I-P
over	O
fasting	B-P
blood	I-P
sugar	I-P
:	O
A	O
clinic	O
based	O
comparative	O
study	O
.	O

Recent	O
studies	O
indicate	O
that	O
modulation	O
of	O
post	O
prandial	O
blood	O
sugar	O
(	O
PPBS	O
)	O
plays	O
an	O
important	O
role	O
in	O
the	O
long	O
term	O
glycemic	O
control	O
.	O

Measurement	B-P
of	I-P
PPBS	I-P
is	O
more	O
convenient	O
for	O
patients	O
attending	O
outpatient	O
clinics	O
than	O
fasting	B-P
blood	I-P
sugar	I-P
(	O
FBS	B-P
)	O
as	O
the	O
former	O
needs	O
only	O
two	O
hours	O
of	O
fasting	O
from	O
the	O
last	O
meal	O
.	O

To	O
assess	O
the	O
value	O
of	O
PPBS	B-P
monitoring	O
in	O
optimization	O
of	O
long	O
term	O
glycemic	O
control	O
among	O
diabetic	O
patients	O
attending	O
an	O
outpatient	O
clinic	O
.	O

A	O
total	O
of	O
240	O
patients	O
with	O
type	O
2	O
diabetes	O
(	O
T2DM	O
)	O
attending	O
an	O
out-patient	O
medical	O
clinic	O
were	O
randomized	O
to	O
either	O
PPBS	B-P
or	O
FBS	B-P
monitoring	O
.	O

Those	O
who	O
selected	O
to	O
PPBS	O
-	O
group	O
underwent	O
blood	B-P
sugar	I-P
measurement	I-P
2-h	O
after	O
last	O
meal	O
on	O
the	O
day	O
of	O
their	O
clinic	O
visits	O
and	O
those	O
in	O
the	O
FBS	O
group	O
underwent	O
blood	B-P
sugar	I-P
measurement	I-P
after	I-P
fasting	I-P
overnight	O
(	O
8-10h	O
)	O
in	O
the	O
morning	O
of	O
their	O
clinic	O
visits	O
.	O

Treating	O
team	O
was	O
asked	O
to	O
optimize	O
the	O
anti-diabetic	O
medications	O
based	O
on	O
the	O
available	O
PPBS	O
or	O
FBS	O
results	O
.	O

All	O
patients	O
were	O
followed	O
up	O
monthly	O
for	O
six	O
months	O
.	O

Glycemic	O
control	O
was	O
assessed	O
with	O
glycosylated	O
hemoglobin	O
(	O
HbA1c	O
)	O
at	O
baseline	O
and	O
six	O
months	O
later	O
.	O

Baseline	O
characteristics	O
of	O
the	O
two	O
arms	O
including	O
age	O
,	O
gender	O
,	O
and	O
duration	O
of	O
T2DM	O
were	O
not	O
significantly	O
different	O
.	O

Mean	O
HbA1c	O
(	O
SD	O
)	O
of	O
FBS	B-P
and	O
PPBS	B-P
arms	O
at	O
baseline	O
were	O
7.20	O
(	O
0.45	O
)	O
,	O
and	O
7.33	O
(	O
0.43	O
)	O
and	O
were	O
not	O
significantly	O
different	O
(	O
P=0.115	O
)	O
.	O

During	O
the	O
study	O
period	O
,	O
HbA1c	O
dropped	O
by	O
0.20	O
in	O
FBS	B-P
arm	O
compared	O
to	O
0.25	O
drop	O
in	O
PPBS	B-P
arm	O
(	O
p=0.59	O
)	O
.	O

Incidence	O
of	O
hypoglycemia	O
was	O
similar	O
in	O
FBS	B-P
(	O
2.42	O
%	O
)	O
and	O
PPBS	B-P
arms	O
(	O
2.70	O
%	O
)	O
.	O

Monitoring	O
of	O
PPBS	O
is	O
a	O
safe	O
and	O
effective	O
alternative	O
to	O
FBS	B-P
to	O
optimize	O
glycemic	O
control	O
in	O
managing	O
patients	O
with	O
T2DM	O
attending	O
outpatient	O
clinics	O
.	O

DNA	O
barcoding	O
and	O
phylogenetic	O
relationships	O
of	O
Ardeidae	O
(	O
Aves	O
:	O
Ciconiiformes	O
)	O
.	O

The	O
avian	O
family	O
Ardeidae	O
comprises	O
long-legged	O
freshwater	O
and	O
coastal	O
birds	O
.	O

There	O
has	O
been	O
considerable	O
disagreement	O
concerning	O
the	O
intrafamilial	O
relationships	O
of	O
Ardeidae	O
.	O

Mitochondrial	O
cytochrome	O
c	O
oxidase	O
subunit	O
I	O
(	O
COI	O
)	O
was	O
used	O
as	O
a	O
marker	O
for	O
the	O
identification	O
and	O
phylogenetic	O
analysis	O
of	O
avian	O
species	O
.	O

In	O
the	O
present	O
study	B-P
,	O
we	O
analyzed	O
the	O
COI	O
barcodes	O
of	O
32	O
species	O
from	O
17	O
genera	O
belonging	O
to	O
the	O
family	O
Ardeidae	O
.	O

Each	O
bird	O
species	O
possessed	O
a	O
barcode	O
distinct	O
from	O
that	O
of	O
other	O
bird	O
species	O
except	O
for	O
Egretta	O
thula	O
and	O
E.	O
garzetta	O
,	O
which	O
shared	O
one	O
barcoding	O
sequence	O
.	O

Kimura	O
two-parameter	O
distances	O
were	O
calculated	O
between	O
barcodes	O
.	O

The	O
average	O
genetic	O
distance	O
between	O
species	O
was	O
34-fold	O
higher	O
than	O
the	O
average	O
genetic	O
distance	O
within	O
species	O
.	O

Neighbor	O
-	O
joining	O
and	O
maximum	O
likelihood	O
methods	O
were	O
used	O
to	O
construct	O
phylogenetic	O
trees	O
.	O

Most	O
species	O
could	O
be	O
discriminated	O
by	O
their	O
distinct	O
clades	O
in	O
the	O
phylogenetic	O
tree	O
.	O

Both	O
methods	O
of	O
phylogenetic	O
reconstruction	O
suggested	O
that	O
Zebrilus	O
,	O
Tigrisoma	O
,	O
and	O
Cochlearius	O
were	O
an	O
offshoot	O
of	O
the	O
primitive	O
herons	O
.	O

COI	O
gene	O
analysis	O
suggested	O
that	O
the	O
other	O
herons	O
could	O
be	O
divided	O
into	O
two	O
clades	O
:	O
Botaurinae	O
and	O
Ardeinae	O
.	O

Our	O
results	O
support	O
the	O
Great	O
Egret	O
and	O
Intermediate	O
Egret	O
being	O
in	O
separate	O
genera	O
,	O
Casmerodius	O
and	O
Mesophoyx	O
,	O
respectively	O
.	O

Sleep	O
Quantity	O
and	O
Quality	O
during	O
Acute	O
Concussion	O
:	O
A	O
Pilot	O
Study	O
.	O

A	O
number	O
of	O
subjective	O
and	O
objective	O
studies	O
provide	O
compelling	O
evidence	O
of	O
chronic	O
post-concussion	O
changes	O
in	O
sleep	O
,	O
yet	O
very	O
little	O
is	O
known	O
about	O
the	O
acute	O
effects	O
of	O
concussion	O
on	O
sleep	O
quality	O
and	O
quantity	O
.	O

Therefore	O
,	O
the	O
purpose	O
of	O
this	O
prospective	O
pilot	O
study	O
was	O
to	O
use	O
actigraphy	B-P
to	O
examine	O
the	O
changes	O
in	O
sleep	O
quality	O
and	O
quantity	O
acutely	O
following	O
concussion	O
at	O
home	O
rather	O
than	O
in	O
a	O
hospital	O
or	O
sleep	O
laboratory	O
.	O

Seventeen	O
young	O
adults	O
(	O
7	O
with	O
acute	O
concussion	O
,	O
10	O
controls	O
)	O
were	O
recruited	O
for	O
this	O
study	O
.	O

All	O
participants	O
completed	O
two	O
5-	O
day	O
testing	O
sessions	O
separated	O
by	O
30	O
days	O
from	O
intake	O
(	O
controls	O
)	O
or	O
day	O
of	O
injury	O
(	O
concussion	O
)	O
.	O

Participants	O
wore	O
actigraphs	O
and	O
kept	O
a	O
sleep	O
journal	O
.	O

Sleep	O
parameter	O
outcomes	O
included	O
nighttime	O
total	O
sleep	O
time	O
(	O
nTST	O
)	O
,	O
24-	O
h	O
total	O
sleep	O
time	O
(	O
TST	O
)	O
,	O
wake	O
after	O
sleep	O
onset	O
(	O
WASO	O
)	O
,	O
and	O
sleep	O
efficiency	O
(	O
SE	O
)	O
.	O

The	O
coefficient	O
of	O
variation	O
(	O
CV	O
)	O
for	O
each	O
sleep	O
parameter	O
was	O
computed	B-P
for	O
each	O
session	O
.	O

nTST	O
and	O
TST	O
CV	O
was	O
significantly	O
greater	O
in	O
the	O
concussion	O
group	O
.	O

There	O
is	O
the	O
additional	O
indication	O
that	O
individuals	O
with	O
a	O
concussion	O
may	O
require	O
and	O
obtain	O
more	O
sleep	O
shortly	O
after	O
injury	O
and	O
subsequently	O
have	O
a	O
shorter	O
duration	O
of	O
sleep	O
at	O
1	O
mo	O
post-injury	O
.	O

This	O
pattern	O
was	O
not	O
seen	O
in	O
the	O
measures	O
of	O
sleep	O
quality	O
(	O
WASO	O
,	O
SE	O
)	O
.	O

Individuals	O
with	O
a	O
concussion	O
demonstrated	O
increased	O
nighttime	O
sleep	O
duration	O
variability	O
.	O

This	O
increase	O
persisted	O
at	O
1	O
mo	O
post-injury	O
and	O
may	O
be	O
associated	O
with	O
previously	O
documented	O
self-reports	O
of	O
poor	O
sleep	O
quality	O
lasting	O
months	O
and	O
years	O
after	O
a	O
concussion	O
.	O

Additionally	O
,	O
this	O
increase	O
may	O
predispose	O
individuals	O
to	O
numerous	O
negative	O
health	O
outcomes	O
if	O
left	O
untreated	O
.	O

Meibomian	O
gland	O
dysfunction	O
and	O
its	O
determinants	O
in	O
Iranian	O
adults	O
:	O
A	O
population-based	O
study	O
.	O

To	O
estimate	O
the	O
prevalence	O
of	O
Meibomian	O
gland	O
dysfunction	O
(	O
MGD	O
)	O
and	O
determine	O
the	O
associated	O
factors	O
in	O
the	O
general	O
population	O
in	O
Iran	O
.	O

This	O
cross-sectional	O
study	O
is	O
based	O
on	O
the	O
data	O
from	O
the	O
second	O
phase	O
of	O
the	O
Shahroud	O
Eye	O
Cohort	O
Study	O
conducted	O
in	O
2014	O
.	O

Of	O
the	O
4737	O
participants	O
of	O
the	O
second	O
phase	O
,	O
data	O
was	O
available	O
for	O
4700	O
people	O
;	O
their	O
mean	O
age	O
was	O
55.9±6.2	O
years	O
and	O
2768	O
(	O
58.9	O
%	O
)	O
were	O
women	O
.	O

Diagnosis	O
of	O
MGD	O
was	O
made	O
based	O
on	O
the	O
classification	O
of	O
the	O
International	O
Workshop	O
on	O
MGD	O
as	O
judged	O
by	O
the	O
examining	O
ophthalmologist	O
.	O

The	O
prevalence	O
of	O
MGD	O
was	O
summarized	O
as	O
percentage	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
,	O
and	O
related	O
factors	O
were	O
studied	O
through	O
simple	O
and	O
multiple	O
logistic	O
regressions	O
.	O

The	O
diagnosis	O
of	O
MGD	O
in	O
at	O
least	O
one	O
eye	O
was	O
recorded	O
for	O
1235	O
(	O
26.3	O
%	O
)	O
participants	O
;	O
the	O
prevalence	O
of	O
unilateral	O
and	O
bilateral	O
MGD	O
was	O
26.3	O
%	O
(	O
95	O
%	O
CI	O
:	O
24.5-28.1	O
)	O
and	O
26.1	O
%	O
(	O
95	O
%	O
CI	O
:	O
24.3-27.9	O
)	O
,	O
respectively	O
.	O

In	O
the	O
multiple	O
logistic	O
regression	O
analyses	O
,	O
MGD	O
significantly	O
correlated	O
with	O
pinguecula	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
=1.3	O
,	O
95	O
%	O
CI	O
:	O
1.12-1.50	O
]	O
,	O
hypertension	O
(	O
OR	O
=1.34	O
,	O
95	O
%	O
CI	O
:	O
1.11-1.61	O
)	O
,	O
high-density	B-P
lipoprotein	I-P
(	I-P
HDL	I-P
)	I-P
level	I-P
(	O
OR	O
=0.0992	O
,	O
95	O
%	O
CI	O
:	O
0.986-0.999	O
)	O
,	O
diabetes	O
mellitus	O
(	O
OR	O
=0.83	O
,	O
95	O
%	O
CI	O
:	O
0.71-0.97	O
)	O
,	O
and	O
years	O
of	O
education	O
(	O
OR	O
=0.98	O
,	O
95	O
%	O
CI	O
:	O
0.96-0.99	O
)	O
.	O

MGD	O
prevalence	O
in	O
this	O
study	O
was	O
lower	O
than	O
the	O
rates	O
reported	O
in	O
other	O
studies	O
on	O
Asian	O
populations	O
.	O

Besides	O
HDL	B-P
level	I-P
,	O
MGD	O
is	O
associated	O
with	O
another	O
ocular	O
surface	O
disorder	O
,	O
namely	O
pinguecula	O
,	O
as	O
well	O
as	O
certain	O
systemic	O
diseases	O
such	O
as	O
hypertension	O
and	O
diabetes	O
mellitus	O
.	O

These	O
associations	O
should	O
be	O
taken	O
into	O
consideration	O
when	O
diagnosing	O
MGD	O
.	O

Identification	O
and	O
functional	O
analysis	O
of	O
the	O
GTPV	O
bidirectional	O
promoter	O
region	O
.	O

The	O
goat	O
pox	O
chick	O
embryo-attenuated	O
virus	O
(	O
GTPV	O
)	O
has	O
been	O
developed	O
as	O
an	O
effective	O
vaccine	O
that	O
can	O
elicit	O
protective	O
immune	O
responses	O
.	O

It	O
possesses	O
a	O
large	O
genome	O
and	O
a	O
robust	O
ability	O
to	O
express	O
exogenous	O
genes	O
.	O

Thus	O
,	O
this	O
virus	O
is	O
an	O
ideal	O
vector	O
for	O
recombinant	O
live	O
vaccines	O
for	O
infectious	O
diseases	O
in	O
ruminant	O
animals	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
a	O
novel	O
bidirectional	O
promoter	O
region	O
of	O
GTPV	O
through	O
screening	O
named	O
PbVV	O
(	O
±	O
)	O
.	O

PbVV	O
(	O
±	O
)	O
is	O
located	O
between	O
ETF-l	O
and	O
VITF-3	O
,	O
which	O
are	O
transcribed	O
in	O
opposite	O
directions	O
.	O

A	O
new	O
recombinant	O
goat	O
pox	O
virus	O
(	O
rGTPV	O
)	O
was	O
constructed	O
,	O
in	O
which	O
duplicate	O
PbVV	O
(	O
+	O
)	O
was	O
used	O
as	O
a	O
promoter	O
element	O
to	O
enhance	O
Brucella	O
OMP31	O
expression	O
,	O
and	O
duplicate	O
PbVV	O
(	O
-	O
)	O
was	O
used	O
as	O
a	O
promoter	O
element	O
to	O
regulate	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
EGFP	O
)	O
at	O
the	O
same	O
time	O
as	O
the	O
selection	O
marker	O
.	O

PbVV	O
(	O
-	O
)	O
promoter	O
activity	O
was	O
compared	O
to	O
that	O
of	O
the	O
P7.5	O
promoter	O
of	O
vaccinia	O
virus	O
,	O
as	O
measured	O
by	O
EGFP	O
expression	O
;	O
the	O
fluorescence	B-P
intensity	I-P
of	O
EGFP	O
expressed	O
in	O
cells	O
was	O
confirmed	O
by	O
fluorescence	B-P
microscopy	I-P
and	O
flow	B-P
cytometry	I-P
.	O

PbVV	O
(	O
+	O
)	O
promoter	O
activity	O
was	O
measured	O
by	O
Brucella	O
OMP31	O
expression	O
.	O

Interaction	O
with	O
the	O
anti-Brucella-OMP31	O
monoclonal	O
antibody	O
was	O
confirmed	O
by	O
western	O
blotting	O
,	O
and	O
OMP31	O
mRNA	O
expression	O
was	O
assessed	O
by	O
qRT-PCR	O
.	O

The	O
results	O
of	O
this	O
study	O
will	O
be	O
useful	O
for	O
the	O
further	O
study	O
of	O
effective	O
multivalent	O
vaccines	O
based	O
on	O
rGTPV	O
.	O

This	O
study	O
also	O
provides	O
a	O
theoretical	O
basis	O
for	O
overcoming	O
the	O
problem	O
of	O
low	O
expression	O
of	O
exogenous	O
genes	O
.	O

Total	O
Arsenic	O
,	O
Cadmium	O
,	O
and	O
Lead	O
Determination	B-P
in	O
Brazilian	O
Rice	O
Samples	O
Using	O
ICP-MS	B-P
.	O

This	O
study	O
is	O
aimed	O
at	O
investigating	O
a	O
suitable	O
method	O
for	O
rice	O
sample	O
preparation	O
as	O
well	O
as	O
validating	O
and	O
applying	O
the	O
method	O
for	O
monitoring	O
the	O
concentration	O
of	O
total	O
arsenic	O
,	O
cadmium	O
,	O
and	O
lead	O
in	O
rice	O
by	O
using	O
Inductively	B-P
Coupled	I-P
Plasma	I-P
Mass	I-P
Spectrometry	I-P
(	O
ICP-MS	B-P
)	O
.	O

Various	O
rice	O
sample	O
preparation	O
procedures	O
were	O
evaluated	O
.	O

The	O
analytical	O
method	O
was	O
validated	O
by	O
measuring	O
several	O
parameters	O
including	O
limit	O
of	O
detection	O
(	O
LOD	O
)	O
,	O
limit	O
of	O
quantification	O
(	O
LOQ	O
)	O
,	O
linearity	O
,	O
relative	O
bias	O
,	O
and	O
repeatability	O
.	O

Regarding	O
the	O
sample	O
preparation	O
,	O
recoveries	O
of	O
spiked	O
samples	O
were	O
within	O
the	O
acceptable	O
range	O
from	O
89.3	O
to	O
98.2	O
%	O
for	O
muffle	O
furnace	O
,	O
94.2	O
to	O
103.3	O
%	O
for	O
heating	O
block	O
,	O
81.0	O
to	O
115.0	O
%	O
for	O
hot	O
plate	O
,	O
and	O
92.8	O
to	O
108.2	O
%	O
for	O
microwave	O
.	O

Validation	O
parameters	O
showed	O
that	O
the	O
method	O
fits	O
for	O
its	O
purpose	O
,	O
being	O
the	O
total	O
arsenic	O
,	O
cadmium	O
,	O
and	O
lead	O
within	O
the	O
Brazilian	O
Legislation	O
limits	O
.	O

The	O
method	O
was	O
applied	O
for	O
analyzing	O
37	O
rice	O
samples	O
(	O
including	O
polished	O
,	O
brown	O
,	O
and	O
parboiled	O
)	O
,	O
consumed	O
by	O
the	O
Brazilian	O
population	O
.	O

The	O
total	O
arsenic	O
,	O
cadmium	O
,	O
and	O
lead	O
contents	O
were	O
lower	O
than	O
the	O
established	O
legislative	O
values	O
,	O
except	O
for	O
total	O
arsenic	O
in	O
one	O
brown	O
rice	O
sample	O
.	O

This	O
study	O
indicated	O
the	O
need	O
to	O
establish	O
monitoring	O
programs	O
for	O
emphasizing	O
the	O
study	O
on	O
this	O
type	O
of	O
cereal	O
,	O
aiming	O
at	O
promoting	O
the	O
Public	O
Health	O
.	O

The	O
influence	O
of	O
different	O
long-circulating	O
materials	O
on	O
the	O
pharmacokinetics	O
of	O
liposomal	O
vincristine	O
sulfate	O
.	O

This	O
study	O
was	O
designed	O
to	O
improve	O
the	O
in	O
vivo	O
pharmacokinetics	O
of	O
long-circulating	O
vincristine	O
sulfate	O
(	O
VS	O
)	O
-loaded	O
liposomes	O
;	O
three	O
different	O
long-circulating	O
materials	O
,	O
chitosan	O
,	O
poly	O
(	O
ethylene	O
glycol	O
)	O
-1,2-distearoyl	O
sn-glycero-3-phosphatidylethanolamine	O
(	O
PEG-DSPE	O
)	O
,	O
and	O
poly	O
(	O
ethylene	O
glycol	O
)	O
-poly-lactide-co-glycolide	O
(	O
PEG-PLGA	O
)	O
,	O
were	O
evaluated	O
at	O
the	O
same	O
coating	O
molar	O
ratio	O
with	O
the	O
commercial	O
product	O
Marqibo	O
(	O
®	O
)	O
(	O
vincristine	O
sulfate	O
liposome	O
injection	O
[	O
VSLI	O
]	O
)	O
.	O

VS-loaded	O
liposomes	O
were	O
prepared	O
by	O
a	O
pH	B-P
gradient	I-P
method	I-P
and	O
were	O
then	O
coated	O
with	O
chitosan	O
,	O
PEG-DSPE	O
,	O
or	O
PEG-PLGA	O
.	O

Physicochemical	O
properties	O
,	O
including	O
the	O
morphology	O
,	O
particle	O
size	O
,	O
zeta	O
potential	O
,	O
encapsulation	O
efficiency	O
(	O
EE	O
%	O
)	O
,	O
pH	O
,	O
drug	O
loading	O
,	O
and	O
in	O
vitro	O
release	O
,	O
were	O
determined	O
.	O

Preservation	B-P
stability	O
and	O
pharmacokinetic	O
studies	O
were	O
performed	O
to	O
compare	O
the	O
membrane-coated	O
liposomes	O
with	O
either	O
commercially	O
available	O
liposomes	O
or	O
the	O
VS	O
solution	O
.	O

The	O
sphere-like	O
morphology	O
of	O
the	O
vesicles	O
was	O
confirmed	O
by	O
transmission	B-P
electron	I-P
microscope	I-P
.	O

Increased	O
particle	O
size	O
,	O
especially	O
for	O
the	O
chitosan	O
formulation	O
,	O
was	O
observed	O
after	O
the	O
coating	O
process	O
.	O

However	O
,	O
the	O
EE	O
%	O
was	O
~99.0	O
%	O
with	O
drug	O
loading	O
at	O
2.0	O
mg/mL	O
,	O
which	O
did	O
not	O
change	O
after	O
the	O
coating	O
process	O
.	O

The	O
coating	O
of	O
long-circulation	O
materials	O
,	O
except	O
for	O
chitosan	O
,	O
resulted	O
in	O
negatively	O
charged	O
and	O
stable	O
vesicles	O
at	O
physiological	O
pH	O
.	O

The	O
near-zero	O
zeta	O
potential	O
exhibited	O
by	O
the	O
PEG-DSPE	O
formulation	O
leads	O
to	O
a	O
long	O
er	O
circulation	O
lifetime	O
and	O
improved	O
absorption	O
for	O
VS	O
,	O
when	O
compared	O
with	O
the	O
PEG-PLGA	O
formulation	O
.	O

Compared	O
with	O
the	O
commercial	O
product	O
,	O
PEG	O
was	O
responsible	O
for	O
a	O
higher	O
plasma	O
VS	O
concentration	O
and	O
a	O
longer	O
half-life	O
.	O

PEG-DSPE	O
coating	O
may	O
be	O
related	O
to	O
better	O
absorption	O
,	O
based	O
on	O
the	O
stability	O
and	O
a	O
pharmacokinetic	O
improvement	O
in	O
the	O
blood	B-P
circulation	I-P
time	I-P
.	O

Association	O
of	O
C-Reactive	O
Protein	O
(	O
rs1205	O
)	O
Gene	O
Polymorphism	O
with	O
Susceptibility	O
to	O
Psoriasis	O
in	O
South	O
Indian	O
Tamils	O
.	O

Psoriasis	O
is	O
a	O
multi-factorial	O
heritable	O
T-helper	O
Th-1	O
/	O
Th-17	O
mediated	O
inflammatory	O
disease	O
,	O
affecting	O
the	O
skin	O
.	O

It	O
is	O
associated	O
with	O
co-morbidities	O
such	O
as	O
Cardiovascular	O
Disease	O
(	O
CVD	O
)	O
.	O

C-Reactive	O
Protein	O
(	O
CRP	O
)	O
is	O
a	O
good	O
inflammatory	O
marker	O
.	O

CRP	O
rs1205	O
polymorphism	O
is	O
associated	O
with	O
circulating	O
plasma	O
CRP	O
levels	O
.	O

Although	O
there	O
is	O
association	O
between	O
the	O
rs1205	O
Single	O
Nucleotide	O
Polymorphism	O
(	O
SNP	O
)	O
and	O
CVD	O
,	O
there	O
are	O
no	O
prior	O
reports	O
regarding	O
the	O
association	O
of	O
CRP	O
rs1205	O
SNP	O
with	O
psoriasis	O
susceptibility	O
.	O

To	O
study	O
the	O
association	O
of	O
the	O
genetic	O
variant	O
rs1205	O
in	O
the	O
CRP	O
gene	O
with	O
susceptibility	O
to	O
the	O
disease	O
and	O
protein	O
levels	O
in	O
South	O
Indian	O
Tamils	O
with	O
psoriasis	O
.	O

In	O
this	O
case-control	O
genetic	O
study	O
,	O
300	O
cases	O
of	O
psoriasis	O
and	O
300	O
age	O
and	O
gender	O
matched	O
controls	O
were	O
genotyped	O
for	O
CRP	O
SNP	O
rs1205	O
using	O
Taq	B-P
Man	I-P
5'allele	I-P
discrimination	I-P
assay	I-P
at	O
Jawaharlal	O
Institute	O
of	O
Postgraduate	O
Medical	O
Education	O
and	O
Research	O
,	O
Puducherry	O
,	O
India	O
from	O
February	O
2014	O
to	O
January	O
2016	O
.	O

Plasma	O
high	B-P
sensitivity	I-P
(	O
hs	B-P
)	O
-	O
CRP	O
levels	O
were	O
estimated	O
by	O
ELISA	B-P
.	O

Disease	O
severity	O
was	O
assessed	O
by	O
Psoriasis	O
Area	O
Severity	O
Index	O
(	O
PASI	O
)	O
.	O

CRP	O
genetic	O
variation	O
rs1205	O
was	O
not	O
associated	O
with	O
psoriasis	O
risk	O
in	O
our	O
South	O
Indian	O
Tamil	O
population	O
.	O

However	O
,	O
the	O
circulating	O
levels	O
of	O
hs	B-P
-	O
CRP	O
was	O
significantly	O
higher	O
in	O
patients	O
with	O
psoriasis	O
,	O
as	O
compared	O
with	O
controls	O
(	O
p	O
<	O
0.0001	O
)	O
and	O
the	O
protein	O
levels	O
were	O
significantly	O
associated	O
with	O
disease	O
severity	O
,	O
as	O
assessed	O
by	O
PASI	O
scoring	O
.	O

No	O
genotype	O
was	O
found	O
significantly	O
associated	O
with	O
PASI	O
or	O
CRP	O
levels	O
.	O

Our	O
results	O
suggest	O
that	O
plasma	O
CRP	O
levels	O
are	O
higher	O
in	O
patients	O
with	O
psoriasis	O
and	O
correlate	O
with	O
disease	O
severity	O
,	O
whilst	O
CRP	O
rs1205	O
is	O
not	O
associated	O
with	O
susceptibility	O
to	O
psoriasis	O
in	O
South	O
Indian	O
Tamils	O
.	O

Nonstenotic	O
carotid	O
plaque	O
on	O
CT	B-P
angiography	I-P
in	O
patients	O
with	O
cryptogenic	O
stroke	O
.	O

To	O
determine	O
whether	O
large	O
(	O
≥3	O
mm	O
thick	O
)	O
but	O
nonstenotic	O
(	O
<	O
50	O
%	O
)	O
carotid	O
artery	O
atherosclerotic	O
plaque	O
predominantly	O
occurs	O
ipsilateral	O
rather	O
than	O
contralateral	O
to	O
cryptogenic	O
stroke	O
.	O

This	O
was	O
a	O
cross-sectional	O
observational	O
study	O
.	O

Using	O
a	O
stroke	O
registry	O
,	O
we	O
identified	O
consecutive	O
patients	O
with	O
anterior	O
circulation	O
embolic	O
stroke	O
of	O
undetermined	O
source	O
(	O
ESUS	O
)	O
.	O

Using	O
CT	B-P
angiography	I-P
,	O
we	O
measured	O
carotid	O
plaque	O
size	O
(	O
thickness	O
,	O
mm	O
)	O
and	O
carotid	O
artery	O
stenosis	O
(	O
North	O
American	O
Symptomatic	O
Carotid	O
Endarterectomy	O
Trial	O
method	O
)	O
for	O
each	O
patient	O
.	O

We	O
dichotomized	O
plaque	O
size	O
at	O
several	O
predefined	O
thresholds	O
and	O
calculated	O
the	O
frequency	O
of	O
plaque	O
size	O
above	O
each	O
threshold	O
ipsilateral	O
vs	O
contralateral	O
to	O
stroke	O
.	O

We	O
included	O
85	O
patients	O
with	O
ESUS	O
.	O

Plaque	O
with	O
thickness	O
≥5	O
mm	O
was	O
present	O
ipsilateral	O
to	O
stroke	O
in	O
11	O
%	O
of	O
patients	O
,	O
and	O
contralateral	O
in	O
1	O
%	O
(	O
9/85	O
vs	O
1/85	O
;	O
p	O
=	O
0.008	O
)	O
.	O

Plaque	O
with	O
thickness	O
≥4	O
mm	O
was	O
present	O
ipsilateral	O
to	O
stroke	O
in	O
19	O
%	O
of	O
patients	O
,	O
and	O
contralateral	O
in	O
5	O
%	O
(	O
16/85	O
vs	O
4/85	O
;	O
p	O
=	O
0.002	O
)	O
.	O

Plaque	O
with	O
thickness	O
≥3	O
mm	O
was	O
present	O
ipsilateral	O
to	O
stroke	O
in	O
35	O
%	O
of	O
patients	O
,	O
and	O
contralateral	O
in	O
15	O
%	O
(	O
30/85	O
vs	O
13/85	O
;	O
p	O
=	O
0.001	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
percentage	O
stenosis	O
ipsilateral	O
vs	O
contralateral	O
to	O
stroke	O
(	O
p	O
=	O
0.98	O
)	O
,	O
and	O
weak	O
correlation	O
between	O
plaque	O
size	O
and	O
stenosis	O
(	O
R	O
(	O
2	O
)	O
=	O
0.26	O
,	O
p	O
<	O
0.001	O
)	O
.	O

Large	O
but	O
nonstenotic	O
carotid	O
artery	O
plaque	O
is	O
considerably	O
more	O
common	O
ipsilateral	O
than	O
contralateral	O
to	O
cryptogenic	O
stroke	O
,	O
suggesting	O
that	O
nonstenotic	O
plaque	O
is	O
an	O
underrecognized	O
cause	O
of	O
stroke	O
.	O

We	O
measured	O
plaque	O
size	O
using	O
CT	B-P
angiography	I-P
,	O
a	O
method	O
that	O
could	O
be	O
easily	O
implemented	O
in	O
clinical	O
practice	O
.	O

Arterial	O
thoracic	O
outlet	O
syndrome	O
:	O
rare	O
and	O
triggering	O
.	O

Arterial	O
thoracic	O
outlet	O
syndrome	O
(	O
TOS	O
)	O
is	O
the	O
least	O
common	O
type	O
of	O
TOS	O
.	O

Patient	O
's	O
symptoms	O
,	O
clinical	O
examination	O
and	O
duplex	B-P
ultrasonography	I-P
usually	O
suffice	O
in	O
deciding	O
patient	O
's	O
management	O
.	O

Our	O
proposed	O
treatment	O
strategies	O
are	O
based	O
on	O
the	O
Scher	O
classification	O
.	O

The	O
choice	O
of	O
the	O
procedure	O
and	O
approach	O
should	O
depend	O
on	O
surgeon	O
's	O
experience	O
and	O
need	O
for	O
arterial	O
reconstruction	O
.	O

Evaluation	O
of	O
the	O
in	O
vitro	O
growth	O
of	O
urinary	O
tract	O
infection	O
-causing	O
gram-negative	O
and	O
gram-positive	O
bacteria	O
in	O
a	O
proposed	O
synthetic	O
human	O
urine	O
(	O
SHU	O
)	O
medium	O
.	O

Bacteriuria	O
is	O
a	O
hallmark	O
of	O
urinary	O
tract	O
infection	O
(	O
UTI	O
)	O
and	O
asymptomatic	O
bacteriuria	O
(	O
ABU	O
)	O
,	O
which	O
are	O
among	O
the	O
most	O
frequent	O
infections	O
in	O
humans	O
.	O

A	O
variety	O
of	O
gram-negative	O
and	O
gram-positive	O
bacteria	O
are	O
associated	O
with	O
these	O
infections	O
but	O
Escherichia	O
coli	O
contributes	O
up	O
to	O
80	O
%	O
of	O
cases	O
.	O

Multiple	O
bacterial	O
species	O
including	O
E.	O
coli	O
can	O
grow	O
in	O
human	O
urine	O
as	O
a	O
means	O
to	O
maintain	O
colonization	O
during	O
infections	O
.	O

In	O
vitro	O
bacteriuria	O
studies	O
aimed	O
at	O
modeling	O
microbial	O
growth	O
in	O
urine	O
have	O
utilized	O
various	O
compositions	O
of	O
synthetic	O
human	O
urine	O
(	O
SHU	O
)	O
and	O
a	O
Composite	O
SHU	O
formulation	O
was	O
recently	O
proposed	O
.	O

In	O
this	O
study	O
,	O
we	O
sought	O
to	O
validate	O
the	O
recently	O
proposed	O
Composite	O
SHU	O
as	O
a	O
medium	O
that	O
supports	O
the	O
growth	O
of	O
several	O
bacterial	O
species	O
that	O
are	O
known	O
to	O
grow	O
in	O
normal	O
human	O
urine	O
and/or	O
artificial	O
urine	O
.	O

Comparative	O
growth	O
assays	O
of	O
gram-negative	O
and	O
gram-positive	O
bacteria	O
E.	O
coli	O
,	O
Pseudomonas	O
aeruginosa	O
,	O
Proteus	O
mirabilis	O
,	O
Streptococcus	O
agalactiae	O
,	O
Staphylococcus	O
saprophyticus	O
and	O
Enterococcus	O
faecalis	O
were	O
undertaken	O
using	O
viable	O
bacterial	B-P
count	I-P
and	O
optical	B-P
density	I-P
measurements	I-P
over	O
a	O
48h	O
culture	B-P
period	O
.	O

Three	O
different	O
SHU	O
formulations	O
were	O
tested	O
in	O
various	O
culture	O
vessels	O
,	O
shaking	O
conditions	O
and	O
volumes	O
and	O
showed	O
that	O
Composite	O
SHU	O
can	O
support	O
the	O
robust	O
growth	O
of	O
gram-negative	O
bacteria	O
but	O
requires	O
supplementation	O
with	O
0.2	O
%	O
yeast	O
extract	O
to	O
support	O
the	O
growth	O
of	O
gram-positive	O
bacteria	O
.	O

Experiments	O
are	O
also	O
presented	O
that	O
show	O
an	O
unexpected	O
but	O
major	O
influence	O
of	O
P.	O
mirabilis	O
towards	O
the	O
ability	O
to	O
measure	O
bacterial	O
growth	O
in	O
generally	O
accepted	O
multiwell	B-P
assays	I-P
using	O
absorbance	O
readings	O
,	O
predicted	O
to	O
have	O
a	O
basis	O
in	O
the	O
release	O
of	O
volatile	O
organic	O
compound	O
(	O
s	O
)	O
from	O
P.	O
mirabilis	O
during	O
growth	O
in	O
Composite	O
SHU	O
medium	O
.	O

This	O
study	O
represents	O
an	O
essential	O
methodological	O
validation	O
of	O
a	O
more	O
chemically	O
defined	O
type	O
of	O
synthetic	O
urine	O
that	O
can	O
be	O
applied	O
to	O
study	O
mechanisms	O
of	O
bacteriuria	O
and	O
we	O
conclude	O
will	O
offer	O
a	O
useful	O
in	O
vitro	O
model	O
to	O
investigate	O
the	O
basis	O
of	O
some	O
of	O
the	O
most	O
common	O
infections	O
of	O
humans	O
.	O

Multifunctional	O
theranostic	O
Pluronic	O
mixed	O
micelles	O
improve	O
targeted	O
photoactivity	O
of	O
Verteporfin	O
in	O
cancer	O
cells	O
.	O

Nanotechnology	O
development	O
provides	O
new	O
strategies	O
to	O
treat	O
cancer	O
by	O
integration	O
of	O
different	O
treatment	O
modalities	O
in	O
a	O
single	O
multifunctional	O
nanoparticle	O
.	O

In	O
this	O
scenario	O
,	O
we	O
applied	O
the	O
multifunctional	O
Pluronic	O
P123	O
/	O
F127	O
mixed	O
micelles	O
for	O
Verteporfin	O
-mediated	O
photodynamic	O
therapy	O
in	O
PC3	O
and	O
MCF-7	O
cancer	O
cells	O
.	O

Micelles	O
functionalization	O
aimed	O
the	O
targeted	O
delivery	O
by	O
the	O
insertion	O
of	O
biotin	O
moiety	O
on	O
micelle	O
surface	O
and	O
fluorescence	B-P
image	I-P
-based	O
through	O
rhodamine-B	O
dye	O
conjugation	O
in	O
the	O
polymer	O
chains	O
.	O

Multifunctional	O
Pluronics	O
formed	O
spherical	O
nanoparticulated	O
micelles	O
that	O
efficiently	O
encapsulated	O
the	O
photosensitizer	O
Verteporfin	O
maintaining	O
its	O
favorable	O
photophysical	O
properties	O
.	O

Lyophilized	O
formulations	O
were	O
stable	O
at	O
least	O
for	O
6	O
months	O
and	O
readily	O
reconstituted	O
in	O
aqueous	O
media	O
.	O

The	O
multifunctional	O
micelles	O
were	O
stable	O
in	O
protein	O
-rich	O
media	O
due	O
to	O
the	O
dual	O
Pluronic	O
mixed	O
micelles	O
characteristic	O
:	O
high	O
drug	O
loading	O
capacity	O
provided	O
by	O
its	O
micellar	O
core	O
and	O
high	O
kinetic	O
stability	O
due	O
its	O
biocompatible	O
shell	O
.	O

Biotin	O
surface	O
functionalized	O
micelles	O
showed	O
higher	O
internalization	O
rates	O
due	O
biotin	O
-mediated	O
endocytosis	O
,	O
as	O
demonstrated	O
by	O
competitive	O
cellular	O
uptake	O
studies	O
.	O

Rhodamine	O
B	O
-tagged	O
micelles	O
allowed	O
monitoring	O
cellular	O
uptake	O
and	O
intracellular	O
distribution	O
of	O
the	O
formulations	O
.	O

Confocal	B-P
microscopy	I-P
studies	O
demonstrated	O
a	O
larger	O
intracellular	O
distribution	O
of	O
the	O
formulation	O
and	O
photosensitizer	O
,	O
which	O
could	O
drive	O
Verteporfin	O
to	O
act	O
on	O
multiple	O
cell	O
sites	O
.	O

Formulations	O
were	O
not	O
toxic	O
in	O
the	O
dark	O
condition	O
,	O
but	O
showed	O
high	O
Verteporfin	O
-induced	O
phototoxicity	O
against	O
both	O
cancer	O
cell	O
lines	O
at	O
low	O
drug	O
and	O
light	O
doses	O
.	O

These	O
results	O
point	O
Verteporfin	O
-loaded	O
multifunctional	O
micelles	O
as	O
a	O
promising	O
tool	O
to	O
further	O
developments	O
in	O
photodynamic	O
therapy	O
of	O
cancer	O
.	O

Liver	O
Fatty	O
Acid	O
Binding	O
Protein	O
Deficiency	O
Provokes	O
Oxidative	O
Stress	O
,	O
Inflammation	O
,	O
and	O
Apoptosis	O
-Mediated	O
Hepatotoxicity	O
Induced	O
by	O
Pyrazinamide	O
in	O
Zebrafish	O
Larvae	O
.	O

Pyrazinamide	O
(	O
PZA	O
)	O
is	O
an	O
essential	O
antitubercular	O
drug	O
,	O
but	O
little	O
is	O
still	O
known	O
about	O
its	O
hepatotoxicity	O
potential	O
.	O

This	O
study	O
examined	O
the	O
effects	O
of	O
PZA	O
exposure	O
on	O
zebrafish	O
(	O
Danio	O
rerio	O
)	O
larvae	O
and	O
the	O
mechanisms	O
underlying	O
its	O
hepatotoxicity	O
.	O

A	O
transgenic	O
line	O
of	O
zebrafish	O
larvae	O
that	O
expressed	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
EGFP	O
)	O
in	O
the	O
liver	O
was	O
incubated	B-P
with	O
1	O
,	O
2.5	O
,	O
and	O
5	O
mM	O
PZA	O
from	O
72	O
h	O
postfertilization	O
(	O
hpf	O
)	O
.	O

Different	O
endpoints	O
such	O
as	O
mortality	O
,	O
morphology	O
changes	O
in	O
the	O
size	O
and	O
shape	O
of	O
the	O
liver	O
,	O
histological	O
changes	O
,	O
transaminase	B-P
analysis	I-P
and	O
apoptosis	O
,	O
markers	O
of	O
oxidative	O
and	O
genetic	O
damage	O
,	O
as	O
well	O
as	O
the	O
expression	O
of	O
certain	O
genes	O
were	O
selected	O
to	O
evaluate	O
PZA	O
-	O
induced	O
hepatotoxicity	O
.	O

Our	O
results	O
confirm	O
the	O
manner	O
of	O
PZA	O
dose-dependent	O
hepatotoxicity	O
.	O

PZA	O
was	O
found	O
to	O
induce	O
marked	O
injury	O
in	O
zebrafish	O
larvae	O
,	O
such	O
as	O
liver	O
atrophy	O
,	O
elevations	O
of	O
transaminase	O
levels	O
,	O
oxidative	O
stress	O
,	O
and	O
hepatocyte	O
apoptosis	O
.	O

To	O
further	O
understand	O
the	O
mechanism	O
behind	O
PZA	O
-	O
induced	O
hepatotoxicity	O
,	O
changes	O
in	O
gene	O
expression	O
levels	O
in	O
zebrafish	O
larvae	O
exposed	O
to	O
PZA	O
for	O
72	O
h	O
postexposure	O
(	O
hpe	O
)	O
were	O
determined	O
.	O

The	O
results	O
of	O
this	O
study	O
demonstrated	O
that	O
PZA	O
decreased	O
the	O
expression	O
levels	O
of	O
liver	O
fatty	O
acid	O
binding	O
protein	O
(	O
L-FABP	O
)	O
and	O
its	O
target	O
gene	O
,	O
peroxisome	O
proliferator-activated	O
receptor	O
α	O
(	O
PPAR-α	O
)	O
,	O
and	O
provoked	O
more	O
severe	O
oxidative	O
stress	O
and	O
hepatitis	O
via	O
the	O
upregulation	O
of	O
inflammatory	O
cytokines	O
such	O
as	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-α	O
)	O
and	O
transforming	O
growth	O
factor	O
β	O
(	O
TGF-β	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
L-FABP	O
-mediated	O
PPAR-α	O
downregulation	O
appears	O
to	O
be	O
a	O
hepatotoxic	O
response	O
resulting	O
from	O
zebrafish	O
larva	O
liver	O
cell	O
apoptosis	O
,	O
and	O
L-FABP	O
can	O
be	O
used	O
as	O
a	O
biomarker	O
for	O
the	O
early	B-P
detection	I-P
of	O
PZA	O
-	O
induced	O
liver	O
damage	O
in	O
zebrafish	O
larvae	O
.	O

Correlation	O
of	O
the	O
HPV	B-P
detection	I-P
,	O
protein	O
expression	O
and	O
DNA	O
content	O
in	O
cutaneous	O
pre-invasive	O
and	O
invasive	O
carcinoma	O
among	O
Croatian	O
patients	O
.	O

Development	O
of	O
cutaneous	O
carcinomas	O
has	O
been	O
associated	O
with	O
HPV	O
infection	O
.	O

There	O
have	O
been	O
various	O
reports	O
on	O
p16	O
,	O
p53	O
and	O
pRb	O
expression	O
in	O
cutaneous	O
carcinomas	O
and	O
on	O
its	O
linkage	O
to	O
HPV	O
status	O
.	O

Association	O
of	O
protein	O
expression	O
and	O
HPV	O
infection	O
with	O
DNA	O
content	O
is	O
not	O
clear	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
a	O
possible	O
correlation	O
between	O
HPV	O
type	O
,	O
protein	O
expression	O
and	O
DNA	O
content	O
in	O
both	O
pre-invasive	O
and	O
invasive	O
squamous	O
cell	O
carcinoma	O
,	O
as	O
well	O
as	O
differences	O
between	O
studied	O
groups	O
in	O
these	O
parameters	O
.	O

Sections	O
of	O
formalin	O
fixed	O
paraffin-embedded	O
tumor	O
tissue	O
from	O
54	O
cases	O
of	O
Morbus	O
Bowen	O
(	O
preinvasive	O
cutaneous	O
carcinoma	O
)	O
and	O
41	O
cases	O
of	O
invasive	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
skin	O
were	O
subjected	O
to	O
HPV	B-P
genotyping	I-P
using	O
Lipa	B-P
(	O
Line	B-P
imuno	I-P
probe	I-P
assay	I-P
)	O
,	O
immunohistochemical	B-P
staining	B-P
for	O
p16	O
(	O
INK4A	O
)	O
,	O
p53	O
,	O
pRb	O
and	O
prepared	O
for	O
flow	B-P
cytometry	I-P
DNA	I-P
content	I-P
analysis	I-P
.	O

Obtained	O
data	O
were	O
analyzed	O
in	O
SPSS	O
using	O
Chi	O
square	O
test	O
.	O

Only	O
p16	O
expression	O
showed	O
statistically	O
significant	O
differences	O
in	O
studied	O
groups	O
.	O

Statistically	O
significant	O
correlations	O
were	O
found	O
only	O
in	O
MB	O
between	O
parameters	O
HPV	O
-	O
p53	O
,	O
p53	O
-	O
pRb	O
and	O
p53	O
-	O
p16	O
.	O

Our	O
results	O
suggest	O
different	O
virus	O
-	O
induced	O
pathobiology	O
pathways	O
for	O
different	O
cutaneous	O
carcinoma	O
groups	O
.	O

Histological	O
evidence	O
of	O
inflammatory	O
reaction	O
associated	O
with	O
fibrosis	O
in	O
the	O
atrial	O
and	O
ventricular	O
walls	O
in	O
a	O
case-control	O
study	O
of	O
patients	O
with	O
history	O
of	O
atrial	O
fibrillation	O
.	O

Chronic	O
inflammation	O
in	O
the	O
atrial	O
myocardium	O
was	O
shown	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
atrial	O
fibrosis	O
in	O
patients	O
with	O
atrial	O
fibrillation	O
(	O
AF	O
)	O
.	O

However	O
,	O
it	O
is	O
not	O
clear	O
to	O
what	O
extent	O
atrial	O
inflammatory	O
reaction	O
associated	O
with	O
AF	O
extends	O
on	O
the	O
ventricular	O
myocardium	O
.	O

Our	O
aim	O
was	O
to	O
assess	O
the	O
extent	O
of	O
fibrosis	O
and	O
lymphomononuclear	O
infiltration	O
in	O
human	O
ventricular	O
myocardium	O
and	O
explore	O
its	O
association	O
with	O
AF	O
.	O

Medical	O
records	O
from	O
consecutive	O
autopsies	B-P
were	O
checked	O
for	O
presence	O
of	O
AF	O
.	O

Heart	O
specimens	O
from	O
30	O
patients	O
died	O
from	O
cardiovascular	O
causes	O
(	O
64	O
±	O
12	O
years	O
,	O
17	O
men	O
)	O
were	O
collected	O
in	O
three	O
equal	O
groups	O
:	O
no	O
AF	O
,	O
paroxysmal	O
AF	O
,	O
and	O
permanent	O
AF	O
.	O

Tissue	O
samples	O
were	O
taken	O
from	O
the	O
Bachmann	O
's	O
bundle	O
,	O
crista	O
terminalis	O
,	O
posterior	O
left	O
atrium	O
,	O
left	O
ventricle	O
and	O
right	O
ventricle	O
free	O
walls	O
and	O
stained	B-P
with	I-P
Masson	I-P
's	I-P
trichrome	I-P
for	O
analysis	O
of	O
fibrosis	O
extent	O
.	O

Immunohistochemistry	B-P
was	O
performed	O
using	O
antibodies	O
against	O
CD3-	O
and	O
CD45-antigens	O
and	O
quantified	O
as	O
number	O
of	O
antigen-positive	O
cells	O
per	O
1	O
mm	O
(	O
2	O
)	O
.	O

Fibrosis	O
extent	O
,	O
CD3+	O
and	O
CD45+	O
cell	B-P
counts	I-P
were	O
elevated	O
in	O
AF	O
patients	O
at	O
all	O
sites	O
(	O
P	O
<	O
0.001	O
for	O
all	O
)	O
.	O

Fibrosis	O
extent	O
demonstrated	O
correlation	O
with	O
both	O
CD3+	O
and	O
CD45+	O
cell	B-P
counts	I-P
in	O
the	O
right	O
(	O
r	O
=	O
0.781	O
,	O
P	O
<	O
0.001	O
for	O
CD45+	O
and	O
r	O
=	O
0.720	O
,	O
P	O
<	O
0.001	O
for	O
CD3+	O
)	O
and	O
the	O
left	O
(	O
r	O
=	O
0.515	O
,	O
P	O
=	O
0.004	O
for	O
CD45+	O
and	O
r	O
=	O
0.573	O
,	O
P	O
=	O
0.001	O
for	O
CD3+	O
)	O
ventricles	O
.	O

Neither	O
fibrosis	O
nor	O
inflammatory	O
cell	B-P
count	I-P
showed	O
association	O
with	O
either	O
age	O
or	O
comorbidities	O
.	O

Histological	O
signs	O
of	O
chronic	O
inflammation	O
affecting	O
ventricular	O
myocardium	O
are	O
strongly	O
associated	O
with	O
AF	O
and	O
demonstrate	O
significant	O
correlation	O
with	O
fibrosis	O
extent	O
that	O
can	O
not	O
be	O
explained	O
by	O
cardiovascular	O
comorbidities	O
otherwise	O
.	O

Predictors	O
of	O
neurologic	O
and	O
nonneurologic	O
death	O
in	O
patients	O
with	O
brain	O
metastasis	O
initially	O
treated	O
with	O
upfront	O
stereotactic	O
radiosurgery	O
without	O
whole-brain	O
radiation	O
therapy	O
.	O

In	O
this	O
study	O
we	O
attempted	O
to	O
discern	O
the	O
factors	O
predictive	O
of	O
neurologic	O
death	O
in	O
patients	O
with	O
brain	O
metastasis	O
treated	O
with	O
upfront	O
stereotactic	O
radiosurgery	O
(	O
SRS	O
)	O
without	O
whole	O
brain	O
radiation	O
therapy	O
(	O
WBRT	O
)	O
while	O
accounting	O
for	O
the	O
competing	O
risk	O
of	O
nonneurologic	O
death	O
.	O

We	O
performed	O
a	O
retrospective	O
single-institution	O
analysis	O
of	O
patients	O
with	O
brain	O
metastasis	O
treated	O
with	O
upfront	O
SRS	O
without	O
WBRT	O
.	O

Competing	O
risks	O
analysis	O
was	O
performed	O
to	O
estimate	O
the	O
subdistribution	O
hazard	O
ratios	O
(	O
HRs	O
)	O
for	O
neurologic	O
and	O
nonneurologic	O
death	O
for	O
predictor	O
variables	O
of	O
interest	O
.	O

Of	O
738	O
patients	O
treated	O
with	O
upfront	O
SRS	O
alone	O
,	O
neurologic	O
death	O
occurred	O
in	O
226	O
(	O
30.6	O
%	O
)	O
,	O
while	O
nonneurologic	O
death	O
occurred	O
in	O
309	O
(	O
41.9	O
%	O
)	O
.	O

Multivariate	O
competing	O
risks	O
analysis	O
identified	O
an	O
increased	O
hazard	O
of	O
neurologic	O
death	O
associated	O
with	O
diagnosis-specific	O
graded	O
prognostic	O
assessment	O
(	O
DS-GPA	O
)	O
≤	O
2	O
(	O
P	O
=	O
.005	O
)	O
,	O
melanoma	O
histology	B-P
(	O
P	O
=	O
.009	O
)	O
,	O
and	O
increased	O
number	O
of	O
brain	O
metastases	O
(	O
P	O
<	O
.001	O
)	O
,	O
while	O
there	O
was	O
a	O
decreased	O
hazard	O
associated	O
with	O
higher	O
SRS	O
dose	O
(	O
P	O
=	O
.004	O
)	O
.	O

Targeted	O
agents	O
were	O
associated	O
with	O
a	O
decreased	O
HR	O
of	O
neurologic	O
death	O
in	O
the	O
first	O
1.5	O
years	O
(	O
P	O
=	O
.04	O
)	O
but	O
not	O
afterwards	O
.	O

An	O
increased	O
hazard	O
of	O
nonneurologic	O
death	O
was	O
seen	O
with	O
increasing	O
age	O
(	O
P	O
=.03	O
)	O
,	O
nonmelanoma	B-P
histology	I-P
(	O
P	O
<	O
.001	O
)	O
,	O
presence	O
of	O
extracranial	O
disease	O
(	O
P	O
<	O
.001	O
)	O
,	O
and	O
progressive	O
systemic	O
disease	O
(	O
P	O
=.004	O
)	O
.	O

Melanoma	O
,	O
DS-GPA	O
,	O
number	O
of	O
brain	O
metastases	O
,	O
and	O
SRS	O
dose	O
are	O
predictive	O
of	O
neurologic	O
death	O
,	O
while	O
age	O
,	O
nonmelanoma	B-P
histology	I-P
,	O
and	O
more	O
advanced	O
systemic	O
disease	O
are	O
predictive	O
of	O
nonneurologic	O
death	O
.	O

Targeted	O
agents	O
appear	O
to	O
delay	O
neurologic	O
death	O
.	O

Three-dimensional	O
morphological	O
characterization	O
of	O
malocclusions	O
with	O
mandibular	O
lateral	O
displacement	O
using	O
cone-beam	B-P
computed	I-P
tomography	I-P
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
morphologic	O
characteristics	O
of	O
MLD	O
malocclusions	O
using	O
3D	B-P
imaging	I-P
.	O

MLD	O
characteristics	O
were	O
examined	O
using	O
CBCT	B-P
data	O
in	O
40	O
subjects	O
.	O

A	O
3D	O
Cephalometric	B-P
analysis	I-P
was	O
developed	O
to	O
describe	O
the	O
spatial	O
position	O
of	O
the	O
mandible	O
and	O
temporal	O
bones	O
.	O

Vertical	O
dental	O
heights	O
were	O
shorter	O
and	O
the	O
posterior	O
occlusal	O
plane	O
(	O
POP	O
)	O
presented	O
a	O
steeper	O
sagittal	O
inclination	O
on	O
the	O
shifted	O
side	O
(	O
the	O
side	O
of	O
the	O
laterally	O
displaced	O
bony	O
chin	O
)	O
than	O
on	O
the	O
contralateral	O
side	O
.	O

(	O
p	O
<	O
0.01	O
)	O
.	O

The	O
MLD	O
was	O
related	O
to	O
a	O
superiorly	O
inclined	O
POP	O
Cant	O
in	O
the	O
same	O
direction	O
(	O
r	O
=	O
0.82	O
;	O
p	O
<	O
0.01	O
)	O
.	O

The	O
shifted	O
side	O
condyle	O
was	O
dislocated	O
medially	O
and	O
was	O
smaller	O
.	O

Temporal	O
bone	O
sagittal	O
inclination	O
showed	O
a	O
more	O
forward	O
and	O
medial	O
inclination	O
on	O
the	O
contralateral	O
side	O
(	O
p	O
<	O
0.01	O
)	O
.	O

A	O
unilateral	O
decrease	O
in	O
the	O
vertical	O
height	O
of	O
the	O
dentition	O
and	O
the	O
subsequent	O
steeper	O
occlusal	O
plane	O
inclinations	O
correlated	O
with	O
(	O
1	O
)	O
mandibular	O
rotational	O
displacement	O
and	O
condylar	O
lateral	O
displacement	O
,	O
(	O
2	O
)	O
mandibular	O
and	O
condylar	O
morphologic	O
changes	O
(	O
3	O
)	O
changes	O
in	O
temporal	O
bone	O
position	O
.	O

Patterns	O
of	O
coronary	O
plaque	O
progression	O
:	O
phasic	O
versus	O
gradual	O
.	O

A	O
combined	O
optical	O
coherence	O
tomography	O
and	O
intravascular	O
ultrasound	O
study	O
.	O

Some	O
plaques	O
grow	O
slowly	O
in	O
a	O
linear	O
manner	O
,	O
whereas	O
others	O
undergo	O
a	O
rapid	O
phasic	O
progression	O
.	O

However	O
,	O
the	O
detailed	O
in-vivo	O
relationship	O
between	O
plaque	O
characteristics	O
and	O
plaque	O
progression	O
pattern	O
has	O
not	O
been	O
reported	O
.	O

The	O
current	O
study	O
aimed	O
to	O
investigate	O
the	O
plaque	O
progression	O
patterns	O
with	O
serial	O
intravascular	B-P
ultrasound	I-P
(	O
IVUS	B-P
)	O
examinations	B-P
,	O
and	O
to	O
correlate	O
baseline	O
plaque	O
characteristics	O
assessed	O
by	O
optical	B-P
coherence	I-P
tomography	I-P
and	O
IVUS	B-P
with	O
plaque	O
progression	O
patterns	O
.	O

A	O
total	O
of	O
248	O
coronary	O
lesions	O
from	O
157	O
patients	O
were	O
identified	O
and	O
imaged	B-P
by	O
both	O
optical	B-P
coherence	I-P
tomography	I-P
and	O
IVUS	B-P
at	O
baseline	O
.	O

IVUS	B-P
examination	B-P
was	O
repeated	O
at	O
6	O
and	O
12	O
months	O
.	O

Plaque	O
progression	O
was	O
defined	O
as	O
greater	O
than	O
or	O
equal	O
to	O
5	O
%	O
increase	O
in	O
percent	O
atheroma	O
volume	O
by	O
IVUS	B-P
.	O

The	O
progression	O
patterns	O
were	O
divided	O
into	O
three	O
groups	O
:	O
no	O
progression	O
,	O
rapid	O
phasic	O
progression	O
,	O
and	O
gradual	O
progression	O
.	O

Among	O
248	O
lesions	O
,	O
190	O
(	O
77	O
%	O
)	O
showed	O
no	O
progression	O
.	O

Among	O
58	O
lesions	O
with	O
progression	O
,	O
20	O
(	O
34	O
%	O
)	O
showed	O
gradual	O
progression	O
,	O
whereas	O
38	O
(	O
66	O
%	O
)	O
showed	O
rapid	O
phasic	O
progression	O
.	O

Multivariate	O
analysis	O
indicated	O
that	O
thin-cap	O
fibroatheroma	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
=5.24	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
2.04-13.4	O
;	O
P=0.001	O
]	O
,	O
microvessel	O
(	O
OR	O
=2.20	O
,	O
95	O
%	O
CI	O
1.10-4.79	O
;	O
P=0.045	O
)	O
,	O
and	O
positive	O
remodeling	O
(	O
OR	O
=2.64	O
,	O
95	O
%	O
CI	O
1.19-5.81	O
;	O
P=0.016	O
)	O
were	O
associated	O
independently	O
with	O
rapid	O
phasic	O
progression	O
.	O

Three-quarters	O
of	O
coronary	O
plaques	O
did	O
not	O
progress	O
over	O
time	O
with	O
contemporary	O
medical	O
treatment	O
.	O

Among	O
the	O
lesions	O
with	O
progression	O
,	O
one-third	O
showed	O
a	O
gradual	O
pattern	O
and	O
two-thirds	O
showed	O
a	O
rapid	O
phasic	O
pattern	O
.	O

The	O
presence	O
of	O
thin-cap	O
fibroatheroma	O
,	O
microvessel	O
,	O
and	O
positive	O
remodeling	O
were	O
the	O
independent	O
predictors	O
for	O
rapid	O
phasic	O
pattern	O
progression	O
of	O
coronary	O
atherosclerotic	O
plaques	O
.	O

Effects	O
of	O
etomidate	O
and	O
propofol	O
on	O
immune	O
function	O
in	O
patients	O
with	O
lung	O
adenocarcinoma	O
.	O

To	O
investigate	O
the	O
effects	O
of	O
etomidate	O
and	O
propofol	O
on	O
immune	O
function	O
in	O
patients	O
with	O
lung	O
adenocarcinoma	O
.	O

Sixty	O
patients	O
who	O
were	O
scheduled	O
for	O
lung	O
cancer	O
surgery	O
under	O
general	O
anesthesia	O
were	O
studied	O
.	O

The	O
patients	O
were	O
randomly	O
divided	O
into	O
an	O
etomidate	O
total	O
intravenous	O
anesthesia	O
group	O
(	O
group	O
E	O
)	O
and	O
a	O
propofol	O
total	O
intravenous	O
anesthesia	O
group	O
(	O
group	O
P	O
)	O
,	O
with	O
30	O
cases	O
in	O
each	O
group	O
.	O

Within	O
group	O
comparison	O
:	O
The	O
percentage	B-P
of	I-P
CD4+	I-P
in	O
the	O
two	O
groups	O
was	O
significantly	O
reduced	O
at	O
24	O
hours	O
post-operation	O
(	O
T2	O
)	O
compared	O
with	O
the	O
percentage	B-P
before	O
surgery	O
,	O
whereas	O
the	O
percentage	O
of	O
CD8+	O
was	O
higher	O
at	O
T2	O
.	O

Between	O
group	O
comparison	O
:	O
The	O
CD4+	B-P
percentage	I-P
of	O
group	O
E	O
was	O
higher	O
than	O
that	O
of	O
group	O
P	O
(	O
P	O
<	O
0.05	O
)	O
at	O
T2	O
,	O
whereas	O
the	O
CD8+	O
percentage	O
was	O
lower	O
than	O
that	O
of	O
group	O
P	O
(	O
P	O
<	O
0.05	O
)	O
at	O
T1	O
.	O

Using	O
etomidate	O
for	O
anesthesia	O
has	O
less	O
of	O
an	O
effect	O
on	O
immune	O
function	O
in	O
patients	O
with	O
lung	O
adenocarcinoma	O
.	O

Systematic	O
and	O
detailed	O
analysis	O
of	O
behavioural	B-P
tests	I-P
in	O
the	O
rat	O
middle	O
cerebral	O
artery	O
occlusion	O
model	O
of	O
stroke	O
:	O
Tests	O
for	O
long-term	O
assessment	O
.	O

In	O
order	O
to	O
test	O
therapeutics	O
,	O
functional	B-P
assessments	I-P
are	O
required	O
.	O

In	O
pre-clinical	O
stroke	O
research	O
,	O
there	O
is	O
little	O
consensus	O
regarding	O
the	O
most	O
appropriate	O
behavioural	B-P
tasks	I-P
to	O
assess	O
deficits	O
,	O
especially	O
when	O
testing	O
over	O
extended	O
times	O
in	O
milder	O
models	O
with	O
short	O
occlusion	O
times	O
and	O
small	O
lesion	O
volumes	O
.	O

In	O
this	O
study	O
,	O
we	O
comprehensively	O
assessed	O
16	O
different	O
behavioural	B-P
tests	I-P
,	O
with	O
the	O
aim	O
of	O
identifying	O
those	O
that	O
show	O
robust	O
,	O
reliable	O
and	O
stable	O
deficits	O
for	O
up	O
to	O
two	O
months	O
.	O

These	O
tasks	O
are	O
regularly	O
used	O
in	O
stroke	O
research	O
,	O
as	O
well	O
as	O
being	O
useful	O
for	O
examining	O
striatal	O
dysfunction	O
in	O
models	O
of	O
Huntington	O
's	O
and	O
Parkinson	O
's	O
disease	O
.	O

Two	O
cohorts	O
of	O
male	O
Wistar	O
rats	O
underwent	O
the	O
intraluminal	O
filament	O
model	O
of	O
middle	O
cerebral	O
artery	O
occlusion	O
(	O
30	O
min	O
)	O
and	O
were	O
imaged	B-P
24	O
h	O
later	O
.	O

This	O
resulted	O
in	O
primarily	O
subcortical	O
infarcts	O
,	O
with	O
a	O
small	O
amount	O
of	O
cortical	O
damage	O
.	O

Animals	O
were	O
tested	O
,	O
along	O
with	O
sham	O
and	O
naïve	O
groups	O
at	O
24	O
h	O
,	O
seven	O
days	O
,	O
and	O
one	O
and	O
two	O
months	O
.	O

Following	O
behavioural	B-P
testing	I-P
,	O
brains	O
were	O
processed	O
and	O
striatal	O
neuronal	O
counts	O
were	O
performed	O
alongside	O
measurements	O
of	O
total	O
brain	O
and	O
white	O
matter	O
atrophy	O
.	O

The	O
staircase	B-P
,	O
adjusting	B-P
steps	I-P
,	O
rotarod	B-P
and	O
apomorphine	B-P
-induced	I-P
rotations	I-P
were	O
the	O
most	O
reliable	O
for	O
assessing	O
long-term	O
deficits	O
in	O
the	O
30	O
min	O
transient	O
middle	O
cerebral	O
artery	O
occlusion	O
model	O
of	O
stroke	O
.	O

Inactivation	O
of	O
Cancer	O
Mutations	O
Utilizing	O
CRISPR/Cas9	O
.	O

Although	O
whole-genome	O
sequencing	O
has	O
uncovered	O
a	O
large	O
number	O
of	O
mutations	O
that	O
drive	O
tumorigenesis	O
,	O
functional	O
ratification	O
for	O
most	O
mutations	O
remains	O
sparse	O
.	O

Here	O
,	O
we	O
present	O
an	O
approach	O
to	O
test	O
functional	O
relevance	O
of	O
tumor	O
mutations	O
employing	O
CRISPR/Cas9	O
.	O

Combining	O
comprehensive	O
sgRNA	O
design	O
and	O
an	O
efficient	O
reporter	O
assay	B-P
to	O
nominate	O
efficient	O
and	O
selective	O
sgRNAs	O
,	O
we	O
establish	O
a	O
pipeline	O
to	O
dissect	O
roles	O
of	O
cancer	O
mutations	O
with	O
potential	O
applicability	O
to	O
personalized	O
medicine	O
and	O
future	O
therapeutic	O
use	O
.	O

Does	O
obtaining	O
an	O
initial	O
magnetic	B-P
resonance	I-P
imaging	I-P
decrease	O
the	O
reamputation	O
rates	O
in	O
the	O
diabetic	O
foot	O
?	O
.	O

Diabetes	O
mellitus	O
(	O
DM	O
)	O
through	O
its	O
over	O
glycosylation	O
of	O
neurovascular	O
structures	O
and	O
resultant	O
peripheral	O
neuropathy	O
continues	O
to	O
be	O
the	O
major	O
risk	O
factor	O
for	O
pedal	O
amputation	O
.	O

Repetitive	O
trauma	O
to	O
the	O
insensate	O
foot	O
results	O
in	O
diabetic	O
foot	O
ulcers	O
,	O
which	O
are	O
at	O
high	O
risk	O
to	O
develop	O
osteomyelitis	O
.	O

Many	O
patients	O
who	O
present	O
with	O
diabetic	O
foot	O
complications	O
will	O
undergo	O
one	O
or	O
more	O
pedal	O
amputations	O
during	O
the	O
course	O
of	O
their	O
disease	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
obtaining	O
an	O
initial	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
,	O
prior	O
to	O
the	O
first	O
amputation	O
,	O
is	O
associated	O
with	O
a	O
decreased	O
rate	O
of	O
reamputation	O
in	O
the	O
diabetic	O
foot	O
.	O

Our	O
hypothesis	O
was	O
that	O
the	O
rate	O
of	O
reamputation	O
may	O
be	O
associated	O
with	O
underutilization	O
of	O
obtaining	O
an	O
initial	O
MRI	B-P
,	O
useful	O
in	O
presurgical	O
planning	O
.	O

This	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
there	O
was	O
an	O
association	O
between	O
the	O
reamputation	O
rate	O
in	O
diabetic	O
patients	O
and	O
utilization	O
of	O
MRI	B-P
in	O
the	O
presurgical	O
planning	O
and	O
prior	O
to	O
initial	O
forefoot	O
amputations	O
.	O

Following	O
approval	O
by	O
our	O
institutional	O
review	O
board	O
,	O
our	O
study	O
design	O
consisted	O
of	O
a	O
retrospective	O
cohort	O
analysis	O
of	O
413	O
patients	O
at	O
Staten	O
Island	O
University	O
Hospital	O
,	O
a	O
700-bed	O
tertiary	O
referral	O
center	O
between	O
2008	O
and	O
2013	O
who	O
underwent	O
an	O
initial	O
great	O
toe	O
(	O
hallux	O
)	O
amputation	O
.	O

Of	O
the	O
413	O
patients	O
with	O
a	O
hallux	O
amputation	O
,	O
there	O
were	O
368	O
eligible	O
patients	O
who	O
had	O
a	O
history	O
of	O
DM	O
with	O
documented	O
hemoglobin	O
A1c	O
(	O
HbA1c	O
)	O
within	O
3	O
months	O
of	O
the	O
initial	O
first	O
ray	O
(	O
hallux	O
and	O
first	O
metatarsal	O
)	O
amputation	O
and	O
available	O
radiographic	O
data	O
.	O

Statistical	O
analysis	O
compared	O
the	O
incidence	O
rates	O
of	O
reamputation	O
between	O
patients	O
who	O
underwent	O
initial	O
MRI	B-P
and	O
those	O
who	O
did	O
not	O
obtain	O
an	O
initial	O
MRI	B-P
prior	O
to	O
their	O
first	O
amputation	O
.	O

The	O
reamputation	O
rate	O
was	O
compared	O
after	O
adjustment	O
for	O
age	O
,	O
gender	O
,	O
ethnicity	O
,	O
HbA1c	O
,	O
cardiovascular	O
disease	O
,	O
hypoalbuminemia	O
,	O
smoking	O
,	O
body	O
mass	O
index	O
,	O
and	O
prior	O
antibiotic	O
treatment	O
.	O

The	O
results	O
of	O
our	O
statistical	O
analysis	O
failed	O
to	O
reveal	O
a	O
significant	O
association	O
between	O
obtaining	O
an	O
initial	O
MRI	B-P
and	O
the	O
reamputation	O
rate	O
.	O

We	O
did	O
,	O
however	O
,	O
find	O
a	O
statistical	O
association	O
between	O
obtaining	O
an	O
early	O
MRI	B-P
and	O
decreased	O
mortality	O
rates	O
.	O

Obtaining	O
an	O
early	O
MRI	B-P
was	O
not	O
associated	O
with	O
the	O
reamputation	O
rate	O
incidence	O
in	O
the	O
treatment	O
of	O
the	O
diabetic	O
foot	O
.	O

It	O
did	O
,	O
however	O
,	O
have	O
a	O
statistically	O
significant	O
association	O
with	O
the	O
mortality	O
rate	O
as	O
demonstrated	O
by	O
the	O
increased	O
survival	O
rate	O
in	O
patients	O
undergoing	O
MRI	B-P
prior	O
to	O
initial	O
amputation	O
.	O

Causes	O
of	O
Death	O
among	O
Children	O
Aged	O
5	O
to	O
14	O
Years	O
Old	O
from	O
2008	O
to	O
2013	O
in	O
Kersa	O
Health	O
and	O
Demographic	O
Surveillance	O
System	O
(	O
Kersa	O
HDSS	O
)	O
,	O
Ethiopia	O
.	O

The	O
global	O
burden	O
of	O
mortality	O
among	O
children	O
is	O
still	O
very	O
huge	O
though	O
its	O
trend	O
has	O
started	O
declining	O
following	O
the	O
improvements	O
in	O
the	O
living	O
standard	O
.	O

It	O
presents	O
serious	O
challenges	O
to	O
the	O
well-being	O
of	O
children	O
in	O
many	O
African	O
countries	O
.	O

Today	O
,	O
Sub-Saharan	O
Africa	O
alone	O
accounts	O
for	O
about	O
50	O
%	O
of	O
global	O
child	O
mortality	O
.	O

The	O
overall	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
magnitude	O
and	O
distribution	O
of	O
causes	O
of	O
death	O
among	O
children	O
aged	O
5	O
to	O
14	O
year	O
olds	O
in	O
the	O
population	O
of	O
Kersa	O
HDSS	O
using	O
verbal	O
autopsy	B-P
method	O
for	O
the	O
period	O
2008	O
to	O
2013	O
.	O

Kersa	O
Health	O
and	O
Demographic	O
Surveillance	O
System	O
(	O
Kersa	O
HDSS	O
)	O
was	O
established	O
in	O
September	O
2007	O
.	O

The	O
center	O
consists	O
of	O
10	O
rural	O
and	O
2	O
urban	O
kebeles	O
which	O
were	O
selected	O
randomly	O
from	O
38	O
kebeles	O
in	O
the	O
district	O
.	O

Thus	O
this	O
study	O
was	O
conducted	O
in	O
Kersa	O
HDSS	O
and	O
data	O
was	O
taken	O
from	O
Kersa	O
HDSS	O
database	O
.	O

The	O
study	O
population	O
included	O
all	O
children	O
aged	O
5	O
to	O
14	O
years	O
registered	O
during	O
the	O
period	O
of	O
2008	O
to	O
2013	O
in	O
Kersa	O
HDSS	O
using	O
age	O
specific	O
VA	O
questionnaires	O
.	O

Data	O
were	O
extracted	O
from	O
SPSS	O
database	O
and	O
analyzed	O
using	O
STATA	O
.	O

A	O
total	O
of	O
229	O
deaths	O
were	O
recorded	O
over	O
the	O
period	O
of	O
six	O
years	O
with	O
a	O
crude	O
death	O
rate	O
of	O
219.6	O
per	O
100,000	O
population	O
of	O
this	O
age	O
group	O
over	O
the	O
study	O
period	O
.	O

This	O
death	O
rate	O
was	O
217.5	O
and	O
221.5	O
per	O
100,000	O
populations	O
for	O
females	O
and	O
males	O
,	O
respectively	O
.	O

75	O
%	O
of	O
deaths	O
took	O
place	O
at	O
home	O
.	O

The	O
study	O
identified	O
severe	O
malnutrition	O
(	O
33.9	O
%	O
)	O
,	O
intestinal	O
infectious	O
diseases	O
(	O
13.8	O
%	O
)	O
and	O
acute	O
lower	O
respiratory	O
infections	O
(	O
9.2	O
%	O
)	O
to	O
be	O
the	O
three	O
most	O
leading	O
causes	O
of	O
death	O
.	O

In	O
broad	O
causes	O
of	O
death	O
classification	O
,	O
injuries	O
have	O
been	O
found	O
to	O
be	O
the	O
second	O
most	O
cause	O
of	O
death	O
next	O
to	O
communicable	O
diseases	O
(	O
56.3	O
%	O
)	O
attributing	O
to	O
13.1	O
%	O
of	O
the	O
total	O
deaths	O
.	O

In	O
specific	O
causes	O
of	O
death	O
classification	O
severe	O
malnutrition	O
,	O
intestinal	O
infectious	O
diseases	O
and	O
acute	O
lower	O
respiratory	O
infections	O
were	O
the	O
three	O
leading	O
causes	O
of	O
death	O
where	O
,	O
in	O
broad	O
causes	O
of	O
death	O
communicable	O
diseases	O
and	O
injuries	O
were	O
among	O
the	O
leading	O
causes	O
of	O
death	O
.	O

Hence	O
,	O
concerned	O
bodies	O
should	O
take	O
measures	O
to	O
avert	O
the	O
situation	O
of	O
mortality	O
from	O
these	O
causes	O
of	O
death	O
and	O
further	O
inferential	O
analysis	O
into	O
the	O
prevention	O
and	O
management	O
of	O
infectious	O
diseases	O
should	O
also	O
be	O
taken	O
.	O

The	O
sensitivity	O
and	O
specifity	O
of	O
DR-70	O
immunoassay	B-P
as	O
a	O
tumor	O
marker	O
for	O
non-small	O
cell	O
lung	O
cancer	O
.	O

Lung	O
cancer	O
is	O
the	O
most	O
important	O
causes	O
of	O
the	O
cancer	O
related	O
mortality	O
.	O

Patients	O
with	O
lung	O
cancer	O
are	O
usually	O
diagnosed	B-P
at	O
advanced	O
or	O
locally	O
advanced	O
stage	O
,	O
for	O
this	O
reason	O
early	B-P
diagnosis	I-P
of	O
lung	O
cancer	O
is	O
very	O
important	O
.	O

For	O
early	B-P
detection	I-P
of	O
lung	O
cancer	O
some	O
methods	O
are	O
emphasized	O
such	O
as	O
low-dose	B-P
computed	I-P
tomography	I-P
or	O
tumor	O
biomarkers	O
.	O

In	O
this	O
study	O
we	O
aimed	O
to	O
evaluate	O
DR-70	O
sensitivity	O
and	O
specificity	O
as	O
a	O
tumor	O
marker	O
in	O
detection	O
of	O
non-small	O
cell	O
lung	O
cancers	O
.	O

Between	O
May	O
2013	O
and	O
April	O
2014	O
,	O
the	O
serum	O
samples	O
from	O
88	O
non	O
lung	O
cancer	O
patients	O
,	O
86	O
patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disesase	O
were	O
obtained	O
.	O

Blood	O
samples	O
from	O
each	O
participant	O
were	O
analyzed	O
for	O
DR-70	O
level	O
.	O

Totally	O
174	O
patients	O
were	O
enrolled	O
to	O
the	O
study	O
(	O
152	O
male	O
,	O
22	O
female	O
)	O
.	O

Histopathologically	O
47	O
(	O
53.4	O
%	O
)	O
patients	O
were	O
diagnosed	B-P
with	O
squamous	O
cell	O
lung	O
cancer	O
,	O
34	O
(	O
38.6	O
%	O
)	O
with	O
adenocarcinoma	O
,	O
and	O
7	O
(	O
8	O
%	O
)	O
with	O
non-small	O
cell	O
lung	O
cancer	O
.	O

The	O
mean	O
serum	O
DR-70	O
levels	O
in	O
lung	O
cancer	O
patients	O
(	O
2.43	O
±	O
1.82	O
µg/mL	O
)	O
was	O
significantly	O
higher	O
compared	O
to	O
the	O
86	O
non-cancerous	O
subjects	O
(	O
1.15	O
±	O
0.70	O
µg/mL	O
)	O
(	O
p	O
<	O
0.01	O
)	O
.	O

DR-70	O
exhibited	O
clinical	O
sensitivity	O
and	O
specificity	O
of	O
54.5	O
and	O
83.7	O
%	O
,	O
respectively	O
,	O
at	O
an	O
optimal	O
cut	O
off	O
at	O
1.98	O
µg/mL	O
.	O

It	O
could	O
be	O
said	O
that	O
the	O
risk	O
of	O
the	O
presence	O
of	O
the	O
disease	O
is	O
6.171	O
times	O
higher	O
in	O
the	O
cases	O
where	O
DR-70	O
level	O
is	O
1.98	O
µg/mL	O
and	O
higher	O
.	O

DR-70	O
,	O
a	O
marker	O
used	O
to	O
measure	O
fibrin	O
degradation	O
products	O
,	O
generated	O
by	O
all	O
major	O
cancers	O
,	O
may	O
helps	O
to	O
find	O
high	O
risk	O
lung	O
cancer	O
patients	O
.	O

Hyperandrogenemia	O
in	O
women	O
with	O
polycystic	O
ovary	O
syndrome	O
:	O
prevalence	O
,	O
characteristics	O
and	O
association	O
with	O
body	O
mass	O
index	O
.	O

Hyperandrogenemia	O
is	O
one	O
of	O
the	O
major	O
diagnostic	O
features	O
for	O
the	O
diagnosis	O
of	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
estimate	O
the	O
prevalence	O
and	O
the	O
characteristics	O
of	O
hyperandrogenemia	O
in	O
women	O
with	O
PCOS	O
and	O
to	O
investigate	O
the	O
association	O
of	O
clinical	O
and	O
biochemical	O
characteristics	O
with	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
according	O
to	O
the	O
presence	O
of	O
hyperandrogenemia	O
.	O

We	O
studied	O
266	O
women	O
diagnosed	O
with	O
PCOS	O
.	O

Hyperandrogenemia	O
was	O
defined	O
by	O
testosterone	O
(	O
T	O
)	O
and/or	O
free	O
testosterone	O
(	O
FT	O
)	O
and/or	O
∆4	O
androstenedione	O
(	O
Δ4-A	O
)	O
higher	O
than	O
75	O
%	O
of	O
the	O
upper	O
limits	O
of	O
each	O
hormone	O
.	O

Patients	O
were	O
stratified	O
in	O
two	O
groups	O
according	O
to	O
a	O
BMI	O
threshold	O
of	O
25	O
kg/m2	O
.	O

Hyperandrogenemia	O
was	O
present	O
in	O
78.2	O
%	O
of	O
the	O
patients	O
.	O

Elevated	O
levels	O
of	O
T	O
were	O
found	O
in	O
58.4	O
%	O
,	O
while	O
elevated	O
levels	O
of	O
FT	O
and	O
Δ4-A	O
were	O
found	O
in	O
42.5	O
%	O
and	O
34.1	O
%	O
of	O
patients	O
.	O

In	O
normal	O
weight	O
women	O
(	O
BMI	O
≤25	O
kg/m2	O
)	O
with	O
hyperandrogenemia	O
lower	O
values	O
of	O
hip	O
circumference	O
and	O
HOMA-IR	B-P
and	O
increased	O
levels	O
of	O
T	O
,	O
FT	O
,	O
Δ4-A	O
,	O
17-hydroxyprogesterone	O
(	O
17-OHP	O
)	O
,	O
dehydroepiandrosterone	O
sulfate	O
(	O
DHEAS	O
)	O
,	O
white	O
blood	O
cells	O
(	O
WBC	O
)	O
and	O
neutrophils	O
were	O
observed	O
compared	O
to	O
women	O
without	O
hyperandrogenemia	O
.	O

Also	O
,	O
in	O
overweight	O
women	O
higher	O
levels	O
of	O
T	O
,	O
FT	O
,	O
Δ4-A	O
,	O
17-OHP	O
,	O
DHEAS	O
and	O
cortisol	O
were	O
measured	O
,	O
while	O
lower	O
thyroid-stimulating	B-P
hormone	I-P
(	I-P
TSH	I-P
)	I-P
levels	I-P
were	O
comparable	O
to	O
women	O
without	O
hyperandrogenemia	O
.	O

This	O
study	O
showed	O
high	O
prevalence	O
of	O
hyperandrogenemia	O
in	O
PCOS	O
women	O
.	O

Women	O
with	O
BMI	O
≤25	O
kg/m2	O
have	O
significant	O
differences	O
in	O
androgens	O
,	O
WBC	O
,	O
neutrophils	O
and	O
HOMA-IR	B-P
and	O
women	O
with	O
BMI	O
≥25	O
kg/m2	O
in	O
androgens	O
,	O
TSH	O
and	O
cortisol	O
according	O
to	O
the	O
presence	O
or	O
not	O
of	O
hyperandrogenemia	O
.	O

What	O
Is	O
the	O
Real	O
Impact	O
of	O
Urinary	O
Incontinence	O
on	O
Female	O
Sexual	O
Dysfunction	O
?	O

A	O
Case	O
Control	O
Study	O
.	O

Urinary	O
incontinence	O
(	O
UI	O
)	O
has	O
been	O
associated	O
with	O
negative	O
effects	O
on	O
women	O
's	O
sexuality	O
.	O

Women	O
's	O
sexuality	O
and	O
sexual	O
function	O
are	O
a	O
complex	O
issue	O
,	O
and	O
the	O
role	O
of	O
UI	O
is	O
not	O
completely	O
clear	O
.	O

To	O
assess	O
the	O
impact	O
of	O
UI	O
on	O
female	O
sexual	O
function	O
by	O
comparing	O
this	O
population	O
with	O
a	O
control	O
group	O
of	O
continent	O
women	O
.	O

We	O
performed	O
a	O
case-control	O
study	O
from	O
August	O
2012	O
to	O
September	O
2013	O
.	O

We	O
evaluated	O
continent	O
and	O
incontinent	O
women	O
(	O
age	O
range	O
=	O
30-70	O
years	O
)	O
for	O
their	O
sexuality	O
.	O

All	O
patients	O
were	O
evaluated	O
by	O
anamnesis	O
,	O
physical	O
examination	O
,	O
and	O
self-report	O
quality-of-life	O
questionnaires	O
.	O

In	O
addition	O
,	O
incontinent	O
women	O
underwent	O
a	O
1-hour	O
pad	B-P
test	I-P
.	O

Patients	O
without	O
sexual	O
activity	O
were	O
evaluated	O
for	O
the	O
role	O
of	O
UI	O
in	O
their	O
sexual	O
abstinence	O
.	O

Sexual	O
abstinence	O
was	O
defined	O
as	O
the	O
absence	O
of	O
sexual	O
activity	O
for	O
more	O
than	O
6	O
months	O
.	O

All	O
sexually	O
active	O
women	O
completed	O
the	O
self-report	O
Sexuality	O
Quotient	O
-	O
Female	O
Version	O
(	O
SQ-F	O
)	O
questionnaire	O
.	O

A	O
total	O
of	O
356	O
women	O
were	O
included	O
in	O
the	O
study	O
(	O
incontinent	O
,	O
n	O
=	O
243	O
;	O
continent	O
,	O
n	O
=	O
113	O
)	O
.	O

Sexual	O
abstinence	O
was	O
found	O
in	O
162	O
women	O
(	O
45	O
%	O
)	O
.	O

Incontinent	O
women	O
presented	O
a	O
higher	O
prevalence	O
(	O
P	O
<	O
.001	O
)	O
of	O
sexual	O
abstinence	O
than	O
their	O
counterparts	O
(	O
129	O
[	O
53	O
%	O
]	O
and	O
33	O
[	O
29.2	O
%	O
]	O
,	O
respectively	O
)	O
.	O

Age	O
,	O
marital	O
status	O
,	O
and	O
UI	O
were	O
found	O
to	O
be	O
isolated	O
predictive	O
factors	O
for	O
more	O
sexual	O
abstinence	O
in	O
incontinent	O
women	O
.	O

Sexually	O
active	O
women	O
(	O
incontinent	O
,	O
n	O
=	O
114	O
;	O
continent	O
,	O
n	O
=	O
80	O
)	O
presented	O
similar	O
demographic	O
data	O
.	O

Despite	O
a	O
similar	O
frequency	O
of	O
sexual	O
activity	O
,	O
incontinent	O
women	O
had	O
less	O
sexual	O
desire	O
,	O
foreplay	O
,	O
harmony	O
with	O
a	O
partner	O
,	O
sexual	O
comfort	O
,	O
and	O
sexual	O
satisfaction	O
than	O
their	O
counterparts	O
.	O

Women	O
with	O
greater	O
urinary	O
leakage	O
during	O
the	O
1-hour	O
pad	B-P
test	I-P
(	O
weight	O
>	O
11	O
g	O
)	O
had	O
the	O
worst	O
sexual	O
function	O
(	O
SQ-F	O
)	O
score	O
.	O

Women	O
with	O
UI	O
were	O
more	O
likely	O
to	O
be	O
sexual	O
abstinent	O
than	O
continent	O
women	O
.	O

Furthermore	O
,	O
women	O
with	O
UI	O
showed	O
less	O
sexual	O
desire	O
,	O
sexual	O
comfort	O
,	O
and	O
sexual	O
satisfaction	O
than	O
their	O
counterparts	O
despite	O
having	O
a	O
similar	O
frequency	O
of	O
sexual	O
activity	O
.	O

Structural	O
investigation	O
on	O
WlaRG	O
from	O
Campylobacter	O
jejuni	O
:	O
A	O
sugar	O
aminotransferase	O
.	O

Campylobacter	O
jejuni	O
is	O
a	O
Gram-negative	O
bacterium	O
that	O
represents	O
a	O
leading	O
cause	O
of	O
human	O
gastroenteritis	O
worldwide	O
.	O

Of	O
particular	O
concern	O
is	O
the	O
link	O
between	O
C.	O
jejuni	O
infections	O
and	O
the	O
subsequent	O
development	O
of	O
Guillain-Barré	O
syndrome	O
,	O
an	O
acquired	O
autoimmune	O
disorder	O
leading	O
to	O
paralysis	O
.	O

All	O
Gram-negative	O
bacteria	O
contain	O
complex	O
glycoconjugates	O
anchored	O
to	O
their	O
outer	O
membranes	O
,	O
but	O
in	O
most	O
strains	O
of	O
C.	O
jejuni	O
,	O
this	O
lipoglycan	O
lacks	O
the	O
O-antigen	O
repeating	O
units	O
.	O

Recent	O
mass	B-P
spectrometry	I-P
analyses	O
indicate	O
that	O
the	O
C.	O
jejuni	O
81116	O
(	O
Penner	O
serotype	O
HS:6	O
)	O
lipoglycan	O
contains	O
two	O
dideoxyhexosamine	O
residues	O
,	O
and	O
enzymological	B-P
assay	I-P
data	O
show	O
that	O
this	O
bacterial	O
strain	O
can	O
synthesize	O
both	O
dTDP-3-acetamido-3,6-dideoxy-d-glucose	O
and	O
dTDP-3-acetamido-3,6-dideoxy-d-galactose	O
.	O

The	O
focus	O
of	O
this	O
investigation	O
is	O
on	O
WlaRG	O
from	O
C.	O
jejuni	O
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
the	O
production	O
of	O
these	O
unusual	O
sugars	O
by	O
functioning	O
as	O
a	O
pyridoxal	O
5'-phosphate	O
dependent	O
aminotransferase	O
.	O

Here	O
,	O
we	O
describe	O
the	O
first	O
three-dimensional	O
structures	O
of	O
the	O
enzyme	O
in	O
various	O
complexes	O
determined	O
to	O
resolutions	O
of	O
1.7	O
Å	O
or	O
higher	O
.	O

Of	O
particular	O
significance	O
are	O
the	O
external	O
aldimine	O
structures	O
of	O
WlaRG	O
solved	O
in	O
the	O
presence	O
of	O
either	O
dTDP-3-amino-3,6-dideoxy-d-galactose	O
or	O
dTDP-3-amino-3,6-dideoxy-d-glucose	O
.	O

These	O
models	O
highlight	O
the	O
manner	O
in	O
which	O
WlaRG	O
can	O
accommodate	O
sugars	O
with	O
differing	O
stereochemistries	O
about	O
their	O
C-4	O
'	O
carbon	O
positions	O
.	O

In	O
addition	O
,	O
we	O
present	O
a	O
corrected	O
structure	O
of	O
WbpE	O
,	O
a	O
related	O
sugar	O
aminotransferase	O
from	O
Pseudomonas	O
aeruginosa	O
,	O
solved	O
to	O
1.3	O
Å	O
resolution	O
.	O

The	O
endocannabinoid	O
hydrolysis	O
inhibitor	O
SA-57	O
:	O
Intrinsic	O
antinociceptive	O
effects	O
,	O
augmented	O
morphine	O
-induced	O
antinociception	O
,	O
and	O
attenuated	O
heroin	O
seeking	O
behavior	O
in	O
mice	O
.	O

Although	O
opioids	O
are	O
highly	O
efficacious	O
analgesics	O
,	O
their	O
abuse	O
potential	O
and	O
other	O
untoward	O
side	O
effects	O
diminish	O
their	O
therapeutic	O
utility	O
.	O

The	O
addition	O
of	O
non-opioid	O
analgesics	O
offers	O
a	O
promising	O
strategy	O
to	O
reduce	O
required	O
antinociceptive	O
opioid	O
doses	O
that	O
concomitantly	O
reduce	O
opioid-related	O
side	O
effects	O
.	O

Inhibitors	O
of	O
the	O
primary	O
endocannabinoid	O
catabolic	O
enzymes	O
fatty	O
acid	O
amide	O
hydrolase	O
(	O
FAAH	O
)	O
and	O
monoacylglycerol	O
lipase	O
(	O
MAGL	O
)	O
show	O
opioid	O
-	O
sparing	O
effects	O
in	O
preclinical	O
models	O
of	O
pain	O
.	O

As	O
simultaneous	O
inhibition	O
of	O
these	O
enzymes	O
elicits	O
enhanced	O
antinociceptive	O
effects	O
compared	O
with	O
single	O
enzyme	O
inhibition	O
,	O
the	O
present	O
study	O
tested	O
whether	O
the	O
dual	O
FAAH	O
-	O
MAGL	O
inhibitor	O
SA-57	O
[	O
4-	O
[	O
2-	O
(	O
4-chlorophenyl	O
)	O
ethyl	O
]	O
-1-piperidinecarboxylic	O
acid	O
2-	O
(	O
methylamino	O
)	O
-2-oxoethyl	O
ester	O
]	O
produces	O
morphine	O
-sparing	O
antinociceptive	O
effects	O
,	O
without	O
major	O
side	O
effects	O
associated	O
with	O
either	O
drug	O
class	O
.	O

SA-57	O
dose	O
-dependently	O
reversed	O
mechanical	O
allodynia	O
in	O
the	O
constriction	O
injury	O
(	O
CCI	O
)	O
of	O
the	O
sciatic	O
nerve	O
model	O
of	O
neuropathic	O
pain	O
and	O
carrageenan	O
inflammatory	O
pain	O
model	O
.	O

As	O
previously	O
reported	O
,	O
SA-57	O
was	O
considerably	O
more	O
potent	O
in	O
elevating	O
anandamide	O
(	O
AEA	O
)	O
than	O
2-arachidonyl	O
glycerol	O
(	O
2-AG	O
)	O
in	O
brain	O
.	O

Its	O
anti-allodynic	O
effects	O
required	O
cannabinoid	O
(	O
CB	O
)	O
1	O
and	O
CB2	O
receptors	O
;	O
however	O
,	O
only	O
CB2	O
receptors	O
were	O
necessary	O
for	O
the	O
anti-edematous	O
effects	O
in	O
the	O
carrageenan	O
assay	B-P
.	O

Although	O
high	O
doses	O
of	O
SA-57	O
alone	O
were	O
required	O
to	O
produce	O
antinociception	O
,	O
low	O
doses	O
of	O
this	O
compound	O
,	O
which	O
elevated	O
AEA	O
and	O
did	O
not	O
affect	O
2-AG	O
brain	O
levels	O
,	O
augmented	O
the	O
antinociceptive	O
effects	O
of	O
morphine	O
,	O
but	O
lacked	O
cannabimimetic	O
side	O
effects	O
.	O

Because	O
of	O
the	O
high	O
abuse	O
liability	O
of	O
opioids	O
and	O
implication	O
of	O
the	O
endocannabinoid	O
system	O
in	O
the	O
reinforcing	O
effects	O
of	O
opioids	O
,	O
the	O
final	O
experiment	O
tested	O
whether	O
SA-57	O
would	O
alter	O
heroin	O
seeking	O
behavior	O
.	O

Strikingly	O
,	O
SA-57	O
reduced	O
heroin	O
-	O
reinforced	O
nose	O
poke	O
behavior	O
and	O
the	O
progressive	O
ratio	O
break	O
point	O
for	O
heroin	O
.	O

In	O
conclusion	O
,	O
the	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
inhibition	O
of	O
endocannabinoid	O
degradative	O
enzymes	O
represents	O
a	O
promising	O
therapeutic	O
approach	O
to	O
decrease	O
effective	O
doses	O
of	O
opioids	O
needed	O
for	O
clinical	O
pain	O
control	O
,	O
and	O
may	O
also	O
possess	O
therapeutic	O
potential	O
to	O
reduce	O
opioid	O
abuse	O
.	O

Tooth	O
replacements	O
in	O
young	O
adults	O
with	O
severe	O
hypodontia	O
:	O
Orthodontic	O
space	O
closure	O
,	O
dental	O
implants	O
,	O
and	O
tooth	O
-supported	O
fixed	O
dental	O
prostheses	O
.	O

A	O
follow-up	O
study	O
.	O

Children	O
with	O
severe	O
hypodontia	O
have	O
a	O
substantial	O
impairment	O
of	O
their	O
dental	O
health	O
starting	O
early	O
in	O
life	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
describe	O
types	O
and	O
locations	O
of	O
substitutes	O
for	O
missing	O
teeth	O
in	O
patients	O
with	O
severe	O
hypodontia	O
and	O
to	O
compare	O
the	O
crown	O
and	O
soft	O
tissue	O
morphologies	O
of	O
orthodontic	O
space	O
closure	O
,	O
dental	O
implants	O
,	O
and	O
tooth	O
-supported	O
fixed	O
dental	O
prostheses	O
for	O
replacing	O
teeth	O
in	O
the	O
anterior	O
region	O
.	O

Fifty	O
patients	O
missing	O
6	O
or	O
more	O
teeth	O
and	O
aged	O
18	O
years	O
or	O
older	O
(	O
mean	O
age	O
,	O
25.6	O
years	O
)	O
took	O
part	O
in	O
a	O
follow-up	O
study	O
.	O

The	O
patients	O
were	O
examined	O
clinically	O
with	O
panoramic	B-P
radiographs	I-P
and	O
clinical	B-P
photographs	I-P
.	O

Crown	O
and	O
soft	O
tissue	O
variables	O
(	O
mucosal	O
discoloration	O
,	O
crown	O
morphology	O
,	O
color	O
,	O
and	O
papilla	O
index	O
)	O
were	O
compared	O
for	O
orthodontic	O
space	O
closure	O
,	O
dental	O
implant	O
fixtures	O
,	O
and	O
fixed	O
dental	O
prostheses	O
.	O

Dental	O
implants	O
,	O
orthodontic	O
space	O
closure	O
,	O
and	O
retaining	O
deciduous	O
teeth	O
were	O
the	O
most	O
commonly	O
prescribed	O
treatments	O
.	O

Persisting	O
deciduous	O
teeth	O
showed	O
a	O
good	O
survival	O
rate	O
at	O
the	O
follow-up	O
examination	O
.	O

Mucosal	O
discoloration	O
was	O
seen	O
only	O
for	O
implant	O
fixtures	O
and	O
was	O
evident	O
for	O
almost	O
all	O
fixtures	O
in	O
the	O
anterior	O
mandible	O
and	O
two	O
thirds	O
of	O
those	O
in	O
the	O
anterior	O
maxilla	O
.	O

The	O
papilla	O
index	O
scored	O
poorer	O
for	O
both	O
implant	O
fixtures	O
and	O
fixed	O
dental	O
prostheses	O
compared	O
with	O
orthodontic	O
space	O
closure	O
.	O

Dental	O
implants	O
in	O
the	O
anterior	O
region	O
proved	O
to	O
be	O
an	O
inadequate	O
treatment	O
modality	O
in	O
patients	O
with	O
severe	O
hypodontia	O
because	O
of	O
pronounced	O
mucosal	O
discoloration	O
.	O

Homogeneous	O
synthesis	O
of	O
Ag	O
nanoparticles	O
-doped	O
water-soluble	O
cellulose	O
acetate	O
for	O
versatile	O
applications	O
.	O

We	O
report	O
a	O
facile	O
and	O
efficient	O
approach	O
for	O
synthesis	O
of	O
well-dispersed	O
and	O
stable	O
silver	O
nanoparticles	O
(	O
Ag	O
NPs	O
)	O
using	O
water-soluble	O
cellulose	O
acetate	O
(	O
CA	O
)	O
as	O
both	O
reductant	O
and	O
stabilizer	O
.	O

Partially	O
substituted	O
CA	O
with	O
highly	O
active	O
hydroxyl	O
groups	O
and	O
excellent	O
water-solubility	O
is	O
able	O
to	O
reduce	O
silver	O
ions	O
in	O
homogeneous	O
aqueous	O
medium	O
effectively	O
.	O

The	O
synthesized	O
Ag	O
NPs	O
were	O
characterized	O
by	O
UV-vis	B-P
spectroscopy	I-P
,	O
X-ray	B-P
diffraction	I-P
,	O
X-ray	B-P
photoelectron	I-P
spectroscopy	I-P
,	O
transmission	B-P
electron	I-P
microscopy	I-P
and	O
energy	B-P
dispersive	I-P
X-ray	I-P
spectroscope	I-P
analysis	B-P
.	O

The	O
as-	O
prepared	O
Ag	O
NPs	O
were	O
well-dispersed	O
,	O
showing	O
a	O
surface	O
plasmon	O
resonance	O
peak	O
at	O
426	O
nm	O
.	O

The	O
resulted	O
Ag	O
NPs	O
@	O
CA	O
nanohybrids	O
exhibit	O
high	O
catalytic	O
activity	O
for	O
the	O
reduction	O
of	O
4-nitrophenol	O
to	O
4-aminophenol	O
in	O
the	O
presence	O
of	O
NaBH4	O
.	O

Meanwhile	O
,	O
the	O
nanohybrids	O
are	O
also	O
effective	O
in	O
inhibiting	O
the	O
growth	O
of	O
bacterial	O
.	O

This	O
environmentally	O
friendly	O
method	O
promotes	O
the	O
use	O
of	O
renewable	O
natural	O
resources	O
to	O
prepare	O
a	O
variety	O
of	O
inorganic-organic	O
materials	O
for	O
catalysis	O
,	O
antibacterial	O
,	O
sensors	O
and	O
other	O
applications	O
.	O

Correcting	O
Concavity	O
of	O
Rabbit	O
Auricular	O
Cartilage	O
:	O
Comparison	O
of	O
Single	O
Scoring	O
Incisions	O
with	O
Butyl	O
Cyanoacrylate	O
-Aided	O
Techniques	O
.	O

The	O
authors	O
present	O
the	O
results	O
of	O
an	O
experimental	O
study	O
in	O
which	O
four	O
different	O
techniques	O
were	O
used	O
for	O
the	O
correction	O
of	O
concave	O
rabbit	O
auricular	O
cartilage	O
.	O

Sixteen	O
New	O
Zealand	O
adult	O
male	O
rabbits	O
were	O
used	O
in	O
the	O
study	O
.	O

Butyl	O
cyanoacrylate	O
-aided	O
cartilage	O
graft	O
fixation	O
and	O
butyl	O
cyanoacrylate	O
-aided	O
bone	O
graft	O
fixation	O
and	O
scoring	O
technique	O
,	O
alone	O
or	O
combined	O
with	O
butyl	O
cyanoacrylate	O
application	O
,	O
were	O
performed	O
to	O
correct	O
the	O
concavity	O
of	O
rabbit	O
auricular	O
cartilage	O
.	O

Angle	O
measurements	O
showed	O
that	O
all	O
four	O
techniques	O
were	O
efficient	O
for	O
correction	O
of	O
the	O
cartilage	O
concavities	O
.	O

However	O
,	O
the	O
mean	O
postsacrifice	O
angles	O
of	O
the	O
graft	O
fixation	O
groups	O
were	O
significantly	O
higher	O
than	O
those	O
of	O
the	O
other	O
study	O
groups	O
,	O
reflecting	O
the	O
fact	O
that	O
graft	O
fixation	O
with	O
butyl	O
cyanoacrylate	O
application	O
was	O
more	O
efficient	O
for	O
preserving	O
the	O
final	O
cartilage	O
shape	O
.	O

Furthermore	O
,	O
in	O
the	O
ninth	O
month	O
,	O
graft	O
fixation	O
groups	O
had	O
the	O
lowest	O
chondrocyte	O
densities	O
,	O
the	O
highest	O
degree	O
of	O
inflammation	O
,	O
the	O
highest	O
degree	O
of	O
foreign	O
body	O
reaction	O
,	O
and	O
the	O
highest	O
butyl	O
cyanoacrylate	O
density	O
.	O

Fibrosis	O
or	O
chondrocyte	O
proliferation	O
on	O
scoring	O
incision	O
lines	O
is	O
not	O
an	O
associated	O
feature	O
of	O
this	O
technique	O
.	O

When	O
the	O
incision	O
depths	O
were	O
standardized	O
,	O
the	O
scoring	O
technique	O
provided	O
efficacy	O
similar	O
to	O
that	O
of	O
the	O
scoring	O
incisions	O
combined	O
with	O
butyl	O
cyanoacrylate	O
application	O
for	O
correction	O
of	O
the	O
cartilage	O
concavity	O
.	O

The	O
scoring	O
incision	O
plus	O
butyl	O
cyanoacrylate	O
group	O
showed	O
less	O
toxicity	O
than	O
the	O
graft	O
fixation	O
groups	O
because	O
of	O
rapid	O
removal	O
of	O
toxic	O
breakdown	O
products	O
.	O

Graft	O
fixation	O
techniques	O
were	O
superior	O
to	O
other	O
corrective	O
procedures	O
with	O
regard	O
to	O
preservation	B-P
of	O
the	O
final	O
cartilage	O
shape	O
.	O

Although	O
they	O
resulted	O
in	O
greater	O
toxicity	O
,	O
the	O
cartilage	O
correction	O
was	O
not	O
affected	O
unfavorably	O
.	O

Multicenter	B-P
Patch	I-P
Testing	I-P
With	O
Methylchloroisothizoline/Methylisothiazolinone	O
in	O
100	O
and	O
200	O
ppm	O
Within	O
the	O
International	O
Contact	O
Dermatitis	O
Research	O
Group	O
.	O

The	O
preservative	O
methylchloroisothiazolinone/methylisothiazolinone	O
(	O
MCI/MI	O
)	O
is	O
a	O
well-known	O
contact	O
sensitizer	O
.	O

Historically	O
,	O
there	O
have	O
been	O
different	O
opinions	O
on	O
the	O
optimal	O
patch	B-P
test	I-P
concentration	O
of	O
MCI/MI	O
,	O
and	O
both	O
0.01	O
%	O
and	O
0.02	O
%	O
aqueous	O
(	O
aq	O
.	O
)	O

have	O
been	O
proposed	O
.	O

In	O
2011	O
,	O
based	O
on	O
literature	O
reviews	O
,	O
it	O
was	O
recommended	O
that	O
the	O
concentration	O
of	O
0.02	O
%	O
aq	O
.	O

should	O
be	O
used	O
in	O
the	O
international	O
baseline	O
series	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
verify	O
the	O
recommendation	O
from	O
2011	O
by	O
comparing	O
the	O
patch	B-P
test	I-P
results	O
from	O
consecutive	O
patch	B-P
testing	I-P
with	O
MCI/MI	O
0.01	O
%	O
and	O
0.02	O
%	O
in	O
clinics	O
representing	O
countries	O
around	O
the	O
world	O
.	O

Two	O
thousand	O
seven	O
hundred	O
three	O
consecutive	O
patients	O
with	O
dermatitis	O
in	O
8	O
dermatology	O
clinics	O
representing	O
8	O
countries	O
were	O
patch	B-P
tested	I-P
with	O
MCI/MI	O
0.01	O
%	O
aq	O
.	O

and	O
,	O
in	O
parallel	O
with	O
MCI/MI	O
0.02	O
%	O
aq.	O
,	O
provisionally	O
included	O
in	O
the	O
baseline	O
series	O
.	O

Contact	O
allergy	O
to	O
MCI/MI	O
at	O
0.01	O
%	O
and	O
0.02	O
%	O
was	O
found	O
in	O
3.7	O
%	O
and	O
5.6	O
%	O
of	O
the	O
patients	O
,	O
respectively	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Methylchloroisothiazolinone/MI	O
0.02	O
%	O
aq	O
.	O

(	O
dose	O
,	O
6	O
μg/cm	O
)	O
diagnoses	O
significantly	O
more	O
contact	O
allergy	O
than	O
0.01	O
%	O
(	O
dose	O
,	O
3	O
μg/cm	O
)	O
,	O
without	O
resulting	O
in	O
more	O
adverse	O
reactions	O
.	O

Methylchloroisothiazolinone/MI	O
at	O
0.02	O
%	O
aq	O
.	O

should	O
therefore	O
be	O
continuously	O
used	O
in	O
the	O
international	O
baseline	O
series	O
.	O

Phenotypic	O
and	O
genetic	O
heterogeneity	O
of	O
tumor	O
tissue	O
and	O
circulating	O
tumor	O
cells	O
in	O
patients	O
with	O
metastatic	O
castration-resistant	O
prostate	O
cancer	O
:	O
A	O
report	O
from	O
the	O
PETRUS	O
prospective	O
study	O
.	O

Molecular	O
characterization	O
of	O
cancer	O
samples	O
is	O
hampered	O
by	O
tumor	O
tissue	O
availability	O
in	O
metastatic	O
castration-resistant	O
prostate	O
cancer	O
(	O
mCRPC	O
)	O
patients	O
.	O

We	O
reported	O
the	O
results	O
of	O
prospective	O
PETRUS	O
study	O
of	O
biomarker	O
assessment	O
in	O
paired	O
primary	O
prostatic	O
tumors	O
,	O
metastatic	O
biopsies	B-P
and	O
circulating	O
tumor	O
cells	O
(	O
CTCs	O
)	O
.	O

Among	O
54	O
mCRPC	O
patients	O
enrolled	O
,	O
38	O
(	O
70	O
%	O
)	O
had	O
biopsies	B-P
containing	O
more	O
than	O
50	O
%	O
tumour	O
cells	O
.	O

28	O
(	O
52	O
%	O
)	O
patients	O
were	O
analyzed	O
for	O
both	O
tissue	O
samples	O
and	O
CTCs	O
.	O

FISH	O
for	O
AR	O
-	O
amplification	O
and	O
TMPRSS2	O
-	O
ERG	O
translocation	O
were	O
successful	O
in	O
54	O
%	O
and	O
32	O
%	O
in	O
metastatic	O
biopsies	B-P
and	O
primary	O
tumors	O
,	O
respectively	O
.	O

By	O
comparing	O
CellSearch	B-P
and	O
filtration	B-P
(	I-P
ISET	I-P
)	O
-enrichment	O
combined	O
to	O
four	O
color	O
immunofluorescent	B-P
staining	I-P
,	O
we	O
showed	O
that	O
CellSearch	B-P
and	O
ISET	B-P
isolated	O
distinct	O
subpopulations	O
of	O
CTCs	O
:	O
CTCs	O
undergoing	O
epithelial-to-mesenchymal	O
transition	O
,	O
CTC	O
clusters	O
and	O
large	O
CTCs	O
with	O
cytomorphological	O
characteristics	O
but	O
no	O
detectable	O
markers	O
were	O
isolated	O
using	O
ISET	B-P
.	O

Epithelial	O
CTCs	O
detected	O
by	O
the	O
CellSearch	B-P
were	O
mostly	O
lost	O
during	O
the	O
ISET-filtration	B-P
.	O

AR	O
-	O
amplification	O
was	O
detected	O
in	O
CellSearch	B-P
-captured	O
CTCs	O
,	O
but	O
not	O
in	O
ISET	B-P
-enriched	O
CTCs	O
which	O
harbor	O
exclusively	O
AR	O
gain	O
of	O
copies	O
.	O

Eighty-eight	O
percent	O
concordance	O
for	O
ERG-rearrangement	O
was	O
observed	O
between	O
metastatic	O
biopsies	B-P
and	O
CTCs	O
even	O
if	O
additional	O
ERG-alteration	O
patterns	O
were	O
detected	O
in	O
ISET	B-P
-enriched	O
CTCs	O
indicating	O
a	O
higher	O
heterogeneity	O
in	O
CTCs	O
.	O

Molecular	O
screening	O
of	O
metastatic	O
biopsies	B-P
is	O
achievable	O
in	O
a	O
multicenter	O
context	O
.	O

Our	O
data	O
indicate	O
that	O
CTCs	O
detected	O
by	O
the	O
CellSearch	B-P
and	O
the	O
ISET-filtration	B-P
systems	I-P
are	O
not	O
only	O
phenotypically	O
but	O
also	O
genetically	O
different	O
.	O

Close	O
attention	O
must	O
be	O
paid	O
to	O
CTC	O
characterization	O
since	O
neither	O
approach	O
tested	O
here	O
fully	O
reflects	O
the	O
tremendous	O
phenotypic	O
and	O
genetic	O
heterogeneity	O
present	O
in	O
CTCs	O
from	O
mCRPC	O
patients	O
.	O

Genetic	O
Diversity	O
in	O
Various	O
Accessions	O
of	O
Pineapple	O
[	O
Ananas	O
comosus	O
(	O
L.	O
)	O
Merr	O
.	O
]	O

Using	O
ISSR	O
and	O
SSR	O
Markers	O
.	O

Inter	O
simple	O
sequence	O
repeat	O
(	O
ISSR	O
)	O
and	O
simple	O
sequence	O
repeat	O
(	O
SSR	O
)	O
markers	O
were	O
used	O
to	O
assess	O
the	O
genetic	O
diversity	O
of	O
36	O
pineapple	O
accessions	O
that	O
were	O
introduced	O
from	O
10	O
countries	O
/	O
regions	O
.	O

Thirteen	O
ISSR	O
primers	O
amplified	B-P
96	O
bands	O
,	O
of	O
which	O
91	O
(	O
93.65	O
%	O
)	O
were	O
polymorphic	O
,	O
whereas	O
20	O
SSR	O
primers	O
amplified	B-P
73	O
bands	O
,	O
of	O
which	O
70	O
(	O
96.50	O
%	O
)	O
were	O
polymorphic	O
.	O

Nei	O
's	O
gene	O
diversity	O
(	O
h	O
=	O
0.28	O
)	O
,	O
Shannon	O
's	O
information	O
index	O
(	O
I	O
=	O
0.43	O
)	O
,	O
and	O
polymorphism	O
information	O
content	O
(	O
PIC	O
=	O
0.29	O
)	O
generated	O
using	O
the	O
SSR	O
primers	O
were	O
higher	O
than	O
that	O
with	O
ISSR	O
primers	O
(	O
h	O
=	O
0.23	O
,	O
I	O
=	O
0.37	O
,	O
PIC	O
=	O
0.24	O
)	O
,	O
thereby	O
suggesting	O
that	O
the	O
SSR	O
system	O
is	O
more	O
efficient	O
than	O
the	O
ISSR	O
system	O
in	O
assessing	O
genetic	O
diversity	O
in	O
various	O
pineapple	O
accessions	O
.	O

Mean	O
genetic	O
similarities	O
were	O
0.74	O
,	O
0.61	O
,	O
and	O
0.69	O
,	O
as	O
determined	O
using	O
ISSR	O
,	O
SSR	O
,	O
and	O
combined	O
ISSR	O
/	O
SSR	O
,	O
respectively	O
.	O

These	O
results	O
suggest	O
that	O
the	O
genetic	O
diversity	O
among	O
pineapple	O
accessions	O
is	O
very	O
high	O
.	O

We	O
clustered	O
the	O
36	O
pineapple	O
accessions	O
into	O
three	O
or	O
five	O
groups	O
on	O
the	O
basis	O
of	O
the	O
phylogenetic	O
trees	O
constructed	O
based	O
on	O
the	O
results	O
of	O
ISSR	O
,	O
SSR	O
,	O
and	O
combined	O
ISSR	O
/	O
SSR	O
analyses	O
using	O
the	O
unweighted	O
pair-group	O
with	O
arithmetic	O
averaging	O
(	O
UPGMA	O
)	O
method	O
.	O

The	O
results	O
of	O
principal	O
components	O
analysis	O
(	O
PCA	O
)	O
also	O
supported	O
the	O
UPGMA	O
clustering	O
.	O

These	O
results	O
will	O
be	O
useful	O
not	O
only	O
for	O
the	O
scientific	O
conservation	O
and	O
management	O
of	O
pineapple	O
germplasm	O
but	O
also	O
for	O
the	O
improvement	O
of	O
the	O
current	O
pineapple	O
breeding	O
strategies	O
.	O

Engineering	O
monolayer	O
poration	O
for	O
rapid	O
exfoliation	O
of	O
microbial	O
membranes	O
.	O

The	O
spread	O
of	O
bacterial	O
resistance	O
to	O
traditional	O
antibiotics	O
continues	O
to	O
stimulate	O
the	O
search	O
for	O
alternative	O
antimicrobial	O
strategies	O
.	O

All	O
forms	O
of	O
life	O
,	O
from	O
bacteria	O
to	O
humans	O
,	O
are	O
postulated	O
to	O
rely	O
on	O
a	O
fundamental	O
host	O
defense	O
mechanism	O
,	O
which	O
exploits	O
the	O
formation	O
of	O
open	O
pores	O
in	O
microbial	O
phospholipid	O
bilayers	O
.	O

Here	O
we	O
predict	O
that	O
transmembrane	O
poration	O
is	O
not	O
necessary	O
for	O
antimicrobial	O
activity	O
and	O
reveal	O
a	O
distinct	O
poration	O
mechanism	O
that	O
targets	O
the	O
outer	O
leaflet	O
of	O
phospholipid	O
bilayers	O
.	O

Using	O
a	O
combination	O
of	O
molecular	O
-	O
scale	O
and	O
real-time	B-P
imaging	I-P
,	O
spectroscopy	B-P
and	O
spectrometry	B-P
approaches	O
,	O
we	O
introduce	O
a	O
structural	O
motif	O
with	O
a	O
universal	O
insertion	O
mode	O
in	O
reconstituted	O
membranes	O
and	O
live	O
bacteria	O
.	O

We	O
demonstrate	O
that	O
this	O
motif	O
rapidly	O
assembles	O
into	O
monolayer	O
pits	O
that	O
coalesce	O
during	O
progressive	O
membrane	O
exfoliation	O
,	O
leading	O
to	O
bacterial	O
cell	O
death	O
within	O
minutes	O
.	O

The	O
findings	O
offer	O
a	O
new	O
physical	O
basis	O
for	O
designing	O
effective	O
antibiotics	O
.	O

Neural	O
activity	O
promotes	O
long-distance	O
,	O
target	O
-	O
specific	O
regeneration	O
of	O
adult	O
retinal	O
axons	O
.	O

Axons	O
in	O
the	O
mammalian	O
CNS	O
fail	O
to	O
regenerate	O
after	O
injury	O
.	O

Here	O
we	O
show	O
that	O
if	O
the	O
activity	O
of	O
mouse	O
retinal	O
ganglion	O
cells	O
(	O
RGCs	O
)	O
is	O
increased	O
by	O
visual	B-P
stimulation	I-P
or	O
using	O
chemogenetics	O
,	O
their	O
axons	O
regenerate	O
.	O

We	O
also	O
show	O
that	O
if	O
enhancement	O
of	O
neural	O
activity	O
is	O
combined	O
with	O
elevation	O
of	O
the	O
cell-growth	O
-promoting	O
pathway	O
involving	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
,	O
RGC	O
axons	O
regenerate	O
long	O
distances	O
and	O
re-innervate	O
the	O
brain	O
.	O

Analysis	O
of	O
genetically	O
labeled	O
RGCs	O
revealed	O
that	O
this	O
regrowth	O
can	O
be	O
target	O
specific	O
:	O
RGC	O
axons	O
navigated	O
back	O
to	O
their	O
correct	O
visual	O
targets	O
and	O
avoided	O
targets	O
incorrect	O
for	O
their	O
function	O
.	O

Moreover	O
,	O
these	O
regenerated	O
connections	O
were	O
successful	O
in	O
partially	O
rescuing	O
a	O
subset	O
of	O
visual	O
behaviors	O
.	O

Our	O
findings	O
indicate	O
that	O
combining	O
neural	O
activity	O
with	O
activation	O
of	O
mTOR	O
can	O
serve	O
as	O
powerful	O
tool	O
for	O
enhancing	O
axon	O
regeneration	O
,	O
and	O
they	O
highlight	O
the	O
remarkable	O
capacity	O
of	O
CNS	O
neurons	O
to	O
re-establish	O
accurate	O
circuit	O
connections	O
in	O
adulthood	O
.	O

Functional	O
Characterization	O
of	O
Pneumocystis	O
carinii	O
Inositol	O
Transporter	O
1	O
.	O

Fungi	O
in	O
the	O
genus	O
Pneumocystis	O
live	O
in	O
the	O
lungs	O
of	O
mammals	O
,	O
where	O
they	O
can	O
cause	O
a	O
fatal	O
pneumonia	O
(	O
PCP	O
[	O
Pneumocystis	O
pneumonia	O
]	O
)	O
in	O
hosts	O
with	O
compromised	O
immune	O
systems	O
.	O

The	O
absence	O
of	O
a	O
continuous	O
in	O
vitro	O
culture	B-P
system	I-P
for	O
any	O
species	O
of	O
Pneumocystis	O
has	O
led	O
to	O
limited	O
understanding	O
of	O
these	O
fungi	O
,	O
especially	O
for	O
the	O
discovery	O
of	O
new	O
therapies	O
.	O

We	O
recently	O
reported	O
that	O
Pneumocystis	O
carinii	O
,	O
Pneumocystis	O
murina	O
,	O
and	O
most	O
significantly	O
,	O
Pneumocystis	O
jirovecii	O
lack	O
both	O
enzymes	O
necessary	O
for	O
myo-inositol	O
biosynthesis	O
but	O
contain	O
genes	O
with	O
homologies	O
to	O
fungal	O
myo-inositol	O
transporters	O
.	O

Since	O
myo-inositol	O
is	O
essential	O
for	O
eukaryotic	O
viability	O
,	O
the	O
primary	O
transporter	O
,	O
ITR1	O
,	O
was	O
functionally	O
and	O
structurally	O
characterized	O
in	O
P.	O
carinii	O
The	O
predicted	O
structure	O
of	O
P.	O
carinii	O
ITR1	O
(	O
PcITR1	O
)	O
contained	O
12	O
transmembrane	O
alpha-helices	O
with	O
intracellular	O
C	O
and	O
N	O
termini	O
,	O
consistent	O
with	O
other	O
inositol	O
transporters	O
.	O

The	O
apparent	O
Km	O
was	O
0.94	O
±	O
0.08	O
(	O
mean	O
±	O
standard	O
deviation	O
)	O
,	O
suggesting	O
that	O
myo-inositol	O
transport	O
in	O
P.	O
carinii	O
is	O
likely	O
through	O
a	O
low-affinity	O
,	O
highly	O
selective	O
transport	O
system	O
,	O
as	O
no	O
other	O
sugars	O
or	O
inositol	O
stereoisomers	O
were	O
significant	O
competitive	O
inhibitors	O
.	O

Glucose	O
transport	O
was	O
shown	O
to	O
use	O
a	O
different	O
transport	O
system	O
.	O

The	O
myo-inositol	O
transport	O
was	O
distinct	O
from	O
mammalian	O
transporters	O
,	O
as	O
it	O
was	O
not	O
sodium	O
dependent	O
and	O
was	O
cytochalasin	O
B	O
resistant	O
.	O

Inositol	O
transport	O
in	O
these	O
fungi	O
offers	O
an	O
attractive	O
new	O
drug	O
target	O
because	O
of	O
the	O
reliance	O
of	O
the	O
fungi	O
on	O
its	O
transport	O
,	O
clear	O
differences	O
between	O
the	O
mammalian	O
and	O
fungal	O
transporters	O
,	O
and	O
the	O
ability	O
of	O
the	O
host	O
to	O
both	O
synthesize	O
and	O
transport	O
this	O
critical	O
nutrient	O
,	O
predicting	O
low	O
toxicity	O
of	O
potential	O
inhibitors	O
to	O
the	O
fungal	O
transporter	O
.	O

myo-Inositol	O
is	O
a	O
sugarlike	O
nutrient	O
that	O
is	O
essential	O
for	O
life	O
in	O
most	O
organisms	O
.	O

Humans	O
and	O
microbes	O
alike	O
can	O
obtain	O
it	O
by	O
making	O
it	O
,	O
which	O
involves	O
only	O
2	O
enzymes	O
,	O
by	O
taking	O
it	O
from	O
the	O
environment	O
by	O
a	O
transport	O
process	O
,	O
or	O
by	O
recycling	O
it	O
from	O
other	O
cellular	O
constituents	O
.	O

Inspection	O
of	O
the	O
genomes	O
of	O
the	O
pathogenic	O
fungi	O
of	O
the	O
genus	O
Pneumocystis	O
showed	O
that	O
these	O
pneumonia	O
-	O
causing	O
parasites	O
could	O
not	O
make	O
myo-inositol	O
,	O
as	O
they	O
lacked	O
the	O
2	O
enzymes	O
.	O

Instead	O
,	O
we	O
found	O
evidence	O
of	O
inositol	O
transporters	O
,	O
which	O
would	O
import	O
the	O
sugar	O
from	O
the	O
lungs	O
where	O
the	O
fungi	O
reside	O
.	O

In	O
the	O
present	O
report	O
,	O
we	O
characterized	O
the	O
transport	O
of	O
myo-inositol	O
in	O
the	O
fungus	O
and	O
found	O
that	O
the	O
transporter	O
was	O
highly	O
selective	O
for	O
myo-inositol	O
and	O
did	O
not	O
transport	O
any	O
other	O
molecules	O
.	O

The	O
transport	O
was	O
distinct	O
from	O
that	O
in	O
mammalian	O
cells	O
,	O
and	O
since	O
mammals	O
can	O
both	O
make	O
and	O
transport	O
myo-inositol	O
,	O
while	O
Pneumocystis	O
fungi	O
must	O
transport	O
it	O
,	O
this	O
process	O
offers	O
a	O
potential	O
new	O
drug	O
target	O
.	O

Low-Pathogenic	O
Influenza	O
A	O
Viruses	O
in	O
North	O
American	O
Diving	O
Ducks	O
Contribute	O
to	O
the	O
Emergence	O
of	O
a	O
Novel	O
Highly	O
Pathogenic	O
Influenza	O
A	O
(	O
H7N8	O
)	O
Virus	O
.	O

Introductions	O
of	O
low-pathogenic	O
avian	O
influenza	O
(	O
LPAI	O
)	O
viruses	O
of	O
subtypes	O
H5	O
and	O
H7	O
into	O
poultry	O
from	O
wild	O
birds	O
have	O
the	O
potential	O
to	O
mutate	O
to	O
highly	O
pathogenic	O
avian	O
influenza	O
(	O
HPAI	O
)	O
viruses	O
,	O
but	O
such	O
viruses	O
'	O
origins	O
are	O
often	O
unclear	O
.	O

In	O
January	O
2016	O
,	O
a	O
novel	O
H7N8	O
HPAI	O
virus	O
caused	O
an	O
outbreak	O
in	O
turkeys	O
in	O
Indiana	O
,	O
USA	O
.	O

To	O
determine	O
the	O
virus	O
's	O
origin	O
,	O
we	O
sequenced	B-P
the	I-P
genomes	I-P
of	O
441	O
wild-bird	O
origin	O
influenza	O
A	O
viruses	O
(	O
IAVs	O
)	O
from	O
North	O
America	O
and	O
subjected	O
them	O
to	O
evolutionary	O
analyses	O
.	O

The	O
results	O
showed	O
that	O
the	O
H7N8	O
LPAI	O
virus	O
most	O
likely	O
circulated	O
among	O
diving	O
ducks	O
in	O
the	O
Mississippi	O
flyway	O
during	O
autumn	O
2015	O
and	O
was	O
subsequently	O
introduced	O
to	O
Indiana	O
turkeys	O
,	O
in	O
which	O
it	O
evolved	O
high	O
pathogenicity	O
.	O

Preceding	O
the	O
outbreak	O
,	O
an	O
isolate	O
with	O
six	O
gene	O
segments	O
(	O
PB2	O
,	O
PB1	O
,	O
PA	O
,	O
HA	O
,	O
NA	O
,	O
and	O
NS	O
)	O
sharing	O
>	O
99	O
%	O
sequence	O
identity	O
with	O
those	O
of	O
H7N8	O
turkey	O
isolates	O
was	O
recovered	O
from	O
a	O
diving	O
duck	O
sampled	O
in	O
Kentucky	O
,	O
USA	O
.	O

H4N8	O
IAVs	O
from	O
other	O
diving	O
ducks	O
possessed	O
five	O
H7N8-like	O
gene	O
segments	O
(	O
PB2	O
,	O
PB1	O
,	O
NA	O
,	O
MP	O
,	O
and	O
NS	O
;	O
>	O
98	O
%	O
sequence	O
identity	O
)	O
.	O

Our	O
findings	O
suggest	O
that	O
viral	O
gene	O
constellations	O
circulating	O
among	O
diving	O
ducks	O
can	O
contribute	O
to	O
the	O
emergence	O
of	O
IAVs	O
that	O
affect	O
poultry	O
.	O

Therefore	O
,	O
diving	O
ducks	O
may	O
serve	O
an	O
important	O
and	O
understudied	O
role	O
in	O
the	O
maintenance	O
,	O
diversification	O
,	O
and	O
transmission	O
of	O
IAVs	O
in	O
the	O
wild-bird	O
reservoir	O
.IMPORTANCE	O
In	O
January	O
2016	O
,	O
a	O
novel	O
H7N8	O
HPAI	O
virus	O
caused	O
a	O
disease	O
outbreak	O
in	O
turkeys	O
in	O
Indiana	O
,	O
USA	O
.	O

To	O
determine	O
the	O
origin	O
of	O
this	O
virus	O
,	O
we	O
sequenced	O
and	O
analyzed	O
441	O
wild-bird	O
origin	O
influenza	O
virus	O
strains	O
isolated	O
from	O
wild	O
birds	O
inhabiting	O
North	O
America	O
.	O

We	O
found	O
that	O
the	O
H7N8	O
LPAI	O
virus	O
most	O
likely	O
circulated	O
among	O
diving	O
ducks	O
in	O
the	O
Mississippi	O
flyway	O
during	O
autumn	O
2015	O
and	O
was	O
subsequently	O
introduced	O
to	O
Indiana	O
turkeys	O
,	O
in	O
which	O
it	O
evolved	O
high	O
pathogenicity	O
.	O

Our	O
results	O
suggest	O
that	O
viral	O
gene	O
constellations	O
circulating	O
among	O
diving	O
ducks	O
can	O
contribute	O
to	O
the	O
emergence	O
of	O
IAVs	O
that	O
affect	O
poultry	O
.	O

Therefore	O
,	O
diving	O
ducks	O
may	O
play	O
an	O
important	O
and	O
understudied	O
role	O
in	O
the	O
maintenance	O
,	O
diversification	O
,	O
and	O
transmission	O
of	O
IAVs	O
in	O
the	O
wild-bird	O
reservoir	O
.	O

Our	O
study	O
also	O
highlights	O
the	O
importance	O
of	O
a	O
coordinated	O
,	O
systematic	O
,	O
and	O
collaborative	O
surveillance	O
for	O
IAVs	O
in	O
both	O
poultry	O
and	O
wild-bird	O
populations	O
.	O

Isradipine	O
attenuates	O
MPTP	O
-	O
induced	O
dopamine	O
neuron	O
degeneration	O
by	O
inhibiting	O
up-regulation	O
of	O
L-type	O
calcium	O
channels	O
and	O
iron	O
accumulation	O
in	O
the	O
substantia	O
nigra	O
of	O
mice	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
effects	O
of	O
L-type	O
calcium	O
channels	O
(	O
LTCCs	O
)	O
on	O
MPTP	O
-	O
induced	O
dopamine	O
(	O
DA	O
)	O
neuron	O
degeneration	O
and	O
iron	O
accumulation	O
in	O
the	O
substantia	O
nigra	O
(	O
SN	O
)	O
of	O
mice	O
.	O

By	O
real-time	O
PCR	O
and	O
western	B-P
blots	I-P
,	O
we	O
first	O
quatified	O
expressions	O
of	O
L-type	O
Cav1.2	O
and	O
Cav1.3	O
calcium	O
channel	O
α1	O
subunits	O
in	O
the	O
SN	O
of	O
experimental	O
mice	O
treated	O
with	O
MPTP	O
.	O

We	O
found	O
that	O
the	O
expressions	O
of	O
Cav1.2	O
and	O
Cav1.3	O
calcium	O
channel	O
α1	O
subunits	O
markedly	O
increased	O
after	O
MPTP	O
treatment	O
for	O
2	O
and	O
3	O
weeks	O
.	O

Secondly	O
,	O
we	O
observed	O
the	O
effects	O
of	O
isradipine	O
,	O
a	O
LTCC	O
antagonist	O
,	O
on	O
MPTP	O
-	O
induced	O
DA	O
neuron	O
degeneration	O
and	O
iron	O
accumulation	O
in	O
the	O
SN	O
.	O

Our	O
results	O
showed	O
that	O
isradipine	O
treatment	O
prevented	O
against	O
MPTP	O
-	O
induced	O
Cav1.2	O
and	O
Cav1.3	O
calcium	O
channel	O
α1	O
subunits	O
up-regulation	O
in	O
the	O
SN	O
.	O

We	O
also	O
found	O
that	O
isradipine	O
prevented	O
against	O
MPTP	O
-	O
induced	O
DA	O
neuron	O
depletion	O
in	O
the	O
SN	O
and	O
partly	O
restored	O
the	O
DA	B-P
content	I-P
in	O
the	O
striatum	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
isradipine	O
inhibited	O
the	O
increase	O
of	O
iron	O
positive	O
cells	O
in	O
the	O
SN	O
of	O
the	O
MPTP	O
-	O
treated	O
mice	O
.	O

Finally	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
isradipine	O
on	O
cellular	O
iron	O
accumulation	O
in	O
the	O
dopaminergic	O
MES23.5	O
cell	O
line	O
.	O

Our	O
studies	O
showed	O
that	O
MPP+	O
treatment	O
accelerated	O
iron	O
influx	O
in	O
the	O
MES23.5	O
cells	O
.	O

Treatment	O
with	O
Bayk8644	O
further	O
aggravated	O
iron	O
accumulation	O
.	O

Treatment	O
with	O
isradipine	O
prevented	O
against	O
MPP+	O
-	O
induced	O
iron	O
influx	O
in	O
the	O
MES23.5	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
up-regulation	O
of	O
LTCCs	O
may	O
be	O
responsible	O
for	O
the	O
DA	O
neuron	O
degeneration	O
in	O
the	O
MPTP	O
-	O
treated	O
mice	O
,	O
The	O
LTCCs	O
may	O
directly	O
contribute	O
to	O
iron	O
influx	O
into	O
DA	O
neurons	O
,	O
and	O
isradipine	O
may	O
suppress	O
cellular	O
iron	O
accumulation	O
and	O
prevents	O
neurodegeneration	O
.	O

Influence	O
of	O
the	O
different	O
anteromedial	O
portal	O
on	O
femoral	O
tunnel	O
orientation	O
during	O
anatomic	O
ACL	O
reconstruction	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
femoral	O
tunnel	O
orientation	O
,	O
drilled	O
through	O
the	O
accessory	O
anteromedial	O
(	O
AAM	O
)	O
portal	O
or	O
the	O
high	O
AM	O
portal	O
in	O
anatomic	O
anterior	O
cruciate	O
ligament	O
(	O
ACL	O
)	O
reconstruction	O
.	O

In	O
16	O
cadaver	O
knees	O
,	O
using	O
o'clock	O
method	O
,	O
centers	O
of	O
the	O
ACL	O
femoral	O
footprint	O
were	O
drilled	O
with	O
an	O
8-mm	O
reamer	O
via	O
an	O
AAM	O
portal	O
(	O
eight	O
knees	O
)	O
or	O
a	O
high	O
AM	O
portal	O
(	O
eight	O
knees	O
)	O
.	O

Computed	B-P
tomography	I-P
(	I-P
CT	I-P
)	I-P
scans	I-P
were	O
taken	O
of	O
each	O
knee	O
.	O

Three-dimensional	O
(	O
3D	O
)	O
models	O
were	O
constructed	O
to	O
identify	O
the	O
femoral	O
tunnel	O
orientation	O
and	O
to	O
create	O
femoral	O
tunnel	O
virtual	O
cylinders	O
for	O
measuring	O
tunnel	O
angles	O
and	O
length	O
.	O

In	O
two	O
of	O
the	O
16	O
specimens	O
,	O
we	O
observed	O
a	O
posterior	O
femoral	O
cortex	O
blowout	O
(	O
PFCB	O
)	O
when	O
drilling	O
through	O
a	O
high	O
AM	O
portal	O
.	O

When	O
drilled	O
through	O
the	O
high	O
AM	O
portal	O
,	O
the	O
femoral	O
tunnel	O
length	O
was	O
significantly	O
shorter	O
than	O
when	O
using	O
an	O
AAM	O
portal	O
(	O
30.3	O
±	O
3.8	O
mm	O
and	O
38.2	O
±	O
3.1	O
mm	O
,	O
p	O
<	O
0.001	O
)	O
.	O

The	O
femoral	O
tunnel	O
length	O
was	O
significantly	O
shorter	O
in	O
the	O
group	O
with	O
PFCB	O
compared	O
to	O
the	O
group	O
with	O
no	O
PFCB	O
(	O
25.9	O
±	O
0.6	O
mm	O
and	O
35.5	O
±	O
4.5	O
mm	O
,	O
p	O
=	O
0.011	O
)	O
.	O

The	O
axial	O
obliquity	O
of	O
the	O
high	O
AM	O
portal	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
AAM	O
portal	O
(	O
52.2	O
±	O
5.9°	O
and	O
43.0	O
±	O
2.3°	O
,	O
p	O
=	O
0.003	O
)	O
.	O

In	O
anatomic	O
ACL	O
reconstruction	O
,	O
a	O
mal-positioned	O
AM	O
portal	O
can	O
cause	O
abnormal	O
tunnel	O
orientation	O
,	O
which	O
may	O
lead	O
to	O
mechanical	O
failure	O
during	O
ACL	O
reconstruction	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
select	O
accurate	O
AM	O
portal	O
positioning	O
,	O
and	O
possibly	O
using	O
an	O
AAM	O
portal	O
by	O
measuring	O
an	O
accurate	O
position	O
when	O
drilling	O
a	O
femoral	O
tunnel	O
in	O
anatomic	O
ACL	O
reconstruction	O
.	O

A	O
sequential	O
approach	O
with	O
imatinib	O
,	O
chemotherapy	O
and	O
transplant	O
for	O
adult	O
Ph+	O
acute	O
lymphoblastic	O
leukemia	O
.	O

Final	O
results	O
of	O
the	O
GIMEMA	O
LAL	O
0904	O
study	O
.	O

In	O
the	O
GIMEMA	O
LAL	O
0904	O
protocol	O
,	O
adult	O
Ph+	O
acute	O
lymphoblastic	O
leukemia	O
patients	O
were	O
treated	O
with	O
chemotherapy	O
for	O
induction	O
and	O
consolidation	O
,	O
followed	O
by	O
maintenance	O
with	O
imatinib	O
.	O

The	O
protocol	O
was	O
subsequently	O
amended	O
and	O
imatinib	O
was	O
incorporated	O
in	O
the	O
induction	O
and	O
post	O
-	O
remission	O
phase	O
together	O
with	O
chemotherapy	O
.	O

Due	O
to	O
the	O
toxicity	O
of	O
this	O
combined	O
approach	O
,	O
the	O
protocol	O
was	O
further	O
amended	O
to	O
a	O
sequential	O
scheme	O
based	O
on	O
imatinib	O
plus	O
steroids	O
as	O
induction	O
,	O
followed	O
by	O
consolidation	O
with	O
chemotherapy	O
plus	O
imatinib	O
and	O
,	O
when	O
applicable	O
,	O
by	O
a	O
hematopoietic	O
stem	O
cell	O
transplant	O
.	O

Fifty-one	O
patients	O
(	O
median	O
age	O
:	O
45.9	O
years	O
)	O
were	O
enrolled	O
in	O
the	O
final	O
sequential	O
protocol	O
,	O
hereby	O
reported	O
.	O

At	O
the	O
end	O
of	O
induction	O
(	O
day	O
+50	O
)	O
,	O
96	O
%	O
of	O
evaluable	O
patients	O
(	O
n=49	O
)	O
achieved	O
a	O
complete	O
hematologic	O
remission	O
;	O
after	O
consolidation	O
,	O
all	O
were	O
in	O
complete	O
hematologic	O
remission	O
.	O

No	O
deaths	O
in	O
induction	O
were	O
recorded	O
.	O

Overall	O
survival	O
and	O
disease-free	O
survival	O
at	O
60	O
months	O
are	O
48.8	O
%	O
and	O
45.8	O
%	O
,	O
respectively	O
.	O

At	O
day	O
+50	O
(	O
end	O
of	O
the	O
imatinib	O
induction	O
)	O
,	O
a	O
log	O
-	O
reduction	O
of	O
BCR-ABL1	O
levels	O
>	O
1.3	O
was	O
associated	O
with	O
a	O
significantly	O
more	O
prolonged	O
disease-free	O
survival	O
(	O
55.6	O
%	O
,	O
C.I	O
.	O

95	O
%	O
:	O
39.0-79.3	O
vs	O
20	O
%	O
,	O
C.I	O
.	O

95	O
%	O
:	O
5.8-69.1	O
;	O
p	O
=0.03	O
)	O
,	O
overall	O
survival	O
(	O
59.1	O
%	O
,	O
C.I	O
.	O

95	O
%	O
:	O
42.3-82.6	O
vs	O
20	O
%	O
,	O
C.I	O
.	O

95	O
%	O
:	O
5.8-69.1	O
,	O
p	O
=0.02	O
)	O
and	O
lower	O
relapse	O
incidence	O
(	O
20.5	O
%	O
,	O
C.I	O
.	O

95	O
%	O
:	O
7.2-38.6	O
vs	O
60.0	O
%	O
,	O
C.I	O
.	O

95	O
%	O
:	O
21.6-84.3	O
,	O
p	O
=0.01	O
)	O
.	O

Mean	O
BCR-ABL1	O
levels	O
remained	O
significantly	O
higher	O
in	O
patients	O
who	O
subsequently	O
relapsed	O
.	O

Finally	O
,	O
BCR-ABL1p190	O
patients	O
showed	O
a	O
significantly	O
faster	O
molecular	O
response	O
than	O
BCR-ABL1p210	O
patients	O
(	O
p	O
=0.023	O
)	O
.	O

Thought	O
the	O
study	O
was	O
not	O
powered	O
to	O
evaluate	O
the	O
role	O
of	O
allogeneic	O
stem	O
cell	O
transplant	O
,	O
allografting	O
positively	O
impacted	O
on	O
overall	O
survival	O
and	O
disease-free	O
survival	O
.	O

A	O
sequential	O
approach	O
with	O
imatinib	O
alone	O
in	O
induction	O
,	O
consolidated	O
by	O
chemotherapy	O
plus	O
imatinib	O
followed	O
by	O
a	O
stem	O
cell	O
transplant	O
is	O
a	O
feasible	O
,	O
well-tolerated	O
and	O
effective	O
strategy	O
for	O
adult	O
Ph+	O
acute	O
lymphoblastic	O
leukemia	O
,	O
leading	O
to	O
the	O
best	O
long-term	O
survival	O
rates	O
so	O
far	O
reported	O
.	O

Trial	O
ID	O
:	O
NCT00458848	O
.	O

Components	O
of	O
treatment	O
delay	O
in	O
rheumatoid	O
arthritis	O
differ	O
according	O
to	O
autoantibody	O
status	O
:	O
validation	O
of	O
a	O
single-centre	O
observation	O
using	O
national	O
audit	O
data	O
.	O

To	O
determine	O
whether	O
time	O
to	O
treatment	O
following	O
symptom	O
onset	O
differs	O
between	O
RA	O
patients	O
according	O
to	O
autoantibody	O
status	O
.	O

A	O
single-centre	O
retrospective	O
analysis	O
of	O
a	O
UK	O
early	O
RA	O
inception	O
cohort	O
was	O
first	O
undertaken	O
to	O
identify	O
those	O
components	O
of	O
the	O
patient	O
journey	O
that	O
differed	O
by	O
serological	O
subtype	O
.	O

Data	O
from	O
a	O
UK	O
national	O
audit	O
of	O
early	O
inflammatory	O
arthritis	O
patients	O
was	O
accessed	O
to	O
replicate	O
the	O
key	O
finding	O
.	O

A	O
total	O
of	O
173	O
RA	O
patients	O
were	O
diagnosed	B-P
over	O
a	O
31-	O
month	O
period	O
,	O
of	O
whom	O
80	O
(	O
46	O
%	O
)	O
were	O
ACPA/RF	O
double-seropositive	O
(	O
ACPA	O
(	O
+	O
)	O
/RF	O
(	O
+	O
)	O
)	O
,	O
53	O
(	O
31	O
%	O
)	O
ACPA	O
(	O
-	O
)	O
/RF	O
(	O
-	O
)	O
,	O
17	O
(	O
10	O
%	O
)	O
ACPA	O
(	O
+	O
)	O
/RF	O
(	O
-	O
)	O
and	O
23	O
(	O
13	O
%	O
)	O
RF	O
(	O
+	O
)	O
/ACPA	O
(	O
-	O
)	O
Overall	O
,	O
ACPA	O
(	O
+	O
)	O
/RF	O
(	O
+	O
)	O
patients	O
experienced	O
significantly	O
longer	O
symptom	O
duration	O
before	O
DMARD	O
initiation	O
.	O

This	O
was	O
accounted	O
for	O
by	O
delays	O
in	O
their	O
presentation	O
to	O
primary	O
care	O
following	O
symptom	O
onset	O
-a	O
finding	O
that	O
was	O
robustly	O
confirmed	O
in	O
an	O
independent	O
dataset	O
of	O
2192	O
UK	O
early	O
RA	O
patients	O
.	O

In	O
contrast	O
,	O
ACPA	O
(	O
-	O
)	O
/RF	O
(	O
-	O
)	O
patients	O
were	O
significantly	O
more	O
likely	O
to	O
experience	O
delays	O
in	O
DMARD	O
initiation	O
after	O
presenting	O
to	O
secondary	O
care	O
.	O

Causes	O
of	O
treatment	O
delays	O
in	O
early	O
RA	O
differ	O
according	O
to	O
patients	O
'	O
autoantibody	O
status	O
.	O

More	O
insidious	O
symptom	O
onset	O
and/or	O
distinct	O
health-seeking	O
behaviours	O
among	O
ACPA	O
(	O
+	O
)	O
/RF	O
(	O
+	O
)	O
patients	O
may	O
contribute	O
to	O
late	O
presentations	O
in	O
primary	O
care	O
,	O
whereas	O
ACPA	O
(	O
-	O
)	O
/RF	O
(	O
-	O
)	O
patients	O
experience	O
delayed	O
diagnosis	O
and	O
treatment	O
in	O
secondary	O
care	O
.	O

These	O
observations	O
inform	O
the	O
research	O
agenda	O
,	O
potentially	O
influencing	O
the	O
design	O
of	O
service	O
delivery	O
for	O
early	O
arthritis	O
patients	O
.	O

Effects	O
of	O
pulmonary	O
static	O
inflation	O
with	O
50	O
%	O
xenon	O
on	O
oxygen	O
impairment	O
during	O
cardiopulmonary	O
bypass	O
for	O
stanford	O
type	O
A	O
acute	O
aortic	O
dissection	O
:	O
A	O
pilot	O
study	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
pulmonary	O
static	O
inflation	O
with	O
50	O
%	O
xenon	O
on	O
postoperative	O
oxygen	O
impairment	O
during	O
cardiopulmonary	O
bypass	O
(	O
CPB	O
)	O
for	O
Stanford	O
type	O
A	O
acute	O
aortic	O
dissection	O
(	O
AAD	O
)	O
.	O

This	O
prospective	O
single-center	O
nonrandomized	O
controlled	O
clinical	O
trial	O
included	O
100	O
adult	O
patients	O
undergoing	O
surgery	O
for	O
Stanford	O
type	O
A	O
AAD	O
at	O
an	O
academic	O
hospital	O
in	O
China	O
.	O

Fifty	O
subjects	O
underwent	O
pulmonary	O
static	O
inflation	O
with	O
50	O
%	O
oxygen	O
from	O
January	O
2013	O
to	O
January	O
2014	O
,	O
and	O
50	O
underwent	O
inflation	O
with	O
50	O
%	O
xenon	O
from	O
January	O
2014	O
to	O
December	O
2014	O
.	O

During	O
CPB	O
,	O
the	O
lungs	O
were	O
inflated	O
with	O
either	O
50	O
%	O
xenon	O
(	O
xenon	O
group	O
)	O
or	O
50	O
%	O
oxygen	O
(	O
control	O
group	O
)	O
to	O
maintain	O
an	O
airway	O
pressure	O
of	O
5	O
cm	O
H2O	O
.	O

The	O
primary	O
outcome	O
was	O
oxygenation	B-P
index	I-P
(	O
OI	B-P
)	O
value	O
after	O
intubation	O
,	O
and	O
10	O
minutes	O
and	O
6	O
hours	O
after	O
the	O
operation	O
.	O

The	O
second	O
outcome	O
was	O
cytokine	O
and	O
reactive	O
oxygen	O
species	O
levels	O
after	O
intubation	O
and	O
10	O
minutes	O
,	O
6	O
hours	O
,	O
and	O
24	O
hours	O
after	O
the	O
operation	O
.	O

Patients	O
treated	O
with	O
xenon	O
had	O
lower	O
OI	B-P
levels	O
compared	O
to	O
the	O
control	O
group	O
before	O
surgery	O
(	O
P	O
=	O
0.002	O
)	O
;	O
however	O
,	O
there	O
was	O
no	O
difference	O
in	O
postoperative	O
values	O
between	O
the	O
2	O
groups	O
.	O

Following	O
surgery	O
,	O
mean	O
maximal	O
OI	B-P
values	O
decreased	O
by	O
18.8	O
%	O
and	O
33.8	O
%	O
,	O
respectively	O
,	O
in	O
the	O
xenon	O
and	O
control	O
groups	O
.	O

After	O
surgery	O
,	O
the	O
levels	O
of	O
interleukin-6	O
(	O
IL-6	O
)	O
,	O
tumor	O
necrosis	O
factor	O
alpha	O
,	O
and	O
thromboxane	O
B2	O
decreased	O
by	O
23.5	O
%	O
,	O
9.1	O
%	O
,	O
and	O
30.2	O
%	O
,	O
respectively	O
,	O
in	O
the	O
xenon	O
group	O
,	O
but	O
increased	O
by	O
10.8	O
%	O
,	O
26.2	O
%	O
,	O
and	O
26.4	O
%	O
,	O
respectively	O
,	O
in	O
the	O
control	O
group	O
.	O

Moreover	O
,	O
IL-10	O
levels	O
increased	O
by	O
28	O
%	O
in	O
the	O
xenon	O
group	O
and	O
decreased	O
by	O
7.5	O
%	O
in	O
the	O
control	O
group	O
.	O

There	O
were	O
significant	O
time	O
and	O
treatment	O
-	O
time	O
interaction	O
effects	O
on	O
methane	O
dicarboxylic	O
aldehyde	O
(	O
P	O
=	O
0.000	O
and	O
P	O
=	O
0.050	O
,	O
respectively	O
)	O
and	O
myeloperoxidase	O
(	O
P	O
=	O
0.000	O
and	O
P	O
=	O
0.001	O
in	O
xenon	O
and	O
control	O
groups	O
,	O
respectively	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
hospital	O
mortality	O
and	O
1-year	O
survival	O
rate	O
between	O
the	O
2	O
groups	O
.	O

Pulmonary	O
static	O
inflation	O
with	O
50	O
%	O
xenon	O
during	O
CPB	O
could	O
attenuate	O
OI	B-P
decreases	O
at	O
the	O
end	O
of	O
surgery	O
for	O
Stanford	O
type	O
A	O
AAD	O
.	O

Thus	O
,	O
xenon	O
may	O
function	O
by	O
triggering	O
anti-inflammatory	O
responses	O
and	O
suppressing	O
pro-inflammatory	O
and	O
oxidative	O
effects	O
.	O

Operative	O
surgical	O
nuances	O
of	O
modified	O
extradural	O
temporopolar	O
approach	O
with	O
mini-peeling	O
of	O
dura	O
propria	O
based	O
on	O
cadaveric	O
anatomical	O
study	O
of	O
lateral	O
cavernous	O
structures	O
.	O

Extradural	O
temporopolar	O
approach	O
(	O
ETA	O
)	O
has	O
been	O
modified	O
as	O
less	O
invasive	O
manner	O
and	O
named	O
as	O
trans-superior	O
orbital	O
fissure	O
(	O
SOF	O
)	O
approach	O
with	O
mini-peeling	O
technique	O
.	O

The	O
present	O
study	O
discusses	O
the	O
operative	O
nuances	O
of	O
this	O
modified	O
technique	O
on	O
the	O
basis	O
of	O
cadaveric	O
study	O
of	O
lateral	O
cavernous	O
structures	O
.	O

In	O
five	O
consecutive	O
cadaveric	O
specimens	O
,	O
we	O
performed	O
an	O
extradural	O
anterior	O
clinoidectomy	O
with	O
mini-peeling	O
of	O
the	O
dura	O
propria	O
to	O
expose	O
the	O
anterior	O
clinoid	O
process	O
entirely	O
.	O

We	O
also	O
investigated	O
the	O
histological	O
characteristics	O
of	O
the	O
lateral	O
cavernous	O
sinus	O
(	O
CS	O
)	O
between	O
the	O
dura	O
propria	O
and	O
periosteal	O
dura	O
at	O
the	O
SOF	O
,	O
foramen	O
rotundum	O
(	O
FR	O
)	O
,	O
and	O
foramen	O
ovale	O
(	O
FO	O
)	O
levels	O
,	O
and	O
of	O
each	O
trigeminal	O
nerve	O
division	O
.	O

Coronal	B-P
histological	I-P
examination	I-P
of	O
the	O
lateral	O
wall	O
of	O
the	O
CS	O
showed	O
invagination	O
of	O
the	O
dura	O
propria	O
and	O
periosteal	O
dura	O
into	O
the	O
SOF	O
.	O

In	O
contrast	O
,	O
no	O
such	O
invagination	O
was	O
observed	O
at	O
the	O
levels	O
of	O
the	O
FR	O
and	O
FO	O
.	O

This	O
finding	O
supports	O
the	O
technical	O
rationale	O
of	O
the	O
only	O
skeletonization	O
of	O
the	O
SOF	O
for	O
peeling	O
of	O
the	O
dura	O
propria	O
but	O
not	O
FR	O
.	O

In	O
addition	O
,	O
our	O
modified	O
ETA	O
method	O
needs	O
only	O
minimal	O
dural	O
incision	O
between	O
the	O
SOF	O
and	O
FR	O
where	O
no	O
cranial	O
nerves	O
are	O
present	O
.	O

Our	O
technical	O
modification	O
of	O
ETA	O
may	O
be	O
recommended	O
for	O
surgical	O
treatment	O
of	O
paraclinoid	O
lesions	O
to	O
reduce	O
the	O
risk	O
of	O
intraoperative	O
neurovascular	O
injury	O
.	O

Reduced	O
haemodynamic	O
coupling	O
and	O
exercise	O
are	O
associated	O
with	O
vascular	O
stiffening	O
in	O
pulmonary	O
arterial	O
hypertension	O
.	O

Inadequate	O
right	O
ventricular	O
(	O
RV	O
)	O
and	O
pulmonary	O
arterial	O
(	O
PA	O
)	O
functional	O
responses	O
to	O
exercise	O
are	O
important	O
yet	O
poorly	O
understood	O
features	O
of	O
pulmonary	O
arterial	O
hypertension	O
(	O
PAH	O
)	O
.	O

This	O
study	O
combined	O
invasive	O
catheterisation	O
with	O
echocardiography	B-P
to	O
assess	O
RV	O
afterload	O
,	O
RV	O
function	O
and	O
ventricular	O
-	O
vascular	O
coupling	O
in	O
subjects	O
with	O
PAH	O
.	O

Twenty-six	O
subjects	O
with	O
PAH	O
were	O
prospectively	O
recruited	O
to	O
undergo	O
right	O
heart	O
catheterisation	O
and	O
Doppler	B-P
echocardiography	I-P
at	O
rest	O
and	O
during	O
incremental	O
exercise	O
,	O
and	O
cardiac	B-P
MRI	I-P
at	O
rest	O
.	O

Measurements	O
at	O
rest	O
included	O
basic	O
haemodynamics	O
,	O
RV	O
function	O
and	O
coupling	O
efficiency	O
(	O
η	O
)	O
.	O

Measurements	O
during	O
incremental	O
exercise	O
included	O
pulmonary	O
vascular	O
resistance	O
(	O
Z0	O
)	O
,	O
characteristic	B-P
impedance	I-P
(	O
ZC	B-P
,	O
a	O
measure	O
of	O
proximal	O
PA	O
stiffness	O
)	O
and	O
proximal	O
and	O
distal	O
PA	O
compliance	O
(	O
CPA	O
)	O
.	O

In	O
patients	O
with	O
PAH	O
,	O
the	O
proximal	O
PAs	O
were	O
significantly	O
stiffer	O
at	O
maximum	O
exercise	O
(	O
ZC	B-P
=2.31±0.38	O
vs	O
1.33±0.15	O
WU×m	O
(	O
2	O
)	O
at	O
rest	O
;	O
p=0.003	O
)	O
and	O
PA	O
compliance	O
was	O
decreased	O
(	O
CPA	O
=0.88±0.10	O
vs	O
1.32±0.17	O
mL/mm	O
Hg/m	O
(	O
2	O
)	O
at	O
rest	O
;	O
p=0.0002	O
)	O
.	O

Z0	O
did	O
not	O
change	O
with	O
exercise	O
.	O

As	O
a	O
result	O
,	O
the	O
resistance-compliance	O
(	O
RC	O
)	O
time	O
decreased	O
with	O
exercise	O
(	O
0.67±0.05	O
vs	O
1.00±0.07	O
s	O
at	O
rest	O
;	O
p	O
<	O
10	O
(	O
-6	O
)	O
)	O
.	O

When	O
patients	O
were	O
grouped	O
according	O
to	O
resting	O
coupling	O
efficiency	O
,	O
those	O
with	O
poorer	O
η	O
exhibited	O
stiffer	O
proximal	O
PAs	O
at	O
rest	O
,	O
a	O
lower	O
maximum	O
exercise	O
level	O
,	O
and	O
more	O
limited	O
CPA	O
reduction	O
at	O
maximum	O
exercise	O
.	O

In	O
PAH	O
,	O
exercise	O
causes	O
proximal	O
and	O
distal	O
PA	O
stiffening	O
,	O
which	O
combined	O
with	O
preserved	O
Z0	O
results	O
in	O
decreased	O
RC	O
time	O
with	O
exercise	O
.	O

Stiff	O
PAs	O
at	O
rest	O
may	O
also	O
contribute	O
to	O
poor	O
haemodynamic	O
coupling	O
,	O
reflecting	O
reduced	O
pulmonary	O
vascular	O
reserve	O
that	O
contributes	O
to	O
limit	O
the	O
maximum	O
exercise	O
level	O
tolerated	O
.	O

Association	O
of	O
Radiomics	O
and	O
Metabolic	O
Tumor	O
Volumes	O
in	O
Radiation	O
Treatment	O
of	O
Glioblastoma	O
Multiforme	O
.	O

To	O
build	O
a	O
framework	O
for	O
investigation	O
of	O
the	O
associations	O
between	O
imaging	B-P
,	O
clinical	O
target	O
volumes	O
(	O
CTVs	O
)	O
,	O
and	O
metabolic	O
tumor	O
volumes	O
(	O
MTVs	O
)	O
features	O
for	O
better	O
understanding	O
of	O
the	O
underlying	O
information	O
in	O
the	O
CTVs	O
and	O
dependencies	O
between	O
these	O
volumes	O
.	O

High-throughput	O
extraction	O
of	O
imaging	B-P
and	O
metabolomic	O
quantitative	O
features	O
from	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
and	O
magnetic	B-P
resonance	I-P
spectroscopic	I-P
imaging	I-P
of	O
glioblastoma	O
multiforme	O
(	O
GBM	O
)	O
results	O
in	O
tens	O
of	O
variables	O
per	O
patient	O
.	O

In	O
radiation	O
therapy	O
of	O
GBM	O
the	O
relevant	O
metabolic	O
tumor	O
volumes	O
(	O
MTVs	O
)	O
are	O
related	O
to	O
aberrant	O
levels	O
of	O
N-acetyl	O
aspartate	O
(	O
NAA	O
)	O
and	O
choline	O
(	O
Cho	O
)	O
.	O

The	O
corresponding	O
clinical	O
target	O
volumes	O
(	O
CTVs	O
)	O
for	O
radiation	O
therapy	O
are	O
based	O
on	O
contrast-enhanced	B-P
T1-weighted	I-P
(	O
CE-T1w	B-P
)	O
and	O
T2-weighted	B-P
(	I-P
T2w	I-P
)	I-P
/fluid-attenuated	I-P
inversion	I-P
recovery	I-P
MRI	I-P
.	O

Necrotic	O
portions	O
,	O
enhancing	O
lesion	O
,	O
and	O
edema	O
were	O
manually	O
contoured	O
on	O
CE-T1w	O
/	O
T2w	O
images	O
for	O
17	O
GBM	O
patients	O
.	O

Clinical	O
target	O
volumes	O
and	O
MTVs	O
for	O
NAA	O
(	O
MTVNAA	O
)	O
and	O
Cho	O
(	O
MTVCho	O
)	O
were	O
constructed	O
.	O

Imaging	B-P
and	O
metabolic	O
features	O
related	O
to	O
size	O
,	O
shape	O
,	O
and	O
signal	O
intensities	O
of	O
the	O
volumes	O
were	O
extracted	O
.	O

Tumors	O
were	O
also	O
scored	O
categorically	O
for	O
10	O
semantic	O
imaging	O
traits	O
by	O
a	O
neuroradiologist	O
.	O

All	O
features	O
were	O
investigated	O
for	O
redundancy	O
.	O

Two-way	O
correlations	O
between	O
imaging	O
and	O
CTVs	O
/	O
MTVs	O
features	O
were	O
visualized	O
as	O
heatmaps	O
.	O

Associations	O
between	O
MTVNAA	O
and	O
MTVCho	O
and	O
imaging	O
features	O
were	O
studied	O
using	O
Spearman	O
correlation	O
.	O

Forty-eight	O
imaging	O
features	O
were	O
extracted	O
per	O
patient	O
.	O

Half	O
of	O
the	O
imaging	O
traits	O
were	O
replaced	O
with	O
automatically	O
extracted	O
continuous	O
variables	O
.	O

Twenty	O
features	O
were	O
extracted	O
from	O
CTVs	O
and	O
MTVs	O
.	O

A	O
series	O
of	O
semantic	O
imaging	O
traits	O
were	O
replaced	O
with	O
automatically	O
extracted	O
continuous	O
variables	O
.	O

There	O
were	O
multiple	O
(	O
22	O
)	O
significant	O
correlations	O
of	O
imaging	O
measures	O
with	O
CTVs	O
/	O
MTVNAA	O
,	O
whereas	O
there	O
were	O
only	O
6	O
with	O
CTVs	O
/	O
MTVCho	O
.	O

A	O
framework	O
for	O
investigation	O
of	O
codependencies	O
between	O
MRI	B-P
and	O
magnetic	B-P
resonance	I-P
spectroscopic	I-P
imaging	I-P
radiomic	O
features	O
and	O
CTVs	O
/	O
MTVs	O
has	O
been	O
established	O
.	O

The	O
MTV	O
for	O
NAA	O
was	O
found	O
to	O
be	O
closely	O
associated	O
with	O
MRI	B-P
volumes	O
,	O
whereas	O
very	O
few	O
imaging	O
features	O
were	O
related	O
to	O
MTVCho	O
,	O
indicating	O
that	O
Cho	O
provides	O
additional	O
information	O
to	O
imaging	B-P
.	O

Multi-hospital	O
occurrence	O
of	O
pan-resistant	O
Klebsiella	O
pneumoniae	O
ST147	O
with	O
an	O
ISEcp1	O
-directed	O
blaOXA-181	O
insertion	O
into	O
the	O
mgrB	O
gene	O
in	O
the	O
United	O
Arab	O
Emirates	O
.	O

The	O
emergence	O
of	O
pan-resistant	O
Klebsiella	O
pneumoniae	O
strains	O
is	O
an	O
increasing	O
concern	O
.	O

In	O
the	O
current	O
study	O
we	O
describe	O
a	O
cluster	O
of	O
9	O
pan-resistant	O
K.	O
pneumoniae	O
ST147	O
isolates	O
encountered	O
in	O
4	O
patients	O
over	O
nearly	O
one	O
year	O
in	O
3	O
hospitals	O
of	O
the	O
United	O
Arab	O
Emirates	O
.	O

The	O
isolates	O
exhibited	O
highly	O
similar	O
genotypes	O
.	O

All	O
produced	O
chromosomally	O
encoded	O
OXA-181	O
and	O
the	O
majority	O
also	O
produced	O
the	O
NDM-5	O
carbapenemase	O
.	O

Similarly	O
to	O
the	O
previously	O
described	O
single	O
isolate	O
from	O
the	O
UAE	O
,	O
MS6671	O
,	O
the	O
mgrB	O
was	O
disrupted	O
by	O
a	O
functional	O
,	O
ISEcp1	O
-driven	O
blaOXA-181	O
insertion	O
causing	O
resistance	O
to	O
carbapenems	O
.	O

The	O
mutation	O
was	O
successfully	O
complemented	O
with	O
an	O
intact	O
mgrB	O
gene	O
indicating	O
that	O
it	O
was	O
responsible	O
for	O
colistin	O
resistance	O
.	O

blaNDM-5	O
was	O
located	O
within	O
a	O
resistance	O
island	O
of	O
an	O
approximately	O
100	O
kb	O
IncFII	O
plasmid	O
carrying	O
ermB	O
,	O
mph	O
(	O
A	O
)	O
,	O
blaTEM-1B	O
,	O
rmtB	O
,	O
blaNDM-5	O
,	O
sul1	O
,	O
aadA2	O
and	O
dfrA12	O
resistance	O
genes	O
.	O

Sequencing	B-P
this	O
plasmid	O
(	O
pABC143-NDM	O
)	O
revealed	O
that	O
its	O
backbone	O
was	O
nearly	O
identical	O
to	O
that	O
of	O
plasmid	O
pMS6671E	O
from	O
which	O
several	O
resistance	O
genes	O
,	O
including	O
blaNDM-5	O
,	O
had	O
been	O
deleted	O
.	O

More	O
extensive	O
similarities	O
of	O
the	O
backbone	O
and	O
the	O
resistance	O
island	O
were	O
found	O
between	O
pABC143C-NDM	O
and	O
the	O
blaNDM-5	O
carrying	O
IncFII	O
plasmids	O
of	O
two	O
K.	O
pneumoniae	O
ST147	O
isolates	O
from	O
South	O
Korea	O
,	O
one	O
of	O
which	O
was	O
colistin	O
resistant	O
,	O
and	O
both	O
also	O
produced	O
OXA-181	O
.	O

Notably	O
one	O
of	O
these	O
strains	O
was	O
isolated	O
from	O
a	O
patient	O
transferred	O
from	O
the	O
UAE	O
.	O

Our	O
data	O
show	O
that	O
this	O
pan-resistant	O
clone	O
has	O
an	O
alarming	O
capacity	O
to	O
maintain	O
itself	O
over	O
an	O
extended	O
period	O
of	O
time	O
,	O
and	O
even	O
likely	O
to	O
be	O
transmitted	O
internationally	O
.	O

High	O
concordance	O
of	O
findings	O
obtained	O
from	O
transgluteal	O
magnetic	B-P
resonance	I-P
imaging	I-P
-	O
and	O
transrectal	B-P
ultrasonography	I-P
-	O
guided	B-P
biopsy	I-P
as	O
compared	O
with	O
prostatectomy	O
specimens	O
.	O

To	O
determine	O
the	O
utility	O
of	O
our	O
transgluteal	O
magnetic	B-P
resonance	I-P
imaging	I-P
(	O
MRI	B-P
)	O
-	O
guided	B-P
prostate	I-P
biopsy	I-P
approach	O
.	O

A	O
total	O
of	O
960	O
biopsy	B-P
series	O
,	O
taken	O
within	O
the	O
period	O
of	O
1	O
year	O
,	O
were	O
evaluated	O
,	O
including	O
301	O
MRI-guided	B-P
and	O
659	O
transrectal	B-P
ultrasonography	I-P
(	O
TRUS	B-P
)	O
-	O
guided	B-P
biopsies	I-P
.	O

The	O
positivity	O
rate	O
and	O
proportion	O
of	O
high	O
grade	O
cancers	O
were	O
significantly	O
higher	O
in	O
MRI-guided	B-P
than	O
in	O
TRUS	B-P
-	O
guided	B-P
biopsies	I-P
.	O

Of	O
301	O
MRI-guided	B-P
biopsies	I-P
,	O
65.4	O
%	O
contained	O
cancer	O
while	O
57.2	O
%	O
of	O
659	O
TRUS	B-P
biopsies	B-P
contained	O
cancer	O
(	O
P	O
=	O
0.016	O
)	O
.	O

Gleason	O
grade	O
3	O
+	O
3	O
=	O
6	O
disease	O
was	O
observed	O
in	O
16.8	O
%	O
of	O
197	O
MRI-guided	B-P
and	O
in	O
36.1	O
%	O
of	O
377	O
TRUS	B-P
-	O
guided	B-P
biopsies	I-P
(	O
P	O
<	O
0.001	O
)	O
.	O

There	O
was	O
also	O
a	O
markedly	O
higher	O
quantity	O
of	O
cancer	O
tissue	O
in	O
MRI-guided	B-P
biopsies	I-P
.	O

In	O
all	O
cancers	O
,	O
the	O
mean	O
cancer	O
surface	O
area	O
was	O
64.8	O
±	O
51.6	O
mm	O
(	O
2	O
)	O
in	O
MRI-guided	B-P
biopsies	I-P
as	O
compared	O
with	O
23.0	O
±	O
31.4	O
mm	O
(	O
2	O
)	O
in	O
non-MRI-guided	O
biopsies	O
(	O
P	O
<	O
0.001	O
)	O
.	O

With	O
respect	O
to	O
the	O
tissue	O
quantity	O
,	O
superiority	O
of	O
MRI-guided	B-P
biopsy	I-P
was	O
highest	O
in	O
Gleason	O
grade	O
3	O
+	O
3	O
=	O
6	O
cancers	O
(	O
20.9	O
±	O
27.9	O
vs	O
5.1	O
±	O
10.2	O
mm	O
(	O
2	O
)	O
;	O
P	O
<	O
0.001	O
)	O
and	O
in	O
Gleason	O
grade	O
3	O
+	O
4	O
=	O
7	O
cancers	O
(	O
59.7	O
±	O
38.0	O
vs	O
17.7	O
±	O
18.4	O
mm	O
(	O
2	O
)	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Comparison	O
of	O
biopsy	B-P
Gleason	O
grades	O
with	O
findings	O
in	O
prostatectomy	O
specimens	O
was	O
possible	O
in	O
80	O
patients	O
with	O
MRI-guided	B-P
and	O
in	O
170	O
patients	O
with	O
non-MRI-guided	O
biopsies	O
.	O

This	O
comparison	O
showed	O
a	O
very	O
high	O
but	O
almost	O
identical	O
concordance	O
of	O
TRUS	B-P
-	O
and	O
MRI-guided	B-P
biopsies	I-P
with	O
the	O
prostatectomy	O
specimen	O
findings	O
.	O

With	O
both	O
approaches	O
,	O
undetected	O
high-risk	O
cancers	O
were	O
present	O
in	O
~10	O
%	O
of	O
patients	O
with	O
low-risk	O
biopsy	B-P
results	O
.	O

A	O
significant	O
difference	O
was	O
observed	O
,	O
however	O
,	O
in	O
the	O
proportion	O
of	O
patients	O
who	O
had	O
clinically	O
insignificant	O
cancers	O
and	O
who	O
underwent	O
surgery	O
.	O

The	O
proportion	O
of	O
patients	O
with	O
Gleason	O
grade	O
3	O
+	O
3	O
=	O
6	O
carcinoma	O
in	O
their	O
prostatectomy	O
specimen	O
was	O
11.2	O
%	O
in	O
the	O
post	O
-	O
TRUS	B-P
biopsy	B-P
cohort	O
,	O
but	O
only	O
2.5	O
%	O
in	O
the	O
post	O
-	O
MRI	B-P
biopsy	I-P
cohort	O
(	O
P	O
=	O
0.021	O
)	O
.	O

MRI-guided	B-P
transgluteal	O
prostate	B-P
biopsy	I-P
has	O
a	O
high	O
detection	O
rate	O
for	O
high-risk	O
carcinomas	O
,	O
while	O
the	O
risk	O
of	O
detecting	O
clinically	O
insignificant	O
carcinomas	O
appears	O
to	O
be	O
reduced	O
.	O

This	O
may	O
by	O
itself	O
lead	O
to	O
a	O
reduction	O
of	O
unnecessary	O
prostatectomies	O
.	O

Overtreatment	O
may	O
be	O
further	O
avoided	O
by	O
better	O
applicability	O
of	O
molecular	B-P
testing	I-P
to	O
MRI-guided	B-P
biopsies	I-P
because	O
of	O
the	O
excessive	O
amount	O
of	O
tissue	O
available	O
for	O
analysis	O
,	O
especially	O
in	O
patients	O
with	O
potential	O
low-risk	O
carcinomas	O
.	O

Aptamer	O
-based	O
surface-enhanced	O
Raman	O
scattering	O
(	O
SERS	O
)	O
sensor	O
for	O
thrombin	O
based	O
on	O
supramolecular	O
recognition	O
,	O
oriented	O
assembly	O
,	O
and	O
local	O
field	O
coupling	O
.	O

A	O
supramolecular	O
recognition	O
and	O
oriented	O
assembly	O
system	O
was	O
developed	O
on	O
chip	O
for	O
the	O
highly	O
selective	O
surface-enhanced	O
Raman	O
scattering	O
(	O
SERS	O
)	O
detection	O
of	O
thrombin	O
by	O
means	O
of	O
the	O
aptamer	O
-based	O
SERS	O
tag	O
method	O
.	O

A	O
15-base	O
thrombin-binding	O
aptamer	O
(	O
TBA15	O
)	O
with	O
a	O
thiol	O
end	O
was	O
first	O
immobilized	O
on	O
an	O
Ag	O
nanoprism	O
array	O
by	O
the	O
S-Ag	O
bond	O
.	O

This	O
aptamer	O
has	O
high	O
binding	O
affinity	O
with	O
thrombin	O
when	O
it	O
folds	O
into	O
a	O
G-quadruplex	O
structure	O
.	O

After	O
the	O
recognition	O
between	O
the	O
aptamer	O
and	O
thrombin	O
,	O
a	O
bridge	O
is	O
built	O
between	O
the	O
SERS	O
tag	O
(	O
4-mercaptobenzoic	O
acid	O
marked	O
Ag	O
nanoparticle	O
)	O
and	O
the	O
fixed	O
thrombin	O
based	O
on	O
the	O
activation	O
of	O
the	O
carboxylic	O
group	O
of	O
4-mercaptobenzoic	O
acid	O
.	O

Thus	O
,	O
the	O
quantitative	O
detection	O
of	O
thrombin	O
can	O
be	O
achieved	O
based	O
on	O
the	O
SERS	O
intensity	O
of	O
the	O
immobilized	O
SERS	O
tags	O
.	O

The	O
obvious	O
advantages	O
of	O
this	O
sensing	O
method	O
are	O
as	O
follows	O
:	O
(	O
1	O
)	O
remarkable	O
SERS	O
enhancement	O
due	O
to	O
the	O
high	O
electric	O
field	O
coupling	O
effect	O
via	O
the	O
gap	O
structure	O
formation	O
,	O
which	O
improves	O
the	O
sensitivity	O
of	O
the	O
SERS	O
detection	O
and	O
the	O
limit	O
of	O
detection	O
of	O
this	O
method	O
arrives	O
in	O
1.6	O
×	O
10	O
(	O
-11	O
)	O
M	O
,	O
(	O
2	O
)	O
high	O
selectivity	O
based	O
on	O
the	O
specific	O
aptamer	O
recognition	O
toward	O
thrombin	O
,	O
which	O
can	O
be	O
extended	O
to	O
other	O
enzymes	O
easily	O
by	O
changing	O
a	O
proper	O
sequence	O
,	O
(	O
3	O
)	O
high	O
repeatability	O
of	O
SERS	O
signals	O
according	O
to	O
a	O
highly	O
ordered	O
structure	O
,	O
and	O
(	O
4	O
)	O
highly	O
efficient	O
oriented	O
assembly	O
of	O
a	O
sandwich	O
structure	O
over	O
an	O
Ag	O
nanoprism	O
array	O
.	O

The	O
proposed	O
method	O
is	O
expected	O
to	O
be	O
a	O
practical	O
implement	O
in	O
medical	B-P
diagnosis	I-P
.	O

Graphical	O
Abstract	O
Illustration	O
of	O
the	O
aptamer	O
-based	O
SERS	O
sensor	O
for	O
thrombin	O
detection	O
.	O

Development	O
of	O
a	O
platelet	O
adhesion	O
transport	O
equation	O
for	O
a	O
computational	O
thrombosis	O
model	O
.	O

Thrombosis	O
is	O
a	O
significant	O
issue	O
for	O
cardiovascular	O
device	O
development	O
and	O
use	O
.	O

While	O
thrombosis	O
models	O
are	O
available	O
,	O
very	O
few	O
are	O
device	O
-	O
related	O
and	O
none	O
have	O
been	O
thoroughly	O
validated	O
experimentally	O
.	O

Here	O
,	O
we	O
introduce	O
a	O
surface	O
adherent	O
platelet	O
transport	O
equation	O
into	O
a	O
continuum	O
model	O
to	O
account	O
for	O
the	O
biomaterial	O
interface/blood	O
interaction	O
.	O

Using	O
a	O
rotating	O
disc	O
system	O
and	O
polyurethane-urea	O
material	O
,	O
we	O
characterize	O
steady	O
and	O
pulsatile	O
flow	O
fields	O
using	O
laser	B-P
Doppler	I-P
velocimetry	I-P
.	O

In	O
vitro	O
measurements	O
of	O
platelet	O
adhesion	O
are	O
used	O
in	O
combination	O
with	O
the	O
LDV	B-P
data	O
to	O
provide	O
further	O
experimental	O
validation	O
.	O

The	O
rotating	O
disc	O
system	O
is	O
computationally	O
studied	O
using	O
the	O
device	O
-	O
induced	O
thrombosis	O
model	O
with	O
the	O
surface	O
platelet	O
adherent	O
transport	O
equation	O
.	O

The	O
results	O
indicate	O
that	O
the	O
flow	O
field	O
is	O
in	O
excellent	O
agreement	O
to	O
the	O
experimental	O
LDV	B-P
data	O
and	O
that	O
the	O
platelet	O
adhesion	O
simulations	O
are	O
in	O
good	O
agreement	O
with	O
the	O
in	O
vitro	O
platelet	O
data	O
.	O

These	O
results	O
provide	O
good	O
evidence	O
that	O
this	O
transport	O
equation	O
can	O
be	O
used	O
to	O
express	O
the	O
relationship	O
between	O
blood	O
and	O
a	O
biomaterial	O
if	O
the	O
correct	O
platelet	O
adhesion	O
characteristics	O
are	O
known	O
for	O
the	O
biomaterial	O
.	O

Further	O
validation	O
is	O
necessary	O
with	O
other	O
materials	O
.	O

Data	O
set	O
of	O
interactomes	O
and	O
metabolic	O
pathways	O
of	O
proteins	O
differentially	O
expressed	O
in	O
brains	O
with	O
Alzheimer׳s	O
disease	O
.	O

Alzheimer׳s	O
disease	O
is	O
one	O
of	O
the	O
main	O
causes	O
of	O
dementia	O
in	O
the	O
elderly	O
and	O
its	O
frequency	O
is	O
on	O
the	O
rise	O
worldwide	O
.	O

It	O
is	O
considered	O
the	O
result	O
of	O
complex	O
interactions	O
between	O
genetic	O
and	O
environmental	O
factors	O
,	O
being	O
many	O
of	O
them	O
unknown	O
.	O

Therefore	O
,	O
there	O
is	O
a	O
dire	O
necessity	O
for	O
the	O
identification	O
of	O
novel	O
molecular	O
players	O
for	O
the	O
understanding	O
of	O
this	O
disease	O
.	O

In	O
this	O
data	O
article	O
we	O
determined	O
the	O
protein	O
expression	O
profiles	O
of	O
whole	O
protein	O
extracts	O
from	O
cortex	O
regions	O
of	O
brains	O
from	O
patients	O
with	O
Alzheimer׳s	O
disease	O
in	O
comparison	O
to	O
a	O
normal	O
brain	O
.	O

We	O
identified	O
721	O
iTRAQ-labeled	O
polypeptides	O
with	O
more	O
than	O
95	O
%	O
in	O
confidence	O
.	O

We	O
analyzed	O
all	O
proteins	O
that	O
changed	O
in	O
their	O
expression	O
level	O
and	O
located	O
them	O
in	O
the	O
KEGG	O
metabolic	O
pathways	O
,	O
as	O
well	O
as	O
in	O
the	O
mitochondrial	O
complexes	O
of	O
the	O
electron	O
transport	O
chain	O
and	O
ATP	O
synthase	O
.	O

In	O
addition	O
,	O
we	O
analyzed	O
the	O
over-	O
and	O
sub-expressed	O
polypeptides	O
through	O
IPA	O
software	O
,	O
specifically	O
Core	O
I	O
and	O
Biomarkers	O
I	O
modules	O
.	O

Data	O
in	O
this	O
article	O
is	O
related	O
to	O
the	O
research	O
article	O
``	O
Identification	O
of	O
proteins	O
that	O
are	O
differentially	O
expressed	O
in	O
brains	O
with	O
Alzheimer	O
's	O
disease	O
using	O
iTRAQ	B-P
labeling	I-P
and	O
tandem	O
mass	O
spectrometry	O
``	O
(	O
Minjarez	O
et	O
al.	O
,	O
2016	O
)	O
[	O
1	O
]	O
.	O

Slow-Growing	O
Large	O
Irritation	O
Fibroma	O
of	O
the	O
Anterior	O
Hard	O
Palate	O
:	O
A	O
Case	O
Report	O
Using	O
Immunohistochemical	B-P
Analysis	I-P
.	O

Irritation	O
fibromas	O
are	O
recognized	O
as	O
fibrous	O
lesions	O
,	O
usually	O
reactive	O
hyperplasias	O
;	O
however	O
,	O
the	O
mechanism	O
of	O
enlargement	O
is	O
unclear	O
.	O

This	O
paper	O
reports	O
on	O
an	O
abnormally	O
large	O
irritation	O
fibroma	O
of	O
extremely	O
gradual	O
growth	O
.	O

The	O
immunohistochemical	B-P
features	O
(	O
CD34	O
,	O
α-SMA	O
,	O
vimentin	O
,	O
Ki-67	O
,	O
and	O
TGF-α	O
)	O
of	O
this	O
irritation	O
fibroma	O
are	O
presented	O
to	O
distinguish	O
reactive	O
hyperplasia	O
from	O
other	O
true	O
fibrous	O
neoplasm	O
diseases	O
.	O

In	O
the	O
only	O
previous	O
study	O
,	O
it	O
was	O
reported	O
that	O
the	O
expression	O
of	O
TGF-α	O
might	O
be	O
associated	O
with	O
the	O
development	O
of	O
oral	O
fibromas	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
relationship	O
between	O
this	O
exceptionally-large	O
fibrous	O
lesion	O
of	O
extremely	O
slow	O
growth	O
and	O
the	O
immunohistochemical	O
reactivity	O
of	O
TGF-α	O
,	O
finding	O
that	O
,	O
in	O
contrast	O
to	O
the	O
previous	O
study	O
,	O
TGF-α	O
was	O
not	O
expressed	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
evaluate	O
the	O
enlargement	O
mechanism	O
of	O
such	O
a	O
large	O
irritation	O
fibroma	O
using	O
the	O
approach	O
of	O
immunohistochemical	B-P
analysis	I-P
,	O
and	O
it	O
indicates	O
that	O
such	O
analysis	B-P
can	O
help	O
elucidate	O
the	O
diverse	O
causes	O
and	O
enlargement	O
mechanisms	O
of	O
irritation	O
fibromas	O
.	O

Alanine	O
to	O
Serine	O
Variant	O
at	O
Position	O
986	O
of	O
Calcium	O
Sensing	O
Receptor	O
and	O
Colorectal	O
Cancer	O
Risk	O
.	O

With	O
regard	O
to	O
the	O
effect	O
of	O
calcium	O
against	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
and	O
considering	O
the	O
key	O
role	O
of	O
calcium	O
sensing	O
receptor	O
(	O
CaSR	O
)	O
in	O
calcium	O
homeostasis	O
,	O
this	O
study	O
investigated	O
whether	O
CaSR	O
gene	O
rs1801725	O
or	O
A986S	O
variant	O
was	O
associated	O
with	O
susceptibility	O
to	O
CRC	O
risk	O
.	O

This	O
study	O
was	O
conducted	O
as	O
a	O
case-control	O
study	O
and	O
303	O
cases	O
with	O
CRC	O
and	O
354	O
controls	O
were	O
enrolled	O
.	O

All	O
657	O
subjects	O
were	O
genotyped	O
for	O
CaSR	O
gene	O
A986S	O
variant	O
using	O
PCR	O
-	O
RFLP	B-P
method	I-P
.	O

No	O
significant	O
difference	O
was	O
observed	O
for	O
the	O
A986S	O
variant	O
of	O
CaSR	O
gene	O
in	O
either	O
genotype	O
or	O
allele	O
frequencies	O
between	O
the	O
cases	O
and	O
the	O
controls	O
and	O
this	O
lack	O
of	O
difference	O
remained	O
non-significant	O
even	O
after	O
adjustment	O
for	O
age	O
,	O
BMI	O
,	O
sex	O
,	O
smoking	O
status	O
,	O
and	O
family	O
history	O
of	O
CRC	O
.	O

No	O
evidence	O
for	O
the	O
effect	O
modification	O
of	O
the	O
association	O
A986S	O
variant	O
and	O
CRC	O
by	O
BMI	O
,	O
sex	O
,	O
or	O
tumor	O
site	O
was	O
also	O
observed	O
.	O

Furthermore	O
,	O
the	O
risk	O
of	O
obesity	O
in	O
relation	O
to	O
the	O
A986S	O
variant	O
in	O
the	O
controls	O
and	O
the	O
cases	O
was	O
separately	O
analyzed	O
and	O
we	O
observed	O
no	O
significant	O
difference	O
between	O
normal	O
weight	O
(	O
BMI	O
<	O
25kg/m	O
(	O
2	O
)	O
)	O
and	O
overweight	O
/	O
obese	O
(	O
BMI	O
≥	O
25kg/m	O
(	O
2	O
)	O
)	O
subjects	O
.	O

Our	O
findings	O
do	O
not	O
support	O
a	O
role	O
for	O
effect	O
of	O
the	O
CaSR	O
gene	O
A986S	O
variant	O
on	O
CRC	O
risk	O
;	O
nevertheless	O
,	O
this	O
finding	O
requires	O
confirmation	O
and	O
the	O
role	O
of	O
the	O
gene	O
variant	O
in	O
carcinogenesis	O
needs	O
to	O
be	O
further	O
investigated	O
.	O

Malignancy	O
is	O
associated	O
with	O
microcalcification	O
and	O
higher	O
AP/T	O
ratio	O
in	O
ultrasonography	B-P
,	O
but	O
not	O
with	O
Hashimoto	O
's	O
thyroiditis	O
in	O
histopathology	B-P
in	O
patients	O
with	O
thyroid	O
nodules	O
evaluated	O
as	O
Bethesda	O
Category	O
III	O
(	O
AUS	O
/	O
FLUS	O
)	O
in	O
cytology	B-P
.	O

The	O
predictors	O
of	O
malignancy	O
are	O
important	O
for	O
the	O
decision	O
of	O
appropriate	O
management	O
in	O
nodules	O
with	O
atypia	O
of	O
undetermined	O
significance	O
/	O
follicular	O
lesion	O
of	O
undetermined	O
significance	O
(	O
AUS	O
/	O
FLUS	O
)	O
.	O

Our	O
aim	O
was	O
to	O
determine	O
the	O
ultrasonographical	O
,	O
clinical	O
,	O
and	O
biochemical	O
predictors	O
of	O
malignancy	O
in	O
these	O
patients	O
.	O

A	O
total	O
of	O
427	O
patients	O
with	O
cytologically	O
Bethesda	O
Category	O
III	O
(	O
AUS	O
/	O
FLUS	O
)	O
thyroid	O
nodules	O
were	O
included	O
in	O
this	O
retrospective	O
study	O
.	O

We	O
divided	O
the	O
nodules	O
into	O
two	O
subgroups	O
according	O
to	O
the	O
histopathology	B-P
as	O
benign	O
and	O
malignant	O
,	O
and	O
compared	O
the	O
preoperative	O
ultrasonographical	O
,	O
clinical	O
,	O
and	O
biochemical	O
findings	O
.	O

In	O
overall	O
,	O
427	O
patients	O
with	O
449	O
AUS	O
/	O
FLUS	O
nodules	O
who	O
had	O
undergone	O
surgery	O
,	O
the	O
rate	O
of	O
malignancy	O
was	O
23.4	O
%	O
(	O
105/449	O
)	O
.	O

When	O
evaluated	O
separately	O
,	O
the	O
rate	O
of	O
malignancy	O
was	O
25.8	O
%	O
in	O
nodules	O
with	O
AUS	O
(	O
82/318	O
)	O
and	O
17.6	O
%	O
in	O
nodules	O
with	O
FLUS	O
(	O
23/131	O
)	O
(	O
p	O
=	O
0.061	O
)	O
.	O

The	O
vast	O
majority	O
of	O
malignant	O
specimens	O
in	O
histopathology	B-P
consisted	O
of	O
papillary	O
thyroid	O
carcinoma	O
(	O
PTC	O
)	O
(	O
n	O
=	O
91	O
,	O
86.7	O
%	O
)	O
.	O

Preoperative	O
ultrasonographic	O
features	O
of	O
105	O
malignant	O
nodules	O
in	O
histopathology	B-P
were	O
compared	O
with	O
the	O
344	O
benign	O
nodules	O
in	O
histopathology	B-P
.	O

Anteroposterior/Transverse	O
(	O
AP/T	O
)	O
ratio	O
was	O
significantly	O
higher	O
in	O
malignant	O
group	O
compared	O
to	O
benign	O
group	O
(	O
p	O
=	O
0.013	O
)	O
.	O

In	O
multiple	O
logistic	O
analysis	O
,	O
we	O
found	O
that	O
higher	O
AP/T	O
ratio	O
and	O
microcalcification	O
were	O
independently	O
associated	O
with	O
malignancy	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
malignancy	O
-associated	O
cut-off	O
value	O
of	O
AP/T	O
ratio	O
at	O
maximum	O
sensitivity	O
and	O
specificity	O
was	O
≥0.81	O
.	O

We	O
did	O
not	O
find	O
any	O
correlation	O
between	O
malignancy	O
and	O
Hashimoto	O
's	O
thyroiditis	O
in	O
histopathology	B-P
in	O
multivariate	O
analysis	O
(	O
p	O
>	O
0.05	O
)	O
.	O

In	O
Bethesda	O
Category	O
III	O
nodules	O
with	O
higher	O
AP/T	O
ratio	O
and	O
microcalcification	O
,	O
surgery	O
might	O
be	O
considered	O
as	O
a	O
first	O
therapeutic	O
option	O
instead	O
of	O
repeat	O
fine-needle	B-P
aspiration	I-P
biopsy	I-P
or	O
observation	O
.	O

Single-cell	B-P
analyses	I-P
of	O
X	O
Chromosome	O
inactivation	O
dynamics	O
and	O
pluripotency	O
during	O
differentiation	O
.	O

Pluripotency	O
,	O
differentiation	O
,	O
and	O
X	O
Chromosome	O
inactivation	O
(	O
XCI	O
)	O
are	O
key	O
aspects	O
of	O
embryonic	O
development	O
.	O

However	O
,	O
the	O
underlying	O
relationship	O
and	O
mechanisms	O
among	O
these	O
processes	O
remain	O
unclear	O
.	O

Here	O
,	O
we	O
systematically	O
dissected	O
these	O
features	O
along	O
developmental	O
progression	O
using	O
mouse	O
embryonic	O
stem	O
cells	O
(	O
mESCs	O
)	O
and	O
single-cell	O
RNA	O
sequencing	O
with	O
allelic	O
resolution	O
.	O

We	O
found	O
that	O
mESCs	O
grown	O
in	O
a	O
ground	O
state	O
2i	O
condition	O
displayed	O
transcriptomic	O
profiles	O
diffused	O
from	O
preimplantation	B-P
mouse	O
embryonic	O
cells	O
,	O
whereas	O
EpiStem	O
cells	O
closely	O
resembled	O
the	O
post-implantation	B-P
epiblast	O
.	O

Sex	O
-related	O
gene	O
expression	O
varied	O
greatly	O
across	O
distinct	O
developmental	O
states	O
.	O

We	O
also	O
identified	O
novel	O
markers	O
that	O
were	O
highly	O
enriched	O
in	O
each	O
developmental	O
state	O
.	O

Moreover	O
,	O
we	O
revealed	O
that	O
several	O
novel	O
pathways	O
,	O
including	O
PluriNetWork	O
and	O
Focal	O
Adhesion	O
,	O
were	O
responsible	O
for	O
the	O
delayed	O
progression	O
of	O
female	O
EpiStem	O
cells	O
.	O

Importantly	O
,	O
we	O
``	O
digitalized	O
``	O
XCI	O
progression	O
using	O
allelic	O
expression	O
of	O
active	O
and	O
inactive	O
X	O
Chromosomes	O
and	O
surprisingly	O
found	O
that	O
XCI	O
states	O
exhibited	O
profound	O
variability	O
in	O
each	O
developmental	O
state	O
,	O
including	O
the	O
2i	O
condition	O
.	O

XCI	O
progression	O
was	O
not	O
tightly	O
synchronized	O
with	O
loss	O
of	O
pluripotency	O
and	O
increase	O
of	O
differentiation	O
at	O
the	O
single-cell	O
level	O
,	O
although	O
these	O
processes	O
were	O
globally	O
correlated	O
.	O

In	O
addition	O
,	O
highly	O
expressed	O
genes	O
,	O
including	O
core	O
pluripotency	O
factors	O
,	O
were	O
in	O
general	O
biallelically	O
expressed	O
.	O

Taken	O
together	O
,	O
our	O
study	O
sheds	O
light	O
on	O
the	O
dynamics	O
of	O
XCI	O
progression	O
and	O
the	O
asynchronicity	O
between	O
pluripotency	O
,	O
differentiation	O
,	O
and	O
XCI	O
.	O

Antibacterial	O
effect	O
of	O
PEO	O
coating	O
with	O
silver	O
on	O
AA7075	O
.	O

In	O
this	O
work	O
,	O
plasma	O
electrolytic	O
oxidation	O
(	O
PEO	O
)	O
coatings	O
were	O
produced	O
on	O
AA7075	O
using	O
alkaline	O
solution	O
containing	O
silicates	O
compounds	O
and	O
silver	O
micrometric	O
particles	O
in	O
order	O
to	O
give	O
to	O
the	O
coating	O
an	O
antimicrobial	O
effect	O
.	O

In	O
the	O
optic	O
of	O
circular	O
economy	O
,	O
silver	O
chloride	O
derived	O
from	O
the	O
acid	O
pre-treatment	O
of	O
electronic	O
scraps	O
was	O
used	O
as	O
raw	O
material	O
and	O
successively	O
silver	O
powders	O
were	O
synthesized	O
from	O
silver	O
chloride	O
solution	O
using	O
glucose	O
syrup	O
as	O
reducing	O
agent	O
.	O

The	O
coatings	O
were	O
characterized	O
by	O
scanning	O
electron	O
microscope	O
(	O
SEM	O
)	O
,	O
X-ray	B-P
diffraction	I-P
analysis	I-P
(	O
XRD	B-P
)	O
,	O
X-ray	B-P
photoelectron	I-P
spectroscopy	I-P
(	O
XPS	B-P
)	O
,	O
potentiodynamic	B-P
polarization	I-P
test	I-P
and	O
antimicrobial	B-P
tests	I-P
.	O

The	O
results	O
evidenced	O
that	O
the	O
obtained	O
coatings	O
were	O
homogenous	O
and	O
give	O
to	O
the	O
samples	O
higher	O
corrosion	O
resistance	O
than	O
untreated	O
alloy	O
.	O

The	O
silver	O
particles	O
,	O
found	O
both	O
inside	O
and	O
outside	O
of	O
the	O
pores	O
that	O
characterize	O
the	O
PEO	O
layer	O
,	O
produced	O
an	O
efficacious	O
antimicrobial	O
effect	O
both	O
against	O
E.	O
coli	O
and	O
S.	O
aureus	O
.	O

Application	O
of	O
Laparoscopic	B-P
Lumbar	O
Discectomy	O
and	O
Artificial	O
Disc	O
Replacement	O
:	O
At	O
Least	O
Two	O
Years	O
of	O
Follow-Up	O
.	O

This	O
prospective	O
observational	O
study	O
included	O
22	O
patients	O
who	O
were	O
diagnosed	O
with	O
symptomatic	O
degenerative	O
disc	O
disease	O
treated	O
via	O
artificial	O
disc	O
replacement	O
(	O
ADR	O
)	O
with	O
a	O
laparoscopic	B-P
technique	O
.	O

The	O
current	O
study	O
aimed	O
to	O
assess	O
the	O
safety	O
and	O
efficacy	O
of	O
ADR	O
using	O
a	O
laparoscopic	B-P
technique	O
for	O
lumbar	O
disc	O
herniation	O
.	O

Symptomatic	O
degenerative	O
disc	O
disease	O
is	O
the	O
major	O
cause	O
of	O
low	O
back	O
pain	O
with	O
lumbar	O
segmental	O
instability	O
.	O

ADR	O
has	O
increased	O
in	O
popularity	O
as	O
an	O
alternative	O
treatment	O
for	O
lumbar	O
disc	O
herniation	O
.	O

However	O
,	O
the	O
traditional	O
approach	O
to	O
spinal	O
surgery	O
carries	O
the	O
risk	O
of	O
catastrophic	O
bleeding	O
from	O
injury	O
to	O
major	O
vessels	O
,	O
as	O
well	O
as	O
iatrogenic	O
injury	O
to	O
the	O
viscera	O
and	O
associated	O
structures	O
.	O

Therefore	O
,	O
laparoscopic	B-P
lumbar	O
discectomy	O
and	O
ADR	O
may	O
represent	O
a	O
useful	O
alternative	O
.	O

Twenty-two	O
patients	O
(	O
8	O
males	O
and	O
14	O
females	O
)	O
who	O
were	O
diagnosed	O
with	O
symptomatic	O
degenerative	O
disc	O
disease	O
were	O
included	O
in	O
this	O
study	O
.	O

Seven	O
cases	O
involved	O
the	O
L4/5	O
level	O
,	O
and	O
15	O
cases	O
involved	O
the	O
L5/S1	O
level	O
.	O

All	O
patients	O
were	O
ineffective	O
after	O
at	O
least	O
6	O
months	O
of	O
conservative	O
treatments	O
;	O
all	O
patients	O
were	O
informed	O
of	O
the	O
surgery	O
before	O
the	O
operation	O
and	O
provided	O
consent	O
.	O

Three-dimensional	O
computed	B-P
tomographic	I-P
angiography	I-P
(	O
3D	O
-	O
CTA	B-P
)	O
of	O
the	O
iliac	O
great	O
blood	O
vessels	O
was	O
completed	O
before	O
the	O
surgery	O
.	O

All	O
surgical	O
procedures	O
were	O
performed	O
under	O
a	O
laparoscope	O
.	O

All	O
patients	O
were	O
followed	O
up	O
.	O

All	O
surgeries	O
were	O
successfully	O
completed	O
.	O

The	O
average	O
operation	O
time	O
was	O
120	O
minutes	O
(	O
range	O
110-150	O
min	O
)	O
,	O
and	O
the	O
average	O
hemorrhage	O
was	O
145	O
mL	O
(	O
range	O
80-360	O
mL	O
)	O
.	O

All	O
cases	O
underwent	O
X-rays	B-P
at	O
3	O
days	O
,	O
3	O
months	O
,	O
6	O
months	O
,	O
1	O
year	O
,	O
and	O
the	O
final	O
postoperative	O
follow-up	O
.	O

The	O
outcome	O
indicated	O
that	O
there	O
was	O
no	O
mobilization	O
,	O
displacement	O
,	O
or	O
subsidence	O
in	O
all	O
patients	O
with	O
the	O
exception	O
of	O
one	O
case	O
with	O
prosthesis	O
migration	O
.	O

The	O
follow-up	O
time	O
was	O
43.8	O
months	O
(	O
range	O
24-64	O
months	O
)	O
.	O

The	O
mean	O
visual	O
analog	O
scale	O
(	O
VAS	O
)	O
and	O
Oswestry	O
scores	O
were	O
decreased	O
postoperatively	O
.	O

The	O
mean	O
improvement	O
rate	O
of	O
the	O
VAS	O
score	O
was	O
73.5	O
%	O
.	O

Lumbar	O
ADR	O
using	O
a	O
laparoscope	O
represents	O
a	O
novel	O
,	O
minimally	O
invasive	O
treatment	O
for	O
symptomatic	O
degenerative	O
disc	O
disease	O
and	O
severe	O
lumbar	O
discogenic	O
pain	O
.	O

Effects	O
of	O
Elevated	O
CO2	O
on	O
the	O
Swainsonine	O
Chemotypes	O
of	O
Astragalus	O
lentiginosus	O
and	O
Astragalus	O
mollissimus	O
.	O

Rapid	O
changes	O
in	O
the	O
Earth	O
's	O
atmosphere	O
and	O
climate	O
associated	O
with	O
human	O
activity	O
can	O
have	O
significant	O
impacts	O
on	O
agriculture	O
including	O
livestock	O
production	O
.	O

CO2	O
concentration	O
has	O
risen	O
from	O
the	O
industrial	O
revolution	O
to	O
the	O
current	O
time	O
,	O
and	O
is	O
expected	O
to	O
continue	O
to	O
rise	O
.	O

Climatic	O
changes	O
alter	O
physiological	O
processes	O
,	O
growth	O
,	O
and	O
development	O
in	O
numerous	O
plant	O
species	O
,	O
potentially	O
changing	O
concentrations	O
of	O
plant	O
secondary	O
compounds	O
.	O

These	O
physiological	O
changes	O
may	O
influence	O
plant	O
population	O
density	O
,	O
growth	O
,	O
fitness	O
,	O
and	O
toxin	O
concentrations	O
and	O
thus	O
influence	O
the	O
risk	O
of	O
toxic	O
plants	O
to	O
grazing	O
livestock	O
.	O

Locoweeds	O
,	O
swainsonine	O
-	O
containing	O
Astragalus	O
species	O
,	O
are	O
one	O
group	O
of	O
plants	O
that	O
may	O
be	O
influenced	O
by	O
climate	O
change	O
.	O

We	O
evaluated	O
how	O
two	O
different	O
swainsonine	O
-	O
containing	O
Astragalus	O
species	O
responded	O
to	O
elevated	O
CO2	O
concentrations	O
.	O

Measurements	O
of	O
biomass	O
,	O
crude	B-P
protein	I-P
,	O
water	O
soluble	O
carbohydrates	B-P
and	O
swainsonine	B-P
concentrations	I-P
were	O
measured	O
in	O
two	O
chemotypes	O
(	O
positive	O
and	O
negative	O
for	O
swainsonine	O
)	O
of	O
each	O
species	O
after	O
growth	O
at	O
CO2	B-P
levels	I-P
near	O
present	O
day	O
and	O
at	O
projected	O
future	O
concentrations	O
.	O

Biomass	O
and	O
water	O
soluble	O
carbohydrate	O
concentrations	O
responded	O
positively	O
while	O
crude	B-P
protein	I-P
concentrations	I-P
responded	O
negatively	O
to	O
elevated	O
CO2	O
in	O
the	O
two	O
species	O
.	O

Swainsonine	O
concentrations	O
were	O
not	O
strongly	O
affected	O
by	O
elevated	O
CO2	O
in	O
the	O
two	O
species	O
.	O

In	O
the	O
different	O
chemotypes	O
,	O
biomass	O
responded	O
negatively	O
and	O
crude	B-P
protein	I-P
concentrations	I-P
responded	O
positively	O
in	O
the	O
swainsonine	O
-	O
positive	O
plants	O
compared	O
to	O
the	O
swainsonine	O
-	O
negative	O
plants	O
.	O

Ultimately	O
,	O
changes	O
in	O
CO2	O
and	O
endophyte	O
status	O
will	O
likely	O
alter	O
multiple	O
physiological	O
responses	O
in	O
toxic	O
plants	O
such	O
as	O
locoweed	O
,	O
but	O
it	O
is	O
difficult	O
to	O
predict	O
how	O
these	O
changes	O
will	O
impact	O
plant	O
herbivore	O
interactions	O
.	O

The	O
Antibacterial	O
Effect	O
of	O
Additional	O
Photodynamic	O
Therapy	O
in	O
Failed	O
Endodontically	O
Treated	O
Teeth	O
:	O
A	O
Pilot	O
Study	O
.	O

Introduction	O
:	O
Root	O
canal	O
therapy	O
as	O
a	O
routine	O
dental	O
procedure	O
has	O
resulted	O
in	O
retention	O
of	O
millions	O
of	O
teeth	O
that	O
would	O
otherwise	O
be	O
lost	O
.	O

Unfortunately	O
,	O
successful	O
outcomes	O
are	O
not	O
always	O
achievable	O
within	O
initial	O
endodontic	O
treatments	O
,	O
and	O
that	O
necessitates	O
further	O
treatment	O
.	O

Nonsurgical	O
retreatment	O
is	O
the	O
first	O
choice	O
in	O
most	O
clinical	O
situations	O
.	O

The	O
aim	O
of	O
this	O
clinical	O
pilot	O
study	O
was	O
to	O
assess	O
the	O
effect	O
of	O
additional	O
photodynamic	O
therapy	O
(	O
PDT	O
)	O
on	O
intraradicular	O
bacterial	O
load	O
following	O
retreatment	O
of	O
failed	O
previously	O
root	O
treated	O
teeth	O
.	O

Methods	O
:	O
Thirty	O
single-rooted	O
/	O
canalled	O
endodontically	O
treated	O
matured	O
teeth	O
(	O
in	O
27	O
healthy	O
patients	O
)	O
accompanied	O
by	O
apical	O
periodontitis	O
(	O
AP	O
)	O
were	O
selected	O
for	O
this	O
study	O
.	O

Standard	O
protocol	O
was	O
followed	O
for	O
nonsurgical	O
retreatment	O
of	O
each	O
tooth	O
.	O

Microbiological	B-P
samples	I-P
were	O
taken	O
after	O
establishment	O
of	O
apical	O
patency	O
,	O
finished	O
cleaning/shaping	O
procedure	O
,	O
and	O
PDT	O
(	O
665	O
nm	O
,	O
1	O
W	O
,	O
240	O
seconds	O
)	O
.	O

All	O
samples	O
were	O
cultured	B-P
for	O
72	O
hours	O
and	O
colony-forming	O
unit	O
(	O
CFU	O
)	O
was	O
counted	O
.	O

McNemar	O
test	O
was	O
used	O
for	O
statistical	O
analysis	O
of	O
the	O
data	O
.	O

The	O
level	O
of	O
significance	O
was	O
set	O
at	O
0.001	O
.	O

Results	O
:	O
Routine	O
cleaning	O
and	O
shaping	O
resulted	O
in	O
twenty	O
four	O
negative	O
(	O
80	O
%	O
)	O
out	O
of	O
30	O
cultures	B-P
.	O

Four	O
additional	O
negative	O
results	O
were	O
obtained	O
after	O
additional	O
PDT	O
(	O
93.3	O
%	O
)	O
.	O

The	O
addition	O
of	O
PDT	O
to	O
routine	O
procedures	O
significantly	O
enhanced	O
the	O
number	O
of	O
bacteria	O
-free	O
samples	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Conclusion	O
:	O
Regarding	O
elimination	O
of	O
intraradicular	O
microbiota	O
,	O
additional	O
PDT	O
may	O
increase	O
the	O
effectiveness	O
of	O
conventional	O
chemomechanical	O
preparation	O
in	O
previously	O
root	O
filled	O
teeth	O
accompanied	O
by	O
AP	O
.	O

Well	O
controlled	O
randomized	O
clinical	O
trials	O
should	O
be	O
planned	O
for	O
future	O
.	O

Mammary	O
Gland	O
Pathology	O
Subsequent	O
to	O
Acute	O
Infection	O
with	O
Strong	O
versus	O
Weak	O
Biofilm	O
Forming	O
Staphylococcus	O
aureus	O
Bovine	O
Mastitis	O
Isolates	O
:	O
A	O
Pilot	O
Study	O
Using	O
Non-Invasive	O
Mouse	O
Mastitis	O
Model	O
.	O

Biofilm	O
formation	O
by	O
Staphylococcus	O
aureus	O
is	O
an	O
important	O
virulence	O
attribute	O
because	O
of	O
its	O
potential	O
to	O
induce	O
persistent	O
antibiotic	O
resistance	O
,	O
retard	O
phagocytosis	O
and	O
either	O
attenuate	O
or	O
promote	O
inflammation	O
,	O
depending	O
upon	O
the	O
disease	O
syndrome	O
,	O
in	O
vivo	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
evaluate	O
the	O
potential	O
significance	O
of	O
strength	O
of	O
biofilm	O
formation	O
by	O
clinical	O
bovine	O
mastitis	O
-associated	O
S.	O
aureus	O
in	O
mammary	O
tissue	O
damage	O
by	O
using	O
a	O
mouse	O
mastitis	O
model	O
.	O

Two	O
S.	O
aureus	O
strains	O
of	O
the	O
same	O
capsular	O
phenotype	O
with	O
different	O
biofilm	O
forming	O
strengths	O
were	O
used	O
to	O
non-invasively	O
infect	O
mammary	O
glands	O
of	O
lactating	O
mice	O
.	O

Biofilm	O
forming	O
potential	O
of	O
these	O
strains	O
were	O
determined	O
by	O
tissue	B-P
culture	I-P
plate	I-P
method	I-P
,	O
ica	O
typing	O
and	O
virulence	O
gene	O
profile	O
per	O
detection	O
by	O
PCR	O
.	O

Delivery	O
of	O
the	O
infectious	O
dose	O
of	O
S.	O
aureus	O
was	O
directly	O
through	O
the	O
teat	O
lactiferous	O
duct	O
without	O
invasive	O
scraping	O
of	O
the	O
teat	O
surface	O
.	O

Both	O
bacteriological	B-P
and	O
histological	B-P
methods	I-P
were	O
used	O
for	O
analysis	O
of	O
mammary	O
gland	O
pathology	O
of	O
mice	O
post	O
-	O
infection	O
.	O

Histopathological	O
analysis	O
of	O
the	O
infected	O
mammary	O
glands	O
revealed	O
that	O
mice	O
inoculated	O
with	O
the	O
strong	O
biofilm	O
forming	O
S.	O
aureus	O
strain	O
produced	O
marked	O
acute	O
mastitic	O
lesions	O
,	O
showing	O
profuse	O
infiltration	O
predominantly	O
with	O
neutrophils	O
,	O
with	O
evidence	O
of	O
necrosis	O
in	O
the	O
affected	O
mammary	O
glands	O
.	O

In	O
contrast	O
,	O
the	O
damage	O
was	O
significantly	O
less	O
severe	O
in	O
mammary	O
glands	O
of	O
mice	O
infected	O
with	O
the	O
weak	O
biofilm-forming	O
S.	O
aureus	O
strain	O
.	O

Although	O
both	O
IL-1β	O
and	O
TNF-α	O
inflammatory	O
biomarkers	O
were	O
produced	O
in	O
infected	O
mice	O
,	O
level	O
of	O
TNF-α	O
produced	O
was	O
significantly	O
higher	O
(	O
p	O
<	O
0.05	O
)	O
in	O
mice	O
inoculated	O
with	O
strong	O
biofilm	O
forming	O
S.	O
aureus	O
than	O
the	O
weak	O
biofilm	O
forming	O
strain	O
.	O

This	O
finding	O
suggests	O
an	O
important	O
role	O
of	O
TNF-α	O
in	O
mammary	O
gland	O
pathology	O
post	O
-	O
infection	O
with	O
strong	O
biofilm-forming	O
S.	O
aureus	O
in	O
the	O
acute	O
mouse	O
mastitis	O
model	O
,	O
and	O
offers	O
an	O
opportunity	O
for	O
the	O
development	O
of	O
novel	O
strategies	O
for	O
reduction	O
of	O
mammary	O
tissue	O
damage	O
,	O
with	O
or	O
without	O
use	O
of	O
antimicrobials	O
and/or	O
anti-inflammatory	O
compounds	O
for	O
the	O
treatment	O
of	O
bovine	O
mastitis	O
.	O

Assessment	O
of	O
Vascular	O
Stent	O
Heating	O
with	O
Repetitive	O
Transcranial	O
Magnetic	O
Stimulation	O
.	O

A	O
high	O
proportion	O
of	O
patients	O
with	O
stroke	O
do	O
not	O
qualify	O
for	O
repetitive	O
transcranial	O
magnetic	O
stimulation	O
(	O
rTMS	O
)	O
clinical	O
studies	O
due	O
to	O
the	O
presence	O
of	O
metallic	O
stents	O
.	O

The	O
ultimate	O
concern	O
is	O
that	O
any	O
metal	O
could	O
become	O
heated	O
due	O
to	O
eddy	O
currents	O
.	O

However	O
,	O
to	O
date	O
,	O
no	O
clinical	O
safety	O
data	O
are	O
available	O
regarding	O
the	O
risk	O
of	O
metallic	O
stents	O
heating	O
with	O
rTMS	O
.	O

We	O
tested	O
the	O
safety	O
of	O
common	O
rTMS	O
protocols	O
(	O
1	O
Hz	O
and	O
10	O
Hz	O
)	O
with	O
stents	O
used	O
commonly	O
in	O
stroke	O
,	O
nitinol	O
and	O
elgiloy	O
.	O

In	O
our	O
method	O
,	O
stents	O
were	O
tested	O
in	O
gelled	O
saline	O
at	O
2	O
different	O
locations	O
:	O
at	O
the	O
center	O
and	O
at	O
the	O
lobe	O
of	O
the	O
coil	O
.	O

In	O
addition	O
,	O
at	O
each	O
location	O
,	O
stent	O
heating	O
was	O
evaluated	O
in	O
3	O
different	O
orientations	O
:	O
parallel	O
to	O
the	O
long	O
axis	O
of	O
coil	O
,	O
parallel	O
to	O
the	O
short	O
axis	O
of	O
the	O
coil	O
,	O
and	O
perpendicular	O
to	O
the	O
plane	O
of	O
the	O
coil	O
.	O

We	O
found	O
that	O
stents	O
did	O
not	O
heat	O
to	O
more	O
than	O
1°C	O
with	O
either	O
1	O
Hz	O
rTMS	O
or	O
10	O
Hz	O
rTMS	O
in	O
any	O
configuration	O
or	O
orientation	O
.	O

Heating	O
in	O
general	O
was	O
greater	O
at	O
the	O
lobe	O
when	O
the	O
stent	O
was	O
oriented	O
perpendicularly	O
.	O

Our	O
study	O
represents	O
a	O
new	O
method	O
for	O
ex	O
vivo	O
quantification	O
of	O
stent	O
heating	O
.	O

We	O
have	O
found	O
that	O
heating	O
of	O
stents	O
was	O
well	O
below	O
the	O
Food	O
and	O
Drug	O
Administration	O
standards	O
of	O
2°C	O
.	O

Thus	O
,	O
our	O
study	O
paves	O
the	O
way	O
for	O
in	O
vivo	O
testing	O
of	O
rTMS	O
(	O
≤10	O
Hz	O
)	O
in	O
the	O
presence	O
of	O
implanted	O
magnetic	B-P
resonance	I-P
imaging	I-P
-	O
compatible	O
stents	O
in	O
animal	O
studies	O
.	O

When	O
planning	O
human	O
safety	O
studies	O
though	O
,	O
geometry	O
,	O
orientation	O
,	O
and	O
location	O
relative	O
to	O
the	O
coil	O
would	O
be	O
important	O
to	O
consider	O
as	O
well	O
.	O

Leonurine	O
Attenuates	O
Hyperalgesia	O
in	O
Mice	O
with	O
Induced	O
Adenomyosis	O
.	O

BACKGROUND	O
Adenomyosis	O
,	O
defined	O
as	O
the	O
invasion	O
of	O
endometrial	O
glands	O
and	O
stroma	O
into	O
the	O
myometrium	O
,	O
is	O
a	O
common	O
gynecological	O
disorder	O
.	O

In	O
the	O
present	O
study	O
we	O
report	O
on	O
the	O
effect	O
of	O
leonurine	O
on	O
ICR	O
mice	O
with	O
adenomyosis	O
induced	O
by	O
neonatal	O
tamoxifen	O
.	O

MATERIAL	O
AND	O
METHODS	O
After	O
being	O
treated	O
with	O
tamoxifen	O
for	O
4	O
,	O
8	O
,	O
and	O
12	O
weeks	O
,	O
we	O
assessed	O
body	O
weight	O
and	O
pain	O
modulation	O
in	O
mice	O
in	O
hotplate	O
tests	B-P
.	O

The	O
mice	O
were	O
divided	O
into	O
5	O
groups	O
:	O
a	O
low-dose	O
leonurine	O
treatment	O
group	O
,	O
a	O
high-dose	O
leonurine	O
treatment	O
group	O
,	O
a	O
valproic	O
acid	O
(	O
VPA	O
)	O
treatment	O
group	O
,	O
a	O
vehicle	O
only	O
treatment	O
group	O
,	O
and	O
a	O
blank	O
control	O
group	O
.	O

We	O
evaluated	O
body	O
weight	O
,	O
pain	O
modulation	O
in	O
hotplate	O
tests	B-P
,	O
and	O
the	O
depth	O
of	O
myometrial	O
infiltration	O
.	O

Immunoreactivity	O
staining	B-P
of	O
progesterone	O
receptor	O
(	O
PR	O
)	O
,	O
nuclear	O
factor-κB	O
phosphorylated-p65	O
(	O
p-p65	O
)	O
,	O
cyclooxygenase-2	O
(	O
COX-2	O
)	O
,	O
and	O
oxytocin	O
receptor	O
(	O
OTR	O
)	O
was	O
evaluated	O
by	O
immunohistochemistry	B-P
.	O

RESULTS	O
The	O
measurement	O
of	O
the	O
body	O
weight	O
,	O
myometrial	O
infiltration	O
,	O
and	O
pain	O
modulation	O
showed	O
that	O
neonatal	O
tamoxifen	O
treatment	O
led	O
to	O
adenomyosis	O
.	O

Leonurine	O
treatment	O
appeared	O
to	O
decrease	O
hyperalgesia	O
and	O
myometrial	O
infiltration	O
.	O

Immunoreactivity	O
staining	B-P
showed	O
decreased	O
p-p65	O
,	O
COX-2	O
,	O
and	O
OTR	O
protein	O
expressions	O
.	O

CONCLUSIONS	O
Our	O
results	O
indicate	O
that	O
leonurine	O
attenuates	O
hyperalgesia	O
in	O
mice	O
with	O
induced	O
adenomyosis	O
via	O
down-regulating	O
expressions	O
of	O
p-P65	O
,	O
COX-2	O
,	O
and	O
OTR	O
,	O
and	O
could	O
be	O
beneficial	O
for	O
treating	O
adenomyosis	O
.	O

Correlations	O
between	O
physical	O
activity	O
and	O
neurocognitive	O
domain	O
functions	O
in	O
patients	O
with	O
schizophrenia	O
:	O
a	O
cross-sectional	O
study	O
.	O

Neurocognitive	O
dysfunction	O
is	O
a	O
critical	O
target	O
symptom	O
of	O
schizophrenia	O
treatment	O
.	O

A	O
positive	O
correlation	O
between	O
physical	O
activity	O
level	O
and	O
neurocognitive	O
function	O
has	O
been	O
reported	O
in	O
healthy	O
individuals	O
,	O
but	O
it	O
is	O
unclear	O
whether	O
such	O
a	O
correlation	O
exists	O
in	O
patients	O
with	O
schizophrenia	O
and	O
whether	O
the	O
relationship	O
is	O
different	O
according	O
to	O
inpatients	O
or	O
outpatients	O
.	O

This	O
study	O
aimed	O
to	O
examine	O
the	O
differences	O
in	O
the	O
correlations	O
between	O
physical	O
activity	O
and	O
multiple	O
neurocognitive	O
domains	O
in	O
inpatients	O
and	O
outpatients	O
with	O
schizophrenia	O
and	O
obtain	O
suggestions	O
for	O
further	O
study	O
to	O
facilitate	O
this	O
field	O
.	O

Twenty-nine	O
patients	O
with	O
schizophrenia	O
were	O
examined	O
(	O
16	O
inpatients	O
and	O
13	O
outpatients	O
,	O
56.0	O
±	O
11.4	O
years	O
of	O
age	O
)	O
.	O

Current	O
symptoms	O
were	O
assessed	O
using	O
the	O
Positive	O
and	O
Negative	O
Symptom	O
Scale	O
and	O
neurocognitive	O
functions	O
using	O
Cognitrax	O
,	O
which	O
yields	O
a	O
composite	O
neurocognitive	B-P
index	I-P
(	O
NCI	B-P
)	O
and	O
11	O
domain	O
scores	O
.	O

After	O
testing	O
,	O
participants	O
wore	O
an	O
HJA-750C	O
accelerometer	O
for	O
one	O
week	O
to	O
measure	O
physical	O
activity	O
levels	O
and	O
durations	O
.	O

Partial	O
correlation	O
analyses	O
were	O
performed	O
between	O
exercise	O
and	O
cognitive	O
parameters	O
.	O

In	O
the	O
outpatient	O
group	O
,	O
higher	O
physical	O
activity	O
was	O
associated	O
with	O
faster	O
Motor	O
and	O
Psychomotor	O
Speeds	O
in	O
outpatients	O
.	O

However	O
,	O
higher	O
physical	O
activity	O
was	O
associated	O
with	O
lower	O
overall	O
NCI	B-P
,	O
Attention	O
score	O
,	O
and	O
Memory	O
scores	O
in	O
inpatients	O
.	O

Although	O
higher	O
physical	O
activity	O
was	O
associated	O
with	O
better	O
neurocognitive	O
functions	O
of	O
outpatients	O
,	O
in	O
inpatients	O
with	O
non-remitted	O
schizophrenia	O
,	O
higher	O
physical	O
activity	O
was	O
associated	O
with	O
worsening	O
of	O
several	O
cognitive	O
domains	O
.	O

In	O
a	O
future	O
study	O
examining	O
the	O
relationship	O
between	O
physical	O
activity	O
and	O
neurocognitive	O
function	O
for	O
facilitating	O
this	O
research	O
field	O
,	O
separation	O
between	O
inpatients	O
and	O
outpatients	O
are	O
needed	O
because	O
the	O
relationship	O
is	O
different	O
between	O
inpatients	O
and	O
outpatients	O
.	O

Initial	O
experience	O
with	O
laparoscopic	O
radical	O
antegrade	O
modular	O
pancreatosplenectomy	O
for	O
left-sided	O
pancreatic	O
cancer	O
in	O
a	O
single	O
institution	O
:	O
technical	O
aspects	O
and	O
oncological	O
outcomes	O
.	O

Laparoscopic	O
surgery	O
has	O
been	O
performed	O
less	O
frequently	O
in	O
the	O
era	O
of	O
pancreatic	O
cancer	O
due	O
to	O
technical	O
difficulties	O
and	O
concerns	O
about	O
oncological	O
safety	O
.	O

Radical	O
antegrade	O
modular	O
pancreatosplenectomy	O
(	O
RAMPS	O
)	O
is	O
expected	O
to	O
be	O
helpful	O
to	O
obtain	O
a	O
negative	O
margin	O
during	O
radical	O
lymph	O
node	O
dissection	O
.	O

We	O
hypothesized	O
that	O
it	O
would	O
also	O
be	O
favorable	O
as	O
a	O
laparoscopic	O
application	O
due	O
to	O
unique	O
features	O
.	O

Fifteen	O
laparoscopic	B-P
RAMPS	O
for	O
well-selected	O
patients	O
with	O
left-sided	O
pancreatic	O
cancer	O
were	O
performed	O
from	O
July	O
2011	O
to	O
April	O
2016	O
.	O

Five	O
trocars	O
were	O
usually	O
used	O
,	O
and	O
the	O
operative	O
procedures	O
and	O
range	O
of	O
dissection	O
were	O
similar	O
to	O
or	O
the	O
same	O
as	O
those	O
of	O
open	O
RAMPS	O
described	O
by	O
Strasberg	O
.	O

All	O
medical	O
records	O
and	O
follow-up	O
data	O
were	O
reviewed	O
and	O
analyzed	O
.	O

All	O
patients	O
had	O
pancreatic	O
ductal	O
adenocarcinoma	O
.	O

Mean	O
operative	O
time	O
was	O
219.3	O
±	O
53.8	O
min	O
,	O
and	O
estimated	O
blood	O
loss	O
was	O
250	O
±	O
70	O
ml	O
.	O

The	O
length	O
of	O
postoperative	O
hospital	O
stay	O
was	O
6.1	O
±	O
1.2	O
days	O
,	O
and	O
postoperative	O
morbidities	O
developed	O
in	O
two	O
patients	O
(	O
13.3	O
%	O
)	O
with	O
urinary	O
retention	O
.	O

The	O
median	O
number	O
of	O
retrieved	O
lymph	O
nodes	O
was	O
18.1	O
±	O
6.2	O
and	O
all	O
had	O
negative	O
margins	O
.	O

Median	O
follow-up	O
time	O
was	O
46.0	O
months	O
,	O
and	O
the	O
3-year	O
disease	O
free	O
survival	O
and	O
overall	O
survival	O
rates	O
were	O
56.3	O
%	O
and	O
74.1	O
%	O
,	O
respectively	O
.	O

Our	O
early	O
experience	O
with	O
laparoscopic	B-P
RAMPS	O
achieved	O
feasible	O
perioperative	O
results	O
accompanied	O
by	O
acceptable	O
survival	O
outcomes	O
.	O

Laparoscopic	B-P
RAMPS	O
could	O
be	O
a	O
safe	O
and	O
oncologically	O
feasible	O
procedure	O
in	O
well-selected	O
patients	O
with	O
left-sided	O
pancreatic	O
cancer	O
.	O

SF2312	O
is	O
a	O
natural	O
phosphonate	O
inhibitor	O
of	O
enolase	O
.	O

Despite	O
being	O
crucial	O
for	O
energy	O
generation	O
in	O
most	O
forms	O
of	O
life	O
,	O
few	O
if	O
any	O
microbial	O
antibiotics	O
specifically	O
inhibit	O
glycolysis	O
.	O

To	O
develop	O
a	O
specific	O
inhibitor	O
of	O
the	O
glycolytic	O
enzyme	B-P
enolase	I-P
2	I-P
(	O
ENO2	B-P
)	O
for	O
the	O
treatment	O
of	O
cancers	O
with	O
deletion	O
of	O
ENO1	O
(	O
encoding	O
enolase	O
1	O
)	O
,	O
we	O
modeled	O
the	O
synthetic	O
tool	O
compound	O
inhibitor	O
phosphonoacetohydroxamate	O
(	O
PhAH	O
)	O
into	O
the	O
active	O
site	O
of	O
human	O
ENO2	B-P
.	O

A	O
ring-stabilized	O
analog	O
of	O
PhAH	O
,	O
in	O
which	O
the	O
hydroxamic	O
nitrogen	O
is	O
linked	O
to	O
Cα	O
by	O
an	O
ethylene	O
bridge	O
,	O
was	O
predicted	O
to	O
increase	O
binding	O
affinity	O
by	O
stabilizing	O
the	O
inhibitor	O
in	O
a	O
bound	O
conformation	O
.	O

Unexpectedly	O
,	O
a	O
structure-based	O
search	O
revealed	O
that	O
our	O
hypothesized	O
backbone-stabilized	O
PhAH	O
bears	O
strong	O
similarity	O
to	O
SF2312	O
,	O
a	O
phosphonate	O
antibiotic	O
of	O
unknown	O
mode	O
of	O
action	O
produced	O
by	O
the	O
actinomycete	O
Micromonospora	O
,	O
which	O
is	O
active	O
under	O
anaerobic	O
conditions	O
.	O

Here	O
,	O
we	O
present	O
multiple	O
lines	O
of	O
evidence	O
,	O
including	O
a	O
novel	O
X-ray	B-P
structure	O
,	O
that	O
SF2312	O
is	O
a	O
highly	O
potent	O
,	O
low	O
-	O
nanomolar	O
inhibitor	O
of	O
enolase	O
.	O

Prognostic	O
and	O
therapeutic	O
value	O
of	O
mitochondrial	O
serine	O
hydroxyl-methyltransferase	O
2	O
as	O
a	O
breast	O
cancer	O
biomarker	O
.	O

Mitochondrial	O
serine	O
hydroxylmethyltransferase	O
2	O
(	O
SHMT2	O
)	O
is	O
a	O
key	O
enzyme	O
in	O
the	O
serine/glycine	O
synthesis	O
pathway	O
.	O

SHMT2	O
has	O
been	O
implicated	O
as	O
a	O
critical	O
component	O
for	O
tumor	O
cell	O
survival	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
prognostic	O
value	O
and	O
efficiency	O
of	O
SHMT2	O
as	O
a	O
biomarker	O
in	O
patients	O
with	O
breast	O
cancer	O
.	O

Individual	O
and	O
pooled	O
survival	O
analyses	O
were	O
performed	O
on	O
five	O
independent	O
breast	O
cancer	O
microarray	O
datasets	O
.	O

Gene	O
signatures	O
enriched	O
by	O
SHMT2	O
were	O
also	O
analyzed	O
in	O
these	O
datasets	O
.	O

SHMT2	O
protein	O
expression	O
was	O
detected	O
using	O
immunohistochemistry	B-P
(	O
IHC	B-P
)	O
assay	B-P
in	O
128	O
breast	O
cancer	O
cases	O
.	O

Gene	O
set	O
enrichment	O
analysis	O
revealed	O
that	O
SHMT2	O
was	O
significantly	O
associated	O
with	O
gene	O
signatures	O
of	O
mitochondrial	O
module	O
,	O
cancer	O
invasion	O
,	O
metastasis	O
and	O
poor	O
survival	O
among	O
breast	O
cancer	O
patients	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
clinical	O
relevance	O
of	O
SHMT2	O
was	O
validated	O
on	O
IHC	B-P
data	O
.	O

The	O
mitochondrial	O
localization	O
of	O
SHMT2	O
protein	O
was	O
visualized	O
on	O
IHC	B-P
staining	B-P
.	O

Independent	O
and	O
pooled	O
analysis	O
confirmed	O
that	O
SHMT2	O
expression	O
was	O
associated	O
with	O
breast	O
cancer	O
tumor	O
aggressiveness	O
(	O
TNM	O
staging	O
and	O
Elson	O
grade	O
)	O
in	O
a	O
dose-dependent	O
manner	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
prognostic	O
performance	O
of	O
SHMT2	O
mRNA	O
was	O
comparable	O
to	O
other	O
gene	O
signatures	O
and	O
proved	O
superior	O
to	O
TNM	O
staging	O
.	O

Further	O
analysis	O
results	O
indicated	O
that	O
SHMT2	O
had	O
better	O
prognostic	O
value	O
for	O
estrogen	O
receptor	O
(	O
ER	O
)	O
-negative	O
breast	O
cancer	O
patients	O
,	O
compared	O
to	O
ER-positive	O
patients	O
.	O

In	O
cases	O
involving	O
stage	O
IIb	O
breast	O
cancer	O
,	O
chemotherapy	O
significantly	O
extended	O
survival	O
time	O
among	O
patients	O
with	O
high	O
SHMT2	O
expression	O
.	O

These	O
results	O
indicate	O
that	O
SHMT2	O
may	O
be	O
a	O
valuable	O
prognostic	O
biomarker	O
in	O
ER-negative	O
breast	O
cancer	O
cases	O
.	O

Furthermore	O
,	O
SHMT2	O
may	O
be	O
a	O
potential	O
target	O
for	O
breast	O
cancer	O
treatment	O
and	O
drug	O
discovery	O
.	O

Persistent	O
Organic	O
Pollutants	O
(	O
POPs	O
)	O
in	O
the	O
atmosphere	O
of	O
three	O
Chilean	O
cities	O
using	O
passive	O
air	O
samplers	O
.	O

In	O
this	O
study	O
passive	O
air	O
samplers	O
containing	O
polyurethane	O
foam	O
(	O
PUF	O
)	O
disks	O
were	O
deployed	O
in	O
three	O
cities	O
across	O
Chile	O
;	O
Santiago	O
(	O
STG	O
)	O
(	O
n=5	O
,	O
sampling	O
sites	O
)	O
,	O
Concepciόn	O
(	O
CON	O
)	O
(	O
n=6	O
)	O
and	O
Temuco	O
(	O
TEM	O
)	O
(	O
n=6	O
)	O
from	O
2008	O
to	O
2009	O
.	O

Polychlorinated	O
biphenyls	O
(	O
PCBs	O
)	O
(	O
7	O
indicator	O
congeners	O
)	O
,	O
chlorinated	O
pesticides	O
hexachlorocyclohexanes	O
(	O
HCHs	O
)	O
,	O
dichlorodiphenyl	O
trichloroethanes	O
(	O
DDTs	O
)	O
and	O
flame	O
retardants	O
such	O
as	O
polybrominated	O
diphenyl	O
ethers	O
(	O
PBDEs	O
)	O
were	O
determined	O
by	O
gas	B-P
chromatography	I-P
coupled	I-P
mass	I-P
spectrometry	I-P
(	O
GC/MS	B-P
)	O
.	O

A	O
sampling	O
rate	O
(	O
R	O
)	O
typical	O
of	O
urban	O
sites	O
(	O
4m	O
(	O
3	O
)	O
/day	O
)	O
was	O
used	O
to	O
estimate	O
the	O
atmospheric	O
concentrations	O
of	O
individual	O
compounds	O
.	O

PCB	O
concentrations	O
in	O
the	O
air	O
(	O
pg/m	O
(	O
3	O
)	O
)	O
ranged	O
from	O
~1-10	O
(	O
TEM	O
)	O
,	O
~1-40	O
(	O
STG	O
)	O
and	O
4-30	O
(	O
CON	O
)	O
.	O

Higher	O
molecular	O
weight	O
PCBs	O
(	O
PCB	O
-153	O
,	O
-180	O
)	O
were	O
detected	O
at	O
industrial	O
sites	O
(	O
in	O
Concepción	O
)	O
.	O

The	O
HCHs	O
showed	O
a	O
prevalence	O
of	O
γ-HCH	O
across	O
all	O
sites	O
,	O
indicative	O
of	O
inputs	O
from	O
the	O
use	O
of	O
lindane	O
but	O
a	O
limited	O
use	O
of	O
technical	O
HCHs	O
in	O
Chile	O
.	O

DDTs	O
were	O
detected	O
with	O
a	O
prevalence	O
of	O
p	O
,	O
p'-DDE	O
accounting	O
for	O
~50	O
%	O
of	O
the	O
total	O
DDTs	O
.	O

PBDE	O
concentrations	O
in	O
air	O
(	O
pg/m	O
(	O
3	O
)	O
)	O
ranged	O
from	O
1	O
to	O
55	O
(	O
STG	O
)	O
,	O
0.5	O
to	O
20	O
(	O
CON	O
)	O
and	O
from	O
0.4	O
to	O
10	O
(	O
TEM	O
)	O
,	O
and	O
were	O
generally	O
similar	O
to	O
those	O
reported	O
for	O
many	O
other	O
urban	O
areas	O
globally	O
.	O

The	O
pattern	O
of	O
PBDEs	O
was	O
different	O
among	O
the	O
three	O
cities	O
;	O
however	O
,	O
PBDE	O
-209	O
was	O
dominant	O
at	O
most	O
of	O
the	O
sites	O
.	O

These	O
results	O
represent	O
one	O
of	O
the	O
few	O
assessments	O
of	O
air	O
concentrations	O
of	O
POPs	O
across	O
different	O
urban	O
areas	O
within	O
the	O
same	O
country	O
.	O

These	O
data	O
will	O
support	O
Chilean	O
commitments	O
as	O
a	O
signatory	O
to	O
the	O
Stockholm	O
Convention	O
on	O
POPs	O
and	O
for	O
reporting	O
as	O
a	O
member	O
country	O
of	O
the	O
Group	O
of	O
Latin	O
America	O
and	O
Caribbean	O
Countries	O
(	O
GRULAC	O
)	O
region	O
.	O

Biogeography	O
and	O
taxonomy	O
of	O
racket-tail	O
hummingbirds	O
(	O
Aves	O
:	O
Trochilidae	O
:	O
<	O
i	O
>	O
Ocreatus	O
<	O
/i	O
>	O
)	O
:	O
evidence	O
for	O
species	O
delimitation	O
from	O
morphology	O
and	O
display	O
behavior	O
.	O

We	O
analyzed	O
geographic	O
variation	O
,	O
biogeography	O
,	O
and	O
intrageneric	O
relationships	O
of	O
racket-tail	O
hummingbirds	O
Ocreatus	O
(	O
Aves	O
,	O
Trochilidae	O
)	O
.	O

Presently	O
,	O
the	O
genus	O
is	O
usually	O
considered	O
monospecific	O
,	O
with	O
O.	O
underwoodii	O
including	O
eight	O
subspecies	O
(	O
polystictus	O
,	O
discifer	O
,	O
underwoodii	O
,	O
incommodus	O
,	O
melanantherus	O
,	O
peruanus	O
,	O
annae	O
,	O
addae	O
)	O
,	O
although	O
up	O
to	O
three	O
species	O
have	O
been	O
recognized	O
by	O
some	O
authors	O
.	O

In	O
order	O
to	O
evaluate	O
the	O
current	O
taxonomy	O
we	O
studied	O
geographic	O
variation	O
in	O
coloration	O
,	O
mensural	O
characters	O
,	O
and	O
behavioral	O
data	O
of	O
all	O
Ocreatus	O
taxa	O
.	O

We	O
briefly	O
review	O
the	O
taxonomic	O
history	O
of	O
the	O
genus	O
.	O

Applying	O
the	O
Biological	O
Species	O
Concept	O
,	O
species	O
delimitation	O
was	O
based	O
on	O
a	O
qualitative	O
-	O
quantitative	O
criteria	O
analysis	O
including	O
an	O
evaluation	O
of	O
character	O
states	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
genus	O
should	O
be	O
considered	O
a	O
superspecies	O
with	O
four	O
species	O
,	O
the	O
monotypic	O
Ocreatus	O
addae	O
,	O
O.	O
annae	O
,	O
and	O
O.	O
peruanus	O
,	O
and	O
the	O
polytypic	O
O.	O
underwoodii	O
(	O
including	O
the	O
subspecies	O
underwoodii	O
,	O
discifer	O
,	O
incommodus	O
,	O
melanantherus	O
,	O
polystictus	O
)	O
.	O

In	O
this	O
taxonomic	O
treatment	O
,	O
O.	O
annae	O
becomes	O
an	O
endemic	O
species	O
to	O
Peru	O
and	O
O.	O
addae	O
is	O
endemic	O
to	O
Bolivia	O
.	O

We	O
recommend	O
additional	O
sampling	B-P
of	O
distributional	O
,	O
ethological	O
,	O
and	O
molecular	O
data	O
for	O
an	O
improved	O
resolution	O
of	O
the	O
evolutionary	O
history	O
of	O
Ocreatus	O
.	O

A	O
Support	O
Vector	O
Machine	O
Classification	O
of	O
Thyroid	O
Bioptic	O
Specimens	O
Using	O
MALDI-MSI	B-P
Data	O
.	O

Biomarkers	O
able	O
to	O
characterise	O
and	O
predict	O
multifactorial	O
diseases	O
are	O
still	O
one	O
of	O
the	O
most	O
important	O
targets	O
for	O
all	O
the	O
``	O
omics	O
``	O
investigations	O
.	O

In	O
this	O
context	O
,	O
Matrix-Assisted	B-P
Laser	I-P
Desorption/Ionisation-Mass	I-P
Spectrometry	I-P
Imaging	I-P
(	O
MALDI-MSI	B-P
)	O
has	O
gained	O
considerable	O
attention	O
in	O
recent	O
years	O
,	O
but	O
it	O
also	O
led	O
to	O
a	O
huge	O
amount	O
of	O
complex	O
data	O
to	O
be	O
elaborated	O
and	O
interpreted	O
.	O

For	O
this	O
reason	O
,	O
computational	O
and	O
machine	O
learning	O
procedures	O
for	O
biomarker	O
discovery	O
are	O
important	O
tools	O
to	O
consider	O
,	O
both	O
to	O
reduce	O
data	O
dimension	O
and	O
to	O
provide	O
predictive	O
markers	O
for	O
specific	O
diseases	O
.	O

For	O
instance	O
,	O
the	O
availability	O
of	O
protein	O
and	O
genetic	O
markers	O
to	O
support	O
thyroid	O
lesion	O
diagnoses	O
would	O
impact	O
deeply	O
on	O
society	O
due	O
to	O
the	O
high	O
presence	O
of	O
undetermined	O
reports	O
(	O
THY3	O
)	O
that	O
are	O
generally	O
treated	O
as	O
malignant	O
patients	O
.	O

In	O
this	O
paper	O
we	O
show	O
how	O
an	O
accurate	O
classification	O
of	O
thyroid	O
bioptic	O
specimens	O
can	O
be	O
obtained	O
through	O
the	O
application	O
of	O
a	O
state-of-the-art	O
machine	O
learning	O
approach	O
(	O
i.e.	O
,	O
Support	O
Vector	O
Machines	O
)	O
on	O
MALDI-MSI	B-P
data	O
,	O
together	O
with	O
a	O
particular	O
wrapper	O
feature	O
selection	O
algorithm	O
(	O
i.e.	O
,	O
recursive	O
feature	O
elimination	O
)	O
.	O

The	O
model	O
is	O
able	O
to	O
provide	O
an	O
accurate	O
discriminatory	O
capability	O
using	O
only	O
20	O
out	O
of	O
144	O
features	O
,	O
resulting	O
in	O
an	O
increase	O
of	O
the	O
model	O
performances	O
,	O
reliability	O
,	O
and	O
computational	O
efficiency	O
.	O

Finally	O
,	O
tissue	O
areas	O
rather	O
than	O
average	O
proteomic	O
profiles	O
are	O
classified	O
,	O
highlighting	O
potential	O
discriminating	O
areas	O
of	O
clinical	O
interest	O
.	O

Single-cell	O
RNA-seq	O
enables	O
comprehensive	O
tumour	O
and	O
immune	B-P
cell	I-P
profiling	I-P
in	O
primary	O
breast	O
cancer	O
.	O

Single-cell	O
transcriptome	O
profiling	O
of	O
tumour	O
tissue	O
isolates	O
allows	O
the	O
characterization	O
of	O
heterogeneous	O
tumour	O
cells	O
along	O
with	O
neighbouring	O
stromal	O
and	O
immune	O
cells	O
.	O

Here	O
we	O
adopt	O
this	O
powerful	O
approach	O
to	O
breast	O
cancer	O
and	O
analyse	O
515	O
cells	O
from	O
11	O
patients	O
.	O

Inferred	O
copy	O
number	O
variations	O
from	O
the	O
single-cell	O
RNA-seq	O
data	O
separate	O
carcinoma	O
cells	O
from	O
non-cancer	O
cells	O
.	O

At	O
a	O
single-cell	O
resolution	O
,	O
carcinoma	O
cells	O
display	O
common	O
signatures	O
within	O
the	O
tumour	O
as	O
well	O
as	O
intratumoral	O
heterogeneity	O
regarding	O
breast	O
cancer	O
subtype	O
and	O
crucial	O
cancer-related	O
pathways	O
.	O

Most	O
of	O
the	O
non-cancer	O
cells	O
are	O
immune	O
cells	O
,	O
with	O
three	O
distinct	O
clusters	O
of	O
T	O
lymphocytes	O
,	O
B	O
lymphocytes	O
and	O
macrophages	O
.	O

T	O
lymphocytes	O
and	O
macrophages	O
both	O
display	O
immunosuppressive	O
characteristics	O
:	O
T	O
cells	O
with	O
a	O
regulatory	O
or	O
an	O
exhausted	O
phenotype	O
and	O
macrophages	O
with	O
an	O
M2	O
phenotype	O
.	O

These	O
results	O
illustrate	O
that	O
the	O
breast	O
cancer	O
transcriptome	O
has	O
a	O
wide	O
range	O
of	O
intratumoral	O
heterogeneity	O
,	O
which	O
is	O
shaped	O
by	O
the	O
tumour	O
cells	O
and	O
immune	O
cells	O
in	O
the	O
surrounding	O
microenvironment	O
.	O

Body	O
burden	O
of	O
heavy	O
metals	O
among	O
HIV	O
high	O
risk	O
population	O
in	O
USA	O
.	O

HIV	O
high	O
risk	O
population	O
may	O
face	O
not	O
only	O
the	O
threat	O
of	O
HIV	O
infection	O
but	O
also	O
a	O
higher	O
chance	O
of	O
exposure	O
to	O
environmental	O
contaminants	O
.	O

However	O
,	O
no	O
previous	O
studies	O
have	O
examined	O
the	O
body	O
burden	O
of	O
environmental	O
pollutants	O
including	O
heavy	O
metals	O
among	O
HIV	O
high	O
risk	O
populations	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
adults	O
aged	O
20-59	O
years	O
old	O
at	O
high	O
risk	O
of	O
HIV	O
infection	O
have	O
higher	O
blood	O
levels	O
of	O
heavy	O
metals	O
compared	O
to	O
those	O
with	O
low	O
risk	O
of	O
HIV	O
infection	O
in	O
United	O
States	O
.	O

We	O
used	O
the	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
(	O
NHANES	O
)	O
1999-2010	O
to	O
compare	O
exposures	O
to	O
heavy	O
metals	O
including	O
cadmium	O
,	O
lead	O
,	O
and	O
total	O
mercury	O
by	O
HIV	O
risk	O
status	O
.	O

The	O
results	O
showed	O
that	O
people	O
at	O
high	O
risk	O
of	O
HIV	O
had	O
higher	O
blood	O
concentrations	O
of	O
all	O
heavy	O
metals	O
compared	O
to	O
their	O
counterparts	O
with	O
lower	O
HIV	O
risks	O
.	O

In	O
multivariate	O
linear	O
regression	O
models	O
,	O
HIV	O
risk	O
status	O
was	O
significantly	O
associated	O
with	O
increased	O
blood	B-P
cadmium	I-P
,	O
lead	B-P
,	O
and	O
total	B-P
mercury	I-P
after	O
adjusting	O
for	O
age	O
,	O
sex	O
,	O
race	O
,	O
education	O
,	O
and	O
poverty	O
income	O
ratio	O
.	O

Our	O
study	O
suggests	O
that	O
people	O
at	O
high	O
risk	O
of	O
HIV	O
have	O
significantly	O
higher	O
body	O
burden	O
of	O
heavy	O
metals	O
including	O
cadmium	O
,	O
lead	O
,	O
and	O
mercury	O
compared	O
to	O
those	O
with	O
low	O
risk	O
of	O
HIV	O
.	O

Further	O
longitudinal	O
study	O
collecting	O
more	O
pollutants	O
are	O
warranted	O
to	O
determine	O
the	O
potential	O
health	O
effects	O
of	O
these	O
elevated	O
pollutants	O
on	O
both	O
HIV-infected	O
and	O
HIV	O
high-risk	O
populations	O
.	O

Somatic	O
molecular	B-P
subtyping	I-P
of	O
prostate	O
tumors	O
from	O
HOXB13	O
G84E	O
carriers	O
.	O

A	O
recurrent	O
germline	O
mutation	O
(	O
G84E	O
)	O
in	O
the	O
HOXB13	O
gene	O
is	O
associated	O
with	O
early	O
onset	O
and	O
family	O
history	O
-positive	O
prostate	O
cancer	O
in	O
patients	O
of	O
European	O
descent	O
,	O
occurring	O
in	O
up	O
to	O
5	O
%	O
of	O
prostate	O
cancer	O
families	O
.	O

To	O
date	O
,	O
the	O
molecular	O
features	O
of	O
prostate	O
tumors	O
occurring	O
in	O
HOXB13	O
G84E	O
carriers	O
have	O
not	O
been	O
studied	O
in	O
a	O
large	O
cohort	O
of	O
patients	O
.	O

We	O
identified	O
101	O
heterozygous	O
carriers	O
of	O
G84E	O
who	O
underwent	O
radical	O
prostatectomy	O
for	O
prostate	O
cancer	O
between	O
1985	O
and	O
2011	O
and	O
matched	O
these	O
men	O
by	O
race	O
,	O
age	O
and	O
tumor	O
grade	O
to	O
99	O
HOXB13	O
wild-type	O
controls	O
.	O

Immunostaining	B-P
for	O
HOXB13	O
,	O
PTEN	O
,	O
ERG	O
,	O
p53	O
and	O
SPINK1	O
as	O
well	O
as	O
RNA	O
in	O
situ	O
hybridization	O
for	O
ETV1	O
/	O
4	O
/	O
5	O
were	O
performed	O
using	O
genetically	B-P
validated	I-P
assays	I-P
.	O

Tumors	O
from	O
G84E	O
carriers	O
generally	O
expressed	O
HOXB13	O
protein	O
at	O
a	O
level	O
comparable	O
to	O
benign	O
and	O
wild-type	O
glands	O
.	O

ETS	O
gene	O
expression	O
(	O
either	O
ERG	O
or	O
ETV1	O
/	O
4	O
/	O
5	O
)	O
was	O
seen	O
in	O
36	O
%	O
(	O
36/101	O
)	O
of	O
tumors	O
from	O
G84E	O
carriers	O
compared	O
to	O
68	O
%	O
(	O
65/96	O
)	O
of	O
the	O
controls	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

PTEN	O
was	O
lost	O
in	O
11	O
%	O
(	O
11/101	O
)	O
of	O
G84E	O
carriers	O
compared	O
to	O
25	O
%	O
(	O
25/99	O
)	O
of	O
the	O
controls	O
(	O
p	O
=	O
0.014	O
)	O
.	O

PTEN	O
loss	O
was	O
enriched	O
among	O
ERG	O
-	O
positive	O
compared	O
to	O
ERG	O
-	O
negative	O
tumors	O
in	O
both	O
groups	O
of	O
patients	O
.	O

Nuclear	O
accumulation	O
of	O
the	O
p53	O
protein	O
,	O
indicative	O
of	O
underlying	O
TP53	O
missense	O
mutations	O
,	O
was	O
uncommon	O
in	O
both	O
groups	O
,	O
occurring	O
in	O
1	O
%	O
(	O
1/101	O
)	O
of	O
the	O
G84E	O
carriers	O
versus	O
2	O
%	O
(	O
2/92	O
)	O
of	O
the	O
controls	O
(	O
p	O
=	O
NS	O
)	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
genes	O
other	O
than	O
ERG	O
and	O
PTEN	O
may	O
drive	O
carcinogenesis	O
/	O
progression	O
in	O
the	O
majority	O
of	O
men	O
with	O
germline	O
HOXB13	O
mutations	O
.	O

Tobacco	O
Consumption	O
and	O
Toxicant	O
Exposure	O
of	O
Cigarette	O
Smokers	O
Using	O
Electronic	O
Cigarettes	O
.	O

There	O
is	O
considerable	O
debate	O
about	O
the	O
benefits	O
and	O
risks	O
of	O
electronic	O
cigarettes	O
(	O
ECs	O
)	O
.	O

To	O
better	O
understand	O
the	O
risk-benefit	O
ratio	O
of	O
ECs	O
,	O
more	O
information	O
is	O
needed	O
about	O
net	O
nicotine	O
consumption	O
and	O
toxicant	O
exposure	O
of	O
cigarette	O
smokers	O
switching	O
to	O
ECs	O
.	O

Forty	O
cigarette	O
smokers	O
(	O
>	O
1	O
year	O
of	O
smoking	O
)	O
interested	O
in	O
switching	O
to	O
ECs	O
but	O
not	O
necessarily	O
quitting	O
smoking	O
were	O
enrolled	O
in	O
a	O
four-	O
week	O
observational	O
study	O
and	O
provided	O
an	O
e-Go	O
C	O
non-variable	O
battery	O
and	O
refillable	O
atomizers	O
and	O
choice	O
of	O
8	O
flavors	O
in	O
12	O
or	O
24	O
mg	O
nicotine	O
dosage	O
.	O

Measurement	B-P
of	I-P
urinary	I-P
cotinine	I-P
(	O
metabolite	O
of	O
nicotine	O
)	O
,	O
4-	O
(	O
methylnitrosamino	O
)	O
-1-	O
(	O
3-pyridyl	O
)	O
-1-butanol	O
(	O
NNAL	O
;	O
a	O
pulmonary	O
carcinogen	O
)	O
,	O
and	O
eight	O
volatile	O
organic	O
compounds	O
(	O
VOCs	O
)	O
that	O
are	O
toxic	O
tobacco	O
smoke	O
constituents	O
was	O
conducted	O
at	O
baseline	O
and	O
Week	O
-4	O
.	O

All	O
participants	O
with	O
follow-up	O
data	O
(	O
92.5	O
%	O
)	O
reported	O
using	O
the	O
study	O
EC	O
.	O

Of	O
the	O
40	O
smokers	O
,	O
16	O
reported	O
no	O
cigarettes	O
at	O
Week	O
-2	O
(	O
40	O
%	O
)	O
and	O
6	O
continued	O
to	O
report	O
no	O
cigarettes	O
at	O
Week	O
-4	O
(	O
15	O
%	O
)	O
.	O

Change	O
in	O
nicotine	O
intake	O
over	O
the	O
4-	O
weeks	O
was	O
non-significant	O
(	O
p=0.90	O
)	O
.	O

Carbon	O
monoxide	O
(	O
p	O
<	O
0.001	O
)	O
,	O
NNAL	O
(	O
p	O
<	O
0.01	O
)	O
and	O
metabolites	O
of	O
benzene	O
(	O
p	O
<	O
0.01	O
)	O
and	O
acrylonitrile	O
(	O
p=0.001	O
)	O
were	O
significantly	O
decreased	O
in	O
the	O
study	O
sample	O
.	O

Smokers	O
switching	O
exclusively	O
to	O
ECs	O
for	O
at	O
least	O
half	O
of	O
the	O
study	O
period	O
demonstrated	O
significant	O
reductions	O
in	O
HEMA	O
(	O
p	O
>	O
=0.03	O
)	O
and	O
AAMA	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Smokers	O
using	O
ECs	O
over	O
4-	O
weeks	O
maintained	O
cotinine	B-P
levels	I-P
and	O
experienced	O
significant	O
reductions	O
in	O
carbon	O
monoxide	O
,	O
NNAL	O
,	O
and	O
two	O
out	O
of	O
eight	O
measured	O
VOC	O
metabolites	O
.	O

Those	O
who	O
switched	O
exclusively	O
to	O
ECs	O
for	O
at	O
least	O
half	O
of	O
the	O
study	O
period	O
significantly	O
reduced	O
two	O
additional	O
VOCs	O
.	O

This	O
study	O
extends	O
current	O
literature	O
by	O
measuring	O
change	O
in	O
smoking	O
dependence	O
and	O
disease-associated	O
biomarkers	O
,	O
4-	O
(	O
methylnitrosamino	O
)	O
-1-	O
(	O
3-pyridyl	O
)	O
-1-butanol	O
(	O
NNAL	O
)	O
and	O
a	O
panel	O
of	O
eight	O
common	O
volatile	O
organic	O
compounds	O
(	O
VOCs	O
)	O
that	O
are	O
toxic	O
tobacco	O
smoke	O
constituents	O
in	O
smokers	O
who	O
switch	O
to	O
electronic	O
cigarettes	O
.	O

The	O
findings	O
support	O
the	O
idea	O
of	O
harm	O
reduction	O
,	O
however	O
some	O
levels	O
of	O
toxicant	O
exposure	O
are	O
still	O
of	O
clinical	O
concern	O
,	O
particularly	O
for	O
dual	O
users	O
.	O

Extrapolation	O
of	O
these	O
results	O
must	O
be	O
careful	O
to	O
separate	O
the	O
different	O
toxic	O
exposure	O
results	O
for	O
exclusive	O
switchers	O
versus	O
dual	O
cigarette	O
+	O
EC	O
users	O
,	O
and	O
not	O
to	O
equate	O
harm	O
reduction	O
with	O
the	O
idea	O
that	O
using	O
ECs	O
is	O
harmless	O
.	O

Systems	B-P
Based	I-P
Study	I-P
of	O
the	O
Therapeutic	O
Potential	O
of	O
Small	O
Charged	O
Molecules	O
for	O
the	O
Inhibition	O
of	O
IL-1	O
Mediated	O
Cartilage	O
Degradation	O
.	O

Inflammatory	O
cytokines	O
are	O
key	O
drivers	O
of	O
cartilage	O
degradation	O
in	O
post-traumatic	O
osteoarthritis	O
.	O

Cartilage	O
degradation	O
mediated	O
by	O
these	O
inflammatory	O
cytokines	O
has	O
been	O
extensively	O
investigated	O
using	O
in	O
vitro	O
experimental	O
systems	O
.	O

Based	O
on	O
one	O
such	O
study	O
,	O
we	O
have	O
developed	O
a	O
computational	O
model	O
to	O
quantitatively	O
assess	O
the	O
impact	O
of	O
charged	O
small	O
molecules	O
intended	O
to	O
inhibit	O
IL-1	O
mediated	O
cartilage	O
degradation	O
.	O

We	O
primarily	O
focus	O
on	O
the	O
simplest	O
possible	O
computational	O
model	O
of	O
small	O
molecular	O
interaction	O
with	O
the	O
IL-1	O
system-direct	O
binding	O
of	O
the	O
small	O
molecule	O
to	O
the	O
active	O
site	O
on	O
the	O
IL-1	O
molecule	O
itself	O
.	O

We	O
first	O
use	O
the	O
model	O
to	O
explore	O
the	O
uptake	O
and	O
release	O
kinetics	O
of	O
the	O
small	O
molecule	O
inhibitor	O
by	O
cartilage	O
tissue	O
.	O

Our	O
results	O
show	O
that	O
negatively	O
charged	O
small	O
molecules	O
are	O
excluded	O
from	O
the	O
negatively	O
charged	O
cartilage	O
tissue	O
and	O
have	O
uptake	O
kinetics	O
in	O
the	O
order	O
of	O
hours	O
.	O

In	O
contrast	O
,	O
the	O
positively	O
charged	O
small	O
molecules	O
are	O
drawn	O
into	O
the	O
cartilage	O
with	O
uptake	O
and	O
release	O
timescales	O
ranging	O
from	O
hours	O
to	O
days	O
.	O

Using	O
our	O
calibrated	O
computational	O
model	O
,	O
we	O
subsequently	O
explore	O
the	O
effect	O
of	O
small	O
molecule	O
charge	O
and	O
binding	O
constant	O
on	O
the	O
rate	O
of	O
cartilage	O
degradation	O
.	O

The	O
results	O
from	O
this	O
analysis	O
indicate	O
that	O
the	O
small	O
molecules	O
are	O
most	O
effective	O
in	O
inhibiting	O
cartilage	O
degradation	O
if	O
they	O
are	O
either	O
positively	O
charged	O
and/or	O
bind	O
strongly	O
to	O
IL-1α	O
,	O
or	O
both	O
.	O

Furthermore	O
,	O
our	O
results	O
showed	O
that	O
the	O
cartilage	O
structural	O
homeostasis	O
can	O
be	O
restored	O
by	O
the	O
small	O
molecule	O
if	O
administered	O
within	O
six	O
days	O
following	O
initial	O
tissue	O
exposure	O
to	O
IL-1α	O
.	O

We	O
finally	O
extended	O
the	O
scope	O
of	O
the	O
computational	O
model	O
by	O
simulating	O
the	O
competitive	O
inhibition	O
of	O
cartilage	O
degradation	O
by	O
the	O
small	O
molecule	O
.	O

Results	O
from	O
this	O
model	O
show	O
that	O
small	O
molecules	O
are	O
more	O
efficient	O
in	O
inhibiting	O
cartilage	O
degradation	O
by	O
binding	O
directly	O
to	O
IL-1α	O
rather	O
than	O
binding	O
to	O
IL-1α	O
receptors	O
.	O

The	O
results	O
from	O
this	O
study	O
can	O
be	O
used	O
as	O
a	O
template	O
for	O
the	O
design	O
and	O
development	O
of	O
more	O
pharmacologically	O
effective	O
osteoarthritis	O
drugs	O
,	O
and	O
to	O
investigate	O
possible	O
therapeutic	O
options	O
.	O

Gut	O
microbiome	O
alterations	O
in	O
patients	O
with	O
stage	O
4	O
hepatitis	O
C.	O
Hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
causes	O
debilitating	O
liver	O
diseases	O
,	O
which	O
may	O
progress	O
to	O
cirrhosis	O
and	O
cancer	O
,	O
and	O
claims	O
500,000	O
annual	O
lives	O
worldwide	O
.	O

While	O
HCV	O
epidemiology	O
,	O
pathophysiology	O
,	O
and	O
therapy	O
are	O
being	O
deeply	O
studied	O
,	O
rare	O
attention	O
is	O
given	O
to	O
reciprocal	O
interactions	O
between	O
HCV	O
infection	O
,	O
HCV	O
-induced	O
chronic	O
liver	O
diseases	O
,	O
and	O
the	O
human	O
gut	O
microbiome	O
.	O

As	O
Egypt	O
has	O
the	O
world	O
's	O
highest	O
prevalence	O
of	O
HCV	O
infections	O
,	O
we	O
launched	O
this	O
study	O
to	O
monitor	O
differences	O
in	O
the	O
gut	O
microbial	O
community	O
composition	O
of	O
Egyptian	O
HCV	O
patients	O
that	O
may	O
affect	O
,	O
or	O
result	O
from	O
,	O
the	O
patients	O
'	O
liver	O
state	O
.	O

To	O
this	O
end	O
,	O
we	O
analyzed	O
stool	O
samples	O
from	O
six	O
stage	O
4	O
-	O
HCV	O
patients	O
and	O
eight	O
healthy	O
individuals	O
by	O
high-throughput	B-P
16S	B-P
rRNA	I-P
gene	I-P
sequencing	I-P
using	O
Illumina	O
MiSeq	O
.	O

Overall	O
,	O
the	O
alpha-diversity	O
of	O
the	O
healthy	O
persons	O
'	O
gut	O
microbiomes	O
was	O
higher	O
than	O
those	O
of	O
the	O
HCV	O
patients	O
.	O

Whereas	O
members	O
of	O
phylum	O
Bacteroidetes	O
were	O
more	O
abundant	O
in	O
HCV	O
patients	O
,	O
healthy	O
individuals	O
had	O
higher	O
abundance	O
of	O
Firmicutes	O
,	O
Proteobacteria	O
,	O
and	O
Actinobacteria	O
.	O

Genus	O
-level	O
analysis	O
showed	O
differential	O
abundance	O
of	O
Prevotella	O
and	O
Faecalibacterium	O
(	O
higher	O
in	O
HCV	O
patients	O
)	O
vs.	O
Ruminococcus	O
and	O
Clostridium	O
(	O
healthy	O
group	O
)	O
,	O
indicating	O
that	O
the	O
higher	O
abundance	O
of	O
Bacteroidetes	O
in	O
HCV	O
patients	O
is	O
most	O
likely	O
due	O
to	O
Prevotella	O
overabundance	O
.	O

The	O
probiotic	O
genus	O
,	O
Bifidobacterium	O
,	O
was	O
only	O
observed	O
in	O
the	O
microbiotas	O
of	O
healthy	O
individuals	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
study	O
provides	O
a	O
first	O
overview	O
of	O
major	O
phyla	O
and	O
genera	O
differentiating	O
stage	O
4	O
-	O
HCV	O
patients	O
from	O
healthy	O
individuals	O
and	O
suggests	O
possible	O
microbiome	O
remodeling	O
in	O
chronic	O
hepatitis	O
C	O
,	O
possibly	O
shaped	O
by	O
bacterial	O
translocation	O
as	O
well	O
as	O
the	O
liver	O
's	O
impaired	O
role	O
in	O
digestion	O
and	O
protein	O
synthesis	O
.	O

Future	O
studies	O
will	O
investigate	O
the	O
microbiome	O
composition	O
and	O
functional	O
capabilities	O
in	O
more	O
patients	O
while	O
tracing	O
some	O
potential	O
biomarker	O
taxa	O
(	O
e.g.	O
,	O
Prevotella	O
,	O
Faecalibacterium	O
vs.	O
Bifidobacterium	O
)	O
.	O

Terahertz	B-P
identification	I-P
and	O
quantification	O
of	O
neurotransmitter	O
and	O
neurotrophy	O
mixture	O
.	O

Terahertz	B-P
spectroscopy	I-P
has	O
been	O
widely	O
used	O
for	O
investigating	O
the	O
fingerprint	B-P
spectrum	I-P
of	O
different	O
substances	O
.	O

For	O
cancerous	O
tissues	O
,	O
the	O
greatest	O
difficulty	O
is	O
the	O
absorption	O
peaks	O
of	O
various	O
substances	O
contained	O
in	O
tissues	O
overlap	O
with	O
each	O
other	O
,	O
which	O
are	O
hard	O
to	O
identify	O
and	O
quantitative	O
analyze	O
.	O

As	O
a	O
result	O
,	O
it	O
is	O
very	O
hard	O
to	O
measure	O
the	O
presence	O
of	O
cancer	O
cell	O
and	O
then	O
to	O
diagnose	O
accurately	O
.	O

In	O
this	O
paper	O
,	O
we	O
select	O
three	O
typical	O
neurotransmitters	O
(	O
γ-aminobutyric	O
acid	O
,	O
L-glutamic	O
acid	O
,	O
dopamine	O
hydrochloride	O
)	O
and	O
two	O
typical	O
metabolites	O
(	O
inositol	O
and	O
creatine	O
)	O
in	O
neurons	O
to	O
measure	O
their	O
terahertz	B-P
spectra	I-P
with	O
different	O
mixture	O
ratios	O
.	O

By	O
choosing	O
characteristic	O
absorption	O
peaks	O
,	O
removing	O
baseline	O
and	O
using	O
the	O
least	O
square	O
method	O
,	O
we	O
can	O
identify	O
the	O
components	O
and	O
proportions	O
of	O
each	O
mixture	O
,	O
where	O
the	O
goodness	O
of	O
fit	O
to	O
practical	O
situation	O
is	O
up	O
to	O
94	O
%	O
.	O

These	O
results	O
provide	O
important	O
evidences	O
for	O
identifying	O
nerve	O
substances	O
and	O
obtaining	O
exact	O
quantitative	O
analysis	O
.	O

Huge	O
retroperitoneal	O
liposarcoma	O
with	O
renal	O
involvement	O
requires	O
nephrectomy	O
:	O
A	O
case	O
report	O
and	O
literature	O
review	O
.	O

A	O
60-year-old	O
female	O
visited	O
Guihang	O
Guiyang	O
Hospital	O
(	O
Guiyang	O
,	O
China	O
)	O
.	O

She	O
presented	O
with	O
abdominal	O
pain	O
in	O
the	O
right	O
side	O
for	O
the	O
previous	O
2-months	O
,	O
with	O
a	O
touchable	O
mass	O
identified	O
for	O
the	O
previous	O
1-month	O
.	O

Computed	B-P
tomography	I-P
with	O
magnetic	B-P
resonance	I-P
imaging	I-P
revealed	O
a	O
huge	O
mass	O
in	O
the	O
right	O
abdomen	O
.	O

The	O
diagnosis	O
of	O
well-differentiated	O
retroperitoneal	O
liposarcoma	O
with	O
renal	O
involvement	O
was	O
made	O
.	O

During	O
surgery	O
,	O
the	O
tumor	O
was	O
removed	O
,	O
including	O
the	O
fatty	O
renal	O
capsule	O
;	O
however	O
,	O
the	O
kidney	O
was	O
preserved	O
.	O

It	O
is	O
currently	O
debatable	O
whether	O
resection	O
of	O
adjacent	O
organs	O
is	O
required	O
to	O
obtain	O
the	O
negative	O
margins	O
.	O

Conventional	O
viewpoints	O
advise	O
that	O
multi-organ	O
resection	O
is	O
required	O
in	O
order	O
to	O
obtain	O
the	O
negative-margin	O
.	O

However	O
,	O
even	O
if	O
an	O
R0	O
resection	O
is	O
achieved	O
,	O
the	O
local	O
recurrence	O
rate	O
remains	O
markedly	O
high	O
.	O

Additionally	O
,	O
the	O
complications	O
of	O
organ	O
resection	O
have	O
more	O
impact	O
on	O
patients	O
.	O

Radiotherapy	O
and	O
chemotherapy	O
are	O
an	O
important	O
adjuvant	O
method	O
for	O
these	O
patients	O
.	O

In	O
conclusion	O
,	O
retroperitoneal	O
liposarcoma	O
is	O
a	O
rare	O
disease	O
with	O
a	O
high	O
rate	O
of	O
recurrence	O
.	O

Complete	O
resection	O
is	O
the	O
predominant	O
treatment	O
;	O
however	O
,	O
combined	O
resection	O
of	O
adjacent	O
organs	O
must	O
be	O
considered	O
.	O

Sensitivity	O
and	O
Specificity	O
of	O
Metal	O
Ion	O
Levels	O
in	O
Predicting	O
``	O
Pseudotumors	O
``	O
due	O
to	O
Taper	O
Corrosion	O
in	O
Patients	O
With	O
Dual	O
Taper	O
Modular	O
Total	O
Hip	O
Arthroplasty	O
.	O

Currently	O
,	O
no	O
serum	O
metal	O
ion	O
threshold	O
exists	O
to	O
identify	O
adverse	O
tissue	O
reactions	O
in	O
total	O
hip	O
arthroplasty	O
(	O
THA	O
)	O
patients	O
with	O
taper	O
corrosion	O
.	O

Our	O
study	O
aims	O
to	O
investigate	O
the	O
sensitivity	O
and	O
specificity	O
of	O
serum	O
metal	O
ions	O
in	O
detecting	O
taper	O
corrosion	O
related	O
pseudotumors	O
in	O
patients	O
with	O
dual	O
taper	O
modular	O
THA	O
.	O

A	O
total	O
of	O
148	O
patients	O
with	O
dual	O
taper	O
modular	O
THA	O
were	O
investigated	O
:	O
(	O
1	O
)	O
90	O
patients	O
with	O
pseudotumors	O
detected	O
with	O
metal	B-P
artifact	I-P
reduction	I-P
sequence-magnetic	I-P
resonance	I-P
imaging	I-P
(	O
MARS-MRI	B-P
)	O
and	O
(	O
2	O
)	O
58	O
patients	O
without	O
pseudotumors	O
on	O
MARS-MRI	B-P
.	O

Receiver	O
operating	O
characteristic	O
curves	O
were	O
constructed	O
to	O
determine	O
the	O
sensitivity	O
and	O
specificity	O
using	O
different	O
metal	O
ion	O
thresholds	O
.	O

The	O
severity	O
of	O
intraoperative	O
tissue	O
damage	O
was	O
correlated	O
with	O
preoperative	O
metal	O
ion	O
levels	O
.	O

Pseudotumor	O
was	O
associated	O
with	O
higher	O
cobalt	O
(	O
5.0	O
μg/L	O
vs	O
3.7	O
μg/L	O
,	O
P	O
<	O
.01	O
)	O
and	O
Co	O
/	O
Cr	O
ratio	O
(	O
6.0	O
vs	O
3.7	O
,	O
P	O
<	O
.01	O
)	O
.	O

The	O
sensitivity	O
and	O
specificity	O
for	O
cobalt	O
level	O
of	O
2.8	O
μg/L	O
and	O
Co	O
/	O
Cr	O
ratio	O
of	O
3.8	O
in	O
detecting	O
taper	O
corrosion	O
-related	O
pseudotumors	O
on	O
MARS-MRI	B-P
was	O
88	O
%	O
and	O
32	O
%	O
and	O
70	O
%	O
and	O
50	O
%	O
,	O
respectively	O
.	O

Higher	O
intraoperative	O
tissue	O
damage	O
grades	O
demonstrated	O
significantly	O
higher	O
Co	O
/	O
Cr	O
ratios	O
(	O
8.6	O
vs	O
3.4	O
,	O
P	O
=	O
.03	O
)	O
.	O

Although	O
metal	O
ion	O
levels	O
alone	O
should	O
not	O
be	O
relied	O
on	O
as	O
the	O
sole	O
parameter	O
to	O
determine	O
revision	O
surgery	O
,	O
cobalt	O
level	O
>	O
2.8	O
μg/L	O
and	O
the	O
Co	O
/	O
Cr	O
ratio	O
>	O
3.8	O
are	O
useful	O
clinical	O
diagnostic	O
adjuncts	O
in	O
the	O
systematic	O
clinical	O
evaluation	O
for	O
taper	O
corrosion	O
-related	O
adverse	O
tissue	O
reactions	O
in	O
patients	O
with	O
dual	O
modular	O
taper	O
THA	O
.	O

Insecticidal	O
effects	O
of	O
deltamethrin	O
in	O
laboratory	O
and	O
field	O
populations	O
of	O
Culicoides	O
species	O
:	O
how	O
effective	O
are	O
host	O
-	O
contact	O
reduction	O
methods	O
in	O
India	O
?	O
.	O

Bluetongue	O
virus	O
(	O
BTV	O
)	O
is	O
transmitted	O
by	O
Culicoides	O
biting	O
midges	O
and	O
causes	O
bluetongue	O
(	O
BT	O
)	O
,	O
a	O
clinical	O
disease	O
observed	O
primarily	O
in	O
sheep	O
.	O

BT	O
has	O
a	O
detrimental	O
effect	O
on	O
subsistence	O
farmers	O
in	O
India	O
,	O
where	O
hyperendemic	O
outbreaks	O
impact	O
on	O
smallholdings	O
in	O
the	O
southern	O
states	O
of	O
the	O
country	O
.	O

In	O
this	O
study	O
,	O
we	O
establish	O
a	O
reliable	O
method	O
for	O
testing	O
the	O
toxic	O
effects	O
of	O
deltamethrin	O
on	O
Culicoides	O
and	O
then	O
compare	O
deltamethrin	O
with	O
traditional	O
control	O
methods	O
used	O
by	O
farmers	O
in	O
India	O
.	O

Effects	O
of	O
deltamethrin	O
were	O
initially	O
tested	O
using	O
a	O
colonised	O
strain	O
of	O
Culicoides	O
nubeculosus	O
Meigen	O
and	O
a	O
modified	O
World	O
Health	O
Organisation	O
exposure	B-P
assay	I-P
.	O

This	O
method	O
was	O
then	O
applied	O
to	O
field	O
populations	O
of	O
Culicoides	O
spp	O
.	O

in	O
India	O
.	O

The	O
field	O
population	O
of	O
C.	O
oxystoma	O
in	O
India	O
had	O
a	O
greater	O
LC50	O
(	O
0.012	O
±	O
0.009	O
%	O
)	O
for	O
deltamethrin	O
than	O
laboratory-reared	B-P
C.nubeculosus	O
(	O
0.0013	O
±	O
0.0002	O
%	O
)	O
.	O

Exposure	O
of	O
C.	O
nubeculosus	O
to	O
deltamethrin	O
at	O
higher	O
ambient	O
temperatures	O
resulted	O
in	O
greater	O
rates	O
of	O
knockdown	O
but	O
a	O
lower	O
mortality	O
rate	O
at	O
24	O
h	O
post-exposure	O
.	O

Behavioural	B-P
assays	I-P
with	O
C.	O
nubeculosus	O
in	O
WHO	O
tubes	O
provided	O
evidence	O
for	O
contact	O
irritancy	O
and	O
spatial	O
repellence	O
caused	O
by	O
deltamethrin	O
.	O

The	O
field	O
experiments	O
in	O
India	O
,	O
however	O
,	O
provided	O
no	O
evidence	O
for	O
repellent	O
or	O
toxic	O
effects	O
of	O
deltamethrin	O
.	O

Traditional	O
methods	O
such	O
as	O
the	O
application	O
of	O
neem	O
oil	O
and	O
burning	O
of	O
neem	O
leaves	O
also	O
provided	O
no	O
protection	O
.	O

Our	O
study	O
demonstrates	O
that	O
field	O
-collected	O
Culicoides	O
in	O
India	O
are	O
less	O
susceptible	O
to	O
deltamethrin	O
exposure	O
than	O
laboratory-bred	B-P
C.	O
nubeculosus	O
and	O
traditional	O
methods	O
of	O
insect	O
control	O
do	O
not	O
provide	O
protection	O
to	O
sheep	O
.	O

These	O
low	O
levels	O
of	O
susceptibility	O
to	O
deltamethrin	O
have	O
not	O
been	O
recorded	O
before	O
in	O
field	O
populations	O
of	O
Culicoides	O
and	O
suggest	O
resistance	O
to	O
synthetic	O
pyrethrioids	O
.	O

Alternative	O
insect	O
control	O
methods	O
,	O
in	O
addition	O
to	O
vaccination	O
,	O
may	O
be	O
needed	O
to	O
protect	O
Indian	O
livestock	O
from	O
BTV	O
transmission	O
.	O

Maternal	O
depression	O
attenuates	O
newborn	O
vitamin	O
D	O
concentrations	O
in	O
winter	O
-	O
spring	O
:	O
a	O
prospective	O
population-based	O
study	O
.	O

We	O
aimed	O
to	O
investigate	O
whether	O
the	O
newborns	O
of	O
mothers	O
with	O
maternal	O
depression	O
(	O
MD	O
)	O
had	O
lower	O
vitamin	B-P
D	I-P
levels	I-P
than	O
newborns	O
of	O
non-MD	O
(	O
NMD	O
)	O
mothers	O
and	O
identify	O
the	O
potential	O
mechanism	O
underlying	O
this	O
association	O
.	O

Maternal	O
depressive	O
symptoms	O
in	O
late	O
pregnancy	O
and	O
concentrations	O
of	O
cord	O
blood	O
25	O
hydroxyvitamin	O
D	O
(	O
25	O
(	O
OH	O
)	O
D	O
)	O
were	O
measured	O
in	O
1491	O
mother	O
-	O
infant	O
pairs	O
.	O

Data	O
on	O
maternal	O
sociodemographic	O
characteristics	O
,	O
health	O
status	O
,	O
lifestyle	O
and	O
birth	O
outcomes	O
were	O
prospectively	O
collected	O
.	O

For	O
infants	O
born	O
in	O
winter	O
-	O
spring	O
,	O
the	O
infants	O
of	O
MD	O
mothers	O
had	O
significantly	O
reduced	O
concentrations	O
of	O
25	O
(	O
OH	O
)	O
D	O
(	O
adjusted	O
β	O
=	O
-3.51	O
nmol/L	O
;	O
95	O
%	O
CI	O
:	O
-6.19	O
,	O
-0.84	O
;	O
P	O
=	O
0.010	O
)	O
and	O
lower	O
birth	O
weight	O
(	O
3267	O
±	O
470	O
g	O
vs	O
3348	O
±	O
598	O
g	O
,	O
F	O
=	O
4.64	O
,	O
P	O
=	O
0.031	O
)	O
,	O
compared	O
with	O
the	O
infants	O
of	O
NMD	O
mothers	O
.	O

A	O
significant	O
,	O
inverse	O
linear	O
relationship	O
was	O
noted	O
between	O
maternal	O
depression	O
scores	O
and	O
the	O
concentration	O
of	O
25	O
(	O
OH	O
)	O
D	O
for	O
infants	O
born	O
in	O
winter	O
-	O
spring	O
(	O
adjusted	O
β	O
=	O
-0.158	O
;	O
95	O
%	O
CI	O
:	O
-0.259	O
,	O
-0.057	O
)	O
.	O

The	O
significant	O
,	O
inverse	O
linear	O
relationship	O
between	O
maternal	O
depression	O
scores	O
and	O
fetomaternal	O
ratios	O
of	O
25	O
(	O
OH	O
)	O
D	O
was	O
also	O
observed	O
among	O
the	O
infants	O
born	O
in	O
winter	O
-	O
spring	O
(	O
adjusted	O
β	O
=	O
-0.005	O
;	O
95	O
%	O
CI	O
:	O
-0.008	O
,	O
-0.003	O
)	O
.	O

MD	O
appears	O
to	O
significantly	O
attenuate	O
the	O
vitamin	O
D	O
concentrations	O
and	O
birth	O
weight	O
of	O
infants	O
born	O
in	O
winter	O
-	O
spring	O
.	O

A	O
decreased	O
fetomaternal	O
ratio	O
of	O
25	O
(	O
OH	O
)	O
D	O
might	O
be	O
involved	O
in	O
this	O
biological	O
pathway	O
.	O

Tracking	O
the	O
relative	O
concentration	O
between	O
Bacteroidales	O
DNA	O
markers	O
and	O
culturable	B-P
Escherichia	O
coli	O
in	O
fecally	O
polluted	O
subtropical	O
seawater	O
:	O
potential	O
use	O
in	O
differentiating	O
fresh	O
and	O
aged	O
pollution	O
.	O

Routine	O
water	O
quality	O
monitoring	O
practices	O
based	O
on	O
the	O
enumeration	O
of	O
culturable	B-P
Escherichia	O
coli	O
provides	O
no	O
information	O
about	O
the	O
source	O
or	O
age	O
of	O
fecal	O
pollution	O
.	O

An	O
emerging	O
strategy	O
is	O
to	O
use	O
culturable	B-P
E.	O
coli	O
and	O
the	O
DNA	O
markers	O
of	O
Bacteroidales	O
complementarily	O
for	O
microbial	O
source	O
tracking	O
.	O

In	O
this	O
study	O
,	O
we	O
consistently	O
observed	O
in	O
seawater	O
microcosms	O
of	O
3	O
different	O
conditions	O
that	O
culturable	B-P
E.	O
coli	O
decayed	O
faster	O
(	O
T99	O
=	O
1.14	O
-	O
4.29	O
days	O
)	O
than	O
Bacteroidales	O
DNA	O
markers	O
did	O
(	O
T99	O
=	O
1.81	O
-	O
200.23	O
days	O
)	O
.	O

Concomitantly	O
,	O
the	O
relative	O
concentration	O
between	O
Bacteroidales	O
DNA	O
markers	O
and	O
culturable	B-P
E.	O
coli	O
increased	O
over	O
time	O
in	O
all	O
treatments	O
.	O

Particularly	O
,	O
the	O
increase	O
during	O
the	O
early	O
stage	O
of	O
the	O
experiments	O
(	O
before	O
T99	O
of	O
E.	O
coli	O
was	O
reached	O
)	O
was	O
faster	O
than	O
during	O
the	O
later	O
stage	O
(	O
after	O
T99	O
of	O
E.	O
coli	O
was	O
attained	O
)	O
.	O

We	O
propose	O
that	O
the	O
tracking	O
of	O
the	O
relative	O
concentration	O
between	O
Bacteroidales	O
DNA	O
markers	O
and	O
culturable	B-P
E.	O
coli	O
provides	O
an	O
opportunity	O
to	O
differentiate	O
a	O
pollution	O
that	O
is	O
relative	O
ly	O
fresh	O
from	O
one	O
that	O
has	O
aged	O
.	O

This	O
method	O
,	O
upon	O
further	O
investigation	O
and	O
validation	O
,	O
could	O
be	O
useful	O
in	O
episodic	O
pollution	O
events	O
where	O
the	O
surge	O
of	O
E.	O
coli	O
concentration	O
causes	O
noncompliance	O
to	O
the	O
single	O
sample	O
maximum	O
criterion	O
that	O
mandates	O
high	O
frequency	O
follow-up	O
monitoring	O
.	O

Epigenetic	O
Editing	O
of	O
Ascl1	O
Gene	O
in	O
Neural	O
Stem	O
Cells	O
by	O
Optogenetics	O
.	O

Enzymes	O
involved	O
in	O
epigenetic	O
processes	O
such	O
as	O
methyltransferases	O
or	O
demethylases	O
are	O
becoming	O
highly	O
utilized	O
for	O
their	O
persistent	O
DNA	O
or	O
histone	O
modifying	O
efficacy	O
.	O

Herein	O
,	O
we	O
have	O
developed	O
an	O
optogenetic	O
toolbox	O
fused	O
to	O
the	O
catalytic	O
domain	O
(	O
CD	O
)	O
of	O
DNA-methyltransferase3A	O
(	O
DNMT3A	O
-	O
CD	O
)	O
or	O
Ten-Eleven	O
Dioxygenase-1	O
(	O
TET1	O
-	O
CD	O
)	O
for	O
loci	O
-	O
specific	O
alteration	O
of	O
the	O
methylation	O
state	O
at	O
the	O
promoter	O
of	O
Ascl1	O
(	O
Mash1	O
)	O
,	O
a	O
candidate	O
proneuron	O
gene	O
.	O

Optogenetical	O
protein	O
pairs	O
,	O
CRY2	O
linked	O
to	O
DNMT3A	O
-	O
CD	O
or	O
TET1	O
-	O
CD	O
and	O
CIB1	O
fused	O
to	O
a	O
Transcription	O
Activator-Like	O
Element	O
(	O
TALE	O
)	O
locating	O
an	O
Ascl1	O
promoter	O
region	O
,	O
were	O
designed	O
for	O
site	O
specific	O
epigenetic	O
editing	O
.	O

A	O
differentially	O
methylated	O
region	O
at	O
the	O
Ascl1	O
promoter	O
,	O
isolated	O
from	O
murine	O
dorsal	O
root	O
ganglion	O
(	O
hypermethylated	O
)	O
and	O
striated	O
cells	O
(	O
hypomethylated	O
)	O
,	O
was	O
targeted	O
with	O
these	O
optogenetic-epigenetic	O
constructs	O
.	O

Optimized	O
blue-light	O
illumination	B-P
triggered	O
the	O
co-localization	O
of	O
TALE	O
constructs	O
with	O
DNMT3A	O
-	O
CD	O
or	O
TET1	O
-	O
CD	O
fusion	O
proteins	O
at	O
the	O
targeted	O
site	O
of	O
the	O
Ascl1	O
promoter	O
.	O

We	O
found	O
that	O
this	O
spatiotemporal	O
association	O
of	O
the	O
fusion	O
proteins	O
selectively	O
alters	O
the	O
methylation	O
state	O
and	O
also	O
regulates	O
gene	O
activity	O
.	O

This	O
proof	O
of	O
concept	O
developed	O
herein	O
holds	O
immense	O
promise	O
for	O
the	O
ability	O
to	O
regulate	O
gene	O
activity	O
via	O
epigenetic	O
modulation	O
with	O
spatiotemporal	O
precision	O
.	O

Structural	O
properties	O
and	O
psychometric	B-P
improvements	O
of	O
the	O
Health	O
Literacy	O
Questionnaire	O
in	O
a	O
Slovak	O
population	O
.	O

Health	O
literacy	O
is	O
an	O
important	O
determinant	O
of	O
health	O
and	O
health	O
equity	O
and	O
therefore	O
requires	O
robust	O
measurement	O
.	O

The	O
aim	O
was	O
to	O
examine	O
the	O
psychometric	B-P
properties	O
of	O
the	O
Slovak	O
version	O
of	O
the	O
Health	O
Literacy	O
Questionnaire	O
(	O
HLQ	O
)	O
including	O
revised	O
wording	O
of	O
response	O
categories	O
.	O

A	O
cross-sectional	O
survey	O
of	O
the	O
general	O
Slovak	O
adult	O
population	O
(	O
N	O
=	O
360	O
,	O
mean	O
age	O
39	O
)	O
was	O
conducted	O
with	O
the	O
HLQ	O
following	O
its	O
translation	O
and	O
cultural	O
adaptation	O
.	O

Psychometric	B-P
tests	O
(	O
confirmatory	O
factor	O
analysis	O
,	O
Cronbach	O
's	O
alpha	O
,	O
composite	O
reliability	O
)	O
and	O
association	O
(	O
linear	O
regression	O
,	O
ANOVA	O
)	O
with	O
sociodemographic	O
variables	O
were	O
undertaken	O
.	O

The	O
performance	O
of	O
alternative	O
version	O
of	O
response	O
options	O
were	O
explored	O
with	O
the	O
Mann-Whittney	O
U	O
test	O
and	O
item	O
response	O
theory	O
.	O

A	O
highly	O
restrictive	O
nine-factor	O
confirmatory	O
factor	O
analysis	O
showed	O
acceptable	O
fit	O
[	O
χ	O
(	O
2	O
)	O
WLSMV	O
=	O
1684	O
(	O
df	O
=	O
866	O
)	O
,	O
p	O
<	O
0.0001	O
;	O
CFI	O
=	O
0.943	O
,	O
TLI	O
=	O
0.938	O
,	O
RMSEA	O
=	O
0.051	O
,	O
WRMR	O
=	O
1.297	O
]	O
and	O
reliability	O
was	O
acceptable	O
(	O
range	O
0.73-0.84	O
)	O
.	O

The	O
revised	O
response	O
categories	O
had	O
a	O
better	O
distribution	O
with	O
lower	O
average	O
scores	O
in	O
three	O
domains	O
,	O
compared	O
with	O
the	O
original	O
,	O
and	O
improved	O
item	O
information	O
curves	O
.	O

The	O
nine	O
HLQ	O
scales	O
are	O
robust	O
,	O
providing	O
a	O
fine-grained	O
assessment	O
of	O
health	O
literacy	O
.	O

The	O
revised	O
response	O
options	O
improve	O
psychometric	B-P
properties	O
and	O
are	O
recommended	O
for	O
future	O
studies	O
.	O

Gleason	O
grade	O
grouping	O
of	O
prostate	O
cancer	O
is	O
of	O
prognostic	O
value	O
in	O
Asian	O
men	O
.	O

The	O
International	O
Society	O
of	O
Urological	O
Pathology	O
made	O
recommendations	O
for	O
the	O
use	O
of	O
Grade	O
Groups	O
(	O
GG	O
)	O
originally	O
described	O
by	O
Epstein	O
and	O
colleagues	O
over	O
Gleason	O
score	O
(	O
GS	O
)	O
alone	O
in	O
2014	O
,	O
which	O
was	O
subsequently	O
adopted	O
by	O
the	O
WHO	O
classification	O
in	O
2016	O
.	O

The	O
majority	O
of	O
studies	O
validating	O
this	O
revision	O
have	O
been	O
in	O
Caucasian	O
populations	O
.	O

We	O
therefore	O
asked	O
whether	O
the	O
new	O
GG	O
system	O
was	O
retrospectively	O
associated	O
with	O
biochemical	O
disease-free	O
survival	O
in	O
a	O
mixed-ethnicity	O
cohort	O
of	O
Asian	O
men	O
.	O

A	O
total	O
of	O
680	O
radical	O
prostatectomies	O
(	O
RPs	O
)	O
from	O
2005	O
to	O
2014	O
were	O
included	O
.	O

GS	O
from	O
initial	O
biopsy	B-P
and	O
RP	O
were	O
compared	O
and	O
used	O
to	O
allocate	O
cases	O
to	O
GG	O
,	O
defined	O
as	O
:	O
1	O
(	O
GS	O
≤6	O
)	O
;	O
2	O
(	O
GS	O
3+4=7	O
)	O
;	O
3	O
(	O
GS	O
4+3=7	O
)	O
;	O
4	O
(	O
GS	O
4+4=8/5+3=8/3+5=8	O
)	O
and	O
5	O
(	O
GS	O
9-10	O
)	O
.	O

Biochemical	O
recurrence	O
was	O
defined	O
as	O
two	O
consecutive	O
post-	O
RP	O
prostate-specific	O
antigen	O
(	O
PSA	O
)	O
levels	O
of	O
>	O
0.2	O
ng/mL	O
after	O
post-	O
RP	O
PSA	O
reaching	O
the	O
nadir	O
of	O
<	O
0.1	O
ng/mL	O
.	O

Our	O
data	O
showed	O
that	O
Kaplan-Meier	O
analysis	O
revealed	O
significant	O
differences	O
in	O
biochemical	O
recurrence	O
within	O
Gleason	O
GG	O
based	O
on	O
either	O
biopsy	B-P
or	O
prostatectomy	O
scoring	O
.	O

Multivariate	O
analysis	O
further	O
confirmed	O
that	O
a	O
higher	O
GG	O
was	O
significantly	O
associated	O
with	O
risk	O
of	O
biochemical	O
recurrence	O
.	O

This	O
GG	O
system	O
had	O
a	O
higher	O
prognostic	O
discrimination	O
for	O
both	O
initial	O
biopsy	B-P
and	O
RP	O
than	O
GS	O
.	O

Our	O
study	O
validates	O
the	O
use	O
of	O
the	O
revised	O
and	O
updated	O
GG	O
system	O
in	O
a	O
mixed-ethnicity	O
population	O
of	O
Asian	O
men	O
.	O

Higher	O
GG	O
was	O
significantly	O
associated	O
with	O
increased	O
risk	O
of	O
biochemical	O
recurrence	O
.	O

We	O
therefore	O
recommend	O
its	O
use	O
to	O
inform	O
clinical	O
management	O
for	O
patients	O
with	O
prostate	O
cancer	O
.	O

The	O
role	O
of	O
the	O
hippocampus	O
and	O
the	O
function	O
of	O
calcitonin	O
gene-related	O
peptide	O
in	O
the	O
mechanism	O
of	O
traumatic	O
brain	O
injury	O
accelerating	O
fracture-healing	O
.	O

This	O
research	O
attempts	O
to	O
identify	O
the	O
part	O
the	O
hippocampus	O
plays	O
in	O
accelerated	O
fracture-healing	O
after	O
traumatic	O
brain	O
injury	O
as	O
well	O
as	O
to	O
test	O
functions	O
of	O
calcitonin	O
gene-related	O
peptide	O
(	O
CGRP	O
)	O
during	O
this	O
process	O
.	O

Experiments	O
were	O
carried	O
out	O
on	O
Male	O
Sprague-Dawley	O
rats	O
that	O
were	O
split	O
into	O
four	O
groups	O
at	O
random	O
:	O
TBI	O
-	O
fracture	O
group	O
,	O
fracture	O
-	O
only	O
group	O
,	O
TBI	O
-	O
only	O
group	O
,	O
and	O
control	O
group	O
.	O

In	O
the	O
first	O
week	O
,	O
blood	O
specimen	O
would	O
be	O
drawn	O
from	O
rats	O
among	O
the	O
groups	O
except	O
those	O
of	O
the	O
control	O
group	O
at	O
three-time	O
points	O
(	O
24	O
,	O
72	O
and	O
168	O
hours	O
)	O
post	O
-	O
damage	O
.	O

These	O
rats	O
would	O
be	O
assessed	O
from	O
the	O
neurological	O
perspective	O
based	O
on	O
their	O
grades	O
of	O
performance	O
in	O
a	O
sequence	O
of	O
tests	O
24	O
hours	O
before	O
and	O
12	O
hours	O
after	O
brain	O
injury	O
.	O

Blood	B-P
samples	I-P
were	O
also	O
taken	O
from	O
the	O
control	O
group	O
24	O
hours	O
before	O
the	O
injury	O
,	O
and	O
whole	O
brain	O
tissues	O
in	O
the	O
injured	O
groups	O
were	O
harvested	O
at	O
72	O
and	O
168	O
hours	O
post	O
-	O
injury	O
.	O

We	O
compared	O
the	O
serum	O
CGRP	O
concentration	O
,	O
the	O
distribution	O
of	O
CGRP	O
,	O
the	O
CGRP	O
expression	O
,	O
and	O
the	O
expression	O
of	O
CGRP	O
in	O
the	O
hippocampus	O
,	O
the	O
expression	O
of	O
CGRP	O
in	O
the	O
hippocampus	O
,	O
the	O
expression	O
of	O
CGRP	O
in	O
the	O
hippocampus	O
,	O
and	O
the	O
expression	O
of	O
CGRP	O
in	O
the	O
brain	O
by	O
immunohistochemistry	B-P
,	O
Western	B-P
blotting	I-P
,	O
RT	O
-	O
Of	O
CGRP	O
RNA	O
expression	O
levels	O
.	O

Neurological	B-P
examinations	I-P
suggested	O
that	O
the	O
functions	O
of	O
the	O
cerebral	O
cortex	O
,	O
cerebellum	O
,	O
and	O
brain	O
stem	O
showed	O
significant	O
differences	O
pre	O
-	O
and	O
post	O
-	O
injury	O
(	O
p	O
<	O
0.001	O
)	O
.	O

ELISA	B-P
analysis	I-P
indicated	O
a	O
great	O
density	O
of	O
CGRP	O
in	O
TBI	O
-	O
fracture	O
group	O
at	O
different	O
time	O
points	O
.	O

Furthermore	O
,	O
in	O
the	O
TBI	O
-	O
fracture	O
group	O
,	O
CGRP	O
in	O
both	O
hippocampus	O
and	O
the	O
whole	O
brain	O
showed	O
a	O
noticeable	O
augment	O
in	O
RT-PCR	O
and	O
western	B-P
blot	I-P
analysis	I-P
at	O
72	O
and	O
168	O
h	O
post	O
-	O
injury	O
,	O
and	O
only	O
in	O
this	O
group	O
,	O
immunohistochemistry	B-P
analysis	I-P
indicated	O
that	O
CGRP	O
was	O
present	O
in	O
the	O
hippocampus	O
at	O
168	O
hours	O
post	O
-	O
injury	O
.	O

We	O
observed	O
that	O
the	O
hippocampus	O
and	O
CGRP	O
were	O
responsible	O
for	O
quick	O
bone-healing	O
mechanisms	O
.	O

We	O
suggest	O
a	O
role	O
for	O
the	O
hippocampus	O
in	O
accelerated	O
fracture	O
healing	O
.	O

CGRP	O
expression	O
,	O
as	O
determined	O
by	O
IHC	B-P
,	O
can	O
not	O
be	O
observed	O
in	O
other	O
groups	O
,	O
indicating	O
that	O
the	O
hippocampus	O
may	O
be	O
the	O
specific	O
component	O
of	O
the	O
brain	O
that	O
responds	O
to	O
``	O
big	O
stress	O
``	O
.	O

Combinatorial	O
Library	O
Screening	O
Coupled	O
to	O
Mass	B-P
Spectrometry	I-P
to	O
Identify	O
Valuable	O
Cyclic	O
Peptides	O
.	O

Combinatorial	O
library	O
screening	O
coupled	O
to	O
mass	B-P
spectrometry	I-P
(	I-P
MS	I-P
)	I-P
analysis	I-P
is	O
a	O
practical	O
approach	O
to	O
identify	O
useful	O
peptides	O
.	O

Cyclic	O
peptides	O
can	O
have	O
high	O
biological	O
activity	O
,	O
selectivity	O
,	O
and	O
affinity	O
for	O
target	O
proteins	O
,	O
and	O
high	O
stability	O
against	O
proteolytic	O
degradation	O
.	O

Here	O
we	O
describe	O
two	O
strategies	O
to	O
prepare	O
combinatorial	O
libraries	O
suitable	O
for	O
MS	B-P
analysis	I-P
to	O
accelerate	O
the	O
discovery	O
of	O
cyclic	O
peptide	O
structures	O
.	O

Both	O
approaches	O
use	O
ChemMatrix	O
resin	O
and	O
the	O
linker	O
4-hydroxymethylbenzoic	O
acid	O
.	O

One	O
strategy	O
involves	O
the	O
synthesis	O
of	O
a	O
one-bead-two-peptides	O
library	O
in	O
which	O
each	O
bead	O
contains	O
both	O
the	O
cyclic	O
peptide	O
and	O
its	O
linear	O
counterpart	O
to	O
facilitate	O
MS	B-P
analysis	I-P
.	O

The	O
other	O
protocol	O
is	O
based	O
on	O
the	O
synthesis	O
of	O
a	O
cyclic	O
depsipeptide	O
library	O
in	O
which	O
a	O
glycolamidic	O
ester	O
group	O
is	O
incorporated	O
by	O
adding	O
glycolic	O
acid	O
.	O

After	O
library	O
screening	O
,	O
the	O
ring	O
is	O
opened	O
and	O
the	O
peptide	O
is	O
released	O
simultaneously	O
for	O
subsequent	O
MS	B-P
analysis	I-P
.	O

©	O
2016	O
by	O
John	O
Wiley	O
&	O
Sons	O
,	O
Inc	O
.	O

Evaluation	O
of	O
the	O
Condom	O
Barriers	O
Scale	O
for	O
Young	O
Black	O
Men	O
Who	O
Have	O
Sex	O
With	O
Men	O
:	O
Reliability	O
and	O
Validity	O
of	O
3	O
Subscales	O
.	O

Reliable	O
and	O
valid	O
scale	O
measures	O
of	O
barriers	O
to	O
condom	O
use	O
are	O
not	O
available	O
for	O
young	O
black	O
men	O
who	O
have	O
sex	O
with	O
men	O
(	O
YBMSM	O
)	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
Condom	O
Barriers	O
Scales	O
for	O
application	O
with	O
YBMSM	O
.	O

A	O
clinic-based	O
sample	O
of	O
600	O
YBMSM	O
completed	O
a	O
computer-assisted	B-P
self-interview	O
.	O

The	O
primary	O
measure	O
was	O
a	O
14-item	O
abbreviated	O
version	O
of	O
the	O
Condom	O
Barriers	O
Scale	O
.	O

Reliability	O
and	O
criterion	O
validity	O
were	O
assessed	O
.	O

All	O
3	O
subscales	O
were	O
reliable	O
:	O
partner	O
-related	O
barriers	O
(	O
Cronbach	O
α	O
=0.73	O
)	O
,	O
sensation	O
-related	O
barriers	O
(	O
α=0.70	O
)	O
,	O
and	O
motivation	O
-related	O
barriers	O
(	O
α	O
=0.81	O
)	O
.	O

A	O
complete	O
absence	O
of	O
barriers	O
was	O
common	O
:	O
47.0	O
%	O
(	O
partner	O
-related	O
)	O
,	O
30.7	O
%	O
(	O
sensation	O
-related	O
)	O
,	O
and	O
46.5	O
%	O
(	O
motivation	O
-related	O
)	O
.	O

Dichotomized	O
subscales	O
were	O
significantly	O
associated	O
with	O
reporting	O
any	O
condomless	O
insertive	O
anal	O
sex	O
(	O
all	O
Ps	O
<	O
0.001	O
)	O
and	O
any	O
condomless	O
receptive	O
anal	O
sex	O
(	O
all	O
Ps	O
<	O
0.001	O
)	O
.	O

The	O
subscales	O
were	O
significantly	O
associated	O
with	O
these	O
measures	O
of	O
condomless	O
sex	O
preserved	O
at	O
a	O
continuous	O
level	O
(	O
all	O
Ps	O
<	O
0.001	O
,	O
except	O
for	O
sensation	O
barriers	O
associated	O
with	O
condomless	O
receptive	O
anal	O
sex	O
=	O
0.03	O
)	O
.	O

Further	O
,	O
the	O
subscales	O
were	O
significantly	O
associated	O
with	O
reporting	O
any	O
condom	O
use	O
problems	O
(	O
all	O
Ps	O
<	O
0.001	O
)	O
and	O
a	O
measure	O
of	O
condomless	O
oral	O
sex	O
(	O
all	O
Ps	O
<	O
0.001	O
,	O
except	O
for	O
partner	O
-related	O
barriers	O
=0.31	O
)	O
.	O

Finally	O
,	O
the	O
sensation	O
-related	O
barriers	O
subscale	O
was	O
significantly	O
associated	O
with	O
testing	O
positive	O
for	O
Chlamydia	O
and/or	O
gonorrhea	O
(	O
P=0.049	O
)	O
.	O

The	O
3	O
identified	O
subscales	O
yielded	O
adequate	O
reliability	O
and	O
strong	O
evidence	O
of	O
validity	O
,	O
thereby	O
suggesting	O
the	O
utility	O
of	O
these	O
brief	O
measures	O
for	O
use	O
in	O
observational	O
and	O
experimental	O
research	O
with	O
YBMSM	O
.	O

Abnormal	O
metabolic	O
brain	O
network	O
associated	O
with	O
Parkinson	O
's	O
disease	O
:	O
replication	O
on	O
a	O
new	O
European	O
sample	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
specific	O
metabolic	O
brain	O
pattern	O
characteristic	O
for	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
:	O
Parkinson	O
's	O
disease-related	O
pattern	O
(	O
PDRP	O
)	O
,	O
using	O
network	O
analysis	O
of	O
[	B-P
18F	I-P
]	I-P
-fluorodeoxyglucose	I-P
positron	I-P
emission	I-P
tomography	I-P
(	O
FDG-PET	B-P
)	O
brain	O
images	O
in	O
a	O
cohort	O
of	O
Slovenian	O
PD	O
patients	O
.	O

Twenty	O
PD	O
patients	O
(	O
age	O
70.1	O
±	O
7.8	O
years	O
,	O
Movement	O
Disorder	O
Society	O
Unified	O
Parkinson	O
's	O
Disease	O
Motor	O
Rating	O
Scale	O
(	O
MDS-UPDRS-III	O
)	O
38.3	O
±	O
12.2	O
;	O
disease	O
duration	O
4.3	O
±	O
4.1	O
years	O
)	O
and	O
20	O
age	O
-	O
matched	O
normal	O
controls	O
(	O
NCs	O
)	O
underwent	O
FDG-PET	B-P
brain	B-P
imaging	I-P
.	O

An	O
automatic	O
voxel-based	O
scaled	O
subprofile	O
model	O
/	O
principal	O
component	O
analysis	O
(	O
SSM	O
/	O
PCA	O
)	O
was	O
applied	O
to	O
these	O
scans	B-P
for	O
PDRP	O
-	O
Slovenia	O
identification	O
.	O

The	O
pattern	O
was	O
characterized	O
by	O
relative	O
hypermetabolism	O
in	O
pallidum	O
,	O
putamen	O
,	O
thalamus	O
,	O
brain	O
stem	O
,	O
and	O
cerebellum	O
associated	O
with	O
hypometabolism	O
in	O
sensorimotor	O
cortex	O
,	O
posterior	O
parietal	O
,	O
occipital	O
,	O
and	O
frontal	O
cortices	O
.	O

The	O
expression	O
of	O
PDRP	O
-	O
Slovenia	O
discriminated	O
PD	O
patients	O
from	O
NCs	O
(	O
p	O
<	O
0.0001	O
)	O
and	O
correlated	O
positively	O
with	O
patients	O
'	O
clinical	O
score	O
(	O
MDS-UPDRS-III	O
,	O
p	O
=	O
0.03	O
)	O
.	O

Additionally	O
,	O
its	O
topography	O
agrees	O
well	O
with	O
the	O
original	O
PDRP	O
(	O
p	O
<	O
0.001	O
)	O
identified	O
in	O
American	O
cohort	O
of	O
PD	O
patients	O
.	O

We	O
validated	O
the	O
PDRP	O
-	O
Slovenia	O
expression	O
on	O
additional	O
FDG-PET	B-P
scans	B-P
of	O
20	O
PD	O
patients	O
,	O
20	O
NCs	O
,	O
and	O
25	O
patients	O
with	O
atypical	O
parkinsonism	O
(	O
AP	O
)	O
.	O

We	O
confirmed	O
that	O
the	O
expression	O
of	O
PDRP	O
-	O
Slovenia	O
manifests	O
good	O
diagnostic	O
accuracy	O
with	O
specificity	O
and	O
sensitivity	O
of	O
85-90	O
%	O
at	O
optimal	O
pattern	O
expression	O
cutoff	O
for	O
discrimination	O
of	O
PD	O
patients	O
and	O
NCs	O
and	O
is	O
not	O
expressed	O
in	O
AP	O
.	O

PDRP	O
-	O
Slovenia	O
proves	O
to	O
be	O
a	O
robust	O
and	O
reproducible	O
functional	B-P
imaging	I-P
biomarker	O
independent	O
of	O
patient	O
population	O
.	O

It	O
accurately	O
differentiates	O
PD	O
patients	O
from	O
NCs	O
and	O
AP	O
and	O
correlates	O
well	O
with	O
the	O
clinical	O
measure	O
of	O
PD	O
progression	O
.	O

Ultrasonographic	B-P
Assessment	I-P
of	O
the	O
Flexor	O
Pollicis	O
Longus	O
Tendon	O
After	O
Plate	O
Fixation	O
.	O

Rupture	O
of	O
the	O
flexor	O
pollicis	O
longus	O
tendon	O
is	O
a	O
major	O
complication	O
after	O
volar	O
locking	O
plate	O
fixation	O
of	O
distal	O
radius	O
fracture	O
.	O

This	O
study	O
used	O
ultrasonography	B-P
to	O
assess	O
the	O
flexor	O
pollicis	O
longus	O
tendon	O
and	O
intermediate	O
tissue	O
.	O

The	O
study	O
assessed	O
27	O
patients	O
(	O
28	O
wrists	O
)	O
who	O
underwent	O
removal	O
of	O
the	O
volar	O
locking	O
plate	O
.	O

Before	O
plate	O
removal	O
,	O
radiography	B-P
and	O
ultrasonography	B-P
were	O
performed	O
to	O
assess	O
the	O
relation	O
between	O
the	O
flexor	O
pollicis	O
longus	O
tendon	O
and	O
the	O
volar	O
locking	O
plate	O
.	O

Intraoperatively	O
,	O
the	O
authors	O
evaluated	O
the	O
intermediate	O
tissues	O
between	O
the	O
flexor	O
pollicis	O
longus	O
tendon	O
and	O
the	O
distal	O
volar	O
margin	O
of	O
the	O
plate	O
.	O

Preoperative	O
and	O
intraoperative	O
findings	O
were	O
compared	O
.	O

Intraoperative	O
findings	O
were	O
strongly	O
related	O
to	O
the	O
distance	O
between	O
the	O
flexor	O
pollicis	O
longus	O
tendon	O
and	O
the	O
volar	O
locking	O
plate	O
on	O
ultrasonography	B-P
.	O

The	O
sensitivity	O
of	O
ultrasonography	B-P
in	O
detecting	O
thin	O
,	O
membrane-like	O
intermediate	O
tissue	O
through	O
which	O
the	O
plate	O
was	O
visible	O
was	O
95	O
%	O
,	O
and	O
the	O
specificity	O
was	O
89	O
%	O
if	O
the	O
distance	O
between	O
the	O
flexor	O
pollicis	O
longus	O
tendon	O
and	O
the	O
plate	O
was	O
less	O
than	O
0.7	O
mm	O
.	O

Compression	O
of	O
the	O
flexor	O
pollicis	O
longus	O
tendon	O
was	O
seen	O
in	O
11	O
cases	O
(	O
39.3	O
%	O
)	O
,	O
and	O
this	O
finding	O
suggested	O
the	O
presence	O
of	O
thin	O
,	O
membrane-like	O
intermediate	O
tissue	O
.	O

The	O
study	O
results	O
showed	O
that	O
ultrasonography	B-P
could	O
be	O
used	O
to	O
identify	O
the	O
type	O
of	O
intermediate	O
tissue	O
between	O
the	O
flexor	O
pollicis	O
longus	O
tendon	O
and	O
the	O
volar	O
locking	O
plate	O
.	O

[	O
Orthopedics	O
.	O

2017	O
;	O
40	O
(	O
1	O
)	O
:	O
e104-e108	O
.	O

]	O
.	O

CD44	O
positive	O
/	O
CD24	O
negative	O
(	O
stem	O
cell	O
like	O
property	O
)	O
breast	O
carcinoma	O
cells	O
as	O
marker	O
of	O
tumor	O
aggression	O
.	O

Cells	O
with	O
stem	O
cell	O
like	O
properties	O
in	O
solid	O
organ	O
malignancies	O
like	O
breast	O
and	O
pancreas	O
have	O
been	O
studied	O
over	O
the	O
last	O
decade	O
and	O
have	O
been	O
found	O
to	O
be	O
associated	O
with	O
poor	O
prognosis	O
.	O

Presence	O
of	O
CD44	O
positive	O
and	O
CD24	O
negative	O
tumor	O
cells	O
in	O
breast	O
carcinoma	O
(	O
cells	O
with	O
'	O
stem	O
cell	O
'	O
like	O
property	O
)	O
as	O
marker	O
of	O
aggressiveness	O
and	O
poor	O
prognosis	O
was	O
checked	O
for	O
association	O
with	O
various	O
markers	O
of	O
disease	O
aggression	O
like	O
age	O
at	O
presentation	O
,	O
size	O
of	O
tumor	O
,	O
histological	O
grade	O
of	O
tumor	O
,	O
triple	O
negative	O
status	O
,	O
level	O
of	O
micro-vessel	O
density	O
,	O
and	O
nodal	O
status	O
.	O

Single	B-P
and	I-P
double	I-P
staining	I-P
immunohistochemistry	I-P
protocol	I-P
was	O
used	O
for	O
CD24	O
and	O
CD44	O
staining	B-P
.	O

The	O
staining	B-P
protocol	I-P
was	O
repeated	O
with	O
more	O
contemporary	O
techniques	O
using	O
fluorescent	O
chromogen	O
also	O
.	O

52	O
cases	O
,	O
all	O
females	O
who	O
underwent	O
modified	O
radical	O
mastectomy	O
at	O
a	O
tertiary	O
care	O
hospital	O
over	O
a	O
period	O
of	O
3	O
years	O
,	O
were	O
evaluated	O
.	O

No	O
association	O
was	O
found	O
between	O
presence	O
of	O
stem	O
cells	O
and	O
size	O
of	O
lesion	O
,	O
histological	O
grade	O
,	O
triple	O
negative	O
status	O
or	O
micro-vessel	O
density	O
.	O

However	O
,	O
significant	O
association	O
was	O
found	O
with	O
respect	O
to	O
younger	O
age	O
of	O
presentation	O
(	O
p	O
value	O
=	O
0.044	O
)	O
.	O

20	O
out	O
of	O
25	O
cases	O
with	O
nodal	O
metastasis	O
were	O
positive	O
for	O
presence	O
of	O
stem	O
cells	O
(	O
p	O
value	O
is	O
0.0003	O
)	O
.	O

Further	O
,	O
18	O
of	O
these	O
20	O
cases	O
also	O
had	O
stem	O
cells	O
in	O
the	O
metastatic	O
nodule	O
.	O

Fluorescent	O
chromogens	O
(	O
FITC	O
and	O
Cyanine	O
Red	O
)	O
revealed	O
similar	O
results	O
.	O

Cases	O
positive	O
for	O
stem	O
cells	O
showed	O
earlier	O
onset	O
of	O
disease	O
and	O
proneness	O
to	O
nodal	O
metastasis	O
.	O

Impact	O
of	O
Soil	O
Salinity	O
on	O
the	O
Structure	O
of	O
the	O
Bacterial	O
Endophytic	O
Community	O
Identified	O
from	O
the	O
Roots	O
of	O
Caliph	O
Medic	O
(	O
Medicago	O
truncatula	O
)	O
.	O

In	O
addition	O
to	O
being	O
a	O
forage	O
crop	O
,	O
Caliph	O
medic	O
(	O
Medicago	O
truncatula	O
)	O
is	O
also	O
a	O
model	O
legume	O
plant	O
and	O
is	O
used	O
for	O
research	O
focusing	O
on	O
the	O
molecular	O
characterization	O
of	O
the	O
interaction	O
between	O
rhizobia	O
and	O
plants	O
.	O

However	O
,	O
the	O
endophytic	O
microbiome	O
in	O
this	O
plant	O
is	O
poorly	O
defined	O
.	O

Endophytic	O
bacteria	O
play	O
a	O
role	O
in	O
supplying	O
plants	O
with	O
the	O
basic	O
requirements	O
necessary	O
for	O
growth	O
and	O
development	O
.	O

Moreover	O
,	O
these	O
bacteria	O
also	O
play	O
a	O
role	O
in	O
the	O
mechanism	O
of	O
salinity	O
stress	O
adaptation	O
in	O
plants	O
.	O

As	O
a	O
prelude	O
to	O
the	O
isolation	B-P
and	O
utilization	O
of	O
these	O
bacteria	O
in	O
Caliph	O
medic	O
farming	O
,	O
41	O
bacterial	O
OTUs	O
were	O
identified	O
in	O
this	O
project	O
from	O
within	O
the	O
interior	O
of	O
the	O
roots	O
of	O
this	O
plant	O
by	O
pyrosequencing	B-P
of	O
the	O
small	O
ribosomal	O
subunit	O
gene	O
(	O
16S	O
rDNA	O
)	O
using	O
a	O
cultivation-independent	B-P
approach	I-P
.	O

In	O
addition	O
,	O
the	O
differential	O
abundance	O
of	O
these	O
bacteria	O
was	O
studied	O
following	O
exposure	O
of	O
the	O
plants	O
to	O
salinity	O
stress	O
.	O

About	O
29,064	O
high-quality	O
reads	O
were	O
obtained	O
from	O
the	O
sequencing	B-P
of	O
six	O
libraries	O
prepared	O
from	O
control	O
and	O
salinity-treated	O
tissues	O
.	O

Statistical	O
analysis	O
revealed	O
that	O
the	O
abundance	O
of	O
~70	O
%	O
of	O
the	O
OTUs	O
was	O
significantly	O
(	O
p	O
≤	O
0.05	O
)	O
altered	O
in	O
roots	O
that	O
were	O
exposed	O
to	O
salinity	O
stress	O
.	O

Sequence	O
analysis	O
showed	O
a	O
similarity	O
between	O
some	O
of	O
the	O
identified	O
species	O
and	O
other	O
,	O
known	O
,	O
growth-promoting	O
bacteria	O
,	O
marine	O
and	O
salt-stressed	O
soil-borne	O
bacteria	O
,	O
and	O
nitrogen-fixing	O
bacterial	O
isolates	O
.	O

Determination	O
of	O
the	O
amendments	O
to	O
the	O
bacteria	O
l	O
community	O
due	O
to	O
salinity	O
stress	O
in	O
Caliph	O
medic	O
provides	O
a	O
crucial	O
step	O
toward	O
developing	O
an	O
understanding	O
of	O
the	O
association	O
of	O
these	O
endophytes	O
,	O
under	O
salt	O
stress	O
conditions	O
,	O
in	O
this	O
model	O
plant	O
.	O

To	O
provide	O
direct	O
evidence	O
regarding	O
their	O
growth	O
promoting	O
activity	O
,	O
a	O
group	O
of	O
endophytic	O
bacteria	O
were	O
isolated	O
from	O
inside	O
of	O
plant	O
roots	O
using	O
a	O
cultivation-dependent	B-P
approach	I-P
.	O

Several	O
of	O
these	O
isolates	O
were	O
able	O
to	O
produce	O
ACC-deaminase	O
,	O
ammonia	O
and	O
IAA	O
;	O
and	O
to	O
solubilize	O
Zn+2	O
and	O
PO4-3	O
.	O

This	O
data	O
is	O
consistent	O
with	O
the	O
predicted	O
occurrence	O
(	O
based	O
on	O
cultivation-independent	B-P
techniques	I-P
)	O
of	O
these	O
bacteria	O
and	O
provides	O
some	O
insight	O
into	O
the	O
importance	O
of	O
the	O
endophytic	O
bacteria	O
in	O
Caliph	O
medic	O
when	O
grown	O
under	O
normal	O
and	O
saline	O
conditions	O
.	O

Neoadjuvant	O
Chemotherapy	O
of	O
Ovarian	O
Cancer	O
Results	O
in	O
Three	O
Patterns	O
of	O
Tumor-Infiltrating	O
Lymphocyte	O
Response	O
with	O
Distinct	O
Implications	O
for	O
Immunotherapy	O
.	O

Purpose	O
:	O
Some	O
forms	O
of	O
chemotherapy	O
can	O
enhance	O
antitumor	O
immunity	O
through	O
immunogenic	O
cell	O
death	O
,	O
resulting	O
in	O
increased	O
T-cell	O
activation	O
and	O
tumor	O
infiltration	O
.	O

Such	O
effects	O
could	O
potentially	O
sensitize	O
tumors	O
to	O
immunotherapies	O
,	O
including	O
checkpoint	O
blockade	O
.	O

We	O
investigated	O
whether	O
platinum	O
-	O
and	O
taxane	O
-based	O
chemotherapy	O
for	O
ovarian	O
cancer	O
induces	O
immunologic	O
changes	O
consistent	O
with	O
this	O
possibility	O
.	O

Experimental	O
Design	O
:	O
Matched	O
pre	O
-	O
and	O
post	O
-	O
neoadjuvant	O
chemotherapy	O
tumor	O
samples	O
from	O
26	O
high-grade	O
serous	O
carcinoma	O
(	O
HGSC	O
)	O
patients	O
were	O
analyzed	O
by	O
immunohistochemistry	B-P
(	O
IHC	B-P
)	O
for	O
a	O
large	O
panel	O
of	O
immune	O
cells	O
and	O
associated	O
factors	O
.	O

The	O
prognostic	O
significance	O
of	O
post	O
-	O
chemotherapy	O
TIL	O
patterns	O
was	O
assessed	O
in	O
an	O
expanded	O
cohort	O
(	O
n	O
=	O
90	O
)	O
.Results	O
:	O
Neoadjuvant	O
chemotherapy	O
was	O
associated	O
with	O
increased	O
densities	O
of	O
CD3	O
(	O
+	O
)	O
,	O
CD8	O
(	O
+	O
)	O
,	O
CD8	O
(	O
+	O
)	O
TIA-1	O
(	O
+	O
)	O
,	O
PD-1	O
(	O
+	O
)	O
and	O
CD20	O
(	O
+	O
)	O
TIL	O
.	O

Other	O
immune	O
subsets	O
and	O
factors	O
were	O
unchanged	O
,	O
including	O
CD79a	O
(	O
+	O
)	O
CD138	O
(	O
+	O
)	O
plasma	O
cells	O
,	O
CD68	O
(	O
+	O
)	O
macrophages	O
,	O
and	O
MHC	O
class	O
I	O
on	O
tumor	O
cells	O
.	O

Immunosuppressive	O
cell	O
types	O
were	O
also	O
unchanged	O
,	O
including	O
FoxP3	O
(	O
+	O
)	O
PD-1	O
(	O
+	O
)	O
cells	O
(	O
putative	O
regulatory	O
T	O
cells	O
)	O
,	O
IDO-1	O
(	O
+	O
)	O
cells	O
,	O
and	O
PD-L1	O
(	O
+	O
)	O
cells	O
(	O
both	O
macrophages	O
and	O
tumor	O
cells	O
)	O
.	O

Hierarchical	O
clustering	O
revealed	O
three	O
response	O
patterns	O
:	O
(	O
i	O
)	O
TIL	O
(	O
high	O
)	O
tumors	O
showed	O
increases	O
in	O
multiple	O
immune	O
markers	O
after	O
chemotherapy	O
;	O
(	O
ii	O
)	O
TIL	O
(	O
low	O
)	O
tumors	O
underwent	O
similar	O
increases	O
,	O
achieving	O
patterns	O
indistinguishable	O
from	O
the	O
first	O
group	O
;	O
and	O
(	O
iii	O
)	O
TIL	O
(	O
negative	O
)	O
cases	O
generally	O
remained	O
negative	O
.	O

Despite	O
the	O
dramatic	O
increases	O
seen	O
in	O
the	O
first	O
two	O
patterns	O
,	O
post-	O
chemotherapy	O
TIL	O
showed	O
limited	O
prognostic	O
significance.Conclusions	O
:	O
Chemotherapy	O
augments	O
pre-existing	O
TIL	O
responses	O
but	O
fails	O
to	O
relieve	O
major	O
immune-suppressive	O
mechanisms	O
or	O
confer	O
significant	O
prognostic	O
benefit	O
.	O

Our	O
findings	O
provide	O
rationale	O
for	O
multipronged	O
approaches	O
to	O
immunotherapy	O
tailored	O
to	O
the	O
baseline	O
features	O
of	O
the	O
tumor	O
microenvironment	O
.	O

Clin	O
Cancer	O
Res	O
;	O
23	O
(	O
4	O
)	O
;	O
925-34	O
.	O

©2016	O
AACR	O
.	O

Fluid-Attenuated	B-P
Inversion	I-P
Recovery	I-P
Hyperintensity	O
Is	O
Associated	O
with	O
Hemorrhagic	O
Transformation	O
following	O
Reperfusion	O
Therapy	O
.	O

It	O
is	O
still	O
controversial	O
whether	O
early	O
fluid-attenuated	B-P
inversion	I-P
recovery	I-P
(	O
FLAIR	B-P
)	O
hyperintensity	O
within	O
acute	O
ischemic	O
lesions	O
carries	O
the	O
risk	O
of	O
hemorrhagic	O
transformation	O
(	O
HT	O
)	O
after	O
reperfusion	O
therapy	O
.	O

Furthermore	O
,	O
the	O
association	O
between	O
the	O
location	O
of	O
FLAIR	B-P
hyperintensity	O
and	O
HT	O
has	O
not	O
been	O
investigated	O
.	O

We	O
retrospectively	O
reviewed	O
patients	O
who	O
underwent	O
reperfusion	O
therapy	O
within	O
6	O
hours	O
of	O
stroke	O
onset	O
and	O
magnetic	B-P
resonance	I-P
imaging	I-P
including	O
a	O
FLAIR	B-P
sequence	O
before	O
completing	O
reperfusion	O
therapy	O
.	O

FLAIR	B-P
hyperintensity	O
within	O
the	O
diffusion-weighted	B-P
imaging	I-P
(	O
DWI	B-P
)	O
lesion	O
was	O
rated	O
qualitatively	O
,	O
and	O
HT	O
was	O
assessed	O
on	O
follow-up	O
gradient	O
echo	B-P
imaging	I-P
.	O

The	O
location	O
of	O
the	O
FLAIR	B-P
change	O
and	O
HT	O
was	O
classified	O
as	O
subcortical	O
,	O
cortical	O
,	O
or	O
cortico-subcortical	O
.	O

Of	O
134	O
patients	O
with	O
acute	O
ischemic	O
stroke	O
included	O
in	O
this	O
study	O
,	O
early	O
FLAIR	B-P
changes	O
within	O
DWI	B-P
lesions	O
were	O
identified	O
in	O
56	O
(	O
41.8	O
%	O
)	O
patients	O
,	O
and	O
HT	O
was	O
noted	O
in	O
51	O
(	O
38.1	O
%	O
)	O
patients	O
.	O

FLAIR	B-P
change	O
was	O
independently	O
associated	O
with	O
HT	O
(	O
odds	O
ratio	O
:	O
4.37	O
,	O
95	O
%	O
confidence	O
interval	O
:	O
1.72-11.12	O
)	O
.	O

Geographically	O
,	O
48.2	O
%	O
of	O
the	O
patients	O
with	O
a	O
FLAIR	B-P
change	O
developed	O
a	O
matched	O
HT	O
(	O
restricted	O
to	O
the	O
region	O
with	O
the	O
FLAIR	B-P
change	O
)	O
,	O
and	O
the	O
risk	O
of	O
HT	O
was	O
further	O
increased	O
in	O
patients	O
with	O
a	O
FLAIR	B-P
change	O
in	O
the	O
cortico-subcortical	O
region	O
(	O
68.8	O
%	O
)	O
.	O

In	O
patients	O
in	O
the	O
acute	O
stage	O
of	O
stroke	O
,	O
an	O
early	O
FLAIR	B-P
change	O
is	O
associated	O
with	O
the	O
risk	O
of	O
HT	O
following	O
reperfusion	O
therapy	O
with	O
a	O
highly	O
matched	O
geographic	O
relationship	O
and	O
common	O
risk	O
factors	O
.	O

Thus	O
,	O
identification	O
of	O
FLAIR	B-P
change	O
may	O
be	O
a	O
useful	O
surrogate	O
marker	O
to	O
assess	O
the	O
likelihood	O
of	O
subsequent	O
HT	O
in	O
patients	O
treated	O
with	O
reperfusion	O
therapy	O
.	O

Complex	O
patterns	O
of	O
multiple	O
biomineralization	O
in	O
single-celled	O
plant	O
trichomes	O
of	O
the	O
Loasaceae	O
.	O

Plants	O
of	O
the	O
family	O
Loasaceae	O
are	O
characterized	O
by	O
a	O
usually	O
dense	O
indument	O
of	O
various	O
trichome	O
types	O
,	O
including	O
two	O
basically	O
different	O
types	O
of	O
mineralized	O
,	O
unicellular	O
trichomes	O
(	O
stinging	O
hairs	O
or	O
setae	O
and	O
scabrid-glochidiate	O
trichomes	O
)	O
.	O

Mineralized	O
trichomes	O
have	O
long	O
been	O
known	O
to	O
have	O
silicified	O
or	O
calcified	O
walls	O
,	O
but	O
recent	O
studies	O
demonstrated	O
that	O
trichomes	O
of	O
Loasaceae	O
may	O
also	O
contain	O
calcium	O
phosphate	O
.	O

The	O
current	O
study	O
investigates	O
the	O
distribution	O
of	O
different	O
biominerals	O
in	O
the	O
mineralized	O
trichomes	O
across	O
several	O
different	O
taxa	O
.	O

Plants	O
from	O
cultivation	O
were	O
studied	O
with	O
scanning	B-P
electron	I-P
microscopy	I-P
including	O
energy	B-P
dispersive	I-P
x-ray	I-P
analyses	I-P
and	O
element	O
mapping	O
.	O

The	O
vast	O
majority	O
of	O
the	O
31	O
species	O
investigated	O
had	O
at	O
least	O
two	O
different	O
biominerals	O
in	O
their	O
trichomes	O
,	O
and	O
22	O
had	O
three	O
different	O
biominerals	O
in	O
their	O
trichomes	O
.	O

Thirty	O
of	O
the	O
species	O
had	O
calcium	O
phosphate	O
in	O
their	O
trichomes	O
.	O

Loasa	O
was	O
mostly	O
free	O
of	O
silica	O
,	O
but	O
contained	O
calcium	O
phosphate	O
in	O
trichome	O
tips	O
and	O
barbs	O
,	O
whereas	O
calcium	O
phosphate	O
and	O
silica	O
were	O
found	O
in	O
representatives	O
of	O
other	O
genera	O
of	O
the	O
family	O
(	O
Blumenbachia	O
,	O
Caiophora	O
,	O
Nasa	O
)	O
.	O

Biomineralization	O
is	O
remarkably	O
diversified	O
between	O
species	O
,	O
different	O
trichome	O
types	O
and	O
parts	O
of	O
the	O
same	O
trichome	O
.	O

Individual	O
genera	O
largely	O
had	O
different	O
patterns	O
of	O
biomineralization	O
.	O

The	O
presence	O
of	O
three	O
biominerals	O
in	O
the	O
trichomes	O
of	O
the	O
basally	O
branching	O
Eucnide	O
urens	O
indicates	O
either	O
an	O
early	O
evolution	O
and	O
subsequent	O
loss	O
or	O
several	O
independent	O
origins	O
of	O
multiple	O
biomineralization	O
.	O

Differential	O
biomineralization	O
of	O
the	O
parts	O
of	O
individual	O
,	O
unicellular	O
trichomes	O
clearly	O
indicates	O
an	O
extraordinary	O
degree	O
of	O
physiological	O
control	O
over	O
this	O
process	O
.	O

The	O
Chinese	O
Herbal	O
Mixture	O
Tien-Hsien	O
Liquid	O
Augments	O
the	O
Anticancer	O
Immunity	O
in	O
Tumor	O
Cell	O
-	O
Vaccinated	O
Mice	O
.	O

Background	O
The	O
Chinese	O
herbal	O
mixture	O
,	O
Tien-Hsien	O
liquid	O
(	O
THL	O
)	O
,	O
has	O
been	O
used	O
as	O
an	O
anticancer	O
dietary	O
supplement	O
for	O
more	O
than	O
20	O
years	O
.	O

Our	O
previous	O
studies	O
have	O
shown	O
that	O
THL	O
can	O
modulate	O
immune	O
response	O
and	O
inhibit	O
tumor	O
growth	O
.	O

In	O
this	O
study	O
,	O
we	O
further	O
evaluated	O
the	O
effect	O
of	O
THL	O
on	O
anticancer	O
immune	O
response	O
in	O
mice	O
vaccinated	O
with	O
γ-ray	O
-	O
irradiated	O
tumor	O
cells	O
.	O

Methods	O
The	O
antitumor	O
effect	O
of	O
THL	O
was	O
determined	O
in	O
mice	O
vaccinated	O
with	O
low-tumorigenic	O
CT-26-low	O
colon	O
cancer	O
cells	O
or	O
γ-ray-irradiated	O
high-tumorigenic	O
CT-26-high	O
colon	O
cancer	O
cells	O
.	O

The	O
number	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
and	O
T	O
lymphocytes	O
in	O
the	O
spleen	O
was	O
analyzed	O
by	O
flow	B-P
cytometry	I-P
.	O

The	O
tumor	O
-	O
killing	O
activities	O
of	O
NK	O
cells	O
and	O
cytotoxic	O
T	O
lymphocytes	O
(	O
CTLs	O
)	O
were	O
analyzed	O
by	O
flow	B-P
cytometry	I-P
using	O
YAC-1	O
and	O
CT-26-high	O
cells	O
,	O
respectively	O
,	O
as	O
target	O
cells	O
.	O

The	O
levels	O
of	O
IFN-γ	O
,	O
IL-2	O
,	O
and	O
TNF-α	O
were	O
determined	O
by	O
ELISA	B-P
.	O

Results	O
THL	O
suppressed	O
the	O
growth	O
of	O
CT-26-high	O
tumor	O
in	O
mice	O
previously	O
vaccinated	O
with	O
low-tumorigenic	O
CT-26-low	O
cells	O
or	O
γ-irradiated	O
CT-26-high	O
cells	O
.	O

THL	O
increased	O
the	O
populations	O
of	O
NK	O
cells	O
and	O
CD4+	O
T	O
lymphocytes	O
in	O
the	O
spleen	O
and	O
enhanced	O
the	O
tumor	O
-	O
killing	O
activities	O
of	O
NK	O
cells	O
and	O
CTL	O
in	O
mice	O
vaccinated	O
with	O
γ-irradiated	O
CT-26-high	O
cells	O
.	O

THL	O
increased	O
the	O
production	O
of	O
IFN-γ	O
,	O
IL-2	O
,	O
and	O
TNF-α	O
in	O
mice	O
vaccinated	O
with	O
γ-irradiated	O
CT-26-high	O
cells	O
.	O

Conclusion	O
THL	O
can	O
enhance	O
the	O
antitumor	O
immune	O
responses	O
in	O
mice	O
vaccinated	O
with	O
killed	O
tumor	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
THL	O
may	O
be	O
used	O
as	O
a	O
complementary	O
medicine	O
for	O
cancer	O
patients	O
previously	O
treated	O
with	O
killed	O
tumor	O
cell	O
vaccines	O
,	O
radiotherapy	O
,	O
or	O
chemotherapy	O
.	O

Prognostic	O
significance	O
of	O
non-HPV16	O
genotypes	O
in	O
oropharyngeal	O
squamous	O
cell	O
carcinoma	O
.	O

Recent	O
studies	O
have	O
found	O
that	O
cases	O
with	O
oropharyngeal	O
squamous	O
cell	O
carcinoma	O
(	O
OPSCC	O
)	O
positive	O
for	O
HPV16	O
genotype	O
have	O
better	O
overall	O
survival	O
compared	O
with	O
cases	O
positive	O
for	O
other	O
HPV	O
genotypes	O
.	O

We	O
sought	O
to	O
further	O
replicate	O
these	O
studies	O
and	O
determine	O
if	O
this	O
relationship	O
is	O
modified	O
by	O
expression	O
of	O
p16	O
tumor	O
suppressor	O
protein	O
.	O

We	O
identified	O
238	O
OPSCC	O
cases	O
from	O
the	O
Carolina	O
Head	O
and	O
Neck	O
Cancer	O
Study	O
(	O
CHANCE	O
)	O
study	O
,	O
a	O
population	O
based	O
case-control	O
study	O
.	O

Tumors	O
that	O
tested	O
positive	O
solely	O
for	O
HPV16	O
genotype	O
and	O
no	O
other	O
genotypes	O
with	O
PCR	O
were	O
classified	O
as	O
HPV16-positive	O
.	O

Tumors	O
positive	O
for	O
any	O
other	O
high-risk	O
HPV	O
genotype	O
were	O
classified	O
as	O
non-HPV16-positive	O
.	O

Expression	O
of	O
p16	O
in	O
the	O
tumor	O
was	O
determined	O
with	O
immunohistochemistry	B-P
.	O

Follow-up	O
time	O
was	O
calculated	O
from	O
the	O
date	O
of	O
diagnosis	O
to	O
date	O
of	O
death	O
or	O
December	O
31	O
,	O
2013	O
.	O

Overall	O
survival	O
was	O
compared	O
with	O
the	O
Kaplan-Meier	O
curves	O
and	O
log-rank	O
test	O
.	O

Hazard	O
ratios	O
(	O
HR	O
)	O
adjusted	O
for	O
smoking	O
,	O
alcohol	O
use	O
,	O
sex	O
,	O
race	O
,	O
and	O
age	O
was	O
calculated	O
with	O
the	O
Cox	O
proportional	O
hazard	O
regression	O
.	O

Cases	O
with	O
HPV16-positive	O
OPSCC	O
had	O
better	O
overall	O
survival	O
than	O
cases	O
with	O
non-HPV16-positive	O
OPSCC	O
(	O
log-rank	O
p-value	O
:	O
0.010	O
)	O
.	O

When	O
restricted	O
to	O
OPSCC	O
cases	O
positive	O
for	O
p16	O
expression	O
,	O
the	O
same	O
trend	O
continued	O
(	O
log-rank	O
p-value	O
:	O
0.002	O
)	O
.	O

In	O
the	O
adjusted	O
model	O
,	O
cases	O
with	O
non-HPV16-positive	O
OPSCC	O
had	O
greater	O
risk	O
of	O
death	O
compared	O
to	O
cases	O
with	O
HPV16-positive	O
tumors	O
(	O
HR	O
:	O
1.92	O
;	O
95	O
%	O
CI	O
:	O
1.03	O
,	O
3.60	O
)	O
.	O

This	O
finding	O
indicates	O
that	O
HPV	O
genotyping	B-P
carries	O
valuable	O
prognostic	O
significance	O
in	O
addition	O
to	O
p16	O
status	O
and	O
future	O
survival	O
studies	O
of	O
OPSCC	O
should	O
take	O
into	O
account	O
differing	O
HPV	O
genotypes	O
.	O

Assessing	O
the	O
manipulative	O
potentials	O
of	O
monkeys	O
,	O
apes	O
and	O
humans	O
from	O
hand	O
proportions	O
:	O
implications	O
for	O
hand	O
evolution	O
.	O

The	O
hand	O
structure	O
possesses	O
a	O
greater	O
potential	O
for	O
performing	O
manipulative	O
skills	O
than	O
is	O
typically	O
observed	O
,	O
whether	O
in	O
humans	O
or	O
non-human	O
anthropoids	O
.	O

However	O
,	O
a	O
precise	O
assessment	O
of	O
the	O
potential	O
manipulative	O
skills	O
of	O
hands	O
has	O
been	O
challenging	O
,	O
which	O
hampers	O
our	O
understanding	O
of	O
the	O
evolution	O
of	O
manipulative	O
abilities	O
in	O
anthropoid	O
hands	O
.	O

Here	O
,	O
we	O
establish	O
a	O
functional	O
model	O
to	O
quantitatively	O
infer	O
the	O
manipulative	O
potentials	O
of	O
anthropoid	O
hands	O
based	O
on	O
hand	O
proportions	O
.	O

Our	O
results	O
reveal	O
a	O
large	O
disparity	O
of	O
manipulative	O
potentials	O
among	O
anthropoid	O
hands	O
.	O

From	O
the	O
aspect	O
of	O
hand	O
proportions	O
,	O
the	O
human	O
hand	O
has	O
the	O
best	O
manipulative	O
potential	O
among	O
anthropoids	O
.	O

However	O
,	O
the	O
species	O
with	O
a	O
manipulative	O
potential	O
closer	O
to	O
that	O
of	O
humans	O
are	O
not	O
our	O
nearest	O
relatives	O
,	O
chimpanzees	O
,	O
but	O
rather	O
,	O
are	O
certain	O
monkey	O
species	O
.	O

In	O
combination	O
with	O
the	O
phylogenetically	B-P
informed	I-P
morphometric	I-P
analyses	I-P
,	O
our	O
results	O
suggest	O
that	O
the	O
morphological	O
changes	O
of	O
non-human	O
anthropoid	O
hands	O
did	O
not	O
coevolve	O
with	O
the	O
brain	O
to	O
facilitate	O
the	O
manipulative	O
ability	O
during	O
the	O
evolutionary	O
process	O
,	O
although	O
the	O
manipulative	O
ability	O
is	O
a	O
survival	O
skill	O
.	O

The	O
changes	O
in	O
non-human	O
anthropoid	O
hands	O
may	O
have	O
more	O
likely	O
evolved	O
under	O
selective	O
pressure	O
for	O
locomotion	O
than	O
manipulation	O
.	O

Crude	O
4-methylcyclohexanemethanol	O
(	O
MCHM	O
)	O
did	O
not	O
cause	O
skin	O
irritation	O
in	O
humans	O
in	O
48-h	O
patch	B-P
test	I-P
.	O

Crude	O
4-methylcyclohexanemethanol	O
(	O
MCHM	O
)	O
is	O
an	O
industrial	O
chemical	O
used	O
to	O
wash	O
and	O
clean	O
coal	O
.	O

On	O
January	O
9th	O
,	O
2014	O
approximately	O
10,000	O
gallons	O
of	O
a	O
mixture	O
containing	O
crude	O
MCHM	O
were	O
released	O
into	O
the	O
Elk	O
River	O
near	O
Charleston	O
,	O
West	O
Virginia	O
,	O
contaminating	O
the	O
local	O
water	O
supply	O
.	O

Following	O
the	O
spill	O
,	O
residents	O
reported	O
numerous	O
health	O
complaints	O
,	O
and	O
sought	O
medical	O
attention	O
for	O
ailments	O
including	O
rashes	O
and	O
itching	O
.	O

The	O
relationship	O
between	O
the	O
complaints	O
and	O
the	O
spill	O
were	O
unknown	O
,	O
as	O
such	O
symptoms	O
are	O
reported	O
frequently	O
in	O
the	O
background	O
.	O

In	O
this	O
study	O
,	O
the	O
primary	O
irritation	O
potential	O
of	O
crude	O
MCHM	O
was	O
evaluated	O
in	O
206	O
individuals	O
who	O
underwent	O
48	O
hour	O
semi-occluded	O
patch	B-P
testing	I-P
.	O

MCHM	O
concentrations	O
assessed	O
in	O
this	O
study	O
were	O
1	O
,	O
5	O
,	O
15	O
,	O
and	O
100	O
ppm	O
.	O

No	O
appreciable	O
skin	O
reactions	O
were	O
observed	O
in	O
individuals	O
at	O
any	O
concentration	O
.	O

Three	O
of	O
the	O
five	O
concentrations	O
evaluated	O
were	O
above	O
the	O
highest	O
measured	O
concentration	O
of	O
MCHM	O
in	O
the	O
tap	O
water	O
of	O
residents	O
in	O
West	O
Virginia	O
(	O
3.7	O
ppm	O
)	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
crude	O
MCHM	O
would	O
not	O
be	O
a	O
dermal	O
irritant	O
for	O
the	O
vast	O
majority	O
,	O
if	O
not	O
all	O
,	O
potentially	O
exposed	O
persons	O
at	O
the	O
concentrations	O
in	O
the	O
water	O
reported	O
after	O
the	O
spill	O
.	O

Analysis	B-P
of	O
tilianin	O
and	O
acacetin	O
in	O
Agastache	O
rugosa	O
by	O
high-performance	B-P
liquid	I-P
chromatography	I-P
with	O
ionic	O
liquids	O
-	O
ultrasound	O
based	O
extraction	B-P
.	O

Ionic	O
liquid	O
1-butyl-3-methylimidazolium	O
bromide	O
-	O
methanol	O
-based	O
ultrasonic	O
-assisted	O
extraction	B-P
(	O
ILUAE	B-P
)	O
was	O
used	O
to	O
extract	B-P
tilianin	O
and	O
acacetin	O
from	O
the	O
aerial	O
parts	O
of	O
Agastache	O
rugose	O
(	O
A.	O
rugose	O
)	O
,	O
and	O
simultaneously	O
determined	O
by	O
reversed	B-P
phase	I-P
high	I-P
performance	I-P
liquid	I-P
chromatographic	I-P
(	O
RP-HPLC	B-P
)	O
method	O
with	O
ultraviolet	O
detection	O
(	O
RP-HPLC-UV	O
)	O
.	O

An	O
InertSustain	O
RP-C18	O
column	O
was	O
used	O
with	O
the	O
mobile	O
phase	O
consisting	O
of	O
methanol	O
and	O
0.2	O
%	O
acetic	O
acid	O
as	O
gradient	O
elution	B-P
at	O
the	O
detection	O
wavelength	O
of	O
332	O
nm	O
.	O

The	O
flow	O
rate	O
was	O
0.8	O
mL/min	O
,	O
and	O
the	O
column	O
temperature	O
was	O
30	O
°C	O
.	O

Under	O
the	O
optimized	O
conditions	O
,	O
tilianin	O
and	O
acacetin	O
displayed	O
good	O
linearity	O
in	O
the	O
ranges	O
of	O
0.0595-4.76	O
and	O
0.0585-4.68	O
μg/mL	O
,	O
respectively	O
,	O
with	O
the	O
average	O
recoveries	O
being	O
96.93	O
and	O
97.88	O
%	O
,	O
respectively	O
.	O

The	O
method	O
of	O
ILUAE	B-P
was	O
compared	O
with	O
the	O
traditional	O
methods	O
,	O
it	O
exhibited	O
higher	O
efficiency	O
,	O
higher	O
reproducibility	O
and	O
environmental	O
friendly	O
in	O
analyzing	O
the	O
active	O
compounds	O
in	O
traditional	O
Chinese	O
medicines	O
(	O
TCMs	O
)	O
.	O

The	O
Latin	O
American	O
Biological	O
Dosimetry	O
Network	O
(	O
LBDNet	O
)	O
.	O

Biological	O
Dosimetry	B-P
is	O
a	O
necessary	O
support	O
for	O
national	O
radiation	O
protection	O
programmes	O
and	O
emergency	O
response	O
schemes	O
.	O

The	O
Latin	O
American	O
Biological	O
Dosimetry	O
Network	O
(	O
LBDNet	O
)	O
was	O
formally	O
founded	O
in	O
2007	O
to	O
provide	O
early	O
biological	O
dosimetry	B-P
assistance	O
in	O
case	O
of	O
radiation	O
emergencies	O
in	O
the	O
Latin	O
American	O
Region	O
.	O

Here	O
are	O
presented	O
the	O
main	O
topics	O
considered	O
in	O
the	O
foundational	O
document	O
of	O
the	O
network	O
,	O
which	O
comprise	O
:	O
mission	O
,	O
partners	O
,	O
concept	O
of	O
operation	O
,	O
including	O
the	O
mechanism	O
to	O
request	O
support	O
for	O
biological	O
dosimetry	B-P
assistance	O
in	O
the	O
region	O
,	O
and	O
the	O
network	O
capabilities	O
.	O

The	O
process	O
for	O
network	O
activation	O
and	O
the	O
role	O
of	O
the	O
coordinating	O
laboratory	O
during	O
biological	O
dosimetry	B-P
emergency	O
response	O
is	O
also	O
presented	O
.	O

This	O
information	O
is	O
preceded	O
by	O
historical	O
remarks	O
on	O
biological	O
dosimetry	B-P
cooperation	O
in	O
Latin	O
America	O
.	O

A	O
summary	O
of	O
the	O
main	O
experimental	O
and	O
practical	O
results	O
already	O
obtained	O
by	O
the	O
LBDNet	O
is	O
also	O
included	O
.	O

Cardioprotective	O
kinase	O
signaling	O
to	O
subsarcolemmal	O
and	O
interfibrillar	O
mitochondria	O
is	O
mediated	O
by	O
caveolar	O
structures	O
.	O

The	O
demonstration	O
that	O
caveolin-3	O
overexpression	O
reduces	O
myocardial	O
ischemia	O
/	O
reperfusion	O
injury	O
and	O
our	O
own	O
finding	O
that	O
multiprotein	O
signaling	O
complexes	O
increase	O
in	O
mitochondria	O
in	O
association	O
with	O
caveolin-3	O
levels	O
,	O
led	O
us	O
to	O
investigate	O
the	O
contribution	O
of	O
caveolae	O
-driven	O
extracellular	O
signal-regulated	O
kinases	O
1	O
/	O
2	O
(	O
ERK1	O
/	O
2	O
)	O
on	O
maintaining	O
the	O
function	O
of	O
cardiac	O
mitochondrial	O
subpopulations	O
from	O
reperfused	O
hearts	O
subjected	O
to	O
postconditioning	O
(	O
PostC	O
)	O
.	O

Rat	O
hearts	O
were	O
isolated	O
and	O
subjected	O
to	O
ischemia	O
/	O
reperfusion	O
and	O
to	O
PostC	O
.	O

Enhanced	O
cardiac	O
function	O
,	O
reduced	O
infarct	O
size	O
and	O
preserved	O
ultrastructure	O
of	O
cardiomyocytes	O
were	O
associated	O
with	O
increased	O
formation	O
of	O
caveolar	O
structures	O
,	O
augmented	O
levels	O
of	O
caveolin-3	O
and	O
mitochondrial	O
ERK1	O
/	O
2	O
activation	O
in	O
PostC	O
hearts	O
in	O
both	O
subsarcolemmal	O
(	O
SSM	O
)	O
and	O
interfibrillar	O
(	O
IFM	O
)	O
subpopulations	O
.	O

Disruption	O
of	O
caveolae	O
with	O
methyl-β-cyclodextrin	O
abolished	O
cardioprotection	O
in	O
PostC	O
hearts	O
and	O
diminished	O
pho-ERK1/2	O
gold	O
-	O
labeling	B-P
in	O
both	O
mitochondrial	O
subpopulations	O
in	O
correlation	O
with	O
suppression	O
of	O
resistance	O
to	O
permeability	O
transition	O
pore	O
opening	O
.	O

Also	O
,	O
differences	O
between	O
the	O
mitochondrial	O
subpopulations	O
in	O
the	O
setting	O
of	O
PostC	O
were	O
evaluated	O
.	O

Caveolae	O
disruption	O
with	O
methyl-β-cyclodextrin	O
abolished	O
the	O
cardioprotective	O
effect	O
of	O
postconditioning	O
by	O
inhibiting	O
the	O
interaction	O
of	O
ERK1	O
/	O
2	O
with	O
mitochondria	O
and	O
promoted	O
decline	O
in	O
mitochondrial	O
function	O
.	O

SSM	O
,	O
which	O
are	O
particularly	O
sensitive	O
to	O
reperfusion	O
damage	O
,	O
take	O
advantage	O
of	O
their	O
location	O
in	O
cardiomyocyte	O
boundary	O
and	O
benefit	O
from	O
the	O
cardioprotective	O
signaling	O
driven	O
by	O
caveolae	O
,	O
avoiding	O
injury	O
propagation	O
.	O

Interleukin-21	O
plays	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
and	O
severity	O
of	O
type	O
I	O
autoimmune	O
hepatitis	O
.	O

Recently	O
,	O
the	O
number	O
of	O
follicular	O
helper	O
T	O
(	O
Tfh	O
)	O
cells	O
expressing	O
interleukin	O
(	O
IL	O
)	O
-21	O
was	O
found	O
to	O
increase	O
in	O
peripheral	O
blood	O
of	O
human	O
and	O
murine	O
models	O
of	O
autoimmune	O
hepatitis	O
(	O
AIH	O
)	O
.	O

IL-21	O
,	O
the	O
most	O
recently	O
discovered	O
member	O
of	O
the	O
type-I	O
cytokine	O
family	O
,	O
exerts	O
various	O
effects	O
on	O
the	O
immune	O
system	O
,	O
including	O
B	O
cell	O
activation	O
,	O
plasma	O
cell	O
differentiation	O
,	O
and	O
immunoglobulin	O
production	O
.	O

We	O
aimed	O
to	O
assess	O
the	O
relationship	O
of	O
serum	O
IL-21	O
levels	O
in	O
patients	O
with	O
type	O
I	O
AIH	O
with	O
clinical	O
and	O
laboratory	O
parameters	O
and	O
histology	O
.	O

Ninety-two	O
Japanese	O
patients	O
with	O
liver	O
disease	O
(	O
22	O
AIH	O
,	O
20	O
primary	O
biliary	O
cholangitis	O
,	O
19	O
drug-induced	O
liver	O
injury	O
,	O
8	O
acute	O
hepatitis	O
B	O
,	O
8	O
chronic	O
hepatitis	O
C	O
,	O
10	O
non-alcoholic	O
steatohepatitis	O
,	O
5	O
viral	O
hepatitis	O
)	O
and	O
10	O
healthy	O
volunteers	O
were	O
recruited	O
.	O

Serum	O
IL-21	O
levels	O
were	O
detected	O
by	O
enzyme-linked	B-P
immunosorbent	I-P
assay	I-P
.	O

Real-time	O
polymerase	O
chain	O
reaction	O
measured	O
mRNA	O
levels	O
of	O
Bcl-6	O
,	O
IL-21	O
,	O
and	O
CXCR5	O
(	O
Tfh-related	O
factors	O
)	O
in	O
peripheral	O
mononuclear	O
cells	O
.	O

Mean	O
age	O
at	O
diagnosis	O
of	O
AIH	O
was	O
58.6	O
years	O
,	O
male-to-female	O
ratio	O
was	O
4:18	O
,	O
18.2	O
%	O
of	O
participants	O
had	O
cirrhosis	O
,	O
and	O
22.7	O
%	O
had	O
severe	O
disease	O
.	O

IL-21	O
levels	O
were	O
significantly	O
increased	O
in	O
the	O
serum	O
of	O
patients	O
with	O
AIH	O
compared	O
to	O
those	O
with	O
other	O
liver	O
diseases	O
and	O
controls	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

Particularly	O
,	O
serum	O
IL-21	O
levels	O
were	O
significantly	O
increased	O
in	O
severe	O
AIH	O
cases	O
compared	O
to	O
non-severe	O
cases	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Serum	O
IL-21	O
levels	O
correlated	O
positively	O
with	O
total	O
serum	O
bilirubin	B-P
levels	I-P
(	O
r	O
=	O
0.46	O
,	O
p	O
<	O
0.05	O
)	O
,	O
grading	O
of	O
necroinflammatory	O
activity	O
(	O
r	O
=	O
0.68	O
,	O
p	O
<	O
0.005	O
)	O
and	O
negatively	O
with	O
serum	O
albumin	O
levels	O
in	O
patients	O
with	O
AIH	O
(	O
r	O
=	O
-0.49	O
,	O
p	O
<	O
0.05	O
)	O
.	O

In	O
patients	O
with	O
biochemical	O
remission	O
of	O
AIH	O
,	O
serum	O
IL-21	O
levels	O
remained	O
elevated	O
and	O
correlated	O
positively	O
with	O
serum	B-P
IgG	I-P
levels	I-P
(	O
r	O
=	O
0.84	O
,	O
p	O
<	O
0.01	O
)	O
.	O

Expression	O
of	O
Tfh-related	O
factors	O
,	O
such	O
as	O
Bcl-6	O
and	O
IL-21	O
,	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
patients	O
with	O
AIH	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
healthy	O
volunteers	O
.	O

IL-21	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
and	O
severity	O
of	O
AIH	O
,	O
and	O
may	O
present	O
a	O
promising	O
target	O
for	O
AIH	O
therapy	O
.	O

Molecular	O
Mechanisms	O
of	O
Resistance	O
to	O
First-	O
and	O
Second-Generation	O
ALK	O
Inhibitors	O
in	O
ALK	O
-Rearranged	O
Lung	O
Cancer	O
.	O

Advanced	O
,	O
anaplastic	O
lymphoma	O
kinase	O
(	O
ALK	O
)	O
-positive	O
lung	O
cancer	O
is	O
currently	O
treated	O
with	O
the	O
first-generation	O
ALK	O
inhibitor	O
crizotinib	O
followed	O
by	O
more	O
potent	O
,	O
second-generation	O
ALK	O
inhibitors	O
(	O
e.g.	O
,	O
ceritinib	O
and	O
alectinib	O
)	O
upon	O
progression	O
.	O

Second-generation	O
inhibitors	O
are	O
generally	O
effective	O
even	O
in	O
the	O
absence	O
of	O
crizotinib	O
-	O
resistant	O
ALK	O
mutations	O
,	O
likely	O
reflecting	O
incomplete	O
inhibition	O
of	O
ALK	O
by	O
crizotinib	O
in	O
many	O
cases	O
.	O

Herein	O
,	O
we	O
analyzed	O
103	O
repeat	O
biopsies	B-P
from	O
ALK	O
-positive	O
patients	O
progressing	O
on	O
various	O
ALK	O
inhibitors	O
.	O

We	O
find	O
that	O
each	O
ALK	O
inhibitor	O
is	O
associated	O
with	O
a	O
distinct	O
spectrum	O
of	O
ALK	O
resistance	O
mutations	O
and	O
that	O
the	O
frequency	O
of	O
one	O
mutation	O
,	O
ALK	O
(	O
G1202R	O
)	O
,	O
increases	O
significantly	O
after	O
treatment	O
with	O
second-generation	O
agents	O
.	O

To	O
investigate	O
strategies	O
to	O
overcome	O
resistance	O
to	O
second-generation	O
ALK	O
inhibitors	O
,	O
we	O
examine	O
the	O
activity	O
of	O
the	O
third-generation	O
ALK	O
inhibitor	O
lorlatinib	O
in	O
a	O
series	O
of	O
ceritinib	O
-	O
resistant	O
,	O
patient	O
-derived	O
cell	O
lines	O
,	O
and	O
observe	O
that	O
the	O
presence	O
of	O
ALK	O
resistance	O
mutations	O
is	O
highly	O
predictive	O
for	O
sensitivity	O
to	O
lorlatinib	O
,	O
whereas	O
those	O
cell	O
lines	O
without	O
ALK	O
mutations	O
are	O
resistant	O
.	O

Secondary	O
ALK	O
mutations	O
are	O
a	O
common	O
resistance	O
mechanism	O
to	O
second-generation	O
ALK	O
inhibitors	O
and	O
predict	O
for	O
sensitivity	O
to	O
the	O
third-generation	O
ALK	O
inhibitor	O
lorlatinib	O
.	O

These	O
findings	O
highlight	O
the	O
importance	O
of	O
repeat	O
biopsies	B-P
and	O
genotyping	O
following	O
disease	O
progression	O
on	O
targeted	O
therapies	O
,	O
particularly	O
second-generation	O
ALK	O
inhibitors	O
.	O

Cancer	O
Discov	O
;	O
6	O
(	O
10	O
)	O
;	O
1118-33	O
.	O

©2016	O
AACRSee	O
related	O
commentary	O
by	O
Qiao	O
and	O
Lovly	O
,	O
p.	O
1084This	O
article	O
is	O
highlighted	O
in	O
the	O
In	O
This	O
Issue	O
feature	O
,	O
p.	O
1069	O
.	O

